PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Reginato, MJ; Zhang, JS; Lazar, MA				Reginato, MJ; Zhang, JS; Lazar, MA			DNA-independent and DNA-dependent mechanisms regulate the differential heterodimerization of the isoforms of the thyroid hormone receptor with retinoid X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGET GENE SPECIFICITY; AMINO-TERMINAL DOMAINS; NUCLEAR RECEPTOR; RESPONSE ELEMENT; BINDING DOMAIN; ACID RECEPTORS; ORPHAN RECEPTORS; ZINC FINGER; DEOXYRIBONUCLEIC-ACID; MONOMER-BINDING	Thyroid hormone receptors (TRs) require heterodimerization with retinoid X receptor (RXR) for maximum DNA binding affinity. Interaction with RXR occurs via two dimerization interfaces, one in the DNA-binding domain and one in the C-terminal ''ninth heptad'' of the receptors. We studied the relative importance of these two dimerization domains in naturally occurring C-terminal TR variants. TR alpha 1 has a conserved ninth heptad and formed stable heterodimers with RXR in solution. TR alpha 1 . RXR heterodimers bound similarly to direct repeat 4 (DR4) sites with different 5'-flanking and spacer sequences. In contrast, TR alpha 2, which contains a highly divergent ninth heptad, did not interact with RXR in solution and bound as a heterodimer with RXR only to specific DR4 sequences in which the downstream half-site was the preferred octameric binding site of TR (TNAGGTCA). Although the ninth heptad of TR alpha 2 was insufficient for interaction with RXR off DNA, this region was required for DNA-dependent heterodimerization with RXR. TR alpha 3, another naturally occurring TR alpha isoform whose ninth heptad differs from those of both TR alpha 1 and TR alpha 2, displayed intermediate behavior in heterodimerization with RXR. Thus, in the absence of a strong ninth heptad interaction an octameric downstream half-site allosterically promotes RXR heterodimerization with TR alpha 2. Differential dependence upon DNA-binding for heterodimerization with RXR may influence transcriptional regulation by TR alpha isoforms.	UNIV PENN,SCH MED,DEPT MED,DIV ENDOCRINOL DIABET & METAB,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,DIV ENDOCRINOL DIABET & METAB,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania			Reginato, Mauricio/I-6155-2013; Lazar, Mitchell A/AAF-3738-2019	Reginato, Mauricio/0000-0002-7541-4094; Zhang, Jinsong/0000-0002-8798-7316	NIDDK NIH HHS [DK43806] Funding Source: Medline; NIGMS NIH HHS [GM15677] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043806, R37DK043806] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM015677] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHEN HW, 1995, P NATL ACAD SCI USA, V92, P422, DOI 10.1073/pnas.92.2.422; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DARLING DS, 1993, J BIOL CHEM, V268, P10221; DAVIS KD, 1994, MOL CELL BIOL, V14, P7105, DOI 10.1128/MCB.14.11.7105; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GREEN S, 1988, EMBO J, V7, P3037, DOI 10.1002/j.1460-2075.1988.tb03168.x; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; HARDING HP, 1995, MOL CELL BIOL, V15, P4791; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KATZ D, 1993, J BIOL CHEM, V268, P20904; KATZ D, 1992, MOL ENDOCRINOL, V6, P805, DOI 10.1210/me.6.5.805; KATZ D, 1995, MOL CELL BIOL, V15, P2341; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIU RT, 1995, MOL ENDOCRINOL, V9, P86, DOI 10.1210/me.9.1.86; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MCBROOM LDB, 1995, MOL CELL BIOL, V15, P796; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MITSUHASHI T, 1989, J BIOL CHEM, V264, P8900; NAGAYA T, 1993, J BIOL CHEM, V268, P24278; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; ONATE SA, 1995, SCIENCE, V270, P1354; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; PATI UK, 1992, GENE, V114, P285, DOI 10.1016/0378-1119(92)90589-H; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; PIEDRAFITA FJ, 1995, MOL ENDOCRINOL, V9, P563, DOI 10.1210/me.9.5.563; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; RASTINEJAD F, 1995, NATURE, V203, P375; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SHULEMOVICH K, 1995, NUCLEIC ACIDS RES, V23, P811, DOI 10.1093/nar/23.5.811; SJOBERG M, 1995, MOL CELL BIOL, V15, P4718; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WILLS KN, 1991, MOL ENDOCRINOL, V5, P1109, DOI 10.1210/mend-5-8-1109; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WONG CW, 1995, MOL ENDOCRINOL, V9, P551, DOI 10.1210/me.9.5.551; YEN PM, 1994, ENDOCRINOLOGY, V134, P1075, DOI 10.1210/en.134.3.1075; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZHANG X, 1991, MOL ENDOCRINOL, V5, P1909, DOI 10.1210/mend-5-12-1909	64	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28199	28205		10.1074/jbc.271.45.28199	http://dx.doi.org/10.1074/jbc.271.45.28199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910436	hybrid			2022-12-25	WOS:A1996VU03300036
J	Simm, M; Pekarskaya, O; Volsky, DJ				Simm, M; Pekarskaya, O; Volsky, DJ			Synthesis of full-length viral DNA in CD4-positive membrane vesicles exposed to HIV-1 - A model for studies of early stages of the HIV-1 life cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 REVERSE TRANSCRIPTION; ROUS-SARCOMA VIRUS; PLASMA-MEMBRANE; SOR GENE; T-CELLS; INFECTION; RNA; EXPRESSION; INVITRO	CD4-positive membrane vesicles (MV) were isolated under isotonic conditions from human T lymphoblastoid cells MT-2 and CEM and tested for their ability to support reverse transcription of viral RNA upon exposure to human immunodeficiency virus, type 1 (HIV-1), MV contained cytoplasms as confirmed by the presence of mitochondrial DNA but were devoid of chromosomal DNA. Virus binding and vesicle lysis assays revealed that 4-19% (depending upon virus dose) of MV-bound HIV-1 entered the vesicles, HIV-1 internalized in MV was able to initiate and complete viral DNA synthesis as determined by the detection of products of reverse transcription using polymerase chain reaction amplification of viral DNA using regions present in early (strong stop) transcripts and full-length double-stranded molecules, Viral DNA was undetectable in MV exposed to HIV-1 at 0 degrees C, in MV exposed to UV-inactivated virus at 37 degrees C, or after exposure to intact virus at 37 degrees C in the presence of reverse transcriptase inhibitors 2',3'-dideoxycytidine and a tetrahydroimidazo[4,5,1-jh](1,4)-benzodiazepin-2-(1H)-thione derivative, indicating that viral DNA detected in HIV-1-exposed MV was synthesized de novo. Kinetic studies revealed that HIV-1 DNA synthesis in MV was very rapid; full-length viral DNA was detected within 15 min of exposure at 37 degrees C, and the DNA levels increased 90-fold after 1 h and declined thereafter, Strong stop viral DNA was 10-fold more abundant than full-length DNA after 1 h at 37 degrees C, indicating that 10% of input viral genomes are fully transcribed in MV within this time frame, This system preserves the critical features of intact CD4-bearing cells to permit studies of HIV-1 entry, uncoating, and reverse transcription of viral RNA.	COLUMBIA UNIV, ST LUKES ROOSEVELT HOSP CTR, MOL VIROL LAB, NEW YORK, NY 10019 USA; COLUMBIA UNIV COLL PHYS & SURG, NEW YORK, NY 10019 USA	Columbia University; Mount Sinai St. Luke's; Mount Sinai West; Columbia University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035466] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43628] Funding Source: Medline; NIAID NIH HHS [AI35466] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; BENZAIR AB, 1993, J VIROL METHODS, V45, P319, DOI 10.1016/0166-0934(93)90116-9; BORROTOESODA K, 1994, ANTIVIR RES, V23, P235, DOI 10.1016/0166-3542(94)90021-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIMITROV DS, 1991, AIDS RES HUM RETROV, V7, P799, DOI 10.1089/aid.1991.7.799; DREXLER HG, 1994, ATLAS HUMAN TUMOR CE, P213; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280; GREWE C, 1990, J ACQ IMMUN DEF SYND, V3, P965; HAROUSE JM, 1991, J LEUKOCYTE BIOL, V49, P605, DOI 10.1002/jlb.49.6.605; HEINZINGER N, 1995, VIROLOGY, V206, P731, DOI 10.1016/S0042-6822(95)80097-2; HOGLUND S, 1994, VIROLOGY, V201, P349, DOI 10.1006/viro.1994.1300; INIS MA, 1990, PCR PROTOCOLS; JUNGHANS RP, 1975, P NATL ACAD SCI USA, V72, P4895, DOI 10.1073/pnas.72.12.4895; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KINNESAFFRAN E, 1989, METHOD ENZYMOL, V172, P3; LORI F, 1992, J VIROL, V66, P5067, DOI 10.1128/JVI.66.8.5067-5074.1992; LUCIW PA, 1992, RETROVIRIDAE, V1, P159; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCCLURE MO, 1988, EMBO J, V7, P513, DOI 10.1002/j.1460-2075.1988.tb02839.x; MICHAELS FH, 1993, AIDS RES HUM RETROV, V9, P1025, DOI 10.1089/aid.1993.9.1025; MONNERON A, 1978, J CELL BIOL, V77, P211, DOI 10.1083/jcb.77.1.211; NAGY K, 1994, J VIROL, V68, P757, DOI 10.1128/JVI.68.2.757-765.1994; OBRIEN WA, 1994, J VIROL, V68, P1258, DOI 10.1128/JVI.68.2.1258-1263.1994; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PAUZA CD, 1988, J CELL BIOL, V107, P959, DOI 10.1083/jcb.107.3.959; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; PELLEGRINO MG, 1991, J BIOL CHEM, V266, P1783; POTASH MJ, 1993, DNA CELL BIOL, V12, P685, DOI 10.1089/dna.1993.12.685; PURI A, 1992, J ACQ IMMUN DEF SYND, V5, P915; ROTHENBERG E, 1976, J VIROL, V17, P168, DOI 10.1128/JVI.17.1.168-174.1976; RUIZ MC, 1994, J VIROL, V68, P4009, DOI 10.1128/JVI.68.6.4009-4016.1994; SAID HM, 1993, P SOC EXP BIOL MED, V202, P428, DOI 10.3181/00379727-202-43554; SAKAI K, 1991, J VIROL, V65, P5765, DOI 10.1128/JVI.65.11.5765-5773.1991; SINANGIL F, 1988, FEBS LETT, V239, P88, DOI 10.1016/0014-5793(88)80551-9; SOVA P, 1993, J VIROL, V67, P6322, DOI 10.1128/JVI.67.10.6322-6326.1993; STAMATATOS L, 1993, J GEN VIROL, V74, P1043, DOI 10.1099/0022-1317-74-6-1043; STEIN BS, 1987, CELL, V49, P659, DOI 10.1016/0092-8674(87)90542-3; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; TRONO D, 1992, J VIROL, V66, P4893, DOI 10.1128/JVI.66.8.4893-4900.1992; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; VERMA IM, 1978, J VIROL, V26, P615, DOI 10.1128/JVI.26.3.615-629.1978; VOLSKY DJ, 1980, P NATL ACAD SCI-BIOL, V77, P5453, DOI 10.1073/pnas.77.9.5453; VOLSKY DJ, 1979, P NATL ACAD SCI USA, V76, P5440, DOI 10.1073/pnas.76.11.5440; WEBB NR, 1989, P NATL ACAD SCI USA, V86, P7731, DOI 10.1073/pnas.86.20.7731; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZHANG H, 1995, J VIROL, V69, P3675, DOI 10.1128/JVI.69.6.3675-3682.1995	51	5	5	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28266	28270		10.1074/jbc.271.45.28266	http://dx.doi.org/10.1074/jbc.271.45.28266			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910445	hybrid			2022-12-25	WOS:A1996VU03300045
J	Wang, ZG; Kiehn, J; Yang, Q; Brown, AM; Wible, BA				Wang, ZG; Kiehn, J; Yang, Q; Brown, AM; Wible, BA			Comparison of binding and block produced by alternatively spliced Kv beta 1 subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL BETA-SUBUNIT; HETEROMULTIMERIC K+ CHANNELS; FUNCTIONAL EXPRESSION; POTASSIUM CHANNELS; RAT-BRAIN; INACTIVATION	Voltage-gated K+ (Kv) channels consist of alpha subunits complexed with cytoplasmic Kv beta subunits. Kv beta 1 subunits enhance the inactivation of currents expressed by the Kv1 alpha subunit subfamily. Binding has been demonstrated between the C terminus of Kv beta 1.1 and a conserved segment of the N terminus of Kv1.4, Kv1.5, and Shaher alpha subunits. Here we have examined the interaction and functional properties of two alternatively spliced human Kv beta subunits, 1.2 and 1.3, with Kv alpha subunits 1.1, 1.2, 1.4, and 1.5. In the yeast two hybrid assay, we found that both Kv beta subunits interact specifically through their conserved C-terminal domains with the N termini of each Kv alpha subunit. In functional experiments, we found differences in modulation of Kv1 alpha subunit currents that we attribute to the unique N-terminal domains of the two Kv beta subunits. Both Kv beta subunits act as open channel blockers at physiological membrane potentials, but hKv beta 1.2 is a more potent blocker than hKv beta 1.3 of Kv1.1, Kv1.2, Kv1.4, and Kv1.5. Moreover, hKv beta 1.2 is sensitive to redox conditions, whereas hKv beta 1.3 is not. We suggest that different Kv beta subunits extend the range over which distinct Kv1 alpha subunits are modulated and may provide a variable mechanism for adjusting K+ currents in response to alterations in cellular conditions.	METROHLTH MED CTR, RAMMELKAMP CTR RES, CLEVELAND, OH 44109 USA; CASE WESTERN RESERVE UNIV, DEPT BIOCHEM, CLEVELAND, OH 44109 USA	MetroHealth System; Case Western Reserve University			Wang, Zhiguo/GRS-4339-2022	Wang, Zhiguo/0000-0002-0811-2045	NHLBI NIH HHS [HL36030] Funding Source: Medline; NINDS NIH HHS [NS23877] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023877] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ENGLAND SK, 1995, J BIOL CHEM, V270, P28531, DOI 10.1074/jbc.270.48.28531; ENGLAND SK, 1995, P NATL ACAD SCI USA, V92, P6309, DOI 10.1073/pnas.92.14.6309; Heinemann SH, 1995, FEBS LETT, V377, P383, DOI 10.1016/0014-5793(95)01377-6; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; KIEHN J, 1995, CIRC RES, V77, P1151, DOI 10.1161/01.RES.77.6.1151; KIRSCH GE, 1992, NEURON, V8, P499, DOI 10.1016/0896-6273(92)90278-L; KOLB HA, 1990, REV PHYSIOL BIOCH P, V115, P51; MAJUMDER K, 1995, FEBS LETT, V361, P13, DOI 10.1016/0014-5793(95)00120-X; MCCORMACK K, 1995, FEBS LETT, V370, P32, DOI 10.1016/0014-5793(95)00785-8; MORALES MJ, 1995, J BIOL CHEM, V270, P6272, DOI 10.1074/jbc.270.11.6272; Nakahira K, 1996, J BIOL CHEM, V271, P7084, DOI 10.1074/jbc.271.12.7084; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RHODES KJ, 1995, J NEUROSCI, V15, P5360; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	23	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28311	28317		10.1074/jbc.271.45.28311	http://dx.doi.org/10.1074/jbc.271.45.28311			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910452	hybrid			2022-12-25	WOS:A1996VU03300052
J	Marcus, SL; Winrow, CJ; Capone, JP; Rachubinski, RA				Marcus, SL; Winrow, CJ; Capone, JP; Rachubinski, RA			A p56(lck) ligand serves as a coactivator of an orphan nuclear hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; THYROID-HORMONE; COUP-TF; X-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; PROTEIN; SUPERFAMILY; REPRESSOR; PROMOTER; GENE	Chicken ovalbumin upstream promoter transcription factor II (COUP-TFII), an orphan member of the nuclear hormone receptor superfamily, acts as a transcriptional repressor by antagonizing the functions of other nuclear hormone receptors and by actively silencing transcription. However, in certain contexts, COUP-TFII stimulates transcription directly. A cellular factor, isolated by interaction cloning, bound COUP-TFII in vitro and allowed COUP-TFII to function as a transcriptional activator in mammalian cells. This factor is identical to a recently described ligand of the tyrosine kinase signaling molecule p56(lch), suggesting that it mediates cross-talk between mitogenic and nuclear hormone receptor signal transduction pathways.	UNIV ALBERTA,DEPT ANAT & CELL BIOL,EDMONTON,AB T6G 2H7,CANADA; MCMASTER UNIV,DEPT BIOCHEM,HAMILTON,ON L8N 3Z5,CANADA	University of Alberta; McMaster University			Winrow, Christopher/K-1864-2014	Winrow, Christopher/0000-0001-8248-4157				ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEGEMANN G, 1995, DEVELOPMENT, V121, P225; BURRIS TP, 1995, P NATL ACAD SCI USA, V92, P9525, DOI 10.1073/pnas.92.21.9525; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Devergne O, 1996, J VIROL, V70, P1143, DOI 10.1128/JVI.70.2.1143-1153.1996; GAUDET F, 1995, J BIOL CHEM, V270, P29916; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; ING NH, 1992, J BIOL CHEM, V267, P17617; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; KADOWAKI Y, 1995, P NATL ACAD SCI USA, V92, P4432, DOI 10.1073/pnas.92.10.4432; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KIMURA A, 1993, J BIOL CHEM, V268, P11125; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KRAMER S, 1995, DEVELOPMENT, V121, P1361; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Leng X, 1996, MOL CELL BIOL, V16, P2332; LU XP, 1994, MOL ENDOCRINOL, V8, P1744; MALIK S, 1995, NUCLEIC ACIDS RES, V23, P1536, DOI 10.1093/nar/23.9.1536; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Marcus SL, 1996, MOL CELL ENDOCRINOL, V120, P31, DOI 10.1016/0303-7207(96)03813-0; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; Miyata KS, 1996, J BIOL CHEM, V271, P9189, DOI 10.1074/jbc.271.16.9189; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; OMALLEY BW, 1992, MOL ENDOCRINOL, V6, P1359, DOI 10.1210/me.6.9.1359; ONATE SA, 1995, SCIENCE, V270, P1354; Park I, 1995, P NATL ACAD SCI USA, V92, P12338, DOI 10.1073/pnas.92.26.12338; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; Power SC, 1996, MOL CELL BIOL, V16, P778; QUI Y, 1996, J STEROID BIOCHEM, V56, P81; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; Wayne ML, 1996, MOL BIOL EVOL, V13, P191, DOI 10.1093/oxfordjournals.molbev.a025555; ZHANG BW, 1993, J BIOL CHEM, V268, P12939; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	41	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27197	27200		10.1074/jbc.271.44.27197	http://dx.doi.org/10.1074/jbc.271.44.27197			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910285	hybrid			2022-12-25	WOS:A1996VQ67900003
J	Thyagarajan, B; Padua, RA; Campbell, C				Thyagarajan, B; Padua, RA; Campbell, C			Mammalian mitochondria possess homologous DNA recombination activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RECA; STRAND-BREAK REPAIR; HUMAN CELL-EXTRACTS; MOUSE L-CELLS; SACCHAROMYCES-CEREVISIAE; GENETIC-RECOMBINATION; MULTIPLE DELETIONS; ANTICANCER AGENTS; ATP HYDROLYSIS; RINR-38 CELLS	Mitochondrial protein extracts from normal and immortalized mammalian somatic cells catalyze homologous recombination of plasmid DNA substrates, Mitochondrial homologous recombination activity required exogenous adenosine triphosphate, although substantial activity remained when non-hydrolyzable analogs were used instead, There was no requirement for added nucleoside triphosphates, and the reaction was not inhibited by dideoxyadenosine triphosphate or aphidicolin, The majority of recombinant plasmid molecules result from a conservative process, indicating that nuclease-mediated strand-annealing is not responsible for the mitochondrial homologous recombination activity. Affinity-purified anti-recA antibodies inhibited the reaction, suggesting that activity is dependent on a mammalian mitochondrial homolog of the bacterial strand-transferase protein, The presence of homologous recombination activity within mammalian mitochondrial extracts suggests that this process is involved in mitochondrial DNA repair.	UNIV MINNESOTA,SCH MED,DEPT PHARMACOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities								ABE H, 1994, ANTICANCER RES, V14, P1807; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BERTRAND H, 1993, MOL CELL BIOL, V13, P6778, DOI 10.1128/MCB.13.11.6778; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BLUME H, 1979, ARCH PHARM, V312, P561, DOI 10.1002/ardp.19793120702; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL CR, 1989, MUTAT RES, V211, P181, DOI 10.1016/0027-5107(89)90118-8; CERUTTI H, 1995, MOL CELL BIOL, V15, P3003; CERUTTI H, 1993, PLANT PHYSIOL, V102, P155, DOI 10.1104/pp.102.1.155; CERUTTI H, 1993, PLANT PHYSIOL, V102, P145, DOI 10.1104/pp.102.1.155; CERUTTI H, 1992, P NATL ACAD SCI USA, V89, P8068, DOI 10.1073/pnas.89.17.8068; CLAYTON DA, 1974, P NATL ACAD SCI USA, V71, P2777, DOI 10.1073/pnas.71.7.2777; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; COX MM, 1994, TRENDS BIOCHEM SCI, V19, P217, DOI 10.1016/0968-0004(94)90025-6; Darley-Usmar V. M., 1987, MITOCHONDRIA PRACTIC; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; FISHMANLOBELL J, 1992, MOL CELL BIOL, V12, P1292, DOI 10.1128/MCB.12.3.1292; FOURY F, 1987, EMBO J, V6, P1441, DOI 10.1002/j.1460-2075.1987.tb02385.x; FRIEDBERG EC, 1995, DNA REPAIR; GANEA D, 1987, MOL CELL BIOL, V7, P3124, DOI 10.1128/MCB.7.9.3124; HINO O, 1991, P NATL ACAD SCI USA, V88, P9248, DOI 10.1073/pnas.88.20.9248; HOWE CJ, 1988, TRENDS GENET, V4, P150, DOI 10.1016/0168-9525(88)90017-0; HOWELL N, 1993, MAMM GENOME, V4, P271, DOI 10.1007/BF00417434; JEONGYU SJ, 1992, MOL CELL BIOL, V12, P112, DOI 10.1128/MCB.12.1.112; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; JESSBERGER R, 1991, MOL CELL BIOL, V11, P445, DOI 10.1128/MCB.11.1.445; KALINOWSKI DP, 1992, NUCLEIC ACIDS RES, V20, P3485, DOI 10.1093/nar/20.13.3485; KUCHERLAPATI R, 1988, GENETIC RECOMBINATIO; KUCHERLAPATI RS, 1985, MOL CELL BIOL, V5, P714, DOI 10.1128/MCB.5.4.714; LEDOUX SP, 1993, CARCINOGENESIS, V14, P913, DOI 10.1093/carcin/14.5.913; LEDOUX SP, 1992, CARCINOGENESIS, V13, P1967, DOI 10.1093/carcin/13.11.1967; LESTIENNE P, 1988, LANCET, V1, P885; LIM LO, 1987, BIOCHEM PHARMACOL, V36, P2769, DOI 10.1016/0006-2952(87)90263-2; LIN FLM, 1990, MOL CELL BIOL, V10, P103, DOI 10.1128/MCB.10.1.103; LIN FLM, 1990, MOL CELL BIOL, V10, P113, DOI 10.1128/MCB.10.1.113; LING F, 1995, EMBO J, V14, P4090, DOI 10.1002/j.1460-2075.1995.tb00081.x; LOPEZ B, 1987, NUCLEIC ACIDS RES, V15, P5643, DOI 10.1093/nar/15.14.5643; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MIQUEL J, 1992, MUTAT RES, V275, P209, DOI 10.1016/0921-8734(92)90024-J; MUNSCHER C, 1993, BIOL CHEM H-S, V374, P1099, DOI 10.1515/bchm3.1993.374.7-12.1099; NAGLEY P, 1992, ANN NY ACAD SCI, V673, P92, DOI 10.1111/j.1749-6632.1992.tb27440.x; OZAWA T, 1990, BIOCHEM BIOPH RES CO, V172, P483, DOI 10.1016/0006-291X(90)90698-M; PETTEPHER CC, 1991, J BIOL CHEM, V266, P3113; RAUTH S, 1986, P NATL ACAD SCI USA, V83, P5587, DOI 10.1073/pnas.83.15.5587; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; REENAN RAG, 1992, GENETICS, V132, P975; ROSSELLI W, 1990, J MOL BIOL, V216, P335, DOI 10.1016/S0022-2836(05)80325-0; ROTIG A, 1989, LANCET, V1, P902; RUDIN N, 1988, MOL CELL BIOL, V8, P3918, DOI 10.1128/MCB.8.9.3918; Sambrook J., 2002, MOL CLONING LAB MANU; SEIDMAN MM, 1987, MOL CELL BIOL, V7, P3561, DOI 10.1128/MCB.7.10.3561; SELVA EM, 1995, GENETICS, V139, P1175; SERVIDEI S, 1991, NEUROLOGY, V41, P1053, DOI 10.1212/WNL.41.7.1053; SHEN CC, 1995, MUTAT RES-DNA REPAIR, V337, P19, DOI 10.1016/0921-8777(95)00008-8; SINDEN RR, 1978, P NATL ACAD SCI USA, V75, P2373, DOI 10.1073/pnas.75.5.2373; SINDEN RR, 1978, J BACTERIOL, V136, P538, DOI 10.1128/JB.136.2.538-547.1978; SINGH G, 1992, PHARMACOL THERAPEUT, V54, P217, DOI 10.1016/0163-7258(92)90033-V; SMITH L, 1955, METHOD BIOCHEM ANAL, P427; SYMINGTON LS, 1983, CELL, V35, P805, DOI 10.1016/0092-8674(83)90113-7; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Thyagarajan B, 1996, SOMAT CELL MOLEC GEN, V22, P31, DOI 10.1007/BF02374374; TOMKINSON AE, 1988, J BIOL CHEM, V263, P12532; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; WALLACE DC, 1995, BBA-MOL BASIS DIS, V1271, P141, DOI 10.1016/0925-4439(95)00021-U; WALLACE DC, 1987, CURR GENET, V12, P81, DOI 10.1007/BF00434661; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; YUZAKI M, 1989, BIOCHEM BIOPH RES CO, V164, P1352, DOI 10.1016/0006-291X(89)91818-4; ZEVIANI M, 1990, AM J HUM GENET, V47, P904; Zeviani M, 1991, Neuromuscul Disord, V1, P165, DOI 10.1016/0960-8966(91)90020-S; ZUCKERMAN SH, 1984, SOMAT CELL MOLEC GEN, V10, P85, DOI 10.1007/BF01534475	71	220	233	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27536	27543		10.1074/jbc.271.44.27536	http://dx.doi.org/10.1074/jbc.271.44.27536			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910339	hybrid			2022-12-25	WOS:A1996VQ67900057
J	Villemain, JL; Giedroc, DP				Villemain, JL; Giedroc, DP			Characterization of a cooperativity domain mutant Lys(3)->Ala (K3A) T4 gene 32 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; NUCLEIC-ACID INTERACTIONS; DIMENSIONAL HOMOGENEOUS LATTICE; SODIUM-CHLORIDE CONCENTRATION; BINDING-PROTEIN; CRYSTAL-STRUCTURE; REPLICATION FORK; SSDNA COMPLEX; LARGE LIGANDS; V PROTEIN	The N-terminal ''B'' domain of T4 gene 32 protein contains a Lys(3)-Arg(4)-Lys(5) sequence that has been postulated to provide a major determinant for cooperative binding, In this report, the equilibrium binding properties of a Lys(3) --> Ala substitution mutant of gp32 (K3A gp32) and described and compared to a set of substitution mutants of Arg(4) previously described (Villemain, J, L., and Giedroc, D, P, (1993) Biochemistry 32, 11235-11246) and further characterized here. K3A gp32 exhibits binding behavior which mirrors that of R4Q gp32, Despite an 6-8-fold decrease in overall binding affinity (K-app = K-int x omega) at pH 8.1, 0.20 M NaCl, 20 degrees C, the magnitude of the cooperativity parameter is at most 2-3-fold smaller than that of the wild-type protein, The magnitude of omega is independent of salt concentration and type over the range in [NaCl] from 0.125 to 0.225 M and [NaF] between 0.20 and 0.32 M (log omega = 2.86 +/- 0.19), For comparison, log omega for wild-type gp32 is 2.91 (+/- 0.21) resolved at 0.275 M NaCl and 3.39 +/- 0.11 in [NaF] between 0.40 and 0.45 M. In contrast to omega, the [NaCl] dependence of K-app is large and markedly nonlinear for both wild-type and K3A gp32s over a [NaCl] range extending from 0.05 M to 0.40 M NaCl. Modeling of the complete salt dependence of K-app for wild-type, K3A, and R4T gp32s in NaCl and NaF with a simple ion-exchange model suggests that substitutions within the basic Lys(3)-Arg(4)-Lys(5) sequence do not strongly modulate the net displacement of cations and anions upon poly(A) complex formation by gp32.	TEXAS A&M UNIV,INST BIOSCI & TECHNOL,CTR MACROMOL DESIGN,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station			Giedroc, David/A-8608-2018	Giedroc, David/0000-0002-2342-1620	NIGMS NIH HHS [GM42569] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM042569, R01GM042569] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUJALOWSKI W, 1987, BIOCHEMISTRY-US, V26, P3099, DOI 10.1021/bi00385a023; BUJALOWSKI W, 1989, BIOPOLYMERS, V28, P1637, DOI 10.1002/bip.360280912; CARROLL RB, 1975, J MOL BIOL, V91, P275, DOI 10.1016/0022-2836(75)90380-0; CASASFINET JR, 1992, P NATL ACAD SCI USA, V89, P1050, DOI 10.1073/pnas.89.3.1050; FOLMER RHA, 1994, J MOL BIOL, V240, P341, DOI 10.1006/jmbi.1994.1449; FRIED MG, 1993, EUR J BIOCHEM, V218, P469, DOI 10.1111/j.1432-1033.1993.tb18398.x; GIEDROC DP, 1991, BIOCHEMISTRY-US, V30, P8230, DOI 10.1021/bi00247a020; GIEDROC DP, 1986, P NATL ACAD SCI USA, V83, P8452, DOI 10.1073/pnas.83.22.8452; GIEDROC DP, 1990, J BIOL CHEM, V265, P11444; GUAN Y, 1995, PROTEIN SCI, V4, P187; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; HA JH, 1992, J MOL BIOL, V228, P252, DOI 10.1016/0022-2836(92)90504-D; HURLEY JM, 1993, J MOL BIOL, V229, P398, DOI 10.1006/jmbi.1993.1042; JIANG H, 1993, J BIOL CHEM, V268, P7904; JOHNSON ML, 1992, METHOD ENZYMOL, V210, P1; Karpel R.L., 1990, BIOL NONSPECIFIC DNA, P103; KHAN R, 1992, J BIOL CHEM, V267, P6689; KNIGHT KL, 1989, J BIOL CHEM, V264, P13706; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; LOHMAN TM, 1984, BIOCHEMISTRY-US, V23, P4656, DOI 10.1021/bi00315a022; LOHMAN TM, 1988, TRENDS BIOCHEM SCI, V13, P250; LOHMAN TM, 1981, J MOL BIOL, V152, P67, DOI 10.1016/0022-2836(81)90096-6; LOHMAN TM, 1984, BIOCHEMISTRY-US, V23, P4665, DOI 10.1021/bi00315a023; MASCOTTI DP, 1990, P NATL ACAD SCI USA, V87, P3142, DOI 10.1073/pnas.87.8.3142; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; OVERMAN LB, 1994, J MOL BIOL, V236, P165, DOI 10.1006/jmbi.1994.1126; OVERMAN LB, 1988, BIOCHEMISTRY-US, V27, P456, DOI 10.1021/bi00401a067; PRIGODICH RV, 1986, BIOCHEMISTRY-US, V25, P3666, DOI 10.1021/bi00360a029; QIU HW, 1994, J BIOL CHEM, V269, P2773; QIU HW, 1994, BIOCHEMISTRY-US, V33, P8139, DOI 10.1021/bi00192a019; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; SALINAS F, 1995, CELL, V82, P111, DOI 10.1016/0092-8674(95)90057-8; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SPICER EK, 1979, J BIOL CHEM, V254, P6433; STASSEN APM, 1992, EUR J BIOCHEM, V206, P605, DOI 10.1111/j.1432-1033.1992.tb16965.x; TERWILLIGER TC, 1994, J MOL BIOL, V236, P556, DOI 10.1006/jmbi.1994.1165; TUCKER PA, 1994, EMBO J, V13, P2994, DOI 10.1002/j.1460-2075.1994.tb06598.x; VILLEMAIN JL, 1993, BIOCHEMISTRY-US, V32, P11235, DOI 10.1021/bi00092a038; WILLIAMS KR, 1978, J BIOL CHEM, V253, P2463; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	44	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27623	27629		10.1074/jbc.271.44.27623	http://dx.doi.org/10.1074/jbc.271.44.27623			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910351	hybrid			2022-12-25	WOS:A1996VQ67900069
J	Higashi, S; Matsumoto, N; Iwanaga, S				Higashi, S; Matsumoto, N; Iwanaga, S			Molecular mechanism of tissue factor-mediated acceleration of factor VIIa activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FACTOR-VII; CARBOXYGLUTAMIC ACID DOMAIN; EXTRINSIC PATHWAY; CRYSTAL-STRUCTURE; COMPLEX; BINDING; PURIFICATION; IDENTIFICATION; ACTIVATION; ASSOCIATION	The mechanism of the acceleration of the catalytic activity of factor VIIa (VIIa) in the presence of tissue factor (TF) was investigated, To explore the VIIa's site(s) that correlates with TF-mediated acceleration, zymogen VII, VIIa, and active site-modified VIIa were prepared, and dissociation constants (K-d) for their bindings to TF or soluble TF in solution were determined. We found that conversion of zymogen VII to VIIa led to an increase in affinity (Delta Delta G = 4.3-4.4 kJ/mol) for TFs., Dansyl-Glu-Gly-Arg chloromethyl ketone (DNS-EGRck) treatment of VIIa led to a further increase in the affinity (Delta Delta G = 7.3-12 kJ/mol), Neither removal of the Gla domain from VIIa nor truncation of the COOH-terminal membrane and cytoplasmic regions of TF affected the affinity enhanced after DNS-EGRck treatment of VIIa. Treatment of VIIa with (p-amidinophenyl)methanesulfonyl fluoride also enhanced its affinity for soluble TF, whereas treatment with 4-(2-aminoethyl)benzenesulfonyl fluoride, phenylmethylsulfonyl fluoride, or diisopropyl fluorophosphate had a slight effect on the affinity, On the other hand, DNS-EGRck and (p-amidinophenyl)methanesulfonyl fluoride treatments, but not diisopropyl fluorophosphate treatment, of VIIa led to protection of its alpha-amino group of Ile-153 from carbamylation, Protection of the alpha-amino group was consistent with formation of a critical salt bridge between Ile-153 and Asp-343 in the protease domain of VIIa, Therefore, TF may preferentially bind to the active conformational state of VIIa. When one assumes that free VIIa exists in equilibrium between minor active and dominant zymogen-like inactive conformational states, preferential binding of TF to the active state leads to a shift in equilibrium, We speculate that TF traps the active conformational state of VIIa and converts its zymogen-like state into an active state, thereby accelerating the VIIa activity.	KYUSHU UNIV 33,DEPT MOL BIOL,GRAD SCH MED SCI,FUKUOKA 81281,JAPAN; KYUSHU UNIV 33,FAC SCI,DEPT BIOL,FUKUOKA 81281,JAPAN	Kyushu University; Kyushu University								BACH R, 1981, J BIOL CHEM, V256, P8324; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BODE W, 1976, J MOL BIOL, V106, P325, DOI 10.1016/0022-2836(76)90089-9; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; BROZE GJ, 1985, J BIOL CHEM, V260, P917; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; HIGASHI S, 1994, J BIOL CHEM, V269, P18891; HIGASHI S, 1990, J BIOCHEM-TOKYO, V108, P654, DOI 10.1093/oxfordjournals.jbchem.a123258; KAZAMA Y, 1993, J BIOL CHEM, V268, P16231; KUMAR A, 1991, J BIOL CHEM, V266, P915; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; MATSUSHITA T, 1994, J BIOL CHEM, V269, P7355; NEMERSON Y, 1988, BLOOD, V71, P1; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; OBRIEN DP, 1994, BIOCHEMISTRY-US, V33, P14162, DOI 10.1021/bi00251a027; OBRIEN DP, 1991, BLOOD, V78, P132; OPPENHEIMER HL, 1966, J BIOL CHEM, V241, P2720; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; SAKAI T, 1990, J BIOL CHEM, V265, P1890; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Segel I. H., 1975, ENZYME KINETICS, P320; SHIGEMATSU Y, 1992, J BIOL CHEM, V267, P21329; SILVERBERG SA, 1977, J BIOL CHEM, V252, P8481; TAKAYENOKI Y, 1991, BIOCHEM BIOPH RES CO, V181, P1145, DOI 10.1016/0006-291X(91)92058-R; TAKEYA H, 1988, J BIOL CHEM, V263, P14868; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; WAXMAN E, 1993, BIOCHEMISTRY-US, V32, P3005, DOI 10.1021/bi00063a011; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016; WILDGOOSE P, 1990, P NATL ACAD SCI USA, V87, P7290, DOI 10.1073/pnas.87.18.7290	33	86	103	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26569	26574		10.1074/jbc.271.43.26569	http://dx.doi.org/10.1074/jbc.271.43.26569			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900128	hybrid			2022-12-25	WOS:A1996VP23300022
J	Kato, K; Ito, H; Inaguma, Y; Okamoto, K; Saga, S				Kato, K; Ito, H; Inaguma, Y; Okamoto, K; Saga, S			Synthesis and accumulation of alpha B crystallin in C6 glioma cells is induced by agents that promote the disassembly of microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-LENTICULAR TISSUES; HEAT-SHOCK PROTEIN; STRESS PROTEINS; EXPRESSION; HSP27; CYCLE; HYBRIDIZATION; STAUROSPORINE; SUPPRESSION; INVOLVEMENT	When C6 cells in culture were exposed at 37 degrees C to 1 mu M colchicine or to 1 mu M colcemid, a tubulin-binding anti-mitotic alkaloid, levels of alpha B crystallin in cells began to increase after about 10 h, reaching a maximum of more than 1 mu g/mg protein after 24 h, The level of alpha B crystallin returned to near the control level within two subsequent days of culture in the normal medium, Northern blot analysis showed that the accumulation of alpha B crystallin was preceded by an increase in the level of the mRNA for alpha B crystallin, Nuclear run-off transcription assays showed that colchicine induced new synthesis of mRNA for alpha B crystallin, Immunofluorescence staining revealed that alpha B crystallin accumulated in the peripheral areas of cells, as did the depolymerized tubulin, after several hours of treatment with colcemid, and then it gradually became more conspicuous in the cytoplasm, Vinblastine and nocodazole, which also promote the disassembly of microtubules by binding to tubulins, also induced the synthesis of alpha B crystallin. Furthermore, induction of alpha B crystallin by these drugs was observed in quiescent cells that had been cultured in serum-free medium. However, taxol, a microtubule-stabilizing anti-mitotic agent, did not stimulate the synthesis of alpha B crystallin, but rather, it suppressed the induction of synthesis of alpha B crystallin by the microtubule-disrupting drugs. Induction of alpha B crystallin by colchicine or by other drugs that promote the disassembly of microtubules was sensitive to staurosporine, an inhibitor of protein kinases, and the induction was completely suppressed in the presence of 10 nM staurosporine. These results suggest that the expression of alpha B crystallin is stimulated, via phosphorylation reactions that are sensitive to staurosporine, when the depolymerization of microtubules is enhanced.	AICHI HUMAN SERV CTR, INST DEV RES, DEPT MORPHOL, KASUGAI, AICHI 48003, JAPAN		Kato, K (corresponding author), AICHI HUMAN SERV CTR, INST DEV RES, DEPT BIOCHEM, KASUGAI, AICHI 48003, JAPAN.			Ito, Hidenori/0000-0002-6527-477X				AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BANERJEE AC, 1979, FEBS LETT, V99, P333, DOI 10.1016/0014-5793(79)80985-0; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; CROSSIN KL, 1981, CELL, V23, P61, DOI 10.1016/0092-8674(81)90270-1; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; DEBRABANDER M, 1981, P NATL ACAD SCI-BIOL, V78, P5608; DEBRABANDER MJ, 1976, CANCER RES, V36, P905; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; DUGUID JR, 1988, P NATL ACAD SCI USA, V85, P5738, DOI 10.1073/pnas.85.15.5738; HEAD MW, 1994, J CELL PHYSIOL, V159, P41, DOI 10.1002/jcp.1041590107; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; INAGUMA Y, 1992, BIOCHEM BIOPH RES CO, V182, P844, DOI 10.1016/0006-291X(92)91809-5; INAGUMA Y, 1995, J BIOCHEM-TOKYO, V117, P1238, DOI 10.1093/oxfordjournals.jbchem.a124850; INAGUMA Y, 1993, J BIOCHEM-TOKYO, V114, P378, DOI 10.1093/oxfordjournals.jbchem.a124184; ITO H, 1995, J BIOCHEM-TOKYO, V118, P629, DOI 10.1093/oxfordjournals.jbchem.a124956; IWAKI T, 1990, J HISTOCHEM CYTOCHEM, V38, P31, DOI 10.1177/38.1.2294148; IWAKI T, 1992, AM J PATHOL, V140, P345; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JEROME V, 1993, EXP CELL RES, V205, P44, DOI 10.1006/excr.1993.1056; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P201, DOI 10.1016/0304-4165(91)90062-L; KATO K, 1992, J BIOL CHEM, V267, P7718; KIM SH, 1993, BIOCHEM BIOPH RES CO, V193, P759, DOI 10.1006/bbrc.1993.1690; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONGONI S, 1990, MOL CELL BIOCHEM, V97, P113, DOI 10.1007/BF00221052; LOWE J, 1990, LANCET, V336, P515, DOI 10.1016/0140-6736(90)92075-S; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; OLMSTED JB, 1973, ANNU REV BIOCHEM, V42, P507, DOI 10.1146/annurev.bi.42.070173.002451; QUAXJEUKEN Y, 1985, P NATL ACAD SCI USA, V82, P5819, DOI 10.1073/pnas.82.17.5819; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SHINOHARA H, 1993, J NEUROL SCI, V119, P203, DOI 10.1016/0022-510X(93)90135-L; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683	34	60	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26989	26994		10.1074/jbc.271.43.26989	http://dx.doi.org/10.1074/jbc.271.43.26989			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900185	hybrid			2022-12-25	WOS:A1996VP23300079
J	Kita, N; Boyd, CM; Garrett, MR; Jurnak, F; Keen, NT				Kita, N; Boyd, CM; Garrett, MR; Jurnak, F; Keen, NT			Differential effect of site-directed mutations in pelC on pectate lyase activity, plant tissue maceration, and elicitor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERWINIA-CHRYSANTHEMI EC16; GRAM-NEGATIVE BACTERIA; PARALLEL BETA-HELIX; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; ASPERGILLUS-NIGER; VIRULENCE FACTOR; MAJOR ALLERGEN; EXPRESSION; GENES	Oligonucleotide site-directed mutations were introduced into the pelC gene of Erwinia chrysanthemi EC16 that directed single or double amino acid changes affecting disulfide linkages, calcium binding, catalysis, and protein folding, Subsequent characterization of the purified PelC mutant proteins demonstrated that pectinolytic function involves amino acids located near the calcium binding site rather than those surrounding an invariant vWiDH sequence. Wild-type PelC and the tested mutant proteins generally macerated plant tissue in proportion to their specific pectinolytic activity in vitro., However, some mutants gave higher maceration activity in plant tissue and elicited greater production of the phytoalexin, glyceollin, in soybean cotyledons than predicted by their in vitro pectinolytic activity, Most notable in this regard were three different mutations at lysine 172 with greatly reduced pectinolytic activity but as much elicitor activity as the wild-type protein, Pelf macerated plant tissue 10 times more efficiently than PelC, as observed previously, but surprisingly showed equal activity in the elicitor assay. The results indicate that factors other than pectinolytic activity per se are involved in plant tissue maceration and elicitor activity.	UNIV CALIF RIVERSIDE,DEPT PLANT PATHOL,RIVERSIDE,CA 92521; UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521	University of California System; University of California Riverside; University of California System; University of California Riverside								AYERS AR, 1976, PLANT PHYSIOL, V57, P751, DOI 10.1104/pp.57.5.751; BARRAS F, 1994, ANNU REV PHYTOPATHOL, V32, P201, DOI 10.1146/annurev.py.32.090194.001221; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDELIER KA, 1990, MOL GEN GENET, V224, P183, DOI 10.1007/BF00271551; COLLMER A, 1986, ANNU REV PHYTOPATHOL, V24, P383, DOI 10.1146/annurev.py.24.090186.002123; CROWE JS, 1991, NUCLEIC ACIDS RES, V19, P184, DOI 10.1093/nar/19.1.184; DELORENZO G, 1991, PHYSIOL MOL PLANT P, V39, P335, DOI 10.1016/0885-5765(91)90015-A; Emsley P, 1996, NATURE, V381, P90, DOI 10.1038/381090a0; GYSLER C, 1990, GENE, V89, P101, DOI 10.1016/0378-1119(90)90211-9; HEFFRON S, 1995, MOL PLANT MICROBE IN, V8, P331, DOI 10.1094/MPMI-8-0331; HENRISSAT B, 1995, PLANT PHYSIOL, V107, P963, DOI 10.1104/pp.107.3.963; KEEN NT, 1983, PLANT PHYSIOL, V71, P466, DOI 10.1104/pp.71.3.466; KEEN NT, 1986, J BACTERIOL, V168, P595, DOI 10.1128/jb.168.2.595-606.1986; KEEN NT, 1984, J BACTERIOL, V159, P825, DOI 10.1128/JB.159.3.825-831.1984; KOTOUJANSKY A, 1987, ANNU REV PHYTOPATHOL, V25, P405, DOI 10.1146/annurev.py.25.090187.002201; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIETZKE SE, 1994, PLANT PHYSIOL, V106, P849, DOI 10.1104/pp.106.3.849; LINDEBERG M, 1992, J BACTERIOL, V174, P7385, DOI 10.1128/jb.174.22.7385-7397.1992; Maniatis T., 1982, MOL CLONING; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; MUSSELL HW, 1969, ANAL BIOCHEM, V28, P353, DOI 10.1016/0003-2697(69)90190-0; PICKERSGILL R, 1994, NAT STRUCT BIOL, V1, P717, DOI 10.1038/nsb1094-717; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; ROGERS HJ, 1992, PLANT MOL BIOL, V20, P493, DOI 10.1007/BF00040608; SCHOEPFER R, 1993, GENE, V124, P83, DOI 10.1016/0378-1119(93)90764-T; SOMEREN MAK, 1991, CURR GENET, V20, P293, DOI 10.1007/BF00318518; Someren MAK, 1992, MOL GEN GENET, V234, P113; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAMAKI SJ, 1988, J BACTERIOL, V170, P3468, DOI 10.1128/jb.170.8.3468-3478.1988; TANIGUCHI Y, 1995, ALLERGY, V50, P90, DOI 10.1111/j.1398-9995.1995.tb02489.x; Wing R. A., 1989, Plant Molecular Biology, V14, P17, DOI 10.1007/BF00015651; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YODER MD, 1995, PLANT PHYSIOL, V107, P349, DOI 10.1104/pp.107.2.349; YODER MD, 1993, STRUCTURE, V1, P241, DOI 10.1016/0969-2126(93)90013-7; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994; YODER MD, 1995, FASEB J, V9, P35; YUCEL I, 1994, MOL PLANT MICROBE IN, V7, P1440	42	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26529	26535		10.1074/jbc.271.43.26529	http://dx.doi.org/10.1074/jbc.271.43.26529			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900122	hybrid			2022-12-25	WOS:A1996VP23300016
J	Rosenberg, AH; Griffin, M; Washington, MT; Patel, SS; Studier, FW				Rosenberg, AH; Griffin, M; Washington, MT; Patel, SS; Studier, FW			Selection, identification, and genetic analysis of random mutants in the cloned primase/helicase gene of bacteriophage T7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICASE-PRIMASE; RNA-POLYMERASE; DNA; PROTEINS; RECOMBINATION; EXPRESSION; FRAGMENTS; SEQUENCE; REGION	T7 gene 4 specifies two overlapping proteins 4A, a 566-amino acid primase/helicase, and 4B, a 503-amino acid helicase whose initiation codon is the 64th codon of the 4A protein, The 4A' gene, which has a leucine codon replacing the 4B initiation codon, specifies a single 566-amino acid protein that can provide the primase and helicase functions required for normal T7 growth, We selected N-methyl-N'-nitro-N-nitrosoguanidine mutants in the cloned 4A' gene that no longer support the growth of a phage that completely lacks gene 4, Genetic mapping of the 76 mutations found them to be distributed throughout the protein, including both the N-terminal and C-terminal halves of the molecule thought to represent primase and helicase domains, respectively, Complementation tests with partially and completely defective phage showed that all but five of the mutants lacked helicase function but retained primase function, The other five, which lacked both functions, all made short proteins, including one missing only 60 amino acids. No mutations lacked only primase function, and none mapped within the first 105 amino acids, which includes the 63-amino acid region unique to 4A that contains elements required to recognize primase sites, Forty-six mutations were sequenced and included 27 missense mutations affecting 25 amino acids, Many mutations in the N-terminal half of the protein affected its solubility in cell extracts. Mutations in the C-terminal half clustered in or near five helicase consensus sequences, Biochemical analysis of nine of the mutant proteins is described in the accompanying paper (Washington, M. T., Rosenberg, A. H., Griffin, K., Studier, F. W., and Patel, S. S. (1996) J. Biol. Chem. 271, 26825-26834).	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210	Ohio State University	Rosenberg, AH (corresponding author), BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973, USA.			Washington, Todd/0000-0001-8680-2992				BECK PJ, 1989, J MOL BIOL, V210, P687, DOI 10.1016/0022-2836(89)90102-2; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; CAMPBELL JL, 1978, P NATL ACAD SCI USA, V75, P2276, DOI 10.1073/pnas.75.5.2276; COULONDRE C, 1977, J MOL BIOL, V117, P577, DOI 10.1016/0022-2836(77)90059-6; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; KERR C, 1975, VIROLOGY, V65, P281, DOI 10.1016/0042-6822(75)90031-8; MENDELMAN LV, 1994, EMBO J, V13, P3909, DOI 10.1002/j.1460-2075.1994.tb06702.x; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; NOTARNICOLA SM, 1995, J BIOL CHEM, V270, P20215, DOI 10.1074/jbc.270.34.20215; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; POWLING A, 1974, MOL GEN GENET, V134, P173, DOI 10.1007/BF00268418; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; STUDIER FW, 1975, J MOL BIOL, V94, P283, DOI 10.1016/0022-2836(75)90083-2; STUDIER FW, 1972, SCIENCE, V176, P367, DOI 10.1126/science.176.4033.367; STUDIER FW, 1981, J MOL BIOL, V153, P503, DOI 10.1016/0022-2836(81)90405-8; STUDIER FW, 1973, J MOL BIOL, V79, P237, DOI 10.1016/0022-2836(73)90003-X; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STUDIER FW, 1969, VIROLOGY, V39, P562, DOI 10.1016/0042-6822(69)90104-4; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825; ZHANG X, 1995, J MOL BIOL, V250, P156, DOI 10.1006/jmbi.1995.0367	26	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26819	26824		10.1074/jbc.271.43.26819	http://dx.doi.org/10.1074/jbc.271.43.26819			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900163	hybrid			2022-12-25	WOS:A1996VP23300057
J	Sato, R; Inoue, J; Kawabe, Y; Kodama, T; Takano, T; Maeda, M				Sato, R; Inoue, J; Kawabe, Y; Kodama, T; Takano, T; Maeda, M			Sterol-dependent transcriptional regulation of sterol regulatory element-binding protein-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; LEUCINE ZIPPER PROTEIN; CULTURED HUMAN-CELLS; NF-Y; GENE; PROMOTER; SEQUENCE; SREBP-1; ACID; ACTIVATION	We show in this manuscript that expression of the mRNA for sterol regulatory element-binding protein-a (SREBP-2) is regulated by the cellular sterol level in cultured HeLa cells. We have cloned the 5'-flanking region of the gene encoding human SREBP-2. Characterization of this region shows the minimum 50-base pair segment, which contains a 10-base pair sterol regulatory element 1 (SRE-1) identical to the one in the human LDL receptor promoter, confers sterol responsiveness when fused to the luciferase reporter gene. Enforced expression of the truncated SREBP-2 protein (amino acid residues 1-481) also shows that this upstream segment contains the information required for transcriptional activation. The luciferase assays using mutant versions of the reporter genes reveal that the sterol dependent transcriptional regulation is mediated by two nearby motifs, the SRE-1 and the NF-Y binding site (the inverted CCAAT box, ATTGGC); the latter is reported to play a critical role in sterol dependent regulation of 3-hydroxy-3-methylglutaryl-coenzyme A synthase and farnesyl diphosphate synthase genes (Jackson, S. M., Ericsson, J., Osborne, T. F., and Edwards, P. A. (1995) J. Biol. Chem. 270, 21445-21448), Gel mobility shift assays demonstrate that the transcription factor NF-Y truly binds to the ATTGGC sequence, These findings suggest that the activity of SREBP-2 is controlled not only post-translationally by proteolytic activation of the precursor protein but also transcriptionally by itself together with NF-Y.	UNIV TOKYO,DEPT MOL BIOL & MED,ADV SCI & TECHNOL RES CTR,TOKYO 153,JAPAN; TEIKYO UNIV,FAC PHARMACEUT SCI,DEPT MICROBIOL & MOL PATHOL,SAGAMIKO,KANAGAWA 19901,JAPAN	University of Tokyo; Teikyo University	Sato, R (corresponding author), OSAKA UNIV,FAC PHARMACEUT SCI,BIOCHEM LAB,1-6 YAMADA OKA,SUITA,OSAKA 565,JAPAN.		INOUE, Jun/O-7352-2016	INOUE, Jun/0000-0003-4145-3754; Kawabe, Yoshiki/0000-0002-6465-7146				BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; KAWABE Y, 1995, BIOCHEM BIOPH RES CO, V208, P405, DOI 10.1006/bbrc.1995.1352; KAWABE Y, 1994, BIOCHEM BIOPH RES CO, V202, P1460, DOI 10.1006/bbrc.1994.2095; Kawabe Y, 1996, BIOCHEM BIOPH RES CO, V219, P515, DOI 10.1006/bbrc.1996.0265; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO R, 1994, J BIOL CHEM, V269, P17267; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; TAMURA S, 1992, FEBS LETT, V298, P137, DOI 10.1016/0014-5793(92)80040-N; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	23	223	228	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26461	26464		10.1074/jbc.271.43.26461	http://dx.doi.org/10.1074/jbc.271.43.26461			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900111	hybrid			2022-12-25	WOS:A1996VP23300005
J	Jenkins, TD; Nakagawa, H; Rustgi, AK				Jenkins, TD; Nakagawa, H; Rustgi, AK			The association of Epstein-Barr virus DNA with esophageal squamous cell carcinoma	ONCOGENE			English	Article						Epstein-Barr virus; esophageal cancer; genomic sequence	LYMPHOEPITHELIOMA-LIKE CARCINOMA; NASOPHARYNGEAL CARCINOMA; GASTRIC ADENOCARCINOMA; HUMAN PAPILLOMAVIRUS; RAS MUTATIONS; CYCLIN D1; EXPRESSION; GENE; CANCER; AMPLIFICATION	The Epstein-Barr virus (EBV), a member of the herpesviruses, is a double stranded 170 kilobase DNA virus important in many human benign and malignant conditions. It has been implicated in the pathogenesis of proliferative diseases of lymphocytes and tumors of epithelial derivation. The etiology and pathogenesis of esophageal squamous cell carcinoma (ESCC) is thought to involve a combination of genetic and environmental events which lead to epithelial cell transformation. The aim of this study was to determine whether an association exists between EBV and ESCC. DNA was extracted from 16 human ESCC cell lines and microdissected tumor specimens from 60 patients. The polymerase chain reaction was used to amplify a 400 base pair fragment corresponding to the BamHIW fragment repeat sequence of EBV. Southern blotting, utilizing an oligonucleotide probe specific for the BamH1W sequence, was used to confirm positive results and increase sensitivity of detection. 5/60 tumor samples and 1/16 ESCC cell Lines were positive for the EBV sequence. Positive tumor samples were estimated to contain one copy of EBV per 20 cellular genomes. Given the role of EBV in other tumors of epithelial derivation, it is possible that EBV may contribute to the molecular pathogenesis of ESCC.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,GASTROINTESTINAL UNIT,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HEMATOL ONCOL UNIT,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital					NIDDK NIH HHS [DK40561, T2DK07191D21] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007191, P30DK040561] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRICHACEK B, 1984, JNCI-J NATL CANCER I, V72, P809; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; BUTLER AE, 1989, AM J SURG PATHOL, V13, P632, DOI 10.1097/00000478-198908000-00002; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHANG FJ, 1992, GASTROENTEROLOGY, V103, P1336, DOI 10.1016/0016-5085(92)91526-A; CHOI PHK, 1993, CANCER-AM CANCER SOC, V72, P2873, DOI 10.1002/1097-0142(19931115)72:10<2873::AID-CNCR2820721003>3.0.CO;2-A; COHEN JI, 1993, ANN INTERN MED, V118, P45; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; HAFIZ MA, 1985, OBSTET GYNECOL, V66, P829; HARN HJ, 1995, HUM PATHOL, V26, P267, DOI 10.1016/0046-8177(95)90056-X; HERBST H, 1991, P NATL ACAD SCI USA, V88, P4766, DOI 10.1073/pnas.88.11.4766; HITT MM, 1989, EMBO J, V8, P2639, DOI 10.1002/j.1460-2075.1989.tb08404.x; HOLLSTEIN MC, 1991, CANCER RES, V51, P4102; HOLLSTEIN MC, 1988, CANCER RES, V48, P5119; HUI PK, 1994, HUM PATHOL, V25, P947, DOI 10.1016/0046-8177(94)90017-5; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1992, CANCER RES, V52, P2980; KIEFF E, 1995, NEW ENGL J MED, V333, P724, DOI 10.1056/NEJM199509143331110; KIEFF E, 1990, VIROLOGY, P1889; KITCHEN VS, 1990, GUT, V31, P1223, DOI 10.1136/gut.31.11.1223; LABRECQUE LG, 1995, CANCER RES, V55, P39; LEWENSOHNFUCHS I, 1994, ANTICANCER RES, V14, P1281; LIU QY, 1995, ONCOGENE, V10, P619; MCGUIRE LJ, 1988, AM J PATHOL, V131, P385; MIN KW, 1991, AM J CLIN PATHOL, V96, P219, DOI 10.1093/ajcp/96.2.219; MORI M, 1994, ARCH PATHOL LAB MED, V118, P998; NAKAGAWA H, 1995, CANCER-AM CANCER SOC, V76, P541, DOI 10.1002/1097-0142(19950815)76:4<541::AID-CNCR2820760402>3.0.CO;2-I; Oikawa Ou, 1995, Hokkaido Journal of Medical Science, V70, P729; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; PATHMANATHAN R, 1995, AM J PATHOL, V146, P1355; ROWLANDS DC, 1993, BRIT J CANCER, V68, P1014, DOI 10.1038/bjc.1993.472; SHIBATA D, 1992, AM J PATHOL, V140, P769; SHIBATA D, 1991, AM J PATHOL, V139, P469; SWANSON SA, 1988, MODERN PATHOL, V1, P359; TOGAWA K, 1994, GASTROENTEROLOGY, V107, P128, DOI 10.1016/0016-5085(94)90070-1; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; Wong Fen-Hwa, 1992, Chinese Journal of Microbiology and Immunology (Taipei), V25, P59; YOUNG LS, 1992, CANCER SURV, V7, P507	38	28	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1809	1813						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895528				2022-12-25	WOS:A1996VM88700027
J	Damaj, BB; McColl, SR; Neote, K; Na, SQ; Ogborn, KT; Hebert, CA; Naccache, PH				Damaj, BB; McColl, SR; Neote, K; Na, SQ; Ogborn, KT; Hebert, CA; Naccache, PH			Identification of G-protein binding sites of the human interleukin-8 receptors by functional mapping of the intracellular loops	FASEB JOURNAL			English	Article						neutrophils; calcium mobilization; signal transduction; Gro-; NAP-2; C-X-C chemokines	FORMYL PEPTIDE RECEPTOR; SIGNAL-TRANSDUCTION; HUMAN-NEUTROPHILS; IL-8 RECEPTOR; A RECEPTOR; CHEMOTAXIS; MUTATION; AFFINITY; DOMAINS; CELLS	Interleukin 8 (IL-8) is considered to be a major mediator of the inflammatory response. Recent evidence indicates that a direct physical association occurs between IL-8 receptors and the alpha subunit of guanine nucleotide regulatory protein (G(i) alpha(2)) upon stimulation of human neutrophils by IL-8. In the present study, we identified by site-directed mutagenesis key residues within the three intracellular loops of the IL-8RA receptor involved in the interaction with G(i) alpha(2). We first systematically mutated, in groups of two to four, all the residues in the three intracellular loops of the IL-8 type A receptor to alanine and analyzed the mutant receptors transiently expressed in 293 cells. Four residues in the second intracellular loop (Y136, L137, I139, V140) and one residue in the third intracellular loop (M241) were shown to be crucial for mediating calcium signaling in response to IL-8. Other residues in the second and third intracellular loops were also found to affect IL-8RA-mediated signaling, but to a lesser extent. These effects were not due to lower expression or low IL-8 binding affinities to the mutated receptors. Mutagenesis of the residues in the first intracellular loop had only weak effects on the mobilization of calcium induced by IL-8. We then used a coimmunoprecipitation protocol with anti-G(i) alpha(2) antibodies to determine the involvement of the two regions defined above in G(i) alpha(2) coupling to IL-8 type A receptors. Whereas the anti-G(i) alpha(2) antibodies coimmunoprecipitated IL-8 receptors in the wild-type cells, this interaction was lost in cells expressing mutated receptors that affected intracellular calcium mobilization. The peptides corresponding to the regions of the type A receptor found to be critical for G(i) alpha(2) coupling and induction of intracellular calcium mobilization were next introduced into cells expressing wild-type IL-8RA or IL-8RB to assess their role in coupling G(i) alpha(2) to both IL-8 receptors. The results obtained in the latter experiments suggest that the same regions of the second intracellular loop (Y136, L137, I139, V140) and of the third intracellular loop (M241) are critically involved in the coupling of both IL-8RA and IL-8 RB to G(i) alpha(2) as well as to a downstream effector (or effecters) involved in calcium mobilization.	CHUL,CTR RECH RHUMATOL & IMMUNOL,ST FOY,PQ G1V 4G2,CANADA; UNIV LAVAL,FAC MED,DEPT MED,ST FOY,PQ G1K 7P4,CANADA; UNIV ADELAIDE,DEPT MICROBIOL & IMMUNOL,N TERR,SA,AUSTRALIA; GENENTECH INC,DEPT IMMUNOL,S SAN FRANCISCO,CA 94080; PFIZER INC,CENT RES,GROTON,CT 06340	Laval University; Laval University; University of Adelaide; Roche Holding; Genentech; Pfizer								BACON KB, 1995, J IMMUNOL, V154, P3654; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BARNETT ML, 1993, BIOCHIM BIOPHYS ACTA, V1177, P275, DOI 10.1016/0167-4889(93)90123-7; BENBARUCH A, 1995, J BIOL CHEM, V270, P9121, DOI 10.1074/jbc.270.16.9121; BIGNOLD LP, 1992, INT ARCH ALLERGY IMM, V97, P350, DOI 10.1159/000236144; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BOMMAKANTI RK, 1995, BIOCHEMISTRY-US, V34, P6720, DOI 10.1021/bi00020a017; CHUNTHARAPAI A, 1994, J IMMUNOL, V152, P1783; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; DAHINDEN CA, 1989, J EXP MED, V170, P1787, DOI 10.1084/jem.170.5.1787; DAMAJ BB, 1996, IN PRESS J BIOL CHEM; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; FAUCHER N, 1987, J CELL PHYSIOL, V132, P483, DOI 10.1002/jcp.1041320310; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HEBERT CA, 1993, CANCER INVEST, V11, P743, DOI 10.3109/07357909309046949; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; LEE J, 1992, J BIOL CHEM, V267, P16283; LEE J, 1992, J IMMUNOL, V148, P1261; LEONG SR, 1994, J BIOL CHEM, V269, P19343; LHEUREUX G, 1994, BLOOD, V85, P522; LOETSCHER P, 1994, FEBS LETT, V341, P187, DOI 10.1016/0014-5793(94)80454-0; Magazin M, 1992, Eur Cytokine Netw, V3, P461; MCCOLL SR, 1993, J IMMUNOL, V150, P4550; MICHEL G, 1992, FEBS LETT, V305, P241, DOI 10.1016/0014-5793(92)80677-9; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MORO O, 1993, J BIOL CHEM, V268, P22273; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEVE KA, 1991, MOL PHARMACOL, V39, P733; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; PETERSEN F, 1994, J IMMUNOL, V152, P2467; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P10686, DOI 10.1074/jbc.270.18.10686; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; ROLLET E, 1994, J IMMUNOL, V153, P353; SANDER B, 1991, IMMUNOL REV, V119, P65, DOI 10.1111/j.1600-065X.1991.tb00578.x; SCHREIBER RE, 1993, J LEUKOCYTE BIOL, V53, P470, DOI 10.1002/jlb.53.4.470; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; SEBOK K, 1993, J IMMUNOL, V150, P1524; TSIEN RY, 1982, J CELL BIOL, V94, P3325; VALIQUETTE M, 1993, BIOCHEMISTRY-US, V32, P4979, DOI 10.1021/bi00070a002; Watson S., 1994, G PROTEIN LINKED REC; WESTWICK J, 1989, IMMUNOL TODAY, V10, P146, DOI 10.1016/0167-5699(89)90164-3; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; XU LL, 1995, J LEUKOCYTE BIOL, V57, P335, DOI 10.1002/jlb.57.2.335	47	58	66	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1996	10	12					1426	1434		10.1096/fasebj.10.12.8903513	http://dx.doi.org/10.1096/fasebj.10.12.8903513			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VP485	8903513				2022-12-25	WOS:A1996VP48500008
J	Michalak, M; Burns, K; Andrin, C; Mesaeli, N; Jass, GH; Busaan, JL; Opas, M				Michalak, M; Burns, K; Andrin, C; Mesaeli, N; Jass, GH; Busaan, JL; Opas, M			Endoplasmic reticulum form of calreticulin modulates glucocorticoid-sensitive gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; MUSCLE SARCOPLASMIC-RETICULUM; CELL-SURFACE CALRETICULIN; AMINO-ACID-SEQUENCE; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATION; TRANSMEMBRANE PROTEIN; SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; CA2+ BINDING	Calreticulin is a ubiquitously expressed Ca2+-binding protein of the endoplasmic reticulum (ER), which inhibits DNA binding in vitro and transcriptional activation in vivo by steroid hormone receptors. Transient transfection assays were carried out to investigate the effects of different intracellular targeting of calreticulin on transactivation mediated by glucocorticoid receptor. BSC40 cells were transfected with either calreticulin expression vector (ER form of calreticulin) or calreticulin expression vector encoding calreticulin minus leader peptide, resulting in cytoplasmic localization of the recombinant protein. Transfection of BSC40 cells with calreticulin expression vector encoding the ER form of the protein led to 40-50% inhibition of the dexamethasone-sensitive stimulation of luciferase expression. However, in a similar experiment, but using the calreticulin expression vector encoding cytoplasmic calreticulin, dexamethasone-stimulated activation of the luciferase reporter gene was inhibited by only 10%. We conclude that the ER, but not cytosolic, form of calreticulin is responsible for inhibition of glucocorticoid receptor-mediated gene expression. These effects are specific to calreticulin, since overexpression of the ER lumenal proteins (BiP, ERp72, or calsequestrin) has no effect on glucocorticoid-sensitive gene expression. The N domain of calreticulin binds to the DNA binding domain of the glucocorticoid receptor in vitro; however, we show that the N+P domain of calreticulin, when synthesized without the ER signal sequence, does not inhibit glucocorticoid receptor function in vivo. Furthermore, expression of the N domain of calreticulin and the DNA binding domain of glucocorticoid receptor as fusion proteins with GAL4 in the yeast two-hybrid system revealed that calreticulin does not interact with glucocorticoid receptor under these conditions. We conclude that calreticulin and glucocorticoid receptor may not interact in vivo and that the calreticulin-dependent modulation of the glucocorticoid receptor function may therefore be due to a calreticulin-dependent signaling from the ER.	UNIV TORONTO,DEPT ANAT & CELL BIOL,TORONTO,ON M5S 1A8,CANADA	University of Toronto	Michalak, M (corresponding author), UNIV ALBERTA,DEPT BIOCHEM,MED RES COUNCIL GRP MOL BIOL MEMBRANES,EDMONTON,AB T6G 2S2,CANADA.			Mesaeli, Nasrin/0000-0003-1456-4643				Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAKSH S, 1991, J BIOL CHEM, V266, P21458; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BENNETT DL, 1995, CURR BIOL, V5, P1225, DOI 10.1016/S0960-9822(95)00243-0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; Burns Kimberly, 1994, Trends in Cell Biology, V4, P152, DOI 10.1016/0962-8924(94)90190-2; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; CAO XJ, 1995, J BIOL CHEM, V270, P494, DOI 10.1074/jbc.270.1.494; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DEDHAR S, 1994, TRENDS BIOCHEM SCI, V19, P269, DOI 10.1016/0968-0004(94)90001-9; Desai D, 1996, J BIOL CHEM, V271, P15153, DOI 10.1074/jbc.271.25.15153; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; GRAY AJ, 1995, J BIOL CHEM, V270, P26602, DOI 10.1074/jbc.270.44.26602; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; HARLOW E, 1988, ANTIBODIES; HOPPS HE, 1963, J IMMUNOL, V91, P416; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; JOHNSON E, 1992, J BIOL CHEM, V267, P14412; KENNEDY TE, 1992, NEURON, V9, P1013, DOI 10.1016/0896-6273(92)90062-I; KUWABARA K, 1995, J BIOL CHEM, V270, P8179, DOI 10.1074/jbc.270.14.8179; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; Lin F, 1996, HEPATOLOGY, V23, P57, DOI 10.1002/hep.510230109; LIU NG, 1994, J BIOL CHEM, V269, P28635; Macaulay C, 1996, J CELL BIOL, V132, P5, DOI 10.1083/jcb.132.1.5; MCMILLAN A, 1994, CURR OPIN BIOTECH, V6, P540; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; MICHALAK M, 1996, CALRETICULIN; MILNER RE, 1992, BIOCHEM J, V288, P1037, DOI 10.1042/bj2881037; MILNER RE, 1991, J BIOL CHEM, V266, P7155; MORI K, 1993, CELL, V74, P743; NAKAMURA M, 1993, EXP CELL RES, V205, P101, DOI 10.1006/excr.1993.1063; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; Otteken A, 1996, J BIOL CHEM, V271, P97, DOI 10.1074/jbc.271.1.97; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; Pahl HL, 1996, J CELL BIOL, V132, P511, DOI 10.1083/jcb.132.4.511; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; SATO R, 1994, J BIOL CHEM, V269, P17267; SCOTT BT, 1988, J BIOL CHEM, V263, P8958; SINGH NK, 1994, P NATL ACAD SCI USA, V91, P12770, DOI 10.1073/pnas.91.26.12770; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; Sontheimer RD, 1993, IMMUNOLOGIST, V1, P155; STARNAUD R, 1995, J CELL BIOL, V131, P1351, DOI 10.1083/jcb.131.5.1351; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; STENDAHL O, 1994, SCIENCE, V265, P1439, DOI 10.1126/science.8073285; TARTAKOFF AM, 1983, J CELL BIOL, V97, P1243, DOI 10.1083/jcb.97.4.1243; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIRTANEN I, 1980, J CELL BIOL, V85, P429, DOI 10.1083/jcb.85.2.429; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WHEELER DG, 1995, NUCLEIC ACIDS RES, V23, P3268, DOI 10.1093/nar/23.16.3268; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926; WINROW CJ, 1995, MOL CELL ENDOCRINOL, V111, P175, DOI 10.1016/0303-7207(95)03563-M; YE Q, 1994, J BIOL CHEM, V269, P11306	64	80	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29436	29445		10.1074/jbc.271.46.29436	http://dx.doi.org/10.1074/jbc.271.46.29436			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910610	hybrid			2022-12-25	WOS:A1996VT05200102
J	Furukawa, Y; Iwase, S; Terui, Y; Kikuchi, J; Sakai, T; Nakamura, M; Kitagawa, S; Kitagawa, M				Furukawa, Y; Iwase, S; Terui, Y; Kikuchi, J; Sakai, T; Nakamura, M; Kitagawa, S; Kitagawa, M			Transcriptional activation of the cdc2 gene is associated with Fas-induced apoptosis of human hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; INHIBITS PHOSPHORYLATION; PROTEIN-KINASES; BUTYROLACTONE-I; LEUKEMIC-CELLS; CYCLE ARREST; ANTI-FAS; C-MYC; EXPRESSION; DEATH	Apoptosis has recently been hypothesized to be the result of aberrant cell cycle control. In this study, we have investigated the role of cell cycle regulatory elements in Fas-induced apoptosis of hematopoietic cells. When HL-60 cells were treated with anti-Fas antibody, rapid activation of growth-associated histone H1 kinase was observed without any change in cell cycle distribution, This was accompanied by the increase in cdc2 mRNA expression and Cdc2 kinase activity. Up-regulation of cdcs mRNA was similarly induced in BCL-2-over-expressing HL-60 subline by anti-Fas treatment independently of the appearance of apoptotic phenotypes. Fas-induced apoptosis was completely inhibited by butyrolactone I, a specific inhibitor of Cdc2 kinase. Moreover, the same phenomenon was observed during Fas-induced but not spontaneous apoptosis of postmitotic granulocytes. Finally, we have found that ''Fas-responsive element'' was located between nucleotides -730 and -552 of the cdc2 promoter and was responsive for transcriptional activation of the cdc2 gene during Fas-induced apoptosis. These results indicate that aberrant activation of Cdc2 is associated with Fas-induced apoptosis of hematopoietic cells, and that the mechanism of cdc2 transcription during Fas-induced apoptosis is different from that in normal cell cycle control.	JICHI MED SCH,DEPT HEMATOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; HITACHI KOKI CO LTD,KATSUTA RES LAB,KATSUTA,IBARAKI 312,JAPAN; BANYU PHARMACEUT CO LTD,TSUKUBA RES INST,TSUKUBA,IBARAKI 30033,JAPAN	Jichi Medical University; Hitachi Limited; Merck & Company; Novartis	Furukawa, Y (corresponding author), JICHI MED SCH,INST HEMATOL,DIV HEMOPOIESIS,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.		Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BELIZARIO JE, 1991, CANCER RES, V51, P2379; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BRADBURY EM, 1974, NATURE, V247, P257, DOI 10.1038/247257a0; COLOMBEL M, 1992, CANCER RES, V52, P4313; COX G, 1995, J IMMUNOL, V154, P4719; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; FURUKAWA Y, 1992, J BIOL CHEM, V267, P17121; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; FURUKAWA Y, 1995, BRIT J HAEMATOL, V90, P94, DOI 10.1111/j.1365-2141.1995.tb03385.x; FURUKAWA Y, 1995, JPN J CANCER RES, V86, P208, DOI 10.1111/j.1349-7006.1995.tb03041.x; FURUKAWA Y, 1994, J BIOL CHEM, V269, P26249; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; ISHIDA Y, 1992, J CELL PHYSIOL, V150, P484, DOI 10.1002/jcp.1041500308; IWAI K, 1994, BLOOD, V84, P1201; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KITAGAWA M, 1994, ONCOGENE, V9, P2549; KITAGAWA M, 1993, ONCOGENE, V8, P2425; KORSMEYER SJ, 1992, BLOOD, V80, P879; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LANG RA, 1987, CELL, V51, P675, DOI 10.1016/0092-8674(87)90136-X; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; MCGOWAN CH, 1990, MOL CELL BIOL, V10, P3847, DOI 10.1128/MCB.10.7.3847; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RAZA A, 1995, BLOOD, V86, P268, DOI 10.1182/blood.V86.1.268.bloodjournal861268; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHIMIZU M, 1995, MOL CELL BIOL, V15, P2882; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TERUI Y, 1995, J BIOCHEM-TOKYO, V117, P77, DOI 10.1093/oxfordjournals.jbchem.a124725; TERUI Y, 1995, J CELL PHYSIOL, V164, P74, DOI 10.1002/jcp.1041640110; Terui Y, 1996, J IMMUNOL, V156, P1981; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; YAMADA H, 1991, BLOOD, V78, P1988; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	59	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28469	28477		10.1074/jbc.271.45.28469	http://dx.doi.org/10.1074/jbc.271.45.28469			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910474	hybrid			2022-12-25	WOS:A1996VU03300074
J	Geier, BM; Wiech, H; Schiebel, E				Geier, BM; Wiech, H; Schiebel, E			Binding of centrins and yeast calmodulin to synthetic peptides corresponding to binding sites in the spindle pole body components Kar1p and Spc110p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; HIGH-LEVEL EXPRESSION; EF-HAND PROTEIN; SACCHAROMYCES-CEREVISIAE; GAMMA-TUBULIN; CHLAMYDOMONAS-REINHARDTII; MUTATIONAL ANALYSIS; MOLECULAR-CLONING; HALF-BRIDGE; CELL-CYCLE	Centrins contain four potential Ca2+ binding sites, known as EF-hands, and have essential functions in centrosome duplication and filament contraction. Here we report that centrins hom yeast, green algae, and humans bound with high affinity to a peptide of the yeast centrosomal component Kar1p, Interestingly, centrin binding was regulated by physiological relevant changes in [Ca2+], and this Ca2+ dependence was influenced by acidic amino acids within the Kar1p peptide, which also prevented efficient binding of the related yeast calmodulin, However, a hybrid protein with the third and fourth EF-hands from the yeast centrin Cdc31p and the amino-terminal half from yeast calmodulin behaved more Like Cdc31p, indicating that the carboxyl-terminal half of Cdc31p influences binding specificity, Besides Kar1p, centrins bound to a yeast calmodulin binding site, explaining the dosage-dependent suppression of a calmodulin mutant by CDC31. Consistent with an essential role of Ca2+ for centrin functions, mutations in the first or the fourth EF-hands of Cdc31p, impairing the Ca2+-induced conformational change of Cdc31p, resulted in nonfunctional proteins in vice, Our results suggest that centrins are involved in Ca2+ signaling likely by influencing the properties of target proteins in response to changes in [Ca2+].	MAX PLANCK INST BIOCHEM, GENZENTRUM, D-82152 MARTINSRIED, GERMANY	Max Planck Society								ANAND S, 1987, BIOCHEM INT, V14, P963; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; Baron Andre T., 1992, P167; BAUM P, 1986, P NATL ACAD SCI USA, V83, P5512, DOI 10.1073/pnas.83.15.5512; BHATTACHARYA D, 1993, PLANT MOL BIOL, V23, P1243, DOI 10.1007/BF00042357; BIGGINS S, 1994, J CELL BIOL, V125, P843, DOI 10.1083/jcb.125.4.843; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYERS B, 1981, CYTOLOGY YEAST LIFE; BYERS B, 1981, A BENZON S, V16, P119; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; COHEN P, 1988, CALMODULIN MOL ASPEC, P91; DAVIS TN, 1992, CELL CALCIUM, V13, P435, DOI 10.1016/0143-4160(92)90056-X; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; ERRABOLU R, 1994, J CELL SCI, V107, P9; FINDLAY WA, 1995, BIOCHEMISTRY-US, V34, P2087, DOI 10.1021/bi00007a001; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; GEISER JR, 1993, MOL CELL BIOL, V13, P7913, DOI 10.1128/MCB.13.12.7913; Geissler S, 1996, EMBO J, V15, P3899, DOI 10.1002/j.1460-2075.1996.tb00764.x; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P12; HAIECH J, 1991, J BIOL CHEM, V266, P3427; HORIO T, 1991, J CELL SCI, V99, P693; HUANG B, 1988, J CELL BIOL, V107, P121, DOI 10.1083/jcb.107.1.121; IIDA H, 1990, J BIOL CHEM, V265, P13391; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KILMARTIN JV, 1993, J CELL BIOL, V123, P1175, DOI 10.1083/jcb.123.5.1175; Kretsinger RH, 1996, NAT STRUCT BIOL, V3, P12, DOI 10.1038/nsb0196-12; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE VD, 1993, P NATL ACAD SCI USA, V90, P11039, DOI 10.1073/pnas.90.23.11039; Levy YY, 1996, CELL MOTIL CYTOSKEL, V33, P298; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; NAKAYAMA S, 1992, J MOL EVOL, V34, P416, DOI 10.1007/BF00162998; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; OHYA Y, 1987, EUR J BIOCHEM, V168, P13, DOI 10.1111/j.1432-1033.1987.tb13380.x; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; ONEIL KT, 1987, SCIENCE, V236, P1454, DOI 10.1126/science.3589665; PAINTRAND M, 1992, J STRUCT BIOL, V108, P107, DOI 10.1016/1047-8477(92)90011-X; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; ROUT MP, 1990, J CELL BIOL, V111, P1913, DOI 10.1083/jcb.111.5.1913; SALISBURY JL, 1984, J CELL BIOL, V99, P962, DOI 10.1083/jcb.99.3.962; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDERS MA, 1994, J CELL BIOL, V124, P795, DOI 10.1083/jcb.124.5.795; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHIEBEL E, 1995, TRENDS CELL BIOL, V5, P197, DOI 10.1016/S0962-8924(00)88999-0; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Spang A, 1996, J CELL SCI, V109, P2229; SPANG A, 1993, J CELL BIOL, V123, P405, DOI 10.1083/jcb.123.2.405; SPANG A, 1995, J CELL BIOL, V128, P863, DOI 10.1083/jcb.128.5.863; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; STIRLING DA, 1994, EMBO J, V13, P4329, DOI 10.1002/j.1460-2075.1994.tb06753.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Sundberg HA, 1996, J CELL BIOL, V133, P111, DOI 10.1083/jcb.133.1.111; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAILLON BE, 1992, J CELL BIOL, V119, P1613, DOI 10.1083/jcb.119.6.1613; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSIEN RY, 1989, METHOD CELL BIOL, V30, P127; VALLEN EA, 1994, GENETICS, V137, P407; WEBER C, 1994, J BIOL CHEM, V269, P15795; Wiech H, 1996, J BIOL CHEM, V271, P22453, DOI 10.1074/jbc.271.37.22453; WRIGHT RL, 1985, J CELL BIOL, V101, P1903, DOI 10.1083/jcb.101.5.1903; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G; ZHU JK, 1992, PLANT PHYSIOL, V99, P1734, DOI 10.1104/pp.99.4.1734	65	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28366	28374		10.1074/jbc.271.45.28366	http://dx.doi.org/10.1074/jbc.271.45.28366			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910460	hybrid			2022-12-25	WOS:A1996VU03300060
J	MagnierGaubil, C; Herbert, JM; Quarck, R; Papp, B; Corvazier, E; Wuytack, F; LevyToledano, S; Enouf, J				MagnierGaubil, C; Herbert, JM; Quarck, R; Papp, B; Corvazier, E; Wuytack, F; LevyToledano, S; Enouf, J			Smooth muscle cell cycle and proliferation - Relationship between calcium influx and sarco-endoplasmic reticulum Ca2+ ATPse regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; INOSITOL TRISPHOSPHATE; EXPRESSION; THAPSIGARGIN; ENTRY; INHIBITION; RECEPTOR; RELEASE; ISOFORM; STORES	The role of Ca2+ influx in the regulation of the sarco-endoplasmic reticulum Ca2+ ATPases (SERCA) associated with intracellular Ca2+ pools was investigated during smooth muscle cell (SMC) proliferation induced by platelet-derived growth factor (PDGF). We first; defined that the previously described up-regulation of the SERCA2a isoform found in vascular SMC after a 24-h stimulation with PDGF (Magnier, C., Papp, E., Corvazier, E., Bredoux, R., Wuytack, F., Eggermont, F., Maclouf, J., and Enouf, J. (1992) J. Biol. Chem. 267, 15808-15815) was precisely associated with SMC entry into S phase as it appeared linked with [H-3]thymidine incorporation, This was further confirmed by testing the effect of transforming growth factor-beta(1), which inhibited both aortic SMC proliferation associated with G(1) cell cycle arrest and PDGF-induced SERCA2a up-stimulation, Then, we tested the role of Ca2+ influx by using SR 33805, a nem Ca2+ channel blocker, which was characterized with regard to the voltage Ca2+ channel blocker nifedipine and the capacitative entry Ca2+ blocker SKF 96865, SR 33805 was found to be the most potent inhibitor of both PDGF-induced SMC proliferation and the associated rise in intracellular Ca2+ concentration with IC50 values of 0.2 +/- 0.1 and 0.51 +/- 0.04 mu M, respectively, Finally, by examining in parallel both SERCA2a and SERCA2b isoforms, in terms of activity and expression we could determine that PDGF-induced stimulation of total SERCA activity (detected by formation of the phosphorylated intermediate, E similar to P) and of SERCA2a expression (Western blotting) were abolished when extracellular Ca2+ entry was prevented by SR 33805, This study demonstrates that SERCA2a up-regulation is: 1) related to the G(1)/S transition step of cell cycle and 2) dependent on Ca2+ entry during PDGF-induced SMC proliferation.	HOP LARIBOISIERE, INSERM U348, IFR CIRCULAT LARIBOISIERE, F-75010 PARIS, FRANCE; SANOFI RECH, CTR TOULOUSE, F-31036 TOULOUSE, FRANCE; CATHOLIC UNIV LEUVEN, PHYSIOL LAB, B-3000 LOUVAIN, BELGIUM	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Sanofi-Aventis; Sanofi France; KU Leuven			Quarck, Rozenn/J-8067-2018	Quarck, Rozenn/0000-0002-8293-6261; Papp, Bela/0000-0002-5025-3087				AMRANI Y, 1995, BRIT J PHARMACOL, V115, P1204, DOI 10.1111/j.1476-5381.1995.tb15026.x; AMRANI Y, 1995, BRIT J PHARMACOL, V114, P4, DOI 10.1111/j.1476-5381.1995.tb14896.x; BAFFY G, 1995, BIOCHEM BIOPH RES CO, V210, P378, DOI 10.1006/bbrc.1995.1672; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BURK SE, 1989, J BIOL CHEM, V264, P18561; CARAFOLI E, 1994, J NEUROBIOL, V25, P312, DOI 10.1002/neu.480250311; CHATELAIN P, 1993, EUR J PHARM-MOLEC PH, V246, P181, DOI 10.1016/0922-4106(93)90030-D; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DELABASTIE D, 1988, FEBS LETT, V229, P45, DOI 10.1016/0014-5793(88)80794-4; DILIBERTO PA, 1992, J BIOL CHEM, V267, P11888; DOL F, 1995, EUR J PHARMACOL, V280, P135, DOI 10.1016/0014-2999(95)00196-R; EGGERMONT JA, 1990, BIOCHEM J, V271, P649, DOI 10.1042/bj2710649; FONTENAY M, 1992, J CELL PHYSIOL, V152, P507, DOI 10.1002/jcp.1041520310; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GILL DL, 1989, NATURE, V342, P16, DOI 10.1038/342016a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOSEY MM, 1988, J MEMBRANE BIOL, V104, P81, DOI 10.1007/BF01870922; KOBAYASHI S, 1994, J BIOL CHEM, V269, P9011; KOBAYASHI S, 1992, JPN J PHARM P, V412; LAPIDOT SA, 1995, ARTERIOSCL THROM VAS, V15, P44, DOI 10.1161/01.ATV.15.1.44; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1992, HEART CARDIOVASCULAR, P1203; MAGNIER C, 1992, J BIOL CHEM, V267, P15808; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEANS AR, 1988, CELL CALCIUM, V9, P313, DOI 10.1016/0143-4160(88)90012-7; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MOGAMI H, 1993, BIOCHEM BIOPH RES CO, V196, P650, DOI 10.1006/bbrc.1993.2299; PAPP B, 1991, J BIOL CHEM, V266, P14593; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; REDDY GPV, 1994, J CELL BIOCHEM, V54, P379, DOI 10.1002/jcb.240540404; REDDY KB, 1993, J CELL PHYSIOL, V156, P48, DOI 10.1002/jcp.1041560108; ROE MW, 1989, J CELL PHYSIOL, V139, P100, DOI 10.1002/jcp.1041390115; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; THASTRUP O, 1987, BIOCHIM BIOPHYS ACTA, V927, P65, DOI 10.1016/0167-4889(87)90066-8; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; TUCKER RW, 1990, EUR J CELL BIOL, V51, P120; VANBREEMEN C, 1989, ANNU REV PHYSIOL, V51, P315, DOI 10.1146/annurev.physiol.51.1.315; WALDRON RT, 1994, J BIOL CHEM, V269, P11927; WHITFIELD J F, 1992, Critical Reviews in Oncogenesis, V3, P55; WUYTACK F, 1989, BIOCHEM J, V264, P765, DOI 10.1042/bj2640765	50	73	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27788	27794		10.1074/jbc.271.44.27788	http://dx.doi.org/10.1074/jbc.271.44.27788			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910375	hybrid			2022-12-25	WOS:A1996VQ67900093
J	RodriguezFernandez, JL; Rozengurt, E				RodriguezFernandez, JL; Rozengurt, E			Bombesin, bradykinin, vasopressin, and phorbol esters rapidly and transiently activate Src family tyrosine kinases in Swiss 3T3 cells - Dissociation from tyrosine phosphorylation of p125 focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; PROTEIN-PHOSPHORYLATION; ACTIN CYTOSKELETON; ANGIOTENSIN-II; TUMOR PROMOTER; DNA-SYNTHESIS; C SUBSTRATE; CROSS-TALK; STIMULATION; ENDOTHELIN	Treatment of quiescent Swiss 3T3 cells with bombesin induces a rapid (less than or equal to 40 s) and transient increase in the kinase activity of the Src family of tyrosine kinases, as determined by autophosphorylation in immune complex kinase assays (4.6 +/- 0.2-fold stimulation, n = 44) and phosphorylation of exogenous substrates. Phorbol 12,13-dibutyrate increased the activity of Src family kinases with similar kinetics but was less effective than bombesin. However, Src family kinase activation by bombesin is not dependent either on protein kinase C or Ca2+. Bombesin stimulation of Src family kinase activity could also be dissociated from p125 focal adhesion kinase tyrosine phosphorylation. Neither treatment with cytochalasin D nor placement of the cells in suspension prevented the stimulation of Src family kinase activity induced by bombesin, but both abolished bombesin-induced tyrosine phosphorylation of p125 focal adhesion kinase. The stimulation of the Src family kinase activity by bombesin was completely prevented by treatment with vanadate, a potent inhibitor of protein-tyrosine phosphatases. Bradykinin and vasopressin also stimulated Src family kinase activity transiently, and this stimulation was also inhibited by vanadate. Our results dissect two separate pathways that lead to protein tyrosine phosphorylation in neuropeptide-stimulated Swiss 3T3 cells.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Rodriguez-Fernandez, Jose Luis/Q-5021-2019	Rodriguez-Fernandez, Jose Luis/0000-0001-8874-1425				BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; Brady-Kalnay Susann, 1994, Trends in Cell Biology, V4, P73, DOI 10.1016/0962-8924(94)90172-4; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; Dent P, 1996, J BIOL CHEM, V271, P3119, DOI 10.1074/jbc.271.6.3119; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; FORCE T, 1991, J BIOL CHEM, V266, P6650; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; LAU KHW, 1989, BIOCHEM J, V257, P23, DOI 10.1042/bj2570023; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LIU XQ, 1993, ONCOGENE, V8, P1119; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RANKIN S, 1994, J BIOL CHEM, V269, P704; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; ROZENGURT E, 1995, OXFORD TXB ONCOLOGY, P12; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SECKL M, 1993, J BIOL CHEM, V268, P9548; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZOR U, 1993, BIOCHEM J, V295, P879, DOI 10.1042/bj2950879	61	113	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27895	27901		10.1074/jbc.271.44.27895	http://dx.doi.org/10.1074/jbc.271.44.27895			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910389	hybrid			2022-12-25	WOS:A1996VQ67900107
J	Sakharov, DV; Lijnen, HR; Rijken, DC				Sakharov, DV; Lijnen, HR; Rijken, DC			Interactions between staphylokinase, plasmin(ogen), and fibrin - Staphylokinase discriminates between free plasminogen and plasminogen bound to partially degraded fibrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT STAPHYLOKINASE; FLUORESCENCE ANISOTROPY; PLASMA CLOT; ACTIVATION; MECHANISM; ALPHA-2-ANTIPLASMIN; STREPTOKINASE; COMPLEX; CONFORMATION; FRAGMENT	Staphylokinase (STA), a protein of bacterial ori,bin, induces highly fibrin-specific thrombolysis both in human plasma in vitro and in pilot clinical trials. Using fluorescence microscopy, we investigated the spatial distribution of fluorescein isothiocyanate (FITC)-labeled STA during lysis of a plasma clot and its binding to purified fibrin clots in the presence or in the absence of plasmin(ogen), STA highly accumulated in a thin superficial layer of the lysing plasma clot following the distribution of plasminogen (Pg) during lysis. Experiments with purified fibrin clots revealed that STA binds to Pg bound to partially degraded fibrin but not to Pg bound to intact fibrin, Binding of FITC-labeled STA to various forms of plasmin(ogen) in a buffer solution was studied by measuring fluorescence anisotropy. The binding constant for Glu-Pg was estimated as 7.4 mu M and for Lys-Pg as 0.28 mu M; for active-site blocked plasmin the binding constant was less than 0.05 mu M. The much lower affinity of STA for Glu-Pg compared with that for active site-blocked plasmin was mainly due to a lower association rate constant, as assessed by real time biospecific interaction analysis. Gel filtration of a mixture of STA with a molar excess of Glu-Pp demonstrated that STA migrated as an unbound 18-kDa protein when activation of Pg into plasmin was precluded by inhibitors of plasmin. When gel-filtered under the same conditions with plasmin, STA migrated in complex with plasmin with an apparent molecular mass of 100 kDa. Confocal fluorescence microscopy finally demonstrated that when FITC-labeled STA was added to plasma before clotting, it did not bind to fibrin fibers during the first minutes (lag phase), although Pg bound to the fibers moderately. Then, both Pg and STA started to accumulate on the fibers progressively, followed by complete lysis of the clot. In conclusion, our results imply that, when STA is added to plasma, only a small percentage associates with Pg. In contrast, STA binds strongly to plasmin and to Pg, which is bound to partially degraded fibrin. These findings add a new mechanism to the known explanations for the inefficient Pg activation by STA in plasma and specify the mechanism for fibrin-dependent activation of Pg.	CATHOLIC UNIV LEUVEN,CTR MOL & VASC BIOL,B-3000 LOUVAIN,BELGIUM	KU Leuven	Sakharov, DV (corresponding author), TNO,GAUBIUS LAB,PREVENT & HLTH,POB 2215,NL-2301 CE LEIDEN,NETHERLANDS.		Lijnen, Roger/AAA-4085-2020					Bachmann F., 1994, HEMOSTASIS THROMBOSI, V3rd, P1592; CEDERHOLMWILLIAMS SA, 1979, EUR J BIOCHEM, V100, P125, DOI 10.1111/j.1432-1033.1979.tb02040.x; COLLEN D, 1994, BLOOD, V84, P680, DOI 10.1182/blood.V84.3.680.680; COLLEN D, 1992, FIBRINOLYSIS, V6, P203, DOI 10.1016/0268-9499(92)90073-Q; COLLEN D, 1993, J BIOL CHEM, V268, P8284; COLLEN D, 1996, IN PRESS CIRCULATION; FLEURY V, 1993, J BIOL CHEM, V268, P18554; HUFF S, 1994, J BIOL CHEM, V269, P15563; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; KOWALSKALOTH B, 1975, ACTA BIOCHIM POL, V22, P327; LIJNEN HR, 1991, J BIOL CHEM, V266, P11826; LIJNEN HR, 1992, BIOCHIM BIOPHYS ACTA, V1118, P144, DOI 10.1016/0167-4838(92)90142-Z; LIJNEN HR, 1994, EUR J BIOCHEM, V224, P143, DOI 10.1111/j.1432-1033.1994.tb20005.x; LIU JN, 1992, BIOCHEMISTRY-US, V31, P6311, DOI 10.1021/bi00142a021; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; Markus G, 1996, FIBRINOLYSIS, V10, P75, DOI 10.1016/S0268-9499(96)80082-8; MATSUO O, 1990, BLOOD, V76, P925; MCCANCE SG, 1995, BIOCHEMISTRY-US, V34, P9581, DOI 10.1021/bi00029a035; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; NORRMAN B, 1985, EUR J BIOCHEM, V149, P193, DOI 10.1111/j.1432-1033.1985.tb08911.x; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; RAMAKRISHNAN V, 1991, BIOCHEMISTRY-US, V30, P3963, DOI 10.1021/bi00230a023; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; SAKHAROV DV, 1995, CIRCULATION, V92, P1883, DOI 10.1161/01.CIR.92.7.1883; Sakharov DV, 1996, J BIOL CHEM, V271, P2133, DOI 10.1074/jbc.271.4.2133; SAKHAROV DV, 1994, FIBRINOLYSIS, V8, P116, DOI 10.1016/0268-9499(94)90268-2; SAKHAROV DV, 1996, FIBRINOLYSIS S3, V10, P75; SCHICK LA, 1974, BIOCHEM BIOPH RES CO, V57, P47, DOI 10.1016/S0006-291X(74)80355-4; SILENCE K, 1995, J BIOL CHEM, V270, P27192, DOI 10.1074/jbc.270.45.27192; SILENCE K, 1993, J BIOL CHEM, V268, P9811; SILENCE K, 1993, BLOOD, V82, P1175, DOI 10.1182/blood.V82.4.1175.bloodjournal8241175; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; URANO T, 1987, J BIOL CHEM, V262, P15959; VANDERSCHUEREN S, 1995, CIRCULATION, V92, P2044, DOI 10.1161/01.CIR.92.8.2044; VANDERSCHUEREN S, 1995, CIRCULATION, V92, P2050, DOI 10.1161/01.CIR.92.8.2050; VANDERSCHUEREN SMF, 1995, FIBRINOLYSIS, V9, P87, DOI 10.1016/S0268-9499(08)80019-7; WEISEL JW, 1994, J MOL BIOL, V235, P1117, DOI 10.1006/jmbi.1994.1061	37	43	49	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27912	27918		10.1074/jbc.271.44.27912	http://dx.doi.org/10.1074/jbc.271.44.27912			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910391	hybrid			2022-12-25	WOS:A1996VQ67900109
J	WeberNordt, RM; Riley, JK; Greenlund, AC; Moore, KW; Darnell, JE; Schreiber, BD				WeberNordt, RM; Riley, JK; Greenlund, AC; Moore, KW; Darnell, JE; Schreiber, BD			Stat-3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; IFN-GAMMA RECEPTOR; CYTOKINE RECEPTORS; INTERFERON-GAMMA; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; BINDING PROTEIN; T-CELLS; ACTIVATION; IL-10	Recent work has shown that IL-10 induces activation of the JAK-STAT signaling pathway. To define the mechanism underlying signal transducer and activator of transcription (STAT) protein recruitment to the interleukin 10 (IL-10) receptor, the STAT proteins activated by IL-10 in different cell populations were first defined using electrophoretic mobility shift assays. In all cells tested, IL-10 activated Stat1 and Stat3 and induced the formation of three distinct DNA binding complexes that contained different combinations of these two transcription factors. IL-10 also activated Stat5 in Ba/F3 cells that stably expressed the murine IL-10 receptor. Using a structure-function mutagenesis approach, two tyrosine residues (Tyr(427) and Tyr(477)) in the intracellular domain of the murine IL-10 receptor were found to be redundantly required for receptor function and for activation of Stat3 beat not for Stat1 car Stat5. Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 hut not Stat1 and blocked IL-10-induced Stat3 phosphorylation in a cell-free system. In contrast, tyrosine-phosphorylated peptides containing Tyr(374) or Tyr(396) did not interact with Stat3 or block Stat3 activation. These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand-activated IL-10 receptor by binding to specific beat redundant receptor intracellular domain sequences containing phosphotyrosine. This study thus supports the concept that utilization of distinct STAT proteins by different cytokine receptors is dependent on the expression of particular ligand-activatable, tyrosine-containing STAT docking sites in receptor intracellular domains.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,CTR IMMUNOL,ST LOUIS,MO 63110; DNAX RES INST MOL & CELLULAR BIOL INC,DEPT MOL BIOL,PALO ALTO,CA 94304; ROCKEFELLER UNIV,MOL CELL BIOL LAB,NEW YORK,NY 10021	Washington University (WUSTL); Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Rockefeller University			Schreiber, Robert D/A-1276-2013	Schreiber, Robert D/0000-0001-6311-0432; Schreiber, Robert/0000-0003-1590-2341	NATIONAL CANCER INSTITUTE [R01CA043059, R37CA043059] Funding Source: NIH RePORTER; NCI NIH HHS [CA43059] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1992, SCIENCE, V257, P813, DOI 10.1126/science.1496402; DIGHE AS, 1993, J BIOL CHEM, V268, P10645; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; FOUNTOULAKIS M, 1992, EUR J BIOCHEM, V208, P781, DOI 10.1111/j.1432-1033.1992.tb17248.x; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; HO ASY, 1995, MOL CELL BIOL, V15, P5043; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HOWARD M, 1992, IMMUNOL TODAY, V13, P198, DOI 10.1016/0167-5699(92)90153-X; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEHMANN J, 1994, J IMMUNOL, V153, P165; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; LIU Y, 1994, J IMMUNOL, V152, P1821; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MOSMANN TR, 1991, INT ARCH ALLER A IMM, V94, P110, DOI 10.1159/000235340; OGARRA A, 1990, INT IMMUNOL, V2, P821, DOI 10.1093/intimm/2.9.821; OSWALD IP, 1992, P NATL ACAD SCI USA, V89, P8676, DOI 10.1073/pnas.89.18.8676; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAGA K, 1993, BLOOD, V81, P2964; TAN JC, 1993, J BIOL CHEM, V268, P21053; WANG HY, 1996, IMMUNITY, V4, P331; WEBERNORDT RM, 1994, J IMMUNOL, V153, P3734; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	43	165	168	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27954	27961		10.1074/jbc.271.44.27954	http://dx.doi.org/10.1074/jbc.271.44.27954			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910398	hybrid			2022-12-25	WOS:A1996VQ67900116
J	Chien, AJ; Carr, KM; Shirokov, RE; Rios, E; Hosey, MM				Chien, AJ; Carr, KM; Shirokov, RE; Rios, E; Hosey, MM			Identification of palmitoylation sites within the L-type calcium channel beta(2a) subunit and effects on channel function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; CLONING	The hydrophilic beta(2a) subunit of the L-type calcium channel was recently shown to be a membrane-localized, post-translationally modified protein (Chien, A. J., Zhao, X. L., Shirokov, R. E., Purl, T. S., Chang, C. F., Sun, D. D., Rios, E., and Hosey, M. M. (1995) J. Biol, Chem, 270, 30036-30044), In this study, we demonstrate that the rat beta(2a) subunit was palmitoylated through a hydroxylamine sensitive thioester linkage, Palmitoylation required a pair of cysteines in the N terminus, Cys(3) and Cys(4); mutation of these residues to serines resulted in mutant beta(2a) subunits that were unable to incorporate palmitic acid, Interestingly, a palmitoylation-deficient beta(2a) mutant still localized to membrane particulate fractions and was still able to target functional channel complexes to the plasma membrane similar to wild-type beta(2a). However, channels formed with a palmitoylation-deficient beta(2a) subunit exhibited a dramatic decrease in ionic current per channel, indicating that although mutations eliminating palmitoylation did not affect channel targeting by the beta(2a) subunit, they were important determinants of channel modulation by the beta(2a) subunit, Three other known beta subunits that were analyzed were not palmitoylated, suggesting that palmitoylation could provide a basis for the regulation of L-type channels through modification of a specific beta isoform.	NORTHWESTERN UNIV,SCH MED,DEPT MOL PHARMACOL & BIOL CHEM S215,CHICAGO,IL 60611; UKRAINIAN ACAD SCI,AA BOGOMOLETZ INST PHYSIOL,UA-252024 KIEV,UKRAINE; RUSH UNIV,DEPT PHYSIOL,CHICAGO,IL 60612	Northwestern University; National Academy of Sciences Ukraine; A.A. Bogomoletz Institute of Physiology; Rush University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL023306, R01HL023306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F30MH010770] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL23306] Funding Source: Medline; NIAMS NIH HHS [AR43113] Funding Source: Medline; NIMH NIH HHS [1 F30 MH10770] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BERTHIAUME L, 1995, J BIOL CHEM, V270, P22399, DOI 10.1074/jbc.270.38.22399; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; CMAP LA, 1995, J BIOL CHEM, V269, P23212; GERHARDSTEIN B, 1996, BIOPHYS J, V70, P186; Josephson IR, 1996, BIOPHYS J, V70, P1285, DOI 10.1016/S0006-3495(96)79685-6; Kamp TJ, 1996, J PHYSIOL-LONDON, V492, P89, DOI 10.1113/jphysiol.1996.sp021291; LINDER ME, 1995, METHOD ENZYMOL, V250, P314; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SHIROKOV R, 1996, BIOPHYS J, V70, P183; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6	17	159	162	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26465	26468		10.1074/jbc.271.43.26465	http://dx.doi.org/10.1074/jbc.271.43.26465			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900112	hybrid			2022-12-25	WOS:A1996VP23300006
J	Shworak, NW; Fritze, LMS; Liu, J; Butler, LD; Rosenberg, RD				Shworak, NW; Fritze, LMS; Liu, J; Butler, LD; Rosenberg, RD			Cell-free synthesis of anticoagulant heparan sulfate reveals a limiting converting activity that modifies an excess precursor pool	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITHROMBIN-BINDING SEQUENCE; ENDOTHELIAL-CELLS; HIGH-AFFINITY; PROTEOGLYCANS; BIOSYNTHESIS; EXPRESSION; RESIDUES; PROTEINS; SITES	LTA cells synthesize a minor population of heparan sulfate proteoglycans (HSPG(act)) bearing anticoagulant heparan sulfate (HSact) with a specific monosaccharide sequence that accelerates the action of antithrombin (AT), LTA cells also synthesize a major population of heparan sulfate proteoglycans endowed with nonanticoagulant heparan sulfate (HSinact) lacking the AT-binding site. To investigate the pathway specific features of HSPG(act) generation, we established a novel detergent-containing cell-free system with unlabeled and labeled microsomes from wild-type and variant LTA cells, respectively, The unlabeled microsomes provide ''HSact conversion activity'' that requires 3'-phosphoadenosine 5'-phosphosulfate to convert [S-35]HSPG(inact) into [S-35] HSPG(act), presumably by sulfation, The reaction kinetics demonstrate that the rate of HSact synthesis is constant over the first 4 h of incubation, During this time, the rate of HSact production is linearly dependent on the amount of unlabeled LTA microsomal protein over a range of 10 to 50 mu g as well as on the level of [S-35]HS substrate over a range of 0.4 to 4.0 mu g, microsomal protein, Compared with labeled microsomes, equivalent or slightly greater levels of HSact were generated from S-35-labeled HSPG, microsomal HS, or cell surface HS, which demonstrates that HSinact is the minimal substrate and that large amounts of HSact precursor exit the Golgi apparatus, Indeed, extensive modification of wild-type LTA cell surface [S-35]HS elevated HSact content from 9 to 35%, The hypothesis that microsomal HSact conversion activity predicts the cellular rate of HSact generation was tested with wild-type or variant LTA cells in which production of HSact has been significantly altered by mutagenesis or overexpression of core protein or growth conditions, The data demonstrate that microsomal HSact conversion activity accurately reflects the cellular rate of HSact synthesis over a very wide range of conditions, The possibility that the reduced HSact generation is due to an inhibitor was excluded by mixing experiments, The possibility that reduced HSact generation is caused by decreased levels of HSact precursor was excluded as equivalent levels of HSact were formed from wild-type and variant [S-35]HS, Based upon the above data, the LTA cell microsomal HSact conversion activity contains one or more limiting components that kinetically regulate the rate of cellular HSact generation and the levels of HSact precursor in HS greatly exceed HSact production.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033014, P01HL041484] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-33014, HL-41484] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; COLLIECJOUAULT S, 1994, J BIOL CHEM, V269, P24953; DEAGOSTINI AL, 1990, P NATL ACAD SCI USA, V87, P9784, DOI 10.1073/pnas.87.24.9784; DEBENHAM PG, 1982, MOL CELL BIOL, V2, P881, DOI 10.1128/MCB.2.8.881; FLEISCHER B, 1970, Biochimica et Biophysica Acta, V219, P301, DOI 10.1016/0005-2736(70)90209-9; KIT S, 1963, EXP CELL RES, V31, P297, DOI 10.1016/0014-4827(63)90007-7; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM LH, 1976, BIOCHEM BIOPH RES CO, V69, P570, DOI 10.1016/0006-291X(76)90558-1; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LINHARDT RJ, 1992, J BIOL CHEM, V267, P2380; LITTLEFIELD JW, 1963, P NATL ACAD SCI USA, V50, P568, DOI 10.1073/pnas.50.3.568; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; MARCUM JA, 1984, J CLIN INVEST, V74, P341, DOI 10.1172/JCI111429; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MARCUM JA, 1989, HEPARIN, P275; MERTENS G, 1992, J BIOL CHEM, V267, P20435; PEJLER G, 1987, J BIOL CHEM, V262, P5036; RAZI N, 1995, J BIOL CHEM, V270, P11267, DOI 10.1074/jbc.270.19.11267; RICE LI, 1967, ARCH BIOCHEM BIOPHYS, V118, P374, DOI 10.1016/0003-9861(67)90363-3; ROSENBERG RD, 1979, P NATL ACAD SCI USA, V76, P1218, DOI 10.1073/pnas.76.3.1218; ROSENBERG RD, 1978, P NATL ACAD SCI USA, V75, P3065, DOI 10.1073/pnas.75.7.3065; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; SILBERT JE, 1967, J BIOL CHEM, V242, P2301	34	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27063	27071		10.1074/jbc.271.43.27063	http://dx.doi.org/10.1074/jbc.271.43.27063			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900197	hybrid			2022-12-25	WOS:A1996VP23300091
J	Conn, KJ; Rich, CB; Jensen, DE; Fontanilla, MR; Bashir, MM; Rosenbloom, J; Foster, JA				Conn, KJ; Rich, CB; Jensen, DE; Fontanilla, MR; Bashir, MM; Rosenbloom, J; Foster, JA			Insulin-like growth factor-I regulates transcription of the elastin gene through a putative retinoblastoma control element - A role for Sp3 acting as a repressor of elastin gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC PROMOTER; RB PROTEIN; BINDING; CELLS; EXPRESSION; FAMILY; DNA; TROPOELASTIN; DISRUPTION; ACTIVATION	Previous studies have demonstrated that insulin-like growth factor-I (IGF-I) increases elastin gene transcription in aortic smooth muscle cells and that this up-regulation is accompanied by a loss of protein binding to the proximal promoter. Sp1 has been identified as one of the factors whose binding is lost, and in the present study we show that Sp3 binding is also abrogated by IGF-I, but in a selected manner. In functional analyses using Drosophila SL-2 cells, Sp1 expression can drive transcription from the elastin proximal promoter, while co expression of Sp3 results in a repression of Sp1 activity. Footprint and gel shift analyses position the IGF-I responsive sequences to a putative retinoblastoma control element (RCE). Mutation of the putative RCE sequence as assessed by transient transfection of smooth muscle cells results in an increase in reporter activity equal in magnitude to that conferred by IGF-I on the wild type promoter. Together these results support the hypothesis that IGF-I-mediated increase in elastin transcription occurs via a mechanism of derepression involving the abrogation of a repressor that appears to be Sp3 binding to the RCE.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; UNIV PENN,SCH DENT MED,DEPT ANAT & HISTOL,PHILADELPHIA,PA 19104	Boston University; University of Pennsylvania					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL13262] Funding Source: Medline; NIA NIH HHS [AG00115] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BASHIR MM, 1989, J BIOL CHEM, V264, P8887; BIRNBAUM MJ, 1995, BIOCHEMISTRY-US, V34, P7648, DOI 10.1021/bi00023a011; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BURNETT W, 1980, BIOCHEMISTRY-US, V19, P1106, DOI 10.1021/bi00547a010; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; FOSTER J, 1987, COLLAGEN REL RES, V7, P161; FOSTER JA, 1989, MATRIX, V9, P328, DOI 10.1016/S0934-8832(89)80009-5; FOSTER JA, 1990, J GERONTOL, V13, P113; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; JENSEN DE, 1995, J BIOL CHEM, V270, P6555, DOI 10.1074/jbc.270.12.6555; JENSEN DE, 1996, THESIS BOSTON U; KINGSLEY C, 1990, MOL CELL BIOL, V13, P2776; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFEVRE M, 1983, BIOCHIM BIOPHYS ACTA, V743, P338, DOI 10.1016/0167-4838(83)90391-6; MAJELLO B, 1995, ONCOGENE, V10, P1841; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MAYFIELD C, 1994, J BIOL CHEM, V269, P18232; MICHELOTTI EF, 1995, J BIOL CHEM, V270, P9494, DOI 10.1074/jbc.270.16.9494; RICH CB, 1993, BIOCHEM BIOPH RES CO, V196, P1316, DOI 10.1006/bbrc.1993.2396; RITZENTHALER JD, 1991, BIOCHEM J, V280, P157, DOI 10.1042/bj2800157; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SHIBAHARA S, 1981, BIOCHEMISTRY-US, V20, P6577, DOI 10.1021/bi00526a009; SWEE MH, 1995, J BIOL CHEM, V270, P1489; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TERPSTRA AJ, 1994, THESIS BOSTON U; TOWBIN H, 1982, J BIOL CHEM, V257, P2709; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLFE BL, 1993, J BIOL CHEM, V268, P12418; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4	44	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28853	28860		10.1074/jbc.271.46.28853	http://dx.doi.org/10.1074/jbc.271.46.28853			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910531	hybrid			2022-12-25	WOS:A1996VT05200023
J	Kincaid, JR; Zheng, YH; AlMustafa, J; Czarnecki, K				Kincaid, JR; Zheng, YH; AlMustafa, J; Czarnecki, K			Resonance Raman spectra of native and mesoheme-reconstituted horseradish peroxidase and their catalytic intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; PI-CATION RADICALS; HEME-LINKED IONIZATION; PORPHYRIN FORCE-FIELD; COMPOUND-I; ENZYMIC CATALYSIS; ISOTOPE SHIFTS; SPECTROSCOPY; CATALASE; METALLOPORPHYRINS	Resonance Raman studies of native and mesohemere-constituted horseradish peroxidase and their catalytic intermediates, known as Compounds I and II, have been conducted using both near UV (similar to 350 nm) and visible (406.7 nm) excitation. Careful power studies indicate that the authentic Compound I spectra are obtainable using near UV excitation, but that use of visible excitation results in contamination of the Compound I spectrum with the spectrum of a Compound II-like photoproduct. Using (H2O2)-O-18, the nu(Fe=O) stretching modes for both systems are unambiguously identified, for the first time, at similar to 790 cm(-1). The authentic Compound I spectra are indicative of an (2)A(1u)-like ground state for both the native and the mesoheme-reconstituted proteins. Finally, the possible biological implications of such information are briefly discussed.			Kincaid, JR (corresponding author), MARQUETTE UNIV,DEPT CHEM,MILWAUKEE,WI 53201, USA.				NIDDK NIH HHS [DK35153] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035153] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASADA K, 1984, PLANT CELL PHYSIOL, V25, P1169; BROWETT WR, 1988, J AM CHEM SOC, V110, P3633, DOI 10.1021/ja00219a044; CHUANG WJ, 1992, J BIOL CHEM, V267, P13293; CZARNECKI K, 1995, THESIS MARQUETTE U; CZERNUSZEWICZ RS, 1989, J AM CHEM SOC, V111, P3860, DOI 10.1021/ja00193a017; DOLPHIN D, 1974, ACCOUNTS CHEM RES, V7, P26, DOI 10.1021/ar50073a005; DU P, 1995, BIOPHYS J, V68, P69, DOI 10.1016/S0006-3495(95)80160-8; DUNFORD HB, 1982, ADV INORG BIOCHEM, V4, P41; Frew J. E., 1984, ADV INORG BIOINORG M, V3, P175; FUJITA I, 1983, J AM CHEM SOC, V105, P3296, DOI 10.1021/ja00348a056; GODZIELA GM, 1986, J AM CHEM SOC, V108, P2237, DOI 10.1021/ja00269a019; GODZIELA GM, 1986, INORG CHEM, V25, P4286, DOI 10.1021/ic00243a044; HANSON LK, 1981, J AM CHEM SOC, V103, P663, DOI 10.1021/ja00393a028; HASHIMOTO S, 1986, P NATL ACAD SCI USA, V83, P2417, DOI 10.1073/pnas.83.8.2417; HU SH, 1991, J AM CHEM SOC, V113, P7189, DOI 10.1021/ja00019a015; KITAGAWA T, 1994, COORDIN CHEM REV, V135, P685, DOI 10.1016/0010-8545(94)80081-2; LAMAR GN, 1981, J BIOL CHEM, V256, P237; LAMAR GN, 1989, J BIOL CHEM, V264, P5428; LI XY, 1990, J PHYS CHEM-US, V94, P47, DOI 10.1021/j100364a008; LI XY, 1990, J PHYS CHEM-US, V94, P31, DOI 10.1021/j100364a007; MACOR KA, 1990, INORG CHEM, V29, P1996, DOI 10.1021/ic00335a044; MORISHIMA I, 1986, BIOCHEMISTRY-US, V25, P3576, DOI 10.1021/bi00360a016; MORISHIMA I, 1984, J AM CHEM SOC, V106, P7666, DOI 10.1021/ja00337a002; OERTLING WA, 1985, J AM CHEM SOC, V107, P6406, DOI 10.1021/ja00308a050; OERTLING WA, 1988, BIOCHEMISTRY-US, V27, P3331, DOI 10.1021/bi00409a032; OERTLING WA, 1989, J PHYS CHEM-US, V93, P1311, DOI 10.1021/j100341a028; OGURA T, 1987, J AM CHEM SOC, V109, P2177, DOI 10.1021/ja00241a044; PAENG KJ, 1988, J AM CHEM SOC, V110, P7913, DOI 10.1021/ja00231a073; PALANIAPPAN V, 1989, J BIOL CHEM, V264, P16046; ROBERTS JE, 1981, J BIOL CHEM, V256, P2118; RUTTER R, 1983, BIOCHEMISTRY-US, V22, P4769, DOI 10.1021/bi00289a024; SANDUSKY PO, 1989, J AM CHEM SOC, V111, P6437, DOI 10.1021/ja00198a074; SHANNON LM, 1966, J BIOL CHEM, V241, P2166; SIMPSON SF, 1986, ANAL CHEM, V58, P3163, DOI 10.1021/ac00127a054; SIMPSON SF, 1983, ANAL CHEM, V55, P1420, DOI 10.1021/ac00259a054; SITTER AJ, 1985, J BIOL CHEM, V260, P7515; Spiro T.G., 1988, BIOL APPL RAMAN SPEC; STILLMAN JS, 1975, BIOCHEMISTRY-US, V14, P3183, DOI 10.1021/bi00685a023; STILLMAN JS, 1975, BIOCHEM BIOPH RES CO, V63, P32, DOI 10.1016/S0006-291X(75)80006-4; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; TERAOKA J, 1982, J AM CHEM SOC, V104, P7354, DOI 10.1021/ja00389a094; VANWART HE, 1985, J AM CHEM SOC, V107, P3379, DOI 10.1021/ja00297a072; YONETANI T, 1968, J BIOL CHEM, V243, P4715	43	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28805	28811		10.1074/jbc.271.46.28805	http://dx.doi.org/10.1074/jbc.271.46.28805			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910524	hybrid			2022-12-25	WOS:A1996VT05200016
J	Rooney, E; Meldolesi, J				Rooney, E; Meldolesi, J			The endoplasmic reticulum in PC12 cells - Evidence for a mosaic of domains differently specialized in Ca2+ handling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; INTRACELLULAR CALCIUM STORES; YEAST SECRETORY PATHWAY; TRANS-GOLGI NETWORK; SUBCELLULAR-DISTRIBUTION; SARCOPLASMIC-RETICULUM; TISSUE DISTRIBUTION; CA-2+ TRANSPORT; RAT-LIVER; PUMP	Velocity and isopycnic gradient centrifugation were employed to fractionate post-nuclear supernatants rapidly prepared from PC12 cells in order to characterize areas of the endoplasmic reticulum involved in various aspects of intracellular Ca2+ homeostasis. The endoplasmic reticulum Ca2+ pumping activity, defined by three properties studied in parallel in the isolated fractions; thapsigargin-sensitive uptake of Ca-45(2+), Ca2+-dependent, thapsigargin-sensitive protein phosphorylation and Western blotting of sarcoplasmic reticulum calcium ATPase (SERCA) 2b and putative SERCA3 ATPases, was concentrated primarily in a few fractions located at the top and toward the bottom of velocity and isopycnic gradients, respectively. The endoplasmic reticulum Ca2+ release channel, the inositol 1,4,5-trisphosphate receptor, was concentrated in the same fractions as the Ca2+ pumps, and additionally in a few fractions distinctly poor in SERCAs. In contrast, two lumenal markers (protein disulfide isomerase and calreticulin, the major Ca2+ storage protein of non-muscle endoplasmic reticulum) were enriched in the middle fractions of the velocity gradients while calnexin, a Ca2+-binding membrane protein, was more widely distributed throughout the gradients. These results document a considerable degree of functional and compositional heterogeneity in the endoplasmic reticulum of neurosecretory PC12 cells. Even in the limited areas that appear specialized for rapid Ca2+ uptake and release the ratio between pumps and channels varies considerably Within the rest of the system, insulated hom short-term fluctuations of Ca2+ concentration, Ca2+-binding proteins appear to be extensively distributed, in agreement with the idea that the Ca2+ content of the endoplasmic reticulum serves multiple functions.	UNIV MILAN,DEPT PHARMACOL,MILAN,ITALY; UNIV MILAN,B CECCARELLI CTR,MILAN,ITALY; SAN RAFFAELE SCI INST,CNR,CTR MOL & CELLULAR PHARMACOL,I-20132 MILAN,ITALY; SAN RAFFAELE SCI INST,DIBIT,I-20132 MILAN,ITALY	University of Milan; University of Milan; Consiglio Nazionale delle Ricerche (CNR); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele								BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BOBE R, 1994, J BIOL CHEM, V269, P1417; BOSSHART H, 1992, EUR J BIOCHEM, V208, P341, DOI 10.1111/j.1432-1033.1992.tb17192.x; BURK SE, 1989, J BIOL CHEM, V264, P18561; Caspersen C, 1995, FEBS LETT, V377, P31, DOI 10.1016/0014-5793(95)01304-0; COLYER J, 1989, BIOCHEM J, V262, P439, DOI 10.1042/bj2620439; ENGELENDER S, 1995, J BIOL CHEM, V270, P21050, DOI 10.1074/jbc.270.36.21050; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; FISCHER GA, 1994, J BIOL CHEM, V269, P19216; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUNTESKIHAMBLIN AM, 1992, BIOCHEMISTRY-US, V31, P7600, DOI 10.1021/bi00148a023; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; KASAI H, 1995, CIBA F SYMP, V188, P104; KOVACS T, 1994, J BIOL CHEM, V269, P6177; LIEVREMONT JP, 1994, BIOCHEM J, V300, P419, DOI 10.1042/bj3000419; Lievremont JP, 1996, BIOCHEM J, V314, P189, DOI 10.1042/bj3140189; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; LYTTON J, 1992, J BIOL CHEM, V267, P14483; NIGAM SK, 1990, J CELL BIOL, V111, P197, DOI 10.1083/jcb.111.1.197; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; PENG YW, 1991, NEURON, V6, P525, DOI 10.1016/0896-6273(91)90055-5; PERRIN D, 1991, FEBS LETT, V294, P47, DOI 10.1016/0014-5793(91)81340-E; POULSEN JCJ, 1995, BIOCHEM J, V307, P749, DOI 10.1042/bj3070749; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; RABOUILLE C, 1995, J CELL SCI, V108, P1617; ROONEY EK, 1994, CELL CALCIUM, V16, P509, DOI 10.1016/0143-4160(94)90081-7; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SHARP AH, 1992, J BIOL CHEM, V267, P7444; SITIA R, 1992, MOL BIOL CELL, V3, P1067, DOI 10.1091/mbc.3.10.1067; TOOZE SA, 1992, METHOD ENZYMOL, V219, P81; TUNWELL REA, 1991, BIOCHEM J, V279, P203, DOI 10.1042/bj2790203; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; VILLA A, 1992, NEUROSCIENCE, V49, P467, DOI 10.1016/0306-4522(92)90111-E; VILLA A, 1993, J CELL BIOL, V121, P1041, DOI 10.1083/jcb.121.5.1041; VIRK SS, 1985, BIOCHEM J, V226, P741, DOI 10.1042/bj2260741; VOLPE P, 1992, P NATL ACAD SCI USA, V89, P6142, DOI 10.1073/pnas.89.13.6142; WICTOME M, 1995, BIOCHEM J, V310, P859, DOI 10.1042/bj3100859; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775; WUYTACK F, 1989, BIOCHEM J, V264, P765, DOI 10.1042/bj2640765; WUYTACK F, 1994, J BIOL CHEM, V269, P1410; ZACHETTI D, 1991, J BIOL CHEM, V266, P20152	46	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29304	29311		10.1074/jbc.271.46.29304	http://dx.doi.org/10.1074/jbc.271.46.29304			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910591				2022-12-25	WOS:A1996VT05200083
J	Sun, YH; Gailani, D				Sun, YH; Gailani, D			Identification of a factor IX binding site on the third apple domain of activated factor XI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION FACTOR; FUNCTIONAL-CHARACTERIZATION; PLASMA; PURIFICATION; DEFICIENCY; MECHANISM; CHAIN	Activated factor XI (factor XIa) participates in blood coagulation by activating factor IX. Previous work has demonstrated that a binding site for factor IX is present on the noncatalytic heavy chain of factor XIa (Sinha, D., Seaman, F. S., and Walsh, P. N. (1987) Biochemistry 26, 3768-3775). Recombinant factor XI proteins were expressed in which each of the four apple domains of the heavy chain (designated A1 through A4) were individually replaced with the corresponding domain from the homologous but functionally distinct protease prekallikrein (PK). To identify the site of factor IX binding, the chimeric proteins were activated with factor Wa and tested for their capacity to activate factor IX in plasma coagulation and purified protein assays. The chimera with the substitution in the third apple domain (factor XI/PKA3) had <1% of the coagulant activity of wild type factor XIa in a plasma coagulation assay, whereas the chimeras with substitutions in A1, A2, and A4 demonstrated significant activity (68-140% of wild type activity). The K-m for activation of factor IX by factor XIa/PKA3 (12.7 mu M) is more than 30-fold higher than the K-m for activation by wild type factor XIa or the other factor XI/PK chimeras (0.11-0.37 mu M) Two monoclonal antibodies (2A12 and 11AE) that recognize epitopes on the factor XI A3 domain were potent inhibitors of factor IX activation by factor XIa, whereas antibodies against the A2 (1A6) and A4 (3G4) domains were poor inhibitors. The data indicate that a binding site for factor IX is present on the third apple domain of factor XIa.	VANDERBILT UNIV,SCH MED,DEPT PATHOL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DIV HEMATOL,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University								BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; BAGLIA FA, 1992, J BIOL CHEM, V267, P4247; Baglia FA, 1996, J BIOL CHEM, V271, P3652; BAGLIA FA, 1993, J BIOL CHEM, V268, P3838; BAJAJ SP, 1982, J BIOL CHEM, V257, P4127; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GAILANI D, 1993, BLOOD, V82, P813; Herwald H, 1996, J BIOL CHEM, V271, P13061, DOI 10.1074/jbc.271.22.13061; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P376; KURACHI K, 1977, BIOCHEMISTRY-US, V16, P5831, DOI 10.1021/bi00645a030; MCCONNELL DJ, 1970, BRIT J PHARMACOL, V38, P490, DOI 10.1111/j.1476-5381.1970.tb10591.x; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; MEIJERS JCM, 1992, BLOOD, V79, P1435; MEIJERS JCM, 1992, BIOCHEMISTRY-US, V31, P4680, DOI 10.1021/bi00134a021; NAITO K, 1991, J BIOL CHEM, V266, P2667; OSTERUD B, 1978, J BIOL CHEM, V253, P5946; PUGH RE, 1995, BLOOD, V85, P1509, DOI 10.1182/blood.V85.6.1509.bloodjournal8561509; SINHA D, 1985, J BIOL CHEM, V260, P714; SINHA D, 1987, BIOCHEMISTRY-US, V26, P3768, DOI 10.1021/bi00387a005; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; WAGENVOORD R, 1990, HAEMOSTASIS, V20, P276; WALSH PN, 1984, J CLIN INVEST, V73, P1392, DOI 10.1172/JCI111343	27	92	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29023	29028		10.1074/jbc.271.46.29023	http://dx.doi.org/10.1074/jbc.271.46.29023			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910554	hybrid			2022-12-25	WOS:A1996VT05200046
J	Tsiotra, PC; Theodorakis, K; Papamatheakis, J; Karagogeos, D				Tsiotra, PC; Theodorakis, K; Papamatheakis, J; Karagogeos, D			The fibronectin domains of the neural adhesion molecule TAX-1 are necessary and sufficient for homophilic binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AXONAL GLYCOPROTEIN TAG-1; CELL-ADHESION; NEURITE OUTGROWTH; IMMUNOGLOBULIN SUPERFAMILY; EXTRACELLULAR DOMAINS; NERVOUS-SYSTEM; NG-CAM; SIGNAL-TRANSDUCTION; L1-LIKE MOLECULE; FASCICLIN-III	Cell adhesion molecules belonging to thcomb come immunoglobulin superfamily promote cell aggregation and neurite outgrowth. These proteins are multidomain molecules comprising a number of distinct modules, notably Ig domains of the C2 class and fibronectin type III repeats. A subgroup of these neural adhesion molecules are linked to the membrane with a glycosylphosphatidylinositol anchor and show a more restricted pattern of expression in the embryo. Among them, the human homologue of the transient axonal glycoprotein, named TAX-1, shares a great degree of similarity at the protein level with rodent TAG-1. In the present study we set out to determine which domains of TAX-1 are involved in promoting the hemophilic, adhesive properties of the molecule. We established stable Schneider-2 cell lines expressing the intact molecule, the fibronectin, or the immunoglobulin domains. The fibronectin domains were necessary and sufficient to mediate homophilic binding and induce cell aggregation, a response also observed with cells expressing the intact TAX-1 molecule. Aggregation was inhibited by the secreted form of the TAG-1 protein. On the other hand, the immunoglobulin domains by themselves mere not able to induce cell aggregation. In addition, TAX-1 was localized in areas of cell contact among aggregating cells, justifying its role as an adhesion molecule.	UNIV CRETE, FDN RES & TECHNOL, INST MOL BIOL & BIOTECHNOL, IRAKLION 71110, CRETE, GREECE; UNIV CRETE, DEPT BIOL, IRAKLION 71110, CRETE, GREECE; UNIV CRETE, SCH MED, DEPT BASIC SCI, IRAKLION 71110, CRETE, GREECE	University of Crete; University of Crete; University of Crete			Tsiotra, Panayoula C./AAE-6086-2019	Tsiotra, Panayoula C./0000-0002-1702-5840; THEODORAKIS, KOSTAS/0000-0002-3933-795X; Karagogeos, Domna/0000-0002-8129-9731				APPEL F, 1993, J NEUROSCI, V13, P4764; ATTASHI JR, 1992, NEURON, V8, P831; Bailly Y, 1996, J COMP NEUROL, V369, P150; BEGGS HE, 1994, J CELL BIOL, V127, P825, DOI 10.1083/jcb.127.3.825; BELOSTA P, 1995, MOL CELL BIOL, V15, P614; BOCIAN M, 1987, AM J MED GENET, V26, P437, DOI 10.1002/ajmg.1320260223; BRONNERFRASER M, 1992, DEV BIOL, V153, P291, DOI 10.1016/0012-1606(92)90114-V; BRUMMENDORF T, 1993, J NEUROCHEM, V61, P1207, DOI 10.1111/j.1471-4159.1993.tb13611.x; BRUMMENDORF T, 1993, NEURON, V10, P711; BURGOON MP, 1995, J CELL BIOL, V130, P733, DOI 10.1083/jcb.130.3.733; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DOHERTY P, 1989, J CELL BIOL, V109, P789, DOI 10.1083/jcb.109.2.789; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; DURBEC P, 1993, EUR J NEUROSCI, V6, P461; ELKINS T, 1990, J CELL BIOL, V110, P1825, DOI 10.1083/jcb.110.5.1825; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FELSENFELD DP, 1994, NEURON, V12, P675, DOI 10.1016/0896-6273(94)90222-4; FREI T, 1992, J CELL BIOL, V118, P177, DOI 10.1083/jcb.118.1.177; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; HOLM J, 1995, J NEUROSCI RES, V42, P9, DOI 10.1002/jnr.490420103; HORSTKORTE R, 1993, J CELL BIOL, V121, P1409, DOI 10.1083/jcb.121.6.1409; HORTSCH M, 1995, J BIOL CHEM, V270, P18809, DOI 10.1074/jbc.270.32.18809; HORTSCH M, 1991, TRENDS BIOCHEM SCI, V16, P283, DOI 10.1016/0968-0004(91)90116-D; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; KARAGOGEOS D, 1991, DEVELOPMENT, V112, P51; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; KUHN TB, 1991, J CELL BIOL, V115, P1113, DOI 10.1083/jcb.115.4.1113; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LANDMESSER L, 1988, DEV BIOL, V130, P645, DOI 10.1016/0012-1606(88)90358-2; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; MAURO VP, 1992, J CELL BIOL, V119, P191, DOI 10.1083/jcb.119.1.191; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; PEREZCASTILLO A, 1984, HUM GENET, V67, P230, DOI 10.1007/BF00273009; PESHEVA P, 1993, NEURON, V10, P69, DOI 10.1016/0896-6273(93)90243-K; RADER C, 1993, EUR J BIOCHEM, V215, P133, DOI 10.1111/j.1432-1033.1993.tb18015.x; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; RATHJEN FG, 1991, NEUROSCIENCES, V3, P297; SARDA P, 1992, CLIN GENET, V41, P25; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; SONDEREGGER P, 1992, J CELL BIOL, V119, P1387, DOI 10.1083/jcb.119.6.1387; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STOECKLI ET, 1995, NEURON, V14, P1165, DOI 10.1016/0896-6273(95)90264-3; TSIOTRA PC, 1993, GENOMICS, V18, P562, DOI 10.1016/S0888-7543(05)80357-X; WALSH FS, 1991, CELL BIOL INT REP, V15, P1151, DOI 10.1016/0309-1651(91)90061-M; YAMAMOTO M, 1990, J NEUROCYTOL, V19, P619, DOI 10.1007/BF01188031; ZICH AH, 1995, MOL CELL NEUROSCI, V6, P263; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203	52	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29216	29222		10.1074/jbc.271.46.29216	http://dx.doi.org/10.1074/jbc.271.46.29216			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910580	hybrid			2022-12-25	WOS:A1996VT05200072
J	Alam, MR; Caldwell, BD; Johnson, RC; Darlington, DN; Mains, RE; Eipper, BA				Alam, MR; Caldwell, BD; Johnson, RC; Darlington, DN; Mains, RE; Eipper, BA			Novel proteins that interact with the COOH-terminal cytosolic routing determinants of an integral membrane peptide-processing enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; ALPHA-AMIDATING MONOOXYGENASE; CYTOPLASMIC DOMAIN; CELL-SURFACE; LOCALIZATION; SPECTRIN; TGN38; FURIN; ORGANIZATION; TRAFFICKING	The steady state distribution of membrane forms of peptidylglycine alpha-amidating monooxygenase (PAM) in the secretory pathway of neurons and endocrine cells depends on signals in its cytosolic COOH-terminal domain (CD). Mutagenesis studies yielded catalytically active PAM proteins that are not properly localized or internalized. Employing the yeast two-hybrid system, we isolated two distinct cDNAs whose protein products showed a strong interaction with the CD of PAM. The interaction of these novel PAM COOH-terminal interactor proteins (P-CIPs) did not occur with a misrouted CD mutant as bait in the yeast system. Both proteins, P-CIP2 and P-CIP10, were expressed as fusion proteins that interacted in vitro with solubilized integral membrane PAM. P-CIP2 was homologous to several serine/threonine and dual specificity protein kinases, while P-CIP10 contained spectrin-like repeats. Endogenous P-CIP2 was localized to the Golgi region of AtT-20 corticotrope tumor cells, and expression of integral membrane PAM disrupted the distribution of endogenous P-CIP2. Both P-CIP2 and P-CIP10 mRNAs were found to be expressed in rat brain neurons also expressing PAM proteins. P-CIP2 and P-CIP10 may be members of a family of cytosolic proteins involved in the routing of membrane proteins that function in the regulated secretory pathway.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205; UNIV MARYLAND,SCH MED,DEPT SURG,BALTIMORE,MD 21201	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore	Alam, MR (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205, USA.		Darlington, Daniel/CAG-1917-2022		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032948, R37DK032949, R56DK032948, R01DK032948, R01DK032949, R56DK032949] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-32949, DK-32948] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECK KA, 1996, AM J PHYSIOL, V39, pC1263; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; Calakos N, 1996, PHYSIOL REV, V76, P1; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CLERMONT Y, 1995, ANAT REC, V242, P289, DOI 10.1002/ar.1092420302; DARLINGTON DN, 1996, J NEUROSCI, V71, P477; DECAMILLI P, 1995, CURR OPIN NEUROBIOL, V5, P559, DOI 10.1016/0959-4388(95)80059-X; DHERMY D, 1991, BIOL CELL, V71, P249; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1993, PROTEIN SCI, V2, P489; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JAHN R, 1993, J NEUROCHEM, V61, P12, DOI 10.1111/j.1471-4159.1993.tb03533.x; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; Milgram SL, 1996, J BIOL CHEM, V271, P17526, DOI 10.1074/jbc.271.29.17526; MILGRAM SL, 1994, J CELL BIOL, V124, P33, DOI 10.1083/jcb.124.1.33; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; OUAFIK L, 1992, MOL ENDOCRINOL, V6, P1571, DOI 10.1210/me.6.10.1571; OYARCE AM, 1993, J NEUROCHEM, V60, P1105, DOI 10.1111/j.1471-4159.1993.tb03261.x; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; TAUSK FA, 1992, MOL ENDOCRINOL, V6, P2185, DOI 10.1210/me.6.12.2185; TAYLOR SS, 1994, PROTEIN KINASES, P1; Viel A, 1996, CURR OPIN CELL BIOL, V8, P49, DOI 10.1016/S0955-0674(96)80048-2; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788; YUN HY, 1995, J BIOL CHEM, V270, P30075; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0	36	72	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28636	28640		10.1074/jbc.271.45.28636	http://dx.doi.org/10.1074/jbc.271.45.28636			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910496	hybrid			2022-12-25	WOS:A1996VU03300096
J	McGuire, TF; Qian, YM; Vogt, A; Hamilton, AD; Sebti, SM				McGuire, TF; Qian, YM; Vogt, A; Hamilton, AD; Sebti, SM			Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; GERANYLGERANYLTRANSFERASE-I; MEMBRANE ASSOCIATION; SIGNAL TRANSDUCTION; MITOGENIC ACTIVITY; RAS FARNESYLATION; FARNESYLTRANSFERASE; INHIBITORS; CELLS; TRANSFERASE	We have used specific inhibitors for farnesyltransferase (FTase) and geranylgeranyltransferase (GGTase) I as well as combinations of lovastatin with geranylgeraniol (GGOH) or farnesol (FOR) to investigate the role of protein prenylation in platelet-derived growth factor (PDGF)-induced PDGF receptor tyrosine phosphorylation, NIH-3T3 cells treated with the highly specific FTase inhibitor FTI-277 had no effect on PDGF receptor tyrosine phosphorylation or PDGF activation of mitogen-activated protein kinase (MAPK) at doses that completely inhibit FTase-dependent processing. In contrast, treatment of these cells with GGTase I inhibitor GGTI-298 strongly inhibited receptor tyrosine phosphorylation, and co-treatment with FTI-277 had no additional effect, Interestingly, the inhibitory effect of GGTI-298 on PDGF activation of MAPK was only partial, Furthermore, although lovastatin, which inhibits both protein geranylgeranylation and protein farnesylation, blocked PDGF receptor tyrosine phosphorylation, co-treatment with GGOH, but mat FOH, reversed the lovastatin block, In addition, although lovastatin was observed to block MAPK activation by PDGF, co-treatment with GGOH, but not FOH, Pestered its activation, Further investigations indicated that inhibition of receptor tyrosine phosphorylation was blot: due to decreased expression of the receptor or to inhibition of GGTase II, Thus, these results demonstrate that PDGF receptor tyrosine phosphorylation requires protein geranylgeranylation but not protein farnesylation and that the tyrosine phosphorylation levels of the receptor are modulated by a protein that is a substrate for GGTase I.	UNIV PITTSBURGH,SCH MED,DEPT PHARMACOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH ARTS & SCI,DEPT CHEM,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER; NCI NIH HHS [U19-CA67771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG SA, 1995, J BIOL CHEM, V270, P7864, DOI 10.1074/jbc.270.14.7864; Bishop WR, 1995, J BIOL CHEM, V270, P30611, DOI 10.1074/jbc.270.51.30611; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1992, J LIPID RES, V33, P1731; CRICK DC, 1995, BIOCHEM BIOPH RES CO, V211, P590, DOI 10.1006/bbrc.1995.1854; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GRAHAM SL, 1994, J MED CHEM, V37, P725, DOI 10.1021/jm00032a004; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1994, J BIOL CHEM, V269, P27705; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCGUIRE TF, 1995, BIOCHEM BIOPH RES CO, V214, P295, DOI 10.1006/bbrc.1995.2287; MCGUIRE TF, 1994, BIOCHEM BIOPH RES CO, V204, P399, DOI 10.1006/bbrc.1994.2472; MCGUIRE TF, 1993, J BIOL CHEM, V268, P22227; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PATEL DV, 1995, J MED CHEM, V38, P435, DOI 10.1021/jm00003a006; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; QIAN YM, 1994, J BIOL CHEM, V269, P12410; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SUN JZ, 1995, CANCER RES, V55, P4243; VOGT A, 1995, J BIOL CHEM, V270, P660, DOI 10.1074/jbc.270.2.660; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; YOKOYAMA K, 1995, BIOCHEMISTRY-US, V34, P1344, DOI 10.1021/bi00004a029; ZUBIAUR M, 1995, J BIOL CHEM, V270, P17221, DOI 10.1074/jbc.270.29.17221	35	105	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27402	27407		10.1074/jbc.271.44.27402	http://dx.doi.org/10.1074/jbc.271.44.27402			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910319	hybrid			2022-12-25	WOS:A1996VQ67900037
J	Kalabokis, VN; Vibert, P; York, ML; SzentGyorgyi, AG				Kalabokis, VN; Vibert, P; York, ML; SzentGyorgyi, AG			Single-headed scallop myosin and regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESSENTIAL LIGHT-CHAIN; CALCIUM-BINDING; HEAVY-MEROMYOSIN; GIZZARD MYOSIN; ACTIN; DOMAINS; PAPAIN; ATPASE	Single-headed scallop myosin (shM) was prepared by papain digestion of filamentous scallop myosin and purified by hydrophobic interaction chromatography. The shM preparation consisted of equimolar amounts of polypeptides corresponding to an intact heavy chain, rod chain, essential light chain, and regulatory light chain, In electron micrographs the shape of shM showed the presence of a single head domain to which a normal looking rod was attached, Myosin and shM bound Ca2+ with association constants of 5 x 10(6) and 11 x 10(6) M(-1), respectively. The ATPase activity of shM was activated about 3-fold by Ca2+, Both heads of myosin and shM had comparable ATPase activities in the presence of Ca2+. The activation of the ATPase activity of single-headed scallop myosin by Ca2+ paralleled closely the Ca2+ binding, in sharp contrast to the activation of intact myosin by Ca2+, which is highly cooperative. Single turnover experiments of myosin with radioactive ATP gave a half-life for the ATPase cycle of similar to 3 min in the presence of EGTA, whereas that of single headed myosin was shorter than similar to 30 s, which was the resolution time of these measurements. The results suggest that the presence of two heads, as well as the attachment of the head to the coiled coil rod, contribute to the regulation of scallop myosin by Ca2+.	BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254	Brandeis University; Brandeis University					NIAMS NIH HHS [AR41803, AR15963] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR041803, R01AR015963, R37AR015963] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; BERGMEYER HU, 1965, METHOD ENZYMAT AN, P10; CHANTLER PD, 1980, J MOL BIOL, V138, P473, DOI 10.1016/S0022-2836(80)80013-1; CHANTLER PD, 1981, BIOCHEMISTRY-US, V20, P473; COOKE R, 1978, J MOL BIOL, V120, P361, DOI 10.1016/0022-2836(78)90424-2; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; FLICKER PF, 1983, J MOL BIOL, V169, P723, DOI 10.1016/S0022-2836(83)80167-3; FROMHERZ S, 1995, P NATL ACAD SCI USA, V92, P7652, DOI 10.1073/pnas.92.17.7652; FUNK MO, 1979, INT J PEPT PROT RES, V13, P296; JACKSON AP, 1988, BIOCHEM J, V251, P527, DOI 10.1042/bj2510527; JANCSO A, 1994, P NATL ACAD SCI USA, V91, P8762, DOI 10.1073/pnas.91.19.8762; KALABOKIS VN, 1994, J MUSCLE RES CELL M, V15, P547, DOI 10.1007/BF00121160; KWON H, 1990, P NATL ACAD SCI USA, V87, P4771, DOI 10.1073/pnas.87.12.4771; KWON H, 1992, J MUSCLE RES CELL M, V13, P315, DOI 10.1007/BF01766459; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; SEIDEL JC, 1980, J BIOL CHEM, V255, P4355; SELLERS JR, 1980, J MOL BIOL, V144, P223, DOI 10.1016/0022-2836(80)90088-1; STAFFORD WF, 1979, BIOCHEMISTRY-US, V18, P5273, DOI 10.1021/bi00591a002; SZENTGYO.AG, 1973, J MOL BIOL, V74, P179, DOI 10.1016/0022-2836(73)90106-X; TAUSSKY HM, 1952, J BIOL CHEM, V202, P675; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; WELLS C, 1984, FEBS LETT, V168, P260, DOI 10.1016/0014-5793(84)80258-6; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	24	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26779	26782		10.1074/jbc.271.43.26779	http://dx.doi.org/10.1074/jbc.271.43.26779			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900158	hybrid			2022-12-25	WOS:A1996VP23300052
J	Marriott, I; Mason, MJ				Marriott, I; Mason, MJ			Evidence for a phorbol ester-insensitive phosphorylation step in capacitative calcium entry in rat thymic lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INTRACELLULAR CA2+ STORES; PLASMA-MEMBRANE; NA+/H+ EXCHANGE; MYRISTATE ACETATE; HUMAN NEUTROPHILS; XENOPUS OOCYTES; CONCANAVALIN-A; OKADAIC ACID; K+ CHANNELS	Experiments were undertaken to investigate the regulation of capacitative Ca2+ entry by phorbol ester-sensitive protein kinase C and serine(threonine protein phosphatase activity, The thapsigargin-activated Ca2+ entry pathway was probed in control cells and cells treated with phosphatase type 1/2A inhibitors, okadaic acid and calyculin A, or with the phorbol ester, phorbol 12-myristate 13-acetate. The permeability state of this pathway was monitored in the presence or absence of these agents using fluorometric measurements of intracellular Ca2+ concentration, unidirectional Mn2+ entry, and membrane potential and unidirectional measurements of Ca2+ uptake using Ca-45(2+). The results of these studies demonstrate that modification of the phosphorylation state of target protein(s) on serine/threonine amino acid residues by inhibition of phosphatase type 1/2A inhibits the capacitative Ca2+ entry pathway in rat thymic lymphocytes, Importantly, the capacitative Ca2+ entry pathway in rat thymic lymphocytes is not modulated by activation of phorbol ester-sensitive protein kinase C.	TULANE UNIV,SCH MED,DEPT PHYSIOL,NEW ORLEANS,LA 70112	Tulane University								BALASUBRAMANYAM M, 1993, AM J PHYSIOL, V265, pC321, DOI 10.1152/ajpcell.1993.265.2.C321; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BODE HP, 1994, FEBS LETT, V339, P307, DOI 10.1016/0014-5793(94)80436-2; GRINSTEIN S, 1987, J BIOL CHEM, V262, P15277; GRINSTEIN S, 1984, J GEN PHYSIOL, V84, P565, DOI 10.1085/jgp.84.4.565; GRINSTEIN S, 1985, J CELL BIOL, V101, P269, DOI 10.1083/jcb.101.1.269; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KANDASAMY RK, 1995, J BIOL CHEM, V270, P29209, DOI 10.1074/jbc.270.49.29209; LAGAST H, 1984, J CLIN INVEST, V73, P878, DOI 10.1172/JCI111284; MACDOUGALL SL, 1988, J CLIN INVEST, V81, P449, DOI 10.1172/JCI113340; MAHAUTSMITH MP, 1991, J PHYSIOL-LONDON, V439, P513, DOI 10.1113/jphysiol.1991.sp018679; MARRIOTT I, 1994, J CELL PHYSIOL, V161, P441, DOI 10.1002/jcp.1041610307; MARRIOTT L, 1995, AM J PHYSIOL, V269, pC766; MASON MJ, 1991, J BIOL CHEM, V266, P10872; MASON MJ, 1990, J MEMBRANE BIOL, V116, P139, DOI 10.1007/BF01868672; MASON MJ, 1993, AM J PHYSIOL, V264, pC654, DOI 10.1152/ajpcell.1993.264.3.C654; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MONTERO M, 1993, J BIOL CHEM, V268, P13055; MONTERO M, 1990, BIOCHEM J, V271, P535, DOI 10.1042/bj2710535; MONTERO M, 1994, J BIOL CHEM, V269, P3963; MURPHY TJ, 1996, BIOCHEM J, V313, P83; NISHIWAKI S, 1990, CARCINOGENESIS, V11, P1837, DOI 10.1093/carcin/11.10.1837; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PETERSEN CCH, 1994, J BIOL CHEM, V269, P32246; POLLOCK WK, 1987, FEBS LETT, V210, P132, DOI 10.1016/0014-5793(87)81322-4; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RANDRIAMAMPITA C, 1995, J BIOL CHEM, V270, P29, DOI 10.1074/jbc.270.1.29; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; RINK TJ, 1980, BIOCHIM BIOPHYS ACTA, V595, P65; SARKADI B, 1990, MOL IMMUNOL, V27, P1297, DOI 10.1016/0161-5890(90)90034-W; THOMAS D, 1995, J BIOL CHEM, V270, P6429, DOI 10.1074/jbc.270.12.6429; WILSON OI, 1994, J MEMBRANE BIOL, V137, P159	35	14	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26732	26738		10.1074/jbc.271.43.26732	http://dx.doi.org/10.1074/jbc.271.43.26732			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900152	hybrid			2022-12-25	WOS:A1996VP23300046
J	Yamaguchi, T; Pang, J; Reddy, KS; Witkowska, HE; Surrey, S; Adachi, K				Yamaguchi, T; Pang, J; Reddy, KS; Witkowska, HE; Surrey, S; Adachi, K			Expression of soluble human beta-globin chains in bacteria and assembly in vitro with alpha-globin chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC PROTEOLYSIS; ESCHERICHIA-COLI; HUMAN HEMOGLOBIN; PROTEINS; BINDING	Authentic soluble human beta-globin chains were produced in Escherichia coli using an expression plasmid (pHE2 beta) containing full-length cDNAs coding for human beta-globin chain and methionine aminopeptidase. Spectral properties of the purified beta-globin were identical to those of authentic beta-globin. Soluble beta-globin showed low (16 kDa) and high molecular mass (32 kDa) forms that could be separated by gel filtration chromatography, SDS-polyacrylamide gel electrophoresis and electrospray mass spectrometry revealed the 32-kDa species was dimeric beta-globin formed by an intermolecular disulfide bond, while the 16-kDa species was authentic monomeric beta-globin. Monomeric forms of beta-globin, like authentic native beta-globin, formed tetrameric hemoglobin (Hb) A (alpha(2) beta(2)) in vitro upon incubation with alpha-globin, while dimeric forms did not, When beta-globin dimers, however, were converted to monomers by incubation with dithiothreitol, the beta-globin chain monomers assembled with alpha-globin and formed hemoglobin tetramers. alpha-Globin was more thermally unstable than beta-globin, while assembled tetramers promoted higher stability. Disulfide-bonded beta-globin dimers showed a slight increase in thermal stability compared with beta-globin; however, dimers were still more unstable than tetrameric Hb A. These results indicate that presence of alpha chains favors assembly with beta-globin, beta-beta dimers cannot bind alpha chains, and that Hb A tetramer formation results in the most thermally stable species.	UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DIV HEMATOL,ABRAMSON CTR,PHILADELPHIA,PA 19104; UNIV PENN,DEPT BIOPHYS,PHILADELPHIA,PA 19104; CHILDRENS HOSP OAKLAND,RES INST,OAKLAND,CA 94609	University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland					NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR006505] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL020985, P60HL038632] Funding Source: NIH RePORTER; NCRR NIH HHS [RR06505] Funding Source: Medline; NHLBI NIH HHS [HL20985, HL38632] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1992, PROTEIN ENG, V5, P807, DOI 10.1093/protein/5.8.807; ASAKURA T, 1974, BIOCHEM BIOPH RES CO, V57, P780, DOI 10.1016/0006-291X(74)90614-7; Ascoli F, 1981, Methods Enzymol, V76, P72; BALDWIN R. L., 1987, PROTEIN ENG, P127; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; BORGSTAHL GEO, 1994, J MOL BIOL, V236, P817, DOI 10.1006/jmbi.1994.1191; BUNN HF, 1983, NATURE, V306, P498, DOI 10.1038/306498a0; Di Iorio E E, 1981, Methods Enzymol, V76, P57; FERRIGE AG, 1992, RAPID COMMUN MASS SP, V6, P707, DOI 10.1002/rcm.1290061115; FRANCHI D, 1982, BIOCHEMISTRY-US, V21, P6181, DOI 10.1021/bi00267a024; FRIEND SH, 1981, BIOCHEMISTRY-US, V20, P580, DOI 10.1021/bi00506a021; FRONTICELLI C, 1991, J PROTEIN CHEM, V10, P495, DOI 10.1007/BF01025477; GROEBE DR, 1992, PROTEIN EXPRES PURIF, V3, P134, DOI 10.1016/S1046-5928(05)80030-0; HERNAN RA, 1992, BIOCHEMISTRY-US, V31, P8619, DOI 10.1021/bi00151a032; HOFFMAN SJ, 1990, P NATL ACAD SCI USA, V87, P8521, DOI 10.1073/pnas.87.21.8521; Ikeda-Saito M, 1981, Methods Enzymol, V76, P113; KLIBANOV AM, 1987, PROTEIN ENG, P213; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIGHTWAHL KJ, 1993, J MASS SPECTROM, V30, P1663; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; Nakanishi T, 1995, J MASS SPECTROM, V30, P1663, DOI 10.1002/jms.1190301205; PERUTZ MF, 1974, NATURE, V247, P341, DOI 10.1038/247341a0; PHILO JS, 1988, J BIOL CHEM, V263, P682; Schroeder W. A., 1984, CRC HDB HPLC SEPARAT, VII, P287; SCHWARTZ E, 1991, HEMATOLOGY BASIC PRI, P368; Shackleton CHL, 1994, MASS SPECTROMETRY CL, V2, P135; SHEN TJ, 1993, P NATL ACAD SCI USA, V90, P8108, DOI 10.1073/pnas.90.17.8108; VALDES R, 1977, J BIOL CHEM, V252, P74; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57; WITKOWSKA HE, 1993, HEMOGLOBIN, V17, P227, DOI 10.3109/03630269308998897	31	23	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26677	26683		10.1074/jbc.271.43.26677	http://dx.doi.org/10.1074/jbc.271.43.26677			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900144	hybrid			2022-12-25	WOS:A1996VP23300038
J	Deng, L; Shuman, S				Deng, L; Shuman, S			An ATPase component of the transcription elongation complex is required for factor-dependent transcription termination by vaccinia RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS EARLY TRANSCRIPTION; CAPPING ENZYME; MESSENGER-RNA; TERNARY COMPLEXES; NASCENT RNA; EARLY GENES; PROMOTER; PURIFICATION; VIRIONS; TRIPHOSPHATE	Vaccinia virus RNA polymerase terminates transcription in response to a specific signal UUUUUNU in the nascent transcript. Transduction of this signal to the elongating polymerase requires a virus-encoded termination factor, VTF. The existence of a second termination factor was suggested by the finding that transient exposure of purified elongation complexes to heparin rendered them refractory to VTF-induced termination. Loss of termination competence correlated with the removal of several polypeptide components of the elongation complex. We present the identification of factor X, an activity that restored VTF responsiveness to heparin-stripped ternary complexes. We propose that factor X, which has an associated DNA-dependent ATPase activity, mediates the requirement for ATP hydrolysis during transcription termination.	SLOAN KETTERING INST,PROGRAM MOL BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NIGMS NIH HHS [GM42498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN BY, 1994, J BIOL CHEM, V269, P7552; BALDICK CJ, 1994, J VIROL, V68, P6052, DOI 10.1128/JVI.68.9.6052-6056.1994; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; BROYLES SS, 1987, MOL CELL BIOL, V7, P7, DOI 10.1128/MCB.7.1.7; BROYLES SS, 1988, J BIOL CHEM, V263, P10761; Condit RC, 1996, VIROLOGY, V218, P169, DOI 10.1006/viro.1996.0177; DENG L, 1994, J BIOL CHEM, V269, P14323; Deng L, 1996, J BIOL CHEM, V271, P19556, DOI 10.1074/jbc.271.32.19556; GERSHOWITZ A, 1978, J VIROL, V27, P399, DOI 10.1128/JVI.27.2.399-408.1978; GOLINI F, 1985, J VIROL, V53, P205, DOI 10.1128/JVI.53.1.205-213.1985; Gross CH, 1996, J VIROL, V70, P2615, DOI 10.1128/JVI.70.4.2615-2619.1996; HAGLER J, 1992, P NATL ACAD SCI USA, V89, P10099, DOI 10.1073/pnas.89.21.10099; HAGLER J, 1994, J BIOL CHEM, V269, P10050; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HAGLER J, 1992, J VIROL, V66, P2982, DOI 10.1128/JVI.66.5.2982-2989.1992; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; KATES J, 1970, J MOL BIOL, V50, P1, DOI 10.1016/0022-2836(70)90100-2; LI J, 1993, J BIOL CHEM, V268, P20016; LI J, 1993, J BIOL CHEM, V268, P2773; LUO Y, 1991, J BIOL CHEM, V266, P13303; LUO Y, 1995, J VIROL, V69, P3852, DOI 10.1128/JVI.69.6.3852-3856.1995; PAOLETTI E, 1974, J BIOL CHEM, V249, P3281; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; SHUMAN S, 1992, P NATL ACAD SCI USA, V89, P10935, DOI 10.1073/pnas.89.22.10935; SHUMAN S, 1980, J BIOL CHEM, V255, P5396; SHUMAN S, 1990, J BIOL CHEM, V265, P11960; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; SHUMAN S, 1988, J BIOL CHEM, V263, P6220; VOS JC, 1991, EMBO J, V10, P2553, DOI 10.1002/j.1460-2075.1991.tb07795.x; Yu L, 1996, J VIROL, V70, P6162, DOI 10.1128/JVI.70.9.6162-6168.1996; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6417, DOI 10.1073/pnas.84.18.6417	32	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29386	29392		10.1074/jbc.271.46.29386	http://dx.doi.org/10.1074/jbc.271.46.29386			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910603	hybrid			2022-12-25	WOS:A1996VT05200095
J	Holloway, DE; Chen, HP; Marsh, ENG				Holloway, DE; Chen, HP; Marsh, ENG			Carboxymethylation of MutS-cysteine-15 specifically inactivates adenosylcobalamin-dependent glutamate mutase - Examination of the role of this residue in coenzyme-binding and catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOND-DISSOCIATION ENERGY; ESCHERICHIA-COLI; CLOSTRIDIUM-TETANOMORPHUM; METHIONINE SYNTHASE; COMPONENT-S; REDUCTION; ENZYMES; CLONING; B-12	The sensitivity of adenosylcobalamin (AdoCbl)-dependent glutamate mutase toward thiol-directed reagents has been investigated. Iodoacetate specifically alkylates one cysteine residue, Cys-15, in MutS with concomitant irreversible loss of enzyme activity. Cys-15 lies between the conserved residues Asp-14 and His-16, that are believed to coordinate cobalt to form a Co-His-Asp hydrogen-bonded ''triad'' when AdoCbl is bound by the enzyme. Although inactive, carboxymethylated MutS still bound AdoCbl with only a 5-fold increase in apparent K-d. To determine whether Cys-15 plays an essential role in catalysis, it was mutated to serine and to alanine. These mutants were active, but both exhibited decreased V-max and increased apparent K-m and K-d for AdoCbl. To mimic the effect of carboxymethylation, Cys15 was mutated to aspartate and, as an isosteric control, to asparagine, Neither of these mutants was active: MutS-C15N bound AdoCbl approximately 10-fold weaker than wild type, whereas MutS-C15N bound AdoCbl over 100 times less strongly than wild type. The results demonstrate both coenzyme-binding and catalysis to be very sensitive to mutations at position 15 that could potentially perturb the Co-His-Asp hydrogen-bonding network.	UNIV MICHIGAN,DEPT CHEM,ANN ARBOR,MI 48109; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND; UNIV CAMBRIDGE,CAMBRIDGE CTR MOL RECOGNIT,CAMBRIDGE CB2 1QW,ENGLAND	University of Michigan System; University of Michigan; University of Cambridge; University of Cambridge			Marsh, Neil/G-7553-2016; Holloway, Daniel E/S-4944-2016; Chen, Hao-Ping/Q-3283-2019	Marsh, Neil/0000-0003-1713-1683; Holloway, Daniel E/0000-0003-0155-6978; Chen, Hao-Ping/0000-0002-6491-2178				BABIOR BM, 1979, CRC CR REV BIOCH MOL, V6, P35, DOI 10.3109/10409237909105424; BARKER HA, 1964, J BIOL CHEM, V239, P3260; BEATRIX B, 1994, EUR J BIOCHEM, V221, P101, DOI 10.1111/j.1432-1033.1994.tb18718.x; BOOKER S, 1994, BIOCHEMISTRY-US, V33, P12676, DOI 10.1021/bi00208a019; DRENNAN CL, 1994, CURR OPIN STRUC BIOL, V4, P919, DOI 10.1016/0959-440X(94)90275-5; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; FINKE RG, 1990, MOLECULAR MECHANISMS IN BIOORGANIC PROCESSES, P244; GEO MK, 1987, J AM CHEM SOC, V107, P1238; GOLDING BT, 1986, ENZYME MECHANISMS, P404; GOODIN DB, 1993, BIOCHEMISTRY-US, V32, P3313, DOI 10.1021/bi00064a014; HALPERN J, 1984, J AM CHEM SOC, V106, P8317, DOI 10.1021/ja00338a065; HALPERN J, 1985, SCIENCE, V227, P869, DOI 10.1126/science.2857503; HAY BP, 1986, J AM CHEM SOC, V108, P4820, DOI 10.1021/ja00276a020; HOLLOWAY DE, 1994, J BIOL CHEM, V269, P20425; HOLLOWAY DE, 1993, FEBS LETT, V317, P44, DOI 10.1016/0014-5793(93)81488-L; HSIANG MW, 1967, J BIOL CHEM, V242, P3079; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; Jarrett JT, 1996, BIOCHEMISTRY-US, V35, P2464, DOI 10.1021/bi952389m; KIM SH, 1988, J AM CHEM SOC, V110, P1320; KRATKY C, 1995, J AM CHEM SOC, V117, P4654, DOI 10.1021/ja00121a022; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9752, DOI 10.1021/bi00155a031; MARSH ENG, 1992, FEBS LETT, V310, P167, DOI 10.1016/0014-5793(92)81321-C; MARSH ENG, 1995, BIOCHEMISTRY-US, V34, P7542, DOI 10.1021/bi00022a030; MARSH ENG, 1995, BIOESSAYS, V17, P431, DOI 10.1002/bies.950170511; NG FTT, 1982, J AM CHEM SOC, V104, P621, DOI 10.1021/ja00366a045; OCHIAI EI, 1994, MET IONS BIOL SYST, V30, P255; Sambrook J., 2002, MOL CLONING LAB MANU; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; SWITZER RL, 1967, J BIOL CHEM, V242, P2658; SWITZER RL, 1969, J BIOL CHEM, V244, P5263; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; ZELDER O, 1995, FEBS LETT, V369, P252, DOI 10.1016/0014-5793(95)00762-X	33	3	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29121	29125		10.1074/jbc.271.46.29121	http://dx.doi.org/10.1074/jbc.271.46.29121			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910568	hybrid			2022-12-25	WOS:A1996VT05200060
J	Kim, KK; Daud, AI; Wong, SC; Pajak, L; Tsai, SC; Wang, H; Henzel, WJ; Field, LJ				Kim, KK; Daud, AI; Wong, SC; Pajak, L; Tsai, SC; Wang, H; Henzel, WJ; Field, LJ			Mouse RAD50 has limited epitopic homology to p53 and is expressed in the adult myocardium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-ANTIGEN TRANSGENES; STRAND BREAK REPAIR; DNA-BINDING DOMAIN; WILD-TYPE P53; SACCHAROMYCES-CEREVISIAE; INSITU HYBRIDIZATION; GENE AMPLIFICATION; TERMINAL DOMAIN; NUCLEIC-ACIDS; HEPTAD-REPEAT	Previous studies have identified a 18O-kDa mouse cardiomyocyte phosphoprotein with limited epitopic homology to p53. In this study, the protein was purified and partially sequenced. Oligonucleotide probes based on the available amino acid sequence data were used to isolate cDNA clones. Sequence analyses revealed that the clones encoded a protein with regional homology to the yeast RAD50 gene product. Expression of the mouse cDNA rescued the methyl methanesulfonate-sensitive phenotype in rad50 mutant yeast, indicating that the cardiomyocyte phosphoprotein is the mammalian homologue of the yeast RAD5O gene product. Fluorescence in situ hybridization analyses localized the mouse RAD50 gene to the A5-B1 region of chromosome 11. Northern blot analyses demonstrated a complex pattern of RAD5O expression during mouse development which was further complicated by the presence of several alternatively spliced transcripts. High levels of RAD5O expression was evident in the adult myocardium, a somewhat surprising observation given the absence of DNA synthesis in adult cardiomyocytes.	INDIANA UNIV,SCH MED,KRANNERT INST CARDIOL,INDIANAPOLIS,IN 46202; GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080	Indiana University System; Indiana University-Purdue University Indianapolis; Roche Holding; Genentech			Daud, Adil/T-3079-2019	Daud, Adil/0000-0002-6617-8421; Henzel, William/0000-0003-2940-3797	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045453] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45453, HL06308] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALANI E, 1989, GENETICS, V122, P47; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DAUD AI, 1993, AM J PHYSIOL, V264, pH1693, DOI 10.1152/ajpheart.1993.264.5.H1693; FENG GS, 1994, ONCOGENE, V9, P1545; FIELD LJ, 1988, SCIENCE, V239, P1029, DOI 10.1126/science.2964082; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GAME JC, 1974, MUTAT RES, V24, P281, DOI 10.1016/0027-5107(74)90176-6; Guthrie C, 1991, GUIDE YEAST GENETICS; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HENZEL WJ, 1987, J CHROMATOGR, V404, P41, DOI 10.1016/S0021-9673(01)86835-7; HENZEL WJ, 1990, ANAL BIOCHEM, V187, P228, DOI 10.1016/0003-2697(90)90448-I; HEUDE M, 1988, MUTAT RES, V194, P151, DOI 10.1016/0167-8817(88)90017-X; IVANOV EL, 1994, MOL CELL BIOL, V14, P3414, DOI 10.1128/MCB.14.5.3414; JOHZUKA K, 1995, GENETICS, V139, P1521; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATZ EB, 1992, AM J PHYSIOL, V262, pH1867, DOI 10.1152/ajpheart.1992.262.6.H1867; KIM KK, 1994, J BIOL CHEM, V269, P22607; KIM KK, 1995, GENOMICS, V28, P520, DOI 10.1006/geno.1995.1184; KOZAK M, 1994, BIOCHIMIE, V76, P815, DOI 10.1016/0300-9084(94)90182-1; KRUTZSCH HC, 1993, ANAL BIOCHEM, V209, P109, DOI 10.1006/abio.1993.1089; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOEB LA, 1991, CANCER RES, V51, P3075; LUDLOW JW, 1995, VIRUS RES, V35, P113, DOI 10.1016/0168-1702(94)00094-S; MALONE RE, 1990, CURR GENET, V18, P111, DOI 10.1007/BF00312598; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Sambrook J., 1989, MOL CLONING; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHIESTL RH, 1994, MOL CELL BIOL, V14, P4493, DOI 10.1128/MCB.14.7.4493; SHEN ZY, 1995, GENOMICS, V25, P199, DOI 10.1016/0888-7543(95)80126-7; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SOONPAA MH, 1994, AM J PHYSIOL, V266, pH1439, DOI 10.1152/ajpheart.1994.266.4.H1439; STEINHELPER ME, 1990, AM J PHYSIOL, V259, pH1826, DOI 10.1152/ajpheart.1990.259.6.H1826; STEINHELPER ME, 1990, TOXICOL PATHOL, V18, P464, DOI 10.1177/0192623390004Part_104; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	57	18	21	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29255	29264		10.1074/jbc.271.46.29255	http://dx.doi.org/10.1074/jbc.271.46.29255			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910585	hybrid			2022-12-25	WOS:A1996VT05200077
J	Lindahl, M; Tabak, S; Cseke, L; Pichersky, E; Andersson, B; Adam, Z				Lindahl, M; Tabak, S; Cseke, L; Pichersky, E; Andersson, B; Adam, Z			Identification, characterization, and molecular cloning of a homologue of the bacterial FtsH protease in chloroplasts of higher plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; ATP-DEPENDENT PROTEASE; ESCHERICHIA-COLI FTSH; PHOTOSYSTEM-II; CHLAMYDOMONAS-REINHARDTII; SPINACH-CHLOROPLASTS; THYLAKOID MEMBRANES; DEGRADATION; CHLOROPHYLL; GENES	In an attempt to identify and characterize chloroplast proteases, we performed an immunological analysis of chloroplasts using an antibody against Escherichia coli FtsH protease, which is an ATP-dependent metalloprotease bound to the cytoplasmic membrane. A cross-reacting protein of 78 kDa was found in the thylakoid membrane of spinach, but not in the soluble stromal fraction. Alkali and high salt washes, as well as trypsin treatment of thylakoid membranes, suggest that the chloroplastic FtsH protein is integral to the membrane, with its hydrophilic portion exposed to the stroma. The protein is not bound to any photosynthetic complex and is exclusively located in the stromally exposed regions of the thylakoid membrane. Its expression is dependent on light, as it is present in green pea seedlings, but absent from etiolated ones. An Arabidopsis cDNA was isolated, and the deduced amino acid sequence demonstrated high similarity to the E. coli FtsH protein, especially in the central region of the protein, containing the ATP- and zinc-binding sites. The product of this clone was capable of import into isolated pea chloroplasts, where it was processed to its mature form and targeted to the thylakoid membrane. The trans-bilayer orientation and lateral location of the FtsH protein in the thylakoid membrane suggest its involvement in the degradation of both soluble stromal proteins and newly inserted or turning-over thylakoid proteins.	HEBREW UNIV JERUSALEM,FAC AGR,DEPT AGR BOT,IL-76100 REHOVOT,ISRAEL; UNIV STOCKHOLM,ARRHENIUS LABS NAT SCI,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN; UNIV MICHIGAN,DEPT BIOL,ANN ARBOR,MI 48109	Hebrew University of Jerusalem; Stockholm University; University of Michigan System; University of Michigan			Lindahl, Marika/H-2259-2017; Andersson, Bertil/C-9328-2009	Lindahl, Marika/0000-0003-1627-0809				ADAM Z, 1993, PLANT PHYSIOL, V102, P35, DOI 10.1104/pp.102.1.35; Adamska I, 1996, EUR J BIOCHEM, V236, P591, DOI 10.1111/j.1432-1033.1996.00591.x; ANDERSON JM, 1982, TRENDS BIOCHEM SCI, V7, P288, DOI 10.1016/0968-0004(82)90014-7; ANDERSSON B, 1980, BIOCHIM BIOPHYS ACTA, V593, P427, DOI 10.1016/0005-2728(80)90078-X; ANDERSSON B, 1976, BIOCHIM BIOPHYS ACTA, V423, P122, DOI 10.1016/0005-2728(76)90106-7; APEL K, 1980, PLANTA, V150, P426, DOI 10.1007/BF00390180; ARELLANO JB, 1994, PHYSIOL PLANTARUM, V91, P369, DOI 10.1111/j.1399-3054.1994.tb02962.x; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BARBER J, 1994, NATURE, V370, P31, DOI 10.1038/370031a0; BURKE JJ, 1978, ARCH BIOCHEM BIOPHYS, V187, P252, DOI 10.1016/0003-9861(78)90031-0; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; Halperin T, 1996, PLANT MOL BIOL, V30, P925, DOI 10.1007/BF00020804; HERMAN C, 1995, P NATL ACAD SCI USA, V92, P3516, DOI 10.1073/pnas.92.8.3516; HOOBER JK, 1992, PLANT PHYSIOL, V99, P932, DOI 10.1104/pp.99.3.932; HUANG LQ, 1992, PLANT PHYSIOL, V99, P247, DOI 10.1104/pp.99.1.247; HUGUENEY P, 1995, P NATL ACAD SCI USA, V92, P5630, DOI 10.1073/pnas.92.12.5630; HURT E, 1981, EUR J BIOCHEM, V117, P591; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; Kowallik KV, 1995, PLANT MOL BIOL REP, V13, P336, DOI 10.1007/BF02669188; KYLE DJ, 1984, BIOCHIM BIOPHYS ACTA, V765, P89, DOI 10.1016/0005-2728(84)90001-X; LEVY M, 1995, PLANT MOL BIOL, V29, P53, DOI 10.1007/BF00019118; LINDAHL M, 1995, EUR J BIOCHEM, V231, P503, DOI 10.1111/j.1432-1033.1995.tb20725.x; MATTOO AK, 1989, CELL, V56, P241, DOI 10.1016/0092-8674(89)90897-0; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MERCHANT S, 1986, J BIOL CHEM, V261, P5850; MULLET JE, 1980, PLANT PHYSIOL, V65, P814, DOI 10.1104/pp.65.5.814; NAKAI T, 1995, MOL CELL BIOL, V15, P4441; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; Ostersetzer O, 1996, PLANT MOL BIOL, V31, P673, DOI 10.1007/BF00042238; Ostersetzer O, 1996, EUR J BIOCHEM, V236, P932, DOI 10.1111/j.1432-1033.1996.00932.x; PAJIC A, 1994, FEBS LETT, V353, P201, DOI 10.1016/0014-5793(94)01046-3; Reith M, 1995, PLANT MOL BIOL REP, V13, P333, DOI 10.1007/BF02669187; SCHMIDT GW, 1983, P NATL ACAD SCI USA, V80, P2623; SHANKLIN J, 1995, PLANT CELL, V7, P1713, DOI 10.1105/tpc.7.10.1713; THOMAS BR, 1993, GENETICS, V135, P895; TOMOYASU T, 1993, J BACTERIOL, V175, P1352, DOI 10.1128/JB.175.5.1352-1357.1993; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; TOMOYASU T, 1993, J BACTERIOL, V175, P1344, DOI 10.1128/JB.175.5.1344-1351.1993; vanWijk KJ, 1996, J BIOL CHEM, V271, P9627, DOI 10.1074/jbc.271.16.9627; YALOVSKY S, 1990, PLANT MOL BIOL, V14, P753, DOI 10.1007/BF00016508; YANG DH, 1995, PHOTOSYNTHESIS LIGHT, V4, P453; [No title captured]	42	159	171	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29329	29334		10.1074/jbc.271.46.29329	http://dx.doi.org/10.1074/jbc.271.46.29329			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910594	hybrid			2022-12-25	WOS:A1996VT05200086
J	Rova, EM; McEwen, B; Fredriksson, PO; Styring, S				Rova, EM; McEwen, B; Fredriksson, PO; Styring, S			Photoactivation and photoinhibition are competing in a mutant of Chlamydomonas reinhardtii lacking the 23-kDa extrinsic subunit of photosystem II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC OXYGEN-EVOLUTION; TYROSINE Y-Z; ELECTRON-TRANSFER; MANGANESE CATALYST; EVOLVING COMPLEX; WATER OXIDATION; CHLORIDE-IONS; O2 EVOLUTION; PROTEIN; MEMBRANES	The process of photoactivation has been studied in dark grown cells of Chlamydomonas reinhardtii. A mutant, FUD 39, lacking the Cl--concentrating 23-kDa psbP protein of photosystem II was found to have a decreased capability to perform photoactivation. The yield of the process never reached wild type level, and contrary to the wild type, it was highly dependent on the intensity of the activating Light, with a very narrow optimum around 1 mu E m(-2) s(-1). The different behavior in the mutant can be explained by a requirement for a longer dark period, between the two photoacts, during the photoactivation. This is proposed to reflect the decreased Cl--affinity in the mutant. Photoactivation in the mutant was also found to be very sensitive to competing photoinhibitory processes. The inhibition was located to the donor side of photosystem II and affected the photoactivation capability before electron transfer from Tyr(z) was inhibited. We propose an extended model for photoactivation in which an intermediate that is sensitive to photoinhibition is formed if Cl- is not functionally bound to the manganese cluster.	LUND UNIV,CTR CHEM,DEPT BIOCHEM,S-22100 LUND,SWEDEN; UNIV KARLSTAD,DEPT CHEM,S-65188 KARLSTAD,SWEDEN	Lund University; Karlstad University			Styring, Stenbjörn/L-8414-2016	Styring, Stenbjörn/0000-0002-2803-9244				ANDERSSON B, 1984, FEBS LETT, V168, P113, DOI 10.1016/0014-5793(84)80217-3; ANDERSSON B, 1992, NEW COMPREHENSIVE BI, V23, P121; ANDERSSON B, 1987, TOPICS PHOTOSYNTHESI, V8, P379; ANDREASSON LE, 1995, BBA-BIOENERGETICS, V1230, P155, DOI 10.1016/0005-2728(95)00047-M; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BLUBAUGH DJ, 1990, BIOCHEMISTRY-US, V29, P5109, DOI 10.1021/bi00473a016; CHENIAE GM, 1971, BIOCHIM BIOPHYS ACTA, V253, P167, DOI 10.1016/0005-2728(71)90242-8; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEVITRY C, 1989, J CELL BIOL, V109, P991, DOI 10.1083/jcb.109.3.991; GHANOTAKIS DF, 1990, ANNU REV PLANT PHYS, V41, P255, DOI 10.1146/annurev.pp.41.060190.001351; GHANOTAKIS DF, 1984, FEBS LETT, V167, P127, DOI 10.1016/0014-5793(84)80846-7; GILCHRIST ML, 1995, P NATL ACAD SCI USA, V92, P9545, DOI 10.1073/pnas.92.21.9545; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; Hoganson CW, 1995, PHOTOSYNTH RES, V46, P177, DOI 10.1007/BF00020428; HOMANN PH, 1987, J BIOENERG BIOMEMBR, V19, P105, DOI 10.1007/BF00762720; JEGERSCHOLD C, 1991, FEBS LETT, V280, P87, DOI 10.1016/0014-5793(91)80210-T; JEGERSCHOLD C, 1990, BIOCHEMISTRY-US, V29, P6179, DOI 10.1021/bi00478a010; JEGERSCHOLD C, 1996, IN PRESS BIOCHEMISTR; JOHNSON GN, 1995, BBA-BIOENERGETICS, V1229, P202, DOI 10.1016/0005-2728(95)00003-2; KLIMOV VV, 1990, PHOTOSYNTH RES, V23, P59, DOI 10.1007/BF00030063; KRIEGER A, 1995, BBA-BIOENERGETICS, V1229, P193, DOI 10.1016/0005-2728(95)00002-Z; KUWABARA T, 1985, BIOCHIM BIOPHYS ACTA, V806, P283, DOI 10.1016/0005-2728(85)90107-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYFIELD SP, 1987, EMBO J, V6, P313, DOI 10.1002/j.1460-2075.1987.tb04756.x; MAYFIELD SP, 1987, P NATL ACAD SCI USA, V84, P749, DOI 10.1073/pnas.84.3.749; MILLER AF, 1991, BIOCHIM BIOPHYS ACTA, V1056, P1, DOI 10.1016/S0005-2728(05)80067-2; MILLER AF, 1990, BIOCHEMISTRY-US, V29, P1385, DOI 10.1021/bi00458a007; MILLER AF, 1989, BIOCHEMISTRY-US, V28, P8181, DOI 10.1021/bi00446a033; MIYAO M, 1985, FEBS LETT, V180, P303, DOI 10.1016/0014-5793(85)81091-7; MIYAO M, 1984, FEBS LETT, V170, P350, DOI 10.1016/0014-5793(84)81342-3; MIYAO M, 1991, BIOCHEMISTRY-US, V30, P5379, DOI 10.1021/bi00236a008; MIYAO M, 1989, BIOCHIM BIOPHYS ACTA, V977, P315, DOI 10.1016/S0005-2728(89)80086-6; MURATA N, 1985, TRENDS BIOCHEM SCI, V10, P122, DOI 10.1016/0968-0004(85)90272-5; RADMER R, 1971, BIOCHIM BIOPHYS ACTA, V253, P182, DOI 10.1016/0005-2728(71)90243-X; Radmer R., 1977, PRIMARY PROCESSES PH, P303; ROVA M, 1994, PHOTOSYNTH RES, V39, P75, DOI 10.1007/BF00027145; RUTHERFORD AW, 1992, TOPICS PHOTOSYNTHESI, V11, P179; Styring Stenbjorn, 1994, P51; TAMURA N, 1987, BIOCHIM BIOPHYS ACTA, V890, P179, DOI 10.1016/0005-2728(87)90019-3; THOMPSON LK, 1989, BIOCHEMISTRY-US, V28, P6686, DOI 10.1021/bi00442a023; TOMMOS C, 1995, J AM CHEM SOC, V117, P10325, DOI 10.1021/ja00146a017; VASS I, 1991, BIOCHEMISTRY-US, V30, P830, DOI 10.1021/bi00217a037; VERMAAS WFJ, 1993, PHOTOSYNTH RES, V38, P249, DOI 10.1007/BF00046750	43	38	38	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28918	28924		10.1074/jbc.271.46.28918	http://dx.doi.org/10.1074/jbc.271.46.28918			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910540	hybrid			2022-12-25	WOS:A1996VT05200032
J	Chen, CD; Kemper, B				Chen, CD; Kemper, B			Different structural requirements at specific proline residue positions in the conserved proline-rich region of cytochrome P450 2C2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; SIGNAL; MEMBRANE; PROTEINS; SEQUENCE; DOMAIN; SUFFICIENT; INSERTION; PEPTIDES; MODEL	Cytochrome P450 is anchored to the endoplasmic reticulum membrane by an N-terminal transmembrane sequence with the catalytic domain facing the cytoplasmic side. Within the peptide sequence linking these two domains is a highly conserved proline-rich region. In cytochrome P450 2C2, this region has the sequence (30)PPG-PTFP37. To examine the structural requirements at these proline residues, each proline was replaced with alanine, glycine, valine, or an acidic amino acid, and the activities of the mutated proteins were determined in transfected COS-1 cells. Lauric acid 1 omega-hydroxylase activities of Pro(30) and Pro(33) mutants were less than 10% of wild type for each substitution except for alanine, which was 25-30%. In striking contrast, substitutions at Pro(31) including an acidic residue, did not substantially alter activity. At positions 35 and 37, acidic amino acid substitutions reduced activity to less than 10% of wild type while substitution of the other three amino acids had little effect. The tolerance of substitutions of charged residues at Pro(31) suggests that the side chain at this position is exposed to a polar environment; conversely, the reduced activity with charged substitutions, but not with uncharged substitutions at positions 35 and 37, suggests that these residues are exposed to a hydrophobic environment, presumably within the folded protein. The loss of activity with substitutions at Pro(30) and Pro(33) implies that the motif PXXP is important for the formation of a functional cytochrome P450 and that this sequence might have a helical structure with a repeat of three, as in the left handed poly-L-proline II helix. Insertion of alanine between positions 29 and 30 did not substantially affect activity, but insertions between either 33 and 34 or 37 and 38 resulted in activity less than 25% of wild type. These data indicate that the position of PXXP, relative to the sequence flanking it on the C-terminal side, may be important for its function.	UNIV ILLINOIS, COLL MED URBANA CHAMPAIGN, DEPT MOL & INTEGRAT PHYSIOL, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035897] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35897] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CORNILLE F, 1995, J BIOL CHEM, V270, P16826, DOI 10.1074/jbc.270.28.16826; DONOHUE J, 1953, P NATL ACAD SCI USA, V39, P470, DOI 10.1073/pnas.39.6.470; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; GrahamLorence S, 1996, FASEB J, V10, P206, DOI 10.1096/fasebj.10.2.8641554; GRAHAMLORENCE S, 1995, PROTEIN SCI, V4, P1065, DOI 10.1002/pro.5560040605; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; ISHIHARA N, 1995, J BIOCHEM-TOKYO, V118, P397, DOI 10.1093/oxfordjournals.jbchem.a124920; KAGIMOTO M, 1990, J BIOL CHEM, V265, P17209; Kouro T, 1996, INT IMMUNOL, V8, P237, DOI 10.1093/intimm/8.2.237; LAETHEM RM, 1992, MOL PHARMACOL, V42, P958; LEBRUN JJ, 1995, J BIOL CHEM, V270, P10664, DOI 10.1074/jbc.270.18.10664; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; NARHI LO, 1987, J BIOL CHEM, V262, P6683; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NELSON DR, 1987, MOL BIOL EVOL, V4, P572; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SAKAGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P3361, DOI 10.1073/pnas.81.11.3361; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; STRAUB P, 1993, J BIOL CHEM, V268, P21997; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; SZCZESNASKORUPA E, 1993, ARCH BIOCHEM BIOPHYS, V304, P170, DOI 10.1006/abbi.1993.1335; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; TSUJITA M, 1993, BIOCHIM BIOPHYS ACTA, V1161, P124, DOI 10.1016/0167-4838(93)90205-6; TUSIELUNA MT, 1991, MOL ENDOCRINOL, V5, P685, DOI 10.1210/mend-5-5-685; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; YAMAZAKI S, 1993, J BIOCHEM-TOKYO, V114, P652, DOI 10.1093/oxfordjournals.jbchem.a124232	31	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28607	28611		10.1074/jbc.271.45.28607	http://dx.doi.org/10.1074/jbc.271.45.28607			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910491	hybrid			2022-12-25	WOS:A1996VU03300091
J	He, ZG; Wong, JMS; Maniar, HS; Brill, SJ; Ingles, CJ				He, ZG; Wong, JMS; Maniar, HS; Brill, SJ; Ingles, CJ			Assessing the requirements for nucleotide excision repair proteins of Saccharomyces cerevisiae in an in vitro system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; TRANSCRIPTION FACTOR TFIIH; CELL NUCLEAR ANTIGEN; REPLICATION FACTOR-A; SIMIAN VIRUS-40 DNA; PIGMENTOSUM GROUP-F; XERODERMA-PIGMENTOSUM; COMPLEX-FORMATION; MAMMALIAN-CELLS; MULTIPLE STAGES	Nucleotide excision repair (NER) is the primary mechanism by which both Saccharomyces cerevisiae and human cells remove the DNA lesions caused by ultraviolet light and other mutagens. This complex process involves the coordinated actions of more than 20 polypeptides. To facilitate biochemical studies of NER in yeast, we have established a simple protocol for preparing whole cell extracts which perform NER in vitro, As expected, this assay of in vitro repair was dependent on the products of RAD genes such as RAD14, RAD4 and RAD2. Interestingly, it was also dependent upon proteins encoded by the RAD7, RAD16, and RAD23 genes whose precise roles in NER are uncertain, but not the RAD26 gene whose product is believed to participate in coupling NER to transcription, Replication protein A (RPA/Rpa), known to be required for NER in human cell extracts, was also shown by antibody inhibition and immunodepletion experiments to be required for NER in our yeast cell extracts. Moreover, yeast cells with temperature sensitive mutations in the RFA2 gene, which encodes the 34-kDa subunit of Rpa, had increased sensitivity to UV and yielded extracts defective in NER in vitro, These data indicate that Rpa is an essential component of the NER machinery in S. cerevisiae as it is in mammalian cells.	UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON M5G 1L6,CANADA; RUTGERS STATE UNIV,DEPT MOL BIOL & BIOCHEM,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08855	University of Toronto; University of Toronto; Rutgers State University New Brunswick					NIAID NIH HHS [AI 20460] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020460, R37AI020460] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BANKMANN M, 1992, NATURE, V355, P555, DOI 10.1038/355555a0; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; BUDD ME, 1995, MOL CELL BIOL, V15, P2173; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FIRMENICH AA, 1995, MOL CELL BIOL, V15, P1620; FRIEDBERG EC, 1995, DNA REPAIR; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HANSSON J, 1989, J BIOL CHEM, V264, P21788; HAROSH I, 1989, J BIOL CHEM, V264, P20532; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HEYER WD, 1989, BIOCHEMISTRY-US, V28, P2856, DOI 10.1021/bi00433a017; LEE SH, 1995, J BIOL CHEM, V270, P21800, DOI 10.1074/jbc.270.37.21800; LEHMANN AR, 1995, TRENDS BIOCHEM SCI, V20, P402, DOI 10.1016/S0968-0004(00)89088-X; LI L, 1995, MOL CELL BIOL, V15, P5396; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, pU3559; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PAETKAU DW, 1994, GENE DEV, V8, P2035, DOI 10.1101/gad.8.17.2035; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; PARK E, 1992, P NATL ACAD SCI USA, V89, P11416, DOI 10.1073/pnas.89.23.11416; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SCHULTZ MC, 1991, P NATL ACAD SCI USA, V88, P1004, DOI 10.1073/pnas.88.3.1004; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUNG P, 1993, J BIOL CHEM, V268, P26391; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; VERHAGE R, 1994, MOL CELL BIOL, V14, P6135, DOI 10.1128/MCB.14.9.6135; Verhage RA, 1996, MOL CELL BIOL, V16, P496; WANG ZG, 1995, MOL CELL BIOL, V15, P2288; WANG ZG, 1993, P NATL ACAD SCI USA, V90, P4907, DOI 10.1073/pnas.90.11.4907; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6	56	40	41	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28243	28249		10.1074/jbc.271.45.28243	http://dx.doi.org/10.1074/jbc.271.45.28243			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910442	hybrid			2022-12-25	WOS:A1996VU03300042
J	Skerlavaj, B; Gennaro, R; Bagella, L; Merluzzi, L; Risso, A; Zanetti, M				Skerlavaj, B; Gennaro, R; Bagella, L; Merluzzi, L; Risso, A; Zanetti, M			Biological characterization of two novel cathelicidin-derived peptides and identification of structural requirements for their antimicrobial and cell lytic activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPOLYSACCHARIDE-BINDING-PROTEIN; PIG MYELOID CELLS; BOVINE NEUTROPHILS; ANTIBACTERIAL PEPTIDE; CHEMICAL SYNTHESIS; MOLECULAR-CLONING; CDNA CLONING; BONE-MARROW; ANTIBIOTIC DODECAPEPTIDE; PROLINE-RICH	Cathelicidins are a family of myeloid antimicrobial peptide precursors that have been identified in several mammalian species (Zanetti, M., Gennaro, R., and Romeo, D. (1995) FEBS Lett, 374, 1-5), Two novel bovine congeners have been deduced from cDNA, Their C-terminal sequences of 27 and 28 residues correspond to putative antimicrobial peptides with a cationic N-terminal region predicted to assume an amphipathic alpha-helical conformation followed by a hydrophobic C-terminal tail, Peptides corresponding to these sequences have been chemically synthesized and shown to exert a potent antimicrobial activity against Gram-negative and Gram positive bacteria, including methicillin-resistant Staphylococcus aureus, and fungi, Both peptides are also cytotoxic to human erythrocytes and neutrophils, although at higher than microbicidal concentrations, The target selectivity has been improved by synthesizing truncated analogues, comprising only the 18 N-terminal residues, which show a great reduction in cytotoxic, but not in antimicrobial activity, The involvement of the C-terminal hydrophobic tail in the cytotoxic activity has been further demonstrated by inducing a major loss of activity in an analogue after replacing highly hydrophobic residues with more hydrophilic ones.	LAB NAZL CONSORZIO INTERUNIV BIOTECNOL, I-34012 TRIESTE, ITALY; UNIV UDINE, DIPARTIMENTO SCI & TECNOL BIOMED, I-33100 UDINE, ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine			Gennaro, Renato/AAJ-2511-2021	Gennaro, Renato/0000-0003-1331-3885; SKERLAVAJ, Barbara/0000-0003-0437-802X; BAGELLA, Luigi/0000-0003-2815-037X				AGERBERTH B, 1995, P NATL ACAD SCI USA, V92, P195, DOI 10.1073/pnas.92.1.195; ALVAREZBRAVO J, 1994, BIOCHEM J, V302, P535, DOI 10.1042/bj3020535; BAGELLA L, 1995, FEBS LETT, V376, P225, DOI 10.1016/0014-5793(95)01285-3; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BOMAN HG, 1994, CIBA FDN S, V186; BUCK MA, 1989, ANAL BIOCHEM, V182, P295, DOI 10.1016/0003-2697(89)90597-6; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COWLAND JB, 1995, FEBS LETT, V368, P173, DOI 10.1016/0014-5793(95)00634-L; DELSAL G, 1992, BIOCHEM BIOPH RES CO, V187, P467, DOI 10.1016/S0006-291X(05)81517-7; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; DOIG AJ, 1995, PROTEIN SCI, V4, P1325, DOI 10.1002/pro.5560040708; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FRANK RW, 1990, J BIOL CHEM, V265, P18871; GAHAY JE, 1994, SCIENCE, V264, P373; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GENNARO R, 1989, INFECT IMMUN, V57, P3142, DOI 10.1128/IAI.57.10.3142-3146.1989; Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x; KOKRYAKOV VN, 1993, FEBS LETT, V327, P231, DOI 10.1016/0014-5793(93)80175-T; LARRICK JW, 1991, BIOCHEM BIOPH RES CO, V179, P170, DOI 10.1016/0006-291X(91)91350-L; LARRICK JW, 1995, INFECT IMMUN, V63, P1291, DOI 10.1128/IAI.63.4.1291-1297.1995; LEE JY, 1989, P NATL ACAD SCI USA, V86, P9159, DOI 10.1073/pnas.86.23.9159; LEVY O, 1993, J BIOL CHEM, V268, P6058; Mahoney MM, 1995, FEBS LETT, V377, P519, DOI 10.1016/0014-5793(95)01390-3; PUNGERCAR J, 1993, FEBS LETT, V336, P284, DOI 10.1016/0014-5793(93)80821-B; ROMEO D, 1988, J BIOL CHEM, V263, P9573; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; SCOCCHI M, 1994, FEBS LETT, V352, P197, DOI 10.1016/0014-5793(94)00954-6; SCOCCHI M, 1992, EUR J BIOCHEM, V209, P589, DOI 10.1111/j.1432-1033.1992.tb17324.x; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; SKERLAVAJ B, 1990, INFECT IMMUN, V58, P3724, DOI 10.1128/IAI.58.11.3724-3730.1990; STORICI P, 1993, BIOCHEM BIOPH RES CO, V196, P1363, DOI 10.1006/bbrc.1993.2403; STORICI P, 1994, FEBS LETT, V337, P303, DOI 10.1016/0014-5793(94)80214-9; STORICI P, 1992, FEBS LETT, V314, P187, DOI 10.1016/0014-5793(92)80971-I; STORICI P, 1993, BIOCHEM BIOPH RES CO, V196, P1058, DOI 10.1006/bbrc.1993.2358; TORICI P, 1996, EUR J BIOCHEM, V238, P769; TOSSI A, 1994, FEBS LETT, V339, P108, DOI 10.1016/0014-5793(94)80395-1; TOSSI A, 1995, EUR J BIOCHEM, V228, P941, DOI 10.1111/j.1432-1033.1995.tb20344.x; ZANETTI M, 1990, J CELL BIOL, V111, P1363, DOI 10.1083/jcb.111.4.1363; ZANETTI M, 1993, J BIOL CHEM, V268, P522; ZANETTI M, 1994, J BIOL CHEM, V269, P7855; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O; ZHANG L, 1993, 3 INT S INN PERSP SO; ZHAO CQ, 1994, FEBS LETT, V346, P285, DOI 10.1016/0014-5793(94)00493-5	47	207	228	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28375	28381		10.1074/jbc.271.45.28375	http://dx.doi.org/10.1074/jbc.271.45.28375			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910461	hybrid			2022-12-25	WOS:A1996VU03300061
J	Faris, M; Kokot, N; Lee, L; Nel, AE				Faris, M; Kokot, N; Lee, L; Nel, AE			Regulation of interleukin-2 transcription by inducible stable expression of dominant negative and dominant active mitogen-activated protein kinase kinase kinase in Jurkat T cells - Evidence for the importance of Ras in a pathway that is controlled by dual receptor stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCESSORY MOLECULE CD28; C-JUN; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; IL-2 GENE; MAMMALIAN-CELLS; JNK; INDUCTION; P21(RAS); PROMOTER	Engagement of the T cell receptor induces the activation of several mitogen-activated protein kinase modules, including the extracellular signal-regulated kinase and c-Jun N-terminal kinase (JNK) cascades. Whereas extracellular signal-regulated kinase is activated by T cell receptor/CD3 ligation alone, activation of JNK requires co-stimulation by the, CD28 receptor, Activation of MEKK-1, which acts as a mitogen-activated protein kinase kinase kinase in the JNK pathway, was also induced by CD3 plus CD28 (CD3/CD28) ligation in Jurkat cells, To study She significance of the JNK: cascade in T lymphocytes, we established stable Jurkat cell lines that inducibly express dominant active (DA) or dominant negative (DN) MEKK-1. Whereas expression of DA-MEKK-1 resulted in the constitutive activation of JNK along with the transcriptional activation of the minimal interleukin-2 (IL-2) promoter, DN-MEKK-1 inhibited JNK responsiveness during CD3/CD28 co-stimulation, In addition to inhibiting CD3/CD28-induced IL-2 mRNA expression, DN-MEKK-1 abrogated the transcriptional activation of the IL-2 promoter and the distal nuclear factor of activated T cells (NFAT)-activating protein 1 (AP-I) response element in that promoter, A c-Jun mutant lacking activation sites for JNK also interfered with the activation of the distal NFAT/AP-1 complex, suggesting that the JNK pathway functions by controlling AP-1 response elements in the IL-2 promoter, Using inducible stable expression of DA- and DN-Ras in Jurkat cells, we found that nas regulates JNK activation in these cells, Our results suggest that the dual ligation of CD3 and CD28 in T cells triggers a cascade of events that involve Ras, the JNK cascade, and one or more AP-I response elements in the IL-2 promoter.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV CLIN IMMUNOL & ALLERGY,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90095	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Kokot, Niels/ABB-5847-2020; Nel, Andre E/J-2808-2012	Kokot, Niels/0000-0001-7388-6373; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034567, U01AI034567] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09120-21] Funding Source: Medline; NIAID NIH HHS [AI-34567] Funding Source: Medline; NIGMS NIH HHS [GM41576] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNERIAH Y, 1995, RES IMMUNOL, V146, P150; BIRD TA, 1994, J BIOL CHEM, V269, P31836; BOISE LH, 1995, CURR OPIN IMMUNOL, V7, P620, DOI 10.1016/0952-7915(95)80067-0; BOUSSIOTIS VA, 1994, CURR OPIN IMMUNOL, V6, P797, DOI 10.1016/0952-7915(94)90087-6; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; FARIS M, 1996, AIDS, V10, P370; FRASER JD, 1992, MOL CELL BIOL, V12, P4357, DOI 10.1128/MCB.12.10.4357; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GRANELLIPIPERNO A, 1991, J IMMUNOL, V147, P2734; GREEN JM, 1994, IMMUNITY, V1, P501, DOI 10.1016/1074-7613(94)90092-2; GUPTA S, 1994, J BIOL CHEM, V269, P17349; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MUELLER DL, 1995, CURR OPIN IMMUNOL, V7, P375, DOI 10.1016/0952-7915(95)80113-8; NEL AE, 1991, J IMMUNOL, V147, P1933; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; PETRAK D, 1994, J IMMUNOL, V153, P2046; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	55	61	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27366	27373		10.1074/jbc.271.44.27366	http://dx.doi.org/10.1074/jbc.271.44.27366			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910314	hybrid			2022-12-25	WOS:A1996VQ67900032
J	GarciaFuentes, L; CamaraArtigas, A; LopezMayorga, O; Baron, C				GarciaFuentes, L; CamaraArtigas, A; LopezMayorga, O; Baron, C			Thermodynamic characterization of 5'-AMP binding to bovine liver glycogen phosphorylase alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; HEAT-CAPACITY; PROTEINS; AMP; SURFACE; CRYSTALLIZATION; TEMPERATURES; PURIFICATION; ACTIVATION; MECHANISM	The binding of adenosine 5'-monophosphate to liver glycogen phosphorylase a (EC 2.4.1.1) has been studied by size exclusion high performance liquid chromatography and isothermal titration microcalorimetry at pH 6.9 over a temperature range of 25 to 35 degrees C. The results are compared with those of the binding of the same nucleotide to the muscle isozyme and to liver phosphorylase b. Calorimetric measurements in various buffer systems with different ionization heats suggest that protons are released during the binding of the nucleotide. The dimer of liver glycogen phosphorylase a has been shown to have two equal and independent sites for 5'-AMP, which would correspond to the activator sites identified in the muscle isozyme. The binding constants as well as the changes in Gibbs energy, enthalpy, and entropy per site for 5'-AMP binding were calculated at each temperature. The results show that the major contribution to the negative value of Delta G(0) stems from the value of Delta H in the range of 25 to 35 degrees C. The enthalpy change of binding is strongly temperature-dependent, arising from a large negative Delta C-p of binding equal to -1.45 +/- 0.02 kJ K-1 (mol of 5'-AMP bound)(-1), which suggests significant changes in the polar and apolar surfaces accessible to the solvent.	UNIV ALMERIA,FAC CIENCIAS EXPT,DEPT QUIM FIS BIOQUIM & QUIM INORGAN,ALMERIA 04120,SPAIN; UNIV GRANADA,INST BIOTECHNOL,GRANADA,SPAIN	Universidad de Almeria; University of Granada			Camara-Artigas, Ana/M-2252-2019; Garcia Fuentes, Luis Sebastian/D-1125-2016	Camara-Artigas, Ana/0000-0003-2197-726X; Garcia Fuentes, Luis Sebastian/0000-0003-2471-8052				APPLEMAN MM, 1966, BIOCHEMISTRY-US, V5, P2101, DOI 10.1021/bi00870a043; BARFORD D, 1989, NATURE, V340, P609, DOI 10.1038/340609a0; BARFORD D, 1991, J MOL BIOL, V218, P233, DOI 10.1016/0022-2836(91)90887-C; BARFORD D, 1992, PROTEIN SCI, V1, P472; BARON C, 1989, J BIOL CHEM, V264, P12872; BUC MH, 1968, 1967 FEBS S REG ENZ, P109; CAMARAARTIGAS A, 1994, PROTEIN EXPRES PURIF, V5, P157; CHRISTENSEN JJ, 1976, HDB PROTON IONIZATIO, P93; COHEN P, 1983, METHOD ENZYMOL, V99, P243; COHEN WE, 1955, NUCL ACIDS, V1, P513; CONNELLY PR, 1994, P NATL ACAD SCI USA, V91, P1964, DOI 10.1073/pnas.91.5.1964; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FLETTERICK RJ, 1979, CAN J BIOCHEM CELL B, V57, P789, DOI 10.1139/o79-098; FLETTERICK RJ, 1980, ANNU REV BIOCHEM, V49, P31, DOI 10.1146/annurev.bi.49.070180.000335; Freire E., 1990, ANAL CHEM, V62, P950; GarciaFuentes L, 1996, BBA-PROTEIN STRUCT M, V1294, P83, DOI 10.1016/0167-4838(95)00272-3; GARCIAFUENTES L, 1995, EUR J BIOCHEM, V232, P641, DOI 10.1111/j.1432-1033.1995.641zz.x; HEDRICK JL, 1965, BIOCHEMISTRY-US, V4, P1337, DOI 10.1021/bi00883a018; HERS HG, 1976, ANNU REV BIOCHEM, V45, P167, DOI 10.1146/annurev.bi.45.070176.001123; HUANG CY, 1970, BIOCHEMISTRY-US, V9, P660, DOI 10.1021/bi00805a028; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; HWANG P, 1984, BIOCHIM BIOPHYS ACTA, V791, P252, DOI 10.1016/0167-4838(84)90016-5; Johnson L. N., 1989, ALLOSTERIC ENZYMES, P81; JOHNSON LN, 1979, J MOL BIOL, V134, P639, DOI 10.1016/0022-2836(79)90371-1; JOHNSON LN, 1993, ANNU REV BIOPH BIOM, V22, P199, DOI 10.1146/annurev.bb.22.060193.001215; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; JOHNSON LN, 1994, PROTEIN SCI, V3, P1726, DOI 10.1002/pro.5560031011; JOHNSON LN, 1990, J MOL BIOL, V211, P645, DOI 10.1016/0022-2836(90)90271-M; KASVINSKY PJ, 1978, J BIOL CHEM, V253, P3343; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; LEDERER B, 1976, BIOCHEM J, V159, P689, DOI 10.1042/bj1590689; LIVINGSTONE JR, 1991, BIOCHEMISTRY-US, V30, P4237, DOI 10.1021/bi00231a019; MADSEN NB, 1986, ENZYMES, V17, P366; MATEO PL, 1984, J BIOL CHEM, V259, P9384; MATEO PL, 1986, J BIOL CHEM, V261, P7067; MCKINNON IR, 1984, ANAL BIOCHEM, V139, P134, DOI 10.1016/0003-2697(84)90398-1; MURPHY KP, 1991, J MOL BIOL, V222, P699, DOI 10.1016/0022-2836(91)90506-2; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; OIKONOMAKOS NG, 1985, BIOCHIM BIOPHYS ACTA, V832, P248, DOI 10.1016/0167-4838(85)90257-2; PRESS WH, 1988, NUMERICAL RECIPES C, P683; PRIVALOV PL, 1990, J MOL BIOL, V213, P385, DOI 10.1016/S0022-2836(05)80198-6; SANSOM MSP, 1985, J MOL STRUCT, V123, P3; SCHIEBEL K, 1992, BIOCHIM BIOPHYS ACTA, V1130, P349, DOI 10.1016/0167-4781(92)90453-7; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; SPOLAR RS, 1992, BIOCHEMISTRY-US, V31, P3947, DOI 10.1021/bi00131a009; SPRANG S, 1979, J MOL BIOL, V131, P523, DOI 10.1016/0022-2836(79)90006-8; SPRANG SR, 1991, SCIENCE, V254, P1367, DOI 10.1126/science.1962195; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; STALMANS W, 1974, EUR J BIOCHEM, V49, P415, DOI 10.1111/j.1432-1033.1974.tb03847.x; STALMANS W, 1981, BIOCHEM J, V20, P327; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; TITANI K, 1977, P NATL ACAD SCI USA, V74, P4762, DOI 10.1073/pnas.74.11.4762; Wang J. H, 1972, ENZYMES, V7, P435; WOLF DP, 1970, BIOCHEMISTRY-US, V9, P1923, DOI 10.1021/bi00811a010	55	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27569	27574		10.1074/jbc.271.44.27569	http://dx.doi.org/10.1074/jbc.271.44.27569			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910343	hybrid			2022-12-25	WOS:A1996VQ67900061
J	Itoh, T; Miura, K; Miki, H; Takenawa, T				Itoh, T; Miura, K; Miki, H; Takenawa, T			beta-tubulin binds Src homology 2 domains through a region different from the tyrosine-phosphorylated protein-recognizing site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT EMBRYO FIBROBLASTS; SH3 DOMAINS; PHOSPHOLIPASE-C; SIGNAL TRANSDUCTION; CRYSTAL-STRUCTURE; ASSOCIATION; RECEPTOR; GRB2; KINASES; INSULIN	Src homology 2 (SH2) domains have been demonstrated to bind tyrosine phosphorylated proteins that participate in signaling by growth factors and oncogenes by recognizing amino acid sequences containing phosphotyrosine residue. We found that SH2 domains such as Ash/Grb2, the 85-kDa subunit of phosphatidylinositol 3-kinase, and phospholipase C gamma 1 also bind beta-tubulin through a different region that recognizes phosphotyrosine in vitro and in vivo. Furthermore, binding occurs even when the SH2 domain is occupied by tyrosine-phosphorylated epidermal growth factor receptors. Using deleted constructs of Ash/Grba SH2, we found that carboxyl-terminal beta strands E and F, and alpha helix B (region ''c'') are required for binding. A synthetic peptide (FLWVVKFNSLNELVDYH) composed of region c inhibited the binding of beta-tubulin to the SH2 domains of Ash/Grb2, phosphatidylinositol 3-kinase, and phospholipase C gamma 1. The co-localization of SH2 proteins and microtubules is also confirmed by immunostaining. These data suggest that microtubules play important roles in the assembly of signaling molecules complexes containing SH2 proteins.	UNIV TOKYO, INST MED SCI, DEPT BIOCHEM, MINATO KU, TOKYO 108, JAPAN	University of Tokyo								ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COHEN S, 1982, J BIOL CHEM, V257, P1523; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HOMMA Y, 1990, BIOCHEM J, V269, P13, DOI 10.1042/bj2690013; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; KAPELLER R, 1995, J BIOL CHEM, V270, P25985, DOI 10.1074/jbc.270.43.25985; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCBRIDE K, 1991, P NATL ACAD SCI USA, V88, P7111, DOI 10.1073/pnas.88.16.7111; MIKI H, 1994, J BIOL CHEM, V269, P5489; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SHIBASAKI F, 1993, BIOCHEM J, V289, P227, DOI 10.1042/bj2890227; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; TOBE K, 1993, J BIOL CHEM, V268, P11167; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WATANABE K, 1995, J BIOL CHEM, V270, P13733, DOI 10.1074/jbc.270.23.13733; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	35	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27931	27935		10.1074/jbc.271.44.27931	http://dx.doi.org/10.1074/jbc.271.44.27931			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910394	hybrid			2022-12-25	WOS:A1996VQ67900112
J	Wilson, KP; Fitzgibbon, MJ; Caron, PN; Griffith, JP; Chen, WY; McCaffrey, PG; Chambers, SP; Su, MSS				Wilson, KP; Fitzgibbon, MJ; Caron, PN; Griffith, JP; Chen, WY; McCaffrey, PG; Chambers, SP; Su, MSS			Crystal structure of p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; PHOSPHORYLATION; THREONINE; STRESS; CELLS	p38 mitogen-activated protein kinase is activated by environmental stress and cytokines and plays a role in transcriptional regulation and inflammatory responses, The crystal structure of the ape, unphosphorylated form of p38 kinase has been solved at 2.3 Angstrom resolution. The fold and topology of p38 is similar to ERK2 (Zhang, F., Strand, A,, Robbins, D., Cobb, MI H., and Goldsmith, E. J. (1994) Nature 367, 704-711), The relative orientation of the two domains of p38 kinase is different from that observed in the active form of cAMP-dependent protein kinase, The twist results in a misalignment of the active site of p38, suggesting that the orientation of the domains would have to change before catalysis could proceed, The residues that are phosphorylated upon activation of p38 are located on a surface loop that occupies the peptide binding channel, Occlusion of the active site by the loop, and misalignment of catalytic residues, may account for the low enzymatic activity of unphosphorylated p38 kinase.	VERTEX PHARMACEUT INC,CAMBRIDGE,MA 02139	Vertex Pharmaceuticals								Bokemeyer D, 1996, KIDNEY INT, V49, P1187, DOI 10.1038/ki.1996.172; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; Brunger AT, 1992, XPLOR VERSION 3 1 MA; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOZA YN, 1995, FEBS LETT, V364, P223, DOI 10.1016/0014-5793(95)00346-B; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; KUMAR S, 1995, J BIOL CHEM, V270, P29043, DOI 10.1074/jbc.270.49.29043; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423	31	202	217	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27696	27700		10.1074/jbc.271.44.27696	http://dx.doi.org/10.1074/jbc.271.44.27696			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910361	hybrid			2022-12-25	WOS:A1996VQ67900079
J	Cippitelli, M; Ye, JP; Viggiano, V; Sica, A; Ghosh, P; Gulino, A; Santoni, A; Young, HA				Cippitelli, M; Ye, JP; Viggiano, V; Sica, A; Ghosh, P; Gulino, A; Santoni, A; Young, HA			Retinoic acid-induced transcriptional modulation of the human interferon-gamma promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A-DEFICIENCY; IMMUNODEFICIENCY-VIRUS TYPE-1; NEGATIVE REGULATORY ELEMENT; LOOP-HELIX PROTEIN; NF-KAPPA-B; GLUCOCORTICOID RECEPTOR; DNA-BINDING; THYROID-HORMONE; FACTOR USF; MAMMALIAN-CELLS	Disregulation of vitamin A metabolism is able to generate different immunological effects, including altered response to infection, reduced IgG production, and differential regulation of cytokine gene expression (including interleukin-2 and -4 and interferon-gamma (IFN-gamma)). In particular, IFN-gamma gene expression is significantly affected by vitamin A and/or its derivatives (e.g. retinoic acid (RA)), Here, we analyze the effect of retinoic acid on IFN-gamma transcription. Transient transfection assays in the human T lymphoblastoid cell line Jurkat demonstrated that the activation of the IFN-gamma promoter was significantly down-regulated in the presence of RA, Surprisingly, two different AP-1/CREB-ATF-binding elements situated in the initial 108 base pairs of the IFN-gamma promoter and previously shown to be critical for tran scriptional activity were unaffected by Rk Utilizing promoter deletions and electrophoretic mobility shift analysis, we identified a USF/EGR-1-binding element cooperating in the modulation of IFN-gamma promoter activity by RA, This element was found to be situated in a position of the IFN-gamma promoter close to a silencer element previously identified in our laboratory, These results suggest that direct modulation of IFN-gamma promoter activity is one of the possible mechanisms involved in the inhibitory effect of retinoids on IFN-gamma gene expression.	NCI,FREDERICK CANC RES & DEV CTR,SCI APPLICAT INT CORP FREDERICK,INTRAMURAL RES SUPPORT PROGRAM,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,DIV BASIC SCI,EXPT IMMUNOL LAB,FREDERICK,MD 21702; UNIV AQUILA,DEPT EXPT MED,I-67100 LAQUILA,ITALY; UNIV ROMA LA SAPIENZA,DEPT EXPT MED & PATHOL,I-00158 ROME,ITALY; REGINA ELENA INST CANC RES,LAB PATHOPHYSIOL,I-00158 ROME,ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of L'Aquila; Sapienza University Rome; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena			Cippitelli, Marco/AAF-4857-2021; Sica, Antonio/AAB-9546-2020; Ye, Jianping/N-1998-2017	Cippitelli, Marco/0000-0002-9620-538X; Ye, Jianping/0000-0003-3875-365X				ABB J, 1982, IMMUNOPHARMACOLOGY, V4, P303, DOI 10.1016/0162-3109(82)90051-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLAZSEK I, 1991, BIOMED PHARMACOTHER, V45, P157, DOI 10.1016/0753-3322(91)90103-Z; BROCKERS JP, 1989, NEURON, V2, P1235; BROWN DA, 1992, EUR J IMMUNOL, V22, P2419, DOI 10.1002/eji.1830220935; BROWN DA, 1991, EUR J IMMUNOL, V21, P1879, DOI 10.1002/eji.1830210815; Cantorna MT, 1996, J IMMUNOL, V156, P2674; CANTORNA MT, 1994, J IMMUNOL, V152, P1515; CANTORNA MT, 1995, EUR J IMMUNOL, V25, P1673, DOI 10.1002/eji.1830250629; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CARMAN JA, 1992, J EXP MED, V175, P111, DOI 10.1084/jem.175.1.111; CARMAN JA, 1991, J IMMUNOL, V147, P1247; CARMAN JA, 1989, J IMMUNOL, V142, P388; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHANG TJ, 1993, MOL ENDOCRINOL, V7, P528, DOI 10.1210/me.7.4.528; CHIRIVIA JC, 1990, J EXP MED, V172, P661; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CICCARONE VC, 1990, J IMMUNOL, V144, P725; CIPPITELLI M, 1995, J BIOL CHEM, V270, P12548, DOI 10.1074/jbc.270.21.12548; COHEN M, 1987, AM J DIS CHILD, V141, P263, DOI 10.1001/archpedi.1987.04460030041020; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; DE LUCA LM, 1991, FASEB J, V5, P2924; DEGRAZIA U, 1994, J EXP MED, V180, P1485, DOI 10.1084/jem.180.4.1485; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FELLI MP, 1991, MOL CELL BIOL, V11, P4771, DOI 10.1128/MCB.11.9.4771; GARBE A, 1992, J EXP MED, V176, P109, DOI 10.1084/jem.176.1.109; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; GIACCA M, 1992, VIROLOGY, V186, P133, DOI 10.1016/0042-6822(92)90067-Y; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HONG D, 1993, EMBO J, V12, P501; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JANOT C, 1990, CELL, V62, P1189; JIAYANG C, 1995, EMBO J, V14, P1187; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; LANIGAN TM, 1993, MOL CELL BIOL, V13, P6079, DOI 10.1128/MCB.13.10.6079; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIN Q, 1994, J BIOL CHEM, V269, P23894; LIPKIN SM, 1992, P NATL ACAD SCI USA, V89, P1209, DOI 10.1073/pnas.89.4.1209; LOTAN R, 1991, BIOMED PHARMACOTHER, V45, P145, DOI 10.1016/0753-3322(91)90102-Y; LU YC, 1990, J VIROL, V64, P5226, DOI 10.1128/JVI.64.10.5226-5229.1990; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MASSACESI L, 1991, J CLIN INVEST, V88, P1331, DOI 10.1172/JCI115438; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PENIX L, 1993, J EXP MED, V178, P1483, DOI 10.1084/jem.178.5.1483; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; RACKE MK, 1995, J IMMUNOL, V154, P450; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; ROBERTS AB, 1984, RETINOIDS, V2, P209; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEMBA RD, 1994, LANCET, V343, P1593, DOI 10.1016/S0140-6736(94)93056-2; SHENEFELT RE, 1972, TERATOLOGY, V5, P103, DOI 10.1002/tera.1420050115; SIDELL N, 1993, CELL IMMUNOL, V146, P28, DOI 10.1006/cimm.1993.1003; SIDELL N, 1988, CELL IMMUNOL, V115, P299, DOI 10.1016/0008-8749(88)90183-9; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; SMITH SM, 1987, P NATL ACAD SCI USA, V84, P5878, DOI 10.1073/pnas.84.16.5878; SMITH SM, 1987, J NUTR, V117, P857, DOI 10.1093/jn/117.5.857; STAUBER C, 1992, NEW BIOL, V4, P527; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STROMSTEDT PE, 1991, MOL CELL BIOL, V11, P3379, DOI 10.1128/MCB.11.6.3379; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WIELAND S, 1991, EMBO J, V10, P2513, DOI 10.1002/j.1460-2075.1991.tb07791.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206; YE JP, 1994, J BIOL CHEM, V269, P25728; YOUNG HA, 1990, PHARMACOL THERAPEUT, V45, P137, DOI 10.1016/0163-7258(90)90012-Q; YOUNG HA, 1994, J IMMUNOL, V153, P3603; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1991, J BIOL CHEM, V266, P8248; ZITNIK RJ, 1994, J IMMUNOL, V152, P1419	93	41	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26783	26793		10.1074/jbc.271.43.26783	http://dx.doi.org/10.1074/jbc.271.43.26783			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900159	hybrid			2022-12-25	WOS:A1996VP23300053
J	Mougey, EB; Pape, LK; SollnerWebb, B				Mougey, EB; Pape, LK; SollnerWebb, B			Virtually the entire Xenopus laevis rDNA multikilobase intergenic spacer serves to stimulate polymerase I transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA GENES; DROSOPHILA-MELANOGASTER; SEQUENCE ORGANIZATION; X-LAEVIS; NONTRANSCRIBED SPACER; NUCLEOTIDE-SEQUENCES; RESTRICTION ANALYSIS; MOLECULAR-BASIS; FACTOR XUBF; DNA	The promoter-distal half of the spacer separating the tandem Xenopus laevis rRNA genes consists of ''0'' and ''1'' repetitive elements that have been considered unimportant in polymerase I transcriptional activation, Utilizing oocyte microinjection, we now demonstrate that the 0/1 region, as well as its component 0 and 1 repeats, substantially stimulate transcription from a ribosomal promoter in cis and inhibit transcription when located in trans. Both the cis and trans responses increase linearly with increasing numbers of 0 or 1 repeats until saturation is approached, The 0/1 block and its component elements stimulate transcription in both orientations, over distances, and when placed downstream of the initiation site, properties for which the 60/81-base pair (bp) repeats have been defined as polymerase I enhancers, In their natural promoter-distal rDNA location, the 0/1 repeats can stimulate transcription from the rRNA gene promoter, above the level afforded by the intervening 60/81-bp repeats and spacer promoter, In addition, as with the 60/81-bp repeats, the 0/1 repeats bind a factor in common with the rDNA promoter. Thus, the entire X. laevis rDNA intergenic spacer (the 0 repeats, 1 repeats, spacer promoter repeats, and 60/ 81-bp repeats) acts together to enhance ribosomal transcription.			Mougey, EB (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205, USA.			Mougey, Edward/0000-0003-1190-6660				ARNHEIM N, 1980, CELL, V22, P179, DOI 10.1016/0092-8674(80)90166-X; BACH R, 1981, NUCLEIC ACIDS RES, V9, P5311, DOI 10.1093/nar/9.20.5311; BECKMANN H, 1995, SCIENCE, V270, P1506, DOI 10.1126/science.270.5241.1506; BELL SP, 1989, CELL, V59, P489, DOI 10.1016/0092-8674(89)90032-9; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; BOSELEY P, 1979, CELL, V17, P19, DOI 10.1016/0092-8674(79)90291-5; BOTCHAN P, 1977, CELL, V11, P599, DOI 10.1016/0092-8674(77)90077-0; BUSBY SJ, 1983, CELL, V34, P989, DOI 10.1016/0092-8674(83)90556-1; CASSIDY BG, 1986, MOL CELL BIOL, V6, P2766, DOI 10.1128/MCB.6.8.2766; COPENHAVER GP, 1994, NUCLEIC ACIDS RES, V22, P2651, DOI 10.1093/nar/22.13.2651; DEWINTER RFJ, 1987, J MOL BIOL, V196, P813, DOI 10.1016/0022-2836(87)90407-4; DEWINTER RFJ, 1986, CELL, V44, P313, DOI 10.1016/0092-8674(86)90765-8; DOELLING JH, 1993, P NATL ACAD SCI USA, V90, P7528, DOI 10.1073/pnas.90.16.7528; ERICKSON JM, 1985, AM J HUM GENET, V37, P311; GERLACH WL, 1979, NUCLEIC ACIDS RES, V7, P1869, DOI 10.1093/nar/7.7.1869; GONZALEZ IL, 1995, GENOMICS, V27, P320, DOI 10.1006/geno.1995.1049; GRIMALDI G, 1990, MOL CELL BIOL, V10, P4667, DOI 10.1128/MCB.10.9.4667; GRIMALDI G, 1988, P NATL ACAD SCI USA, V85, P5502, DOI 10.1073/pnas.85.15.5502; HU CH, 1994, MOL CELL BIOL, V14, P2871, DOI 10.1128/MCB.14.5.2871; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KOMINAMI R, 1981, NUCLEIC ACIDS RES, V9, P3219, DOI 10.1093/nar/9.14.3219; KUHN A, 1990, P NATL ACAD SCI USA, V87, P7527, DOI 10.1073/pnas.87.19.7527; LABHART P, 1984, CELL, V37, P285, DOI 10.1016/0092-8674(84)90324-6; LABHART P, 1987, NUCLEIC ACIDS RES, V15, P3623, DOI 10.1093/nar/15.8.3623; LABHART P, 1987, MOL CELL BIOL, V7, P1900, DOI 10.1128/MCB.7.5.1900; LABHART P, 1985, NUCLEIC ACIDS RES, V13, P8999, DOI 10.1093/nar/13.24.8999; LEBLANC B, 1993, EMBO J, V12, P513, DOI 10.1002/j.1460-2075.1993.tb05683.x; LONG EO, 1979, NUCLEIC ACIDS RES, V7, P205, DOI 10.1093/nar/7.1.205; LONG EO, 1980, ANNU REV BIOCHEM, V49, P727, DOI 10.1146/annurev.bi.49.070180.003455; MCSTAY B, 1991, EMBO J, V10, P2297, DOI 10.1002/j.1460-2075.1991.tb07766.x; MOSS T, 1983, NATURE, V302, P223, DOI 10.1038/302223a0; Moss T, 1985, Oxf Surv Eukaryot Genes, V2, P207; MOSS T, 1980, NUCLEIC ACIDS RES, V8, P467, DOI 10.1093/nar/8.3.467; PAALMAN MH, 1995, MOL CELL BIOL, V15, P4648; PAPE LK, 1990, GENE DEV, V4, P52, DOI 10.1101/gad.4.1.52; PAPE LK, 1989, MOL CELL BIOL, V9, P5093, DOI 10.1128/MCB.9.11.5093; PAULE MR, 1994, TRANSCRIPTION MECHAN, P83; PIKAARD CS, 1990, MOL CELL BIOL, V10, P4816, DOI 10.1128/MCB.10.9.4816; PIKAARD CS, 1989, GENE DEV, V3, P1779, DOI 10.1101/gad.3.11.1779; PIKAARD CS, 1988, MOL CELL BIOL, V8, P4282, DOI 10.1128/MCB.8.10.4282; PIKAARD CS, 1994, P NATL ACAD SCI USA, V91, P464, DOI 10.1073/pnas.91.2.464; PROBST E, 1979, J MOL BIOL, V135, P709, DOI 10.1016/0022-2836(79)90173-6; PUTNAM CD, 1994, MOL CELL BIOL, V14, P6476, DOI 10.1128/MCB.14.10.6476; PUTNAM CD, 1992, MOL CELL BIOL, V12, P4970, DOI 10.1128/MCB.12.11.4970; REEDER RH, 1984, CELL, V38, P349, DOI 10.1016/0092-8674(84)90489-6; REEDER RH, 1983, CELL, V35, P449, DOI 10.1016/0092-8674(83)90178-2; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; SAMBROOK J, 1989, MOL CLONINGG LAB MAN; SIMEONE A, 1985, NUCLEIC ACIDS RES, V13, P1089, DOI 10.1093/nar/13.4.1089; SKRYABIN KG, 1984, NUCLEIC ACIDS RES, V12, P2955, DOI 10.1093/nar/12.6.2955; SOLLNERWEBB B, 1979, CELL, V18, P485, DOI 10.1016/0092-8674(79)90066-7; SOLLNERWEBB B, 1982, NUCLEIC ACIDS RES, V10, P3391, DOI 10.1093/nar/10.11.3391; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.bi.55.070186.004101; SYLVESTER JE, 1986, HUM GENET, V73, P193, DOI 10.1007/BF00401226; TAUTZ D, 1987, J MOL BIOL, V195, P525, DOI 10.1016/0022-2836(87)90181-1; TOWER J, 1986, MOL CELL BIOL, V6, P3451, DOI 10.1128/MCB.6.10.3451; WELLAUER PK, 1976, J MOL BIOL, V105, P461, DOI 10.1016/0022-2836(76)90229-1; WELLAUER PK, 1974, P NATL ACAD SCI USA, V71, P2823, DOI 10.1073/pnas.71.7.2823; WINDLE J, 1986, MOL CELL BIOL, V6, P1228, DOI 10.1128/MCB.6.4.1228; WINDLE JJ, 1986, MOL CELL BIOL, V6, P4585, DOI 10.1128/MCB.6.12.4585; YANG Q, 1994, NUCLEIC ACIDS RES, V22, P4798, DOI 10.1093/nar/22.22.4798	62	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27138	27145		10.1074/jbc.271.43.27138	http://dx.doi.org/10.1074/jbc.271.43.27138			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900206	hybrid			2022-12-25	WOS:A1996VP23300100
J	Song, JS; Gomez, J; Stancato, LF; Rivera, J				Song, JS; Gomez, J; Stancato, LF; Rivera, J			Association of a p95 Vav-containing signaling complex with the Fc epsilon RI gamma chain in the RBL-2H3 mast cell line - Evidence for a constitutive in vivo association of Vav with Grb2, Raf-1, and ERK2 in an active complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; AFFINITY IGE RECEPTOR; BASOPHILIC LEUKEMIA-CELLS; T-CELL; IMMUNOGLOBULIN-E; HISTAMINE-RELEASE; EXCHANGE ACTIVITY; CROSS-LINKING; SH2 DOMAIN; B-CELLS	Aggregation of the high affinity receptor for IgE (Fc epsilon RI) on the mucosal mast cell line, RBL-2H3, results in the rapid and persistent tyrosine phosphorylation of Vav. Immunoprecipitation of Vav from activated cells revealed co-immunoprecipitated phosphoproteins of molecular weights identical to the Fc epsilon RI beta and gamma chains, and the former was reactive with antibody to the Fc epsilon RI beta chain. Conversely, Western blots revealed the presence of p95 Vav in Fc epsilon RI immunoprecipitates. The association of Vav and of Grb2 with the receptor was found to be regulated by aggregation of the receptor, and the interaction of Vav with the Fc epsilon RI was localized to the gamma chain. To gain insight on the signaling pathway in which Vav participates, we investigated the in vivo associations of Vav with other molecules. A reducible chemical cross-linking agent was used to covalently maintain protein interactions under nonreducing conditions. A fraction of Vav increased in mass to form a complex of > 300 kDa in molecular mass. Under reducing conditions the cross-linked Vav immunoprecipitates showed the presence of Grb2, Raf-1, and p42(mapk) (ERK2). In vitro kinase assays of Raf-1 activity associated with Vav revealed that this complex had an activity greater than that of Raf-1 derived from nonactivated cells, and aggregation of the Fc epsilon RI did not modulate this activity. In contrast, aggregation of the Fc epsilon RI increased the total Raf-1 activity by 2-5-fold. These results demonstrate that Vav associates constitutively with components of the mitogen-activated protein kinase pathway to form an active multimeric signaling complex whose in vitro activity and associations may be directed by aggregation of the Fc epsilon RI. The findings of this study may also be relevant to other members of the immune recognition receptor family that share the T-cell antigen receptor zeta/gamma chains.	NIAMSD,SECT CHEM IMMUNOL,NIH,BETHESDA,MD 20892; NIAMSD,CELLULAR & MOL BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)								ADAMS JM, 1992, ONCOGENE, V7, P611; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CLEVENGER CV, 1995, J BIOL CHEM, V270, P13246, DOI 10.1074/jbc.270.22.13246; EISEMAN E, 1992, NATURE, V355, P78; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FURUICHI K, 1984, J IMMUNOL, V133, P1513; GERMANO P, 1994, J BIOL CHEM, V269, P23102; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, J IMMUNOL, V152, P2123; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; HOBERT O, 1994, J BIOL CHEM, V269, P20225; HOLOWKA D, 1982, MOL IMMUNOL, V19, P219, DOI 10.1016/0161-5890(82)90334-0; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LIU FT, 1980, J IMMUNOL, V124, P2728; MAO SY, 1995, BIOCHEMISTRY-US, V34, P1968, DOI 10.1021/bi00006a018; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MORISHIMAKAWASH, 1996, MOL BIOL CELL, V7, P893; OFFERMANNS S, 1994, J IMMUNOL, V152, P250; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PRIBLUDA VS, 1992, P NATL ACAD SCI USA, V89, P11446, DOI 10.1073/pnas.89.23.11446; QUARTO R, 1986, MOL IMMUNOL, V11, P1215; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; TSAI M, 1993, EUR J IMMUNOL, V23, P3286, DOI 10.1002/eji.1830231234; TURNER H, 1995, J BIOL CHEM, V270, P9500, DOI 10.1074/jbc.270.16.9500; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1995, MOL CELL BIOL, V15, P4337; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; ZMUIDZINAS A, 1995, EMBO J, V14, P1	45	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26962	26970		10.1074/jbc.271.43.26962	http://dx.doi.org/10.1074/jbc.271.43.26962			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900182	hybrid			2022-12-25	WOS:A1996VP23300076
J	Plaumann, B; Fritsche, M; Rimpler, H; Brandner, G; Hess, RD				Plaumann, B; Fritsche, M; Rimpler, H; Brandner, G; Hess, RD			Flavonoids activate wild-type p53	ONCOGENE			English	Article						flavonoids; p53; cell cycle; G2M; apoptosis; DNA damage	CELL-CYCLE CHECKPOINTS; DNA-DAMAGE; LIPID-PEROXIDATION; INDUCED APOPTOSIS; GROWTH ARREST; QUERCETIN; EXPRESSION; PROTEIN; DIFFERENTIATION; ACCUMULATION	Flavonoids are diphenyl propanoids widely distributed in edible plants. They play a dual role in mutagenesis and carcinogenesis. Some of them act as anticarcinogens or inhibit the growth of tumour cells, whereas others act as cocarcinogens, are mutagenic or able to induce DNA damage. To further elucidate this dual role, we investigated the influence of apigenin, luteolin and quercetin on the tumour suppressor protein p53, regarding p53 accumulation, cell cycle arrest, apoptosis, and biological activity. We found that incubation of the non-tumour cell line C3H10T1/2CL8 with these flavonoids resulted in induction of p53 accumulation and apoptosis. Apoptosis occurred out of the G(2)/M phase of the cell cycle, The G(2)/M arrest seems to be p53-dependent as it did not occur in p53 knockout fibroblasts which further supports the recent finding that p53 is involved in the G(2)/M checkpoint control. Differences between the flavonoids tested concerned p53 accumulation kinetics as well as the biological activity of accumulated p53 and might be due to different modes of flavonoid action. These data suggest that both aspects of flavonoid effects, i.e. inhibition of tumour growth through cell cycle arrest and induction of apoptosis, are functionally related to p53.	UNIV FREIBURG, INST MED MIKROBIOL & HYG, ABT VIROL, D-79104 FREIBURG, GERMANY; INST EXPT KREBSFORSCH, KLIN TUMORBIOL, D-79106 FREIBURG, GERMANY; UNIV FREIBURG, INST PHARMAZEUT BIOL, D-79104 FREIBURG, GERMANY	University of Freiburg; University of Freiburg								AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; AHMAD MS, 1992, CARCINOGENESIS, V13, P605, DOI 10.1093/carcin/13.4.605; AHMED MS, 1994, CARCINOGENESIS, V15, P1627, DOI 10.1093/carcin/15.8.1627; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; ASKEW DS, 1991, ONCOGENE, V6, P1915; AUSTIN CA, 1992, BIOCHEM J, V282, P883, DOI 10.1042/bj2820883; BABICH H, 1987, TOXICOL IN VITRO, V1, P3, DOI 10.1016/0887-2333(87)90031-2; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BORENFREUND E, 1988, TOXICOL IN VITRO, V2, P1, DOI 10.1016/0887-2333(88)90030-6; CANADA AT, 1990, FREE RADICAL BIO MED, V9, P441, DOI 10.1016/0891-5849(90)90022-B; CARIA H, 1995, MUTAT RES-GENET TOX, V343, P85, DOI 10.1016/0165-1218(95)90075-6; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; FIALA ES, 1985, ANNU REV NUTR, V5, P295, DOI [10.1146/annurev.nu.05.070185.001455, 10.1146/annurev.nutr.5.1.295]; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GORCZYCA W, 1993, CANCER RES, V53, P3186; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GUILLOUF C, 1995, ONCOGENE, V10, P2263; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HENDERSON D, 1995, NAT MED, V1, P525, DOI 10.1038/nm0695-525; HOTZ MA, 1994, CYTOMETRY, V15, P237, DOI 10.1002/cyto.990150309; JUVEN T, 1993, ONCOGENE, V8, P3411; KANTENGWA S, 1991, BIOCHEM BIOPH RES CO, V180, P308, DOI 10.1016/S0006-291X(05)81293-8; KINOSHITA T, 1985, CHEM PHARM BULL, V33, P4109; Kuhnau J, 1976, World Rev Nutr Diet, V24, P117; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAUGHTON MJ, 1989, BIOCHEM PHARMACOL, V38, P2859, DOI 10.1016/0006-2952(89)90442-5; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MANACH C, 1995, J NUTR, V125, P1911, DOI 10.1093/jn/125.7.1911; MARKAVERICH BM, 1983, J BIOL CHEM, V258, P1663; MATSUKAWA Y, 1993, CANCER RES, V53, P1328; MCGREGOR JT, 1986, GENETIC TOXICOLOGY D, P33; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; OCHIAI M, 1984, MUTAT RES, V129, P19, DOI 10.1016/0027-5107(84)90118-0; PENNIE WD, 1992, VIROLOGY, V190, P861, DOI 10.1016/0042-6822(92)90926-G; RAHMAN A, 1989, CARCINOGENESIS, V10, P1833, DOI 10.1093/carcin/10.10.1833; RENZING J, 1995, ONCOGENE, V10, P1865; SAHU SC, 1994, CANCER LETT, V85, P159, DOI 10.1016/0304-3835(94)90269-0; SATO F, 1994, BIOCHEM BIOPH RES CO, V204, P578, DOI 10.1006/bbrc.1994.2498; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHIMOI K, 1994, CARCINOGENESIS, V15, P2669, DOI 10.1093/carcin/15.11.2669; SIEGEL J, 1995, ONCOGENE, V11, P1363; STEWART N, 1995, ONCOGENE, V10, P109; THOMPSON RS, 1972, J CHEM SOC PERK T 1, P1387, DOI 10.1039/p19720001387; TOREL J, 1994, PHYTOCHEMISTRY, V26, P2489; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEI YQ, 1994, CANCER RES, V54, P4952; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHANG W, 1993, ONCOGENE, V8, P2555	54	216	224	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1605	1614						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895505				2022-12-25	WOS:A1996VM88700004
J	Zhang, N; Shen, WF; Ho, AD; Lu, M				Zhang, N; Shen, WF; Ho, AD; Lu, M			Three distinct domains in the HOX-11 homeobox oncoprotein are required for optimal transactivation	ONCOGENE			English	Article						homeoprotein; leukemia; oncogene; transactivation	ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING SPECIFICITY; T-CELL LEUKEMIA; CHROMOSOMAL TRANSLOCATIONS; TRANSCRIPTION FACTOR; HOX11 GENE; PROTEIN; PROTOONCOGENE; T(10-14)(Q24-Q11); EXTRADENTICLE	HOX-11 (tcl-3) is a homeobox oncogene isolated from the breakpoint region of the t(10;14) chromosomal translocation recurring in T-cell acute lymphoblastic leukemia. Here we demonstrate that the HOX-11 homeoprotein mediates transactivation of reporter genes through various promoters in both mammalian and yeast cells. By deletion analysis, the transactivation domains of HOX-11 have been mapped to three amino acid stretches in the homeoprotein, the glycine-proline-rich region at the amino terminus, the homeodomain and the glutamine-rich region at the carboxyl terminus. The three distinct functional domains of HOX-11 act in concert for optimal transactivation. In addition, the homeodomain of HOX-11 appears to be differentially utilized in a promoter-dependent manner. Our data support the notion that the HOX-11 homeoprotein functions as an oncogenic transcription activator in leukemogenesis.	UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94121 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Francisco								CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROCE CM, 1991, CANCER RES, V51, pS5015; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DEAR TN, 1995, DEVELOPMENT, V121, P2909; DUBE ID, 1991, BLOOD, V78, P2996; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HAWLEY RG, 1994, ONCOGENE, V9, P1; KAGAN J, 1989, P NATL ACAD SCI USA, V86, P4161, DOI 10.1073/pnas.86.11.4161; KAGAN J, 1994, CANCER RES, V54, P226; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; LU M, 1992, NUCLEIC ACIDS RES, V20, P263, DOI 10.1093/nar/20.2.263; LU M, 1994, HUM GENE THER, V5, P203, DOI 10.1089/hum.1994.5.2-203; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; LU M, 1990, GENE CHROMOSOME CANC, V2, P217, DOI 10.1002/gcc.2870020309; MING L, 1992, ONCOGENE, V7, P1325; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PARK JK, 1992, GENE CHROMOSOME CANC, V4, P32, DOI 10.1002/gcc.2870040105; PEERS B, 1995, MOL CELL BIOL, V15, P7091; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; SAUER F, 1995, SCIENCE, V270, P1825, DOI 10.1126/science.270.5243.1825; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; ZHANG N, 1995, CANCER RES, V55, P1117; ZHANG N, 1993, ONCOGENE, V8, P3265; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	33	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1781	1787						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895525				2022-12-25	WOS:A1996VM88700024
J	Argetsinger, LS; Norstedt, G; Billestrup, N; White, MF; CarterSu, C				Argetsinger, LS; Norstedt, G; Billestrup, N; White, MF; CarterSu, C			Growth hormone, interferon-gamma, and leukemia inhibitory factor utilize insulin receptor substrate-2 in intracellular signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; MEMBRANE-PROXIMAL REGION; C-FOS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOTYROSINE PHOSPHATASE; 3T3-F442A PREADIPOCYTES; CYTOPLASMIC REGIONS; HEMATOPOIETIC-CELLS; 2-HYBRID SYSTEM; SYP PHOSPHATASE	In this report, we demonstrate that insulin receptor substrate-2 (IRS-2) is tyrosyl-phosphorylated following stimulation of 3T3-F442A fibroblasts with growth hormone (GH), leukemia inhibitory factor and interferon-gamma. In response to GH and leukemia inhibitory factor, IRS-2 is immediately phosphorylated, with maximal phosphorylation detected at 15 min; the signal is substantially diminished by 60 min. In response to interferon-gamma, tyrosine phosphorylation of IRS-S was prolonged, with substantial signal still detected at 60 min. Characterization of the mechanism of signaling utilized by GH indicated that tyrosine residues in GH receptor are not necessary for tyrosyl phosphorylation of IRS-2; however, the regions of GH receptor necessary for IRS-2 tyrosyl phosphorylation are the same as those required for JAK2 association and tyrosyl phosphorylation. The role of IRS-2 as a signaling molecule for GH is further demonstrated by the finding that GH stimulates association of IRS-2 with the 85-kDa regulatory subunit of phosphatidylinositol 3'-kinase and with the protein-tyrosine phosphatase SHP2. These results are consistent with the possibility that IRS-2 is a downstream signaling partner of multiple members of the cytokine family of receptors that activate JAK kinases.	UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA; JOSLIN DIABET CTR, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02215 USA; KAROLINSKA INST, CTR BIOTECHNOL, S-14157 STOCKHOLM, SWEDEN; HAGEDORN RES LAB, DK-2820 GENTOFTE, DENMARK	University of Michigan System; University of Michigan; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Karolinska Institutet; Novo Nordisk; Hagedorn Research Institute				Billestrup, Nils/0000-0002-4968-8067	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034171, R01DK043808] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK36836, R01 DK034171, R01 DK043808, R01-DK34171, R01-DK 43808] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; ANDERSON NG, 1992, BIOCHEM J, V284, P649, DOI 10.1042/bj2840649; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; DASILVA L, 1994, J BIOL CHEM, V269, P18267; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KAMEGAI J, 1994, ENDOCRINOLOGY, V135, P2765, DOI 10.1210/en.135.6.2765; Kaplan DH, 1996, J BIOL CHEM, V271, P9, DOI 10.1074/jbc.271.1.9; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KHARITONENKOV A, 1995, J BIOL CHEM, V270, P29189, DOI 10.1074/jbc.270.49.29189; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MALABARBA MG, 1995, J BIOL CHEM, V270, P9630, DOI 10.1074/jbc.270.16.9630; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MEYER DJ, 1993, P NATL ACAD SCI USA, V90, P6721, DOI 10.1073/pnas.90.14.6721; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MOLDRUP A, 1991, J BIOL CHEM, V266, P17441; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OKADA S, 1995, 77 ANN M END SOC JUN, P80; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; RIDDERSTRALE M, 1994, BIOCHEM BIOPH RES CO, V203, P306, DOI 10.1006/bbrc.1994.2182; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROUPAS P, 1995, 77 ANN M END SOC BET, P346; SILVA CM, 1994, J BIOL CHEM, V269, P27532; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TANNER JW, 1992, BIOCHEM J, V282, P99, DOI 10.1042/bj2820099; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; TOKER A, 1994, J BIOL CHEM, V269, P32358; URICH M, 1995, J BIOL CHEM, V270, P29286, DOI 10.1074/jbc.270.49.29286; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; VANDERKUUR JA, 1995, J BIOL CHEM, V270, P21738, DOI 10.1074/jbc.270.37.21738; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WANG YD, 1995, MOL ENDOCRINOL, V9, P303, DOI 10.1210/me.9.3.303; WHITE MF, 1994, J BIOL CHEM, V269, P1; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; XIAO S, 1994, J BIOL CHEM, V269, P21244; XU B, 1995, J BIOL CHEM, V270, P29825; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YIN TG, 1994, J BIOL CHEM, V269, P26614; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	63	105	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29415	29421		10.1074/jbc.271.46.29415	http://dx.doi.org/10.1074/jbc.271.46.29415			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910607				2022-12-25	WOS:A1996VT05200099
J	Bottger, G; Nagelkerken, B; vanderSluijs, P				Bottger, G; Nagelkerken, B; vanderSluijs, P			Rab4 and Rab7 define distinct nonoverlapping endosomal compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN RAB4; TRANS-GOLGI NETWORK; ENDOCYTIC PATHWAY; FUSION INVITRO; MDCK CELLS; RECEPTOR; BIOGENESIS; ANTIBODIES; LYSOSOMES; HEMAGGLUTININ	Several Rab GTPases have been localized to distinct compartments of the endocytic pathway. Rab4 is associated with early endosomes and recycling vesicles and regulates membrane recycling from early endosomes. Rab7 is localized to late endosomes and is involved in the regulation of membrane transport between late endosomes and lysosomes. Although Rab4 and Rab7 appear to regulate distinct transport events in endocytosis, it is not clear whether they perform their activities in related or entirely distinct intracellular compartments. To address this question, we generated stable cell lines expressing Rab4 tagged with a novel X31 influenza hemagglutinin (NH) epitope tag. These antibodies are characterized in this paper and were used to immunoisolate endocytic vesicles with cytoplasmically exposed NHRab4. Immunoisolated membranes contain internalized I-I25-transferrin, but are devoid of Rab7. Confocal immunofluorescence microscopy showed that the early endosomal GTPases Rab4 and Rab5 both do not codistribute with Rab7 within the same cell. These observations suggest that each of the three Rab GTPases operationally defines a distinct station of the endocytic pathway.	UNIV UTRECHT,SCH MED,DEPT CELL BIOL,NL-3584 CX UTRECHT,NETHERLANDS	Utrecht University								APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; DUNN KW, 1992, J CELL BIOL, V117, P301, DOI 10.1083/jcb.117.2.301; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GETHING MJ, 1980, NATURE, V287, P301, DOI 10.1038/287301a0; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P45; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; MERESSE S, 1995, J CELL SCI, V108, P3349; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOLARI R, 1985, J BIOL CHEM, V260, P1141; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; VANDERSLUIJS P, 1990, J CELL SCI, V95, P545; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VANDERSLUIJS P, 1992, EMBO J, V11, P4379, DOI 10.1002/j.1460-2075.1992.tb05538.x; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; WILSON IA, 1981, NATURE, V289, P367; ZERIAL M, 1995, SMALL GTPASES, P295	35	72	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29191	29197		10.1074/jbc.271.46.29191	http://dx.doi.org/10.1074/jbc.271.46.29191			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910576	hybrid			2022-12-25	WOS:A1996VT05200068
J	Cianflone, K; Zhang, ZJ; Vu, H; KohenAvramoglu, R; Kalant, D; Sniderman, AD				Cianflone, K; Zhang, ZJ; Vu, H; KohenAvramoglu, R; Kalant, D; Sniderman, AD			The effect of individual amino acids on ApoB100 and Lp(a) secretion by HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-B GENE; DENSITY LIPOPROTEIN SECRETION; CULTURED RAT HEPATOCYTES; SOYBEAN PROTEIN-DIET; SOY PROTEIN; RECEPTOR ACTIVITY; MESSENGER-RNA; APO-B; HYPERCHOLESTEROLEMIC PATIENTS; HEPATOMA-CELLS	The rate at which HepG2 cells secrete apoB100 lipoproteins is inversely related to the concentration of amino acids in the medium (Zhang, Z., Sniderman, A. D., Kalant, D., Vu, H., Monge, J. C., Tao, Y., and Cianflone, g. (1993) J. Biol. Chem. 268, 26920-26926). The purpose of the present study was to determine the effect of individual amino acids on apoB100 and lipoprotein secretion. Asparagine was associated with modestly increased secretion. The branched chain amino acids (leucine, isoleucine, and valine) and lysine had minor inhibitory effects. The other amino acids, by contrast, decreased apoB secretion, although the magnitude of the effect varied considerably, the most potent being tyrosine, cysteine, phenylalanine, tryptophan, methionine, and glutamine. Although the effect on Lp(a) generally paralleled that on apoB100, it was usually much less pronounced. No amino acid caused a marked decrease in albumin, apoAI, or total protein secreted from the HepG2 cells. The amino acid effect on apoB was paralleled by similar decreases in secreted cholesterol ester (CE) primarily in the low density lipoprotein density range (d < 1.006-1.063 g/ml), although there was no significant change in intracellular CE. Neither intracellular nor secreted triglycerides (TG) or free cholesterol changed, resulting in a slightly larger TG-enriched particle being secreted The effect was confirmed in cultured primary hamster hepatocytes, where a mixture of amino acids also caused a decrease in apoB secretion (up to 40%). ApoAI appeared to increase as with the HepG2 cells. Secreted CE paralleled apoB. There was no change in intracellular or secreted TG or free cholesterol, resulting in a substantially larger TG-rich particle being secreted. mRNA for apoB100 increased with asparagine, decreased moderately with branched chain amino acids, and decreased further with glutamine, as shown by dot blot and Northern blotting. Pulse chase studies indicated that there was no change in apoB secretion efficiency under any condition. These results extend our previous observations by demonstrating specificity of the amino acid effect on apoB100 secretion. Although an effect on transcription is the likely mechanism, the exact basis for this remains to be determined.	MCGILL UNIV, MCGILL UNIT PREVENT CARDIOVASC DIS, MONTREAL, PQ H3A 1A1, CANADA	McGill University								Avramoglu RK, 1995, J LIPID RES, V36, P2513; BOSELLO O, 1988, ANN NUTR METAB, V32, P206, DOI 10.1159/000177443; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS AR, 1992, MOL CELL BIOL, V12, P1134, DOI 10.1128/MCB.12.3.1134; CARLSSON P, 1990, GENE, V94, P295, DOI 10.1016/0378-1119(90)90401-C; CARROLL KK, 1991, J AM DIET ASSOC, V91, P820; CARROLL KK, 1981, J AM OIL CHEM SOC, V58, P416, DOI 10.1007/BF02582391; CIANFLONE K, 1994, ATHEROSCLEROSIS, V107, P125, DOI 10.1016/0021-9150(94)90014-0; COHN JS, 1985, ATHEROSCLEROSIS, V56, P247, DOI 10.1016/0021-9150(85)90024-3; DASHTI N, 1992, J BIOL CHEM, V267, P7160; DAVIS RA, 1980, J BIOL CHEM, V255, P2039; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; EAGLE H, 1959, SCIENCE, V130, P432, DOI 10.1126/science.130.3373.432; EVERSON WV, 1989, AM J PHYSIOL, V256, pC18, DOI 10.1152/ajpcell.1989.256.1.C18; FILLIOS LC, 1954, METABOLISM, V3, P16; FLAIM KE, 1982, J BIOL CHEM, V257, P2939; FLESS GM, 1989, J LIPID RES, V30, P651; FUMAGALLI R, 1982, ATHEROSCLEROSIS, V43, P341, DOI 10.1016/0021-9150(82)90034-X; GARLICH JD, 1970, AM J CLIN NUTR, V23, P1626; GERBER DA, 1971, AM J CLIN NUTR, V24, P1382; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEVIA P, 1980, J NUTR, V110, P1231, DOI 10.1093/jn/110.6.1231; HILL EG, 1966, J NUTR, V89, P143, DOI 10.1093/jn/89.2.143; HOPGOOD MF, 1977, BIOCHEM J, V164, P399, DOI 10.1042/bj1640399; HUFF MW, 1984, AM J CLIN NUTR, V39, P888, DOI 10.1093/ajcn/39.6.888; KALOPISSIS AD, 1995, METABOLISM, V44, P19, DOI 10.1016/0026-0495(95)90284-8; KARDASSIS D, 1992, J BIOL CHEM, V267, P2622; KATAN MB, 1982, ATHEROSCLEROSIS, V43, P381, DOI 10.1016/0021-9150(82)90037-5; KHOSLA P, 1989, BIOCHIM BIOPHYS ACTA, V1002, P157, DOI 10.1016/0005-2760(89)90282-8; KRITCHEVSKY D, 1987, J AM OIL CHEM SOC, V64, P1167, DOI 10.1007/BF02612995; KUROWSKA EM, 1992, BIOCHIM BIOPHYS ACTA, V1126, P185, DOI 10.1016/0005-2760(92)90289-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAINE RO, 1991, J BIOL CHEM, V266, P16969; LEVEILLE GA, 1962, J NUTR, V76, P321, DOI 10.1093/jn/76.4.321; LINCOLN AJ, 1994, GENE DEV, V8, P1131, DOI 10.1101/gad.8.9.1131; LOVATI MR, 1987, J CLIN INVEST, V80, P1498, DOI 10.1172/JCI113232; LOVATI MR, 1992, J NUTR, V122, P1971, DOI 10.1093/jn/122.10.1971; LOVATI MR, 1985, ATHEROSCLEROSIS, V56, P243, DOI 10.1016/0021-9150(85)90023-1; MANN GV, 1960, AM J CLIN NUTR, V8, P491, DOI 10.1093/ajcn/8.4.491; MANN GV, 1953, J EXP MED, V98, P195, DOI 10.1084/jem.98.3.195; MARTEN NW, 1994, FASEB J, V8, P538, DOI 10.1096/fasebj.8.8.8181673; METZGER S, 1990, J BIOL CHEM, V265, P9978; METZGER S, 1993, J BIOL CHEM, V268, P16831; MONTOYA A, 1989, IN VITRO CELL DEV B, V25, P358; MURTHY S, 1992, ARTERIOSCLER THROMB, V12, P691, DOI 10.1161/01.ATV.12.6.691; NOSEDA G, 1980, DRUGS AFFECTING LIPI, P355; Olson R E, 1970, Trans Assoc Am Physicians, V83, P196; OLSON RE, 1970, AM J CLIN NUTR, V23, P1614; PENTTILA IM, 1987, CLIN CHIM ACTA, V170, P143, DOI 10.1016/0009-8981(87)90122-7; PERET J, 1994, METAZBOLISM, V33, P200; PFEUFFER M, 1986, ANN NUTR METAB, V30, P281, DOI 10.1159/000177205; PHILLIPS LS, 1991, DIABETES, V40, P1525, DOI 10.2337/diabetes.40.11.1525; PHILLIPS ML, 1993, BIOCHEMISTRY-US, V32, P3722, DOI 10.1021/bi00065a026; POHJANPELTO P, 1990, MOL CELL BIOL, V10, P5814, DOI 10.1128/MCB.10.11.5814; RAJA PK, 1975, J PHARM SCI, V64, P691, DOI 10.1002/jps.2600640427; ROCHA DM, 1972, J CLIN INVEST, V51, P2346, DOI 10.1172/JCI107046; RODA E, 1983, NEW TRENDS PATHOPHYS, P309; ROTHSCHILD MA, 1969, J NUTR, V98, P395, DOI 10.1093/jn/98.4.395; SAMMAN S, 1989, LIPIDS, V24, P169, DOI 10.1007/BF02535230; SANCHEZ A, 1991, MED HYPOTHESES, V36, P27, DOI 10.1016/0306-9877(91)90160-Z; SCANU AM, 1988, SEMIN THROMB HEMOST, V14, P266, DOI 10.1055/s-2007-1002788; SEIDEL J. C, 1960, JOUR LIPID RES, V1, P474; SIDRANSKY H, 1990, ANN NY ACAD SCI, V598, P464, DOI 10.1111/j.1749-6632.1990.tb42317.x; SIDRANSKY H, 1989, EXP MOL PATHOL, V51, P68, DOI 10.1016/0014-4800(89)90008-7; SIRTORI CR, 1993, ANN NY ACAD SCI, V676, P188, DOI 10.1111/j.1749-6632.1993.tb38734.x; SIRTORI CR, 1984, J NUTR, V114, P1493, DOI 10.1093/jn/114.8.1493; SNIDERMAN AD, 1993, ARTERIOSCLER THROMB, V13, P629, DOI 10.1161/01.ATV.13.5.629; SNIDERMAN AD, 1993, CIRCULATION, V88, P176; SOMMERCORN JM, 1981, J BIOL CHEM, V256, P4816; Sparks Janet D., 1993, Current Opinion in Lipidology, V4, P177, DOI 10.1097/00041433-199306000-00002; STRAUS DS, 1993, ENDOCRINOLOGY, V132, P1090, DOI 10.1210/en.132.3.1090; SUGANO M, 1982, J NUTR, V112, P855, DOI 10.1093/jn/112.5.855; TRUSWELL AS, 1964, P NUTR SOC, V23, pR46; Wade David P., 1993, Current Opinion in Lipidology, V4, P244, DOI 10.1097/00041433-199306000-00011; WHITE AL, 1994, J BIOL CHEM, V269, P28716; WILKINSON J, 1994, J LIPID RES, V35, P1896; WOLFE BM, 1991, METABOLISM, V40, P338, DOI 10.1016/0026-0495(91)90142-J; WOODSIDE KH, 1972, J BIOL CHEM, V247, P6474; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; YOUNG SG, 1986, CLIN CHEM, V32, P1484; ZHANG XZ, 1993, BRIT J NUTR, V69, P767, DOI 10.1079/BJN19930077; ZHANG ZJ, 1993, J BIOL CHEM, V268, P26920	83	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29136	29145		10.1074/jbc.271.46.29136	http://dx.doi.org/10.1074/jbc.271.46.29136			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910570	hybrid			2022-12-25	WOS:A1996VT05200062
J	DAndrea, L; Lytle, C; Matthews, JB; Hofman, P; Forbush, B; Madara, JL				DAndrea, L; Lytle, C; Matthews, JB; Hofman, P; Forbush, B; Madara, JL			Na:K:2Cl cotransporter (NKCC) of intestinal epithelial cells - Surface expression in response to cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORTER; FUNCTIONAL EXPRESSION; F-ACTIN; PROTEINS; CLONING	During intestinal chloride secretion, epithelial uptake of salts is accomplished largely by a bumetanide-sensitive Na:K:2Cl cotransporter designated here as NKCC, Using monoclonal antibodies directed against NKCC from the human crypt epithelial cell line, T84, we define its surface localization as a function of cotransporter activation, Immunoelectron microscopy, confocal localization, and selective surface biotinylation studies revealed that the 195-kDa NKCC protein is polarized to the basolateral domain. Following immunoprecipitation, several polypeptides coprecipitated with the 195-kDa cotransporter including two prominent proteins of molecular mass 160 and 130 kDa, Immunoblotting with three distinct anti NKCC monoclonal antibodies in conjunction with deglycosylation experiments suggested that the 160- and 130-kDa bands represented novel proteins unrelated to the cotransporter. Stimulation of T84 monolayers with cAMP agonists, a condition which elicits chloride secretion and leads to microfilament-dependent NKCC activation, did not significantly increase the number of bumetanide-binding sites and only marginally increased surface expression of the 195-kDa cotransporter available for surface biotinylation, In contrast, cAMP agonist stimulation increased the surface expression of the coprecipitating 160- and 130-kDa proteins similar to 6-fold, The increase in surface 160- and 130-kDa proteins was attenuated by phalloidin preloading the cells, a condition which also prevents activation of NKCC without influencing the activity of other membrane transporters participating in chloride secretion, These studies define the polarized distribution of the NKCC protein on intestinal epithelia, indicate that NKCC may be associated with two other previously unidentified membrane proteins and such association is influenced by the F-actin cytoskeleton.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV CALIF RIVERSIDE, DIV BIOMED SCI, RIVERSIDE, CA 92521 USA; BETH ISRAEL HOSP, DEPT SURG, BOSTON, MA 02115 USA; YALE UNIV, DEPT CELLULAR & MOL PHYSIOL, NEW HAVEN, CT 06510 USA	Harvard University; Harvard Medical School; University of California System; University of California Riverside; Harvard University; Beth Israel Deaconess Medical Center; Yale University	DAndrea, L (corresponding author), BRIGHAM & WOMENS HOSP, DEPT PATHOL, DIV GASTROINTESTINAL PATHOL, 75 FRANCIS ST, THORN 1423, BOSTON, MA 02115 USA.		Hofman, Paul/P-7654-2018; Lytle, Christian/X-2836-2019	Hofman, Paul/0000-0003-0431-9353; Lytle, Christian/0000-0001-5442-1546	NIDDK NIH HHS [DK47662, DK35932, DK48010] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047662, R37DK035932, R29DK048010, R01DK035932, R01DK048010] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DAWSON DC, 1991, ANNU REV PHYSIOL, V53, P321; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; DIAMOND JM, 1982, NATURE, V300, P683, DOI 10.1038/300683a0; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; HAAS M, 1994, AM J PHYSIOL-CELL PH, V267, pC869, DOI 10.1152/ajpcell.1994.267.4.C869; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; KAOUTZANI P, 1993, AM J PHYSIOL, V264, pC1327, DOI 10.1152/ajpcell.1993.264.5.C1327; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYTLE C, 1992, J BIOL CHEM, V267, P25438; Lytle C, 1995, AM J PHYSIOL-CELL PH, V269, pC1496, DOI 10.1152/ajpcell.1995.269.6.C1496; MADARA JL, 1993, AM J PHYSIOL, V264, pC1096, DOI 10.1152/ajpcell.1993.264.5.C1096; MADARA JL, 1985, J CELL BIOL, V101, P2124, DOI 10.1083/jcb.101.6.2124; MATSUDAIRA PT, 1978, ANAL BIOCHEM, V87, P386, DOI 10.1016/0003-2697(78)90688-7; MATTHEWS JB, 1994, J BIOL CHEM, V269, P15703; MATTHEWS JB, 1992, J CLIN INVEST, V90, P1608, DOI 10.1172/JCI116030; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; PAYNE JA, 1995, CURR OPIN CELL BIOL, V7, P493, DOI 10.1016/0955-0674(95)80005-0; ROTH J, 1982, TECHNIQUES IMMUNOCYT, V1, P107; SHAPIRO M, 1991, J CLIN INVEST, V87, P1903, DOI 10.1172/JCI115215; SUN A, 1991, J MEMBRANE BIOL, V120, P83, DOI 10.1007/BF01868594; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEYHL M, 1993, J BIOL CHEM, V268, P25041; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201	23	84	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28969	28976		10.1074/jbc.271.46.28969	http://dx.doi.org/10.1074/jbc.271.46.28969			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910547				2022-12-25	WOS:A1996VT05200039
J	Hausken, ZE; DellAcqua, ML; Coghlan, VM; Scott, JD				Hausken, ZE; DellAcqua, ML; Coghlan, VM; Scott, JD			Mutational analysis of the A-kinase anchoring protein (AKAP)-binding site on RII - Classification of side chain determinants for anchoring and isoform selective association with AKAPs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT RII; II-BETA; BINDING PROTEINS; BOVINE BRAIN; CLONING; DOMAIN; CELLS; IDENTIFICATION; LOCALIZATION; CYTOSKELETON	Compartmentalization of the type II cAMP-dependent protein kinase is conferred by interaction of the regulatory subunit (RII) with (A) under bar-(K) under bar inase (A) under bar nchoring (P) under bar roteins (AKAPs). The AKAP-binding site involves amino-terminal residues on each RII protomer and is formed through dimerization. A site-directed mutagenesis strategy was utilized to assess the contribution of individual residues in either RII isoform, RII alpha or RII beta, for interaction with various anchoring proteins. Substitution of long-chain or bulky hydrophobic groups (leucines or phenylalanines) for isoleucines at positions 3 and 5 in RII alpha decreased AKAP-binding up to 24 +/- 3 (n = 8)-fold, whereas introduction of valines had minimal effects. Replacement with hydrophilic residues (serine or asparigine) at both positions abolished AKAP binding. Mutation of proline 6 in RII alpha reduced binding for four AKAPs (Ht31, MAP2, AKAP79, and AKAP95) from 2.3 to 20-fold (n = 4) whereas introduction of an additional proline at position 6 in RII beta increased or conferred binding toward these anchoring proteins. Therefore, we conclude thats-branched side chains at positions 3 and 5 are favored determinants for AKAP-binding and pro lines at positions 6 and 7 increase or stabilize RII alpha interaction with selected anchoring proteins.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University				Dell'Acqua, Mark/0000-0003-3798-3461	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044239] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 44239] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRANDON EP, 1995, RECENT PROG HORM RES, V50, P403; BRANDON EP, 1995, P NATL ACAD SCI USA, V92, P8851, DOI 10.1073/pnas.92.19.8851; BROSTROM CO, 1971, P NATL ACAD SCI USA, V68, P2444, DOI 10.1073/pnas.68.10.2444; CARR DW, 1992, TRENDS BIOCHEM SCI, V17, P246, DOI 10.1016/0968-0004(92)90402-U; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; CARR DW, 1993, J BIOL CHEM, V268, P20729; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; CORBIN JD, 1977, J BIOL CHEM, V252, P910; FLETCHER WH, 1986, J BIOL CHEM, V261, P5504; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; GOODMAN RH, 1990, ANNU REV NEUROSCI, V13, P111, DOI 10.1146/annurev.neuro.13.1.111; HARPER JF, 1985, VITAM HORM, V42, P197; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HAUSKEN ZE, 1996, OVERLAY LIGAND BLOTT; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; KERYER G, 1993, P NATL ACAD SCI USA, V90, P5418, DOI 10.1073/pnas.90.12.5418; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEISER M, 1986, J BIOL CHEM, V261, P1904; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; LUO ZJ, 1990, J BIOL CHEM, V265, P21804; RANNELS SR, 1985, J BIOL CHEM, V260, P3423; REIMANN EM, 1986, BIOCHEMISTRY-US, V25, P119, DOI 10.1021/bi00349a018; RINGHEIM GE, 1990, J BIOL CHEM, V265, P4800; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; STOFKOHAHN RE, 1992, FEBS LETT, V302, P274, DOI 10.1016/0014-5793(92)80458-S; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503	40	66	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29016	29022		10.1074/jbc.271.46.29016	http://dx.doi.org/10.1074/jbc.271.46.29016			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910553	hybrid			2022-12-25	WOS:A1996VT05200045
J	Tebar, F; Sorkina, T; Sorkin, A; Ericsson, M; Kirchhausen, T				Tebar, F; Sorkina, T; Sorkin, A; Ericsson, M; Kirchhausen, T			Eps15 is a component of clathrin-coated pits and vesicles and is located at the rim of coated pits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; GROWTH-FACTOR RECEPTOR; PROTEIN; DYNAMIN; DOMAIN; AP-2; ENDOCYTOSIS	Eps15, a phosphorylation substrate of the epidermal growth factor (EGF) receptor kinase, has been shown to bind to the alpha-subunit of the clathrin-associated protein complex AP-2. Here we report that in cells, virtually all Eps15 interacts with the cytosol and membrane-bound forms of AP-2. This association is not affected by the treatment of cells with EGF. Immunofluorescence microscopy reveals nearly absolute co-localization of Eps15 with AP-2 and clathrin, and analysis by immunoelectron microscopy shows that the localization of membrane-associated Eps15 is restricted to the profiles corresponding to endocytic coated pits and vesicles. Unexpectedly, Eps15 was found at the edge of forming coated pits and at the rim of budding coated vesicles. This asymmetric distribution is in sharp contrast to the localization of AP-2 that shows an even distribution along the same types of clathrin-coated structures. These findings suggest several possible regulatory roles of Eps15 during the formation of coated pits.	UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02215; CTR BLOOD RES,BOSTON,MA 02115	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)			Tebar, Francesc/H-1498-2015	Tebar, Francesc/0000-0002-9522-9726; Sorkin, Alexander/0000-0002-4446-1920	NIDDK NIH HHS [DK46817] Funding Source: Medline; NIGMS NIH HHS [GM36548] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046817] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036548] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECK KA, 1991, J BIOL CHEM, V266, P4442; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; BOLL W, 1996, IN PRESS EMBO J; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GOODMAN OB, 1995, J BIOL CHEM, V270, P23768, DOI 10.1074/jbc.270.40.23768; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN; HARRISON SC, 1983, CELL, V33, P650, DOI 10.1016/0092-8674(83)90007-7; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; KIRCHHAUSEN T, 1993, CURR OPIN STRUC BIOL, V3, P182, DOI 10.1016/S0959-440X(05)80150-2; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; SCHMID SL, 1995, FASEB J, V9, P1445, DOI 10.1096/fasebj.9.14.7589986; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; Seaman MNJ, 1996, CURR OPIN CELL BIOL, V8, P549, DOI 10.1016/S0955-0674(96)80034-2; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; VELU TJ, 1989, MOL CELL BIOL, V9, P1772, DOI 10.1128/MCB.9.4.1772; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	26	211	214	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28727	28730		10.1074/jbc.271.46.28727	http://dx.doi.org/10.1074/jbc.271.46.28727			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910509	hybrid			2022-12-25	WOS:A1996VT05200001
J	Holt, EH; Broadus, AE; Brines, ML				Holt, EH; Broadus, AE; Brines, ML			Parathyroid hormone-related peptide is produced by cultured cerebellar granule cells in response to L-type voltage-sensitive Ca2+ channel flux via a Ca2+/calmodulin-dependent kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CALCIUM CHANNELS; GENE-EXPRESSION; MALIGNANT HYPERCALCEMIA; MEMBRANE DEPOLARIZATION; CALMODULIN ANTAGONISTS; HIPPOCAMPAL-NEURONS; GANGLION CELLS; CA-2+ CHANNELS; RAT-BRAIN	Parathyroid hormone (PTH) related peptide (PTHrP) is expressed in the adult mammalian brain, but its function is unknown. Here we show that PTHrP and the PTH/PTHrP receptor are products of cerebellar granule cells in primary culture. Granule cells maintained under depolarizing conditions (25 mM K+) make and release PTHrP. Further, PTHrP-(1-36) stimulates cAMP accumulation in granule neurons in a dose-dependent manner with half-maximal activation at similar to 16 nM. Granule cell PTHrP mRNA is activity-dependent, and the pathway of regulation depends absolutely on the flux of Ca2+ ions through the L-type voltage-sensitive Ca2+ channel and the Ca2+/calmodulin kinase cascade. PTHrP is therefore a neuropeptide whose regulation depends upon L-type voltage-sensitive Ca2+ channel activity, and the gene is expressed under conditions that promote granule cell survival.	YALE UNIV,SCH MED,DEPT INTERNAL MED,ENDOCRINOL SECT,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT CELLULAR & MOL PHYSIOL,NEW HAVEN,CT 06520	Yale University; Yale University			Brinesd, Michael/AAE-6072-2020	Brines, Michael/0000-0003-4151-4449				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ARMSTRONG D, 1987, P NATL ACAD SCI USA, V84, P2518, DOI 10.1073/pnas.84.8.2518; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASS LF, METHOD ENZYMOL, V169, P371; BROADUS AE, 1994, PARATHYROIDS; BURTIS WJ, 1990, NEW ENGL J MED, V322, P1106, DOI 10.1056/NEJM199004193221603; CARTER CJ, 1987, NEUROSCI LETT, V82, P201, DOI 10.1016/0304-3940(87)90130-3; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; COLLINS F, 1989, BRAIN RES, V502, P99, DOI 10.1016/0006-8993(89)90465-4; COLLINS F, 1991, J NEUROSCI, V11, P2582; DAIFOTIS AG, 1992, J BIOL CHEM, V267, P23455; DEERAUSQUIN GA, 1990, P NATL ACAD SCI USA, V87, P8017, DOI 10.1073/pnas.87.20.8017; DeKoninck P, 1995, J NEUROSCI, V15, P7966; DIDIER M, 1993, EUR J PHARM-MOLEC PH, V244, P57, DOI 10.1016/0922-4106(93)90059-I; DOROSHENKO PA, 1988, NEUROSCIENCE, V27, P1073, DOI 10.1016/0306-4522(88)90211-4; FUKAYAMA S, 1995, P NATL ACAD SCI USA, V92, P10182, DOI 10.1073/pnas.92.22.10182; GALLO V, 1987, J NEUROSCI, V7, P2203; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GREENBERG DA, 1987, BRAIN RES, V404, P401, DOI 10.1016/0006-8993(87)91403-X; HACK N, 1993, NEUROSCIENCE, V57, P9, DOI 10.1016/0306-4522(93)90108-R; HARVEY S, 1993, J ENDOCRINOL, V139, P353, DOI 10.1677/joe.0.1390353; HASHIMOTO H, 1994, BIOCHEM BIOPH RES CO, V200, P1042, DOI 10.1006/bbrc.1994.1555; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; HOLT EH, 1994, J NEUROCHEM, V62, P1239; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KARAPLIS AC, 1990, MOL ENDOCRINOL, V4, P441, DOI 10.1210/mend-4-3-441; KINGSBURY A, 1987, EUR J PHARMACOL, V140, P275, DOI 10.1016/0014-2999(87)90284-6; KINGSBURY AE, 1985, DEV BRAIN RES, V17, P17, DOI 10.1016/0165-3806(85)90128-2; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; LEE KC, 1995, ENDOCRINOLOGY, V136, P453, DOI 10.1210/en.136.2.453; LI GD, 1992, MOL PHARMACOL, V42, P489; LUCHOWSKI EM, 1984, J PHARMACOL EXP THER, V230, P607; MARTIN TJ, 1990, Q J MED, V76, P771; MCDONOUGH PM, 1994, J BIOL CHEM, V269, P9466; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; NISSENSON RA, 1992, PARATHYROID HORMONE, P145; NUTLEY MT, 1995, ENDOCRINOLOGY, V136, P5600, DOI 10.1210/en.136.12.5600; ORLOFF JJ, 1991, J BONE MINER RES, V6, P279; PAUWELS PJ, 1990, J PHARMACOL EXP THER, V255, P1117; Schousboe A., 1989, DISSECTION TISSUE CU, P203; SCULPTOREANU A, 1993, NATURE, V364, P240, DOI 10.1038/364240a0; SKEEN GA, 1993, MOL PHARMACOL, V44, P443; STREWLER GJ, 1990, WESTERN J MED, V153, P635; STRUCKHOFF G, 1995, BRAIN RES, V676, P1, DOI 10.1016/0006-8993(95)00088-8; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TANAKA S, 1995, DEV BIOL, V168, P166, DOI 10.1006/dbio.1995.1069; THIEDE MA, 1991, ENDOCRINOLOGY, V129, P1958, DOI 10.1210/endo-129-4-1958; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TRENKNER E, 1991, CULTURING NERVE CELL, P283; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455; WATSON PA, 1991, FASEB J, V5, P2013, DOI 10.1096/fasebj.5.7.1707019; WEAVER DR, 1995, MOL BRAIN RES, V28, P296, DOI 10.1016/0169-328X(94)00222-Z; WEIR EC, 1990, P NATL ACAD SCI USA, V87, P108, DOI 10.1073/pnas.87.1.108; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WROBLEWSKA B, 1993, J NEUROCHEM, V61, P943, DOI 10.1111/j.1471-4159.1993.tb03606.x; WYLLIE DJA, 1994, NEURON, V13, P635, DOI 10.1016/0896-6273(94)90031-0; WYSOLMERSKI JJ, 1995, DEVELOPMENT, V121, P3539; WYSOLMERSKI JJ, 1994, P NATL ACAD SCI USA, V91, P1133, DOI 10.1073/pnas.91.3.1133; YAMAMOTO M, 1992, P NATL ACAD SCI USA, V89, P5326, DOI 10.1073/pnas.89.12.5326; YATANI A, 1985, CIRC RES, V57, P868	62	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28105	28111		10.1074/jbc.271.45.28105	http://dx.doi.org/10.1074/jbc.271.45.28105			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910424	hybrid			2022-12-25	WOS:A1996VU03300024
J	Jarnagin, K; Bhakta, S; Zuppan, P; Yee, C; Ho, T; Phan, T; Tahilramani, R; Pease, JHB; Miller, A; Freedman, R				Jarnagin, K; Bhakta, S; Zuppan, P; Yee, C; Ho, T; Phan, T; Tahilramani, R; Pease, JHB; Miller, A; Freedman, R			Mutations in the B-2 bradykinin receptor reveal a different pattern of contacts for peptidic agonists and peptidic antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; PHARMACOLOGICAL CHARACTERIZATION; CONFORMATIONAL-ANALYSIS; EXPRESSION CLONING; MAGNETIC-RESONANCE; BOVINE RHODOPSIN; BINDING-SITES; HOE-140; PROTEIN; MUTAGENESIS	The B-2 bradykinin receptor, a seven-helix transmembrane receptor, binds the inflammatory mediator bradykinin (BK) and the structurally related peptide antagonist HOE-140, The binding of HOE-140 and the binding of bradykinin are mutually exclusive and competitive. Fifty-four site-specific receptor mutations were made, BK's affinity is reduced 2200-fold by F261A, 490-fold by T265A, 60-fold by D286A, and 3-10-fold by N200A, D268A, and Q290A, In contrast, HOE-140 affinity is reduced less than 7-fold by F254A, F261A, Y297A, and Q262A. The almost complete discordance of mutations that affect BK binding versus HOE-140 binding is surprising, but it was paralleled by the effect of single changes in BK and HOE-140. [Ala(9)]BK and [Ala(6)]BK are reduced in receptor binding affinity 27,000- and 150-fold, respectively, while [Ala(9)]HOE-140 affinity is reduced 7-fold and [Ala(6)]HOE-140 affinity is unchanged. NMR spectroscopy of all of the peptidic analogs of BK or HOE-140 revealed a beta-turn at the C terminus. Models of the receptor-ligand complex suggested that bradykinin is bound partially inside the helical bundle of the receptor with the amino terminus emerging from the extracellular side of helical bundle, In these models a salt bridge occurs between Arg(9) and Asp(286); the models also place Phe(8) in a hydrophobic pocket midway through the transmembrane region. Models of HOE-140 binding to the receptor place its beta-turn one alpha-helical turn deeper and closer to helix 7 and helix 1 as compared with bradykinin-receptor complex models.	ROCHE BIOSCI,MED CHEM,PALO ALTO,CA 94304; ROCHE BIOSCI,MOL STRUCT GRP,INFLAMMATORY DIS UNIT,PALO ALTO,CA 94304	Roche Holding; Roche Holding	Jarnagin, K (corresponding author), ROCHE BIOSCI,MOL PHARMACOL,S3-1,3401 HILLVIEW AVE,PALO ALTO,CA 94304, USA.			BHAKTA, SUNIL/0000-0002-1554-7098				Abd Alla S., 1996, J BIOL CHEM, V271, P1748; ALLEN MC, 1981, J CHEM SOC PERK T 1, P2040, DOI 10.1039/p19810002040; ARIENS EJ, 1971, DRUG DESIGN, P176; AUSTIN CE, 1994, BRIT J PHARMACOL, V111, P969, DOI 10.1111/j.1476-5381.1994.tb14835.x; CANN JR, 1987, INT J PEPT PROT RES, V29, P486; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; COSTELLO AH, 1989, EUR J PHARMACOL, V171, P259, DOI 10.1016/0014-2999(89)90118-0; CUTHBERT AW, 1992, BRIT J PHARMACOL, V107, P797, DOI 10.1111/j.1476-5381.1992.tb14526.x; DAUGAARD H, 1994, EXP NEPHROL, V2, P240; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; DENYS L, 1982, BIOCHEMISTRY-US, V21, P6531, DOI 10.1021/bi00268a032; DRAY A, 1993, TRENDS NEUROSCI, V16, P99, DOI 10.1016/0166-2236(93)90133-7; EVANS EA, 1974, TRITIUM ITS COMPOUND, P326; FRESHNEY RI, 1983, CULTURE ANIMAL CELLS; GETHER U, 1993, REGUL PEPTIDES, V46, P49, DOI 10.1016/0167-0115(93)90011-V; GRIESBACHER T, 1994, BRIT J PHARMACOL, V112, P1004, DOI 10.1111/j.1476-5381.1994.tb13182.x; GUBA W, 1994, J AM CHEM SOC, V116, P7532, DOI 10.1021/ja00096a009; HALL JM, 1992, PHARMACOL THERAPEUT, V56, P131, DOI 10.1016/0163-7258(92)90016-S; HEAPY CG, 1993, BRIT J PHARMACOL, V108, P209, DOI 10.1111/j.1476-5381.1993.tb13464.x; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HENKE S, 1989, Patent No. 370453; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; HOCK FJ, 1991, BRIT J PHARMACOL, V102, P769, DOI 10.1111/j.1476-5381.1991.tb12248.x; KRSTENANSKY JL, 1994, LETT PEPT SCI, V1, P523; KYLE DJ, 1994, BRAZ J MED BIOL RES, V27, P1757; KYLE DJ, 1994, J MED CHEM, V37, P1347, DOI 10.1021/jm00035a015; KYLE DJ, 1991, J MED CHEM, V34, P1230, DOI 10.1021/jm00107a052; KYLE DJ, 1990, BRADYKININ ANTAGONIS, P131; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEATHERBARROW RJ, 1990, TRENDS BIOCHEM SCI, V15, P455, DOI 10.1016/0968-0004(90)90295-M; LEE SC, 1990, INT J PEPT PROT RES, V35, P367; LINTNER K, 1979, BIOCHEM BIOPH RES CO, V91, P803, DOI 10.1016/0006-291X(79)91951-X; MARTINA YC, 1990, COMPREHENSIVE MED CH, P349; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MENKE JG, 1994, J BIOL CHEM, V269, P21583; MIRMIRA SR, 1990, MAGN RESON CHEM, V28, P587, DOI 10.1002/mrc.1260280706; MULUTIS F, 1985, INT J PEPT PROT RES, V26, P460; NAKAYAMA TA, 1990, J BIOL CHEM, V265, P15762; NAKAYAMA TA, 1991, J BIOL CHEM, V266, P4269; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4417, DOI 10.1073/pnas.91.10.4417; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; NOVOTNY EA, 1994, BIOCHEM BIOPH RES CO, V201, P523, DOI 10.1006/bbrc.1994.1733; OTTER A, 1993, BIOPOLYMERS, V33, P769, DOI 10.1002/bip.360330506; PARK J, 1994, BRAZ J MED BIOL RES, V27, P1707; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; PROUD D, 1994, BRAZ J MED BIOL RES, V27, P2021; RHALEB NE, 1992, EUR J PHARMACOL, V210, P115, DOI 10.1016/0014-2999(92)90661-M; Sambrook J., 2002, MOL CLONING LAB MANU; SAWUTZ DG, 1994, BIOCHEMISTRY-US, V33, P2373, DOI 10.1021/bi00175a004; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SRIVASTAVA S, 1991, PROTEINS : STRUCTURE, DYNAMICS AND DESIGN, P57; STERANKA LR, 1987, EUR J PHARMACOL, V136, P261, DOI 10.1016/0014-2999(87)90723-0; STERANKA LR, 1988, P NATL ACAD SCI USA, V85, P3245, DOI 10.1073/pnas.85.9.3245; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1989, J BIOL CHEM, V264, P16470; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VILLARREAL XC, 1991, ANAL BIOCHEM, V197, P362, DOI 10.1016/0003-2697(91)90405-I; WEIPERT J, 1988, BRIT J PHARMACOL, V94, P282, DOI 10.1111/j.1476-5381.1988.tb11526.x; WHALLEY ET, 1992, AGENT ACTION SUPPL, V38, P413; WILSON DD, 1989, CIRC SHOCK, V27, P93; YOUNG JK, 1994, BIOPOLYMERS, V34, P611, DOI 10.1002/bip.360340504; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918	68	62	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28277	28286		10.1074/jbc.271.45.28277	http://dx.doi.org/10.1074/jbc.271.45.28277			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910447	hybrid			2022-12-25	WOS:A1996VU03300047
J	Krane, SM; Byrne, MH; Lemaitre, V; Henriet, P; Jeffrey, JJ; Witter, JP; Liu, X; Wu, H; Jaenisch, R; Eeckhout, Y				Krane, SM; Byrne, MH; Lemaitre, V; Henriet, P; Jeffrey, JJ; Witter, JP; Liu, X; Wu, H; Jaenisch, R; Eeckhout, Y			Different collagenase gene products have different roles in degradation of type I collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASES; INTERSTITIAL COLLAGENASE; FIBROBLAST COLLAGENASE; SEQUENCE-ANALYSIS; HUMAN STROMELYSIN; CLEAVAGE SITE; MESSENGER-RNA; CELLS; PURIFICATION; CLONING	Vertebrate collagenases, matrix metalloproteinases (MMPs), cleave type I collagen at a single helical locus. We show here that rodent interstitial collagenases (MMP-13), but not human fibroblast collagenase (MMP-1), cleave type I collagen at an additional aminoitelopeptide locus. Collagenase cDNAs and chimeric constructs in pET-3d, juxtaposing MMP-13 sequences amino-terminal to the active site in the catalytic domain and MMP-1 sequences carboxyl-terminal and vice versa, were expressed in Escherichia coli. Assays utilized collagen from wild type (+/+) mice or mice that carry a targeted mutation (r/r) that encodes substitutions in alpha 1(I) chains that prevent collagenase cleavage at the helical locus, MMP-13 and chimeric molecules that contained the MMP-13 sequences amino-terminal to the active site cleaved (+/+) collagen at the helical locus and cleaved cross-linked (r/r) collagen in the aminotelopeptide (beta components converted to ct chains), Human MMP-1 and chimeric MMP-1/MMP-13 with MMP-1 sequences aminoterminal to the active site cleaved collagen at the helical locus but not in the aminotelopeptide. All activities were inhibited by TIMP-1, 1,10-phenanthroline, and EDTA. Sequences in the distal two-thirds of the catalytic domain determine the aminotelopeptide-degrading capacity of MMP-13.	MASSACHUSETTS GEN HOSP, ARTHRIT UNIT, BOSTON, MA 02114 USA; UNIV LOUVAIN, CONNECT TISSUE GRP, B-1200 BRUSSELS, BELGIUM; INT INST CELLULAR & MOL PATHOL, B-1200 BRUSSELS, BELGIUM; ALBANY MED COLL, DEPT MED, DIV HEMATOL, ALBANY, NY 12208 USA; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Harvard University; Massachusetts General Hospital; Universite Catholique Louvain; Albany Medical College; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Krane, SM (corresponding author), HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02114 USA.			Henriet, Patrick/0000-0003-4602-8888	NIAMS NIH HHS [AR-03564, TR-AR-07258] Funding Source: Medline; NICHD NIH HHS [HD-05291] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD005291, R01HD005291] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR003564, T32AR007258] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alexander CM, 1989, CURR OPIN CELL BIOL, V1, P974, DOI 10.1016/0955-0674(89)90068-9; BAILEY AJ, 1995, BIOCHEM J, V305, P385, DOI 10.1042/bj3050385; BERGMAN I, 1963, ANAL CHEM, V35, P1961, DOI 10.1021/ac60205a053; BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; Burleigh M. C., 1977, PROTEINASES MAMMALIA, P285; DAYER JM, 1981, FEBS LETT, V124, P253, DOI 10.1016/0014-5793(81)80149-4; DELAISSE JM, 1993, J CELL SCI, V106, P1071; EECKHOUT Y, 1977, BIOCHEM J, V166, P21, DOI 10.1042/bj1660021; FIELDS GB, 1987, J BIOL CHEM, V262, P6221; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GACK S, 1995, CELL GROWTH DIFFER, V6, P759; GOLDRING MB, 1987, J BIOL CHEM, V262, P16724; GROSS J, 1981, CELL BIOL EXTRACELLU, P217; HENRIET P, 1992, FEBS LETT, V310, P175, DOI 10.1016/0014-5793(92)81323-E; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; KRANE SM, 1993, ARTHRITIS ALLIED CON, P763; LIGHT ND, 1980, BIOCHEM J, V189, P111, DOI 10.1042/bj1890111; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MATTOT V, 1995, J CELL SCI, V108, P529; Moore DD, 1995, GLOB MOB SURV; MURPHY G, 1992, J BIOL CHEM, V267, P9612; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; NAGASE H, 1981, J BIOL CHEM, V256, P1951; QUINN CO, 1990, J BIOL CHEM, V265, P22342; ROSWIT WT, 1983, ARCH BIOCHEM BIOPHYS, V225, P285, DOI 10.1016/0003-9861(83)90032-2; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P393; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WU H, 1994, P NATL ACAD SCI USA, V91, P2819, DOI 10.1073/pnas.91.7.2819; WU H, 1990, P NATL ACAD SCI USA, V87, P5888, DOI 10.1073/pnas.87.15.5888; YE QZ, 1992, BIOCHEMISTRY-US, V31, P11231, DOI 10.1021/bi00160a038	36	98	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28509	28515		10.1074/jbc.271.45.28509	http://dx.doi.org/10.1074/jbc.271.45.28509			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910479	hybrid			2022-12-25	WOS:A1996VU03300079
J	Lin, XY; Tombler, E; Nelson, PJ; Ross, M; Gelman, IH				Lin, XY; Tombler, E; Nelson, PJ; Ross, M; Gelman, IH			A novel src- and ras-suppressed protein kinase c substrate associated with cytoskeletal architecture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE INTERACTIONS; SECONDARY-STRUCTURE; PLASMA-MEMBRANE; FOCAL ADHESION; V-SRC; FIBROBLASTS; CELLS; EXPRESSION; CALMODULIN; ONCOGENES	We previously identified a novel src- and ras-suppressed gene, 322, encoding a mitogenic regulatory function (Lin, X., Nelson, P. J., Frankfort, B., Tombler, E., Johnson, R., and Gelman, I. H. (1995) Mol. Cell. Biol. 15, 2754-2762). Here, we characterize the 322 gene product as an in vivo and in vitro substrate of protein kinase C (PKC). Hence, we named this product SSeCKS (pronounced essex) for Src Suppressed C Kinase Substrate. Rabbit polyclonal sera raised against glutathione S-transferase (GST)-SSeCKS recognized a myristylated 280/290-kDa doublet in Rat-6 fibroblasts. SSeCKS levels in src- and ras-transformed Rat-6 cells were 15- and 8-fold less, respectively, than those in untransformed cells. Short-term addition of phorbol ester resulted in a Ei-fold increase in SSeCKS phosphorylation a which was inhibited by bis-indolylmaleimide. In vitro phosphorylation of GST-SSeCKS by purified rabbit brain PKC-alpha was enhanced by phosphatidylserine and blocked by excess PKC pseudosubstrate inhibitor peptide. GST-SSeCKS bound purified PKC-alpha or PKC from Rat-6 lysates in a phosphatidylserine-dependent manner. Four SSeCKS domains containing Lys/Arg-rich moths similar to the PHC phosphorylation site in MARCKS were phosphorylated in vitro by PKC. Immunofluorescence analysis showed SSeCKS present throughout the cytoplasm with enrichment in podosomes and at the cell edge. Short-term addition of phorbol esters caused the movement of SSeCKS from plasma membrane sites to the perinucleus coincident with a loss of actin stress fibers. These data suggest a role for SSeCKS in the control of cellular cytoskeletal architecture.	MT SINAI SCH MED,DEPT MICROBIOL,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai					NATIONAL CANCER INSTITUTE [R29CA065787] Funding Source: NIH RePORTER; NCI NIH HHS [CA-65787] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; BORNER C, 1992, J BIOL CHEM, V267, P12900; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; Chapline C, 1996, J BIOL CHEM, V271, P6417, DOI 10.1074/jbc.271.11.6417; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DEHBI M, 1993, BIOCH CELL BIOL, V70, P980; DEVEREUX J, 1993, GCG SEQUENCE ANAL SO; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; FRANKFORT BJ, 1995, BIOCHEM BIOPH RES CO, V206, P916, DOI 10.1006/bbrc.1995.1130; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GELMAN IH, 1993, ONCOGENE, V8, P2995; GELMAN IH, 1987, J VIROL, V61, P2286, DOI 10.1128/JVI.61.7.2286-2296.1987; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HERGET T, 1993, P NATL ACAD SCI USA, V90, P2945, DOI 10.1073/pnas.90.7.2945; HOLTZ RW, 1994, PROTEIN KINASE C, P269; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HYATT SL, 1994, CELL GROWTH DIFFER, V5, P495; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; JAHNER D, 1991, ONCOGENE, V6, P1259; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIN XY, 1995, MOL CELL BIOL, V15, P2754; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MAEKAWA S, 1993, J BIOL CHEM, V268, P13703; MAHONEY CW, 1994, PROTEIN KINASE C, P16; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; NEEL VA, 1994, DEVELOPMENT, V120, P2235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PEARSON RB, 1991, METHOD ENZYMOL, V200, P63; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Sambrook J., 2002, MOL CLONING LAB MANU; WOLF H, 1988, COMPUT APPL BIOSCI, V4, P187; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	42	120	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28430	28438		10.1074/jbc.271.45.28430	http://dx.doi.org/10.1074/jbc.271.45.28430			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910468	hybrid			2022-12-25	WOS:A1996VU03300068
J	Marino, MW; Dunbar, JD; Wu, LW; Ngaiza, JR; Han, HM; Guo, DQ; Matsushita, M; Nairn, AC; Zhang, YH; Kolesnick, R; Jaffe, EA; Donner, DB				Marino, MW; Dunbar, JD; Wu, LW; Ngaiza, JR; Han, HM; Guo, DQ; Matsushita, M; Nairn, AC; Zhang, YH; Kolesnick, R; Jaffe, EA; Donner, DB			Inhibition of tumor necrosis factor signal transduction in endothelial cells by dimethylaminopurine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CERVICAL-CARCINOMA CELLS; PROTEIN-KINASE ACTIVITY; ELONGATION FACTOR-II; FACTOR RECEPTOR; PROSTACYCLIN SYNTHESIS; CYTOPLASMIC DOMAIN; TNF RECEPTOR; OOCYTE MATURATION; HUMAN FIBROBLASTS; MAMMALIAN-CELLS	Tumor necrosis factor (TNF) promotes diverse responses in endothelial cells that are important to the host response to infections and malignancies; however, less is known of the postreceptor events important to TNF action in endothelial cells than in many other cell types. Since phosphorylation cascades are implicated in cytokine signaling, the effects of the protein kinase inhibitor dimethylaminopurine (DMAP) on TNF action in bovine aortic endothelial cells (BAEC) were investigated. In BAEC, TNF promotes phosphorylation of eukaryotic initiation factor 4E (eIF-4E), c-Jun N-terminal kinase (JNK) and ceramide-activated protein kinase activities, Jun-b expression, prostacyclin production, and, when protein synthesis is inhibited, cytotoxicity. DMAP abrogated or significantly attenuated each of these responses to TNF, without affecting the specific binding of TNF to its receptors. Histamine, another agent active in the endothelium, promotes phosphorylation of elongation factor-2 (EF-2) and prostacyclin production, but not phosphorylation of eIF-4E in BAEC. Histamine-stimulated EF-2 phosphorylation was not inhibited and prostacyclin production was unaffected by DMAP. These observations demonstrate that a distinct signal transduction cascade, which can be selectively inhibited by DMAP, promotes the response of BAEC to TNF. Thus, we have identified a reagent, DMAP, that may be useful for characterizing the TNF signal transduction pathway.	INDIANA UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA; ROCKEFELLER UNIV, MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, LUDWIG INST CANC RES, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, MOL & CELLULAR NEUROSCI LAB, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT MED, DIV HEMATOL ONCOL, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, SPECIALIZED CTR RES THROMBOSIS, NEW YORK, NY 10021 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Memorial Sloan Kettering Cancer Center; Rockefeller University; Ludwig Institute for Cancer Research; Rockefeller University; Rockefeller University; Cornell University; Cornell University			Wu, Li-Wha/AAH-7768-2021	Wu, Li-Wha/0000-0001-7010-6220; Nairn, Angus/0000-0002-7075-0195	NATIONAL CANCER INSTITUTE [R01CA067891, R55CA067891] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050402] Funding Source: NIH RePORTER; NCI NIH HHS [CA-67891] Funding Source: Medline; NHLBI NIH HHS [SCOR HL18828] Funding Source: Medline; NIGMS NIH HHS [GM-50402] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAENZIGER NL, 1980, BIOCHEM BIOPH RES CO, V92, P1435, DOI 10.1016/0006-291X(80)90447-7; BEYAERT R, 1993, CANCER RES, V53, P2623; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DARNAY BG, 1994, J BIOL CHEM, V269, P20299; DARNAY BG, 1994, J BIOL CHEM, V269, P19687; DUSTING GJ, 1977, PROSTAGLANDINS, V13, P3, DOI 10.1016/0090-6980(77)90037-5; ENDO H, 1988, BIOCHEM BIOPH RES CO, V156, P1007, DOI 10.1016/S0006-291X(88)80944-6; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; GRAU GE, 1993, RES IMMUNOL, V144, P355, DOI 10.1016/S0923-2494(93)80080-I; GUY GR, 1991, J BIOL CHEM, V266, P14343; GUY GR, 1992, J BIOL CHEM, V267, P1846; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HELLER RA, 1992, CELL, V70, P47; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jaffe EA, 1984, BIOL ENDOTHELIAL CEL, P1; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KAWAKAMI M, 1986, BIOCHEM BIOPH RES CO, V141, P482, DOI 10.1016/S0006-291X(86)80198-X; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LANGELER EG, 1991, ARTERIOSCLER THROMB, V11, P872, DOI 10.1161/01.ATV.11.4.872; LESSLAUER W, 1992, IMMUNOL RES, V11, P81; LIU J, 1994, J BIOL CHEM, V269, P3047; MACKIE KP, 1989, J BIOL CHEM, V264, P1748; MANCHESTER KM, 1993, BIOCHEM J, V290, P185, DOI 10.1042/bj2900185; MARINO MW, 1989, P NATL ACAD SCI USA, V86, P8417, DOI 10.1073/pnas.86.21.8417; MARINO MW, 1991, J BIOL CHEM, V266, P2685; MONCADA S, 1977, LANCET, V1, P18; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; NEANT I, 1988, EXP CELL RES, V176, P68, DOI 10.1016/0014-4827(88)90121-8; NGAIZA JR, 1992, J CELL PHYSIOL, V151, P190, DOI 10.1002/jcp.1041510124; NOLOP KB, 1990, AM J PHYSIOL, V259, pL123, DOI 10.1152/ajplung.1990.259.2.L123; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; POHLMAN TH, 1989, CELL IMMUNOL, V119, P41, DOI 10.1016/0008-8749(89)90222-0; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; RIME H, 1989, DEV BIOL, V133, P169, DOI 10.1016/0012-1606(89)90308-4; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATO N, 1986, JNCI-J NATL CANCER I, V76, P1113; SCHLEGEL R, 1990, CELL GROWTH DIFFER, V1, P171; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SCHUTZE S, 1992, SEMIN ONCOL, V19, P16; SHIMADA Y, 1990, J CELL PHYSIOL, V142, P31, DOI 10.1002/jcp.1041420105; SIDHU RS, 1993, PHARMACOL THERAPEUT, V57, P79, DOI 10.1016/0163-7258(93)90037-E; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; SONG HY, 1995, BIOCHEM J, V309, P825, DOI 10.1042/bj3090825; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; SUN XJ, 1992, J BIOL CHEM, V267, P22662; SZOLLOSI MS, 1991, CHROMOSOMA, V100, P339, DOI 10.1007/BF00360533; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TOTPAL K, 1992, CANCER RES, V52, P2557; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; VIETOR I, 1993, J BIOL CHEM, V268, P18994; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WONG GHW, 1992, J IMMUNOL, V149, P3350; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	65	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28624	28629		10.1074/jbc.271.45.28624	http://dx.doi.org/10.1074/jbc.271.45.28624			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910494	hybrid			2022-12-25	WOS:A1996VU03300094
J	Murai, N; Makino, Y; Yoshida, M				Murai, N; Makino, Y; Yoshida, M			GroEL locked in a closed conformation by an interdomain cross-link can bind ATP and polypeptide but cannot process further reaction steps	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CHAPERONIN GROEL; THERMUS-THERMOPHILUS; PROTEIN; COOPERATIVITY; PURIFICATION; MUTAGENESIS; HYDROLYSIS; STABILITY; BACTERIUM	It has been believed that when GroEL binds to GroES its apical domain moves upward and outward, To inhibit this ''opening'' movement, its equatorial and apical domains were cross-linked through a disulfide bond between mutationally introduced cysteine residues at the positions of Asp-83 and Lys-327. To avoid possible undesired cross-linking, we at first prepared a mutant GroEL (GroEL(NC); Cys-138 --> Ser, Cys-458 --> Ser, Cys-519 --> Ser) in which all cysteine residues in wild-type GroEL were replaced by serine residues, GroEL(NC) was fully functional as a chaperonin, We then introduced the above two point mutations into GroEL(NC), to generate a mutant (GroEL(AEX); Cys-138 --> Ser, Cys-458 --> Ser, Cys-519 --> Ser and Asp-83 --> Cys, Lys 327 --> Cys). Oxidized GroEL(AEX), which is locked in a ''closed'' conformation by an interdomain disulfide bond, can bind 6-7 mol of ATP, which remain bound without hydrolysis, This ATP-bound, oxidized GroEL(AEX) can bind the stably nonnative substrate protein isopropylmalate dehydrogenase, whereas the nucleotide-free oxidized GroEL(AEX) binds it with a weaker affinity, However, oxidized GroEL(AEX) fails to process further reaction steps such as ATP hydrolysis, binding of GroES, dissociation of substrate protein from GroEL, and facilitating protein folding, When disulfide bonds in oxidized GroEL(AEX) are reduced, GroEL(AEX) exerts the ability to process all the reactions just as GroEL(NC) and wild-type GroEL. Indications from these results are: hydrolysis of ATP may require opening movement of the apical domain; GroES binds to an open form of GroEL; and substrate polypeptide is released from GroEL coupled with either ATP hydrolysis or opening movement of the apical domain.	TOKYO INST TECHNOL,RESOURCES UTILIZAT RES LAB,YOKOHAMA,KANAGAWA 226,JAPAN	Tokyo Institute of Technology			MURAI, NORIYUKI/V-5747-2018	MURAI, NORIYUKI/0000-0002-1552-5104				BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BOCHKAREVA ES, 1994, J BIOL CHEM, V269, P44; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Clarke AR, 1996, CURR OPIN STRUC BIOL, V6, P43, DOI 10.1016/S0959-440X(96)80093-5; DATE T, 1990, GENE, V90, P141, DOI 10.1016/0378-1119(90)90450-6; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GETHING MJH, 1972, EUR J BIOCHEM, V30, P352; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HISABORI T, 1992, J BIOL CHEM, V267, P4551; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; ITO K, 1991, MOL MICROBIOL, V5, P2243, DOI 10.1111/j.1365-2958.1991.tb02154.x; KUBO T, 1993, J BIOL CHEM, V268, P19346; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACHIDA M, 1975, CHEM PHARM BULL, V23, P1385, DOI 10.1248/cpb.23.1385; MACHIDA M, 1977, CHEM PHARM BULL, V25, P1285; Mande SC, 1996, SCIENCE, V271, P203, DOI 10.1126/science.271.5246.203; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; MURAI N, 1995, J BIOL CHEM, V270, P19957, DOI 10.1074/jbc.270.34.19957; Penefsky H S, 1979, Methods Enzymol, V56, P527; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; TAGUCHI H, 1991, J BIOL CHEM, V266, P22411; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TODD MJ, 1995, J BIOL CHEM, V270, P5388, DOI 10.1074/jbc.270.10.5388; VIITANEN PV, 1992, PROTEIN SCI, V1, P361; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; YAMADA T, 1990, J BIOCHEM-TOKYO, V108, P449, DOI 10.1093/oxfordjournals.jbchem.a123220; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001	41	45	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28229	28234		10.1074/jbc.271.45.28229	http://dx.doi.org/10.1074/jbc.271.45.28229			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910440	hybrid			2022-12-25	WOS:A1996VU03300040
J	Petrovic, N; Comi, A; Ettinger, MJ				Petrovic, N; Comi, A; Ettinger, MJ			Copper incorporation into superoxide dismutase in menkes lymphoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSON DISEASE GENE; S-ADENOSYLHOMOCYSTEINE HYDROLASE; CANDIDATE GENE; STAPHYLOCOCCUS-AUREUS; BINDING-PROTEIN; CLONING; CADMIUM; PLASMID; EFFLUX; ATPASE	The incorporation of copper into Cu,Zn-superoxide dismutase (SOD) was examined in Menkes lymphoblasts that express a genetic defect of copper metabolism, SOD activity was approximate to 40% higher in Menkes than normal lymphoblasts, Since Menkes lymphoblasts contain elevated copper levels, the higher SOD activity is most likely due to near copper saturation of an apoSOD pool that is in normal lymphoblasts. Cycloheximide markedly inhibited Cu-64(II) incorporation into SOD in Menkes lymphoblasts under conditions in which no significant, de novo synthesis of SOD protein was detected with normal lymphoblasts, The maximal amount of Cu-64 incorporation into newly synthesized SOD in Menkes lymphoblasts was approximately equal to the maximal amount of Cu-64 that could be incorporated into the apoSOD pool in normal lymphoblasts. The increased synthesis of SOD in Menkes lymphoblasts may play a protective role against copper toxicity in Menkes lymphoblasts. The protonophore, CCCP markedly inhibited Cu-64 incorporation into SOD in both normal and Menkes lymphoblasts, which is consistent with Cu-64 incorporation into SOD within a membrane-bounded compartment in both cell types, When Cu-64-incorporation into SOD was blocked with CCCP, copper accumulated in a Superose column fraction that contains S-adenosylhomocysteine hydrolase (SAHH), which has a high affinity for copper, SAHH may play a role in delivering copper to SOD.	SUNY BUFFALO,DEPT BIOCHEM,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								ANDERSON MLM, 1991, J BIOCHEM BIOPH METH, V22, P207, DOI 10.1016/0165-022X(91)90069-9; BETHIN KE, 1995, J BIOL CHEM, V270, P20703, DOI 10.1074/jbc.270.35.20703; BETHIN KE, 1995, J BIOL CHEM, V270, P20698, DOI 10.1074/jbc.270.35.20698; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; CRAPO JD, 1992, P NATL ACAD SCI USA, V89, P10405, DOI 10.1073/pnas.89.21.10405; Danks D. M., 1989, METABOLIC BASIS INHE; DAS S, 1994, AM J HUM GENET, V55, P883; ETTINGER MJ, 1984, LIFE CHEM REPORTS, V5, P169; HERD SM, 1987, BIOCHEM J, V247, P341, DOI 10.1042/bj2470341; HUNT DM, 1982, LIFE SCI, V31, P417, DOI 10.1016/0024-3205(82)90326-5; KELLER GA, 1991, P NATL ACAD SCI USA, V88, P7381, DOI 10.1073/pnas.88.16.7381; LEONE A, 1985, CELL, V40, P301, DOI 10.1016/0092-8674(85)90144-8; MENKES JH, 1962, PEDIATRICS, V29, P764; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; OYANAGUI Y, 1984, ANAL BIOCHEM, V142, P290; PACKMAN S, 1983, J INORG BIOCHEM, V19, P203, DOI 10.1016/0162-0134(83)85025-9; PARDO CA, 1995, P NATL ACAD SCI USA, V92, P954, DOI 10.1073/pnas.92.4.954; Petrovic N, 1996, J BIOL CHEM, V271, P28331, DOI 10.1074/jbc.271.45.28331; PETRUKHIN K, 1993, NAT GENET, V5, P338, DOI 10.1038/ng1293-338; RIORDAN JR, 1982, J BIOL CHEM, V257, P4639; SCHMIDT CJ, 1983, GENE, V24, P137, DOI 10.1016/0378-1119(83)90139-7; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; TYNECKA Z, 1981, J BACTERIOL, V147, P313, DOI 10.1128/JB.147.2.313-319.1981; VOLPE C, 1993, NAT GENET, V3, P7; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471	31	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28335	28340		10.1074/jbc.271.45.28335	http://dx.doi.org/10.1074/jbc.271.45.28335			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910456	hybrid			2022-12-25	WOS:A1996VU03300056
J	RomeroGraillet, C; Aberdam, E; Biagoli, N; Massabni, W; Ortonne, JP; Ballotti, R				RomeroGraillet, C; Aberdam, E; Biagoli, N; Massabni, W; Ortonne, JP; Ballotti, R			Ultraviolet B radiation acts through the nitric oxide and cGMP signal transduction pathway to stimulate melanogenesis in human melanocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN MELANOCYTES; PROTEIN-KINASE-C; MELANOMA-CELLS; SEQUENCE-ANALYSIS; CHOLERA-TOXIN; PHORBOL ESTER; TYROSINASE; EXPRESSION; HORMONE; DIFFERENTIATION	Ultraviolet B (UVB) radiation is the main physiological stimulus for human skin pigmentation; however, the molecular mechanisms underlying this process are still unclear. Recently, nitric oxide (NO) and cGMP have been involved in mediation of skin erythema induced by UVB. Therefore, we investigated the role of NO and cGMP in UVB-induced melanogenesis. In this study, we demonstrated that UVB stimulation of melanogenesis was mimicked by exogenous NO donors. Additionally, me showed that NO stimulated cGMP synthesis and that cGMP was also a potent stimulator of melanogenesis, Furthermore, the inhibition of the melanogenic effect of NO by guanylate cyclase inhibitor demonstrated that NO mediated its effect through the activation of guanylyl cyclase. Interestingly, 1 min after WE irradiation, we observed a significant increase in cGMP content in melanocytes. The effects of UVB on cGMP production and on melanogenesis were blocked by both guanylate cyclase and NO synthase inhibitors. Additionally, inhibition of cGMP-dependent kinase also prevented the stimulation of melanogenesis by UVB and NO. Therefore, we concluded that NO and cGMP production is required for UVB-induced melanogenesis and that cGMP mediated its melanogenic effects mainly through the activation of cGMP-dependent kinase.			RomeroGraillet, C (corresponding author), FAC MED NICE, INSERM, U385, AVE VALOMBROSE, F-06107 NICE 02, FRANCE.		BALLOTTI, Robert/F-8825-2013	BALLOTTI, Robert/0000-0002-7322-4908				ABDELMALEK ZA, 1992, PIGM CELL RES, P43; ABERDAM E, 1993, J CELL SCI, V106, P1015; AGIN PP, 1991, PHOTODERMATOL PHOTO, V8, P51; BRECHLER V, 1992, J BIOL CHEM, V267, P15496; CARSBERG CJ, 1994, J CELL SCI, V107, P2591; DELICONSTANTINOS G, 1995, BRIT J PHARMACOL, V114, P1257, DOI 10.1111/j.1476-5381.1995.tb13341.x; DUHE RJ, 1994, J BIOL CHEM, V269, P7290; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; FRIEDMANN PS, 1987, J CELL PHYSIOL, V133, P88, DOI 10.1002/jcp.1041330111; FRIEDMANN PS, 1990, J CELL PHYSIOL, V142, P334, DOI 10.1002/jcp.1041420216; FULLER BB, 1987, J BIOL CHEM, V262, P4024; FULLER BB, 1981, J NATL CANCER I, V66, P799; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; GORDON PR, 1989, J INVEST DERMATOL, V93, P700, DOI 10.1111/1523-1747.ep12319900; HEARING VJ, 1976, BIOCHEM J, V157, P549, DOI 10.1042/bj1570549; HUNT G, 1994, J CELL SCI, V107, P205; KWON BS, 1988, BIOCHEM BIOPH RES CO, V153, P1301, DOI 10.1016/S0006-291X(88)81370-6; LIBOW LF, 1988, PIGM CELL RES, V1, P397, DOI 10.1111/j.1600-0749.1988.tb00142.x; LOTAN R, 1980, CANCER RES, V40, P3345; LOTAN R, 1981, J CELL PHYSIOL, V106, P179, DOI 10.1002/jcp.1041060203; MURAD F, 1993, ADV SEC MESS PHOSPH, V28, P101; NAEYAERT JM, 1991, BRIT J DERMATOL, V125, P297, DOI 10.1111/j.1365-2133.1991.tb14161.x; OIKAWA A, 1972, ARCH BIOCHEM BIOPHYS, V148, P548, DOI 10.1016/0003-9861(72)90173-7; OKEEFE E, 1974, P NATL ACAD SCI USA, V71, P2500, DOI 10.1073/pnas.71.6.2500; PARK HY, 1993, J BIOL CHEM, V268, P11742; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; POMERANTZ SH, 1969, SCIENCE, V164, P838, DOI 10.1126/science.164.3881.838; PONNAZHAGAN S, 1994, J INVEST DERMATOL, V102, P744, DOI 10.1111/1523-1747.ep12376924; RAMIREZBOSCA A, 1992, ARCH DERMATOL RES, V284, P358, DOI 10.1007/BF00372040; ROMERO C, 1994, J CELL SCI, V107, P1095; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; TOMITA Y, 1988, J INVEST DERMATOL, V90, P882, DOI 10.1111/1523-1747.ep12462151; WARREN JB, 1994, FASEB J, V8, P247, DOI 10.1096/fasebj.8.2.7509761; YAU KW, 1994, P NATL ACAD SCI USA, V91, P3481, DOI 10.1073/pnas.91.9.3481	36	143	155	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28052	28056		10.1074/jbc.271.45.28052	http://dx.doi.org/10.1074/jbc.271.45.28052			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910416	hybrid			2022-12-25	WOS:A1996VU03300016
J	Tang, KC; Wu, HJ; Mahata, SK; Taupenot, L; Rozansky, DJ; Parmer, RJ; OConnor, DT				Tang, KC; Wu, HJ; Mahata, SK; Taupenot, L; Rozansky, DJ; Parmer, RJ; OConnor, DT			Stimulus-transcription coupling in pheochromocytoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-HYDROXYLASE GENE; CHROMOGRANIN-A GENE; CHROMAFFIN CELLS; MESSENGER-RNA; DIFFERENTIAL REGULATION; CATECHOLAMINE RELEASE; NUCLEOTIDE-SEQUENCE; 2ND MESSENGERS; EXPRESSION; RAT	To explore stimulus-transcription coupling in pheochromocytoma cells, we studied the biosynthetic response of chromogranin A, the major soluble protein co-stored and co-released with catecholamines, to chromaffin cells' physiologic nicotinic cholinergic secretory stimulation. Chromogranin A mRNA showed a time-dependent 3.87-fold response to nicotinic stimulation, and a nuclear run-off experiment indicated that the response occurred at a transcriptional level, Transfected chromogranin A promoter/luciferase reporter constructs were activated by nicotinic stimulation, in time- and dose-dependent fashions, in both rat PC12 pheochromocytoma cells and bovine chromaffin cells. Cholinergic subtype agents indicated that nicotinic stimulation was required, Promoter deletions established both positive and negative nicotinic response domains. Transfer of candidate promoter domains to a heterologous (thymidine kinase) promoter conferred region-specific nicotinic responses onto that promoter. A proximal promoter domain (from -93 to -62 base pairs) was activated in copy number- and distance-dependent fashion, and thus displayed features of a promoter element, Its activation was sufficient to account for the overall positive response to nicotine, Within this proximal region, a cAMP response element (CRE) was implicated as a major nicotinic response element, since a CRE point-gap mutation decreased nicotinic induction, transfer of CRE to a thymidine kinase promoter augmented the promoter's response to nicotine, and nicotine activated the CRE-binding protein CREB through phosphorylation at serine 133. We conclude that secretory stimulation of pheochromocytoma cells also activates the biosynthesis of the major secreted protein (chromogranin A), that the activation is transcriptional, and that a small proximal domain, including the CRE box, is, at least in part, both necessary and sufficient to account for the positive response to nicotine.	UNIV CALIF SAN DIEGO,DEPT MED 9111H,SAN DIEGO,CA 92161; UNIV CALIF SAN DIEGO,CTR MOL GENET,SAN DIEGO,CA 92161; DEPT VET AFFAIRS MED CTR,SAN DIEGO,CA 92161	University of California System; University of California San Diego; University of California System; University of California San Diego			Mahata, Sushil/AAF-8781-2021	Taupenot, Laurent/0000-0003-2316-3825				ABMAYR SB, 1989, CURRENT PROTOCOLS MO; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BANERJEE SA, 1992, J NEUROSCI, V12, P4460; BARBOSA JA, 1991, ENDOCRINOLOGY, V128, P174, DOI 10.1210/endo-128-1-174; BAUER JW, 1993, J BIOL CHEM, V268, P1586; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOCK AE, 1994, J NEUROCHEM, V62, P1863; CHODOSH LA, 1989, CURRENT PROTOCOLS MO; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COKER GT, 1988, BIOCHEM BIOPH RES CO, V157, P1341, DOI 10.1016/S0006-291X(88)81022-2; DEWET JR, 1986, MOL CELL BIOL, V6, P1663; EIDEN LE, 1987, J NEUROCHEM, V49, P65, DOI 10.1111/j.1471-4159.1987.tb03395.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FORSSPETTER S, 1989, J MOL NEUROSCI, V1, P63, DOI 10.1007/BF02918892; GAETANO C, 1995, EUR J CANCER, V31A, P447, DOI 10.1016/0959-8049(95)00038-K; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1989, CURRENT PROTOCOLS MO; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HASEL KW, 1990, NUCLEIC ACIDS RES, V18, P4019, DOI 10.1093/nar/18.13.4019; HIREMAGALUR B, 1993, J BIOL CHEM, V268, P23704; IACANGELO AL, 1991, MOL ENDOCRINOL, V5, P1651, DOI 10.1210/mend-5-11-1651; IACANGELO AL, 1995, REGUL PEPTIDES, V58, P65, DOI 10.1016/0167-0115(95)00069-N; ICARDLIEPKALNS C, 1992, J NEUROSCI RES, V32, P290, DOI 10.1002/jnr.490320219; ICARDLIEPKALNS C, 1993, J PHYSIOLOGY-PARIS, V87, P153, DOI 10.1016/0928-4257(93)90026-P; KILBOURNE EJ, 1992, J BIOL CHEM, V267, P7563; LASLOP A, 1989, REGUL PEPTIDES, V26, P191, DOI 10.1016/0167-0115(89)90187-0; LIVETT BG, 1987, STIMULUS SECRETION C, P118; MCKNIGHT SL, 1982, BIOL MED PARIS, V4, P81; MOULAND AJ, 1994, J BIOL CHEM, V269, P6918; NANKOVA B, 1993, J NEUROCHEM, V61, P776; OCONNOR DT, 1984, J BIOL CHEM, V259, P3237; PARMER RJ, 1993, J CLIN INVEST, V92, P1042, DOI 10.1172/JCI116609; PARMER RJ, 1989, HYPERTENSION, V14, P434; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROZANSKY DJ, 1994, J CLIN INVEST, V94, P2357, DOI 10.1172/JCI117601; SERCKHANSSEN G, 1984, J BIOL CHEM, V259, P1597; SIMON JP, 1988, P NATL ACAD SCI USA, V85, P1712, DOI 10.1073/pnas.85.5.1712; SIMON JP, 1989, BIOCHEM J, V260, P915, DOI 10.1042/bj2600915; STACHOWIAK MK, 1990, BRAIN RES, V510, P277, DOI 10.1016/0006-8993(90)91378-T; Tabor S, 1989, CURRENT PROTOCOLS MO; TAKIYYUDDIN MA, 1990, CIRCULATION, V81, P185, DOI 10.1161/01.CIR.81.1.185; TAKIYYUDDIN MA, 1990, HYPERTENSION, V15, P237, DOI 10.1161/01.HYP.15.3.237; TAKIYYUDDIN MA, 1991, J CLIN ENDOCR METAB, V72, P616, DOI 10.1210/jcem-72-3-616; TANG K, 1993, ENDOCRINOLOGY, V123, P2518; TSCHERNITZ C, 1995, MOL BRAIN RES, V31, P131, DOI 10.1016/0169-328X(95)00045-T; WAN DC, 1991, MOL BRAIN RES, V9, P103, DOI 10.1016/0169-328X(91)90135-K; WU HJ, 1994, J CLIN INVEST, V94, P118, DOI 10.1172/JCI117297; WU HJ, 1991, J BIOL CHEM, V266, P13130; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YOUDIM MBH, 1986, NEUROSCIENCE, V19, P1311, DOI 10.1016/0306-4522(86)90145-4	52	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28382	28390		10.1074/jbc.271.45.28382	http://dx.doi.org/10.1074/jbc.271.45.28382			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910462	hybrid			2022-12-25	WOS:A1996VU03300062
J	Zhang, WY; Gaynor, PM; Kruth, HS				Zhang, WY; Gaynor, PM; Kruth, HS			Apolipoprotein E produced by human monocyte-derived macrophages mediates cholesterol efflux that occurs in the absence of added cholesterol acceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; MOUSE MACROPHAGES; APOPROTEIN-E; DIFFERENT MECHANISMS; CA++ ANTAGONISTS; E GENE; A-I; EXPRESSION; SECRETION; PROTEIN	Human monocyte-derived macrophages can efflux accumulated cholesterol without exogenously added cholesterol accepters (Kruth, H. S., Skarlatos, S. I., Gaynor, P. M., and Gamble, W. (1994) J. Biol. Chem. 269, 24511-24518). Most of the effluxed cholesterol accumulates in the medium as apolipoprotein E-discoidal lipid particles. In the current study, we determined whether and to what degree cholesterol efflux from human monocyte-macrophages depended on apolipoprotein E secretion. Unexpectedly, 2-week-old differentiated monocyte-macrophages secreted similar amounts of apolipoprotein E without or with cholesterol enrichment. Apolipoprotein E mRNA levels in these macrophages were not increased by cholesterol enrichment and were comparable with levels in HepG2 cells. Without cholesterol enrichment, monocyte-macrophages secreted lipid-poor apolipoprotein E with a density > 1.21 g/ml. By contrast, cholesterol enrichment of monocyte macrophages induced the association of apoE with phospholipid and cholesterol to form discoidal particles that floated at densities of 1.08-1.10 g/ml. An anti-apolipoprotein E monoclonal antibody added to the culture medium significantly inhibited cholesterol and phospholipid efflux from the monocyte-macrophages. This showed that apolipoprotein E was required for most of the cholesterol efflux, and that apolipoprotein E did not leave macrophages with lipid but rather associated with lipid after it was secreted. Thus, 1) apolipoprotein E was constitutively secreted by differentiated human monocyte-macrophages, 2) apolipoprotein E only formed discoidal particles following macrophage cholesterol enrichment, 3) apolipoprotein E was necessary for cholesterol efflux to occur in the absence of added cholesterol accepters and, in addition 4) the level of macrophage unesterified cholesterol was not rate-limiting for this cholesterol efflux, and 5) net phospholipid synthesis occurred in macrophages secondary to apoE-mediated loss of macrophage phospholipid. In conclusion, apolipoprotein E functions in an autocrine pathway that mediates cholesterol efflux from human monocyte-derived macrophages.	NIH,NHLBI,SECT EXPT ATHEROSCLEROSIS,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; BASU SK, 1983, SCIENCE, V219, P871, DOI 10.1126/science.6823554; BASU SK, 1982, J BIOL CHEM, V257, P9788; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; BIELICKI JK, 1992, J LIPID RES, V33, P1699; BROWN MS, 1980, J BIOL CHEM, V255, P9344; DORY L, 1989, J LIPID RES, V30, P809; FORTE TM, 1993, J LIPID RES, V34, P317; GORDON V, 1983, J BIOL CHEM, V258, P6202; HARA H, 1991, J BIOL CHEM, V266, P3080; HERSCOVITZ H, 1992, J LIPID RES, V33, P971; KOO C, 1985, J BIOL CHEM, V260, P1934; KRUTH HS, 1995, J CELL BIOL, V129, P133, DOI 10.1083/jcb.129.1.133; KRUTH HS, 1994, J BIOL CHEM, V269, P24511; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAHLEY RW, 1989, J CLIN INVEST, V83, P2125, DOI 10.1172/JCI114126; MAZZONE T, 1987, J BIOL CHEM, V262, P11657; MAZZONE T, 1989, J LIPID RES, V30, P1055; MAZZONE T, 1994, J LIPID RES, V35, P1345; REARDON CA, 1986, J BIOL CHEM, V261, P9858; ROBENEK H, 1988, ARTERIOSCLEROSIS, V8, P57, DOI 10.1161/01.ATV.8.1.57; SCHMITZ G, 1985, EMBO J, V4, P2773, DOI 10.1002/j.1460-2075.1985.tb04003.x; SCHMITZ G, 1988, ARTERIOSCLEROSIS, V8, P46, DOI 10.1161/01.ATV.8.1.46; SCHMITZ G, 1990, J LIPID RES, V31, P1741; SHIMANO H, 1991, BIOCHIM BIOPHYS ACTA, V1086, P245, DOI 10.1016/0005-2760(91)90166-F; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; SHIRATORI Y, 1994, J BIOL CHEM, V269, P11337; VOGEL T, 1985, P NATL ACAD SCI USA, V82, P8696, DOI 10.1073/pnas.82.24.8696; WERB Z, 1983, J BIOL CHEM, V258, P642; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YAMADA N, 1989, P NATL ACAD SCI USA, V86, P665, DOI 10.1073/pnas.86.2.665; ZANNIS VI, 1984, J BIOL CHEM, V259, P5495; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028	33	133	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28641	28646		10.1074/jbc.271.45.28641	http://dx.doi.org/10.1074/jbc.271.45.28641			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910497	hybrid			2022-12-25	WOS:A1996VU03300097
J	Krosl, J; Damen, JE; Krystal, G; Humphries, RK				Krosl, J; Damen, JE; Krystal, G; Humphries, RK			Interleukin-3 (IL-3) inhibits erythropoietin-induced differentiation in Ba/F3 cells via the IL-3 receptor alpha subonit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; GROWTH SIGNAL-TRANSDUCTION; ERYTHROID PROGENITOR CELLS; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN; GENE-EXPRESSION; BETA-SUBUNIT; LINE; PROLIFERATION; HEMOGLOBIN	Introduction of erythropoietin receptors (EpoRs) into the interleukin-3 (IL-3)-dependent murine hemopoietic cell line, Ba/F3, enables these cells to not only proliferate, after an initial lag in G(1), but also to increase beta-globin mRNA levels in response to erythropoietin (Epo), With IL-3 and Epo costimulation, IL-3-induced signaling appears to be dominant since no increase in beta-globin mRNA occurs, Differentiation and proliferation signals may be uncoupled since EpoRs lacking all eight intracellular tyrosines were compromised in proliferative signaling but retained erythroid differentiation ability, intriguingly, a chimeric receptor of the extracellular domain of the EpoR and the transmembrane and intracellular domains of IL-3R beta(IL-3) chain (EpoR/IL-3R beta(IL-3)) was capable of Epo-induced proliferative and differentiating signaling suggesting either the existence of a second EpoR subunit responsible for differentiation or that the a! subunit of the IL-3 receptor (IL-3R) prevents it. Arguing against the former, a truncated EpoR lacking an intracellular domain was incapable of promoting proliferation or differentiation. An EpoR/IL-3R alpha chimera, in contrast, was capable of transmitting a weak Epo-induced proliferative signal but failed to stimulate accumulation of beta-globin mRNA, Most significantly, coexpression of the EpoR/IL-3R alpha chimera with either EpoR/IL-3R beta or wild-type EpoRs suppressed Epo-induced beta-globin mRNA accumulation, Taken together, these results suggest an active role for the IL-3R alpha subunit in inhibiting EpoR-specific differentiating signals.	BRITISH COLUMBIA CANC RES CTR, TERRY FOX LAB, VANCOUVER, BC V5Z 1L3, CANADA; UNIV BRITISH COLUMBIA, DEPT PATHOL, VANCOUVER, BC V6T 1Z1, CANADA; UNIV BRITISH COLUMBIA, DEPT MED, VANCOUVER, BC V6T 1Z1, CANADA	British Columbia Cancer Agency; University of British Columbia; University of British Columbia				Krystal, Gerald/0000-0002-1961-6281; Humphries, Richard/0000-0003-0540-7005				BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BONDURANT MC, 1985, MOL CELL BIOL, V5, P675, DOI 10.1128/MCB.5.4.675; CARROLL M, 1995, P NATL ACAD SCI USA, V92, P2869, DOI 10.1073/pnas.92.7.2869; CARROLL M, 1994, P SOC EXP BIOL MED, V206, P289; CHIBA T, 1993, P NATL ACAD SCI USA, V90, P11593, DOI 10.1073/pnas.90.24.11593; CORNELIS S, 1995, EUR J IMMUNOL, V25, P1857, DOI 10.1002/eji.1830250710; DAMEN J, 1992, BLOOD, V80, P1923; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; EDER M, 1994, J BIOL CHEM, V269, P30173; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KITAMURA T, 1992, BLOOD, V80, P84; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KOURY MJ, 1986, J CELL PHYSIOL, V126, P259, DOI 10.1002/jcp.1041260216; KRANTZ SB, 1991, BLOOD, V77, P419; KROSL J, 1995, BLOOD, V85, P50, DOI 10.1182/blood.V85.1.50.bloodjournal85150; LIBOI E, 1993, P NATL ACAD SCI USA, V90, P11351, DOI 10.1073/pnas.90.23.11351; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARUYAMA K, 1994, J BIOL CHEM, V269, P5976; MINEGISHI N, 1994, J BIOL CHEM, V269, P27700; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIYAJIMA A, 1993, BLOOD, V82, P1960; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; POLOTSKAYA A, 1994, J BIOL CHEM, V269, P14607; QUELLE FW, 1991, J BIOL CHEM, V266, P609; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SAWADA K, 1990, J CELL PHYSIOL, V142, P219, DOI 10.1002/jcp.1041420202; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; WEISS M, 1993, BLOOD, V82, P3298; WICKREMA A, 1992, BLOOD, V80, P1940, DOI 10.1182/blood.V80.8.1940.1940; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WOGNUM AW, 1990, BLOOD, V76, P697	33	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27432	27437		10.1074/jbc.271.44.27432	http://dx.doi.org/10.1074/jbc.271.44.27432			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910323	hybrid			2022-12-25	WOS:A1996VQ67900041
J	Saenko, EL; Shima, M; Gilbert, M; Scandella, D				Saenko, EL; Shima, M; Gilbert, M; Scandella, D			Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; PORCINE FACTOR-VIII; SURFACE-PLASMON RESONANCE; COAGULATION FACTOR-VIII; VONWILLEBRAND-FACTOR; LIGHT-CHAIN; BINDING-SITE; DOMAIN; PHOSPHATIDYLSERINE; INACTIVATION	The anti-factor VIII (fVIII) C2 domain monoclonal antibody ESH8 inhibits fVIII activity only when fVIII is bound to von Willebrand factor (vWf). However, ESH8 binds with similar affinity to fVIII and fVIII . vWf complex, and it does not affect the kinetics of thrombin cleavage at positions 372 and 740 within the fVIII heavy chain and at 1689 within the light chain, The latter is required for fVIII release from vWf. We showed that ESH8 reduced the initial rate of thrombin-activated fVIII (fVIIIa) release from vWf by 4.3-fold compared to that in the absence of antibody. The complex of vWf . fVIII . ESH8 was activated, and the rate constant determined for fVIIIa dissociation from vWf was 4 x 10(-3) s(-1). We constructed a mathematical. model incorporating the measured rates for fVIIIa release from vWf and for inactivation of heterotrimeric fVIIIa due to the spontaneous loss of the A2 subunit and found that the decreased release rate is sufficient to explain our experimentally observed inhibition of Nm activity by ESH8. We hypothesize that the slowed rate of fVIIIa release from vWf in the presence of ESH8 allows time for inactivation of unstable fVIIIa prior its participation in the formation of the factor Xase complex, The relevance of these findings is illustrated by our observation that reduction of fVIIIa release from vWf represents an additional mechanism of MII inhibition by an anti-C2 domain antibody (epitope 2218-2307) from a hemophilia A patient. This rare antibody binds to a more amino-terminal epitope than other human anti-Ca inhibitors, resulting in its lack of inhibition of fVIII binding to vWf but not to phospholipid. These two MII ligands therefore bind to C2 sites which do not overlap completely.	AMER RED CROSS,HOLLAND LAB,ROCKVILLE,MD 20855; NARA MED UNIV,DEPT PEDIAT,NARA,JAPAN; BRIGHAM & WOMENS HOSP,BROCKTON W ROXBURY VET AFFAIRS MED CTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	American Red Cross; Nara Medical University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NHLBI NIH HHS [R01-HL36094, HL02587, P50-HL44336] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL044336, K08HL002587] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; BOWIE EJW, 1984, DISORDERS HEMOSTASIS, P43; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FOSTER PA, 1990, BLOOD, V75, P1999; FOSTER PA, 1988, J BIOL CHEM, V263, P5230; GIRMA JP, 1986, BIOCHEMISTRY-US, V25, P3156, DOI 10.1021/bi00359a013; HAMER RJ, 1987, EUR J BIOCHEM, V166, P37, DOI 10.1111/j.1432-1033.1987.tb13480.x; HILLEUBANKS DC, 1990, J BIOL CHEM, V265, P17854; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; HOYER LW, 1982, METHOD ENZYMOL, V84, P51; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869; LAJMANOVICH A, 1981, BIOCHIM BIOPHYS ACTA, V678, P132, DOI 10.1016/0304-4165(81)90056-8; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LEYTE A, 1989, BIOCHEM J, V257, P679, DOI 10.1042/bj2570679; LEYTE A, 1991, J BIOL CHEM, V266, P740; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1994, J CLIN INVEST, V93, P2497, DOI 10.1172/JCI117259; LOLLAR P, 1988, BLOOD, V71, P137; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NESHEIM M, 1991, J BIOL CHEM, V266, P17815; NISHINO M, 1989, BLOOD, V74, P1591; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; PERSSON E, 1995, BIOCHEMISTRY-US, V34, P12775, DOI 10.1021/bi00039a038; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; SAENKO EL, 1995, J BIOL CHEM, V270, P13826, DOI 10.1074/jbc.270.23.13826; SAENKO EL, 1994, J BIOL CHEM, V269, P11601; SCANDELLA D, 1989, BLOOD, V74, P1618; SCANDELLA D, 1992, THROMB HAEMOSTASIS, V67, P665; SCANDELLA D, 1988, P NATL ACAD SCI USA, V85, P6152, DOI 10.1073/pnas.85.16.6152; SCNADELLA D, 1995, BLOOD, V86, P1811; SHIMA M, 1995, BRIT J HAEMATOL, V91, P714, DOI 10.1111/j.1365-2141.1995.tb05374.x; SHIMA M, 1991, INT J HEMATOL, V54, P515; SHIMA M, 1993, THROMB HAEMOSTASIS, V69, P240; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TULEY EA, 1991, P NATL ACAD SCI USA, V88, P6377, DOI 10.1073/pnas.88.14.6377; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0	45	122	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27424	27431		10.1074/jbc.271.44.27424	http://dx.doi.org/10.1074/jbc.271.44.27424			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910322	hybrid			2022-12-25	WOS:A1996VQ67900040
J	Satoh, T; Yamada, M; Iwasaki, T; Mori, M				Satoh, T; Yamada, M; Iwasaki, T; Mori, M			Negative regulation of the gene for the preprothyrotropin-releasing hormone from the mouse by thyroid hormone requires additional factors in conjunction with thyroid hormone receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT GENE; MESSENGER-RNA; RETINOIC ACID; PARAVENTRICULAR NUCLEUS; RESPONSE ELEMENTS; PROMOTER ACTIVITY; RAT HYPOTHALAMUS; C-ERBA; TRANSCRIPTION; BINDING	To gain additional insights into the negative gene regulatory action by triiodothyronine (T-3), we isolated a 2-kilobase pair 5'-flanking region of the mouse preprothyrotropin-releasing hormone (ppTRH) gene and characterized the DNA elements mediating inhibitory regulation by T-3 in the promoter region. In GH(4)C(1) cells, the expression of the 2-kilobase pair mouse ppTRH 5'-flanking region fused to the luciferase reporter gene occurred by transfection and was significantly suppressed by T-3. In contrast, T-3 suppression was not observed in T-3 receptor (T(3)R)-deficient CV-1 cells, suggesting that T(3)Rs were required for the negative regulation. Cotransfected mouse T(3)R alpha 1, beta 1, and beta 2 possessed indistinguish able potency for the negative regulation. Deletion analysis localized the element mediating the negative regulation to the region between -83 and +46, and the sequence downstream of the transcription start site (TSS) between +12 and +46 was found to be essential for the inhibitory regulation. In mobility shift assays, only T(3)R monomers bound to the element containing a T-3 response element half-site at -57. No apparent T(3)R binding was observed to the element downstream of TSS. Neither the T-3 response element half-site nor the element downstream of the TSS confer T-3 suppression individually in heterologous promoters. These results indicate that the negative regulation of murine ppTRH gene by T-3 might be mediated by the cooperation of T(3)R monomers with unknown factor(s) interacting with the element downstream of the TSS.			Satoh, T (corresponding author), GUNMA UNIV, SCH MED, DEPT INTERNAL MED 1, 3-39-15 SHOWA MACHI, MAEBASHI, GUMMA 371, JAPAN.							AYER DE, 1990, MOL CELL BIOL, V10, P3635, DOI 10.1128/MCB.10.7.3635; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BODENNER DL, 1991, J BIOL CHEM, V266, P21666; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNSIDE J, 1989, J BIOL CHEM, V264, P6886; CARR FE, 1992, J BIOL CHEM, V267, P18689; CARR FE, 1989, MOL ENDOCRINOL, V3, P709, DOI 10.1210/mend-3-4-709; COOK CB, 1992, ENDOCRINOLOGY, V130, P1077, DOI 10.1210/en.130.2.1077; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FENG P, 1994, BIOCHEM BIOPH RES CO, V200, P171, DOI 10.1006/bbrc.1994.1430; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; HODIN RA, 1990, J CLIN INVEST, V85, P101, DOI 10.1172/JCI114398; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; JACKSON IMD, 1982, NEW ENGL J MED, V306, P145, DOI 10.1056/NEJM198201213060305; KOLLER KJ, 1987, P NATL ACAD SCI USA, V84, P7329, DOI 10.1073/pnas.84.20.7329; KRISHNA V, 1989, P NATL ACAD SCI USA, V86, P9114; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LECHAN RM, 1986, SCIENCE, V231, P159, DOI 10.1126/science.3079917; LEE SL, 1988, J BIOL CHEM, V263, P16604; LEZOUALCH F, 1992, MOL ENDOCRINOL, V6, P1797, DOI 10.1210/me.6.11.1797; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; NG L, 1995, MOL ENDOCRINOL, V9, P1202, DOI 10.1210/me.9.9.1202; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; PARK HY, 1993, MOL ENDOCRINOL, V7, P319, DOI 10.1210/me.7.3.319; PIEDRAFITA FJ, 1995, MOL ENDOCRINOL, V9, P563, DOI 10.1210/me.9.5.563; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SARAPURA VD, 1990, ENDOCRINOLOGY, V127, P1352, DOI 10.1210/endo-127-3-1352; SATOH T, 1992, MOL BRAIN RES, V14, P131, DOI 10.1016/0169-328X(92)90020-C; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SEGERSON TP, 1987, SCIENCE, V238, P78, DOI 10.1126/science.3116669; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; THOMPSON KL, 1992, MOL ENDOCRINOL, V6, P627, DOI 10.1210/me.6.4.627; UMEDA PK, 1990, J BIOL CHEM, V264, P10672; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WOOD WM, 1991, MOL ENDOCRINOL, V5, P1049, DOI 10.1210/mend-5-8-1049; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; YAMADA M, 1990, MOL ENDOCRINOL, V4, P551, DOI 10.1210/mend-4-4-551	49	73	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27919	27926		10.1074/jbc.271.44.27919	http://dx.doi.org/10.1074/jbc.271.44.27919			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910392	hybrid			2022-12-25	WOS:A1996VQ67900110
J	Gamby, C; Waage, MC; Allen, RG; Baizer, L				Gamby, C; Waage, MC; Allen, RG; Baizer, L			Analysis of the role of calmodulin binding and sequestration in neuromodulin (GA1-43) function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-ASSOCIATED PROTEIN; KINASE-C SUBSTRATE; BRAIN POLYPHOSPHOINOSITIDE METABOLISM; MEMBRANE TARGETING DOMAIN; LONG-TERM POTENTIATION; B-50 GAP-43; NEURITE OUTGROWTH; NERVOUS-SYSTEM; RAT-BRAIN; ADULT-RAT	We demonstrated previously that forced expression of the neuronal phosphoprotein neuromodulin (also known as GAP-43, F1, B-50, and p57) in mouse anterior pituitary AtT-20 cells enhances depolarization mediated. secretion and alters cellular morphology. Here we analyze the role of calmodulin binding by neuromodulin in these responses, In cells expressing mild-type neuromodulin, a complex with calmodulin that is sensitive to intracellular calcium and phosphorylation is localized to the plasma membrane, Transfection of several mutant forms of neuromodulin shows that the effects of this protein on secretion are dependent on both calmodulin binding and association with the plasma membrane, In contrast, the morphological changes depend only oh membrane association. Thus, the multitude of effects of neuromodulin noted in previous studies may result from divergent properties of this protein.	GOOD SAMARITAN HOSP, RS DOW NEUROL SCI INST, PORTLAND, OR 97209 USA; OREGON HLTH SCI UNIV, CTR RES OCCUPAT & ENVIRONM TOXICOL, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT CELL BIOL & ANAT, PORTLAND, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS026806] Funding Source: NIH RePORTER; NINDS NIH HHS [NS26806] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIGNER L, 1993, J CELL BIOL, V123, P417, DOI 10.1083/jcb.123.2.417; AIGNER L, 1995, J CELL BIOL, V128, P647, DOI 10.1083/jcb.128.4.647; AIGNER L, 1995, CELL, V83, P269, DOI 10.1016/0092-8674(95)90168-X; ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALLSOPP TE, 1989, J NEUROSCI, V9, P13; ANDREASEN TJ, 1981, P NATL ACAD SCI-BIOL, V78, P2782, DOI 10.1073/pnas.78.5.2782; ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4615, DOI 10.1021/bi00289a001; Apel E D, 1992, Perspect Dev Neurobiol, V1, P3; Baetge E E, 1992, Perspect Dev Neurobiol, V1, P21; BAETGE EE, 1991, NEURON, V6, P21, DOI 10.1016/0896-6273(91)90118-J; BASI GS, 1987, CELL, V49, P785, DOI 10.1016/0092-8674(87)90616-7; BENOWITZ LI, 1989, J NEUROSCI, V9, P990; BENOWITZ LI, 1987, TRENDS NEUROSCI, V10, P527, DOI 10.1016/0166-2236(87)90135-4; BENOWITZ LI, 1988, J NEUROSCI, V8, P339; BIFFO S, 1990, EUR J NEUROSCI, V2, P487, DOI 10.1111/j.1460-9568.1990.tb00440.x; BURNS ME, 1995, CELL, V83, P187, DOI 10.1016/0092-8674(95)90160-4; BURRY RW, 1991, J NEUROCYTOL, V20, P133, DOI 10.1007/BF01279617; CAMPAGNE MV, 1989, J NEUROCYTOL, V18, P479, DOI 10.1007/BF01474544; CHAN SY, 1986, J NEUROSCI, V6, P3618; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHAPMAN ER, 1992, J BIOL CHEM, V267, P25233; CIMLER BM, 1985, J BIOL CHEM, V260, P784; COGGINS PJ, 1993, J NEUROCHEM, V60, P368, DOI 10.1111/j.1471-4159.1993.tb05862.x; DEGRAAN PNE, 1990, J NEUROCHEM, V55, P2139; DEGRAAN PNE, 1985, NEUROSCI LETT, V61, P235, DOI 10.1016/0304-3940(85)90470-7; DEGUNZBURG J, 1989, P NATL ACAD SCI USA, V86, P4007; DEKKER LV, 1989, J NEUROCHEM, V52, P24, DOI 10.1111/j.1471-4159.1989.tb10893.x; DEKKER LV, 1989, NATURE, V342, P74, DOI 10.1038/342074a0; DELAMONTE SM, 1989, DEV BRAIN RES, V46, P161, DOI 10.1016/0165-3806(89)90279-4; ESTEP RP, 1990, CURR TOP CELL REGUL, V30, P161; Gamby C, 1996, J BIOL CHEM, V271, P10023, DOI 10.1074/jbc.271.17.10023; GIANOTTI C, 1992, NEURON, V8, P843, DOI 10.1016/0896-6273(92)90198-M; GISPEN WH, 1985, BRAIN RES, V328, P381, DOI 10.1016/0006-8993(85)91054-6; GORGELS TGMF, 1989, J NEUROSCI, V9, P3861; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GOSLIN K, 1988, NATURE, V336, P672, DOI 10.1038/336672a0; GOSLIN K, 1990, J NEUROSCI, V10, P588; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HATFIELD JM, 1988, DEV BIOL, V126, P164, DOI 10.1016/0012-1606(88)90250-3; HENS JJH, 1993, J NEUROCHEM, V61, P602; HENS JJH, 1995, J NEUROCHEM, V64, P1127; IGARASHI M, 1993, SCIENCE, V259, P77, DOI 10.1126/science.8418498; ITOH H, 1984, J BIOCHEM-TOKYO, V96, P1721, DOI 10.1093/oxfordjournals.jbchem.a135004; IVINS KJ, 1993, J NEUROCHEM, V60, P626, DOI 10.1111/j.1471-4159.1993.tb03194.x; JACOBSON RD, 1986, J NEUROSCI, V6, P1843; JOLLES J, 1980, NATURE, V286, P623, DOI 10.1038/286623a0; KALIL K, 1986, J NEUROSCI, V6, P2563; KUMAGAI C, 1992, J NEUROCHEM, V59, P41, DOI 10.1111/j.1471-4159.1992.tb08873.x; KUMAGAITOHDA C, 1993, J NEUROCHEM, V61, P526; LABATE ME, 1989, NEURON, V3, P299, DOI 10.1016/0896-6273(89)90254-7; LIU YC, 1991, NEURON, V6, P411, DOI 10.1016/0896-6273(91)90249-Y; LIU YC, 1993, BIOCHEMISTRY-US, V32, P10714, DOI 10.1021/bi00091a023; LIU YC, 1994, J NEUROSCI, V14, P5807; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LOVINGER DM, 1985, BRAIN RES, V343, P137, DOI 10.1016/0006-8993(85)91167-9; MASLIAH E, 1991, EXP NEUROL, V113, P131, DOI 10.1016/0014-4886(91)90169-D; MASSOM L, 1990, BIOCHEMISTRY-US, V29, P671, DOI 10.1021/bi00455a012; Meiri KF, 1996, J NEUROBIOL, V29, P213, DOI 10.1002/(SICI)1097-4695(199602)29:2<213::AID-NEU7>3.0.CO;2-D; MEIRI KF, 1986, P NATL ACAD SCI USA, V83, P3537, DOI 10.1073/pnas.83.10.3537; MEIRI KF, 1990, J NEUROSCI, V10, P256; MORTON AJ, 1992, EUR J NEUROSCI, V4, P910, DOI 10.1111/j.1460-9568.1992.tb00117.x; MOSS DJ, 1990, J NEUROCHEM, V54, P729, DOI 10.1111/j.1471-4159.1990.tb02312.x; MOYA KL, 1987, DEV BRAIN RES, V31, P183, DOI 10.1016/0165-3806(87)90116-7; NEVE RL, 1991, MOL NEUROBIOL, V5, P131, DOI 10.1007/BF02935542; NEVE RL, 1988, P NATL ACAD SCI USA, V85, P3638, DOI 10.1073/pnas.85.10.3638; NEVE RL, 1987, MOL BRAIN RES, V2, P177, DOI 10.1016/0169-328X(87)90012-X; ROUTTENBERG A, 1985, BEHAV NEURAL BIOL, V43, P3, DOI 10.1016/S0163-1047(85)91426-8; SHAO S, 1994, SOC NEUR ABSTR, V20, P659; SHEA TB, 1991, J NEUROSCI, V11, P1685; SILVER PJ, 1986, BIOCHEM PHARMACOL, V35, P2545, DOI 10.1016/0006-2952(86)90052-3; SKENE JHP, 1986, SCIENCE, V233, P783, DOI 10.1126/science.3738509; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SKENE JHP, 1981, J CELL BIOL, V89, P96, DOI 10.1083/jcb.89.1.96; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; STRITTMATTER SM, 1994, J NEUROSCI, V14, P5503; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STRITTMATTER SM, 1992, J NEUROBIOL, V23, P507, DOI 10.1002/neu.480230506; STRITTMATTER SM, 1994, J CELL SCI, V107, P195; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; STRITTMATTER SM, 1993, P NATL ACAD SCI USA, V90, P5327, DOI 10.1073/pnas.90.11.5327; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; WIDMER F, 1993, J CELL BIOL, V120, P503, DOI 10.1083/jcb.120.2.503; YANKNER BA, 1990, MOL BRAIN RES, V7, P39, DOI 10.1016/0169-328X(90)90071-K; ZUBER MX, 1989, SCIENCE, V244, P1193, DOI 10.1126/science.2658062; ZUBER MX, 1989, NATURE, V341, P345, DOI 10.1038/341345a0	85	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26698	26705		10.1074/jbc.271.43.26698	http://dx.doi.org/10.1074/jbc.271.43.26698			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900147	hybrid			2022-12-25	WOS:A1996VP23300041
J	Guzov, VM; Houston, HL; Murataliev, MB; Walker, FA; Feyereisen, R				Guzov, VM; Houston, HL; Murataliev, MB; Walker, FA; Feyereisen, R			Molecular cloning, overexpression in Escherichia coli, structural and functional characterization of house fly cytochrome b(5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER MITOCHONDRIAL-MEMBRANE; OXIDATION REDUCTION EQUILIBRIUM; PROTON MAGNETIC-RESONANCE; TOTAL ENZYMIC-SYNTHESIS; AMINO-ACID-RESIDUES; BACTERIAL EXPRESSION; MUSCA-DOMESTICA; P450 REDUCTASE; PROTEIN; PURIFICATION	A microsomal cytochrome b(5) cDNA from the house fly, Musca domestica, was cloned and sequenced, The deduced amino acid sequence of the full-length house fly cytochrome b(5) (134 residues) is 48% identical to that of rat microsomal cytochrome b(5). The house fly cyto chrome b(5) protein was overexpressed in Escherichia coli, purified, and characterized. Absorption and EPR spectroscopy reveal properties very similar to cytochromes b(5) from vertebrates, NMR spectra indicate that the orientation of the heme in the protein relative to its alpha,gamma meso axis is about 1:1. A redox potential of -26 mV versus standard hydrogen electrode was measured by cyclic voltammetry on a modified gold electrode in the presence of hexamminechromium(III) chloride. The cytochrome b(5) is reduced by house fly cytochrome P450 reductase in a reconstituted system at a high rate (5.5 s(-1)), and it stimulates heptachlor epoxidation when res constituted with house fly cytochrome P450 reductase, cytochrome P450 6A1, phospholipid, and detergent. Cytochrome b(5) decreases the apparent K-m for P450 reductase and increases the V-max for heptachlor epoxidation at constant cytochrome P450 6A1 concentrations. The results indicate that cytochrome b(5) stimulates a step following the first electron transfer during cytochrome P450 6A1 turnover.	UNIV ARIZONA,DEPT ENTOMOL,TUCSON,AZ 85721; UNIV ARIZONA,DEPT CHEM,TUCSON,AZ 85721	University of Arizona; University of Arizona			Feyereisen, René/Y-7514-2019; Walker, Frances A/O-4395-2016; Feyereisen, René/I-3140-2012	Feyereisen, René/0000-0002-9560-571X; Feyereisen, René/0000-0002-9560-571X	NIDDK NIH HHS [DK 31038] Funding Source: Medline; NIEHS NIH HHS [ES 06694] Funding Source: Medline; NIGMS NIH HHS [GM 39014] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031038, R56DK031038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039014] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN JF, 1994, BIOCHEMISTRY-US, V33, P2171, DOI 10.1021/bi00174a025; BAUER S, 1974, BIOTECHNOL BIOENG, V16, P933, DOI 10.1002/bit.260160707; BLACK SD, 1994, ARCH BIOCHEM BIOPHYS, V310, P126, DOI 10.1006/abbi.1994.1148; BOISPOLTORATSKY R, 1967, EUR J BIOCHEM, V2, P361, DOI 10.1111/j.1432-1033.1967.tb00146.x; BURCH AM, 1990, SCIENCE, V247, P831, DOI 10.1126/science.2154849; ENOCH HG, 1979, J BIOL CHEM, V254, P8976; FEYEREISEN R, 1989, P NATL ACAD SCI USA, V86, P1465, DOI 10.1073/pnas.86.5.1465; FEYEREISEN R, 1993, HDB EXPT PHARM, V105, P311; FUKUSHIMA H, 1981, J BIOL CHEM, V256, P4822; FUNK WD, 1990, BIOCHEMISTRY-US, V29, P5500, DOI 10.1021/bi00475a013; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; GOLLY I, 1988, ARCH BIOCHEM BIOPHYS, V260, P232, DOI 10.1016/0003-9861(88)90445-6; GONZALEZ FJ, 1990, TRENDS GENET, V6, P182, DOI 10.1016/0168-9525(90)90174-5; GRINSTEAD GF, 1982, J BIOL CHEM, V257, P3937; GRUENKE LD, 1995, J BIOL CHEM, V270, P24707, DOI 10.1074/jbc.270.42.24707; HEGESH E, 1986, NEW ENGL J MED, V314, P757, DOI 10.1056/NEJM198603203141206; HEWSON R, 1993, PROTEIN ENG, V6, P953, DOI 10.1093/protein/6.8.953; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; Hodgson E, 1985, COMPREHENSIVE INSECT, P225; HOLMANS PL, 1994, ARCH BIOCHEM BIOPHYS, V312, P554, DOI 10.1006/abbi.1994.1345; ITO A, 1980, J BIOCHEM, V87, P63, DOI 10.1093/oxfordjournals.jbchem.a132753; KATAGIRI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P343, DOI 10.1006/abbi.1995.1173; KAWANO T, 1994, J BIOL CHEM, V269, P9024; KELLER RM, 1972, BIOCHIM BIOPHYS ACTA, V285, P326, DOI 10.1016/0005-2795(72)90317-0; KELLER RM, 1980, BIOCHIM BIOPHYS ACTA, V621, P204, DOI 10.1016/0005-2795(80)90172-5; KOENER JF, 1993, INSECT BIOCHEM MOLEC, V23, P439, DOI 10.1016/0965-1748(93)90051-S; KULA ME, 1995, J MOL EVOL, V41, P430, DOI 10.1007/BF00160314; LADOKHIN AS, 1991, BIOCHEMISTRY-US, V30, P10200, DOI 10.1021/bi00106a018; LAMAR GN, 1981, J BIOL CHEM, V256, P6075; LEE KB, 1991, J AM CHEM SOC, V113, P3576, DOI 10.1021/ja00009a054; LEE KB, 1990, BIOCHEMISTRY-US, V29, P9623, DOI 10.1021/bi00493a017; LEVIN RJ, 1989, NUCLEIC ACIDS RES, V13, P631; LLOYD E, 1994, BIOCHEMISTRY-US, V33, P11432, DOI 10.1021/bi00204a005; LOOMAN AC, 1987, EMBO J, V6, P2489, DOI 10.1002/j.1460-2075.1987.tb02530.x; MATHEWS FS, 1985, PROG BIOPHYS MOL BIO, V45, P1, DOI 10.1016/0079-6107(85)90004-5; MATHEWS FS, 1979, PORPHYRINS, V7, P107; MCFADDEN KA, 1979, INSECT BIOCHEM, V9, P301, DOI 10.1016/0020-1790(79)90010-6; MCLACHLAN SJ, 1988, BIOCHIM BIOPHYS ACTA, V957, P430, DOI 10.1016/0167-4838(88)90234-8; NOSHIRO M, 1981, EUR J BIOCHEM, V116, P521, DOI 10.1111/j.1432-1033.1981.tb05367.x; OKADA Y, 1969, J BIOCHEM-TOKYO, V65, P581, DOI 10.1093/oxfordjournals.jbchem.a129051; OMURA T, 1964, J BIOL CHEM, V239, P2370; PALTAUF F, 1974, J BIOL CHEM, V249, P2661; PASSON PG, 1972, BIOCHIM BIOPHYS ACTA, V275, P51, DOI 10.1016/0005-2728(72)90023-0; PEISACH J, 1973, ANN NY ACAD SCI, V206, P310, DOI 10.1111/j.1749-6632.1973.tb43219.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Peterson JA, 1986, CYTOCHROME P 450 STR, P89; POMPON D, 1987, BIOCHEMISTRY-US, V26, P6429, DOI 10.1021/bi00394a020; POMPON D, 1984, J BIOL CHEM, V259, P5377; REID LS, 1982, J AM CHEM SOC, V104, P841, DOI 10.1021/ja00367a032; REID LS, 1982, J AM CHEM SOC, V104, P7516, DOI 10.1021/ja00390a021; RIVERA M, 1994, BIOCHEMISTRY-US, V33, P2161, DOI 10.1021/bi00174a024; RIVERA M, 1992, BIOCHEMISTRY-US, V31, P12233, DOI 10.1021/bi00163a037; RODGERS KK, 1991, J AM CHEM SOC, V113, P9419, DOI 10.1021/ja00024a087; Sambrook J., 2002, MOL CLONING LAB MANU; SANBORN RC, 1950, J GEN PHYSIOL, V33, P579, DOI 10.1085/jgp.33.5.579; Sanders J., 1993, MODERN NMR SPECTROSC, P163; SATTERLEE JD, 1986, MET IONS BIOL SYST, V21, P121; SHICHI H, 1962, J BIOL CHEM, V237, P2959; SHINZAWA K, 1985, BIOCHIM BIOPHYS ACTA, V833, P151; SMITH MA, 1994, BIOCHEM J, V303, P73, DOI 10.1042/bj3030073; SPATZ L, 1971, P NATL ACAD SCI USA, V68, P1042, DOI 10.1073/pnas.68.5.1042; STRITTMATTER P, 1956, J BIOL CHEM, V221, P253; TAMBURINI PP, 1986, BIOCHEM BIOPH RES CO, V134, P519, DOI 10.1016/S0006-291X(86)80451-X; VERGERES G, 1995, BIOCHIMIE, V77, P604, DOI 10.1016/0300-9084(96)88176-4; VONBODMAN SB, 1986, P NATL ACAD SCI USA, V83, P9443; WALKER FA, 1988, J AM CHEM SOC, V110, P6234, DOI 10.1021/ja00226a045; WALKER FA, 1986, J AM CHEM SOC, V108, P5288, DOI 10.1021/ja00277a038; WHEELOCK GD, 1989, INSECT BIOCHEM, V19, P481, DOI 10.1016/0020-1790(89)90030-9; Yamazaki H, 1996, ARCH BIOCHEM BIOPHYS, V325, P174, DOI 10.1006/abbi.1996.0022; YOSHIDA Y, 1974, J BIOCHEM, V75, P1211, DOI 10.1093/oxfordjournals.jbchem.a130504; ZHANG ML, 1994, ARCH INSECT BIOCHEM, V27, P205, DOI 10.1002/arch.940270306	71	61	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26637	26645		10.1074/jbc.271.43.26637	http://dx.doi.org/10.1074/jbc.271.43.26637			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900138				2022-12-25	WOS:A1996VP23300032
J	Lim, BL; Reid, KBM; Ghebrehiwet, B; Peerschke, EIB; Leigh, LAE; Preissner, KT				Lim, BL; Reid, KBM; Ghebrehiwet, B; Peerschke, EIB; Leigh, LAE; Preissner, KT			The binding protein for globular heads of complement C1q, gC1qR - Functional expression and characterization as a novel vitronectin binding factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PROTEIN; ALPHA(V)BETA(5) INTEGRIN; RECEPTOR; IDENTIFICATION; LOCALIZATION; ASSOCIATION; COMPLEXES; SURFACE; SYSTEM; CELLS	A binding protein for the globular head domains of complement component C1q, designated gC1qR, recently described to be present on vascular and blood cells (Ghebrehiwet, B., Lim, B,-L., Peerschke, E. I. B., Willis, A. C., and Reid, K. B. M. (1994) J. Exp. Med. 179, 1809-1821 was expressed in recombinant form in bacteria to investigate its functional and structural properties. The recombinant gC1qR was found to be functional because tetramerization of the 24.3-kDa polypeptide occurred as described for the native protein, and the binding of the ligand C1q by recombinant gC1qR was indistinguishable from binding shown by gC1qR isolated from Raji cells, Recombinant gC1qR immobilized to microspheres was used to search for additional binding proteins unrelated to C1q. Surprisingly, it was found that vitronectin or complexes containing vitronectin were retained from plasma or serum, and subsequent analysis revealed the specific binding of the ternary vitronectin-thrombin-antithrombin complex to gC1qR. Because the thrombin antithrombin complex was unable to interact with gC1qR, direct binding with vitronectin was investigated in a purified system. The heparin binding multimeric form of vitronectin but not the plasma form of vitronectin was found to bind specifically to gC1qR isolated from Raji cell membrane as well as to recombinant gC1qR. This interaction was saturable (K-D similar to 20 nM) and inhibitable by glycosaminoglycans such as heparin but not by chondroitin sulfate. C1q and vitronectin did not compete with each other for binding to gC1qR, and both ligands seem to interact with different parts of the gC1qR because a truncated version of recombinant gC1qR lacking the N-terminal 22-amino acid portion hardly interacted with vitronectin but bound C1q as well as the intact gC1qR. These findings establish gC1qR as a novel vitronectin-binding protein that may participate in the clearance of vitronectin containing complexes or opsonized particles or cooperate with vitronectin in the inhibition of complement-mediated cytolysis.	MAX PLANCK INST, KERCKHOFF KLIN, HAEMOSTASIS RES UNIT, D-61231 BAD NAUHEIM, GERMANY; UNIV HONG KONG, DEPT ZOOL, HONG KONG, HONG KONG; UNIV OXFORD, DEPT BIOCHEM, MED RES CTR, IMMUNOCHEM UNIT, OXFORD OX1 3QU, ENGLAND; SUNY STONY BROOK, DEPT MED, STONY BROOK, NY 11794 USA; SUNY STONY BROOK, DEPT PATHOL, STONY BROOK, NY 11794 USA	Kerckhoff Clinic; Max Planck Society; University of Hong Kong; University of Oxford; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Lim, Boon Leong/D-3104-2009	Lim, Boon Leong/0000-0002-2720-2353				DEBOER HC, 1992, J BIOL CHEM, V267, P2264; DEBOER HC, 1993, J BIOL CHEM, V268, P1279; DEITCH EA, 1993, ARCH SURG-CHICAGO, V128, P1222; EGGLETON P, 1995, J CLIN INVEST, V95, P1569, DOI 10.1172/JCI117830; ERDEI A, 1988, BIOCHEM J, V255, P493; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DA, 1987, J BIOL CHEM, V262, P16343; MALHOTRA R, 1990, J EXP MED, V172, P955, DOI 10.1084/jem.172.3.955; MALHOTRA R, 1993, BIOCHEM J, V293, P15, DOI 10.1042/bj2930015; PANETTI TS, 1993, J BIOL CHEM, V268, P11492; PARKER CJ, 1988, BLOOD, V71, P86; Preissner K.T., 1993, NATURAL IMMUNE SYSTE, P281; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; Reid K B, 1989, Behring Inst Mitt, P8; REID KBM, 1981, METHOD ENZYMOL, V80, P16; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SCHREIBER RD, 1984, SPRINGER SEMIN IMMUN, V7, P221, DOI 10.1007/BF01893021; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDENBERG RH, 1996, MOL IMMUNOL S1, V33, P21; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WALPORT MJ, 1988, ARTHRITIS RHEUM, V31, P153, DOI 10.1002/art.1780310201; WEI Y, 1994, J BIOL CHEM, V269, P32380	28	92	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26739	26744		10.1074/jbc.271.43.26739	http://dx.doi.org/10.1074/jbc.271.43.26739			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900153	hybrid			2022-12-25	WOS:A1996VP23300047
J	Nicholson, SE; Starr, R; Novak, U; Hilton, DJ; Layton, JE				Nicholson, SE; Starr, R; Novak, U; Hilton, DJ; Layton, JE			Tyrosine residues in the granulocyte colony-stimulating factor (G-CSF) receptor mediate G-CSF induced differentiation of murine myeloid leukemic (M1) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; CYTOKINE RECEPTORS; KINASE JAK1; ACTIVATION; BINDING; PHOSPHORYLATION; PROLIFERATION	The cytoplasmic tyrosine residues of many growth factor receptors have been shown to be important for receptor signal transduction via the recruitment of proteins containing phosphotyrosine-binding domains. This study demonstrates the importance of specific tyrosine residues in the granulocyte colony-stimulating factor (G-CSF) receptor cytoplasmic domain in G-CSF-induced macrophage cell differentiation. Site-directed mutagenesis was used to generate a series of G-CSF receptor (G-CSF-R) mutants in which the tyrosine residues were replaced with phenylalanine either singly or in combination, The mouse myeloid leukemic cell line (M1) transfected with G-CSF-R cDNA can be induced to differentiate into macrophages in response to G-CSF. The effect of the tyrosine mutations on this differentiation response was assessed by examining cell morphology and differentiation in soft agar colony assays. Although three of the four cytoplasmic tyrosine residues appeared to contribute to the differentiation response, mutation of a single residue (Tyr(744)) significantly reduced the ability of the M1 cells to differentiate. The STAT family of signaling molecules (Stat1, Stat3, and Stat5) were activated by G-CSF in M1 cells expressing those G-CSF-R tyrosine mutants unable to mediate G-CSF-induced differentiation. Furthermore, activation of STAT proteins was shown to occur in the absence of all four cytoplasmic tyrosine residues, suggesting an alternative mechanism for STAT activation other than direct interaction with receptor phosphotyrosines.	UNIV MELBOURNE,LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,PARKVILLE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,DEPT MED,PARKVILLE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; University of Melbourne; University of Melbourne; Walter & Eliza Hall Institute; University of Melbourne			Hilton, Douglas J/C-7250-2013	Hilton, Douglas J/0000-0002-7698-2392; , Sandra/0000-0002-1314-2134	NATIONAL CANCER INSTITUTE [R01CA022556, R37CA022556] Funding Source: NIH RePORTER; NCI NIH HHS [CA-22556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVALOS BR, 1995, BLOOD, V85, P3117, DOI 10.1182/blood.V85.11.3117.bloodjournal85113117; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; deKoning JP, 1996, BLOOD, V87, P132; deKoning JP, 1996, BLOOD, V87, P1335, DOI 10.1182/blood.V87.4.1335.bloodjournal8741335; DEMETRI GD, 1991, BLOOD, V78, P2791; DONG F, 1994, P NATL ACAD SCI USA, V91, P4480, DOI 10.1073/pnas.91.10.4480; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; FUKUNAGA R, 1993, CELL, V74, P1; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HACKETT RH, 1995, J BIOL CHEM, V270, P21326, DOI 10.1074/jbc.270.36.21326; HIRAOKA O, 1994, J BIOL CHEM, V269, P22412; INHORN RC, 1995, P NATL ACAD SCI USA, V92, P8665, DOI 10.1073/pnas.92.19.8665; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIESCHKE GJ, 1994, BLOOD, V84, P1737; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; METCALF D, 1984, CLONAL CULTURE HEMOP, P19; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; NICOLA NA, 1990, COLONY STIMULATING F, P77; NICOLSON SE, 1995, BLOOD, V86, P3698; NOVAK U, 1996, IN PRESS GROWTH FACT, V13; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; PAN CX, 1993, J BIOL CHEM, V268, P25818; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SOLER C, 1994, J BIOL CHEM, V269, P12320; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TANIGAWA T, 1995, BLOOD, V85, P379; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TIAN SS, 1994, BLOOD, V84, P1760; TWEARDY DJ, 1995, BLOOD, V86, P4409, DOI 10.1182/blood.V86.12.4409.bloodjournal86124409; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILKS AF, 1994, BIOESSAYS, V16, P313, DOI 10.1002/bies.950160505; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YOSHIKAWA A, 1995, EMBO J, V14, P5288, DOI 10.1002/j.1460-2075.1995.tb00213.x; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	59	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26947	26953		10.1074/jbc.271.43.26947	http://dx.doi.org/10.1074/jbc.271.43.26947			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900180	hybrid			2022-12-25	WOS:A1996VP23300074
J	Rhee, KY; Parekh, BS; Hatfield, GW				Rhee, KY; Parekh, BS; Hatfield, GW			Leucine-responsive regulatory protein-DNA interactions in the leader region of the ilvGMEDA operon of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID SYNTHASE ISOZYMES; GLOBAL REGULATOR; RNA-POLYMERASE; ILVIH OPERON; LRP; TRANSCRIPTION; BINDING; K-12; SEQUENCE; PROMOTER	The leucine-responsive regulatory protein (Lrp) regulates the expression of many operons in Escherichia coli including several involved in the metabolism of the branched-chain amino acids, L-isoleucine, L-valine, and L-leucine. The ilvGMEDA operon contains the genes for four of the five enzymes of the common pathway for the biosynthesis of these amino acids, A high affinity, consensus-like Lrp-DNA binding site has been identified at an unusual position in the leader region of this operon 226 base pairs downstream of the transcriptional initiation site between the attenuator and the ilvG gene, Binding to this site facilitates the cooperative binding of a second Lrp protomer to an adjacent, upstream, secondary site, At higher Lrp concentrations, binding to a third site is observed, Chemical, enzymatic, and alkylation protection and interference footprinting experiments demonstrate that the Lrp homodimer contacts the DNA helix at symmetrical half-sites present in adjacent major grooves and that the primary and secondary binding sites are separated by one helical turn and aligned along the same face of the DNA helix, In vivo, Lrp represses transcription through the leader-attenuator region of the ilvGMEDA operon, Lrp-dependent production of attenuated RNA transcripts is also observed in vitro. No transcriptional effects are observed, in vivo or in vitro, in the absence of an intact Lrp primary binding site, A possible physiological role for Lrp in the regulation of ilvGMEDA operon expression is discussed.	UNIV CALIF IRVINE, DEPT MICROBIOL & MOL GENET, COLL MED, IRVINE, CA 92697 USA	University of California System; University of California Irvine					NIGMS NIH HHS [GM49388] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049388] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON JJ, 1976, J BACTERIOL, V126, P80, DOI 10.1128/JB.126.1.80-90.1976; BARAK Z, 1987, J BACTERIOL, V169, P3750, DOI 10.1128/jb.169.8.3750-3756.1987; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; CALVO JM, 1994, MICROBIOL REV, V58, P466, DOI 10.1128/MMBR.58.3.466-490.1994; COLE JR, 1986, P NATL ACAD SCI USA, V83, P4129, DOI 10.1073/pnas.83.12.4129; CUI YH, 1995, J BACTERIOL, V177, P4872, DOI 10.1128/jb.177.17.4872-4880.1995; Cui YH, 1996, J BIOL CHEM, V271, P6611, DOI 10.1074/jbc.271.12.6611; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIEDBERG D, 1995, J BACTERIOL, V177, P1624, DOI 10.1128/jb.177.6.1624-1626.1995; HANEY SA, 1992, J BACTERIOL, V174, P108, DOI 10.1128/jb.174.1.108-115.1992; HAUSER CA, 1985, J BIOL CHEM, V260, P1765; Hildebrand F. B., 1974, INTRO NUMERICAL ANAL; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; LAWTHER RP, 1981, P NATL ACAD SCI-BIOL, V78, P922, DOI 10.1073/pnas.78.2.922; LAWTHER RP, 1980, P NATL ACAD SCI-BIOL, V77, P1862, DOI 10.1073/pnas.77.4.1862; LAWTHER RP, 1987, NUCLEIC ACIDS RES, V15, P2132; LIN RT, 1992, J BACTERIOL, V174, P1948, DOI 10.1128/jb.174.6.1948-1955.1992; LIN RT, 1990, J BACTERIOL, V172, P4529; Maxam A M, 1980, Methods Enzymol, V65, P499; Miller J.H., 1972, EXPT MOL GENETICS; NEWMAN EB, 1995, ANNU REV MICROBIOL, V49, P747, DOI 10.1146/annurev.mi.49.100195.003531; PAGEL JM, 1991, J BIOL CHEM, V266, P1985; Parekh BS, 1996, P NATL ACAD SCI USA, V93, P1173, DOI 10.1073/pnas.93.3.1173; PLATKO JV, 1990, J BACTERIOL, V172, P4563, DOI 10.1128/jb.172.8.4563-4570.1990; PLATKO JV, 1993, J BACTERIOL, V175, P1110, DOI 10.1128/JB.175.4.1110-1117.1993; REX JH, 1991, J BACTERIOL, V173, P5944, DOI 10.1128/jb.173.19.5944-5953.1991; RICCA E, 1989, J BACTERIOL, V171, P1658, DOI 10.1128/jb.171.3.1658-1664.1989; Sambrook J., 2002, MOL CLONING LAB MANU; SENEAR DF, 1991, J BIOL CHEM, V266, P13661; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; Umbarger HE, 1987, ESCHERICHIA COLI SAL, P352; WANG Q, 1993, J MOL BIOL, V229, P306, DOI 10.1006/jmbi.1993.1036; WANG Q, 1993, EMBO J, V12, P2495, DOI 10.1002/j.1460-2075.1993.tb05904.x; WEK RC, 1986, NUCLEIC ACIDS RES, V14, P2763, DOI 10.1093/nar/14.6.2763; WEK RC, 1988, J MOL BIOL, V203, P643, DOI 10.1016/0022-2836(88)90199-4; WEK RC, 1985, NUCLEIC ACIDS RES, V13, P3995, DOI 10.1093/nar/13.11.3995; WILLINS DA, 1991, J BIOL CHEM, V266, P10768; WINKELMAN JW, 1990, J BIOL CHEM, V265, P10055; WISSMANN A, 1991, METHOD ENZYMOL, V208, P365	42	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26499	26507		10.1074/jbc.271.43.26499	http://dx.doi.org/10.1074/jbc.271.43.26499			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900118	hybrid			2022-12-25	WOS:A1996VP23300012
J	Chen, CH; Nussenzweig, A; Guo, M; Kim, D; Li, GC; Ling, CC				Chen, CH; Nussenzweig, A; Guo, M; Kim, D; Li, GC; Ling, CC			Down-regulation of gadd153 by c-myc in rat fibroblasts and its effect on cell growth and radiation-induced apoptosis	ONCOGENE			English	Article						c-myc; gadd153; growth arrest; apoptosis	DNA-DAMAGING AGENTS; MESSENGER-RNA; DIFFERENTIAL DISPLAY; GENOTOXIC STRESS; EMBRYO CELLS; GENE; PROTEIN; ARREST; BCL-2; INDUCTION	Using differential display reverse transcription PCR (DDRT-PCR), we found that a 360 bp cDNA fragment was absent in several c-myc transfected rat fibroblasts: REC:myc, REC:myc + ras and rat1-myc. These cells also showed enhanced sensitivity to gamma ray-induced apoptosis. This cDNA fragment was present in the parental REC (Rat Embryo Cells) and rat1 cells, and in c-Ha-ras transfected REC (REC:ras), all of which were relatively resistant to gamma ray-induced apoptosis. The cDNA fragment was subsequently cloned and used as a probe to screen a rat1 cDNA library, and identified as one of the growth arrest and DNA damaging-inducible genes, gadd153. In addition to the down-regulation of rat gadd153 in all the c-myc transfectants, methyl methanesulfonate (MMS)-induced transcription of the gadd153 was attenuated. The rat1-myc cells, when successfully transfected with and stably expressing the rat gadd153, showed a significantly longer doubling time compared to the parental cells. However, overexpression of gadd153 in rat1-myc cells did not affect gamma ray-induced apoptosis. Thus, the suppression of gadd153 appears to be inversely correlated with that of myc, but not involved in the myc-dependent apoptotic pathway.	MEM SLOAN KETTERING CANC CTR, DEPT MED PHYS, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Chen, CH (corresponding author), MEM SLOAN KETTERING CANC CTR, LAB RADIAT BIOPHYS, 1275 YORK AVE, NEW YORK, NY 10021 USA.				NATIONAL CANCER INSTITUTE [R01CA052713] Funding Source: NIH RePORTER; NCI NIH HHS [CA52713] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; ASKEW DS, 1991, ONCOGENE, V6, P1915; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BAUER D, 1993, NUCLEIC ACIDS RES, V21, P4272, DOI 10.1093/nar/21.18.4272; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CHEN CH, 1994, RADIAT RES, V139, P307, DOI 10.2307/3578828; CHOI AMK, 1992, EXP CELL RES, V199, P85, DOI 10.1016/0014-4827(92)90464-J; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ENDLICH B, 1992, RADIAT RES, V132, P301, DOI 10.2307/3578238; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FISHER TC, 1993, CANCER RES, V53, P3321; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; GATELY DP, 1994, BRIT J CANCER, V70, P1102, DOI 10.1038/bjc.1994.455; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; JACKMAN J, 1994, CANCER RES, V54, P5656; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KORSMEYER SJ, 1992, CANCER SURV, V15, P105; LAND H, 1983, NATURE, V297, P474; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LING CC, 1989, RADIAT RES, V120, P267, DOI 10.2307/3577713; LOKE SL, 1988, CURR TOP MICROBIOL, V141, P282; LORD KA, 1990, ONCOGENE, V5, P387; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MIYASHITA T, 1993, BLOOD, V81, P151; MIYASHITA T, 1992, CANCER RES, V52, P5407; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; PRICE BD, 1992, CANCER RES, V52, P3814; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SUN Y, 1994, CANCER RES, V54, P1139; WYLLIE AH, 1992, CANCER METAST REV, V11, P95, DOI 10.1007/BF00048057; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	48	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1659	1665						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895511				2022-12-25	WOS:A1996VM88700010
J	Kerr, J; Leary, JA; Hurst, T; Shih, YC; Antalis, TM; Friedlander, M; Crawford, E; Khoo, SK; Ward, B; ChenevixTrench, G				Kerr, J; Leary, JA; Hurst, T; Shih, YC; Antalis, TM; Friedlander, M; Crawford, E; Khoo, SK; Ward, B; ChenevixTrench, G			Allelic loss on chromosome 7q in ovarian adenocarcinomas: Two critical regions and a rearrangement of the PLANH1 locus	ONCOGENE			English	Article						loss of heterozygosity; ovarian adenocarcinomas; tumour suppressor genes; PAI-1	TUMOR-SUPPRESSOR GENE; SQUAMOUS-CELL; FREQUENT LOSS; CARCINOMAS; HETEROZYGOSITY; CANCER; EXPRESSION; DELETION; 7Q31.1	The presence of a tumour suppressor gene on chromosome 7q is indicated by cytogenetic, loss of heterozygosity (LOH) and chromosome transfer studies, One candidate gene in this region is Plasminogen Activator Inhibitor-1 (PAI-1), The PAI-1 gene product is involved in proteolysis and may therefore influence tumour spread and invasion, We have analysed a series of 139 ovarian epithelial tumours at four loci in the region 7q21-q31 which includes the PAI-1 gene, The highest rates of loss were found in malignant tumours (FIGO stages I-IV) at markers D7S471 (38%, 20/52 informative cases) and D7S522 (34%, 15/44), No loss was seen in benign tumours and only one out of 27 (4%) informative LMP tumours demonstrated LOH, The smallest region of overlap (SRO) lies between D7S471 and PAI-1, We also identified a rearrangement in one tumour in the PAI-1 gene, suggesting that this may be the inactivated gene in this region, In addition LOH at the more distal marker, D7S522, which lies outside the SRO, shows significant association with stage (P=0.0343) and with LOH on chromosome 13 (P=0.0024), This is in contrast to all other markers examined, These data suggest the presence of two critical regions on 7q which may be important in subsets of epithelial ovarian tumours.	QUEENSLAND INST MED RES, QUEENSLAND CANC FUND RES UNIT, BRISBANE, QLD 4029, AUSTRALIA; UNIV SYDNEY, WESTMEAD HOSP, DEPT MED ONCOL, SYDNEY, NSW 2006, AUSTRALIA; UNIV SYDNEY, WESTMEAD HOSP, DEPT OBSTET & GYNAECOL, SYDNEY, NSW 2006, AUSTRALIA; UNIV QUEENSLAND, ROYAL BRISBANE HOSP, DEPT OBSTET & GYNAECOL, HERSTON, QLD 4029, AUSTRALIA; PRINCE WALES HOSP, DEPT MED ONCOL, SYDNEY, NSW 2031, AUSTRALIA	QIMR Berghofer Medical Research Institute; University of Sydney; University of Sydney; Royal Brisbane & Women's Hospital; University of Queensland			Chenevix-Trench, Georgia/AAV-2014-2020	Chenevix-Trench, Georgia/0000-0002-1878-2587				ATKIN NB, 1993, CANCER GENET CYTOGEN, V67, P123, DOI 10.1016/0165-4608(93)90164-H; CHENEVIXTRENCH G, 1992, ONCOGENE, V7, P1059; CHENEVIXTRENCH G, 1994, AM J HUM GENET, V55, P143; CHENEVIXTRENCH G, 1996, IN PRESS GENES CHROM; DAWSON S, 1991, ARTERIOSCLER THROMB, V11, P183, DOI 10.1161/01.ATV.11.1.183; ECCLES DM, 1992, ONCOGENE, V7, P2069; FOLLO M, 1989, GENE, V84, P447, DOI 10.1016/0378-1119(89)90519-2; GALLION HH, 1992, GYNECOL ONCOL, V47, P137, DOI 10.1016/0090-8258(92)90096-2; KERE J, 1989, BLOOD, V73, P230; KUPRYJANCZYK J, 1995, HUM PATHOL, V26, P387, DOI 10.1016/0046-8177(95)90138-8; LEARY JA, 1995, INT J CANCER, V64, P189, DOI 10.1002/ijc.2910640308; LEVI S, 1991, CANCER RES, V51, P3497; LOSKUTOFF DJ, 1987, BIOCHEMISTRY-US, V26, P3763, DOI 10.1021/bi00387a004; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; OSELLA P, 1992, CANCER GENET CYTOGEN, V59, P73, DOI 10.1016/0165-4608(92)90162-2; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; PEJOVIC T, 1992, GENE CHROMOSOME CANC, V4, P58, DOI 10.1002/gcc.2870040108; ROBERTS CG, 1990, CANCER GENET CYTOGEN, V48, P243, DOI 10.1016/0165-4608(90)90127-V; RODABAUGH KJ, 1995, CANCER RES, V55, P2169; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347	25	44	47	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1815	1818						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895529				2022-12-25	WOS:A1996VM88700028
J	Ahmed, MM; Venkatasubbarao, K; Fruitwala, SM; Muthukkumar, S; Wood, DP; Sells, SF; Mohiuddin, M; Rangnekar, VM				Ahmed, MM; Venkatasubbarao, K; Fruitwala, SM; Muthukkumar, S; Wood, DP; Sells, SF; Mohiuddin, M; Rangnekar, VM			EGR-1 induction is required for maximal radiosensitivity in A375-C6 melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR EGR-1; TUMOR-GROWTH ARREST; WILD-TYPE P53; PROTEIN; APOPTOSIS; DIFFERENTIATION; IRRADIATION; EXPRESSION; RADIATION	Exposure to ionizing radiation leads to induction of the immediate-early gene, early growth response-1 (Egr-1). Previous studies have suggested distinct cell type- and inducer-specific roles for EGR-1 protein in cellular growth inhibition. The present study was undertaken to determine the functional role of EGR-1 in growth inhibition caused by exposure of tumor cells to ionizing radiation. Exposure to ionizing radiation caused induction of EGR-1 protein in human melanoma cells A375-C6. Inhibition of either the function of EGR-1 protein by stable transfection with a dominant-negative mutant or the expression of EGR-1 by transient transfection with an antisense oligomer resulted in a diminished growth-inhibitory response to ionizing radiation. Because previous studies have suggested that mutations in the tumor-suppressor gene p53 confer radio-resistance, we examined the p53 status of A375-C6 cells. Interestingly, both the parental and the transfected A375-C6 cells showed trisomy for wild-type p53 alleles. Exposure to ionizing radiation resulted in induction of p53 protein that localized to the nucleus in A375-C6 cells. These data suggest that inhibition of EGR-1 function confers radio resistance despite the induction of wild-type nuclear p53. Thus, EGR-1 is required for the growth-inhibitory response to ionizing radiation in A375-C6 cells.	UNIV KENTUCKY,DEPT SURG,DIV UROL,LEXINGTON,KY 40536; UNIV KENTUCKY,DEPT RADIAT MED,LEXINGTON,KY 40536; UNIV KENTUCKY,DEPT MICROBIOL & IMMUNOL,LEXINGTON,KY 40536; UNIV KENTUCKY,LUCILLE P MARKEY CANC CTR,LEXINGTON,KY 40536	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky			Ahmed, Mansoor/AAK-5988-2020		NATIONAL CANCER INSTITUTE [R29CA052837, R01CA060872] Funding Source: NIH RePORTER; NCI NIH HHS [CA52837, CA60872] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HOPMAN AHN, 1988, HISTOCHEMISTRY, V89, P307, DOI 10.1007/BF00500631; HUANG RP, 1995, ONCOGENE, V10, P467; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; RANGNEKAR VV, 1992, J BIOL CHEM, V267, P6240; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; SELLS SF, 1995, MOL CELL BIOL, V15, P682; SUGGS SV, 1990, NUCLEIC ACIDS RES, V18, P4283, DOI 10.1093/nar/18.14.4283; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Svaren J, 1996, MOL CELL BIOL, V16, P3545; URMANSKY SR, 1991, APOPTOSIS MOL BASIS, P193	23	68	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29231	29237		10.1074/jbc.271.46.29231	http://dx.doi.org/10.1074/jbc.271.46.29231			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910582	hybrid			2022-12-25	WOS:A1996VT05200074
J	Ariazi, EA; Gould, MN				Ariazi, EA; Gould, MN			Identifying differential gene expression in monoterpene-treated mammary carcinomas using subtractive display	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; FACTOR-II RECEPTOR; PROTEIN MESSENGER-RNA; FACTOR-BETA RECEPTORS; D-LIMONENE; PERILLYL ALCOHOL; INDUCED REGRESSION; AMYLOID PROTEIN; PCR PRODUCTS; INHIBITION	Monoterpene-induced/repressed genes were identified in regressing rat mammary carcinomas treated with dietary limonene using a newly developed method termed subtractive display. The subtractive display screen identified 42 monoterpene-induced genes comprising 9 known genes and 33 unidentified genes, as well as 58 monoterpene-repressed genes comprising I known gene and 57 unidentified genes. Several of the identified differentially expressed genes are involved in the mitoinhibitory transforming growth factor beta signal tranduction pathway, as demonstrated by isolation of the mannose 6-phosphate/insulin-like growth factor II receptor and the transforming growth factor beta type II receptor. The monoterpene-induced/repressed genes indicate that apoptosis and differentiation act in concert to effect-carcinoma regression. Apoptosis is suggested by the cloning of a marker of programmed cell death, lipocortin 1. Consistent with a differentiation/remodeling process occurring during tumor regression, subtractive display identified YWK-II and neuroligin 1. Thus far, of the cDNAs putatively identified as differentially expressed in this complex in situ carcinoma model, 5 were tested, and each one has been confirmed to be differentially expressed. Additionally, many of the identified known genes are expressed as rare transcripts and exhibit small but significant changes in abundance. Together, these points demonstrate the unique utility of this new gene expression screen to identify altered gene expression in a complex in vivo environment.	UNIV WISCONSIN,DEPT HUMAN ONCOL,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison			Gould, Michael N/C-7414-2014		NATIONAL CANCER INSTITUTE [R37CA038128] Funding Source: NIH RePORTER; NCI NIH HHS [R37-CA38128] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1990, J MOL BIOL, V215, P403; ARAKI N, 1993, J BONE MINER RES, V8, P313; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; CALLARD D, 1994, BIOTECHNIQUES, V16, P1096; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; CROWELL PL, 1992, CARCINOGENESIS, V13, P1261, DOI 10.1093/carcin/13.7.1261; CROWELL PL, 1994, CRIT REV ONCOGENESIS, V5, P1; CROWELL PL, 1991, J BIOL CHEM, V266, P17679; CROWELL PL, 1994, BIOCHEM PHARMACOL, V47, P1405, DOI 10.1016/0006-2952(94)90341-7; DEBUIRE B, 1995, CLIN CHEM, V41, P819; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DESOUZA AT, 1995, ONCOGENE, V10, P1725; ELEGBEDE JA, 1984, CARCINOGENESIS, V5, P661, DOI 10.1093/carcin/5.5.661; ELSON CE, 1988, CARCINOGENESIS, V9, P331, DOI 10.1093/carcin/9.2.331; Filmus Jorge, 1993, Current Opinion in Oncology, V5, P123; FUKUCHI K, 1992, J NEUROCHEM, V58, P1863, DOI 10.1111/j.1471-4159.1992.tb10063.x; GEBHARDT A, 1994, J LIPID RES, V35, P976; GELB MH, 1995, CANCER LETT, V91, P169, DOI 10.1016/0304-3835(95)03747-K; GOULD MN, 1994, CANCER RES, V54, P3540; GOULD MN, 1995, J CELL BIOCHEM, P139; HAAG JD, 1994, CANCER CHEMOTH PHARM, V34, P477, DOI 10.1007/BF00685658; HAAG JD, 1992, CANCER RES, V52, P4021; HADMAN M, 1995, ANAL BIOCHEM, V266, P383; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; JIRTLE RL, 1993, CANCER RES, V53, P3849; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KAWAGUCHI H, 1994, ENDOCR RES, V20, P219, DOI 10.1080/07435809409035860; KONIG G, 1990, FEBS LETT, V269, P305, DOI 10.1016/0014-5793(90)81181-M; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KOVACINA KS, 1989, BIOCHEM BIOPH RES CO, V160, P393, DOI 10.1016/0006-291X(89)91669-0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1995, METHOD ENZYMOL, V254, P304; LIANG P, 1995, CURR OPIN IMMUNOL, V7, P274, DOI 10.1016/0952-7915(95)80015-8; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MALTZMAN TH, 1989, CARCINOGENESIS, V10, P781, DOI 10.1093/carcin/10.4.781; MCKANNA JA, 1995, ANAT REC, V242, P1, DOI 10.1002/ar.1092420102; MCNAMEE D, 1993, LANCET, V342, P801, DOI 10.1016/0140-6736(93)91561-Y; MOU LJ, 1994, BIOCHEM BIOPH RES CO, V199, P564, DOI 10.1006/bbrc.1994.1265; Mularoni A, 1995, BIOCHEM BIOPH RES CO, V217, P1105, DOI 10.1006/bbrc.1995.2883; REN ZB, 1994, CANCER LETT, V76, P185, DOI 10.1016/0304-3835(94)90396-4; RUSSIN WA, 1989, CARCINOGENESIS, V10, P2161, DOI 10.1093/carcin/10.11.2161; SANGUINETTI CJ, 1994, BIOTECHNIQUES, V17, P914; SHI WG, 1995, CANCER LETT, V95, P1, DOI 10.1016/0304-3835(95)03859-U; SUE SR, 1995, ANN SURG, V222, P171, DOI 10.1097/00000658-199508000-00009; VANAGE G, 1992, BIOCHEM BIOPH RES CO, V183, P538, DOI 10.1016/0006-291X(92)90515-M; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAN YC, 1990, P NATL ACAD SCI USA, V87, P2405, DOI 10.1073/pnas.87.7.2405; YAN YC, 1992, ARCH ANDROLOGY, V28, P1; ZHAO JS, 1995, GENE, V155, P159, DOI 10.1016/0378-1119(94)00895-Y; ZHAO S, 1995, BIOTECHNIQUES, V18, P842	54	31	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29286	29294		10.1074/jbc.271.46.29286	http://dx.doi.org/10.1074/jbc.271.46.29286			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910589	hybrid			2022-12-25	WOS:A1996VT05200081
J	Diamond, SE; GutierrezHartmann, A				Diamond, SE; GutierrezHartmann, A			A 26-amino acid insertion domain defines a functional transcription switch motif in Pit-1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; GROWTH-HORMONE; POU-DOMAIN; PITUITARY; PROMOTER; PROTEIN; RAS; PIT-1/GHF-1; ACTIVATION; SEQUENCE	Pit-1, a pituitary-specific POU homeodomain transcription factor, specifies three anterior pituitary lineages; governs growth hormone, prolactin, and thyrotropin gene expression; and mediates basal and Ras-stimulated prolactin promoter activity in GH(4) pituitary cells. Alternate splicing of the Pit-1 message produces the Pit-1 beta isoform, which contains a 26 amino acid insertion, the beta-domain, within the amino-terminal transactivation domain. The beta-domain functions as a molecular switch, such that Pit-1 beta blocks both basal and Ras-stimulated prolactin promoter activity in GH(4) pituitary cells yet preferentially enhances protein kinase A-stimulated prolactin promoter activity in a HeLa reconstitution system. To determine whether the amino acid sequence of the beta-domain dictates function, we replaced it with five different 26-amino acid sequences. These mutants fail to block basal or Ras stimulated rat prolactin promoter activity and fail to optimally enhance the protein kinase A response of prolactin promoter. These data demonstrate that the amino acid sequence of the beta-domain specifies its role as a molecular switch. Additionally, the presence of both Pit-1 and Pit-1 beta in pituitary cells allows diverse incoming signals to utilize structurally different forms of the same gene product, which can interact with distinct co-factors, integrating multiple signaling pathways at the level of the nucleus.	UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,PROGRAM MOL BIOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,COLORADO CANC CTR,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Gutierrez-Hartmann, Arthur/F-1295-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009160] Funding Source: NIH RePORTER; NIDDK NIH HHS [F32 DK09160, DK37644] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; CONRAD KE, 1992, ONCOGENE, V7, P1279; DELHASE M, 1995, GENE, V155, P273, DOI 10.1016/0378-1119(94)00757-J; DEMINIE CA, 1993, J VIROL, V67, P6499, DOI 10.1128/JVI.67.11.6499-6506.1993; DIAMOND SE, 1994, J VIROL, V68, P863, DOI 10.1128/JVI.68.2.863-876.1994; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; HAUGEN BR, 1994, MOL ENDOCRINOL, V8, P1574, DOI 10.1210/me.8.11.1574; HAUGEN BR, 1993, J BIOL CHEM, V268, P20818; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JARVIS TC, 1992, EMBO J, V11, P3135, DOI 10.1002/j.1460-2075.1992.tb05386.x; KEECH CA, 1989, MOL ENDOCRINOL, V3, P832, DOI 10.1210/mend-3-5-832; KONZAK KE, 1992, MOL ENDOCRINOL, V6, P241, DOI 10.1210/me.6.2.241; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MORRIS AE, 1992, NUCLEIC ACIDS RES, V20, P1355, DOI 10.1093/nar/20.6.1355; ONO M, 1992, GENE, V116, P275, DOI 10.1016/0378-1119(92)90525-T; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; PICKETT CA, 1996, PITUITARY DIS DIAGNO; RAJNARAYAN S, 1995, MOL ENDOCRINOL, V9, P502, DOI 10.1210/me.9.4.502; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; THEILL LE, 1992, EMBO J, V11, P2261, DOI 10.1002/j.1460-2075.1992.tb05285.x; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WONG EA, 1992, DNA CELL BIOL, V11, P651, DOI 10.1089/dna.1992.11.651; YEN PM, 1994, MOL ENDOCRINOL, V8, P1450, DOI 10.1210/me.8.11.1450	35	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28925	28932		10.1074/jbc.271.46.28925	http://dx.doi.org/10.1074/jbc.271.46.28925			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910541	hybrid			2022-12-25	WOS:A1996VT05200033
J	Dong, MQ; Penin, F; Baggetto, LG				Dong, MQ; Penin, F; Baggetto, LG			Efficient purification and reconstitution of P-glycoprotein for functional and structural studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; PERFORMANCE LIQUID-CHROMATOGRAPHY; HAMSTER OVARY CELLS; MULTIDRUG-RESISTANT CELLS; NUCLEOTIDE-BINDING DOMAIN; SODIUM DODECYL-SULFATE; ATPASE ACTIVITY; ESCHERICHIA-COLI; DRUG TRANSPORT; PROTEINS	Plasma membrane P-glycoprotein is known as an ATP-dependent drug efflux pump that confers multidrug resistance to tumor cells. None of the reported purification procedures worked properly for our P-glycoprotein overproducing cell lines, i.e. murine lymphoid leukemia P388/ADR25, rat hepatoma AS30-D/COL10 and human lymphoblastic leukemia CEM/VLB5 cells. We have thus developed a general procedure for efficient purification of P-glycoprotein by combining solubilization with sodium dodecyl sulfate and chromatography on ceramic hydroxyapatite. This procedure was successful for the three cell lines and yielded 70% of the P-glycoprotein present in the starting plasma membranes with more than 99% purity. After exchanging sodium dodecyl sulfate into dodecyl maltoside and reconstitution into liposomes, purified P-glycoprotein exhibited a specific ATPase activity of about 200 nmol/min/mg, which was very similar to that obtained for P-glycoprotein solubilized and purified with 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonic acid. This ATPase activity was sensitive to orthovanadate inhibition and stimulated by verapamil and other drugs. More importantly, drug transport properties of the reconstituted P-glycoprotein were comparable with those of P-glycoprotein embedded in plasma membranes. Since it is virtually devoid of lipids, this preparation is suitable for both functional and structural investigations.	INST BIOL & CHIM PROT, CNRS, UPR 412, F-69367 LYON 07, FRANCE	Centre National de la Recherche Scientifique (CNRS)			PENIN, Francois/A-7315-2008	, Loris G/0000-0002-2412-8661				AMBUDKAR SV, 1995, J BIOENERG BIOMEMBR, V27, P23, DOI 10.1007/BF02110327; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AULAND ME, 1994, P NATL ACAD SCI USA, V91, P10938, DOI 10.1073/pnas.91.23.10938; BAGGETTO LG, 1987, J BIOL CHEM, V262, P9535; BAUBICHONCORTAY H, 1994, J BIOL CHEM, V269, P22983; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BLOOM H, 1987, ELECTROPHORESIS, V8, P93; BOSCOBOINIK D, 1990, BIOCHIM BIOPHYS ACTA, V1027, P225, DOI 10.1016/0005-2736(90)90311-B; BRAIMAN MS, 1987, J BIOL CHEM, V262, P9271; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; Eytan GD, 1996, J BIOL CHEM, V271, P3172, DOI 10.1074/jbc.271.6.3172; FOX JL, 1978, ANAL BIOCHEM, V87, P253, DOI 10.1016/0003-2697(78)90591-2; GARRIGOS M, 1993, BIOCHEM BIOPH RES CO, V196, P1034, DOI 10.1006/bbrc.1993.2355; GONZALO P, 1995, ANAL BIOCHEM, V225, P178, DOI 10.1006/abio.1995.1133; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAGIWARA M, 1991, CANCER LETT, V60, P103, DOI 10.1016/0304-3835(91)90215-4; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1995, J BIOENERG BIOMEMBR, V27, P63, DOI 10.1007/BF02110332; HJERTEN S, 1988, BIOCHIM BIOPHYS ACTA, V939, P476, DOI 10.1016/0005-2736(88)90094-6; HORIGOME T, 1989, EUR J BIOCHEM, V186, P63, DOI 10.1111/j.1432-1033.1989.tb15178.x; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; ICHIMURA T, 1995, ANAL BIOCHEM, V224, P250, DOI 10.1006/abio.1995.1037; KADOYA T, 1988, J LIQ CHROMATOGR, V11, P2951, DOI 10.1080/01483918808076771; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LELONG IH, 1992, FEBS LETT, V304, P256, DOI 10.1016/0014-5793(92)80632-Q; LONDON E, 1982, BIOTECHNIQUES, V6, P47; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; MOLLER JV, 1988, METHOD ENZYMOL, V157, P261; NAITO M, 1995, J CANCER RES CLIN, V121, P582, DOI 10.1007/BF01197774; OBLAS B, 1983, ANAL BIOCHEM, V130, P1, DOI 10.1016/0003-2697(83)90641-3; PENIN F, 1984, BIOCHIM BIOPHYS ACTA, V775, P239, DOI 10.1016/0005-2736(84)90175-5; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PORUCHYNSKY MS, 1994, BIOCHEMISTRY-US, V33, P4163, DOI 10.1021/bi00180a009; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; RIORDAN JR, 1979, J BIOL CHEM, V254, P2701; RIVAS E, 1982, ANAL BIOCHEM, V123, P194, DOI 10.1016/0003-2697(82)90643-1; SCHLEMMER SR, 1994, J BIOL CHEM, V269, P31059; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHARMA S, 1995, J BIOL CHEM, V270, P14085, DOI 10.1074/jbc.270.23.14085; SHAROM FJ, 1995, BIOCHEM J, V308, P381, DOI 10.1042/bj3080381; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; SHAROM FJ, 1995, J BIOENERG BIOMEMBR, V27, P15, DOI 10.1007/BF02110326; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; WATTS CKW, 1986, BIOCHEM J, V236, P903, DOI 10.1042/bj2360903	50	58	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28875	28883		10.1074/jbc.271.46.28875	http://dx.doi.org/10.1074/jbc.271.46.28875			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910534				2022-12-25	WOS:A1996VT05200026
J	Sanderson, RJ; Mosbaugh, DW				Sanderson, RJ; Mosbaugh, DW			Identification of specific carboxyl groups on uracil-DNA glycosylase inhibitor protein that are required for activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; POLYMERASE-BETA; RAT-LIVER; COMPLEX; BACTERIOPHAGE-PBS2; PROCESSIVITY; CARBODIIMIDE; GLYCOSIDASE	The bacteriophage PBS2 uracil-DNA glycosylase inhibitor (Ugi) protein inactivates uracil-DNA glycosylase (Ung) by forming an exceptionally stable protein-protein complex in which Ugi mimics electronegative and structural features of duplex DNA (Beger, R. D., Balasubramanian, S., Bennett, S. E., Mosbaugh, D. W., and Bolton, P. H. (1995) J. Biol. Chem. 270, 16840-16847; Mol, C. D., Arvai, A. S., Sanderson, a J., Slupphaug, G., Kavli, B., Krokan, H. E., Mosbaugh, D. W., and Tainer, J. A. (1995) Cell 82, 701-708). The role of specific carboxylic amino acid residues in forming the Ung-Ugi complex was investigated using selective chemical modification techniques. Ugi treated with carbodiimide and glycine ethyl ester produced five discrete protein species (forms I-V) that were purified and characterized. Analysis by mass spectrometry revealed that Ugi form I escaped protein modification, and forms II-V showed increasing incremental amounts of acyl-glycine ethyl ester adduction. Ugi forms II-V retained their ability to form a Ung Ugi complex but exhibited a reduced ability to inactivate Escherichia coli Ung, directly reaecting the extent of modification. Competition experiments using modified forms II-V with unmodified Ugi as a competitor protein revealed that unmodified Ugi preferentially formed complex. Furthermore, unmodified Ugi and poly(U) were capable of displacing forms II-V from a preformed Ung Ugi complex but were unable to displace Ugi form I. The primary sites of acyl-glycine ethyl ester adduction were located in the alpha 2-helix of Ugi at Glu-28 and Glu-31. We infer that these two negatively charged amino acids play an important role in mediating a conformational change in Ugi that precipitates the essentially irreversible Ung/Ugi interaction.	OREGON STATE UNIV,DEPT AGR CHEM,CORVALLIS,OR 97331; OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331; OREGON STATE UNIV,CTR ENVIRONM HLTH SCI,CORVALLIS,OR 97331	Oregon State University; Oregon State University; Oregon State University					NIEHS NIH HHS [ES00210] Funding Source: Medline; NIGMS NIH HHS [GM32823] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032823] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALASUBRAMANIAN S, 1995, J BIOL CHEM, V270, P296, DOI 10.1074/jbc.270.1.296; BEGER RD, 1995, J BIOL CHEM, V270, P16840, DOI 10.1074/jbc.270.28.16840; BENNETT SE, 1993, J BIOL CHEM, V268, P26879; BENNETT SE, 1992, J BIOL CHEM, V267, P22512; BENNETT SE, 1995, BIOCHEMISTRY-US, V34, P6109, DOI 10.1021/bi00018a014; BUECHLER JA, 1990, BIOCHEMISTRY-US, V29, P1937, DOI 10.1021/bi00459a039; CARADONNA S, 1996, EXP CELL RES, V222, P245; Carraway K L, 1972, Methods Enzymol, V25, P616, DOI 10.1016/S0076-6879(72)25060-1; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DOMENA JD, 1985, BIOCHEMISTRY-US, V24, P7320, DOI 10.1021/bi00346a045; FRIEDBERG EC, 1975, J VIROL, V16, P315, DOI 10.1128/JVI.16.2.315-321.1975; GEREN LM, 1984, J BIOL CHEM, V259, P2155; HAUGLAND RP, 1992, HDB FLUORESCENT PROB, P22; HIGLEY M, 1993, MUTAT RES, V294, P109, DOI 10.1016/0921-8777(93)90019-D; JENSEN ON, 1993, RAPID COMMUN MASS SP, V7, P496, DOI 10.1002/rcm.1290070619; KARRAN P, 1981, BIOCHEMISTRY-US, V20, P6092, DOI 10.1021/bi00524a027; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TD, 1989, P 37 AM SOC MASS SPE; LINDAHL T, 1977, J BIOL CHEM, V252, P3286; MEDINA M, 1992, EUR J BIOCHEM, V203, P373, DOI 10.1111/j.1432-1033.1992.tb16560.x; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; MOSBAUGH DW, 1994, PROG NUCLEIC ACID RE, V48, P315, DOI 10.1016/S0079-6603(08)60859-4; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; OLSEN LC, 1989, EMBO J, V8, P3121, DOI 10.1002/j.1460-2075.1989.tb08464.x; REISNER AH, 1984, METHOD ENZYMOL, V104, P439; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; SAVVA R, 1995, NAT STRUCT BIOL, V2, P752, DOI 10.1038/nsb0995-752; SAVVA R, 1995, PROTEINS, V22, P287, DOI 10.1002/prot.340220310; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; TAKAHASHI I, 1963, NATURE, V197, P194; TIMKOVICH R, 1977, ANAL BIOCHEM, V79, P135, DOI 10.1016/0003-2697(77)90387-6; VARSHNEY U, 1988, J BIOL CHEM, V263, P7776; WANG Z, 1989, J BIOL CHEM, V264, P1163; WANG ZG, 1991, GENE, V99, P31	38	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29170	29181		10.1074/jbc.271.46.29170	http://dx.doi.org/10.1074/jbc.271.46.29170			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910574	hybrid			2022-12-25	WOS:A1996VT05200066
J	Chen, G; Oh, S; Monia, BP; Stacey, DW				Chen, G; Oh, S; Monia, BP; Stacey, DW			Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POINT MUTATION; GENE FAMILY; CELL-PROLIFERATION; ONCOGENE PROTEINS; MESSENGER-RNA; NUDE-MICE; EXPRESSION; INHIBITION; GROWTH; REQUIREMENT	Although members of the RAS protein family (Ha-, Ki-, and N-RAS) are known to play a key role in normal cell proliferation and to be frequently mutated in naturally occurring tumors, it remains unclear which of these proteins functions to regulate growth in normal cells, Gene-specific oligonucleotides (oligos) against c-Ki-RAS (ISIS 6957), c-Ha-RAS (ISIS 2503), and oncogenic Ha-RAS (ISIS 2570) were used to analyze the requirement for individual RAS proteins in the proliferation of diploid human lung fibroblasts (MRC-5), and human bladder carcinoma cell lines with (T24) or without (J-82) a RAS mutation. The oncogenic Ha RAS oligo substantially inhibited T24 cell proliferation, whereas the c-Ki-RAS and control (ISIS 1966) oligos had little effect, Interestingly, in MRC-5 cells the c-Ki-RAS but not c-Ha-RAS oligo was effective in inhibiting cell proliferation, No inhibition was seen in the J-82 cells with either oligo, In Western analysis, p21 RAS protein was decreased following treatment with the oncogenic Ha-RAS oligo in T24 cells or the c-Ki-RAS oligo in MRC-B cells, whereas no reductions were observed in J-82 cells with either oligo, The specificity of these oligos was demonstrated in Northern analyses in which both Ha-RAS and Hi-RAS oligo treatment resulted in reduced levels of their respective mRNAs in all three cell lines, whereas the mutant Ha-RAS mRNA in T24 cells was most effectively reduced with the oncogenic Ha-RAS oligo, These results demonstrate that oncogenic Ha-RAS plays an important role in the proliferation of T24 cells, whereas c-Ki-RAS contributes predominantly to the proliferation of normal MRC 5 cells.	CLEVELAND CLIN FDN,DEPT MOL BIOL,CLEVELAND,OH 44195; ISIS PHARMACEUT,CARLSBAD,CA 92008	Cleveland Clinic Foundation; Isis Pharmaceuticals Inc					NCI NIH HHS [CA53496] Funding Source: Medline; NIGMS NIH HHS [GM52271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052271] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENNETT CF, 1996, ANTISENSE THERAPEUTI; BIZUB D, 1987, ONCOGENE, V1, P131; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1989, CANCER RES, V49, P4682; CHANG EH, 1991, BIOCHEMISTRY-US, V30, P8283, DOI 10.1021/bi00098a001; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; DEAN NM, 1994, P NATL ACAD SCI USA, V91, P11762, DOI 10.1073/pnas.91.24.11762; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FOX PL, 1994, ONCOGENE, V9, P3519; FURTH ME, 1987, ONCOGENE, V1, P47; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GRAY GD, 1993, CANCER RES, V53, P577; HELENE C, 1994, EUR J CANCER, V30A, P1721, DOI 10.1016/0959-8049(93)E0352-Q; HOKE GD, 1991, NUCLEIC ACIDS RES, V19, P5743, DOI 10.1093/nar/19.20.5743; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; LOWRY DR, 1991, TRENDS GENET, V7, P346; LOWY DR, 1986, CANCER SURV, V5, P275; MARSHALL CJ, 1991, TRENDS GENET, V7, P791; MIZUKAMI Y, 1988, CANCER, V61, P873, DOI 10.1002/1097-0142(19880301)61:5<873::AID-CNCR2820610504>3.0.CO;2-W; MONIA BP, 1992, J BIOL CHEM, V267, P19954; MONIA BP, 1993, J BIOL CHEM, V268, P14514; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MUKHOPADHYAY T, 1991, CANCER RES, V51, P1744; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SAISONBEHMOARAS T, 1991, EMBO J, V10, P1111, DOI 10.1002/j.1460-2075.1991.tb08051.x; Sambrook J., 1989, MOL CLONING; SHIMIZU M, 1990, HUM PATHOL, V21, P607, DOI 10.1016/S0046-8177(96)90006-4; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SHWAB G, 1994, P NATL ACAD SCI USA, V91, P10460; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STACEY DW, 1991, ONCOGENE, V6, P2297; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STACEY DW, 1987, EXP CELL RES, V171, P232, DOI 10.1016/0014-4827(87)90266-7; STACEY DW, 1988, COLD SPRING HARB SYM, V3, P871; WILLUMSEN BM, 1992, RAS TRANSFORMING PRO	42	62	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28259	28265		10.1074/jbc.271.45.28259	http://dx.doi.org/10.1074/jbc.271.45.28259			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910444	hybrid			2022-12-25	WOS:A1996VU03300044
J	Keenleyside, WJ; Whitfield, C				Keenleyside, WJ; Whitfield, C			A novel pathway for O-polysaccharide biosynthesis in Salmonella enterica serovar Borreze	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; RFB GENE-CLUSTER; ENTEROBACTERIAL COMMON ANTIGEN; NEISSERIA-GONORRHOEAE LIPOOLIGOSACCHARIDE; KLEBSIELLA-PNEUMONIAE SEROTYPE-O1; CASSETTE TRANSPORT-SYSTEM; GRAM-NEGATIVE BACTERIA; D-GALACTAN-I; RHIZOBIUM-MELILOTI; NUCLEOTIDE-SEQUENCE	The plasmid-encoded gene cluster for O:54 O-polysaccharide synthesis in Salmonella enterica serovar Borreze (rfb(O:54)) contains three genes that direct synthesis of a ManNAc homopolymer with alternating beta 1,3 and beta 1,4 linkages. In Escherichia coli K-12, RfbA(O:54) adds the first ManNAc residue to the Rfe (UDP-GlcpNac::undecaprenylphosphate GlcpNAc-1-phosphate transferase)modified lipopolysaccharide core. Hydrophobic cluster analysis of RfbA(O:54) indicates this protein belongs to the ExoU family of nonprocessive beta-glycosyltransferases. Two putative catalytic residues and a potential substrate-binding motif were identified in RfbA(O:54). Topological analysis of RfbB(O:54) predicts four transmembrane domains and a large central cytoplasmic domain. The latter shares homology with a similar domain in the processive beta-glycosyltransferases Cps3S of Streptococcus pneumoniae and HasA of Streptococcus pyogenes. Hydrophobic cluster analysis of RfbB(O:54) and Cps3S indicates both possess the structural features characteristic of the HasA family of processive beta-glycosyltransferases. Four potential catalytic residues and a putative substrate-binding motif were identified in RfbB(O:54). In Delta rfb E. coli K-12, RfbA(O:54) and RfbB(O:54) direct synthesis of smooth O:54 lipopolysaccharide, indicating that this O-polysaccharide involves a novel pathway for O-antigen transport. Based on sequence and structural conservation, 15 new ExoU-related and 17 new HasA-related transferases were identified.	UNIV GUELPH, DEPT MICROBIOL, GUELPH, ON N1G 2W1, CANADA	University of Guelph								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Arrecubieta C, 1995, GENE, V167, P1, DOI 10.1016/0378-1119(95)00657-5; BECKER A, 1993, MOL GEN GENET, V241, P367, DOI 10.1007/BF00284690; BRONNER D, 1994, MOL MICROBIOL, V14, P505, DOI 10.1111/j.1365-2958.1994.tb02185.x; BUGERT P, 1995, MOL MICROBIOL, V15, P917, DOI 10.1111/j.1365-2958.1995.tb02361.x; BULAWA CE, 1986, CELL, V46, P213, DOI 10.1016/0092-8674(86)90738-5; BULAWA CE, 1992, MOL CELL BIOL, V12, P1764, DOI 10.1128/MCB.12.4.1764; CABIB E, 1983, P NATL ACAD SCI-BIOL, V80, P3318, DOI 10.1073/pnas.80.11.3318; CHENWU JL, 1992, MOL MICROBIOL, V6, P497, DOI 10.1111/j.1365-2958.1992.tb01494.x; CLARKE AJ, 1991, ANAL BIOCHEM, V199, P68, DOI 10.1016/0003-2697(91)90270-4; CLARKE AJ, 1996, BIODEGRADATION CELLU, P113; CLARKE BR, 1995, J BACTERIOL, V177, P5411, DOI 10.1128/jb.177.19.5411-5418.1995; CLARKE BR, 1992, J BACTERIOL, V174, P4614, DOI 10.1128/JB.174.14.4614-4621.1992; COLLINSEMERSON JM, 1990, NUCLEIC ACIDS RES, V18, P6690, DOI 10.1093/nar/18.22.6690; DANAHER RJ, 1995, J BACTERIOL, V177, P7275, DOI 10.1128/jb.177.24.7275-7279.1995; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DENARIE J, 1993, CELL, V74, P951, DOI 10.1016/0092-8674(93)90717-5; DILLARD JP, 1995, J EXP MED, V181, P973, DOI 10.1084/jem.181.3.973; DOUGHERTY BA, 1994, J BIOL CHEM, V269, P169; EGELHOFF TT, 1985, DNA-J MOLEC CELL BIO, V4, P241, DOI 10.1089/dna.1985.4.241; EWING WH, 1984, METHOD MICROBIOL, V14, P113, DOI 10.1016/S0580-9517(08)70448-3; FALT IC, 1993, EUR J BIOCHEM, V213, P573, DOI 10.1111/j.1432-1033.1993.tb17796.x; FernandezLopez M, 1996, MOL MICROBIOL, V20, P993, DOI 10.1111/j.1365-2958.1996.tb02540.x; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; GEREMIA RA, 1994, P NATL ACAD SCI USA, V91, P2669, DOI 10.1073/pnas.91.7.2669; GLUCKSMANN MA, 1993, J BACTERIOL, V175, P7033, DOI 10.1128/jb.175.21.7033-7044.1993; GOETHALS K, 1989, MOL GEN GENET, V219, P289, DOI 10.1007/BF00261190; GOHMANN S, 1994, MICROB PATHOGENESIS, V16, P53, DOI 10.1006/mpat.1994.1005; GOTSCHLICH EC, 1994, J EXP MED, V180, P2181, DOI 10.1084/jem.180.6.2181; Heilmann C, 1996, MOL MICROBIOL, V20, P1083, DOI 10.1111/j.1365-2958.1996.tb02548.x; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; HOLLAND D, 1990, J BACTERIOL, V172, P3131, DOI 10.1128/jb.172.6.3131-3137.1990; HOLST O, 1991, CARBOHYD RES, V215, P323, DOI 10.1016/0008-6215(91)84031-9; JANN K, 1982, EUR J BIOCHEM, V127, P157, DOI 10.1111/j.1432-1033.1982.tb06850.x; JANSSON PE, 1981, EUR J BIOCHEM, V115, P571; KEENLEYSIDE WJ, 1994, MOL MICROBIOL, V11, P437, DOI 10.1111/j.1365-2958.1994.tb00325.x; KEENLEYSIDE WJ, 1995, J BACTERIOL, V177, P5247, DOI 10.1128/jb.177.18.5247-5253.1995; KENT JL, 1968, BIOCHEMISTRY-US, V7, P4396, DOI 10.1021/bi00852a036; KIDO N, 1995, J BACTERIOL, V177, P2178, DOI 10.1128/jb.177.8.2178-2187.1995; KLENA JD, 1992, J BACTERIOL, V174, P7297, DOI 10.1128/jb.174.22.7297-7307.1992; KLENA JD, 1993, MOL MICROBIOL, V9, P393, DOI 10.1111/j.1365-2958.1993.tb01700.x; KNIREL YA, 1994, BIOCHEMISTRY-MOSCOW+, V59, P1325; KUHN HM, 1988, FEMS MICROBIOL LETT, V54, P195, DOI 10.1111/j.1574-6968.1988.tb02743.x; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LIDHOLT K, 1994, CARBOHYD RES, V255, P87, DOI 10.1016/S0008-6215(00)90972-8; Liu D, 1996, J BACTERIOL, V178, P2102, DOI 10.1128/jb.178.7.2102-2107.1996; MAHARAJ R, 1993, GENE, V136, P267, DOI 10.1016/0378-1119(93)90477-K; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MAROLDA CL, 1993, J BACTERIOL, V175, P148, DOI 10.1128/JB.175.1.148-158.1993; MATTHYSSE AG, 1995, J BACTERIOL, V177, P1069, DOI 10.1128/jb.177.4.1069-1075.1995; MEIERDIETER U, 1990, J BIOL CHEM, V265, P13490; MEIERDIETER U, 1992, J BIOL CHEM, V267, P746; NAGAHASHI S, 1995, J BIOL CHEM, V270, P13961, DOI 10.1074/jbc.270.23.13961; NEUHARD J, 1976, J BACTERIOL, V126, P999, DOI 10.1128/JB.126.2.999-1001.1976; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; REEVES PR, 1992, FEMS MICROBIOL LETT, V100, P509, DOI 10.1016/0378-1097(92)90254-L; REEVES PR, 1994, BACTERIAL CELL WALL, V27, P281; REIZER J, 1992, PROTEIN SCI, V1, P1326, DOI 10.1002/pro.5560011012; REUBER TL, 1993, CELL, V74, P269, DOI 10.1016/0092-8674(93)90418-P; RICK PD, 1994, J BACTERIOL, V176, P2877, DOI 10.1128/JB.176.10.2877-2884.1994; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; ROSSEN L, 1984, NUCLEIC ACIDS RES, V12, P9497, DOI 10.1093/nar/12.24.9497; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAXENA IM, 1990, PLANT MOL BIOL, V15, P673, DOI 10.1007/BF00016118; SAXENA IM, 1994, J BACTERIOL, V176, P5735, DOI 10.1128/JB.176.18.5735-5752.1994; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; SHUTTLEWORTH H, 1986, NUCLEIC ACIDS RES, V14, P8689, DOI 10.1093/nar/14.21.8689; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SKURNIK M, 1995, MOL MICROBIOL, V17, P575, DOI 10.1111/j.1365-2958.1995.mmi_17030575.x; SMITS PHM, 1994, YEAST, V10, pS75, DOI 10.1002/yea.320100010; Stingele F, 1996, J BACTERIOL, V178, P1680, DOI 10.1128/jb.178.6.1680-1690.1996; SUDOH M, 1993, MOL GEN GENET, V241, P351, DOI 10.1007/BF00284688; SZABO M, 1995, J BACTERIOL, V177, P1544, DOI 10.1128/jb.177.6.1544-1553.1995; TOROK I, 1984, NUCLEIC ACIDS RES, V12, P9509, DOI 10.1093/nar/12.24.9509; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; VALDIVIESO MH, 1991, J CELL BIOL, V114, P101, DOI 10.1083/jcb.114.1.101; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; VAZQUEZ M, 1991, J BACTERIOL, V173, P1250, DOI 10.1128/jb.173.3.1250-1258.1991; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WEISGERBER C, 1982, EUR J BIOCHEM, V127, P165, DOI 10.1111/j.1432-1033.1982.tb06851.x; WHITFIELD C, 1993, ADV MICROB PHYSIOL, V35, P135, DOI 10.1016/S0065-2911(08)60099-5; WHITFIELD C, 1995, TRENDS MICROBIOL, V3, P178, DOI 10.1016/S0966-842X(00)88917-9	87	108	117	5	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28581	28592		10.1074/jbc.271.45.28581	http://dx.doi.org/10.1074/jbc.271.45.28581			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910488	hybrid			2022-12-25	WOS:A1996VU03300088
J	Klafki, HW; Abramowski, D; Swoboda, R; Paganetti, PA; Staufenbiel, M				Klafki, HW; Abramowski, D; Swoboda, R; Paganetti, PA; Staufenbiel, M			The carboxyl termini of beta-amyloid peptides 1-40 and 1-42 are generated by distinct gamma-secretase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; MAMMALIAN-CELLS; MUTATION; PATHWAY; RELEASE; APP	We have studied the effects of peptide aldehyde protease inhibitors on the secretion of beta-amyloid peptide 1-40 (A beta(1-40)) and A beta(1-42) by HEK 293 and COS-1 cells expressing beta-amyloid precursor protein with the Swedish double mutation. A multiphasic SDS-polyacrylamide gel electrophoresis system was used for the discrimination of A beta(1-40) and A beta(1-42). Calpain inhibitor I, carbobenzoxyl-Leu-Leu-leucinal, and calpeptin were found to reduce the amount of A beta(1-40) released into the medium in a dose-dependent manner. The reduction of A beta(1-40) after treatment with 50 mu M calpain inhibitor I or 5 mu M carbobenzoxyl-Leu-Leu-leucinal was accompanied by a slight increase of A beta(1-42) released into the medium. These observations suggest that the cleavages at residues 40 and 42 are accomplished by different enzyme activities.	SANDOZ PHARMA LTD,DEPT PRECLIN RES,CH-4002 BASEL,SWITZERLAND; SANDOZ RES INST BERN LTD,CH-3001 BERN,SWITZERLAND	Novartis; Sandoz; Novartis; Sandoz			Paganetti, Paolo/AAF-8039-2020	Paganetti, Paolo/0000-0003-1896-6324				Andra K, 1996, NEUROBIOL AGING, V17, P183, DOI 10.1016/0197-4580(95)02066-7; ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DOVEY HF, 1993, NEUROREPORT, V4, P1039, DOI 10.1097/00001756-199308000-00011; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; EVIN G, 1994, AMYLOID, V1, P263, DOI 10.3109/13506129409146118; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JOHNSTON JA, 1994, FEBS LETT, V354, P274, DOI 10.1016/0014-5793(94)01137-0; Klafki HW, 1996, ANAL BIOCHEM, V237, P24, DOI 10.1006/abio.1996.0195; Klafki HW, 1995, NEUROSCI LETT, V201, P29, DOI 10.1016/0304-3940(95)12122-K; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SchraderFischer G, 1996, BRAIN RES, V716, P91, DOI 10.1016/0006-8993(96)00002-9; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TAMAOKA A, 1994, J BIOL CHEM, V269, P32721; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	32	155	162	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28655	28659		10.1074/jbc.271.45.28655	http://dx.doi.org/10.1074/jbc.271.45.28655			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910499	hybrid			2022-12-25	WOS:A1996VU03300099
J	Plater, ML; Goode, D; Crabbe, MJC				Plater, ML; Goode, D; Crabbe, MJC			Effects of site-directed mutations on the chaperone-like activity of alpha B-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; HETEROLOGOUS EXPRESSION; MOLECULAR CHAPERONE; ESCHERICHIA-COLI; GAMMA; EVOLUTION; STABILITY; GENE; DNA	Recombinant alpha B-crystallin has been shown to exhibit chaperone-like activity, suppressing the thermal aggregation of gamma-crystallin and aggregation of the reduced insulin B chain conferring thermotolerance to Escherichia coli BL21(DE3) cells. Mutations were made in three specific areas of the alpha B-crystallin, the N terminus D2G, the conserved phenylalanine-rich region, F24R, F27R, F27A, and the two C-terminal lysines K174L/K175L, K174G/K175G. Biophysical characterization of the mutant alpha B-crystallins using far-UV CD revealed no change in secondary structural elements. Tryptophan fluorescence demonstrated global structural changes. Heat stability of the mutant alpha B-crystallins was not significantly affected as indicated by tryptophan fluorescence of heat-treated proteins. Mutations within the phenylalanine-rich region abolish the chaperone-like activity as measured by bath in vivo and in vitro assays. Proteins with mutations at the C terminus demonstrated no significant chaperone-like activity, failing to confer thermotolerance on E. coli and demonstrating no significant inhibition of protein aggregation in either gamma-crystallin or reduced insulin B chain assays. The N-terminal mutation D2G demonstrated a significant reduction in efficiency of the chaperone-like activity although some thermotolerance was conferred in the E. coli assay. In vitro assays showed that complete inhibition of aggregation was only achieved at 10-fold higher concentrations of D2G than that required by the native alpha B-crystallin. Consistent changes in the chaperone-like activity of the site-directed mutants were demonstrated by the three assays. The results suggested that both charge-charge and hydrophobic interactions are important in protein binding by alpha B-crystallin and that the conserved RLFDQFF region is vital for chaperone-like activity.	UNIV READING, SCH ANIM & MICROBIAL SCI, WOLFSON LAB, READING RG6 6AJ, BERKS, ENGLAND	University of Reading					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARBOSA P, 1991, J BIOL CHEM, V266, P5286; BETTELHEIM FA, 1992, BIOCHEM BIOPH RES CO, V187, P39, DOI 10.1016/S0006-291X(05)81455-X; BOYLE D, 1994, EXP EYE RES, V58, P9, DOI 10.1006/exer.1994.1190; CARVER JA, 1995, BBA-PROTEIN STRUCT M, V1252, P251, DOI 10.1016/0167-4838(95)00146-L; CHITPINITYOL S, 1996, PERSPECTIVES PROTEIN, P29; CRABBE MJC, 1994, BIOCHEM J, V297, P653, DOI 10.1042/bj2970653; CRABBE MJC, 1994, DESKTOP MOL MODELLER; CRABBE MJC, 1995, PP INT FOR ADV TECHN, P28; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; DILSIZ N, 1994, ANAL BIOCHEM, V222, P510, DOI 10.1006/abio.1994.1527; DILSIZ N, 1995, BIOCHEM J, V305, P753, DOI 10.1042/bj3050753; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GOODE D, 1995, COMPUT CHEM, V19, P65, DOI 10.1016/0097-8485(95)00027-P; GOODE D, 1994, ARCH BIOCHEM BIOPHYS, V315, P104, DOI 10.1006/abbi.1994.1477; Harding J., 1991, CATARACT BIOCH EPIDE; Harding JJ, 1991, POST TRANSLATIONAL M; Harding JJ, 1984, EYE B, V1b, P207; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; IWAKI T, 1994, J CELL BIOL, V125, P1385, DOI 10.1083/jcb.125.6.1385; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LUBSEN NH, 1988, PROG BIOPHYS MOL BIO, V51, P47, DOI 10.1016/0079-6107(88)90010-7; PALMISANO DV, 1995, BBA-PROTEIN STRUCT M, V1246, P91, DOI 10.1016/0167-4838(94)00176-H; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; Rao PV, 1995, BBA-GEN SUBJECTS, V1245, P439, DOI 10.1016/0304-4165(95)00125-5; RENKAWEK K, 1992, ACTA NEUROPATHOL, V83, P323; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Smith JB, 1996, EXP EYE RES, V63, P125, DOI 10.1006/exer.1996.0100; SMULDERS RHPH, 1995, EUR J BIOCHEM, V232, P834, DOI 10.1111/j.1432-1033.1995.834zz.x; TAKEMOTO L, 1993, BIOCHEM J, V294, P435, DOI 10.1042/bj2940435; VANNOORT JM, 1995, NATURE, V375, P798, DOI 10.1038/375798a0; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; WOLFF SP, 1985, BIOCHEM J, V226, P625, DOI 10.1042/bj2260625; Zahn R, 1996, SCIENCE, V271, P642, DOI 10.1126/science.271.5249.642	42	127	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28558	28566		10.1074/jbc.271.45.28558	http://dx.doi.org/10.1074/jbc.271.45.28558			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910485	hybrid			2022-12-25	WOS:A1996VU03300085
J	Rudolph, AE; Mullane, MP; PorcheSorbet, R; Tsuda, S; Miletich, JP				Rudolph, AE; Mullane, MP; PorcheSorbet, R; Tsuda, S; Miletich, JP			Factor X(St Louis II) - Identification of a glycine substitution at residue 7 and characterization of the recombinant protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RUSSELLS VIPER VENOM; HUMAN FACTOR-X; COAGULATION FACTOR; BLOOD-COAGULATION; ACTIVATING ENZYME; FACTOR-IX; DEFICIENCY	A molecular defect in factor X (fX) results from a point mutation that causes glycine substitution for gamma-carboxylated glutamic acid at position 7. The variant (fX(St. Louis II)) and wild type (fX(WT)) proteins were produced in a mammalian expression system and characterized. fX(St. Louis II) has <1% and similar to 3% of normal clotting activity in modified prothrombin time and partial thromboplastin time assays, respectively. The rate of activation of fX(St. Louis II) by factor VIIa and tissue factor is undetectable under conditions that result in complete activation of fX(WT); activation by factors VIIIa and IXa is similar to 30% of normal activation. The X-activating protein from Russell's viper venom activates fX(St. Louis II) completely but at a reduced rate. Thrombin generation on phoshopolipid vesicles or activated platelets is similar to 30% or similar to 5%, respectively. Membrane-dependent autolysis is markedly reduced for fX(St. Louis II). In reactions that are not surface-dependent, fX(St. Louis II) is nearly identical to that of fX(WT). The rate of inhibition by antithrombin is indistiguishable, as is the rate of thrombin formation in the absence of phospholipid, with or without factor Va.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV LAB MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV LAB MED,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NHLBI NIH HHS [HL14147] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BROZE GJ, 1984, J CLIN INVEST, V73, P933, DOI 10.1172/JCI111317; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; FASS DN, 1982, BLOOD, V59, P594; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JESTY J, 1975, J BIOL CHEM, V250, P4497; JESTY J, 1974, J BIOL CHEM, V249, P5614; KIM DJ, 1995, HUM GENET, V95, P212; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MILETICH JP, 1980, ANAL BIOCHEM, V105, P304, DOI 10.1016/0003-2697(80)90462-5; NEMERSON Y, 1982, PROG HEMOST THROMB, V6, P237; NEMERSON Y, 1986, BLOOD, V71, P1; PFEIFFER RA, 1982, HUM GENET, V62, P358, DOI 10.1007/BF00304557; REDDY SV, 1989, BLOOD, V74, P1486; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; TAKEYA H, 1992, J BIOL CHEM, V267, P14109; TENG CM, 1981, THROMB RES, V22, P213, DOI 10.1016/0049-3848(81)90323-6; WATZKE HH, 1990, J BIOL CHEM, V265, P11982	23	29	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28601	28606		10.1074/jbc.271.45.28601	http://dx.doi.org/10.1074/jbc.271.45.28601			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910490	hybrid			2022-12-25	WOS:A1996VU03300090
J	Thomas, JE; Smith, M; Rubinfeld, B; Gutowski, M; Beckmann, RP; Polakis, P				Thomas, JE; Smith, M; Rubinfeld, B; Gutowski, M; Beckmann, RP; Polakis, P			Subcellular localization and analysis of apparent 180-kDa and 220-kDa proteins of the breast cancer susceptibility gene, BRCA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN-CANCER; FAMILIAL BREAST; TYROSINE KINASE; EXPRESSION; DIFFERENTIATION; TISSUES; REGION; CELLS	The breast cancer susceptibility gene BRCA1 encodes an 1863-amino acid protein that acts as a tumor suppressor. The biochemical function of BRCA1 is unknown, and there are conflicting results describing its subcellular location. We have identified a 220-kDa protein, which is reactive with three antibodies raised against the amino- and carboxy-terminal regions of BRCA1. Immunoflourescence staining with an antibody to the carboxyl terminus of BRCA1 localized the protein to the nucleus of breast, ovarian, and cervical carcinoma-derived cell lines. A similar result was observed by biochemical subcellular fractionation that indicated that the 220-kDa protein was localized primarily to the nucleus of cell lines established from breast carcinomas. In addition to the 220-kDa protein, one antibody, C-20, also recognized a 180-kDa protein in MDA-MB-468 total cell lysates that was not detected by the other two antibodies. Several observations suggest the 180-kDa protein is the epidermal growth factor (EGF) receptor: (i) C-20 reacted avidly with a 180-kDa protein immunoprecipitated by an antibody to the EGF receptor; (ii) an EGF receptor antibody detected a 180-kDa protein immunoprecipitated by C-20; (iii) the affinity purified EGF receptor was both immunoprecipitated and detected on immunoblots by the C-20 antibody but not another BRCA1 antibody; (iv) similar phosphopeptide maps were generated from the EGF receptor and the 180-kDa protein immunoprecipitated by C-20, and this peptide map was distinct from the 220-kDa phosphoprotein; and (v) the C-20 immunizing peptide bears sequence identity to the EGF receptor. These results indicate that BRCA1 is a 220-kDa nuclear protein and that the 180-kDa protein reported previously may be unrelated to BRCA1.	ONYX PHARMACEUT INC,RICHMOND,CA 94806		Thomas, JE (corresponding author), ELI LILLY & CO,LILLY CORP CTR,CANC RES,LILLY RES LABS,DC0434,INDIANAPOLIS,IN 46285, USA.			Rubinfeld, Bonnee/0000-0001-9861-6775				BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; EASTON DF, 1993, AM J HUM GENET, V52, P678; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Genetic Computer Group, 1994, PROGR MAN WISC PACK; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; GUDAS JM, 1995, CANCER RES, V55, P4561; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; Jensen RA, 1996, NAT GENET, V13, P269, DOI 10.1038/ng0796-269; KELSELL DP, 1993, HUM MOL GENET, V2, P1823; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Merajver SD, 1995, CLIN CANCER RES, V1, P539; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wilson CA, 1996, NAT GENET, V13, P264, DOI 10.1038/ng0796-264	26	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28630	28635		10.1074/jbc.271.45.28630	http://dx.doi.org/10.1074/jbc.271.45.28630			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910495	hybrid			2022-12-25	WOS:A1996VU03300095
J	Lee, K; Du, C; Horn, M; Rabinow, L				Lee, K; Du, C; Horn, M; Rabinow, L			Activity and autophosphorylation of LAMMER protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; DROSOPHILA-MELANOGASTER; CONSERVED FEATURES; FAMILY; IDENTIFICATION; LOCUS; PHOSPHORYLATION; REGULATORS; THREONINE; MEMBERS	Clk/STY, the murine homologue of the recently described LAMMER family of protein kinases, autophosphorylates on serine/threonine and tyrosine residues in vitro and in, vivo, LAMMER kinases are found throughout eukaryotes and possess virtually complete amino acid identity in many domains critical for kinase function, leading to the question of whether other family members also possess dual specificity. We report here that the Drosophila family member DOA, human SK-G1, and the Saccharomyces cerevisiae KNS1, all possess protein kinase activity and autophosphorylate with dual specificity in vitro, suggesting that the entire family possesses this activity. Although the LAMMER kinases are closely related to the mitogen-activated protein kinase family, they possess different substrate specificity in vitro, based on phosphorylation of peptide and protein substrates and sequencing of a phosphorylation site in a common substrate.	UNIV NEBRASKA, MED CTR, DEPT BIOCHEM & MOL BIOL, OMAHA, NE 68198 USA; RUTGERS STATE UNIV, WAKSMAN INST, PISCATAWAY, NJ 08855 USA	University of Nebraska System; University of Nebraska Medical Center; Rutgers State University New Brunswick			Du, Cheng/F-1569-2013	Du, Cheng/0000-0002-8882-2513				Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BENDER J, 1994, P NATL ACAD SCI USA, V91, P12105, DOI 10.1073/pnas.91.25.12105; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DOUVILLE E, 1994, CANCER METAST REV, V13, P1, DOI 10.1007/BF00690414; DUNCAN PI, 1995, J BIOL CHEM, V270, P21524, DOI 10.1074/jbc.270.37.21524; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; HANES J, 1994, J MOL BIOL, V244, P665, DOI 10.1006/jmbi.1994.1763; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MCCLELLAND M, 1994, NUCLEIC ACIDS RES, V22, P4419, DOI 10.1093/nar/22.21.4419; PADMANABHA R, 1991, MOL GEN GENET, V229, P1; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RABINOW L, 1989, EMBO J, V8, P879, DOI 10.1002/j.1460-2075.1989.tb03449.x; RABINOW L, 1993, GENETICS, V134, P1175; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SANGHERA JS, 1990, FEBS LETT, V273, P223, DOI 10.1016/0014-5793(90)81090-B; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; WETTENHALL REH, 1991, METHOD ENZYMOL, V201, P186; YUN B, 1994, GENE DEV, V8, P1160, DOI 10.1101/gad.8.10.1160; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	29	49	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27299	27303		10.1074/jbc.271.44.27299	http://dx.doi.org/10.1074/jbc.271.44.27299			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910305	hybrid			2022-12-25	WOS:A1996VQ67900023
J	Bergwitz, C; Gardella, TJ; Flannery, MR; Potts, JT; Kronenberg, HM; Goldring, SR; Juppner, H				Bergwitz, C; Gardella, TJ; Flannery, MR; Potts, JT; Kronenberg, HM; Goldring, SR; Juppner, H			Full activation of chimeric receptors by hybrids between parathyroid hormone and calcitonin - Evidence for a common pattern of ligand-receptor interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE RECEPTOR; EXPRESSION CLONING; MOLECULAR-CLONING; HUMORAL HYPERCALCEMIA; SECRETIN RECEPTOR; SALMON-CALCITONIN; BINDING; GLUCAGON; GENE; MUTAGENESIS	Calcitonin (CT) and parathyroid hormone (PTH), whose receptors belong to the same family of G protein-coupled receptors, share no amino acid sequence homology and selectively activate either CT or PTH receptors. We now show, however, that reciprocal hybrid ligands (CT/PTH and PTH/CT), which do not activate the ''wild-type'' receptors, activate PTH/CT and CT/PTH receptor chimeras, respectively, Our findings indicate that PTH and CT share a similar architecture with at least two functional, receptor-specific domains, These domains are sufficiently independent to permit synthetic hybrid ligands to efficiently activate appropriate receptor chimeras. Therefore, both ligands follow, despite their very different primary sequences, a common pattern of ligand-receptor interaction.	MASSACHUSETTS GEN HOSP, ENDOCRINE UNIT, DEPT MED, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, ARTHRITIS UNIT, DEPT MED, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, CHILDRENS SERV, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Fitzsimons, Chris/B-4171-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK11794-28] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ALBRANDT K, 1995, ENDOCRINOLOGY, V136, P5377, DOI 10.1210/en.136.12.5377; BARDEN JA, 1989, EUR J BIOCHEM, V184, P379, DOI 10.1111/j.1432-1033.1989.tb15030.x; BARNAY G, 1979, PEPTIDES, V2, P1; BUGGY JJ, 1995, J BIOL CHEM, V270, P7474, DOI 10.1074/jbc.270.13.7474; CHOREVV M, 1994, PARATHYROIDS, V1, P139; EPAND RM, 1985, BIOPHYS CHEM, V23, P39, DOI 10.1016/0301-4622(85)80062-4; FEYEN JHM, 1992, BIOCHEM BIOPH RES CO, V187, P8, DOI 10.1016/S0006-291X(05)81450-0; GARDELLA TJ, 1994, ENDOCRINOLOGY, V135, P1186, DOI 10.1210/en.135.3.1186; Gardella TJ, 1996, J BIOL CHEM, V271, P12820, DOI 10.1074/jbc.271.22.12820; GARDELLA TJ, 1993, ENDOCRINOLOGY, V132, P2024, DOI 10.1210/en.132.5.2024; HJORTH SA, 1994, J BIOL CHEM, V269, P30121; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; HOUSSAMI S, 1995, MOL PHARMACOL, V47, P798; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; JUPPNER H, 1988, J BIOL CHEM, V263, P8557; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KONG XF, 1994, BIOCHEM BIOPH RES CO, V200, P1290, DOI 10.1006/bbrc.1994.1591; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; MAGET B, 1994, FEBS LETT, V351, P271, DOI 10.1016/0014-5793(94)00875-2; MCCUAIG KA, 1994, P NATL ACAD SCI USA, V91, P5051, DOI 10.1073/pnas.91.11.5051; MEYER JP, 1991, BIOPOLYMERS, V31, P233, DOI 10.1002/bip.360310210; MORELLI MAC, 1992, J BIOMOL NMR, V2, P335, DOI 10.1007/BF01874812; NUSSBAUM SR, 1980, J BIOL CHEM, V255, P183; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; REAGAN JD, 1994, J BIOL CHEM, V269, P9; Rosenblatt M, 1981, Pathobiol Annu, V11, P53; SCHIPANI E, 1995, J CLIN ENDOCR METAB, V80, P1611, DOI 10.1210/jc.80.5.1611; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; Turner PR, 1996, J BIOL CHEM, V271, P9205, DOI 10.1074/jbc.271.16.9205; WRAY V, 1994, BIOCHEMISTRY-US, V33, P1684, DOI 10.1021/bi00173a010; WRAY V, 1993, BIOCHEMISTRY-US, V32, P5832, DOI 10.1021/bi00073a016; ZAIDI M, 1990, CRIT REV CL LAB SCI, V28, P109, DOI 10.3109/10408369009105900; ZOLNIEROWICZ S, 1994, J BIOL CHEM, V269, P19530	43	132	143	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26469	26472		10.1074/jbc.271.43.26469	http://dx.doi.org/10.1074/jbc.271.43.26469			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900113				2022-12-25	WOS:A1996VP23300007
J	Luo, YD; Gabriel, JL; Wang, F; Zhan, X; Maciag, T; Kan, M; Mckeehan, WL				Luo, YD; Gabriel, JL; Wang, F; Zhan, X; Maciag, T; Kan, M; Mckeehan, WL			Molecular modeling and deletion mutagenesis implicate the nuclear translocation sequence in structural integrity of fibroblast growth factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING DOMAIN; FACTOR RECEPTOR; 3-DIMENSIONAL STRUCTURE; MITOGENIC ACTIVITY; FACTOR-I; IDENTIFICATION; FGF-1; MECHANISM; AFFINITY; COMPLEX	The sequence NYKKPKL in the NH2 terminus of fibroblast growth factor (FGF)-1 has been proposed to affect the long term activities of FGF-1 through its function as a nuclear translocation signal or its role in stabilization of the structure required to sustain binding and activation of the transmembrane receptor kinase. A dynamic molecular model of FGF-1 docked into a duplex of the FGF receptor ectodomain and a hexadecameric heparin chain suggests that the NYKKPKL sequence does not directly interact with heparin or the receptor, but rather the lysine-leucine residues within the sequence indirectly stabilize a major receptor-binding domain, Concurrent with a marked increase in dependence on exogenous heparin for optimal activity, sequential deletion of residues in the NYKKPKL sequence in FGF-1 resulted in a progressive loss of thermal stability, resistance to protease, mitogenic activity, and affinity for the transmembrane receptor. The largest change resulted from deletion of the entire sequence through the lysine-leucine residues. In the presence of sufficiently high concentrations of heparin, the deletion mutants exhibited mitogenic activity equal to wild-type FGF-1. The results confirm that a primary role of the NYKKPKL sequence domain is to maintain the structural integrity of FGF-1 required for optimal binding to and activation of the heparan sulfate-transmembrane receptor complex.	TEXAS A&M UNIV, DEPT BIOCHEM & BIOPHYS, ALBERT B ALKEK INST BIOSCI & TECHNOL, CTR CANC BIOL & NUTR, HOUSTON, TX 77030 USA; TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA; AMER RED CROSS, JEROME H HOLLAND LAB BIOMED SCI, DEPT EXPT PATHOL, ROCKVILLE, MD 20855 USA; AMER RED CROSS, JEROME H HOLLAND LAB BIOMED SCI, DEPT MOL BIOL, ROCKVILLE, MD 20855 USA	Texas A&M University System; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; American Red Cross; American Red Cross					NATIONAL CANCER INSTITUTE [R01CA059971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038639, R01DK035310] Funding Source: NIH RePORTER; NCI NIH HHS [CA59971] Funding Source: Medline; NIDDK NIH HHS [DK38639, DK35310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CRABB JW, 1986, BIOCHEMISTRY-US, V25, P4988, DOI 10.1021/bi00366a003; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; ERIKSSON AE, 1993, PROTEIN SCI, V2, P1274, DOI 10.1002/pro.5560020810; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Feng SJ, 1996, BBA-MOL CELL RES, V1310, P67, DOI 10.1016/0167-4889(95)00146-8; FRIEDMAN S, 1994, BIOCHEM BIOPH RES CO, V198, P1203, DOI 10.1006/bbrc.1994.1170; GABRIEL JL, 1993, P NATL ACAD SCI USA, V90, P4186, DOI 10.1073/pnas.90.9.4186; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; IMAMURA T, 1995, BBA-MOL CELL RES, V1266, P124, DOI 10.1016/0167-4889(95)00009-H; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; KAN M, 1991, METHOD ENZYMOL, V198, P158; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MCKEEHAN WL, 1994, MOL REPROD DEV, V39, P69, DOI 10.1002/mrd.1080390112; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PRUDOVSKY I, 1994, J BIOL CHEM, V269, P31720; Prudovsky IA, 1996, J BIOL CHEM, V271, P14198, DOI 10.1074/jbc.271.24.14198; QUARTO N, 1991, J CELL PHYSIOL, V147, P311, DOI 10.1002/jcp.1041470217; ROSENGART TK, 1988, BIOCHEM BIOPH RES CO, V152, P432, DOI 10.1016/S0006-291X(88)80732-0; SHI E, 1991, J BIOL CHEM, V266, P5774; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; VOLKIN DB, 1993, ARCH BIOCHEM BIOPHYS, V300, P30, DOI 10.1006/abbi.1993.1005; WANG F, 1995, J BIOL CHEM, V270, P10231, DOI 10.1074/jbc.270.17.10231; WANG F, 1995, J BIOL CHEM, V270, P10222, DOI 10.1074/jbc.270.17.10222; XU J, 1992, J BIOL CHEM, V267, P11792; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; ZHAN X, 1993, J BIOL CHEM, V268, P9611; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHU HY, 1995, J BIOL CHEM, V270, P21869, DOI 10.1074/jbc.270.37.21869; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	33	27	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26876	26883		10.1074/jbc.271.43.26876	http://dx.doi.org/10.1074/jbc.271.43.26876			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900171	hybrid			2022-12-25	WOS:A1996VP23300065
J	Sienaert, I; DeSmedt, H; Parys, JB; Missiaen, L; Vanlingen, S; Sipma, H; Casteels, R				Sienaert, I; DeSmedt, H; Parys, JB; Missiaen, L; Vanlingen, S; Sipma, H; Casteels, R			Characterization of a cytosolic and a luminal Ca2+ binding site in the type I inositol 1,4,5-trisphosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CHANNEL RYANODINE RECEPTOR; DYE STAINS-ALL; ENDOPLASMIC-RETICULUM; CALCIUM-RELEASE; DROSOPHILA-MELANOGASTER; CA-2+-BINDING PROTEINS; INSP3 RECEPTOR; LIGAND-BINDING; RUTHENIUM RED	To study the Ca2+ regulation of the inositol 1,4,5-trisphosphate receptor (InsP(3)R) at the molecular level, we expressed various cytosolic and luminal regions of the mouse type I InsP(3)R as glutathione S-transferase fusion proteins. Ca-45(2+) and ruthenium red overlay studies and Stains-all spectra and staining revealed both a cytosolic and a luminal Ca2+ binding site, The luminal Ca2+ binding site was mapped to the nonconserved acidic subregion of the luminal loop between amino acids 2463 and 2528, A K-0.5 of 0.3 mu M and a Hill coefficient of 1.1 were determined by Ca-45(2+) overlay by quantification of Ca-45(2+) binding on blots, The cytosolic Ca2+ binding site was localized in a region just preceding the transmembrane domain M1. The Ca2+ binding was mapped to a 23-amino acid stretch between amino acids 2124 and 2146, This cytosolic region showed a single high affinity site for Ca2+, with a K-0.5, of 0.8 mu M and a Hill coefficient of 1.0, Neither of the identified Ca2+ binding regions contained an EF-hand motif, We conclude that the type I InsP(3)R has at least two quite distinct types of Ca2+ binding sites, which are localized in different structural regions of the protein.			Sienaert, I (corresponding author), KATHOLIEKE UNIV LEUVEN, FYSIOL LAB, CAMPUS GASTHUISBERG O-N, HERESTR 49, B-3000 LOUVAIN, BELGIUM.			Parys, Jan/0000-0002-3591-4967				BAKSH S, 1991, J BIOL CHEM, V266, P21458; BEAN RC, 1965, J PHYS CHEM-US, V69, P4368, DOI 10.1021/j100782a050; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BOOTMAN MD, 1995, BIOCHEM J, V306, P445, DOI 10.1042/bj3060445; CADAY CG, 1985, J BIOL CHEM, V260, P5985; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; CHARUK JHM, 1990, ANAL BIOCHEM, V188, P123, DOI 10.1016/0003-2697(90)90539-L; CHEN SRW, 1992, J BIOL CHEM, V267, P23318; CHEN SRW, 1994, J BIOL CHEM, V269, P22698; Combettes L, 1996, EMBO J, V15, P2086, DOI 10.1002/j.1460-2075.1996.tb00562.x; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; GAMBERUCCI A, 1995, CELL CALCIUM, V17, P431, DOI 10.1016/0143-4160(95)90089-6; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Joseph SK, 1996, CELL SIGNAL, V8, P1, DOI 10.1016/0898-6568(95)02012-8; KAY RE, 1964, J PHYS CHEM-US, V68, P1896, DOI 10.1021/j100789a040; KENDALL JM, 1994, ANAL BIOCHEM, V221, P173, DOI 10.1006/abio.1994.1394; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; LOIRAND G, 1994, J PHYSIOL-LONDON, V479, P41, DOI 10.1113/jphysiol.1994.sp020276; LOOMISHUSSELBEE JW, 1993, BIOCHEM J, V289, P861, DOI 10.1042/bj2890861; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MARSDEN BJ, 1990, BIOCHEM CELL BIOL, V68, P587, DOI 10.1139/o90-084; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MISSIAEN L, 1994, J BIOL CHEM, V269, P7238; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OLDERSHAW KA, 1993, BIOCHEM J, V292, P631, DOI 10.1042/bj2920631; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PARYS JB, 1993, J BIOL CHEM, V268, P25206; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUGIYAMA T, 1995, AM J PHYSIOL-CELL PH, V269, pC813, DOI 10.1152/ajpcell.1995.269.3.C813; TAKESHIMA H, 1994, FEBS LETT, V337, P81, DOI 10.1016/0014-5793(94)80634-9; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; YAMADA N, 1994, BIOCHEM J, V302, P781, DOI 10.1042/bj3020781; YAMAMOTOHINO M, 1992, RECEPTOR CHANNEL, V2, P2; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; YOSHIKAWA S, 1992, J BIOL CHEM, V267, P16613; ZHANG BX, 1993, J BIOL CHEM, V268, P10997	55	99	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27005	27012		10.1074/jbc.271.43.27005	http://dx.doi.org/10.1074/jbc.271.43.27005			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900188				2022-12-25	WOS:A1996VP23300082
J	Srinivasula, SM; FernandesAlnemri, T; Zangrilli, J; Robertson, N; Armstrong, RC; Wang, LJ; Trapani, JA; Tomaselli, KJ; Litwack, G; Alnemri, ES				Srinivasula, SM; FernandesAlnemri, T; Zangrilli, J; Robertson, N; Armstrong, RC; Wang, LJ; Trapani, JA; Tomaselli, KJ; Litwack, G; Alnemri, ES			The Ced-3/interleukin 1 beta converting enzyme-like homolog Mch6 and the lamin-cleaving enzyme Mch2 alpha are substrates for the apoptotic mediator CPP32	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH GENE CED-3; CELL-DEATH; INTERLEUKIN-1-BETA-CONVERTING ENZYME; IL-1-BETA-CONVERTING ENZYME; CYSTEINE PROTEASES; MOLECULAR-CLONING; IDENTIFICATION; EXPRESSION; PROTEINASE; INDUCTION	Recent evidence suggests that CPP32 is an essential component of an aspartate-specific cysteine protease (ASCP) cascade responsible for apoptosis execution in mammalian cells, Activation of CPP32 could lead to activation of other downstream ASCPs, resulting in late morphological changes such as lamin cleavage and DNA fragmentation, observed in cells undergoing apoptosis, Here we describe the identification and cloning of a novel human ASCP named Mch6 from Jurkat T lymphocytes. We demonstrate that the pro-enzymes of Mch6 and the lamin-cleaving enzyme Mch2 alpha are substrates for mature CPP32, Site-directed mutagenesis revealed that CPP32 processes pro-Mch6 preferentially at Asp(330) to generate two subunits of molecular masses 37 kDa (p37) and 10 kDa (p10), However, CPP32 processes pro-Mch2 alpha at three aspartate processing sites (Asp(23), Asp(179), and Asp(193)) to produce the large (p18) and small (p11) subunits of the mature Mch2 alpha enzyme. The CPP32-processed Mch2 alpha is capable of cleaving the VEIDN lamin cleavage site, indicating that CPP32 can, in fact, activate pro-Mch2 alpha. Granzyme B at a concentration that allows processing and activation of CPP32 failed to process pro-Mch2 alpha. However, incubation of pro-Mch2 alpha with granzyme B in the presence of a cellular extract containing pro-CPP32 resulted in activation of pro CPP32 and subsequent processing of pro-Mch2 alpha. Interestingly, granzyme B can also process pro-Mch6 but at a site N-terminal to that cleaved by CPP32, These data suggest that Mch2 alpha and Mch6 are downstream proteases activated in CPP32- and granzyme B-mediated apoptosis, This is the first demonstration of a protease cascade involving granzyme B, CPP32, Mch2 alpha, and Mch6 and evidence that the lamin-cleaving enzyme Mch2 is a target of mature CPP32.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MOL PHARMACOL & BIOCHEM,CTR APOPTOSIS RES,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,KIMMEL CANC INST,PHILADELPHIA,PA 19107; AUSTIN RES INST,CELLULAR CYTOTOXIC LAB,HEIDELBERG,VIC,AUSTRALIA; IDUN PHARMACEUT,SAN DIEGO,CA 92121	Jefferson University; Jefferson University; Austin Research Institute				Trapani, Joseph/0000-0003-0983-1532	NIAID NIH HHS [AI 35035] Funding Source: Medline; NIA NIH HHS [AG 13487] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013487] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; ALNEMRI ES, 1996, IN PRESS J CELL BIOC, V62; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; HARVEY NL, 1996, IN PRESS GENES CELLS, V1; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RAMAGE P, 1995, J BIOL CHEM, V270, P9378, DOI 10.1074/jbc.270.16.9378; SHI L, 1991, J EXP MED, V175, P553; SMYTH MJ, 1995, IMMUNOL TODAY, V16, P202, DOI 10.1016/0167-5699(95)80122-7; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; TAKAHASHI A, 1995, P NATL ACAD SCI USA, V93, P8395; TRAPANI JA, 1994, J BIOL CHEM, V269, P18359; TRAPANI JA, 1993, BIOCHEM BIOPH RES CO, V195, P910, DOI 10.1006/bbrc.1993.2131; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0	33	268	301	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27099	27106		10.1074/jbc.271.43.27099	http://dx.doi.org/10.1074/jbc.271.43.27099			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900201	hybrid			2022-12-25	WOS:A1996VP23300095
J	Winegarden, NA; Wong, KS; Sopta, M; Westwood, JT				Winegarden, NA; Wong, KS; Sopta, M; Westwood, JT			Sodium salicylate decreases intracellular ATP, induces both heat shock factor binding and chromosomal puffing, but does not induce hsp 70 gene transcription in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENATURED PROTEIN INDUCERS; XENOPUS-LAEVIS OOCYTES; DNA-BINDING; STRESS RESPONSE; ACTIVATION; YEAST; GLUE; OLIGOMERIZATION; PHOSPHORYLATION; INHIBITION	Sodium salicylate has long been known to be an inducer of the heat shock puffs and presumably heat shock gene transcription in the polytene chromosomes of drosophila salivary gland cells. Stress induced transcription of the heat shock genes is mediated by the transcription factor known as Heat Shock Factor (HSF). In yeast, sodium salicylate has been reported to induce the DNA binding of HSF but not heat shock gene transcription itself, and similar findings have been reported in human cells. This apparent discrepancy in the induction of certain aspects of the heat shock response between these organisms prompted us to carefully reexamine the induction of the heat shock response in Drosophila salivary gland cells of third instar larvae and Drosophila tissue culture (SL2) cells. Sodium salicylate (3-30 mM) decreases intracellular ATP levels in SL2 cells and induces HSF binding activity in SL2 and salivary gland cells in a dose dependent manner, Despite the induction of HSF binding and heat shock puffs in polytene chromosomes, we found no evidence for increased hsp 70 gene transcription suggesting that chromosomal puffing and gene transcription may be separable events. Salicylate did not induce the HSF hyperphosphorylation that is normally associated with HSF activation. Furthermore, salicylate (30 mM) prevented heat-induced hyperphosphorylation of HSF and hsp 70 gene transcription indicating that salicylate's inhibitory effect on hsp 70 transcription may be independent of its effect on HSF binding activity. We propose that the reduction in intracellular ATP caused by the addition of salicylate likely plays a role in the activation of HSF binding and the inhibition of both HSF hyperphosphorylation and hsp 70 gene transcription.	UNIV TORONTO, ERINDALE COLL, DEPT ZOOL, MISSISSAUGA, ON L5L 1C6, CANADA	University of Toronto; University Toronto Mississauga				Winegarden, Neil/0000-0001-5964-5899				ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; ASHBURNER M, 1970, CHROMOSOMA, V31, P356, DOI 10.1007/BF00321231; ASHBURNER M, 1979, CELL, V17, P241, DOI 10.1016/0092-8674(79)90150-8; BEHNEL J, 1975, EXP CELL RES, V91, P119, DOI 10.1016/0014-4827(75)90149-4; BERENDES HD, 1968, CHROMOSOMA, V24, P418; BONNER JJ, 1981, DEV BIOL, V86, P409, DOI 10.1016/0012-1606(81)90199-8; CROSBY MA, 1986, DEV BIOL, V118, P593, DOI 10.1016/0012-1606(86)90029-1; CROWLEY TE, 1984, CELL, V39, P149, DOI 10.1016/0092-8674(84)90200-9; DELANEY TP, 1994, SCIENCE, V266, P1247, DOI 10.1126/science.266.5188.1247; Fernandes M., 1994, BIOL HEAT SHOCK PROT, P375; FIRESTONE GL, 1990, METHOD ENZYMOL, V182, P688; FRYDMAN J, 1994, BIOL HEAT SHOCK PROT, P251; GIARDINA C, 1995, J BIOL CHEM, V270, P10369, DOI 10.1074/jbc.270.18.10369; HOJ A, 1994, EMBO J, V13, P2617; Jurivich D.A., 1994, BIOL HEAT SHOCK PROT, P417; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; JURIVICH DA, 1995, J BIOL CHEM, V270, P24489, DOI 10.1074/jbc.270.41.24489; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LEENDERS HJ, 1974, EXP CELL RES, V86, P25, DOI 10.1016/0014-4827(74)90642-9; LEENDERS HJ, 1972, CHROMOSOMA, V37, P433; LI N, 1992, PLANT MOL BIOL, V18, P477, DOI 10.1007/BF00040664; LIS JT, 1983, CELL, V35, P403, DOI 10.1016/0092-8674(83)90173-3; LIVAK KJ, 1978, P NATL ACAD SCI USA, V75, P5613, DOI 10.1073/pnas.75.11.5613; MAGER WH, 1995, MICROBIOL REV, V59, P506, DOI 10.1128/MMBR.59.3.506-531.1995; MEYEROWITZ EM, 1987, TRENDS GENET, V3, P288, DOI 10.1016/0168-9525(87)90270-8; MIFFLIN LC, 1994, J BIOL CHEM, V269, P15710; MIFFLIN LC, 1994, J BIOL CHEM, V269, P15718; Moore DD, 1995, GLOB MOB SURV; MYOHARA M, 1991, DEV BIOL, V122, P396; NGUYEN VT, 1994, EUR J BIOCHEM, V220, P239; NOVER L., 1991, HEAT SHOCK RESPONSE; OLSON JE, 1992, METAB BRAIN DIS, V7, P183, DOI 10.1007/BF01000245; RENSING L, 1973, CELL DIFFER DEV, V2, P221, DOI 10.1016/0045-6039(73)90010-9; RITOSSA F, 1962, EXPERIENTIA, V18, P571, DOI 10.1007/BF02172188; Ritossa F, 1963, DROSOPHILA INFORMATI, V37, P122, DOI 10.1016/0014-4827(64)90147-8; RITOSSA FM, 1964, EXP CELL RES, V35, P601, DOI 10.1016/0014-4827(64)90147-8; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SEROZ T, 1995, CURR OPIN GENET DEV, V5, P217, DOI 10.1016/0959-437X(95)80011-5; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; WU C, 1994, BIOL HEAT SHOCK PROT, P365; ZIMARINO V, 1990, MOL CELL BIOL, V10, P752, DOI 10.1128/MCB.10.2.752; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	48	56	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26971	26980		10.1074/jbc.271.43.26971	http://dx.doi.org/10.1074/jbc.271.43.26971			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900183	hybrid			2022-12-25	WOS:A1996VP23300077
J	Meloche, S; Beatty, BG; Pellerin, J				Meloche, S; Beatty, BG; Pellerin, J			Primary structure, expression and chromosomal locus of a human homolog of rat ERK3	ONCOGENE			English	Article						protein kinase; MAP kinase; gene cloning; chromosomal mapping	ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASES; MAP KINASE; INSITU HYBRIDIZATION; GROWTH-FACTOR; CELLS; DIFFERENTIATION; P44(MAPK); CLONING; FAMILY	We report the cloning and characterization of a human cDNA encoding a novel homolog of rat extracellular signal-regulated kinase 3 (ERK3). The cDNA encodes a predicted protein of 721 amino acids which shares 92% amino acid identity with rat ERK3 over their shared length. Interestingly, the human protein contains a unique extension of 178 amino acids at its carboxy terminal extremity, The human ERK3 protein also displays various degrees of homology to other members of the MAP kinases family, but does not contain the typical TXY regulatory motif between subdomains VII and Vm. Northern blot analysis revealed that ERK3 mRNA is widely distributed in human tissues, with the highest expression detected in skeletal muscle. The human ERK3 gene was mapped by fluorescence lit situ hybridization to chromosome 15q21, a region associated with chromosomal abnormalities in acute nonlymphoblastic leukemias. This information should prove valuable in designing studies to define the cellular function of the ERK3 protein kinase.	UNIV MONTREAL, DEPT PHARMACOL, MONTREAL, PQ H2W 1T8, CANADA; HOSP SICK CHILDREN, DEPT PATHOL, TORONTO, ON M5G 1X8, CANADA	Universite de Montreal; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Meloche, S (corresponding author), HOP HOTEL DIEU, CTR RECH, MONTREAL, PQ H2W 1T8, CANADA.							ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE AL, 1992, GENOMICS, V12, P106, DOI 10.1016/0888-7543(92)90412-L; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHAREST DL, 1993, MOL CELL BIOL, V13, P4679, DOI 10.1128/MCB.13.8.4679; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUARTE MHO, 1990, CANCER GENET CYTOGEN, V49, P25, DOI 10.1016/0165-4608(90)90160-C; FUKUDA M, 1995, ONCOGENE, V11, P239; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; L'Allemain Gilles, 1994, Progress in Growth Factor Research, V5, P291, DOI 10.1016/0955-2235(94)90011-6; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LIND L, 1995, HUM MOL GENET, V4, P109, DOI 10.1093/hmg/4.1.109; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MOHIT AA, 1995, NEURON, V14, P67, DOI 10.1016/0896-6273(95)90241-4; *OMIM, 1996, ONL MEND INH MAN; OWAKI H, 1992, BIOCHEM BIOPH RES CO, V182, P1416, DOI 10.1016/0006-291X(92)91891-S; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUCIU S, 1990, CANCER GENET CYTOGEN, V44, P15, DOI 10.1016/0165-4608(90)90193-E; YUNIS JJ, 1981, NEW ENGL J MED, V305, P135, DOI 10.1056/NEJM198107163050304; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; ZHU AX, 1994, MOL CELL BIOL, V14, P8202, DOI 10.1128/MCB.14.12.8202	36	22	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1575	1579						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875998				2022-12-25	WOS:A1996VL38400025
J	Murguia, JR; Belles, JM; Serrano, R				Murguia, JR; Belles, JM; Serrano, R			The yeast HAL2 nucleotidase is an in vivo target of salt toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SULFATE ACTIVATION; PAPS-REDUCTASE; TOLERANCE; GENE; PLANTS; ENZYME; 3'(2')-PHOSPHOHYDROLASE; EXPRESSION	The yeast halotolerance gene HAL2 encodes a nucleotidase that dephosphorylates 3'-phosphoadenosine 5'-phosphate (PAP) and 3'-phosphoadenosine 5'-phosphosulfate (PAPS), intermediates of the sulfate assimilation pathway. This nucleotidase is inhibited by Na+ and Li+ but not by K+. Incubation of wild-type yeast cells with NaCl and LiCl, but not with KCl, increased intracellular PAP to millimolar concentrations. No depletion of the pool of adenine nucleotides (AMP, ADP, ATP) was observed. Other stresses such as heat shock or oxidative stress did not result in PAP accumulation. PAPS concentrations also increased during salt stress but remained lower than 0.5 mu M. S-Adenosylmethionine concentrations decreased by 50%, reflecting inhibition of sulfate assimilation during salt stress. Salt-induced PAP accumulation was attenuated in a yeast strain overexpressing HAL2. This strain grew better than the wild type under salt stress. These results suggest that the cation sensitivity of the HAL2 nucleotidase is an important determinant of the inhibition of yeast growth by sodium and lithium salts. In addition to blocking sulfate assimilation by product inhibition of PAPS reductase, PAP accumulation may have other unidentified toxic effects.	UNIV POLITECN VALENCIA, CSIC, INST BIOL MOL & CELULAR PLANTAS, VALENCIA 46022, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Politecnica de Valencia; CSIC-UPV - Instituto de Biologia Molecular y Celular de Plantas (IBMCP)			Murguia, Jose R./H-4419-2015; Bellés, José María/H-4734-2015	Murguia, Jose R./0000-0001-9364-4603; Bellés, José María/0000-0003-0362-9616				ASHRAF M, 1994, CRIT REV PLANT SCI, V13, P17, DOI 10.1080/713608051; BRUNNGRABER EG, 1958, J BIOL CHEM, V233, P472; FERRANDO A, 1995, MOL CELL BIOL, V15, P5470; GAXIOLA R, 1992, EMBO J, V11, P3157, DOI 10.1002/j.1460-2075.1992.tb05392.x; GIMMLER H, 1984, Z PFLANZENPHYSIOL, V114, P131, DOI 10.1016/S0044-328X(84)80026-4; GLASER HU, 1993, EMBO J, V12, P3105, DOI 10.1002/j.1460-2075.1993.tb05979.x; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; International Union of Biochemistry and Molecular Biology, 1992, ENZ NOM; JAKUBOWSKI H, 1993, J BACTERIOL, V175, P5469, DOI 10.1128/JB.175.17.5469-5476.1993; JAKUBOWSKI H, 1991, EMBO J, V10, P593, DOI 10.1002/j.1460-2075.1991.tb07986.x; JAKUBOWSKI H, 1986, P NATL ACAD SCI USA, V83, P2378, DOI 10.1073/pnas.83.8.2378; Wyn Jones R. G., 1983, Inorganic plant nutrition, P528; KEATING DH, 1995, J BIOL CHEM, V270, P22229, DOI 10.1074/jbc.270.38.22229; LEYH TS, 1993, CRIT REV BIOCHEM MOL, V28, P515, DOI 10.3109/10409239309085137; LI F, 1989, J CHROMATOGR, V461, P353, DOI 10.1016/S0021-9673(00)94302-4; METZLER DE, 1977, BIOCHEMISTRY-US, P686; MOUNTAIN HA, 1991, YEAST, V7, P781, DOI 10.1002/yea.320070804; MURGUIA JR, 1995, SCIENCE, V267, P232; MURGUIA JR, UNPUB; NAHORSKI SR, 1991, TRENDS PHARMACOL SCI, V12, P297, DOI 10.1016/0165-6147(91)90581-C; NEUWALD AF, 1992, J BACTERIOL, V174, P415, DOI 10.1128/jb.174.2.415-425.1992; PENG ZH, 1995, J BIOL CHEM, V270, P29105, DOI 10.1074/jbc.270.49.29105; Quintero FJ, 1996, PLANT CELL, V8, P529, DOI 10.1105/tpc.8.3.529; RAMASWAMY SG, 1987, J BIOL CHEM, V262, P10044; SCHMIDT A, 1992, ANNU REV PLANT PHYS, V43, P325, DOI 10.1146/annurev.pp.43.060192.001545; SCHWENN JD, 1988, ARCH MICROBIOL, V150, P313, DOI 10.1007/BF00408300; SCHWENN JD, 1987, Z NATURFORSCH C, V42, P93; SERRANO R, 1994, CRIT REV PLANT SCI, V13, P121, DOI 10.1080/713608057; Serrano R, 1995, METHOD CELL BIOL, V50, P481, DOI 10.1016/S0091-679X(08)61052-3; THOMAS D, 1992, J GEN MICROBIOL, V138, P2021, DOI 10.1099/00221287-138-10-2021; TSANG MLS, 1976, EUR J BIOCHEM, V65, P113; VALLEJO CG, 1989, YEAST, V5, P307, DOI 10.1002/yea.320050411; WATSON TG, 1970, J GEN MICROBIOL, V64, P91, DOI 10.1099/00221287-64-1-91; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; YANG LM, 1994, EUR J BIOCHEM, V224, P743, DOI 10.1111/j.1432-1033.1994.00743.x; YORK JD, 1990, P NATL ACAD SCI USA, V87, P9548, DOI 10.1073/pnas.87.24.9548; [No title captured]	37	105	112	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29029	29033		10.1074/jbc.271.46.29029	http://dx.doi.org/10.1074/jbc.271.46.29029			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910555				2022-12-25	WOS:A1996VT05200047
J	OGrady, SM; Elmquist, E; Filtz, TM; Nicholas, RA; Harden, TK				OGrady, SM; Elmquist, E; Filtz, TM; Nicholas, RA; Harden, TK			A guanine nucleotide-independent inwardly rectifying cation permeability is associated with P2Y(1) receptor expression in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TURKEY ERYTHROCYTE-MEMBRANES; GATED ION CHANNELS; PHOSPHOLIPASE-C; ATP RECEPTOR; FUNCTIONAL EXPRESSION; PURINERGIC RECEPTOR; CLONING; PURINOCEPTORS; KINETICS; CELLS	The functional properties of the G protein-coupled P2Y(1) receptor were investigated in Xenopus oocytes. Incubation of oocytes expressing either the human or turkey P2Y(1) receptor with adenine nucleotide agonists resulted in an increase in Cl- current and activation of a novel cation current with an inwardly rectifying current-voltage relationship. Activation of either the human P2Y(2) (P-2U-purinergic) or M1 muscarinic receptor expressed in oocytes resulted in an increase in Cl- current similar to that observed in P2Y(1) receptor-expressing oocytes but had no effect on cation current. P2 receptor agonists stimulated both the cation current and Cl- current in P2Y(1) receptor expressing oocytes with EC(50) values and an order of potency (2-methylthioadenosine diphosphate > 2-methylthioadenosine triphosphate (2MeSATP) > ATP > UTP) that were similar to those previously observed for activation of phospholipase C in 1321N1 human astrocytoma cells stably expressing the human or turkey P2Y(1) receptor. The P2Y receptor antagonists suramin and pyridoxal phosphate 6-azophenyl-2'-4'-disulfonic acid both shifted to the right the concentration-response relationship for 2MeSATP for stimulation of oocyte currents. Although injection of oocytes with either GDP beta S (granuyl-5'-yl thiophosphate) or GTP gamma S (guanosine 5'3-O-(thio)triphosphate) resulted in loss of adenine nucleotide-promoted Cl- channel activation, neither guanine nucleotide altered the 2MeSATP-stimulated cation current. These data are consistent with the view that activation of the novel cation current by the P2Y(1) receptor does not involve a G protein. Tail current analysis of the novel P2Y(1) receptor-associated cation conductance revealed that the open channel current-voltage relationship was outwardly rectifying with a reversal potential of -38 mV for the turkey P2Y(1) receptor and -36 mV for the human P2Y(1) receptor. Replacement of Na+ with K+ ions in the bathing solution produced a shift in reversal potential to near zero mV, but significant outward rectification remained. The cation current was not permeable to either Ca2+ or Ba2+ and exhibited steady-state inactivation at holding potentials below -60 mV. These results indicate that the P2Y(1) receptor exhibits both metabotropic properties and a novel G protein-independent ionotropic response when expressed in Xenopus oocytes.	UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	OGrady, SM (corresponding author), UNIV MINNESOTA,DEPT PHYSIOL & ANIM SCI,495 ANIM SCI VET MED BLDG,ST PAUL,MN 55108, USA.			Filtz, Theresa/0000-0002-5348-1114	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038213] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32322] Funding Source: Medline; NIGMS NIH HHS [GM38213] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; BOARDER MR, 1995, TRENDS PHARMACOL SCI, V16, P133, DOI 10.1016/S0165-6147(00)89001-X; BOYER JL, 1989, J BIOL CHEM, V264, P884; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152; Communi D, 1995, J BIOL CHEM, V270, P30849, DOI 10.1074/jbc.270.52.30849; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; FILTZ TM, 1994, MOL PHARMACOL, V46, P8; FILTZ TM, 1996, IN PRESS PURINERGIC; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; FURUKAWA K, 1994, J NEUROPHYSIOL, V71, P868, DOI 10.1152/jn.1994.71.3.868; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; HARDEN TK, 1987, J BIOL CHEM, V262, P9057; HARDEN TK, 1988, BIOCHEM J, V252, P583, DOI 10.1042/bj2520583; HENDERSON DJ, 1995, BIOCHEM BIOPH RES CO, V212, P648, DOI 10.1006/bbrc.1995.2018; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; Nguyen T, 1995, J BIOL CHEM, V270, P30845, DOI 10.1074/jbc.270.52.30845; Nicholas RA, 1996, MOL PHARMACOL, V50, P224; PARKER KE, 1995, AM J PHYSIOL-HEART C, V269, pH789, DOI 10.1152/ajpheart.1995.269.3.H789; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; Schachter JB, 1996, BRIT J PHARMACOL, V118, P167, DOI 10.1111/j.1476-5381.1996.tb15381.x; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; SHIBASAKI T, 1987, J PHYSIOL-LONDON, V387, P227, DOI 10.1113/jphysiol.1987.sp016571; SURPRENANT A, 1995, TRENDS NEUROSCI, V18, P224, DOI 10.1016/0166-2236(95)93907-F; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; Zuhlke R.D., 1995, METHODS NEUROSCI, V25, P67	29	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29080	29087		10.1074/jbc.271.46.29080	http://dx.doi.org/10.1074/jbc.271.46.29080			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910562	Green Published, hybrid			2022-12-25	WOS:A1996VT05200054
J	Osborne, MA; Zenner, G; Lubinus, M; Zhang, XL; Songyang, Z; Cantley, LC; Majerus, P; Burn, P; Kochan, JP				Osborne, MA; Zenner, G; Lubinus, M; Zhang, XL; Songyang, Z; Cantley, LC; Majerus, P; Burn, P; Kochan, JP			The inositol 5'-phosphatase SHIP binds to immunoreceptor signaling motifs and responds to high affinity IgE receptor aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHORYLATED PROTEINS; T-CELL ACTIVATION; FC-EPSILON-RI; SH2 DOMAINS; POLYPHOSPHATE 5-PHOSPHATASE; CROSS-LINKING; PHOSPHOTYROSINE; GRB2; MEMBRANE; YEAST	Immunoreceptors such as the high affinity IgE receptor, Fc epsilon RI, and T-cell receptor associated proteins share a common motif, the immunoreceptor tyrosine-based activation motif (ITAM). We used the yeast tribrid system to identify downstream effecters of the phosphorylated Fc epsilon RI ITAM-containing subunits beta and gamma. One novel cDNA was isolated that encodes a protein that is phosphorylated on tyrosine, contains a Src-homology 2 (SH2) domain, inositolpolyphosphate 5-phosphatase activity, three NXXY motifs, several proline-rich regions, and is called SHIP. Mutation of the conserved tyrosine or leucine residues within the Fc epsilon RI beta or ITAMs eliminates SHIP binding and indicates that the SHIP-ITAM interaction is specific. SHIP also binds to ITAMs from the CD3 complex and T cell receptor zeta chain in vitro. SHIP protein possesses both phosphatidylinositol-3,4,5-trisphosphate 5'-phosphatase and inositol-1,3,4,5-tetrakisphosphate 5'-phosphatase activity. Phosphorylation of SHIP by a protein-tyrosine kinase, Lck, results in a reduction in enzyme activity. Fc epsilon RI activation induces the association of several tyrosine phosphoproteins with SHIP. SHIP is constitutively tyrosine-phosphorylated and associated with She and Grb2. These data suggest that SHIP may serve as a multifunctional linker protein in receptor activation.	HOFFMANN LA ROCHE INC, DEPT METAB DIS, NUTLEY, NJ 07110 USA; WASHINGTON UNIV, SCH MED, DIV HEMATOL, ST LOUIS, MO 63110 USA; BETH ISRAEL HOSP, DEPT MED, DIV SIGNAL TRANSDUCT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Roche Holding; Washington University (WUSTL); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, R01HL016634, R37HL016634, T32HL007088] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16634, HL14147, HL07088] Funding Source: Medline; NIGMS NIH HHS [R01 GM041890] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTREE O, 1992, NATURE, V358, P239; BARKER SA, 1995, MOL BIOL CELL, V6, P1145, DOI 10.1091/mbc.6.9.1145; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BUDAY L, 1994, J BIOL CHEM, V269, P9019; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CASTELLANOS RMP, 1985, J BIOL CHEM, V260, P8240; Crowley MT, 1996, J BIOL CHEM, V271, P1145, DOI 10.1074/jbc.271.2.1145; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; deKoning JP, 1996, BLOOD, V87, P132; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Galandrini R, 1996, J EXP MED, V183, P179, DOI 10.1084/jem.183.1.179; HOWE LR, 1995, TRENDS BIOCHEM SCI, V20, P59, DOI 10.1016/S0968-0004(00)88958-6; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; KIHARA H, 1994, J BIOL CHEM, V269, P22427; Kimura T, 1996, MOL CELL BIOL, V16, P1471; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; KOYASU S, 1994, P NATL ACAD SCI USA, V91, P6693, DOI 10.1073/pnas.91.14.6693; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; OSBORNE MA, 1997, YEAST 2 HYBRID SYSTE; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROSS TS, 1991, J BIOL CHEM, V266, P20283; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SAXTON TM, 1994, J IMMUNOL, V153, P623; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TOKER A, 1994, J BIOL CHEM, V269, P32358; TURNER H, 1995, J BIOL CHEM, V270, P9500, DOI 10.1074/jbc.270.16.9500; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Wolfe PC, 1996, J BIOL CHEM, V271, P6658, DOI 10.1074/jbc.271.12.6658; ZENNER G, 1996, IN PRESS J CELL BIOC; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	47	161	165	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29271	29278		10.1074/jbc.271.46.29271	http://dx.doi.org/10.1074/jbc.271.46.29271			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910587	hybrid			2022-12-25	WOS:A1996VT05200079
J	Pillot, T; Goethals, M; Vanloo, B; Talussot, C; Brasseur, R; Vandekerckhove, J; Rosseneu, M; Lins, L				Pillot, T; Goethals, M; Vanloo, B; Talussot, C; Brasseur, R; Vandekerckhove, J; Rosseneu, M; Lins, L			Fusogenic properties of the C-terminal domain of the Alzheimer beta-amyloid peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; MEMBRANE-FUSION ACTIVITY; PHOSPHOLIPID-VESICLES; STRUCTURAL REQUIREMENTS; BILAYER-MEMBRANES; LIPID BILAYER; PROTEIN; DISEASE; MODEL; AGGREGATION	A series of natural peptides and mutants, derived from the Alzheimer beta-amyloid peptide, was synthesized, and the potential of these peptides to induce fusion of unilamellar lipid vesicles was investigated. These peptide domains were identified by computer modeling and correspond to respectively the C-terminal (e.g. residues 29-40 and 29-42) and a central domain (13-28) of the beta-amyloid peptide. The C-terminal peptides are predicted to insert in an oblique way into a lipid membrane through their N-terminal end, while the mutants are either parallel or perpendicular to the lipid bilayer. Peptide induced vesicle fusion was demonstrated by several techniques, including lipid-mixing and core-mixing assays using pyrene-labeled vesicles. The effect of peptide elongation toward the N-terminal end of the entire beta-amyloid peptide was also investigated. Peptides corresponding to residues 22-42 and 12-42 were tested using the same techniques. Both the 29-40 and 29-42 beta-amyloid peptides were able to induce fusion of unilamellar lipid vesicles and calcein leakage, and the amyloid 29-42 peptide was the most potent fusogenic peptide. Neither the two mutants or the 13-28 beta-amyloid peptide had any fusogenic activity. Circular dichroism measurements showed an increase of the alpha-helical content of the two C-terminal peptides at increasing concentrations of trifluoroethanol, which was accompanied by an increase of the fusogenic potential of the peptides. Our data suggest that the alpha-helical content and the angle of insertion of the peptide into a lipid bilayer are critical for the fusogenic activity of the C-terminal domain of the amyloid peptide. The differences observed between the fusogenic capacity of the amyloid 29-40 and 29-42 peptides might result from differences in the degree of penetration of the peptides into the membrane and the resulting membrane destabilization. The longer peptides, residues 22-42 and 12-42, had decreased, but significant, fusogenic properties associated with perturbation of the membrane permeability. These data suggest that the fusogenic properties of the C-terminal domain of the beta-amyloid peptide might contribute to the cytotoxicity of the peptide by destabilizing the cell membrane.	STATE UNIV GHENT, LAB LIPOPROT CHEM, FAC MED, B-9000 GHENT, BELGIUM; STATE UNIV GHENT VIB, FAC MED, DEPT BIOCHEM, B-9000 GHENT, BELGIUM; FAC SCI AGRON ETAT GEMBLOUX, CTR BIOPHYS MOL NUMER, GEMBLOUX, BELGIUM	Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; University of Liege			LINS, LAURENCE/Y-1661-2019; lins, laurence/E-3953-2012	LINS, LAURENCE/0000-0001-7772-6748; 				ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLUMENTHAL R, 1983, J BIOL CHEM, V258, P3409; BRASSEUR R, 1986, BIOCHEM J, V238, P1; BRASSEUR R, 1993, BIOCHIM BIOPHYS ACTA, V1170, P1, DOI 10.1016/0005-2760(93)90168-9; BRASSEUR R, 1991, J BIOL CHEM, V266, P16120; BURDICK D, 1992, J BIOL CHEM, V267, P546; DEFRISEQUERTAIN F, 1989, BIOCHEMISTRY-US, V28, P3406, DOI 10.1021/bi00434a040; DOMS RW, 1985, J BIOL CHEM, V260, P2973; GASSET M, 1990, BIOCHEM J, V265, P815, DOI 10.1042/bj2650815; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; HORTH M, 1991, EMBO J, V10, P2747, DOI 10.1002/j.1460-2075.1991.tb07823.x; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KENDALL DA, 1982, J BIOL CHEM, V257, P3892; LANSBURY PT, 1995, NAT STRUCT BIOL, V2, P990, DOI 10.1038/nsb1195-990; MARTIN I, 1994, J VIROL, V68, P1139, DOI 10.1128/JVI.68.2.1139-1148.1994; MATTSON MP, 1995, NAT STRUCT BIOL, V2, P926, DOI 10.1038/nsb1195-926; MATTSON MP, 1992, J NEUROSCI, V12, P379; MOE GR, 1985, BIOCHEMISTRY-US, V24, P1971, DOI 10.1021/bi00329a026; MORRIS SJ, 1988, SPECTROSCOPIC MEMBRA, V1, P161; MOUSLI M, 1990, TRENDS PHARMACOL SCI, V11, P358, DOI 10.1016/0165-6147(90)90179-C; MUGA A, 1994, BIOCHEMISTRY-US, V33, P4444, DOI 10.1021/bi00181a002; NIEVA JL, 1994, BIOCHEMISTRY-US, V33, P3201, DOI 10.1021/bi00177a009; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Poduslo S E, 1975, Methods Enzymol, V35, P561, DOI 10.1016/0076-6879(75)35185-9; RAFALSKI M, 1991, BIOCHEMISTRY-US, V30, P10211, DOI 10.1021/bi00106a020; RAPAPORT D, 1994, J BIOL CHEM, V269, P15124; SCHUBERT D, 1995, P NATL ACAD SCI USA, V92, P1989, DOI 10.1073/pnas.92.6.1989; Selkoe Dennis J., 1994, Current Opinion in Neurobiology, V4, P708, DOI 10.1016/0959-4388(94)90014-0; SIMMONS LK, 1993, MOL PHARMACOL, V15, P373; SONG DL, 1993, EUR J PHARM-MOLEC PH, V247, P283; UEDA K, 1994, BRAIN RES, V639, P240, DOI 10.1016/0006-8993(94)91736-1; VANCOMPERNOLLE K, 1992, EMBO J, V11, P4739, DOI 10.1002/j.1460-2075.1992.tb05579.x; VANLOO B, 1991, J LIPID RES, V32, P1253; VONECHE V, 1992, P NATL ACAD SCI USA, V89, P3810, DOI 10.1073/pnas.89.9.3810; WEISS JH, 1994, J NEUROCHEM, V62, P372; ZIMMERBERG J, 1993, ANNU REV BIOPH BIOM, V22, P433, DOI 10.1146/annurev.bb.22.060193.002245	40	142	148	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28757	28765		10.1074/jbc.271.46.28757	http://dx.doi.org/10.1074/jbc.271.46.28757			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910517	hybrid			2022-12-25	WOS:A1996VT05200009
J	Zhang, B; Peng, ZY				Zhang, B; Peng, ZY			Defective folding of mutant p16(INK4) proteins encoded by tumor-derived alleles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; FAMILIAL MELANOMA; BETA-LACTAMASE; MUTATIONS; BINDING; P16; INHIBITION; STATE; GENE	p16(INK4) is a specific cyclin D-dependent kinase inhibitor and a multiple tumor suppressor. Inactivation of p16 is frequent in both primary tumors and tumor-derived cell lines. We describe here the conformational properties and oligomerization state of seven mutant p16 proteins; all of them are deficient in function. Four of the seven proteins show significantly disrupted secondary structure and backbone folding. The other three adopt partially folded, molten globule-like conformations. These proteins have near-native levels of secondary structure, but lack the ability to undergo a cooperative thermal transition and are substantially less resistant to proteolysis than is wild type p16. At low concentrations, two of the seven proteins are monomers, three exhibit an apparent molecular weight between the value of a monomer and a dimer, and the other two aggregate significantly. Our results strongly suggest that defective protein folding and/or aggregation is a common mechanism for inactivation of p16.	UNIV CONNECTICUT,CTR HLTH,DEPT BIOCHEM,FARMINGTON,CT 06032	University of Connecticut			Zhang, Bin/AAJ-1481-2020					Blacklow SC, 1996, NAT STRUCT BIOL, V3, P758, DOI 10.1038/nsb0996-758; Boice JA, 1996, PROTEIN SCI, V5, P1776, DOI 10.1002/pro.5560050903; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BYCHKOVA VE, 1995, FEBS LETT, V359, P6, DOI 10.1016/0014-5793(95)00004-S; CORDONCARDO C, 1995, AM J PATHOL, V147, P545; CRAIG S, 1985, J MOL BIOL, V185, P681, DOI 10.1016/0022-2836(85)90053-1; DOERING D, 1992, THESIS MIT; DOLGIKH DA, 1984, FEBS LETT, V165, P88, DOI 10.1016/0014-5793(84)80020-4; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HEROLD M, 1990, BIOCHEMISTRY-US, V29, P1907, DOI 10.1021/bi00459a035; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KO YH, 1993, J BIOL CHEM, V268, P24330; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUWAJIMA K, 1989, J MOL BIOL, V206, P547, DOI 10.1016/0022-2836(89)90500-7; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LIM WA, 1992, BIOCHEMISTRY-US, V31, P4324, DOI 10.1021/bi00132a025; Liu X, 1996, P NATL ACAD SCI USA, V93, P4554, DOI 10.1073/pnas.93.10.4554; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PARRY D, 1996, MOL CELL BIOL, V7, P3844; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Taubes G, 1996, SCIENCE, V271, P1493, DOI 10.1126/science.271.5255.1493; Tevelev A, 1996, BIOCHEMISTRY-US, V35, P9475, DOI 10.1021/bi960211+; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; WICK ST, 1995, ONCOGENE, V11, P2013; WU YS, 1995, CHEM BIOL, V2, P91, DOI 10.1016/1074-5521(95)90281-3; YANG R, 1995, CANCER RES, V55, P2503; YU MH, 1995, NAT STRUCT BIOL, V2, P363, DOI 10.1038/nsb0595-363	37	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28734	28737		10.1074/jbc.271.46.28734	http://dx.doi.org/10.1074/jbc.271.46.28734			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910511	hybrid			2022-12-25	WOS:A1996VT05200003
J	Fang, YF; Fliss, AE; Robins, DM; Caplan, AJ				Fang, YF; Fliss, AE; Robins, DM; Caplan, AJ			Hsp90 regulates androgen receptor hormone binding affinity in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; GLUCOCORTICOID RECEPTOR; STEROID-RECEPTOR; LIGAND-BINDING; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; EXPRESSION SYSTEM; DUAL ROLES; COMPLEXES; DNA	The regulation of human androgen receptor (AR) by the molecular chaperone Hsp90 was investigated using the yeast Saccharomyces cerevisiae as a model system. These studies were performed in strains expressing a conditional temperature-sensitive mutant allele of the hsp82 gene, which encodes Hsp90 protein. At the restrictive temperature in the mutant, there is a decrease in hormone-dependent transactivation by the AR, although steady state levels of AR protein are unchanged. Quantitative hormone binding studies at the permissive temperature revealed the presence of both high affinity and low affinity hormone binding states. At the restrictive temperature in the hsp82 mutant, the high affinity state was abolished, and only the low affinity state was observed. The change in hormone binding affinity was further investigated by a competition assay with the anti-androgen hydroxyflutamide. Under permissive conditions, hydroxyflutamide competes poorly for the synthetic androgen R1881, but under restrictive conditions in the hsp82 mutant strain, hydroxyflutamide was shown to be a potent competitive inhibitor. Our findings indicate that Hsp90 participates in the activation process by maintaining apoAR in a high affinity ligand binding conformation which is important for efficient response to hormone.	CUNY, MT SINAI MED CTR, DEPT CELL BIOL & ANAT, NEW YORK, NY 10029 USA; UNIV MICHIGAN, SCH MED, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Michigan System; University of Michigan			Caplan, Avrom/GPT-0824-2022	Robins, Diane M./0000-0001-6727-6309	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049065] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-49065] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; BOHEN SP, 1995, J BIOL CHEM, V270, P29433, DOI 10.1074/jbc.270.49.29433; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CAPLAN AJ, 1995, J BIOL CHEM, V270, P5251, DOI 10.1074/jbc.270.10.5251; CHANG CS, 1992, P NATL ACAD SCI USA, V89, P5946, DOI 10.1073/pnas.89.13.5946; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; Dey B, 1996, MOL BIOL CELL, V7, P91, DOI 10.1091/mbc.7.1.91; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOHFELD J, 1995, CELL, V83, P589; HOLLEY SJ, 1995, MOL BIOL CELL, V6, P1833, DOI 10.1091/mbc.6.12.1833; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; MAK P, 1994, RECENT PROG HORM RES, V49, P347; MARIVOET S, 1992, MOL CELL ENDOCRINOL, V88, P165, DOI 10.1016/0303-7207(92)90021-W; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; NEMOTO T, 1990, BIOCHEMISTRY-US, V29, P1880, DOI 10.1021/bi00459a031; NEMOTO T, 1992, J STEROID BIOCHEM, V42, P803, DOI 10.1016/0960-0760(92)90088-Z; NEMOTO T, 1993, J BIOCHEM-TOKYO, V113, P769; OHARANEMOTO Y, 1991, J BIOCHEM, V109, P113, DOI 10.1093/oxfordjournals.jbchem.a123330; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PURVIS IJ, 1991, GENE, V106, P35, DOI 10.1016/0378-1119(91)90563-Q; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P742, DOI 10.1021/bi00147a029; WAKELING AE, 1981, J STEROID BIOCHEM, V15, P355, DOI 10.1016/0022-4731(81)90297-1; WONG CI, 1995, J BIOL CHEM, V270, P19998, DOI 10.1074/jbc.270.34.19998; XIE YB, 1992, J BIOL CHEM, V267, P4939	37	170	176	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28697	28702		10.1074/jbc.271.45.28697	http://dx.doi.org/10.1074/jbc.271.45.28697			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910505	hybrid			2022-12-25	WOS:A1996VU03300105
J	Jiang, HB; Wang, Y; Huang, YL; Mulnix, AB; Kadel, J; Cole, K; Kanost, MR				Jiang, HB; Wang, Y; Huang, YL; Mulnix, AB; Kadel, J; Cole, K; Kanost, MR			Organization of serpin gene-1 from Manduca sexta - Evolution of a family of alternate exons encoding the reactive site loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR-1 GENE; PROTEINASE-INHIBITORS; TOBACCO HORNWORM; DROSOPHILA; SUPERFAMILY; DIVERGENCE; EXPRESSION; SEQUENCES; ISOFORMS; CLONING	Manduca sexta serpin gene-1 encodes a family of serpins whose amino acid sequences are identical in their amino terminal 336 residues but variable in their carboxyl-terminal 39-46 residues, which includes the reactive site loop (Jiang, H., Wang, Y., and Kanost, M.R. (1994) J. Biol. Chem, 269, 55-58). Here, we report the gene's complete nucleotide sequence and exon-intron structure. A unique characteristic of this gene is its exon 9, which is present in 12 alternate forms between exons 8 and 10. Isolation and characterization of cDNA clones containing exons 9C, 9H, and 9I, which were not found previously, indicate that all 12 alternate forms of exon 9 can be utilized to generate 12 different serpins. The splicing pathway apparently allows inclusion of only one exon 9 per molecule of mature serpin-1 mRNA. Analysis of exon-intron border sequences reveals unique features that may be involved in regulation of RNA splicing. The exon 9 region has apparently evolved through rounds of exon duplication and sequence divergence. The exons near the center of the region may have evolved recently, whereas the outermost exons are the most ancient. Exons 9G and 9H were duplicated as a pair from exons 9E and 9F, an event that may have occurred more than once in the history of this gene.	KANSAS STATE UNIV, DEPT BIOCHEM, MANHATTAN, KS 66506 USA; EARLHAM COLL, DEPT BIOL, RICHMOND, IN 47374 USA; NATL INST STAND & TECHNOL, DIV BIOTECHNOL, GAITHERSBURG, MD 20899 USA	Kansas State University; Earlham College; National Institute of Standards & Technology (NIST) - USA				Kanost, Michael/0000-0002-6827-0061; Jiang, Haobo/0000-0003-1357-1315	NIGMS NIH HHS [GM41247, R37 GM041247] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041247, R01GM041247, R29GM041247] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONIEWSKI C, 1993, INSECT BIOCHEM MOLEC, V23, P105, DOI 10.1016/0965-1748(93)90088-A; BARBAS JA, 1993, MOL CELL BIOL, V13, P1433, DOI 10.1128/MCB.13.3.1433; BENSON S A, 1984, Biotechniques, V2, P126; BILLINGSLEY GD, 1993, AM J HUM GENET, V52, P343; BORRIELLO F, 1991, P NATL ACAD SCI USA, V88, P9417, DOI 10.1073/pnas.88.21.9417; BOSMA PJ, 1988, J BIOL CHEM, V263, P9129; BRADFIELD JY, 1983, CHROMOSOMA, V88, P190, DOI 10.1007/BF00285619; BRUZDZINSKI CJ, 1990, J BIOL CHEM, V265, P2078; CHERBAS L, 1993, INSECT BIOCHEM MOLEC, V23, P81, DOI 10.1016/0965-1748(93)90085-7; COLE KD, 1990, INSECT BIOCHEM, V20, P381, DOI 10.1016/0020-1790(90)90058-3; *GEN COMP GROUP, 1991, PROGR MAN GCG PACK V; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HILL RE, 1987, NATURE, V326, P96, DOI 10.1038/326096a0; HORODYSKI FM, 1989, P NATL ACAD SCI USA, V86, P8123, DOI 10.1073/pnas.86.20.8123; HWANG SR, 1994, P NATL ACAD SCI USA, V91, P9579, DOI 10.1073/pnas.91.20.9579; Jiang H, 1995, INSECT BIOCHEM MOLEC, V25, P1093, DOI 10.1016/0965-1748(95)00042-9; JIANG HB, 1994, J BIOL CHEM, V269, P55; KANOST MR, 1989, J BIOL CHEM, V264, P965; KANOST MR, 1995, INSECT BIOCHEM MOLEC, V25, P285, DOI 10.1016/0965-1748(94)00067-R; KANOST MR, 1996, IN PRESS SOS PUBLICA; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; MIURA Y, 1995, J BIOL CHEM, V270, P558, DOI 10.1074/jbc.270.2.558; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; REBERS JE, 1988, J MOL BIOL, V203, P411, DOI 10.1016/0022-2836(88)90009-5; RHEAUME C, 1994, J MOL EVOL, V38, P121, DOI 10.1007/BF00166159; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI T, 1991, EUR J BIOCHEM, V202, P255, DOI 10.1111/j.1432-1033.1991.tb16370.x; Sugumaran Manickam, 1993, P317; WANG XY, 1989, GENE, V80, P259, DOI 10.1016/0378-1119(89)90290-4; WILLOTT E, 1989, J BIOL CHEM, V264, P19052; WRIGHT HT, 1993, J MOL EVOL, V36, P136, DOI 10.1007/BF00166249	33	74	77	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28017	28023		10.1074/jbc.271.45.28017	http://dx.doi.org/10.1074/jbc.271.45.28017			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910411	hybrid			2022-12-25	WOS:A1996VU03300011
J	Krovat, BC; Jantsch, MF				Krovat, BC; Jantsch, MF			Comparative mutational analysis of the double-stranded RNA binding domains of Xenopus laevis RNA-binding protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE DAI PKR; MESSENGER-RNA; DROSOPHILA STAUFEN; INTERFERON ACTION; ESCHERICHIA-COLI; MOTIF; IDENTIFICATION; LOCALIZATION; MECHANISM	Xenopus laevis RNA-binding protein A is a ubiquitously expressed, double-stranded RNA-binding protein that is associated with the majority of cellular RNAs, ribosomal RNAs, and hnRNAs, X. laevis RNA-binding protein A contains three copies of the double-stranded RNA-binding domain (dsRBD) in tandem arrangement, Two of them, xl1 and xl2, belong to the type A group of dsRBDs that show strong homologies to the entire length of a defined consensus sequence. The xl3 domain, in contrast, is a type B dsRBD which only matches the basic C-terminal end of the dsRBD consensus sequence, Here we show that only xl2 but neither xl1 nor xl3 are able to bind double-stranded RNA substrates in vitro, suggesting that different dsRBD copies have varying RNA binding activities. By fine mapping mutagenesis of the isolated xl2 domain, we identified at least two central aromatic amino acids and a C-terminal alpha-helix that are indispensable for dsRNA binding. Furthermore, we show that different charge distributions within the C-terminal alpha-helices of xl1 and xl2 seem responsible for the different RNA binding behaviors of these two dsRBDs. Analyses of the RNA binding properties of constructs containing various combinations of different dsRBDs reveal that type A dsRBDs exhibit a cooperative binding effect, whereas type B dsRBDs show a rather low binding activity, thus contributing only to a minor extent to a stable RNA-protein interaction.	UNIV VIENNA,INST BOT,DEPT CYTOL & GENET,A-1030 VIENNA,AUSTRIA	University of Vienna			Jantsch, Michael/N-7873-2019; Jantsch, Michael/E-9122-2015	Jantsch, Michael/0000-0003-1747-0853; Jantsch, Michael/0000-0003-1747-0853				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; BASS BL, 1993, RNA WORLD, P383; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; CHANG HW, 1993, VIROLOGY, V194, P537, DOI 10.1006/viro.1993.1292; CLARKE PA, 1994, NUCLEIC ACIDS RES, V22, P4364, DOI 10.1093/nar/22.21.4364; CLARKE PA, 1995, RNA, V1, P7; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; GATIGNOL A, 1993, MOL CELL BIOL, V13, P2193, DOI 10.1128/MCB.13.4.2193; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MCCORMACK SJ, 1994, VIROLOGY, V198, P92, DOI 10.1006/viro.1994.1011; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SCHMEDT C, 1995, J MOL BIOL, V249, P29, DOI 10.1006/jmbi.1995.0278; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEITZ TA, 1993, RNA WORLD, P219; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13	31	63	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28112	28119		10.1074/jbc.271.45.28112	http://dx.doi.org/10.1074/jbc.271.45.28112			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910425	hybrid			2022-12-25	WOS:A1996VU03300025
J	OgierDenis, E; Houri, JJ; Bauvy, C; Codogno, P				OgierDenis, E; Houri, JJ; Bauvy, C; Codogno, P			Guanine nucleotide exchange on heterotrimeric G(i3) protein controls autophagic sequestration in HT-29 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; GTP-BINDING PROTEINS; N-LINKED GLYCOPROTEINS; ENTEROCYTIC DIFFERENTIATION; ADENYLATE-CYCLASE; ADP-RIBOSYLATION; ALPHA-SUBUNIT; REGULATORY COMPONENT; EPITHELIAL-CELLS; GOLGI MEMBRANES	Recent results have shown that autophagic sequestration in the human colon cancer cell line HT-29 is controlled by the pertussis toxin-sensitive heterotrimeric G(i3) protein. Here we show that transfection of an antisense oligodeoxynucleotide to the alpha(i3)-subunit markedly inhibits autophagic sequestration, whereas transfection of an antisense oligodeoxynucleotide to the alpha(i2)-subunit does not change the rate of autophagy in HT-29 cells. Autophagic sequestration was arrested in cells transfected with a mutant of the alpha(i3)-subunit (Q204L) that is restricted to the GTP-bound form. In Q204L expressing cells, 3-methyladenine-sensitive degradation of long lived [C-14]valine-labeled proteins was severely impaired and could not be stimulated by nutrient deprivation. Autophagy was also reduced when dissociation of the beta gamma dimer from the GTP-bound alpha(i3)-subunit was impaired in cells transfected with the G203A mutant. In contrast, a high rate of pertussis toxin-sensitive autophagy was observed in cells transfected with an alpha(i3)-subunit mutant (S47N) which has an increased guanine nucleotide exchange rate and increased preference for GDP over GTP. Cells that express pertussis toxin-insensitive mutants of either wild-type alpha(i3)-subunit (C351S) or S47N alpha(i3)-subunit (S47N/C351S) exhibit a high rate of autophagy.	UNIV PARIS 07,INSERM,U410,F-75018 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Ogier-Denis, Eric/E-5030-2016; Codogno, Patrice/G-1384-2013	Codogno, Patrice/0000-0002-5492-3180; Ogier-Denis, Eric/0000-0002-0057-7593				ARIDOR M, 1993, SCIENCE, V262, P1569, DOI 10.1126/science.7504324; BARR FA, 1991, FEBS FED EUR BIOCH S, V293, P1; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; BOMSEL M, 1993, J BIOL CHEM, V268, P25824; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COLEMAN DE, 1994, J MOL BIOL, V238, P630, DOI 10.1006/jmbi.1994.1320; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; FENGSRUD M, 1995, EXP CELL RES, V221, P504, DOI 10.1006/excr.1995.1402; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; HERMOUET S, 1992, FEBS LETT, V312, P223, DOI 10.1016/0014-5793(92)80940-I; HILDEBRANDT JD, 1991, MOL CELL BIOL, V11, P4830, DOI 10.1128/MCB.11.10.4830; HOLEN I, 1995, J BIOL CHEM, V270, P12823, DOI 10.1074/jbc.270.21.12823; HOURI JJ, 1995, BIOCHEM J, V309, P521, DOI 10.1042/bj3090521; HOURI JJ, 1992, EUR J BIOCHEM, V205, P1169, DOI 10.1111/j.1432-1033.1992.tb16887.x; HUNT TW, 1994, J BIOL CHEM, V269, P29565; ITOH H, 1988, J BIOL CHEM, V263, P6656; JOURNOT L, 1991, J BIOL CHEM, V266, P9009; KADOWAKI M, 1994, J BIOL CHEM, V269, P3703; KOPITZ J, 1990, J CELL BIOL, V111, P941, DOI 10.1083/jcb.111.3.941; KOVACS AL, 1985, EXP CELL RES, V157, P83, DOI 10.1016/0014-4827(85)90154-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE BP, 1992, J CELL SCI, V102, P515; LEE E, 1992, J BIOL CHEM, V267, P1212; MAIER O, 1995, BIOCHEM BIOPH RES CO, V208, P135, DOI 10.1006/bbrc.1995.1315; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MIOTTO G, 1994, J BIOL CHEM, V269, P25348; Mortimore G. E., 1994, CELLULAR PROTEOLYTIC, P65; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; MURAYAMA T, 1983, J BIOL CHEM, V258, P3319; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OGIERDENIS E, 1988, J BIOL CHEM, V263, P6031; OGIERDENIS E, 1995, J BIOL CHEM, V270, P13, DOI 10.1074/jbc.270.1.13; OHASHI M, 1994, J BIOL CHEM, V269, P24897; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; PUNNONEN EL, 1993, EUR J CELL BIOL, V61, P54; RABOUILLE C, 1993, J CELL BIOL, V120, P897, DOI 10.1083/jcb.120.4.897; RIBEIRONETO FAP, 1989, P NATL ACAD SCI USA, V86, P2577, DOI 10.1073/pnas.86.8.2577; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SCHWORER CM, 1981, J BIOL CHEM, V256, P7652; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SEGLEN PO, 1986, EXP CELL RES, V162, P273, DOI 10.1016/0014-4827(86)90446-5; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Seglen PO, 1987, LYSOSOMES THEIR ROLE, P369; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TRUGNAN G, 1991, J BIOL CHEM, V266, P20849; VANDENBERGHE N, 1991, BIOCHEM J, V278, P565, DOI 10.1042/bj2780565; VITALE N, 1993, J BIOL CHEM, V268, P14715; Voisin T, 1996, J BIOL CHEM, V271, P574, DOI 10.1074/jbc.271.1.574; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; WILSON BS, 1993, P NATL ACAD SCI USA, V90, P1681, DOI 10.1073/pnas.90.5.1681; ZWEIBAUM A, 1985, J CELL PHYSIOL, V122, P21, DOI 10.1002/jcp.1041220105	62	94	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28593	28600		10.1074/jbc.271.45.28593	http://dx.doi.org/10.1074/jbc.271.45.28593			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910489	hybrid			2022-12-25	WOS:A1996VU03300089
J	Sexton, DJ; Carver, TE; Berdis, AJ; Benkovic, SJ				Sexton, DJ; Carver, TE; Berdis, AJ; Benkovic, SJ			Protein-protein and protein-DNA interactions at the bacteriophage T4 DNA replication fork - Characterization of a fluorescently labeled DNA polymerase sliding clamp	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE HOLOENZYME PARTICLE; ACCESSORY PROTEINS; ESCHERICHIA-COLI; III HOLOENZYME; PRIMER-TEMPLATE; ATP HYDROLYSIS; COMPLEX; PURIFICATION; MACHINE; LOADER	The T4 DNA polymerase holoenzyme is composed of the polymerase enzyme complexed to the sliding clamp (the 45 protein), which is loaded onto DNA by an ATP-dependent clamp loader (the 44/62 complex). This paper describes a new method to directly investigate the mechanism of holoenzyme assembly using a fluorescently labeled cysteine mutant of the 45 protein. This protein possessed unaltered function yet produced substantial changes in probe fluorescence intensity upon interacting with other components of the holoenzyme. These fluorescence changes provide insight into the role of ATP hydrolysis in holoenzyme assembly. Using either ATP or the non-hydrolyzable ATP analog, adenosine 5'O-(3-thiophosphate), events in holoenzyme assembly were assigned as either dependent or independent of ATP hydrolysis. A holoenzyme assembly mechanism is proposed in which the 44/62 complex mediates the association of the 45 protein with DNA in an ATP-dependent manner not requiring ATP hydrolysis. Upon ATP hydrolysis, the 44/62 complex triggers a conformational change in the 45 protein that may be attributed to the clamp loading onto DNA.	PENN STATE UNIV, DEPT CHEM, DAVEY LAB 152, UNIVERSITY PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park				Sexton, Daniel J/0000-0001-9604-5948	NIGMS NIH HHS [GM13306] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berdis AJ, 1996, BIOCHEMISTRY-US, V35, P9253, DOI 10.1021/bi952569w; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; Kaboord BF, 1996, BIOCHEMISTRY-US, V35, P1084, DOI 10.1021/bi9520747; KABOORD BF, 1995, CURR BIOL, V5, P149, DOI 10.1016/S0960-9822(95)00036-4; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION, VSecond, P113; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; MUNN MM, 1991, J BIOL CHEM, V266, P20024; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; NOSSAL NG, 1979, J BIOL CHEM, V254, P6026; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ONRUST R, 1991, J BIOL CHEM, V266, P21681; PIPERNO JR, 1978, J BIOL CHEM, V253, P5174; RUSH J, 1989, J BIOL CHEM, V264, P10943; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; XIAO H, 1995, J BIOL CHEM, V270, P13378, DOI 10.1074/jbc.270.22.13378; YODER BL, 1991, J BIOL CHEM, V266, P22689; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	25	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28045	28051		10.1074/jbc.271.45.28045	http://dx.doi.org/10.1074/jbc.271.45.28045			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910415	hybrid			2022-12-25	WOS:A1996VU03300015
J	Smith, LL; Cheung, HK; Ling, LE; Chen, J; Sheppard, D; Pytela, R; Giachelli, CM				Smith, LL; Cheung, HK; Ling, LE; Chen, J; Sheppard, D; Pytela, R; Giachelli, CM			Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha(9)beta(1) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR CELL-ADHESION; SMOOTH-MUSCLE CELLS; EXTRACELLULAR-MATRIX; IN-VITRO; FUNCTIONAL REGULATION; FIBRONECTIN RECEPTOR; TISSUE DISTRIBUTION; CYTOPLASMIC DOMAIN; THROMBIN-CLEAVAGE; BETA(3) INTEGRIN	Osteopontin is an adhesive glycoprotein implicated in numerous diseases associated with inflammation and remodeling. There are several structural domains in osteopontin that are of particular interest. The RGD motif is a cell attachment sequence shown to be critical for cell adhesion through alpha(v)-containing integrins. In close proximity to the RGD domain is the thrombin cleavage site. Previous observations suggest that thrombin cleavage of osteopontin occurs in vivo and may be physiologically important. To study the functional significance of osteopontin cleavage by thrombin, we made glutathione S-transferase-osteopontin fusion proteins. These proteins contain either the N- or C-terminal domains expected to be formed following thrombin cleavage at the Arg(169)Ser(170) peptide bond, We compared these osteopontin fragments with native osteopontin in their ability to support adhesion of several different cell lines and identified the receptors mediating these interactions. Our data show that the N-terminal osteopontin fragment, which contains the RGD domain, supports adhesion of a melanoma cell line that is unable to bind native osteopontin. This suggests that osteopontin adhesive interactions may be regulated by thrombin cleavage. We also demonstrate that osteopontin contains a cryptic binding activity, which can be recognized by a novel osteopontin receptor. This receptor has been identified as the alpha(9) beta(1) integrin.	UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195; BIOGEN INC,DEPT BIOL RES,CAMBRIDGE,MA 02142; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,LUNG BIOL CTR,SAN FRANCISCO,CA 94110	University of Washington; University of Washington Seattle; Biogen; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-18645] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07270-20] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; BROWN LF, 1992, MOL BIOL CELL, V3, P1169, DOI 10.1091/mbc.3.10.1169; BUSCH G, 1989, EUR J CELL BIOL, V50, P257; BUSK M, 1992, J BIOL CHEM, V267, P5790; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHEN YP, 1994, BLOOD, V84, P1857; CHEN YP, 1995, BLOOD, V86, P2606, DOI 10.1182/blood.V86.7.2606.bloodjournal8672606; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; DAMSKY CH, 1992, J CLIN INVEST, V89, P210, DOI 10.1172/JCI115565; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DERRICO JA, 1995, J PERIODONTAL RES, V30, P34, DOI 10.1111/j.1600-0765.1995.tb01250.x; DEVRIES JE, 1986, INT J CANCER, V38, P465, DOI 10.1002/ijc.2910380403; GAILIT J, 1988, J BIOL CHEM, V263, P12927; Gajdusek C. M., 1983, IN VITRO, V19, P394; GIACHELLI CM, 1995, TRENDS CARDIOVAS MED, V5, P88, DOI 10.1016/1050-1738(95)00005-T; GIACHELLI CM, 1993, J CLIN INVEST, V92, P1686, DOI 10.1172/JCI116755; GIACHELLI CM, 1995, ANN NY ACAD SCI, V760, P109, DOI 10.1111/j.1749-6632.1995.tb44624.x; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; HELFRICH MH, 1992, J BONE MINER RES, V7, P335; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HORTON MA, 1994, BONE, V15, P639, DOI 10.1016/8756-3282(94)90312-3; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KIEFER MC, 1989, NUCLEIC ACIDS RES, V17, P3306, DOI 10.1093/nar/17.8.3306; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LIAW L, 1995, CIRC RES, V77, P665, DOI 10.1161/01.RES.77.4.665; LIAW L, 1994, CIRC RES, V74, P214, DOI 10.1161/01.RES.74.2.214; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; LUQUE A, 1994, FEBS LETT, V346, P278, DOI 10.1016/0014-5793(94)00490-0; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; MURRY CE, 1994, AM J PATHOL, V145, P1450; NASU K, 1995, BIOCHEM J, V307, P257, DOI 10.1042/bj3070257; OBRIEN KD, 1995, CIRCULATION, V92, P2163, DOI 10.1161/01.CIR.92.8.2163; PACIFICI R, 1994, J IMMUNOL, V153, P2222; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; SCHNAPP LM, 1995, J CELL SCI, V108, P537; SENGER DR, 1989, BIOCHIM BIOPHYS ACTA, V996, P43, DOI 10.1016/0167-4838(89)90092-7; SENGER DR, 1995, ANN NY ACAD SCI, V760, P83, DOI 10.1111/j.1749-6632.1995.tb44622.x; SENGER DR, 1994, MOL BIOL CELL, V5, P565, DOI 10.1091/mbc.5.5.565; SENGER DR, 1989, ANTICANCER RES, V9, P1291; STEPP MA, 1995, J HISTOCHEM CYTOCHEM, V43, P353, DOI 10.1177/43.4.7534781; VANDIJK S, 1993, J BONE MINER RES, V8, P1499; VANSTRIJP JAG, 1993, J IMMUNOL, V151, P3324; WANG A, 1996, IN PRESS AM J RESP C; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WEINACKER A, 1995, AM J RESP CELL MOL, V12, P547, DOI 10.1165/ajrcmb.12.5.7537970; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; XUAN JW, 1995, J CELL BIOCHEM, V57, P680, DOI 10.1002/jcb.240570413; XUAN JW, 1994, J CELL BIOCHEM, V54, P247, DOI 10.1002/jcb.240540213; YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V	55	220	225	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28485	28491		10.1074/jbc.271.45.28485	http://dx.doi.org/10.1074/jbc.271.45.28485			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910476	hybrid			2022-12-25	WOS:A1996VU03300076
J	Su, J; Yang, LT; Sap, J				Su, J; Yang, LT; Sap, J			Association between receptor protein-tyrosine phosphatase RPTP alpha and the Grb2 adaptor - Dual Src homology (SH)2/SH3 domain requirement and functional consequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; BINDING-SITE; SH3 DOMAINS; PHOSPHOTYROSINE PHOSPHATASE; SIGNAL-TRANSDUCTION; T-CELLS; KINASE ACTIVATION; RAS PATHWAY; PHOSPHORYLATION; DIFFERENTIATION	Receptor protein-tyrosine phosphatase RPTP alpha is found associated in vivo with the adaptor protein Grb2. Formation of this complex, which contains no detectable levels of Sos, is known to depend on a C-terminal phosphorylated tyrosine residue (Tyr(798)) in RPTP alpha and on the Src homology (SH) 2 domain in Grb2 (1, 2). We show here that association of Grb2 with RPTP alpha also involves a critical function for the C-terminal SH3 domain of Grb2. Furthermore, Grb2 SH3 binding peptides interfere with RPTP alpha-Grb2 association in vitro, and the RPTP alpha protein can dissociate the Grb2-Sos complex in vivo. These observations constitute a novel mode of Grb2 association and suggest a model in which association with a tyrosine-phosphorylated protein restricts the repertoire of SH3 binding proteins with which Grb2 can simultaneously interact. The function of the Tyr(798) tyrosine phosphorylation/Grb2 binding site in RPTP alpha was studied further by expression of wild type or mutant RPTP alpha proteins in PC12 cells. In these cells, wild type RPTP alpha interferes with acidic fibroblast growth factor-induced neurite outgrowth; this effect requires both the catalytic activity and the Grb2 binding Tyr(798) residue in RPTP alpha. In contrast, expression of catalytically active RPTP alpha containing a mutated tyrosine phosphorylation/Grb2 association site enhances neurite outgrowth. Our observations associate a functional effect with tyrosine phosphorylation of, and ensuing association of signaling proteins with, a receptor protein-tyrosine phosphatase and raise the possibility that RPTP alpha association may modulate Grb2 function and vice versa.	NYU, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA; NYU, MED CTR, KAPLAN COMPREHENS CANC CTR, NEW YORK, NY 10016 USA	New York University; New York University					NCI NIH HHS [R29 CA68365-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA068365] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BELLOT F, 1990, J CELL BIOL, V110, P491, DOI 10.1083/jcb.110.2.491; BENJAMIN CW, 1994, J BIOL CHEM, V269, P31346; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BOULTER CA, 1988, ONCOGENE, V2, P207; Brady-Kalnay Susann, 1994, Trends in Cell Biology, V4, P73, DOI 10.1016/0962-8924(94)90172-4; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAUM G, 1994, J BIOL CHEM, V269, P10524; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DENHERTOG J, 1995, CELL GROWTH DIFFER, V6, P303; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEMMON MA, 1994, J BIOL CHEM, V269, P31653; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARU Y, 1995, MOL CELL BIOL, V15, P835; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MIKI H, 1994, J BIOL CHEM, V269, P5489; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; RAABE T, 1995, EMBO J, V14, P2509, DOI 10.1002/j.1460-2075.1995.tb07248.x; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; REIF K, 1994, J BIOL CHEM, V269, P14081; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHMIDT JW, 1992, J CELL BIOL, V116, P1019, DOI 10.1083/jcb.116.4.1019; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STOCKSCHLAEDER MAR, 1991, HUM GENE THER, V2, P33, DOI 10.1089/hum.1991.2.1-33; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; SU J, 1994, J BIOL CHEM, V269, P18731; SUPERTIFURGA G, 1995, FEBS LETT, V369, P62, DOI 10.1016/0014-5793(95)00636-N; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0; ZHOU M, 1995, THESIS NEW YORK U; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	74	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28086	28096		10.1074/jbc.271.45.28086	http://dx.doi.org/10.1074/jbc.271.45.28086			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910422	hybrid			2022-12-25	WOS:A1996VU03300022
J	Noguchi, T; Matozaki, T; Fujioka, Y; Yamao, T; Tsuda, M; Takada, T; Kasuga, M				Noguchi, T; Matozaki, T; Fujioka, Y; Yamao, T; Tsuda, M; Takada, T; Kasuga, M			Characterization of a 115-kDa protein that binds to SH-PTP2, a protein-tyrosine phosphatase with Src homology 2 domains, in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; INSULIN-RECEPTOR SUBSTRATE-1; SIGNAL-TRANSDUCTION; MITOGENIC SIGNAL; SYP PHOSPHATASE; KINASE; SHPTP2; IDENTIFICATION; ACTIVATION; EXPRESSION	SN-PTP2, a non-transmembrane-type protein-tyrosine phosphatase with two Src homology 2 domains, was previously shown to play a positive signaling role in the insulin-induced activation of Ras and mitogen-activated protein kinase, SH-PTP2 was shown to associate with a 115-kDa tyrosine phosphorylated protein (pp115), as well as with insulin receptor substrate 1, in insulin-stimulated Chinese hamster ovary cells that overexpress human insulin receptors (CHO-IR cells). In vivo and in vitro binding experiments revealed that SH-PTP2 bound to pp115 through one or both of its SH2 domains. The pp115 protein was partially purified from insulin stimulated CHO-TR. cells that; overexpress a catalytically inactive SH-PTP2 by a combination of immunoaffinity and lectin-affinity chromatography, A monoclonal antibody to pp115 was then generated by injecting the partially purified protein into mice, Experiments with this monoclonal antibody revealed that pp115 is a transmembrane protein with a domain exposed on the cell surface and that it binds to SH-PTP2 in response to insulin. The insulin receptor kinase appeared to phosphorylate pp115 on tyrosine residues both in vivo and in vitro, The extent of tyrosine phosphorylation of pp115 associated with SH-PTP2 was greatly increased in CHO-IR cells that overexpress catalytically inactive SH-PTP2 compared with that observed in CHO-Ln cells overexpressing wild-type SH-PTP2, Furthermore, recombinant SH-PTP2 preferentially dephosphorylated pp115 in vitro, indicating that SH-PTP2 may catalyze the dephosphorylation of phosphotyrosine residues in pp115 after it binds to this protein. These results suggest that pp115 may act as a transmembrane anchor to which SH-PTP2 binds in response to insulin. Furthermore, pp115 may be a physiological substrate for both the insulin receptor kinase and SH-PTP2.	KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE,HYOGO 650,JAPAN	Kobe University								ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; KASUGA M, 1983, P NATL ACAD SCI-BIOL, V80, P2137, DOI 10.1073/pnas.80.8.2137; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MATOZAKI T, 1994, J BIOL CHEM, V269, P2075; MATOZAKI T, 1994, BIOCHEM BIOPH RES CO, V204, P874, DOI 10.1006/bbrc.1994.2541; MATOZAKI T, 1992, CANCER RES, V52, P1; MATOZAKI T, 1995, ADV PROTEIN PHOSPHAT, V9, P319; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PERRIMON N, 1993, CELL, V74, P219, DOI 10.1016/0092-8674(93)90412-J; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P14871, DOI 10.1074/jbc.270.25.14871; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	34	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27652	27658		10.1074/jbc.271.44.27652	http://dx.doi.org/10.1074/jbc.271.44.27652			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910355	hybrid			2022-12-25	WOS:A1996VQ67900073
J	Quimby, BB; Wells, L; Wilkinson, KD; FridovichKeil, JL				Quimby, BB; Wells, L; Wilkinson, KD; FridovichKeil, JL			Functional requirements of the active site position 185 in the human enzyme galactose-1-phosphate uridylyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; YEAST; GALACTOSEMIA; MUTAGENESIS	The active site of galactose-1-phosphate uridylyltransferase (GALT) includes a HPH sequence that has been conserved in all species examined from Escherichia coli to humans, The crystal structure of the E. coli enzyme suggests that this proline is important in positioning the active site histidine (His-166) near the substrate, To examine the role of this proline in the homologous human sequence, we have performed saturating mutagenesis at Pro 185 within human GALT and characterized each resultant mutant enzyme using a yeast expression system, Activity analyses in crude lysates indicated that only proline at position 185 produced wild type levels of activity, although five other amino acids, Ala, Gly, Ser, Gln, and Glu, all produced partially active enzymes, Western blot analyses of the GALT proteins in these lysates demonstrated that abundance varied from 9-118% of wild-type and was independent of activity, All five active mutant proteins were purified and characterized with regard to specific activity, apparent K-m for both substrates, and temperature-dependence of activity, Finally, modeling of these mutations onto the conserved E. coli active site structure was performed, Together, these results provide functional evidence demonstrating the critical role of Pro-185 in facilitating the transferase reaction.	EMORY UNIV,SCH MED,DEPT MOL & MED GENET,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,GRAD PROGRAM GENET & MOL BIOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,GRAD PROGRAM BIOCHEM & MOL BIOL,ATLANTA,GA 30322	Emory University; Emory University; Emory University; Emory University			Wells, Lance/H-3118-2013	Wells, Lance/0000-0003-4956-5363	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046403, R29DK046403] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030308] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46403] Funding Source: Medline; NIGMS NIH HHS [GM30308] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANROQUES J, 1981, BIOCHIM BIOPHYS ACTA, V657, P374, DOI 10.1016/0005-2744(81)90323-5; BANROQUES J, 1983, BIOCHIMIE, V65, P7, DOI 10.1016/S0300-9084(83)80023-6; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BEUTLER D, 1966, J LAB CLIN MED, V67, P947; Cornish-Bowden A., 1981, FUNDAMENTALS ENZYME; ELSAS LJ, 1995, AM J HUM GENET, V56, P630; Elsas LJ, 1993, INT PEDIATR, V8, P101; Elsevier JP, 1996, P NATL ACAD SCI USA, V93, P7166, DOI 10.1073/pnas.93.14.7166; FIELD TL, 1989, BIOCHEMISTRY-US, V28, P2094, DOI 10.1021/bi00431a019; FREDOVICHKEIL JL, 1995, BIOCHEM MOL MED, V56, P121; FREY PA, 1982, METHOD ENZYMOL, V87, P20; FRIDOVICHKEIL JL, 1993, P NATL ACAD SCI USA, V90, P398, DOI 10.1073/pnas.90.2.398; HELMER GR, 1981, ARCH BIOCHEM BIOPHYS, V210, P573, DOI 10.1016/0003-9861(81)90223-X; MARKUS HB, 1977, J BIOL CHEM, V252, P5363; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; MUCKE M, 1994, BIOCHEMISTRY-US, V33, P14608; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; REICHARDT JKV, 1991, P NATL ACAD SCI USA, V88, P2633, DOI 10.1073/pnas.88.7.2633; Sambrook J., 2002, MOL CLONING LAB MANU; Segal S, 1995, METABOLIC MOL BASIS, P967; WEDEKIND JE, 1995, BIOCHEMISTRY-US, V34, P11049, DOI 10.1021/bi00035a010; WILLIAMS VP, 1978, ARCH BIOCHEM BIOPHYS, V191, P182, DOI 10.1016/0003-9861(78)90080-2; WONG LJ, 1974, J BIOL CHEM, V249, P2322; WONG LJ, 1977, BIOCHEMISTRY-US, V16, P1010, DOI 10.1021/bi00624a032; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P961, DOI 10.1002/pro.5560010801	25	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26835	26842		10.1074/jbc.271.43.26835	http://dx.doi.org/10.1074/jbc.271.43.26835			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900165	hybrid			2022-12-25	WOS:A1996VP23300059
J	Resnick, D; Chatterton, JE; Schwartz, K; Slayter, H; Krieger, M				Resnick, D; Chatterton, JE; Schwartz, K; Slayter, H; Krieger, M			Structure of class A macrophage scavenger receptors - Electron microscopic study of flexible, multidomain, fibrous proteins and determination of the disulfide bond pattern of the scavenger receptor cysteine-rich domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; MACROMOLECULES; CONTAINS; EXPRESSION; CLONING; GENE	Structures of secreted forms of the human type I and II class A macrophage scavenger receptors were studied using biochemical and biophysical methods. Proteolytic analysis was used to determine the intramolecular disulfide bonds in the type I-specific scavenger receptor cysteine-rich (SRCR) domain: Cys(2)-Cys(7), Cys(3)-Cys(8), and Cys(5)-Cys(6). This pattern is likely to be shared by the highly homologous domains in the many other members of the SRCR domain superfamily. Electron microscopy using rotary shadowing and negative staining showed that the type I and II receptors are extended molecules whose contour lengths are similar to 440 Angstrom. They comprised two adjacent fibrous segments, an alpha-helical coiled-coil (similar to 230 Angstrom, including a contribution from the N-terminal spacer domain) and a collagenous triple helix (similar to 210 Angstrom). The type I molecules also contained a C-terminal globular structure (similar to 58 x 76 Angstrom) composed of three SRCR domains. The fibrous domains were joined by an extremely flexible hinge. The angle between these domains varied from 0 to 180 degrees and depended on the conditions of sample preparation. Unexpectedly, at physiologic pH, the prevalent angle seen using rotary shadowing was 0 degrees, resulting in a structure that is significantly more compact than previously suggested. The apparent juxtaposition of the fibrous domains at neutral pH provides a frame-work for future structure-function studies of these unusual multiligand receptors.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; ARRIS PHARMACEUT CORP, San Francisco, CA 94080 USA; DANA FARBER CANC INST, BOSTON, MA 02115 USA	Massachusetts Institute of Technology (MIT); Harvard University; Dana-Farber Cancer Institute			Krieger, Marco/AAE-8611-2020		NHLBI NIH HHS [HL 52212, HL 33014, HL 41484] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052212, P01HL041484, P01HL033014] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARQUINT M, 1987, P NATL ACAD SCI USA, V84, P600, DOI 10.1073/pnas.84.2.600; ASHKENAS J, 1993, J LIPID RES, V34, P983; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; Cheng H, 1996, ANAT REC, V244, P327; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; EMI M, 1993, J BIOL CHEM, V268, P2120; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; KITAMOTO Y, 1994, P NATL ACAD SCI USA, V91, P7588, DOI 10.1073/pnas.91.16.7588; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KOZARSKY KF, 1986, J CELL BIOL, V102, P1567, DOI 10.1083/jcb.102.5.1567; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LI XJ, 1995, J BIOL CHEM, V270, P17674, DOI 10.1074/jbc.270.30.17674; Lu J, 1993, Behring Inst Mitt, P6; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAITO M, 1991, AM J PATHOL, V139, P1411; NUNES DP, 1995, BIOCHEM J, V310, P41, DOI 10.1042/bj3100041; RESNICK D, 1993, J BIOL CHEM, V268, P3538; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; RESNICK D, 1996, THESIS MIT; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SCHUMAKER VN, 1981, J MOL BIOL, V148, P191, DOI 10.1016/0022-2836(81)90511-8; SLAYTER HS, 1983, ANN NY ACAD SCI, V408, P131, DOI 10.1111/j.1749-6632.1983.tb23241.x; SLAYTER HS, 1976, ULTRAMICROSCOPY, V1, P341, DOI 10.1016/0304-3991(76)90050-4; SLAYTER HS, 1989, METHOD ENZYMOL, V169, P326; SLAYTER HS, 1991, ELECTRON MICROS, P151; SMITH CA, 1984, J ULTRA MOL STRUCT R, V89, P111, DOI 10.1016/S0022-5320(84)80008-8; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; VALENTINE RC, 1968, BIOCHEMISTRY-US, V7, P2143, DOI 10.1021/bi00846a017; WHITNEY GS, 1995, J BIOL CHEM, V270, P18187, DOI 10.1074/jbc.270.31.18187	33	74	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26924	26930		10.1074/jbc.271.43.26924	http://dx.doi.org/10.1074/jbc.271.43.26924			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900177	hybrid			2022-12-25	WOS:A1996VP23300071
J	McMasters, KM; Luna, RMD; Pena, JR; Lozano, G				McMasters, KM; Luna, RMD; Pena, JR; Lozano, G			mdm2 Deletion does not alter growth characteristics of p53-deficient embryo fibroblasts	ONCOGENE			English	Article						G(1) arrest; genomic instability; p53 null cells	WILD-TYPE P53; SOFT-TISSUE SARCOMAS; GENE AMPLIFICATION; MDM2-DEFICIENT MICE; ONCOPROTEIN MDM2; PROTEIN; ABNORMALITIES; LETHALITY; APOPTOSIS; ONCOGENE	The mdma gene encodes a protein that is necessary for the negative regulation of p53 function in vivo. Deletion of the mdm2 gene in mice results in early embryonic death while concomitant mdm2 and p53 deletion results in viable offspring. The viability of these mice prompted us to ask if MDM2, had an important growth regulatory function independent of p53. We established mouse embryo fibroblasts null for both p53 and mdma and compared them with p53-null fibroblasts. The cells did not differ in their growth rates or their ability to bypass a G(1) arrest. Both cell lines formed colonies efficiently when plated at low density and showed a similar degree of genetic instability. Thus, the analysis of several growth parameters indicated no difference between p53-null and p53/mdm2-null cell lines.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL GENET,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT SURG ONCOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA47296] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047296, R29CA047296] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CORDONCARDO C, 1994, CANCER RES, V54, P794; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Godley LA, 1996, GENE DEV, V10, P836, DOI 10.1101/gad.10.7.836; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HARVEY M, 1993, ONCOGENE, V8, P2457; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; LADANYI M, 1993, CANCER RES, V53, P16; LEACH FS, 1993, CANCER RES, V53, P2231; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LUNA RMD, 1995, NATURE, V378, P203; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; QUESNEL B, 1994, EUR J CANCER, V30A, P982, DOI 10.1016/0959-8049(94)90128-7; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SHEIKH MS, 1993, CANCER RES, V53, P3226; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	30	48	49	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1731	1736						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895519				2022-12-25	WOS:A1996VM88700018
J	Arnold, CS; Johnson, GVW; Cole, RN; Dong, DLY; Lee, M; Hart, GW				Arnold, CS; Johnson, GVW; Cole, RN; Dong, DLY; Lee, M; Hart, GW			The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; CYTOPLASMIC PROTEINS; ALZHEIMERS-DISEASE; 67-KDA POLYPEPTIDE; PHOSPHORYLATION; GLYCOSYLATION; NUCLEAR; GLCNAC; PEPTIDE; KINASE	Tau is a family of phosphoproteins that are important in modulating microtubule stability in neurons. In Alzheimer's disease tau is abnormally hyperphosphorylated, no longer binds microtubules, and self-assembles to form paired helical filaments that likely contribute to neuron death. Here we demonstrate that normal bovine tau is multiply modified by Ser(Thr)-O-linked N-acetylglucosamine, a dynamic and abundant post-translational modification that is often reciprocal to Ser(Thr)phosphorylation. O-GlcNAcylation of tau was demonstrated by blotting with succinylated wheat germ agglutinin and by probing with bovine milk beta(1,4)galactosyltransferase. Structural analyses confirm the linkage and the saccharide structure. Tau splicing variants are multiply O-GlcNAcylated at similar sites, with an average stoichiometry of greater than 4 mol of O-linked N-acetylglucosamine/mol of tau. However, the number of sites occupied appears to be greater than 12, suggesting substoichiometric occupancy at any given site. A similar relationship between average stoichiometry and site-occupancy has also been described for the phosphorylation of tau. Site-specific or stoichiometric changes in O-GlcNAcylation may not only modulate tau function but may also play a role in the formation of paired helical filaments.	UNIV ALABAMA, SCH MED, DEPT BIOCHEM & MOL GENET, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH MED, DEPT PSYCHIAT & BEHAV NEUROBIOL, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH DENT, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham			Lee, Michael K/D-9491-2013; Johnson, Gail V.W./K-4723-2012	Lee, Michael K/0000-0001-5865-9682; Johnson, Gail V.W./0000-0003-3464-0404; Hart, Gerald/0000-0001-7812-4351	NATIONAL CANCER INSTITUTE [R01CA042486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027538] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 42486] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM08111-10] Funding Source: Medline; NINDS NIH HHS [R01 NS 27538] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANCHER C, 1991, BRAIN RES, V539, P11, DOI 10.1016/0006-8993(91)90681-K; BRANDT R, 1995, J CELL BIOL, V131, P1327, DOI 10.1083/jcb.131.5.1327; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; DATTA B, 1989, J BIOL CHEM, V264, P20620; DATTA B, 1988, P NATL ACAD SCI USA, V85, P3324, DOI 10.1073/pnas.85.10.3324; Ding M, 1996, J BIOL CHEM, V271, P12555, DOI 10.1074/jbc.271.21.12555; DONG DLY, 1993, J BIOL CHEM, V268, P16679; DONG DLY, 1994, J BIOL CHEM, V269, P19321; DRESCHEL DN, 1992, MOL BIOL CELL, V3, P1141; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; Fleming LM, 1996, EXP NEUROL, V138, P252, DOI 10.1006/exnr.1996.0064; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; Greis KD, 1996, ANAL BIOCHEM, V234, P38, DOI 10.1006/abio.1996.0047; GRIFFITH LS, 1995, J NEUROSCI RES, V41, P270, DOI 10.1002/jnr.490410214; GRIFFITH LS, 1995, BIOCHEM BIOPH RES CO, V213, P424, DOI 10.1006/bbrc.1995.2149; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HART GW, 1995, PURE APPL CHEM, V67, P1637, DOI 10.1351/pac199567101637; HART GW, 1994, ALFRED BENZON SYMP S, V36, P280; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HART GW, 1993, DNA REPLICATION CELL, P91; HART GW, 1987, IN PRESS ANN REV BIO, V66; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HAYES BK, 1995, ANAL BIOCHEM, V228, P115, DOI 10.1006/abio.1995.1322; HAYES BK, 1993, J BIOL CHEM, V268, P16170; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; HOLT GE, 1997, J CELL BIOL, V104, P1157; HUANG CC, 1970, CARBOHYD RES, V13, P127, DOI 10.1016/S0008-6215(00)84902-2; IHARA Y, 1986, J BIOCH, V99, P1087; JOHNSON GVW, 1989, BIOCHEM BIOPH RES CO, V163, P1505, DOI 10.1016/0006-291X(89)91150-9; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KELLY WG, 1993, J BIOL CHEM, V268, P10416; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDESMA MD, 1994, J BIOL CHEM, V269, P26164; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; LOOMIS PA, 1990, P NATL ACAD SCI USA, V87, P8422, DOI 10.1073/pnas.87.21.8422; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTHI T, 1991, J NEUROCHEM, V56, P1493; MEEK JL, 1980, P NATL ACAD SCI-BIOL, V77, P1632, DOI 10.1073/pnas.77.3.1632; MONSIGNY M, 1980, EUR J BIOCHEM, V104, P147, DOI 10.1111/j.1432-1033.1980.tb04410.x; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; ROQUEMORE EP, 1992, J BIOL CHEM, V267, P555; Roquemore EP, 1996, BIOCHEMISTRY-US, V35, P3578, DOI 10.1021/bi951918j; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SCHAFFNER W, 1973, ANAL BIOCHEM, V197, P65; Shaw P, 1996, ONCOGENE, V12, P921; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TORRES CR, 1984, J BIOL CHEM, V259, P3308; Wang JZ, 1996, NAT MED, V2, P871, DOI 10.1038/nm0896-871; Wang XH, 1996, BIOCHEM BIOPH RES CO, V219, P591, DOI 10.1006/bbrc.1996.0278; WATANABE N, 1992, J NEUROCHEM, V58, P960, DOI 10.1111/j.1471-4159.1992.tb09349.x	61	276	295	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28741	28744		10.1074/jbc.271.46.28741	http://dx.doi.org/10.1074/jbc.271.46.28741			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910513	hybrid			2022-12-25	WOS:A1996VT05200005
J	Biscardi, JS; Denhez, F; Buehler, GF; Chesnutt, DA; Baragona, SC; OBryan, JP; Der, CJ; Fiordalisi, JJ; Fults, DW; Maness, PF				Biscardi, JS; Denhez, F; Buehler, GF; Chesnutt, DA; Baragona, SC; OBryan, JP; Der, CJ; Fiordalisi, JJ; Fults, DW; Maness, PF			rek, A gene expressed in retina and brain, encodes a receptor tyrosine kinase of the Axl/Tyro3 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK NEURAL RETINA; GROWTH-FACTOR; NERVOUS-SYSTEM; PROTEIN-S; CHROMOSOMAL LOCALIZATION; MOLECULAR-CLONING; CELL TYPE; PROTOONCOGENE; ONCOGENE; LIGANDS	Rek (retina-expressed kinase) has been identified as a putative novel receptor-type tyrosine kinase of the Axl/Tyro3 family with a potential role in neural cell development, rek clones were isolated from a chick embryonic brain cDNA library with a DNA probe obtained by reverse transcriptase-polymerase chain reaction of mRNA from Muller glia-like cells cultured from chick embryonic retina. Sequence analysis indicated that Rek is a protein of 873 amino acids with an extracellular region composed of two immunoglobulin-like domains followed by two fibronectin type III domains with eight predicted N-glycosylation sites. Two consensus src homology 2 domain binding sites are present in the cytoplasmic domain, suggesting that Rek activates several signal transduction pathways. Northern analysis of rek mRNA revealed a 5.5-kilobase transcript in chick brain, retina, and kidney and in primary cultures of retinal Muller glia-like cells. Rek protein was identified by immunoprecipitation and immunoblotting as a 140-kDa protein expressed in the chick retina at embryonic days 6-13, which corresponded to the major period of neuronal and glial differentiation. Transfection of rek cDNA into COS cells resulted in transient expression of a putative precursor of 106 kDa that autophosphorylated in immune complex protein kinase assays. Overexpression of rek cDNA in mouse NIH3T3 fibroblasts resulted in activation of the 140-kDa rek kinase and induction of morphologically transformed foci. These properties indicated that Rek has oncogenic potential when overexpressed, but its normal function is likely to be related to cell-cell recognition events governing the differentiation or proliferation of neural cells.	UNIV N CAROLINA, SCH MED, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; UNIV UTAH, SCH MED, DEPT NEUROL SURG, SALT LAKE CITY, UT 84132 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Utah System of Higher Education; University of Utah				O'Bryan, John/0000-0001-5386-1080; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA042978] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY008975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026620] Funding Source: NIH RePORTER; NCI NIH HHS [CA42978] Funding Source: Medline; NEI NIH HHS [EY08975] Funding Source: Medline; NINDS NIH HHS [NS26620] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADLER R, 1989, SCIENCE, V243, P391, DOI 10.1126/science.2911751; ADLER R, 1990, METHODS NEUROSCIENCE, V2, P134; ANCHAN RM, 1991, NEURON, V6, P923, DOI 10.1016/0896-6273(91)90233-P; APPEL F, 1993, J NEUROSCI, V13, P4764; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; BISCARDI JS, 1993, EXP EYE RES, V56, P281, DOI 10.1006/exer.1993.1037; BISCARDI JS, 1991, CURR EYE RES, V10, P1121, DOI 10.3109/02713689109024129; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; BRUMMENDORF T, 1993, NEURON, V10, P711; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; DAI W, 1994, ONCOGENE, V9, P975; DEPOMERAI DI, 1982, EXP EYE RES, V34, P553; DEPOMERAI DL, 1982, DEV BRAIN RES, V2, P303; DERYNCK R, 1980, NATURE, V287, P193, DOI 10.1038/287193a0; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOUPE AJ, 1985, J NEUROSCI, V5, P2119; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; FAUST M, 1992, ONCOGENE, V7, P1287; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; INGRAHAM CA, 1992, ONCOGENE, V7, P95; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; KAHN AJ, 1974, DEV BIOL, V38, P30, DOI 10.1016/0012-1606(74)90256-5; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAI C, 1994, ONCOGENE, V9, P2567; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEMMON V, 1986, J NEUROSCI, V6, P43; Lemmon V, 1983, Brain Res, V313, P191; LEWIS GP, 1992, J NEUROSCI, V12, P3968; LI HP, 1984, TISSUE CELL, V16, P843, DOI 10.1016/0040-8166(84)90066-1; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LINSER P, 1983, DEV BIOL, V96, P529, DOI 10.1016/0012-1606(83)90190-2; Maness P.F., 1992, Seminars in Cell Biology, V3, P117; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARK MR, 1994, J BIOL CHEM, V269, P10720; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARU Y, 1990, ONCOGENE, V5, P445; NEWMAN EA, 1986, ASTROCYTES DEV MORPH, V1, P149; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RESCIGNO J, 1991, ONCOGENE, V6, P1909; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAP J, 1994, MOL CELL BIOL, V14, P1; SCHWECHHEIMER K, 1994, HUM PATHOL, V25, P772, DOI 10.1016/0046-8177(94)90246-1; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHORES CG, 1989, J NEUROSCI RES, V24, P59, DOI 10.1002/jnr.490240109; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; STEMPLE DL, 1988, NEURON, V1, P517, DOI 10.1016/0896-6273(88)90182-1; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; SWOFFORD DL, 1993, J GEN PHYSIOL, V102, pA9; Taylor ICA, 1995, ONCOGENE, V11, P2619; TAYLOR ICA, 1995, J BIOL CHEM, V270, P6872, DOI 10.1074/jbc.270.12.6872; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; WIEDEMANN P, 1992, SURV OPHTHALMOL, V36, P373, DOI 10.1016/0039-6257(92)90115-A; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	85	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29049	29059		10.1074/jbc.271.46.29049	http://dx.doi.org/10.1074/jbc.271.46.29049			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910558	hybrid			2022-12-25	WOS:A1996VT05200050
J	Quilliam, LA; Lambert, QT; MickelsonYoung, LA; Westwick, JK; Sparks, AB; Kay, BK; Jenkins, NA; Gilbert, DJ; Copeland, NG; Der, CJ				Quilliam, LA; Lambert, QT; MickelsonYoung, LA; Westwick, JK; Sparks, AB; Kay, BK; Jenkins, NA; Gilbert, DJ; Copeland, NG; Der, CJ			Isolation of a NCK-associated kinase, PRK2, an SH3-binding protein and potential effector of Rho protein signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH SYNDROME; EPIDERMAL GROWTH-FACTOR; C-CBL PROTOONCOGENE; TRANSCRIPTIONAL ACTIVATION; SH3 DOMAINS; MOUSE; GENE; PHOSPHORYLATION; RECEPTORS; CELLS	The NCK adapter protein is comprised of three consecutive Src homology 3 (SH3) protein-protein interaction domains and a C-terminal SH2 domain. Although the association of NCK with activated receptor protein-tyrosine kinases, via its SH2 domain, implicates NCK as a mediator of growth factor-induced signal transduction, little is known about the pathway(s) downstream of NCK. recruitment. To identify potential downstream effecters of NCR we screened a bacterial expression library to isolate proteins that bind its SH3 domains. Two molecules were isolated, the Wiskott-Aldrich syndrome protein (WASP, a putative CDC42 effector) and a serine/threonine protein kinase (PRK2, closely related to the putative Rho effector PKN). Using interspecific backcross analysis the Prk2 gene was mapped to mouse chromosome 3. Unlike WASP, which bound the SH3 domains of several signaling proteins, PRK2 specifically bound to the middle SH3 domain of NCK and (weakly) that of phospholipase C gamma. PRK2 also specifically bound to Rho in a GTP-dependent manner and cooperated with Rho family proteins to induce transcriptional activation via the serum response factor. These data suggest that PRK2 may coordinately mediate signal transduction from activated receptor protein-tyrosine kinases and Rho and that NCK may function as an adapter to connect receptor-mediated events to Rho protein signaling.	INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599; NCI,MAMMALIAN GENET LAB,ABL,BASIC RES PROGRAM,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Quilliam, LA (corresponding author), INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,635 BARNHILL DR,MS 410,INDIANAPOLIS,IN 46202, USA.		Quilliam, Lawrence/B-6447-2015; Quilliam, Lawrence/Q-4987-2019	Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA042978, R01CA052072, R29CA063139] Funding Source: NIH RePORTER; NCI NIH HHS [CA52072, CA63139, CA42978] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; GALANG CK, 1994, ONCOGENE, V9, P2913; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Green EL, 1981, GENETICS PROBABILITY, P77; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HAMEL CP, 1994, GENOMICS, V20, P509, DOI 10.1006/geno.1994.1212; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HU QJ, 1995, MOL CELL BIOL, V15, P1169; HUFF SY, 1997, IN PRESS ONCOGENE; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; LANE PW, 1992, J HERED, V83, P315, DOI 10.1093/oxfordjournals.jhered.a111221; LANE PW, 1972, J HERED, V63, P135, DOI 10.1093/oxfordjournals.jhered.a108252; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P8978; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RemoldODonnell E, 1996, BLOOD, V87, P2621, DOI 10.1182/blood.V87.7.2621.bloodjournal8772621; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WESTWICK JK, 1995, METHOD ENZYMOL, V255, P342; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	43	136	141	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28772	28776		10.1074/jbc.271.46.28772	http://dx.doi.org/10.1074/jbc.271.46.28772			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910519	hybrid, Green Published			2022-12-25	WOS:A1996VT05200011
J	Campos, M; Fadden, P; Alms, G; Qian, ZD; Haystead, TAJ				Campos, M; Fadden, P; Alms, G; Qian, ZD; Haystead, TAJ			Identification of protein phosphatase-1-binding proteins by microcystin-biotin affinity chromatography	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; LIGHT-CHAIN PHOSPHATASE; KINASE-II-BETA; SMOOTH-MUSCLE; REGULATORY SUBUNIT; CELLULAR-REGULATION; MOLECULAR-CLONING; CATALYTIC SUBUNIT; BINDING SUBUNIT; GLYCOGEN	Biotinylated microcystin was used to affinity purify over avidin-Sepharose the entire cellular content of active forms of protein phosphatase (PP) 1 and 2A holoenzymes present in three subcellular fractions of skeletal muscle. Biotinylated microcystin displayed IC,, values in the nM range against PP-1C (1.58 +/- 0.61 nM S.E., n = 3), PP-2AC (0.63 +/- 0.2 nM S.E., n = 3) and SMPP-1M (5.9 +/- 1.3 S.E., n = 3). Subsequent anion-exchange chromatography and SDS-polyacrylamide gel electrophoresis of the microcystin-biotin eluates of the three fractions revealed a complex pattern of proteins associated with PP-1C and PP-2AC, Far Western analysis and the rebinding interaction with recombinant PP-1C distinguished proteins in the eluates that bound PP-1C from those that bound PP-2AC. In Far Western analysis, 29 distinct proteins were identified to bind PP-1C, Significantly, these same proteins, plus seven others, were also recovered fi om the isothiocyanate eluates from microcystin-Sepharose by a rebinding interaction with PP-1C-microcystin-biotin. The number of proteins and range of novel molecular masses (18-125 kDa) identified to interact with PP-1C by these two techniques cannot be accounted for by the previously characterized subunits of PP-1. Our findings further support the concept that PP-1C is regulated in vivo by multiple and distinct substrate-targeting subunits.	UNIV VIRGINIA, HLTH SCI CTR, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, MARKEY CTR CELL SIGNALING, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NHLBI NIH HHS [P01 HL19242-20] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AITKEN A, 1982, EUR J BIOCHEM, V126, P235, DOI 10.1111/j.1432-1033.1982.tb06771.x; ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; CHEN YH, 1994, FEBS LETT, V356, P51, DOI 10.1016/0014-5793(94)01231-8; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; Haystead CMM, 1995, FEBS LETT, V377, P123, DOI 10.1016/0014-5793(95)01318-0; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; HIRAGA A, 1986, EUR J BIOCHEM, V161, P763, DOI 10.1111/j.1432-1033.1986.tb10505.x; HIRANO K, 1995, J BIOL CHEM, V270, P19786, DOI 10.1074/jbc.270.34.19786; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HUBBARD MJ, 1990, EUR J BIOCHEM, V189, P243, DOI 10.1111/j.1432-1033.1990.tb15483.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P701, DOI 10.1111/j.1432-1033.1989.tb15263.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Ichikawa K, 1996, J BIOL CHEM, V271, P4733; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MACKINTOSH RW, 1995, FEBS LETT, V371, P236, DOI 10.1016/0014-5793(95)00888-G; MOORHEAD G, 1994, FEBS LETT, V356, P46, DOI 10.1016/0014-5793(94)01232-6; MOORHEAD G, 1995, FEBS LETT, V362, P101, DOI 10.1016/0014-5793(95)00197-H; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; RUNNEGAR M, 1995, BIOCHEM BIOPH RES CO, V216, P162, DOI 10.1006/bbrc.1995.2605; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P3; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; STEWART AA, 1981, EUR J BIOCHEM, V115, P197; STRSLFORS P, 1985, EUR J BIOCH A, V149, P295; TANG PM, 1991, J BIOL CHEM, V266, P15782; TRINKLEMULCAHY L, 1995, J BIOL CHEM, V270, P18191, DOI 10.1074/jbc.270.31.18191; WU J, 1992, BIOCHEM J, V285, P701, DOI 10.1042/bj2850701	46	68	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28478	28484		10.1074/jbc.271.45.28478	http://dx.doi.org/10.1074/jbc.271.45.28478			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910475	hybrid			2022-12-25	WOS:A1996VU03300075
J	Kolodziej, SJ; Penczek, PA; Schroeter, JP; Stoops, JK				Kolodziej, SJ; Penczek, PA; Schroeter, JP; Stoops, JK			Structure-function relationships of the Saccharomyces cerevisiae fatty acid synthase - Three-dimensional structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYOELECTRON MICROSCOPY; RIBOSOMAL-SUBUNITS; ESCHERICHIA-COLI; 3-DIMENSIONAL RECONSTRUCTION; NUCLEOTIDE-SEQUENCE; NEGATIVE-STAIN; LOW-RESOLUTION; FAS1 GENE; YEAST; SYNTHETASE	The three-dimensional structure of the Saccharomyces cerevisie fatty acid synthase was computed from electron microscopy of stain images. The barrel-shaped structure (point group symmetry 32) has major and minor axes of similar to 245 x 220 Angstrom respectively, and consists of two different subunits organized in an alpha(6) beta(6) complex (M(r) = 2.5 x 10(6)). Two sets of three beta subunits form triangle-shaped caps that enclose the ends of the barrel. The wall of the barrel appears to consist of three N-shaped alpha subunit pairs each with an over and underlying arch-shaped beta subunit. Inside the molecule there are three major interconnected cavities that are tilted similar to 20 degrees with respect to its major axis. An axle-shaped structure extends the length of the cavity on the 3-fold axis and is connected to the two ends of the barrel, The cavities are partially divided on the equator of the molecule by three spokes that extend hom the axle on the 2-fold axis to the exterior wall. We propose that these six cavities constitute the six equivalent sites of fatty acid synthesis resulting in an extraordinary structure-function relationship with the 42 catalytic sites involved in fatty acid synthesis inside the molecule. The six cavities each have two funnel-shaped openings (similar to 20 Angstrom in diameter) which may serve to permit the diffusion of substrates and products in and out of these functional units. The subunits appear to be arranged in a manner that affords extensive intermolecular interactions contributing to the stability of this macromolecular complex.	UNIV TEXAS, HLTH SCI CTR, DEPT PATHOL & LAB MED, HOUSTON, TX 77030 USA; NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, ALBANY, NY 12201 USA	University of Texas System; University of Texas Health Science Center Houston; State University of New York (SUNY) System; Wadsworth Center					NIGMS NIH HHS [GM 29169, GM 46278] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029169, R01GM029169, R01GM046278] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; CARAZO JM, 1989, BIOPHYS J, V55, P465, DOI 10.1016/S0006-3495(89)82840-1; CHIRALA SS, 1987, J BIOL CHEM, V262, P4231; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; FRANK J, 1981, SCIENCE, V214, P1353, DOI 10.1126/science.7313694; Frank J., 1996, 3 DIMENSIONAL ELECT, Ved, ppp 54; FRANK J, 1985, NEW METHODOLOGIES ST, P36; HACKENJOS WA, 1987, BIOL CHEM H-S, V368, P19, DOI 10.1515/bchm3.1987.368.1.19; HESSLER D, 1992, MICROSCOPY KEY RES T, P73; HOPPE W, 1976, Z NATURFORSCH A, V31, P1380; Kolodziej SJ, 1996, J STRUCT BIOL, V116, P366, DOI 10.1006/jsbi.1996.0054; LYNEN F, 1980, EUR J BIOCHEM, V112, P431; MOHAMED AH, 1988, J BIOL CHEM, V263, P12315; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; Schroeter JP, 1996, J STRUCT BIOL, V116, P131, DOI 10.1006/jsbi.1996.0021; SCHWEIZER E, 1987, FETT WISS TECHNOL, V89, P570; SCHWEIZER E, 1984, NEW COMPR BIOCH, V7, P59; SCHWEIZER M, 1986, MOL GEN GENET, V203, P479, DOI 10.1007/BF00422073; SINGH N, 1985, BIOCHEMISTRY-US, V24, P6598, DOI 10.1021/bi00344a044; STOFFLERMEILICKE M, 1988, METHOD ENZYMOL, V164, P503; STOOPS JK, 1992, J BIOL CHEM, V267, P24769; STOOPS JK, 1978, BIOCHEM BIOPH RES CO, V84, P225, DOI 10.1016/0006-291X(78)90286-3; STOOPS JK, 1981, J BIOL CHEM, V256, P8364; STOOPS JK, 1980, P NATL ACAD SCI-BIOL, V77, P4544, DOI 10.1073/pnas.77.8.4544; STOOPS JK, 1992, P NATL ACAD SCI USA, V89, P6585, DOI 10.1073/pnas.89.14.6585; STOOPS JK, 1990, J BIOL CHEM, V265, P16971; STOOPS JK, 1978, J BIOL CHEM, V253, P4464; STOOPS JK, 1979, J BIOL CHEM, V254, P7418; STOOPS JK, 1991, J ELECTRON MICR TECH, V18, P157, DOI 10.1002/jemt.1060180210; UNSER M, 1987, ULTRAMICROSCOPY, V23, P39, DOI 10.1016/0304-3991(87)90225-7; VANHEEL M, 1985, EMBO J, V4, P2389, DOI 10.1002/j.1460-2075.1985.tb03944.x; WIELAND F, 1978, P NATL ACAD SCI USA, V75, P5792, DOI 10.1073/pnas.75.12.5792; WIELAND F, 1979, EUR J BIOCHEM, V94, P189, DOI 10.1111/j.1432-1033.1979.tb12885.x	34	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28422	28429		10.1074/jbc.271.45.28422	http://dx.doi.org/10.1074/jbc.271.45.28422			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910467	hybrid			2022-12-25	WOS:A1996VU03300067
J	AbdAlla, S; Jarnagin, K; MullerEsterl, W; Quitterer, U				AbdAlla, S; Jarnagin, K; MullerEsterl, W; Quitterer, U			The N-terminal amino group of [Tyr(8)]bradykinin is bound adjacent to analogous amino acids of the human and rat B-2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST BINDING-SITE; NEUROKININ-1 RECEPTOR; EXTRACELLULAR DOMAIN; BRADYKININ RECEPTOR; B2 RECEPTOR; IDENTIFICATION; ANTAGONIST; RESIDUES; AFFINITY; POLYACRYLAMIDE	To obtain data of the bradykinin B-2 receptor's agonist binding site, Ne used a combined approach of affinity labeling and ''immunoidentification'' of receptor fragments generated by cyanogen bromide cleavage. Domain-specific antibodies to the various extracellular receptor domains mere applied to detect receptor fragments with covalently attached [I-125-Tyr(8)]bradykinin, As a cross-linker we used the homobifunctional reagent disuccinimidyl tartarate (DST), which reacts preferentially with primary amines, With this technique a [I-125-Tyr(8)]bradykinin-labeled receptor fragment derived from the third extracellular domain was identified. The epsilon-amino group of lysine (Lys(172)) of the human B-2 receptor provides the only primary amino group within this receptor fragment. This strongly suggests that DST attached the N-terminal amino group of [Tyr(8)]bradykinin to Lys(172) of the human B-2 receptor, Next me asked whether DST attaches [Tyr(8)]bradykinin to the analogous residue, Lys(174) of the rat B-2 receptor, which is 81% identical to the human B-2 receptor, and we attempted to label the wild-type rat B-2 receptor and a rat B-2 receptor mutant where Lys(174) had been exchanged for alanine. Affinity labeling of the wild-type rat B-2 receptor worked efficiently, whereas DST did not attach detectable amounts of [I-125-Tyr(8)]bradykinin to the K174A rat B-2 receptor mutant, Taken together these observations indicate that the N-terminal amino group of [Tyr(8)]bradykinin is bound to analogous positions of the rat and of the human B-2 receptor, i.e. [Tyr(8)]bradykinin's N terminus is bound adjacent to Lys(172) of the human and Lys(174) of the rat B-2 receptor.	UNIV WURZBURG,INST PHARMACOL & TOXICOL,D-97078 WURZBURG,GERMANY; UNIV MAINZ,INST PHYSIOL CHEM & PATHOBIOCHEM,D-55099 MAINZ,GERMANY; ROCHE BIOSCI,INFLAMMATORY DIS UNIT,PALO ALTO,CA 94304	University of Wurzburg; Johannes Gutenberg University of Mainz; Roche Holding								Abd Alla S., 1996, J BIOL CHEM, V271, P1748; AbdAlla S, 1996, BIOCHEMISTRY-US, V35, P7514, DOI 10.1021/bi9601060; ABDALLA S, 1993, J BIOL CHEM, V268, P17277; BURCH RM, 1993, MOL BIOL PHARM BRADY, P81; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GALZI JL, 1990, J BIOL CHEM, V265, P10430; HERWALD H, 1993, J BIOL CHEM, V268, P14527; HERZIG MCS, 1995, J BIOL CHEM, V270, P20591, DOI 10.1074/jbc.270.35.20591; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; HUDGIN RL, 1974, J BIOL CHEM, V249, P5536; KOJRO E, 1993, BIOCHEMISTRY-US, V32, P13537, DOI 10.1021/bi00212a020; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; KYLE DJ, 1994, J MED CHEM, V37, P1347, DOI 10.1021/jm00035a015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONG SR, 1994, J BIOL CHEM, V269, P19343; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4417, DOI 10.1073/pnas.91.10.4417; NOVOTNY EA, 1994, BIOCHEM BIOPH RES CO, V201, P523, DOI 10.1006/bbrc.1994.1733; QUITTERER U, 1995, J BIOL CHEM, V270, P1992, DOI 10.1074/jbc.270.5.1992; ROSCHER AA, 1983, J CLIN INVEST, V72, P626, DOI 10.1172/JCI111012; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; WIRTH K, 1991, BRIT J PHARMACOL, V102, P774, DOI 10.1111/j.1476-5381.1991.tb12249.x; ZHAO LJ, 1993, METHOD ENZYMOL, V217, P218	30	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27382	27387		10.1074/jbc.271.44.27382	http://dx.doi.org/10.1074/jbc.271.44.27382			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910316	hybrid			2022-12-25	WOS:A1996VQ67900034
J	Araujo, F; Tan, S; Ruano, D; Schoemaker, H; Benavides, J; Vitorica, J				Araujo, F; Tan, S; Ruano, D; Schoemaker, H; Benavides, J; Vitorica, J			Molecular and pharmacological characterization of native cortical gamma-aminobutyric acid(A) receptors containing both alpha(1) and alpha(3) subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA-A RECEPTORS; RAT CEREBRAL-CORTEX; BENZODIAZEPINE RECEPTORS; MONOCLONAL-ANTIBODIES; ALCOHOL ANTAGONIST; MESSENGER-RNAS; BINDING-SITES; BRAIN; SUBTYPES; COMPLEX	We have investigated the existence, molecular composition, and benzodiazepine binding properties of native cortical alpha(1)-alpha(3) gamma-aminobutyric acid(A) (GABA(A)) receptors using subunit-specific antibodies. The co-existence of alpha(1) and alpha(3) subunits in native GABA(A) receptors was demonstrated by immunoblot analysis of the anti-alpha(1)- or anti-alpha(3)-immunopurified receptors and by immunoprecipitation experiments of the [H-3]zolpidem binding activity. Furthermore, immunodepletion experiments indicated that the alpha(1)-alpha(3) GABA(A) receptors represented 54.7 +/- 5.0 and 23.6 +/- 3.3% of the alpha(3) and alpha(1) populations, respectively. Therefore, alpha(1) and alpha(3) subunits are associated in the same native GABA(A) receptor complex, but, on the other hand, these alpha(1)-alpha(3) GABA(A) receptors from the cortex constitute a large proportion of the total alpha(3) population and a relatively minor component of the alpha(1) population. The pharmacological analysis of the alpha(1)- or alpha(3)-immunopurified receptors demonstrated the presence of two different benzodiazepine binding sites in each receptor population with high (type I binding sites) and low (type II binding sites) affinities for zolpidem and CI 218,872. These results indicate the existence of native GABA(A) receptors possessing both alpha(1) and alpha(3) subunits, with alpha(1) and ag subunits expressing their characteristic benzodiazepine pharmacology. The molecular characterization of the anti-alpha(1)-anti-alpha(3) double-immunopurified receptors demonstrated the presence of stoichiometric amounts of alpha(1) and alpha(3) subunits, associated with beta(2/3), and gamma(2) subunits. The pharmacological analysis of alpha(1)-alpha(3) GABA(A) receptors demonstrated that, despite the fact that each alpha subunit retained its benzodiazepine binding properties, the relative proportion between type I and II binding sites or between 51- and 59-61-kDa [H-3]Ro15-4513-photolabeled peptides was 70:30. Therefore, the alpha(1) subunit is pharmacologically predominant over the alpha(3) subunit. These results indicate the existence of active and nonactive alpha subunits in the native alpha(1)-alpha(3) GABA(A) receptors from rat cortex.	UNIV SEVILLA,FAC FARM,DEPT BIOQUIM BROMATOL & TOXICOL,SEVILLE 41012,SPAIN; SYNTHELABO RECH,CENT NERVOUS SYST RES DEPT,F-92225 BAGNEUX,FRANCE	University of Sevilla; Sanofi-Aventis; Sanofi France			Araujo, Francisco/ABC-6873-2020; IBIS, ALZHEIMER/O-9867-2015; CABALLERO, DIEGO RUANO/I-4471-2014	CABALLERO, DIEGO RUANO/0000-0001-6131-3033; Vitorica Ferrandez, Javier/0000-0002-0641-7902; Araujo, Francisco/0000-0001-5737-2938				ARBILLA S, 1986, EUR J PHARMACOL, V130, P257, DOI 10.1016/0014-2999(86)90276-1; BACKUS KH, 1993, NEUROREPORT, V5, P285, DOI 10.1097/00001756-199312000-00026; BENAVIDES J, 1993, BRAIN RES, V604, P240, DOI 10.1016/0006-8993(93)90375-W; BENAVIDES J, 1988, J PHARMACOL EXP THER, V245, P1033; BENKE D, 1994, J BIOL CHEM, V269, P27100; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; DUGGAN MJ, 1991, J BIOL CHEM, V266, P24778; DUGGAN MJ, 1992, J NEUROCHEM, V58, P72, DOI 10.1111/j.1471-4159.1992.tb09278.x; EBERT B, 1994, MOL PHARMACOL, V46, P957; ENDO S, 1993, J NEUROCHEM, V60, P1388, DOI 10.1111/j.1471-4159.1993.tb03300.x; EWERT M, 1992, BRAIN RES, V569, P57, DOI 10.1016/0006-8993(92)90368-J; FRITSCHY JM, 1995, J COMP NEUROL, V359, P154, DOI 10.1002/cne.903590111; IM WB, 1995, J BIOL CHEM, V270, P26063, DOI 10.1074/jbc.270.44.26063; ITEM C, 1994, J NEUROCHEM, V63, P1119; KHAN ZU, 1994, J NEUROCHEM, V63, P1466; Khan ZU, 1996, J NEUROCHEM, V66, P685; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER SZ, 1988, PHARMACOL BIOCHEM BE, V29, P763, DOI 10.1016/0091-3057(88)90202-X; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUDDENS H, 1990, NATURE, V346, P648, DOI 10.1038/346648a0; MCKERNAN RM, 1991, NEURON, V7, P667, DOI 10.1016/0896-6273(91)90379-E; MERTENS S, 1993, J BIOL CHEM, V268, P5965; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NIELSEN M, 1980, NATURE, V286, P606, DOI 10.1038/286606a0; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PARK D, 1991, J NEUROCHEM, V56, P1962, DOI 10.1111/j.1471-4159.1991.tb03454.x; POLLARD S, 1995, J BIOL CHEM, V270, P21285, DOI 10.1074/jbc.270.36.21285; POLLARD S, 1993, J BIOL CHEM, V268, P3753; PRITCHETT DB, 1990, J NEUROCHEM, V54, P1802, DOI 10.1111/j.1471-4159.1990.tb01237.x; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; QUIRK K, 1994, J BIOL CHEM, V269, P16020; QUIRK K, 1994, MOL PHARMACOL, V45, P1061; RUANO D, 1991, J PHARMACOL EXP THER, V256, P902; RUANO D, 1993, EUR J PHARM-MOLEC PH, V246, P81, DOI 10.1016/0922-4106(93)90013-Y; RUANO D, 1994, EUR J PHARM-MOLEC PH, V267, P123, DOI 10.1016/0922-4106(94)90233-X; RUANO D, 1994, MOL BRAIN RES, V25, P225, DOI 10.1016/0169-328X(94)90157-0; RUANO D, 1993, BRAIN RES, V600, P134, DOI 10.1016/0006-8993(93)90411-F; RUANO D, 1992, J NEUROCHEM, V58, P485, DOI 10.1111/j.1471-4159.1992.tb09747.x; SIEGHART W, 1995, PHARMACOL REV, V47, P181; SIEGHART W, 1987, J NEUROCHEM, V48, P46, DOI 10.1111/j.1471-4159.1987.tb13125.x; SQUIRES RF, 1984, HDB NEUROCHEMISTRY, V6, P261; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; TALLMAN JF, 1985, ANNU REV NEUROSCI, V8, P21, DOI 10.1146/annurev.ne.08.030185.000321; TURNER DM, 1991, J PHARMACOL EXP THER, V257, P1236; VERDOORN TA, 1994, MOL PHARMACOL, V45, P475; VITORICA J, 1990, J NEUROCHEM, V54, P187, DOI 10.1111/j.1471-4159.1990.tb13300.x; VITORICA J, 1988, J NEUROSCI, V8, P615; WISDEN W, 1992, J NEUROSCI, V12, P1040	51	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27902	27911		10.1074/jbc.271.44.27902	http://dx.doi.org/10.1074/jbc.271.44.27902			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910390	hybrid			2022-12-25	WOS:A1996VQ67900108
J	Cai, K; Schirch, V				Cai, K; Schirch, V			Structural studies on folding intermediates of serine hydroxymethyltransferase using fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ASPARTATE-AMINOTRANSFERASE; PYRIDOXAL 5'-PHOSPHATE; REACTION SPECIFICITY; TRYPTOPHAN SYNTHASE; RESIDUE; ENZYMES; ORIGIN	Previous studies have demonstrated that the in vitro folding pathway of Escherichia coli serine hydroxymethyltransferase has both monomer and dimer intermediates that are stable for periods of minutes to hours at 4 degrees C (Cai K., Schirch, D., and Schirch, V. (1995) J. Biol. Chem, 270, 19294-19299), Single Trp mutant enzymes were constructed and used in combination with other methods to show that on the folding pathway of this enzyme two domains rapidly fold to form a monomer in which the amino-terminal 55 amino acid residues and a segment around the active site region of Lys(229) remain in a largely disordered form, This partially folded enzyme can form dimers and slowly undergoes a rate-determining conformational change in which the unstructured segments assume their native state (Cai, K., and Schirch, V. (1996) J. Biol. Chem. 271, 2987-2994), To further assess the kinetics and structural details of the intermediates during folding, fluorescence energy transfer and fluorescence anisotropy measurements were made of the three Trp residues and pyridoxal 5'-phosphate, attached covalently to the active site by reduction to a secondary amine by sodium cyanoborohydride, These studies confirmed that the basic kinetic folding pathway remained the same in the reduced enzyme as compared to the earlier studies with the apoenzyme, Both equilibrium and kinetic intermediates were identified and their structural characteristics determined, The results show that the active site Lys(229)-bound pyridoxyl 5'-phosphate remains more than 50 angstroms from any Trp residues until the final rate-determining conformational change when it approaches each Trp residue at the same rate, The environment of each Trp residue and the pyridoxyl phosphate in both an equilibrium folding intermediate and a kinetic folding intermediate are described.	VIRGINIA COMMONWEALTH UNIV,DEPT BIOCHEM & MOL BIOPHYS,RICHMOND,VA 23298	Virginia Commonwealth University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028143] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28143] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; ANGELACCIO S, 1992, BIOCHEMISTRY-US, V31, P155, DOI 10.1021/bi00116a023; BLOND S, 1986, Proteins Structure Function and Genetics, V1, P247, DOI 10.1002/prot.340010307; Cai K, 1996, J BIOL CHEM, V271, P2987, DOI 10.1074/jbc.271.6.2987; CAI K, 1995, J BIOL CHEM, V270, P19294, DOI 10.1074/jbc.270.33.19294; CHAFFOTTE AF, 1983, BIOCHEMISTRY-US, V22, P2708, DOI 10.1021/bi00280a019; CHEN R F, 1967, Analytical Letters, V1, P35; CUPO JF, 1983, BIOCHEMISTRY-US, V22, P2654, DOI 10.1021/bi00280a010; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; HEROLD M, 1991, BIOCHEMISTRY-US, V30, P3612, DOI 10.1021/bi00229a004; LAKOWICZ JR, 1994, PROTEIN SCI, V3, P628; LEISTLER B, 1992, EUR J BIOCHEM, V205, P603, DOI 10.1111/j.1432-1033.1992.tb16818.x; MATTHEWS CR, 1981, BIOCHEMISTRY-US, V20, P784, DOI 10.1021/bi00507a021; NATH U, 1995, BIOCHEMISTRY-US, V34, P1702, DOI 10.1021/bi00005a027; PACE CN, 1975, CRIT REV BIOCH, V3, P11; PASCARELLA S, 1993, FEBS LETT, V331, P145, DOI 10.1016/0014-5793(93)80314-K; PLAMANN MD, 1983, NUCLEIC ACIDS RES, V11, P2065, DOI 10.1093/nar/11.7.2065; SCHIRCH LVG, 1963, J BIOL CHEM, V238, P1032; SCHIRCH V, 1985, J BACTERIOL, V163, P1; SCHIRCH V, 1991, J BIOL CHEM, V266, P759; SCHMID XF, 1992, PROTEIN FOLDING, P203; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; STOVER P, 1992, J BIOL CHEM, V267, P17679; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; T Forster, 1965, MODERN QUANTUM CHEMI, VIII, P93; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134	26	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27311	27320		10.1074/jbc.271.44.27311	http://dx.doi.org/10.1074/jbc.271.44.27311			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910307	hybrid			2022-12-25	WOS:A1996VQ67900025
J	PedrazaAlva, G; Merida, LB; Burakoff, SJ; Rosenstein, Y				PedrazaAlva, G; Merida, LB; Burakoff, SJ; Rosenstein, Y			CD43-specific activation of T cells induces association of CD43 to Fyn kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH SYNDROME; PHOSPHATIDYLINOSITOL 3-KINASE; SURFACE SIALOGLYCOPROTEIN; SIALOPHORIN; ANTIGEN; RECEPTOR; BINDING; DOMAIN; PHOSPHORYLATION; PROLIFERATION	CD43, the most abundant membrane protein of T lymphocytes, is able to initiate signal transduction pathways that lead to Ca2+ mobilization and interleukin-2 production, yet the molecular events involved in CD43's signal transduction pathway are poorly understood. In the present report we show that: activation of both purified T lymphocytes and Jurkat cells, through CD43 cross-linking with the anti-CD43 L10 monclonal antibody, induced CD43 association to Fyn kinase, This association is mediated by the Sre Homology 3 (SH3) domain of Fyn, since a glutathione S-transferase-Fyn SH3 fusion protein was able to precipitate CD43 from lysates of CD43-activated T cells. A synthetic peptide containing the SH3 binding sites of p85, located within the amino acid sequence (300)ERQPAPALPPKPPKP(314) was able to inhibit binding of CD43 to Fyn as well as to the glutathione S-transferase-Fyn SH3 fusion protein. We also provide evidence that upon CD48 cross-linking Fyn is tyrosine-phosphorylated in a time-dependent manner. Our results suggest that CD43 cross-linking on the T cell surface induces the interaction between CD43 and Fyn, presumably through the Fyn SH3 domain and a putative SH3 binding site in CD43, leading to Fyn tyrosine phosphorylation and signal propagation.	UNIV NACL AUTONOMA MEXICO, INST BIOTECHNOL, CUERNAVACA 62250, MORELOS, MEXICO; DANA FARBER CANC INST, BOSTON, MA 02115 USA	Universidad Nacional Autonoma de Mexico; Harvard University; Dana-Farber Cancer Institute								ALVARADO M, 1995, EUR J IMMUNOL, V25, P1051, DOI 10.1002/eji.1830250429; AXELSSON B, 1985, EUR J IMMUNOL, V15, P427, DOI 10.1002/eji.1830150503; AXELSSON B, 1988, J IMMUNOL, V141, P2912; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; BORCHE L, 1987, EUR J IMMUNOL, V17, P1523, DOI 10.1002/eji.1830171023; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; HAHN WC, 1992, P NATL ACAD SCI USA, V89, P7179, DOI 10.1073/pnas.89.15.7179; HUTCHCROFT JE, 1995, P NATL ACAD SCI USA, V92, P8808, DOI 10.1073/pnas.92.19.8808; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; MENTZER SJ, 1987, J EXP MED, V165, P1383, DOI 10.1084/jem.165.5.1383; PARK JK, 1991, NATURE, V350, P706, DOI 10.1038/350706a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEREZ L, 1995, VIROLOGY, V208, P26, DOI 10.1006/viro.1995.1126; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PILLER F, 1991, J EXP MED, V173, P1501, DOI 10.1084/jem.173.6.1501; PILLER F, 1988, J BIOL CHEM, V263, P15146; PILLER V, 1989, J BIOL CHEM, V264, P18824; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; REMOLDODONNELL E, 1987, BLOOD, V70, P104; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; Rosenstein Yvonne, 1993, P249; SHIOTA J, 1994, CELL IMMUNOL, V155, P402, DOI 10.1006/cimm.1994.1133; SILVERMAN LB, 1989, J IMMUNOL, V142, P4194; SPERLING AI, 1995, J EXP MED, V182, P139, DOI 10.1084/jem.182.1.139; TOMLINSON JA, 1994, J IMMUNOL, V153, P3426; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WONG RCK, 1990, J IMMUNOL, V144, P1455; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	30	60	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27564	27568		10.1074/jbc.271.44.27564	http://dx.doi.org/10.1074/jbc.271.44.27564			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910342	hybrid			2022-12-25	WOS:A1996VQ67900060
J	Yogalingam, G; Litjens, T; Bielicki, J; Crawley, AC; Muller, V; Anson, DS; Hopwood, JJ				Yogalingam, G; Litjens, T; Bielicki, J; Crawley, AC; Muller, V; Anson, DS; Hopwood, JJ			Feline mucopolysaccharidosis type VI - Characterization of recombinant N-acetylgalactosamine 4-sulfatase and identification of a mutation causing the disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARYLSULFATASE-B; FULL-LENGTH CDNA; ENZYME; N-ACETYLGALACTOSAMINE-4-SULFATASE; PURIFICATION; FIBROBLASTS; EXPRESSION; DIAGNOSIS; SULFATASE; THERAPY	Mucopolysaccharidosis type VI (RIPS VI) is an autosomal recessive disease caused by a deficiency of N-acetylgalactosamine 4-sulfatase (4S) leading to the lysosomal accumulation and urinary excretion of dermatan sulfate, RIPS VI has also been described in the Siamese cat, As an initial step toward enzyme replacement therapy with recombinant feline 4S (rf4S) in RIPS VI cats, the feline 4S cDNA was isolated and expressed in CHO-KI cells and rf4S was immunopurified from the culture medium. SDS-polyacrylamide gel electrophoresis analysis showed that the precursor form of immunopurified rf4S was a 66-kDa polypeptide that underwent maturation to a 43-44-kDa polypeptide. Endocytosis of rf4S by cultured feline RIPS VI myoblasts was predominantly mediated by a mannose g-phosphate receptor and resulted in the correction of dermatan sulfate storage, The mutation causing feline MPS VI was identified as a base substitution at codon 476, altering a leucine codon to a proline (L476P), The L476P allele displayed no detectable 45 activity when expressed in CHO-KI. cells and was observed only as a ''precursor'' polypeptide that was not secreted into the medium, Identification of the mutation has allowed the development of a rapid PCR-based screening method to genotype individuals within the cat colony.	WOMENS & CHILDRENS HOSP,DEPT CHEM PATHOL,LYSOSOMAL DIS RES UNIT,ADELAIDE,SA 5006,AUSTRALIA	Womens & Childrens Hospital Australia								ANSON DS, 1992, BIOCHEM J, V284, P789, DOI 10.1042/bj2840789; BAUDHUIN P, 1964, LAB INVEST, V13, P1139; BIELICKI J, 1991, BIOCHEM J, V279, P515, DOI 10.1042/bj2790515; BOUGHARIOS G, 1993, HISTOCHEM J, V25, P593, DOI 10.1007/BF00157873; BROOKS DA, 1990, J INHERIT METAB DIS, V13, P108, DOI 10.1007/BF01799338; BROOKS DA, 1991, J INHERIT METAB DIS, V14, P5, DOI 10.1007/BF01804381; BROOKS DA, 1994, BIOCHEM MED METAB B, V53, P58, DOI 10.1006/bmmb.1994.1058; BROOKS DA, 1991, AM J HUM GENET, V48, P710; CHANG PL, 1988, EXP CELL RES, V176, P258, DOI 10.1016/0014-4827(88)90329-1; Crawley AC, 1996, J CLIN INVEST, V97, P1864, DOI 10.1172/JCI118617; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; FRIEDMANN T, 1972, SCIENCE, V175, P949, DOI 10.1126/science.175.4025.949; GIBSON GJ, 1987, BIOCHEM J, V248, P755, DOI 10.1042/bj2480755; HASKINS ME, 1979, PEDIATR RES, V13, P1203, DOI 10.1203/00006450-197911000-00001; HOPWOOD JJ, 1986, BIOCHEM J, V234, P507, DOI 10.1042/bj2340507; HOPWOOD JJ, 1990, MOL BIOL MED, V7, P381; HUARD J, 1994, HUM GENE THER, V5, P949, DOI 10.1089/hum.1994.5.8-949; JACKSON CE, 1992, GENOMICS, V14, P403, DOI 10.1016/S0888-7543(05)80233-2; KAMPINE JP, 1966, SCIENCE, V155, P86; KOBAYASHI T, 1992, BIOCHIM BIOPHYS ACTA, V1159, P243, DOI 10.1016/0167-4838(92)90051-E; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEABACK DH, 1961, BIOCHEM J, V78, P151, DOI 10.1042/bj0780151; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCEWEN JE, 1994, AM J HUM GENET, V55, P196; MCGOVERN MM, 1982, J BIOL CHEM, V257, P2605; Neufeld EF, 1995, METABOLIC MOL BASES, P2465; PETERS C, 1990, J BIOL CHEM, V265, P3374; SCHUCHMAN EH, 1990, GENOMICS, V6, P149, DOI 10.1016/0888-7543(90)90460-C; TOMATSU S, 1991, BIOCHEM BIOPH RES CO, V181, P677, DOI 10.1016/0006-291X(91)91244-7; UNGER EG, 1994, BIOCHEM J, V304, P43, DOI 10.1042/bj3040043; VINE DT, 1981, AM J HUM GENET, V33, P916	32	59	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27259	27265		10.1074/jbc.271.44.27259	http://dx.doi.org/10.1074/jbc.271.44.27259			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910299	hybrid			2022-12-25	WOS:A1996VQ67900017
J	Keely, PJ; Parise, LV				Keely, PJ; Parise, LV			The alpha(2)beta(1) integrin is a necessary co-receptor for collagen-induced activation of Syk and the subsequent phosphorylation of phospholipase C gamma 2 in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE P72(SYK); MEDIATED CELL-ADHESION; GLYCOPROTEIN-IIB-IIIA; FC-GAMMA-RII; SIGNAL-TRANSDUCTION; DEPENDENT ADHESION; CA2+ MOBILIZATION; EXTRACELLULAR-MATRIX; INDUCED AGGREGATION; PHENYLARSINE OXIDE	Although there are multiple potential collagen-binding proteins on platelets, the contribution of each to collagen-induced signaling events and platelet activation is unclear. We investigated which early platelet signaling events, if any, could be attributed specifically to the binding of calf ages to one of its receptors, the alpha(2) beta(1) integrin. Treatment of platelets with collagen induced a rapid activation of the non-receptor tyrosine kinase, Syk, as measured by an increase in phosphorylation and kinase activity, Collagen also induced the rapid phosphorylation of phospholipase C gamma 2 (PLC gamma 2). The phosphorylation of bath Syk and PLC gamma 2, as well as platelet aggregation, was blocked by an anti-alpha(2) beta(1) integrin monoclonal antibody (P1E6), demonstrating that collagen binding to alpha(2) beta(1) is necessary for signaling, Gross-linking of the alpha(2) beta(1) integrin with stimulatory monoclonal antibody against either the beta(1) or alpha(2) subunit stimulated the phosphorylation of bath Syk and PLC gamma 2. However, antibody stimulation was dependent on co-stimulation of the Fc gamma II receptor (CD32) since specific F(ab')(2) fragments did not induce Syk and PLC gamma 2 phosphorylation. Thus, these results suggest that occupancy of alpha(2) beta(1) by collagen is necessary, but that a co-receptor, in addition to alpha(2) beta(1), is required for these collagen-induced signaling events, Moreover, the P1E6 antibody did not inhibit all collagen-induced tyrosine phosphorylation events, demonstrating that collagen also induces phosphorylation events that are, independent of the alpha(2) beta(1) integrin. In addition to Syk and PLC gamma 2, we identified the Fc gamma II receptor (Fc gamma RII) as being rapidly phosphorylated in response to collagen stimulation even in the absence of antibodies. Finally, to determine if Syk activation precedes and directly contributes to the phosphorylation of PLC gamma 2, platelets were preincubated with the Syk-selective kinase inhibitor, piceatannol. A concentration of piceatannol that inhibited the phosphorylation and kinase activity of Syk, but had no effect on Src kinase activity, blocked the collagen-induced phosphorylation of PLC gamma 2 and also inhibited collagen-induced platelet aggregation. Our results begin to delineate a signaling pathway whereby occupancy of the alpha(2) beta(1) integrin is required, but not sufficient, for collagen-induced activation of Syk and the subsequent phosphorylation of PLC gamma 2. These events are. necessary for platelet activation and aggregation in response to collagen.			Keely, PJ (corresponding author), UNIV N CAROLINA, DEPT PHARMACOL, CB 7365, 1106 FLOB, CHAPEL HILL, NC 27599 USA.				NHLBI NIH HHS [F32-HL09399-01, 1-P01-HL45100] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009399, P01HL045100] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI M, 1995, BRIT J HAEMATOL, V89, P124, DOI 10.1111/j.1365-2141.1995.tb08900.x; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; BEXDITCHEVSKI F, 1996, MOL BIOL CELL, V7, P193; BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; Chacko GW, 1996, J BIOL CHEM, V271, P10775, DOI 10.1074/jbc.271.18.10775; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; CHIANG TM, 1982, J BIOL CHEM, V257, P7581; CHIANG TM, 1987, J IMMUNOL, V139, P887; CLARK EA, 1994, J BIOL CHEM, V269, P28859; COLLER BS, 1989, BLOOD, V74, P182; DANIEL JL, 1994, BIOCHEM J, V302, P617, DOI 10.1042/bj3020617; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FUJII C, 1994, EUR J BIOCHEM, V226, P243, DOI 10.1111/j.1432-1033.1994.tb20047.x; GEAHLEN RL, 1994, ROLE SYK CELL SIGNAL, P103; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GRAHAM IL, 1993, J CELL BIOL, V120, P1509, DOI 10.1083/jcb.120.6.1509; GREENWALT DE, 1994, BRIT J HAEMATOL, V88, P830, DOI 10.1111/j.1365-2141.1994.tb05124.x; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HILLERY CA, 1991, J BIOL CHEM, V266, P14663; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; ICHINOHE T, 1995, J BIOL CHEM, V270, P28029; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JEWELL K, 1995, J CELL SCI, V108, P1165; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KARNIGUIAN A, 1990, BIOCHEM J, V268, P325, DOI 10.1042/bj2680325; KATZ DA, 1995, SURGERY, V118, P154, DOI 10.1016/S0039-6060(05)80318-6; KEELY PJ, 1995, J CELL SCI, V108, P595; KEHREL B, 1993, BLOOD, V82, P3364; KEHREL B, 1988, BLOOD, V71, P1074; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; KURODA K, 1995, J IMMUNOL, V155, P4427; LIN TH, 1994, J CELL BIOL, V126, P1585, DOI 10.1083/jcb.126.6.1585; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MAEDA H, 1993, BIOCHEM BIOPH RES CO, V197, P62, DOI 10.1006/bbrc.1993.2441; MCKEOWN L, 1994, BLOOD, V83, P2866, DOI 10.1182/blood.V83.10.2866.2866; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; OZAKI Y, 1995, J BIOL CHEM, V270, P15119, DOI 10.1074/jbc.270.25.15119; PATCH LA, 1995, J CELL SCI, V108, P1371; POLANOWSKAGRABOWSKA R, 1993, BIOCHEM J, V296, P543, DOI 10.1042/bj2960543; RIILKONEN T, 1995, J BIOL CHEM, V270, P13548; ROSALES C, 1995, BBA-REV CANCER, V1242, P77, DOI 10.1016/0304-419X(95)00005-Z; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; SAELMAN EUM, 1994, BLOOD, V83, P3240, DOI 10.1182/blood.V83.11.3240.bloodjournal83113240; SAELMAN EUM, 1994, BLOOD, V83, P1244; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SANTORO SA, 1991, CELL REGUL, V2, P905, DOI 10.1091/mbc.2.11.905; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; SMITH JB, 1993, BIOCHEM BIOPH RES CO, V191, P695, DOI 10.1006/bbrc.1993.1273; SMITH JB, 1992, BIOCHEM J, V283, P889, DOI 10.1042/bj2830889; SMITH JB, 1992, BIOCHEM J, V288, P925, DOI 10.1042/bj2880925; SORISKY A, 1992, BIOCHEM J, V286, P581, DOI 10.1042/bj2860581; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; SUGIYAMA T, 1987, BLOOD, V69, P1712; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TATE BF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P281, DOI 10.1016/0167-4889(93)90205-4; TING AT, 1995, J BIOL CHEM, V270, P16415, DOI 10.1074/jbc.270.27.16415; TOBYAMA Y, 1994, J BIOL CHEM, V269, P32796; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WORTHINGTON RE, 1990, BRIT J HAEMATOL, V74, P216, DOI 10.1111/j.1365-2141.1990.tb02568.x; YAMAMOTO N, 1990, BLOOD, V76, P1698; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471; YANAGA F, 1995, FEBS LETT, V368, P377, DOI 10.1016/0014-5793(95)00670-5; YANAGI S, 1994, EUR J BIOCHEM, V224, P329, DOI 10.1111/j.1432-1033.1994.00329.x	85	135	137	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26668	26676		10.1074/jbc.271.43.26668	http://dx.doi.org/10.1074/jbc.271.43.26668			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900143	hybrid			2022-12-25	WOS:A1996VP23300037
J	Rarick, HM; Opgenorth, TJ; vonGeldern, TW; WuWong, JSR; Solaro, RJ				Rarick, HM; Opgenorth, TJ; vonGeldern, TW; WuWong, JSR; Solaro, RJ			An essential myosin light chain peptide induces supramaximal stimulation of cardiac myofibrillar ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE-FIBERS; TROPONIN-C; 3-DIMENSIONAL STRUCTURE; SHORTENING VELOCITY; MOLECULAR MOTOR; BINDING-SITES; THIN FILAMENT; HEAD COMPLEX; ACTIN; ISOFORMS	The N-terminal region of skeletal myosin light chain-1 (MLC-1) binds to the C terminus of actin, yet the functional significance of this interaction is unclear. We studied a fragment (MLC-pep; residues 5-14) of the ventricular MLC-1. When added to rat cardiac myofibrils, 10 nM MLC-pep induced a supramaximal increase in the MgATPase activity at submaximal Ca2+ levels with no effect at low and maximal Ca2+ levels. A nonsense, scrambled sequence peptide had no effect at any pCa value. MLC-pep did not affect myosin KEDTA and CaATPase activities or actin-activated MgATPase activities in the absence or presence of tropomyosin, The MLC-pep did not alter the ability of troponin I to inhibit MgATPase activity. Moreover, when troponin I and troponin C were extracted from the myofibrils, the MLC-pep lost its ability to stimulate the ATPase rate, This effect was fully restored upon reconstitution of the extracted myofibrils with troponin I-troponin C complex, Thus, activation of MgATPase activity by the peptide required a full complement of thin filament regulatory proteins. Interestingly, the stimulatory effect occurred at a ratio of 4 peptides to 1 thin filament, suggesting that the peptide engages in a highly cooperative process that may involve activation of the entire thin filament.	UNIV ILLINOIS, COLL MED MC 901, DEPT PHYSIOL & BIOPHYS, CHICAGO, IL 60612 USA; ABBOTT LABS, ABBOTT PK, IL 60064 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Abbott Laboratories					NHLBI NIH HHS [R01-HL-49934, R01-HL-22231, F32-HL-09009] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049934, F32HL009009, R01HL022231] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTON PJR, 1985, BIOCHEM J, V231, P249, DOI 10.1042/bj2310249; BOTTINELLI R, 1994, J MUSCLE RES CELL M, V15, P413, DOI 10.1007/BF00122115; BRANDT PW, 1984, J MOL BIOL, V180, P379, DOI 10.1016/S0022-2836(84)80010-8; CHANTLER PD, 1975, EUR J BIOCHEM, V60, P67, DOI 10.1111/j.1432-1033.1975.tb20976.x; CHAUSSEPIED P, 1989, NATURE, V342, P950, DOI 10.1038/342950a0; DOBROWOLSKI Z, 1991, J BIOL CHEM, V266, P5703; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FRASER IDC, 1995, J BIOL CHEM, V270, P7836, DOI 10.1074/jbc.270.14.7836; GREASER ML, 1988, J PHYSIOL-LONDON, V406, P85, DOI 10.1113/jphysiol.1988.sp017370; GUO XD, 1994, J BIOL CHEM, V269, P15210; HATAKENAKA M, 1992, EUR J BIOCHEM, V205, P985, DOI 10.1111/j.1432-1033.1992.tb16865.x; HENRY GD, 1985, BIOCHIM BIOPHYS ACTA, V830, P233, DOI 10.1016/0167-4838(85)90279-1; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; LABBE JP, 1986, BIOCHEMISTRY-US, V25, P8325, DOI 10.1021/bi00373a029; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LHEUREUX K, 1993, BIOCHEMISTRY-US, V32, P10005, DOI 10.1021/bi00089a016; LOWEY S, 1993, J BIOL CHEM, V268, P20414; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MORANO I, 1995, CIRC RES, V76, P720, DOI 10.1161/01.RES.76.5.720; MORNET D, 1981, NATURE, V292, P301, DOI 10.1038/292301a0; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PAGANI ED, 1984, METHOD PHARMACOL, V5, P49; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; PRINCE HP, 1981, EUR J BIOCHEM, V121, P213, DOI 10.1111/j.1432-1033.1981.tb06451.x; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RAYMENT I, 1994, TRENDS BIOCHEM SCI, V19, P129, DOI 10.1016/0968-0004(94)90206-2; SHETERLINE P, 1983, MECH CELL MOTILITY M, P36; SHIVERICK KT, 1975, BIOCHIM BIOPHYS ACTA, V393, P124, DOI 10.1016/0005-2795(75)90222-6; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; SWEENEY HL, 1995, BIOPHYS J, V68, pS112; SWEENEY HL, 1988, J BIOL CHEM, V263, P9034; TRAYER HR, 1985, FEBS LETT, V180, P170, DOI 10.1016/0014-5793(85)81065-6; TRAYER IP, 1987, EUR J BIOCHEM, V164, P259, DOI 10.1111/j.1432-1033.1987.tb11019.x; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; Winstanley MA, 1979, BIOCHEM SOC T, V7, P703, DOI 10.1042/bst0070703	37	53	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27039	27043		10.1074/jbc.271.43.27039	http://dx.doi.org/10.1074/jbc.271.43.27039			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900193				2022-12-25	WOS:A1996VP23300087
J	Yuan, YP; Schoenwaelder, SM; Salem, HH; Jackson, SP				Yuan, YP; Schoenwaelder, SM; Salem, HH; Jackson, SP			The bioactive phospholipid, lysophosphatidylcholine, induces cellular effects via G-protein-dependent activation of adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; LYMPHOCYTE-T ACTIVATION; ENDOTHELIAL-CELLS; SIGNAL-TRANSDUCTION; HUMAN-PLATELETS; CULTURED HUMAN; NITRIC-OXIDE; FATTY-ACIDS; RECEPTOR; IDENTIFICATION	The naturally occurring phospholipid, lysophosphatidylcholine (lyso-PC), regulates a broad range of cell processes, including gene transcription, mitogenesis, monocyte chemotaxis, smooth muscle relaxation, and platelet activation, Despite the growing list of cellular effects attributable to lyso-PC, the mechanism(s) by which it alters cell function have not been elucidated, In this report, we have examined the effects of exogenous lyso-PC on signal transduction processes within a variety of lyso-PC-responsive cells, including: human platelets, monocyte-like THP-1 cells, and the megakaryoblastic cell line, MEG-01. Pretreatment. of each of these cells with increasing concentrations of lyso-PC (25-150 mu g/ml) was associated with a progressive increase in the cytosolic concentration of cAMP, The accumulation of cAMP in platelets correlated closely with the ability of lyso-PC to inhibit multiple platelet processes, including platelet aggregation, agonist-induced protein kinase C activation, thromboxane A(2) generation, and the tyrosine phosphorylation of platelet proteins. In each of the cell types examined, the ability of lyso-PC to increase the cellular levels of cAMP was synergistically enhanced by pretreating the cells with the cAMP phosphodiesterase inhibitor, theophylline (5 mM), and was specifically inhibited by the P-site inhibitor of adenylyl cyclase, 2,5-dideoxyadenosine. A role for the stimulatory G-protein, Gs, in the lyso-PC-induced activation of adenylyl cyclase was suggested by the ability of the GTPase inhibitor, guanylyl 5'-thiophosphate (0.2 mM), to inhibit the lyso-PC-stimulated increase in cAMP, and also by the ability of cholera toxin to inhibit increases in membrane GTPase activity in response to lyso-PC. The functional significance of lyso-PC-induced activation of adenylyl cyclase was investigated in MEG-01 cells, Treatment of these cells with either lyso-PC or dibutyryl cAMP for 36-40 h resulted in a 3-5-fold increase in the surface expression of the natural anticoagulant protein, thrombomodulin (TM). The ability of lyso-PC to increase TM expression was abolished by pretreating these cells with the adenylyl cyclase inhibitor, 2,5-dideoxyadenosine, whereas the dibutyryl cAMP-induced increase in TM remained insensitive to adenylyl cyclase inhibition. These studies define an important role for the adenylyl cyclase signaling system in mediating cellular effects induced by lyso-PC.	BOX HILL HOSP,DEPT PATHOL,BOX HILL,VIC 3128,AUSTRALIA	Box Hill Hospital	Yuan, YP (corresponding author), MONASH UNIV SCH MED,BOX HILL HOSP,DEPT MED,BOX HILL,VIC 3128,AUSTRALIA.		Jackson, Shaun P/E-9633-2011; Yuan, Yuan/GVS-5120-2022; Schoenwaelder, Simone/E-9506-2011	Schoenwaelder, Simone/0000-0003-0465-5840; Jackson, Shaun/0000-0002-4750-1991				ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; ASAOKA Y, 1993, P NATL ACAD SCI USA, V90, P716, DOI 10.1073/pnas.90.2.716; Baenziger N L, 1974, Methods Enzymol, V31, P149; BENTON AM, 1982, BLOOD, V60, P642; BRASS LF, 1988, PLATELET MEMBRANE RE, P441; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; DUTTAROY AK, 1987, J BIOL CHEM, V262, P12685; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; HOLMSEN H, 1987, PLATELET RESPONSES M, V3, P52; HOUSLAY MD, 1986, BIOCHEM J, V234, P737, DOI 10.1042/bj2340737; INSEL PA, 1982, J BIOL CHEM, V257, P7485; ITO T, 1990, THROMB RES, V58, P615, DOI 10.1016/0049-3848(90)90307-X; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; KROLL MH, 1989, BLOOD, V74, P1181; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; MCMURRAY HF, 1993, J CLIN INVEST, V92, P1004, DOI 10.1172/JCI116605; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NGWENYA BZ, 1990, P SOC EXP BIOL MED, V193, P118; PARTHASARATHY S, 1985, P NATL ACAD SCI USA, V82, P3000, DOI 10.1073/pnas.82.9.3000; PORTMAN OW, 1969, J LIPID RES, V10, P158; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RESNICK RJ, 1994, J BIOL CHEM, V269, P32336; SAITO T, 1988, P NATL ACAD SCI USA, V85, P8246, DOI 10.1073/pnas.85.21.8246; SAKAI M, 1994, J BIOL CHEM, V269, P31430; SCHRODER T, 1980, SCAND J GASTROENTERO, V15, P633, DOI 10.3109/00365528009182227; SEAMON K, 1981, J BIOL CHEM, V256, P9799; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SHIER WT, 1976, P NATL ACAD SCI USA, V73, P1586, DOI 10.1073/pnas.73.5.1586; SHIER WT, 1977, BIOCHEM BIOPH RES CO, V78, P1168, DOI 10.1016/0006-291X(77)91416-4; STEER ML, 1979, J BIOL CHEM, V254, P791; SWEATT JD, 1986, J BIOL CHEM, V261, P8667; SWEATT JD, 1986, J BIOL CHEM, V261, P8660; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TETSUTARO S, 1991, P NATL ACAD SCI USA, V88, P5149; TSAI SC, 1985, P NATL ACAD SCI USA, V82, P8310, DOI 10.1073/pnas.82.24.8310; Ulrich K. H., 1981, PHARMACOL REV, V33, P17; VADAS P, 1986, LAB INVEST, V55, P391; VALONE FH, 1988, PLATELET MEMBRANE RE, P319; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; WELTZIEN HU, 1979, BIOCHIM BIOPHYS ACTA, V559, P259, DOI 10.1016/0304-4157(79)90004-2; YAMAMOTO N, 1991, J IMMUNOL, V147, P273; YUAN YP, 1995, BLOOD, V86, P4166, DOI 10.1182/blood.V86.11.4166.bloodjournal86114166; ZEMBOWICZ A, 1995, J CLIN INVEST, V96, P1688, DOI 10.1172/JCI118211; ZEMBOWICZ A, 1995, J BIOL CHEM, V270, P17006, DOI 10.1074/jbc.270.28.17006	52	79	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27090	27098		10.1074/jbc.271.43.27090	http://dx.doi.org/10.1074/jbc.271.43.27090			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900200	hybrid			2022-12-25	WOS:A1996VP23300094
J	Kondo, S; Morimura, T; Barnett, GH; Kondo, Y; Peterson, JW; Kaakaji, R; Takeuchi, J; Toms, SA; Liu, JB; Werbel, B; Barna, BP				Kondo, S; Morimura, T; Barnett, GH; Kondo, Y; Peterson, JW; Kaakaji, R; Takeuchi, J; Toms, SA; Liu, JB; Werbel, B; Barna, BP			The transforming activities of MDM2 in cultured neonatal rat astrocytes	ONCOGENE			English	Article						MDM2; astrocyte; p53; bFGF; PDGF; glioma	FIBROBLAST GROWTH-FACTOR; HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN GLIOBLASTOMA CELLS; HUMAN-MALIGNANT GLIOMAS; TUMOR-SUPPRESSOR GENE; SOFT-TISSUE SARCOMAS; HUMAN-BRAIN-TUMORS; P53 MUTATIONS; MESSENGER-RNA; SV40-TRANSFORMED CELLS	Although the molecular events regulating the pathogenesis of malignant astrocytomas remains unclear, the inactivation of tumor suppressor genes may be a key factor. The inactivation of p53 by mutation or deletion, however, is not the only obligatory step in astrocytoma genesis. The MDM2, protein has been shown to bind to and downmodulate p53 function, and to have oncogenic capacity. The MDM2 gene is also amplified and overexpressed in a subset of malignant astrocytomas without p53 mutation. Here we show that overexpression of MDM2 promoted the DNA synthesis of cultured neonatal rat astrocytes (RNB cells), abrogated the transcriptional activity of wild-type p53, conferred invasive activity, and subsequently induced the transformation from astrocytes to high-grade astrocytomas. Intriguingly, MDM2 enhanced the expression of angiogenic mitogens; basic fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF) in RNB cells. These results indicate that MDM2 may play an important role in the progression of astrocytomas, by not only conferring invasive activity but also stimulating the expression of angiogenic growth factors.	CLEVELAND CLIN FDN,DEPT NEUROSCI,CLEVELAND,OH 44195; NATL UTANO HOSP,DEPT NEUROSURG,UKYO KU,KYOTO 616,JAPAN	Cleveland Clinic Foundation	Kondo, S (corresponding author), CLEVELAND CLIN FDN,DEPT NEUROSURG S80,BRAIN TUMOR CTR,CTR CANC,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.			Peterson, John/0000-0002-5528-8561				ANTONIADES HN, 1987, ONCOGENES GENES GROW, P1; BOGLER O, 1995, CANCER RES, V55, P2476; COLLINS MKL, 1983, J BIOL CHEM, V258, P1689; CORDONCARDO C, 1994, CANCER RES, V54, P794; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FRANKEL RH, 1992, CANCER RES, V52, P1427; FUJIMOTO M, 1989, GENOMICS, V4, P210, DOI 10.1016/0888-7543(89)90302-9; FULTS D, 1989, CANCER RES, V49, P6572; FULTS D, 1992, CANCER RES, V52, P674; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GUHA A, 1995, J NEUROL NEUROSUR PS, V58, P711, DOI 10.1136/jnnp.58.6.711; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IWASAKI K, 1993, J NEUROSURG, V78, P952, DOI 10.3171/jns.1993.78.6.0952; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KONDO S, 1995, BRIT J CANCER, V71, P282, DOI 10.1038/bjc.1995.57; KONDO S, 1995, ONCOGENE, V10, P2001; KONDO S, 1992, NEUROSURGERY, V30, P506; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEACH FS, 1993, CANCER RES, V53, P2231; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALKIN D, 1993, PRINCIPLES PRACTICE, V7, P1; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MAXWELL M, 1990, J CLIN INVEST, V86, P131, DOI 10.1172/JCI114675; MAXWELL M, 1991, CANCER RES, V51, P1345; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORRISON RS, 1993, J NEUROSCI RES, V34, P502, DOI 10.1002/jnr.490340503; MURPHY PR, 1990, MOL ENDOCRINOL, V4, P196, DOI 10.1210/mend-4-2-196; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Potapova O, 1996, CANCER RES, V56, P280; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU JK, 1993, NEUROSURGERY, V33, P824; XIANO ZX, 1995, NATURE, V375, P694	51	20	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1773	1779						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895524				2022-12-25	WOS:A1996VM88700023
J	Itakura, O; Yamada, S; Narita, M; Kikuta, H				Itakura, O; Yamada, S; Narita, M; Kikuta, H			High prevalence of a 30-base pair deletion and single-base mutations within the carboxy terminal end of the LMP-1 oncogene of Epstein-Barr virus in the Japanese population	ONCOGENE			English	Article						EBV; LMP-1; 30-bp deletion; six point mutations; Japanese population	T-CELL LYMPHOMAS; MEMBRANE-PROTEIN LMP-1; NF-KAPPA-B; NASOPHARYNGEAL CARCINOMA; HODGKINS-DISEASE; BNLF-1 GENE; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; HEMOPHAGOCYTIC SYNDROME; HIGH-FREQUENCY; EBV INFECTION	The presence of 30-base pair (bp) deletion mutants within the carboxy terminal end of the LMP-1 oncogene (BNLF-1 gene) of Epstein-Barr virus (EBV) has been reported in EBV-associated neoplasms. We analysed the 30-bp deletion and the single-base mutations of the LMP-1 gene in 13 spontaneously established lymphoblastoid cell lines (LCLs) from peripheral blood mononuclear cells of three healthy children, four patients with EBV-unrelated acute febrile illnesses, three patients with infectious mononucleosis (IM), and three patients with chronic active EBV infection (CEBV), and six frozen samples from four patients with CEBV and two patients with EBV-associated hemophagocytic syndrome (EBV-AHS). For molecular analysis of the carboxy terminal end of the LMP-1 gene, PCR was performed using primers spanning the carboxy terminal region of the LMP-1 gene. Direct sequence analysis of the PCR products revealed identical 30-bp deletion in 14 of 19 samples (74%). Six point mutations at nucleotide positions 168357, 168355, 168320, 168308, 168295, and 168225 were frequently identified regardless of disease status. Our findings revealed the carboxy terminal end of the LMP-1 gene was mutational hot spots. The 30-bp deletion mutant is widely spread in the Japanese population and is not implicated in EBV-associated lymphoproliferative diseases.	HOKKAIDO UNIV,SCH MED,DEPT PEDIAT,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University								ANAGNOSTOPOULOS I, 1992, BLOOD, V80, P1804; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAICHWAL VR, 1988, ONCOGENE, V2, P461; CHEN CL, 1993, J VIROL, V67, P6303, DOI 10.1128/JVI.67.10.6303-6308.1993; Chen WG, 1996, AM J PATHOL, V148, P17; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; GREGORY CD, 1988, J EXP MED, V167, P1811, DOI 10.1084/jem.167.6.1811; HARABUCHI Y, 1990, LANCET, V335, P128, DOI 10.1016/0140-6736(90)90002-M; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HENNESSY K, 1984, P NATL ACAD SCI-BIOL, V81, P7207, DOI 10.1073/pnas.81.22.7207; HERBST H, 1991, P NATL ACAD SCI USA, V88, P4766, DOI 10.1073/pnas.88.11.4766; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; HUEN DS, 1995, ONCOGENE, V10, P549; KIKUTA H, 1988, NATURE, V333, P455, DOI 10.1038/333455a0; KIKUTA H, 1993, BLOOD, V82, P3259; KIKUTA H, 1989, J INFECT DIS, V160, P546; KNECHT H, 1995, ONCOGENE, V10, P523; KNECHT H, 1993, BLOOD, V82, P2937; KNECHT H, 1995, LEUKEMIA, V9, P458; Liebowitz David, 1993, P107; MANN KP, 1987, J VIROL, V61, P2100, DOI 10.1128/JVI.61.7.2100-2108.1987; MOORTHY R, 1990, J VIROL, V64, P829, DOI 10.1128/JVI.64.2.829-837.1990; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOORTHY RK, 1993, J VIROL, V67, P2637, DOI 10.1128/JVI.67.5.2637-2645.1993; Palefsky JM, 1996, J INFECT DIS, V173, P710, DOI 10.1093/infdis/173.3.710; PALLESEN G, 1993, ADV CANCER RES, V62, P179, DOI 10.1016/S0065-230X(08)60319-X; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; SANDVEJ K, 1994, BLOOD, V84, P4053, DOI 10.1182/blood.V84.12.4053.bloodjournal84124053; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; TOBI M, 1982, LANCET, V1, P61; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WEISS LM, 1987, AM J PATHOL, V129, P86; WILSON ER, 1981, J PEDIATR-US, V98, P260, DOI 10.1016/S0022-3476(81)80654-3; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; ZHOU XG, 1994, HISTOPATHOLOGY, V24, P115, DOI 10.1111/j.1365-2559.1994.tb01289.x; ZURHAUSE.H, 1970, NATURE, V228, P1056, DOI 10.1038/2281056a0	42	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1549	1553						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875994				2022-12-25	WOS:A1996VL38400021
J	Kessler, N; PerlTreves, D; Addadi, L				Kessler, N; PerlTreves, D; Addadi, L			Monoclonal antibodies that specifically recognize crystals of dinitrobenzene	FASEB JOURNAL			English	Article						immunogenicity; cholesterol; crystal; dinitrobenzene; monoclonal antibodies	3-DIMENSIONAL STRUCTURE; ANTIGEN; COMPLEX; AUTOANTIBODIES; CHOLESTEROL; ADSORPTION; HAPTEN	Monoclonal antibodies have been elicited and selected after injection of crystals of 1,4-dinitrobenzene (1,4-DNB) and cholesterol monohydrate in mice. The reactivity of some of these antibodies to 1,4-DNB crystals, cholesterol monohydrate crystals, and other solid substrates has been characterized. Two of the antibodies selectively recognize 1,4-DNB crystal surfaces in an appropriately modified ELISA. They do not interact either with 1,4-DNB/BSA conjugates or with polystyrene and cholesterol monohydrate surfaces. They do interact with 1,2-DNB crystal surfaces, albeit with much lower reactivity. It is consequently suggested that these antibodies are not specific to the DNB molecule but rather to a repetitive motif of molecular moieties exposed at the crystal surfaces. Characterization of their binding regions may help to elucidate the interactions of antibodies with solid substrates and, in general, with antigens exposed on biological and artificial surfaces.	WEIZMANN INST SCI,DEPT BIOL STRUCT,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science				Perl-Treves, Daniele/0000-0001-6312-4092				AIZENBERG J, 1994, J CRYST GROWTH, V142, P156, DOI 10.1016/0022-0248(94)90283-6; ALVING CR, 1989, BIOCHEM SOC T, V17, P637, DOI 10.1042/bst0170637; AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; BRUNGER AT, 1991, J MOL BIOL, V221, P239, DOI 10.1016/0022-2836(91)90817-P; CHITARRA V, 1993, P NATL ACAD SCI USA, V90, P7711, DOI 10.1073/pnas.90.16.7711; CHOTHIA C, 1991, CURR OPIN STRUC BIOL, V1, P43; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DINTZIS RZ, 1989, J IMMUNOL, V143, P1239; DIRIENZO F, 1980, ACTA CRYSTALLOGR B, V36, P586, DOI 10.1107/S056774088000386X; Engvall E, 1980, Methods Enzymol, V70, P419; Eshhar Z., 1985, HYBRIDOMA TECHNOLOGY, P3; GARCIA KC, 1992, SCIENCE, V257, P502, DOI 10.1126/science.1636085; GOLDBLUM RM, 1992, LANCET, V340, P510, DOI 10.1016/0140-6736(92)91710-P; GREENSPAN NS, 1992, IMMUNOL TODAY, V13, P164, DOI 10.1016/0167-5699(92)90120-V; Guyton John R., 1994, Current Opinion in Lipidology, V5, P376, DOI 10.1097/00041433-199410000-00010; JAMES RW, 1935, P ROY SOC LOND A MAT, V153, P225; KAM M, 1992, FASEB J, V6, P2608, DOI 10.1096/fasebj.6.8.1592211; KAM M, 1995, NATURE, V273, P105; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOZIN F, 1982, J COLLOID INTERF SCI, V88, P326, DOI 10.1016/0021-9797(82)90262-4; LIN JN, 1991, J CHROMATOGR, V542, P41; LIN JN, 1989, J IMMUNOL METHODS, V125, P67, DOI 10.1016/0022-1759(89)90079-3; MICHAELIDES MC, 1974, J EXP MED, V140, P687, DOI 10.1084/jem.140.3.687; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.iy.13.040195.003255; PerlTreves D, 1996, MOL CRYST LIQ CRYS A, V278, P1, DOI 10.1080/10587259608033652; PERLTREVES D, 1996, IN PRESS CHEM BIO, V3; SEEGMILLER JE, 1962, JAMA-J AM MED ASSOC, V180, P125; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; URBAIN J, 1993, J AUTOIMMUN, V6, P663, DOI 10.1006/jaut.1993.1054; WASSEF NM, 1989, J IMMUNOL, V143, P2990; WISSLER RW, 1993, ARTERIOSCLER THROMB, V13, P1291; ZIEGLER M, 1994, BIOMATERIALS, V15, P859, DOI 10.1016/0142-9612(94)90043-4	33	22	22	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1996	10	12					1435	1442		10.1096/fasebj.10.12.8903514	http://dx.doi.org/10.1096/fasebj.10.12.8903514			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VP485	8903514				2022-12-25	WOS:A1996VP48500009
J	Agou, F; Waller, JP; Mirande, M				Agou, F; Waller, JP; Mirande, M			Expression of rat aspartyl-tRNA synthetase in Saccharomyces cerevisiae - Role of the NH2-terminal polypeptide extension on enzyme activity and stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; AMINOACYL-TRANSFER-RNA; ASPARAGINYL-TRANSFER RNA; ARGINYL-TRANSFER RNA; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; THERMUS-THERMOPHILUS; SHEEP LIVER; AMPHIPHILIC HELIX; DELETION ANALYSIS	Cytoplasmic aspartyl-tRNA synthetase from mammals is one of the components of a multienzyme complex comprising nine synthetase activities. The presence of an amino-terminal extension composed of about 40 residues is a characteristic of the eukaryotic enzyme. We report here the expression in the yeast Saccharomyces cerevisiae of a native form of rat aspartyl-tRNA synthetase and of two truncated derivatives lacking 20 or 36 amino acid residues from their amino-terminal polypeptide extension. The three recombinant enzyme species were purified to homogeneity. They behave as alpha(2) dimers and display catalytic parameters in the tRNA aminoacylation reaction identical to those determined for the native, complex-associated form of aspartyl-tRNA synthetase isolated from rat liver. Because the dimer dissociation constant of rat AspRS is much higher than that of its bacterial and yeast counterparts, we could establish a direct correlation between dissociation of the dimer and inactivation of the enzyme. Our results clearly show that the monomer is devoid of amino acid activation and tRNA aminoacylation activities, indicating that dimerization is essential to confer an active conformation on the catalytic site. The two NH2-terminal truncated derivatives were fully active, but proved to be more unstable than the recombinant native enzyme, suggesting that the polypeptide extension fulfills structural rather than catalytic requirements.	CNRS, ENZYMOL & BIOCHIM STRUCT LAB, GIF SUR YVETTE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			, AGOU/GXA-2760-2022					ARNEZ JG, 1995, EMBO J, V14, P4143, DOI 10.1002/j.1460-2075.1995.tb00088.x; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BEC G, 1994, J BIOL CHEM, V269, P2086; BELRHALI H, 1994, SCIENCE, V263, P1432, DOI 10.1126/science.8128224; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; CAVARELLI J, 1993, FASEB J, V7, P79, DOI 10.1096/fasebj.7.1.8422978; CAVARELLI J, 1994, EMBO J, V13, P327, DOI 10.1002/j.1460-2075.1994.tb06265.x; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CIRAKOGLU B, 1985, BIOCHIM BIOPHYS ACTA, V829, P173, DOI 10.1016/0167-4838(85)90186-4; CIRAKOGLU B, 1985, EUR J BIOCHEM, V151, P101, DOI 10.1111/j.1432-1033.1985.tb09074.x; COMMANS S, 1995, BIOCHEMISTRY-US, V34, P8180, DOI 10.1021/bi00025a025; DAVIS MW, 1994, BIOCHEMISTRY-US, V33, P9904, DOI 10.1021/bi00199a012; DELARUE M, 1994, EMBO J, V13, P3219, DOI 10.1002/j.1460-2075.1994.tb06623.x; ERIANI G, 1990, NUCLEIC ACIDS RES, V18, P7109, DOI 10.1093/nar/18.23.7109; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; ERIANI G, 1991, EUR J BIOCHEM, V200, P337, DOI 10.1111/j.1432-1033.1991.tb16190.x; ERIANI G, 1993, P NATL ACAD SCI USA, V90, P10816, DOI 10.1073/pnas.90.22.10816; ESCALANTE C, 1993, J BIOL CHEM, V268, P6014; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACOBOMOLINA A, 1989, J BIOL CHEM, V264, P16608; KELLERMANN O, 1979, EUR J BIOCHEM, V99, P541, DOI 10.1111/j.1432-1033.1979.tb13286.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LAZARD M, 1985, BIOCHEMISTRY-US, V24, P5099, DOI 10.1021/bi00340a021; LEE ML, 1969, J BIOL CHEM, V244, P223; LOGAN DT, 1995, EMBO J, V14, P4156, DOI 10.1002/j.1460-2075.1995.tb00089.x; LU Y, 1994, J BIOL CHEM, V269, P12137; LUDMERER SW, 1993, J BIOL CHEM, V268, P5519; MADERN D, 1992, FEBS LETT, V299, P85, DOI 10.1016/0014-5793(92)80106-Q; MARTINEZ R, 1992, EUR J BIOCHEM, V207, P1, DOI 10.1111/j.1432-1033.1992.tb17012.x; MIRANDE M, 1992, EUR J BIOCHEM, V203, P459, DOI 10.1111/j.1432-1033.1992.tb16570.x; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MIRANDE M, 1989, J BIOL CHEM, V264, P842; MOSYAK L, 1995, NAT STRUCT BIOL, V2, P537, DOI 10.1038/nsb0795-537; ONESTI S, 1995, STRUCTURE, V3, P163, DOI 10.1016/S0969-2126(01)00147-2; REED VS, 1994, J BIOL CHEM, V269, P32937; RIPMASTER TL, 1995, P NATL ACAD SCI USA, V92, P4932, DOI 10.1073/pnas.92.11.4932; ROMANOS MA, 1992, YEAST, V8, P423, DOI 10.1002/yea.320080602; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANNI A, 1991, P NATL ACAD SCI USA, V88, P8387, DOI 10.1073/pnas.88.19.8387; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; URBAN P, 1990, BIOCHIMIE, V72, P463, DOI 10.1016/0300-9084(90)90070-W; VELLEKAMP G, 1985, J BIOL CHEM, V260, P9843; WALTER P, 1989, J BIOL CHEM, V264, P17126	47	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29295	29303		10.1074/jbc.271.46.29295	http://dx.doi.org/10.1074/jbc.271.46.29295			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910590	Green Published, hybrid			2022-12-25	WOS:A1996VT05200082
J	Petrovic, N; Comi, A; Ettinger, MJ				Petrovic, N; Comi, A; Ettinger, MJ			Identification of an apo-superoxide dismutase (Cu,Zn) pool in human lymphoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLHOMOCYSTEINE HYDROLASE; HUMAN K562 CELLS; COPPER-DEFICIENT; CU,ZN-SUPEROXIDE DISMUTASE; PROTEIN; ENZYME; ACTIVATION; BINDING; LIVER; DIFFERENTIATION	Copper incorporation (Cu-64(II)) into Cu,Zn-superoxide dismutase (SOD) was studied in human lymphoblasts, Rapid incorporation of copper with a proportionate increase in SOD activity was detected, No copper incorporation or SOD activation was detected when Cu-64(II) was added to cell cytosols rather than to intact cells, Thus, incorporation of Cu-64 was not due to isotopic exchange. Cycloheximide had no significant effect on copper incorporation and activation of SOD when the data were corrected for total cell copper, Thus, the data were consistent with copper incorporation into a preexisting apoSOD pool rather than newly synthesized SOD, and no new SOD synthesis was detected over a 15-h incubation period, The size of the apoSOD pool was estimated to be approximate to 35% of the total SOD in lymphoblasts, When cells were preincubated for 15 h with excess copper (15 mu M Cu(II)), the size of the apo pool markedly decreased but was not eliminated, suggesting that the apoSOD was not due to copper deficiency, These experiments also indicated that newly arrived copper was preferentially incorporated into the apoSOD pool, while the function(s) of an apoSOD pool remains unknown, Copper binding to apoSOD may provide a rapid protective response against copper toxicity.	SUNY BUFFALO,DEPT BIOCHEM,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								AUWERX JH, 1989, BLOOD, V74, P1807; BETHIN KE, 1995, J BIOL CHEM, V270, P20703, DOI 10.1074/jbc.270.35.20703; BETHIN KE, 1995, J BIOL CHEM, V270, P20698, DOI 10.1074/jbc.270.35.20698; CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169; CHUNG K, 1988, J NUTR, V118, P859, DOI 10.1093/jn/118.7.859; CRAPO JD, 1992, P NATL ACAD SCI USA, V89, P10405, DOI 10.1073/pnas.89.21.10405; DAMERON CT, 1987, BIOCHEM J, V248, P663, DOI 10.1042/bj2480663; DAMERON CT, 1987, BIOCHEM J, V248, P669, DOI 10.1042/bj2480669; Danks DM, 1989, METABOLIC BASIS INHE, P1411; DISILVESTRO RA, 1989, ARCH BIOCHEM BIOPHYS, V274, P298, DOI 10.1016/0003-9861(89)90442-6; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; HARRIS ED, 1992, J NUTR, V122, P636, DOI 10.1093/jn/122.suppl_3.636; KELLER GA, 1991, P NATL ACAD SCI USA, V88, P7381, DOI 10.1073/pnas.88.16.7381; OYANAGUI Y, 1984, ANAL BIOCHEM, V142, P290; PARDO CA, 1995, P NATL ACAD SCI USA, V92, P954, DOI 10.1073/pnas.92.4.954; PERCIVAL SS, 1991, BIOCHEM J, V274, P153, DOI 10.1042/bj2740153; PERCIVAL SS, 1992, J NUTR, V122, P2424, DOI 10.1093/jn/122.12.2424; Petrovic N, 1996, J BIOL CHEM, V271, P28335, DOI 10.1074/jbc.271.45.28335; ROSSI L, 1994, BIOCHEM BIOPH RES CO, V203, P1028, DOI 10.1006/bbrc.1994.2285; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEINKUHLER C, 1994, BIOCHEM J, V302, P687, DOI 10.1042/bj3020687; STEINKUHLER C, 1991, J BIOL CHEM, V266, P24580	22	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28331	28334		10.1074/jbc.271.45.28331	http://dx.doi.org/10.1074/jbc.271.45.28331			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910455	hybrid			2022-12-25	WOS:A1996VU03300055
J	Sung, P; Stratton, SA				Sung, P; Stratton, SA			Yeast Rad51 recombinase mediates polar DNA strand exchange in the absence of ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RECA PROTEIN; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; FILAMENT; BREAKS; SITE	Saccharomyces cerevisiae RAD51 gene is required for genetic recombination and recombinational repair of DNA strand breaks. Rad51 protein has a DNA-dependent ATPase activity, and it catalyzes ATP-dependent pairing and strand exchange between homologous DNA molecules. We show here that the rad51 Arg-191 protein, which is devoid of ATPase activity, mediates the pairing and strand exchange reaction upon binding ATP. In addition, the wild type Rad51 protein can catalyze pairing and strand exchange in the presence of the nonhydrolyzable ATP analogues adenylyl-imidodiphosphate and adenosine 5'-O-thiotriphosphate. Thus, homologous pairing and the unidirectional transfer of greater than 5 kilobases of DNA can occur efficiently without the need for nucleotide hydrolysis. Consistent with the results from the biochemical analyses, expression of the rad51 Arg-191 protein in a rad51 null mutant confers normal cellular resistance to the DNA damaging agent methylmethane sulfonate, suggesting that nucleotide binding by Rad51 is sufficient for biological function.			Sung, P (corresponding author), UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555, USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES07061] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		CameriniOtero RD, 1995, ANNU REV GENET, V29, P509, DOI 10.1146/annurev.genet.29.1.509; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; HONIGBERG SM, 1985, J BIOL CHEM, V260, P1845; KONFORTI BB, 1992, J MOL BIOL, V227, P38, DOI 10.1016/0022-2836(92)90680-I; KONOLA JT, 1994, J MOL BIOL, V237, P20, DOI 10.1006/jmbi.1994.1206; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; PRAKASH L, 1977, GENETICS, V86, P33; RADDING CM, 1991, J BIOL CHEM, V266, P5355; RATTRAY AJ, 1994, GENETICS, V138, P587; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; ROSSELLI W, 1990, J MOL BIOL, V216, P335, DOI 10.1016/S0022-2836(05)80325-0; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x	22	148	149	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					27983	27986		10.1074/jbc.271.45.27983	http://dx.doi.org/10.1074/jbc.271.45.27983			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910403	hybrid			2022-12-25	WOS:A1996VU03300003
J	Chu, RY; Lin, YL; Rao, MS; Reddy, JK				Chu, RY; Lin, YL; Rao, MS; Reddy, JK			Cloning and identification of rat deoxyuridine triphosphatase as an inhibitor of peroxisome proliferator-activated receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; ACYL-COA OXIDASE; THYROID-HORMONE; BETA-OXIDATION; SIGNALING PATHWAYS; PROTEIN; SEQUENCE; FAMILY; LIVER; DNA	Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor superfamily that transcriptionally regulate responsive genes by binding to the peroxisome proliferator response elements, Protein(s) interacting with PPAR, isoforms (alpha, delta, and gamma) may modulate the PPAR-mediated transcriptional activation, Using a yeast two-hybrid system to screen a rat liver cDNA library, we have identified rat deoxyuridine-triphosphatase (dUTPase, EC 3.6.1.23) as a PPAR alpha-interacting protein, This cDNA encodes a polypeptide of 203 amino acids; the C-terminal 141-amino acid segment of this protein corresponds to the full-length human enzyme, which exhibits 92% identity with human dUTPase; the N-terminal extra Ga-amino acid residue region is arginine-rich, In vitro binding assays indicate that rat dUTPase interacts with all three isoforms of mouse PPAR, but not with retinoid X receptor and thyroid hormone receptor, Interaction of PPAR alpha with dUTPase is with the N-terminal fia-amino acid segment of rat dUTPase, Full-length rat dUTPase prevents PPAR-retinoid X receptor heterodimerization resulting in an inhibition of PPAR activity in a ligand-independent manner. Immunostaining of human kidney tsA201 cells, transiently expressing dUTPase showed that this protein is present predominantly in the cytoplasm but translocates into the nucleus with PPAR alpha when PPAR alpha is coexpressed with dUTPase, Northern blot hybridization shows that rat dUTPase is encoded by an abundant 1-kilobase mRNA species present in all rat tissues, The identification of dUTPase as a PPAR-interacting protein suggests a possible link between tumorigenic peroxisome proliferators and the enzyme system involved in the maintenance of DNA fidelity.	NORTHWESTERN UNIV, SCH MED, DEPT PATHOL, CHICAGO, IL 60611 USA	Northwestern University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023750] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM 23750] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYANE M, 1991, NUCLEIC ACIDS RES, V19, P1273, DOI 10.1093/nar/19.6.1273; BERGMAN AC, 1994, VIROLOGY, V204, P420, DOI 10.1006/viro.1994.1547; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHU RY, 1995, P NATL ACAD SCI USA, V92, P11593, DOI 10.1073/pnas.92.25.11593; CHU S, 1995, P NATL ACAD SCI USA, V92, P7080, DOI 10.1073/pnas.92.15.7080; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GADSDEN MH, 1993, EMBO J, V12, P4425, DOI 10.1002/j.1460-2075.1993.tb06127.x; GARVEY JS, 1977, METHOD IMMUNOL, P7; GIBSON GM, 1993, P SOC PHOTO-OPT INS, V2204, P119; GRAFSTROM RH, 1978, CELL, V15, P131, DOI 10.1016/0092-8674(78)90089-2; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HUANG Q, 1994, J BIOL CHEM, V269, P8493; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JOW L, 1995, J BIOL CHEM, V270, P3836, DOI 10.1074/jbc.270.8.3836; KAIKAUS RM, 1993, J BIOL CHEM, V268, P9593; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LUNBERG LG, 1983, GENE, V23, P115; LUNDBERG LG, 1983, EMBO J, V2, P967, DOI 10.1002/j.1460-2075.1983.tb01529.x; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MCGEOCH DJ, 1990, NUCLEIC ACIDS RES, V18, P4105, DOI 10.1093/nar/18.14.4105; MCINTOSH EM, 1992, P NATL ACAD SCI USA, V89, P8020, DOI 10.1073/pnas.89.17.8020; MERCER AA, 1989, VIROLOGY, V172, P665, DOI 10.1016/0042-6822(89)90212-2; NATION MD, 1989, BIOCHEM J, V259, P593, DOI 10.1042/bj2590593; ONATE SA, 1995, SCIENCE, V270, P1354; PERLMANN T, 1995, NATURE, V377, P387; PRIHADASH A, 1992, PLANT CELL, V4, P149, DOI 10.1105/tpc.4.2.149; PYLES RB, 1994, J VIROL, V68, P4514, DOI 10.1128/JVI.68.7.4514-4524.1994; RAO MS, 1994, PHARMACOL TOXICOL, P175; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; REDDY JK, 1986, TRENDS PHARMACOL SCI, V7, P438, DOI 10.1016/0165-6147(86)90416-5; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; TYE BK, 1977, J MOL BIOL, V117, P293, DOI 10.1016/0022-2836(77)90128-0; WHEELER L, 1992, J BIOL CHEM, V267, P7664; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	55	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27670	27676		10.1074/jbc.271.44.27670	http://dx.doi.org/10.1074/jbc.271.44.27670			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910358	hybrid			2022-12-25	WOS:A1996VQ67900076
J	Haugeto, O; Ullensvang, K; Levy, LM; Chaudhry, FA; Honore, T; Nielsen, M; Lehre, KP; Danbolt, NC				Haugeto, O; Ullensvang, K; Levy, LM; Chaudhry, FA; Honore, T; Nielsen, M; Lehre, KP; Danbolt, NC			Brain glutamate transporter proteins form homomultimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCITATORY SYNAPTIC TRANSMISSION; RADIATION TARGET ANALYSIS; RAT-BRAIN; ASPARTATE TRANSPORTER; RNA-POLYMERASE; DIFFERENTIAL EXPRESSION; BENZODIAZEPINE RECEPTOR; OLIGOMERIC STRUCTURE; CHLORIDE CHANNEL; AMINO-ACIDS	Removal of excitatory amino acids from the extracellular fluid is essential for synaptic transmission and for avoiding excitotoxicity, The removal is accomplished by glutamate transporters located in the plasma membranes of both neurons and astroglia. The uptake system consists of several different transporter proteins that are carefully regulated, indicating more refined functions than simple transmitter inactivation, Here we show by chemical cross-linking, followed by electrophoresis and immunoblotting, that three rat brain glutamate transporter proteins (GLAST, GLT and EAAC) form homomultimers. The multimers exist not only in intact brain membranes but also after solubilization and after reconstitution in liposomes, Increasing the crosslinker concentration increased the immunoreactivity of the bands corresponding to trimers at the expense of the dimer and monomer bands. However, the immunoreactivities of the dimer bands did not disappear, indicating a mixture of dimers and trimers. GLT and GLAST do not complex with each other, but as demonstrated by double labeling post-embedding electron microscopic immunocytochemistry, they co-exist side by side in the same astrocytic cell membranes, The oligomers are held together noncovalently in vivo. In vitro, oxidation induces formation of covalent bonds (presumably -S-S-) between the subunits of the oligomers leading to the appearance of oligomer bands on SDS-polyacrylamide gel electrophoresis. Immunoprecipitation experiments suggest that GLT is the quantitatively dominant glutamate transporter in the brain. Radiation inactivation analysis gives a molecular target size of the functional complex corresponding to oligomeric structure. We postulate that the glutamate transporters operate as homomultimeric complexes.	UNIV OSLO,INST BASIC MED SCI,DEPT ANAT,N-0317 OSLO,NORWAY; NOVO NORDISK AS,DK-2760 MALOV,DENMARK; ST HANS HOSP,DK-4000 ROSKILDE,DENMARK	University of Oslo; Novo Nordisk			Danbolt, Niels Christian/A-1907-2014	Danbolt, Niels Christian/0000-0003-4227-4520				BARBOUR B, 1994, NEURON, V12, P1331, DOI 10.1016/0896-6273(94)90448-0; BELIVEAU R, 1988, BIOCHEM J, V252, P807, DOI 10.1042/bj2520807; BELIVEAU R, 1990, BIOCHEM J, V268, P195, DOI 10.1042/bj2680195; BERGER SP, 1994, MOL PHARMACOL, V46, P726; BETTLER B, 1995, NEUROPHARMACOLOGY, V34, P123, DOI 10.1016/0028-3908(94)00141-E; Bjoras M, 1996, MOL BRAIN RES, V36, P163, DOI 10.1016/0169-328X(95)00279-2; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; CASADO M, 1993, J BIOL CHEM, V268, P27313; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; CONRADT M, 1995, EUR J BIOCHEM, V229, P682, DOI 10.1111/j.1432-1033.1995.tb20514.x; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; DANBOLT NC, 1994, PROG NEUROBIOL, V44, P377, DOI 10.1016/0301-0082(94)90033-7; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; DEAS J, 1992, BRAIN RES, V575, P251, DOI 10.1016/0006-8993(92)90087-P; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HEBERT DN, 1992, J BIOL CHEM, V267, P23829; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1993, FEBS LETT, V325, P95, DOI 10.1016/0014-5793(93)81421-U; KEMPNER ES, 1993, TRENDS BIOCHEM SCI, V18, P236, DOI 10.1016/0968-0004(93)90169-N; KEMPNER ES, 1986, ANAL BIOCHEM, V156, P140, DOI 10.1016/0003-2697(86)90165-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRE KP, 1995, J NEUROSCI, V15, P1835; LEVY LM, 1993, FEBS LETT, V317, P79, DOI 10.1016/0014-5793(93)81495-L; LEVY LM, 1995, EUR J NEUROSCI, V7, P2036, DOI 10.1111/j.1460-9568.1995.tb00626.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKI R, 1994, J NEUROSCI, V14, P6754; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; MILNER HE, 1994, BBA-BIOMEMBRANES, V1190, P185, DOI 10.1016/0005-2736(94)90051-5; NIELSEN M, 1984, LIFE SCI, V35, P325, DOI 10.1016/0024-3205(84)90116-4; NIELSEN M, 1985, BIOCHEM PHARMACOL, V34, P3633, DOI 10.1016/0006-2952(85)90223-0; NIELSEN M, 1988, J BIOL CHEM, V263, P11900; OLNEY JW, 1990, ANNU REV PHARMACOL, V30, P47; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; SCHULTE S, 1995, EUR J BIOCHEM, V233, P947, DOI 10.1111/j.1432-1033.1995.947_3.x; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TAKAHASHI M, 1995, J NEUROSCI, V15, P5693; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; TORP R, 1994, EUR J NEUROSCI, V6, P936, DOI 10.1111/j.1460-9568.1994.tb00587.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trotti D, 1996, J BIOL CHEM, V271, P5976, DOI 10.1074/jbc.271.11.5976; TROTTI D, 1995, J BIOL CHEM, V270, P9890, DOI 10.1074/jbc.270.17.9890; VOLTERRA A, 1994, J NEUROSCI, V14, P2924; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; WANG BL, 1985, HISTOCHEMISTRY, V83, P47, DOI 10.1007/BF00495299; WANG Y, 1995, FEBS LETT, V368, P389, DOI 10.1016/0014-5793(95)00685-3; ZAFRA F, 1995, J NEUROSCI, V15, P3952	54	402	406	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27715	27722		10.1074/jbc.271.44.27715	http://dx.doi.org/10.1074/jbc.271.44.27715			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910364	hybrid			2022-12-25	WOS:A1996VQ67900082
J	Puthalakath, H; Burke, J; Gleeson, PA				Puthalakath, H; Burke, J; Gleeson, PA			Glycosylation defect in Lec1 Chinese hamster ovary mutant is due to a point mutation in N-acetylglucosaminyltransferase I gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-3-D-MANNOSIDE BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFERASE-I GENE; ASPARAGINE-LINKED OLIGOSACCHARIDES; MOLECULAR-CLONING; CELLS; COMPLEX; EXPRESSION; LOCALIZATION; DEFICIENT; PROTEIN; HYBRID	The Lec1 Chinese hamster ovary (CHO) mutant is a leuco-phytohemagglutinin resistant cell line unable to synthesize complex and hybrid N-glycans due to the lack of N-acetylglucosaminyltransferase I (GnTI) activity. Here we have identified the lec1 mutation, Using specific antibodies to GnTI we demonstrate that Led cells synthesize an inactive GnTI protein identical in size to the wild-type CHO enzyme, We have cloned and sequenced the gene coding GnTI from parental CHO and Led mutant cells, Comparison of GnTI sequences detected three mutations within the luminal domain of Led GnTI, each resulting in an amino acid substitution, The effect of each mutation an enzyme activity was analyzed bg site-directed mutagenesis of wild-type rabbit GnTI and transient expression in COS cells. One of the three mutations (Cys(123)-->Arg(123)) resulted in complete loss of activity, whereas the other two mutations had no apparent effect on enzyme activity. This conclusion was confirmed by expression of GnTI mutants in the GnTI null background of Saccharomyces cerevisiae. Both Led GnTI and the GnTI mutant (Cys(123)-->Arg(123)) are correctly localized to the Golgi apparatus, indicating that the inactive GnTI molecules are sufficiently well folded for efficient transport from the endoplasmic reticulum. These results demonstrate that the Zed mutation is a point mutation and that Cys(123) is a critical residue for GnTI activity.	MONASH UNIV, DEPT PATHOL & IMMUNOL, SCH MED, PRAHRAN, VIC 3181, AUSTRALIA	Monash University			Puthalakath, Hamsa/B-8541-2011	Gleeson, Paul/0000-0002-5336-6503; Puthalakath, Hamsa/0000-0001-5178-1175				BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BRILES EB, 1982, INT REV CYTOL, V75, P101, DOI 10.1016/S0074-7696(08)61003-7; BURKE J, 1992, J BIOL CHEM, V267, P24433; BURKE J, 1994, J BIOL CHEM, V269, P12049; FUKADA T, 1994, BIOSCI BIOTECH BIOCH, V58, P200, DOI 10.1271/bbb.58.200; GOTTLIEB C, 1975, J BIOL CHEM, V250, P3303; HULL E, 1991, BIOCHEM BIOPH RES CO, V176, P608, DOI 10.1016/S0006-291X(05)80227-X; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; KOOY J, 1992, J BIOL CHEM, V267, P20255; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KREZDORN CM, 1994, EUR J BIOCHEM, V225, P1229; KUMAR R, 1989, MOL CELL BIOL, V9, P5713, DOI 10.1128/MCB.9.12.5713; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; KUMAR R, 1992, GLYCOBIOLOGY, V2, P383, DOI 10.1093/glycob/2.4.383; MEAGER A, 1976, BIOCHEM J, V154, P113, DOI 10.1042/bj1540113; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; Narasimhan S., 1993, Glycobiology, V3, P531; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; POWNALL S, 1992, GENOMICS, V12, P699, DOI 10.1016/0888-7543(92)90297-6; ROBERTSON MA, 1978, CELL, V13, P515, DOI 10.1016/0092-8674(78)90325-2; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SCHACHTER H, 1983, METHOD ENZYMOL, V98, P98; SCHWIENTEK T, 1996, J BIOL CHEM, V271, P3393; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; STANLEY P, 1975, P NATL ACAD SCI USA, V72, P3323, DOI 10.1073/pnas.72.9.3323; STANLEY P, 1987, TRENDS GENET, V3, P77, DOI 10.1016/0168-9525(87)90180-6; STANLEY P, 1995, FASEB J, V9, P1436, DOI 10.1096/fasebj.9.14.7589985; VISCHER P, 1981, EUR J BIOCHEM, V117, P275, DOI 10.1111/j.1432-1033.1981.tb06334.x; WANG Y, 1994, BIOCHEM BIOPH RES CO, V204, P701, DOI 10.1006/bbrc.1994.2516; Warren Charles E., 1992, Glycobiology, V2, P488	35	54	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27818	27822		10.1074/jbc.271.44.27818	http://dx.doi.org/10.1074/jbc.271.44.27818			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910379	hybrid			2022-12-25	WOS:A1996VQ67900097
J	Rao, GN; Glasgow, WC; Eling, TE; Runge, MS				Rao, GN; Glasgow, WC; Eling, TE; Runge, MS			Role of hydroperoxyeicosatetraenoic acids in oxidative stress-induced activating protein 1 (AP-1) activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; LOW-DENSITY-LIPOPROTEIN; OXYGEN FREE-RADICALS; ARACHIDONIC-ACID; HYDROGEN-PEROXIDE; MESSENGER-RNA; GENE-EXPRESSION; C-FOS; GROWTH; ATHEROSCLEROSIS	We have previously reported that hydrogen peroxide, an active oxygen species and a cellular oxidant, induces c-Fos and c-Jun mRNA expression and DNA synthesis in vascular smooth muscle cells and that these events require arachidonic acid release and metabolism through the lipoxygenase pathway. Here we have identified the eicosanoids that mediate the hydrogen peroxide-induced growth-related events in these cells. Hydrogen peroxide stimulated the production of 12- and 15-hydroperoxyeicosatetraenoic acids in vascular smooth muscle cells, Both 12- and 15-hydroperoxyeicosatetraenoic acids induced the expression of c-Fos and c-Jun protein and increased activating protein 1 (AP-1) activity, as measured by AP-1-DNA binding and AP-1-dependent human collagenase promoter-driven chloramphenicol acetyltransferase reporter gene transcription. Hydrogen peroxide and arachidonic acid also induced the expression of c-Fos and c-dun protein and AP-1 activity, Nordihydroguaiaretic acid, an inhibitor of the lipoxygenase pathway, significantly inhibited both hydrogen peroxide and arachidonic acid-stimulated c-Fos and c-Jun protein expression and AP-1 activity. Together, these findings suggest that hydrogen peroxide induces the production of eicosanoids and that the eicosanoids are potential mediators of the oxidative stress-stimulated growth-related events in vascular smooth muscle cells.	NIEHS,MOL BIOPHYS LAB,NIH,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Rao, GN (corresponding author), UNIV TEXAS,MED BRANCH,DIV CARDIOL,9138 MED RES BLDG,RT 1064,301 UNIV BLVD,GALVESTON,TX 77555, USA.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CRANE FL, 1985, BIOCHIM BIOPHYS ACTA, V811, P233, DOI 10.1016/0304-4173(85)90013-8; CRAWFORD D, 1988, ONCOGENE, V3, P27; CRAWFORD DW, 1991, ATHEROSCLEROSIS, V89, P97, DOI 10.1016/0021-9150(91)90049-9; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; ESTERBAUER H, 1986, BIOCHIM BIOPHYS ACTA, V876, P154, DOI 10.1016/0005-2760(86)90329-2; FANTONE JC, 1982, AM J PATHOL, V107, P394; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HADA T, 1994, BBA-LIPID LIPID MET, V1211, P221, DOI 10.1016/0005-2760(94)90272-0; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; HAMMARSTROM S, 1975, P NATL ACAD SCI USA, V72, P5130, DOI 10.1073/pnas.72.12.5130; HANDLER JA, 1990, J BIOL CHEM, V265, P3669; HENRIKSSON P, 1985, BIOCHIM BIOPHYS ACTA, V834, P272, DOI 10.1016/0005-2760(85)90166-3; JOLLY SR, 1984, CIRC RES, V54, P277, DOI 10.1161/01.RES.54.3.277; MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241; MILLER AM, 1989, J LAB CLIN MED, V113, P355; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; NAKAO J, 1982, ATHEROSCLEROSIS, V44, P339, DOI 10.1016/0021-9150(82)90008-9; NATARAJAN R, 1993, P NATL ACAD SCI USA, V90, P4947, DOI 10.1073/pnas.90.11.4947; POSTOAK D, 1990, AM J PHYSIOL, V259, pC849, DOI 10.1152/ajpcell.1990.259.6.C849; RALPH RK, 1990, CANCER LETT, V49, P181, DOI 10.1016/0304-3835(90)90156-R; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; RAO GN, 1994, J BIOL CHEM, V269, P32586; RAO GN, 1995, BBA-MOL CELL RES, V1265, P67, DOI 10.1016/0167-4889(95)91997-Z; Rao GN, 1996, J BIOL CHEM, V271, P20805, DOI 10.1074/jbc.271.34.20805; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SETTY BNY, 1987, J BIOL CHEM, V262, P17613; SHIBANUMA M, 1990, ONCOGENE, V5, P1025; STEINBERG D, 1992, CIRCULATION, V85, P2338, DOI 10.1161/01.CIR.85.6.2337; WANG T, 1991, BIOCHIM BIOPHYS ACTA, V1084, P129, DOI 10.1016/0005-2760(91)90211-Y; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111	40	69	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27760	27764		10.1074/jbc.271.44.27760	http://dx.doi.org/10.1074/jbc.271.44.27760			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910370	hybrid			2022-12-25	WOS:A1996VQ67900088
J	Xu, WF; Chung, DW; Davie, EW				Xu, WF; Chung, DW; Davie, EW			The assembly of human fibrinogen - The role of the amino-terminal and coiled-coil regions of the three chains in the formation of the alpha gamma and beta gamma heterodimers and alpha beta gamma half-molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN FIBRINOGEN; GCN4 LEUCINE-ZIPPER; FIBROUS PROTEINS; SECRETION; DNA; MICROSCOPY; FRAGMENTS; SEQUENCE; MODEL	Fibrinogen is a plasma protein consisting of six polypeptide chains which are linked by disulfide bonds. During protein synthesis, assembly of the molecule proceeds through the formation of alpha gamma and beta gamma heterodimers followed by the generation of alpha beta gamma half-molecules and dimerizing to generate the mature six-chain molecule. In the present study, sequences required for the formation of the alpha gamma and beta gamma heterodimers were examined in stably transfected baby hamster kidney cells expressing combinations of normal as web as modified polypeptide chains. Deletion of the amino terminus and the proximal first half of the coiled-coil region of the three fibrinogen chains had little or no effect on heterodimer and half-molecule formation. These deletions, however, did prevent half-molecules from forming the six-chain molecule. Deletion of the distal second half of the coiled-coil region of each chain completely prevented the assembly process. Point mutations ill the second half of the coiled-coil region also indicated that hydrophilic residues that form ion pahs between interacting chains were not critical in the formation of the heterodimeric complexes. These results suggest that the initial formation of the alpha gamma and beta gamma complexes depends primarily on hydrophobic interactions of amino acids located in the second half of the coiled-coil region of the molecule. These interactions occur in the rough endoplasmic reticulum in the presence of various chaperones such as BiP.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle			Sessum, Rachel/F-7312-2015	Sessum, Rachel/0000-0002-2444-7056				BECK K, 1993, J MOL BIOL, V231, P311, DOI 10.1006/jmbi.1993.1284; CHUNG DW, 1990, ADV EXP MED BIOL, V281, P39; CONWAY JF, 1990, INT J BIOL MACROMOL, V12, P328, DOI 10.1016/0141-8130(90)90023-4; CONWAY JF, 1991, INT J BIOL MACROMOL, V13, P14, DOI 10.1016/0141-8130(91)90004-E; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DOOLITTLE RF, 1978, J MOL BIOL, V120, P311, DOI 10.1016/0022-2836(78)90070-0; FARRELL DH, 1991, BIOCHEMISTRY-US, V30, P9414, DOI 10.1021/bi00103a004; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HARTWIG R, 1991, J BIOL CHEM, V266, P6578; HENRY I, 1984, AM J HUM GENET, V36, P760; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; HUANG SM, 1993, J BIOL CHEM, V268, P8919; JOHN M, 1994, J BIOL CHEM, V269, P16247; KANT JA, 1985, P NATL ACAD SCI USA, V82, P2344, DOI 10.1073/pnas.82.8.2344; MCKEE PA, 1966, ARCH BIOCHEM BIOPHYS, V116, P271, DOI 10.1016/0003-9861(66)90033-6; Medved L V, 1990, Blood Coagul Fibrinolysis, V1, P439, DOI 10.1097/00001721-199010000-00012; MULVIHILL E, 1988, Patent No. 39944; NORTON PA, 1981, P NATL ACAD SCI-BIOL, V78, P1661, DOI 10.1073/pnas.78.3.1661; RAO SPS, 1991, J MOL BIOL, V222, P89, DOI 10.1016/0022-2836(91)90739-S; ROY SN, 1995, J BIOL CHEM, V270, P23761, DOI 10.1074/jbc.270.40.23761; ROY SN, 1991, J BIOL CHEM, V266, P4758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VEKLICH YI, 1993, J BIOL CHEM, V268, P13577; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058	27	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27948	27953		10.1074/jbc.271.44.27948	http://dx.doi.org/10.1074/jbc.271.44.27948			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910397	hybrid			2022-12-25	WOS:A1996VQ67900115
J	Kang, R; Saito, H; Ihara, Y; Miyoshi, E; Koyama, N; Sheng, Y; Taniguchi, N				Kang, R; Saito, H; Ihara, Y; Miyoshi, E; Koyama, N; Sheng, Y; Taniguchi, N			Transcriptional regulation of the N-acetylglucosaminyltransferase V gene in human bile duct carcinoma cells (HuCC-T1) is mediated by Ets-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER-KIDNEY CELLS; ASN-LINKED OLIGOSACCHARIDES; SEQUENCE-SPECIFIC BINDING; PROTEINS COOPERATE; STRUCTURAL-CHANGES; RESPONSE ELEMENT; MESSENGER-RNA; C-JUN; EXPRESSION; PROMOTER	N-Acetylglucosaminyltransferase V (GnT-V) catalyzes the transfer of N-acetylglucosamine from UDP-N-acetyl-glucosamine to alpha-6-D-mannoside to produce the beta 1-6 linked branching of N-glycan oligosaccharides, which controls the polylactosamine content, The expression of N-acetylglucosaminyltransferase V, which contains 17 exons and spans 155 kilobase pairs, is expressed in a tissue- and cell type-specific manner and is regulated at the level of transcription by multiple promoters (Saito, H., Gu, J., Nishikawa, A., Ihara, Y., Fujii, J., Kohgo, Y., and Taniguchi, N. (1995) Eur. J. Biochem. 233, 18-26). To elucidate the mechanism by which the GnT-V gene is expressed in a cell- and tissue-specific manner, cell-restricted expression was analyzed using the 5'-upstream regions of the human GnT-V gene spanning base pairs -2760 to +23 in a human bile duct carcinoma cell line, HuCC-T1. We characterized two cis-acting elements that are potentially important in HuCC-T1 cell-specific expression, The two elements each contain an Ets-1 binding site, 5'-GGA-3'. Specific binding of Ets-1 to the respective elements was demonstrated by competition analysis as well as by antibody supershift experiments. Cotransfection of an Ets-1 expression plasmid along with a GnT-V promoter-luciferase reporter plasmid revealed the participation of Ets-1 in the regulation of the GnT-V gene transcription. These data indicated that the transcriptional regulation of the GnT-V gene was mediated by transcription factor Ets-1.	OSAKA UNIV, SCH MED, DEPT BIOCHEM, SUITA, OSAKA 565, JAPAN	Osaka University			Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; 				DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1989, ONCOGENE, V4, P853; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FERNANDES B, 1991, CANCER RES, V51, P718; FISHER RJ, 1992, J BIOL CHEM, V267, P17957; GU J, 1993, J BIOCH, V113, P111; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; Kaya M, 1996, ONCOGENE, V12, P221; KLAES A, 1994, CELL, V78, P149, DOI 10.1016/0092-8674(94)90581-9; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LIAHAKK NB, 1996, CANCER RES, V56, P190; LU Y, 1993, MOL CELL BIOCHEM, V122, P85, DOI 10.1007/BF00925741; MIYAGIWA M, 1989, IN VITRO CELL DEV B, V25, P503; MIYOSHI E, 1995, J BIOL CHEM, V270, P6216, DOI 10.1074/jbc.270.11.6216; MIYOSHI E, 1993, CANCER RES, V53, P3899; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; PERNG GS, 1994, GLYCOBIOLOGY, V4, P867, DOI 10.1093/glycob/4.6.867; PIERCE M, 1986, J BIOL CHEM, V261, P772; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; SAITO H, 1995, EUR J BIOCHEM, V233, P18, DOI 10.1111/j.1432-1033.1995.018_1.x; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SETH A, 1994, ONCOGENE, V9, P469; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; SUZUKI H, 1995, P NATL ACAD SCI USA, V92, P4442, DOI 10.1073/pnas.92.10.4442; TANIGUCHI N, 1995, GLYCOCONJUGATE J, V12, P733, DOI 10.1007/BF00731232; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; TYMMS MJ, 1994, MOL REPROD DEV, V39, P208, DOI 10.1002/mrd.1080390214; VANDENBUNDER B, 1994, INVAS METAST, V14, P198; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WERNERT N, 1992, AM J PATHOL, V140, P119; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; YAGEL S, 1989, INT J CANCER, V37, P607; YAMAMOTO K, 1984, EUR J BIOCHEM, V143, P133, DOI 10.1111/j.1432-1033.1984.tb08352.x; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; YAMASHITA K, 1984, J BIOL CHEM, V259, P834; YOGEESWARAN G, 1981, SCIENCE, V212, P1514, DOI 10.1126/science.7233237; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	54	105	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26706	26712		10.1074/jbc.271.43.26706	http://dx.doi.org/10.1074/jbc.271.43.26706			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900148				2022-12-25	WOS:A1996VP23300042
J	Ohsuga, H; Su, SN; Takahashi, N; Yang, SY; Nakagawa, H; Shimada, I; Arata, Y; Lee, YC				Ohsuga, H; Su, SN; Takahashi, N; Yang, SY; Nakagawa, H; Shimada, I; Arata, Y; Lee, YC			The carbohydrate moiety of the Bermuda grass antigen BG60 - New oligosaccharides of plant origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; ACER-PSEUDOPLATANUS L; CYNODON-DACTYLON POLLEN; SUBSTRATE-SPECIFICITY; SYCAMORE CELLS; XYLOSE; GLYCOPROTEINS; ALLERGENS; PATHWAY; LECTINS	BG60 is an important allergen of Bermuda grass (Cynodon dactylon) pollen, which causes allergic responses in human. It was suggested that its carbohydrate moiety may be relevant to allergic reaction (Su, S. N., Lau, G. X., Shu, P., Yang, S. Y., Huang, S. W., and Lee, Y. C. (1996) J. Allergy Clin. Immunol., in press). Therefore, the structure of the carbohydrate moiety in BG60 was investigated. The N-linked oligosaccharides were released from the glycopeptides of BG60 by digesting with a glycoamidase from sweet almond and reductively aminated with a fluorescent reagent, 2-aminopyridine. The mixture of pyridylaminated oligosaccharides were separated by high-performance liquid chromatography (HPLC) using an octadecylsilyl (ODS) column. Five oligosaccharide fractions were isolated, and each fraction was found to be homogeneous by HPLC on an amide-silica column. The structure of each of the oligosaccharides was analyzed by the two dimensional mapping technique (Tomiya, N., Awaya, J., Kurono, RI., Endo, S., Arata, Y., and Takahashi, N. (1988) Anal. Biochem. 171, 73-90), in tandem with sequential exoglycosidase digestion. The two most abundant oligosaccharides, A and B, have an unusual structural feature, i.e. the presence of an L-Fuc alpha-(1,3)-linked to Asn-linked GlcNAc without a Xyl beta-(1,2) linked to the branching Man (see below). To the best of our knowledge, these are the first such oligosaccharides found in plant glycoproteins.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; JOHNS HOPKINS UNIV, MCCOLLUM PRATT INST, BALTIMORE, MD 21218 USA; NAKANO VINEGAR CO LTD, NAKANO CENT RES INST, GLYCOLAB, HANDA 475, JAPAN; VET GEN HOSP, DEPT MED RES, TAIPEI 11217, TAIWAN; UNIV TOKYO, FAC PHARMACEUT SCI, TOKYO 113, JAPAN	Johns Hopkins University; Johns Hopkins University; University of Tokyo					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK009970, R01DK009970] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09970] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTMANN F, 1995, GLYCOCONJUGATE J, V12, P84, DOI 10.1007/BF00731873; ASHFORD D, 1987, EUR J BIOCHEM, V166, P311, DOI 10.1111/j.1432-1033.1987.tb13516.x; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang HN, 1984, CLIN MED J, V34, P376; DANDREA G, 1988, GLYCOCONJUGATE J, V5, P151, DOI 10.1007/BF01061204; FORD SA, 1987, J ALLERGY CLIN IMMUN, V79, P711, DOI 10.1016/0091-6749(87)90201-6; FOURNET B, 1987, EUR J BIOCHEM, V166, P321, DOI 10.1111/j.1432-1033.1987.tb13517.x; FRANCOIS C, 1962, BIOCHEM J, V83, P335, DOI 10.1042/bj0830335; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; HASE S, 1986, J BIOCHEM-TOKYO, V100, P1; HAYASHI M, 1990, EUR J BIOCHEM, V191, P287, DOI 10.1111/j.1432-1033.1990.tb19122.x; HIJIKATA A, 1994, INT ARCH ALLERGY IMM, V105, P198, DOI 10.1159/000236826; KIMURA Y, 1987, J BIOCHEM-TOKYO, V101, P1051, DOI 10.1093/oxfordjournals.jbchem.a121947; KING TP, 1962, BIOCHEMISTRY-US, V1, P709, DOI 10.1021/bi00910a027; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; KITAGAKIOGAWA H, 1986, EUR J BIOCHEM, V161, P779, DOI 10.1111/j.1432-1033.1986.tb10507.x; KOBTA A, 1993, GLYCOBIOLOGY PRACTIC, V123, P165; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; KUROSAKA A, 1991, J BIOL CHEM, V266, P4168; LEE YC, 1990, ANAL BIOCHEM, V188, P259, DOI 10.1016/0003-2697(90)90603-7; MATTHIESEN F, 1989, J ALLERGY CLIN IMMUN, V83, P1124, DOI 10.1016/0091-6749(89)90456-9; ORREN A, 1975, INT ARCH ALLER A IMM, V49, P814, DOI 10.1159/000231465; SHEN HD, 1988, CLIN ALLERGY, V18, P401, DOI 10.1111/j.1365-2222.1988.tb02888.x; STRUM A, 1987, J BIOL CHEM, V262, P13392; SU S-N, 1986, Chinese Journal of Microbiology and Immunology (Taipei), V19, P263; SU S-N, 1990, Proceedings of the National Science Council Republic of China Part B Life Sciences, V14, P85; SU SN, 1991, CLIN EXP ALLERGY, V21, P449, DOI 10.1111/j.1365-2222.1991.tb01685.x; SU SN, 1996, IN PRESS J ALLERGY C; TAKAHASHI N, 1986, BIOCHEMISTRY-US, V25, P388, DOI 10.1021/bi00350a018; TAKAHASHI N, 1993, ANAL BIOCHEM, V208, P96, DOI 10.1006/abio.1993.1013; TAKAHASHI N, 1992, HDB ENDOGLYCOSIDASES, P199; TAKAYAMA S, 1986, AGR BIOL CHEM TOKYO, V50, P1673, DOI 10.1080/00021369.1986.10867633; TEZUKA K, 1992, EUR J BIOCHEM, V203, P401, DOI 10.1111/j.1432-1033.1992.tb16564.x; TEZUKA K, 1993, BIOCHEM MOL BIOL INT, V29, P395; TEZUKA K, 1993, ANAL BIOCHEM, V211, P205, DOI 10.1006/abio.1993.1258; TOMIYA N, 1991, ANAL BIOCHEM, V193, P90, DOI 10.1016/0003-2697(91)90047-W; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; TRINCA J C, 1962, Med J Aust, V49(1), P969; YASUDA Y, 1970, BIOCHEMISTRY-US, V9, P25, DOI 10.1021/bi00803a004	42	44	46	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26653	26658		10.1074/jbc.271.43.26653	http://dx.doi.org/10.1074/jbc.271.43.26653			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900140	hybrid			2022-12-25	WOS:A1996VP23300034
J	Schleiff, E; Schmitz, A; McIlhinney, RAJ; Manenti, S; Vergeres, G				Schleiff, E; Schmitz, A; McIlhinney, RAJ; Manenti, S; Vergeres, G			Myristoylation does not modulate the properties of MARCKS-related protein (MRP) in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C SUBSTRATE; LIGHT-CHAIN KINASE; MEMBRANE ASSOCIATION; MAJOR SUBSTRATE; CALMODULIN-BINDING; DEPENDENT BINDING; BOVINE BRAIN; RAT-BRAIN; PHOSPHORYLATION; PEPTIDES	The members of the myristoylated alanine-rich C kinase Substrate (MARCKS) family ape proteins essential for brain development and phagocytosis. MARCKS proteins bind to actin filaments and calmodulin (CaM) and are phosphorylated by protein kinase C. In order to investigate how these interactions are regulated, we have characterized the properties of both the myristoylated (myr) and unmyristoylated (unmyr) forms of recombinant MARCKS-related protein (MRP), a 20-kDa member of the MARCKS family. Ultracentrifugation and circular dichroic spectroscopy reveal that MRP is an elongated protein, with an axis ratio estimated between 7 and 12 and with an apparent random coil conformation, MRP binds to CaM with high affinity (K-d,K-myr = 4 nM; K-d,K-unmyr = 7 nM) and with a second order rate constant, k(+1, unmyr), of 1.6 x 10(8) M(-1) s(-1). In contrast to classical ligands such as the myosine light chain kinase, binding of MRP to CaM does not induce the formation of an alpha-helix in MRP. The catalytic subunit of protein kinase C (PKM) phosphorylates myr MRP with high affinity ([S](0.5) = 3.5 mu M), positive cooperativity (n(H) = 2.5) and a turnover number of 130 min(-1). CaM inhibits the phosphorylation of myr MRP with a half-maximum rate of phosphorylation at a [CaM]/[MRP] ratio of 0.7, indicating that CaM might efficiently regulate the phosphorylation of MRP in vivo. Interestingly, Ca2+ inhibits the binding of MRP to CaM as well as its phosphorylation by PKM in the millimolar concentration range, suggesting that MRP has a weak affinity for Ca2+. Finally, unmyr MRP can be stoichiometrically myristoylated by N-myristoyl transferase in vitro. Since neither binding of CaM nor phosphorylation by PKM inhibits myristoylation, the N terminus of unmyr MRP is exposed on the surface of the protein and is well separated from the effector domain, In view of the observations that unmyr and myr MRP do not exhibit significant differences in their properties in solution, the function of myristoylation is most probably to modulate. the interactions of MRP with membranes.	UNIV BASEL, BIOCTR, DEPT BIOPHYS CHEM, CH-4056 BASEL, SWITZERLAND; UNIV OXFORD, DEPT PHARMACOL, MRC, ANAT NEUROPHARMACOL UNIT, OXFORD OX1 3TH, ENGLAND; HOP PURPAN, INSERM, CJF 9510, F-31059 TOULOUSE, FRANCE	University of Basel; University of Oxford; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)			Schleiff, Enrico/C-5105-2017; manenti, stephane/P-1518-2014	Schleiff, Enrico/0000-0002-0518-3489; manenti, stephane/0000-0002-4793-3196; Schmitz, Arndt/0000-0002-7104-6191				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ADEREM AA, 1986, P NATL ACAD SCI USA, V83, P5817, DOI 10.1073/pnas.83.16.5817; ALBERT KA, 1984, P NATL ACAD SCI-BIOL, V81, P3622, DOI 10.1073/pnas.81.12.3622; Alberts B. D., 1989, MOL BIOL CELL, P301; ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS CL, 1993, J AM CHEM SOC, V115, P11034, DOI 10.1021/ja00076a089; BURGOYNE RD, 1995, TRENDS NEUROSCI, V18, P191, DOI 10.1016/0166-2236(95)93900-I; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; BYERS DM, 1982, BIOCHEMISTRY-US, V21, P229, DOI 10.1021/bi00531a005; CHAKRAVARTHY BR, 1995, J BIOL CHEM, V270, P24911, DOI 10.1074/jbc.270.42.24911; CHAKRAVARTHY BR, 1995, J BIOL CHEM, V270, P1362, DOI 10.1074/jbc.270.3.1362; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Creighton T. E., 1993, PROTEINS STRUCTURES; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HUANG KP, 1986, BIOCHEM BIOPH RES CO, V139, P320, DOI 10.1016/S0006-291X(86)80116-4; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JOHNSON JD, 1983, BIOCHEM J, V211, P473, DOI 10.1042/bj2110473; KIM JY, 1994, J BIOL CHEM, V269, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; Kuntz I D Jr, 1974, Adv Protein Chem, V28, P239, DOI 10.1016/S0065-3233(08)60232-6; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; LOBACH DF, 1993, GENOMICS, V17, P194, DOI 10.1006/geno.1993.1301; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACNICOL M, 1992, J BIOL CHEM, V267, P12197; MANENTI S, 1994, J BIOL CHEM, V269, P8309; MANENTI S, 1993, J BIOL CHEM, V268, P6878; MANENTI S, 1992, J BIOL CHEM, V267, P22310; MCILHINNEY RAJ, 1990, BIOCHEM J, V271, P681, DOI 10.1042/bj2710681; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MELLHINNEY RAJ, 1994, EUR J BIOCHEM, V222, P137; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PATEL J, 1987, J BIOL CHEM, V262, P16686; PAUL C, 1980, ANAL BIOCHEM, V101, P442, DOI 10.1016/0003-2697(80)90211-0; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; Qin ZH, 1996, BIOCHEMISTRY-US, V35, P2917, DOI 10.1021/bi9521452; RANDAZZO PA, 1995, J BIOL CHEM, V270, P14809, DOI 10.1074/jbc.270.24.14809; ROSEN A, 1989, J BIOL CHEM, V264, P9118; Segel I. H., 1975, ENZYME KINETICS, P360; SOBIESZEK A, 1995, BIOCHEMISTRY-US, V34, P11855, DOI 10.1021/bi00037a025; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; TANIGUCHI H, 1994, J BIOL CHEM, V269, P18299; TOROK K, 1994, BIOCHEMISTRY-US, V33, P12807, DOI 10.1021/bi00209a012; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; UCHIDA T, 1984, J BIOL CHEM, V259, P2311; UMEKAGE T, 1991, FEBS LETT, V286, P147, DOI 10.1016/0014-5793(91)80961-2; VANHOLDE KE, 1958, J PHYS CHEM-US, V62, P734, DOI 10.1021/j150564a025; VERGERES G, 1995, J BIOL CHEM, V270, P19879, DOI 10.1074/jbc.270.34.19879; VERGERES G, 1995, SIGNALING MECH TRANS, P125; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; WALKER JM, 1990, J BIOL CHEM, V265, P8016; WEI J, 1995, BIOCHEMISTRY-US, V34, P6408, DOI 10.1021/bi00019a021; Wu M, 1996, P NATL ACAD SCI USA, V93, P2110, DOI 10.1073/pnas.93.5.2110; YAMAMOTO H, 1995, J NEUROCHEM, V65, P802; ZHAO D, 1991, BIOCHEM J, V277, P445, DOI 10.1042/bj2770445; ZHU ZX, 1995, J BIOL CHEM, V270, P17652, DOI 10.1074/jbc.270.30.17652; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	71	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26794	26802		10.1074/jbc.271.43.26794	http://dx.doi.org/10.1074/jbc.271.43.26794			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900160	hybrid			2022-12-25	WOS:A1996VP23300054
J	Sheu, JJ; Yu, TS; Tong, WF; Yu, SM				Sheu, JJ; Yu, TS; Tong, WF; Yu, SM			Carbohydrate starvation stimulates differential expression of rice alpha-amylase genes that is modulated through complicated transcriptional and posttranscriptional processes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON CATABOLITE REPRESSION; COMPLETE NUCLEOTIDE-SEQUENCE; BARLEY ALEURONE CELLS; SACCHAROMYCES-CEREVISIAE; METABOLIC REPRESSION; GLUCOSE REPRESSION; SUGAR UTILIZATION; CULTURED-CELLS; MESSENGER-RNAS; HIGHER-PLANTS	Expression of alpha-amylase genes in cultured rice suspension cells is induced by sucrose starvation, To study the mechanism of sugar metabolite regulation on the expression of individual alpha-amylase genes, DNA fragments specific to each of eight rice alpha-amylase genes were synthesized and used as gene-specific probes, Comparison of the relative abundance of mRNA revealed that expression of the eight alpha-amylase genes in rice cells was differentially regulated by sucrose starvation. Accumulation of all the alpha-amylase mRNAs increased in response to sucrose starvation; however, levels of the alpha Amy3 and alpha Amy8 mRNAs were distinctly higher and constituted 90% of total alpha-amylase mRNAs, RNA gel blot and nuclear run-on transcription analyses demonstrated a positive correlation between the increased transcription rates and the elevated steady-state levels of alpha-amylase mRNAs induced by sucrose starvation, The half-lives of alpha Amy3, alpha Amy7, and alpha Amy8 were prolonged by sucrose-starvation; however, the stability of the three mRNAs seems controlled by different mechanisms, The translation inhibitors cycloheximide and anisomycin preferentially blocked the sucrose-suppressed expression of alpha Amy3 but mot that of alpha Amy7 and alpha Amy8. These inhibitors also enhanced the sucrose starvation-induced accumulation of alpha Amy3 mRNA but not that of alpha Amy7 or alpha Amy8 mRNAs. Cycloheximide did mot significantly alter the transcription rates of alpha-amylase genes, suggesting that labile proteins may selectively stabilize the alpha Amy7 and alpha Amy8 mRNAs but destabilize the alpha Amy3 mRNA.	ACAD SINICA,INST MOL BIOL,TAIPEI 11529,TAIWAN; NATL DEF MED CTR,GRAD INST LIFE SCI,TAIPEI,TAIWAN; NATL TAIWAN NORMAL UNIV,DEPT BIOL,TAIPEI 11718,TAIWAN	Academia Sinica - Taiwan; National Defense Medical Center; National Taiwan Normal University			Yu, Su-May/ABB-6950-2021	Yu, Su-May/0000-0001-8744-9246				ATWATER JA, 1990, ANNU REV GENET, V24, P519; BELANGER FC, 1986, P NATL ACAD SCI USA, V83, P1354, DOI 10.1073/pnas.83.5.1354; BRODL MR, 1991, PLANT PHYSIOL, V96, P1048, DOI 10.1104/pp.96.4.1048; CARLSON M, 1987, J BACTERIOL, V169, P4873, DOI 10.1128/jb.169.11.4873-4877.1987; CHAN MT, 1993, PLANT MOL BIOL, V22, P491, DOI 10.1007/BF00015978; CHAN MT, 1994, J BIOL CHEM, V269, P17635; CHAO YC, 1992, J VIROL, V66, P1442, DOI 10.1128/JVI.66.3.1442-1448.1992; CHEN MH, 1994, PLANT J, V6, P625, DOI 10.1046/j.1365-313X.1994.6050625.x; ENTIAN KD, 1992, TRENDS BIOCHEM SCI, V17, P506, DOI 10.1016/0968-0004(92)90341-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALLING G, 1982, ENCY PLANT PHYSL B, V14, P663; GANCEDO JM, 1992, EUR J BIOCHEM, V206, P297, DOI 10.1111/j.1432-1033.1992.tb16928.x; GRAHAM IA, 1994, PLANT CELL, V6, P761, DOI 10.1105/tpc.6.5.761; HUANG N, 1990, NUCLEIC ACIDS RES, V18, P7007, DOI 10.1093/nar/18.23.7007; HUANG N, 1993, PLANT MOL BIOL, V23, P737, DOI 10.1007/BF00021529; Jacobsen J. V., 1987, Plant hormones and their role in plant growth and development, P164; JANG JC, 1994, PLANT CELL, V6, P1665, DOI 10.1105/tpc.6.11.1665; KARRER EE, 1992, PLANT J, V2, P517; MAGOULAS C, 1993, GENETICS, V134, P507; MCELROY D, 1990, PLANT CELL, V2, P163, DOI 10.1105/tpc.2.2.163; MCGRANE MM, 1992, TRENDS BIOCHEM SCI, V17, P40, DOI 10.1016/0968-0004(92)90426-A; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAIER MH, 1991, NEW BIOL, V3, P1137; Sambrook J., 2002, MOL CLONING LAB MANU; SANO Y, 1990, GENOME, V33, P209, DOI 10.1139/g90-033; SCHUSTER JR, 1989, YEAST GENETIC ENG, P83; SHEEN J, 1990, PLANT CELL, V2, P1027, DOI 10.1105/tpc.2.10.1027; SHEEN J, 1994, PHOTOSYNTH RES, V39, P427, DOI 10.1007/BF00014596; SHEU JJ, 1994, PLANT J, V5, P655, DOI 10.1111/j.1365-313X.1994.00655.x; SHIRLEY BW, 1990, NUCLEIC ACIDS RES, V18, P3377, DOI 10.1093/nar/18.11.3377; TAKAIWA F, 1985, GENE, V37, P255; TAKAIWA F, 1984, NUCLEIC ACIDS RES, V12, P5441, DOI 10.1093/nar/12.13.5441; THOMAS BR, 1994, PLANT PHYSIOL, V106, P1235, DOI 10.1104/pp.106.4.1235; THOMPSON DM, 1990, NUCLEIC ACIDS RES, V18, P3621, DOI 10.1093/nar/18.12.3621; TRUMBLY RJ, 1992, MOL MICROBIOL, V6, P15, DOI 10.1111/j.1365-2958.1992.tb00832.x; TSUCHIYA K, 1992, BIOSCI BIOTECH BIOCH, V56, P1849, DOI 10.1271/bbb.56.1849; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; WATSON JC, 1986, METHOD ENZYMOL, V118, P57; YU SM, 1992, GENE, V122, P247, DOI 10.1016/0378-1119(92)90212-8; YU SM, 1991, J BIOL CHEM, V266, P21131; Yu SM, 1996, PLANT MOL BIOL, V30, P1277, DOI 10.1007/BF00019558	42	84	87	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26998	27004		10.1074/jbc.271.43.26998	http://dx.doi.org/10.1074/jbc.271.43.26998			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900187				2022-12-25	WOS:A1996VP23300081
J	Solomon, V; Goldberg, AL				Solomon, V; Goldberg, AL			Importance of the ATP-ubiquitin-proteasome pathway in the degradation of soluble and myofibrillar proteins in rabbit muscle extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEOLYTIC SYSTEM; RAT SKELETAL-MUSCLE; RED-BLOOD-CELLS; OXIDANT-DAMAGED HEMOGLOBIN; ALPHA-ACETYLATED PROTEINS; DENERVATION ATROPHY; MULTICATALYTIC PROTEINASE; ABNORMAL PROTEINS; MAMMALIAN-CELLS; MESSENGER-RNA	Recent studies have suggested that activation of the ubiquitin-proteasome pathway is primarily responsible for the rapid loss of muscle proteins in various types of atrophy. The present studies were undertaken to test if different. classes of muscle proteins are degraded by this pathway. In extracts of rabbit psoas muscle, the complete degradation of soluble proteins to amino acids was stimulated up to 6-fold by ATP. Peptide aldehyde inhibitors of the proteasome or the removal of proteasomes markedly inhibited only the ATP-dependent process. Addition of purified myosin, actin, troponin, or tropomyosin to these extracts showed that these proteins served as substrates for the ubiquitin-proteasome pathway. By contrast, degradation of myoglobin did not require ATP, proteasomes, or any known proteases in muscles. When myosin, actin, and troponin were added as actomyosin complexes or as intact myofibrils to these extracts, they were not hydrolyzed at a, significant rate, probably because in these multicomponent complexes, these proteins are protected from degradation Accordingly, actin (but not albumin or troponin) inhibited the degradation of I-125-myosin, and actin was found to selectively inhibit ubiquitin conjugation to I-125-myosin. Also, the presence of tropomyosin inhibited the degradation of I-125-troponin. However, neither actin nor tropomyosin inhibited the degradation of I-125-lysozyme or soluble muscle proteins. Thus, specific interactions between the myofibrillar proteins appear to protect them from ubiquitin-dependent degradation, and the rate-limiting step in their degradation is probably their dissociation from the myofibril.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School								BAILEY JL, 1996, IN PRESS J CLIN INVE; BARACOS VE, 1995, AM J PHYSIOL-ENDOC M, V268, pE996, DOI 10.1152/ajpendo.1995.268.5.E996; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JL, 1976, J BIOL CHEM, V251, P1009; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COUX O, 1995, IN PRESS ANN REV BIO; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; DEMARTINO GN, 1981, ENZYME, V26, P1; DHAESE J, 1987, BIOCHEM J, V248, P397, DOI 10.1042/bj2480397; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; DOTTAVIOMARTIN D, 1978, ANAL BIOCHEM, V87, P562, DOI 10.1016/0003-2697(78)90706-6; DRISCOLL J, 1989, P NATL ACAD SCI USA, V86, P787, DOI 10.1073/pnas.86.3.787; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; FAGAN JM, 1986, J BIOL CHEM, V261, P5705; FAGAN JM, 1992, J BIOL CHEM, V267, P23015; FAGAN JM, 1987, BIOCHEM J, V243, P335, DOI 10.1042/bj2430335; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FISHER M, 1994, FEBS LETT, V355, P69; FULKS RM, 1975, J BIOL CHEM, V250, P290; FUNATSU T, 1994, J MUSCLE RES CELL M, V15, P158, DOI 10.1007/BF00130426; FURUNO K, 1986, BIOCHEM J, V237, P859, DOI 10.1042/bj2370859; FURUNO K, 1990, J BIOL CHEM, V265, P8550; GIULIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329, DOI 10.1006/abbi.1994.1245; GOLDBERG AL, 1995, CHEM BIOL, V2, P503, DOI 10.1016/1074-5521(95)90182-5; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; Goll DE, 1989, ANIMAL GROWTH REGULA, P141; GONEN H, 1994, P NATL ACAD SCI USA, V91, P7648, DOI 10.1073/pnas.91.16.7648; GONEN H, 1991, J BIOL CHEM, V266, P19221; GOODMAN MN, 1987, BIOCHEM J, V241, P121, DOI 10.1042/bj2410121; GRONOSTAJSKI RM, 1985, J BIOL CHEM, V260, P3344; HARTL FU, 1995, CURR OPIN STRUC BIOL, V5, P92; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HERSHKO A, 1982, J BIOL CHEM, V257, P3964; HERSHKO A, 1986, PROG NUCLEIC ACID RE, V33, P19, DOI 10.1016/S0079-6603(08)60019-7; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; KETTELHUT IC, 1988, DIABETES METAB REV, V4, P751, DOI 10.1002/dmr.5610040805; KIRSCHNER RJ, 1983, J BIOL CHEM, V258, P967; LARDEUX BR, 1987, J BIOL CHEM, V262, P14514; LIBBY P, 1980, BIOCHEM J, V188, P213, DOI 10.1042/bj1880213; LOWELL BB, 1986, BIOCHEM J, V234, P237, DOI 10.1042/bj2340237; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; MCGUIRE MJ, 1988, BIOCHIM BIOPHYS ACTA, V967, P195, DOI 10.1016/0304-4165(88)90009-8; MEDINA R, 1991, BIOMED BIOCHIM ACTA, V50, P347; MEDINA R, 1995, BIOCHEM J, V307, P631, DOI 10.1042/bj3070631; MEYER A, 1989, SCIENCE, V244, P1480; MILLWARD DJ, 1981, ACTA BIOL MED GER, V40, P1309; MITCH WE, 1994, J CLIN INVEST, V93, P2127, DOI 10.1172/JCI117208; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; PERRY SV, 1958, BIOCHEM J, V68, P5, DOI 10.1042/bj0680005; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; TEMPARIS S, 1994, CANCER RES, V54, P568; TIAO G, 1994, J CLIN INVEST, V94, P2255, DOI 10.1172/JCI117588; VANDERWESTHUYZEN DR, 1981, J BIOL CHEM, V256, P1791; WING SS, 1995, BIOCHEM J, V307, P639, DOI 10.1042/bj3070639; WING SS, 1993, AM J PHYSIOL, V264, pE688	59	321	329	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26690	26697		10.1074/jbc.271.43.26690	http://dx.doi.org/10.1074/jbc.271.43.26690			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900146	hybrid			2022-12-25	WOS:A1996VP23300040
J	Uribe, JM; Keely, SJ; TraynorKaplan, AE; Barrett, KE				Uribe, JM; Keely, SJ; TraynorKaplan, AE; Barrett, KE			Phosphatidylinositol 3-kinase mediates the inhibitory effect of epidermal growth factor on calcium-dependent chloride secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; CL SECRETION; BINDING-SITE; P85 SUBUNIT; T84 CELLS; ACTIVATION; PROTEIN; KINASE; RECEPTOR; WORTMANNIN	Epidermal growth factor (EGF) and carbachol both inhibit calcium-activated chloride secretion by the human colonic epithelial cell line, T-84. Although the inhibitory mechanism for the carbachol effect involves the 3,4,5,6-isomer of inositol tetrakisphosphate, the mechanisms responsible for the EGF effect have not yet, been fully elucidated, Here, we studied the Pole of phosphatidylinositol 3-kinase (PI 3-kinase) in the inhibitory effect of EGF, The PI 3-kinase inhibitor, wortmannin, slightly increased basal chloride secretion and potentiated the secretory response to thapsigargin. Wortmannin also partially reversed EGF-induced, but not carbachol-induced, inhibition of thapsigargin-stimulated chloride secretion. Wortmannin alone had no effect on carbacholor histamine-induced chloride secretion and completely reversed EGF-induced inhibition of the secretory response to these agonists, EGF, carbachol, histamine, and thapsigargin all increased levels of the 85-kDa regulatory subunit of PI 3-kinase in antiphosphotyrosine immunoprecipitates. However, only EGF significantly increased levels of the 110-kDa catalytic subunit. Furthermore, only EGF increased PI 3-kinase activity in an in vitro kinase assay. High levels of phosphatidylinositol (3)-monophosphate were present in unstimulated cells and significantly reduced by wortmannin. EGF, but not carbachol, rapidly increased levels of phosphatidylinositol (3,4)-bisphosphate and phosphatidylinositol (3,4,5)-trisphosphate. Production of these lipids was also sensitive to wortmannin. Our data suggest that EGF activates PI 3-kinase and that its lipid products may mediate the inhibitory effect of EGF on calcium-dependent chloride secretion. Our data also suggest that a phosphatidylinositol-specific 3-kinase activity is present in unstimulated TS, cells and may regulate production of phosphatidylinositol (3)-monophosphate and basal secretory tone.	UNIV CALIF SAN DIEGO,MED CTR,SCH MED,DEPT MED,SAN DIEGO,CA 92103	University of California System; University of California San Diego			Barrett, Kim/AAE-2794-2022; Barrett, Kim Elaine/AAE-7762-2019	Barrett, Kim Elaine/0000-0002-6704-998X; Keely, Stephen/0000-0002-6315-3587	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047240, R01DK028305, T32DK007202] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07202, DK28305, DK47240] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMED MU, 1995, J BIOL CHEM, V270, P23816, DOI 10.1074/jbc.270.40.23816; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; BARRETT KE, 1993, AM J PHYSIOL, V264, pC446, DOI 10.1152/ajpcell.1993.264.2.C446; BARRETT KE, 1993, AM J PHYSIOL, V265, pC859; CARTWRIGHT CA, 1985, J CLIN INVEST, V76, P1837, DOI 10.1172/JCI112176; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; DePaolo D, 1996, MOL CELL BIOL, V16, P1450; DHARMSATHAPHORN K, 1989, AM J PHYSIOL, V256, pC1224, DOI 10.1152/ajpcell.1989.256.6.C1224; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; ISMAILOV II, 1996, IN PRESS P NATL ACAD; KACHINTORN U, 1993, BRIT J PHARMACOL, V109, P510, DOI 10.1111/j.1476-5381.1993.tb13599.x; KACHINTORN U, 1993, AM J PHYSIOL, V264, pC671, DOI 10.1152/ajpcell.1993.264.3.C671; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Keely SJ, 1996, GASTROENTEROLOGY, V110, pA336; KHURANA S, 1996, GASTROENTEROLOGY, V101, pA337; MA YH, 1994, J BIOL CHEM, V269, P30734; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; MATTHEWS JB, 1992, J CLIN INVEST, V90, P1608, DOI 10.1172/JCI116030; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; OKADA T, 1994, J BIOL CHEM, V269, P3568; REENSTRA WW, 1993, AM J PHYSIOL, V264, pC161, DOI 10.1152/ajpcell.1993.264.1.C161; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SEYNAEVE CM, 1994, MOL PHARMACOL, V45, P1207; SMITH JA, 1996, GASTROENTEROLOGY S, V110, pA362; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STOYANOV B, 1995, SCIENCE, V269, P689; SUNG CK, 1994, J BIOL CHEM, V269, P12503; TOKER A, 1994, J BIOL CHEM, V269, P32358; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; URIBE JM, 1996, IN PRESS AM J PHYSL; VAJANAPHANICH M, 1994, NATURE, V371, P711, DOI 10.1038/371711a0; VAJANAPHANICH M, 1993, AM J PHYSIOL, V264, pC1210, DOI 10.1152/ajpcell.1993.264.5.C1210; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; WENNSTROM S, 1994, ONCOGENE, V9, P651; WINITZ S, 1993, J BIOL CHEM, V268, P19196	44	71	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26588	26595		10.1074/jbc.271.43.26588	http://dx.doi.org/10.1074/jbc.271.43.26588			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900131				2022-12-25	WOS:A1996VP23300025
J	Fueyo, J; GomezManzano, C; Bruner, JM; Saito, Y; Zhang, BH; Zhang, W; Levin, VA; Yung, WKA; Kyritsis, AP				Fueyo, J; GomezManzano, C; Bruner, JM; Saito, Y; Zhang, BH; Zhang, W; Levin, VA; Yung, WKA; Kyritsis, AP			Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas	ONCOGENE			English	Article						p16/CDKN2; glioma; methylation; tumor suppressor genes	CHRONIC MYELOGENOUS LEUKEMIA; TUMOR-SUPPRESSOR GENE; DNA METHYLATION; P16(INK4) EXPRESSION; BRAIN-TUMORS; RETINOBLASTOMA; DELETION; CANCERS; P16	There is considerable evidence that lack of p16 protein expression is a frequent event in human gliomas. Nevertheless, the molecular mechanisms underlying this absence of p16 protein expression are not completely understood. In some gliomas, homozygous deletions are the main cause of p16/CDKN2 gene inactivation. However, other gliomas lacking p16 expression exhibit intact p16/CDKN2 gene, suggesting that p16/CDKN2 is down-regulated at the transcriptional level. In this study we investigated whether aberrant p16/CDKN2 gene methylation correlated with absence of p16 expression in the latter group of gliomas. In a series of 27 gliomas, 12 malignant tumors exhibited loss of p16/CDKN2 expression but not gene deletion. Methylation analysis of the CpG island in the 5' region of the p16/CDKN2 gene showed that exon 1 was extensively methylated in six and partially methylated in the other six of the 12 malignant gliomas. In contrast, no methylation was observed in four other malignant gliomas and two low-grade gliomas that expressed p16 protein. These results indicate that abnormal hypermethylation of the CpG island encompassing the 5' end of the p16/CDKN2 gene may be a mechanism of transcriptional silencing in gliomas without homozygous deletions.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL,HOUSTON,TX	University of Texas System; UTMD Anderson Cancer Center	Fueyo, J (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROONCOL,HOUSTON,TX 77030, USA.			Fueyo, Juan/0000-0001-6941-2335; Gomez-Manzano, Candelaria/0000-0002-1259-2133	NATIONAL CANCER INSTITUTE [P01CA055261] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA55261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAP W, 1995, CANCER RES, V55, P1351; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BURGER PC, 1991, SURGICAL PATHOLOGY N, P193; Fueyo J, 1996, ONCOGENE, V12, P103; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GERADTS J, 1995, CANCER RES, V55, P6006; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; JEN J, 1994, CANCER RES, V54, P6353; JUNG JM, 1995, ONCOGENE, V11, P2021; Kyritsis AP, 1996, ONCOGENE, V12, P63; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NELKIN BD, 1991, BLOOD, V77, P2431; NISHIKAWA R, 1995, CANCER RES, V55, P1941; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SINGERSAM J, 1990, NUCLEIC ACID METHYLA, V128, P285; Ueki K, 1996, CANCER RES, V56, P150; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; YEAGER T, 1995, CANCER RES, V55, P493; ZION M, 1994, P NATL ACAD SCI USA, V91, P10722, DOI 10.1073/pnas.91.22.10722	28	77	81	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1615	1619						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895506				2022-12-25	WOS:A1996VM88700005
J	Ahmed, SA; McPhie, P; Miles, EW				Ahmed, SA; McPhie, P; Miles, EW			Mechanism of activation of the tryptophan synthase alpha(2)beta(2) complex - Solvent effects of the co-substrate beta-mercaptoethanol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ULTRAVIOLET VISIBLE SPECTROSCOPY; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; BIENZYME COMPLEX; L-SERINE; ASPARTATE-AMINOTRANSFERASE; 3-DIMENSIONAL STRUCTURE; ALLOSTERIC INTERACTIONS; 10-18-PPM RANGE; H-1 RESONANCES	To characterize the conformational transitions that lead to activation of catalysis by the tryptophan synthase alpha(2) beta(2), complex, we have determined the solvent effects of a co-substrate, beta-mercaptoethanol, and of a model nonsubstrate, ethanol, on the catalytic and spectroscopic properties of the enzyme. Our results show that ethanol and beta-mercaptoethanol both alter the equilibrium distribution of pyridoxal 5'-phosphate intermediates formed in the reactions of L-serine at the beta site in the alpha(2) beta(2) complex. Addition of increasing concentrations of ethanol increases the proportion of the external aldimine of L-serine and decreases the proportion of the external aldimine of aminoacrylate. Low concentrations of the co-substrate beta-mercaptoethanol (K-d = similar to 13 mM) decrease the proportion of the external aldimine of aminoacrylate and induce formation of the quinonoid of S-hydroxyethyl-L-cysteine. Higher concentrations of beta-mercaptoethanol decrease the concentration of the quinonoid intermediate and increase the proportion of the external aldimine of L-serine. Data analysis shows that beta-mercaptoethanol and ethanol both interact or bind preferentially with the conformer of the enzyme that predominates when the aldimine of L-serine is formed and shift the equilibrium in favor of this conformer. We propose that a nonpolar region of the beta subunit, possibly the hydrophobic indole tunnel, becomes less exposed to solvent in the conformational transition that activates the alpha(2) beta(2) complex.	NIDDK, BIOCHEM PHARMACOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								AHMED SA, 1991, J BIOL CHEM, V266, P21548; AHMED SA, 1994, J BIOL CHEM, V269, P16486; ANDERSON KS, 1995, J BIOL CHEM, V270, P29936; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; ARAKAWA T, 1990, CRYOBIOLOGY, V27, P401, DOI 10.1016/0011-2240(90)90017-X; AVDULOV NA, 1996, BICOHEMISTRY, V35, P840; BANIK U, 1995, BIOCHEMISTRY-US, V34, P12704, DOI 10.1021/bi00039a029; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; Butler JAV, 1933, J CHEM SOC, P674, DOI 10.1039/jr9330000674; COOK PF, 1976, J BIOL CHEM, V251, P2023; DREWE WF, 1986, BIOCHEMISTRY-US, V25, P2494, DOI 10.1021/bi00357a032; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; DUNN MF, 1987, INDIAN J BIOCHEM BIO, V24, P44; DUNN MF, 1994, ADV LIF SCI-SERIES, P119; EINHOFF W, 1987, BIOL CHEM H-S, V368, P405, DOI 10.1515/bchm3.1987.368.1.405; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; GOLDBERG ME, 1968, BIOCHEMISTRY-US, V7, P3662, DOI 10.1021/bi00850a045; HOUBEN KF, 1990, BIOCHEMISTRY-US, V29, P2421, DOI 10.1021/bi00461a028; Hur O, 1996, BIOCHEMISTRY-US, V35, P7378, DOI 10.1021/bi960240k; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JACOBSON RH, 1992, PROTEIN SCI, V1, P46; KALLEN RG, 1985, TRANSAMINASES, P37; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KIRLEY TL, 1990, J BIOL CHEM, V265, P4227; LANE AN, 1981, EUR J BIOCHEM, V120, P379, DOI 10.1111/j.1432-1033.1981.tb05715.x; LANE AN, 1983, EUR J BIOCHEM, V129, P561; LANE AN, 1983, EUR J BIOCHEM, V129, P571; LEJA CA, 1995, BIOCHEMISTRY-US, V34, P6552, DOI 10.1021/bi00019a037; METZLER CM, 1980, J AM CHEM SOC, V102, P6075, DOI 10.1021/ja00539a017; METZLER DE, 1994, J BIOL CHEM, V269, P28027; METZLER DE, 1994, J BIOL CHEM, V269, P28017; Miles E W, 1995, Subcell Biochem, V24, P207; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; Miles E.W., 1986, PYRIDOXAL PHOSPHAT B, V1, P253; Miles Edith Wilson, 1994, P127, DOI 10.1002/9783527615971.ch7; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1989, J BIOL CHEM, V264, P6280; MILES EW, 1968, BIOCHEMISTRY-US, V7, P2742, DOI 10.1021/bi00848a008; MILES EW, 1980, BIOCH MED ASPECTS TR, P137; MOZZARELLI A, 1989, J BIOL CHEM, V264, P15774; MOZZARELLI A, 1991, INT UNION B, V199, P273; Pan P, 1996, BIOCHEMISTRY-US, V35, P5002, DOI 10.1021/bi960033k; Peracchi A, 1996, BIOCHEMISTRY-US, V35, P1872, DOI 10.1021/bi951889c; PERRY LJ, 1984, SCIENCE, V226, P555, DOI 10.1126/science.6387910; REKKER RF, 1979, EUR J MED CHEM, V14, P479; RUVINOV SB, 1995, J BIOL CHEM, V270, P17333, DOI 10.1074/jbc.270.29.17333; RUVINOV SB, 1995, J BIOL CHEM, V270, P6357, DOI 10.1074/jbc.270.11.6357; SCHNACKERZ KD, 1979, BIOCHEMISTRY-US, V18, P3557, DOI 10.1021/bi00583a019; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Swift S, 1991, Biotechnol Genet Eng Rev, V9, P229; Timasheff S N, 1995, Methods Mol Biol, V40, P253; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; TONG HX, 1995, BIOCHEMISTRY-US, V34, P3362, DOI 10.1021/bi00010a027; WOEHL EU, 1995, BIOCHEMISTRY-US, V34, P9466, DOI 10.1021/bi00029a023; Wyman J, 1968, Q Rev Biophys, V1, P35; YANG XJ, 1992, PROTEIN EXPRES PURIF, V3, P347, DOI 10.1016/1046-5928(92)90011-K; YANOFSKY C, 1972, ENZYMES, V7, P1	58	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29100	29106		10.1074/jbc.271.46.29100	http://dx.doi.org/10.1074/jbc.271.46.29100			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910565	hybrid			2022-12-25	WOS:A1996VT05200057
J	Nakshatri, H; BhatNakshatri, P; Currie, RA				Nakshatri, H; BhatNakshatri, P; Currie, RA			Subunit association and DNA binding activity of the heterotrimeric transcription factor NF-Y is regulated by cellular redox	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT-BINDING; CLASS-II; HETEROLOGOUS SUBUNITS; GENE-TRANSCRIPTION; ACTIVITY INVITRO; REPAIR ENZYME; KAPPA-B; PROTEIN; ACTIVATION; COMPLEX	NF-Y is a heterotrimeric transcription factor that specifically recognizes a CCAAT box motif found in a variety of eukaryotic promoter and enhancer elements. The subunit association and DNA binding properties of the NF-Y complex were examined as a function of redox state using recombinant NP-YA, NF-YB, and NF-YC subunits. Reduction of NF-YB by dithiothreitol (DTT) was essential for reconstitution of specific NF-Y CCAAT box DNA binding activity in vitro. Approximately 30% of the Escherichia coli-derived NF-YB subunit existed as intermolecular disulfide-linked dimers. NF-YB mutants in which the highly conserved cysteine residues at positions 85 and 89 had been converted to serines existed only as monomers and did not require DTT for functional NF-Y DNA binding activity. DTT was required, however, for the functional association of NF-YC with wild-type NF-YB but not with the NF-YB cysteine mutants. The cellular redox factors Ref-1 and adult T-cell leukemia-derived factor stimulated the DNA binding activity of recombinant NF-Y in the absence of DTT. Cells treated with 1-chloro-2,4-dinitrobenzene, an irreversible inhibitor of thioredoxin reductase, exhibited reduced endogenous NF-Y DNA binding activity. Together these results suggest that the cellular redox environment of mammalian cells is an important posttranscriptional regulator of NF-Y subunit association and DNA binding activities.	PICOWER INST MED RES,LAB GENE REGULAT,MANHASSET,NY 11030	Northwell Health			; Currie, Richard/N-6074-2017	Nakshatri, Harikrishna/0000-0001-8876-0052; Currie, Richard/0000-0002-6528-3326	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047272, R29DK047272] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47272] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARNER ESJ, 1995, J BIOL CHEM, V270, P3479, DOI 10.1074/jbc.270.8.3479; ARNONE MI, 1995, J BIOL CHEM, V270, P12048, DOI 10.1074/jbc.270.20.12048; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; BENEZRA R, 1994, CELL, V79, P1057, DOI 10.1016/0092-8674(94)90036-1; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BOUCHER PD, 1995, MOL CELL BIOL, V15, P5144; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLELAND JL, 1992, BIO-TECHNOL, V10, P1013, DOI 10.1038/nbt0992-1013; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; Duh JL, 1995, J BIOL CHEM, V270, P30499, DOI 10.1074/jbc.270.51.30499; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; Harlow E., 1988, ANTIBODIES LAB MANUA; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; INOSTROZA JA, 1992, CELL, V70, P477; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; KWON JB, 1993, GENE, V132, P227, DOI 10.1016/0378-1119(93)90200-M; LARSSON LG, 1993, LEUKEMIA, V7, P226; LI XY, 1992, NUCLEIC ACIDS RES, V20, P1087, DOI 10.1093/nar/20.5.1087; LI XY, 1992, J BIOL CHEM, V267, P8984; LLOBERAS J, 1995, MOL CELL BIOL, V15, P5092; MAITY SN, 1992, J BIOL CHEM, V267, P8286; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; MATHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821; MCBRIDE AA, 1992, P NATL ACAD SCI USA, V89, P7531, DOI 10.1073/pnas.89.16.7531; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; NAKSHATRI H, 1995, J BIOL CHEM, V270, P19613, DOI 10.1074/jbc.270.33.19613; OLESEN JT, 1990, GENE DEV, V4, P1714, DOI 10.1101/gad.4.10.1714; PELEG S, 1989, BIOCHEMISTRY-US, V28, P7373, DOI 10.1021/bi00444a034; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; Sambrook J., 2002, MOL CLONING LAB MANU; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SILVA CM, 1989, J BIOL CHEM, V264, P6638; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SINHA S, 1996, MOL CELL BIOL, V16, P31; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; VANHUIJSDUIJNEN RAMH, 1987, NUCLEIC ACIDS RES, V15, P7265, DOI 10.1093/nar/15.18.7265; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XING YY, 1993, EMBO J, V12, P4647, DOI 10.1002/j.1460-2075.1993.tb06153.x; XING YY, 1994, P NATL ACAD SCI USA, V91, P3009, DOI 10.1073/pnas.91.8.3009; YAO Y, 1995, ENVIRON HEALTH PERSP, V103, P366, DOI 10.2307/3432290; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	57	82	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28784	28791		10.1074/jbc.271.46.28784	http://dx.doi.org/10.1074/jbc.271.46.28784			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910521	hybrid, Green Published			2022-12-25	WOS:A1996VT05200013
J	Tachias, K; Madison, EL				Tachias, K; Madison, EL			Converting tissue-type plasminogen activator into a zymogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; SITE-DIRECTED MUTAGENESIS; REFINED CRYSTAL-STRUCTURE; STRONG LIGAND-BINDING; BOVINE TRYPSINOGEN; CRYSTALLOGRAPHIC REFINEMENT; PROTEOLYTIC-ENZYMES; ONE-CHAIN; STREPTOKINASE; RESOLUTION	In striking contrast to most other members of the chymotrypsin family of serine proteases, tissue-type plasminogen activator (t-PA) is not synthesized and secreted as a true zymogen. The zymogenicity, or ratio of the catalytic efficiencies of the mature, two-chain enzyme and the single-chain precursor, is only 5-10 for t-PA. This exceptional property of t-PA, however, is not shared by urokinase (u-PA), a plasminogen activator that is very closely related to t-PA. The molecular basis of this important functional distinction between these two intimately related serine proteases has not been previously investigated. Based on observation of the recently described structures of the protease domains of two-chain t-PA and u-PA, and molecular modeling of the corresponding single-chain enzymes, we propose that the presence or absence of an acidic residue at position 144 (chymotrypsin numbering system) is the primary determinant of the distinct zymogenicities of the two enzymes. Consistent with this hypothesis, mutation of histidine 144 of t-PA to an acidic residue, as in u-PA, selectively suppressed the activity of single-chain t-PA and thereby significantly enhanced the enzyme's zymogenicity. A variant of t-PA containing an aspartate residue at position 144, for example, exhibited a zymogenicity of 150, compared to a value of 9 for wild type t-PA and 250 for u-PA.	Scripps Res Inst, RES INST, DEPT VASC BIOL VB1, LA JOLLA, CA 92037 USA	Scripps Research Institute					NHLBI NIH HHS [P01 HL31950, R01 HL52475] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052475, P01HL031950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEATTY K, 1980, J BIOL CHEM, V255, P3931; BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; BODE W, 1976, FEBS LETT, V68, P231, DOI 10.1016/0014-5793(76)80443-7; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1979, J MOL BIOL, V127, P357, DOI 10.1016/0022-2836(79)90227-4; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; BOOSE JA, 1989, BIOCHEMISTRY-US, V28, P635, DOI 10.1021/bi00428a033; COLLEN D, 1991, BLOOD, V78, P3114; COLLEN D, 1995, THROMB HAEMOSTASIS, V74, P167; COLLEN D, 1992, HEART CARDIOVASCULAR, P275; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P3585, DOI 10.1021/bi00466a023; FEHLHAMMER H, 1977, J MOL BIOL, V111, P415, DOI 10.1016/S0022-2836(77)80062-4; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; GERTLER A, 1974, BIOCHEMISTRY-US, V13, P1302, DOI 10.1021/bi00703a038; HEMKER HC, 1975, BIOCHIM BIOPHYS ACTA, V379, P180, DOI 10.1016/0005-2795(75)90020-3; HENDRIX H, 1983, J BIOL CHEM, V258, P3637; HIGH K, 1995, MOL BASIS THROMBOSIS; HOLMES WE, 1987, BIOCHEMISTRY-US, V26, P5133, DOI 10.1021/bi00390a036; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; HUBER R, 1983, BIOPOLYMERS, V22, P261, DOI 10.1002/bip.360220136; KERR MA, 1976, BIOCHEMISTRY-US, V15, P5566, DOI 10.1021/bi00670a022; KOSSIAKOFF AA, 1977, BIOCHEMISTRY-US, V16, P654, DOI 10.1021/bi00623a016; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMBA B, 1996, J MOL BIOL, V258, P117; LIJNEN HR, 1992, FIBRINOLYSIS, V6, P33, DOI 10.1016/0268-9499(92)90045-J; LIJNEN HR, 1990, J BIOL CHEM, V265, P5232; LIJNEN HR, 1991, THROMB HAEMOSTASIS, V66, P88; LIJNEN HR, 1988, ENZYME, V40, P90, DOI 10.1159/000469150; LIJNEN HR, 1990, THROMB RES S10, V57, P45; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MADISON EL, 1993, SCIENCE, V262, P419, DOI 10.1126/science.8211162; MADISON EL, 1994, FIBRINOLYSIS, V8, P221, DOI 10.1016/0268-9499(94)90720-X; MANN K, 1993, METHOD ENZYMOL, V223, P145; MATTHEWS BW, 1967, NATURE, V214, P652, DOI 10.1038/214652a0; MILES LA, 1985, J BIOL CHEM, V260, P4303; NEINABER VL, 1992, BIOCHEMISTRY-US, V31, P3852; NEURATH H, 1989, TRENDS BIOCHEM SCI, V14, P268, DOI 10.1016/0968-0004(89)90061-3; NEURATH H, 1986, J CELL BIOCHEM, V32, P35, DOI 10.1002/jcb.240320105; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; PETERSEN LC, 1988, BIOCHIM BIOPHYS ACTA, V952, P245, DOI 10.1016/0167-4838(88)90123-9; RANBY M, 1982, THROMB RES, V27, P175, DOI 10.1016/0049-3848(82)90197-9; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; REDDY KNN, 1988, ENZYME, V40, P79, DOI 10.1159/000469149; ROBINSON NC, 1973, BIOCHEMISTRY-US, V12, P420, DOI 10.1021/bi00727a010; SCHICK LA, 1973, BIOCHEMISTRY-US, V12, P4315, DOI 10.1021/bi00746a003; SIGLER PB, 1968, J MOL BIOL, V35, P143, DOI 10.1016/S0022-2836(68)80043-9; SILVERBERG M, 1982, BLOOD, V60, P64; Smith JW, 1995, J BIOL CHEM, V270, P30486, DOI 10.1074/jbc.270.51.30486; SPRAGGON G, 1995, STRUCTURE, V3, P681, DOI 10.1016/S0969-2126(01)00203-9; STEITZ TA, 1969, J MOL BIOL, V46, P337, DOI 10.1016/0022-2836(69)90426-4; STRANDBERG L, 1995, J BIOL CHEM, V270, P23444, DOI 10.1074/jbc.270.40.23444; STROUD RM, 1974, J MOL BIOL, V83, P185, DOI 10.1016/0022-2836(74)90387-8; SUMMARIA L, 1974, J BIOL CHEM, V249, P4760; TACHIAS K, 1995, J BIOL CHEM, V270, P18319, DOI 10.1074/jbc.270.31.18319; TATE KM, 1987, BIOCHEMISTRY-US, V26, P338, DOI 10.1021/bi00376a002; WANG DC, 1985, J MOL BIOL, V185, P595, DOI 10.1016/0022-2836(85)90074-9; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	59	31	44	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28749	28752		10.1074/jbc.271.46.28749	http://dx.doi.org/10.1074/jbc.271.46.28749			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910515	hybrid			2022-12-25	WOS:A1996VT05200007
J	Dang, Q; Taylor, J				Dang, Q; Taylor, J			In vivo footprinting analysis of the hepatic control region of the human apolipoprotein E/C-I/C-IV/C-II gene locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; LIGATION-MEDIATED PCR; DOMINANT CONTROL REGION; MOUSE ALBUMIN PROMOTER; TRANSGENIC MICE; GLOBIN GENE; C-I; NUCLEAR PROTEINS; ALZHEIMERS-DISEASE; REGULATORY ELEMENT	Expression of both the apolipoprotein (apo)E and apoC-I genes in the liver is specified by a 319-nucleotide hepatic control region (HCR-1) that is located 15 kilobase pairs downstream of the apoE gene and 5 kilobase pairs downstream of the apoC-I gene. In vivo footprint analysis of HCR-1 in intact nuclei revealed several liver-specific protein-binding sites that were not detectable by in vitro methods. In addition to three previously identified in vitro footprints, four in vivo footprints were identified in a region of HCR-1 that is required for directing gene expression to hepatocytes. Prominent liver-specific DNase I-hypersensitive sites were associated with these footprints. Liver-specific nuclear protein binding to these sites was confirmed by oligonucleotide gel-retention assays. The in vivo analysis also identified a cluster of nuclear protein-binding sites in the Alu family repeat segment adjacent to the domain required for liver expression. Micrococcal nuclease digestion indicated the presence of a nucleosome in the central domain of HCR-1 in liver chromatin that was in phase with the nucleosome location in tissues that did not express the transgene. These results suggest that HCR-1 functions in a highly structured chromatin environment requiring a complex interaction of liver enriched transcription factors.	UNIV CALIF SAN FRANCISCO, GLADSTONE INST CARDIOVASC DIS, CARDIOVASC RES INST, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco					NHLBI NIH HHS [HL07731, HL37063] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037063] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN CM, 1995, J BIOL CHEM, V270, P26278, DOI 10.1074/jbc.270.44.26278; ALLAN CM, 1995, GENOMICS, V28, P291, DOI 10.1006/geno.1995.1144; ARCINAS M, 1994, J BIOL CHEM, V269, P21919; BRECKENRIDGE WC, 1978, NEW ENGL J MED, V298, P1265, DOI 10.1056/NEJM197806082982301; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHANG DJ, 1990, J BIOL CHEM, V265, P9496; CHURCHILL MEA, 1995, EMBO J, V14, P1264, DOI 10.1002/j.1460-2075.1995.tb07110.x; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; COWIE A, 1988, MOL CELL BIOL, V8, P3122, DOI 10.1128/MCB.8.8.3122; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DANG Q, 1995, J BIOL CHEM, V270, P22577, DOI 10.1074/jbc.270.38.22577; DAS HK, 1985, J BIOL CHEM, V260, P6240; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; ENGLANDER EW, 1995, J BIOL CHEM, V270, P10091, DOI 10.1074/jbc.270.17.10091; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FENG WC, 1994, J BIOL CHEM, V269, P1493; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; GANTER B, 1993, J MOL BIOL, V234, P975, DOI 10.1006/jmbi.1993.1652; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GONG QH, 1991, MOL CELL BIOL, V11, P2558, DOI 10.1128/MCB.11.5.2558; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GUMUCIO DL, 1992, MOL CELL BIOL, V12, P4919, DOI 10.1128/MCB.12.11.4919; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; JACKSON JR, 1993, NUCLEIC ACIDS RES, V21, P957, DOI 10.1093/nar/21.4.957; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; LAUER SJ, 1988, J BIOL CHEM, V263, P7277; LI Q, 1995, MOL CELL BIOL, V15, P4375; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; LIU JK, 1988, GENE DEV, V2, P528, DOI 10.1101/gad.2.5.528; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1984, J LIPID RES, V25, P1277; Maxam A M, 1980, Methods Enzymol, V65, P499; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; METZGER S, 1990, J BIOL CHEM, V265, P9978; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; OCHOA A, 1989, NUCLEIC ACIDS RES, V17, P119, DOI 10.1093/nar/17.1.119; OLAISEN B, 1982, HUM GENET, V62, P233, DOI 10.1007/BF00333526; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PAIK YK, 1985, P NATL ACAD SCI USA, V82, P3445, DOI 10.1073/pnas.82.10.3445; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PHILIPSEN S, 1993, EMBO J, V12, P1077, DOI 10.1002/j.1460-2075.1993.tb05749.x; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; REARDON CA, 1986, J BIOL CHEM, V261, P9858; SAFFER JD, 1989, MOL CELL BIOL, V9, P355, DOI 10.1128/MCB.9.2.355; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SEHAYEK E, 1991, J BIOL CHEM, V266, P18259; SHACHTER NS, 1993, J LIPID RES, V34, P1699; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SIMONET WS, 1991, J BIOL CHEM, V266, P8651; SIMONET WS, 1990, J BIOL CHEM, V265, P10809; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SUN JM, 1992, NUCLEIC ACIDS RES, V20, P6385, DOI 10.1093/nar/20.23.6385; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; WATT P, 1990, NUCLEIC ACIDS RES, V18, P1339, DOI 10.1093/nar/18.6.1339; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; WHITELAW E, 1990, MOL CELL BIOL, V10, P6596, DOI 10.1128/MCB.10.12.6596; Wolffe AP, 1996, TRENDS GENET, V12, P58, DOI 10.1016/0168-9525(96)81401-6; ZHANG QY, 1993, MOL CELL BIOL, V13, P2298, DOI 10.1128/MCB.13.4.2298	71	18	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28667	28676		10.1074/jbc.271.45.28667	http://dx.doi.org/10.1074/jbc.271.45.28667			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910501	hybrid			2022-12-25	WOS:A1996VU03300101
J	Ershov, AV; Lukiw, WJ; Bazan, NG				Ershov, AV; Lukiw, WJ; Bazan, NG			Selective transcription factor induction in retinal pigment epithelial cells during photoreceptor phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTORS ENCODES; ROD OUTER SEGMENTS; BINDING PROTEIN; PHYSIOLOGICAL-ROLE; GENE-EXPRESSION; DNA-BINDING; RAT; RECEPTOR; CULTURE; SPECIFICITY	Expression of early response genes during rod outer segment phagocytosis by normal Long Evans and Royal College of Surgeons-rdy(+)p(+) rats and by dystrophic Royal College of Surgeons-p(+) rat retinal pigment epithelial cells was studied in primary cell culture. Northern analysis revealed that the abundance of zif-268 (egr-1), c-fos, and tis-1 (NGF1-B) mRNA was rapidly and transiently increased in normal retinal pigment epithelial cells during rod outer segment phagocytosis but not during phagocytosis of latex particles. No increase in gene expression was found in Royal College of Surgeons-p(+) dystrophic retinal pigment epithelial cells challenged with rod outer segments. As shown by electrophoretic mobility shift assay, a prominent short term increase in the intensity of the gel-shifted band was detected using nuclear protein extracts derived from rod outer segment-challenged, control retinal pigment epithelial cells and zif-268, AP-1, AP-2, or tis-1 consensus oligonucleotides. No such increase was detected when using nuclear factor KB consensus oligonucleotide or when the early response gene prostaglandin H synthase-2 mRNA was measured over the time course studied. The results suggest that in retinal pigment epithelial cells, rad outer segment-specific phagocytosis is accompanied by the selective expression of early response genes coding for transcription factors. The specific pattern of the induction of these transcription factors is predicted to modulate the expression of gene cascades.	LOUISIANA STATE UNIV,MED CTR,CTR NEUROSCI,NEW ORLEANS,LA 70112; LOUISIANA STATE UNIV,MED CTR,DEPT OPHTHALMOL,NEW ORLEANS,LA 70112	Louisiana State University System; Louisiana State University System			Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444	NEI NIH HHS [EY05121] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005121] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adunyah SE, 1996, BIOCHEM BIOPH RES CO, V221, P213, DOI 10.1006/bbrc.1996.0576; ARENANDER AT, 1989, J NEUROSCI RES, V23, P257, DOI 10.1002/jnr.490230303; BAUER R, 1994, NUCLEIC ACIDS RES, V22, P1413, DOI 10.1093/nar/22.8.1413; BAZAN NG, 1992, ADV EXP MED BIOL, V318, P295; BAZAN NG, 1985, J BIOL CHEM, V260, P3677; BOK D, 1971, J CELL BIOL, V49, P664, DOI 10.1083/jcb.49.3.664; BOYLE D, 1991, INVEST OPHTH VIS SCI, V32, P1464; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CEGLAREK JA, 1989, ELECTROPHORESIS, V10, P360, DOI 10.1002/elps.1150100514; CHAITIN MH, 1983, INVEST OPHTH VIS SCI, V24, P812; CHEN HM, 1993, EXP EYE RES, V57, P369, DOI 10.1006/exer.1993.1136; CHEN Y, 1994, BIOCHEMISTRY-US, V33, P10658, DOI 10.1021/bi00201a013; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COLLART MA, 1989, ONCOGENE, V4, P237; DOUCET JP, 1990, MOL NEUROBIOL, V4, P27, DOI 10.1007/BF02935584; EDWARDS RB, 1977, SCIENCE, V197, P1001, DOI 10.1126/science.560718; ERSHOV AV, 1995, INVEST OPHTH VIS SCI, V36, pS815; HALL MO, 1987, EXP EYE RES, V45, P907, DOI 10.1016/S0014-4835(87)80105-7; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; LAVAIL MM, 1981, INVEST OPHTH VIS SCI, V20, P671; LIM RW, 1987, ONCOGENE, V1, P263; LUKIW WJ, 1994, MOL BRAIN RES, V22, P121, DOI 10.1016/0169-328X(94)90039-6; MAASS A, 1994, BIOCHEM BIOPH RES CO, V202, P1337, DOI 10.1006/bbrc.1994.2077; MAYERSON PL, 1986, J CELL BIOL, V103, P299, DOI 10.1083/jcb.103.1.299; MAYERSON PL, 1985, INVEST OPHTH VIS SCI, V26, P1599; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOSER M, 1993, NUCLEIC ACIDS RES, V21, P4844, DOI 10.1093/nar/21.20.4844; OBANION MK, 1991, J BIOL CHEM, V266, P23261; OKAJIMA TIL, 1990, P NATL ACAD SCI USA, V87, P6907, DOI 10.1073/pnas.87.17.6907; OKAJIMA TIL, 1994, J BIOL CHEM, V269, P21983; ONG DE, 1994, BIOCHEMISTRY-US, V33, P1835, DOI 10.1021/bi00173a029; PEPPERBERG DR, 1993, MOL NEUROBIOL, V7, P61, DOI 10.1007/BF02780609; PHILP NJ, 1981, EXP EYE RES, V33, P47, DOI 10.1016/S0014-4835(81)80080-2; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; RYSECK RP, 1992, CELL GROWTH DIFFER, V3, P443; SEYFRIEDWILLIAMS R, 1984, EXP CELL RES, V154, P500, DOI 10.1016/0014-4827(84)90174-5; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; ZHANG DE, 1990, J BIOL CHEM, V265, P3382	46	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28458	28462		10.1074/jbc.271.45.28458	http://dx.doi.org/10.1074/jbc.271.45.28458			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910472	hybrid			2022-12-25	WOS:A1996VU03300072
J	Kalb, A; Bluethmann, H; Moore, MW; Lesslauer, W				Kalb, A; Bluethmann, H; Moore, MW; Lesslauer, W			Tumor necrosis factor receptors (Tnfr) in mouse fibroblasts deficient in Tnfr1 or Tnfr2 are signaling competent and activate the mitogen-activated protein kinase pathway with differential kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HEAT-SHOCK PROTEIN; FACTOR INCREASE PHOSPHORYLATION; MAP KINASE; FACTOR-ALPHA; CYTOPLASMIC DOMAIN; TYROSINE PHOSPHORYLATION; PROLONGED ACTIVATION; MOLECULAR-CLONING; VIRAL-PROTEINS	To dissect tumor necrosis factor receptor (Tnfr)-1 (CD120a) and Tnfr2 (CD120b)-dependent signal transduction pathways, primary fibroblasts isolated from inguinal adipose tissue of wild type (wt), tnfr1 degrees, tnfr2 degrees, and tnfr1 degrees/tnfr2 degrees mice were studied. The mitogen-activated protein kinases Erk1 and Erk2 were found to be tyrosine-phosphorylated and activated by Tnf treatment in all wt, tnfr1 degrees, and tnfr2 degrees fibroblasts; the activation was down-regulated 60 min after the start of steady state Tnf treatment. Distinct kinetics of Erk1 and Erk2 activation were detected; the Tnfr1-mediated activation of Erk1 and Erk2 started more slowly and persisted for more prolonged times as compared with Tnfr2 activation. Raf-1, Raf-B, Mek-1, Mek kinase, and p90(rsh) kinases were also shown to be activated independently in a distinct time-dependent pattern through the two Tnf receptors. In addition, both Tnfr1 and Tnfr2 mediated independently the activation of the transcription factor Ap-1 albeit with parallel activation kinetics. In contrast, Tnfr1 exclusively mediated activation of NF-kappa B and fibroblast proliferation; however, Tnfr2 enhanced proliferation triggered through Tnfr1 These findings indicate distinct but also overlapping roles of Tnfr1 and Tnfr2 in primary mouse fibroblasts and suggest different regulation mechanisms of signal transduction pathways under the control of both Tnf receptors.	HOFFMANN LA ROCHE AG, DEPT NERVOUS SYST DIS PRPN, CH-4070 BASEL, SWITZERLAND; HOFFMANN LA ROCHE AG, DEPT GENE TECHNOL PRPG, CH-4070 BASEL, SWITZERLAND; GENENTECH INC, DEPT IMMUNOL, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Roche Holding; Roche Holding; Genentech								ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Bazzoni F, 1995, J INFLAMM, V45, P221; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BEUTLER BE, 1992, TUMOR NECROSIS FACTO; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CATLING AD, 1994, J BIOL CHEM, V269, P30014; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; DARNAY BG, 1994, J BIOL CHEM, V269, P20299; DARNAY BG, 1995, J BIOL CHEM, V270, P14867, DOI 10.1074/jbc.270.25.14867; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; EVANS TJ, 1994, J EXP MED, V180, P2173, DOI 10.1084/jem.180.6.2173; GEHR G, 1992, J IMMUNOL, V149, P911; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUESDON F, 1994, BIOCHEM J, V304, P761, DOI 10.1042/bj3040761; GUY GR, 1991, J BIOL CHEM, V266, P14343; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HELLER RA, 1993, CELL, V73, P216, DOI 10.1016/0092-8674(93)90223-D; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KAUR P, 1989, FEBS LETT, V258, P269, DOI 10.1016/0014-5793(89)81671-0; KAUR P, 1988, FEBS LETT, V241, P6, DOI 10.1016/0014-5793(88)81019-6; KOHNO M, 1990, BIOCHEM J, V267, P91, DOI 10.1042/bj2670091; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; LOETSCHER H, 1990, J BIOL CHEM, V265, P20131; LOETSCHER H, 1991, CANCER CELL-MON REV, V3, P221; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOETSCHER H, 1993, INT CONGR SER, V1020, P455; MACKAY F, 1994, J IMMUNOL, V153, P5274; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; MOSIALOS G, 1995, CELL, V80, P1; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SAKLATVALA J, 1993, FEBS LETT, V334, P189, DOI 10.1016/0014-5793(93)81709-9; SAKLATVALA J, 1991, BIOCHEM J, V277, P635, DOI 10.1042/bj2770635; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SIDHU RS, 1993, PHARMACOL THERAPEUT, V57, P79, DOI 10.1016/0163-7258(93)90037-E; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; STORM SM, 1990, ONCOGENE, V5, P345; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TRAVERSE S, 1994, FEBS LETT, V350, P13, DOI 10.1016/0014-5793(94)00723-3; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VIETOR I, 1993, J BIOL CHEM, V268, P18994; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WIEGMANN K, 1992, J BIOL CHEM, V267, P24069; WONG GHW, 1992, J IMMUNOL, V149, P3350; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5	75	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28097	28104		10.1074/jbc.271.45.28097	http://dx.doi.org/10.1074/jbc.271.45.28097			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910423	hybrid			2022-12-25	WOS:A1996VU03300023
J	Li, Y; Zhang, YL; Yan, HG				Li, Y; Zhang, YL; Yan, HG			Kinetic and thermodynamic characterizations of yeast guanylate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR SUPPRESSOR GENE; AMINO-ACID SEQUENCE; ADENYLATE KINASE; SUBSTRATE GMP; X-RAY; PROTEIN; EXPRESSION; MECHANISM; DIFFUSION; PHOSPHORYLATION	Yeast guanylate kinase was expressed at high level in Escherichia coli using pET-17b vector. It was purified to homogeneity by a simple two-column procedure with an average yield of similar to 100 mg/liter. The steady-state kinetic parameters for both forward and reverse reactions were determined by initial velocity measurements. The turnover numbers (k(cat)) were 394 s(-1) for the forward reaction (formation of ADP and GDP) and 90 s(-1) for the reverse reaction (formation of ATP and GMP). K-m values were 0.20, 0.091, 0.017, and 0.097 mM for MgATP, GMP, MgADP, and GDP, respectively. Analysis of the initial velocity patterns indicated a sequential mechanism. GMP was found to have partial substrate inhibition. The substrate inhibition was not competitive with MgATP and could be attributed to formation of the abortive complex guanylate kinase . MgADP . GMP. The equilibrium constant of the reaction was measured under various conditions by NMR and a radiometric assay. The results showed that the steady-state kinetic parameters were consistent with the thermodynamic constant. NMR titration and equilibrium dialysis showed that both substrates and products could bind to free guanylate kinase, The dissociation constants were 0.090, 0.18, 0.029, 0.084, and 0.12 mM for MgATP, ATP, GMP, MgADP, and GDP, respectively, Viscosity-dependent kinetics was used to identify the rate-limiting steps of the reaction. The results indicated that the reaction rate is largely controlled by the chemical step.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA	Michigan State University					NIGMS NIH HHS [GM51901] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051901] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; Agarwal K C, 1978, Methods Enzymol, V51, P483; BERGER A, 1989, EUR J BIOCHEM, V184, P433, DOI 10.1111/j.1432-1033.1989.tb15035.x; BLACKLOW SC, 1988, BIOCHEMISTRY-US, V27, P1158, DOI 10.1021/bi00404a013; BOEHME RE, 1984, J BIOL CHEM, V259, P2346; BROUWER AC, 1982, BIOCHEMISTRY-US, V21, P1302, DOI 10.1021/bi00535a030; BRYANT PJ, 1992, CELL, V68, P621, DOI 10.1016/0092-8674(92)90136-Z; CALDWELL SR, 1991, BIOCHEMISTRY-US, V30, P7438, DOI 10.1021/bi00244a010; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Cleland W. W., 1986, INVESTIGATIONS RATES, V6, P791; CLELAND WW, 1975, BIOCHEMISTRY-US, V14, P3220, DOI 10.1021/bi00685a029; GAIDAROV IO, 1993, FEBS LETT, V335, P81, DOI 10.1016/0014-5793(93)80444-Y; GENTRY D, 1993, J BIOL CHEM, V268, P14316; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLICKMAN MH, 1995, BIOCHEMISTRY-US, V34, P14077, DOI 10.1021/bi00043a013; HALL SW, 1986, EUR J BIOCHEM, V161, P551, DOI 10.1111/j.1432-1033.1986.tb10477.x; HARDY LW, 1984, BIOCHEMISTRY-US, V23, P1282, DOI 10.1021/bi00301a041; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KONRAD M, 1992, J BIOL CHEM, V267, P25652; Kramers HA, 1940, PHYSICA, V7, P284, DOI 10.1016/S0031-8914(40)90098-2; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; LIANG P, 1991, PROTEINS, V9, P28, DOI 10.1002/prot.340090105; MILLER WH, 1980, J BIOL CHEM, V255, P7204; MORIGUCHI M, 1980, BIOCHIM BIOPHYS ACTA, V662, P165; MULLERDIECKMANN HJ, 1995, J MOL BIOL, V246, P522; STEHLE T, 1992, J MOL BIOL, V224, P1127, DOI 10.1016/0022-2836(92)90474-X; STEHLE T, 1990, J MOL BIOL, V211, P249, DOI 10.1016/0022-2836(90)90024-G; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SU S, 1968, J BIOL CHEM, V243, P3826; TIAN G, 1990, BIOCHEMISTRY-US, V29, P4296, DOI 10.1021/bi00470a006; TSAI MD, 1991, BIOCHEMISTRY-US, V30, P6806, DOI 10.1021/bi00242a002; WEBER G, 1992, ADV ENZYME REGUL, V32, P57; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; ZSCHOCKE PD, 1993, EUR J BIOCHEM, V213, P263, DOI 10.1111/j.1432-1033.1993.tb17757.x	34	47	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28038	28044		10.1074/jbc.271.45.28038	http://dx.doi.org/10.1074/jbc.271.45.28038			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910414	hybrid			2022-12-25	WOS:A1996VU03300014
J	McCallum, CD; Hapak, RC; Neuenschwander, PF; Morrissey, JH; Johnson, AE				McCallum, CD; Hapak, RC; Neuenschwander, PF; Morrissey, JH; Johnson, AE			The location of the active site of blood coagulation factor VIIa above the membrane surface and its reorientation upon association with tissue factor - A fluorescence energy transfer study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND IMMUNOGLOBULIN-E; FACTOR-X; PHOSPHOLIPID SURFACE; CONFORMATIONAL SENSITIVITY; ORIENTATION FACTOR; COFACTOR FUNCTION; PROTEASE DOMAIN; BINDING-SITE; FACTOR-IXA; FACTOR-VA	The topography of membrane-bound blood coagulation factor VIIa (fVIIa) was examined by positioning a fluorescein dye in the active site of fVIIa via a tripeptide tether to yield fluorescein-D-phenylalanyI-L-prolyl-L-arginy-L-fVIIa (FI-FPR-fVIIa). The location of the active-site probe relative to the membrane surface was determined, both in the presence and absence of tissue factor (TF), using fluorescence energy transfer between the fluorescein dye and octadecylrhodamine (OR) at the phospholipid vesicle surface. When FI-FPR-fVIIa was titrated with phospholipid vesicles containing OR, the magnitude of OR-, calcium ion-, and phosphatidylserine-dependent fluorescence energy transfer revealed that the average distance of closest approach between fluorescein in the active site of fVIIa and OR at the vesicle surface is 82 Angstrom assuming a random orientation of donor and acceptor dyes (kappa(2) = 2/3; the orientational uncertainty totals similar to 10%). The active site of fVIIa is therefore located far above the membrane surface, and the elongated fVIIa molecule must bind at one end to the membrane and project approximately perpendicularly out of the membrane. When FI-FPR-fVIIa was titrated with vesicles that contained TF, the efficiency of energy transfer was increased by a TF-dependent translational and/or rotational movement of the fVIIa protease domain relative to the membrane surface. if this movement was solely translational, the height of the active site of fVIIa was lowered by an average of 6 Angstrom after binding to TF. The association of fVIIa with TF on the membrane surface therefore causes a significant reorientation of the active site relative to the membrane surface. This cofactor-dependent realignment of the active-site groove presumably facilitates and optimizes fVIIa cleavage of its membrane-bound substrates.	TEXAS A&M UNIV, HLTH SCI CTR, COLL MED, DEPT MED BIOCHEM & GENET, COLLEGE STN, TX 77843 USA; TEXAS A&M UNIV, DEPT CHEM, COLLEGE STN, TX 77843 USA; TEXAS A&M UNIV, DEPT BIOCHEM & BIOPHYS, COLLEGE STN, TX 77843 USA; OKLAHOMA MED RES FDN, CARDIOVASC BIOL RES PROGRAM, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, DEPT CHEM & BIOCHEM, NORMAN, OK 73019 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma - Norman			Morrissey, James H/H-4933-2011; Johnson, Arthur E/G-3457-2012; Morrissey, James H./GLR-5645-2022	Morrissey, James H/0000-0002-1570-1569; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032934, T32HL007207, R01HL047014] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 32934, R01 HL 47014, T32 HL 07207] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; ASHTON AW, 1995, FEBS LETT, V374, P141, DOI 10.1016/0014-5793(95)01093-T; BAIRD B, 1985, BIOCHEMISTRY-US, V24, P6252, DOI 10.1021/bi00343a032; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; BUTENAS S, 1993, BIOCHEMISTRY-US, V32, P6531, DOI 10.1021/bi00077a006; BUTENAS S, 1994, BIOCHEMISTRY-US, V33, P3449, DOI 10.1021/bi00177a039; CERIONE RA, 1983, BIOCHEMISTRY-US, V22, P769, DOI 10.1021/bi00273a010; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; DAVIE EW, 1995, THROMB HAEMOSTASIS, V74, P1; DELL VA, 1990, BIOCHEMISTRY-US, V29, P1757, DOI 10.1021/bi00459a014; DEWEY TG, 1980, BIOPHYS J, V32, P1023, DOI 10.1016/S0006-3495(80)85033-8; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; HOLOWKA D, 1983, BIOCHEMISTRY-US, V22, P3466, DOI 10.1021/bi00283a025; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; ISAACS BS, 1986, BIOCHEMISTRY-US, V25, P4958, DOI 10.1021/bi00365a036; LIM TK, 1977, BIOCHEMISTRY-US, V16, P4177, DOI 10.1021/bi00638a007; LU RL, 1989, J BIOL CHEM, V264, P12956; Muller YA, 1996, J MOL BIOL, V256, P144, DOI 10.1006/jmbi.1996.0073; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; NEUENSCHWANDER PF, 1993, J BIOL CHEM, V268, P21489; NEUENSCHWANDER PF, 1995, BIOCHEMISTRY-US, V34, P13988, DOI 10.1021/bi00043a004; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; PABORSKY LR, 1989, BIOCHEMISTRY-US, V28, P8072, DOI 10.1021/bi00446a016; Payne MA, 1996, BIOCHEMISTRY-US, V35, P7100, DOI 10.1021/bi9529770; RADCLIFFE R, 1976, J BIOL CHEM, V251, P4797; Reinhart G D, 1991, J Fluoresc, V1, P153, DOI 10.1007/BF00865362; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; RUF W, 1991, J BIOL CHEM, V266, P16256; SABHARWAL AK, 1995, J BIOL CHEM, V270, P15523, DOI 10.1074/jbc.270.26.15523; WAXMAN E, 1993, BIOCHEMISTRY-US, V32, P3005, DOI 10.1021/bi00063a011; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016; WU PG, 1992, BIOCHEMISTRY-US, V31, P7939, DOI 10.1021/bi00149a027; YE J, 1991, J BIOL CHEM, V266, P23016	44	64	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28168	28175		10.1074/jbc.271.45.28168	http://dx.doi.org/10.1074/jbc.271.45.28168			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910432	hybrid			2022-12-25	WOS:A1996VU03300032
J	Strub, JM; Goumon, Y; Lugardon, K; Capon, C; Lopez, M; Moniatte, M; VanDorsselaer, A; Aunis, D; MetzBoutigue, MH				Strub, JM; Goumon, Y; Lugardon, K; Capon, C; Lopez, M; Moniatte, M; VanDorsselaer, A; Aunis, D; MetzBoutigue, MH			Antibacterial activity of glycosylated and phosphorylated chromogranin A-derived peptide 173-194 from bovine adrenal medullary chromaffin granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ANTIMICROBIAL PEPTIDES; MAGNETIC-RESONANCE; MASS-SPECTROMETRY; TERMINAL DOMAIN; SECRETOGRANIN-I; CDNA SEQUENCE; AMINO-ACIDS; PANCREASTATIN; SECRETION	Recently, we have isolated from bovine chromaffin granules and identified two natural peptides possessing antibacterial activity: secretolytin (chromogranin B 614-626) and enkelytin (proenkephalin-A 209-237). Here, we characterize a large natural fragment, corresponding to chromogranin A 79-431, that inhibits growth of both Gram-positive and Gram-negative bacteria. The aim of the present work was to determine the shortest active peptide located in the 79-431 chromogranin A region. Three peptides, which shared the same 173-194 chromogranin A sequence (YPGPQAKEDSEGPSQGPASREK) but differed in post-translational modifications, including O-glycosylation and tyrosine phosphorylation, were isolated. A detailed study using microsequencing and mass spectrometry allowed us to correlate their antibacterial activity with these posttranslational modifications. The chromogranin A precursor fragment (79-431) and the active glycosylated and phosphorylated peptides were, respectively, named prochromacin and chromacin (P, G, and PG for phosphorylated, glycosylated, and phosphorylated-glycosylated form).	INSERM,U338,UNITE BIOL COMMUN CELLULAIRE,F-67084 STRASBOURG,FRANCE; CNRS,CHIM BIOL LAB,UMR 111,F-59655 VILLENEUVE DASCQ,FRANCE; CNRS,LAB SPECTROMETRIE MASSE BIOORGAN,URA 31,F-67084 STRASBOURG,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)			Dominique, Aunis/W-1419-2019	Strub, Jean-Marc/0000-0001-6224-3428; Moniatte, Marc/0000-0003-2235-4523				AARDAL S, 1993, J NEUROENDOCRINOL, V5, P405, DOI 10.1111/j.1365-2826.1993.tb00501.x; AARDAL S, 1992, REGUL PEPTIDES, V41, P9, DOI 10.1016/0167-0115(92)90509-S; AUNIS D, 1977, J NEUROCHEM, V29, P439, DOI 10.1111/j.1471-4159.1977.tb10692.x; BAUER JW, 1991, BIOCHIM BIOPHYS ACTA, V1089, P124, DOI 10.1016/0167-4781(91)90094-3; BENEDUM UM, 1987, EMBO J, V6, P1203, DOI 10.1002/j.1460-2075.1987.tb02355.x; BERGEY EJ, 1986, BIOCHEM J, V234, P43, DOI 10.1042/bj2340043; BULET P, 1995, BIOCHEMISTRY-US, V34, P7394, DOI 10.1021/bi00022a012; BULET P, 1993, J BIOL CHEM, V268, P14893; BURTON PM, 1987, INT J IMMUNOPHARMACO, V9, P297, DOI 10.1016/0192-0561(87)90054-3; CASTEELS P, 1989, EMBO J, V8, P2387, DOI 10.1002/j.1460-2075.1989.tb08368.x; CASTEELS P, 1990, EUR J BIOCHEM, V187, P381, DOI 10.1111/j.1432-1033.1990.tb15315.x; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COCIANCICH S, 1994, BIOCHEM J, V300, P567, DOI 10.1042/bj3000567; DILLEN L, 1993, NEUROCHEM INT, V22, P315, DOI 10.1016/0197-0186(93)90016-X; DREE BM, 1994, ENDOCRINOLOGY, V129, P3381; EFENDIC S, 1987, P NATL ACAD SCI USA, V84, P7257, DOI 10.1073/pnas.84.20.7257; FASCIOTTO BH, 1993, ENDOCRINOLOGY, V133, P461, DOI 10.1210/en.133.2.461; FRANK RW, 1990, J BIOL CHEM, V265, P18871; Goumon Y, 1996, EUR J BIOCHEM, V235, P516, DOI 10.1111/j.1432-1033.1996.t01-1-00516.x; HARA S, 1995, BIOCHEM J, V310, P651, DOI 10.1042/bj3100651; HELLE KB, 1993, J NEUROENDOCRINOL, V5, P413, DOI 10.1111/j.1365-2826.1993.tb00502.x; HELLE KB, 1990, NEUROCHEM INT, V17, P165, DOI 10.1016/0197-0186(90)90139-K; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOBBS MV, 1987, J IMMUNOL, V138, P2581; HOLAK TA, 1988, BIOCHEMISTRY-US, V27, P7620, DOI 10.1021/bi00420a008; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; HUTTON JC, 1988, ENDOCRINOLOGY, V122, P1014, DOI 10.1210/endo-122-3-1014; IACANGELO A, 1988, FEBS LETT, V227, P115, DOI 10.1016/0014-5793(88)80880-9; IACANGELO A, 1986, NATURE, V323, P82, DOI 10.1038/323082a0; IACANGELO AL, 1988, ENDOCRINOLOGY, V122, P2339, DOI 10.1210/endo-122-5-2339; ISHIZUKA J, 1989, PANCREAS, V4, P277, DOI 10.1097/00006676-198906000-00001; JANUSZ M, 1987, MOL IMMUNOL, V24, P1029, DOI 10.1016/0161-5890(87)90069-1; KAMERLING JP, 1975, BIOCHEM J, V151, P491, DOI 10.1042/bj1510491; KAWASAKI K, 1992, CHEM PHARM BULL, V40, P3253, DOI 10.1248/cpb.40.3253; KIANG WL, 1982, J BIOL CHEM, V257, P1651; KONECKI DS, 1987, J BIOL CHEM, V262, P17026; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS JJ, 1989, BIOCHEM BIOPH RES CO, V163, P667, DOI 10.1016/0006-291X(89)92275-4; LINARD CG, 1990, NUCLEIC ACIDS RES, V18, P1298, DOI 10.1093/nar/18.5.1298; LOTAN R, 1975, J BIOL CHEM, V250, P8518; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; METZBOUTIGUE MH, 1984, EUR J BIOCHEM, V145, P659, DOI 10.1111/j.1432-1033.1984.tb08607.x; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; Montreuil J, 1986, CARBOHYDRATE ANAL PR, P143; RINDERLE SJ, 1989, J BIOL CHEM, V264, P16123; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; SCHLUESENER HJ, 1993, J NEUROIMMUNOL, V47, P199, DOI 10.1016/0165-5728(93)90030-3; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SETTLEMAN J, 1985, J BIOL CHEM, V260, P1645; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SIMON JP, 1988, P NATL ACAD SCI USA, V85, P1712, DOI 10.1073/pnas.85.5.1712; SIMON JP, 1989, BIOCHEM J, V262, P1; SMITH AD, 1967, BIOCHEM J, V103, P483, DOI 10.1042/bj1030483; Strub JM, 1996, FEBS LETT, V379, P273, DOI 10.1016/0014-5793(95)01529-9; STRUB JM, 1995, EUR J BIOCHEM, V229, P356, DOI 10.1111/j.1432-1033.1995.0356k.x; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; VAESSEN RTMJ, 1981, FEBS LETT, V124, P193, DOI 10.1016/0014-5793(81)80134-2; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; VORM O, 1994, J AM SOC MASS SPECTR, V5, P955, DOI 10.1016/1044-0305(94)80013-8; WANG WC, 1988, J BIOL CHEM, V263, P4576; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WU HJ, 1991, J BIOL CHEM, V266, P13130	66	108	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28533	28540		10.1074/jbc.271.45.28533	http://dx.doi.org/10.1074/jbc.271.45.28533			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910482	hybrid			2022-12-25	WOS:A1996VU03300082
J	Bullock, ED; Johnson, EM				Bullock, ED; Johnson, EM			Nerve growth factor induces the expression of certain cytokine genes and bcl-2 in mast cells - Potential role in survival promotion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONNECTIVE-TISSUE-TYPE; NECROSIS-FACTOR-ALPHA; MESSENGER-RNA; MEDIATED ACTIVATION; CYCLOSPORINE-A; SUBSTANCE-P; KIT-LIGAND; TNF-ALPHA; RAT; MOUSE	Nerve growth factor (NGF) promotes mast cell survival in vitro (Horigome, K., Bullock, E. D., and Johnson, E. M., Jr. (1994) J. Biol. Chem, 269, 2695-2702). NGF survival promotion is cell density-dependent, and conditioned medium experiments have shown that NGF increases the production of an autocrine mast cell survival activity. Cytokines are potential candidates for autocrine survival factors, In rat peritoneal mast cells (RPMC), NGF caused an increase in the messenger RNAs for interleukin (IL)-3, IL-4, IL-10, tumor necrosis factor-alpha, and granulocyte-macrophage colony-stimulating factor, This induction was NGF dose-dependent, was blocked bg NGF-neutralizing antibodies, and was not observed in the non-mast peritoneal cell population. The immunosuppressive agent, cyclosporin A, blocked both cytokine induction and NGF-activated survival promotion but not survival promotion activated by IL-3 or stem cell factor, suggesting that NGF enhanced RPMC survival by increasing cytokine production, me also examine the effects of NGF on the expression levels of some members of the bcl-2 family and the interleukin-1 beta-converting enzyme-like cysteine protease families. NGF markedly increased bcl-2 expression but had little or no effect on the other genes studied. The induction of bcl-2 mRNA by NGF was not blocked by cyclosporin A. These data suggest that induced cytokine gene expression but not increased expression of bcl-2 mediates NGF-survival promotion in RPMC.	WASHINGTON UNIV, SCH MED, DEPT MOL BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT NEUROL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024679] Funding Source: NIH RePORTER; NHLBI NIH HHS [5T32HL07275] Funding Source: Medline; NIA NIH HHS [R01-AG12947] Funding Source: Medline; NINDS NIH HHS [R01-NS24679] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALOE L, 1986, P NATL ACAD SCI USA, V83, P6184, DOI 10.1073/pnas.83.16.6184; ALOE L, 1977, BRAIN RES, V133, P358, DOI 10.1016/0006-8993(77)90772-7; ANSEL JC, 1993, J IMMUNOL, V150, P4478; BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; BRUNI A, 1982, FEBS LETT, V138, P190, DOI 10.1016/0014-5793(82)80438-9; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CAUX C, 1995, IMMUNOL TODAY, V16, P2, DOI 10.1016/0167-5699(95)80061-1; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CLAMAN HN, 1985, IMMUNOL TODAY, V6, P192, DOI 10.1016/0167-5699(85)90115-X; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COHEN DR, 1986, NUCLEIC ACIDS RES, V14, P3641, DOI 10.1093/nar/14.9.3641; CREEDON D, 1991, HYPERTENSION, V18, P730, DOI 10.1161/01.HYP.18.6.730; DIMARCO E, 1991, J BIOL CHEM, V266, P21718; DONNERER J, 1992, NEUROSCIENCE, V49, P693, DOI 10.1016/0306-4522(92)90237-V; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P5423, DOI 10.1073/pnas.90.12.5423; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P10984, DOI 10.1073/pnas.90.23.10984; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; ESTUS S, 1996, IN PRESS NEUROMETHOD; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GALLI SJ, 1990, LAB INVEST, V62, P5; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GETCHELL ML, 1995, NEUROREPORT, V6, P1261, DOI 10.1097/00001756-199506090-00008; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GURISH MF, 1991, J IMMUNOL, V146, P1527; HAIG DM, 1994, BLOOD, V83, P72; HAMAGUCHI Y, 1987, J EXP MED, V165, P268, DOI 10.1084/jem.165.1.268; HATTORI A, 1993, J BIOL CHEM, V268, P2577; HEFTI F, 1994, J NEUROBIOL, V25, P1418, DOI 10.1002/neu.480251109; HEFTI F, 1986, J NEUROSCI, V6, P2155; HORIGOME K, 1993, J BIOL CHEM, V268, P14881; HORIGOME K, 1994, J BIOL CHEM, V269, P2695; KANNAN Y, 1991, BLOOD, V77, P1320; KAYE RE, 1992, P NATL ACAD SCI USA, V89, P8542, DOI 10.1073/pnas.89.18.8542; LAFFERTY KJ, 1980, AUST J EXP BIOL MED, V58, P533, DOI 10.1038/icb.1980.55; LEVIMONTALCINI R, 1995, J NEUROL SCI, V130, P119, DOI 10.1016/0022-510X(95)00007-O; LI AKC, 1980, P NATL ACAD SCI-BIOL, V77, P4379, DOI 10.1073/pnas.77.7.4379; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LINDHOLM D, 1988, J BIOL CHEM, V263, P16348; MATSUDA H, 1991, J EXP MED, V174, P7, DOI 10.1084/jem.174.1.7; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; Osborne Barbara A., 1994, Trends in Cell Biology, V4, P394; OTTEN U, 1984, EUR J PHARMACOL, V106, P199, DOI 10.1016/0014-2999(84)90697-6; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; PEARCE FL, 1986, J PHYSIOL-LONDON, V372, P379, DOI 10.1113/jphysiol.1986.sp016014; PLANT M, 1989, NATURE, V339, P64; RAZIN E, 1991, J IMMUNOL, V146, P981; SCULLY JL, 1995, CELL BIOL INT, V19, P459, DOI 10.1006/cbir.1995.1089; SHANAHAN F, 1985, J IMMUNOL, V135, P1331; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; SULLIVAN TJ, 1975, J IMMUNOL, V114, P1473; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507; TSAI M, 1991, J EXP MED, V174, P125, DOI 10.1084/jem.174.1.125; TSUJI K, 1990, BLOOD, V75, P421; VALENT P, 1991, Progress in Growth Factor Research, V3, P27, DOI 10.1016/0955-2235(91)90011-R; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; WERSHIL BK, 1995, J IMMUNOL, V154, P1391; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; YAN Q, 1991, CLIN SCI, V80, P565, DOI 10.1042/cs0800565; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	65	76	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27500	27508		10.1074/jbc.271.44.27500	http://dx.doi.org/10.1074/jbc.271.44.27500			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910334	hybrid			2022-12-25	WOS:A1996VQ67900052
J	Chen, LM; Ma, JX; Liang, YM; Chao, L; Chao, J				Chen, LM; Ma, JX; Liang, YM; Chao, L; Chao, J			Tissue kallikrein-binding protein reduces blood pressure in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; URINARY KALLIKREIN; INHIBITOR; GENE; KALLISTATIN; IDENTIFICATION; HYPOTENSION; EXPRESSION; SEQUENCE; KININS	The kallikrein-kinin system participates in blood pressure regulation. One of the kallikrein-kinin system components, krallikrein-binding protein, binds to tissue kallikrein and inhibits its activity in vitro. To investigate potential roles of rat kallikrein-binding protein (RKBP) in vivo, we have developed transgenic mice that express an RKBP gene under the control of the mouse metallothionein metal-responsive promoter. Expression of the transgene, RKBP, was detected in the liver, kidney, lung, heart, pancreas, salivary glands, spleen, brain, testis, and adrenal gland at the mRNA and protein levels, Systolic blood pressures of homozygous transgenic mice were 85.5 +/- 0.8 mm Hg (mean +/- S.E., n = 19, P < 0./001 for one line and 88.8 +/- 1.6 mm Hg (mean +/- S.E., n = 19, P < 0.001) for another, as compared with 100.5 +/- 0.8 mm Ng (mean +/- S.E., n = 18) for control mice, Direct blood pressure measurements of these transgenic mice through an arterial cannula showed similar reductions of blood pressure, Intravenous injection of purified RB;EP into mice via a catheter produced a dose-dependent reduction of the mean arterial blood pressure, Our findings suggest that RKBP may function as vasodilator in vivo, independent of regulating the activity of tissue kallikrein.	MED UNIV S CAROLINA,DEPT BIOCHEM & MOL BIOL,CHARLESTON,SC 29425	Medical University of South Carolina					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044083] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 44083] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERRY TD, 1989, HYPERTENSION, V13, P3, DOI 10.1161/01.HYP.13.1.3; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; CHAI KX, 1993, J BIOL CHEM, V268, P24498; CHAI KX, 1991, J BIOL CHEM, V266, P16029; CHAI KX, 1991, BIOCHIM BIOPHYS ACTA, V1129, P127, DOI 10.1016/0167-4781(91)90227-D; CHAO J, 1988, J HYPERTENS, V6, P551, DOI 10.1097/00004872-198807000-00006; CHAO J, 1986, BIOCHEM J, V239, P325, DOI 10.1042/bj2390325; CHAO J, 1990, J BIOL CHEM, V265, P1694; Chao JL, 1996, J LAB CLIN MED, V127, P612, DOI 10.1016/S0022-2143(96)90152-3; CHEN LM, 1995, KIDNEY INT, V48, P690, DOI 10.1038/ki.1995.339; CLEMENTS JA, 1989, ENDOCR REV, V10, P393, DOI 10.1210/edrv-10-4-393; ECKE S, 1992, J BIOL CHEM, V267, P7048; GEIGER R, 1981, H-S Z PHYSIOL CHEM, V362, P317, DOI 10.1515/bchm2.1981.362.1.317; GUESDON JL, 1979, J HISTOCHEM CYTOCHEM, V27, P1131, DOI 10.1177/27.8.90074; LINDPAINTNER K, 1996, IN PRESS J CLIN INVE; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA JX, 1995, J BIOL CHEM, V270, P451, DOI 10.1074/jbc.270.1.451; MA JX, 1996, IN PRESS BIOCH BIOPH; Maniatis T., 1982, MOL CLONING; MARGOLIUS HS, 1989, ANNU REV PHARMACOL, V29, P343; MURRAY SR, 1990, J CADIOVASC PHARM S6, V15, P7; PAGES G, 1990, EUR J BIOCHEM, V190, P385, DOI 10.1111/j.1432-1033.1990.tb15587.x; SERVEAU C, 1992, FEBS LETT, V309, P405, DOI 10.1016/0014-5793(92)80817-Z; SERVEAU C, 1992, FEBS LETT, V312, P269; WANG J, 1994, HYPERTENSION, V23, P236, DOI 10.1161/01.HYP.23.2.236; ZHOU GX, 1992, J BIOL CHEM, V267, P25873	26	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27590	27594		10.1074/jbc.271.44.27590	http://dx.doi.org/10.1074/jbc.271.44.27590			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910346	hybrid			2022-12-25	WOS:A1996VQ67900064
J	GarciaCardena, G; Fan, R; Stern, DF; Liu, JW; Sessa, WC				GarciaCardena, G; Fan, R; Stern, DF; Liu, JW; Sessa, WC			Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; CALMODULIN; CELLS	The regulation of endothelial nitric oxide synthase (eNOS) by phosphorylation is poorly understood. Here, we demonstrate that eNOS is tyrosine-phosphorylated in bovine aortic endothelial cells (BAEC) using P-32 metabolic labeling followed by phosphoamino acid analysis and by phosphotyrosine specific Western blotting. Treatment of BAEC with hydrogen peroxide and the protein tyrosine phosphatase inhibitor, sodium orthovanadate, increases eNOS tyrosine phosphorylation. Utilizing a novel immunoNOS assay, the increase in tyrosine phosphorylation is associated with a 50% decrease in the specific activity of the enzyme. Because eNOS is localized in plasmalemma caveolae, we examined if tyrosine phosphorylated eNOS interacts with caveolin-1, the coat protein of caveolae, Immunoprecipitation of eNOS from bovine lung microvascular endothelial cells resulted in the co-precipitation of caveolin-1. Conversely, immunoprecipitation of caveolin-1 resulted in the co-precipitation of tyrosine-phosphorylated eNOS. Thus, tyrosine phosphorylation is a novel regulatory mechanism for eNOS and caveolin-1 is the first eNOS-associated protein. Collectively, these observations provide a novel regulatory mechanism for eNOS and suggest that tyrosine phosphorylation may influence its activity, subcellular trafficking, and interaction with other caveolin-interacting proteins in caveolae.	YALE UNIV, SCH MED, BOYER CTR MOL MED, DEPT PHARMACOL, NEW HAVEN, CT 06536 USA; YALE UNIV, SCH MED, BOYER CTR MOL MED, MOL CARDIOBIOL PROGRAM, NEW HAVEN, CT 06536 USA; YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06536 USA	Yale University; Yale University; Yale University			Garcia-Cardena, Guillermo/Q-6649-2019; Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938	NATIONAL CANCER INSTITUTE [R01CA045708] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009224, R29HL051948] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA-45708] Funding Source: Medline; NHLBI NIH HHS [F32-HL09224, HL 51948] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ayajiki K, 1996, CIRC RES, V78, P750, DOI 10.1161/01.RES.78.5.750; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; DELVECCHIO PJ, 1992, IN VITRO CELL DEV-AN, V28A, P711; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Gibbons GH, 1996, SCIENCE, V272, P689, DOI 10.1126/science.272.5262.689; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HIRATA K, 1995, HYPERTENSION, V25, P180, DOI 10.1161/01.HYP.25.2.180; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTENSEN TM, 1982, J BIOL CHEM, V257, P9648; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MONCADA S, 1991, PHARMACOL REV, V43, P109; OHARA Y, 1995, HYPERTENSION, V25, P415, DOI 10.1161/01.HYP.25.3.415; ONEILL WC, 1995, AM J PHYSIOL-CELL PH, V269, pC863, DOI 10.1152/ajpcell.1995.269.4.C863; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TSUKAHARA H, 1994, KIDNEY INT, V45, P598, DOI 10.1038/ki.1994.78	29	427	434	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27237	27240		10.1074/jbc.271.44.27237	http://dx.doi.org/10.1074/jbc.271.44.27237			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910295	hybrid			2022-12-25	WOS:A1996VQ67900013
J	Black, BL; Ligon, KL; Zhang, Y; Olson, EN				Black, BL; Ligon, KL; Zhang, Y; Olson, EN			Cooperative transcriptional activation by the neurogenic basic helix-loop-helix protein MASH1 and members of the myocyte enhancer factor-2 (MEF2) family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC ENHANCER; ACHAETE-SCUTE HOMOLOG-1; DNA-BINDING; MYOGENIC LINEAGE; CARCINOMA-CELLS; NERVOUS-SYSTEM; MRF4 PROMOTER; GENE; EXPRESSION; MYOD	Establishment of skeletal muscle and neural cell types is controlled by families of myogenic and neurogenic basic helix-loop-helix (bHLH) proteins, respectively, Myogenic bHLH proteins have been shown to activate skeletal muscle transcription in collaboration with members of the myocyte enhancer factor-2 (MEF2) family of MCM1-agamous-deficiens serum response factor (MADS)-box transcription factors, which are expressed in differentiated myocytes and neurons, Here, we show that the neurogenic bHLH protein MASH1 interacts with members of the MEF2 family and that this interaction, mediated by the DNA binding and dimerization domains of these factors, results in synergistic activation of transcription through either the MASH1 or the MEF2 DNA binding site, Consistent with their involve ment in activation of neuronal gene expression, members of the MEF2 family are expressed in p19 embryonal carcinoma cells that have been induced to form neurons following treatment with retinoic acid. These results suggest that members of the MEF2 family perform similar roles in synergistic activation of transcription in myogenic and neurogenic lineages by serving as cofactors for cell type-specific bHLH proteins.	UNIV TEXAS,SW MED CTR,HAMON CTR BASIC CANC RES,DEPT MOL BIOL & ONCOL,DALLAS,TX 75235; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOL BIOL,HOUSTON,TX 77030	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center				Black, Brian/0000-0002-6664-8913				BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; BLACK BL, 1995, J BIOL CHEM, V270, P2889, DOI 10.1074/jbc.270.7.2889; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; FIRULLI AB, 1996, CIRC RES, V78, P1196; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; JOHNSON JE, 1992, DEVELOPMENT, V114, P75; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LEIFER D, 1994, NEUROSCIENCE, V63, P1067, DOI 10.1016/0306-4522(94)90573-8; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; Mao ZX, 1996, J BIOL CHEM, V271, P14371, DOI 10.1074/jbc.271.24.14371; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MARTINEZ C, 1993, MOL CELL BIOL, V13, P3514, DOI 10.1128/MCB.13.6.3514; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MUMMERY CL, 1986, EXP CELL RES, V165, P229, DOI 10.1016/0014-4827(86)90547-1; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAIDU PS, 1995, MOL CELL BIOL, V15, P2707; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Schulz RA, 1996, ONCOGENE, V12, P1827; VANDOREN M, 1991, DEVELOPMENT, V113, P245; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WONG MW, 1994, DEV BIOL, V166, P683, DOI 10.1006/dbio.1994.1347; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	42	63	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26659	26663		10.1074/jbc.271.43.26659	http://dx.doi.org/10.1074/jbc.271.43.26659			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900141	hybrid			2022-12-25	WOS:A1996VP23300035
J	Dabrowski, A; VanderKuur, JA; CarterSu, C; Williams, JA				Dabrowski, A; VanderKuur, JA; CarterSu, C; Williams, JA			Cholecystokinin stimulates formation of Shc-Grb2 complex in rat pancreatic acinar cells through a protein kinase C-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; GROWTH-HORMONE RECEPTOR; SHC ADAPTER PROTEIN; TYROSINE-KINASE; MAP KINASE; SIGNALING PATHWAYS; COUPLED RECEPTORS; ACTIVATION; PHOSPHORYLATION; ASSOCIATION	Cholecystokinin (CCK) has recently been shown to activate the mitogen activated protein kinase (MAPK) cascade (Ras-Raf-MAPK kinase-MAPK) in pancreatic acini, The mechanism by which the G(q) protein-coupled CCK receptor activates Ras, however, is currently unknown, Growth factor receptors are known to activate Ras by means of adaptor proteins that bind to phosphotyrosine domains, We therefore compared the effects of CCK and epidermal growth factor (EGF) on Tyr phosphorylation of the adaptor proteins Shc and its association with Grb2 and the guanine nucleotide exchange factor SOS. Three major isoforms of Shc (p46, p52, p66) were detected in isolated rat pancreatic acini with p52 Shc being the predominant form, CCK and EGF increased tyrosyl phosphorylation of Shc (251 and 337% of control, respectively), CCK-stimulated tyrosyl phosphorylation of Shc as well as Shc-Grb2 complex formation was significant at 2.5 min, maximal at 5 min, and persisted for at least 30 min, Finally, SOS was found to be associated with Grb2 as assessed by probing of anti-Grb2 immunoprecipitates with anti-SOS, Since MAPK in pancreatic acini is activated via protein kinase C (PKC), we studied the effect of phorbol esters on Shc phosphorylation and found 12-O-tetradecanoylphorbol-13-acetate to be as potent as CCK. Furthermore, GF-109203X, a PKC inhibitor, abolished the effect of 12-O-tetradecanoylphorbol-13-acetate and also the effect of CCK but not the effect of EGF on Shc tyrosyl phosphorylation, CCK-induced tyrosyl phosphorylation of Shc was found to be phosphatidylinositol 3-kinase-independent, and CCK did not cause EGF receptor activation, These results suggest that formation of an Shc-Grb2-SOS complex via a PKC-dependent mechanism may provide the link between G(q) protein-coupled CCK receptor stimulation and Ras activation in these cells.	UNIV MICHIGAN,DEPT PHYSIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan			Dabrowski, Andrzej/T-8656-2018	Dabrowski, Andrzej/0000-0002-5996-394X; Williams, John/0000-0002-6063-7615	NIDDK NIH HHS [P30 DK034933, R01 DK041122, DK41122, DK34171, R01 DK034171, DK41225] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041122, R01DK041225, P30DK034933, R01DK034171, R37DK041122, R37DK034171] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BRAGADO MJ, 1996, IN PRESS AM J PHYSL; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; Dabrowski A, 1996, J BIOL CHEM, V271, P5686, DOI 10.1074/jbc.271.10.5686; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DUAN RD, 1995, AM J PHYSIOL-GASTR L, V268, pG1060, DOI 10.1152/ajpgi.1995.268.6.G1060; DUAN RD, 1994, AM J PHYSIOL, V267, pG401, DOI 10.1152/ajpgi.1994.267.3.G401; DUAN RG, 1994, AM J PHYSIOL, V266, pG303, DOI 10.1152/ajpgi.1994.266.2.G303; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; GARCIA LJ, 1996, GASTROENTEROLOGY, V110, P390; Haimovich B, 1996, BLOOD, V87, P152, DOI 10.1182/blood.V87.1.152.bloodjournal871152; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOWE LR, 1993, J BIOL CHEM, V268, P20717; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; LANDGREN E, 1995, ONCOGENE, V10, P2027; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOGSDON CD, 1986, AM J PHYSIOL, V250, pG440, DOI 10.1152/ajpgi.1986.250.4.G440; LU L, 1992, AM J PHYSIOL, V263, pG327, DOI 10.1152/ajpgi.1992.263.3.G327; LUTZ MP, 1993, J BIOL CHEM, V268, P11119; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SADOSHIMA J, 1995, CIRC RES, V76, P1; SCHICK J, 1984, J CELL BIOL, V99, P1559; SOLOMON TE, 1983, AM J PHYSIOL, V245, pG99, DOI 10.1152/ajpgi.1983.245.1.G99; SOLOMON TE, 1994, PHYSL GASTROINTESTIN, V2, P1499; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WANG XY, 1992, J BIOL CHEM, V267, P17390; WANK SA, 1995, AM J PHYSIOL-GASTR L, V269, pG628, DOI 10.1152/ajpgi.1995.269.5.G628; WILLIAMS JA, 1978, AM J PHYSIOL, V235, pE517, DOI 10.1152/ajpendo.1978.235.5.E517; WILLIAMS JA, 1993, EXOCRINE PANCREAS, P167; WINITZ S, 1993, J BIOL CHEM, V268, P19196	46	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27125	27129		10.1074/jbc.271.43.27125	http://dx.doi.org/10.1074/jbc.271.43.27125			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900204	hybrid			2022-12-25	WOS:A1996VP23300098
J	Hanson, DA; Eyre, DR				Hanson, DA; Eyre, DR			Molecular site specificity of pyridinoline and pyrrole cross-links in type I collagen of human bone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ARTICULAR-CARTILAGE; EHRLICH CHROMOGEN; LOCATION; PROCOLLAGEN; CHAIN; GENE; IDENTIFICATION; CROSSLINKING; PEPTIDES; CONFIRMS	Compared with soft tissue collagens, bone type I collagen displays a distinctive pattern of covalent cross-linking with evidence of preferred sites of molecular interaction and a prominence of both immature, divalent crosslinks and mature, trivalent cross-links in the adult tissue. In this study the she-specificity of the mature cross-links in human bone collagen was examined. Peptides containing fluorescent pyridinoline cross-links and Ehrlich's-reactive pyrrole cross-links were isolated from a bacterial collagenase digest of demineralized bone matrix. The digest was fractionated by molecular sieve chromatography, monitoring for peptide absorbance, pyridinoline fluorescence, pyrroles by Ehrlich's reagent, and immunoassay for crosslinked N-telopeptides. Individual cross-linked peptides were resolved by ion-exchange and reverse-phase HPLC. Structures were established by NK2-terminal microsequencing, cross link analysis, electrospray mass spectrometry, and immunoassay. Two, about equally occupied sites of pyridinoline cross-linking were identified, N-teIopeptide to helix and C-telopeptide to helix, Pyrroles were alternative cross-linking products at the same sites, but concentrated (85%) at the N-telopeptide end. Only one combination of chains was cross-linked by pyridinolines at the C-telopeptide to helix site, [alpha 1(I)(c)1(2) alpha 1(I)(helix). Several peptide combinations arose from the N-telopeptide to helix site, but the main source of pyridinolines was from the locus, alpha 1(I))(N) alpha 2(I)(N) alpha 1(I)helix. Pyridinolines Linking two alpha 1(N) telopeptides were a minor component. Pyrroles were concentrated at the locus, alpha 1(I)(N) alpha 2(I)(N) alpha 2(I)(helix). The cross-link ratio of hydroxylysylpyridinoline to lysylpyridinoline differed between N-telopeptide and C-telopeptide sites, and between the individual interchain combinations. Cross linked N-telopeptides accounted for two-thirds of the total lysylpyridinoline in bone, N-telopeptide pyridinoline fluorescence was quenched on chromatography, so that reliance on peptide fluorescence alone can underestimate the level of N-telopeptide pyridinoline cross-linking.	UNIV WASHINGTON,ORTHOPAED RES LABS,DEPT ORTHOPAED,SEATTLE,WA 98195; UNIV WASHINGTON,ORTHOPAED RES LABS,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NIAMS NIH HHS [R37 AR037318, AR37318, R01 AR036794] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036794, R37AR037318, R01AR037318] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAILEY AJ, 1974, NATURE, V251, P105, DOI 10.1038/251105a0; BARNES MJ, 1971, BIOCHEM J, V125, P433, DOI 10.1042/bj1250433; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P1139, DOI 10.1021/bi00274a023; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; DALESSIO M, 1988, GENE, V67, P105, DOI 10.1016/0378-1119(88)90013-3; EYRE D, 1987, METHOD ENZYMOL, V144, P115; EYRE DR, 1973, BIOCHEM BIOPH RES CO, V52, P663, DOI 10.1016/0006-291X(73)90764-X; Eyre DR, 1995, ACTA ORTHOP SCAND, V66, P166, DOI 10.3109/17453679509157685; EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441; EYRE DR, 1980, BIOCHEM BIOPH RES CO, V92, P403, DOI 10.1016/0006-291X(80)90347-2; EYRE DR, 1981, DEV BIOCHEM, V22, P51; EYRE DR, 1988, BIOCHEM J, V175, P1; FUJIMOTO D, 1977, BIOCHEM BIOPH RES CO, V76, P1124, DOI 10.1016/0006-291X(77)90972-X; FUJIMOTO D, 1980, BIOCHEM BIOPH RES CO, V93, P948, DOI 10.1016/0006-291X(80)91167-5; HANSON DA, 1992, J BONE MINER RES, V7, P1251; HENKEL W, 1976, EUR J BIOCHEM, V69, P223, DOI 10.1111/j.1432-1033.1976.tb10877.x; HENKEL W, 1987, EUR J BIOCHEM, V165, P427, DOI 10.1111/j.1432-1033.1987.tb11456.x; HORGAN DJ, 1990, ARCH BIOCHEM BIOPHYS, V281, P21, DOI 10.1016/0003-9861(90)90407-P; KANG AH, 1972, BIOCHEMISTRY-US, V11, P1828, DOI 10.1021/bi00760a015; KEMP PD, 1988, BIOCHEM J, V252, P387, DOI 10.1042/bj2520387; KUBOKI Y, 1981, CONNECT TISSUE RES, V9, P107, DOI 10.3109/03008208109160248; KUBOKI Y, 1981, BIOCHEM BIOPH RES CO, V102, P119, DOI 10.1016/0006-291X(81)91497-2; KUIVANIEMI H, 1988, BIOCHEM J, V252, P633, DOI 10.1042/bj2520633; KUYPERS R, 1994, MEAT SCI, V37, P67, DOI 10.1016/0309-1740(94)90146-5; KUYPERS R, 1992, BIOCHEM J, V283, P129, DOI 10.1042/bj2830129; LIGHT N, 1985, FEBS LETT, V182, P503, DOI 10.1016/0014-5793(85)80363-X; MECHANIC GL, 1987, BIOCHEMISTRY-US, V26, P3500, DOI 10.1021/bi00386a038; MILLER EJ, 1973, BIOCHEM BIOPH RES CO, V54, P432, DOI 10.1016/0006-291X(73)90940-6; OGAWA T, 1982, BIOCHEM BIOPH RES CO, V107, P1252, DOI 10.1016/S0006-291X(82)80132-0; PINNELL SR, 1971, BIOCHIM BIOPHYS ACTA, V229, P119, DOI 10.1016/0005-2795(71)90325-4; Risteli J., 1994, J BONE MINER RES, V9, pS186; ROBINS SP, 1983, BIOCHEM J, V215, P175, DOI 10.1042/bj2150175; ROBINS SP, 1987, BIOCHIM BIOPHYS ACTA, V914, P233, DOI 10.1016/0167-4838(87)90282-2; ROBINS SP, 1973, BIOCHEM J, V131, P771, DOI 10.1042/bj1310771; SCOTT JE, 1981, BIOSCIENCE REP, V1, P611, DOI 10.1007/BF01116276; SCOTT JE, 1983, BIOCHEM J, V209, P263, DOI 10.1042/bj2090263; TANZER ML, 1973, SCIENCE, V180, P561, DOI 10.1126/science.180.4086.561; VEIS A, 1993, J BONE MINER RES S2, V8, P3493; WU JJ, 1984, BIOCHEMISTRY-US, V23, P1850, DOI 10.1021/bi00303a041; Yamauchi M, 1989, Connect Tissue Res, V21, P159, DOI 10.3109/03008208909050006; YAMAUCHI M, 1986, BIOCHEMISTRY-US, V25, P4907, DOI 10.1021/bi00365a027; YAMAUCHI M, 1993, CONNECT TISSUE RES, V29, P82	42	141	158	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26508	26516		10.1074/jbc.271.43.26508	http://dx.doi.org/10.1074/jbc.271.43.26508			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900119	hybrid			2022-12-25	WOS:A1996VP23300013
J	Pike, LJ; Casey, L				Pike, LJ; Casey, L			Localization and turnover of phosphatidylinositol 4,5-bisphosphate in caveolin-enriched membrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; ANCHORED PROTEINS; EGF RECEPTOR; CELLS; COMPLEX; EXPRESSION; TRANSPORT; MOLECULES; COMPONENT	Caveolae are small, plasma membrane invaginations that have been implicated in cell signaling. In A431 cells, approximately half of the total cellular phosphatidylinositol 4,5-bisphosphate (PtdIns 4,5-P-2) was found to be localized in low density, Triton-insoluble membrane domains enriched in caveolin. Treatment of cells with either epidermal growth factor or bradykinin for 5 min at 37 degrees C resulted in approximately a 50% decrease in this caveolar PtdIns 4,5-P-2 with no change in the levels of plasma membrane PtdIns 4,5-P-2. These data suggest that the PtdIns 4,5-P-2 present in cells is largely compartmentalized and that the caveolar PtdIns 4,5-P-2 is subject to hydrolysis by hormone-stimulated phospholipase C. As growth factor receptors, seven transmembrane domain receptors, heterotrimeric G proteins, and the inositol trisphosphate receptor have all been shown to be enriched in caveolae, these findings suggest that both the generation and response to inositol trisphosphate is highly compartmentalized within the cell.			Pike, LJ (corresponding author), WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,660 SO EUCLID,BOX 8231,ST LOUIS,MO 63110, USA.				NICHD NIH HHS [P01 HD20805208A1] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD020805] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; AUGERT G, 1989, J BIOL CHEM, V264, P2574; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; Hope HR, 1996, MOL BIOL CELL, V7, P843, DOI 10.1091/mbc.7.6.843; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MONACO ME, 1992, ENDOCR REV, V13, P707, DOI 10.1210/er.13.4.707; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SCHUH SM, 1994, MOL BIOL CELL, V5, P739, DOI 10.1091/mbc.5.7.739; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; TILLY BC, 1988, BIOCHEM J, V252, P857, DOI 10.1042/bj2520857; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WAHL MI, 1987, BIOCHEM BIOPH RES CO, V142, P688, DOI 10.1016/0006-291X(87)91469-0; ZURZOLO C, 1994, EMBO J, V13, P42, DOI 10.1002/j.1460-2075.1994.tb06233.x	26	325	328	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26453	26456		10.1074/jbc.271.43.26453	http://dx.doi.org/10.1074/jbc.271.43.26453			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900109	hybrid			2022-12-25	WOS:A1996VP23300003
J	Shimizu, K; Kawabe, H; Minami, S; Honda, T; Takaishi, K; Shirataki, H; Takai, Y				Shimizu, K; Kawabe, H; Minami, S; Honda, T; Takaishi, K; Shirataki, H; Takai, Y			SMAP, an Smg GDS-associating protein having Arm repeats and phosphorylated by Src tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP/GTP EXCHANGE PROTEIN; GTP-BINDING PROTEINS; CELL-CELL-ADHESION; MOLECULAR-CLONING; BETA-CATENIN; MEMBRANE; GENE; TRANSLOCATION; SUPPRESSOR; CYTOPLASM	Smg GDS is a regulator having two activities on a group of small G proteins including the Rho and Rap1 family members and Ki-Ras; one is to stimulate their GDP/GTP exchange reactions, and the other is to inhibit their interactions with membranes. Structurally, it has 11 Arm repeats, a protein interaction motif, found in the Drosophila Armadillo protein, a homolog of mammalian beta-catenin. We have isolated here an Smg GDS-interacting protein from a human brain cDNA library by use of the yeast two-hybrid method and named it SMAP (Smg GDS-associated protein). SMAP was a protein with a M(r) of 91,189 and 792 amino acids. SMAP had 9 Arm repeats. Recombinant SMAP interacted with recombinant Smg GDS but did not affect the two activities of Smg GDS on RhoA. SMAP was tyrosine phosphorylated by v-Src, and this phosphorylation reduced the affinity of SMAP for Smg GDS. Tissue and subcellular distribution analyses indicated that SMAP was ubiquitously expressed and highly concentrated at the endoplasmic reticulum area, Searches for sequence homology to SMAP revealed that SMAP was significantly homologous to sea urchin SpKAP115, suggesting that SMAP is a mammalian counterpart of SpKAP115 or its related protein. SpKAP115 is an accessory subunit of sea urchin kinesin II, an ATPase motor that transports vesicles along microtubules. These results suggest that SMAP serves as an adaptor for both Smg GDS and kinesin II or its related protein and links them with both the Smg GDS-regulated small G protein and Src tyrosine kinase signalings.	OSAKA UNIV,SCH MED,DEPT MOL BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Osaka University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)			Kawabe, Hiroshi/U-7325-2018	Kawabe, Hiroshi/0000-0001-5650-8696				BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GUAN C, 1987, GENE, V67, P21; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KATO M, 1994, BIOCHEM BIOPH RES CO, V205, P1776, DOI 10.1006/bbrc.1994.2875; KAWAMURA M, 1993, BIOCHEM BIOPH RES CO, V190, P832, DOI 10.1006/bbrc.1993.1124; KAWAMURA S, 1991, BIOCHEM BIOPH RES CO, V174, P1095, DOI 10.1016/0006-291X(91)91533-I; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Komuro R, 1996, BIOCHEM BIOPH RES CO, V219, P435, DOI 10.1006/bbrc.1996.0251; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; Nomanbhoy TK, 1996, J BIOL CHEM, V271, P10004, DOI 10.1074/jbc.271.17.10004; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; REDMOND T, 1992, CELL GROWTH DIFFER, V3, P567; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Sambrook J., 2002, MOL CLONING LAB MANU; Scholey JM, 1996, J CELL BIOL, V133, P1, DOI 10.1083/jcb.133.1.1; SHIRATAKI H, 1994, J BIOL CHEM, V269, P32717; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wedaman KP, 1996, J CELL BIOL, V132, P371, DOI 10.1083/jcb.132.3.371; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; Yamazaki H, 1996, P NATL ACAD SCI USA, V93, P8443, DOI 10.1073/pnas.93.16.8443; YAMAZAKI H, 1995, J CELL BIOL, V130, P1387, DOI 10.1083/jcb.130.6.1387; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	41	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27013	27017		10.1074/jbc.271.43.27013	http://dx.doi.org/10.1074/jbc.271.43.27013			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900189	hybrid			2022-12-25	WOS:A1996VP23300083
J	Spillman, MA; Bowcock, AM				Spillman, MA; Bowcock, AM			BRCA1 and BRCA2 mRNA levels are coordinately elevated in human breast cancer cells in response to estrogen	ONCOGENE			English	Article						estrogen; BRCA1; BRCA2; breast cancer; cycloheximide; cell line	SUSCEPTIBILITY GENE; OVARIAN-CANCER; EXPRESSION; RECEPTOR; PROLIFERATION; GROWTH; DIFFERENTIATION; CARCINOMAS; SEQUENCES; TISSUES	The steady state levels of BRCA1 and BRCA2 mRNAs were shown to be coordinately elevated by the steroid hormone estrogen but not progesterone in the human breast cancer cell lines BT-483 and MCF-7. Two different antiestrogens, trans 4'-hydroxytamoxifen and ICI 182,780, blocked the elevation of BRCA1 and BRCA2 mRNA levels, confirming that the effect was mediated through the estrogen receptor. In BT-483 cells, BRCA1 and BRCA2: mRNA levels were both elevated 18 to 24 h after estrogen stimulation, suggesting that the effect of estrogen was indirect. Cycloheximide blocked the estrogen effect implying that estrogen induces synthesis of an unidentified estrogen-responsive protein(s) that then result in the elevation of BRCA1 and BRCA2 mRNAs.	UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,MCDERMOTT CTR HUMAN GROWTH & DEV,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Bowcock, Anne/0000-0001-8691-9090	NCI NIH HHS [CA60650] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060650] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; DRIFE JO, 1986, ANN NY ACAD SCI, V464, P58, DOI 10.1111/j.1749-6632.1986.tb15993.x; DUBIK D, 1987, CANCER RES, V47, P6517; EASTON DF, 1993, AM J HUM GENET, V52, P678; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREEN S, 1990, J STEROID BIOCHEM, V37, P747, DOI 10.1016/0960-0760(90)90415-H; GUDAS JM, 1995, CANCER RES, V55, P4561; GUDAS JM, 1996, CELL GROWTH DIFFER, V7, P171; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; HECHT JR, 1994, AM J CLIN PATHOL, V102, pS25; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HORWITZ KB, 1978, J BIOL CHEM, V253, P2223; KASID A, 1987, J STEROID BIOCHEM, V27, P465, DOI 10.1016/0022-4731(87)90341-4; KING RJB, 1993, BREAST CANCER RES TR, V27, P3, DOI 10.1007/BF00683189; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; LASFARGUES EY, 1978, J NATL CANCER I, V61, P967; LONGACRE TA, 1986, AM J SURG PATHOL, V10, P382, DOI 10.1097/00000478-198606000-00003; MACLEAN HE, 1995, MOL CELL ENDOCRINOL, V112, P133, DOI 10.1016/0303-7207(95)03608-A; MARCUS JN, 1994, MONOGR NATL CANC I, V16, P23; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MAY FEB, 1986, CANCER RES, V46, P6034; MCGUIRE WL, 1992, J STEROID BIOCHEM, V43, P243, DOI 10.1016/0960-0760(92)90214-4; Merajver SD, 1995, CLIN CANCER RES, V1, P539; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD SA, 1995, AM J HUM GENET, V56, P254; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; REW DA, 1992, BRIT J SURG, V79, P335, DOI 10.1002/bjs.1800790418; Sambrook J., 2002, MOL CLONING LAB MANU; SHI YE, 1994, HUM REPROD, V9, P162, DOI 10.1093/humrep/9.suppl_1.162; Spillman M. A., 1995, American Journal of Human Genetics, V57, pA5; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; WAKELING AE, 1991, CANCER RES, V51, P3867; WAKELING AE, 1989, J MOL ENDOCRINOL, V2, P255; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	40	104	107	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1639	1645						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895509				2022-12-25	WOS:A1996VM88700008
J	Bouvier, F; dHarlingue, A; Hugueney, P; Marin, E; MarionPoll, A; Camara, B				Bouvier, F; dHarlingue, A; Hugueney, P; Marin, E; MarionPoll, A; Camara, B			Xanthophyll biosynthesis - Cloning, expression, functional reconstitution, and regulation of beta-cyclohexenyl carotenoid epoxidase from pepper (Capsicum annuum)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCES; SQUALENE EPOXIDASE; MOLECULAR-CLONING; CHROMOPLAST MEMBRANES; ESCHERICHIA-COLI; LYCOPENE CYCLIZATION; HIGHER-PLANTS; FATTY-ACIDS; PROTEIN; INHIBITION	Pepper (Capsicum annuum) beta-cyclohexenyl xanthophyll epoxidase cDNA was cloned and the corresponding enzyme overexpressed and purified from Escherichia coli, for investigation of its catalytic activity. The recombinant protein did not directly accept NADPH for epoxidation of cyclohexenyl carotenoids, nor did it operate according to a peroxygenase-based mechanism. Instead, the reducing power of NADPH was transferred to the epoxidase via reduced ferredoxin as shown by reconstitution of epoxidase activity in the presence of NADPH, ferredoxin oxidoreductase, and ferredoxin. Bacterial rubredoxin could be substituted for ferredoxin. The pepper epoxidase acted specifically on the beta-ring of xanthophylls such as beta-cryptoxanthin, zeaxan thin, and antheraxanthin. The proposed reaction mechanism for epoxidation involves the formation of a transient carbocation. This characteristic allows selective inhibition of the epoxidase activity by different nucleophilic diethylamine derivatives, p-dimethylaminobenzenediazonium fluoroborate and N,N-dimethyl-2-phenylaziridinium. It was also shown that the epoxidase gene was up-regulated during oxidative stress and when chloroplasts undergo differentiation into chromoplasts in pepper fruit.	UNIV STRASBOURG 1,CNRS,INST BIOL MOL PLANTES,F-67084 STRASBOURG,FRANCE; UNIV PARIS 06,LAB PATHOL & BIOCHIM VEGETALES,F-75250 PARIS,FRANCE; INST BIOL ZELLBIOL 2,D-79104 FREIBURG,GERMANY; INRA,BIOL CELLULAIRE LAB,F-78026 VERSAILLES,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Sorbonne Universite; INRAE; UDICE-French Research Universities; Universite Paris Saclay			Hugueney, Philippe/AAU-5903-2020	Hugueney, Philippe/0000-0002-1641-9274				Alonso JM, 1995, PLANT MOL BIOL, V29, P1211, DOI 10.1007/BF00020463; ATTAASAFOADJEI E, 1993, J BIOL CHEM, V268, P9681; BLEE E, 1990, J BIOL CHEM, V265, P12887; BODEA C, 1969, Pure and Applied Chemistry, V20, P517, DOI 10.1351/pac196920040517; BOTTING CH, 1995, BIOTECHNIQUES, V19, P362; BOUVIER F, 1994, PLANT J, V6, P45, DOI 10.1046/j.1365-313X.1994.6010045.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMARA B, 1985, PHYTOCHEMISTRY, V24, P2751, DOI 10.1016/S0031-9422(00)80718-9; CAMARA B, 1993, METHOD ENZYMOL, V214, P352; CAMARA B, 1985, METHOD ENZYMOL, V110, P244; CAMARA B, 1985, BIOCHIM BIOPHYS ACTA, V836, P262, DOI 10.1016/0005-2760(85)90074-8; Camara B, 1995, INT REV CYTOL, V163, P175, DOI 10.1016/S0074-7696(08)62211-1; CAMARA B, 1986, PLANT PHYSIOL, V80, P172, DOI 10.1104/pp.80.1.172; CAMARA B, 1985, METHOD ENZYMOL, V110, P274; CHANGEUX JP, 1967, P NATL ACAD SCI USA, V58, P2063, DOI 10.1073/pnas.58.5.2063; COGDELL RJ, 1987, BIOCHIM BIOPHYS ACTA, V895, P63, DOI 10.1016/S0304-4173(87)80008-3; COSTES C, 1979, FEBS LETT, V103, P17, DOI 10.1016/0014-5793(79)81241-7; Davies B., 1976, CAROTENOIDS CHEM BIO, P38, DOI [DOI 10.1590/S0101-20612001000200017, 10.1007/978-3-642-66632-2_11, DOI 10.1007/978-3-642-66632-2_11]; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; ENTSCH B, 1995, FASEB J, V9, P476, DOI 10.1096/fasebj.9.7.7737455; GALLIARD T, 1977, PHYTOCHEMISTRY, V16, P339, DOI 10.1016/0031-9422(77)80060-5; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; GOELDNER MP, 1980, P NATL ACAD SCI-BIOL, V77, P6439, DOI 10.1073/pnas.77.11.6439; GREEN BR, 1991, TRENDS BIOCHEM SCI, V16, P181, DOI 10.1016/0968-0004(91)90072-4; GREEN LS, 1991, PLANT PHYSIOL, V96, P1207, DOI 10.1104/pp.96.4.1207; GRUSZECKI WI, 1993, BIOCHIM BIOPHYS ACTA, V1144, P97, DOI 10.1016/0005-2728(93)90036-F; HAGER A, 1994, PLANTA, V192, P581, DOI 10.1007/BF00203597; HAMBERG M, 1990, ARCH BIOCH BIOPHYS, V283; HENGEN PN, 1995, TRENDS BIOCHEM SCI, V20, P285, DOI 10.1016/S0968-0004(00)89045-3; HIRASAWA M, 1990, ARCH BIOCHEM BIOPHYS, V276, P251, DOI 10.1016/0003-9861(90)90035-W; HUGUENEY P, 1992, EUR J BIOCHEM, V209, P399, DOI 10.1111/j.1432-1033.1992.tb17302.x; HUNDLE BS, 1993, FEBS LETT, V315, P329, DOI 10.1016/0014-5793(93)81188-6; JANDROSITZ A, 1991, GENE, V107, P155, DOI 10.1016/0378-1119(91)90310-8; KHUDAIRI AK, 1972, AM SCI, V60, P696; KNOELL HE, 1974, EUR J BIOCHEM, V50, P245, DOI 10.1111/j.1432-1033.1974.tb03893.x; KOSUGA K, 1995, BBA-GENE STRUCT EXPR, V1260, P345, DOI 10.1016/0167-4781(94)00245-X; KRINSKY NI, 1979, PURE APPL CHEM, V51, P649, DOI 10.1351/pac197951030649; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Marin E, 1996, EMBO J, V15, P2331, DOI 10.1002/j.1460-2075.1996.tb00589.x; MATSUI K, 1994, BIOSCI BIOTECH BIOCH, V58, P140, DOI 10.1271/bbb.58.140; McDermott J C, 1973, Pure Appl Chem, V35, P29, DOI 10.1351/pac197335010029; MONEGER R, 1968, PHYSIOL VEG, V6, P367; NARULA AS, 1981, J AM CHEM SOC, V103, P2408, DOI 10.1021/ja00399a045; ONO T, 1982, BIOCHIM BIOPHYS ACTA, V709, P84, DOI 10.1016/0167-4838(82)90424-1; PALUMAA P, 1982, BIOORG CHEM, V11, P394, DOI 10.1016/0045-2068(82)90030-X; PAN ZQ, 1995, J BIOL CHEM, V270, P8487, DOI 10.1074/jbc.270.15.8487; PENG YL, 1994, J BIOL CHEM, V269, P3755; PURDIE JE, 1969, BIOCHIM BIOPHYS ACTA, V185, P122, DOI 10.1016/0005-2744(69)90288-5; ROCK CD, 1991, P NATL ACAD SCI USA, V88, P7496, DOI 10.1073/pnas.88.17.7496; Rockholm DC, 1996, PLANT PHYSIOL, V110, P697, DOI 10.1104/pp.110.2.697; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAKAKIBARA J, 1995, J BIOL CHEM, V270, P17, DOI 10.1074/jbc.270.1.17; Sambrook J, 1989, MOL CLONING LABORATO, P545; SCHMITT P, 1987, PHYTOCHEMISTRY, V26, P2709, DOI 10.1016/S0031-9422(00)83577-3; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SINGH RK, 1973, BIOCHEM J, V132, P649, DOI 10.1042/bj1320649; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; SUKIGARA M, 1967, B CHEM SOC JPN, V40, P1077, DOI 10.1246/bcsj.40.1077; TESTA B, 1973, MOL PHARMACOL, V9, P10; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362; VETTER HP, 1992, PLANT PHYSIOL, V100, P998, DOI 10.1104/pp.100.2.998; VICK BA, 1987, PLANT PHYSIOL, V85, P1073, DOI 10.1104/pp.85.4.1073; WADA K, 1989, J BIOCHEM, V105, P619, DOI 10.1093/oxfordjournals.jbchem.a122714; WOFSY L, 1962, BIOCHEMISTRY-US, V1, P1031, DOI 10.1021/bi00912a013; YAMAMOTO HY, 1979, PURE APPL CHEM, V51, P639, DOI 10.1351/pac197951030639; YOUNG A, 1989, Z NATURFORSCH C, V44, P959; ZIEGLER DM, 1988, DRUG METAB REV, V19, P1, DOI 10.3109/03602538809049617	68	131	147	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28861	28867		10.1074/jbc.271.46.28861	http://dx.doi.org/10.1074/jbc.271.46.28861			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910532	hybrid, Green Published			2022-12-25	WOS:A1996VT05200024
J	Lett, CM; Berghuis, AM; Frey, HE; Lepock, JR; Guillemette, JG				Lett, CM; Berghuis, AM; Frey, HE; Lepock, JR; Guillemette, JG			The role of a conserved water molecule in the redox-dependent thermal stability of iso-1-cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE ISO-1-CYTOCHROME-C; SITE-DIRECTED MUTAGENESIS; AMINO-ACID REPLACEMENTS; HYDROGEN-BOND NETWORK; YEAST CYTOCHROME-C; PROTEIN STABILITY; TYROSINE-67; SUBSTITUTIONS; CONSEQUENCES; REDUCTION	Eukaryotic cytochromes c contain a buried mater molecule (Wat166) next to the heme that is associated through a network of hydrogen bonds to three invariant residues: tyrosine 67, asparagine 52, and threonine 78. Single-site mutations to two of these residues (Y67F, N52I, N52A) and the double-she mutation (Y67F/N52I) were introduced into Saccharomyces cerevisiae iso-1-cytochrome c to disrupt the hydrogen bonding network associated with Wat166. The N52I and Y67F/N52I mutations lead to a loss of Wat166 while N52A and Y67F modifications lead to the addition of a new water molecule (Wat166) at an adjacent site (Berghuis, A. M., Guillemette, J. G., McLendon, G., Sherman, F., Smith, M., and Brayer, G. D. (1994) J. Mol. Biol. 236, 786-799; Berghuis, A. M., Guillemette, J. G., Smith, M., and Brayer, G. D. (1994) J. Mol. Biol. 235, 1326-1341; Rafferty, S. P., Guillemette, J. G., Berghuis, A. M., Smith, M., Brayer, G. D., and Mauk, A. G. (1996) Biochemistry, 35, 10784-10792). We used differential scanning calorimetry (DSC) to determine the change in heat capacity (Delta C-P) and the temperature dependent enthalpy (Delta H-vH) for the thermal denaturation of both the oxidized and reduced forms of the iso-l cytochrome c variants. The relative stabilities were expressed as the difference in the free energy of denaturation (Delta G(D)) between the wild type and mutant proteins in both redox states. The disruption of the hydrogen bonding network results in increased stability for all of the mutant proteins in both redox states with the exception of the reduced Y67F variant which has approximately the same stability as the reduced wild type protein. For the oxidized proteins, Delta G(D) values of 1.3, 4.1, 1.5, and 5.8 kcal/mol were determined for N52A, N52I, Y67F, and Y67F/N52I, respectively. The oxidized proteins were 8.2-11.5 kcal/mol less stable than the reduced proteins due to a redox-dependent increase in the entropy of unfolding.	UNIV WATERLOO,DEPT CHEM,WATERLOO,ON N2L 3G1,CANADA; UNIV WATERLOO,GUELPH WATERLOO CTR GRAD WORK CHEM,WATERLOO,ON N2L 3G1,CANADA; UNIV WATERLOO,DEPT PHYS,WATERLOO,ON N2L 3G1,CANADA; MCMASTER UNIV,DEPT BIOCHEM,HAMILTON,ON L8S 4L8,CANADA	University of Waterloo; University of Guelph; University of Waterloo; University of Waterloo; McMaster University			Berghuis, Albert M/A-6495-2008	Berghuis, Albert/0000-0002-2663-025X				BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BERGHUIS AM, 1994, J MOL BIOL, V235, P1326, DOI 10.1006/jmbi.1994.1086; BERGHUIS AM, 1992, J MOL BIOL, V223, P959, DOI 10.1016/0022-2836(92)90255-I; BERGHUIS AM, 1994, J MOL BIOL, V236, P786, DOI 10.1006/jmbi.1994.1189; CHURG AK, 1986, BIOCHEMISTRY-US, V25, P1675, DOI 10.1021/bi00355a035; COHEN DS, 1995, J AM CHEM SOC, V117, P1675, DOI 10.1021/ja00111a001; CUTLER RL, 1987, PROTEIN ENG, V1, P95, DOI 10.1093/protein/1.2.95; DAS G, 1989, P NATL ACAD SCI USA, V86, P496, DOI 10.1073/pnas.86.2.496; DUNITZ JD, 1994, SCIENCE, V264, P670, DOI 10.1126/science.264.5159.670; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; FRAUENHOFF MM, 1992, PROTEINS, V14, P202, DOI 10.1002/prot.340140207; GAO Y, 1991, BIOCHEMISTRY-US, V30, P1928, DOI 10.1021/bi00221a028; GUILLEMETTE JG, 1994, BIOCHIMIE, V76, P592, DOI 10.1016/0300-9084(94)90136-8; HICKEY DR, 1991, J BIOL CHEM, V266, P11686; INGLIS SC, 1991, PROTEIN ENG, V4, P569, DOI 10.1093/protein/4.5.569; KOMARPANICUCCI S, 1994, BIOCHEMISTRY-US, V33, P10556, DOI 10.1021/bi00200a042; KOSHY TI, 1994, BIOCHEM J, V299, P347, DOI 10.1042/bj2990347; LANGEN R, 1992, J MOL BIOL, V224, P589, DOI 10.1016/0022-2836(92)90546-V; LEVITT M, 1993, STRUCTURE, V1, P223, DOI 10.1016/0969-2126(93)90011-5; LIGGINS JR, 1994, BIOCHEMISTRY-US, V33, P9209, DOI 10.1021/bi00197a024; LINSKEOCONNELL LI, 1995, BIOCHEMISTRY-US, V34, P7094, DOI 10.1021/bi00021a022; LUNTZ TL, 1989, P NATL ACAD SCI USA, V86, P3524, DOI 10.1073/pnas.86.10.3524; MARGOLIASH E, 1959, BIOCHEM J, V71, P570, DOI 10.1042/bj0710570; McGee WA, 1996, BIOCHEMISTRY-US, V35, P1995, DOI 10.1021/bi951228f; MEYER E, 1992, PROTEIN SCI, V1, P1543, DOI 10.1002/pro.5560011203; MOORE GR, 1990, CYTOCHROMES EVOLUTIO, P309; PACE CN, 1992, J MOL BIOL, V226, P29, DOI 10.1016/0022-2836(92)90121-Y; PIELAK GJ, 1995, BIOCHEMISTRY-US, V34, P3268, DOI 10.1021/bi00010a017; RAFFERTY SP, 1990, BIOCHEMISTRY-US, V29, P9365, DOI 10.1021/bi00492a009; Rafferty SP, 1996, BIOCHEMISTRY-US, V35, P10784, DOI 10.1021/bi960430v; SCHEJTER A, 1994, BIOCHEM J, V302, P95, DOI 10.1042/bj3020095; SCHELLMAN JA, 1987, ANNU REV BIOPHYS BIO, V16, P115, DOI 10.1146/annurev.bb.16.060187.000555; SCOTT RA, 1996, CYTOCHROME C MULTIDI, P1; SHIRLEY BA, 1992, BIOCHEMISTRY-US, V31, P725, DOI 10.1021/bi00118a013; SHORTLE D, 1989, J BIOL CHEM, V264, P5313; TAKANO T, 1981, J MOL BIOL, V153, P79, DOI 10.1016/0022-2836(81)90528-3; TEETER MM, 1991, ANNU REV BIOPHYS BIO, V20, P577, DOI 10.1146/annurev.bb.20.060191.003045; WALLACE CJA, 1989, J BIOL CHEM, V264, P15199; WHITFORD D, 1991, EUR J BIOCHEM, V200, P359, DOI 10.1111/j.1432-1033.1991.tb16193.x	39	46	46	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29088	29093		10.1074/jbc.271.46.29088	http://dx.doi.org/10.1074/jbc.271.46.29088			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910563	hybrid			2022-12-25	WOS:A1996VT05200055
J	Li, SW; Couet, J; Lisanti, MP				Li, SW; Couet, J; Lisanti, MP			Src tyrosine kinases, G(alpha) subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin - Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; TRANS-GOLGI-NETWORK; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; TRANSFORMING PROTEIN; PHEROMONE RESPONSE; 14-3-3 PROTEIN; SH3 DOMAINS; PP60C-SRC; ASSOCIATION	Caveolae are plasma membrane specializations present in most cell types, Caveolin, a 22-kDa integral membrane protein, is a principal structural and regulatory component of caveolae membranes. Previous studies have demonstrated that caveolin co-purifies with lipid modified signaling molecules, including G(alpha) subunits, H-ras c-Src, and other related Src family tyrosine kinases. In addition, it has been shown that caveolin interacts directly with G(alpha) subunits and H-Ras, preferentially recognizing the inactive conformation of these molecules. However, it is not known whether caveolin interacts directly or indirectly with Src family tyrosine kinases. Here, we examine the structural and functional interaction of caveolin with Src family tyrosine kinases. Caveolin was recombinantly expressed as a glutathione S-transferase fusion. Using an established in vitro binding assay, we find that caveolin interacts with wild-type Src (c-Src) but does not form a stable complex with mutationally activated Src (v-Src). Thus, it appears that caveolin prefers the inactive conformation of Src. Deletion mutagenesis indicates that the Src-interacting domain of caveolin is located within residues 82-101, a cytosolic membrane-proximal region of caveolin. A caveolin peptide derived hom this region (residues 82- 101) functionally suppressed the auto-activation of purified recombinant c-Src tyrosine kinase and Fyn, a related Src family tyrosine kinase. We further analyzed the effect of caveolin on c-Src activity in vivo by transiently co-expressing full-length caveolin and c-Src tyrosine kinase in 293T cells. Co-expression with caveolin dramatically suppressed the tyrosine kinase activity of c-Src as measured via an immune complex kinase assay. Thus, it appears that caveolin structurally and functionally interacts with wild-type c-Src via caveolin residues 82-101. Besides interacting with Src family kinases, this cytosolic caveolin domain (residues 82-101) has the following unique features. First,it is required to form multivalent homo-oligomers of caveolin. Second, it interacts with G-protein alpha-subunits and down-regulates their GTPase activity. Third, it binds to wild-type H-Ras. Fourth, it is membrane-proximal, suggesting that it may be involved in other potential protein-protein interactions. Thus, we have termed this 20-amino acid stretch of caveolin residues the caveolin scaffolding domain.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute			Li, Shengwen Calvin/H-1725-2012; Lisanti, Michael P/C-6866-2013; Lisanti, Michael/B-6131-2018	Li, Shengwen Calvin/0000-0002-9699-9204; Lisanti, Michael/0000-0003-2034-1382; Couet, Jacques/0000-0001-5409-8689	NATIONAL CANCER INSTITUTE [F32CA071326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA071326, CA-71326] Funding Source: Medline; NIGMS NIH HHS [GM-50443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BROWN MT, 1996, IN PRESS BIOCH BIOPH; BUSS JE, 1984, MOL CELL BIOL, V4, P2697, DOI 10.1128/MCB.4.12.2697; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FAN JY, 1983, J CELL SCI, V61, P219; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; FEDER D, 1990, J BIOL CHEM, V265, P8205; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; HENNIPMAN A, 1989, CANCER RES, V49, P516; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KRUEGER JG, 1982, CELL, V28, P889, DOI 10.1016/0092-8674(82)90068-X; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P3863; Lisanti Michael P., 1995, Seminars in Developmental Biology, V6, P47, DOI 10.1016/S1044-5781(06)80084-8; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1988, BIOCHEM BIOPH RES CO, V154, P796, DOI 10.1016/0006-291X(88)90210-0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSUSKY M, 1995, J BIOL CHEM, V270, P25729, DOI 10.1074/jbc.270.43.25729; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELLMAN D, 1985, P NATL ACAD SCI USA, V82, P1623, DOI 10.1073/pnas.82.6.1623; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; SEVERS NJ, 1988, J CELL SCI, V90, P341; SHOELSON SE, 1989, J BIOL CHEM, V264, P7831; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; SNYDER MA, 1984, VIROLOGY, V136, P375, DOI 10.1016/0042-6822(84)90174-0; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; SUMMERS M, 1987, MANUAL METHODS BARCU; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; TANG ZL, 1994, GENE, V147, P299, DOI 10.1016/0378-1119(94)90087-6; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0	80	659	671	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29182	29190		10.1074/jbc.271.46.29182	http://dx.doi.org/10.1074/jbc.271.46.29182			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910575	Green Accepted, hybrid			2022-12-25	WOS:A1996VT05200067
J	Marquez, LA; RehaKrantz, LJ				Marquez, LA; RehaKrantz, LJ			Using 2-aminopurine fluorescence and mutational analysis to demonstrate an active role of bacteriophage T4 DNA polymerase in strand separation required for 3'->5'-exonuclease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC ACID POLYMERASES; 5' EXONUCLEASE ACTIVITY; BIOCHEMICAL BASIS; KLENOW FRAGMENT; REPLICATION FIDELITY; MUTATOR; ANTIMUTATOR	The fluorescence of S-aminopurine deoxynucleotide positioned in a 3'-terminal mismatch was used to evaluate the pre-steady state kinetics of the 3' --> 5' exonuclease activity of bacteriophage T4 DNA polymerase on defined DNA substrates, DNA substrates with one, two, or three preformed terminal mispairs simulated increasing degrees of strand separation at a primer terminus. The effects of base pair stability and local DNA sequence on excision rates were investigated by using DNA substrates that were either relatively G + C- or A + T-rich. The importance of strand separation as a prerequisite to the hydrolysis of a terminal nucleotide was demonstrated by using a unique mutant DNA polymerase that could degrade single-stranded but not double-stranded DNA, unless two or more 3'-terminal nucleotides were unpaired. Our results led us to conclude that the reduced exonuclease activity of this mutant DNA polymerase on duplex DNA substrates is due to a defect in melting the primer terminus in preparation for the excision reaction, The mutated amino acid (serine substitution for glycine at codon 255) resides in a critical loop structure determined from a crystallographic study of an amino-terminal fragment of T4 DNA polymerase. These results suggest an active role for amino acid residues in the exonuclease domain of the T4 DNA polymerase in the strand separation step.	UNIV ALBERTA,DEPT BIOL SCI,EDMONTON,AB T6G 2E9,CANADA	University of Alberta			Marquez-Curtis, Leah A/M-7152-2015; Reha-Krantz, Linda/A-3748-2014	Marquez-Curtis, Leah A/0000-0002-4047-2227; Reha-Krantz, Linda/0000-0003-4497-423X				BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BESSMAN MJ, 1977, J MOL BIOL, V116, P115, DOI 10.1016/0022-2836(77)90122-X; BLOOM LB, 1994, BIOCHEMISTRY-US, V33, P7576, DOI 10.1021/bi00190a010; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; CARVER TE, 1994, P NATL ACAD SCI USA, V91, P10670, DOI 10.1073/pnas.91.22.10670; CONNOLLY BA, 1991, OLIGONUCLEOTIDES ANA, P162; COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; ERITJA R, 1986, NUCLEIC ACIDS RES, V14, P5869, DOI 10.1093/nar/14.14.5869; FASSMAN GD, 1975, HDB BIOCH MOL BIOL N, V1, P589; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; GOPALAKRISHNAN V, 1994, J BIOL CHEM, V269, P21123; HERSHFIELD MS, 1972, J BIOL CHEM, V247, P3393; HOCHSTRASSER RA, 1994, BIOCHEMISTRY-US, V33, P11971, DOI 10.1021/bi00205a036; HUANG WM, 1972, J BIOL CHEM, V247, P3139; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; LIN TC, 1987, P NATL ACAD SCI USA, V84, P7000, DOI 10.1073/pnas.84.20.7000; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; REDDY MK, 1992, J BIOL CHEM, V267, P14157; REHAKRANTZ LJ, 1993, J BIOL CHEM, V268, P27100; RehaKrantz LJ, 1995, METHOD ENZYMOL, V262, P323; REHAKRANTZ LJ, 1993, J VIROL, V67, P60, DOI 10.1128/JVI.67.1.60-66.1993; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; REHAKRANTZ LJ, 1988, J MOL BIOL, V202, P711, DOI 10.1016/0022-2836(88)90552-9; REHAKRANTZ LJ, 1994, J BIOL CHEM, V269, P5635; REHAKRANTZ LJ, 1995, TRENDS BIOCHEM SCI, V202, P133; SOWERS LC, 1986, P NATL ACAD SCI USA, V83, P5434, DOI 10.1073/pnas.83.15.5434; STOCKI SA, 1995, J MOL BIOL, V254, P15, DOI 10.1006/jmbi.1995.0595; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; Wang J, 1996, BIOCHEMISTRY-US, V35, P8110, DOI 10.1021/bi960178r	35	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28903	28911		10.1074/jbc.271.46.28903	http://dx.doi.org/10.1074/jbc.271.46.28903			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910538				2022-12-25	WOS:A1996VT05200030
J	Yebra, M; Parry, GCN; Stromblad, S; Mackman, N; Rosenberg, S; Mueller, BM; Cheresh, DA				Yebra, M; Parry, GCN; Stromblad, S; Mackman, N; Rosenberg, S; Mueller, BM; Cheresh, DA			Requirement of receptor-bound urokinase-type plasminogen activator for integrin alpha v beta 5-directed cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; IN-VITRO; EPITHELIAL-CELLS; U-PA; MONOCLONAL-ANTIBODIES; SIGNAL-TRANSDUCTION; BINDING REGION; SCATTER FACTOR; EGF RECEPTOR; HUMAN-PLASMA	The urokinase plasminogen activator (uPA) interacts with its cell surface receptor (uPAR), providing an inducible, localized cell surface proteolytic activity, thereby promoting cellular invasion. Evidence is provided for a novel function of cell surface-associated uPA . uPAR. Specifically, induction of cell surface expression of uPA uPAR by growth factors or phorbol ester was necessary for vitronectin-dependent carcinoma cell migration, an event mediated by integrin alpha v beta 5. Cell migration on vitronectin was blocked with either a soluble form of uPAR, an antibody that disrupts uPA binding to uPAR, or a monoclonal antibody to alpha v beta 5. Moreover, plasminogen activator inhibitor type 2 blocked this migration event but did not affect adhesion, suggesting a direct role for uPA enzyme activity in this process and that migration but not adhesion of these cells is regulated by uPA . uPAR. Growth factor-mediated induction of uPA . uPAR on the carcinoma cell surface promotes a specific motility event mediated by integrin alpha v beta 5, since cells transfected with the beta 3 integrin subunit expressed alpha v beta 3 and migrated on vitronectin independently of growth factors or uPA . uPAR expression, This relationship between alpha v beta 5 and the uPA uPAR system has significant implications for regulation of motility events associated with development, angiogenesis, and tumor metastasis.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; CHIRON CORP, EMERYVILLE, CA 94608 USA	Scripps Research Institute; Scripps Research Institute; Novartis				Stromblad, Staffan/0000-0002-1236-6339	NATIONAL CANCER INSTITUTE [R01CA045726, R37CA050286, R01CA050286] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054444] Funding Source: NIH RePORTER; NCI NIH HHS [CA-45726, CA-50286] Funding Source: Medline; NHLBI NIH HHS [HL54444] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BRODSKY FM, 1982, J IMMUNOL, V128, P129; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; CIAMBRONE GJ, 1992, J BIOL CHEM, V267, P13617; CONFORTI G, 1994, BLOOD, V83, P994; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DELROSSO M, 1993, BIOCHEM BIOPH RES CO, V190, P347, DOI 10.1006/bbrc.1993.1054; DENT MAR, 1993, EUR J NEUROSCI, V5, P633, DOI 10.1111/j.1460-9568.1993.tb00529.x; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GOLD LI, 1989, BIOCHEM J, V262, P529, DOI 10.1042/bj2620529; GOODSON RJ, 1994, P NATL ACAD SCI USA, V91, P7129, DOI 10.1073/pnas.91.15.7129; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; Higazi AAR, 1996, BLOOD, V88, P542, DOI 10.1182/blood.V88.2.542.bloodjournal882542; HOLTING T, 1995, EUR J ENDOCRINOL, V132, P229, DOI 10.1530/eje.0.1320229; HUBER K, 1984, J LAB CLIN MED, V103, P684; JENSEN PJ, 1993, J CELL PHYSIOL, V155, P333, DOI 10.1002/jcp.1041550214; KESSLER TL, 1993, FIBRINOLYSIS, V7, P31, DOI 10.1016/0268-9499(93)90052-W; Kindzelskii AL, 1996, J IMMUNOL, V156, P297; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; KOBAYASHI H, 1992, CANCER RES, V52, P3610; KOST C, 1992, J BIOL CHEM, V267, P12098; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; LEAVESLEY DI, 1992, J CELL BIOL, V117, P1101, DOI 10.1083/jcb.117.5.1101; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; MATTHAY MA, 1993, J CELL SCI, V106, P869; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MOHANAM S, 1993, CANCER RES, V53, P4143; MOSER TL, 1995, BIOCHEM J, V307, P867, DOI 10.1042/bj3070867; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NIP J, 1995, CANCER METAST REV, V14, P241, DOI 10.1007/BF00690295; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; PADMANABHAN J, 1995, THROMB HAEMOSTASIS, V73, P829; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; QUIGLEY JP, 1987, P NATL ACAD SCI USA, V84, P2776, DOI 10.1073/pnas.84.9.2776; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; REINARTZ J, 1995, EXP CELL RES, V220, P274, DOI 10.1006/excr.1995.1316; Sambrook J., 2002, MOL CLONING LAB MANU; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; STAHL A, 1994, CANCER RES, V54, P3066; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; VARKI NM, 1984, CANCER RES, V44, P681; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; VIRCA GD, 1990, BIOTECHNIQUES, V8, P370; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; WEI Y, 1994, J BIOL CHEM, V269, P32380; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; XUE W, 1994, J IMMUNOL, V152, P4630; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; YEBRA M, 1995, MOL BIOL CELL, V6, P841, DOI 10.1091/mbc.6.7.841	54	208	214	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29393	29399		10.1074/jbc.271.46.29393	http://dx.doi.org/10.1074/jbc.271.46.29393			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910604	hybrid			2022-12-25	WOS:A1996VT05200096
J	Gibbs, VC; Takahashi, M; Aguet, M; Chuntharapai, A				Gibbs, VC; Takahashi, M; Aguet, M; Chuntharapai, A			A negative regulatory region in the intracellular domain of the human interferon-alpha receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; PATHWAY; PHOSPHATASE; ACTIVATION; BINDING; INTERLEUKIN-10; ASSOCIATION	Interferon-alpha (IFN-alpha)-mediated intracellular signaling is initiated by ligand-induced receptor dimerization, tyrosine phosphorylation of the Tyk2 and Jak1 tyrosine kinases, and subsequent phosphorylation of the Stat1 and Stat2 proteins. The IFN-alpha receptor consists of at least two distinct subunits. One subunit, IFNAR1, has low affinity binding for interferon yet is required for signal transduction. We introduced mutations in the cytoplasmic domain of human IFNAR1 in order to identify residues involved in the mediation of biological responses. We took advantage of the species specificity of the interferon receptors by analyzing human IFN-alpha-induced major histocompatibility complex class I antigen expression in mouse L929 cells stably transfected with mutant human receptors. The membrane proximal 60-amino acids were insufficient to signal a biological response even though within these residues Tyk2 and Stat2 binding sites have been identified. IFN-alpha-induced receptor tyrosine phosphorylation was not critical for signaling because mutation of Tyr residues to Phe did not prevent the biological response to IFN-alpha. The deletion of a 16-amino acid region highly homologous between species created a receptor which signals an enhanced response. Tyrosine dephosphorylation is a component of this enhanced response as mutation of the Tyr residues within this region to Phe resulted in a receptor with increased sensitivity to IFN. The known signaling molecules that interact with IFNAR1 are positive regulators of IFN-alpha function. The presence of this domain in the COOH-terminal region suggests that the receptor may interact with signaling molecules that negatively regulate interferon responses.	GENENTECH INC,DEPT MOL ONCOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT BIOANALYT TECHNOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech	Gibbs, VC (corresponding author), SFVAMC,SURG SERV 112,DEPT SURG,4150 CLEMENT ST,SAN FRANCISCO,CA 94131, USA.							AGUET M, 1984, VIROLOGY, V132, P211, DOI 10.1016/0042-6822(84)90105-3; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; DAVID M, 1993, J BIOL CHEM, V268, P6593; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVID M, 1995, MOL CELL BIOL, V15, P7050; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; HO ASY, 1995, MOL CELL BIOL, V15, P5043; HWANG SY, 1995, P NATL ACAD SCI USA, V92, P11284, DOI 10.1073/pnas.92.24.11284; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LIM JK, 1993, BIOCHIM BIOPHYS ACTA, V1173, P314, DOI 10.1016/0167-4781(93)90129-2; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PLATANIAS LC, 1993, J IMMUNOL, V150, P3382; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; Yan H, 1996, MOL CELL BIOL, V16, P2074; YETTER A, 1995, J BIOL CHEM, V270, P18179, DOI 10.1074/jbc.270.31.18179	29	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28710	28716		10.1074/jbc.271.45.28710	http://dx.doi.org/10.1074/jbc.271.45.28710			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910507	hybrid			2022-12-25	WOS:A1996VU03300107
J	Gilbert, M; Watson, DC; Cunningham, AM; Jennings, MP; Young, NM; Wakarchuk, WW				Gilbert, M; Watson, DC; Cunningham, AM; Jennings, MP; Young, NM; Wakarchuk, WW			Cloning of the lipooligosaccharide alpha-2,3-sialyltransferase from the bacterial pathogens Neisseria meningitidis and Neisseria gonorrhoeae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYLTRANSFERASE; EXPRESSION; GENES; LIPOPOLYSACCHARIDE; SYSTEM	The genes encoding the alpha-2,3-sialyltransferases involved in lipooligosaccharide biosynthesis from Neisseria meningitidis and Neisseria gonorrhoeae have been cloned and expressed in Escherichia coli, A high sensitivity enzyme assay using a synthetic fluorescent glycosyltransferase acceptor and capillary electrophoresis was used to screen a genomic library of N. meningitidis MC58 L3 in a ''divide and conquer'' strategy, The gene, denoted 1st, was found on a 2.0 kilobase fragment of DNA, and its sequence was determined and then used to design probes to amplify and subsequently clone the corresponding Ist genes from N. meningitidis 406Y L3, N. meningitidis M982B L7, and N. gonorrhoeae F62, Functional sialyltransferase was produced from the genes derived from both L3 N. meningitidis strains and the N. gonorrhoeae F62, However, the N. meningitidis M982B L7 gene contained a frameshift mutation that renders it inactive, The expression of the 1st gene was easily detected using the enzyme assay, and the protein expression could be detected when an immunodetection tag was added to the COOH-terminal end of the protein, Using the synthetic acceptor N-acetyllactosamineaminophenyl-(6-(5-(fluorescein-carboxamido)-hexanoic acid amide), the alpha-2,3 specificity of the enzyme was confirmed by NMR examination of the reaction product. The enzyme could also use synthetic accepters with lactose or galactose as the saccharide portion, This study is the first example of the cloning, expression, and examination of alpha-2,5-sialyltransferase activity from a bacterial source.	NATL RES COUNCIL CANADA,INST BIOL SCI,OTTAWA,ON K1A 0R6,CANADA; JOHN RADCLIFFE HOSP,INST MOL MED,DEPT PAEDIAT,HEADINGTON OX3 9DU,OXFORD,ENGLAND	National Research Council Canada; University of Oxford			Wakarchuk, Warren/Q-9514-2017; Jennings, Michael P/G-4822-2013; Wakarchuk, Warren/AAO-2774-2020	Wakarchuk, Warren/0000-0002-1539-1679; Jennings, Michael P/0000-0002-1027-4684; Wakarchuk, Warren/0000-0002-1539-1679; Gilbert, Michel/0000-0002-0204-4408	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASPINALL GO, 1994, BIOCHEMISTRY-US, V33, P241, DOI 10.1021/bi00167a032; BRAMLEY J, 1995, MICROB PATHOGENESIS, V18, P187, DOI 10.1016/S0882-4010(95)90040-3; GANGULI S, 1994, J BACTERIOL, V176, P4583, DOI 10.1128/JB.176.15.4583-4589.1994; HarduinLepers A, 1995, GLYCOBIOLOGY, V5, P741, DOI 10.1093/glycob/5.8.741; Jennings MP, 1995, MOL MICROBIOL, V18, P729, DOI 10.1111/j.1365-2958.1995.mmi_18040729.x; MACKENZIE CR, 1994, BIO-TECHNOL, V12, P390, DOI 10.1038/nbt0494-390; MANDRELL RE, 1993, MICROB PATHOGENESIS, V14, P315, DOI 10.1006/mpat.1993.1031; MANDRELL RE, 1993, MICROB PATHOGENESIS, V14, P307, DOI 10.1006/mpat.1993.1030; MCLAUGHLIN R, 1992, J BACTERIOL, V174, P6455, DOI 10.1128/JB.174.20.6455-6459.1992; NAKAI K, 1991, PROTEINS, V11, P95, DOI 10.1002/prot.340110203; PAVLIAK V, 1993, J BIOL CHEM, V268, P14146; Rest RF, 1995, MICROB PATHOGENESIS, V19, P379, DOI 10.1006/mpat.1995.0073; Sambrook J., 2002, MOL CLONING LAB MANU; Smith H, 1995, MICROB PATHOGENESIS, V19, P365, DOI 10.1006/mpat.1995.0071; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Wakarchuk W, 1996, J BIOL CHEM, V271, P19166, DOI 10.1074/jbc.271.32.19166; WILLIAMS MA, 1995, GLYCOCONJUGATE J, V12, P755, DOI 10.1007/BF00731235; ZHAO JY, 1994, GLYCOBIOLOGY, V4, P239, DOI 10.1093/glycob/4.2.239	18	139	161	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28271	28276		10.1074/jbc.271.45.28271	http://dx.doi.org/10.1074/jbc.271.45.28271			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910446	hybrid			2022-12-25	WOS:A1996VU03300046
J	Inoue, G; Cheatham, B; Kahn, CR				Inoue, G; Cheatham, B; Kahn, CR			Different pathways of postreceptor desensitization following chronic insulin treatment and in cells overexpressing constitutively active insulin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; GROWTH-FACTOR-I; DOWN-REGULATION; TRANSMEMBRANE DOMAIN; SOS-GRB2 COMPLEX; RAS ACTIVATION; S6 KINASE; SIGNAL; SHC; DISASSOCIATION	We have reported previously that substitution of the transmembrane domain of the insulin receptor with that of the erbB-2 oncogene (IR(erbV-->E)) results in constitutive activation of the insulin receptor kinase. Compared to NIH3T3 cells overexpressing wild-type insulin receptors (IR(wt)), cells overexpressing IR(erbV-->E) displayed a decrease in IRS-1 protein content by 55%, but basal tyrosine phosphorylation of IRS-1 was increased. This resulted in an increased association of IRS-1 with the p85 subunit of phosphatidylinositol 3-kinase, increased phosphatidylinositol 3-kinase activity in anti-IRS-1 immunoprecipitates, constitutive activation of p70 S6 protein kinase, and an increased association of Grb2 with She in the absence of Ligand. However, Grb2 association with IRS-1 could not be detected in the basal or insulin-stimulated states, and mitogen-activated protein kinase (MAPK) activity could not be stimulated by insulin, epidermal growth factor, or platelet-derived growth factor. In contrast to IR(erbV-->E), the insulin receptor content and its tyrosine phosphorylation were significantly decreased in IR(wt) cells chronically stimulated (>24 h) with insulin, With decreased IRS-1 content, tyrosine phosphorylation of IRS-1 was decreased by over 75%, leading to decreased IRS-1-associated PI 3-kinase and Grb2. In addition, Grb2 association with She and activation of MAPK and the p70 S6 kinase were insensitive to insulin stimulation, By contrast, association of Grb2 with She and activation of MAPK; but not the p70 S6 kinase, could be stimulated by epidermal growth factor or platelet-derived growth factor. These data suggest that there are multiple levels of postreceptor desensitization to insulin action. These are used somewhat differently in these two different models, probably due in part to the difference in receptor down-regulation.	BRIGHAM & WOMENS HOSP, DEPT MED, JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NIDDK NIH HHS [DK 36836, DK 31036] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R37DK031036, R01DK031036] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; CHEATHAM B, 1993, P NATL ACAD SCI USA, V90, P7336, DOI 10.1073/pnas.90.15.7336; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768; GARVEY WT, 1985, J CLIN INVEST, V76, P22, DOI 10.1172/JCI111950; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; KENNER KA, 1993, J BIOL CHEM, V268, P25455; KLARLUND JK, 1995, J BIOL CHEM, V270, P23421, DOI 10.1074/jbc.270.40.23421; KNUTSON VP, 1991, J BIOL CHEM, V266, P15656; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; MAEGAWA H, 1995, J BIOL CHEM, V270, P7724, DOI 10.1074/jbc.270.13.7724; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; REED DK, 1989, J BIOL CHEM, V264, P12673; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; RICE KM, 1992, J BIOL CHEM, V267, P10163; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; TAKAHASHI K, 1995, J BIOL CHEM, V270, P19041, DOI 10.1074/jbc.270.32.19041; UEKI K, 1994, J BIOL CHEM, V269, P15756; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WAY BA, 1993, J BIOL CHEM, V268, P26409; WENG QP, 1995, MOL CELL BIOL, V15, P2333; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMADA K, 1992, J BIOL CHEM, V267, P12452; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107	35	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28206	28211		10.1074/jbc.271.45.28206	http://dx.doi.org/10.1074/jbc.271.45.28206			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910437	hybrid			2022-12-25	WOS:A1996VU03300037
J	Ohtsu, H; Kuramasu, A; Suzuki, S; Igarashi, K; Ohuchi, Y; Sato, M; Tanaka, S; Nakagawa, S; Shirato, K; Yamamoto, M; Ichikawa, A; Watanabe, T				Ohtsu, H; Kuramasu, A; Suzuki, S; Igarashi, K; Ohuchi, Y; Sato, M; Tanaka, S; Nakagawa, S; Shirato, K; Yamamoto, M; Ichikawa, A; Watanabe, T			Histidine decarboxylase expression in mouse mast cell line P815 is induced by mouse peritoneal cavity incubation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONNECTIVE-TISSUE-TYPE; BINDING TRANSCRIPTION FACTORS; MASTOCYTOMA P-815 CELLS; LEUCINE ZIPPER PROTEIN; EMBRYONIC STEM-CELLS; C-KIT LIGAND; CARBOXYPEPTIDASE-A; FACTOR NF-E2; BONE-MARROW; ERYTHROID DEVELOPMENT	Phenotype of P815 mouse mast cells changes markedly during culture in the peritoneal cavity of syngenic BDF1 mice. The cells, cultured for 1 week in the peritoneal cavity of syngenic BDF1 mice, proliferate and express high levels of L-histidine decarboxylase (HDC) and mouse mast cell protease (MMCP)-6 mRNAs, indicating the ability of P815 cells to differentiate toward mature connective tissue mast cells. Peritoneal fluid aspirated from P815-inoculated BDF1 mouse and added to cultured P815 cells in vitro was also found to induce HDC mRNA expression, suggesting that at least some of the humoral factors in the peritoneal fluid induce HDC mRNA transcription, Among the erythroid transcription factors, P815 cells expressed GATA-2 but not GATA-1 mRNA before and after the intraperitoneal incubation. In contrast, the expression of NF-E2 subunit p45 disappeared, while expression of subunit mafK was markedly reduced after incubation. Cotransfection assays using HDC-luciferase reporter and p45 and/or mafK expression constructs showed that NF-E2 affects the transactivation of HDC gene, These results suggest that NF-E2 is also an important transcription factor in mast cell differentiation.	TOHOKU UNIV,SCH MED,DEPT INTERNAL MED 1,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; UNIV TSUKUBA,CTR TSUKUBA ADV RES ALLIANCE,DIV MOL & DEV BIOL,TSUKUBA,IBARAKI 305,JAPAN; KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,KYOTO 60601,JAPAN	Tohoku University; University of Tsukuba; Kyoto University	Ohtsu, H (corresponding author), TOHOKU UNIV,SCH MED,DEPT PHARMACOL 1,AOBA KU,2-1 SEIRYO MACHI,SENDAI,MIYAGI 98077,JAPAN.		Tanaka, Satoshi/H-6800-2019; TANAKA, Satoshi/B-1624-2011; Yamamoto, Masayuki/A-4873-2010	Tanaka, Satoshi/0000-0002-3468-7694; TANAKA, Satoshi/0000-0002-3468-7694; Yamamoto, Masayuki/0000-0002-9073-9436; Igarashi, Kazuhiko/0000-0002-2470-2475				ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENBURG JA, 1992, BLOOD, V79, P846; DUNN TB, 1957, J NATL CANCER I, V18, P587; EKLUND KK, 1993, J IMMUNOL, V151, P4266; GHILDYAL N, 1992, J IMMUNOL, V149, P2123; GHILDYAL N, 1993, J IMMUNOL, V151, P3206; GURISH MF, 1992, J EXP MED, V175, P1003, DOI 10.1084/jem.175.4.1003; HARA T, 1994, BLOOD, V84, P189; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; IHLE JN, 1983, J IMMUNOL, V131, P282; KASUGAI T, 1993, AM J PATHOL, V143, P1337; KITAMURA Y, 1979, NATURE, V281, P154, DOI 10.1038/281154a0; KITAMURA Y, 1989, ANNU REV IMMUNOL, V7, P59, DOI 10.1146/annurev.iy.07.040189.000423; KOBAYASHI T, 1986, J IMMUNOL, V136, P1378; MATSUDA H, 1991, J EXP MED, V174, P7, DOI 10.1084/jem.174.1.7; MCNEIL HP, 1992, J IMMUNOL, V149, P2466; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MORII E, 1994, BIOCHEM BIOPH RES CO, V205, P1299, DOI 10.1006/bbrc.1994.2806; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; OHGOH M, 1993, BIOCHEM BIOPH RES CO, V196, P1113, DOI 10.1006/bbrc.1993.2366; OHMORI E, 1990, J BIOCHEM, V107, P834, DOI 10.1093/oxfordjournals.jbchem.a123134; OHTANI H, 1992, J HISTOCHEM CYTOCHEM, V40, P1139, DOI 10.1177/40.8.1619278; ORKIN SH, 1992, BLOOD, V80, P575; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PEVNY L, 1995, DEVELOPMENT, V121, P163; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; Sambrook J., 2002, MOL CLONING LAB MANU; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1987, J IMMUNOL, V139, P3771; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI M, 1991, J EXP MED, V174, P125, DOI 10.1084/jem.174.1.125; VALENT P, 1992, BLOOD, V80, P2237; Weiss DL, 1996, MOL CELL BIOL, V16, P228; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; YAMAMOTO J, 1990, FEBS LETT, V276, P214, DOI 10.1016/0014-5793(90)80545-T; YAMATODANI A, 1985, J CHROMATOGR, V344, P115, DOI 10.1016/S0378-4347(00)82012-5; ZON LI, 1991, J BIOL CHEM, V266, P22948	44	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28439	28444		10.1074/jbc.271.45.28439	http://dx.doi.org/10.1074/jbc.271.45.28439			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910469	hybrid			2022-12-25	WOS:A1996VU03300069
J	Kramer, RM; Roberts, EF; Um, SL; BorschHaubold, AG; Watson, SP; Fisher, MJ; Jakubowski, JA				Kramer, RM; Roberts, EF; Um, SL; BorschHaubold, AG; Watson, SP; Fisher, MJ; Jakubowski, JA			p38 Mitogen-activated protein kinase phosphorylates cytosolic phospholipase A(2) (cPLA(2)) in thrombin-stimulated platelets - Evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPLA(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR AGONIST PEPTIDE; MAP KINASE; PHOSPHATIDIC-ACID; RELEASE; METABOLISM; INHIBITOR; PHOSPHATIDYLINOSITOL; INTERLEUKIN-1; LIBERATION; COLLAGEN	The Ca2+-sensitive 85-kDa cytosolic phospholipase A(2) (cPLA(2)) is responsible for thrombin-stimulated mobilization of arachidonic acid for the synthesis of thromboxane A(2) in human platelets, We have previously shown that thrombin activates p38 kinase, a recently discovered new member of the mitogen activated protein kinase family (Kramer, R. M., Roberts, E. F., Strifler, B. A., and Johnstone, E. M. (1995) J. Biol. Chem. 270, 27395-27398) and also induces phosphorylation of cPLA(2), thereby increasing its intrinsic catalytic activity, In the present study we have examined the role of p38 kinase in the phosphorylation and activation of cPLA(2) in stimulated platelets, We have observed that activation of p38 kinase accompanies receptor-mediated events in platelets and coincides with cPLA(2) phosphorylation, Furthermore, in the presence of inhibitors of p38 kinase, the proline-directed phosphorylation of cPLA(2) was completely blocked in platelets stimulated with the thrombin receptor agonist peptide SFLLRN and was suppressed during the early (up to 2 min) phase of platelet stimulation caused by thrombin, Unexpectedly, we found that prevention of proline-directed phosphorylation of cPLA(2) in stimulated platelets did not attenuate its ability to release arachidonic acid from platelet phospholipids, We conclude that: 1) cPLA(2) is a physiological target of p38 kinase; 2) p38 kinase is involved in the early phosphorylation of cPLA(2) in stimulated platelets; and 3) proline-directed phosphorylation of cPLA(2) is not required for its receptor-mediated activation.	UNIV OXFORD,OXFORD OX1 3QT,ENGLAND	University of Oxford	Kramer, RM (corresponding author), ELI LILLY & CO,LILLY RES LABS,CARDIOVASC RES,INDIANAPOLIS,IN 46285, USA.		Watson, Stephen P/Q-6292-2016	Watson, Stephen P/0000-0002-7846-7423				ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; ADAMS JL, 1993, Patent No. 9314081; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; BEST LC, 1979, BIOCHIM BIOPHYS ACTA, V583, P344, DOI 10.1016/0304-4165(79)90458-6; BorschHaubold AG, 1996, BIOCHEM J, V318, P207; BORSCHHAUBOLD AG, 1995, J BIOL CHEM, V270, P25885, DOI 10.1074/jbc.270.43.25885; BROEKMAN MJ, 1986, J LIPID RES, V27, P884; BROEKMAN MJ, 1980, J CLIN INVEST, V66, P275, DOI 10.1172/JCI109854; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; HUI KY, 1992, BIOCHEM BIOPH RES CO, V184, P790, DOI 10.1016/0006-291X(92)90659-9; JAKUBOWSKI JA, 1985, BRIT J HAEMATOL, V60, P635, DOI 10.1111/j.1365-2141.1985.tb07467.x; KEHREL B, 1995, PLATELETS, V6, P11, DOI 10.3109/09537109509013256; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; KRAMER RM, 1994, SIGNAL ACTIVATED PHO, P13; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lundblad R L, 1976, Methods Enzymol, V45, P156; MCKEAN ML, 1981, J BIOL CHEM, V256, P1522; NEUFELD EJ, 1983, J BIOL CHEM, V258, P2461; PURDON AD, 1987, BIOCHIM BIOPHYS ACTA, V920, P205, DOI 10.1016/0005-2760(87)90096-8; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; RITTENHOUSE SE, 1982, J CLIN INVEST, V70, P1216, DOI 10.1172/JCI110720; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; SMITH JB, 1985, BIOCHIM BIOPHYS ACTA, V835, P344, DOI 10.1016/0005-2760(85)90290-5	39	416	425	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27723	27729		10.1074/jbc.271.44.27723	http://dx.doi.org/10.1074/jbc.271.44.27723			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910365	hybrid			2022-12-25	WOS:A1996VQ67900083
J	Trombetta, ES; Simons, JF; Helenius, A				Trombetta, ES; Simons, JF; Helenius, A			Endoplasmic reticulum glucosidase II is composed of a catalytic subunit, conserved from yeast to mammals, and a tightly bound noncatalytic HDEL-containing subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE ISOMERASE; TRYPANOSOMATID PROTOZOA; MOLECULAR CHAPERONE; BINDING PROTEINS; GLYCOPROTEIN; OLIGOSACCHARIDE; CALRETICULIN; CALNEXIN; SEQUENCE; GLYCOSYLATION	Trimming of glucoses from N-linked core glycans on newly synthesized glycoproteins occurs sequentially through the action of glucosidases I and II in the endoplasmic reticulum (ER), We isolated enzymatically active glucosidase II from rat liver and found that, in contrast with previous reports, it contains two subunits (alpha and beta), Sequence analysis of peptides derived from them allowed us to identify their corresponding human cDNA sequences, The sequence of the alpha subunit predicted a soluble protein (104 kDa) devoid of known signals for residence in the ER, It showed homology with several other glucosidases but not with glucosidase I. Among the homologues, we identified a Saccharomyces cerevisiae gene, which we showed by gene disruption experiments to be the functional catalytic subunit of glucosidase II. The disrupted yeast strains had no detectable growth defect, The sequence of the beta subunit (58 kDa) showed no sequence homology with other known proteins, It encoded a soluble protein rich in glutamic and aspartic acid with a putative ER retention signal (HDEL) at the C terminus, This suggested that the beta subunit is responsible for the ER localization of the enzyme.	YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06520 USA	Yale University					NIGMS NIH HHS [GM 55972] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM055972] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BOSCH M, 1988, J BIOL CHEM, V263, P17360; BRADA D, 1984, EUR J BIOCHEM, V141, P149, DOI 10.1111/j.1432-1033.1984.tb08169.x; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BURNS DM, 1982, J BIOL CHEM, V257, P9991; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ESMON B, 1984, J BIOL CHEM, V259, P322; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; Fleischer S, 1974, Methods Enzymol, V31, P6; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HERSCOVICS A, 1987, ANAL BIOCHEM, V166, P85, DOI 10.1016/0003-2697(87)90550-1; HINO Y, 1985, BIOCHEMISTRY-US, V24, P800, DOI 10.1021/bi00324a040; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; KALZFULLER B, 1995, EUR J BIOCHEM, V231, P344, DOI 10.1111/j.1432-1033.1995.tb20706.x; KAUSHAL GP, 1990, J BIOL CHEM, V265, P16271; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kreibich G, 1974, Methods Enzymol, V31, P215; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCOCQ JM, 1986, J CELL BIOL, V102, P2137, DOI 10.1083/jcb.102.6.2137; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; RAY MK, 1991, J BIOL CHEM, V266, P22818; REITMAN ML, 1982, J BIOL CHEM, V257, P357; SAKAI K, 1989, GENOMICS, V5, P309, DOI 10.1016/0888-7543(89)90063-3; SAXENA S, 1987, BIOCHEM J, V247, P563, DOI 10.1042/bj2470563; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TROMBETTA SE, 1989, BIOCHEMISTRY-US, V28, P8108, DOI 10.1021/bi00446a022; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WADA I, 1995, J BIOL CHEM, V270, P20298, DOI 10.1074/jbc.270.35.20298	49	193	201	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27509	27516		10.1074/jbc.271.44.27509	http://dx.doi.org/10.1074/jbc.271.44.27509			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910335	hybrid			2022-12-25	WOS:A1996VQ67900053
J	Winitz, D; Shachar, I; Elkabetz, Y; Amitay, R; Samuelov, M; BarNun, S				Winitz, D; Shachar, I; Elkabetz, Y; Amitay, R; Samuelov, M; BarNun, S			Degradation of distinct assembly forms of immunoglobulin M occurs in multiple sites in permeabilized B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASIALOGLYCOPROTEIN RECEPTOR SUBUNITS; LIVER ENDOPLASMIC-RETICULUM; RETINOL-BINDING PROTEIN; PRE-GOLGI COMPARTMENT; SECRETORY PATHWAY; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; INTRACELLULAR DEGRADATION; CYSTEINE PROTEASE; APOLIPOPROTEIN-B; LYMPHOCYTES-B	Protein degradation is essential for quality control which retains and eliminates abnormal, unfolded, or partially assembled subunits of oligomeric proteins, The localization of this nonlysosomal pre-Golgi degradation to the endoplasmic reticulum (ER) has been mostly deduced from kinetic studies and carbohydrate analyses, while direct evidence for degradation within the ER has been provided by in vitro reconstitution of this process. In this article, we took advantage of the transport incompetence of permeabilized cells to directly demonstrate that the selective degradation of secretory IgM (sIgM) in B lymphocytes is transport-dependent, We show that, upon permeabilization of the plasma membrane with either streptolysin O or digitonin, sIgM is not degraded unless transport is allowed, Nevertheless, upon complete reduction of interchain disulfide bonds with thiols, the free mu heavy chains are degraded by a transport-independent quality control mechanism within the ER. This latter degradation is nonselective to the secretory heavy chain mu s, and the membrane heavy chain mu m, which is normally displayed on the surface of the B cell, is also eliminated. Moreover, the degradation of free mu s is no longer restricted to B lymphocytes, and it takes place also in the ER of plasma cells which normally secrete polymers of sIgM, Conversely, when assembled with the light chain, the degradation is selective to sIgM, is restricted to B lymphocytes, and is a transport-dependent post-ER event.	TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT BIOCHEM, IL-69978 TEL AVIV, ISRAEL	Tel Aviv University								ADELI K, 1994, J BIOL CHEM, V269, P9166; ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; AMITAY R, 1991, J BIOL CHEM, V266, P12568; AMITAY R, 1992, J BIOL CHEM, V267, P20694; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BREWER JW, 1994, J BIOL CHEM, V269, P17338; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CORRELL CC, 1994, J BIOL CHEM, V269, P633; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; DULIS BH, 1982, J BIOL CHEM, V257, P4369; FINGER A, 1993, EUR J BIOCHEM, V218, P565, DOI 10.1111/j.1432-1033.1993.tb18410.x; FRA AM, 1993, EMBO J, V12, P4755, DOI 10.1002/j.1460-2075.1993.tb06164.x; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GARDNER AM, 1993, J BIOL CHEM, V268, P25940; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GUENZI S, 1994, EUR J IMMUNOL, V24, P2477, DOI 10.1002/eji.1830241033; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAYASHI SI, 1995, BIOCHEM J, V306, P1; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; INOUE S, 1991, J BIOL CHEM, V266, P13311; KAJI EH, 1993, J BIOL CHEM, V268, P22195; KAJI EH, 1993, J BIOL CHEM, V268, P22188; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LE A, 1990, J BIOL CHEM, V265, P14001; LODISH HF, 1993, J BIOL CHEM, V268, P20598; MARQUARDT T, 1993, J BIOL CHEM, V268, P19618; MEIGS TE, 1992, J BIOL CHEM, V267, P13547; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PLUNTER H, 1992, J CELL BIOL, V119, P1097; RABINOVICH E, 1993, J BIOL CHEM, V268, P24145; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SATO R, 1990, J BIOL CHEM, V265, P11880; SCHIMKE RT, 1973, ADV ENZYMOL RAMB, V37, P135; SHACHAR I, 1992, J BIOL CHEM, V267, P24241; SHACHAR I, 1994, J BIOL CHEM, V269, P27344; SIDMAN C, 1981, CELL, V23, P379, DOI 10.1016/0092-8674(81)90133-1; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; TAN A, 1992, J CELL BIOL, V116, P1357, DOI 10.1083/jcb.116.6.1357; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; URADE R, 1992, J BIOL CHEM, V267, P15152; URADE R, 1993, J BIOL CHEM, V268, P22004; VALETTI C, 1994, MOL BIOL CELL, V5, P1311, DOI 10.1091/mbc.5.12.1311; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; WIKSTROM L, 1992, J BIOL CHEM, V267, P5; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973; WILEMAN T, 1991, CELL REGUL, V2, P753, DOI 10.1091/mbc.2.9.753; YE SQ, 1993, J BIOL CHEM, V268, P8497	63	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27645	27651		10.1074/jbc.271.44.27645	http://dx.doi.org/10.1074/jbc.271.44.27645			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910354	hybrid			2022-12-25	WOS:A1996VQ67900072
J	Crawford, LE; Milliken, EE; Irani, K; Zweier, JL; Becker, LC; Johnson, TM; Eissa, NT; Crystal, RG; Finkel, T; GoldschmidtClermont, PJ				Crawford, LE; Milliken, EE; Irani, K; Zweier, JL; Becker, LC; Johnson, TM; Eissa, NT; Crystal, RG; Finkel, T; GoldschmidtClermont, PJ			Superoxide mediated actin response in post-hypoxic endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; TYROSINE KINASE; STRESS FIBERS; PROTEIN; RECEPTOR; REOXYGENATION; ANGIOGENESIS; STIMULATION; GENERATION; MECHANISM	The mechanism leading to changes in the superstructure of endothelial cells exposed to ischemia and reperfusion remains uncharacterized, We show that in posthypoxic endothelial cells, the simple re-addition of oxygen induces a profound reorganization of the actin cytoskeleton. The total filamentous actin pool increases by 41% and translocation of actin filaments to the submembranous network is observed, Concurrent with the actin polymerization, increased tyrosine phosphorylation of endothelial cell substrates is detected on Western blots. Overexpression of superoxide dismutase using replication incompetent adenovirus inhibits the actin and tyrosine phosphorylation responses to reoxygenation. Inhibition of tyrosine kinases with the isoflavone genistein also suppressed the actin polymerization response to reoxygenation, but unlike superoxide dis mutase, genistein also induced the collapse of the superstructure of endothelial cells upon reoxygenation. These experiments support the concept that reoxygenation following a period of hypoxia can induce the remodeling of the actin cytoskeleton in endothelial cells, Such a response requires the intact coupling of superoxide producing pathway(s) with tyrosine kinase pathway(s).	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CARDIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205; NHLBI,CARDIOL BRANCH,NIH,BETHESDA,MD 20892; NHLBI,PULM & CRIT CARE BRANCH,NIH,BETHESDA,MD 20892; CORNELL UNIV,MED CTR,PULM & CRIT CARE BRANCH,NEW YORK,NY 10021	Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Cornell University				Irani, Kaikobad/0000-0001-9194-7387	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052315] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52315] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FINKEL T, 1994, P NATL ACAD SCI USA, V91, P1510, DOI 10.1073/pnas.91.4.1510; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FURMAN MI, 1994, CIRC RES, V75, P172, DOI 10.1161/01.RES.75.1.172; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; HEINTZ D, 1994, EUR J BIOCHEM, V223, P345, DOI 10.1111/j.1432-1033.1994.tb19000.x; HELDMAN AW, 1996, IN PRESS CIRC RES, V78; JACKSON D, 1994, SCIENCE, V266, P1581, DOI 10.1126/science.7527157; JONOS N, 1979, CELL, V17, P683; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LI J, 1995, CIRCULATION, V92, P713; LUM H, 1992, CIRC RES, V70, P991, DOI 10.1161/01.RES.70.5.991; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OMANN GM, 1994, ARCH BIOCHEM BIOPHYS, V308, P407, DOI 10.1006/abbi.1994.1057; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SULCINER DJ, 1996, BIOCHEM J, V318, P379; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; WALTENBERGER J, 1995, CIRCULATION, V92, P749; ZWEIER JL, 1994, J BIOL CHEM, V269, P24156	29	80	80	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26863	26867		10.1074/jbc.271.43.26863	http://dx.doi.org/10.1074/jbc.271.43.26863			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900169	hybrid			2022-12-25	WOS:A1996VP23300063
J	Harant, H; deMartin, R; Andrew, PJ; Foglar, E; Dittrich, C; Lindley, IJD				Harant, H; deMartin, R; Andrew, PJ; Foglar, E; Dittrich, C; Lindley, IJD			Synergistic activation of interleukin-8 gene transcription by all-trans-retinoic acid and tumor necrosis factor-alpha involves the transcription factor NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR MECHANISM; ENDOTHELIAL-CELLS; IL-8 EXPRESSION; OCTAMER MOTIF; MESSENGER-RNA; RECEPTOR; BINDING; FIBROBLASTS; INDUCTION; PROMOTER	Induction of interleukin-8 (IL-8) by IL-1 or tumor necrosis factor (TNF), and repression by interferons or glucocorticoids have been shown to involve sequences between nucleotides -94 and -71 of the 5'-flanking region, and the transcription factors NF-IL-6 and NF-kappa B. The A3 cell line was derived from the human melanoma cell line G-361 by stable transfection with part of the IL-8 promoter (nucleotides -101 to +40 from transcription start) fused to the luciferase coding region. These regulatory sequences were sufficient for transcriptional activation by all-trans-retinoic acid (ATRA), 9-cis-retinoic acid, IL-1 beta, or TNF-alpha. Simultaneous treatment of A3 cells with ATRA and TNF-alpha resulted in a dose- and time-dependent synergistic increase in luciferase expression and IL-8 mRNA levels. Transient transfections of the parental cell line demonstrated that the NF-kappa B binding site is essential for this synergistic transactivation. Electrophoretic mobility shift assays with nuclear extracts of A3 cells showed that stimulation with ATRA and TNF-alpha for more than 16 h resulted in enhanced NF-kappa B binding compared to that induced by TNF-alpha alone. The simultaneous treatment with ATRA and TNF-alpha also resulted in changes in the composition of NF-kappa B complexes bound to the IL-8 NF-kappa B site, preventing the formation of two TNF-alpha-inducible binding activities. We suggest that these complexes consist of repressive factors which, when removed, allow enhanced binding of NF-kappa B to its cognate site.	KAISER FRANZ JOSEF HOSP,LUDWIG BOLTZMANN INST APPL CANC RES,A-1100 VIENNA,AUSTRIA; VIENNA INT RES COOPERAT CTR,DEPT VASC BIOL & THROMBOSIS RES,A-1235 VIENNA,AUSTRIA	Kaiser-Franz-Josef Hospital; Ludwig Boltzmann Institute	Harant, H (corresponding author), SANDOZ GMBH,RES INST,DEPT GEN DERMATOL,BRUNNER STR 59,A-1235 VIENNA,AUSTRIA.		Hanna, Harant/AAA-7120-2022	Hanna, Harant/0000-0003-3842-0249				ANDREW PJ, 1995, BIOCHEM BIOPH RES CO, V214, P949, DOI 10.1006/bbrc.1995.2378; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ATKINS KB, 1995, BLOOD, V86, P2475; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRABTREE JE, 1994, J CLIN PATHOL, V47, P61, DOI 10.1136/jcp.47.1.61; DEGRAZIA U, 1994, J EXP MED, V180, P1485, DOI 10.1084/jem.180.4.1485; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; FELLI MP, 1991, MOL CELL BIOL, V11, P4771, DOI 10.1128/MCB.11.9.4771; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Gudas Lorraine J., 1994, P443; HARANT H, 1995, BIOCHEM BIOPH RES CO, V210, P898, DOI 10.1006/bbrc.1995.1742; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; KUNSCH C, 1994, J IMMUNOL, V153, P153; LINDLEY I, 1988, P NATL ACAD SCI USA, V85, P9199, DOI 10.1073/pnas.85.23.9199; LINDLEY IJD, 1993, IMMUNOL TODAY, V14, P24; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; Mangelsdorf David J., 1994, P319; MIELKE V, 1990, J IMMUNOL, V144, P153; MOLL T, 1995, J BIOL CHEM, V270, P3849, DOI 10.1074/jbc.270.8.3849; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; NAKAMURA H, 1991, J BIOL CHEM, V266, P19611; OKAMOTO S, 1993, ADV EXP MED BIOL, V351, P87; OLIVEIRA IC, 1994, MOL CELL BIOL, V14, P5300, DOI 10.1128/MCB.14.8.5300; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SEGARS JH, 1993, MOL CELL BIOL, V13, P6157, DOI 10.1128/MCB.13.10.6157; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; TAKASHIBA S, 1992, INFECT IMMUN, V60, P5253, DOI 10.1128/IAI.60.12.5253-5258.1992; VANDAMME J, 1991, CYTOKINE HDB IMMUNOL, P201; YANG KD, 1993, PEDIATR RES, V34, P720, DOI 10.1203/00006450-199312000-00005; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG QY, 1992, J IMMUNOL, V149, P1402	46	90	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26954	26961		10.1074/jbc.271.43.26954	http://dx.doi.org/10.1074/jbc.271.43.26954			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900181				2022-12-25	WOS:A1996VP23300075
J	Lee, SF; Egelhoff, TT; Mahasneh, A; Cote, GP				Lee, SF; Egelhoff, TT; Mahasneh, A; Cote, GP			Cloning and characterization of a Dictyostelium myosin I heavy chain kinase activated by Cdc42 and Rac	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; ACANTHAMOEBA-CASTELLANII; SUBCELLULAR-LOCALIZATION; CELL-GROWTH; RHO-FAMILY; PHOSPHORYLATION; PURIFICATION; GTPASES; YEAST; DISCOIDEUM	The motile activities of the small, single-headed class I myosins (myosin I) from the lower eukaryotes Acanthamoeba and Dictyostelium are activated by phosphorylation of a single serine or threonine residue in the head domain of the heavy chain, Recently, we purified a myosin I heavy chain kinase (MIHCK) from Dictyostelium based on its ability to activate the Dictyostelium myosin ID isozyme (Lee, S.-F., and Cote, G. P. (1995) J. Biol. Chem. 270, 11776-11782). The complete sequence of the Dictyostelium MIHCK has now been determined, revealing a protein of 98 kDa that is composed of an amino-terminal domain rich in proline, glutamine, and serine, a putative Cdc42/Rac binding motif, and a carboxyl-terminal kinase catalytic domain, MIHCK shares significant sequence identity with the Saccharomyces cerevisiae Ste20p kinase and the mammalian p21-activated kinase, Gel overlay assays and affinity chromatography experiments showed that MIHCK interacted with GTP gamma S (guanosine 5'-3-O-(thiotriphosphate))-labeled Cdc42 and Rac1 but not RhoA, In the presence of GTP gamma S-Rac1 MIHCK autophosphorylation increased from 1 to 9 mol of phosphate/mol, and the rate of Dictyostelium myosin ID phosphorylation was stimulated 10-fold, MIHCK may therefore provide a direct link between Cdc42/Rac signaling pathways and motile processes driven by myosin I molecules.	QUEENS UNIV, DEPT BIOCHEM, KINGSTON, ON K7L 3N6, CANADA; CASE WESTERN RESERVE UNIV, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA	Queens University - Canada; Case Western Reserve University			Mahasneh, Amjad/AAA-1732-2022	Mahasneh, Amjad/0000-0002-4931-8699	NIGMS NIH HHS [GM50009] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050009, R29GM050009] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAINES IC, 1995, J CELL BIOL, V130, P591, DOI 10.1083/jcb.130.3.591; BEMENT WM, 1995, CELL MOTIL CYTOSKEL, V31, P87, DOI 10.1002/cm.970310202; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; BRZESKA H, 1992, J BIOL CHEM, V267, P23870; BRZESKA H, 1990, J BIOL CHEM, V265, P3591; Brzeska H, 1996, J BIOL CHEM, V271, P16983, DOI 10.1074/jbc.271.29.16983; Brzeska H, 1996, J BIOL CHEM, V271, P27056, DOI 10.1074/jbc.271.43.27056; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; BUSH J, 1993, GENE, V136, P61, DOI 10.1016/0378-1119(93)90448-C; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COTE GP, 1985, J BIOL CHEM, V260, P4543; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Drouin G, 1995, J MOL EVOL, V41, P841, DOI 10.1007/BF00173163; FUJISAKI H, 1985, J BIOL CHEM, V260, P1183; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HAMMER JA, 1984, J BIOL CHEM, V259, P3224; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HATZ P, 1994, J BIOL CHEM, V269, P16802; Jakobi R, 1996, J BIOL CHEM, V271, P6206, DOI 10.1074/jbc.271.11.6206; Jung G, 1996, J CELL BIOL, V133, P305, DOI 10.1083/jcb.133.2.305; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KUMA K, 1995, J MOL EVOL, V41, P238; Larochelle DA, 1996, J CELL BIOL, V133, P1321, DOI 10.1083/jcb.133.6.1321; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEE SF, 1995, J BIOL CHEM, V270, P11776, DOI 10.1074/jbc.270.20.11776; LEE SF, 1995, MOL BIOL CELL, V6, P863; LEE SF, 1993, J BIOL CHEM, V268, P20923; LYNCH TJ, 1989, J BIOL CHEM, V264, P19333; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MANSER E, 1996, METHOD ENZYMOL, V256, P215; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MCGOLDRICK CA, 1995, J CELL BIOL, V128, P577, DOI 10.1083/jcb.128.4.577; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOVAK KD, 1995, J CELL BIOL, V131, P1205, DOI 10.1083/jcb.131.5.1205; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; RUPPERT C, 1995, J CELL SCI, V108, P3775; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; WAGNER MC, 1992, J CELL BIOL, V119, P163, DOI 10.1083/jcb.119.1.163; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; ZIMAN M, 1993, MOL BIOL CELL, V4, P1307, DOI 10.1091/mbc.4.12.1307; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	50	77	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27044	27048		10.1074/jbc.271.43.27044	http://dx.doi.org/10.1074/jbc.271.43.27044			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900194	hybrid			2022-12-25	WOS:A1996VP23300088
J	Yuan, ZM; Huang, YY; Fan, MM; Sawyers, C; Kharbanda, S; Kufe, D				Yuan, ZM; Huang, YY; Fan, MM; Sawyers, C; Kharbanda, S; Kufe, D			Genotoxic drugs induce interaction of the c-Abl tyrosine kinase and the tumor suppressor protein p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; 1-BETA-D-ARABINOFURANOSYLCYTOSINE INCORPORATION; DNA; BINDING; PHOSPHORYLATION; GROWTH; ONCOPROTEIN; ACTIVATION; ELONGATION; INHIBITION	The function of the c-Abl protein tyrosine kinase is unknown. The present studies demonstrate that the antimetabolite 1-beta-D-arabinofuranosylcytosine (ara-C) induces binding of c-Abl and p53. Ara-C treatment of cells that express wild type or a dominant negative, kinase-inactive c-Abl(K-R) was associated with formation of c-Abl-p53 complexes and increased expression of the cyclin dependent kinase (Cdk) inhibitor p21. However, down-regulation of Cdk2 by ara-C was found in cells expressing wild type c-Abl and not in cells expressing c-Abl(K-R) or those deficient in p53. Similar findings were obtained following treatment of cells with the alkylating agent methyl methanesulfonate (RIMS). Cells that express the c-Abl dominant negative or are null for c-Abl exhibited partial abrogation of Cdk2 down-regulation and G1 arrest in response to RIMS exposure, Cells lacking the c-abl gene also responded to ara-C and RIMS with increases in p53 levels and induction of p21. These findings indicate that the cellular response to certain genotoxic drugs involves binding of c-Abl to p53 and down-regulation of Cdk2 by a c-Abl kinase/p53-dependent mechanism.	UNIV CALIF LOS ANGELES,INST MOL BIOL,DEPT MED,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles	Yuan, ZM (corresponding author), HARVARD UNIV,SCH MED,DIV CANC PHARMACOL,DANA FARBER CANC INST,BOSTON,MA 02115, USA.		Sawyers, Charles/G-5327-2016		NCI NIH HHS [CA29431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GOGA A, 1995, ONCOGENE, V11, P791; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HIRANO Y, 1995, ONCOGENE, V10, P1879; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KUFE DW, 1984, MOL PHARMACOL, V26, P128; KUFE DW, 1980, J BIOL CHEM, V255, P8997; MAJOR PP, 1981, P NATL ACAD SCI-BIOL, V78, P3235, DOI 10.1073/pnas.78.5.3235; MATTIONI T, 1995, ONCOGENE, V10, P1325; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; OHNO Y, 1988, CANCER RES, V48, P1494; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARTZ JL, 1986, CARCINOGENESIS, V7, P159, DOI 10.1093/carcin/7.1.159; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	33	65	66	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26457	26460		10.1074/jbc.271.43.26457	http://dx.doi.org/10.1074/jbc.271.43.26457			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900110	hybrid			2022-12-25	WOS:A1996VP23300004
J	Hodgins, R; Gwozd, C; Arnason, T; Cummings, M; Ellison, MJ				Hodgins, R; Gwozd, C; Arnason, T; Cummings, M; Ellison, MJ			The tail of a ubiquitin-conjugating enzyme redirects multi-ubiquitin chain synthesis from the lysine 48-linked configuration to a novel nonlysine-linked form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; MULTIUBIQUITIN CHAIN; DNA-REPAIR; CARRIER PROTEIN; RNA-POLYMERASE; CDC34 UBC3; DEGRADATION; GENE; EXPRESSION; RAD6	The UBC1 ubiquitin-conjugating enzyme from Saccharomyces cerevisiae has an overlapping function with the UBC4 and UBC5 enzymes in the yeast stress response and an important role in the G(0) to G(1) transition that accompanies spore germination (Seufert, W., McGrath, J. P., and Jentsch, S. (1990) EMBO J. 9, 4573-4541). In the present work we report that the UBC1 enzyme assembles onto itself a multi-ubiquitin chain in vitro whose linkage configuration is dependent on the unconserved carboxyl-terminal extension or tail that is appended to its catalytic domain. Using chemical cleavage and site-specific mutagenesis, we have mapped the location of the chain to lysine 93 which lies near the active site within the catalytic domain The ubiquitin molecule that anchors the chain is transferred to this lysine from the active site of the same UBC1 molecule. When the tail of UBC1 is deleted, the catalytic-domain synthesizes a chain that consists of ubiquitin molecules uniformly linked to one another via lysine 48. In the presence of the tail, however, a chain is assembled that is composed of linkages that are stable to alkali but which do not utilize lysines. Furthermore, when the amino terminus of ubiquitin is blocked by an appended peptide tag, chain assembly reverts from this alternative configuration to the canonical lysine 48 variety. Taken together, these results suggest that the alternative chain is composed of linkages in which one ubiquitin molecule forms a peptide bond with the alpha-amino terminus of another, thereby supporting the emerging view that Ub can be attached to itself or other proteins in a variety of ways.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA	University of Alberta								ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; BANERJEE A, 1993, J BIOL CHEM, V268, P5668; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; COOK WJ, 1992, J BIOL CHEM, V267, P15116; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HAAS AL, 1991, J BIOL CHEM, V266, P5104; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HODGINS RRW, 1992, J BIOL CHEM, V267, P8807; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; PTAK C, 1994, J BIOL CHEM, V269, P26539; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SILVER ET, 1992, EMBO J, V11, P3091, DOI 10.1002/j.1460-2075.1992.tb05381.x; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VANNOCKER S, 1991, P NATL ACAD SCI USA, V88, P10297, DOI 10.1073/pnas.88.22.10297; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	31	53	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28766	28771		10.1074/jbc.271.46.28766	http://dx.doi.org/10.1074/jbc.271.46.28766			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910518	hybrid			2022-12-25	WOS:A1996VT05200010
J	Mahoney, CW; Pak, JH; Huang, KP				Mahoney, CW; Pak, JH; Huang, KP			Nitric oxide modification of rat brain neurogranin - Identification of the cysteine residues involved in intramolecular disulfide bridge formation using site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; KINASE-C SUBSTRATE; CALMODULIN-BINDING-PROTEIN; AMINO-ACID-SEQUENCE; RC3 NEUROGRANIN; PHOSPHORYLATION; LOCALIZATION; GLUTAREDOXIN; PEROXYNITRITE; NITROSYLATION	Neurogranin (Ng) is a neuron-specific protein kinase C-selective substrate, which binds calmodulin (CaM) in the dephosphorylated form at low levels of Ca2+. This protein contains redox active Cys residues that are readily oxidized by several nitric oxide (NO) donors and other oxidants to form intramolecular disulfide. Identification of the Cys residues of rat brain Ng, Cys(3), Cys(4), Cys(9), and Cys(51), involved in NO-mediated intramolecular disulfide bridge formation was examined by site-directed mutagenesis. Mutation of all four Cys residues or single mutation of Cys(51) blocked the oxidant-mediated intramolecular disulfide formation as monitored by the downward mobility shift under nonreducing SDS-polyacrylamide gel electrophoresis. Single mutation of Cys(3), Cys(4), or Cys(9) or double mutation of any pair of these three Cys residues did not block such intramolecular disulfide formation, although the rates of oxidation of these mutant proteins were different. Thus, Cys(51) is an essential pairing partner in NO-mediated intramolecular disulfide formation in Ng. Cys(3), Cys(4), and Cys(9) individually could pair with Cys(51), and the order of reactivity was Cys(9) > Cys(4) > Cys(3), suggesting that Cys(9) and Cys(51) form the preferential disulfide bridge. In all cases tested, the intramolecularly disulfide bridged Ng proteins displayed dramatically attenuated CaM-binding affinity and similar to 2-3-fold weaker protein kinase C substrate phosphorylation activity. The data indicate that the N-terminal Cys(3), Cys(4), and Cys(9) are in close proximity to the C-terminal Cys(51) in solution. The disulfide bridge between the N- and C-terminal domains of Ng renders the central CaM-binding and phosphorylation site domain in a fixed conformation unfavorable for binding to CaM and as a substrate of protein kinase C.	NICHHD, METAB REGULAT SECT, ENDOCRINOL & REPROD RES BRANCH, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; COGGINS PJ, 1991, NEUROSCI RES COMMUN, V8, P49; COHEN RW, 1993, BRAIN RES, V627, P147, DOI 10.1016/0006-8993(93)90758-F; COLLEY PA, 1993, BRAIN RES REV, V18, P115, DOI 10.1016/0165-0173(93)90009-O; DEKKER LV, 1989, NATURE, V342, P74, DOI 10.1038/342074a0; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GERENDASY DD, 1995, J BIOL CHEM, V270, P6741, DOI 10.1074/jbc.270.12.6741; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; HESS DT, 1993, NATURE, V366, P562, DOI 10.1038/366562a0; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOLMGREN A, 1986, THIOREDOXIN GLUTARED, P1; HUANG KP, 1993, ARCH BIOCHEM BIOPHYS, V305, P570, DOI 10.1006/abbi.1993.1463; HUANG KP, 1991, METHOD ENZYMOL, V200, P241; KLANN E, 1993, P NATL ACAD SCI USA, V90, P8337, DOI 10.1073/pnas.90.18.8337; KLANN E, 1992, J NEUROCHEM, V58, P1576, DOI 10.1111/j.1471-4159.1992.tb11382.x; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; MARTZEN MR, 1995, J NEUROCHEM, V64, P92; ODONNELL ME, 1983, J BIOL CHEM, V258, P3795; RADI R, 1991, J BIOL CHEM, V266, P4244; RAMAKERS GMJ, 1995, J BIOL CHEM, V270, P13892, DOI 10.1074/jbc.270.23.13892; REPRESA A, 1990, J NEUROSCI, V10, P3782, DOI 10.1523/JNEUROSCI.10-12-03782.1990; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sheu FS, 1996, J BIOL CHEM, V271, P22407, DOI 10.1074/jbc.271.37.22407; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; WAKIM BT, 1987, BIOCHEMISTRY-US, V26, P7466, DOI 10.1021/bi00397a040; WATSON JB, 1992, P NATL ACAD SCI USA, V89, P8581, DOI 10.1073/pnas.89.18.8581; WATSON JB, 1994, MOL BRAIN RES, V27, P323, DOI 10.1016/0169-328X(94)90017-5; WATSON JB, 1990, J NEUROSCI RES, V26, P397, DOI 10.1002/jnr.490260402; ZHANG J, 1995, ANNU REV PHARMACOL, V35, P213	39	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28798	28804		10.1074/jbc.271.46.28798	http://dx.doi.org/10.1074/jbc.271.46.28798			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910523				2022-12-25	WOS:A1996VT05200015
J	Seckl, MJ; Higgins, T; Rozengurt, E				Seckl, MJ; Higgins, T; Rozengurt, E			[D-Arg(1),D-Trp(5,7,9),Leu(11)]substance P coordinately and reversibly inhibits bombesin- and vasopressin-induced signal transduction pathways in Swiss 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE HYDROLYSIS; STIMULATE TYROSINE PHOSPHORYLATION; PASTEURELLA-MULTOCIDA TOXIN; PEPTIDE ANTAGONIST RC-3095; LUNG-CANCER CELLS; PHOSPHOLIPASE-C; RAPIDLY STIMULATE; ALPHA-SUBUNITS; PHORBOL ESTERS	The novel substance P (SP) analogue, [D-Arg(1),D-Trp(5,7,9),Leu(11)]SP like [D-Arg(1),D-Phe(5),D-Trp(7,9),Leu(11)]SP inhibited DNA synthesis induced by bombesin, vasopressin, and bradykinin, but did not interfere with the mitogenic response induced by other growth factors or pharmacological agents in Swiss 3T3 cells. [D-Arg(1),D-Trp(5,7,9),Leu(11)]SP reversibly inhibited bombesin-induced DNA synthesis, causing a 6-fold greater rightward shift in the bombesin dose response than [D-Arg(1),D-Phe(5),D-Trp(7,9),Leu(11)]SP at identical concentrations (10 mu M). We found that the new, more potent, SP analogue coordinately and reversibly inhibited bombesin-induced Ca2+ mobilization and protein kinase C (PKC) and mitogen-activated protein (MAP) kinase activation. The dose-response curves for bombesin-induced Ca2+ mobilization and MAP kinase activation were similarly displaced (51- and 40-fold, respectively) by [D-Arg(1),D-Trp(5,7,9),Leu(11)]SP. In addition, [D-Arg(1),D-Trp(5,7,9),Leu(11)]SP reversibly inhibited bombesin-induced tyrosine phosphorylation of M(r) 110,000-130,000 and 70,000-80,000 bands as well. as p125 focal adhesion kinase. [D-Arg(1),D-Trp(5,7,9),Leu(11)]SP also reversibly and coordinately inhibited vasopressin-induced Ca2+ mobilization, PKC stimulation, MAP kinase activation, tyrosine phosphorylation, and DNA synthesis in Swiss 3T3 cells. Surprisingly, deletion of the terminal Leu of [D-Arg(1),D-Phe(5),D-Trp(7,9),Leu(11)]SP to yield [D-Arg(1),D-Phe(5),D-Trp(7,9)]SP1-10 resulted in a selective loss of inhibitory activity of this analogue against bombesin but not vasopressin-stimulated DNA synthesis, Ca2+ mobilization, and MAP kinase activation. Collectively, these results suggest that SP analogues act at the receptor level to coordinately and reversibly antagonize bombesin- or vasopressin-induced signal transduction in Swiss 3T3 cells.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BROOKS SF, 1991, EMBO J, V10, P2497, DOI 10.1002/j.1460-2075.1991.tb07789.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Charlesworth A, 1996, ONCOGENE, V12, P1337; COFFER A, 1990, FEBS LETT, V263, P80, DOI 10.1016/0014-5793(90)80710-Z; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; ERUSALIMSKY JD, 1989, J CELL PHYSIOL, V141, P253, DOI 10.1002/jcp.1041410204; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; JONES DA, 1995, PEPTIDES, V16, P777, DOI 10.1016/0196-9781(95)00048-O; KIEHNE K, 1994, J CELL PHYSIOL, V160, P502, DOI 10.1002/jcp.1041600313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGDON S, 1992, CANCER RES, V52, P4554; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; MURPHY AC, 1992, J BIOL CHEM, V267, P25296; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; OFFERMANNS S, 1994, FEBS LETT, V349, P201, DOI 10.1016/0014-5793(94)00667-9; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PINSKI J, 1994, CANCER RES, V54, P169; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROZENGURT E, 1988, PROG NUCLEIC ACID RE, V35, P261, DOI 10.1016/S0079-6603(08)60616-9; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; ROZENGURT E, 1995, OXFORD TXB ONCOLOGY, P12; ROZENGURT E, 1993, TRENDS EXP CLIN MED, V3, P145; SECKL M, 1993, J BIOL CHEM, V268, P9548; SECKL MJ, 1995, J CELL PHYSIOL, V163, P87, DOI 10.1002/jcp.1041630110; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SETHI T, 1992, CANCER RES, V52, pS2737; Seufferlein T, 1996, J BIOL CHEM, V271, P21471, DOI 10.1074/jbc.271.35.21471; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SINNETTSMITH J, 1990, BIOCHEM J, V265, P485, DOI 10.1042/bj2650485; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STADDON JM, 1991, J BIOL CHEM, V266, P4840; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WITHERS DJ, 1995, J BIOL CHEM, V270, P21411, DOI 10.1074/jbc.270.36.21411; WOLL PJ, 1990, CANCER RES, V50, P3968; WOLL PJ, 1988, P NATL ACAD SCI USA, V85, P1859, DOI 10.1073/pnas.85.6.1859; WOLL PJ, 1993, CANC CHEMOTHER, P128; YANO T, 1992, CANCER RES, V52, P4545; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1987, BIOCHEM BIOPH RES CO, V146, P456, DOI 10.1016/0006-291X(87)90551-1; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	61	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29453	29460		10.1074/jbc.271.46.29453	http://dx.doi.org/10.1074/jbc.271.46.29453			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910612	hybrid			2022-12-25	WOS:A1996VT05200104
J	Yang, WL; Carman, GM				Yang, WL; Carman, GM			Phosphorylation and regulation of CTP synthetase from Saccharomyces cerevisiae by protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTIDINE 5'-TRIPHOSPHATE SYNTHETASE; HAMSTER OVARY CELLS; SUBSTRATE-SPECIFICITY; MUTATOR GENE; URA7 GENE; MUTANTS; PHOSPHATASES; TUMORS; YEAST	The phosphorylation and regulation of the URA7-encoded CTP synthetase (EC 6.3.4.2, UTP:ammonia ligase (ADP-forming)) from Saccharomyces cerevisiae by cAMP-dependent protein kinase (protein kinase A) were examined. Protein kinase A is the principal mediator of signals transmitted through the RAS/cAMP pathway in S. cerevisiae. The results of labeling experiments indicated that the phosphorylation of CTP synthetase was mediated by the RAS/cAMP pathway in vivo. In vitro, protein kinase A phosphorylated CTP synthetase at a serine residue with a stoichiometry consistent with one phosphorylation site per CTP synthetase subunit. Protein kinase A activity was dose- and time-dependent using CTP synthetase as a substrate. The dependence of protein kinase A activity on CTP synthetase was cooperative (n = 1.8) and the K-m value for CTP synthetase was 73 nM. Phosphorylation of CTP synthetase with protein kinase A resulted in the stimulation (190%) of activity. The mechanism of this stimulation included an increase in the V-max of the reaction with respect to UTP and ATP, a decrease in the K-m for ATP, and a decrease in the cooperative kinetic behavior of the enzyme. Phosphorylated CTP synthetase was less sensitive to product inhibition by CTP, Protein kinase C also phosphorylates and activates CTP synthetase. Phosphorylation of CTP synthetase with protein kinases A and C together resulted in an increase in CTP synthetase activity that was slightly greater than that obtained when the enzyme was phosphorylated with either protein kinase alone.	RUTGERS STATE UNIV, COOK COLL, NEW JERSEY AGR EXPT STN, DEPT FOOD SCI, NEW BRUNSWICK, NJ 08903 USA	Rutgers State University New Brunswick					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-50679] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONOW B, 1984, J BIOL CHEM, V259, P9035; BEULLENS M, 1993, J BIOL CHEM, V268, P13172; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; CHU EHY, 1984, BIOCHEM GENET, V22, P701, DOI 10.1007/BF00485854; CULBERTSON MR, 1975, GENETICS, V80, P23; HAID A, 1983, METHOD ENZYMOL, V96, P192; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KAUFMAN ER, 1986, MUTAT RES, V161, P19, DOI 10.1016/0027-5107(86)90096-5; KAWAMOTO S, 1987, J BIOL CHEM, V262, P7282; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIZAKI H, 1980, CANCER RES, V40, P3921; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P241, DOI 10.1021/bi00752a015; LIEBERMAN I, 1956, J BIOL CHEM, V222, P765; LONG CW, 1967, J BIOL CHEM, V242, P4715; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; MEUTH M, 1979, P NATL ACAD SCI USA, V76, P6505, DOI 10.1073/pnas.76.12.6505; MEUTH M, 1982, SOMAT CELL GENET, V8, P423, DOI 10.1007/BF01538705; NADKARNI AK, 1995, J BIOL CHEM, V270, P24982, DOI 10.1074/jbc.270.42.24982; OZIERKALOGEROPOULOS O, 1991, MOL GEN GENET, V231, P7, DOI 10.1007/BF00293815; OZIERKALOGEROPOULOS O, 1994, MOL GEN GENET, V242, P431, DOI 10.1007/BF00281793; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; THEVELEIN JM, 1985, J GEN MICROBIOL, V131, P3199; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TRUDEL M, 1984, J BIOL CHEM, V259, P2355; VANDENBERG AA, 1993, EUR J BIOCHEM, V216, P161; VINCENT BRD, 1980, BIOCHIM BIOPHYS ACTA, V610, P352; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WEBER G, 1980, LIFE SCI, V27, P793, DOI 10.1016/0024-3205(80)90333-1; Weber G, 1978, Adv Enzyme Regul, V17, P1; Yang WL, 1996, J BIOL CHEM, V271, P11113, DOI 10.1074/jbc.271.19.11113; YANG WL, 1994, BIOCHEMISTRY-US, V33, P10785, DOI 10.1021/bi00201a028; YANG WL, 1995, J BIOL CHEM, V270, P14983, DOI 10.1074/jbc.270.25.14983	43	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28777	28783		10.1074/jbc.271.46.28777	http://dx.doi.org/10.1074/jbc.271.46.28777			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910520	hybrid			2022-12-25	WOS:A1996VT05200012
J	Fu, HW; Moomaw, JF; Moomaw, CR; Casey, PJ				Fu, HW; Moomaw, JF; Moomaw, CR; Casey, PJ			Identification of a cysteine residue essential for activity of protein farnesyltransferase - Cys(299) is exposed only upon removal of zinc from the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERANYLGERANYLTRANSFERASE TYPE-I; ALPHA-SUBUNIT; METAL REQUIREMENTS; KINETIC MECHANISM; PEPTIDE-BINDING; CDNA CLONING; EXPRESSION; RAT; TRANSFERASE; SYSTEM	Protein farnesyltransferase (FTase) is a zinc metalloenzyme that performs a post-translational modification on many proteins that is critical for their function. The importance of cysteine residues in FTase activity was investigated using cysteine-specific reagents. Zinc-depleted FTase (apo-FTase), but not the holoenzyme, was completely inactivated by treatment with N-ethylmaleimide (NEM). Similar effects were detected after treatment of the enzyme with iodoacetamide. The addition of zinc to apo-FTase protects it from inactivation by NEM, These findings indicated the presence of specific cysteine residue(s), potentially located at the zinc binding site, that are required for FTase activity. We performed a selective labeling strategy whereby the cysteine residues exposed upon removal of zinc from the enzyme were modified with [H-3]NEM. The enzyme so modified was digested with trypsin, and four labeled peptides were identified and sequenced, one peptide being the major site of labeling and the remaining three labeled to lesser extents. The major labeled peptide contained a radiolabeled cysteine residue, Cys(299), that is in the beta subunit of FTase and is conserved in all known protein prenyltransferases. This cysteine residue was changed to both alanine and serine by site-directed mutagenesis, and the mutant proteins were produced in Escherichia coli and purified, While both mutant proteins retained the ability to bind farnesyl diphosphate, they were found to have lost essentially all catalytic activity and ability to bind zinc. These results indicate that the Cys(299) in the beta subunit of FTase plays a critical role in catalysis by the enzyme and is likely to be one of the residues that directly coordinate the zinc atom in this enzyme.	DUKE UNIV,MED CTR,DEPT MOL CANC BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Duke University; Duke University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Fu, Hua-Wen/0000-0002-6346-2785; Casey, Patrick/0000-0002-7366-9309	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46372] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRES DA, 1993, J BIOL CHEM, V268, P1383; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; BUKHTIYAROV YE, 1995, J BIOL CHEM, V270, P19035, DOI 10.1074/jbc.270.32.19035; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; FURFINE ES, 1995, BIOCHEMISTRY-US, V34, P6857, DOI 10.1021/bi00020a032; LIU TY, 1977, PROTEINS, V3, P239; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P610; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOOMAW JF, 1995, METHOD ENZYMOL, V250, P12; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, J BIOL CHEM, V266, P10672; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAFER WR, 1992, ANNU REV GENET, V30, P209; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; STONE KL, 1993, PRACTICAL GUIDE PROT, P55; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; YING WL, 1994, J BIOL CHEM, V269, P470; YOKOYAMA K, 1995, BIOCHEMISTRY-US, V34, P1344, DOI 10.1021/bi00004a029; ZHANG FL, 1994, J BIOL CHEM, V269, P3175; Zhang FL, 1996, BIOCHEMISTRY-US, V35, P8166, DOI 10.1021/bi960574+; ZHANG FL, 1994, J BIOL CHEM, V269, P23465; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; ZHANG FL, 1996, IN PRESS BIOCH J	31	45	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28541	28548		10.1074/jbc.271.45.28541	http://dx.doi.org/10.1074/jbc.271.45.28541			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910483	hybrid			2022-12-25	WOS:A1996VU03300083
J	Grigoryev, S; Stewart, AE; Kwon, YT; Arfin, SM; Bradshaw, RA; Jenkins, NA; Copeland, NG; Varshavsky, A				Grigoryev, S; Stewart, AE; Kwon, YT; Arfin, SM; Bradshaw, RA; Jenkins, NA; Copeland, NG; Varshavsky, A			A mouse amidase specific for N-terminal asparagine - The gene, the enzyme, and their function in the N-end rule pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-DEPENDENT PROTEOLYSIS; SHORT-LIVED PROTEIN; SACCHAROMYCES-CEREVISIAE; DEGRADATION SIGNAL; RECOGNITION COMPONENT; TRANSCRIPTION FACTORS; MULTIUBIQUITIN CHAIN; ESCHERICHIA-COLI; BINDING-PROTEINS; MESSENGER-RNA	The N-end rule relates the in vivo half-life of a protein to the identity of its N-terminal residue. In both fungi and mammals, the tertiary destabilizing N-terminal residues asparagine and glutamine function through their conversion, by enzymatic deamidation, into the secondary destabilizing residues aspartate and glutamate, whose destabilizing activity requires their enzymatic conjugation to arginine, one of the primary destabilizing residues. We report the isolation and analysis of a mouse cDNA and the corresponding gene (termed Ntan1) that encode a 310-residue amidohydrolase (termed Nt(N)-amidase) specific for N-terminal asparagine, The similar to 17-kilobase pair Ntan1 gene is located in the proximal region of mouse chromosome 16 and contains 10 exons ranging from 54 to 177 base pairs in length. The similar to 1.4 kilobase pair Ntan1 mRNA is expressed in all of the tested mouse tissues and cell lines and is down-regulated upon the conversion of myoblasts into myotubes. The Ntan1 promoter is located similar to 500 base pairs upstream of the Ntan1 start codon. The deduced amino acid sequence of mouse Nt(N)-amidase is 88% identical to the sequence of its porcine counterpart, but bears no significant similarity to the sequence of the NTA1-encoded N-terminal amidohydrolase of the yeast Saccharomyces cerevisiae, which can deamidate either N-terminal asparagine or glutamine. The expression of mouse Nt(N)-amidase in S. cerevisiae nta1 Delta was used to verify that Nt(N)-amidase retains its asparagine selectivity in. vivo and can implement the asparagine-specific subset of the N-end rule. Further dissection of mouse Ntan1, including its null phenotype analysis, should illuminate the functions of the N-end rule, most of which are still unknown.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; UNIV CALIF IRVINE, COLL MED, DEPT BIOL CHEM, IRVINE, CA 92717 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA	California Institute of Technology; University of California System; University of California Irvine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Bradshaw, Ralph A/K-1515-2013		NIDDK NIH HHS [DK32461, DK39520] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039520, R37DK039520, R56DK039520] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAGRAMAM K, 1995, MOL MICROBIOL, V15, P225, DOI 10.1111/j.1365-2958.1995.tb02237.x; ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; AUGEREAU P, 1986, EMBO J, V5, P1791, DOI 10.1002/j.1460-2075.1986.tb04428.x; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1995, J BIOL CHEM, V270, P12065, DOI 10.1074/jbc.270.20.12065; BAKER RT, 1991, P NATL ACAD SCI USA, V88, P1090, DOI 10.1073/pnas.88.4.1090; BALZI E, 1990, J BIOL CHEM, V265, P7464; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; BURATOWSKI S, 1992, TRANSCRIPTIONAL REGU, P227; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; DEGROOT RJ, 1991, P NATL ACAD SCI USA, V88, P8967, DOI 10.1073/pnas.88.20.8967; DESHAIES RJ, 1995, TRENDS CELL BIOL, V5, P428, DOI 10.1016/S0962-8924(00)89102-3; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; DOHMEN RJ, 1991, YEAST, V7, P691, DOI 10.1002/yea.320070704; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GHISLAIN M, 1996, IN PRESS EMBO J; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GONDA DK, 1989, J BIOL CHEM, V264, P16700; Green EL, 1981, GENETICS PROBABILITY, P77; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HILL CP, 1993, P NATL ACAD SCI USA, V90, P4136, DOI 10.1073/pnas.90.9.4136; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HONDERMARCK H, 1992, BIOCHEM BIOPH RES CO, V189, P280, DOI 10.1016/0006-291X(92)91555-5; JAKOBY WB, 1988, METHOD ENZYMOL, V58; JENKINS NA, 1995, GENOMICS, V28, P333, DOI 10.1006/geno.1995.1150; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; Levy F, 1996, P NATL ACAD SCI USA, V93, P4907, DOI 10.1073/pnas.93.10.4907; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MADURA K, 1993, J BIOL CHEM, V268, P12046; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Mount SM, 1996, SCIENCE, V271, P1690, DOI 10.1126/science.271.5256.1690; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; PIERCE JC, 1992, MAMM GENOME, V3, P550, DOI 10.1007/BF00350620; PUHLER G, 1994, SYST APPL MICROBIOL, V16, P734; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RITHETTI PG, 1990, GEL ELECTROPHORESIS, P149; ROMANOSPICA V, 1995, J IMMUNOL, V154, P2724; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHWARZENBACH H, 1995, J BIOL CHEM, V270, P898, DOI 10.1074/jbc.270.2.898; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Sherman F., 1986, METHODS YEAST GENETI; SHRADER TE, 1993, J BACTERIOL, V175, P4364, DOI 10.1128/JB.175.14.4364-4374.1993; SIKORSKI RS, 1989, GENETICS, V122, P19; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; STEWART A, 1995, TRENDS GENETICS GENE; STEWART AE, 1994, J BIOL CHEM, V269, P23509; STEWART AE, 1995, J BIOL CHEM, V270, P25, DOI 10.1074/jbc.270.1.25; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VARSHAVSKY A, 1991, CELL, V64, P13, DOI 10.1016/0092-8674(91)90202-A; Varshavsky A, 1995, COLD SPRING HARB SYM, V60, P461, DOI 10.1101/SQB.1995.060.01.051; VIERSTRA RD, 1993, ANNU REV PLANT PHYS, V44, P385, DOI 10.1146/annurev.pp.44.060193.002125; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WING SS, 1992, J BIOL CHEM, V267, P6495; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; [No title captured]	86	71	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28521	28532		10.1074/jbc.271.45.28521	http://dx.doi.org/10.1074/jbc.271.45.28521			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910481	Green Accepted, hybrid			2022-12-25	WOS:A1996VU03300081
J	Laakkonen, P; Ahola, T; Kaariainen, L				Laakkonen, P; Ahola, T; Kaariainen, L			The effects of palmitoylation on membrane association of Semliki Forest virus RNA capping enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS PROTEINS; FATTY ACYLATION; PLASMA-MEMBRANE; ATTACHMENT; EXPRESSION; PALMITATE; METHYLTRANSFERASE; IDENTIFICATION; STIMULATION; REPLICASE	The nonstructural protein Nsp1 of Semliki Forest virus has guanine-7-methyltransferase and guanylyltransferase-like activities, required in the capping of viral mRNAs. It is palmitoylated and tightly associated with the cytoplasmic surface of the plasma membrane, endosomes, and lysosomes, To localize the acylation site(s) and the putative membrane-targeting domain, a number of deletions were made in the nsp1 gene. Most deletions resulted in the expression of nonpalmitoylated, enzymatically inactive, cytoplasmic protein. Palmitate could be released from Nsp1 with neutral hydroxylamine, indicating a thioester linkage to a cysteine residue, Therefore we mutated the conserved cysteine residues of Nsp1 to alanine. Triple mutation of Cys(418), Cys(419), and Cys(420) resulted in nonpalmitoylated Nsp1, which was enzymatically active and still associated with membranes. However, it could be released from the membranes with 1 M NaCl, whereas 50 mm sodium carbonate (pH 12) was required to release wild type Nsp1, suggesting a conversion from an integral to a peripheral membrane protein, Indirect confocal immunofluorescence microscopy showed that the nonpalmitoylated Nsp1 colocalized with the plasma membrane marker, concanavalin A. However, it was not detected in filopodia, which were heavily stained in cells expressing wild type Nsp1. These results indicate that the acylation of Nsp1 was not needed for its targeting to the plasma membrane, but it was necessary for the migration to the filopodial extensions of the plasma membrane.			Laakkonen, P (corresponding author), UNIV HELSINKI,INST BIOTECHNOL,POB 56,VIIKINKAARI 9,FIN-00014 HELSINKI,FINLAND.			Laakkonen, Pirjo/0000-0002-9620-095X				AHOLA T, 1995, P NATL ACAD SCI USA, V92, P507, DOI 10.1073/pnas.92.2.507; BIZZOZERO OA, 1994, NEUROCHEM RES, V19, P923, DOI 10.1007/BF00968702; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; COUVE A, 1995, P NATL ACAD SCI USA, V92, P5987, DOI 10.1073/pnas.92.13.5987; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; FROSHAUER S, 1988, J CELL BIOL, V107, P2075, DOI 10.1083/jcb.107.6.2075; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GRIMLEY PM, 1968, J VIROL, V2, P1326, DOI 10.1128/JVI.2.11.1326-1338.1968; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JAMES G, 1989, J BIOL CHEM, V264, P20998; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; JUNG V, 1995, MOL CELL BIOL, V15, P1333; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LAAKKONEN P, 1994, J VIROL, V68, P7418, DOI 10.1128/JVI.68.11.7418-7425.1994; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; MCILHINNEY RAJ, 1985, EMBO J, V4, P1145, DOI 10.1002/j.1460-2075.1985.tb03752.x; MI S, 1989, VIROLOGY, V170, P385, DOI 10.1016/0042-6822(89)90429-7; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OLSON EN, 1986, J BIOL CHEM, V261, P2458; OLSON EN, 1988, PROG LIPID RES, V27, P177, DOI 10.1016/0163-7827(88)90012-4; PEPPERBERG DR, 1995, METHOD ENZYMOL, V250, P348; PERANEN J, 1995, VIROLOGY, V208, P610, DOI 10.1006/viro.1995.1192; PERANEN J, 1991, J VIROL, V65, P1623; PERANEN J, 1988, J GEN VIROL, V69, P2165, DOI 10.1099/0022-1317-69-9-2165; PERANEN J, 1990, THESIS YLIOPISTOPAIN; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; ROSE JK, 1984, P NATL ACAD SCI-BIOL, V81, P2050, DOI 10.1073/pnas.81.7.2050; Sambrook J., 2002, MOL CLONING LAB MANU; SHI YG, 1994, J CELL BIOL, V124, P927, DOI 10.1083/jcb.124.6.927; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; Wang HL, 1996, VIROLOGY, V217, P527, DOI 10.1006/viro.1996.0147; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001	37	88	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28567	28571		10.1074/jbc.271.45.28567	http://dx.doi.org/10.1074/jbc.271.45.28567			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910486	hybrid			2022-12-25	WOS:A1996VU03300086
J	Lia, F; Rajotte, D; Clark, SC; Hoang, T				Lia, F; Rajotte, D; Clark, SC; Hoang, T			A dominant negative granulocyte-macrophage colony-stimulating factor receptor alpha chain reveals the multimeric structure of the receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON BETA-SUBUNIT; GM-CSF RECEPTOR; ACUTE MYELOBLASTIC-LEUKEMIA; SIGNAL-TRANSDUCTION; 2 DISTINCT; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAINS; EXPRESSION CLONING; IL-5 RECEPTORS; BLAST CELLS	The receptor for the hemopoietic growth factor granulocyte-macrophage colony-stimulating factor (GM-CSF) is composed of two chains, both of which belong to the superfamily of cytokine receptors. The alpha chain confers low affinity binding only, whereas the beta chain (beta(c)) confers high affinity binding when associated with alpha. Ectopic expression of both chains of the receptor in murine NIH-3T3 fibroblasts results in signal transduction, mitogenesis, and morphologic transformation. The cytoplasmic domain of the GM-CSF receptor alpha subunit (GMR-alpha) comprises 54 amino acids that have been shown to be important for signal transduction through the beta chain. The present study was designed to address the possibility of receptor oligomerization and its functional implication Cross-linking studies with I-125-GM-CSF on NIH-3T3 transfectants is consistent with the presence of alpha and beta(c) dimers and of receptor oligomers. We have, therefore, generated an inert alpha chain through polymerase chain reaction-mediated truncation of 47 amino acids of the COOH-terminal domain of alpha (alpha(t)), and coexpressed alpha(t), alpha, and beta(c) in NIH-3T3. In cells in which alpha(t) and alpha are present in stoichiometric proportion within the GM-CSF-binding complex, we provide evidence that alpha(t) is dominant negative over wild type alpha on the basis of two different functional assays: cell proliferation and foci formation. Hence, our results suggest the requirement for at least two functional alpha chains for signal transduction. Together with the cross-linking studies, our data indicate that the functional GMR is an oligomer that contains at least two alpha chains.	CLIN RES INST MONTREAL, HEMOPOIESIS & LEUKEMIA LAB, MONTREAL, PQ H2W 1R7, CANADA; UNIV MONTREAL, DEPT PHARMACOL, MONTREAL, PQ H3C 3J7, CANADA; UNIV MONTREAL, DEPT BIOCHEM, MONTREAL, PQ H3C 3J7, CANADA; UNIV MONTREAL, DEPT MOL BIOL, MONTREAL, PQ H3C 3J7, CANADA; GENET INST INC, CAMBRIDGE, MA 02140 USA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal								ARECES LB, 1993, P NATL ACAD SCI USA, V90, P3963, DOI 10.1073/pnas.90.9.3963; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN CB, 1995, BLOOD, V85, P1488, DOI 10.1182/blood.V85.6.1488.bloodjournal8561488; BUDEL LM, 1993, J BIOL CHEM, V268, P10154; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; D'Andrea AD, 1990, CURR OPIN CELL BIOL, V2, P648, DOI 10.1016/0955-0674(90)90106-O; DANDREA R, 1994, BLOOD, V83, P2802, DOI 10.1182/blood.V83.10.2802.2802; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DOVER GA, 1991, CELL, V65, P9, DOI 10.1016/0092-8674(91)90401-J; EDER M, 1994, J BIOL CHEM, V269, P30173; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HOANG T, 1993, J BIOL CHEM, V268, P11881; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; KAWAHARA A, 1994, MOL CELL BIOL, V14, P5433, DOI 10.1128/MCB.14.8.5433; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; MELOCHE S, 1986, J BIOL CHEM, V261, P1525; METCALF D, 1993, BLOOD, V82, P3515; MIYAJIMA A, 1993, BLOOD, V82, P1960; Muto A, 1996, J EXP MED, V183, P1911, DOI 10.1084/jem.183.4.1911; NAKAMURA Y, 1994, SCIENCE, V264, P588, DOI 10.1126/science.8160019; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; ONETTOPOTHIER N, 1990, BLOOD, V75, P59; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; POLOTSKAYA A, 1994, J BIOL CHEM, V269, P14607; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RAJOTTE D, 1992, J BIOL CHEM, V267, P9980; RAJOTTE D, 1996, IN PRESS BLOOD, V88; RODRIGUEZCIMADEVILLA JC, 1990, BLOOD, V76, P1481; RONCO LV, 1994, J BIOL CHEM, V269, P277; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SASAKI K, 1993, J BIOL CHEM, V268, P13697; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; VALLANCE SJ, 1990, BIOCHEM J, V265, P359, DOI 10.1042/bj2650359; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; WEISS M, 1993, BLOOD, V82, P3298; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	44	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28287	28293		10.1074/jbc.271.45.28287	http://dx.doi.org/10.1074/jbc.271.45.28287			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910448	hybrid			2022-12-25	WOS:A1996VU03300048
J	Pimental, RA; Julian, J; Gendler, SJ; Carson, DD				Pimental, RA; Julian, J; Gendler, SJ; Carson, DD			Synthesis and intracellular trafficking of Muc-1 and mucins by polarized mouse uterine epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA-ASSOCIATED MUCIN; TUMOR-ASSOCIATED MUCIN; O-GLYCOSYLATION; ENDOPLASMIC-RETICULUM; SURFACE EXPRESSION; MOLECULAR-CLONING; GLYCOPROTEINS; EPISIALIN; SIALOMUCIN; PROTEINS	Mucins function as a protective layer rendering the apical surface of epithelial cells nonadhesive to a variety of microorganisms and macromolecules. Muc-1 is a transmembrane mucin expressed at the apical cell surface of mouse uterine epithelial cells (UEC) that disappears as UEC become receptive for embryo implantation (Surveyor, G. A., Gendler, S. J., Pemberton, L., Das, S. K. Chakraborty, I., Julian, J., Pimental, R. A., Wegner, C. W., Dey, S. H., and Carson, D. D. (1995) Endocrinology 136, 3639-3647). In the present study, the kinetics of Muc-1 assembly, cell surface expression, release, and degradation were examined in polarized mouse UEC in vitro. Mucins were identified as the predominant glycoconjugates synthesized, apically expressed, and vectorially released in both wild-type and Muc-1 null mice. When mucins were released, greater than 95% were directed to the apical compartment. Approximately half of the cell-associated mucins lost during a 24-h period were found in the apical compartment. Vectorial biotinylation detected apically disposed, cell-surface mucin and indicated that at least 34% of these mucins are released apically within 24 h. This suggests that release of mucin ectodomains is part of the mechanism of mucin removal from the apical cell surface of UEC. The half-lives of total cell-associated mucins and Muc-1 were 19.5 +/- 1 and 16.5 +/- 0.8 h, respectively. Muc-1 represented approximately 10% of the [H-3]glucosamine-labeled, cell-associated mucins. Studies of the kinetics of intracellular transport of Muc-1 indicated transit times of 21 +/- 15 min from the rough endoplasmic reticulum to Golgi apparatus and 111 +/- 28 min from the Golgi apparatus to the cell surface. Collectively, these studies provide the first comprehensive description of Muc-1 and mucin maturation, metabolism, and release by polarized cells, as well as defining a major metabolic fate for mucins expressed by UEC. Normal metabolic processing appears to be sufficient to account for the removal of Muc-1 protein during the transition of UEC to a receptive state.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT BIOCHEM & MOL BIOL, HOUSTON, TX 77030 USA; MAYO CLIN, SCOTTSDALE, AZ 85259 USA	University of Texas System; UTMD Anderson Cancer Center; Mayo Clinic; Mayo Clinic Phoenix					NCI NIH HHS [CA-16672] Funding Source: Medline; NICHD NIH HHS [HD-29963] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD029963, R01HD029963] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAECKSTROM D, 1991, J BIOL CHEM, V266, P21537; BAECKSTROM D, 1994, J BIOL CHEM, V269, P14430; BANSIL R, 1995, ANNU REV PHYSIOL, V57, P635, DOI 10.1146/annurev.ph.57.030195.003223; BARND DL, 1989, P NATL ACAD SCI USA, V86, P7159, DOI 10.1073/pnas.86.18.7159; BAYER EA, 1988, ANAL BIOCHEM, V170, P371; BRAGA VMM, 1993, J CELL SCI, V105, P397; CARSON DD, 1990, J BIOL CHEM, V265, P2947; DEVINE PL, 1992, BIOESSAYS, V14, P619, DOI 10.1002/bies.950140909; DOHI DF, 1993, J BIOL CHEM, V268, P10133; DUTT A, 1990, J BIOL CHEM, V265, P430; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060; HANSKI C, 1993, CANCER RES, V53, P4082; HILKENS J, 1992, TRENDS BIOCHEM SCI, V17, P359, DOI 10.1016/0968-0004(92)90315-Z; Ho S B, 1991, Semin Cancer Biol, V2, P389; HO SB, 1993, CANCER RES, V53, P641; JACOBS AL, 1990, ENDOCRINOLOGY, V126, P2125, DOI 10.1210/endo-126-4-2125; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KAIFU R, 1979, CARBOHYD RES, V69, P79, DOI 10.1016/S0008-6215(00)85753-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; LINSLEY PS, 1988, J BIOL CHEM, V263, P8390; LITVINOV SV, 1993, J BIOL CHEM, V268, P21364; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORELL AG, 1971, J BIOL CHEM, V246, P1461; MORRIS JE, 1988, J BIOL CHEM, V263, P4172; NARASIMHAN S, 1986, CARBOHYD RES, V149, P65, DOI 10.1016/S0008-6215(00)90370-7; ODONNELL ER, 1987, BIOCHEMISTRY-US, V26, P3908; PLANTNER JJ, 1972, METHOD ENZYMOL, V28, P46; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; PSYCHOYOS A, 1986, ANN NY ACAD SCI, V476, P36, DOI 10.1111/j.1749-6632.1986.tb20920.x; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; SCHLAFKE S, 1975, BIOL REPROD, V12, P41, DOI 10.1095/biolreprod12.1.41; SCHWEIZER A, 1994, J BIOL CHEM, V269, P4035; SPICER AP, 1995, J BIOL CHEM, V270, P30093; SPICER AP, 1991, J BIOL CHEM, V266, P15099; SPIELMAN J, 1987, J BIOL CHEM, V262, P269; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; SURVEYOR GA, 1995, ENDOCRINOLOGY, V136, P3639, DOI 10.1210/en.136.8.3639; TANG JP, 1987, J BIOL CHEM, V262, P12832; VANDEWIELVANKEMENADE E, 1993, J IMMUNOL, V151, P767; WEBER W, 1985, BIOCHEM BIOPH RES CO, V126, P630, DOI 10.1016/0006-291X(85)90652-7; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8	46	47	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28128	28137		10.1074/jbc.271.45.28128	http://dx.doi.org/10.1074/jbc.271.45.28128			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910427	hybrid			2022-12-25	WOS:A1996VU03300027
J	Gu, MX; Majerus, PW				Gu, MX; Majerus, PW			The properties of the protein tyrosine phosphatase PTPMEG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; PHOSPHOTYROSINE PHOSPHATASE; CA-2+-DEPENDENT PROTEASE; SEQUENCE HOMOLOGY; BINDING PROTEIN; PHOSPHORYLATION; MEMBRANE; DOMAINS; IDENTIFICATION; ACTIVATION	We previously cloned a cDNA encoding a protein tyrosine phosphatase (PTP) containing sequence homology to protein 4.1, designated PTPMEG. Recombinant protein and amino- and carboxyl-terminal peptides were used to obtain polyclonal antibodies against PTPMEG to identify endogenous PTPMEG in A172 cells and to show that the enzyme is primarily localized to the membrane and cytoskeletal fractions of these cells. We prepared recombinant protein in Sf9 and COS-7 cells to further characterize it. The protein was phosphorylated in both cell types on serine and threonine residues. The multiple sites of phosphorylation were all within the intermediate domain of the protein between amino acids 386 and 503. This region also contains two PEST sequences and two proline-rich motifs that may confer binding to Src homology 3 domains. The recombinant protein was cleaved by trypsin and calpain in this region and thereby activated 4-8-fold as assayed using Raytide as substrate. We immunoprecipitated the protein from human platelets with both amino- and carboxyl-terminal antipeptide antibodies to assess the state of the enzyme in these cells. The full-length molecule was found in extracts from unstimulated platelets, whereas extracts from both calcium ionophore and thrombin-treated platelets contained proteolyzed and activated forms of the enzyme, indicating that proteolysis by calpain is evoked in response to thrombin. Prior incubation of platelets with calpeptin, an inhibitor of calpain, blocked the agonist induced proteolysis.	WASHINGTON UNIV, SCH MED, DIV HEMATOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)					NHLBI NIH HHS [HL 07088, HL 14147, HL 16634] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016634, P50HL014147, R37HL016634, T32HL007088] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; ANDERSON RA, 1984, NATURE, V307, P655, DOI 10.1038/307655a0; Baenziger N L, 1974, Methods Enzymol, V31, P149; BERNATOWICZ MS, 1986, ANAL BIOCHEM, V155, P95, DOI 10.1016/0003-2697(86)90231-9; BRYANT PJ, 1992, CELL, V68, P621, DOI 10.1016/0092-8674(92)90136-Z; CHO HJ, 1992, BIOCHEMISTRY-US, V31, P133, DOI 10.1021/bi00116a019; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CONBOY JG, 1993, SEMIN HEMATOL, V30, P58; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; FOX JEB, 1987, BLOOD, V69, P537; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1991, J BIOL CHEM, V266, P13289; FOX JEB, 1993, MECHANISMS PLATELET; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LANG TL, 1995, CELL, V80, P473; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; STONE RL, 1994, J BIOL CHEM, V269, P31323; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUZUKI K, 1992, ANN NY ACAD SCI, V674, P218, DOI 10.1111/j.1749-6632.1992.tb27490.x; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG SH, 1995, J BIOL CHEM, V270, P20067, DOI 10.1074/jbc.270.34.20067; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	52	47	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27751	27759		10.1074/jbc.271.44.27751	http://dx.doi.org/10.1074/jbc.271.44.27751			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910369	hybrid			2022-12-25	WOS:A1996VQ67900087
J	Parsell, DA; Mak, JY; Amento, EP; Unemori, EN				Parsell, DA; Mak, JY; Amento, EP; Unemori, EN			Relaxin binds to and elicits a response from cells of the human monocytic cell line, THP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN RELAXIN; LABELED HUMAN RELAXIN; IN-VITRO; RECEPTORS; INSULIN; LOCALIZATION; EXPRESSION; PLATELETS; COLLAGEN; PEPTIDE	Relaxin is a 6-kDa peptide of the insulin family that is present at increased levels in the circulation during pregnancy. Its functions at that time are thought to include maintenance of myometrial quiescence, regulation of plasma volume, and release of neuropeptides, such as oxytocin and vasopressin. The protein also promotes connective tissue remodeling, which allows cervical ripening and separation of the pelvic symphysis in various mammalian species. In this report, we provide evidence for a novel target of relaxin, the human monocytic cell line, THP-1. Relaxin bound with high affinity (K-d = 102 pM) to a specific receptor on THP-1 cells. Receptor density was low (similar to 275 receptors/cell), but binding of relaxin triggered intracelluar signaling events. Receptor density was not modulated by pretreatment with estrogen, progesterone, or a number of other agents known to induce differentiation of THP-I cells. Cross-linking studies showed radiolabeled relaxin bound primarily to cell surface proteins with an apparent molecular mass of >200 kDa. Other members of the insulin-like family of proteins (insulin, insulin-like growth factors I and II, and relaxin-like factor) were unable to displace the binding of relaxin to THP-1 cells, suggesting that a distinct receptor for relaxin exists on this monocyte/macrophage cell line.	CONNECT THERAPEUT INC,PALO ALTO,CA 94303									ADHAM IM, 1993, J BIOL CHEM, V268, P26668; BANI D, 1995, PLATELETS, V6, P330, DOI 10.3109/09537109509078467; BANI D, 1995, LAB INVEST, V73, P709; BENNETT AE, 1986, HORM METAB RES, V18, P49, DOI 10.1055/s-2007-1012223; BULLESBACH EE, 1995, J BIOL CHEM, V270, P16011, DOI 10.1074/jbc.270.27.16011; CARRELL DT, 1995, ENDOCR RES, V21, P697, DOI 10.1080/07435809509030484; EIGENBROT C, 1991, J MOL BIOL, V221, P15, DOI 10.1016/0022-2836(91)90796-9; FEI DTW, 1990, BIOCHEM BIOPH RES CO, V170, P214, DOI 10.1016/0006-291X(90)91262-Q; GARIBAYTUPAS JL, 1995, J ENDOCRINOL, V145, P441, DOI 10.1677/joe.0.1450441; GEDDES BJ, 1995, J NEUROENDOCRINOL, V7, P411, DOI 10.1111/j.1365-2826.1995.tb00777.x; GOLDSMITH LT, 1995, ENDOCRIN METAB CLIN, V24, P171, DOI 10.1016/S0889-8529(18)30058-6; GUNNERSEN JM, 1995, MOL CELL ENDOCRINOL, V110, P55, DOI 10.1016/0303-7207(95)03516-A; KRAMER SM, 1990, IN VITRO CELL DEV B, V26, P647; MASINI E, 1994, J CLIN INVEST, V94, P1974, DOI 10.1172/JCI117549; McConnell HM, 1991, CURR OPIN STRUC BIOL, V1, P647, DOI 10.1016/S0959-440X(05)80091-0; NAKANE PK, 1967, J CELL BIOL, V33, P307, DOI 10.1083/jcb.33.2.307; OSHEROFF PL, 1993, J BIOL CHEM, V268, P15193; OSHEROFF PL, 1990, J BIOL CHEM, V265, P9396; OSHEROFF PL, 1992, P NATL ACAD SCI USA, V89, P2384, DOI 10.1073/pnas.89.6.2384; OSHEROFF PL, 1991, P NATL ACAD SCI USA, V88, P6413, DOI 10.1073/pnas.88.15.6413; OSHEROFF PL, 1995, ENDOCRINOLOGY, V136, P4377, DOI 10.1210/en.136.10.4377; OWICKI JC, 1990, P NATL ACAD SCI USA, V87, P4007, DOI 10.1073/pnas.87.10.4007; PITCHFORD S, 1995, AM J PHYSIOL-CELL PH, V268, pC936, DOI 10.1152/ajpcell.1995.268.4.C936; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; SCHWABE C, 1994, FASEB J, V8, P1152, DOI 10.1096/fasebj.8.14.7958621; SHIRE SJ, 1991, BIOCHEMISTRY-US, V30, P7703, DOI 10.1021/bi00245a006; Siddle Kenneth, 1992, Progress in Growth Factor Research, V4, P301, DOI 10.1016/0955-2235(92)90013-8; TAYLOR MJ, 1994, J ENDOCRINOL, V143, pR5, DOI 10.1677/joe.0.143R005; UNEMORI E, 1996, J INVEST MED, V44, P315; UNEMORI EN, 1993, J INVEST DERMATOL, V101, P280, DOI 10.1111/1523-1747.ep12365206; UNEMORI EN, 1990, J BIOL CHEM, V265, P10681; WADA HG, 1993, J CELL PHYSIOL, V154, P129, DOI 10.1002/jcp.1041540116; YANG S, 1992, ENDOCRINOLOGY, V130, P179, DOI 10.1210/en.130.1.179	33	84	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27936	27941		10.1074/jbc.271.44.27936	http://dx.doi.org/10.1074/jbc.271.44.27936			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910395	hybrid			2022-12-25	WOS:A1996VQ67900113
J	Schivell, AE; Batchelor, RH; Bajjalieh, SM				Schivell, AE; Batchelor, RH; Bajjalieh, SM			Isoform-specific, calcium-regulated interaction of the synaptic vesicle proteins SV2 and synaptotagmin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL EXPRESSION; BINDING-PROTEIN; C2 DOMAIN; MEMBRANE; SYNAPTOPHYSIN; IDENTIFICATION; TRANSPORTER; CHANNEL; RELEASE; NEUREXINS	The identification and functional characterization of proteins localized to synaptic vesicles has contributed significantly to our understanding of neurotransmission, Studies of synaptic vesicle protein interactions have both led to the identification of novel synaptic proteins and suggested hypotheses of protein function, Synaptic vesicle protein 2 (SV2), is an integral membrane glycoprotein present in all synaptic vesicles. There are two characterized isoforms, SV2A and SV2B. Despite their homology to transporter proteins, the function of the SV2s remains unknown, In an effort to determine SV2 function and identify cofactors required for SV2 activity, we examined the protein interactions of SV2 using a combination of cross-linking, immunoprecipitation, and recombinant protein affinity chromatography, We report that SV2 is part of a large protein complex that contains the synaptic vesicle protein synaptotagmin, The interaction between SV2 and synaptotagmin is direct, specific to SV2A, and inhibited by calcium with an EC(50) of approximately 10 mu M. Interaction is mediated by the cytoplasmic amino terminus of SV2A and the C2B domain of synaptotagmin, Our observations suggest a regulatory relationship between these two proteins.	UNIV WASHINGTON,DEPT PHARMACOL,SCH MED,SEATTLE,WA 98195; UNIV WASHINGTON,GRAD PROGRAM NEUROBIOL & BEHAV,SCH MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 T32 GM07270-21] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAJJALIEH SM, 1992, SCIENCE, V257, P1271, DOI 10.1126/science.1519064; BAJJALIEH SM, 1993, P NATL ACAD SCI USA, V90, P2150, DOI 10.1073/pnas.90.6.2150; BAJJALIEH SM, 1994, J NEUROSCI, V14, P5223, DOI 10.1523/jneurosci.14-09-05223.1994; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; CALAKOS N, 1994, J BIOL CHEM, V269, P24534; DAVLETOV BA, 1994, J BIOL CHEM, V269, P28547; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; FEANY MB, 1992, CELL, V70, P861, DOI 10.1016/0092-8674(92)90319-8; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GINGRICH JA, 1992, FEBS LETT, V312, P115, DOI 10.1016/0014-5793(92)80917-6; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HUTTNER WB, 1983, J CELL BIOL, V96, P1373; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; Kee Y, 1996, J NEUROSCI, V16, P1975; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LINIAL M, 1993, TRENDS BIOCHEM SCI, V18, P248, DOI 10.1016/0968-0004(93)90173-K; MARTIN KC, 1995, P NATL ACAD SCI USA, V92, P11307, DOI 10.1073/pnas.92.24.11307; MORIMOTO T, 1995, NEURON, V15, P689, DOI 10.1016/0896-6273(95)90156-6; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OREGAN S, 1995, MOL BRAIN RES, V32, P135, DOI 10.1016/0169-328X(95)00071-Y; PERIN MS, 1994, J BIOL CHEM, V269, P8576; REHM H, 1986, EMBO J, V5, P535, DOI 10.1002/j.1460-2075.1986.tb04243.x; RIORDAN JR, 1992, BIOCHIM BIOPHYS ACTA, V1101, P221, DOI 10.1016/0005-2728(92)90230-Y; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; WIEDENMANN B, 1985, J CELL BIOL, V101, P12, DOI 10.1083/jcb.101.1.12; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	39	116	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27770	27775		10.1074/jbc.271.44.27770	http://dx.doi.org/10.1074/jbc.271.44.27770			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910372	hybrid			2022-12-25	WOS:A1996VQ67900090
J	Brzeska, H; Martin, BM; Korn, ED				Brzeska, H; Martin, BM; Korn, ED			The catalytic domain of Acanthamoeba myosin I heavy chain kinase .1. Identification and characterization following tryptic cleavage of the native enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PHOSPHORYLATION SITES; ACTIN-FILAMENTS; AUTOPHOSPHORYLATION; ACTIVATION; PURIFICATION; FAMILY; LOCALIZATION; CASTELLANII; SUBSTRATE	The actin-activated Mg2+-ATPase activities of the myosin I isoenzymes from Acanthamoeba castellanii are greatly increased by phosphorylation catalyzed by myosin I heavy chain kinase (MIHC kinase), a monomeric 97-kDa protein whose activity is greatly enhanced by acidic phospholipids and by autophosphorylation of multiple sites, In this paper, we show that the 35-kDa COOH-terminal fragment obtained by trypsin cleavage of maximally activated, autophosphorylated kinase retains the full activity and two to three of the autophosphorylation sites of the native enzyme, Other autophosphorylation sites occur in the middle third of the native enzyme, A trypsin cleavage site within the 35-kDa region is protected in phosphorylated kinase but is readily cleaved in unphosphorylated kinase producing catalytically inactive 25 and 11-kDa fragments from the NH2- and COOH-terminal ends, respectively, of the 35-kDa peptide, This implies that the conformation around the ''25/11'' cleavage site changes upon phosphorylation of the native enzyme, The position of this site corresponds to the activation loop of protein kinase A (see the accompanying paper: Brzeska, H., Szczepanowska, J., Hoey, J., and Korn, E. D. (1996) J. Biol. Chem. 271, 27056-27062), Exogenously added MIHC kinase phosphorylates the 11-kDa fragment, but not the 25-kDa fragment, indicating that the phosphorylation sites of the 35-kDa catalytic fragment are located within the COOH-terminal 11 kDa, The accompanying paper describes the cloning, sequencing, and expression of a fully active 35-kDa catalytic domain.	NIMH,NIH,CLIN NEUROSCI BRANCH,BETHESDA,MD 20892; NHLBI,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295				ADAMS RJ, 1986, NATURE, V322, P754, DOI 10.1038/322754a0; ALBANESI JP, 1985, J BIOL CHEM, V260, P8649; BEMENT WM, 1995, CELL MOTIL CYTOSKEL, V31, P87, DOI 10.1002/cm.970310202; BENNER GE, 1995, J BIOL CHEM, V270, P21121, DOI 10.1074/jbc.270.36.21121; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; BRZESKA H, 1990, J BIOL CHEM, V265, P16138; BRZESKA H, 1989, J BIOL CHEM, V264, P10243; BRZESKA H, 1992, J BIOL CHEM, V267, P23870; BRZESKA H, 1990, J BIOL CHEM, V265, P3591; Brzeska H, 1996, J BIOL CHEM, V271, P16983, DOI 10.1074/jbc.271.29.16983; Brzeska H, 1996, J BIOL CHEM, V271, P27056, DOI 10.1074/jbc.271.43.27056; BRZESKA H, 1992, J BIOL CHEM, V267, P4949; COTE GP, 1985, J BIOL CHEM, V260, P4543; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; GOODSON HV, 1995, CELL MOTIL CYTOSKEL, V30, P73, DOI 10.1002/cm.970300109; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JUNG G, 1993, J BIOL CHEM, V268, P14981; KULESZALIPKA D, 1993, J BIOL CHEM, V268, P17995; LEE SF, 1995, J BIOL CHEM, V270, P11776, DOI 10.1074/jbc.270.20.11776; LYNCH TJ, 1989, J BIOL CHEM, V264, P19333; LYNCH TJ, 1990, METHOD ENZYMOL, V196, P12; LYNCH TJ, 1990, BIOPHYS J, V57, pA335; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MCGOLDRICK CA, 1995, J CELL BIOL, V128, P577, DOI 10.1083/jcb.128.4.577; Ostap EM, 1996, J CELL BIOL, V132, P1053, DOI 10.1083/jcb.132.6.1053; PINES J, 1995, NATURE, V376, P294, DOI 10.1038/376294a0; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TITUS MA, 1989, CELL REGUL, V1, P65; WANG ZY, 1995, J BIOL CHEM, V270, P27969, DOI 10.1074/jbc.270.46.27969; YONEMOTO W, 1993, J BIOL CHEM, V268, P18626; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	38	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27049	27055		10.1074/jbc.271.43.27049	http://dx.doi.org/10.1074/jbc.271.43.27049			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900195				2022-12-25	WOS:A1996VP23300089
J	Corradi, N; Borgonovo, B; Clementi, E; Bassetti, M; Racchetti, G; Consalez, GG; Huttner, WB; Meldolesi, J; Rosa, P				Corradi, N; Borgonovo, B; Clementi, E; Bassetti, M; Racchetti, G; Consalez, GG; Huttner, WB; Meldolesi, J; Rosa, P			Overall lack of regulated secretion in a PC12 variant cell clone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; NERVE GROWTH-FACTOR; I CHROMOGRANIN-B; MEMBRANE-PROTEIN; SECRETOGRANIN-I; CHROMAFFIN GRANULES; SYNAPTIC VESICLES; AGGREGATION; EXPRESSION; COMPLEX	A stable clone of PC12 neuroendocrine cells, named 27, known from previous studies to exhibit a defect of regulated secretion (lack of regulated secretory proteins, of synaptophysin, of dense granules and of catecholamine uptake and release; Clementi, E., Racchetti, G., Zacchetti, D., Panzeri, M. C., and Meldolesi, J. (1992) Eur. J. Neurosci. 4, 944-953) was characterized in detail to clarify the nature of its phenotype and the mechanisms of its establishment, The neuroendocrine nature of the PC12-27 phenotype was documented by specific markers: synapsins, neurofilament subunit H, neuronal kinesin, and alpha-latrotoxin receptor. Moreover, various intracellular membrane systems of PC12-27, including the endoplasmic reticulum and the Golgi complex, appeared similar to control PC12 in both morphology and marker expression. In contrast, all the investigated markers located either in dense granules (dopamine-beta-hydroxylase), in synaptic-like microvesicles (the acetylcholine transporter) or in both these regulated secretory organelles (VAMP2/synaptobrevin-2, synaptotagmin) were missing in PC12-27 cells, and the same was true also for the cytosolic and plasmalemma proteins involved in regulated exocytosis (Rab3, SNAP25, syntaxin). Pulse labeling and in vitro translation experiments revealed the defect to consist in a protein synthesis blockade that mRNA studies (reverse transcription-polymerase chain reaction, Northern blotting and actinomycin D experiments) revealed to take place primarily at the transcriptional level. The secretion defect of PC12-27 cells was modified neither by various types of long term stimulation nor by nerve growth factor treatment. Moreover, when one of the missing regulated secretory proteins, chromogranin B, was expressed by cDNA transfection, it was secreted, however via the constitutive pathway. Our results demonstrate that PC12-27 cells are fully incompetent for both branches of regulated secretion, those of dense granules and synaptic-like microvesicles, possibly because of the impairment of a general expression control system that appears to operate independently of neuroendocrine cell differentiation.	UNIV MILAN, CNR, CELLULAR & MOL PHARMACOL CTR, DEPT PHARMACOL, I-20129 MILAN, ITALY; UNIV REGGIO CALABRIA, FAC PHARM, DEPT PHARMACOL, I-88100 CATANZARO, ITALY; UNIV HEIDELBERG, INST NEUROBIOL, D-6900 HEIDELBERG, GERMANY; SAN RAFFAELE SCI INST, DEPT BIOL & TECHNOL RES, I-20132 MILAN, ITALY; SAN RAFFAELE SCI INST, B CECCARELLI NEUROBIOL CTR, I-20132 MILAN, ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Milan; Universita Mediterranea di Reggio Calabria; Ruprecht Karls University Heidelberg; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele			Huttner, Wieland B./P-4080-2018; racchetti, Gabriella/ABG-7347-2020; Bassetti, Matteo/L-3081-2019; Consalez, Giacomo/AAA-2146-2019	Consalez, Giacomo/0000-0003-4594-6273; Rosa, Patrizia/0000-0002-2590-6955; Racchetti, Gabriella/0000-0003-0062-8300				Barr FA, 1996, FEBS LETT, V384, P65, DOI 10.1016/0014-5793(96)00285-2; BASSETTI M, 1995, ENDOCRINOLOGY, V136, P1168, DOI 10.1210/en.136.3.1168; BAUERFEIND R, 1993, NEURON, V11, P105, DOI 10.1016/0896-6273(93)90275-V; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BENEDUM UM, 1987, EMBO J, V6, P1203, DOI 10.1002/j.1460-2075.1987.tb02355.x; BERRARD S, 1995, J NEUROCHEM, V65, P939; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; Chen YG, 1996, J BIOL CHEM, V271, P5297, DOI 10.1074/jbc.271.10.5297; CHILCOTE TJ, 1995, J CELL BIOL, V129, P219, DOI 10.1083/jcb.129.1.219; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENTI E, 1992, EUR J NEUROSCI, V4, P944, DOI 10.1111/j.1460-9568.1992.tb00121.x; CORRADI A, 1996, IN PRESS GENOMICS; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DAY R, 1995, DNA CELL BIOL, V14, P175, DOI 10.1089/dna.1995.14.175; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRONTALI N, 1976, J CELL BIOL, V68, P462, DOI 10.1083/jcb.68.3.462; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; Gratzl M, 1991, MARKERS NEURAL ENDOC; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALBAN PA, 1994, BIOCHEM J, V299, P1; HASHIMOTO S, 1987, J CELL BIOL, V105, P1579, DOI 10.1083/jcb.105.4.1579; HEUMANN R, 1983, EXP CELL RES, V145, P179, DOI 10.1016/S0014-4827(83)80019-6; HUNTER A, 1989, EXP CELL RES, V182, P445, DOI 10.1016/0014-4827(89)90249-8; Huttner WB, 1995, COLD SPRING HARB SYM, V60, P315, DOI 10.1101/SQB.1995.060.01.036; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; JONES SM, 1993, J CELL BIOL, V122, P775, DOI 10.1083/jcb.122.4.775; JUNGLING S, 1994, EUR J BIOCHEM, V226, P925, DOI 10.1111/j.1432-1033.1994.00925.x; KEHLENBACH RH, 1994, NATURE, V372, P804; LEDOUARIN NM, 1988, CELL, V53, P169, DOI 10.1016/0092-8674(88)90375-3; LINDENBAUM MH, 1987, J BIOL CHEM, V262, P605; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; LOWE AW, 1988, J CELL BIOL, V106, P51, DOI 10.1083/jcb.106.1.51; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MALGAROLI A, 1995, SCIENCE, V268, P1624, DOI 10.1126/science.7777862; MARZLUFF WF, 1985, TRANSCRIPTION TRANSL, P89; OBENDORF D, 1988, J NEUROCHEM, V51, P1573, DOI 10.1111/j.1471-4159.1988.tb01127.x; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; PAPINI E, 1995, J BIOL CHEM, V270, P1332, DOI 10.1074/jbc.270.3.1332; PEARSE AGE, 1979, FED PROC, V38, P2288; ROSA P, 1989, J CELL BIOL, V109, P17, DOI 10.1083/jcb.109.1.17; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; ROSA P, 1992, J HISTOCHEM CYTOCHEM, V40, P523, DOI 10.1177/40.4.1552186; ROSA P, 1992, J BIOL CHEM, V267, P12227; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHELLER RH, 1995, NEURON, V14, P893; SCHIAVO G, 1995, J BIOL CHEM, V270, P10566, DOI 10.1074/jbc.270.18.10566; SHENNAN KIJ, 1994, J BIOL CHEM, V269, P18646; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; TOOZE SA, 1993, MECHANISMS INTRACELL, P157; TSCHERNITZ C, 1995, MOL BRAIN RES, V31, P131, DOI 10.1016/0169-328X(95)00045-T; VALTORTA F, 1992, J BIOL CHEM, V267, P7195; VELASCO A, 1991, Journal of Cell Biology, V115, p410A; Vignali G, 1996, EUR J NEUROSCI, V8, P536, DOI 10.1111/j.1460-9568.1996.tb01238.x; WINKLER H, 1987, ANN NY ACAD SCI, V493, P3, DOI 10.1111/j.1749-6632.1987.tb27176.x; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N	66	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27116	27124		10.1074/jbc.271.43.27116	http://dx.doi.org/10.1074/jbc.271.43.27116			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900203	hybrid			2022-12-25	WOS:A1996VP23300097
J	Albor, A; Thraves, PJ; Dritschilo, A; Notario, V				Albor, A; Thraves, PJ; Dritschilo, A; Notario, V			Oncogenic activation of the tyrosine kinase domain of the human trk protooncogene by fusion to a cell adhesion molecule	ONCOGENE			English	Article						radiation transformation; human keratinocytes; beta-1,4-galactosyltransferase; tumorigenicity assays; cosmid cloning	HUMAN EPIDERMAL-KERATINOCYTES; PAPILLARY THYROID CARCINOMAS; HAMSTER-EMBRYO FIBROBLASTS; NEOPLASTIC TRANSFORMATION; DNA REARRANGEMENT; POINT MUTATION; PROTO-ONCOGENE; GROWTH-FACTOR; GENE; GALACTOSYLTRANSFERASE	To investigate the mechanisms of radiation-induced neoplastic conversion, DNA from X-ray transformed human epidermal keratinocytes (RHEK-1) was used in sequential cycles of NM3T3 transfection followed by nude mice tumorigenicity assays. NM3T3-derived transformants retained discrete DNA fragments hybridizing to human alu probes. Pour clones were isolated from a cosmid library prepared from one of these transformants (49-7G) using human DNA as the probe. Analyses of DNAs from 49-7G cells and the four cosmid clones with probes for a number of human oncogenes demonstrated that the cloned sequences were related to the trk oncogene. Transfection of NM3T3 cells with the cosmid DNAs did not result in the appearance of transformed foci when the murine fibroblasts were cultured on plastic. However, foci developed when transfected cells were cultured on plates coated with various extracellular matrix (ECM) components. Neomycin-resistant cosmid-transfected NIH3T3 cells did induce tumors in nude mice, and their tumorigenicity correlated with their level of trk expression. Nucleotide sequence analyses of cDNA clones isolated from a 49-7G library with a human trk probe revealed that the cloned sequences resulted from the fusion between 5' sequences from the human beta-1,4-galactosyltransferase gene, which encodes a membrane protein involved in cell-cell and cell-matrix interactions, and 3' sequences from the human trk proto-oncogene. The 76 kDa protein product of the chimeric gene, designated bgt-trk, has been identified in NM3T3 cells transfected with cosmid 19/2 or with bgt-trk cDNA expression constructs, and its phosphorylation in tyrosine has been found to increase when the transfected cells were seeded on plates coated with ECM components which also elicited foci formation in NIH3T3 transformation assays. The fusion of the trk tyrosine kinase domain to a cell adhesion molecule may explain tbe ECM dependence for the expression of the full transforming potential of the resulting oncogene product.	GEORGETOWN UNIV,MED CTR,DEPT RADIAT MED,WASHINGTON,DC 20007	Georgetown University			/AAB-6461-2022; /AFP-0764-2022		NATIONAL CANCER INSTITUTE [R01CA052954] Funding Source: NIH RePORTER; NCI NIH HHS [CA52954] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBOR A, 1994, CANCER RES, V54, P4502; ALBOR A, 1994, MOL CARCINOG, V11, P1339; AVILA MA, 1995, ONCOGENE, V10, P963; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARCELLOSHOFF MH, 1992, EXP CELL RES, V201, P225, DOI 10.1016/0014-4827(92)90367-H; BARKER PA, 1993, J BIOL CHEM, V268, P15150; BAYNA EM, 1988, CELL, V53, P145, DOI 10.1016/0092-8674(88)90496-5; BLAIR DG, 1982, SCIENCE, V218, P1122, DOI 10.1126/science.6293052; BUTTI MG, 1995, GENOMICS, V28, P15, DOI 10.1006/geno.1995.1100; CALZONE FJ, 1987, METHOD ENZYMOL, V152, P611; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER GM, 1982, SCIENCE, V218, P801; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; DUNCAN AMV, 1986, BIOCHEM BIOPH RES CO, V141, P1185, DOI 10.1016/S0006-291X(86)80169-3; ECKSTEIN DJ, 1992, EXP CELL RES, V201, P83, DOI 10.1016/0014-4827(92)90350-H; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GONG XH, 1995, SCIENCE, V269, P1718, DOI 10.1126/science.7569899; GRECO A, 1995, MOL CELL BIOL, V15, P6118; GRECO A, 1992, ONCOGENE, V7, P237; GRECO A, 1993, GENOMICS, V18, P397, DOI 10.1006/geno.1993.1482; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; ISHIKAWA F, 1986, P NATL ACAD SCI USA, V83, P3209, DOI 10.1073/pnas.83.10.3209; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; MENGLEGAW L, 1991, BIOCHEM BIOPH RES CO, V176, P1269, DOI 10.1016/0006-291X(91)90423-5; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; NOTARIO V, 1990, ONCOGENE, V5, P1425; OHUCHI T, 1992, ONCOGENE, V7, P331; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPER NL, 1986, SOMAT CELL MOLEC GEN, V12, P633, DOI 10.1007/BF01671948; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; THRAVES P, 1990, P NATL ACAD SCI USA, V87, P1174, DOI 10.1073/pnas.87.3.1174; THRAVES P, 1991, MECH CARCINOGENESIS, P93; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; ZIEMIECKI A, 1990, EMBO J, V9, P191, DOI 10.1002/j.1460-2075.1990.tb08095.x	46	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1755	1763						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895522				2022-12-25	WOS:A1996VM88700021
J	Wada, T; Yokoyama, H; Furuichi, K; Kobayashi, KI; Harada, K; Naruto, M; Su, SB; Akiyama, M; Mukaida, N; Matsushima, K				Wada, T; Yokoyama, H; Furuichi, K; Kobayashi, KI; Harada, K; Naruto, M; Su, SB; Akiyama, M; Mukaida, N; Matsushima, K			Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1)	FASEB JOURNAL			English	Article						chemokine; glomerular base membrane; macrophage; proteinuria	INTERCELLULAR-ADHESION MOLECULE-1; CHEMOATTRACTANT PROTEIN-1; MESANGIAL CELLS; EXPRESSION; NEPHRITIS; RAT; INTERLEUKIN-8; PROLIFERATION; PURIFICATION; PEPTIDE-1	We investigated the pathophysiological cole of a potent macrophage (M phi) chemotactic cytokine (chemokine), monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 (MCAF/MCP-1), in an animal model of crescentic glomerulonephritis. Administration of a small dose of nephrotoxic sera induced severe proliferative and necrotizing glomerulonephritis, with crescentic formation in the early phase and glomerulosclerosis in the later phase, in Wistar-Kyoto rats. MCAF/MCP-1 protein was detected immunohistochemic ally in glomeruli, vascular endothelial cells, and tubular epithelial cells in the early phase of injured kidney tissues but not in normal ones. Anti-MCAF/MCP-1 antibodies decreased the number of M phi in glomeruli, and prevented crescentic formation and the fusion of epithelial cell foot process in nephritic rats, thereby decreasing the excreted amounts of protein to normal levels on days 3 and 6. Furthermore, anti-MCAF/MCP-1 antibodies remarkably reduced glomerulosclerosis and improved renal dysfunction as well as proteinuria in the later phase (56 days). These results indicate that MCAF/MCP-1 essentially participates in the impairment of renal functions associated with crescentic glomerulonephritis by recruiting and activating M phi.	KANAZAWA UNIV,CANC RES INST,DEPT PHARMACOL,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,SCH MED,DEPT INTERNAL MED 1,KANAZAWA,ISHIKAWA 920,JAPAN; TORAY INDUSTRIES LTD,BASIC RES LABS,KAMAKURA,KANAGAWA,JAPAN	Kanazawa University; Kanazawa University; Toray Industries, Inc.			Mukaida, Naofumi/D-7623-2011	Mukaida, Naofumi/0000-0002-4193-1851				BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BROWN Z, 1992, KIDNEY INT, V42, P95, DOI 10.1038/ki.1992.266; CAMUSSI G, 1990, KIDNEY INT, V38, P1047, DOI 10.1038/ki.1990.311; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; EGIDO J, 1993, KIDNEY INT, V43, pS59; JOHNSON RJ, 1987, J CLIN INVEST, V79, P1379, DOI 10.1172/JCI112965; JOHNSON RJ, 1991, J CLIN INVEST, V87, P847, DOI 10.1172/JCI115089; JONES ML, 1992, J IMMUNOL, V149, P2147; KAWASAKI K, 1992, KIDNEY INT, V41, P1517, DOI 10.1038/ki.1992.221; KRAKOWER CA, 1951, AMA ARCH PATHOL, V51, P629; KURKI P, 1986, EXP CELL RES, V166, P209, DOI 10.1016/0014-4827(86)90520-3; LAN HY, 1995, KIDNEY INT, V48, P753, DOI 10.1038/ki.1995.347; MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485; MULLIGAN MS, 1993, J CLIN INVEST, V91, P577, DOI 10.1172/JCI116237; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; NISHIKAWA K, 1993, J EXP MED, V177, P667, DOI 10.1084/jem.177.3.667; NOLASCO FEB, 1987, KIDNEY INT, V31, P1160, DOI 10.1038/ki.1987.123; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; ROVIN BH, 1993, KIDNEY INT, V43, P218, DOI 10.1038/ki.1993.35; ROVIN BH, 1994, LAB INVEST, V71, P536; SCHMOUDER RL, 1993, KIDNEY INT, V44, P43, DOI 10.1038/ki.1993.211; STAHL RAK, 1993, KIDNEY INT, V44, P1036, DOI 10.1038/ki.1993.346; TANG WW, 1994, LAB INVEST, V70, P631; WADA T, 1994, J EXP MED, V180, P1135, DOI 10.1084/jem.180.3.1135; WADA T, 1994, KIDNEY INT, V46, P455, DOI 10.1038/ki.1994.293; Wada T, 1996, KIDNEY INT, V49, P761, DOI 10.1038/ki.1996.105; YOSHIMURA T, 1991, BIOCHEM BIOPH RES CO, V174, P504, DOI 10.1016/0006-291X(91)91445-I; YOSHIMURA T, 1989, J IMMUNOL, V142, P1956	29	184	197	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1996	10	12					1418	1425		10.1096/fasebj.10.12.8903512	http://dx.doi.org/10.1096/fasebj.10.12.8903512			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VP485	8903512				2022-12-25	WOS:A1996VP48500007
J	Camerer, E; Rottingen, JA; Iversen, JG; Prydz, H				Camerer, E; Rottingen, JA; Iversen, JG; Prydz, H			Coagulation factors VII and X induce Ca2+ oscillations in Madin-Darby canine kidney cells only when proteolytically active	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-TISSUE FACTOR; MOLECULAR-CLONING; ENDOTHELIAL-CELLS; RECEPTOR; CDNA; CALCIUM; EXPRESSION; PROTEIN; GENE	We have recently reported that the activated serine protease and blood coagulation Factor VII (FVIIa) can induce Ca2+ oscillations in Madin-Darby canine kidney cells. We now demonstrate a similar response by Madin-Darby canine kidney cells to the active coagulation Factor X (FXa), which is also a serine protease and a substrate of the tissue factor (TF)-FVIIa complex in the initiation of the coagulation cascade. The phosphatidyl inositol-specific phospholipase C inhibitor U73122 inhibited the signals elicited by both FVIIa and FXa. Lack of sensibility to the tyrosine kinase inhibitors herbimycin A, genistein, and the tyrphostin AG18 and discordance between TF expression and FVIIa responsiveness argued against TF acting as a cytokine-like receptor, with tyrosine kinase-mediated activation by FVIIa. As demonstrated using the protease inhibitor benzamidine and by specific active site inhibition with 1,5-dansyl-Glu-Gly-Arg chloromethyl ketone, both FVIIa and FXa lost their ability to elicit a calcium response when devoid of their proteolytic activity. Consistent with this, the native (zymogen) form of Factor X did not induce Ca2+ transients. Homologous but not heterologous inhibition of FVIIa- and FXa-evoked Ca2+ signals by 1,5-dansyl-Glu-Gly-Arg chloromethyl ketone-inactivated FVIIa and FXa suggested that each factor had its own specific cell surface anchoring receptor. The two coagulation factors did not show homologous desensitization as seen for thrombin stimulation. Studies with hirudin excluded involvement of the established activation pathway through thrombin itself. Lack of desensitization of the response to FVIIa or FXa by thrombin ruled out any involvement of proteinase activated receptor-1 (PAR-1), the thrombin receptor. We speculate that FXa and FVIIa may work via a receptor (possibly common) analogous to PAR-I or its functional homologue PAR-2. Although TF is essential for the FVIIa-induced signaling event; its role in the phosphatidyl inositol-specific phospholipase C-mediated Ca2+ signal may be in anchoring FVIIa to the cell surface rather than in transmembrane signal mediation.	BIOTECHNOL CTR OSLO,N-0371 OSLO,NORWAY; UNIV OSLO,INST BASIC MED SCI,DEPT PHYSIOL,LAB INTRACELLULAR SIGNALING,N-0316 OSLO,NORWAY	University of Oslo			Camerer, Eric/K-4161-2017	Camerer, Eric/0000-0002-6271-7125				ALTIERI DC, 1994, CELL IMMUNOL, V155, P372, DOI 10.1006/cimm.1994.1130; BACH R, 1988, J CELL BIOL, V107, P825; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; Camerer E, 1996, BLOOD, V88, P1339, DOI 10.1182/blood.V88.4.1339.bloodjournal8841339; CARMELIET P, 1995, THROMB HAEMOSTASIS, V69, P1177; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; DRAKE TA, 1989, J CELL BIOL, V109, P389, DOI 10.1083/jcb.109.1.389; ESMON CT, 1995, CURR BIOL, V5, P743, DOI 10.1016/S0960-9822(95)00150-3; FISHER KL, 1987, THROMB RES, V48, P89, DOI 10.1016/0049-3848(87)90349-5; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEIN L, 1994, J BIOL CHEM, V269, P27719; HJORT PF, 1957, SCAND J CLIN LAB I S, V9; Hwa JJ, 1996, CIRC RES, V78, P581, DOI 10.1161/01.RES.78.4.581; Mirza H, 1996, J CLIN INVEST, V97, P1705, DOI 10.1172/JCI118597; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; ROTNES JS, 1992, CELL CALCIUM, V13, P487, DOI 10.1016/0143-4160(92)90017-M; ROTTINGEN JA, 1995, J BIOL CHEM, V270, P4650, DOI 10.1074/jbc.270.9.4650; SANTULLI RJ, 1995, P NATL ACAD SCI USA, V92, P9151, DOI 10.1073/pnas.92.20.9151; SCARPATI EM, 1987, BIOCHEMISTRY-US, V26, P5234, DOI 10.1021/bi00391a004; Sevinsky JR, 1996, J CELL BIOL, V133, P293, DOI 10.1083/jcb.133.2.293; SPICER EK, 1987, P NATL ACAD SCI USA, V84, P5148, DOI 10.1073/pnas.84.15.5148; STEINBERG SF, 1985, THROMB HAEMOSTASIS, V54, P168	27	120	123	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29034	29042		10.1074/jbc.271.46.29034	http://dx.doi.org/10.1074/jbc.271.46.29034			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910556	hybrid			2022-12-25	WOS:A1996VT05200048
J	Espeso, EA; Penalva, MA				Espeso, EA; Penalva, MA			Three binding sites for the Aspergillus nidulans PacC zinc-finger transcription factor are necessary and sufficient for regulation by ambient pH of the isopenicillin N synthase gene promoter.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN BIOSYNTHETIC GENE; MOLECULAR CHARACTERIZATION; EXPRESSION; SYNTHETASE; IPNA; ACVA	The isopenicillin N synthase (ipnA) gene, encoding a key penicillin biosynthetic enzyme in Aspergillus nidulans, represents a prototype of an alkaline-expressed gene. ipnA is under ambient pH regulation, and its promoter (ipnA(p)) contains binding sites for the zinc-finger transcription factor PacC. We show here that three of these sites, denoted ipnA2, ipnA3, and ipnA4AB, are efficiently recognized by the protein in an isolated sequence context. Single, double, and triple inactivation of these sites in any possible combination reduced promoter activity under alkaline conditions but had no effect under acidic conditions (under which promoter activity was low), as measured by the expression of wildtype and mutant ipnA(p)::lacZ fusion genes integrated in single copy into a common chromosomal location. This establishes a physiological role for these PacC binding sites and demonstrates a direct role for PacC in ambient pH regulation of ipnA gene expression. In addition, this confirms our previous proposal that PacC is an activator for alkaline-expressed genes. Notably, our experiments show that ipnA2, the highest affinity site for PacC in the ipnA(p), contributes relatively modestly to PacC-mediated activation. By contrast, the lower affinity sites ipnA3 and ipnA4AB contribute more substantially to regulation by ambient pH. Inactivation of these three binding sites reduced promoter activity under alkaline conditions to that observed under acidic conditions, showing that these three PacC sites at ipnA(p) are sufficient to account for its activation by alkaline ambient pH.	CSIC,CTR INVEST BIOL,DEPT MOL MICROBIOL,E-28006 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)			Espeso, Eduardo A/C-5259-2011; Penalva, Miguel A/G-2295-2015; Espeso, Eduardo A/AAC-7238-2022	Espeso, Eduardo A/0000-0002-5873-6059; Penalva, Miguel A/0000-0002-3102-2806; Espeso, Eduardo A/0000-0002-5873-6059				ARST HN, 1994, MOL GEN GENET, V245, P787, DOI 10.1007/BF00297286; BRAKHAGE AA, 1992, J BACTERIOL, V174, P3789, DOI 10.1128/JB.174.11.3789-3799.1992; CADDICK MX, 1986, MOL GEN GENET, V203, P346, DOI 10.1007/BF00333978; CLUTTERBUCK AJ, 1993, GENETIC MAPS LOCUS M, V3; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; DENISON SH, 1995, J BIOL CHEM, V270, P28519, DOI 10.1074/jbc.270.48.28519; ESPESO EA, 1993, EMBO J, V12, P3947, DOI 10.1002/j.1460-2075.1993.tb06072.x; ESPESO EA, 1994, FEBS LETT, V342, P43, DOI 10.1016/0014-5793(94)80581-4; ESPESO EA, 1992, MOL MICROBIOL, V6, P1457, DOI 10.1111/j.1365-2958.1992.tb00866.x; MACCABE AP, 1991, J BIOL CHEM, V266, P12646; MacCabe AP, 1996, MOL GEN GENET, V250, P367, DOI 10.1007/s004380050087; OREJAS M, 1995, GENE DEV, V9, P1622, DOI 10.1101/gad.9.13.1622; PEREZESTEBAN B, 1993, MOL MICROBIOL, V9, P881, DOI 10.1111/j.1365-2958.1993.tb01746.x; ROSSI A, 1990, FEMS MICROBIOL LETT, V66, P51, DOI 10.1016/0378-1097(90)90257-Q; Sarkar S, 1996, BIOCHEM SOC T, V24, P360, DOI 10.1042/bst0240360; Suarez T, 1996, MOL MICROBIOL, V20, P529, DOI 10.1046/j.1365-2958.1996.5421065.x; TILBURN J, 1983, GENE, V26, P205, DOI 10.1016/0378-1119(83)90191-9; TILBURN J, 1995, EMBO J, V14, P779, DOI 10.1002/j.1460-2075.1995.tb07056.x; XU HE, 1995, P NATL ACAD SCI USA, V92, P7677, DOI 10.1073/pnas.92.17.7677	19	84	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28825	28830		10.1074/jbc.271.46.28825	http://dx.doi.org/10.1074/jbc.271.46.28825			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910527	hybrid, Green Published			2022-12-25	WOS:A1996VT05200019
J	Hiesberger, T; Hodits, R; Ullrich, R; Exner, M; Kerjaschki, D; Schneider, WJ; Nimpf, J				Hiesberger, T; Hodits, R; Ullrich, R; Exner, M; Kerjaschki, D; Schneider, WJ; Nimpf, J			Receptor-associated protein and members of the low density lipoprotein receptor family share a common epitope - An extended model for the development of passive Heymann nephritis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN OOCYTE RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; IMMUNOELECTRON MICROSCOPY; MULTIFUNCTIONAL RECEPTOR; ANTIGENIC COMPLEX; INSULIN-RECEPTOR; LIGAND-BINDING; 39-KDA PROTEIN; ANTI-IDIOTYPES; MEGALIN GP330	Heymann nephritis is an experimental rat model for human membranous glomerulonephritis. Two target antigens have been identified in the proximal tubule brush border of rat kidneys. One of them is megalin, a 600-kDa membrane protein that belongs to the family of low density lipoprotein receptor (LDLR)-related proteins. The other one is receptor-associated protein (RAP), a polypeptide of 40 kDa that associates with members of the LDLR family. Here we show that antibodies produced against recombinant human RAP strongly crossreact with the chicken oocyte receptor for very low density Lipoprotein and vitellogenin (LR8), and with two other members of the LDLR family, LDLR-related protein and megalin. The interaction of this antibody with LR8 showed binding characteristics exactly as those demonstrated for the physiological ligands of this receptor, in that binding of the antibody: (i) is Ca2+-dependent; (ii) is abolished by unfolding of the cysteine-rich binding domain by reduction; and (iii) interferes with the binding of very low density Lipoprotein and vitellogenin. Immunopurification of the LR8-specific subpopulation of the polyclonal antiserum yielded an IgG fraction strongly reacting with LR8 as well as with RAP. Using recombinant fragments of RAP and peptide mapping, the cross-reacting epitope(s) could be narrowed down to three short sequences (5-7 residues) in the COOH-terminal part of the protein. After immunization with RAP, anti-LR8 antibodies and anti-RAP antibodies arise simultaneously, indicating that the receptor-specific activity is not due to anti-idiotypic antibodies. These findings suggest the existence of a common epitope(s) on RAP and members of the LDL receptor family Based on these results, we present an extended molecular model for the development of passive Heymann nephritis.	BIOCTR,DEPT MOL GENET,A-1030 VIENNA,AUSTRIA; UNIV VIENNA,A-1030 VIENNA,AUSTRIA; UNIV VIENNA,DEPT CLIN PATHOL,SECT ULTRASTRUCT PATHOL & CELL BIOL,A-1090 VIENNA,AUSTRIA	University of Vienna; University of Vienna				Nimpf, Johannes/0000-0002-9273-3492				BARBER DL, 1991, J BIOL CHEM, V266, P18761; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BROWN MS, 1974, P NATL ACAD SCI USA, V71, P788, DOI 10.1073/pnas.71.3.788; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; BUJO H, 1995, J BIOL CHEM, V270, P23546, DOI 10.1074/jbc.270.40.23546; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; ELIAS D, 1984, J BIOL CHEM, V259, P6416; FARQUHAR MG, 1995, J AM SOC NEPHROL, V6, P35; GAULTON GN, 1986, ANNU REV IMMUNOL, V4, P253, DOI 10.1146/annurev.iy.04.040186.001345; GEORGE R, 1987, J BIOL CHEM, V262, P16838; HAYASHI K, 1989, J BIOL CHEM, V264, P3131; HERZ J, 1991, J BIOL CHEM, V266, P21232; HIESBERGER T, 1995, J BIOL CHEM, V270, P18219, DOI 10.1074/jbc.270.31.18219; JACOBSEN L, 1995, J BIOL CHEM, V270, P6468, DOI 10.1074/jbc.270.12.6468; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KERJASCHKI D, 1986, KIDNEY INT, V30, P229, DOI 10.1038/ki.1986.175; KERJASCHKI D, 1992, P NATL ACAD SCI USA, V89, P11179, DOI 10.1073/pnas.89.23.11179; Kerjaschki D, 1996, J EXP MED, V183, P2007, DOI 10.1084/jem.183.5.2007; KERJASCHKI D, 1982, P NATL ACAD SCI-BIOL, V79, P5557, DOI 10.1073/pnas.79.18.5557; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MUKONO H, 1994, J BIOL CHEM, V269, P13238; NIMPF J, 1988, J LIPID RES, V29, P657; NIMPF J, 1994, J BIOL CHEM, V269, P212; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; ORLANDO RA, 1995, J AM SOC NEPHROL, V6, P61; PIETROMONACO S, 1990, P NATL ACAD SCI USA, V87, P1811, DOI 10.1073/pnas.87.5.1811; Raychowdhury R, 1996, AM J PATHOL, V148, P1613; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SCHNEIDER WJ, 1980, J BIOL CHEM, V255, P1442; Schneider Wolfgang J., 1995, Current Opinion in Lipidology, V6, P92, DOI 10.1097/00041433-199504000-00006; SEGE K, 1978, P NATL ACAD SCI USA, V75, P2443, DOI 10.1073/pnas.75.5.2443; SHECHTER Y, 1982, SCIENCE, V216, P542, DOI 10.1126/science.7041258; STEYRER E, 1990, J BIOL CHEM, V265, P19575; STIFANI S, 1988, BIOCHEM J, V250, P467, DOI 10.1042/bj2500467; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537	47	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28792	28797		10.1074/jbc.271.46.28792	http://dx.doi.org/10.1074/jbc.271.46.28792			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910522	hybrid			2022-12-25	WOS:A1996VT05200014
J	Meagher, JL; Huntington, JA; Fan, BQ; Gettins, PGW				Meagher, JL; Huntington, JA; Fan, BQ; Gettins, PGW			Role of arginine 132 and lysine 133 in heparin binding to and activation of antithrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL CHANGE; THROMBIN REACTION; VARIANT; SITE; MECHANISM; IDENTIFICATION; ACCELERATION; MODEL	The binding of heparin to antithrombin greatly accelerates the rate of inhibition of the target proteinases thrombin and factor Xa. Acceleration of the rate of inhibition of factor Xa involves a conformational change in antithrombin that is translated from the heparin binding site to the reactive center loop, A mechanism has been proposed for generation and propagation of the conformational change in which the binding of the negatively charged heparin reduces ionic repulsions be tween positively charged residues on and adjacent to the D-helix in the heparin binding site of antithrombin (van Boeckel, C. A. A., Grootenhuis, P. D. J., and Visser, A, (1994) Nature Struct, Biol, 1, 423-425), This charge neutralization is proposed to elongate the D-helix and initiate the conformational change which is then translated to the reactive center loop. Several basic residues, including arginine 132 and lysine 133, were predicted to be important both in heparin binding and in this mechanism of heparin activation, To test both the helix extension mechanism and the role of these two residues in heparin binding and factor Xa inhibition, we individually changed arginine 132 and lysine 133 to uncharged methionine by site-directed mutagenesis. The K-d values for binding of R132M and K133M variants to the high affinity pentasaccharide were weakened only 2.3- and 4.5-fold respectively, suggesting a location for R132 and K133 peripheral to the main pentasaccharide binding site. However, the K-d values for long chain high affinity heparin were weakened at least 17-fold for both R132M and K133M, indicating involvement of each residue in binding extended chain heparin species. These reductions in affinity were ionic strength-dependent. The rates of inhibition of factor Xa and thrombin by each variant, however, were indistinguishable from those of control antithrombin, and the accelerations of the rate of inhibition produced by heparin were normal. We conclude that neither arginine 132 nor lysine 133 plays an important role in the binding of heparin pentasaccharide or in the mechanism of heparin activation, suggesting that D-helix extension through charge neutralization is not the mechanism for transmission of conformational change from the heparin binding site to the reactive center region, Arginine 132 and lysine 133 do, however, play a role in tight binding of longer chain heparin species through ionic interactions.	UNIV ILLINOIS,DEPT BIOCHEM,CHICAGO,IL 60612; VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Vanderbilt University					NHLBI NIH HHS [HL49234] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049234, R37HL049234] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BORG JY, 1990, FEBS LETT, V266, P163, DOI 10.1016/0014-5793(90)81530-2; BORG JY, 1988, J CLIN INVEST, V81, P1292, DOI 10.1172/JCI113447; BRENNAN SO, 1987, FEBS LETT, V219, P431, DOI 10.1016/0014-5793(87)80266-1; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CHANG JY, 1989, J BIOL CHEM, V264, P3111; FAN BQ, 1994, BIOCHEMISTRY-US, V33, P14156, DOI 10.1021/bi00251a026; FAN BQ, 1993, J BIOL CHEM, V268, P17588; GANDRILLE S, 1990, J BIOL CHEM, V265, P18997; Garone L, 1996, BIOCHEMISTRY-US, V35, P8881, DOI 10.1021/bi960542m; GETTINS P, 1992, J BIOL CHEM, V267, P21946; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P8385, DOI 10.1021/bi00084a001; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; GROOTENHUIS PDJ, 1991, J AM CHEM SOC, V113, P2743, DOI 10.1021/ja00007a058; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; KOIDE T, 1984, P NATL ACAD SCI-BIOL, V81, P289, DOI 10.1073/pnas.81.2.289; MILETICH JP, 1980, ANAL BIOCHEM, V105, P304, DOI 10.1016/0003-2697(80)90462-5; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Olson Steven T., 1994, Perspectives in Drug Discovery and Design, V1, P479, DOI 10.1007/BF02171861; PETERSON CB, 1987, J BIOL CHEM, V262, P8061; PETERSON CB, 1985, J BIOL CHEM, V260, P610; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; TURKO IV, 1993, FEBS LETT, V335, P9, DOI 10.1016/0014-5793(93)80429-X; VANBOECKEL CAA, 1994, NAT STRUCT BIOL, V1, P423, DOI 10.1038/nsb0794-423; Zettlmeissl G, 1988, Behring Inst Mitt, P26	27	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29353	29358		10.1074/jbc.271.46.29353	http://dx.doi.org/10.1074/jbc.271.46.29353			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910598	hybrid			2022-12-25	WOS:A1996VT05200090
J	Bradrick, TD; Shattuck, C; Strader, MB; Wicker, C; Eisenstein, E; Howell, EE				Bradrick, TD; Shattuck, C; Strader, MB; Wicker, C; Eisenstein, E; Howell, EE			Redesigning the quaternary structure of R67 dihydrofolate reductase - Creation of an active monomer from a tetrameric protein by quadruplication of the gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRIOSEPHOSPHATE ISOMERASE; CRYSTAL-STRUCTURE; LIGAND-BINDING; PLASMID R67; CONSTRUCTION; EQUILIBRIUM; ASYMMETRY; STABILITY; SUBUNITS	R67 dihydrofolate reductase (DHFR) provides resistance to the antibacterial drug trimethoprim. This R-plasmid-encoded enzyme does not share any homology with chromosomal DHFR. A recent crystal structure of active, homotetrameric R67 DHFR (Narayana, N., Matthews, D. A., Howell, E. E., and Xuong, N.-H. (1995) Nat. Struct. Biol. 2, 1018-1025) indicates that a single active site pore traverses the length of the molecule. Since the center of the pore possesses exact 222 symmetry, site-directed mutagenesis of residues in the pore will produce four mutations/active site. To break this inevitable symmetry, four copies of the gene have been linked in frame to create an active monomer possessing the essential tertiary structure of native tetrameric R67 DHFR. The protein product, quadruple R67 DHFR, is 4 times the molecular mass of native R67 DHFR in SDS-polyacrylamide gel electrophoresis and is monomeric under nondenaturing conditions as measured by sedimentation equilibrium experiments. The catalytic activity of quadruple R67 DHFR is decreased only slightly when compared with native R67 DHFR, Folding of quadruple R67 DHFR is completely reversible at pH 5. However, at pH 8, folding is not fully reversible; this is likely due to a competition between productive intramolecular versus nonproductive intermolecular domain association. The production of a fully active, monomeric R67 DHFR variant will enable the design of more meaningful site directed mutants where single substitutions per active site pore can be generated.	UNIV TENNESSEE,DEPT BIOCHEM CELL & MOL BIOL,KNOXVILLE,TN 37996; MYCOGEN CORP,SAN DIEGO,CA 92121; CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850; UNIV MARYLAND,DEPT CHEM & BIOCHEM,BALTIMORE,MD 21229	University of Tennessee System; University of Tennessee Knoxville; University System of Maryland; University of Maryland Baltimore				Howell, Elizabeth/0000-0001-6157-433X	NIGMS NIH HHS [GM35308] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM035308, R01GM035308] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON SA, 1980, BIOPOLYMERS, V19, P1475, DOI 10.1002/bip.1980.360190805; BABE LM, 1992, PROTEIN SCI, V1, P1244, DOI 10.1002/pro.5560011003; BACCANARI D, 1975, BIOCHEMISTRY-US, V14, P5267, DOI 10.1021/bi00695a006; BLAKLEY RL, 1960, NATURE, V188, P231, DOI 10.1038/188231a0; BORCHERT TV, 1993, STRUCTURE, V1, P205, DOI 10.1016/0969-2126(93)90021-8; BORCHERT TV, 1994, P NATL ACAD SCI USA, V91, P1515, DOI 10.1073/pnas.91.4.1515; Bradrick TD, 1996, BIOCHEMISTRY-US, V35, P11414, DOI 10.1021/bi960205d; BRADSHAW TP, 1993, BIOCHEMISTRY-US, V32, P12774, DOI 10.1021/bi00210a029; BREITER DR, 1994, PROTEIN SCI, V3, P2023, DOI 10.1002/pro.5560031115; BRISSON N, 1984, GENE, V28, P271, DOI 10.1016/0378-1119(84)90266-X; Cantor C. R., 1980, BIOPHYSICAL CHEM 2, P560; CHENG YSE, 1990, P NATL ACAD SCI USA, V87, P9660, DOI 10.1073/pnas.87.24.9660; DAY PJ, 1995, BIOCHEMISTRY-US, V34, P6416, DOI 10.1021/bi00019a022; DILANNI C L, 1990, Journal of Biological Chemistry, V265, P17348; EFTINK MR, 1994, BIOPHYS J, V66, P482, DOI 10.1016/S0006-3495(94)80799-4; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; Fersht A. R., 1985, ENZYME STRUCTURE MEC, P155; GRAHAM GJ, 1992, BIOTECHNIQUES, V13, P780; HALLEWELL RA, 1989, J BIOL CHEM, V264, P5260; HORECKER BL, 1948, J BIOL CHEM, V175, P385; HOWELL EE, 1987, BIOCHEMISTRY-US, V26, P8591, DOI 10.1021/bi00400a015; IWAKURA M, 1992, PROTEIN ENG, V5, P791, DOI 10.1093/protein/5.8.791; KUCHINKE W, 1985, EMBO J, V4, P1067, DOI 10.1002/j.1460-2075.1985.tb03740.x; LIANG H, 1993, P NATL ACAD SCI USA, V90, P7010, DOI 10.1073/pnas.90.15.7010; MATTHEWS DA, 1986, BIOCHEMISTRY-US, V25, P4194, DOI 10.1021/bi00363a005; NARAYANA N, 1995, NAT STRUCT BIOL, V2, P1018, DOI 10.1038/nsb1195-1018; NICHOLS R, 1993, BIOCHEMISTRY-US, V32, P1695, DOI 10.1021/bi00058a002; PREDKI PF, 1995, BIOCHEMISTRY-US, V34, P9834, DOI 10.1021/bi00031a003; REECE LJ, 1991, BIOCHEMISTRY-US, V30, P10895, DOI 10.1021/bi00109a013; Robinson CR, 1996, BIOCHEMISTRY-US, V35, P109, DOI 10.1021/bi9521194; ROYER CA, 1993, PROTEIN SCI, V2, P1844, DOI 10.1002/pro.5560021106; SMYTHE JA, 1994, PROTEIN ENG, V7, P145, DOI 10.1093/protein/7.2.145; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; WARD WHJ, 1988, BIOCHEMISTRY-US, V27, P1041, DOI 10.1021/bi00403a029; YANG YR, 1980, P NATL ACAD SCI-BIOL, V77, P5187, DOI 10.1073/pnas.77.9.5187; ZHUANG P, 1993, J BIOL CHEM, V268, P22672	36	13	13	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28031	28037		10.1074/jbc.271.45.28031	http://dx.doi.org/10.1074/jbc.271.45.28031			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910413	hybrid			2022-12-25	WOS:A1996VU03300013
J	Jeneson, JAL; Wiseman, RW; Westerhoff, HV; Kushmerick, MJ				Jeneson, JAL; Wiseman, RW; Westerhoff, HV; Kushmerick, MJ			The signal transduction function for oxidative phosphorylation is at least second order in ADP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; HUMAN SKELETAL-MUSCLE; ATP SYNTHESIS; RESPIRATORY CONTROL; CARRIER; METABOLISM; MECHANISM	To maintain ATP constant in the cell, mitochondria must sense cellular ATP utilization and transduce this demand to F-0-F-1-ATPase. In spite of a considerable research effort over the past three decades, no combination of signal(s) and kinetic function has emerged with the power to explain ATP homeostasis in all mammalian cells. We studied this signal transduction problem in intact human muscle using P-31 NMR spectroscopy. We find that the apparent kinetic order of the transduction function of the signal cytosolic ADP concentration ([ADP]) is at least second order and not first order as has been assumed. We show that amplified mitochondrial sensitivity to cytosolic [ADP] harmonizes with in vitro kinetics of [ADP] stimulation of respiration and explains ATP homeostasis also in mouse liver and canine heart. This result may well be generalizable to all mammalian cells.	UNIV WASHINGTON,SCH MED,DEPT RADIOL,NMR RES LAB,SEATTLE,WA 98195; FREE UNIV AMSTERDAM,FAC BIOL,DEPT MICROBIAL PHYSIOL,NL-1081 HV AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,BIOCTR,EC SLATER INST,NL-1018 TV AMSTERDAM,NETHERLANDS; UNIV WASHINGTON,SCH MED,DEPT PHYSIOL & BIOPHYS,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,CTR BIOENGN,SEATTLE,WA 98185	University of Washington; University of Washington Seattle; Vrije Universiteit Amsterdam; University of Amsterdam; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Westerhoff, Hans V/I-5762-2012	Westerhoff, Hans V/0000-0002-0443-6114	NIAMS NIH HHS [AR36281, AR41793, AR41928] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041928, R29AR041793, R01AR036281] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BALABAN RS, 1986, SCIENCE, V232, P1121, DOI 10.1126/science.3704638; BERKICH DA, 1991, J BIOL CHEM, V266, P123; BISELL CC, 1994, CONTROL ENG, P1; BLEI ML, 1993, J PHYSIOL-LONDON, V465, P203, DOI 10.1113/jphysiol.1993.sp019673; BRANDOLIN G, 1993, J BIOENERG BIOMEMBR, V25, P459, DOI 10.1007/BF01108403; BYGRAVE FL, 1967, P NATL ACAD SCI USA, V57, P1409, DOI 10.1073/pnas.57.5.1409; CHANCE B, 1955, J BIOL CHEM, V217, P383; CHANCE B, 1985, P NATL ACAD SCI USA, V82, P8384, DOI 10.1073/pnas.82.24.8384; CHANCE B, 1965, J GEN PHYSIOL, V49, P163, DOI 10.1085/jgp.49.1.163; DEMARTINO C, 1979, CELL TISSUE RES, V196, P1; DUDLEY GA, 1987, J BIOL CHEM, V262, P9109; DUYCKAERTS C, 1980, EUR J BIOCHEM, V106, P1; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; HUANG AH, 1988, CIRC RES, V62, P286, DOI 10.1161/01.RES.62.2.286; JACOBUS WE, 1982, J BIOL CHEM, V257, P2397; JENESON JAL, 1995, AM J PHYSIOL-CELL PH, V268, pC1474, DOI 10.1152/ajpcell.1995.268.6.C1474; JENESON JAL, 1996, IN PRESS MOL CELL BI; KATZ LA, 1989, AM J PHYSIOL, V256, pH265, DOI 10.1152/ajpheart.1989.256.1.H265; KORETSKY AP, 1995, PHYSIOL REV, V75, P667, DOI 10.1152/physrev.1995.75.4.667; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; LANOUE KF, 1986, BIOCHEMISTRY-US, V25, P7667, DOI 10.1021/bi00371a058; LANOUE KF, 1995, ADV MOL CEL, V11, P207; LIGETI E, 1985, BIOCHEMISTRY-US, V24, P4423, DOI 10.1021/bi00337a025; MAJIMA E, 1995, J BIOL CHEM, V270, P29548, DOI 10.1074/jbc.270.49.29548; MCCORMACK JG, 1986, TRENDS BIOCHEM SCI, V9, P71; PALMIERI F, 1993, J BIOENERG BIOMEMBR, V25, P525, DOI 10.1007/BF01108409; PFAFF E, 1969, EUR J BIOCHEM, V10, P484, DOI 10.1111/j.1432-1033.1969.tb00715.x; ROSING J, 1972, BIOCHIM BIOPHYS ACTA, V267, P275, DOI 10.1016/0005-2728(72)90116-8; ROTTENBERG H, 1973, BIOPHYS J, V13, P503, DOI 10.1016/S0006-3495(73)86004-7; Segel IH, 1975, ENZYME KINETICS, P346; SLUSEGOFFART CM, 1996, BIOTHERMOKINETICS LI, P218; SOUVERIJN JH, 1973, BIOCHIM BIOPHYS ACTA, V305, P185, DOI 10.1016/0005-2728(73)90168-0; VANDAM K, 1987, THERMODYNAMICS CONTR, P228	33	138	139	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					27995	27998		10.1074/jbc.271.45.27995	http://dx.doi.org/10.1074/jbc.271.45.27995			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910406	Green Published, hybrid			2022-12-25	WOS:A1996VU03300006
J	Kawashima, H; Sequeira, DJ; Nelson, DR; Strobel, HW				Kawashima, H; Sequeira, DJ; Nelson, DR; Strobel, HW			Genomic cloning and protein expression of a novel rat brain cytochrome P-450 CYP2D18 catalyzing imipramine N-demethylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION OXIDASE SYSTEM; C6 CELL-LINE; PARKINSONS-DISEASE; GENE-EXPRESSION; SUBFAMILY; IDENTIFICATION; DEBRISOQUINE; METABOLISM; P450; 4-HYDROXYLATION	We have previously reported the isolation of two cDNA clones, designated 2d-29 and 2d-35, which have identical open reading frames and code for a novel brain cytochrome P-450 (P-450) belonging to the CYP2D subfamily, and noted that the mRNA of clone 2d-35 seems to be expressed in the brain but not in the liver (1). Although the deduced amino acid sequence of these clones differs from that of the liver CYP2D4 by only 5 amino acids distributed in the C-terminal region, this new P-450 cDNA clone contained st unique 5'-extension, and we posit in this report by analysis of a genomic clone that this 5'-untranslated sequence is derived from a gene distinct from that of CYP2D4. Thus, this novel P-450 was named P-450 2D18 according to the recommended nomenclature (2), The expressibility of this cDNA was confirmed by in vitro translation using a reticulocyte system, and protein expression was performed using COS-M6 cells. Immunoblot analysis showed a cross-reacting band of the predicted size range with anti-P-450 2D6 antiserum, which was not seen in control cells. Furthermore, the CYP2D18-expressed COS cell lysate showed N-demethylation activity toward imipramine, whereas another brain P-450 CYP4F6-expressed COS cell lysate showed 10-hydroxylation activity. This is the first report that associates an individual P-450 isozyme in brain with a particular metabolic alteration of the antidepressant imipramine.	UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOL BIOL,HOUSTON,TX 77225; UNIV TENNESSEE,DEPT BIOCHEM,MEMPHIS,TN 38163	University of Texas System; University of Tennessee System; University of Tennessee Health Science Center				Nelson, David/0000-0003-0583-5421	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044923] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 44923] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BARBEAU A, 1985, LANCET, V2, P1213; BERGH AF, 1992, J NEUROCHEM, V59, P575, DOI 10.1111/j.1471-4159.1992.tb09408.x; BROSEN K, 1991, CLIN PHARMACOL THER, V49, P609, DOI 10.1038/clpt.1991.77; GENG J, 1993, BIOCHEM BIOPH RES CO, V197, P1179, DOI 10.1006/bbrc.1993.2601; GENG J, 1995, J NEUROCHEM, V65, P554; GONZALEZ F J, 1988, Genomics, V2, P174, DOI 10.1016/0888-7543(88)90100-0; GONZALEZ FJ, 1988, NATURE, V331, P442, DOI 10.1038/331442a0; HARADA N, 1992, BIOCHEM BIOPH RES CO, V189, P1001, DOI 10.1016/0006-291X(92)92303-F; HODGSON AV, 1993, MOL CELL BIOCHEM, V120, P171, DOI 10.1007/BF00926090; HONDA S, 1994, BIOCHEM BIOPH RES CO, V198, P1153, DOI 10.1006/bbrc.1994.1163; ISHIDA N, 1988, BIOCHEM BIOPH RES CO, V156, P681, DOI 10.1016/S0006-291X(88)80896-9; JOHANSSON I, 1994, MOL PHARMACOL, V46, P452; KAWASHIMA H, 1995, BIOCHEM BIOPH RES CO, V209, P535, DOI 10.1006/bbrc.1995.1534; Kawashima H, 1995, BIOCHEM BIOPH RES CO, V217, P1137, DOI 10.1006/bbrc.1995.2887; KOMORI M, 1993, BIOCHEM BIOPH RES CO, V196, P721, DOI 10.1006/bbrc.1993.2309; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAHENDROO MS, 1993, J BIOL CHEM, V268, P19463; MATSUNAGA E, 1990, J MOL EVOL, V30, P155, DOI 10.1007/BF02099942; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Schuetz JD, 1996, MOL PHARMACOL, V49, P63; SEQUEIRA DJ, 1995, J CHROMATOGR B, V673, P251, DOI 10.1016/0378-4347(95)00274-X; SEQUEIRA DJ, 1996, IN PRESS BRAIN RES; STROBEL HW, 1989, PHARMACOL RES, V21, P169, DOI 10.1016/1043-6618(89)90235-1; SUZUKI T, 1992, FASEB J, V6, P771, DOI 10.1096/fasebj.6.2.1537468; TODA K, 1995, EUR J BIOCHEM, V231, P292, DOI 10.1111/j.1432-1033.1995.tb20699.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUNEOKA Y, 1993, J BIOCHEM, V114, P263, DOI 10.1093/oxfordjournals.jbchem.a124164; WYSS A, 1995, MOL PHARMACOL, V47, P1148	29	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28176	28180		10.1074/jbc.271.45.28176	http://dx.doi.org/10.1074/jbc.271.45.28176			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910433	hybrid			2022-12-25	WOS:A1996VU03300033
J	Singh, J; Su, L; Snow, ET				Singh, J; Su, L; Snow, ET			Replication across O6-methylguanine by human DNA polymerase beta in vitro - Insights into the futile cytotoxic repair and mutagenesis of O6-methylguanine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-CELLS; IN-VITRO; BASE SUBSTITUTION; ESCHERICHIA-COLI; HUMAN-TUMOR; O-6-METHYLGUANINE; GENE; OLIGONUCLEOTIDE; EXCISION; RESIDUES	Replication in vivo across unrepaired O-6-methylguanine (m(6)dG) lesions by mammalian DNA polymerase beta (pol beta) during short patch repair may contribute to the cytotoxicity and mutagenesis of m(6)dG. We have employed in vitro steady state kinetic analysis to investigate the replication of oligonucleotide templates containing site-specific m(6)dG by human pol beta. Our results show that m(6)dG is a strong but not absolute block to replication by pol beta. pol beta exhibits mixed kinetic discrimination during overall replication across dG and m(6)dG. pol beta preferentially inserts dTMP rather than dCMP opposite m(6)dG. However, pol beta extends from the dC-m(6)dG base pair more efficiently than from the dT-m(6)dG base pair. This is in strong contrast to other polymerases such as the exonuclease-deficient Klenow fragment of Escherichia coli DNA polymerase I (exo(-)KF) that preferentially extends dT-m(6)dG by a factor of 10 over dC-m(6)dG. When both insertion and extension are considered, pol beta has a 15-fold overall preference for incorporation of the mutagenic substrate dTTP rather than the nonmutagenic substrate dCTP during replication across m(6)dG. This suggests that pol beta, in concert with the T:G-specific thymine DNA glycosylase, may be intricately involved in the futile cytotoxic repair induced by m(6)dG. Our results also suggest that replication across m(6)dG by pol beta may contribute to m(6)dG-induced G --> A transition mutations.	NYU, MED CTR, NELSON INST ENVIRONM MED, TUXEDO PK, NY 10987 USA	New York University			Snow, Elizabeth T/J-7394-2014	Snow, Elizabeth T/0000-0002-9363-5130	NCI NIH HHS [CA13343] Funding Source: Medline; NIEHS NIH HHS [ES064983, ES001248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES001248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; BHANOT OS, 1986, P NATL ACAD SCI USA, V83, P7348, DOI 10.1073/pnas.83.19.7348; BOOSALIS MS, 1989, J BIOL CHEM, V264, P11360; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; DAY RS, 1980, NATURE, V288, P724, DOI 10.1038/288724a0; DEVEREUX TR, 1993, MOL CARCINOGEN, V8, P177, DOI 10.1002/mc.2940080308; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIGIUSEPPE JA, 1989, BIOCHEMISTRY-US, V28, P9515, DOI 10.1021/bi00450a040; DOBASHI Y, 1994, CANCER RES, V54, P2827; DOSANJH MK, 1991, BIOCHEMISTRY-US, V30, P11595, DOI 10.1021/bi00113a015; DOSANJH MK, 1993, P NATL ACAD SCI USA, V90, P3983, DOI 10.1073/pnas.90.9.3983; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; DUGGLEBY RG, 1981, ANAL BIOCHEM, V110, P9, DOI 10.1016/0003-2697(81)90104-4; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; GOTH R, 1974, Z KREBSFORSCH KLIN O, V82, P37, DOI 10.1007/BF00304382; Grunberger D., 1983, MOL BIOL MUTAGENS CA, P55; HOFFMANN JS, 1995, P NATL ACAD SCI USA, V92, P5356, DOI 10.1073/pnas.92.12.5356; KALNIK MW, 1989, BIOCHEMISTRY-US, V28, P6170, DOI 10.1021/bi00441a008; KAMIYA H, 1991, JPN J CANCER RES, V82, P997, DOI 10.1111/j.1349-7006.1991.tb01934.x; KAMIYA H, 1993, NUCLEIC ACIDS RES, V21, P2355, DOI 10.1093/nar/21.10.2355; KARRAN P, 1993, J BIOL CHEM, V268, P15878; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Korn D, 1983, NEW APPROACHES EUKAR, P17; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1983, BIOCHEMISTRY-US, V22, P2387; LOECHLER EL, 1984, P NATL ACAD SCI-BIOL, V81, P6271, DOI 10.1073/pnas.81.20.6271; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1989, MOL CELL BIOL, V9, P3750, DOI 10.1128/MCB.9.9.3750; MENICHINI P, 1994, MUTAT RES, V307, P53, DOI 10.1016/0027-5107(94)90277-1; MOSBAUGH DW, 1980, J BIOL CHEM, V255, P239; NARAYAN S, 1995, BIOCHEMISTRY-US, V34, P73, DOI 10.1021/bi00001a009; PAINTER RB, 1980, MUTAT RES, V70, P337, DOI 10.1016/0027-5107(80)90023-8; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PATEL DJ, 1986, BIOCHEMISTRY-US, V25, P1027, DOI 10.1021/bi00353a012; PEGG AE, 1990, CANCER RES, V50, P6119; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PERRINO FW, 1990, MUTAT RES, V236, P289, DOI 10.1016/0921-8777(90)90012-T; RANDAHL H, 1988, J BIOL CHEM, V263, P12228; SAMBROOK J, 1989, MOL CLONING LAB MAN, V3; SCANLON KJ, 1991, P NATL ACAD SCI USA, V88, P10591, DOI 10.1073/pnas.88.23.10591; SIBGHATULLAH, 1995, BIOCHEMISTRY-US, V34, P6869, DOI 10.1021/bi00020a034; SIBGHATULLAH, 1993, NUCLEIC ACIDS RES, V21, P1281, DOI 10.1093/nar/21.5.1281; SINGER B, 1989, P NATL ACAD SCI USA, V86, P8271, DOI 10.1073/pnas.86.21.8271; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; SNOW ET, 1984, J BIOL CHEM, V259, P8095; ULLAH S, 1992, BIOCHEMISTRY-US, V31, P7998; VOIGT JM, 1995, CARCINOGENESIS, V16, P1775, DOI 10.1093/carcin/16.8.1775; WANG LM, 1992, CANCER RES, V52, P4824; Werneburg BG, 1996, BIOCHEMISTRY-US, V35, P7041, DOI 10.1021/bi9527202; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WILSON S, 1988, BIOCHIM BIOPHYS ACTA, V949, P149, DOI 10.1016/0167-4781(88)90078-4; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199; YAROSH DB, 1984, MUTAT RES, V131, P27, DOI 10.1016/0167-8817(84)90044-0; YAROSH DB, 1983, CARCINOGENESIS, V4, P199, DOI 10.1093/carcin/4.2.199; ZAIDI NH, 1995, CARCINOGENESIS, V16, P461, DOI 10.1093/carcin/16.3.461	56	38	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28391	28398		10.1074/jbc.271.45.28391	http://dx.doi.org/10.1074/jbc.271.45.28391			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910463	hybrid			2022-12-25	WOS:A1996VU03300063
J	YamamotoHonda, R; Honda, Z; Ueki, K; Tobe, K; Kaburagi, Y; Takahashi, Y; Tamemoto, H; Suzuki, T; Itoh, K; Akanuma, Y; Yazaki, Y; Kadowaki, T				YamamotoHonda, R; Honda, Z; Ueki, K; Tobe, K; Kaburagi, Y; Takahashi, Y; Tamemoto, H; Suzuki, T; Itoh, K; Akanuma, Y; Yazaki, Y; Kadowaki, T			Mutant of insulin receptor substrate-1 incapable of activating phosphatidylinositol 3-kinase did not mediate insulin-stimulated maturation of Xenopus laevis oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; GLYCOGEN-SYNTHASE KINASE-3; SRC HOMOLOGY-2 DOMAINS; PROTEIN-KINASE; MAP KINASE; SIGNAL-TRANSDUCTION; MEIOTIC MATURATION; RAS PROTEINS; S6 KINASE; PHAS-I	Insulin receptor substrate-1 (IRS-1) is rapidly phosphorylated on multiple tyrosine residues in response to insulin and binds several Src homology 2 domain-containing proteins, thereby initiating downstream signaling. To assess the tyrosine phosphorylation sites that mediate relevant downstream signaling and biological effects, we created site-directed mutants of IRS-1 and overexpressed them in the Xenopus laevis oocyte. In oocytes overexpressing IRS-1 or IRS-1-895F (Tyr-895 replaced with phenylalanine), insulin activated phosphatidylinositol (PI) 3-kinase, p70 S6 kinase, and mitogen-activated protein kinase and induced oocyte maturation. In contrast, in oocytes overexpressing IRS-1-4F (Tyr-460, Tyr-608, Tyr-939, and Tyr-987 of IRS-1 replaced with phenylalanine), insulin did not activate PI 3-kinase, p70 S6 kinase, and mitogen-activated protein kinase and failed to induce oocyte maturation. These observations indicate that in X. laevis oocytes overexpressing IRS-1, the association of PI 3-kinase rather than Grb2 (growth factor-bound protein 2) with IRS-1 plays a major role in insulin induced oocyte maturation. Activation of PI 3-kinase may lie upstream of mitogen-activated protein kinase activation and p70 S6 kinase activation in response to insulin.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED & PHYS THERAPY,BUNKYO KU,TOKYO 113,JAPAN; ASAHI LIFE FDN,INST DIABET CARE & RES,CHIYODA KU,TOKYO 100,JAPAN	University of Tokyo; University of Tokyo; Asahi Life Foundation								ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; CHUANG LM, 1994, J BIOL CHEM, V269, P27645; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CUNG J, 1994, NATURE, V370, P71; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; FUKUDA M, 1994, J BIOL CHEM, V269, P33097; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; GRIGORESCU F, 1994, DIABETES, V43, pA3; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HONDA Z, 1995, J BIOL CHEM, V270, P4840, DOI 10.1074/jbc.270.9.4840; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; ITOH F, 1992, EXP MED, V11, P382; JANICOT M, 1991, J BIOL CHEM, V266, P9382; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KORN LJ, 1987, SCIENCE, V236, P1502; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LANE HA, 1992, EMBO J, V11, P1743, DOI 10.1002/j.1460-2075.1992.tb05226.x; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIU XJ, 1995, MOL CELL BIOL, V15, P3563; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MATSUOKA K, 1993, EMBO J, V12, P3467; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PONS S, 1995, MOL CELL BIOL, V15, P4453; ROCCHI S, 1995, ENDOCRINOLOGY, V136, P5291, DOI 10.1210/en.136.12.5291; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TOBE K, 1993, J BIOL CHEM, V268, P11167; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107	53	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28677	28681		10.1074/jbc.271.45.28677	http://dx.doi.org/10.1074/jbc.271.45.28677			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910502	hybrid			2022-12-25	WOS:A1996VU03300102
J	Escola, JM; Deleuil, F; Stang, E; Boretto, J; Chavrier, P; Gorvel, JP				Escola, JM; Deleuil, F; Stang, E; Boretto, J; Chavrier, P; Gorvel, JP			Characterization of a lysozyme major histocompatibility complex class II molecule-loading compartment as a specialized recycling endosome in murine B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; RECEPTOR-MEDIATED ENDOCYTOSIS; INVARIANT-CHAIN; IMMUNOELECTRON MICROSCOPY; INTRACELLULAR-TRANSPORT; CARCINOMA A431-CELLS; TRANSFERRIN RECEPTOR; SURFACE EXPRESSION; CARRIER VESICLES; FUSION INVITRO	We have previously identified an intracellular compartment involved in the association between processed lysozyme and IA(k) major histocompatibility complex class II molecules (called the lysozyme-loading compartment (LLC)), Here, we show that She LLC polypeptide composition analyzed by two-dimensional gel electrophoresis shares similarities with that of early endosomes, but not with that of late endosomes, The transferrin receptor, a well known marker for both early and recycling endosomes, colocalizes with IA(k) molecules in LLC. Moreover, both transferrin and fluid-phase markers have access to LLC after 15 min of internalization. In the presence of concanamycin B, SDS-stable dimer formation and transport of class II molecules out of LLC are impaired, In contrast, nocodazole treatment has no effect. These results suggest that LLC is a specialized compartment of the recycling pathway involved in lysozyme loading and in the targeting of lysozyme-major histocompatibility class II complexes toward the cell surface.	CNRS, INSERM, CTR IMMUNOL, F-13288 MARSEILLE 09, FRANCE; UNIV OSLO, DEPT BIOL, ELECTRON MICROSCOPY UNIT BIOL SCI, N-0316 OSLO, NORWAY	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Oslo			CHAVRIER, Philippe/AAG-2645-2020; CHAVRIER, Philippe/B-4707-2010; Gorvel, Jean-Pierre/O-1332-2018	CHAVRIER, Philippe/0000-0002-7351-733X; CHAVRIER, Philippe/0000-0002-7351-733X; Gorvel, Jean-Pierre/0000-0002-2829-9804				AMIGORENA S, 1995, J EXP MED, V181, P1729, DOI 10.1084/jem.181.5.1729; AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BENAROCH P, 1995, EMBO J, V14, P37, DOI 10.1002/j.1460-2075.1995.tb06973.x; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRAVO R, 1984, 2 DIMENSIONAL GEL EL, P3; CALAFAT J, 1994, J CELL BIOL, V126, P967, DOI 10.1083/jcb.126.4.967; CASTELLINO F, 1995, IMMUNITY, V2, P73, DOI 10.1016/1074-7613(95)90080-2; CELIS JE, 1990, ELECTROPHORESIS, V11, P989, DOI 10.1002/elps.1150111202; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; CRESSWELL P, 1985, P NATL ACAD SCI USA, V82, P8188, DOI 10.1073/pnas.82.23.8188; DABORA SL, 1988, CELL, V54, P27, DOI 10.1016/0092-8674(88)90176-6; DEBRABANDER M, 1988, CELL MOTIL CYTOSKEL, V9, P30, DOI 10.1002/cm.970090105; ESCOLA JM, 1995, J CELL SCI, V108, P2337; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GHOSH RN, 1994, J CELL SCI, V107, P2177; GRIFFITHS G, 1983, METHOD ENZYMOL, V96, P466; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HARDER T, 1993, J CELL BIOL, V123, P1119, DOI 10.1083/jcb.123.5.1119; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; KLEIJMEER MJ, 1994, J INVEST DERMATOL, V103, P516, DOI 10.1111/1523-1747.ep12395666; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KLIONSKY DJ, 1992, J BIOL CHEM, V267, P3416; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; LIN J, 1988, J MOL CELL IMMUNOL, V3, P321; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MARIC MA, 1994, P NATL ACAD SCI USA, V91, P2171, DOI 10.1073/pnas.91.6.2171; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MERESSE S, 1995, J CELL SCI, V108, P3349; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NIJMAN HW, 1995, J EXP MED, V182, P163, DOI 10.1084/jem.182.1.163; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Robinson MS, 1996, CELL, V84, P13, DOI 10.1016/S0092-8674(00)80988-5; ROMAGNOLI P, 1993, J EXP MED, V177, P583, DOI 10.1084/jem.177.3.583; RUDENSKY AY, 1994, IMMUNITY, V1, P585, DOI 10.1016/1074-7613(94)90048-5; SIMONSEN A, 1993, INT IMMUNOL, V5, P903, DOI 10.1093/intimm/5.8.903; SUNG E, 1981, MOL IMMUNOL, V18, P899, DOI 10.1016/0161-5890(81)90013-4; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; TURNER JR, 1989, J CELL BIOL, V109, P2081, DOI 10.1083/jcb.109.5.2081; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; ZACHGO S, 1992, J CELL SCI, V103, P811	60	16	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27360	27365		10.1074/jbc.271.44.27360	http://dx.doi.org/10.1074/jbc.271.44.27360			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910313	hybrid			2022-12-25	WOS:A1996VQ67900031
J	Pathan, NI; Geahlen, RL; Harrison, ML				Pathan, NI; Geahlen, RL; Harrison, ML			The protein-tyrosine kinase Lck associates with and is phosphorylated by Cdc2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; CYCLIN-DEPENDENT KINASES; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; CROSS-LINKING; LYMPHOCYTES-T; B-LYMPHOCYTES; CD4 RECEPTOR; SH2 DOMAIN; C-SRC	The protein-tyrosine kinase Lck is essential for signaling through the T-cell antigen receptor, Treatment of T-cells with a variety of extracellular stimuli increases the phosphorylation of Lck on serine residues, This results in shifts in the apparent molecular weight of Lck to forms that exhibit reduced electrophoretic mobility on SDS-polyacrylamide gels, We found that as a result of arresting cells in mitosis, forms of Lck were generated that migrated with slower mobilities on SDS-polyacrylamide gels, This suggested that a serine/threonine kinase, active at mitosis, was phosphorylating Lck, Using antibodies to Lck and to the cyclin-dependent serine kinase, Cdc2, as well as the cyclin-dependent kinase affinity resin, Suc1-agarose, we detected a stable interaction between Lck and Cdc2, The interaction was mediated through the Src homology 3 domain of Lck and was selective, as only the active form of Cdc2 was found to associate with Lck, Moreover, Cdc2 was able to phosphorylate Lck in vitro and shift its electrophoretic mobility to a more slowly migrating form, An association between active Cdc2 and the Src-related kinases Lyn and Fyn was also demonstrated, although Cdc2 was not found associated with the tyrosine kinases, Csk and Syk, These results demonstrate that at mitosis, Cdc2 associates with and phosphorylates Lck.	PURDUE UNIV,DEPT MED CHEM & MOL PHARMACOL,W LAFAYETTE,IN 47907; PURDUE UNIV,DEPT BIOL,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus				Geahlen, Robert/0000-0001-8400-2924	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048099] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48099] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; CARRERA AC, 1995, J BIOL CHEM, V270, P3385, DOI 10.1074/jbc.270.7.3385; CASNELLIE JE, 1986, J BIOL CHEM, V261, P4921; CASNELLIE JE, 1983, J BIOL CHEM, V258, P738; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P552; CHURCHER Y, 1993, J BIOL CHEM, V268, P26144; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DANIELIAN S, 1989, EUR J IMMUNOL, V19, P2183, DOI 10.1002/eji.1830191202; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; EINSPAHR KJ, 1990, J IMMUNOL, V145, P1490; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FORD CE, 1994, J BIOL CHEM, V269, P30378; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOLD MR, 1994, J IMMUNOL, V153, P2369; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; HOWE LR, 1995, TRENDS BIOCHEM SCI, V20, P59, DOI 10.1016/S0968-0004(00)88958-6; HURLEY TR, 1989, ONCOGENE, V4, P265; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KHARBANDA S, 1994, ONCOGENE, V9, P3005; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; KIM YH, 1992, J IMMUNOL, V149, P17; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; LUO K, 1990, ONCOGENE, V5, P803; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARIECARDINE A, 1994, EUR J IMMUNOL, V24, P1255, DOI 10.1002/eji.1830240603; MARTH JD, 1989, J IMMUNOL, V142, P2430; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PERI KG, 1993, ONCOGENE, V8, P2765; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SEFTON BM, 1991, ONCOGENE, V6, P683; SEFTON BM, 1994, CURR OPIN IMMUNOL, V6, P372, DOI 10.1016/0952-7915(94)90115-5; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; SOULA M, 1993, J BIOL CHEM, V268, P27420; SRINIVAS PR, 1991, ALLERGY IMMUNOL, V10, P61; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; WANG QM, 1991, BIOCHEM J, V279, P567, DOI 10.1042/bj2790567; WATTS JD, 1993, J BIOL CHEM, V268, P23275; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WINKLER DG, 1993, P NATL ACAD SCI USA, V90, P5176, DOI 10.1073/pnas.90.11.5176; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N; YUAN ZM, 1995, BIOCHEMISTRY-US, V34, P1058, DOI 10.1021/bi00003a041; ZIONCHECK TF, 1988, J BIOL CHEM, V263, P19195	66	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27517	27523		10.1074/jbc.271.44.27517	http://dx.doi.org/10.1074/jbc.271.44.27517			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910336	hybrid			2022-12-25	WOS:A1996VQ67900054
J	Reynolds, JE; Eastman, A				Reynolds, JE; Eastman, A			Intracellular calcium stores are not required for Bcl-2-mediated protection from apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; ENDONUCLEASE ACTIVATION; C-MYC; DNA FRAGMENTATION; IN-VITRO; BCL-2; CA-2+; THYMOCYTES; PROTEIN; OXYGEN	The ability of Bcl-2 to inhibit cell death is well documented but its mechanism of action remains elusive. Recent reports have suggested that Bcl-2 prevents apoptosis by inhibiting the release of Ca2+ from the thapsigargin-sensitive Ca2+ store. The mobilization of Ca2+ from this store has been implicated as a signal regulating apoptotic cell death induced by glucocorticoids and by interleukin-3 withdrawal, The present study was designed to determine if Bcl-2 would still inhibit apoptosis after depletion of intracellular Ca2+ stores. We compared the response of two Chinese hamster ovary cell lines (5AHSmyc and 5A300bcl-2.2) following incubation with the calcium ionophore ionomycin to deplete intracellular Ca2+ stores. Continued incubation of 5AHSmyc cells in calcium-free media induced substantial apoptotic DNA fragmentation within 4 h and >95% loss of viability within 48 h. However, 5A300bcl-2.2 cells showed no evidence of DNA fragmentation or loss of viability over the same time period. Intracellular Ca2+ was analyzed with the Ca2+-sensitive fluorescent dye INDO-1 and confirmed that ionomycin was capable of releasing Ca2+ from intracellular stores in both cell lines. These results show that depletion of intracellular Ca2+ stores induces apoptosis and that these Ca2+ stores are not required for the protection afforded by Bcl-2.	DARTMOUTH COLL SCH MED,DEPT PHARMACOL,HANOVER,NH 03755	Dartmouth College					NCI NIH HHS [CA23108, CA50224] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA050224, R01CA050224, P30CA023108] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; BARRY MA, 1993, CANCER RES, V53, P2349; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; BISONETTE RP, 1992, NATURE, V359, P552; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; COHEN JJ, 1984, J IMMUNOL, V132, P38; Distelhorst CW, 1996, ONCOGENE, V12, P2051; EARNSHAW WC, 1995, TRENDS CELL BIOL, V5, P217, DOI 10.1016/S0962-8924(00)89006-6; EASTMAN A, 1993, TOXICOL APPL PHARM, V121, P160, DOI 10.1006/taap.1993.1141; EASTMAN A, 1992, CANCER INVEST, V10, P229, DOI 10.3109/07357909209032765; EASTMAN A, 1995, METHOD CELL BIOL, V46, P41; EASTMAN A, 1995, SEMIN CANCER BIOL, V6, P45, DOI 10.1006/scbi.1995.0006; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; JONES DP, 1989, J BIOL CHEM, V264, P6398; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANEKO Y, 1994, CANCER LETT, V97, P147; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KLUCK RM, 1994, BBA-MOL CELL RES, V1223, P247, DOI 10.1016/0167-4889(94)90233-X; LAM M, 1993, MOL ENDOCRINOL, V7, P686, DOI 10.1210/me.7.5.686; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; MARTIKAINEN P, 1991, CANCER RES, V51, P4693; MARTIN SJ, 1995, CELL, V82, P348; MASON MJ, 1993, BIOCHEM J, V296, P33, DOI 10.1042/bj2960033; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MCCONKEY DJ, 1990, FASEB J, V4, P2661, DOI 10.1096/fasebj.4.9.2347464; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; MUSCHEL RJ, 1995, CANCER RES, V55, P995; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NIKONOVA LV, 1982, BIOCHIM BIOPHYS ACTA, V699, P281, DOI 10.1016/0167-4781(82)90118-X; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; REYNOLDS JE, 1994, CANCER RES, V54, P6348; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; STBIRD GJ, 1992, J BIOL CHEM, V267, P18382; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WANG HG, 1994, ONCOGENE, V9, P2751; WURM FM, 1986, P NATL ACAD SCI USA, V83, P5414, DOI 10.1073/pnas.83.15.5414; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHIVOTOVSKY B, 1993, EXP CELL RES, V207, P163, DOI 10.1006/excr.1993.1176	52	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27739	27743		10.1074/jbc.271.44.27739	http://dx.doi.org/10.1074/jbc.271.44.27739			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910367	hybrid			2022-12-25	WOS:A1996VQ67900085
J	VanCriekinge, W; Beyaert, R; VandeCraen, M; Vandenabeele, P; Schotte, P; DeValck, D; Fiers, W				VanCriekinge, W; Beyaert, R; VandeCraen, M; Vandenabeele, P; Schotte, P; DeValck, D; Fiers, W			Functional characterization of the prodomain of interleukin-1 beta-converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CONVERTING-ENZYME; IL-1-BETA-CONVERTING ENZYME; CYSTEINE PROTEASE; MAMMALIAN HOMOLOG; MICE DEFICIENT; GENE CED-3; APOPTOSIS; IL-1-BETA; ICE	Interleukin 1 beta-converting enzyme (ICE) has been identified as the main protease responsible for maturation of the prodomain of interleukin-1 beta. Recently, it was shown to belong to a larger gene family, members of which play an important role in programmed cell death. A common feature of the ICE family proteases is the presence of a prodomain that has been hypothesized to keep the enzyme in an inactive form. Expression analysis in yeast revealed autocatalytic degradation of p45ICE, but not of p30ICE lacking a prodomain. We further demonstrate that p45ICE, in which the critical cysteine has been mutated, is still able to dimerize in vivo, Dimerization requires the prodomain and occurs prior to autoprocessing. These results provide evidence for a regulatory role of the prodomain of ICE.	FLANDERS INTERUNIV INST BIOTECHNOL,MOL BIOL LAB,B-9000 GHENT,BELGIUM; STATE UNIV GHENT,B-9000 GHENT,BELGIUM	Ghent University			Beyaert, Rudi/B-2589-2009; Vandenabeele, Peter/C-8597-2009; Vandenabeele, Peter/AAD-5793-2022	Vandenabeele, Peter/0000-0002-6669-8822; Beyaert, Rudi/0000-0002-5704-582X				Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BLACK RA, 1988, J BIOL CHEM, V263, P9437; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; DINARELLO CA, 1994, EUR CYTOKINE NETW, V5, P517; DUAN H, 1996, J BIOL CHEM, V271, P35013; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HOWARD AD, 1995, J IMMUNOL, V154, P2321; JACOBSON MD, 1994, CURR BIOL, V4, P337, DOI 10.1016/S0960-9822(00)00073-7; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MILLER DK, 1993, J BIOL CHEM, V268, P18062; Miossec C, 1996, EUR J IMMUNOL, V26, P1032, DOI 10.1002/eji.1830260512; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NALIN CM, 1995, STRUCTURE, V3, P143, DOI 10.1016/S0969-2126(01)00144-7; NUNEZ G, 1994, IMMUNOL TODAY, V15, P582, DOI 10.1016/0167-5699(94)90221-6; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WHYTE M, 1995, NATURE, V376, P17, DOI 10.1038/376017a0; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yin X M, 1995, Curr Top Microbiol Immunol, V194, P331	40	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27245	27248		10.1074/jbc.271.44.27245	http://dx.doi.org/10.1074/jbc.271.44.27245			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910297	hybrid			2022-12-25	WOS:A1996VQ67900015
J	Weinstein, J; Sundaram, S; Wang, XH; Delgado, D; Basu, R; Stanley, P				Weinstein, J; Sundaram, S; Wang, XH; Delgado, D; Basu, R; Stanley, P			A point mutation causes mistargeting of Golgi GlcNAc-TV in the Lec4A Chinese hamster ovary glycosylation mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-V; NH2-TERMINAL SIGNAL ANCHOR; LINKED OLIGOSACCHARIDES; ENDOPLASMIC-RETICULUM; CELL-SURFACE; CHO CELLS; PROTEIN; GLYCOSYLTRANSFERASES; EXPRESSION; GENE	The Lec4A and Lec4 Chinese hamster ovary glycosylation mutants lack N-linked glycans with GlcNAc beta-(1,6)Man alpha(1,6) branches that are initiated by the transferase termed GlcNAc-TV. Detergent extracts of Lec4 cells have no detectable GlcNAc-TV activity, but Lec4A extracts have activity equivalent to that of parental Chinese hamster ovary cells. This discrepancy occurs because Lec4A GlcNAc-TV activity co-localizes with membranes of the endoplasmic reticulum (ER) instead of with Golgi membranes (Chaney, W., Sundaram, S,, Friedman, N,, and Stanley, P, (1989) J, Cell, Biol, 109, 2089-2096), cDNAs from the coding region of the GlcNAc-TV gene have now been isolated from each mutant line. Lec4 GlcNAc-TV cDNA was found to possess two insertions, the first of which shifts the open reading frame and codes for a truncated transferase missing 585 amino acids from the catalytic domain. By contrast, Lec4A GlcNAc-TV cDNA possesses a single point mutation from T to G, which results in a change from Leu to Arg at position 188. When transfected into Lec4 cells, both cDNAs gave the appropriate phenotype; Lec4 cDNA was unable to restore GlcNAc-TV activity, whereas Lec4A cDNA converted Lec4 cells to the Lec4A. phenotype, with an active GlcNAc-TV mislocalized to ER membranes. Moreover Lec4A cDNA cured of its mutation restored a functional, Golgi-localized GlcNAc-TV to Lec4 cells. The results demonstrate that a single change in the 740 amino acids of GlcNAc-TV serves to functionally inactivate the transferase in an intact cell by causing it to localize to the En instead of the Golgi compartment. The mislocalized transferase retains full enzyme activity, showing that it is well folded and stable and suggesting that the L188R mutation either prevents association with exit complexes from the ER or causes retrograde transport from a Golgi compartment.	AMGEN INC, THOUSAND OAKS, CA 91320 USA; ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, NEW YORK, NY 10461 USA	Amgen; Yeshiva University				Stanley, Pamela/0000-0001-5704-3747	PHS HHS [R01 36434, R01 13330] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CHANEY W, 1989, J CELL BIOL, V109, P2089, DOI 10.1083/jcb.109.5.2089; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; CORNIL I, 1990, J CELL BIOL, V111, P773, DOI 10.1083/jcb.111.2.773; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; GARDNER AM, 1993, J BIOL CHEM, V268, P25940; GLEESON PA, 1994, GLYCOCONJUGATE J, V11, P381, DOI 10.1007/BF00731273; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KAHN SH, 1993, J BIOL CHEM, V268, P2468; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUMAR R, 1990, MOL CELL BIOL, V10, P3857; KUMAR R, 1989, MOL CELL BIOL, V9, P5713, DOI 10.1128/MCB.9.12.5713; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Ma JY, 1996, J BIOL CHEM, V271, P7758, DOI 10.1074/jbc.271.13.7758; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PELTOLA M, 1994, HUM MOL GENET, V3, P2237, DOI 10.1093/hmg/3.12.2237; PERNG GS, 1994, GLYCOBIOLOGY, V4, P867, DOI 10.1093/glycob/4.6.867; RACCHI M, 1993, J BIOL CHEM, V268, P5735; SAITO H, 1994, BIOCHEM BIOPH RES CO, V198, P318, DOI 10.1006/bbrc.1994.1045; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; SIFERS RN, 1988, J BIOL CHEM, V263, P7330; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; STANLEY P, 1983, METHOD ENZYMOL, V96, P157; STANLEY P, 1981, CELL, V23, P763, DOI 10.1016/0092-8674(81)90440-2; STANLEY P, 1982, ARCH BIOCHEM BIOPHYS, V219, P128, DOI 10.1016/0003-9861(82)90141-2; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963	36	25	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27462	27469		10.1074/jbc.271.44.27462	http://dx.doi.org/10.1074/jbc.271.44.27462			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910328	hybrid			2022-12-25	WOS:A1996VQ67900046
J	Brzeska, H; Szczepanowska, J; Hoey, J; Korn, ED				Brzeska, H; Szczepanowska, J; Hoey, J; Korn, ED			The catalytic domain of Acanthamoeba myosin I heavy chain kinase .2. Expression of active catalytic domain and sequence homology to p21-activated kinase (PAK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PHOSPHORYLATION SITES; CRYSTAL-STRUCTURE; AMINO-ACID; MAP KINASE; ACTIVATION; AUTOPHOSPHORYLATION; SUBUNIT; CDC42; LOCALIZATION	Acanthamoeba myosin I heavy chain (MIHC) kinase is a monomeric 97-kDa protein that is activated by binding to acidic phospholipids or by autophosphorylation. Activation by phospholipids is inhibited by Ca2+-calmodulin. In the accompanying paper (Brzeska, H., Martin, B., and Korn, E. D. (1996) J. Biol. Chem. 271, 27049-27055), we identified the catalytic domain as the COOH-terminal 35 kDa produced by trypsin digestion of phosphorylated MIHC kinase, In this paper, we report the cloning and sequencing of the corresponding cDNA and expression of fully active catalytic domain. The expressed catalytic domain has substrate specificity similar to that of native kinase and resistance to trypsin similar to that of fully phosphorylated MIHC kinase, MIHC kinase catalytic domain has only 25% sequence identity to the catalytic domain of protein kinase A and similarly low sequence identity to the catalytic domains of protein kinase C- and calmodulin-dependent kinases, but 50% sequence identity and 70% similarity to the p21-activated kinase (PAK) and STE20 family of kinases. This suggests that MIHC kinase is (at least) evolutionarily related to the PAK family, whose activities are regulated by small GTP-binding proteins, The homology includes the presence of a potential MIHC kinase autophosphorylation site as well as conserved Tyr and Ser/Thr residues in the region corresponding to the P+1 loop of protein kinase A. A synthetic peptide corresponding to this region of MIHC kinase is phosphorylated by both the expressed catalytic domain and native MIHC kinase.	NHLBI,NIH,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Korn, Edward D/F-9929-2012	Szczepanowska, Joanna/0000-0002-0434-1262; Korn, Edward/0000-0003-3867-6295				ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BAINES IC, 1995, J CELL BIOL, V130, P591, DOI 10.1083/jcb.130.3.591; BENNER GE, 1995, J BIOL CHEM, V270, P21121, DOI 10.1074/jbc.270.36.21121; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; BRZESKA H, 1990, J BIOL CHEM, V265, P16138; BRZESKA H, 1992, J BIOL CHEM, V267, P23870; BRZESKA H, 1990, J BIOL CHEM, V265, P3591; Brzeska H, 1996, J BIOL CHEM, V271, P16983, DOI 10.1074/jbc.271.29.16983; BRZESKA H, 1992, J BIOL CHEM, V267, P4949; Brzeska H, 1996, J BIOL CHEM, V271, P27049, DOI 10.1074/jbc.271.43.27049; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; HAMMER JA, 1984, J BIOL CHEM, V259, P3224; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Higuchi R., 1989, PCR TECHNOLOGY, P61; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lee S. F., 1995, Molecular Biology of the Cell, V6, p149A; Lee SF, 1996, J BIOL CHEM, V271, P27044, DOI 10.1074/jbc.271.43.27044; LEE SF, 1995, J BIOL CHEM, V270, P11776, DOI 10.1074/jbc.270.20.11776; LYNCH TJ, 1989, J BIOL CHEM, V264, P19333; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Masaracchia R, 1996, FASEB J, V10, P1538; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; SHOJI S, 1979, J BIOL CHEM, V254, P6211; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; WANG ZY, 1995, J BIOL CHEM, V270, P27969, DOI 10.1074/jbc.270.46.27969; YONEMOTO W, 1993, J BIOL CHEM, V268, P18626; ZHANG B, 1991, J BIOL CHEM, V266, P990; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	43	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27056	27062		10.1074/jbc.271.43.27056	http://dx.doi.org/10.1074/jbc.271.43.27056			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900196				2022-12-25	WOS:A1996VP23300090
J	Kumble, KD; Kornberg, A				Kumble, KD; Kornberg, A			Endopolyphosphatases for long chain inorganic polyphosphate in yeast and mammals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PROPIONIBACTERIUM-SHERMANII; EXOPOLYPHOSPHATASE; PURIFICATION; KINASE; GENE; GLUCOKINASE; MECHANISM; PROTEIN	Whereas exopolyphosphatases have been purified from yeast and a variety of bacteria, this is the first report characterizing endopolyphosphatases that act on long chain inorganic polyphosphate (polyP). The activity from Saccharomyces cerevisiae, localized in vacuoles, has been purified to homogeneity from a strain that possesses vacuolar proteases. The endopolyphosphatase is a dimer of 35-kDa subunits. Distributive action on polyP(750) produces shorter chains to a limit of about polyP(60), as well as the more abundant release of polyP(3); the K-m for polyP(750) is 185 nM. Endopolyphosphatases have been identified in a wide variety of sources, except for most eubacteria tested. The activity has been partially purified from rat and bovine brain where its abundance is about 10 times higher than in other tissues but less than 1/10 that of yeast; the limit product of digestion of the partially purified brain enzyme is polyP(3).	STANFORD UNIV, SCH MED, BECKMAN CTR, DEPT BIOCHEM, STANFORD, CA 94305 USA	Stanford University								AHN KH, 1990, J BIOL CHEM, V265, P11734; AKIYAMA M, 1993, J BIOL CHEM, V268, P633; AKIYAMA M, 1992, J BIOL CHEM, V267, P22556; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; GABEL N W, 1990, Evolutionary Theory, V9, P181; INGELMAN B, 1947, ACTA CHEM SCAND, V1, P422, DOI 10.3891/acta.chem.scand.01-0422; JAZWINSKI SM, 1990, METHOD ENZYMOL, V182, P154; KEASLING JD, 1993, P NATL ACAD SCI USA, V90, P7029, DOI 10.1073/pnas.90.15.7029; KORNBERG A, 1995, J BACTERIOL, V177, P491, DOI 10.1128/jb.177.3.491-496.1995; KORNBERG SR, 1956, J BIOL CHEM, V218, P23; KOWALCZYK TH, 1993, ANAL BIOCHEM, V212, P194, DOI 10.1006/abio.1993.1312; KOWALCZYK TH, 1991, FASEB J, V5, P288; KRISHNAN PS, 1952, ARCH BIOCHEM BIOPHYS, V37, P224, DOI 10.1016/0003-9861(52)90180-X; KRITSKII MS, 1972, BIOCHEMISTRY-US, V37, P822; KULAEV I S, 1971, Biochemistry (Moscow), V36, P356; Kulaev IS, 1979, BIOCH INORGANIC POLY; KUMBLE KD, 1995, J BIOL CHEM, V270, P5818, DOI 10.1074/jbc.270.11.5818; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGEN P, 1958, BIOCHEM Z, V330, P455; LORENZ B, 1994, J BIOL CHEM, V269, P22198; MATTENHEIMER H, 1956, HOPPESEYLER Z PHYSL, V303, P11; MERRIL CR, 1990, METHOD ENZYMOL, V182, P477; MUHAMMED A, 1959, J GEN MICROBIOL, V20, P482, DOI 10.1099/00221287-20-3-482; MURATA K, 1980, AGR BIOL CHEM TOKYO, V44, P61, DOI 10.1080/00021369.1980.10863915; PEPIN CA, 1986, J BIOL CHEM, V261, P4476; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROBINSON NA, 1986, J BIOL CHEM, V261, P4481; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; TINSLEY CR, 1993, INFECT IMMUN, V61, P3703, DOI 10.1128/IAI.61.9.3703-3710.1993; URECH K, 1978, ARCH MICROBIOL, V116, P275, DOI 10.1007/BF00417851; VANGROENESTIJN JW, 1987, ARCH MICROBIOL, V148, P14, DOI 10.1007/BF00429640; WIECKOWSKI EU, 1991, FASEB J, V5, P290; WURST H, 1994, J BIOL CHEM, V269, P10996; WURST H, 1995, J BACTERIOL, V177, P898, DOI 10.1128/jb.177.4.898-906.1995	34	92	101	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27146	27151		10.1074/jbc.271.43.27146	http://dx.doi.org/10.1074/jbc.271.43.27146			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900207	hybrid			2022-12-25	WOS:A1996VP23300101
J	Towner, JS; Ho, TV; Semler, BL				Towner, JS; Ho, TV; Semler, BL			Determinants of membrane association for poliovirus protein RAB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; RNA REPLICATION; CYTOPLASMIC MEMBRANES; MICROSOMAL-MEMBRANES; VIRAL REPLICATION; 3AB; CYTOCHROME-B5; TOPOGRAPHY; EXPRESSION; POLYMERASE	Poliovirus protein 3AB may serve as the lipophilic carrier of a, protein primer (VPg or 3B) used for the initiation of genomic viral RNA synthesis, Tn order to study the membrane-protein interactions of 3AB required for its role in poliovirus RNA replication, we have developed an in vitro a membrane association assay capable of distinguishing membrane-bound from nonmembrane-bound proteins that are cotranslated together in the presence of canine microsomal membranes. This assay utilizes equilibrium sedimentation analysis in high density sucrose gradients to measure membrane association of both wild type and mutated Terms of 3AB, Using this assay and other biochemical assays, we have identified the following properties of the 3AB-membrane interaction: (a) 3AB is able to post-translationally associate with microsomal membraues, (b) 3AB is able to associate with membranes in a manner consistent with that of an integral membrane protein, (c) 3AB contains a critical hydrophobic sequence within the carboxyl-terminal half of the protein that is required for membrane association, and (d) the introduction of charged residues into this hydrophobic sequence disrupts the 3AB membrane-protein interaction, Taken together, these studies indicate that poliovirus protein 3AB associates tightly with biological membranes de novo in a manner that would allow it to serve as a lipophilic anchor for the assembly of the poliovirus RNA replication complex.	UNIV CALIF IRVINE,COLL MED,DEPT MICROBIOL & MOL GENET,IRVINE,CA 92697	University of California System; University of California Irvine			Semler, Bert/AAV-8795-2020; Towner, Jonathan/ABC-3780-2020	Semler, Bert/0000-0002-2424-5155; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022693] Funding Source: NIH RePORTER; NIAID NIH HHS [AI22693, R01 AI022693] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON DJ, 1983, P NATL ACAD SCI-BIOL, V80, P7249, DOI 10.1073/pnas.80.23.7249; ARINC E, 1987, J BIOL CHEM, V262, P15563; BIENZ K, 1992, J VIROL, V66, P2740, DOI 10.1128/JVI.66.5.2740-2747.1992; BIENZ K, 1987, VIROLOGY, V160, P220, DOI 10.1016/0042-6822(87)90063-8; BIENZ K, 1990, J VIROL, V64, P1156, DOI 10.1128/JVI.64.3.1156-1163.1990; CALIGUIRI LA, 1970, VIROLOGY, V42, P100, DOI 10.1016/0042-6822(70)90242-4; CALIGUIRI LA, 1970, VIROLOGY, V42, P112, DOI 10.1016/0042-6822(70)90243-6; CALIGUIRI LA, 1969, SCIENCE, V166, P885, DOI 10.1126/science.166.3907.885; CHARINI WA, 1991, J VIROL, V65, P2655, DOI 10.1128/JVI.65.5.2655-2665.1991; DAILEY HA, 1981, J BIOL CHEM, V256, P3951; DATTA U, 1994, J VIROL, V68, P4468, DOI 10.1128/JVI.68.7.4468-4477.1994; ECHEVERRI AC, 1995, VIROLOGY, V208, P540, DOI 10.1006/viro.1995.1185; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FROSHAUER S, 1988, J CELL BIOL, V107, P2075, DOI 10.1083/jcb.107.6.2075; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GIACHETTI C, 1991, J VIROL, V65, P2647, DOI 10.1128/JVI.65.5.2647-2654.1991; GIACHETTI C, 1990, NEW ASPECTS OF POSITIVE-STRAND RNA VIRUSES, P83; GIACHETTI C, 1992, J VIROL, V66, P6045, DOI 10.1128/JVI.66.10.6045-6057.1992; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; HARRIS KS, 1994, J BIOL CHEM, V269, P27004; JENNINGS ML, 1989, ANNU REV BIOCHEM, V58, P999; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMA J, 1994, J BIOL CHEM, V269, P66; LAMA J, 1992, J BIOL CHEM, V267, P15932; LAMA J, 1995, J BIOL CHEM, V270, P14430, DOI 10.1074/jbc.270.24.14430; LI SC, 1992, FEBS LETT, V311, P217, DOI 10.1016/0014-5793(92)81106-V; LI SC, 1994, NAT STRUCT BIOL, V1, P558; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; PAUL AV, 1994, VIROLOGY, V199, P188, DOI 10.1006/viro.1994.1111; PLOTCH SJ, 1995, J VIROL, V69, P7169, DOI 10.1128/JVI.69.11.7169-7179.1995; RATNAM M, 1986, BIOCHEMISTRY-US, V25, P2633, DOI 10.1021/bi00357a052; RESTREPOHARTWIG MA, 1994, J VIROL, V68, P2388, DOI 10.1128/JVI.68.4.2388-2397.1994; Sankaram M.B., 1993, NEW COMPREHENSIVE BI, VVolume 25, P127; SEMLER BL, 1982, CELL, V28, P405, DOI 10.1016/0092-8674(82)90358-0; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; Singer S. J., 1971, STRUCTURE FUNCTION B, P145; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; TAKEGAMI T, 1983, VIROLOGY, V128, P33, DOI 10.1016/0042-6822(83)90316-1; TERSHAK DR, 1984, J VIROL, V52, P777, DOI 10.1128/JVI.52.3.777-783.1984; WALTER P, 1983, METHOD ENZYMOL, V96, P84; Whitley P, 1996, J BIOL CHEM, V271, P7583, DOI 10.1074/jbc.271.13.7583; XIANG WK, 1995, J VIROL, V69, P3658, DOI 10.1128/JVI.69.6.3658-3667.1995; Xiang WK, 1995, RNA, V1, P892; YU J, 1973, Journal of Supramolecular Structure, V1, P233, DOI 10.1002/jss.400010308	45	123	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26810	26818		10.1074/jbc.271.43.26810	http://dx.doi.org/10.1074/jbc.271.43.26810			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900162	hybrid			2022-12-25	WOS:A1996VP23300056
J	Weng, GZ; Li, JR; Dingus, J; Hildebrandt, JD; Weinstein, H; Iyengar, R				Weng, GZ; Li, JR; Dingus, J; Hildebrandt, JD; Weinstein, H; Iyengar, R			G beta subunit interacts with a peptide encoding region 956-982 of adenylyl cyclase 2 - Cross-linking of the peptide to free G beta gamma but not the heterotrimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEINS; SIGNALS; ALPHA	The region encoded by amino acids 956-982 of adenylyl cyclase 2 is important for G beta gamma stimulation. Interactions of a peptide encoding the 956-982 region of adenylyl cyclase 2 (QEHAQEPERQYMHIGTMVEFAYALVGK (QEHA peptide)) with G beta gamma subunits were studied, QEHA peptide was covalently attached to beta subunit of free G beta gamma by the cross-linker N-succinimidyl(4-iodoacetyl)aminobenzoate. Cross-linking was proportional to the amount of QEHA peptide added; other control peptides crosslinked minimally. When G(o) was used, very little crosslinking was observed with GDP and EDTA, but upon activation by guanosine 5'-3-O-(thio)triphosphate and Mg2+, specific cross-linking of the QEHA peptide to G beta was observed. We conclude that beta subunits of G proteins contain effector interaction domains that are occluded by G alpha subunits in the heterotrimer. Molecular modeling studies used to dock the QEHA peptide on to G beta indicate that amino acids 75-165 of G beta may be involved in effector interactions.	CUNY MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029; MED UNIV S CAROLINA,DEPT PHARMACOL,CHARLESTON,SC 29425	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Medical University of South Carolina	Weng, GZ (corresponding author), CUNY MT SINAI SCH MED,DEPT PHARMACOL,BOX 1215,NEW YORK,NY 10029, USA.		WEINSTEIN, HAREL/O-8245-2019	WEINSTEIN, HAREL/0000-0003-3473-9818	NIDDK NIH HHS [DK37219, DK38761] Funding Source: Medline; NIGMS NIH HHS [GM54508] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761, R01DK037219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054508] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DINGUS J, 1994, METHOD ENZYMOL, V238, P457; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; LAMBRIGHT DG, 1996, NATURE, V379, P369; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PRONIN AN, 1994, METHOD ENZYMOL, V237, P482; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SONDEK J, 1996, NATURE, V379, P311; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; UEDA N, 1994, J BIOL CHEM, V269, P4388; Yan K, 1996, J BIOL CHEM, V271, P17597, DOI 10.1074/jbc.271.30.17597	20	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26445	26448		10.1074/jbc.271.43.26445	http://dx.doi.org/10.1074/jbc.271.43.26445			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900107	hybrid			2022-12-25	WOS:A1996VP23300001
J	Savio, M; Stivala, LA; Scovassi, AI; Bianchi, L; Prosperi, E				Savio, M; Stivala, LA; Scovassi, AI; Bianchi, L; Prosperi, E			P21(waf1/cip1) protein associates with the detergent-insoluble form of PCNA concomitantly with disassembly of PCNA at nucleotide excision repair sites	ONCOGENE			English	Article						PCNA; p21waf1/cip1; DNA damage; nucleotide excision repair	CELL NUCLEAR ANTIGEN; CYCLIN-DEPENDENT KINASES; DNA-POLYMERASE-DELTA; P53-MEDIATED G(1) ARREST; HUMAN FIBROBLASTS; COMPLEX-FORMATION; BINDING DOMAINS; LEUKEMIA-CELLS; GROWTH ARREST; HELA-CELLS	Evidence is presented that after exposure of normal human fibroblasts to UV-C light, nuclear binding of the proliferating cell nuclear antigen (PCNA) required for nucleotide excision repair, was rapidly triggered in the G(1) and G(2) phases of the cell cycle. Association to repair sites of the detergent-insoluble form of PCNA reached a peak 15-30 min after irradiation, and then decreased to basal levels within 24-48 h. In contrast, the nuclear association of p21 protein showed a slower kinetics, reaching maximal levels between 24 and 48h but, similarly to PCNA, occurring only in G(1) and G(2) phases. Although the two proteins are known to be associated as detergent-soluble proteins, it is unknown whether they associate also in the detergent-insoluble form. To address this question, the chromatin-bound form of PCNA was released by using DNAse I. DNA digestion resulted in the almost complete release of PCNA from its binding sites, while only about 60% of nuclear-bound p21 could be solubilized. Immunoprecipitation of PCNA and p21 released by enzymatic digestion showed that p21 was associated with PCNA bound to late DNA repair sites. These results indicate that during nucleotide excision repair, nuclear binding of PCNA precedes that of p21 protein, and suggest that temporal association of p21 with the detergent-insoluble fraction is coincident with the disassembly of PCNA from DNA repair sites.	CNR,CTR STUDIO ISTOCHIM,I-27100 PAVIA,ITALY; CNR,IST GENET BIOCHIM & EVOLUZIONIST,I-27100 PAVIA,ITALY; UNIV PAVIA,IST PATOL GEN,I-27100 PAVIA,ITALY	Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); University of Pavia			Prosperi, Ennio/A-3439-2014; Scovassi, Anna Ivana/F-2458-2010	Prosperi, Ennio/0000-0001-5391-5157; Scovassi, Anna Ivana/0000-0003-3484-9881				BOHR V A, 1988, Trends in Biochemical Sciences, V13, P429, DOI 10.1016/0968-0004(88)90216-2; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; Chen IT, 1996, ONCOGENE, V12, P595; CHEN IT, 1995, ONCOGENE, V11, P1931; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FANG F, 1993, J CELL SCI, V106, P983; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GOUBIN F, 1995, ONCOGENE, V10, P2281; HALL PA, 1995, ONCOGENE, V10, P2427; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HAVELY O, 1995, SCIENCE, V267, P1018; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; JAUMOT M, 1994, BIOCHEM BIOPH RES CO, V203, P1527, DOI 10.1006/bbrc.1994.2359; JENSEN KA, 1990, BIOCHEMISTRY-US, V29, P4773, DOI 10.1021/bi00472a005; JIANG HP, 1994, ONCOGENE, V9, P3397; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LANDBERG G, 1991, CANCER RES, V51, P4750; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI Y, 1994, ONCOGENE, V9, P2216; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MICHIELI P, 1994, CANCER RES, V54, P3391; MIURA M, 1992, EXP CELL RES, V201, P541, DOI 10.1016/0014-4827(92)90308-U; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2442; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PROSPERI E, 1993, EXP CELL RES, V205, P320, DOI 10.1006/excr.1993.1092; PROSPERI E, 1994, EXP CELL RES, V215, P352; SADAIE MR, 1986, EXP CELL RES, V163, P423, DOI 10.1016/0014-4827(86)90073-X; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SOBCZAKTHEPOT J, 1993, EXP CELL RES, V206, P43, DOI 10.1006/excr.1993.1118; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WALDMAN T, 1995, CANCER RES, V55, P5187; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZENG XR, 1994, J BIOL CHEM, V269, P24027; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHANG W, 1995, CANCER RES, V55, P668	64	42	43	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1591	1598						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895503				2022-12-25	WOS:A1996VM88700002
J	Froelich, CJ; Orth, K; Turbov, J; Seth, P; Gottlieb, R; Babior, B; Shah, GM; Bleackley, RC; Dixit, VM; Hanna, W				Froelich, CJ; Orth, K; Turbov, J; Seth, P; Gottlieb, R; Babior, B; Shah, GM; Bleackley, RC; Dixit, VM; Hanna, W			New paradigm for lymphocyte granule-mediated cytotoxicity - Target cells bind and internalize granzyme B, but an endosomolytic agent is necessary for cytosolic delivery and subsequent apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA FRAGMENTATION; LYSIS; INHIBITION; PROTEASES; PERFORIN; PHOSPHATIDYLSERINE; PURIFICATION; ADENOVIRUS; POLYMERASE; PATHWAYS	Lymphocyte granule-mediated apoptosis is postulated to entail the formation of membrane pores by perforin. Then soluble granzyme reaches the cytosol either through these pores or by reparative pinocytosis. We demonstrate here that Jurkat cells bind and internalize granzyme B via high affinity binding sites without toxic consequence. Apoptosis occurs, however, if sublytic perforin is added to targets washed free of soluble granzyme B, We suggest that granule-mediated apoptosis mimics viral strategies for cellular entry. Accordingly, co-internalization of granzyme B with adenovirus, a virus that escapes endosomes to reach the cytosol, also induced apoptosis. Poly(ADP-ribose) polymerase cleavage and processing of CPP32, ICE-LAP3, and Mch2 were detected at 30 min, while cytosolic acidification and DNA fragmentation occurred at 60 min. Annexin V binding and membrane permeabilization arose at 4 h. The concurrent activation of the Ced-3 proteases differed from the rate at which each cysteine protease is cleaved in vitro by granzyme B. Thus, granzyme B may not directly process these proteases in whole cells but rather may function by activating a more proximal enzyme. These results indicate that adenovirus-mediated delivery of granzyme B is suitable for elucidating biochemical events that accompany granule-mediated apoptosis.	NORTHWESTERN UNIV, EVANSTON HOSP, DEPT MED, EVANSTON, IL 60201 USA; UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA; NCI, MED BRANCH, NIH, BETHESDA, MD 20892 USA; SCRIPPS RES INST, DIV BIOCHEM, SAN DIEGO, CA 92037 USA; UNIV LAVAL, HOSP & RES CTR, UNIT HLTH & ENVIRONM, POLY ADP RIBOSE METAB GRP, QUEBEC CITY, PQ G1V 4G2, CANADA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2H7, CANADA	NorthShore University Health System; Northwestern University; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Scripps Research Institute; Laval University; University of Alberta			Shah, Girish M/A-5153-2008; dixit, vishva m/A-4496-2012; Orth, Kim/AAV-4421-2021	dixit, vishva m/0000-0001-6983-0326; Orth, Kim/0000-0002-0678-7620; Shah, Girish/0000-0002-9291-1164	NCI NIH HHS [CA68769] Funding Source: Medline; NIA NIH HHS [AG-13501] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA068769] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013501] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLEACKLEY RC, 1988, IMMUNOL REV, V10, P5; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chinnaiyan AM, 1996, CURR BIOL, V6, P897, DOI 10.1016/S0960-9822(02)00614-0; CHRISTIAANSEN JE, 1985, P NATL ACAD SCI USA, V82, P4482, DOI 10.1073/pnas.82.13.4482; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; GORCZYCA W, 1993, CANCER RES, V53, P1945; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; GREBER UF, 1993, CELL, V75, P477, DOI 10.1016/0092-8674(93)90382-Z; Greenberg A H, 1995, Curr Top Microbiol Immunol, V198, P95; Gu Y, 1996, J BIOL CHEM, V271, P10816, DOI 10.1074/jbc.271.18.10816; HANNA WL, 1993, PROTEIN EXPRES PURIF, V4, P398, DOI 10.1006/prep.1993.1052; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HUDIG D, 1991, J IMMUNOL, V147, P1360; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KAUFMANN SH, 1993, CANCER RES, V53, P3976; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Meisenholder GW, 1996, J BIOL CHEM, V271, P16260, DOI 10.1074/jbc.271.27.16260; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; PODACK ER, 1995, CURR OPIN IMMUNOL, V7, P11, DOI 10.1016/0952-7915(95)80023-9; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; SETH P, 1994, BIOCHEM BIOPH RES CO, V205, P1318, DOI 10.1006/bbrc.1994.2809; SETH P, 1994, BIOCHEM BIOPH RES CO, V203, P582, DOI 10.1006/bbrc.1994.2222; SHAH GM, 1995, ANAL BIOCHEM, V227, P1, DOI 10.1006/abio.1995.1245; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Sower LE, 1996, CELL IMMUNOL, V171, P159, DOI 10.1006/cimm.1996.0187; Sower LE, 1996, J IMMUNOL, V156, P2585; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TSCHOPP J, 1990, ANNU REV IMMUNOL, V8, P279, DOI 10.1146/annurev.immunol.8.1.279; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wagner Robert R., 1996, P561; ZYCHLINSKY A, 1991, J IMMUNOL, V146, P393	42	305	313	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29073	29079		10.1074/jbc.271.46.29073	http://dx.doi.org/10.1074/jbc.271.46.29073			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910561	hybrid			2022-12-25	WOS:A1996VT05200053
J	Medrano, FJ; Gasset, M; LopezZumel, C; Usobiaga, P; Garcia, JL; Menendez, M				Medrano, FJ; Gasset, M; LopezZumel, C; Usobiaga, P; Garcia, JL; Menendez, M			Structural characterization of the unligated and choline-bound forms of the major pneumococcal autolysin LytA amidase - Conformational transitions induced by temperature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM SPECTRA; STREPTOCOCCUS-PNEUMONIAE; ULTRAVIOLET-ABSORPTION; MUREIN HYDROLASES; DECONVOLUTION; PURIFICATION; DERIVATIVES; DOMAIN	The secondary and tertiary structures of the choline-dependent major pneumococcal autolysin LytA amidase and of its COOH-terminal domain, C-LytA, have been investigated by circular dichroism (CD) and Fourier transform infrared (FTIR) spectroscopy. Deconvolution analysis shows that the far-UV CD spectrum of both proteins is governed by chiral contributions, ascribed to aromatic residue clusters contained in the COOH-terminal module. The secondary structure of LytA, determined from the FTIR spectral features of the amide I' band, results in 19% of alpha-helix and tight loops, 47% of beta-sheets, 23% of turns, and 11% of irregular structures. Similar values are obtained for C-LytA. The addition of choline significantly modifies the far- and near-UV CD spectra of LytA and C-LytA. These changes are attributed to alterations in the environment of their aromatic clusters, since the FTIR spectra indicate that the secondary structure is essentially unaffected. CD choline titration curves at different wavelengths show the existence of two types of binding sites/subunit. Data analysis assuming protein dimerization upon saturation of the high affinity sites reveals positive cooperativity between the low affinity sites. Thermal denaturation of both proteins occurs with the formation of unfolding intermediates and the presence of residual secondary structure in the final denatured state. The irreversibility of the thermal denaturation of LytA and C-LytA results from the collapse of the polypeptide chain into intermolecular extended structures. At saturating concentrations, choline prevents the formation of these structures in the isolated COOH-terminal module.	CSIC,INST QUIM FIS ROCASOLANO,E-28006 MADRID,SPAIN; CSIC,CTR INVEST BIOL,E-28006 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)			Gasset, Maria/I-2050-2014; Gasset, Maria/K-4339-2012; Espinosa, Manuel/M-5282-2019; Medrano, Francisco Javier/ABF-9860-2020; Menendez, Margarita/M-1795-2014; Garcia Lopez, Jose Luis/G-9139-2015	Gasset, Maria/0000-0001-6436-4055; Gasset, Maria/0000-0001-6436-4055; Menendez, Margarita/0000-0002-3267-4443; Garcia Lopez, Jose Luis/0000-0002-9238-2485; Medrano, Francisco/0000-0002-8185-9751				ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P25; AUER HE, 1973, J AM CHEM SOC, V95, P3003, DOI 10.1021/ja00790a046; BERRY AM, 1989, INFECT IMMUN, V57, P2324, DOI 10.1128/IAI.57.8.2324-2330.1989; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; CUDELL DR, 1995, NATURE, V377, P435; DAY LA, 1973, BIOCHEMISTRY-US, V12, P5329, DOI 10.1021/bi00750a017; GALZI JL, 1994, CURR OPIN STRUC BIOL, V4, P554, DOI 10.1016/S0959-440X(94)90218-6; GARCIA E, 1988, P NATL ACAD SCI USA, V85, P914, DOI 10.1073/pnas.85.3.914; GARCIA JL, 1987, ARCH MICROBIOL, V149, P52, DOI 10.1007/BF00423136; GARCIA JL, 1994, J BACTERIOL, V176, P4066, DOI 10.1128/JB.176.13.4066-4072.1994; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; GOORMAGHTIGH E, 1995, PHYSICOCHEMICAL METH, P329; GORNETSCHELNOKOW U, 1993, EUR J BIOCHEM, V213, P1235, DOI 10.1111/j.1432-1033.1993.tb17874.x; GRISHINA IB, 1994, FARADAY DISCUSS, V99, P245, DOI 10.1039/fd9949900245; HOLTJE JV, 1975, J BIOL CHEM, V250, P6072; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKAY JP, 1994, J AM CHEM SOC, V116, P4581, DOI 10.1021/ja00090a006; MANNING MC, 1988, BIOPHYS CHEM, V31, P77, DOI 10.1016/0301-4622(88)80011-5; Menendez M, 1995, EUR J BIOCHEM, V234, P887, DOI 10.1111/j.1432-1033.1995.887_a.x; MUGA A, 1991, BIOCHEMISTRY-US, V30, P2629, DOI 10.1021/bi00224a010; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; PERCZEL A, 1992, PROTEINS, V13, P57, DOI 10.1002/prot.340130106; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; SANCHEZPUELLES JM, 1990, GENE, V89, P69, DOI 10.1016/0378-1119(90)90207-8; SANZ JM, 1988, FEBS LETT, V232, P308, DOI 10.1016/0014-5793(88)80759-2; SANZ JM, 1992, MOL MICROBIOL, V6, P921, DOI 10.1111/j.1365-2958.1992.tb01542.x; SHAN F, 1990, LANCET, V335, P38; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; Susi H, 1986, METHOD ENZYMOL, V130, P91; Sussman JL, 1992, CURR OPIN STRUC BIOL, V2, P721; TOMASZ A, 1989, Pediatric Infectious Disease Journal, V8, P902, DOI 10.1097/00006454-198912000-00034; TOUMANEN E, 1985, J INFECT DIS, V11, P535; TOUMANEN E, 1995, NEW ENGL J MED, V332, P1280; Usobiaga P, 1996, J BIOL CHEM, V271, P6832, DOI 10.1074/jbc.271.12.6832; WILDER CL, 1992, BIOCHEMISTRY-US, V31, P27, DOI 10.1021/bi00116a006; Woody RW, 1974, PEPTIDES POLYPEPTIDE, P338; YANG JT, 1986, METHOD ENZYMOL, V130, P208	39	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29152	29161		10.1074/jbc.271.46.29152	http://dx.doi.org/10.1074/jbc.271.46.29152			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910572	Green Published, hybrid			2022-12-25	WOS:A1996VT05200064
J	Rhee, S; Ebensperger, C; Dembic, Z; Pestka, S				Rhee, S; Ebensperger, C; Dembic, Z; Pestka, S			The structure of the gene for the second chain of the human interferon-gamma receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; ACCESSORY FACTOR; SIGNAL-TRANSDUCTION; BINDING PROTEINS; PROMOTER REGION; CDNA SEQUENCE; HUMAN-CELLS; BETA CHAIN; EXPRESSION; CLONING	The gene for the second chain of the human interferon-gamma receptor was analyzed from cosmid DNA clones. The gene spans over 33 kilobases of DNA and contains seven exons. The signal peptide is encoded by exons 1 and 2, the extracellular domain by exons 2, 3, 4, 5, and by part of 6. Exon 6 also encodes the whole transmembrane domain and part of the intracellular domain. Exon 7 encodes the remainder of the intracellular domain and contains the 3'-untranslated region. The sequences at the exon/intron boundaries are well conserved with respect to canonical acceptor/donor sites (AG/GT). The 5'-flanking region was sequenced and analyzed for transcription factor binding sites. No TATA or CAAT boxes in the promoter region were identified. Consistent with the lack of a TATA box, analysis of the mRNAs by primer extension showed multiple transcription start sites. Promoter activity of the 5'-flanking region was investigated with a luciferase reporter gene and the cytomegalovirus minimal promoter. Segments of the 5' region with promoter activity were identified.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MOL GENET & MICROBIOL,PISCATAWAY,NJ 08854; F HOFFMAN LA ROCHE AG,DEPT PRECLIN RES,CH-4002 BASEL,SWITZERLAND	Rutgers State University New Brunswick; Rutgers State University Medical Center; Roche Holding			Dembic, Zlatko/A-1833-2008	Dembic, Zlatko/0000-0002-9970-6497	NCI NIH HHS [R01-CA52363, R01-CA46465] Funding Source: Medline; NIAID NIH HHS [R01-AI/GM36450] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046465, R01CA052363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036450] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; BACH EA, 1995, SCIENCE, V270, P1215, DOI 10.1126/science.270.5239.1215; BECK TW, 1990, MOL CELL BIOL, V10, P3325, DOI 10.1128/MCB.10.7.3325; COFANO F, 1990, J BIOL CHEM, V265, P4064; COOK JR, 1994, J BIOL CHEM, V269, P7013; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; EBENSPERGER C, 1995, IN PRESS SCAND J IMM; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAY PW, 1989, P NATL ACAD SCI USA, V86, P8497, DOI 10.1073/pnas.86.21.8497; HEMMI S, 1989, P NATL ACAD SCI USA, V86, P9901, DOI 10.1073/pnas.86.24.9901; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HIBINO Y, 1991, J BIOL CHEM, V266, P6948; HUANG DH, 1988, J BIOL CHEM, V263, P12596; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; JUNG V, 1988, SOMAT CELL MOLEC GEN, V14, P583, DOI 10.1007/BF01535312; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAESTNER KH, 1994, GENOMICS, V20, P377, DOI 10.1006/geno.1994.1191; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOH J, 1993, J BIOL CHEM, V268, P15912; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; KUMAR CS, 1989, J BIOL CHEM, V264, P17939; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MUNRO S, 1989, P NATL ACAD SCI USA, V86, P9248, DOI 10.1073/pnas.86.23.9248; PERNIS A, 1995, SCIENCE, V269, P245, DOI 10.1126/science.7618088; RASHIDBAIGI A, 1986, P NATL ACAD SCI USA, V83, P384, DOI 10.1073/pnas.83.2.384; Sambrook J., 2002, MOL CLONING LAB MANU; SKRENTA H, 1996, EUR CYTOKINE NETW, V7, P622; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9	32	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28947	28952		10.1074/jbc.271.46.28947	http://dx.doi.org/10.1074/jbc.271.46.28947			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910544	hybrid			2022-12-25	WOS:A1996VT05200036
J	Wang, PH; Zweier, JL				Wang, PH; Zweier, JL			Measurement of nitric oxide and peroxynitrite generation in the postischemic heart - Evidence for peroxynitrite-mediated reperfusion injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARAMAGNETIC-RESONANCE SPECTROSCOPY; HYDROXYL RADICAL PRODUCTION; IN-VIVO; ACTIVATED MACROPHAGES; LIPID-PEROXIDATION; XANTHINE-OXIDASE; RELAXING FACTOR; SUPEROXIDE; DECOMPOSITION; ENDOTHELIUM	Altered nitric oxide (NO.) production is a critical factor in tissue reperfusion injury; however, controversy remains regarding these alterations and how they cause injury. Since superoxide (O-2(.-)) generation is triggered during the early period of reperfusion the cytotoxic oxidant peroxynitrite (ONOO-) could be formed, but it is not known if this occurs. Therefore electron paramagnetic resonance and chemiluminescence studies were performed of the magnitude and time course of NO., O-2(.-), and ONOO- formation in the postischemic heart. Isolated rat hearts were subjected either to normal perfusion or to reperfusion after 30 min of ischemia in the presence of the NO. trap Fe2+-N-methyl-D-glucamine dithiocarbamate with electron paramagnetic resonance measurements performed on the effluent. Although only trace signals were present prior to ischemia, prominent NO. adduct signals were seen during the first 2 min of reflow which were abolished by nitric oxide synthase (NOS) inhibition. Similar studies with the O-2(.-) trap 5,5 -dimethyl-1-pyrroline N-oxide demonstrated a burst of O-2(.-) generation over the first 2 min of reflow. Chemiluminescence measurements using 5-amino-2,2-dihydro-1,4-phthalazinedione (luminol) demonstrated a similar marked increase in ONOO- which was blocked by NOS inhibitors or superoxide dismutase. NOS inhibition or superoxide dismutase greatly enhanced the recovery of contractile function in postischemic hearts. Immunohistology demonstrated that the ONOO--mediated nitration product nitrotyrosine was formed in postischemic hearts but not in normally perfused controls. Thus, NO. formation is increased during the early period of reflow and reacts with O-2(.-) to form ONOO-, which results in amino acid nitration and cellular injury.	JOHNS HOPKINS BAYVIEW MED CTR,JOHNS HOPKINS MED INST,DEPT MED,DIV CARDIOL,BALTIMORE,MD 21224; JOHNS HOPKINS BAYVIEW MED CTR,JOHNS HOPKINS MED INST,ELECTRON PARAMAGNET RESONANCE CTR,BALTIMORE,MD 21224	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038324, R29HL038324] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38324] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUGUSTO O, 1994, ARCH BIOCHEM BIOPHYS, V310, P118, DOI 10.1006/abbi.1994.1147; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BECKMAN JS, 1990, NATURE, V345, P27, DOI 10.1038/345027b0; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BLOUGH NV, 1985, INORG CHEM, V24, P3504; COOKE JP, 1993, CIRCULATION, V88, P2451, DOI 10.1161/01.CIR.88.5.2451; Crow J P, 1995, Curr Top Microbiol Immunol, V196, P57; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DELELLIS RA, 1981, BASIC TECHNIQUES IMM; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; FEIGL EO, 1988, NATURE, V331, P490, DOI 10.1038/331490a0; FINKELSTEIN E, 1982, MOL PHARMACOL, V21, P262; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; HESS ML, 1995, ANN THORAC SURG, V60, P760, DOI 10.1016/0003-4975(95)00574-5; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; IGNARRO LJ, 1986, J BIOL CHEM, V261, P4997; KING PA, 1992, J AM CHEM SOC, V114, P5430, DOI 10.1021/ja00039a068; KOOY NW, 1994, ARCH BIOCHEM BIOPHYS, V310, P352, DOI 10.1006/abbi.1994.1178; KUKREJA RC, 1992, CARDIOVASC RES, V26, P641, DOI 10.1093/cvr/26.7.641; LAI CS, 1994, FEBS LETT, V345, P120, DOI 10.1016/0014-5793(94)00422-6; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LEMERCIER JN, 1995, ARCH BIOCHEM BIOPHYS, V321, P31, DOI 10.1006/abbi.1995.1364; MA XL, 1993, CIRC RES, V72, P403, DOI 10.1161/01.RES.72.2.403; MARBAN E, 1989, CIRCULATION, V80, P17; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MONCADA S, 1986, P NATL ACAD SCI USA, V83, P9164, DOI 10.1073/pnas.83.23.9164; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORDVINTCEV P, 1991, ANAL BIOCHEM, V199, P142, DOI 10.1016/0003-2697(91)90282-X; MORENO JJ, 1992, CHEM RES TOXICOL, V5, P425, DOI 10.1021/tx00027a017; MORITA K, 1995, J THORAC CARDIOV SUR, V110, P1200, DOI 10.1016/S0022-5223(95)70006-4; MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702; PATEL VC, 1993, BIOCHEM BIOPH RES CO, V194, P234, DOI 10.1006/bbrc.1993.1809; POU S, 1992, J BIOL CHEM, V267, P24173; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; RADI R, 1993, BIOCHEM J, V290, P51, DOI 10.1042/bj2900051; RUBBO H, 1994, J BIOL CHEM, V269, P26066; SARAN M, 1994, CHEM-BIOL INTERACT, V90, P35, DOI 10.1016/0009-2797(94)90109-0; SHINOBU LA, 1984, ACTA PHARMACOL TOX, V54, P189; SQUADRITO GL, 1995, CHEM-BIOL INTERACT, V96, P203, DOI 10.1016/0009-2797(94)03591-U; THOMPSONGORMAN SL, 1990, J BIOL CHEM, V265, P6656; VANDERVLIET A, 1994, FEBS LETT, V339, P89, DOI 10.1016/0014-5793(94)80391-9; VILLA LM, 1994, P NATL ACAD SCI USA, V91, P12383, DOI 10.1073/pnas.91.26.12383; WINK DA, 1994, ANN NY ACAD SCI, V738, P69; XIA Y, 1995, J BIOL CHEM, V270, P18797, DOI 10.1074/jbc.270.32.18797; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; YU L, 1994, P NATL ACAD SCI USA, V91, P1691, DOI 10.1073/pnas.91.5.1691; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804; ZWEIER JL, 1988, J BIOL CHEM, V263, P1353; ZWEIER JL, 1995, J BIOL CHEM, V270, P304, DOI 10.1074/jbc.270.1.304; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	52	484	509	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29223	29230		10.1074/jbc.271.46.29223	http://dx.doi.org/10.1074/jbc.271.46.29223			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910581	hybrid			2022-12-25	WOS:A1996VT05200073
J	Charpentier, S; Jarvie, KR; Severynse, DM; Caron, MG; Tiberi, M				Charpentier, S; Jarvie, KR; Severynse, DM; Caron, MG; Tiberi, M			Silencing of the constitutive activity of the dopamine D1B receptor - Reciprocal mutations between D1 receptor subtypes delineate residues underlying activation properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE RECEPTOR; PRECOCIOUS PUBERTY; BETA(2)-ADRENERGIC RECEPTOR; NIGHT BLINDNESS; GENE; RHODOPSIN; EXPRESSION; CLONING; MUTANT; RESPONSIVENESS	Recently, we have shown that the dopamine D1B/D5 receptor displays binding and coupling properties that are reminiscent of those of the constitutively activated G protein-coupled receptors when compared with the related D1A/D1 receptor subtype (Tiberi, M., and Caron, M. G. (1994) J. Biol. Chem. 269, 27925-27931). The carboxyl-terminal region of the third cytoplasmic loop of several G protein coupled receptors has been demonstrated to be important for the regulation of the equilibrium between inactive and active receptor conformations. In this cytoplasmic region, the primary structure of dopamine D1A and D1B receptors differs by only two residues: Phe(264)/Arg(266) present in D1A receptor compared with Ile(288)/Lys(290) in the D1B receptor. To investigate whether these structural differences could account for the distinct binding and coupling properties of these dopamine receptor subtypes, we swapped the variant residues located in the carboxyl-terminal region by site-directed mutagenesis. The exchange of the D1A receptor residue Phe(264) by the D1B receptor counterpart isoleucine led to a D1A receptor mutant exhibiting D1B-like constitutive properties. In contrast, substitution of D1B receptor Ile(288) by the D1A receptor counterpart phenylalanine resulted in a loss of constitutive activation of the D1B receptor with binding and coupling properties similar to the D1A receptor. The Arg/Lys substitution had no effect on the function of either receptor. These results demonstrate that the carboxyl-terminal region, and in particular residue Ile(288), is a major determinant of the constitutive activity of the dopamine D1B receptor. Moreover, these results establish that not only can agonist-independent activity of a receptor be induced, but when given the appropriate mutation, it can be re versed or silenced.	DUKE UNIV, MED CTR, DEPT CELL BIOL, HOWARD HUGHES MED INST LABS, DURHAM, NC 27710 USA	Duke University								Burstein ES, 1996, J BIOL CHEM, V271, P2882, DOI 10.1074/jbc.271.6.2882; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; DRYJA TP, 1993, NAT GENET, V4, P280, DOI 10.1038/ng0793-280; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; GRANDY DK, 1991, P NATL ACAD SCI USA, V88, P9175, DOI 10.1073/pnas.88.20.9175; HOGGER P, 1995, J BIOL CHEM, V270, P7405; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KREMER H, 1993, HUM MOL GENET, V2, P1779, DOI 10.1093/hmg/2.11.1779; LATRONICO AC, 1995, J CLIN ENDOCR METAB, V80, P2490, DOI 10.1210/jc.80.8.2490; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MATUSLEIBOVITCH N, 1995, J BIOL CHEM, V270, P1041, DOI 10.1074/jbc.270.3.1041; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; Perez DM, 1996, MOL PHARMACOL, V49, P112; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; REN Q, 1993, J BIOL CHEM, V268, P16483; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SOKOLOFF P, 1995, TRENDS PHARMACOL SCI, V16, P270, DOI 10.1016/S0165-6147(00)89044-6; Spalding TA, 1995, J PHARMACOL EXP THER, V275, P1274; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; TIBERI M, 1994, J BIOL CHEM, V269, P27925; TIBERI M, 1991, P NATL ACAD SCI USA, V88, P7491, DOI 10.1073/pnas.88.17.7491; WEISHANK RL, 1991, J BIOL CHEM, V266, P22427	36	49	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28071	28076		10.1074/jbc.271.45.28071	http://dx.doi.org/10.1074/jbc.271.45.28071			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910419	hybrid			2022-12-25	WOS:A1996VU03300019
J	Chen, SM; Zack, DJ				Chen, SM; Zack, DJ			Ret 4, a positive acting rhodopsin regulatory element identified using a bovine retina in vitro transcription system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; HOMEOBOX-CONTAINING GENE; NUCLEAR-PROTEIN BINDING; RAT OPSIN GENE; TRANSGENIC MICE; IN-VITRO; INVITRO TRANSCRIPTION; VISUAL PIGMENTS; UPSTREAM REGION; PINEAL COMPLEX	Previous transgenic mouse studies demonstrated that the bovine rhodopsin sequence between -222 and +70 base pairs (bp) contains a minimal promoter, which is sufficient to direct photoreceptor cell-specific expression of a lacZ reporter gene. To more fully define the DNA regulatory elements and protein factors involved in regulating rhodopsin transcription, we have developed an in vitro transcription system derived from bovine retinal nuclear extracts. Retinal extracts, as compared to liver, HeLa, and Drosophila embryonic cell extracts, demonstrated preferential activity for the rhodopsin promoter. A template spanning the bovine rhodopsin upstream region from -590 to +15 bp showed significant activation relative to the basal activity seen with a TATA box containing -38 to +15 bp template. Deletion analysis indicated that the region between -85 and -38 bp contained significant positive regulatory activity. This activity was not observed with HeLa extracts, suggesting that it might be retina-specific. Systematic site-directed mutagenesis of the subregion from -64 to -38 bp indicated that sequences between -60 and -58 bp and between -48 and -40 bp harbor critical elements. The former sequence is part of the binding site for the retina-specific transcription factor Nrl, which has been implicated in rhodopsin regulation. Electrophoretic mobility shift assays showed that the latter sequence (-48 to -40 bp), and flanking DNA, designated Ret 4, is bound by both retina-specific and ubiquitously expressed protein factors. Shift assays with mutant oligomers further defined the putative recognition sequences for these protein factors. Together, our results suggest that multiple promoter elements and transcriptional factors are involved in regulating photoreceptor-specific rhodopsin transcription.	JOHNS HOPKINS UNIV,SCH MED,DEPT OPHTHALMOL,WILMER EYE INST,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University				Zack, Don/0000-0002-7966-1973	NATIONAL EYE INSTITUTE [R01EY009769, F32EY006614] Funding Source: NIH RePORTER; NEI NIH HHS [EY06614, EY09769, F32 EY006614] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADLER R, 1993, INVEST OPHTH VIS SCI, V34, P1677; Ahmad I, 1995, Brain Res Dev Brain Res, V90, P184; ARAKI M, 1992, DEV BRAIN RES, V69, P149, DOI 10.1016/0165-3806(92)90153-N; BAEHR W, 1988, FEBS LETT, V238, P253, DOI 10.1016/0014-5793(88)80490-3; Bellorini M, 1996, MOL CELL BIOL, V16, P503; BOGENMANN E, 1988, SCIENCE, V240, P76, DOI 10.1126/science.2451289; BORST D E, 1991, Journal of Cell Biology, V115, p312A; BUCHANAN KL, 1995, J IMMUNOL, V155, P4270; DENTE L, 1988, GENE DEV, V2, P259, DOI 10.1101/gad.2.2.259; DESJARDIN LE, 1993, J BIOL CHEM, V268, P6953; DesJardin LE, 1996, INVEST OPHTH VIS SCI, V37, P154; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIPOLO A, 1995, P NATL ACAD SCI USA, V92, P4016, DOI 10.1073/pnas.92.9.4016; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; DURAND B, 1994, MOL CELL BIOL, V14, P6839, DOI 10.1128/MCB.14.10.6839; GONG QH, 1993, MOL CELL BIOL, V13, P911, DOI 10.1128/MCB.13.2.911; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; KAMAKAKA RT, 1991, P NATL ACAD SCI USA, V88, P1024, DOI 10.1073/pnas.88.3.1024; KIKUCHI T, 1993, MOL CELL BIOL, V13, P4400, DOI 10.1128/MCB.13.7.4400; KUMAR R, 1996, IN PRESS J BIOL CHEM, V271; KUMAR R, 1995, MOL GENETICS OCULAR, P139; LEM J, 1991, NEURON, V6, P201, DOI 10.1016/0896-6273(91)90356-5; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; MASUDA H, 1994, TISSUE CELL, V26, P101, DOI 10.1016/0040-8166(94)90086-8; MIZUSHIMASUGANO J, 1986, P NATL ACAD SCI USA, V83, P8511, DOI 10.1073/pnas.83.22.8511; MORABITO MA, 1991, J BIOL CHEM, V266, P9667; NATHANS J, 1994, CELL, V78, P357, DOI 10.1016/0092-8674(94)90414-6; NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; Nie ZQ, 1996, J BIOL CHEM, V271, P2667, DOI 10.1074/jbc.271.5.2667; PAO CI, 1995, J BIOL CHEM, V270, P24917, DOI 10.1074/jbc.270.42.24917; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; POLITI LE, 1988, INVEST OPHTH VIS SCI, V29, P534; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; SAMSON SLA, 1995, J BIOL CHEM, V270, P25194, DOI 10.1074/jbc.270.42.25194; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAYRE MH, 1993, CELL MOL BIOL RES, V39, P349; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SHERIDAN PL, 1995, GENE DEV, V9, P2090, DOI 10.1101/gad.9.17.2090; SHESHBERADARAN H, 1994, MOL CELL NEUROSCI, V5, P309, DOI 10.1006/mcne.1994.1037; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; TAN SY, 1994, J BIOL CHEM, V269, P25684; TIMMERS AM, 1993, EXP EYE RES, V56, P257, DOI 10.1006/exer.1993.1034; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TREISMAN JE, 1988, MOL CELL BIOL, V8, P1570, DOI 10.1128/MCB.8.4.1570; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; WERNER M, 1990, J NEUROSCI RES, V25, P50, DOI 10.1002/jnr.490250107; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; YAMAKI K, 1990, J BIOL CHEM, V265, P20757; YOSHIKAWA T, 1994, ZOOL SCI, V11, P675; YU X, 1994, J MOL NEUROSCI, V5, P259, DOI 10.1007/BF02736726; YU X, 1993, BIOCHEM BIOPH RES CO, V191, P76, DOI 10.1006/bbrc.1993.1186; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4; ZACK DJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P1477, DOI 10.1001/archopht.1993.01090110043019; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZIMMERMAN K, 1990, MOL CELL BIOL, V10, P2096, DOI 10.1128/MCB.10.5.2096	62	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28549	28557		10.1074/jbc.271.45.28549	http://dx.doi.org/10.1074/jbc.271.45.28549			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910484	hybrid			2022-12-25	WOS:A1996VU03300084
J	Ried, C; Wahl, C; Miethke, T; Wellnhofer, G; Landgraf, C; SchneiderMergener, J; Hoess, A				Ried, C; Wahl, C; Miethke, T; Wellnhofer, G; Landgraf, C; SchneiderMergener, J; Hoess, A			High affinity endotoxin-binding and neutralizing peptides based on the crystal structure of recombinant Limulus anti-lipopolysaccharide factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI SEPSIS; ANTILIPOPOLYSACCHARIDE FACTOR; HORSESHOE-CRAB; SYNTHETIC PEPTIDES; IMPROVES SURVIVAL; SEPTIC SHOCK; LPS FACTOR; PROTEIN; BACTERIAL; SITE	Lipid A, the conserved portion of endotoxin or lipopolysaccharide, is the major mediator of septic shock, and therefore endotoxin-neutralizing molecules could have important clinical applications. The crystal structure of recombinant Limulus anti-lipopolysaccharide factor (rLALF) (Hoess, A., Watson, S., Siber, G. R., and Liddington, R. (1993) EMBO J. 12, 3351-3356), has been used to design synthetic peptides comprising different parts of the exposed amphipathic loop in the proposed endotoxin-binding domain of rLALF. We investigated the minimal requirements of rLALF for endotoxin and lipid A binding with linear 10-mer peptides. Only one Linear peptide, corresponding to amino acids 36-45 of rLALF, was able to bind lipid A and endotoxin above background levels. Cyclic peptides, however, bind lipid A and endotoxin with high affinity, presumably by mimicking the three dimensional characteristics of the exposed hairpin loop. The cyclic peptide including amino acids 36-47, LALF-14, has a Lipid A binding activity comparable to the high affinity endotoxin-binding peptide polymyxin B. LALF-14 has an improved serum half-life compared with its linear counterpart, and it is not toxic for cultured human monocytes or red blood cells. In mice, it blocks tumor necrosis factor-alpha induction after endotoxin challenge. The characterization of the minimal endotoxin-binding domain of rLALF and, importantly, its structure provided a basis for designing small molecules that could have prophylactic and/or therapeutic properties in humans for the management of septic shock.	MORPHOSYS GMBH, D-80807 MUNICH, GERMANY; TECH UNIV MUNICH, INST MED MICROBIOL & HYG, D-81675 MUNICH, GERMANY; HUMBOLDT UNIV BERLIN, INST MED IMMUNOL, D-10098 BERLIN, GERMANY	MorphoSys; Technical University of Munich; Humboldt University of Berlin								AKETAGAWA J, 1986, J BIOL CHEM, V261, P7357; ALEXANDER HR, 1991, J EXP MED, V173, P1029, DOI 10.1084/jem.173.4.1029; ALPERT G, 1992, J INFECT DIS, V165, P494, DOI 10.1093/infdis/165.3.494; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; CALANDRA T, 1991, PROG CLIN BIOL RES, V367, P141; DESCH CE, 1989, INFECT IMMUN, V57, P1612, DOI 10.1128/IAI.57.5.1612-1614.1989; GALLAY P, 1993, P NATL ACAD SCI USA, V90, P9935, DOI 10.1073/pnas.90.21.9935; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; Hirata M, 1994, Prog Clin Biol Res, V388, P147; Hoess A, 1995, Prog Clin Biol Res, V392, P327; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; IWANAGA S, 1986, J PROTEIN CHEM, V5, P255, DOI 10.1007/BF01025424; KLOCZEWIAK M, 1994, J INFECT DIS, V170, P1490, DOI 10.1093/infdis/170.6.1490; LARRICK JW, 1994, J IMMUNOL, V152, P231; LEVIN J, 1964, B JOHNS HOPKINS HOSP, V115, P265; LITTLE RG, 1994, J BIOL CHEM, V269, P1865; MARASTONI M, 1994, ARZNEIMITTEL-FORSCH, V44-2, P1073; MORITA T, 1985, J BIOCHEM, V97, P1611, DOI 10.1093/oxfordjournals.jbchem.a135218; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; MORRISON DC, 1993, IMMUNOBIOLOGY, V187, P212, DOI 10.1016/S0171-2985(11)80340-2; MUTA T, 1987, J BIOCHEM-TOKYO, V101, P1321, DOI 10.1093/oxfordjournals.jbchem.a121999; NACHUM R, 1979, J INVERTEBR PATHOL, V33, P290, DOI 10.1016/0022-2011(79)90029-6; NELSON D, 1995, CRIT CARE MED, V23, P92, DOI 10.1097/00003246-199501000-00017; PARRILLO JE, 1990, ANN INTERN MED, V113, P227, DOI 10.7326/0003-4819-113-3-227; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; RIETSCHEL ET, 1992, SCI AM, V267, P54, DOI 10.1038/scientificamerican0892-54; RUSTICI A, 1993, SCIENCE, V259, P361, DOI 10.1126/science.8420003; SALADINO R, 1994, CIRC SHOCK, V42, P104; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; TAYLOR AH, 1995, J BIOL CHEM, V270, P17934, DOI 10.1074/jbc.270.30.17934; TOBIAS PS, 1993, IMMUNOBIOLOGY, V187, P227, DOI 10.1016/S0171-2985(11)80341-4; TSCHOPP JF, 1993, CORONARY ARTERY DIS, V4, P809, DOI 10.1097/00019501-199309000-00008; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; WAINWRIGHT NR, 1990, INT CONGR SER, V923, P315; WARREN HS, 1992, INFECT IMMUN, V60, P2506, DOI 10.1128/IAI.60.6.2506-2513.1992; WONG YN, 1994, BIOPHARM DRUG DISPOS, V15, P535, DOI 10.1002/bdd.2510150702; WRIGHT SD, 1992, J EXP MED, V176, P719, DOI 10.1084/jem.176.3.719	38	108	117	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28120	28127		10.1074/jbc.271.45.28120	http://dx.doi.org/10.1074/jbc.271.45.28120			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910426	hybrid			2022-12-25	WOS:A1996VU03300026
J	Yorita, K; Aki, K; OhkumaSoyejima, T; Kokubo, T; Misaki, H; Massey, V				Yorita, K; Aki, K; OhkumaSoyejima, T; Kokubo, T; Misaki, H; Massey, V			Conversion of L-lactate oxidase to a long chain alpha-hydroxyacid oxidase by site-directed mutagenesis of alanine 95 to glycine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINACH GLYCOLATE OXIDASE; RAT-KIDNEY; (S)-MANDELATE DEHYDROGENASE; PSEUDOMONAS-PUTIDA; BAKERS-YEAST; ACID OXIDASE; FLAVOCYTOCHROME-B2; RESOLUTION; SEQUENCE	A mutant form of L-lactate oxidase (LOX) from Aerococcus viridans in which alanine 95 was replaced by glycine was constructed as a mimic of L-lactate monooxygenase but proved instead to be a mimic of the long chain alpha-hydroxyacid oxidase from rat kidney. A95G-LOX keeps oxidase activity with L-lactate at the same level as wild type LOX but has much enhanced oxidase activity with longer chain L-alpha-hydroxyacids, alpha-hydroxy-n-butyric acid, alpha-hydroxy-n-valeric acid, etc., and also the aromatic alpha-hydroxyacid, L-mandelic acid. Kinetic analysis of the activity with these substrates indicates that the reduction of the enzyme bound flavin by substrates is the rate-limiting step in A95G-LOX. The affinity of pyruvate for the reduced enzyme is increased, and sulfite binding to the oxidized enzyme is weaker in A95G-LOX than in native enzyme. Wild type LOX stabilizes both the neutral and anionic flavin semiquinones with a pK(a) of 6.1, but A95G LOX stabilizes only the anionic semiquinone form. These results strongly suggest that the environment around the N5-C4a region of the flavin isoalloxazine ring is changed by this mutation.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN; CIBA GEIGY JAPAN,TAKARAZUKA,HYOGO 665,JAPAN; ASAHI CHEM IND CO LTD,OHITO DIAGNOST PLANT,SHIZUOKA 41023,JAPAN	University of Michigan System; University of Michigan; Tokushima University					NIGMS NIH HHS [GM11106] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011106, R37GM011106] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chance B, 1943, J BIOL CHEM, V151, P553; CROMARTIE TH, 1975, BIOCHEMISTRY-US, V14, P2588, DOI 10.1021/bi00683a005; Ghisla S., 1991, CHEM BIOCH FLAVOENZY, P243; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LE KHD, 1991, J BIOL CHEM, V266, P20877; LEDERER F, 1991, CHEM BIOCH FLAVOENZY, V2, P153; LINDQVIST Y, 1989, J MOL BIOL, V209, P151, DOI 10.1016/0022-2836(89)90178-2; LINDQVIST Y, 1989, J BIOL CHEM, V264, P3624; LOCKRIDGE O, 1972, J BIOL CHEM, V247, P8097; MAEDAYORITA K, 1995, BIOCHIMIE, V77, P631, DOI 10.1016/0300-9084(96)88178-8; MASSEY V, 1969, J BIOL CHEM, V244, P3999; MITRA B, 1993, BIOCHEMISTRY-US, V32, P12959, DOI 10.1021/bi00211a003; SMEKAL O, 1993, BIOCHEM J, V290, P103, DOI 10.1042/bj2900103; Sun WM, 1996, J BIOL CHEM, V271, P17226, DOI 10.1074/jbc.271.29.17226; TSOU AY, 1990, BIOCHEMISTRY-US, V29, P9856, DOI 10.1021/bi00494a015; URBAN P, 1988, BIOCHEMISTRY-US, V27, P7365, DOI 10.1021/bi00419a029; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M; XIA ZX, 1987, P NATL ACAD SCI USA, V84, P2629, DOI 10.1073/pnas.84.9.2629	19	32	33	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28300	28305		10.1074/jbc.271.45.28300	http://dx.doi.org/10.1074/jbc.271.45.28300			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910450	hybrid			2022-12-25	WOS:A1996VU03300050
J	Biemann, HP; Harmer, SL; Koshland, DE				Biemann, HP; Harmer, SL; Koshland, DE			An aspartate insulin receptor chimera mitogenically activates fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; LIGAND-BINDING DOMAIN; ESCHERICHIA-COLI; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; BETA-SUBUNIT; CHEMOTAXIS; ALPHA; CHEMORECEPTOR; EXPRESSION	A gene encoding the ligand-binding domain of the Escherichia coli aspartate receptor fused to the cytoplasmic domain of the insulin receptor tyrosine kinase to produce the chimeric aspartate insulin receptor (AIR) was expressed in mammalian cells. A murine fibroblast transfectant line designated CA3 was generated that stably expressed the AIR receptor. This 70,000 M(r) receptor containing the tyrosine kinase of the insulin receptor was recognized by aspartate receptor-specific antisera. When isolated in cellular membrane preparations, AIR was found to be capable of autophosphorylation and phosphorylation of histone H2B on tyrosine. The receptor was found to be predominately cytoplasmic and to be situated in the endoplasmic reticulum and Golgi membranes by immunofluorescence imaging of CA3 cells. Mitogenic effects of AIR were observed; CA3 cells continued DNA synthesis under serum deprivation conditions that prevented parental cells from cycling. These results demonstrate that a chimeric receptor containing procaryotic transmembrane sequences is expressed by a eucaryotic cell in intracellular membranes and functionally couples to cellular signaling pathways.	UNIV CALIF BERKELEY,DEPT MOL & CELLULAR BIOL,BERKELEY,CA 94720; GENZYME CORP,DEPT CELL BIOL,CAMBRIDGE,MA 02139; UNIV CALIF SAN FRANCISCO,GEORGE WILLIAMS HOOPER FDN,SAN FRANCISCO,CA 94143	University of California System; University of California Berkeley; Sanofi-Aventis; Genzyme Corporation; University of California System; University of California San Francisco			Harmer, Sarah/G-5572-2016	Harmer, Sarah/0000-0002-5627-5500; Harmer, Stacey/0000-0001-6813-6682	PHS HHS [9765] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BIEMANN HP, 1994, BIOCHEMISTRY-US, V33, P629, DOI 10.1021/bi00169a002; BOGONEZ E, 1985, P NATL ACAD SCI USA, V82, P4891, DOI 10.1073/pnas.82.15.4891; CELIS JE, 1994, CELL BIOL LAB HDB, V1, P297; DANIELSON MA, 1994, BIOCHEMISTRY-US, V33, P6100, DOI 10.1021/bi00186a009; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DEMEYTS P, 1994, DIABETOLOGIA, V37, P135; DINTZIS SM, 1994, J BIOL CHEM, V269, P12159; ELLIS L, 1987, MOL ENDOCRINOL, V1, P15, DOI 10.1210/mend-1-1-15; ELLIS L, 1986, P NATL ACAD SCI USA, V83, P8137, DOI 10.1073/pnas.83.21.8137; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; HARUTA T, 1995, BIOCHEM J, V305, P599, DOI 10.1042/bj3050599; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LANKFORD SP, 1993, J BIOL CHEM, V268, P4814; LEBWOHL DE, 1991, J BIOL CHEM, V266, P386; LEE J, 1994, AM J PHYSIOL, V94, pC319; LEE JS, 1993, J BIOL CHEM, V268, P4092; Mares J, 1992, GROWTH FACTORS, V6, P93, DOI 10.3109/08977199209011013; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MILLIGAN DL, 1993, J BIOL CHEM, V268, P19991; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; MOE GR, 1989, P NATL ACAD SCI USA, V86, P5683, DOI 10.1073/pnas.86.15.5683; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; SWEET LJ, 1987, J BIOL CHEM, V262, P6939; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057	29	9	9	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27927	27930		10.1074/jbc.271.44.27927	http://dx.doi.org/10.1074/jbc.271.44.27927			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910393	hybrid			2022-12-25	WOS:A1996VQ67900111
J	Blake, DA; Chakrabarti, P; Khosraviani, M; Hatcher, FM; Westhoff, CM; Goebel, P; Wylie, DE; Blake, RC				Blake, DA; Chakrabarti, P; Khosraviani, M; Hatcher, FM; Westhoff, CM; Goebel, P; Wylie, DE; Blake, RC			Metal binding properties of a monoclonal antibody directed toward metal-chelate complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MERCURIC IONS; PROTEINS	A monoclonal antibody that recognizes cadmium-EDTA complexes has been produced by the injection of BALB/c mice with a metal-chelate complex covalently coupled to a carrier protein, The ability of purified antibody to recognize 16 different metal-EDTA complexes was assessed by measuring equilibrium binding constants using a KinExA(TM) immunoassay instrument, The antibody bound to cadmium- and mercury-EDTA complexes with equilibrium dissociation constants of 21 and 26 nm, respectively, All other metal EDTA complexes tested, including those of Mn(II), In(III), Ni(II), Zn(II), Ga(III), Mg(II), and AI(III) bound with affinities from 20- to 40,000-fold less than that determined for the cadmium-EDTA complex, With the exception of mercury and magnesium, the binding of divalent metal-chelate complexes was well-correlated with the size of the metal ion, The amino acid sequences of the heavy and light chain variable regions were deduced from polymerase chain reaction-amplified regions of the corresponding genes and subsequently used to construct molecular models of the antigen binding region, The key residue for cadmium binding in the model for 2A81G5 appeared to be histidine 96 in the heavy chain.	MEHARRY MED COLL,DEPT MICROBIOL,NASHVILLE,TN 37208; UNIV NEBRASKA,DEPT BIOL,LINCOLN,NE 68588; XAVIER UNIV,DEPT BASIC PHARMACEUT SCI,NEW ORLEANS,LA 70125	Meharry Medical College; University of Nebraska System; University of Nebraska Lincoln; Xavier University of Louisiana	Blake, DA (corresponding author), TULANE UNIV,SCH MED,DEPT OPHTHALMOL,1430 TULANE AVE,NEW ORLEANS,LA 70112, USA.							ANDERSON WHK, 1992, HYBRIDOMA, V12, P677; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMERA L, 1994, J NUCL MED, V35, P882; CHAKRABARTI P, 1994, ANAL BIOCHEM, V217, P70, DOI 10.1006/abio.1994.1084; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; GANSOW OA, 1991, NUCL MED BIOL, V18, P369, DOI 10.1016/0883-2897(91)90063-Q; GEFTER ML, 1977, SOMAT CELL GENET, V3, P231, DOI 10.1007/BF01551818; GILLETTE RW, 1989, J IMMUNOL METHODS, V124, P277, DOI 10.1016/0022-1759(89)90364-5; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; Kabat EA, 1991, SEQUENCES PROTEINS I; KOZAK RW, 1989, CANCER RES, V49, P2639; KRUCK TPA, 1976, CAN J CHEM, V8, P1300; Lide D. R., 1995, CRC HDB CHEM PHYS, P12; LIND MD, 1964, INORG CHEM, V3, P34, DOI 10.1021/ic50011a007; LOVE RA, 1993, BIOCHEMISTRY-US, V32, P10950, DOI 10.1021/bi00092a004; Meyer DL, 1990, BIOCONJUGATE CHEM, V1, P278, DOI 10.1021/bc00004a009; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; QUICHO FA, 1971, ADV PROTEIN CHEM, V25, P1; REARDAN DT, 1985, NATURE, V316, P265, DOI 10.1038/316265a0; REGAN L, 1993, ANNU REV BIOPH BIOM, V22, P257, DOI 10.1146/annurev.bb.22.060193.001353; THIERS R E, 1957, Methods Biochem Anal, V5, P273; TOMA S, 1991, BIOCHEMISTRY-US, V30, P97, DOI 10.1021/bi00215a015; WYLIE DE, 1991, ANAL BIOCHEM, V194, P381, DOI 10.1016/0003-2697(91)90245-O; WYLIE DE, 1992, P NATL ACAD SCI USA, V89, P4104, DOI 10.1073/pnas.89.9.4104	24	143	172	2	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27677	27685		10.1074/jbc.271.44.27677	http://dx.doi.org/10.1074/jbc.271.44.27677			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910359	hybrid			2022-12-25	WOS:A1996VQ67900077
J	Glaven, JA; Whitehead, IP; Nomanbhoy, T; Kay, R; Cerione, RA				Glaven, JA; Whitehead, IP; Nomanbhoy, T; Kay, R; Cerione, RA			Lfc and Lsc oncoproteins represent two new guanine nucleotide exchange factors for the Rho GTP-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DBL ONCOGENE PRODUCT; ACTIN STRESS FIBERS; SEQUENCE SIMILARITY; EXPRESSION CLONING; CDC42 GTPASES; RAC; HOMOLOGY; ENCODES; KINASE; GENE	Lfc and Lsc are two recently identified oncoproteins that contain a Dbl homology domain in tandem with a pleckstrin homology domain and thus share sequence similarity with a number of other growth regulatory proteins including Dbl, Tiam-1, and Lbc. We show here that Lfc and Lsc, like their closest relative Lbc, are highly specific guanine nucleotide exchange factors (GEFs) for Rho, causing a > 10-fold stimulation of [H-3]GDP dissociation from Rho and a marked stimulation of GDP-[S-35]GTP gamma s (guanosine 5'-O-(3-thiotriphosphate) exchange, All three proteins (Lbc, Lfc, and Lsc) are able to act catalytically in stimulating the guanine nucleotide exchange activity, such Chat a single molecule of each of these oncoproteins can activate a number of molecules of Rho, Neither Lfc nor ise shows any ability to stimulate GDP dissociation from other related GTP-binding proteins ouch as Rac, Cdc42, or Res, Thus Lbc, Lfc, and Lsc appear to represent a subgroup of Dbl-related proteins that function as highly specific GEFs toward Rho and can be distinguished from Dbl, Ost, and Dbs which are less specific and show GEF activity toward both Rho and Cdc42, Consistent with these results, Lbc, Lfc, and Lsc each form tight complexes with the guanine nucleotide depleted form of Rho and bind weakly to the GDP- and GTP gamma S-bound states. None of these oncoproteins are able to form complexes with Cdc42 or Ras, However, Lfc (but not Lbc nor Lsc) can bind to Rac, and this binding occurs equally well when Rac is nucleotide-depleted or is in the GDP- or GTP gamma S-bound state, These findings raise the possibility that in addition to acting directly as a GEF for BI-ro, Lfc may play other roles that influence the signaling activities of Rac and/or coordinate the activities of the Rac and Rho proteins.	CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; BRITISH COLUMBIA CANC AGCY,TERRY FOX LAB,VANCOUVER,BC V5Z 4E6,CANADA	Cornell University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; British Columbia Cancer Agency					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008210, R01GM047458] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM08210, GM47458] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; CHAN AML, 1994, ONCOGENE, V9, P1057; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PASTERIS NG, 1994, CELL, V79, P669; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1991, NEW BIOL, V3, P372; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; TOKSOZ D, 1994, ONCOGENE, V9, P621; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; Zheng Y, 1996, J BIOL CHEM, V271, P23815, DOI 10.1074/jbc.271.39.23815; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	35	105	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27374	27381		10.1074/jbc.271.44.27374	http://dx.doi.org/10.1074/jbc.271.44.27374			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910315	Green Published, hybrid			2022-12-25	WOS:A1996VQ67900033
J	Skouteris, GG; Schroder, CH				Skouteris, GG; Schroder, CH			The hepatocyte growth factor receptor kinase-mediated phosphorylation of lipocortin-1 transduces the proliferating signal of the hepatocyte growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCATTER FACTOR-RECEPTOR; C-MYC EXPRESSION; DEPENDENT PHOSPHORYLATION; CELL-LINE; ANNEXIN-I; PROTEIN; MITOGEN; PHOSPHOLIPASE-A2; EGF; TRANSFORMATION	Hepatocyte growth factor (HGF), which is identical to scatter factor (SF) through coupling to its receptor the product of c-met oncogene, was found to induce proliferation of A549 lung carcinoma cell line, accompanied by release of prostaglandin E(2) (PGE(2)), This activity was sensitive to 0.1-100 mu m indomethacin and to 5-50 nM of verapamil. Lipocortin-1, a dexamethasone-inducible inhibitor of phospholipase A(2), was shown to be phosphorylated on tyrosine 10 min upon addition of HGF and to translocate 60 the membrane fraction for up to 6 h upon ligand stimulation, Lipocortin-l was found to associate in vivo with the HGP receptor species, and this association was independent of the phosphorylation state of the beta-subunit of the HGF receptor (p145 beta(MET). ImmobiLized HGF receptor kinase species associated and phosphorylated in vitro lipocortin-1, thus providing evidence that lipocortin-l is directly phosphorylated by the p145 beta(MET). Incubation of A549 cells with antisense 21-mer lipocortin-1 oligonucleotides reduced the synthesis and the HGF-stimulated phosphorylation of lipocortin-1 as well as the HGF-stimulated cell proliferation, In processes where the HGF receptor tyrosine kinase is activated, phosphorylation of lipocortin-1 may function as a ''signal amplifier'' promoting the release of intercellular messengers (PGE(2)) with pluripotent roles in cell proliferation, chemotaxis, and vascular remodeling.			Skouteris, GG (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM, RES PROGRAM APPL TUMOR VIROL, DIV VIRUS HOST INTERACT, D-69120 HEIDELBERG, GERMANY.							ADACHI T, 1995, HEPATOLOGY, V21, P1668; BARDELLI A, 1992, ONCOGENE, V7, P1973; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARK S, 1991, BIOCHEM J, V274, P715, DOI 10.1042/bj2740715; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CROXTALL JD, 1993, INT J CANCER, V54, P153, DOI 10.1002/ijc.2910540124; FLOWER RJ, 1988, BRIT J PHARMACOL, V94, P987, DOI 10.1111/j.1476-5381.1988.tb11614.x; FLOWER RJ, 1976, BIOCHEM PHARMACOL, V25, P285, DOI 10.1016/0006-2952(76)90216-1; GANDINO G, 1994, EMBO J, V13, P3524; GANDINO L, 1991, J BIOL CHEM, V266, P16098; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HAYASHI J, 1993, BIOCHEM MOL BIOL INT, V31, P143; HIRATA F, 1984, P NATL ACAD SCI-BIOL, V81, P4717, DOI 10.1073/pnas.81.15.4717; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MASAKI T, 1994, HEPATOLOGY, V20, P425, DOI 10.1002/hep.1840200224; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; PALIOGIANNI F, 1995, J IMMUNOL, V155, P1809; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; PEPINSKY RB, 1991, METHOD ENZYMOL, V198, P260; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; SAKATA T, 1988, NUCLEIC ACIDS RES, V16, P11818, DOI 10.1093/nar/16.24.11818; SKOUTERIS GG, 1992, BIOCHEM J, V281, P729, DOI 10.1042/bj2810729; SKOUTERIS GG, 1988, J CELL PHYSIOL, V135, P516, DOI 10.1002/jcp.1041350321; SKOUTERIS GG, 1991, BIOCHEM BIOPH RES CO, V178, P1240, DOI 10.1016/0006-291X(91)91026-9; SOLITO E, 1994, BRIT J PHARMACOL, V112, P347, DOI 10.1111/j.1476-5381.1994.tb13075.x; WEIDNER KM, 1990, J CELL BIOL, V111, P1815; ZARNEGAR R, 1989, CANCER RES, V49, P3314	37	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27266	27273		10.1074/jbc.271.44.27266	http://dx.doi.org/10.1074/jbc.271.44.27266			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910300	hybrid			2022-12-25	WOS:A1996VQ67900018
J	Teramoto, H; Coso, OA; Miyata, H; Igishi, T; Miki, T; Gutkind, JS				Teramoto, H; Coso, OA; Miyata, H; Igishi, T; Miki, T; Gutkind, JS			Signaling from the small GTP-binding proteins Rac1 and Cdc42 to the c-Jun N-terminal kinase stress-activated protein kinase pathway - A role for mixed lineage kinase 3 protein-tyrosine kinase 1, a novel member of the mixed lineage kinase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH3 DOMAIN; IDENTIFICATION; CLONING; SUBFAMILY; CASCADE; BEARING; BRAIN	Certain small GTP-binding proteins control the enzymatic activity of a family of closely related serine-threonine kinases known as mitogen-activated protein kinases (MAPKs), In turn, these MAPKs, such as p44(mapk) and p42(mapk), referred to herein as MAPKs, and stress activated protein kinases, also termed c-Jun N-terminal kinases (JNKs), phosphorylate and regulate the activity of key molecules that ultimately control the expression of genes essential for many cellular processes, Whereas Ras controls the activation of MAPK, we and others have recently observed that two members of the Rho family of small GTP-binding proteins, Rad and Cdc42, regulate the activity of JNKs. The identity of molecules communicating Rad and Cdc42 to JNK is still poorly understood. It has been suggested that Pak1 is the most upstream kinase connecting these GTPases to JNK; however, we have observed that coexpression of Pak1 with activated forms of Cdc42 or Rad diminishes rather than enhances JNK activation. This prompted us to explore the possibility that kinases other than Pak might participate in signaling from GTP binding proteins to JNK, In this regard, a computer-assisted search for proteins containing areas of homology to that in Pak1 that is involved in binding to Rad and Cdc42 led to the identification of mixed lineage kinase 3 (MLK3), also known as protein-tyrosine kinase 1, as a potential candidate for this function, In this study, we found that MLK3 overexpression is sufficient to activate JNK po tently without affecting the phosphorylating activity of MAPK or p38. Furthermore, we present evidence that MLK3 binds the GTP-binding proteins Cdc42 and Rad in vivo and that MLK3 mediates activation of MEKK-SEK-JNK kinase cascade by Rad and Cdc42. Taken together, these findings strongly suggest that members of the novel MLK family of highly related kinases link small GTP-binding proteins to the JNK signaling pathway.	NIDR,CELLULAR DEV & ONCOL LAB,MOL SIGNALING UNIT,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 				BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; EZOE K, 1994, ONCOGENE, V9, P935; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; GALLO KA, 1994, J BIOL CHEM, V269, P15092; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; ING YL, 1994, ONCOGENE, V9, P1745; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KATOH M, 1995, ONCOGENE, V10, P1447; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER C, 1994, SCIENCE, V260, P315; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LIM PS, 1990, J INFECT DIS, V162, P1263, DOI 10.1093/infdis/162.6.1263; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	25	312	321	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27225	27228		10.1074/jbc.271.44.27225	http://dx.doi.org/10.1074/jbc.271.44.27225			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910292	hybrid			2022-12-25	WOS:A1996VQ67900010
J	Ihn, H; Ohnishi, K; Tamaki, T; LeRoy, EC; Trojanowska, M				Ihn, H; Ohnishi, K; Tamaki, T; LeRoy, EC; Trojanowska, M			Transcriptional regulation of the human alpha 2(I) collagen gene - Combined action of upstream stimulatory and inhibitory cis-acting elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; CCAAT-BINDING-FACTOR; DNA-BINDING; PRO-ALPHA-2(I) COLLAGEN; FUNCTIONAL-ANALYSIS; PROMOTER; ACTIVATION; ALPHA-1(I); PURIFICATION; EXPRESSION	This study identifies three regions of the human alpha 2(I) collagen promoter involved in the binding of nuclear factors. These regions include sequences from -173 to -155 (footprint I), -133 to -119 (footprint II), and -101 to -72 (footprint III). A novel positive cis-element containing a TCCTCC motif was identified within footprint II. In addition, we demonstrated that a pyrimidine-rich region within footprint I is a binding site for a transcriptional repressor, and a CCAAT motif within footprint III is a binding site for a transcriptional activator, Comparative functional analysis of the cis-acting elements within the proximal 350 base pairs of this promoter, including previously characterized Sp1 binding sites at -300, indicates that constitutive activity of this promoter is regulated equivalently by the three positive cis-acting elements at -300, -125, and -80. Mutations in the repressor site at -160 increase constitutive activity by 4-6 fold. However, simultaneous mutations of the repressor site and the cis-regulatory element at either the -300 or -125 sites result in no increase in constitutive transcription activity suggesting interaction between the activators and repressor elements, In contrast, simultaneous mutation of the CCAAT motif and the repressor site results in about a 4-fold increase, suggesting that activation via the CCAAT motif may be independent of this repressor.	MED UNIV S CAROLINA,DEPT MED,DIV RHEUMATOL,CHARLESTON,SC 29425	Medical University of South Carolina				Trojanowska, Maria/0000-0001-9550-7178	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042334] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42334] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BOAST S, 1990, J BIOL CHEM, V265, P13351; BORNSTEIN P, 1980, ANNU REV BIOCHEM, V49, P957, DOI 10.1146/annurev.bi.49.070180.004521; CHANG E, 1995, J BIOL CHEM, V270, P4473, DOI 10.1074/jbc.270.9.4473; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; DICKSON LA, 1985, NUCLEIC ACIDS RES, V13, P3427, DOI 10.1093/nar/13.10.3427; HATAMOCHI A, 1993, FEBS LETT, V327, P325, DOI 10.1016/0014-5793(93)81014-Q; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; IBARAKI K, 1993, GENE, V130, P225, DOI 10.1016/0378-1119(93)90423-Z; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; KARSENTY G, 1988, J BIOL CHEM, V263, P13909; KARSENTY G, 1991, J BIOL CHEM, V266, P24842; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; KARSENTY G, 1991, BIOCHEM BIOPH RES CO, V177, P538, DOI 10.1016/0006-291X(91)92017-E; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; RAMIREZ F, 1990, FASEB J, V4, P1616, DOI 10.1096/fasebj.4.6.2180769; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201	23	114	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26717	26723		10.1074/jbc.271.43.26717	http://dx.doi.org/10.1074/jbc.271.43.26717			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900150	hybrid			2022-12-25	WOS:A1996VP23300044
J	Negrescu, EV; Siess, W				Negrescu, EV; Siess, W			Dissociation of the alpha(IIb)beta(3)-Integrin by EGTA stimulates the tyrosine kinase pp72(syk) without inducing platelet activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IIB-IIIA COMPLEX; INTEGRIN CYTOPLASMIC DOMAINS; MEMBRANE GLYCOPROTEIN-IIB; OUT SIGNAL-TRANSDUCTION; FOCAL ADHESION KINASE; MONOCLONAL-ANTIBODIES; CALCIUM DEPRIVATION; DIVALENT-CATIONS; LIGAND-BINDING; PHOSPHORYLATION	Incubation of human platelets with EG;TA under conditions that dissociate the alpha(IIb)beta(3)-integrin stimulated tyrosine phosphorylation of pp72(syk) (6.8-fold) and of pro teins of 62 (2.2-fold), 68 (2.5-fold) and 130 kDa (1.4-fold), Stimulation of tyrosine phosphorylation of pp72(syk) was associated with an increase of pp72(syk) kinase activity, In contrast to pp72(syk), tyrosine phosphorylation of the fo cal adhesion kinase pp125(FAK) was not stimulated by EGTA. Preincubation of platelets with the monoclonal antibody P2, which binds to the alpha(IIb)beta(3) complex and thus stabilizes it, strongly reduced the increase of tyrosine phosphorylation of pp72(syk), p62, and p68 induced by EGTA, The Y2/51 monoclonal antibody, which recog nizes only the beta(3) glycoprotein, did not inhibit the stimulation of protein tyrosine phosphorylation evoked by EGTA, Stimulation of tyrosine phosphorylation of pp72(syk), p62, p68, and p130 induced by EGTA was not observed in thrombasthenic platelets, which lack the alpha(IIb)beta(3)-integrin. The results indicate that the dissociation of the alpha(IIb)beta(3) complex in intact platelets activates pp72(syk). The mechanism of activation was found to be insensitive to inhibition by cAMP and cGMP and only partially dependent on cytosolic Ca2+, suggesting a close functional coupling of alpha(IIb)beta(3)-integrin and pp72(syk). Since platelets retain their discoid shape after EG;TA treatment, we further conclude that pp72(syk) stimulation alone is not sufficient for platelet activation.	UNIV MUNICH,INST PROPHYLASE & EPIDEMIOL,KREISLAUFKRANKHEITEN,D-80336 MUNICH,GERMANY	University of Munich			Siess, Wolfgang/A-6430-2009	Siess, Wolfgang/0000-0003-0698-6416				BRASS LF, 1985, J BIOL CHEM, V260, P7875; BRASS LF, 1985, J BIOL CHEM, V260, P2231; BRASS LF, 1984, J CLIN INVEST, V73, P626, DOI 10.1172/JCI111252; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; CHAPPELL LT, 1993, J ADV MED, V6, P139; CHEN YP, 1994, J BIOL CHEM, V269, P18307; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; CLARK EA, 1994, J BIOL CHEM, V269, P28859; DASH D, 1995, J BIOL CHEM, V270, P17321, DOI 10.1074/jbc.270.29.17321; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; FALET H, 1994, FEBS LETT, V345, P87, DOI 10.1016/0014-5793(94)00414-5; FOX JEB, 1993, ADV EXP MED BIOL, V344, P175; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; FUJII C, 1994, EUR J BIOCHEM, V226, P243, DOI 10.1111/j.1432-1033.1994.tb20047.x; GACHET C, 1993, J CELL BIOL, V120, P1021, DOI 10.1083/jcb.120.4.1021; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; GOGSTAD GO, 1982, BIOCHIM BIOPHYS ACTA, V689, P21, DOI 10.1016/0005-2736(82)90184-5; GOGSTAD GO, 1982, BLOOD, V60, P663; HAGEN I, 1982, BIOCHIM BIOPHYS ACTA, V701, P1, DOI 10.1016/0167-4838(82)90303-X; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; KUNICKI TJ, 1981, BLOOD, V58, P268; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MCGREGOR JL, 1986, EUR J BIOCHEM, V159, P443, DOI 10.1111/j.1432-1033.1986.tb09906.x; NEGRESCU EV, 1995, J BIOL CHEM, V270, P1057, DOI 10.1074/jbc.270.3.1057; NOMURA S, 1987, THROMB RES, V47, P47, DOI 10.1016/0049-3848(87)90239-8; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PEERSCHKE EI, 1980, BRIT J HAEMATOL, V46, P247, DOI 10.1111/j.1365-2141.1980.tb05963.x; PIDARD D, 1986, BLOOD, V67, P604; PIDARD D, 1983, J BIOL CHEM, V258, P2582; SARGEANT P, 1994, EXP PHYSIOL, V79, P269, DOI 10.1113/expphysiol.1994.sp003762; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SHATTIL SJ, 1992, J BIOL CHEM, V267, P18424; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SIESS W, 1990, ADV EXP MED BIOL, V273, P119; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; VANRIJ AM, 1994, CIRCULATION, V90, P1194, DOI 10.1161/01.CIR.90.3.1194; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; WHITE JG, 1968, SCAND J HAEMATOL, V5, P241; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471; ZUCKER MB, 1954, BLOOD, V9, P602, DOI 10.1182/blood.V9.6.602.602; ZUCKER MB, 1978, BLOOD, V52, P505	48	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26547	26553		10.1074/jbc.271.43.26547	http://dx.doi.org/10.1074/jbc.271.43.26547			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900125	hybrid			2022-12-25	WOS:A1996VP23300019
J	ODonohue, MJ; Beaumont, A				ODonohue, MJ; Beaumont, A			The roles of the prosequence of thermolysin in enzyme inhibition and folding in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA ELASTASE; SITE-DIRECTED MUTAGENESIS; PROTEASE PRO-REGION; IN-VIVO FORMATION; NEUTRAL PROTEASE; BACILLUS-SUBTILIS; CARBOXYPEPTIDASE-Y; ESCHERICHIA-COLI; DENATURED SUBTILISIN; CATALYTIC ACTIVITY	The zinc endopeptidase thermolysin (EC 3.4.24.27), an extracellular enzyme from Bacillus thermoproteolyticus, is synthesized as a preproprotein, with the prosequence (204 residues) being two thirds the size of the mature enzyme (316 residues). This prosequence, expressed in and purified from Escherichia coli, inhibited thermolysin in vitro with an IC50 value of 14 nM. It also inhibited a closely related enzyme produced by Bacillus stearothermophillus, albeit with a 16-fold higher IC50 value (220 nM). The IC50 value for thermolysin inhibition was also increased 15-fold (210 nm) by a monoclonal antibody that recognizes an epitope close to, but not forming a part of, the active site. At a prosequence concentration of 5 mu M a mammalian, thermolysin-like enzyme, neutral endopeptidase 24.11, was not inhibited. The prosequence appeared to act as a mixed, noncompetitive inhibitor of thermolysin activity, with a K-i value of 6 nM for its interaction with the enzyme alone and a K-i' value of 20 nM for its interaction with the enzyme substrate complex. In addition, when thermolysin was denatured in 6 M guanidinium hydrochloride at acid pH and then brought to neutral pH by rapid dilution, the prosequence was found to facilitate the recovery of active enzyme in a stoichiometric manner.	UNIV PARIS 05, CNRS,UNITE RECH ASSOCIEE D1500, DEPT PHARMACOCHIM MOL & STRUCT,INSERM, U266, F-75270 PARIS 06, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			O'Donohue, Michael/ABD-9239-2021; O'Donohue, Michael J/E-9183-2013	O'Donohue, Michael/0000-0003-4246-3938; O'Donohue, Michael J/0000-0003-4246-3938				AUBRY M, 1987, BIOCHEM CELL BIOL, V65, P398, DOI 10.1139/o87-050; BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BEAUMONT A, 1995, J BIOL CHEM, V270, P16803, DOI 10.1074/jbc.270.28.16803; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braun P, 1996, MOL MICROBIOL, V19, P297, DOI 10.1046/j.1365-2958.1996.381908.x; BRYAN P, 1995, BIOCHEMISTRY-US, V34, P10310, DOI 10.1021/bi00032a026; CHANG SC, 1994, J BIOL CHEM, V269, P3548; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; EDER J, 1993, J MOL BIOL, V233, P293, DOI 10.1006/jmbi.1993.1507; FORTENBERRY SC, 1995, J BIOL CHEM, V270, P9778, DOI 10.1074/jbc.270.17.9778; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; KAWAMOTO S, 1993, INFECT IMMUN, V61, P1400, DOI 10.1128/IAI.61.4.1400-1405.1993; KESSLER E, 1994, J BIOL CHEM, V269, P22726; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; MCIVER K, 1991, J BACTERIOL, V173, P7781, DOI 10.1128/jb.173.24.7781-7789.1991; MELCHIORI A, 1992, CANCER RES, V52, P2353; ODONOHUE MJ, 1994, BIOCHEM J, V300, P599, DOI 10.1042/bj3000599; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; RAMOS C, 1994, J BIOL CHEM, V269, P7006; ROQUES BP, 1993, PHARMACOL REV, V45, P87; Sambrook J, 1989, MOL CLONING LAB MANU, P1; SANSEGUNDO B, 1982, BIOCHIM BIOPHYS ACTA, V707, P74, DOI 10.1016/0167-4838(82)90398-3; SCHECHTER I, 1968, BIOCHEM BIOPH RES CO, V32, P898, DOI 10.1016/0006-291X(68)90326-4; SIGNOR G, 1990, EUR J BIOCHEM, V189, P221, DOI 10.1111/j.1432-1033.1990.tb15480.x; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SIMONEN M, 1993, MICROBIOL REV, V57, P109, DOI 10.1128/MMBR.57.1.109-137.1993; SMITH SM, 1989, J BIOL CHEM, V264, P20487; STARK W, 1992, EUR J BIOCHEM, V207, P781, DOI 10.1111/j.1432-1033.1992.tb17109.x; STRAUSBERG S, 1993, BIOCHEMISTRY-US, V32, P8112, DOI 10.1021/bi00083a009; TAYLOR M, 1995, PROTEIN ENG, V15, P59; THAYER MM, 1991, J BIOL CHEM, V266, P2864; TOMA S, 1989, PROTEIN ENG, V2, P359, DOI 10.1093/protein/2.5.359; TSURU D, 1993, J BIOCHEM-TOKYO, V113, P101, DOI 10.1093/oxfordjournals.jbchem.a123991; VANDENHAZEL HB, 1993, J BIOL CHEM, V268, P18002; VOGEL Z, 1977, FEBS LETT, V80, P332, DOI 10.1016/0014-5793(77)80469-9; VRIEND G, 1993, J COMPUT AID MOL DES, V7, P367, DOI 10.1007/BF02337558; WETMORE DR, 1992, MOL MICROBIOL, V6, P1593, DOI 10.1111/j.1365-2958.1992.tb00884.x; WETMORE DR, 1994, MOL MICROBIOL, V12, P747, DOI 10.1111/j.1365-2958.1994.tb01062.x; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; WINTHER JR, 1994, J BIOL CHEM, V269, P22007; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	43	50	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26477	26481		10.1074/jbc.271.43.26477	http://dx.doi.org/10.1074/jbc.271.43.26477			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900115	Green Published, hybrid			2022-12-25	WOS:A1996VP23300009
J	Janknecht, R; Monte, D; Baert, JL; deLaunoit, Y				Janknecht, R; Monte, D; Baert, JL; deLaunoit, Y			The ETS-related transcription factor ERM is a nuclear target of signaling cascades involving MAPK and PKA	ONCOGENE			English	Article						Ets protein; ERM; phosphorylation; signaling; transcription	ACTIVATED PROTEIN-KINASE; DNA-BINDING; TRANSDUCTION PATHWAYS; C-FOS; MOLECULAR-CLONING; GENE-EXPRESSION; ONCOGENE FAMILY; GROWTH-FACTOR; DOMAIN; PROMOTER	Recent studies support a model for signal transduction from activated receptor tyrosine kinases to Ras which, in turn, activates the pathway of the mitogen-activated protein kinase (MARK), Although some members of the Ets transcription factor family have been shown to be activated by this signaling pathway, no data are available on the activation of the PEA3 group of Ets proteins, This group is composed of three members PEA3, ER81 and ERM - which are very similar in the DNA-binding domain, the ETS domain, in the 32 residue amino-terminal acidic domain and in the 61 residue carboxy-terminal domain, First of all we demonstrated that ERM-transfected cells contain a positive labeling in the nucleus, and rye concluded that a nuclear localization signal might be situated in the ETS domain, We then showed that of four putative reporter plasmids, ERM activated the artificial 3 x TORU plasmid which contains an Ets binding site contiguous to an AP1 one, This transactivation enhancement requires the presence of the ERM amino-terminal domain, In contrast, although the lack of the carboxy-terminal domain induced a decrease in transactivation, this latter domain is not crucial, By using the E74-reporter plasmid system which is not basically activated by ERM, we showed that the activation of the Ras/Raf-1/MAPK pathway significantly enhanced ERM-mediated transactivation, The deletion of the amino-terminal transactivation domain abolished the capacity of stimulated MAPK to activate ERM, We also demonstrated that ERM can also be activated through the protein kinase A (PKA), another signaling pathway, Nevertheless, the MAPK and PKA activation of ERM are not synergistic, Finally, we showed that this Ets transcription factor is in vitro phosphorylated by both activated ERK-2 and activated PKA, ERM has thus been identified as a transcription factor which is a target for two different signaling pathways and might therefore be involved in the mitogenic response of cells.	INST PASTEUR,CNRS URA 1160,UNITE ONCOL MOL,F-59019 LILLE,FRANCE; HANNOVER MED SCH,INST MOL BIOL,D-30623 HANNOVER,GERMANY	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Hannover Medical School				Janknecht, Ralf/0000-0003-1741-1562; monte, didier/0000-0002-0613-6203				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; COFFER P, 1994, ONCOGENE, V9, P911; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; Crepieux Pascale, 1993, Gene Expression, V3, P215; deLaunoit Y, 1996, BREAST CANCER - ADVANCES IN BIOLOGY AND THERAPEUTICS, P115; DICKSON B, 1995, TRENDS GENET, V11, P106, DOI 10.1016/S0168-9525(00)89011-3; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; JANKNECHT R, 1995, ONCOGENE, V10, P1209; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JEON IS, 1995, ONCOGENE, V10, P1229; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLAES A, 1994, CELL, V78, P149, DOI 10.1016/0092-8674(94)90581-9; Laget MP, 1996, ONCOGENE, V12, P1325; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PICKETT CA, 1995, MOL CELL BIOL, V15, P6777; RAO VN, 1993, ONCOGENE, V8, P2167; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; Stacey D W, 1988, Adv Exp Med Biol, V234, P141; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	40	79	80	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1745	1754						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895521				2022-12-25	WOS:A1996VM88700020
J	Akiyama, T; Hogan, ME				Akiyama, T; Hogan, ME			Microscopic DNA flexibility analysis - Probing the base composition and ion dependence of minor groove compression with an artificial DNA bending agent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-HELIX FORMATION; 434 REPRESSOR; AFFINITY; OPERATOR; BINDING; THERMODYNAMICS; COMPLEXES; TETRAPLEX	We have used an artificial DNA bending agent to monitor the local. flexibility of the DNA helix as a function of Mg2+ cation concentration, sequence, and temperature. A DNA bending agent was constructed from a pair of triple helix-forming oligonucleotides connected by a flexible polymeric linker, which, when the Linker is short enough, causes a bend in a minor groove region separating the two sites of triple helix formation. The unique aspect of this system is that, since the bent region is not in direct contact with the linker or the triple helix-forming oligonucleotides, the free energy reflecting the bendability of the minor helix groove can be estimated from a comparison of binding affinity between the bent and unbent triple helices. A binding competition experiment and association and dissociation kinetic assays executed at 37 degrees C in the presence of 10 man Mg2+ have revealed an extremely small difference in binding affinity between bent (50 degrees) and straight triple helices, suggesting that DNA flexibility with respect to minor groove compression is extremely high and virtually independent of the sequence of the distorted duplex. This unexpectedly small difference in binding affinity was detected over the temperature range from 25 to 65 degrees C, and over a Mg2+ concentration range from 0.3 to 10 mM. Thus, these findings provide evidence that DNA bendability for minor groove compression is inherently high and independent of DNA sequence, temperature, or a 30-fold variation of Mg2+ ion concentration.	BAYLOR COLL MED,DEPT MOL PHYSIOL & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine								AKIYAMA T, 1996, IN PRESS P NATL ACAD; ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; BALDWIN JP, 1975, NATURE, V253, P245, DOI 10.1038/253245a0; BARKLEY MD, 1979, J CHEM PHYS, V70, P2991, DOI 10.1063/1.437838; BURLINGAME RW, 1985, SCIENCE, V228, P546, DOI 10.1126/science.3983639; CHEN HH, 1978, J BIOMOL STRUCT DYN, V2, P709; CLOAD ST, 1993, J AM CHEM SOC, V115, P5005, DOI 10.1021/ja00065a008; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DURLAND RH, 1991, BIOCHEMISTRY-US, V30, P9246, DOI 10.1021/bi00102a017; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; GRAY HB, 1968, J MOL BIOL, V35, P111, DOI 10.1016/S0022-2836(68)80041-5; HARRINGTON RE, 1978, BIOPOLYMERS, V17, P919, DOI 10.1002/bip.1978.360170410; HOGAN M, 1983, NATURE, V304, P752, DOI 10.1038/304752a0; HOGAN ME, 1987, NATURE, V329, P263, DOI 10.1038/329263a0; JIN R, 1990, SCIENCE, V250, P543, DOI 10.1126/science.2237404; JIN RZ, 1992, P NATL ACAD SCI USA, V89, P8832, DOI 10.1073/pnas.89.18.8832; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; KORNBERG RD, 1974, SCIENCE, V184, P868, DOI 10.1126/science.184.4139.868; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; KOUDELKA GB, 1992, NATURE, V355, P89, DOI 10.1038/355089a0; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; KOVACIC RT, 1977, BIOCHEMISTRY-US, V16, P1490, DOI 10.1021/bi00626a038; LEVENE SD, 1986, J MOL BIOL, V189, P61, DOI 10.1016/0022-2836(86)90381-5; MAHER LJ, 1990, BIOCHEMISTRY-US, V29, P8820, DOI 10.1021/bi00489a045; Maniatis T, 1989, DECONTAMINATION DILU; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; MARINI JC, 1982, P NATL ACAD SCI-BIOL, V79, P7664, DOI 10.1073/pnas.79.24.7664; NOONBERG SB, 1995, NUCLEIC ACIDS RES, V23, P1956, DOI 10.1093/nar/23.11.1956; OLSON WK, 1993, J MOL BIOL, V232, P530, DOI 10.1006/jmbi.1993.1409; PILSCH DS, 1991, BIOCHEMISTRY-US, V30, P6081; ROUGEE M, 1992, BIOCHEMISTRY-US, V31, P9269, DOI 10.1021/bi00153a021; SARAI A, 1989, BIOCHEMISTRY-US, V28, P7842, DOI 10.1021/bi00445a046; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795; STRAUSS JK, 1994, SCIENCE, V266, P1829, DOI 10.1126/science.7997878; THOMAS TJ, 1983, NUCLEIC ACIDS RES, V11, P1919, DOI 10.1093/nar/11.6.1919; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VESNAVER G, 1991, P NATL ACAD SCI USA, V88, P3569, DOI 10.1073/pnas.88.9.3569; ZHURKIN VB, 1991, P NATL ACAD SCI USA, V88, P7046, DOI 10.1073/pnas.88.16.7046	40	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29126	29135		10.1074/jbc.271.46.29126	http://dx.doi.org/10.1074/jbc.271.46.29126			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910569	hybrid			2022-12-25	WOS:A1996VT05200061
J	Cao, YH; Ji, RW; Davidson, D; Schaller, J; Marti, D; Sohndel, S; McCance, SG; OReilly, MS; Llinas, M; Folkman, J				Cao, YH; Ji, RW; Davidson, D; Schaller, J; Marti, D; Sohndel, S; McCance, SG; OReilly, MS; Llinas, M; Folkman, J			Kringle domains of human angiostatin - Characterization of the anti-proliferative activity on endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HUMAN PLASMINOGEN KRINGLE-4; FIBROBLAST GROWTH-FACTOR; LEWIS-LUNG-CARCINOMA; N-TERMINAL FRAGMENT; ANGIOGENESIS INHIBITOR; TUMOR ANGIOGENESIS; POTENT INHIBITOR; BINDING; PURIFICATION	Recently we have identified angiostatin, an endogenous angiogenesis inhibitor of 38 kDa which specifically blocks the growth of endothelial cells (O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. (1994) Cell 79, 315-328; Folkman, J. (1995) Nat. Med. 1, 27-31). Angiostatin was shown to represent an internal fragment of plasminogen containing the first four kringle structures. We now report on the inhibitory effects of individual or combined kringle structures of angiostatin on capillary endothelial cell proliferation. Recombinant kringle 1 and kringle 3 exhibit potent inhibitory activity with half-maximal concentrations (ED(50)) of 320 nM and 460 nM, respectively. Also, recombinant kringle 2 displays a significant inhibition, although decreased compared with both kringle 1 and kringle 3. In contrast, kringle 4 is an ineffective inhibitor of basic fibroblast growth factor-stimulated endothelial cell proliferation. Among the tandem kringle arrays, the recombinant kringle 2-3 fragment exerts inhibitory activity similar to kringle 2 alone. However, relative to kringle 2-3, a marked enhancement in inhibition is observed when individual kringle 2 and kringle 3 are added together to endothelial cells. This implies that it is necessary to open the cystine bridge between kringle 2 and kringle 3 to obtain the maximal inhibitory effect of kringle 2-3. An increased (<2-fold) inhibitory activity is observed for the kringle 1-3 fragment (ED(50) = 70 nM) compared with kringle 1-4 (ED(50) = 135 nn). These data indicate that the anti-proliferative activity of angiostatin on endothelial cells is shared by kringle 1, kringle 2, and kringle 3, but probably not by kringle 4 and that more potent inhibition results when kringle 4 is removed from angiostatin. Thus, in view of the variable lysine affinity of the homologous domains, it would appear that lysine binding capability does not correlate with the relative inhibitory effects of the kringle-containing constructs. However, as we also demonstrate, appropriate folding of kringle structures is essential for angiostatin to maintain its full anti-endothelial activity.	HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; ABBOTT LABS,DIV PHARMACEUT PROD,ABBOTT PK,IL 60064; UNIV BERN,INST BIOCHEM,CH-3012 BERN,SWITZERLAND; CARNEGIE MELLON UNIV,DEPT CHEM,PITTSBURGH,PA 15213; AMER BIOGENET SCI INC,S BEND,IN 46635; UNIV NOTRE DAME,DEPT CHEM,S BEND,IN 46556	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Abbott Laboratories; University of Bern; Carnegie Mellon University; University of Notre Dame				Davidson, Donald/0000-0002-8669-9814	NHLBI NIH HHS [HL 29409] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029409] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOUCK N, 1990, CANCER CELL-MON REV, V2, P179; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CAO Y, 1996, J BIOL CHEM, V271, P9154; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; Cao YH, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037497; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; CLEARY S, 1989, BIOCHEMISTRY-US, V28, P1884, DOI 10.1021/bi00430a068; COX M, 1994, CHEM PHYS LIPIDS, V67-8, P43, DOI 10.1016/0009-3084(94)90123-6; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; DONATE LE, 1994, PROTEIN SCI, V3, P2378, DOI 10.1002/pro.5560031222; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GUNZLER WA, 1982, H-S Z PHYSIOL CHEM, V363, P1155, DOI 10.1515/bchm2.1982.363.2.1155; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; HOCHSCHWENDER SM, 1983, ARCH BIOCHEM BIOPHYS, V223, P58, DOI 10.1016/0003-9861(83)90571-4; HOMANDBERG GA, 1985, AM J PATHOL, V120, P327; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; LUKKER NA, 1994, PROTEIN ENG, V7, P892; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MARTI D, 1994, EUR J BIOCHEM, V219, P455, DOI 10.1111/j.1432-1033.1994.tb19959.x; MARTI D, 1994, THESIS U BERNE SWITZ; Mathews II, 1996, BIOCHEMISTRY-US, V35, P2567, DOI 10.1021/bi9521351; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MENHART N, 1991, BIOCHEMISTRY-US, V30, P1948, DOI 10.1021/bi00221a031; MENHART N, 1993, BIOCHEMISTRY-US, V32, P8799, DOI 10.1021/bi00085a010; MULICHAK AM, 1991, BIOCHEMISTRY-US, V30, P10576, DOI 10.1021/bi00107a029; NELSON J, 1995, CANCER RES, V55, P3772; NGUYEN M, 1994, J NATL CANCER I, V86, P356, DOI 10.1093/jnci/86.5.356; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PENNICA D, 1983, NATURE, V301, P579; POWELL JR, 1981, BIOCHEM BIOPH RES CO, V102, P46, DOI 10.1016/0006-291X(81)91486-8; REJANTE MR, 1991, BIOCHEMISTRY-US, V30, P11081, DOI 10.1021/bi00110a010; REJANTE MR, 1994, EUR J BIOCHEM, V221, P939, DOI 10.1111/j.1432-1033.1994.tb18809.x; SENGER DR, 1990, CANCER RES, V50, P1774; Sohndel S, 1996, BIOCHEMISTRY-US, V35, P2357, DOI 10.1021/bi9520949; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; STRIETER RM, 1994, SCIENCE, V4, P155; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; WALZ DA, 1977, P NATL ACAD SCI USA, V74, P1969, DOI 10.1073/pnas.74.5.1969; WILSON C, 1993, P NATL ACAD SCI USA, V90, P7109, DOI 10.1073/pnas.90.15.7109; WINN ES, 1980, EUR J BIOCHEM, V104, P579, DOI 10.1111/j.1432-1033.1980.tb04461.x; WU TP, 1994, BLOOD COAGUL FIBRIN, V5, P157, DOI 10.1097/00001721-199404000-00001	54	347	437	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29461	29467		10.1074/jbc.271.46.29461	http://dx.doi.org/10.1074/jbc.271.46.29461			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910613	hybrid			2022-12-25	WOS:A1996VT05200105
J	Han, JD; Rubin, CS				Han, JD; Rubin, CS			Regulation of cytoskeleton organization and paxillin dephosphorylation by cAMP - Studies on murine Y1 adrenal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CYCLIC-AMP; TYROSINE KINASE; EXPRESSION; PHOSPHORYLATION; ACTIVATION; CLONING; GENE; PATHWAYS; ADHESION	Cyclic AMP induces corticosteroid production, differential gene transcription, and cell cycle arrest in adrenal cortex-derived Y1 cells. These responses follow a cAMP-controlled transformation in Y1 cell morphology: the conversion of flat epithelial cells into rounded, highly refractile cells with short processes. Little is known about effector proteins and mechanisms that link activated protein kinase A to the alteration in cell shape, We now report that cAMP causes rapid (less than or equal to 1 min) and selective tyrosine dephosphorylation of paxillin, a focal adhesion protein. Paxillin is maximally dephosphorylated before other physiological effects of cAMP are detected in Y1 cells. Dephosphopaxillin translocates from focal adhesions to the cytoplasm as stress fibers vanish and F-actin accumulates in membrane ruffles and cytoplasmic aggregates. Remnants of focal adhesion complexes dissociate from the cell cortex and coalesce into large structures that contain aggregated F-actin. Pervanadate, an inhibitor of protein-tyrosine phosphatases, abrogates all effects of cAMP. Conversely, genistein-sensitive protein-tyrosine kinase activity is essential for establishing epithelial morphology and reversing effects of cAMP in Y1 cells. Thus, cAMP/protein kinase A (PKA) actions are initially targeted to focal adhesions and cortical actin cytoskeleton; paxillin is an early and unexpected downstream target in a PKA-mediated signaling pathway, and protein-tyrosine phosphatase activity provides an essential link between PKA. activation and the control of cell shape.	ALBERT EINSTEIN COLL MED,DEPT MOL PHARMACOL,ATRAN LABS,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine				Han, Jing-Dong J./0000-0002-9270-7139	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022792] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22792] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEEBE SJ, 1986, ENZYMES, V17, P44; BRAUTIGAN DL, 1991, P NATL ACAD SCI USA, V88, P6696, DOI 10.1073/pnas.88.15.6696; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EVANS GA, 1994, J BIOL CHEM, V269, P23407; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUTMANN NS, 1978, J CELL PHYSIOL, V97, P451, DOI 10.1002/jcp.1040970320; HANDLER JD, 1988, J BIOL CHEM, V263, P13068; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; LAND M, 1994, J BIOL CHEM, V269, P9234; MOUW AR, 1989, J BIOL CHEM, V264, P1305; OSAWA S, 1984, J CELL BIOL, V99, P1335, DOI 10.1083/jcb.99.4.1335; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schimmer B P, 1980, Adv Cyclic Nucleotide Res, V13, P181; SCHIMMER BP, 1977, MOL CELL ENDOCRINOL, V8, P135, DOI 10.1016/0303-7207(77)90025-9; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; YASUMURA Y, 1966, CANCER RES, V26, P529	26	97	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29211	29215		10.1074/jbc.271.46.29211	http://dx.doi.org/10.1074/jbc.271.46.29211			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910579	hybrid			2022-12-25	WOS:A1996VT05200071
J	Hao, MM; Lowy, AM; Kapoor, M; Deffie, A; Liu, G; Lozano, G				Hao, MM; Lowy, AM; Kapoor, M; Deffie, A; Liu, G; Lozano, G			Mutation of phosphoserine 389 affects p53 function in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING FUNCTION; CELL-CYCLE CONTROL; SV40 LARGE-T; PHOSPHORYLATION SITE; MAMMALIAN-CELLS; 3T3 CELLS; GENE; TRANSFORMATION	To study the importance of phosphorylation for p53 transactivation function, we generated mutations at each of its known phosphorylated serine amino acids. Mutations of murine p53 serine residues individually to either alanine or glutamic acid at positions 7, 9, 12, 18, 37, 312, and 389 resulted in equivalent levels of transcriptional activation in standard transient transfection experiments. However, when p53 transcriptional activity was measured in cells that attain G(1) arrest upon contact inhibition, wild-type p53 was inactive, and only alteration at serine 389 to glutamic acid resulted in a functional p53 protein. This Ser --> Glu mutant also has an increased ability to bind DNA. Elimination of the phosphorylation site by substitution of an alanine amino acid resulted in loss of transcriptional activity. We also demonstrated that specific phosphorylation of p53 at serine 389 is induced by cyclin E overexpression in high-density cells. Our data establish for the first time that phosphorylation of p53 at serine 389 is important in activating its function in vivo.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOL GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [T32CA009599, R29CA047296, P30CA016672, R01CA047296] Funding Source: NIH RePORTER; NCI NIH HHS [2-T32-CA09599, CA47296, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DANG CV, 1989, J BIOL CHEM, V264, P18019; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DEFFIE A, 1995, MOL CELL BIOL, V15, P3926; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISCELLA M, 1994, ONCOGENE, V9, P3249; FISCELLA M, 1993, ONCOGENE, V8, P1519; FUCHS B, 1995, ONCOGENE, V10, P789; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HAO MM, 1993, ONCOGENE, V8, P299; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MIYASHITA T, 1995, CELL, V80, P293; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OKAMOTO K, 1994, EMBO J, V13, P4819; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; ROLLEY N, 1994, ONCOGENE, V9, P3067; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Shaw P, 1996, ONCOGENE, V12, P921; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x	53	101	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29380	29385		10.1074/jbc.271.46.29380	http://dx.doi.org/10.1074/jbc.271.46.29380			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910602	hybrid			2022-12-25	WOS:A1996VT05200094
J	Higaki, M; Sakaue, H; Ogawa, W; Kasuga, M; Shimokado, K				Higaki, M; Sakaue, H; Ogawa, W; Kasuga, M; Shimokado, K			Phosphatidylinositol 3-kinase-independent signal transduction pathway for platelet-derived growth factor-induced chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; BINDING PROTEIN-RHO; PHOSPHOINOSITIDE 3-KINASE; PHOSPHOLIPASE A(2); GLUCOSE-TRANSPORT; ACTIVATION; RECEPTOR; KINASE; INHIBITOR; WORTMANNIN	Platelet derived growth factor (PDGF)-BB is a potent chemoattractant for mesenchymal cells. Intracellular signal transduction for PDGF-induced chemotactic response has been reported to be dependent on phosphatidylinositol 3-kinase (PI3K) activation. Here, we report a PI3K-independent pathway operating for PDGF-induced chemotaxis in vascular smooth muscle cells and other cell types. Two different PI3K inhibitors, wortmannin (WT, 1 nM-1 mu M) and LY294002 (100 nM-10 mu m), did not inhibit PDGF-induced chemotaxis in smooth muscle cells and Swiss 3T3 cells, whereas WT inhibited activity of PI3K that were immunopurified from PDGF-stimulated cells as well as PI3K purified from cells that were stimulated with PDGF in the presence of the same concentrations of WT. Similarly, WT (100 nar) abolished the increase in intracellular phosphatidylinositol 3,4,5-triphosphate after PDGF stimulation. Furthermore, Chinese hamster ovary/Delta p85 cells overexpressing a dominant negative p85 subunit of PI3K showed a chemotactic response comparable to that of parental cells while showing a remarkable decrease in PI3K activity. Rapamycin, a specific inhibitor of pp70 S6 kinase, which is one of the well characterized downstreams of PI3K did not inhibit PDGF-induced chemotaxis. Both WT and LY294002 inhibited PDGF-induced amino acid uptake and actin-stress fiber reorganization and partly inhibited PDGF-induced glucose incorporation in Swiss 3T3 cells. Our findings indicate that, in vascular smooth muscle cells and other cell types, the signal transduction for PDGF-induced chemotaxis is independent of PI3K activity while the signal transduction for PDGF-induced amino acid uptake, glucose incorporation, and cytoskeletal reorganization is dependent on PI3K.	NATL CARDIOVASC CTR,RES INST,SUITA,OSAKA 565,JAPAN; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE,HYOGO 650,JAPAN	National Cerebral & Cardiovascular Center - Japan; Kobe University			OGAWA, Wataru/AAQ-9586-2020; Sakaue, Hiroshi/ABE-2337-2021	Sakaue, Hiroshi/0000-0002-2468-2363				BAR RS, 1989, ENDOCRINOLOGY, V124, P1841, DOI 10.1210/endo-124-4-1841; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; DERMAN MP, 1996, AM J PHYSIOL, V271, P4251; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; JOLYM, 1995, J BIOL CHEM, V270, P13225; KAMOHARA S, 1995, P NATL ACAD SCI USA, V92, P1077, DOI 10.1073/pnas.92.4.1077; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; MA YH, 1994, J BIOL CHEM, V269, P30734; MARX SO, 1995, CIRC RES, V76, P412, DOI 10.1161/01.RES.76.3.412; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKADA T, 1994, J BIOL CHEM, V269, P3568; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; OWEN AJ, 1982, P NATL ACAD SCI-BIOL, V79, P3203, DOI 10.1073/pnas.79.10.3203; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; ROLLINS BJ, 1988, J BIOL CHEM, V263, P16523; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SHIMOKADO K, 1994, ARTERIOSCLER THROMB, V14, P973, DOI 10.1161/01.ATV.14.6.973; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VLAHOS CJ, 1992, FEBS LETT, V309, P242, DOI 10.1016/0014-5793(92)80781-B; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WENNSTROM S, 1994, ONCOGENE, V9, P651; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; YOKOTA T, 1993, CIRCULATION, V88, P657; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; ZHANG J, 1993, J BIOL CHEM, V268, P22251	42	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29342	29346		10.1074/jbc.271.46.29342	http://dx.doi.org/10.1074/jbc.271.46.29342			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910596	hybrid			2022-12-25	WOS:A1996VT05200088
J	Ishida, T; Mizushima, S; Azuma, S; Kobayashi, N; Tojo, T; Suzuki, K; Aizawa, S; Watanabe, T; Mosialos, G; Kieff, E; Yamamoto, T; Inoue, J				Ishida, T; Mizushima, S; Azuma, S; Kobayashi, N; Tojo, T; Suzuki, K; Aizawa, S; Watanabe, T; Mosialos, G; Kieff, E; Yamamoto, T; Inoue, J			Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-CD40 MONOCLONAL-ANTIBODY; GROWTH-FACTOR RECEPTOR; DEATH DOMAIN; KAPPA-B; ACTIVATION MOLECULE; CROSS-LINKING; ANTIGEN; INTERACTS; FAMILY; PHOSPHORYLATION	CD40 signalings play crucial roles in B-cell function. To identify molecules which transduce CD40 signalings, we have utilized the yeast two-hybrid system to clone cDNAs encoding proteins that bind the cytoplasmic tail of CD40. A cDNA encoding a putative signal transducer, designated TRAF6, has been molecularly cloned. TRAF6 has a tumor necrosis factor receptor (TNFR)-associated factor (TRAF) domain in its carboxyl terminus and has a RING finger domain, a cluster of zinc fingers and a coiled coil domain, which are also present in other TRAF family proteins. TRAF6 does not associate with the cytoplasmic tails of TNFR2, CD30, lymphotoxin-beta receptor, and LMP1 of Epstein-Barr virus. Deletion analysis showed that residues 246-269 of CD40 which are required for its association with TRAF2, TRAF3, and TRAF5 are dispensable for its interaction with TRAF6, whereas residues 230-245 were required. Overexpression of TRAF6 activates transcription factor NF kappa B, and its TRAF-C domain suppresses NF kappa B activation triggered by CD40 lacking residues 246-277. These results suggest that TRAF6 could mediate the CD40 signal that is transduced by the amino-terminal domain (230-245) of the CD40 cytoplasmic region and appears to be independent of other known TRAF family proteins.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN; UNIV TOKYO,INST MED SCI,DEPT PATHOL,MINATO KU,TOKYO 108,JAPAN; MOCHIDA PHARMACEUT CO LTD,BIOSCI RES LAB,KITA KU,TOKYO 115,JAPAN; BRIGHAM & WOMENS HOSP,DIV INFECT DIS,BOSTON,MA 02115	University of Tokyo; University of Tokyo; Mochida Pharmaceutical Co Ltd; Harvard University; Brigham & Women's Hospital					NCI NIH HHS [CA4706] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; CAMERINI D, 1991, J IMMUNOL, V147, P3165; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DEFRANCE T, 1992, EUR J IMMUNOL, V22, P2831, DOI 10.1002/eji.1830221112; FARIS M, 1994, J EXP MED, V179, P1923, DOI 10.1084/jem.179.6.1923; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; ISHIDA T, 1995, J IMMUNOL, V155, P5527; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; LING NR, 1987, LEUCOCYTE TYPING, V3, P302; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHRIEVER F, 1989, J EXP MED, V169, P2043, DOI 10.1084/jem.169.6.2043; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; UCKUN FM, 1991, J BIOL CHEM, V266, P17478; Ware C F, 1995, Curr Top Microbiol Immunol, V198, P175	35	427	447	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28745	28748		10.1074/jbc.271.46.28745	http://dx.doi.org/10.1074/jbc.271.46.28745			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910514	hybrid			2022-12-25	WOS:A1996VT05200006
J	Nielsen, FS; Andersen, PS; Jensen, KF				Nielsen, FS; Andersen, PS; Jensen, KF			The B form of dihydroorotate dehydrogenase from Lactococcus lactis consists of two different subunits, encoded by the pyrDb and pyrK genes, and contains FMN, FAD, and [FeS] redox centers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; PURIFICATION; ENZYME	The B form of dihydroorotate dehydrogenase from Lactococcus lactis (DHOdehase B) is encoded by the pyrDb gene. However, recent genetic evidence has revealed that a co-transcribed gene, pyrK is needed to achieve the proper physiological function of the enzyme. We have purified DHOdehase B from two strains of Escherichia cold, which harbored either the pyrDb gene or both the pyrDb and the pyrK genes of L. lactis on multicopy plasmids. The enzyme encoded by pyrDb alone (herein called the delta-enzyme) was a bright yellow, dimeric protein that contained one molecule of tightly bound FMN per subunit. The delta-enzyme exhibited dihydroorotate dehydrogenase activity with dichloroindophenol, potassium hexacyanoferrate(III), and molecular oxygen as electron accepters but could not use NAD(+). The DHOdehase B purified from the E. coli strain that carried both the pyrDb and pyrK genes on a multicopy plasmid (herein called the GK-enzyme) was quite different, since it was formed as a complex of equal amounts of the two polypeptides, i.e. two PyrDB and two PyrK subunits. The GK-enzyme was orange-brown and contained 2 mol of FAD, 2 mol of FMN, and 2 mol of [2Fe-2S] redox clusters per mol of native protein as tightly bound prosthetic groups. The delta K-enzyme was able to use NAD(+) as well as dichloroindophenol, potassium hexacyanoferrate(III), and to some extent molecular oxygen as electron accepters for the conversion of dihydroorotate to orotate, and it was a considerably more efficient catalyst than the purified delta-enzyme. Based on these results and on analysis of published sequences, we propose that the architecture of the delta K-enzyme is representative for the dihydroorotate dehydrogenases from Gram-positive bacteria.	UNIV COPENHAGEN,CTR ENZYME RES,INST MOL BIOL,DK-1307 COPENHAGEN K,DENMARK; TECH UNIV DENMARK,INST BIOTECHNOL,DK-2800 LYNGBY,DENMARK; UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Copenhagen; Technical University of Denmark; University of Illinois System; University of Illinois Urbana-Champaign			Andersen, Paal S/H-2087-2015	Andersen, Paal S/0000-0001-5656-0427				ALEMAN V, 1967, J BIOL CHEM, V242, P4087; Andersen PS, 1996, J BACTERIOL, V178, P5005, DOI 10.1128/jb.178.16.5005-5012.1996; ANDERSEN PS, 1994, J BACTERIOL, V176, P3975, DOI 10.1128/JB.176.13.3975-3982.1994; COPELAND RA, 1995, ARCH BIOCHEM BIOPHYS, V323, P79, DOI 10.1006/abbi.1995.0012; DEUTSCHLE U, 1986, EMBO J, V5, P2987; FISCHER DS, 1964, CLIN CHEM, V10, P21, DOI 10.1016/0009-8981(64)90210-4; FORMAN HJ, 1978, ARCH BIOCHEM BIOPHYS, V191, P23, DOI 10.1016/0003-9861(78)90063-2; GHIM SY, 1994, MICROBIOL-UK, V140, P479, DOI 10.1099/00221287-140-3-479; HINES V, 1986, J BIOL CHEM, V261, P1386; HINES V, 1989, BIOCHEMISTRY-US, V28, P1222, DOI 10.1021/bi00429a040; Kahler AE, 1996, J BACTERIOL, V178, P5013, DOI 10.1128/jb.178.16.5013-5016.1996; Karibian D, 1978, Methods Enzymol, V51, P58; KING TE, 1967, METHOD ENZYMOL, V10, P634; KRUNGKRAI J, 1991, BIOCHEMISTRY-US, V30, P1934, DOI 10.1021/bi00221a029; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN JN, 1985, EUR J BIOCHEM, V151, P59, DOI 10.1111/j.1432-1033.1985.tb09068.x; LED JJ, 1983, EUR J BIOCHEM, V136, P469, DOI 10.1111/j.1432-1033.1983.tb07765.x; LI XT, 1995, J BACTERIOL, V177, P6866, DOI 10.1128/jb.177.23.6866-6873.1995; LIEBERMAN I, 1953, BIOCHIM BIOPHYS ACTA, V12, P223, DOI 10.1016/0006-3002(53)90141-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Miller J.H., 1972, EXPT MOL GENETICS; MILLER RW, 1971, ARCH BIOCHEM BIOPHYS, V146, P256, DOI 10.1016/S0003-9861(71)80063-2; MILLER RW, 1965, J BIOL CHEM, V240, P1453; MILLER RW, 1975, CAN J BIOCHEM CELL B, V53, P1288, DOI 10.1139/o75-175; Nielsen FS, 1996, PROTEIN SCI, V5, P857; PASCAL RA, 1983, BIOCHEMISTRY-US, V22, P171, DOI 10.1021/bi00270a025; QUINN CL, 1991, J BIOL CHEM, V266, P9113; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; UNTUCHGRAU R, 1982, FLAVINS FLAVOPROTEIN	29	65	67	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29359	29365		10.1074/jbc.271.46.29359	http://dx.doi.org/10.1074/jbc.271.46.29359			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910599	hybrid			2022-12-25	WOS:A1996VT05200091
J	Roy, B; Li, WW; Lee, AS				Roy, B; Li, WW; Lee, AS			Calcium-sensitive transcriptional activation of the proximal CCAAT regulatory element of the grp78/BiP promoter by the human nuclear factor CBF/NF-Y	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-STIMULATED ADENOSINE 5'-TRIPHOSPHATASE; CA2+-ATPASE INHIBITOR THAPSIGARGIN; RAT-LIVER NUCLEI; ENDOPLASMIC-RETICULUM; C-FOS; BINDING FACTOR; PROTEIN; GENES; EXPRESSION; IONOPHORE	Transcription of the gene encoding GRP78/BiP, a calcium-binding molecular chaperone localized in the endoplasmic reticulum, is induced in mammalian cells through gradual depletion of the intracellular calcium stores. The multimeric CCAAT binding factor, CBF/NF-Y, binds to the most proximal CCAAT regulatory element (C1) of the grp78 promoter required for both basal level expression and stress response. Using an in vitro transcription system, we show through factor competition and immunodepletion that the grp78 C1-mediated enhancement of transcription requires primarily CBF. Correlating with the previous observation that CBF binding to the 78C1 site is enhanced by EGTA and EDTA, these divalent cation chelators specifically stimulate 78C1-directed transcription. In contrast, increasing amounts of calcium ions are inhibitory. These results provide evidence that CBF is functionally important in transactivating the grp78 C1 transcriptional activity, and suggest a possible mechanism by which grp78 transcription is stimulated by calcium depletion. We further discovered that in addition to binding CBF, both the 78C1 element and the CBF binding site of the alpha 2(I) collagen promoter interact weakly with the multifunctional transcription factor YY1. Our studies show that the binding sites for CBF and YY1 are distinct for the two promoter sites, suggesting that YY1 and other interacting factors could exert differential effects on individual promoters bearing the same CBF site.	UNIV SO CALIF,SCH MED,DEPT BIOCHEM & MOL BIOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,KENNETH NORRIS JR COMPREHENS CANC CTR,LOS ANGELES,CA 90033	University of Southern California; University of Southern California				Lee, Amy/0000-0002-0378-5443				ALEXANDRE S, 1991, MOL ENDOCRINOL, V5, P1862, DOI 10.1210/mend-5-12-1862; BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; CAO XJ, 1995, J BIOL CHEM, V270, P494, DOI 10.1074/jbc.270.1.494; CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GUO B, 1995, P NATL ACAD SCI USA, V92, P10526, DOI 10.1073/pnas.92.23.10526; HECHTENBERG S, 1993, BIOCHEM J, V289, P757, DOI 10.1042/bj2890757; Humbert JP, 1996, J BIOL CHEM, V271, P478, DOI 10.1074/jbc.271.1.478; Kong SK, 1996, BIOCHEM BIOPH RES CO, V218, P595, DOI 10.1006/bbrc.1996.0105; LANINI L, 1992, J BIOL CHEM, V267, P11548; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LI WW, 1994, MOL CELL BIOL, V14, P5533, DOI 10.1128/MCB.14.8.5533; LI WWF, 1993, J BIOL CHEM, V268, P12003; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIN AY, 1986, MOL CELL BIOL, V6, P1235, DOI 10.1128/MCB.6.4.1235; LIU ES, 1991, NUCLEIC ACIDS RES, V19, P5425, DOI 10.1093/nar/19.19.5425; MAITY SN, 1992, J BIOL CHEM, V267, P8286; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; RAMAKRISHNAN M, 1996, IN PRESS J CELL PHYS; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RESENDEZ E, 1988, MOL CELL BIOL, V8, P4579, DOI 10.1128/MCB.8.10.4579; RESENDEZ E, 1986, J CELL BIOL, V103, P2145, DOI 10.1083/jcb.103.6.2145; ROY B, 1995, MOL CELL BIOL, V15, P2263; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMAS D, 1995, J BIOL CHEM, V270, P6429, DOI 10.1074/jbc.270.12.6429; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612; YAMAGUCHI M, 1993, MOL CELL BIOCHEM, V125, P43, DOI 10.1007/BF00926833; YAMAGUCHI M, 1994, MOL CELL BIOCHEM, V131, P167, DOI 10.1007/BF00925953	37	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28995	29002		10.1074/jbc.271.46.28995	http://dx.doi.org/10.1074/jbc.271.46.28995			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910550	Green Accepted			2022-12-25	WOS:A1996VT05200042
J	Cheung, HS; Kurup, IV; Sallis, JD; Ryan, LM				Cheung, HS; Kurup, IV; Sallis, JD; Ryan, LM			Inhibition of calcium pyrophosphate dihydrate crystal formation in articular cartilage vesicles and cartilage by phosphocitrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NTP PYROPHOSPHOHYDROLASE; INORGANIC PYROPHOSPHATE; IN-VITRO; CITRATE; HYDROXYAPATITE; DISEASE; GROWTH; ATP	Articular cartilage vesicles (ACV), isolated by differential centrifugation of adult hyaline articular cartilage collagenase digests, mineralized in the presence of calcium and ATP. Mineral analysis by microscopy, chemical analysis, energy-dispersive analysis, and infrared spectroscopy revealed crystals resembling calcium pyrophosphate dihydrate (CPPD). Adult articular cartilage also underwent ATP-dependent mineralization, supporting the contention that vesicles in situ fostered adult articular cartilage mineralization. Phosphocitrate (PC) is a recognized in vitro inhibitor of hydroxyapatite and calcium oxalate monohydrate crystal formation, but it is not known whether PC can similarly restrict CPPD crystal development. In the present study we examine the effect of PC, citrate, and n-sulfo-2-amino-tricarballylate (SAT, a PC analogue) on the ATP-induced CPPD crystal formation in both ACV and articular cartilage models. Only PC (10-1000 mu M) blocked both the ATP-dependent and -independent mineralization in ACV in a dose-dependent fashion, At 1 mM, SAT and citrate blocked the ATP-independent mineralization. Similarly, only PC blocked both the ATP- and non-ATP-dependent mineralization in native articular cartilage slices, PC, SAT, and citrate had no effect on ACV nucleoside triphosphate pyrophosphohydrolase activity, suggesting that none of these agents blocked mineralization through the inhibition of nucleoside triphosphate pyrophosphohydrolase activity, which generates inorganic pyrophosphate from ATP.	UNIV TASMANIA, DEPT BIOCHEM, HOBART, TAS 7001, AUSTRALIA	University of Tasmania	Cheung, HS (corresponding author), MED COLL WISCONSIN, DIV RHEUMATOL, MILWAUKEE, WI 53226 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038421, R01AR038656] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR38421-06, AR38656-07] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BROWN MR, 1985, UROLITHIASIS RELATED, P891; CHEUNG HS, 1990, BIOCHEM BIOPH RES CO, V171, P20, DOI 10.1016/0006-291X(90)91350-2; Cheung HS, 1996, BBA-MOL BASIS DIS, V1315, P105, DOI 10.1016/0925-4439(95)00106-9; CHEUNG HS, 1993, JOINT CARTILAGE DEGR, P209; CHEUNG HS, 1994, REV BRAS REUMATOL, V34, pS117; DERFUS B, 1995, J RHEUMATOL, V22, P1514; DERFUS BA, 1992, ARTHRITIS RHEUM, V35, P231, DOI 10.1002/art.1780350218; DERFUS BA, 1994, ARTHRITIS RHEUM, V37, pS142; HALVERSON PB, 1992, ARTHRITIS ALLIED CON, P1857; HOWARD JE, 1976, JOHNS HOPKINS MED J, V139, P239; HOWELL DS, 1984, ARTHRITIS RHEUM, V27, P193, DOI 10.1002/art.1780270211; JOHNSSON M, 1991, CALCIFIED TISSUE INT, V49, P134, DOI 10.1007/BF02565136; KRANENDONK S, 1994, J BONE JT SURG ORTHO, V18, P502; KRUG HE, 1993, ARTHRITIS RHEUM, V36, P1603, DOI 10.1002/art.1780361116; MASUDA I, 1995, J CLIN INVEST, V95, P699, DOI 10.1172/JCI117716; PANKOWSKI AH, 1994, TETRAHEDRON LETT, V35, P927, DOI 10.1016/S0040-4039(00)76002-3; RACHOW JW, 1988, ARTHRITIS RHEUM, V31, P408, DOI 10.1002/art.1780310313; RYAN LM, 1992, ARTHRITIS RHEUM, V35, P1520, DOI 10.1002/art.1780351216; RYAN LM, 1991, J RHEUMATOL, V18, P716; RYAN LM, 1984, ARTHRITIS RHEUM, V27, P404, DOI 10.1002/art.1780270407; RYAN LM, 1992, ARTHRITIS ALLIED CON, P1835; SALLIS JD, 1995, SCANNING MICROSCOPY, V9, P127; SALLIS JD, 1991, ACS SYM SER, V444, P149; SALLIS JD, 1995, SURFACE REACTIVE PEP, P87; SHANKAR R, 1985, ATHEROSCLEROSIS, V50, P191; SIEGEL SA, 1983, J BIOL CHEM, V258, P8601; SUGINO Y, 1964, J BIOL CHEM, V239, P2360; TENENBAUM J, 1981, ARTHRITIS RHEUM, V24, P492, DOI 10.1002/art.1780240307; TEW WP, 1981, P NATL ACAD SCI-BIOL, V78, P5528, DOI 10.1073/pnas.78.9.5528; WARD LC, 1987, ATHEROSCLEROSIS, V65, P117, DOI 10.1016/0021-9150(87)90013-X; WIERZBICKI A, 1995, CALCIFIED TISSUE INT, V56, P297, DOI 10.1007/BF00318050; WILLIAMS G, 1982, CALCIFIED TISSUE INT, V34, P169, DOI 10.1007/BF02411229	32	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28082	28085		10.1074/jbc.271.45.28082	http://dx.doi.org/10.1074/jbc.271.45.28082			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910421	hybrid			2022-12-25	WOS:A1996VU03300021
J	Richardson, RM; Haribabu, B; Ali, H; Snyderman, R				Richardson, RM; Haribabu, B; Ali, H; Snyderman, R			Cross-desensitization among receptors for platelet activating factor and peptide chemoattractants - Evidence for independent regulatory pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; PHOSPHOLIPASE-C; 48-KDA PROTEIN; PHOSPHORYLATION; LEUKOCYTE; INTERLEUKIN-8; EXPRESSION; RHODOPSIN; KINASES; CLONING	Cross desensitization among receptors for peptide chemoattractants have been shown to involve two independent processes, receptor phosphorylation and inhibition of phospholipase C (PLC) activation. Receptors for lipid chemoattractants, i.e. platelet activating factor (PAF) and leukotriene B-4, did not inhibit the responses of peptide chemoattractant receptors, suggesting distinct signaling pathways. To examine cross-desensitization between receptors for lipid and peptide chemoattractants, cDNA encoding the PAF receptor (PAFR) was co-expressed into RBL-2H3 cells with cDNAs encoding receptors for either formylated peptides (FR), a product of the fifth component of complement (C5aR) or interleukin-8 A (IL-8RA). PAFR was homologously phosphorylated and desensitized by PAF, and cross-phosphorylated and cross-desensitized by fMet-Leu-Phe, C5a, and IL-8. In contrast, the receptors for peptide chemoattractants were neither cross-phosphorylated nor cross-desensitized by PAF. Staurosporine blocked cross-phosphorylation and cross-desensitization of the PAFR by peptide chemoattractants. Truncation of the cytoplasmic tail of PAFR (mPAFR) abolished its homologous and cross-phosphorylation. mPAFR was also resistant to cross-desensitization by peptide chemoattractants at the level of PLC activation. Interestingly, mPAFR mediated a sustained Ca2+ mobilization in response to PAF and was more active in inducing GTPase activity, phosphoinositide hydrolysis, secretion, and phospholipase D activation than the wild type PAFR. In contrast to PAFR, stimulation of the mPAFR cross-phosphorylated and cross-desensitized responses to IL-8RA. As expected, FR, which is resistant to cross-phosphorylation by C5aR and IL-8RA, was not phosphorylated by mPAFR. However, unlike C5aR and IL-8RA, mPAFR did not inhibit the ability of FR to activate PLC. Blocking Ca2+ influx inhibited mPAFR-mediated sustained Ca2+ response, phospholipase D activation and secretion, but not phosphoinositide hydrolysis and cross-phosphorylation and cross-desensitization of IL-8RA. The data herein suggest that cross-desensitization of PAFR by peptide chemoattractants is solely due to receptor phosphorylation. The PAFR and the peptide chemoattractant receptors do not cross-regulate each other at the level of PLC, suggesting distinct regulatory pathways.	DUKE UNIV,MED CTR,DEPT IMMUNOL,DURHAM,NC 27710	Duke University	Richardson, RM (corresponding author), DUKE UNIV,MED CTR,DEPT MED,BOX 3680,DURHAM,NC 27710, USA.		Bodduluri, Haribabu/A-2584-2010	Bodduluri, Haribabu/0000-0002-8261-3294	NHLBI NIH HHS [HL-54166] Funding Source: Medline; NIAID NIH HHS [AI-38910] Funding Source: Medline; NIDCR NIH HHS [DE-03738] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL054166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038910, R29AI038910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE003738] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALI H, 1994, J BIOL CHEM, V269, P24557; ALI H, 1993, J BIOL CHEM, V268, P24247; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; DHAR A, 1994, J BIOL CHEM, V269, P9123; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HONDA Z, 1995, J BIOL CHEM, V270, P4840, DOI 10.1074/jbc.270.9.4840; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HOSEY MM, 1994, REGULATION SIGNAL TR, P113; KRAUSE KH, 1985, J CLIN INVEST, V76, P1348, DOI 10.1172/JCI112109; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; KURUVILLA A, 1993, J IMMUNOL, V151, P637; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LIGGETT SB, 1994, REGULATION CELLULAR, P71; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OZCELEBI F, 1995, MOL PHARMACOL, V48, P818; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; RICHARDON RM, 1995, J BIOL CHEM, V270, P27829, DOI 10.1074/jbc.270.46.27829; RICHARDSON RM, 1995, BIOCHEMISTRY-US, V34, P14193, DOI 10.1021/bi00043a025; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; SICILIANO SJ, 1990, J BIOL CHEM, V265, P19568; SNYDERMAN R, 1992, INFLAMMATION BASIC P, P421; STRADER CD, 1987, J BIOL CHEM, V262, P16439; TAKANO T, 1994, J BIOL CHEM, V269, P22453; THELEN M, 1994, CURR OPIN IMMUNOL, V6, P106, DOI 10.1016/0952-7915(94)90041-8; TOMHAVE E, 1994, J IMMUNOL, V154, P3267; TRUETT AP, 1988, P NATL ACAD SCI USA, V85, P1549, DOI 10.1073/pnas.85.5.1549; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; YANG J, 1995, MOL PHARMACOL, V48, P477; Zhu X, 1996, P NATL ACAD SCI USA, V93, P2827, DOI 10.1073/pnas.93.7.2827	38	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28717	28724		10.1074/jbc.271.45.28717	http://dx.doi.org/10.1074/jbc.271.45.28717			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910508	hybrid			2022-12-25	WOS:A1996VU03300108
J	Feldmann, H; Driller, L; Meier, B; Mages, G; Kellermann, J; Winnacker, EL				Feldmann, H; Driller, L; Meier, B; Mages, G; Kellermann, J; Winnacker, EL			HDF2, the second subunit of the Ku homologue from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HUMAN AUTOANTIGEN KU; DOUBLE-STRAND BREAKS; HIGHER EUKARYOTES; DNA-DAMAGE; ANTIGEN; RECOMBINATION; YEAST; GENE; CDNA	The high affinity DNA binding factor (HDF) protein of Saccharomyces cerevisiae is composed of two subunits and specifically binds ends of double-stranded DNA, The 70-kDa subunit, HDF1, shows significant homology with the 70-kDa subunit of the human Ku protein, Like the Ku protein, HDF1 has been shown to be involved in recombination and double stranded DNA break repair, We have purified and cloned HDF2, the second subunit of the HDF protein, The amino acid sequence of HDF2 shows a 45.6% homology with the 80-kDa subunit of the Ku protein. HDF1 by itself does not bind DNA, while HDF2 protein on its own seems to displays DNA binding activity. Targeted disruption of the HDF2 gene causes a temperature sensitive phenotype for growth comparable to the phenotype of hdf1(-) strains. The human Ku protein cannot complement this temperature-sensitive phenotype, hdf2(-) strains are sensitive to bleomycin and methyl methanesulfonate, but this sensitivity is reduced in comparison with hdf1(-) strains.	UNIV MUNICH,INST BIOCHEM,D-81377 MUNICH,GERMANY; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	University of Munich; Max Planck Society								ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Beall EL, 1996, GENE DEV, V10, P921, DOI 10.1101/gad.10.8.921; BEALL EL, 1994, P NATL ACAD SCI USA, V91, P12681, DOI 10.1073/pnas.91.26.12681; BEZZUBOVA O, 1993, NUCLEIC ACIDS RES, V21, P1577, DOI 10.1093/nar/21.7.1577; BEZZUBOVA OY, 1994, EXPERIENTIA, V50, P270, DOI 10.1007/BF01924010; BEZZUBOVA OY, 1993, NUCLEIC ACIDS RES, V21, P5945, DOI 10.1093/nar/21.25.5945; BLIER PR, 1993, J BIOL CHEM, V268, P7594; CARR AM, 1995, TRENDS CELL BIOL, V5, P32, DOI 10.1016/S0962-8924(00)88934-5; DANDREA AD, 1978, P NATL ACAD SCI USA, V75, P3608, DOI 10.1073/pnas.75.8.3608; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FALZON M, 1993, J BIOL CHEM, V268, P10546; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; FINNIE N, 1993, BIOCHEM SOC T, V21, P930, DOI 10.1042/bst0210930; FRIEDBERG EC, 1995, DNA REPAIR; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HARTLEY KO, 1995, CELL, V82, P1; HWANG PI, 1995, FASEB J, V9, pA1398; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kaiser C. S., 1994, METHODS YEAST GENETI, P207; KESZENMAN DJ, 1992, J BACTERIOL, V174, P3125, DOI 10.1128/jb.174.10.3125-3132.1992; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Mages GJ, 1996, J BIOL CHEM, V271, P7910, DOI 10.1074/jbc.271.14.7910; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1986, J BIOL CHEM, V261, P375; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; REEVES WH, 1989, J BIOL CHEM, V264, P5047; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; Siede W, 1996, GENETICS, V142, P91; SIKORSKI RS, 1989, GENETICS, V122, P19; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; STEIGHNER RJ, 1990, P NATL ACAD SCI USA, V87, P8350, DOI 10.1073/pnas.87.21.8350; Tsukamoto Y, 1996, NUCLEIC ACIDS RES, V24, P2067, DOI 10.1093/nar/24.11.2067; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; YANEVA M, 1989, J BIOL CHEM, V264, P13407	44	71	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27765	27769		10.1074/jbc.271.44.27765	http://dx.doi.org/10.1074/jbc.271.44.27765			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910371	hybrid			2022-12-25	WOS:A1996VQ67900089
J	Hinder, B; Schellenberg, M; Rodon, S; Ginsburg, S; Vogt, E; Martinoia, E; Matile, P; Hortensteiner, S				Hinder, B; Schellenberg, M; Rodon, S; Ginsburg, S; Vogt, E; Martinoia, E; Matile, P; Hortensteiner, S			How plants dispose of chlorophyll catabolites - Directly energized uptake of tetrapyrrolic breakdown products into isolated vacuoles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENESCENT BARLEY LEAVES; REDUCED FERREDOXIN; IN-VITRO; RAPE; CONSTITUTION; REQUIREMENT; PROTOPLASTS; COTYLEDONS; PORPHYRIN; CLEAVAGE	During the yellowing of leaves the porphyrin moiety of chlorophyll is cleaved into colorless linear tetrapyrrolic catabolites, which eventually are deposited in the central vacuoles of mesophyll cells, In senescent cotyledons of rape, Brassica napus, three nonfluorescent chlorophyll catabolites (NCCs), accounting for practically all the chlorophyll broken down, were found to be located in the vacuoles (vacuoplasts) prepared from protoplasts, Transport of catabolites across the tonoplast was studied with vacuoles isolated from barley mesophyll protoplasts in conjunction with a radiolabeled NCC, Bn-NCC-1, prepared from senescent rape cotyledons, The uptake of Bn-NCC-1 into vacuoles was against a concentration gradient and strictly dependent on MgATP and it followed saturation kinetics with a K-m of approximately 100 mu M. Although the hydrolysis of ATP was required, transport was apparently independent of the vacuolar proton pumps: accumulation of the NCC occurred both in the presence of the H+-ATPase inhibitor bafilomycin and after destroying the Delta pH between the vacuolar sap and the medium, ATP could be replaced by GTP or UTP, and the transport was inhibited in the presence of vanadate, Chlorophyll catabolites isolated from senescent barley leaves competed with the rape-specific substrate for uptake into the vacuoles, Compounds such as the glutathione conjugate of N-ethylmaleimide and taurocholate, which are known to be transported across the tonoplast in a primary active mode, did not significantly inhibit uptake of Bn-NCC-1, Although the heme catabolites biliverdin and bilirubin inhibited the uptake of the NCC, this effect is caused by unspecific binding to the vacuolar membrane rather than to the specific inhibition of carrier-mediated transport, Taken together, the results demonstrate that barley mesophyll vacuoles are constitutively equipped with a directly energized carrier that transports tetrapyrrolic catabolites of chlorophyll into the vacuole.	UNIV ZURICH,DEPT PLANT BIOL,CH-8008 ZURICH,SWITZERLAND; ETH ZURICH,INST PLANT SCI,CH-8092 ZURICH,SWITZERLAND; UNIV POITIERS,INST BIOL VEGETAL,F-86022 POITIERS,FRANCE	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; Universite de Poitiers			Martinoia, Enrico/AAH-8712-2021					BALZI E, 1994, BBA-BIOENERGETICS, V1187, P152, DOI 10.1016/0005-2728(94)90102-3; BORTLIK K, 1990, J PLANT PHYSIOL, V136, P161, DOI 10.1016/S0176-1617(11)81659-7; BORTLIK KH, 1990, THESIS U ZURICH; DUGGELIN T, 1988, J PLANT PHYSIOL, V133, P492; GINSBURG S, 1993, PLANT PHYSIOL, V102, P521, DOI 10.1104/pp.102.2.521; GINSBURG S, 1994, PLANT PHYSIOL, V105, P545, DOI 10.1104/pp.105.2.545; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HORTENSTEINER S, 1995, NEW PHYTOL, V129, P237, DOI 10.1111/j.1469-8137.1995.tb04293.x; HORTENSTEINER S, 1992, PLANTA, V187, P113, DOI 10.1007/BF00201632; HORTENSTEINER S, 1993, J BIOL CHEM, V268, P18466; KAISER G, 1986, PLANTA, V169, P345, DOI 10.1007/BF00392130; KRAUTLER B, 1992, PLANT PHYSIOL BIOCH, V30, P333; KRAUTLER B, 1991, ANGEW CHEM INT EDIT, V30, P1315, DOI 10.1002/anie.199113151; MARRS KA, 1995, NATURE, V375, P397, DOI 10.1038/375397a0; MARTINOIA E, 1993, NATURE, V364, P247, DOI 10.1038/364247a0; MATILE P, 1992, PLANTA, V187, P230, DOI 10.1007/BF00201944; MATILE P, 1984, NATURWISSENSCHAFTEN, V71, P18, DOI 10.1007/BF00365975; MATILE P, 1988, P NATL ACAD SCI USA, V85, P9529, DOI 10.1073/pnas.85.24.9529; Matile P., 1992, CHLOROPLAST SENESCEN, P413; Muhlecker W, 1996, PLANT PHYSIOL BIOCH, V34, P61; MUHLECKER W, 1993, HELV CHIM ACTA, V76, P2976, DOI 10.1002/hlca.19930760822; PEISKER C, 1990, J PLANT PHYSIOL, V136, P544, DOI 10.1016/S0176-1617(11)80211-7; PEISKER C, 1991, THESIS U ZURICH; RENTSCH D, 1991, PLANTA, V184, P532, DOI 10.1007/BF00197903; SCHELLENBERG M, 1993, PLANTA, V191, P417, DOI 10.1007/BF00195702; Tommasini R, 1996, P NATL ACAD SCI USA, V93, P6743, DOI 10.1073/pnas.93.13.6743	26	87	95	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27233	27236		10.1074/jbc.271.44.27233	http://dx.doi.org/10.1074/jbc.271.44.27233			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910294	hybrid			2022-12-25	WOS:A1996VQ67900012
J	Zamir, LO; Nikolakakis, A; Devor, KA; Sauriol, F				Zamir, LO; Nikolakakis, A; Devor, KA; Sauriol, F			Biosynthesis of the trichothecene 3-acetyldeoxynivalenol - Is isotrichodermin a biosynthetic precursor?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSARIUM-CULMORUM; METABOLITES	3-Acetyldeoxynivalenol is the major trichothecene produced by the fungus Fusarium culmorum, The first proven tricyclic intermediate in the biosynthesis of 3-acetyldeoxynivalenol has been shown by in vivo studies to be isotrichodermin, a natural metabolite of F. culmorum, Indeed, the feeding of ring-deuterated isotrichodermin resulted in ring-deuterated 3-acetyldeoxynivalenol as shown by NMR studies, In this work, we have shown that the 3-acetyl group of isotrichodermin is mostly lost in its metabolism to 3-acetyldeoxynivalenol. We have shown by two different approaches that the deacetylation occurs at an early step after the first oxygenation step at C-15, Derivatives of isotrichodermin lacking the 3-acetyl such as 3-deacetyl isotrichodermin or 3-oxo-12, 13-epoxytrichothec-9-ene are not precursors to 3-acetyldeoxynivalenol. The role of this acetyl exchange mechanism is not clear presently.	MCGILL UNIV,DEPT CHEM,MONTREAL,PQ H3Z 2K6,CANADA	McGill University	Zamir, LO (corresponding author), UNIV QUEBEC,INST ARMAND FRAPPIER,CTR RECH MICROBIOL APPL,531 BLVD PRAIRIES,LAVAL,PQ H7V 1B7,CANADA.							GLEDHILL L, 1991, FEMS MICROBIOL LETT, V81, P241, DOI 10.1111/j.1574-6968.1991.tb04765.x; GREENHALGH R, 1984, J AGR FOOD CHEM, V32, P945, DOI 10.1021/jf00124a060; GREENHALGH R, 1986, J AGR FOOD CHEM, V34, P98, DOI 10.1021/jf00067a027; HOHN TM, 1995, MOL GEN GENET, V248, P95, DOI 10.1007/BF02456618; MOHR P, 1984, HELV CHIM ACTA, V67, P406, DOI 10.1002/hlca.19840670208; Schenkman J B, 1978, Methods Enzymol, V52, P83; STILL WC, 1978, J ORG CHEM, V43, P2923, DOI 10.1021/jo00408a041; ZAMIR LO, 1991, J BIOL CHEM, V266, P14992; ZAMIR LO, 1990, J BIOL CHEM, V265, P6713; ZAMIR LO, 1987, J BIOL CHEM, V262, P15348; Zamir LO, 1996, CAN J MICROBIOL, V42, P828, DOI 10.1139/m96-104	11	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27353	27359		10.1074/jbc.271.44.27353	http://dx.doi.org/10.1074/jbc.271.44.27353			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910312	hybrid			2022-12-25	WOS:A1996VQ67900030
J	Trifillis, P; Adachi, K; Yamaguchi, T; Schwartz, E; Surrey, S				Trifillis, P; Adachi, K; Yamaguchi, T; Schwartz, E; Surrey, S			Expression studies of delta-globin gene alleles associated with reduced hemoglobin A(2) levels in Greek cypriots	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCEPTOR SPLICE SITE; BETA-THALASSEMIA; SEQUENCE-ANALYSIS; NUCLEOTIDE SUBSTITUTION; MOLECULAR-BASIS; AMPLIFIED DNA; RNA; KNOSSOS; MUTATIONS; VARIANT	We previously identified five delta-globin gene alleles associated with reduced hemoglobin (Hb) A(2) (Trifillis, P., Ioannou, P., Schwartz, E., and Surrey, S. (1991) Blood 78, 3298-3305). We have now evaluated functional consequences of the changes after expression in COS-1 cells to monitor effects on RNA splicing. In addition, variant Hb A(2) tetramers were expressed in yeast to assess effects of amino acid changes on oxygen binding and stability to heat and mechanical agitation. The G --> T change at codon 27 and the A --> G change in IVS-2 both affect RNA splicing, whereas the C --> T change at codon 97 and the AT deletion in IVS-2 have no effect. Oxygen equilibrium curves of the Hb A(2) variants expressed in yeast were similar to that of wild type Hb A(2). None of the three variant Hb A(2) tetramers (Thr --> Ile at codon 4 (Hb delta T4I), Ala --> Ser at codon 27 (Hb delta A27S), and Arg --> Cys at codon 116 (Hb delta R116C)) showed decreased heat stability compared with Hb A(2), whereas the Hb delta T4I variant showed highest instability to mechanical agitation, Coexpression in yeast of alpha-globin chain and the delta-chain variant containing a Leu --> Pro change at codon 141 yielded no identifiable tetramers, suggesting lack of assembly or severe tetramer instability, These studies show the probable cause for decreased Hb A(2) for two alleles is due to defective splicing, whereas decreased protein stability, increased tetramer association with red cell membranes, increased interdisulfide bond formation of delta-chains, which inhibits assembly with alpha-chains, and/or reduced assembly is suggested for the other three alleles.	CHILDRENS HOSP PHILADELPHIA,ABRAMSON PEDIAT RES CTR,DIV HEMATOL,PHILADELPHIA,PA 19104	University of Pennsylvania; Childrens Hospital of Philadelphia					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016691] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38632] Funding Source: Medline; NIDDK NIH HHS [DK 16691] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI K, 1993, J BIOL CHEM, V268, P21650; ADACHI K, 1978, J BIOL CHEM, V253, P382; ADACHI K, 1993, FEBS LETT, V315, P47, DOI 10.1016/0014-5793(93)81130-R; ADACHI K, 1992, PROTEIN ENG, V5, P807, DOI 10.1093/protein/5.8.807; ANTONARAKIS SE, 1984, P NATL ACAD SCI-BIOL, V81, P1154, DOI 10.1073/pnas.81.4.1154; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; AROUS N, 1982, FEBS LETT, V147, P247, DOI 10.1016/0014-5793(82)81052-1; ASAKURA T, 1974, BIOCHEM BIOPH RES CO, V57, P780, DOI 10.1016/0006-291X(74)90614-7; ASAKURA T, 1974, P NATL ACAD SCI USA, V71, P1594, DOI 10.1073/pnas.71.5.1594; ATWEH GF, 1985, NUCLEIC ACIDS RES, V13, P777, DOI 10.1093/nar/13.3.777; BLACKWELL RQ, 1971, BIOCHIM BIOPHYS ACTA, V243, P467; *BOLT BER NEWM LAB, EMBL GENB DAT; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CODRINGTON JF, 1989, BIOCHIM BIOPHYS ACTA, V1009, P87, DOI 10.1016/0167-4781(89)90083-3; DELANO JJM, 1993, P NATL ACAD SCI USA, V90, P918; FESTA RS, 1979, TRANSFUSION, V19, P107, DOI 10.1046/j.1537-2995.1979.19279160278.x; GALANELLO R, 1990, BLOOD, V75, P1747; GARCIA CR, 1983, HEMOGLOBIN, V7, P435, DOI 10.3109/03630268309038412; GOLDSMITH ME, 1983, P NATL ACAD SCI-BIOL, V80, P2318, DOI 10.1073/pnas.80.8.2318; HAYASHI A, 1971, NATURE-NEW BIOL, V230, P264, DOI 10.1038/newbio230264a0; HIRANO M, 1981, BLOOD, V57, P697; HUISMAN THJ, 1993, HEMOGLOBIN, V17, P89; INGRAM VM, 1959, BIOCHIM BIOPHYS ACTA, V36, P402, DOI 10.1016/0006-3002(59)90183-0; KELLER MA, 1993, PCR METH APPL, V3, P32; KLEIHAUER EF, 1968, BIOCHIM BIOPHYS ACTA, V154, P220, DOI 10.1016/0005-2795(68)90274-2; KLIPSTEIN FA, 1960, J CLIN INVEST, V39, P1894, DOI 10.1172/JCI104213; KULOZIK AE, 1988, BLOOD, V71, P457; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORKIN PA, 1975, BIOCHIM BIOPHYS ACTA, V386, P256, DOI 10.1016/0005-2795(75)90266-4; LORROWMURRAY D, 1991, FOCUS, V13, P65; LOSEKOOT M, 1989, HUM GENET, V83, P75, DOI 10.1007/BF00274153; LOUDIANOS G, 1991, BLOOD, V77, P2087; MATSUDA M, 1992, BLOOD, V80, P1347; MOI P, 1988, BLOOD, V72, P530; NAGEL RL, 1995, BLOOD S, V86, P251; NAKAMURA T, 1987, BLOOD, V70, P809; OLDS RJ, 1991, BRIT J HAEMATOL, V78, P430, DOI 10.1111/j.1365-2141.1991.tb04460.x; ORKIN SH, 1984, BLOOD, V64, P311; ORKIN SH, 1982, NATURE, V300, P768, DOI 10.1038/300768a0; PERUTZ MF, 1975, NATURE, V255, P256, DOI 10.1038/255256a0; PERUTZ MF, 1968, NATURE, V219, P131, DOI 10.1038/219131a0; PERUTZ MF, 1965, J MOL BIOL, V13, P646, DOI 10.1016/S0022-2836(65)80133-4; PIRASTU M, 1983, BLOOD, V62, P341; PIRASTU M, 1990, ANN NY ACAD SCI, V612, P90; PONCZ M, 1983, J BIOL CHEM, V258, P1599; Shackleton CHL, 1994, MASS SPECTROMETRY CL, V2, P135; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; STEINBERG MH, 1991, BLOOD, V78, P2165; TONDO C, 1974, BIOCHIM BIOPHYS ACTA, V342, P15, DOI 10.1016/0005-2795(74)90101-9; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; TRIFILLIS P, 1993, BLOOD, V82, P1647, DOI 10.1182/blood.V82.5.1647.bloodjournal8251647; TRIFILLIS P, 1991, BLOOD, V78, P3298; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57; WILLIAMSON D, 1993, BLOOD REV, V7, P146, DOI 10.1016/0268-960X(93)90002-L	54	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26931	26938		10.1074/jbc.271.43.26931	http://dx.doi.org/10.1074/jbc.271.43.26931			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900178				2022-12-25	WOS:A1996VP23300072
J	Ambartsumian, NS; Grigorian, MS; Larsen, IF; Karlstrom, O; Sidenius, N; Rygaard, J; Georgiev, G; Lukanidin, E				Ambartsumian, NS; Grigorian, MS; Larsen, IF; Karlstrom, O; Sidenius, N; Rygaard, J; Georgiev, G; Lukanidin, E			Metastasis of mammary carcinomas in GRS/A hybrid mice transgenic for the mts1 gene	ONCOGENE			English	Article						transgenic mice; mts1 gene; MMTV induced mammary carcinomas; metastasis	CALCIUM-BINDING PROTEIN; TUMOR VIRUS; NONMUSCLE MYOSIN; EXPRESSION; ONCOGENE; INDUCTION; ACTIVATION; INVASION; TISSUES; DISEASE	Transgenic mice, carrying the mts1 gene, one of the genes involved in the acquisition of the metastatic phenotype, were generated, The mts1 gene was placed under the control of the mouse mammary tumor virus (MMTV) long terminal repeat (LTR) promoter leading to overexpression in the lactating mammary gland of transgenic animals, Animals bearing the transgene appear phenotypically normal, Animals of two transgenic lines (Tg463 and Tg507) were crossed with the GRS/A mice, The GRS/A strain is characterized by high incidence of mammary tumors which rarely metastasize, 40% of the tumor bearing hybrid GRS/A mts1 females mere found to develop secondary tumors in the lungs, The Mts1 protein was detected in the transgene primary tumor cells as well as in the corresponding metastases, Nontransgenic littermates expressed the Mts1 protein only in the stromal cells surrounding the tumor but not in the tumor cells by itself, Taken together these observations indicate that overexpression of the mts1 gene in the mouse mammary carcinoma cells gives rise to more aggressive tumors which are able to metastasize.	ARMENIAN ACAD SCI, INST MOL BIOL, YEREVAN 44, ARMENIA; UNIV COPENHAGEN, DEPT MOL CELL BIOL, DK-1353 COPENHAGEN K, DENMARK; KOMMUNE HOSP COPENHAGEN, BARTHOLIN INST, DK-1399 COPENHAGEN K, DENMARK; RUSSIAN ACAD SCI, INST GENE BIOL, MOSCOW, RUSSIA	National Academy of Sciences of Armenia; Institute of Molecular Biology - NAS RA; University of Copenhagen; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences	Ambartsumian, NS (corresponding author), DANISH CANC SOC, DEPT MOL CANC BIOL, STRANDBLVD 49, DK-2100 COPENHAGEN O, DENMARK.		Sidenius, Nicolai/M-9643-2015	Sidenius, Nicolai/0000-0002-7825-7629				CARDIFF RD, 1993, CANCER SURV, V16, P97; CHOI YW, 1987, J VIROL, V61, P3013, DOI 10.1128/JVI.61.10.3013-3019.1987; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIES BR, 1993, ONCOGENE, V8, P999; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; FORD HL, 1995, ONCOGENE, V10, P1597; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GRIGORIAN M, 1996, IN PRESS INT J CANC; GRIGORIAN MS, 1993, GENE, V135, P229, DOI 10.1016/0378-1119(93)90070-J; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HALTER SA, 1992, AM J PATHOL, V140, P1131; HOGAN B, 1986, MANIPULATING MOUSE E; KOZAK C, 1987, J VIROL, V61, P1651, DOI 10.1128/JVI.61.5.1651-1654.1987; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Lukanidin EM, 1996, CURR TOP MICROBIOL, V213, P171; MACDONALD NJ, 1993, CANCER SURV, V16, P175; MESTER J, 1987, J VIROL, V61, P1073, DOI 10.1128/JVI.61.4.1073-1078.1987; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NICOLSON GL, 1994, FRONT RADIAT THER ON, V28, P11; NIGAM AK, 1994, GUT, V35, P996, DOI 10.1136/gut.35.7.996; Nusse R, 1991, Curr Top Microbiol Immunol, V171, P43; ROELINK H, 1992, ONCOGENE, V7, P487; ROLLINI P, 1992, J VIROL, V66, P4580, DOI 10.1128/JVI.66.7.4580-4586.1992; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHUURING E, 1990, ONCOGENE, V5, P459; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAMP G, 1992, CELL GROWTH DIFFER, V3, P929; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; TAKENAGA K, 1994, JPN J CANCER RES, V85, P831, DOI 10.1111/j.1349-7006.1994.tb02955.x; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; VANDERVALK MA, 1981, MAMMARY TUMORS MOUSE, P46; VANNIE R, 1971, J NATL CANCER I, V46, P885; VANNIE R, 1981, MAMMARY TUMORS MOUSE, P202; VINEY JL, 1995, CANCER METAST REV, V14, P77, DOI 10.1007/BF00665792; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	38	167	169	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1621	1630						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895507				2022-12-25	WOS:A1996VM88700006
J	Chuang, TT; Paolucci, L; DeBlasi, A				Chuang, TT; Paolucci, L; DeBlasi, A			Inhibition of G protein-coupled receptor kinase subtypes by Ca2+/calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; CALMODULIN-BINDING; ADENYLATE-CYCLASE; RHODOPSIN KINASE; FAMILY; PHOSPHORYLATION; EXPRESSION; CALCIUM; GRK5; IDENTIFICATION	G protein-coupled receptor kinases (GRKs) are implicated in the homologous desensitization of G protein-coupled receptors. Six GRK subtypes have so far been identified, named GRK1 to GRK6. The functional state of the GRKs can be actively regulated in different ways. In particular, it was found that retinal rhodopsin kinase (GRK1), but not the ubiquitous beta ARK1 (GRK2), can be inhibited by the photoreceptor-specific Ca2+-binding protein recoverin through direct binding. The present study was aimed to investigate regulation of other GRKs by alternative Ca2+-binding proteins such as calmodulin (CaM). We found that G beta gamma-activated GRK2 and GRK3 were inhibited by CaM to similar extents (IC50 similar to 2 mu M), while a 50-fold more potent inhibitory effect was observed on GRK5 (IC50 = 40 nM). Inhibition by CaM was strictly dependent on Ca2+ and was prevented by the CaM inhibitor CaMBd. Since G beta gamma, which is a binding target of Ca2+/CaM, is critical for the activation of GRK2 and GRK3, it provides a possible site of interaction between these proteins. However, since GRK5 is G beta gamma-independent, an alternative mechanism is conceivable. A direct interaction between GRK5 and Ca2+/CaM was revealed using CaM-conjugated Sepharose 4B. This binding does not influence the catalytic activity as demonstrated using the soluble GRK substrate casein. Instead, Ca2+/CaM significantly reduced GRK5 binding to the membrane. The mechanism of GRK5 inhibition appeared to be through direct binding to Ca2+/CaM, resulting in inhibition of membrane association and hence receptor phosphorylation. The present study provides the first evidence for a regulatory effect of Ca2+/CaM on some GRK subtypes, thus expanding the range of different mechanisms regulating the functional states of these kinases.	IST RIC FARMACOL MARIO NEGRI,CONSORZIO MARIO NEGRI SUD,I-66030 SANTA MARIA IMBAR,ITALY	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS								ABRAMS TW, 1991, J NEUROSCI, V11, P2655; BENOVIC JL, 1986, NATURE, V321, P869, DOI 10.1038/321869a0; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; DEBLASI A, 1995, J CLIN INVEST, V95, P203, DOI 10.1172/JCI117641; DECASTRO E, 1995, BIOCHEM BIOPH RES CO, V216, P133, DOI 10.1006/bbrc.1995.2601; GNEGY ME, 1993, ANNU REV PHARMACOL, V33, P45, DOI 10.1146/annurev.pa.33.040193.000401; Haske TN, 1996, J BIOL CHEM, V271, P2941, DOI 10.1074/jbc.271.6.2941; Iacovelli L, 1996, MOL ENDOCRINOL, V10, P1138, DOI 10.1210/me.10.9.1138; INGLESE J, 1992, J BIOL CHEM, V267, P1422; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KATADA T, 1987, J BIOL CHEM, V262, P11897; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUHN H, 1978, BIOCHEMISTRY-US, V21, P4389; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LAKEY T, 1985, BIOCHEM J, V225, P581, DOI 10.1042/bj2250581; MANGELS LA, 1992, BIOCHEM J, V283, P683, DOI 10.1042/bj2830683; Nagayama Y, 1996, J BIOL CHEM, V271, P10143, DOI 10.1074/jbc.271.17.10143; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PAPADOPOULOS V, 1990, ENDOCRINOLOGY, V126, P2465, DOI 10.1210/endo-126-5-2465; PARRUTI G, 1993, J BIOL CHEM, V268, P9753; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; PREMONT RT, 1996, J BIOL CHEM, V271, P6408; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; WILSON CJ, 1993, CURR BIOL, V3, P683, DOI 10.1016/0960-9822(93)90068-Y	36	86	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28691	28696		10.1074/jbc.271.45.28691	http://dx.doi.org/10.1074/jbc.271.45.28691			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910504	hybrid			2022-12-25	WOS:A1996VU03300104
J	Johnson, RE; Kovvali, GK; Guzder, SN; Amin, NS; Holm, C; Habraken, Y; Sung, P; Prakash, L; Prakash, S				Johnson, RE; Kovvali, GK; Guzder, SN; Amin, NS; Holm, C; Habraken, Y; Sung, P; Prakash, L; Prakash, S			Evidence for involvement of yeast proliferating cell nuclear antigen in DNA mismatch repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLE REPETITIVE DNA; MICROSATELLITE INSTABILITY; SACCHAROMYCES-CEREVISIAE; GASTRIC-CANCER; MUTATIONS; GENE; REPLICATION; EXTRACTS; TRACTS	DNA mismatch repair plays a key role in the maintenance of genetic fidelity. Mutations in the human mismatch repair genes hMSH2, hMLR1, hPMS1, and hPMS2 are associated with hereditary nonpolyposis colorectal cancer. The proliferating cell nuclear antigen (PCNA) is essential for DNA replication, where it acts as a processivity factor. Here, we identify a point mutation, pol30-104, in the Saccharomyces cerevisiae POL30 gene encoding PCNA that increases the rate of instability of simple repetitive DNA sequences and raises the rate of spontaneous forward mutation. Epistasis analyses with mutations in mismatch repair genes MSH2, MLH1, and PMS1 suggest that the pol30-104 mutation impairs MSH2/ MLH1/PMS1-dependent mismatch repair, consistent with the hypothesis that PCNA functions in mismatch repair. MSH2 functions in mismatch repair with either MSH3 or MSH6, and the MSH2 MSH3 and MSH2-MSH6 heterodimers have a role in the recognition of DNA mismatches. Consistent with the genetic data, we find specific interaction of PCNA with the MSH2-MSH3 heterodimer.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,DIV CELLULAR & MOL MED,LA JOLLA,CA 92093	University of Texas System; University of Texas Medical Branch Galveston; University of California System; University of California San Diego			Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NCI NIH HHS [CA41261] Funding Source: Medline; NIGMS NIH HHS [GM36510, GM19261] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041261, R37CA041261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036510, R01GM019261] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; GLEBOV OK, 1994, CANCER RES, V54, P3703; Habraken Y, 1996, CURR BIOL, V6, P1185, DOI 10.1016/S0960-9822(02)70686-6; HAN HJ, 1993, CANCER RES, V53, P5087; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; MERLO A, 1994, CANCER RES, V54, P2098; MIRONOV NM, 1994, CANCER RES, V54, P41; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; MORRISON A, 1993, EMBO J, V12, P1467, DOI 10.1002/j.1460-2075.1993.tb05790.x; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; STRAND M, 1995, P NATL ACAD SCI USA, V92, P10418, DOI 10.1073/pnas.92.22.10418; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x	22	175	177	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					27987	27990		10.1074/jbc.271.45.27987	http://dx.doi.org/10.1074/jbc.271.45.27987			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910404	hybrid			2022-12-25	WOS:A1996VU03300004
J	Pshezhetsky, AV; Potier, M				Pshezhetsky, AV; Potier, M			Association of N-acetylgalactosamine-6-sulfate sulfatase with the multienzyme lysosomal complex of beta-galactosidase, cathepsin A, and neuraminidase - Possible implication for intralysosomal catabolism of keratan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MORQUIO-DISEASE; HUMAN-PLACENTA; DEFICIENCY; PROTEIN; ENZYME; ORGANIZATION; PURIFICATION; DIAGNOSIS; BINDING; ASSAY	N-Acetylgalactosamine-6-sulfate sulfatase (GALNS) catalyzes the first step of intralysosomal keratan sulfate (HS) catabolism. In Morquio type A syndrome GALNS deficiency causes the accumulation of HS in tissues and results in generalized skeletal dysplasia in affected patients. We show that in normal cells GALNS is in a 1.27 MDa complex with three other lysosomal hydrolases: beta-galactosidase, alpha-neuraminidase, and cathepsin A (protective protein). GALNS copurifies with the complex by different chromatography techniques: affinity chromatography on both cathepsin A-binding and beta-galactosidase-binding columns, gel filtration, and chromatofocusing. Anti-human cathepsin A rabbit antiserum coprecipitates GALNS together with cathepsin A, beta-galactosidase, and Lu-neuraminidase in both a purified preparation of the 1.27-MDa complex and crude glycoprotein fraction from human placenta extract. Gel filtration analysis of fibroblast extracts of patients deficient in either beta-galactosidase (beta-galactosidosis) or cathepsin A (galactosialidosis), which accumulate KS, demonstrates that the 1.27-MDa complex is disrupted and that GALNS is present only in free homodimeric form. The GALNS activity and cross-reacting material are reduced in the fibroblasts of patients affected with galactosialidosis, indicating that the complex with cathepsin A may protect GALNS in the lysosome. We suggest that the 1.27-MDa complex of lysosomal hydrolases is essential for RS catabolism and that the disruption of this complex may be responsible for the KS accumulation in beta-galactosidosis and galactosialidosis patients.	UNIV MONTREAL,FAC MED,DEPT PEDIAT,MONTREAL,PQ H3T 1C5,CANADA	Universite de Montreal	Pshezhetsky, AV (corresponding author), HOP ST JUSTINE,SERV GENET MED,3175 COTE ST CATHERINE,MONTREAL,PQ H3T 1C5,CANADA.			A, Pshezhetsky/0000-0002-6612-1062				ARBISSER AI, 1977, AM J MED GENET, V1, P195, DOI 10.1002/ajmg.1320010205; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAZZO A, 1982, P NATL ACAD SCI-BIOL, V79, P4535, DOI 10.1073/pnas.79.15.4535; FUKUDA S, 1992, J CLIN INVEST, V90, P1049, DOI 10.1172/JCI115919; GLOSSL J, 1978, CLIN CHIM ACTA, V88, P111, DOI 10.1016/0009-8981(78)90157-2; HOOGEVEEN AT, 1983, J BIOL CHEM, V258, P2143; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASUE M, 1991, J BIOCHEM-TOKYO, V110, P965, DOI 10.1093/oxfordjournals.jbchem.a123697; Matalon R, 1974, BIOCHEM BIOPH RES CO, V61, P709; MORREAU H, 1989, J BIOL CHEM, V264, P20655; Neufeld E. F., 1995, METABOLIC MOL BASES, V2; OKADA S, 1968, SCIENCE, V160, P1002, DOI 10.1126/science.160.3831.1002; OKAMURAOHO Y, 1996, BIOCHEMISTRY J, V313, P78; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; PSHEZHETSKY AV, 1995, BIOCHEMISTRY-US, V34, P2431, DOI 10.1021/bi00008a005; PSHEZHETSKY AV, 1994, ARCH BIOCHEM BIOPHYS, V313, P64, DOI 10.1006/abbi.1994.1359; PSHEZHETSKY AV, 1993, BIOCHEM BIOPH RES CO, V195, P354, DOI 10.1006/bbrc.1993.2051; ROBINSON JB, 1985, J BIOL CHEM, V260, P800; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; SINGH J, 1976, J CLIN INVEST, V57, P1036, DOI 10.1172/JCI108345; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; Suzuki Y., 1995, METABOLIC MOL BASES, VII; THOMAS GH, 1995, METABOLIC MOL BASES, V2; TOMATSU S, 1991, BIOCHEM BIOPH RES CO, V181, P677, DOI 10.1016/0006-291X(91)91244-7; TRANCHEMONTAGNE J, 1990, BIOCHEM BIOPH RES CO, V168, P22, DOI 10.1016/0006-291X(90)91669-J; VANDERHORST GTJ, 1989, J BIOL CHEM, V264, P1317; VANDERHORST GTJ, 1993, THESIS; VANDIGGELEN OP, 1990, CLIN CHIM ACTA, V187, P131, DOI 10.1016/0009-8981(90)90339-T	28	69	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28359	28365		10.1074/jbc.271.45.28359	http://dx.doi.org/10.1074/jbc.271.45.28359			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910459	hybrid			2022-12-25	WOS:A1996VU03300059
J	Zerangue, N; Kavanaugh, MP				Zerangue, N; Kavanaugh, MP			ASCT-1 is a neutral amino acid exchanger with chloride channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT-SYSTEM ASC; GLUTAMATE TRANSPORTER; GLIAL-CELLS; ION FLUXES; EXPRESSION; POTASSIUM; SODIUM; ERYTHROCYTES; CLONING; FAMILY	The ubiquitous transport activity known as system ASC is characterized by a preference for small neutral amino acids including alanine, serine, and cysteine. ASCT-1 and ASCT-2, recently cloned transporters exhibiting system ASC-like selectivity, are members of a major amino acid transporter family that includes a number of glutamate transporters. Here we show that ASCT1 functions as an electroneutral exchanger that mediates negligible net amino acid flux. The electrical currents previously shown to be associated with ASCT1-mediated transport result from activation of a thermodynamically uncoupled chloride conductance with permeation properties similar to those described for the glutamate transporter subfamily. Like glutamate transporters, ASCT1 activity requires extracellular Na+. However, unlike glutamate transporters, which mediate net flux and complete a transport cycle by countertransport of K+, ASCT-1 mediates only homo- and heteroexchange of amino acids and is insensitive to K+. The properties of ASCT-1 suggest that it may function to equilibrate different pools of neutral amino acids and provide a mechanism to link amino acid concentration gradients.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University					NIGMS NIH HHS [GM 48709] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048709] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSALEH EA, 1982, BIOCHIM BIOPHYS ACTA, V684, P157, DOI 10.1016/0005-2736(82)90001-3; AMATO A, 1994, J PHYSIOL-LONDON, V479, P371, DOI 10.1113/jphysiol.1994.sp020302; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; BUSSOLATI O, 1992, J BIOL CHEM, V267, P8330; CHRISTENSEN HN, 1967, J BIOL CHEM, V242, P5237; CHRISTENSEN HN, 1982, PHYSIOL REV, V62, P1193, DOI 10.1152/physrev.1982.62.4.1193; CHRISTENSEN HN, 1972, NA LINKED TRANSPORT, P161; Eliasof S, 1996, P NATL ACAD SCI USA, V93, P4153, DOI 10.1073/pnas.93.9.4153; ELWYN DH, 1966, FED PROC, V25, P854; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; GAZZOLA GC, 1980, J BIOL CHEM, V255, P929; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; KANAI Y, 1993, FASEB J, V7, P1450, DOI 10.1096/fasebj.7.15.7903261; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P6327, DOI 10.1021/bi00267a044; KAVANAUGH MP, 1996, IN PRESS J BIOL CHEM, V271; Larsson HP, 1996, BIOPHYS J, V70, P733, DOI 10.1016/S0006-3495(96)79613-3; LIAO K, 1995, BIOCHEM BIOPH RES CO, V208, P1008, DOI 10.1006/bbrc.1995.1434; MAENZ DD, 1992, J BIOL CHEM, V267, P1510; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; SEPULVEDA FV, 1978, J PHYSIOL-LONDON, V282, P73, DOI 10.1113/jphysiol.1978.sp012449; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; SHOTWELL MA, 1981, J BIOL CHEM, V256, P5422; STALLCUP WB, 1979, J NEUROCHEM, V32, P57, DOI 10.1111/j.1471-4159.1979.tb04509.x; Tamarappoo BK, 1996, BBA-BIOMEMBRANES, V1279, P131, DOI 10.1016/0005-2736(95)00259-6; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; VADGAMA JV, 1984, J BIOL CHEM, V259, P3648; VALDEOLMILLOS M, 1986, BIOCHIM BIOPHYS ACTA, V858, P181, DOI 10.1016/0005-2736(86)90304-4; VANDENBERG RJ, 1995, J BIOL CHEM, V270, P17668, DOI 10.1074/jbc.270.30.17668; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; YOUNG JD, 1980, PROC R SOC SER B-BIO, V209, P355, DOI 10.1098/rspb.1980.0100; Zerangue N, 1996, J PHYSIOL-LONDON, V493, P419, DOI 10.1113/jphysiol.1996.sp021393; ZERANGUE N, 1996, IN PRESS NATURE	34	133	140	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					27991	27994		10.1074/jbc.271.45.27991	http://dx.doi.org/10.1074/jbc.271.45.27991			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910405	hybrid, Green Published			2022-12-25	WOS:A1996VU03300005
J	Borgne, A; Meijer, L				Borgne, A; Meijer, L			Sequential dephosphorylation of p34(cdc2) on Thr-14 and Tyr-15 at the prophase/metaphase transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; MATURATION-PROMOTING FACTOR; XENOPUS CDC25 PHOSPHATASE; P34CDC2 KINASE ACTIVATION; WEE1 PROTEIN-KINASE; FISSION YEAST CDC2; M-PHASE; TYROSINE PHOSPHORYLATION; DEPENDENT KINASES; MEIOTIC MATURATION	The G(2)-M transition of the cell cycle is triggered by the p34(cdc2)/cyclin B kinase. During the prophase/metaphase transition, the inactive, Thr-14/Tyr-15 phosphorylated form of p34(cdc2) (T-P-Y-P) is modified to an active, Thr-14/Tyr-15 dephosphorylated form (T-Y) by the cdc25 dual-specificity phosphatase. Using highly synchronized starfish oocytes as a cellular model, we show that dephosphorylation in vivo and in vitro occurs in two steps: Thr-14 dephosphorylation precedes Tyr-15 dephosphorylation. The transient intermediate form (T-Y-P), which can be obtained in vitro by treatment of T-P-Y-P by protein phosphatase 2A, displays low but significant kinase activity. These results raise the possibility that the intermediate form T-Y-P may be involved in the autocatalytic amplification of the p34(cdc2)/cyclin B complex through phosphorylation/activation of the cdc25 phosphatase and phosphorylation/inactivation of the wee1 kinase.			Borgne, A (corresponding author), CNRS, BIOL STN, BP 74, F-29682 ROSCOFF, FRANCE.			, laurent/0000-0003-3511-4916				AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; AOKI F, 1992, DEV BIOL, V154, P66, DOI 10.1016/0012-1606(92)90048-L; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; AZZI L, 1994, J BIOL CHEM, V269, P13279; BARATTE B, 1992, ANTICANCER RES, V12, P873; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; CAYLA X, 1994, J BIOL CHEM, V269, P15668; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DENHAESE GJ, 1995, MOL BIOL CELL, V6, P371, DOI 10.1091/mbc.6.4.371; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; ENDICOTT JA, 1994, PROTEIN ENG, V7, P243, DOI 10.1093/protein/7.2.243; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; GENEVIEREGARRIGUES AM, 1995, J CELL SCI, V108, P2693; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOFFMANN I, 1994, J CELL SCI, P75; HONDA R, 1995, CHROMOSOME RES, V3, P300, DOI 10.1007/BF00713068; HONDA R, 1993, FEBS LETT, V318, P331, DOI 10.1016/0014-5793(93)80540-B; HONDA R, 1992, BIOCHEM BIOPH RES CO, V186, P1333, DOI 10.1016/S0006-291X(05)81552-9; IZUMI T, 1995, MOL BIOL CELL, V6, P215, DOI 10.1091/mbc.6.2.215; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KERNS J, 1995, BIOORG CHEM, V23, P101, DOI 10.1006/bioo.1995.1008; KORNBLUTH S, 1994, MOL BIOL CELL, V5, P273, DOI 10.1091/mbc.5.3.273; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KUANG J, 1994, MOL BIOL CELL, V5, P135, DOI 10.1091/mbc.5.2.135; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEE MS, 1994, J BIOL CHEM, V269, P30530; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LOCK RB, 1992, CANCER RES, V52, P1817; LUKAS J, 1992, EUR J BIOCHEM, V207, P169, DOI 10.1111/j.1432-1033.1992.tb17034.x; LUNGREN K, 1991, CELL, V64, P1111; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; Meijer L., 1995, PROGR CELL CYCLE RES, V1; Meijer Laurent, 1994, Seminars in Developmental Biology, V5, P165, DOI 10.1006/sedb.1994.1022; MILLAR JBA, 1992, EMBO J, V11, P4933, DOI 10.1002/j.1460-2075.1992.tb05600.x; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; NAGATA A, 1991, NEW BIOL, V3, P959; NAITO K, 1995, DEV BIOL, V168, P627, DOI 10.1006/dbio.1995.1107; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; OGG S, 1994, J BIOL CHEM, V269, P30461; OOKATA K, 1992, EMBO J, V11, P1763, DOI 10.1002/j.1460-2075.1992.tb05228.x; OOKATA K, 1995, J CELL BIOL, V128, P849, DOI 10.1083/jcb.128.5.849; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PAULES RS, 1995, CANCER RES, V55, P1763; PICKHAM KM, 1992, MOL CELL BIOL, V12, P3192, DOI 10.1128/MCB.12.7.3192; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; RIME H, 1994, BIOL CELL, V82, P11, DOI 10.1016/0248-4900(94)90061-2; RIME H, 1991, EXP CELL RES, V196, P241, DOI 10.1016/0014-4827(91)90257-U; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SCHULZEGAHMEN U, 1995, PROTEINS, V22, P378, DOI 10.1002/prot.340220408; SCHUTTLEWORTH J, 1995, PROG CELL CYCLE RES, V1, P229; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Shapiro H, 1941, J CELL COMPAR PHYSL, V18, P61, DOI 10.1002/jcp.1030180108; SOLOMON MJ, 1994, TRENDS BIOCHEM SCI, V19, P496, DOI 10.1016/0968-0004(94)90137-6; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; VANHOOF C, 1994, EUR J BIOCHEM, V226, P899; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; YAMASHITA M, 1991, DEV GROWTH DIFFER, V33, P617	91	125	134	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27847	27854		10.1074/jbc.271.44.27847	http://dx.doi.org/10.1074/jbc.271.44.27847			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910383	hybrid			2022-12-25	WOS:A1996VQ67900101
J	Kimura, T; Kihara, H; Bhattacharyya, S; Sakamoto, H; Appella, E; Siraganian, RP				Kimura, T; Kihara, H; Bhattacharyya, S; Sakamoto, H; Appella, E; Siraganian, RP			Downstream signaling molecules bind to different phosphorylated immunoreceptor tyrosine-based activation motif (ITAM) peptides of the high affinity IgE receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; BASOPHILIC LEUKEMIA-CELLS; PHOSPHOTYROSINE-CONTAINING PEPTIDES; IMMUNOGLOBULIN-E RECEPTOR; T-CELL; ANTIGEN RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; MAST-CELLS; ZETA-CHAIN; RBL-2H3 CELLS	The cytoplasmic tails of both the beta and gamma subunits of the high affinity IgE receptor (Fc epsilon RI) contain a consensus sequence termed the immunoreceptor tyrosine-based activation motif (ITAM). This motif plays a critical role in receptor-mediated signal transduction. Synthetic peptides based on the ITAM sequences of the beta and gamma subunits of Fc epsilon RI were used to investigate which proteins associate with these motifs. Tyrosine-phosphorylated beta and gamma ITAM peptides immobilized on beads precipitated Syk, Lyn, Shc, Grb2, and phospholipase C-gamma 1 from lysates of rat basophilic leukemia RBL-2H3 cells. Syk was precipitated predominantly by the tyrosine-diphosphorylated gamma ITAM peptide, but much less by the diphosphorylated beta ITAM peptide or by the monophosphorylated peptides. Phospholipase C-gamma 1, Shc, and Grb2 were precipitated only by the diphosphorylated beta ITAM peptide. Non-phosphorylated ITAM peptides did not precipitate these proteins. In membrane binding assays, fusion proteins containing the Src homology 2 domains of phospholipase C-gamma 1, Shc, Syk, and Lyn directly bound the tyrosine-phosphorylated ITAM peptides. Although the ITAM sequences of the beta and gamma subunits of Fc epsilon RI are similar, once they are tyrosine-phosphorylated they preferentially bind different downstream signaling molecules. Tyrosine phosphorylation of the ITAM of the gamma subunit recruits and activates Syk, whereas the beta subunit may be important for the Ras signaling pathway.	NCI,CELL BIOL LAB,NATL INST HLTH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kimura, T (corresponding author), NIDR,IMMUNOL LAB,NATL INST HLTH,BLDG 10,RM 1N106,BETHESDA,MD 20892, USA.		Sakamoto, Hiroshi/A-3181-2011					ALBER G, 1991, J BIOL CHEM, V266, P22613; AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; ATKINSON TP, 1992, J IMMUNOL, V148, P2194; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Busse WW, 1993, ALLERGY PRINCIPLES P, P105; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; DASGUPTA JD, 1992, J EXP MED, V175, P285, DOI 10.1084/jem.175.1.285; EISEMAN E, 1992, J BIOL CHEM, V267, P21027; EISEMAN E, 1992, NATURE, V355, P78; FUKAMACHI H, 1992, P NATL ACAD SCI USA, V89, P9524, DOI 10.1073/pnas.89.20.9524; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; HAMAWY MM, 1995, CELL SIGNAL, V7, P535, DOI 10.1016/0898-6568(95)00024-J; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; JOHNSON SA, 1995, J IMMUNOL, V155, P4596; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KIHARA H, 1994, J BIOL CHEM, V269, P22427; Kimura T, 1996, MOL CELL BIOL, V16, P1471; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; MINOGUCHI K, 1994, J BIOL CHEM, V269, P16902; MINOGUCHI K, 1994, J BIOL CHEM, V269, P5249; OFFERMANNS S, 1994, J IMMUNOL, V152, P250; OTTINGER EA, 1993, BIOCHEMISTRY-US, V32, P4354, DOI 10.1021/bi00067a027; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIVERA VM, 1995, MOL CELL BIOL, V15, P1582; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SANTINI F, 1993, J BIOL CHEM, V268, P22716; SAXTON TM, 1994, J IMMUNOL, V153, P623; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; SILLMAN AL, 1995, J BIOL CHEM, V270, P11806, DOI 10.1074/jbc.270.20.11806; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; TAYLOR JA, 1995, MOL CELL BIOL, V15, P4149; TURNER H, 1995, J BIOL CHEM, V270, P9500, DOI 10.1074/jbc.270.16.9500; WILSON BS, 1995, J BIOL CHEM, V270, P4013, DOI 10.1074/jbc.270.8.4013; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251	62	64	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27962	27968		10.1074/jbc.271.44.27962	http://dx.doi.org/10.1074/jbc.271.44.27962			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910399	hybrid			2022-12-25	WOS:A1996VQ67900117
J	Mazumder, A; Neamati, N; Pilon, AA; Sunder, S; Pommier, Y				Mazumder, A; Neamati, N; Pilon, AA; Sunder, S; Pommier, Y			Chemical trapping of ternary complexes of human immunodeficiency virus type I integrase, divalent metal, and DNA substrates containing an abasic site - Implications for the role of lysine 136 in DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 INTEGRASE; VIRAL-DNA; STABLE COMPLEX; PROTEIN; CLEAVAGE; SEQUENCE; REGION; VITRO; IDENTIFICATION; HETERODUPLEXES	We report a novel assay for monitoring the DNA binding of human immunodeficiency virus type 1 (HIV-1) integrase and the effect of cofactors and inhibitors. The assay uses depurinated oligonucleotides that can form a Schiff base between the aldehydic abasic site and a nearby enzyme lysine epsilon-amino group which can subsequently be trapped by reduction with sodium borohydride. Chemically depurinated duplex substrates representing the U5 end of the HIV-1 DNA were initially used. We next substituted an enzymatically generated abasic site for each of 10 nucleotides normally present in a 21-mer duplex oligonucleotide representing the U5 end of the HIV-1 DNA. Using HIV-1, HIV-2, or simian immunodeficiency virus integrases, the amount of covalent enzyme-DNA complex trapped decreased as the abasic site was moved away from the conserved CA dinucleotide. The enzyme-DNA complexes formed in the presence of manganese were not reversed by subsequent addition of EDTA, indicating that the divalent metal required for integrase catalysis is tightly bound in a ternary enzyme-metal-DNA complex. Both the N- and C-terminal domains of integrase contributed to efficient DNA binding, and mutation of Lys-136 significantly reduced Schiff base formation, implicating this residue in viral DNA binding.	NCI,MOL PHARMACOL LAB,DIV BASIC SCI,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; CUNIASSE P, 1987, NUCLEIC ACIDS RES, V15, P8003, DOI 10.1093/nar/15.19.8003; ELLISON V, 1994, P NATL ACAD SCI USA, V91, P7316, DOI 10.1073/pnas.91.15.7316; ELLISON V, 1995, J BIOL CHEM, V270, P3320, DOI 10.1074/jbc.270.7.3320; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; ENGELMAN A, 1995, J VIROL, V69, P5908, DOI 10.1128/JVI.69.9.5908-5911.1995; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; GRANDGENETT DP, 1978, VIROLOGY, V89, P119, DOI 10.1016/0042-6822(78)90046-6; HOHENEGGER M, 1994, J BIOL CHEM, V269, P32008; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAFEMINA RL, 1991, J VIROL, V65, P5624, DOI 10.1128/JVI.65.10.5624-5630.1991; LEAVITT AD, 1992, J VIROL, V66, P2359, DOI 10.1128/JVI.66.4.2359-2368.1992; LEE SP, 1995, BIOCHEMISTRY-US, V34, P10215, DOI 10.1021/bi00032a015; Lee SP, 1996, BIOCHEMISTRY-US, V35, P3837, DOI 10.1021/bi952056p; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LIPFORD JR, 1994, J ACQ IMMUN DEF SYND, V7, P1215; LUTZKE RAP, 1994, NUCLEIC ACIDS RES, V22, P4125, DOI 10.1093/nar/22.20.4125; MANOHARAN M, 1988, J AM CHEM SOC, V110, P1620, DOI 10.1021/ja00213a044; MAZUMDER A, 1995, NUCLEIC ACIDS RES, V23, P2865, DOI 10.1093/nar/23.15.2865; Mazumder A, 1996, J MED CHEM, V39, P2472, DOI 10.1021/jm960074e; Mazumder A, 1996, MOL PHARMACOL, V49, P621; OJWANG JO, 1995, ANTIMICROB AGENTS CH, V39, P2426, DOI 10.1128/AAC.39.11.2426; POMMIER Y, 1995, P NATL ACAD SCI USA, V92, P8861, DOI 10.1073/pnas.92.19.8861; PRUSS D, 1995, NUCLEUS, V1, P3; ROTH MJ, 1988, J MOL BIOL, V203, P131, DOI 10.1016/0022-2836(88)90097-6; SCHAUER M, 1992, BIOCHEM BIOPH RES CO, V185, P874, DOI 10.1016/0006-291X(92)91708-X; SHERMAN PA, 1992, J VIROL, V66, P3593, DOI 10.1128/JVI.66.6.3593-3601.1992; VANDENENT FMI, 1994, J VIROL, V68, P7825, DOI 10.1128/JVI.68.12.7825-7832.1994; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; VANGENT DC, 1991, NUCLEIC ACIDS RES, V19, P3821, DOI 10.1093/nar/19.14.3821; VARSHNEY U, 1991, BIOCHEMISTRY-US, V30, P4055, DOI 10.1021/bi00230a033; VINK C, 1994, NUCLEIC ACIDS RES, V22, P4103, DOI 10.1093/nar/22.20.4103; VINK C, 1991, J VIROL, V65, P4636, DOI 10.1128/JVI.65.9.4636-4644.1991; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691; VINK C, 1993, TRENDS GENET, V9, P433, DOI 10.1016/0168-9525(93)90107-S; WILDE JA, 1989, J AM CHEM SOC, V111, P1894, DOI 10.1021/ja00187a062; WITHERSWARD ES, 1994, GENE DEV, V8, P1473, DOI 10.1101/gad.8.12.1473; WITHKA JM, 1991, BIOCHEMISTRY-US, V30, P9931, DOI 10.1021/bi00105a017; WOERNER AM, 1992, AIDS RES HUM RETROV, V8, P297, DOI 10.1089/aid.1992.8.297; WOERNER AM, 1993, NUCLEIC ACIDS RES, V21, P3507, DOI 10.1093/nar/21.15.3507; Wolfe AL, 1996, J VIROL, V70, P1424, DOI 10.1128/JVI.70.3.1424-1432.1996; YOSHINAGA T, 1994, J VIROL, V68, P5690, DOI 10.1128/JVI.68.9.5690-5697.1994	47	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27330	27338		10.1074/jbc.271.44.27330	http://dx.doi.org/10.1074/jbc.271.44.27330			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910309	hybrid			2022-12-25	WOS:A1996VQ67900027
J	Trotta, E; DAmbrosio, E; Ravagnan, G; Paci, M				Trotta, E; DAmbrosio, E; Ravagnan, G; Paci, M			Simultaneous and different binding mechanisms of 4',6-diamidino-2-phenylindole to DNA hexamer (d(CGATCG))(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINOR-GROOVE BINDING; DIMENSIONAL NMR-SPECTROSCOPY; SEQUENTIAL RESONANCE ASSIGNMENTS; H-1-NMR SPECTRA; NUCLEIC-ACIDS; PROTON RESONANCES; AQUEOUS-SOLUTION; DAPI; INTERCALATION; DRUGS	The solution structure of the complex between 4',6-diamidino-2-phenylindole (DAPI) and DNA oligomer (d(CGATCG))(2) at a 2:1 drug/duplex ratio has been characterized by combined use of proton one- and two-dimensional NMR spectroscopy, molecular mechanics, and molecular dynamics computations. Intermolecular nuclear Overhauser effects (NOEs), DNA structure perturbations, and resonance shifts induced by binding provide evidence that DAPI interacts with DNA hexamer by two different binding mechanisms, in fast exchange on the NMR. time scale, without any significant distortion of the B-type conformation of DNA hexamer, The results indicate that the ligand binds into the minor groove of the central 5'-ATC-3' region of the hexamer and on the outside of the oligomer by a pi pi-stacking interaction with the terminal C1:G6 base pairs, A model for both binding mechanisms that accounts for all experimental data was generated by molecular mechanics and dynamics calculations based on experimental NOEs, In the minor groove binding, N2 amino group of G2 precludes a deep insertion of phenyl ring of DAPI into the groove, Position and orientation of the drug in the external stacking interaction resemble those suggested for intercalation of DAPI between C:G base pairs.	CNR,IST MED SPERIMENTALE,I-00137 ROME,ITALY; UNIV ROMA TOR VERGATA,DIPARTIMENTO SCI & TECNOL CHIM,I-00133 ROME,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Rome Tor Vergata			Trotta, Edoardo/AAW-4697-2020	Trotta, Edoardo/0000-0002-1417-9238				ALTONA C, 1982, RECL TRAV CHIM PAY B, V101, P413; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BOELENS R, 1985, J MAGN RESON, V62, P378, DOI 10.1016/0022-2364(85)90207-0; BOELENS R, 1990, SOFTWARE PROCESSING; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CHIANG SY, 1994, BIOCHEMISTRY-US, V33, P7033, DOI 10.1021/bi00189a003; CLORE GM, 1985, FEBS LETT, V179, P187, DOI 10.1016/0014-5793(85)80516-0; CONTE MR, 1995, EUR J BIOCHEM, V229, P443; DAVIES DB, 1978, PROG NUCL MAG RES SP, V12, P135, DOI 10.1016/0079-6565(78)80006-5; ERIKSSON S, 1993, BIOCHEMISTRY-US, V32, P2987, DOI 10.1021/bi00063a009; FEIGON J, 1984, J MED CHEM, V27, P450, DOI 10.1021/jm00370a007; HARE DR, 1983, J MOL BIOL, V171, P319, DOI 10.1016/0022-2836(83)90096-7; HOSUR RV, 1988, MAGN RESON CHEM, V26, P927, DOI 10.1002/mrc.1260261019; HOSUR RV, 1985, MAGNETIC RESONANCE B, P243; JANSEN K, 1993, J AM CHEM SOC, V115, P10527, DOI 10.1021/ja00076a009; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAPUSCINSKI J, 1979, NUCLEIC ACIDS RES, V6, P3519, DOI 10.1093/nar/6.11.3519; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; KASTRUP RV, 1978, BIOCHEMISTRY-US, V17, P4855, DOI 10.1021/bi00616a002; KIM SK, 1993, J AM CHEM SOC, V115, P3441, DOI 10.1021/ja00062a006; KUBISTA M, 1987, BIOCHEMISTRY-US, V26, P4545, DOI 10.1021/bi00388a057; LARSEN TA, 1989, J BIOMOL STRUCT DYN, V7, P477, DOI 10.1080/07391102.1989.10508505; LOONTIENS FG, 1991, BIOCHEMISTRY-US, V30, P182, DOI 10.1021/bi00215a027; LOWN JW, 1984, NUCLEIC ACIDS RES, V12, P2519, DOI 10.1093/nar/12.5.2519; MANZINI G, 1983, NUCLEIC ACIDS RES, V11, P8861, DOI 10.1093/nar/11.24.8861; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MOHAN S, 1994, J BIOMOL STRUCT DYN, V11, P849, DOI 10.1080/07391102.1994.10508037; MUELLER L, 1987, J MAGN RESON, V72, P191, DOI 10.1016/0022-2364(87)90188-0; PALU G, 1987, BIOCHEM BIOPH RES CO, V145, P40, DOI 10.1016/0006-291X(87)91284-8; PAROLIN C, 1990, FEMS MICROBIOL LETT, V68, P341, DOI 10.1016/S0378-1097(05)80065-5; PAROLIN C, 1995, BIOCHEM BIOPH RES CO, V208, P332, DOI 10.1006/bbrc.1995.1342; PATEL DJ, 1987, Q REV BIOPHYS, V20, P35, DOI 10.1017/S0033583500004224; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REID DG, 1983, BIOCHEMISTRY-US, V22, P2019, DOI 10.1021/bi00277a044; Samuelson Per, 1994, Journal of Molecular Recognition, V7, P233, DOI 10.1002/jmr.300070313; SCHEEK RM, 1984, BIOCHEMISTRY-US, V23, P1371, DOI 10.1021/bi00302a006; SCHEEK RM, 1983, J AM CHEM SOC, V105, P2914, DOI 10.1021/ja00347a075; SEHLSTEDT U, 1993, J AM CHEM SOC, V115, P12258, DOI 10.1021/ja00079a004; SKLENAR V, 1987, J MAGN RESON, V74, P469, DOI 10.1016/0022-2364(87)90269-1; STORL K, 1993, FEBS LETT, V317, P157, DOI 10.1016/0014-5793(93)81513-Y; STRANEY DC, 1987, BIOCHEMISTRY-US, V26, P1987, DOI 10.1021/bi00381a031; TANIOUS FA, 1994, J BIOMOL STRUCT DYN, V11, P1063, DOI 10.1080/07391102.1994.10508053; TANIOUS FA, 1992, BIOCHEMISTRY-US, V31, P3103, DOI 10.1021/bi00127a010; TROTTA E, 1995, NUCLEIC ACIDS RES, V23, P1333, DOI 10.1093/nar/23.8.1333; TROTTA E, 1993, J BIOL CHEM, V268, P3944; WELCH JJ, 1994, J BIOL CHEM, V269, P31051; WILSON WD, 1989, J AM CHEM SOC, V111, P5008, DOI 10.1021/ja00195a080; WILSON WD, 1990, ANTI-CANCER DRUG DES, V5, P31; WILSON WD, 1990, BIOCHEMISTRY-US, V29, P8452, DOI 10.1021/bi00488a036; [No title captured]	50	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27608	27614		10.1074/jbc.271.44.27608	http://dx.doi.org/10.1074/jbc.271.44.27608			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910349	hybrid			2022-12-25	WOS:A1996VQ67900067
J	Yamazaki, H; Johnson, WW; Ueng, YF; Shimada, T; Guengerich, FP				Yamazaki, H; Johnson, WW; Ueng, YF; Shimada, T; Guengerich, FP			Lack of electron transfer from cytochrome b(5) in stimulation of catalytic activities of cytochrome P450 3A4 - Characterization of a reconstituted cytochrome P450 3A4 NADPH-cytochrome P450 reductase system and studies with apo-cytochrome b(5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; OXIDATIVE DRUG-METABOLISM; GENETIC-POLYMORPHISM; ESCHERICHIA-COLI; N-DEMETHYLATION; FUSION PROTEIN; PURIFICATION; MECHANISM; ENZYMES; LM2	Many catalytic activities of cytochrome P450 (P450) 3A4, the major human liver P450 enzyme, require cytochrome b(5) (b(5)) for optimal rates, The stimulatory effect of b(5) on P450 reactions has generally been thought to be due to transfer of electrons from ferrous b(5) to the ferrous P-450-O-2-substrate complex. We found that apo-b(5), devoid of heme, could substitute for b(5) in stimulating two prototypic activities, testosterone 6 beta hydroxylation and nifedipine oxidation. The stimulatory effect was not seen with albumin, hemoglobin, catalase, or cytochrome c. Apo-b(5) could not substitute for b(5) in a testosterone 6 beta hydroxylation system composed of NADH-b(5) reductase and P450 3A4. Rates of electron transfer from NADPH-P450 reductase to ferric P450 3A4 were too slow (<2 min(-1)) to support testosterone 6 beta hydroxylation (similar to 14 min(-1)) unless b(5) or apo-b(5) was present, when rates of similar to 700 min(-1) were measured. The oxidation-reduction potential (E(m,7)) of the ferric/ferrous couple of P450 3A4 was unchanged (similar to-310 mV) under different conditions in which the kinetics of reduction vp ere altered by the addition of substrate and/or apo-b(5). Rapid reduction of P450 3A4 required substrate and a preformed complex of P450 3A4, NADPH-P450 reductase, and b(5); the rates of binding of the proteins to each other were 2-3 orders of magnitude less than reduction rates. We conclude that b(5) can facilitate some P450 3A4-catalyzed oxidations by complexing with P450 3A4 and enhancing its reduction by NADPH-P450 reductase, without directly transferrin,b electrons to P450.	OSAKA PREFECTURAL INST PUBL HLTH, OSAKA 537, JAPAN; VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, CTR MOL TOXICOL, NASHVILLE, TN 37232 USA	Osaka Prefectural Institute of Public Health; Vanderbilt University; Vanderbilt University			Yamazaki, Hiroshi/A-6081-2011	Yamazaki, Hiroshi/0000-0002-1068-4261; Shimada, Tsutomu/0000-0003-2552-4348	NATIONAL CANCER INSTITUTE [R35CA044353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267, F32ES005663] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA44353] Funding Source: Medline; NIEHS NIH HHS [P30 ES00267, F32 ES05663] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BACKES WL, 1989, J BIOL CHEM, V264, P6252; BACKES WL, 1988, J BIOL CHEM, V263, P247; BACKES WL, 1980, BIOCHEM BIOPH RES CO, V97, P860, DOI 10.1016/0006-291X(80)91456-4; Bell LC, 1996, FASEB J, V10, P2872; BONFILS C, 1981, J BIOL CHEM, V256, P9457; BRIAN WR, 1990, BIOCHEMISTRY-US, V29, P11280, DOI 10.1021/bi00503a018; BURLEIGH BD, 1969, ANAL BIOCHEM, V27, P536, DOI 10.1016/0003-2697(69)90067-0; CAWLEY GF, 1995, BIOCHEMISTRY-US, V34, P1244, DOI 10.1021/bi00004a018; CHIANG JYL, 1983, BIOCHIM BIOPHYS ACTA, V750, P291, DOI 10.1016/0005-2760(83)90031-0; Chun YJ, 1996, ARCH BIOCHEM BIOPHYS, V330, P48, DOI 10.1006/abbi.1996.0224; CINTI DL, 1975, BIOCHIM BIOPHYS ACTA, V410, P32, DOI 10.1016/0005-2744(75)90205-3; Clark W. M., 1960, OXIDATION REDUCTION; de Montellano PR Ortiz, 1995, CYTOCHROME P450 STRU; DIEHL H, 1970, H-S Z PHYSIOL CHEM, V351, P1359, DOI 10.1515/bchm2.1970.351.2.1359; FISHER MT, 1985, J AM CHEM SOC, V107, P5018, DOI 10.1021/ja00303a045; GIGON PL, 1969, MOL PHARMACOL, V5, P109; GILLAM EMJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P123, DOI 10.1006/abbi.1993.1401; GOLLY I, 1988, ARCH BIOCHEM BIOPHYS, V260, P232, DOI 10.1016/0003-9861(88)90445-6; Guengerich F. P., 1995, CYTOCHROME P, P473; Guengerich F. Peter, 1994, P1259; GUENGERICH FP, 1990, CHEM RES TOXICOL, V3, P21, DOI 10.1021/tx00013a004; GUENGERICH FP, 1986, J BIOL CHEM, V261, P5051; GUENGERICH FP, 1983, BIOCHEMISTRY-US, V22, P2811, DOI 10.1021/bi00281a007; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; GUENGERICH FP, 1990, CHEM RES TOXICOL, V3, P363, DOI 10.1021/tx00016a015; GUENGERICH FP, 1994, ADV DRUG METABOLISM, P179; GUENGERICH FP, 1994, SCHERING FDN WORKSHO, V13, P161; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; HUANG YY, 1986, BIOCHEMISTRY-US, V25, P1390, DOI 10.1021/bi00354a030; IMAOKA S, 1992, BIOCHEMISTRY-US, V31, P6063, DOI 10.1021/bi00141a015; IngelmanSundberg M, 1996, BIOCHEM BIOPH RES CO, V221, P318, DOI 10.1006/bbrc.1996.0593; JANSSON I, 1987, DRUG METAB DISPOS, V15, P344; KAMINSKY LS, 1985, EUR J BIOCHEM, V149, P479, DOI 10.1111/j.1432-1033.1985.tb08950.x; KERR BM, 1994, BIOCHEM PHARMACOL, V47, P1969, DOI 10.1016/0006-2952(94)90071-X; KOLARS JC, 1991, LANCET, V338, P1488, DOI 10.1016/0140-6736(91)92302-I; LIPKA JJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P152, DOI 10.1016/0003-9861(89)90576-6; MIHARA K, 1975, J BIOCHEM-TOKYO, V78, P1057, DOI 10.1093/oxfordjournals.jbchem.a130983; MORGAN ET, 1984, DRUG METAB DISPOS, V12, P358; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OPRIAN DD, 1979, J BIOL CHEM, V254, P8895; PALMER G, 1992, J BIOL CHEM, V267, P665; PETERSON JA, 1976, J BIOL CHEM, V251, P4010; Peterson JA, 1986, CYTOCHROME P 450 STR, P89; POMPON D, 1987, BIOCHEMISTRY-US, V26, P6429, DOI 10.1021/bi00394a020; POMPON D, 1984, J BIOL CHEM, V259, P5377; PORTER TD, 1991, J BIOL CHEM, V266, P13469; SANDHU P, 1994, ARCH BIOCHEM BIOPHYS, V309, P168, DOI 10.1006/abbi.1994.1099; SCHENKMAN JB, 1994, ARCH BIOCHEM BIOPHYS, V314, P234, DOI 10.1006/abbi.1994.1435; SCHMIDER J, 1995, J PHARMACOL EXP THER, V275, P592; SHET MS, 1993, P NATL ACAD SCI USA, V90, P11748, DOI 10.1073/pnas.90.24.11748; SHET MS, 1995, ARCH BIOCHEM BIOPHYS, V318, P314, DOI 10.1006/abbi.1995.1235; SHIMADA T, 1986, J BIOL CHEM, V261, P909; SHIMADA T, 1989, P NATL ACAD SCI USA, V86, P462, DOI 10.1073/pnas.86.2.462; SHOU M, 1994, BIOCHEMISTRY-US, V33, P6450, DOI 10.1021/bi00187a009; Strittmatter P, 1978, Methods Enzymol, V52, P97; UENG YF, 1995, CHEM RES TOXICOL, V8, P218, DOI 10.1021/tx00044a006; VELICK SF, 1956, J BIOL CHEM, V221, P265; WISLOCKI PG, 1980, ENZYMATIC BASIS DETO, V1, P135; WRIGHTON SA, 1992, CRIT REV TOXICOL, V22, P1, DOI 10.3109/10408449209145319; YAMAZAKI H, 1995, BIOCHEMISTRY-US, V34, P8380, DOI 10.1021/bi00026a020; Yamazaki H, 1996, ARCH BIOCHEM BIOPHYS, V325, P174, DOI 10.1006/abbi.1996.0022; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337	62	171	172	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27438	27444		10.1074/jbc.271.44.27438	http://dx.doi.org/10.1074/jbc.271.44.27438			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910324	hybrid			2022-12-25	WOS:A1996VQ67900042
J	Zeng, L; An, SZ; Goetzl, EJ				Zeng, L; An, SZ; Goetzl, EJ			Regulation of expression of matrix metalloproteinase-9 in early human T cells of the HSB.2 cultured line by the EP(3) subtype of prostaglandin E(2) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL TAIL; IV COLLAGENASE; HUMAN MONOCYTES; H SYNTHASE-2; EP2 SUBTYPE; CA2+ STORES; CLONING; INHIBITION; SPECIFICITY; STIMULATION	The expression by T lymphocytes (T cells) of more than one of the functionally distinct subtypes of prostaglandin E(2) (PGE(2)) receptors (Rs), designated EP(1), EP(2), EP(3), and EP(4) RS, is a principal determinant of specificity and diversity of the immune effects of PGE(2). The cultured line of human leukemic T cells, termed HSB.2, co-expresses a total of 7282 +/- 1805 EP(3), EP(4), and EP(2) Rs per cell with a K-d of 3.7 +/- 1.4 nM (mean +/- S.E., n = 9), The EP(3)/EP(1) R-selective agonist sulprostone, EP(3)/EP(2)/EP(4) R-selective agonists M&B 28767 and misoprostol, and EP(2) R-selective agonist butaprost but not the EP(1) R-selective antagonist SC-19220 competitively inhibited the binding of [H-3]PGE(2) to HSB.2 cells, Stimulation of increases in the intracellular concentration of cyclic AMP ([cAMP](i)) by PGE(2), misoprostol, and butaprost and of increases in the intracellular concentration of calcium ([Ca2+](i)) by PGE(2) and sulprostone demonstrated the respective involvement of EP(2)/EP(4) Rs and EP(3) Rs in transduction of biochemical signals, Matrix metalloproteinase (MMP)-9 was identified by zymography and Western blots as the principal MMP secreted by HSB.2 cells, The cytosolic level and secretion of MMP-9 were increased maximally after 24 h of incubation of HSB.2 cells with 10(-8)-10(-6) M PGE(2), sulprostone, M&B 28767, and misoprostol but not with 10(-6) M PGF(2 alpha), PGD(2), PGI(2), or butaprost, suggesting a principal dependence on EP(3) Rs. That stimulation of MMP-9 secretion by PGE(2) was not diminished in Ca2+-free medium but was suppressed significantly and dose-dependently by thapsigargin, an inhibitor of endomembrane Ca2+-ATPase, suggested that MMP-9 expression by HSB.2 cells is mediated by increases in [Ca2+](i) attributable to release of Ca2+ from intracellular stores, The lack of effect of dibutyryl cAMP, forskolin, and SQ 22536, an adenylyl cyclase inhibitor, on MMP-9 secretion by HSB.2 cells argued against any role for cAMP-dependent mechanisms linked to EP(2)/EP(4) Rs, Cycloheximide and actinomycin D, which respectively inhibited protein and RNA synthesis, suppressed basal and PGE(2) induction of MMP-9 production by HSB.2 cells, Northern analysis indicated that PGE(2) and sulprostone time-dependently increased expression of MMP-9 mRNA, Thus, stimulation of MMP-9 in HSB.2 T cells by PGE(2) is attributable to [Ca2+](i)-dependent EP(3) R-mediation of increases in message transcription.	UNIV CALIF SAN FRANCISCO, DEPT MED, MED CTR, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT IMMUNOL MICROBIOL, MED CTR, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 31809] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS RA, 1970, EXP CELL RES, V62, P5, DOI 10.1016/0014-4827(79)90504-4; AN SZ, 1994, BIOCHEMISTRY-US, V33, P14496, DOI 10.1021/bi00252a016; AN SZ, 1993, BIOCHEM BIOPH RES CO, V197, P263, DOI 10.1006/bbrc.1993.2470; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; Coleman RA, 1990, COMPREHENSIVE MED CH, P643; CORCORAN ML, 1994, ARCH BIOCHEM BIOPHYS, V310, P481, DOI 10.1006/abbi.1994.1196; CORCORAN ML, 1992, J BIOL CHEM, V267, P515; Goetzl EJ, 1996, J IMMUNOL, V156, P1; GOETZL EJ, 1995, FASEB J, V9, P1051, DOI 10.1096/fasebj.9.11.7649404; GOUY H, 1990, EUR J IMMUNOL, V20, P2269, DOI 10.1002/eji.1830201016; HARA J, 1988, J CLIN INVEST, V81, P989, DOI 10.1172/JCI113453; HONDA A, 1993, J BIOL CHEM, V268, P7759; IRIE A, 1993, EUR J BIOCHEM, V217, P313, DOI 10.1111/j.1432-1033.1993.tb18248.x; LEPPERT D, 1995, FASEB J, V9, P1473, DOI 10.1096/fasebj.9.14.7589989; MCCARTHY JB, 1980, J IMMUNOL, V124, P2405; MERTZ PM, 1994, J BIOL CHEM, V269, P21322; MISSIAEN L, 1992, J BIOL CHEM, V267, P22961; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; PREMACK BA, 1994, J IMMUNOL, V152, P5226; REGAN JW, 1994, MOL PHARMACOL, V46, P213; ROPER RL, 1992, J IMMUNOL, V149, P2984; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATO H, 1993, J BIOL CHEM, V268, P23460; WATABE A, 1993, J BIOL CHEM, V268, P20175; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; XIE B, 1994, J IMMUNOL, V152, P3637; Zeng L, 1995, IMMUNOLOGY, V86, P620; ZHOU H, 1993, BIOCHIM BIOPHYS ACTA, V1177, P174, DOI 10.1016/0167-4889(93)90037-P	30	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27744	27750		10.1074/jbc.271.44.27744	http://dx.doi.org/10.1074/jbc.271.44.27744			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910368	hybrid			2022-12-25	WOS:A1996VQ67900086
J	Andralojc, PJ; Keys, AJ; Martindale, W; Dawson, GW; Parry, MAJ				Andralojc, PJ; Keys, AJ; Martindale, W; Dawson, GW; Parry, MAJ			Conversion of D-hamamelose into 2-carboxy-D-arabinitol and 2-carboxy-D-arabinitol 1-phosphate in leaves of Phaseolus vulgaris L.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BISPHOSPHATE CARBOXYLASE ACTIVITY; 2-CARBOXYARABINITOL 1-PHOSPHATE; NOCTURNAL INHIBITOR; RUBISCO; 2'-CARBOXYARABINITOL; PHOSPHATASE; IDENTIFICATION; OXYGENASE; CARBON	[1-C-14]Hamamelose (2-hydroxymethyl-D-ribose) was synthesized by reaction of ribulose B-phosphate with potassium [C-14]cyanide, catalytic hydrogenation of the resulting cyanohydrin, and dephosphorylation of the product, Its identity was established by a chromatographic comparison with hamamelose isolated from the bark of witch hazel (Hamamelis virginiana L.). Following vacuum infiltration of the [1-C-14]hamamelose into leaf discs from Phaseolus vulgaris L., C-14-labeled 2-carboxy-D-arabinitol (CA) and 2-carboxy-D-arabinitol 1-phosphate (CA1P) were formed, in the dark. Conversion of hamamelose to both CA and CA1P in the leaf discs was inhibited by dithiothreitol and sodium fluoride, although at high concentrations of these inhibitors conversion into CA was still evident when conversion into CA1P was totally inhibited. Wheat (Triticum aestivum L.) leaves converted hamamelose into CA without formation of CA1P, Leaves from P. vulgaris contained 68 nmol . g(-1) fresh weight of hamamelose in the light and 35 nmol . g(-1) fresh weight in the dark, A pathway for the biosynthesis of CA1P from Calvin cycle intermediates is proposed which includes the sequence: hamamelose --> CA --> CA1P.	IACR ROTHAMSTED, DEPT BIOL & ECOL CHEM, HARPENDEN AL5 2JQ, HERTS, ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Andralojc, PJ (corresponding author), IACR ROTHAMSTED, DEPT BIOCHEM & PHYSIOL, HARPENDEN AL5 2JQ, HERTS, ENGLAND.		Martindale, Wayne/R-8135-2017	Martindale, Wayne/0000-0003-0117-1875; Parry, Martin/0000-0002-4477-672X				ANDRALOJC PJ, 1994, BIOCHEM J, V304, P781, DOI 10.1042/bj3040781; BECK E, 1989, PLANT PHYSIOL, V90, P13, DOI 10.1104/pp.90.1.13; Beck E., 1982, Encyclopedia of plant physiology. New series. Volume 13 A. Plant carbohydrates.I. Intracellular carbohydrates [Loewus, R.A.; Tanner, W. (Editors)], P124; BERRY JA, 1987, P NATL ACAD SCI USA, V84, P734, DOI 10.1073/pnas.84.3.734; BILCK H, 1975, CARBOHYD RES, V39, P160; DEMOORE B, 1991, PLANT PHYSIOL, V96, P208, DOI 10.1104/pp.96.1.208; GILCK H, 1974, Z PFLANZENPHYSIOL, V72, P395, DOI 10.1016/S0044-328X(74)80061-9; GUTTERIDGE S, 1986, NATURE, V324, P274, DOI 10.1038/324274a0; GUTTERIDGE S, 1989, FEBS LETT, V254, P225, DOI 10.1016/0014-5793(89)81044-0; HOLBROOK GP, 1989, PLANT PHYSIOL, V90, P673, DOI 10.1104/pp.90.2.673; KEYS AJ, 1995, J EXP BOT, V46, P1245, DOI 10.1093/jxb/46.special_issue.1245; KINGSTONSMITH AH, 1992, BIOCHEM J, V287, P821, DOI 10.1042/bj2870821; LEE YC, 1990, ANAL BIOCHEM, V189, P151, DOI 10.1016/0003-2697(90)90099-U; MCFADDEN BA, 1986, PHOTOSYNTH RES, V8, P53, DOI 10.1007/BF00028476; MOORE B, 1992, PLANT PHYSIOL, V99, P1551, DOI 10.1104/pp.99.4.1551; MOORE BD, 1992, PLANT PHYSIOL, V99, P1546, DOI 10.1104/pp.99.4.1546; Moore BD, 1995, PHOTOSYNTH RES, V45, P219, DOI 10.1007/BF00015562; ROBINSON SP, 1988, FEBS LETT, V233, P413, DOI 10.1016/0014-5793(88)80473-3; SASSENRATHCOLE GF, 1994, PLANT PHYSIOL, V105, P1115, DOI 10.1104/pp.105.4.1115; SCHILLING G, 1977, LIEBIGS ANN CHEM, P1475; SEEMANN JR, 1985, P NATL ACAD SCI USA, V82, P8024, DOI 10.1073/pnas.82.23.8024; SELLMAIR J, 1977, PHYTOCHEMISTRY, V16, P1201, DOI 10.1016/S0031-9422(00)94360-7; SERIANNI AS, 1982, METHOD ENZYMOL, V89, P73; SERVAITES JC, 1986, PLANT PHYSIOL, V82, P1161, DOI 10.1104/pp.82.4.1161; SHAFIZADEH F, 1956, ADV CARBOHYD CHEM, V11, P263	25	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26803	26809		10.1074/jbc.271.43.26803	http://dx.doi.org/10.1074/jbc.271.43.26803			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900161	hybrid			2022-12-25	WOS:A1996VP23300055
J	Chamberlain, NL; Whitacre, DC; Miesfeld, RL				Chamberlain, NL; Whitacre, DC; Miesfeld, RL			Delineation of two distinct type I activation functions in the androgen receptor amino-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RECEPTOR; TRANSCRIPTIONAL ACTIVATION; RESPONSE ELEMENT; STEROID-BINDING; GENE-EXPRESSION; RETINOIC ACID; TRANSACTIVATION; PROTEINS; VP16; IDENTIFICATION	Based on the finding that some transcription factors contain multiple transcriptional regulatory activities, we constructed a panel of rat androgen receptor (AR) mutants containing small internal deletions and point mutations within the amino-terminal region of the receptor. Trans-activation assays in CV-1 cells using AR-responsive reporter genes were performed and led to the identification of two noncontiguous trans-activation regions in the AR amino terminus, One of these regions, termed activator function 1a (AF-1a) is a highly-conserved 14-amino acid segment that is predicted to form a beta-turn followed by an acidic amphipathic alpha-helix. Point mutagenesis within AF-1a revealed that two adjacent hydrophobic residues were required for full AR transactivation function, as arginine substitutions resulted in a 60% reduction in transcriptional activity. A second amino-terminal region was also identified and has been designated AF-1b. Deletion of the 65-amino acid AF-1b segment, which contains numerous glutamate and aspartate residues, caused a 55% decrease in trans-activation function, An AF-1a/AF-1b double mutant retains less than 10% trans-activation function compared, with wild-type AR, suggesting that AF-1a and AF-1b may each contribute separately to maximal AR activity, To determine whether AF-1a and AF-1b play a role in AR-mediated trans-repression of AP-1 function, we tested single and double AF-1a/AF-1b mutants in a transient trans-repression assay, Our results showed that neither AF-1a nor AF-1b was required for AP-1 trans-repression, demonstrating that AR-mediated trans-repression and trans-activation are discrete functions.	UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721; UNIV ARIZONA,DEPT MOL & CELLULAR BIOL,TUCSON,AZ 85721	University of Arizona; University of Arizona					NCI NIH HHS [CA 09213] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009213] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; Blau J, 1996, MOL CELL BIOL, V16, P2044; CHAMBERLAIN NL, 1994, NUCLEIC ACIDS RES, V22, P3181, DOI 10.1093/nar/22.15.3181; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DAHLMANWRIGHT K, 1994, P NATL ACAD SCI USA, V91, P1619, DOI 10.1073/pnas.91.5.1619; DIEKEN ES, 1992, MOL CELL BIOL, V12, P589, DOI 10.1128/MCB.12.2.589; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GORDON DA, 1995, EXP CELL RES, V217, P368, DOI 10.1006/excr.1995.1099; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; KUPFER SR, 1994, J BIOL CHEM, V269, P20622; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Massari ME, 1996, MOL CELL BIOL, V16, P121; McKnight SL, 1996, GENE DEV, V10, P367, DOI 10.1101/gad.10.4.367; MIESFELD RL, 1989, CRIT REV BIOCHEM MOL, V24, P101, DOI 10.3109/10409238909086395; Moore DD, 1995, GLOB MOB SURV; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; RUNDLETT SE, 1992, EXP CELL RES, V203, P214, DOI 10.1016/0014-4827(92)90057-F; RUNDLETT SE, 1990, MOL ENDOCRINOL, V4, P708, DOI 10.1210/mend-4-5-708; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WONG CI, 1993, J BIOL CHEM, V268, P19004; ZANDI E, 1993, J MOL BIOL, V230, P124, DOI 10.1006/jmbi.1993.1130; ZOPPI S, 1993, J CLIN INVEST, V91, P1105, DOI 10.1172/JCI116269	34	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26772	26778		10.1074/jbc.271.43.26772	http://dx.doi.org/10.1074/jbc.271.43.26772			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900157	hybrid			2022-12-25	WOS:A1996VP23300051
J	Shibata, N; Inoue, T; Fukuhara, K; Nagara, Y; Kitagawa, R; Harada, S; Kasai, N; Uemura, K; Kato, K; Yokota, A; Kai, Y				Shibata, N; Inoue, T; Fukuhara, K; Nagara, Y; Kitagawa, R; Harada, S; Kasai, N; Uemura, K; Kato, K; Yokota, A; Kai, Y			Orderly disposition of heterogeneous small subunits in D-ribulose-1,5-bisphosphate carboxylase/oxygenase from spinach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE 1,5-BISPHOSPHATE CARBOXYLASE/OXYGENASE; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; CRYSTAL-STRUCTURE; PLANT RUBISCO; X-RAY; OXYGENASE; BISPHOSPHATE; RESOLUTION; EXPRESSION; REFINEMENT	We determined the crystal structure of spinach ribulose 1,5-bisphosphate carboxylase/oxygenase (Rubisco) by x-ray diffraction at 1.8-Angstrom resolution and found that the enzyme contained two kinds of S, S-I and S-II, present in equal number and disposed in an orderly way within the Rubisco holoenzyme. The electron density maps suggested that leucine was at residue 56 in S-I, although histidine was at that position in S-II. There were other residue differences. Thus, spinach Rubisco has a L(8)S(4)(I)S(II)4 subunit structure. The orderly disposition of the heterogeneous small subunits in the Rubisco holoenzyme provides accounts of a multigene family of S in plants.	OSAKA UNIV,FAC ENGN,DEPT APPL CHEM,SUITA,OSAKA 565,JAPAN; RES INST INNOVAT TECHNOL EARTH,PLANT MOL PHYSIOL LAB,KYOTO 61902,JAPAN	Osaka University; Research Institute of Innovative Technology for the Earth			Shibata, Naoki/AFK-9971-2022	Shibata, Naoki/0000-0002-5096-1104				AKAZAWA T, 1979, ENCY PLANT PHYSL, V6, P208; Andersson I, 1996, J MOL BIOL, V259, P160, DOI 10.1006/jmbi.1996.0310; ANDERSSON I, 1984, J MOL BIOL, V172, P363, DOI 10.1016/S0022-2836(84)80033-9; Andrews T.J., 1987, BIOCH PLANTS, P131, DOI 10.1016/B978-0-12-675410-0.50009-9; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHAPMAN MS, 1988, SCIENCE, V241, P71, DOI 10.1126/science.3133767; CHAPMAN MS, 1987, NATURE, V329, P354, DOI 10.1038/329354a0; CURMI PMG, 1992, J BIOL CHEM, V267, P16980; DEAN C, 1987, TAILORING GENES CROP, P59; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; JOHNS TA, 1985, METHOD ENZYMOL, V115, P157; KNIGHT S, 1989, SCIENCE, V244, P702, DOI 10.1126/science.244.4905.702; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; MANZARA T, 1988, PHOTOSYNTH RES, V16, P117, DOI 10.1007/BF00039489; MARTIN PG, 1979, AUST J PLANT PHYSIOL, V6, P401; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MEIER I, 1995, PLANT PHYSIOL, V107, P1105, DOI 10.1104/pp.107.4.1105; MULLET JE, 1988, ANNU REV PLANT PHYS, V39, P475, DOI 10.1146/annurev.arplant.39.1.475; NEWMAN J, 1993, J BIOL CHEM, V268, P25876; NEWMAN J, 1993, ACTA CRYSTALLOGR D, V49, P548, DOI 10.1107/S090744499300530X; REN L, 1991, PLANT SCI, V74, P1, DOI 10.1016/0168-9452(91)90249-8; SAKABE N, 1983, J APPL CRYSTALLOGR, V16, P542, DOI 10.1107/S0021889883010973; SCHREUDER HA, 1993, PROTEIN SCI, V2, P1136, DOI 10.1002/pro.5560020708; Taylor TC, 1996, NAT STRUCT BIOL, V3, P95, DOI 10.1038/nsb0196-95; WASMANN CC, 1989, P NATL ACAD SCI USA, V86, P1198, DOI 10.1073/pnas.86.4.1198; Yokota A, 1996, J BIOCHEM-TOKYO, V119, P487; YOKOTA A, 1994, PLANT CELL PHYSIOL, V35, P317; YOKOTA A, 1991, J BIOCHEM-TOKYO, V110, P246, DOI 10.1093/oxfordjournals.jbchem.a123565; YOKOTA A, 1991, J BIOCHEM-TOKYO, V110, P253, DOI 10.1093/oxfordjournals.jbchem.a123566; ZURAWSKI G, 1981, NUCLEIC ACIDS RES, V9, P3251, DOI 10.1093/nar/9.14.3251	30	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26449	26452		10.1074/jbc.271.43.26449	http://dx.doi.org/10.1074/jbc.271.43.26449			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900108	hybrid			2022-12-25	WOS:A1996VP23300002
J	Slekar, KH; Kosman, DJ; Culotta, VC				Slekar, KH; Kosman, DJ; Culotta, VC			The yeast copper zinc superoxide dismutase and the pentose phosphate pathway play overlapping roles in oxidative stress protection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ENCODING GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; SULFATE ASSIMILATION; TRANSKETOLASE GENE; STRUCTURAL GENE; ENZYME; SEQUENCE; PROTEIN; MUTANTS; SULFUR	In Saccharomyces cerevisiae, loss of cytosolic superoxide dismutase (Sod1) results in several air-dependent mutant phenotypes, including methionine auxotrophy and oxygen sensitivity. Here we report that these two sod1 Delta phenotypes were specifically suppressed by elevated expression of the TKL1 gene, encoding transketolase of the pentose phosphate pathway. The apparent connection between Sod1 and the pentose phosphate pathway prompted an investigation of mutants defective in glucose-6-phosphate dehydrogenase (Zwf1), which catalyzes the rate-limiting NADPH-producing step of this pathway. We confirmed that zwf1 Delta mutants are methionine auxotrophs and report that they also are oxygen-sensitive. We determined that a functional ZWF1 gene product was required for TKL1 to suppress sod1 Delta, leading us to propose that increased flux through the oxidative reactions of the pentose phosphate pathway can rescue sod1 methionine auxotrophy. To better understand this methionine growth requirement, we examined the sulfur compound requirements of sod1 Delta and zwf1 Delta mutants, and noted that these mutants exhibit the same apparent defect in sulfur assimilation. Our studies suggest that this defect results from the impaired redox status of aerobically grown sod1 and zwf1 mutants, implicating Sod1 and the pentose phosphate pathway as being critical for maintenance of the cellular redox state.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT ENVIRONM HLTH SCI, DIV TOXICOL SCI, BALTIMORE, MD 21205 USA; SUNY BUFFALO, DEPT BIOCHEM, BUFFALO, NY 14214 USA	Johns Hopkins University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046787, R01GM050016, R37GM050016] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES07141] Funding Source: Medline; NIGMS NIH HHS [GM 50016, GM 46787] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FA, 1990, CURRENT PROTOCOLS MO; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BERMINGHAMMCDONOGH O, 1988, P NATL ACAD SCI USA, V85, P4789, DOI 10.1073/pnas.85.13.4789; BERTHON HA, 1992, BIOCHEMISTRY-US, V31, P12792, DOI 10.1021/bi00166a012; Bostek C C, 1989, AANA J, V57, P231; CHANG EC, 1990, J BACTERIOL, V172, P1840, DOI 10.1128/jb.172.4.1840-1845.1990; CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169; CHAUNCEY TR, 1983, BIOCHIM BIOPHYS ACTA, V744, P304, DOI 10.1016/0167-4838(83)90204-2; CHEREST H, 1992, GENETICS, V130, P51; CULOTTA VC, 1994, J BIOL CHEM, V269, P25295; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; FLETCHER TS, 1992, BIOCHEMISTRY-US, V31, P1892, DOI 10.1021/bi00121a044; FLINT DH, 1993, J BIOL CHEM, V268, P25547; FRIDOVICH I, 1983, ANNU REV PHARMACOL, V23, P239, DOI 10.1146/annurev.pa.23.040183.001323; GALIAZZO F, 1991, EUR J BIOCHEM, V196, P545, DOI 10.1111/j.1432-1033.1991.tb15848.x; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GONZALEZ.P, 1970, J BIOL CHEM, V245, P2371; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; GUIDOT DM, 1993, J BIOL CHEM, V268, P26699; Halliwell B., 1985, FREE RADICALS BIOL M, DOI 10.1016/0748-5514(85)90140-0; KELLER GA, 1991, P NATL ACAD SCI USA, V88, P7381, DOI 10.1073/pnas.88.16.7381; KLETZIEN RF, 1994, FASEB J, V8, P174, DOI 10.1096/fasebj.8.2.8119488; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; Lawrence C.W., 1978, METHODS YEAST GENETI, P178; LEE KS, 1994, J BIOL CHEM, V269, P19725; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; LIU XF, 1992, J BIOL CHEM, V267, P18298; LIU XF, 1994, MOL CELL BIOL, V14, P7037, DOI 10.1128/MCB.14.11.7037; MARRES CAM, 1985, EUR J BIOCHEM, V147, P153, DOI 10.1111/j.1432-1033.1985.tb08731.x; MASSELOT M, 1977, MOL GEN GENET, V154, P23, DOI 10.1007/BF00265572; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MoradasFerreira P, 1996, MOL MICROBIOL, V19, P651, DOI 10.1046/j.1365-2958.1996.403940.x; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; NOGAE I, 1990, GENE, V96, P161, DOI 10.1016/0378-1119(90)90248-P; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAAFF I, 1990, EUR J BIOCHEM, V188, P597, DOI 10.1111/j.1432-1033.1990.tb15440.x; SCHAAFFGERSTENSCHLAGER I, 1993, CURR GENET, V24, P373, DOI 10.1007/BF00351843; SCHAAFFGERSTENSCHLAGER I, 1993, EUR J BIOCHEM, V217, P487, DOI 10.1111/j.1432-1033.1993.tb18268.x; SCHNEIDER JC, 1991, METHOD ENZYMOL, V194, P373; SUNDSTROM M, 1993, J BIOL CHEM, V268, P24346; THOMAS D, 1992, J GEN MICROBIOL, V138, P2021, DOI 10.1099/00221287-138-10-2021; THOMAS D, 1991, EMBO J, V10, P547, DOI 10.1002/j.1460-2075.1991.tb07981.x; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WOOD T, 1985, PENTOSE PHOSPHATE PA	46	174	178	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28831	28836		10.1074/jbc.271.46.28831	http://dx.doi.org/10.1074/jbc.271.46.28831			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910528	hybrid			2022-12-25	WOS:A1996VT05200020
J	Suidan, HS; Niclou, SP; Dreessen, J; Beltraminelli, N; Monard, D				Suidan, HS; Niclou, SP; Dreessen, J; Beltraminelli, N; Monard, D			The thrombin receptor is present in myoblasts and its expression is repressed upon fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH-FACTOR; RAT LUMBRICAL MUSCLES; AORTIC SMOOTH-MUSCLE; TERMINAL DIFFERENTIATION; MAP KINASE; FACTOR-BETA; NEURITE RETRACTION; MOUSE MYOBLASTS; PROTEIN-KINASES; NEURONAL CELLS	Cultured myoblasts derived from limb muscle of newborn rats express thrombin receptor immunoreactivity on their surface. Receptor expression is repressed upon myoblast fusion. This is due at least in part to a decrease in the amount of the thrombin receptor mRNA. Addition of thrombin triggers calcium transients only in mono- but not multinucleated muscle cells. Furthermore, thrombin increases the rate of myoblast proliferation that coincides with an activation of mitogen-activated protein kinase. Northern analysis of thrombin receptor mRNA expression in skeletal muscle showed that the transcript is present at a relatively high level at birth, but is almost undetectable in the adult. By in situ hybridization, the mRNA at birth appeared to be present mostly in mononucleated cells grouped in clusters, but not in muscle fibers. Very few nuclei surrounded by a mRNA signal were present on muscle sections of rats 24 days postnatally. These results suggest that the thrombin receptor plays a role in muscle development.	CIBA GEIGY LTD,CH-4002 BASEL,SWITZERLAND	Novartis	Suidan, HS (corresponding author), FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND.		Niclou, Simone/P-2304-2018	Niclou, Simone/0000-0002-3417-9534				BEECHER KL, 1994, J NEUROSCI RES, V37, P108, DOI 10.1002/jnr.490370115; BHAT NR, 1995, J CELL PHYSIOL, V165, P417, DOI 10.1002/jcp.1041650223; BIZIOS R, 1986, J CELL PHYSIOL, V128, P485, DOI 10.1002/jcp.1041280318; BRASS LF, 1993, THROMB HAEMOSTASIS, V70, P217; BRUNET A, 1994, ONCOGENE, V9, P3379; CAVANAUGH KP, 1990, J NEUROCHEM, V54, P1735, DOI 10.1111/j.1471-4159.1990.tb01228.x; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chen X, 1995, BIOCHEM BIOPH RES CO, V217, P445, DOI 10.1006/bbrc.1995.2796; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; COUGHLIN SR, 1994, TRENDS CARDIOVAS MED, V4, P77, DOI 10.1016/1050-1738(94)90013-2; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EWTON DZ, 1988, J BIOL CHEM, V263, P4029; GLENN KC, 1979, NATURE, V278, P711, DOI 10.1038/278711a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HU JS, 1990, J BIOL CHEM, V265, P7914; HUANG CL, 1987, NATURE, V329, P849, DOI 10.1038/329849a0; ISHII K, 1993, J BIOL CHEM, V268, P9780; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; JENKINS AL, 1995, J CELL SCI, V108, P3059; KELVIN DJ, 1989, J CELL BIOL, V108, P169, DOI 10.1083/jcb.108.1.169; KOLODNEY MS, 1992, J CELL BIOL, V117, P73, DOI 10.1083/jcb.117.1.73; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; LAPOSATA M, 1983, BLOOD, V62, P549; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LIM RW, 1984, J CELL BIOL, V98, P739, DOI 10.1083/jcb.98.2.739; LIM RW, 1984, DEV BIOL, V105, P48, DOI 10.1016/0012-1606(84)90260-4; LIU Y, 1994, P NATL ACAD SCI USA, V91, P10300, DOI 10.1073/pnas.91.22.10300; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NELSON PG, 1995, PERSPECT DEV NEUROBI, V2, P399; NELSON PG, 1996, M GERM NEUR SOC, P51; NELSON RB, 1990, DEV BRAIN RES, V54, P93, DOI 10.1016/0165-3806(90)90069-B; NEYLON CB, 1994, CIRC RES, V75, P733, DOI 10.1161/01.RES.75.4.733; NICLOU S, 1994, CELL MOL BIOL, V40, P421; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLWIN BB, 1988, J CELL BIOL, V107, P761, DOI 10.1083/jcb.107.2.761; ONTALL M, 1978, AM J ANAT, V152, P539; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PILCHER BK, 1994, EXP CELL RES, V211, P368, DOI 10.1006/excr.1994.1100; PLANTIER JL, 1994, BRIT J HAEMATOL, V87, P755, DOI 10.1111/j.1365-2141.1994.tb06735.x; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; ROSS JJ, 1987, DEVELOPMENT, V100, P395; ROSS JJ, 1987, DEVELOPMENT, V100, P383; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHUBERT D, 1974, J CELL BIOL, V61, P398, DOI 10.1083/jcb.61.2.398; SOIFER SJ, 1994, AM J PATHOL, V144, P60; STEINBERG SF, 1991, CIRC RES, V68, P1216, DOI 10.1161/01.RES.68.5.1216; SUGAMA Y, 1992, J CELL BIOL, V119, P935, DOI 10.1083/jcb.119.4.935; SUIDAN HS, 1994, P NATL ACAD SCI USA, V91, P8112, DOI 10.1073/pnas.91.17.8112; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; Sullivan R, 1996, BLOOD, V87, P648, DOI 10.1182/blood.V87.2.648.bloodjournal872648; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; VIRDEE K, 1995, EUR J NEUROSCI, V7, P2159, DOI 10.1111/j.1460-9568.1995.tb00637.x; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WALZ DA, 1985, P SOC EXP BIOL MED, V180, P518; WEINSTEIN JR, 1995, J NEUROSCI, V15, P2906; Yoshida S, 1996, J CELL BIOL, V132, P181, DOI 10.1083/jcb.132.1.181	64	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29162	29169		10.1074/jbc.271.46.29162	http://dx.doi.org/10.1074/jbc.271.46.29162			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910573				2022-12-25	WOS:A1996VT05200065
J	Zhang, GH; Melvin, JE				Zhang, GH; Melvin, JE			Na+-dependent release of Mg2+ from an intracellular pool in rat sublingual mucous acini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRET RED-CELLS; MAGNESIUM TRANSPORT; CYTOSOLIC SODIUM; BLOOD-CELLS; COTRANSPORT; INFLUX; MG-2+; INDICATORS; CALCIUM; SYSTEM	Muscarinic stimulation induces release of Mg2+ from an intracellular pool in rat sublingual mucous acini (Zhang, G. H., and Melvin, J. E. (1992) J. Biol. Chem. 267, 20721-20727). In the present study we examined the interdependence of Mg2+ mobilization on intracellular Na+ and Ca2+ by monitoring the intracellular free concentrations of Na+ ([Na+](i)), Mg2+ ([Mg2+](i)), and Ca2+ ([Ca2+](i)) using ion-sensitive fluorescent indicators. Gramicidin increased the intracellular concentrations of all three ions. Comparable to agonist-stimulated mobilization of Mg2+, the gramicidin-induced [Mg2+](i) increase was independent of extracellular Mg2+ indicating release of Mg2+ from an intracellular pool. Clamping the [Ca2+](i) near 30 nM with the Ca2+-selective chelator BAPTA failed to alter the [Na+](i) or [Mg2+](i) increases generated by gramicidin. In contrast, depletion of intracellular Na+ markedly suppressed the muscarinic-stimulated [Mg2+](i) increase, whereas the [Ca2+](i) increase was similar to that seen in physiological extracellular Na+. These results revealed that intracellular Mg2+ mobilization did not directly relate to the [Ca2+](i), but required an increase in [Na+](i). Consistent with this hypothesis, increasing [Na+](i) by activating Na+ influx via the Na+/H+ exchanger also increased the [Mg2+]i(.) The Na+/Mg2+ exchange inhibitor quinidine suppressed both the gramicidin- and muscarinic-induced discharge of internal Mg2+. These results suggest that release of Mg2+ from an intracellular pool is mediated by a Na+ dependent Mg2+ transport mechanism in salivary acinar cells.	UNIV ROCHESTER, DEPT DENT RES, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, DEPT NEUROBIOL & ANAT, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester					NIDCR NIH HHS [DE10655, DE08921] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE010655, R37DE008921] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADAMS SR, 1989, J AM CHEM SOC, V111, P7957, DOI 10.1021/ja00202a042; BEYENBACH KW, 1990, MAGNESIUM TRACE ELEM, V9, P233; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; DAI LJ, 1991, J CLIN INVEST, V88, P1255, DOI 10.1172/JCI115429; DELPIRE E, 1991, J PHYSIOL-LONDON, V441, P219, DOI 10.1113/jphysiol.1991.sp018747; FERAY JC, 1986, BIOCHIM BIOPHYS ACTA, V856, P76, DOI 10.1016/0005-2736(86)90012-X; FLATMAN PW, 1990, J PHYSIOL-LONDON, V431, P11, DOI 10.1113/jphysiol.1990.sp018318; FLATMAN PW, 1988, J PHYSIOL-LONDON, V397, P471, DOI 10.1113/jphysiol.1988.sp017013; FLATMAN PW, 1991, ANNU REV PHYSIOL, V53, P259, DOI 10.1146/annurev.ph.53.030191.001355; GRUBBS RD, 1984, J BIOL CHEM, V259, P2184; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTHER T, 1990, BIOCHIM BIOPHYS ACTA, V1023, P455, DOI 10.1016/0005-2736(90)90139-F; GYLFE E, 1990, BIOCHIM BIOPHYS ACTA, V1055, P82, DOI 10.1016/0167-4889(90)90094-T; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; MELVIN JE, 1991, AM J PHYSIOL, V261, pG1043, DOI 10.1152/ajpgi.1991.261.6.G1043; MINTA A, 1989, J BIOL CHEM, V264, P19449; NAUNTOFTE B, 1986, AM J PHYSIOL, V251, pC175, DOI 10.1152/ajpcell.1986.251.2.C175; NISHIURA A, 1988, PHARMACEUT RES, V5, P209, DOI 10.1023/A:1015985511653; QUAMME GA, 1990, AM J PHYSIOL, V259, pC521, DOI 10.1152/ajpcell.1990.259.3.C521; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; RINK TJ, 1980, BIOCHIM BIOPHYS ACTA, V595, P15, DOI 10.1016/0005-2736(80)90243-6; ROTEVATN S, 1991, ACTA PHYSIOL SCAND, V142, P125; TURNER RJ, 1986, J MEMBRANE BIOL, V94, P143, DOI 10.1007/BF01871194; WONG MMY, 1991, SCIENCE, V254, P1014, DOI 10.1126/science.1948071; ZHANG GH, 1994, J BIOL CHEM, V269, P10352; ZHANG GH, 1993, AM J PHYSIOL, V264, pC54, DOI 10.1152/ajpcell.1993.264.1.C54; ZHANG GH, 1992, J BIOL CHEM, V267, P20721; ZHANG GH, 1995, FEBS LETT, V371, P52, DOI 10.1016/0014-5793(95)00869-B	28	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29067	29072		10.1074/jbc.271.46.29067	http://dx.doi.org/10.1074/jbc.271.46.29067			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910560	hybrid			2022-12-25	WOS:A1996VT05200052
J	Watson, AJ; Aragay, AM; Slepak, VZ; Simon, MI				Watson, AJ; Aragay, AM; Slepak, VZ; Simon, MI			A novel form of the G protein beta subunit G beta(5) is specifically expressed in the vertebrate retina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; GAMMA-SUBUNITS; PHOSPHOLIPASE-C; ALPHA-SUBUNIT; SIGNAL TRANSDUCTION; FAMILY; RECEPTORS; DIVERSITY; BRAIN	The G protein beta subunit, G beta(5), is predominantly expressed in the central nervous system. In rodent brain, G beta(5) is expressed as a protein with an apparent molecular mass of 39,000 daltons (39 kDa). We have identified an additional G beta(5) immunoreactive protein of apparent size 44 kDa in the vertebrate retina, Molecular cloning and sequencing of polymerase chain reaction products revealed that the cDNA encoding the larger species of G beta(5) (G beta(5L)) was identical to the shorter form with the addition of 126 base pairs of 5' DNA sequence potentially encoding an in-frame 42-amino acid extension. Sequencing of mouse G beta(5) genomic clones demonstrated that the 126-base pair of retinal-specific coding material is derived hom a hitherto undetected 5' exon. During sucrose density gradient fractionation of bovine retinas, the 44-kDa G beta(5L) protein co-purified with rod outer segment membranes. Incubation of rod outer segment membranes with the nonhydrolyzable guanine nucleotide, GTP gamma S (guanosine 5'-3-O-(thio)triphosphate), which released the G beta subunit of transducin (G beta(1)), failed to remove G beta(5L). The 39-kDa G beta(5) protein displayed differential association with retinal and brain membranes. In the retina, G beta(5) was present as a soluble protein and was undetectable in the membrane fraction, whereas in the brain approximately 70% of G beta(5) was associated with cellular membranes. In transient COS-7 cell expression experiments, G beta(5L) formed functional G beta gamma dimers and G alpha beta gamma heterotrimers, and activated phosphoinositide-specific phospholipase C beta(2) in a manner indistinguishable from the 39-kDa G beta(2) protein. The cloning of the retinal-specific G beta(5L) cDNA suggests the existence of potentially novel G protein-mediated signaling cascades in photoreception.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology			Aragay, Anna M/K-3813-2014	Aragay, Anna M/0000-0002-8240-4126	NIGMS NIH HHS [GM34236] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034236, R37GM034236] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1994, NATURE, V368, P474, DOI 10.1038/368474a0; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BIGAY J, 1994, METHOD ENZYMOL, V237, P139; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CHANG H, 1995, BIOCHEMISTRY-US, V34, P16662; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GHALAYINI AJ, 1991, J NEUROCHEM, V57, P1405, DOI 10.1111/j.1471-4159.1991.tb08307.x; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KALYANARAMAN S, 1995, BIOCHEM BIOPH RES CO, V216, P126, DOI 10.1006/bbrc.1995.2600; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KEHLENBACH RH, 1994, NATURE, V372, P804; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; ONG OC, 1995, J BIOL CHEM, V270, P8495, DOI 10.1074/jbc.270.15.8495; PENG YW, 1992, P NATL ACAD SCI USA, V89, P10882, DOI 10.1073/pnas.89.22.10882; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; Sambrook J., 2002, MOL CLONING LAB MANU; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WATSON JB, 1994, J NEUROSCI RES, V39, P108, DOI 10.1002/jnr.490390113; Watson S., 1994, G PROTEIN LINKED REC; WENSEL TG, 1988, ENZYME DYNAMICS REGU, P102; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; WRIGHT AF, 1992, TRENDS GENET, V8, P85, DOI 10.1016/0168-9525(92)90195-A; Yan K, 1996, J BIOL CHEM, V271, P7141, DOI 10.1074/jbc.271.12.7141	35	127	134	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28154	28160		10.1074/jbc.271.45.28154	http://dx.doi.org/10.1074/jbc.271.45.28154			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910430	hybrid			2022-12-25	WOS:A1996VU03300030
J	Kritharides, L; Kus, M; Brown, AJ; Jessup, W; Dean, RT				Kritharides, L; Kus, M; Brown, AJ; Jessup, W; Dean, RT			Hydroxypropyl-beta-cyclodextrin-mediated efflux of 7-ketocholesterol from macrophage foam cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CELLULAR CHOLESTEROL EFFLUX; SMOOTH-MUSCLE CELLS; UNESTERIFIED CHOLESTEROL; TRANSPORT; LDL; 25-HYDROXYCHOLESTEROL; ATHEROSCLEROSIS; ESTER; HPLC	Atherosclerosis involves the arterial accumulation of lipid-laden ''foam cells'' containing oxidized and unoxidized sterols and their esters (Mattsson-Hulten, L., Lindmark, H., Diczfalusy, U., Bjorkhem, I., Ottosson, M., Liu, Y., Bondjers, G., and Wiklund, O, (1996) J, Clin, Invest, 97, 461-8), Oxidized sterols are probably critical to atherogenesis because they inhibit cholesterol removal from cells and are cytotoxic. We recently reported that there is deficient induction of cellular cholesterol efflux by apolipoprotein A-I, the main initial acceptor of cellular cholesterol from macrophages loaded in vitro with oxidized low density lipoprotein (Kritharides, L., Jessup, W., Mander, E., and Dean, R. T. (1995) Arterioscler. Thromb. 15, 276-289). There was an even more marked impairment of the release of 7-ketocholesterol which is a major oxysterol in these cells and in human atherosclerotic lesions. Here we show that hydroxypropyl-beta-cyclodextrin can induce selective efflux of 7-ketocholesterol. Efflux of 7-ketocholesterol was time and concentration dependent, and the rate of its removal was 50-fold greater for hydroxypropyl-beta-cyclodextrin than for apolipoprotein A-I. Over a defined range of concentrations (0-5 mg/ml), efflux of 7-ketocholesterol was preferred over that of cholesterol and occurred without cell toxicity. Efflux of free 7-ketocholesterol was associated with decreased intracellular free and esterified 7-ketocholesterol, Hydroxypropyl-beta-cyclodextrin also enhanced efflux of other oxysterols. The physical solubilization of 7-ketocholesterol by the cyclodextrin was much greater than that of cholesterol, in accordance with its differential effects on efflux, These data highlight the importance of extracellular sterol solubilization in the efflux of cellular oxysterols and the mobilization of intracellular free and esterified oxysterol pools in macrophages loaded with oxidized low density lipoprotein. Synthetic sterol-solubilizing agents such as hydroxypropyl-beta-cyclodextrin are thus potential prototypes for the further development of oxysterol-removing agents.			Kritharides, L (corresponding author), HEART RES INST,CELL BIOL UNIT,SYDNEY,NSW,AUSTRALIA.		Kritharides, Leonard/AAQ-2720-2020; Kuś, Marek/V-2023-2019	Kuś, Marek/0000-0002-2767-3251; Dean, Roger Thornton/0000-0002-8859-8902				BARCZA L, 1989, CARBOHYD RES, V192, P103, DOI 10.1016/0008-6215(89)85170-5; Bender M. L., 1978, CYCLODEXTRIN CHEM; BREWSTER ME, 1989, J PARENT SCI TECHN, V43, P231; BROOKS CJW, 1966, BIOCHIM BIOPHYS ACTA, V125, P620, DOI 10.1016/0005-2760(66)90055-5; Brown AJ, 1996, J LIPID RES, V37, P320; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CHUNG BH, 1986, METHOD ENZYMOL, V128, P181; CLAUDY P, 1991, J THERM ANAL, V37, P2497; FIELDING CJ, 1995, J LIPID RES, V36, P211; FROMMING KH, 1993, EUR J PHARM BIOPHARM, V39, P148; Gelissen IC, 1996, J BIOL CHEM, V271, P17852, DOI 10.1074/jbc.271.30.17852; GUYTON JR, 1990, AM J PATHOL, V137, P125; HARA H, 1991, J BIOL CHEM, V266, P3080; HODIS HN, 1994, J LIPID RES, V35, P669; HUGHES H, 1994, ARTERIOSCLER THROMB, V14, P1177, DOI 10.1161/01.ATV.14.7.1177; IRIE T, 1992, J PHARM SCI, V81, P521, DOI 10.1002/jps.2600810609; JIALAL I, 1991, ARTERIOSCLER THROMB, V11, P482, DOI 10.1161/01.ATV.11.3.482; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KAN CC, 1992, BIOCHEMISTRY-US, V31, P1866, DOI 10.1021/bi00121a040; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; KILSDONK EPC, 1995, J LIPID RES, V36, P505; KRITHARIDES L, 1995, ARTERIOSCL THROM VAS, V15, P276, DOI 10.1161/01.ATV.15.2.276; KRITHARIDES L, 1993, ANAL BIOCHEM, V213, P79, DOI 10.1006/abio.1993.1389; KRITHARIDES L, 1994, THESIS U SYDNEY; LANGE Y, 1995, J LIPID RES, V36, P1092; LISCUM L, 1992, J LIPID RES, V33, P1239; MAOR I, 1994, J LIPID RES, V35, P803; MATTSSONHULTEN L, 1996, J CLIN INVEST, V97, P461; OHTANI Y, 1989, EUR J BIOCHEM, V186, P17, DOI 10.1111/j.1432-1033.1989.tb15171.x; ORAM JF, 1983, J CLIN INVEST, V72, P1611, DOI 10.1172/JCI111120; PETRACK B, 1993, J LIPID RES, V34, P643; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RYE KA, 1990, BIOCHIM BIOPHYS ACTA, V1042, P227, DOI 10.1016/0005-2760(90)90013-N; SHARMA A, 1991, CLIN CHIM ACTA, V199, P129, DOI 10.1016/0009-8981(91)90104-K; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SUGIYAMA S, 1995, ARTERIOSCL THROM VAS, V15, P1968, DOI 10.1161/01.ATV.15.11.1968; ZHANG HF, 1990, J LIPID RES, V31, P1361	37	55	57	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27450	27455		10.1074/jbc.271.44.27450	http://dx.doi.org/10.1074/jbc.271.44.27450			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910326	hybrid, Green Submitted			2022-12-25	WOS:A1996VQ67900044
J	Gress, TM; MullerPillasch, F; Geng, M; Zimmerhackl, F; Zehetner, G; Friess, H; Buchler, M; Adler, G; Lehrach, H				Gress, TM; MullerPillasch, F; Geng, M; Zimmerhackl, F; Zehetner, G; Friess, H; Buchler, M; Adler, G; Lehrach, H			A pancreatic cancer-specific expression profile	ONCOGENE			English	Article						pancreatic cancer; EST; differential expression; cDNA; database	GENE-EXPRESSION; SEQUENCE TAGS; MOLECULAR-CLONING; HUMAN CARCINOMAS; MESSENGER-RNA; GROWTH-FACTOR; HUMAN GENOME; HUMAN BRAIN; CELL-LINES; IDENTIFICATION	We present an approach making use of technology established in the context of the genome project to describe a pancreatic cancer-specific expression profile and to identify new potential disease genes or disease-associated-genes, By use of gridded arrays of pancreatic cancer cDNA libraries and differential hybridizations we show that 4% the gridded cDNA library clones contain sequences preferentially expressed in pancreatic cancer. EST-sequencing of 369 distinct (408 total), differentially expressed sequences identified novel genes (32.5%) or homologs to EST-sequences with unknown function (26.3%). Homologies to known genes allow to determine a pancreatic cancer-specific expression profile, which provides for the first time evidence for complex primary and secondary alterations of gene expression responsible for the development of the phenotype of pancreatic cancer cells. In addition this has led to the identification of novel differentially expressed genes, which represent potential oncogenes or disease-associated markers and may be helpful for the development of therapeutic or diagnostic modalities.	UNIV ULM,DEPT INTERNAL MED 1,D-89081 ULM,GERMANY; MAX PLANCK INST MOL GENET,D-14195 BERLIN,GERMANY; UNIV BERN,INSELSPITAL,DEPT VISZERAL & TRANSPLANTAT SURG,CH-3010 BERN,SWITZERLAND	Ulm University; Max Planck Society; University of Bern; University Hospital of Bern				Gress, Thomas/0000-0002-9333-5461				ADACHI Y, 1994, J BIOL CHEM, V269, P2258; ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; ALTSCHUL SF, 1990, J MOL BIOL, V215, P402; AUGENLICHT LH, 1987, CANCER RES, V47, P6017; BALDWIN GS, 1994, P NATL ACAD SCI USA, V91, P7593, DOI 10.1073/pnas.91.16.7593; BARTKOVA J, 1995, CANCER RES, V55, P949; BARTSCH S, 1995, FEBS LETT, V357, P255, DOI 10.1016/0014-5793(94)01303-I; CHEN JS, 1995, CANCER RES, V55, P174; DRAPER MP, 1995, MOL CELL BIOL, V15, P3487; EDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186; ELSASSER HP, 1992, VIRCHOWS ARCH B, V61, P295, DOI 10.1007/BF02890431; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; FORNEROD M, 1995, ONCOGENE, V10, P1739; GIBSON S, 1993, BLOOD, V82, P1561; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GRANT AG, 1992, INT J CANCER, V51, P740; GRESS TM, 1992, MAMM GENOME, V3, P609, DOI 10.1007/BF00352477; GRESS TM, 1994, EUR J CANCER, V30A, P1391, DOI 10.1016/0959-8049(94)90191-0; GROUDINE M, 1980, P NATL ACAD SCI-BIOL, V77, P5351, DOI 10.1073/pnas.77.9.5351; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HARA E, 1993, ANAL BIOCHEM, V214, P58, DOI 10.1006/abio.1993.1456; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; HOOG C, 1991, NUCLEIC ACIDS RES, V19, P6123, DOI 10.1093/nar/19.22.6123; INKI P, 1994, BRIT J CANCER, V70, P319, DOI 10.1038/bjc.1994.300; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KLEVER P, 1992, LANCET, V340, P1158, DOI 10.1016/0140-6736(92)93183-N; KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001; KOTHS K, 1993, J BIOL CHEM, V268, P1425; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; LEWIN B, 1994, GENES, V5; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIU QY, 1995, ONCOGENE, V10, P619; MAIER E, 1992, NAT GENET, V1, P273, DOI 10.1038/ng0792-273; MEIEREWERT S, 1993, NATURE, V361, P375, DOI 10.1038/361375a0; MIYAGI Y, 1995, CANCER LETT, V91, P247, DOI 10.1016/0304-3835(95)03737-H; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURPHY D, 1983, CELL, V35, P865, DOI 10.1016/0092-8674(83)90119-8; MURR MM, 1994, CA-CANCER J CLIN, V44, P304, DOI 10.3322/canjclin.44.5.304; MYERS MH, 1989, CA-CANCER J CLIN, V39, P21, DOI 10.3322/canjclin.39.1.21; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; NEKARDA H, 1994, CANCER RES, V54, P2900; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; SARGENT T D, 1983, Science (Washington D C), V222, P135, DOI 10.1126/science.6688681; SCHRAML P, 1994, CANCER RES, V54, P5236; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCOTT MRD, 1983, CELL, V34, P556; SIMON B, 1994, GASTROENTEROLOGY, V106, P1645, DOI 10.1016/0016-5085(94)90422-7; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; TAKAGI S, 1995, INT J CANCER, V61, P706, DOI 10.1002/ijc.2910610519; TAKEDA J, 1993, HUM MOL GENET, V2, P1793, DOI 10.1093/hmg/2.11.1793; TAWARAGI Y, 1988, BIOCHEM BIOPH RES CO, V150, P89, DOI 10.1016/0006-291X(88)90490-1; VANERP HE, 1991, CANCER, V15, P2595; VIDAL F, 1993, P NATL ACAD SCI USA, V90, P208, DOI 10.1073/pnas.90.1.208; Vila Maya R., 1994, Zentralblatt fuer Pathologie, V140, P225; VISHWANATHA JK, 1993, CARCINOGENESIS, V14, P2575, DOI 10.1093/carcin/14.12.2575; Wagner R. P., 1993, CHROMOSOMES SYNTHESI; WATSON MA, 1994, CANCER RES, V54, P4598; WEINHOUSE S, 1983, ADV ENZYME REGUL, V21, P369, DOI 10.1016/0065-2571(83)90024-9; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102; ZEHETNER G, 1994, NATURE, V367, P489, DOI 10.1038/367489a0	64	158	184	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1819	1830						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895530				2022-12-25	WOS:A1996VM88700029
J	Obata, M; Nishimori, H; Ogawa, K; Lee, GH				Obata, M; Nishimori, H; Ogawa, K; Lee, GH			Identification of the Par2 (Pulmonary adenoma resistance) locus on mouse chromosome 18, a major genetic determinant for lung carcinogen resistance in BALB/cByJ mice	ONCOGENE			English	Article						lung tumor; resistance gene; urethane; mouse	K-RAS ONCOGENE; TUMOR SUSCEPTIBILITY; INTESTINAL NEOPLASIA; COLORECTAL CANCERS; ACTIVATION; MAP; PROTOONCOGENE; MUTATIONS; MODIFIER; LOSSES	The A/J mouse strain is 14 times more susceptible to urethane-induction of lung carcinogenesis than the BALB/cByJ strain (BALE). The relative resistance of BALE is dominant over the high sensitivity of A/J, since (BALBxA/J)F-1 mice are phenotypically similar to the parental BALE mice. BALE mice must thus possess modifier genes suppressing phenotypic expression of the Pas (Pulmonary adenoma susceptibility) genes, which are known to be dominant genetic determinants for lung carcinogenesis in A/J mice. In order to genetically dissect the dominant resistance of the BALB mouse, we performed a linkage analysis to chromosomally map modifier genes by using 130 (A/JxBALB)F(1)xA/J backcross mice. Each backcross mouse was injected i.p. with urethane (1 mg/g bw) at 6 weeks of age and lung tumors were enumerated after 120 days. When the backcross mice were genotyped at multiple simple sequence repeat marker loci distributed on all the chromosomes, a significant linkage between the presence of a BALE allele and resistance to lung tumor induction was found on distal chromosome 18 (maximum LOD = 12.2). Thus, distal chromosome 18 of the BALE mouse contains a modifier gene for lung carcinogenesis: The locus, designated Par2 (Pulmonary adenoma resistance), accounted for 38% of the phenotypic variance in the backcross population, indicating a major role in protection against lung tumor development.	ASAHIKAWA MED COLL,DEPT PATHOL,ASAHIKAWA,HOKKAIDO 078,JAPAN	Asahikawa Medical College								ATCHLEY WR, 1991, SCIENCE, V254, P554, DOI 10.1126/science.1948030; BELINSKY SA, 1989, CANCER RES, V49, P5305; CHEN B, 1994, P NATL ACAD SCI USA, V91, P1589, DOI 10.1073/pnas.91.4.1589; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DRAGANI TA, 1991, CANCER RES, V51, P6299; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; FIJNEMAN RJA, 1994, ONCOGENE, V9, P1417; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HEGI ME, 1994, CANCER RES, V54, P6257; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JOHNSON KR, 1994, MAMM GENOME, V5, pS259; JUSTICE MJ, 1992, GENOMICS, V13, P1281, DOI 10.1016/0888-7543(92)90047-V; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1989, GENETICS, V121, P185; LEE GH, 1987, HEPATOLOGY, V7, P937, DOI 10.1002/hep.1840070524; LEE GH, 1995, GENETICS, V139, P387; LEE GH, 1995, CARCINOGENESIS, V16, P1993, DOI 10.1093/carcin/16.8.1993; LUONGO C, 1993, GENOMICS, V15, P3, DOI 10.1006/geno.1993.1002; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MALKINSON AM, 1985, J NATL CANCER I, V75, P971, DOI 10.1093/jnci/75.5.971; MALKINSON AM, 1984, J NATL CANCER I, V73, P925; MALKINSON AM, 1983, J NATL CANCER I, V70, P931; Manenti G, 1996, NAT GENET, V12, P455, DOI 10.1038/ng0496-455; MANENTI G, 1995, GENOMICS, V29, P438, DOI 10.1006/geno.1995.9984; OREFFO VI, 1996, SPEC C AM ASS CANC R, pA34; PITOT HC, 1987, CARCINOGENESIS, V8, P1491, DOI 10.1093/carcin/8.10.1491; RYAN J, 1987, J NATL CANCER I, V79, P1351; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; SUZUKI Y, 1990, ONCOGENE, V5, P1037; WISEMAN RW, 1994, P NATL ACAD SCI USA, V91, P3759, DOI 10.1073/pnas.91.9.3759; Wright S., 1968, EVOLUTION GENETICS P, P373; YAMAMOTO F, 1984, NUCLEIC ACIDS RES, V12, P8873, DOI 10.1093/nar/12.23.8873; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804	41	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1599	1604						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895504				2022-12-25	WOS:A1996VM88700003
J	Kuroda, H; White, PS; Sulman, EP; Manohar, CF; Reiter, JL; Cohn, SL; Brodeur, GM				Kuroda, H; White, PS; Sulman, EP; Manohar, CF; Reiter, JL; Cohn, SL; Brodeur, GM			Physical mapping of the DDX1 gene to 340 kb 5' of MYCN	ONCOGENE			English	Article						DDX1; DEAD box protein; MYCN; neuroblastoma; amplification	DEAD BOX PROTEIN; N-MYC; HUMAN NEUROBLASTOMAS; CELL-LINES; AMPLIFICATION; EXPRESSION; DNA; COAMPLIFICATION; ASSOCIATION; HOMOLOGY	One of the most important prognostic factors in neuroblastoma is amplification of the MYCN gene, which is strongly associated with advanced stages of disease and a poor prognosis. Although the MYCN amplicon sometimes spans more than 1 Mb, no other consistently expressed sequences from the MYCN amplicon have been reported. However, DDX1, a gene encoding a DEAD box protein, was recently mapped to chromosome 2p24 and is frequently co-amplified with MYCN. Therefore, we performed genomic mapping with YACs to determine the physical relationship between DDX1 and MYCN, and whether DDX1 was contained within the core region of amplification, Based on YAC restriction mapping and content analysis, DDX1 maps 340 kb 5' of MYCN, outside the core domain of consistent amplification. Interestingly, we also determined by sequence analysis and detailed restriction mapping that G21, previously isolated as a 'neuroblastoma-specific' cDNA clone from an MYCN amplicon, is a partial cDNA of DDX1. Our data confirm that DDX1 is amplified in some but not all MYCN-amplified tumors, and that it is rearranged in other cases. This suggests that the co-amplification of DDX1 is due to its proximity to MYCN.	CHILDRENS HOSP PHILADELPHIA, DIV ONCOL, PHILADELPHIA, PA 19104 USA; NORTHWESTERN UNIV, DEPT PEDIAT, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, ROBERT H LURIE CANC CTR, CHICAGO, IL 60611 USA; MAYO CLIN, DEPT BIOCHEM & MOL BIOL, ROCHESTER, MN USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Mayo Clinic			Reiter, Jill/AGZ-7331-2022; Cohn, Susan/AAB-6010-2021; Reiter, Jill L/J-3335-2013	Reiter, Jill/0000-0001-5460-2355; Reiter, Jill L/0000-0001-5460-2355; Sulman, Erik/0000-0003-4933-9120; Cohn, Susan/0000-0001-5749-7650	NATIONAL CANCER INSTITUTE [R01CA039771] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA K, 1991, NUCLEIC ACIDS RES, V19, P6887, DOI 10.1093/nar/19.24.6887; AMLER LC, 1989, MOL CELL BIOL, V9, P4903, DOI 10.1128/MCB.9.11.4903; Amler LC, 1996, GENE CHROMOSOME CANC, V15, P134, DOI 10.1002/(SICI)1098-2264(199602)15:2<134::AID-GCC9>3.0.CO;2-4; BRODEUR GM, 1994, SEMIN DIAGN PATHOL, V11, P118; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; DEVALOIR T, 1991, P NATL ACAD SCI USA, V88, P2113, DOI 10.1073/pnas.88.6.2113; George RE, 1996, ONCOGENE, V12, P1583; GODBOUT R, 1993, P NATL ACAD SCI USA, V90, P7578, DOI 10.1073/pnas.90.16.7578; GODBOUT R, 1994, GENE, V138, P243, DOI 10.1016/0378-1119(94)90816-8; IOST I, 1994, NATURE, V372, P193, DOI 10.1038/372193a0; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; MANOHAR CF, 1995, GENE CHROMOSOME CANC, V14, P196, DOI 10.1002/gcc.2870140307; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Noguchi T, 1996, GENE CHROMOSOME CANC, V15, P129, DOI 10.1002/(SICI)1098-2264(199602)15:2<129::AID-GCC8>3.3.CO;2-M; Reiter JL, 1996, GENOMICS, V32, P97, DOI 10.1006/geno.1996.0081; REITER JL, 1996, UNPUB GENOMICS; Reynolds C P, 1988, Prog Clin Biol Res, V271, P291; Sambrook J., MOL CLONING LAB MANU; SCHNEIDER SS, 1992, MOL CELL BIOL, V12, P5563, DOI 10.1128/MCB.12.12.5563; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SQUIRE JA, 1995, ONCOGENE, V10, P1417	26	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1561	1565						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875996				2022-12-25	WOS:A1996VL38400023
J	Huffine, ME; Scholtz, JM				Huffine, ME; Scholtz, JM			Energetic implications for protein phosphorylation - Conformational stability of HPr variants that mimic phosphorylated forms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTAINING PHOSPHOCARRIER PROTEIN; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; PHOSPHOTRANSFERASE SYSTEMS; CRYSTAL-STRUCTURE; PHOSPHOENOLPYRUVATE; BACTERIA; KINASE; COOPERATIVITY; CONSEQUENCES	The HPr protein from Bacillus subtilis is a key protein in the phosphoenolpyruvate-sugar transport system. HPr has two biological phosphorylation sites. The active site histidine is transiently phosphorylated in the phosphotransferase reaction while phosphorylation of serine 46 diminishes the activity of HPr. Here, we use protein engineering and equilibrium protein folding experiments to determine if the two phosphorylation events are energetically coupled. Our approach is to use structural mimics of the two phosphorylated forms of HPr, where histidine 15 is replaced by a negatively charged glutamate and serine 46 is changed to an aspartate, both alone and in combination. The thermodynamic analysis of the differences in conformational stability between the single and double mutants shows that the two phosphorylation sites are not energetically coupled in the HPr protein. We also show that single mutants of the active site histidine residue can have dramatic effects on the conformational stability of HPr. Combined with structural information the method employed here will be of general use in unraveling the biological effects of phosphorylation on protein activity.	TEXAS A&M UNIV,CTR MACROMOL DESIGN,DEPT MED BIOCHEM & GENET,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station								ALBER T, 1989, ANNU REV BIOCHEM, V58, P765, DOI 10.1146/annurev.biochem.58.1.765; BARFORD D, 1989, NATURE, V340, P609, DOI 10.1038/340609a0; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; DOIG AJ, 1995, PROTEIN SCI, V4, P1325, DOI 10.1002/pro.5560040708; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; HOROVITZ A, 1990, J MOL BIOL, V214, P613, DOI 10.1016/0022-2836(90)90275-Q; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; HURLEY JH, 1990, J BIOL CHEM, V265, P3599; JOHNSON LN, 1993, ANNU REV BIOPH BIOM, V22, P199, DOI 10.1146/annurev.bb.22.060193.001215; KENNEY LJ, 1995, P NATL ACAD SCI USA, V92, P8866, DOI 10.1073/pnas.92.19.8866; KIM YH, 1993, J BIOL CHEM, V268, P18513; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREBS EG, 1956, BIOCHIM BIOPHYS ACTA, V20, P150, DOI 10.1016/0006-3002(56)90273-6; MONERA S, 1995, BIOCHEMISTRY-US, V34, P11062; MOTOJIMA K, 1993, FEBS LETT, V319, P75, DOI 10.1016/0014-5793(93)80040-2; Nicholson EM, 1996, BIOCHEMISTRY-US, V35, P11369, DOI 10.1021/bi960863y; Pace C N, 1986, Methods Enzymol, V131, P266; PACE CN, 1990, BIOCHEMISTRY-US, V29, P2564, DOI 10.1021/bi00462a019; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; PULLEN K, 1995, PROTEIN SCI, V4, P2478, DOI 10.1002/pro.5560041204; RAJAGOPAL P, 1994, BIOCHEMISTRY-US, V33, P15271, DOI 10.1021/bi00255a008; REIZER J, 1992, J BIOL CHEM, V267, P9158; REIZER J, 1989, EMBO J, V8, P2111, DOI 10.1002/j.1460-2075.1989.tb03620.x; REIZER J, 1984, J BACTERIOL, V160, P333, DOI 10.1128/JB.160.1.333-340.1984; RICHARDSON JS, 1988, SCIENCE, V240, P1645; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHOLTZ JM, 1995, PROTEIN SCI, V4, P35; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; Thapar R, 1996, BIOCHEMISTRY-US, V35, P11268, DOI 10.1021/bi960349s; WITTEKIND M, 1992, PROTEIN SCI, V1, P1363, DOI 10.1002/pro.5560011016; WOLODKO WT, 1994, J BIOL CHEM, V269, P10883	35	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28898	28902		10.1074/jbc.271.46.28898	http://dx.doi.org/10.1074/jbc.271.46.28898			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910537	hybrid			2022-12-25	WOS:A1996VT05200029
J	Murphy, BJ; Rogers, J; Perdichizzi, AP; Colvin, AA; Catterall, WA				Murphy, BJ; Rogers, J; Perdichizzi, AP; Colvin, AA; Catterall, WA			cAMP-dependent phosphorylation of two sites in the alpha subunit of the cardiac sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NA+ CHANNEL; SELECTIVE PHOSPHORYLATION; FUNCTIONAL EXPRESSION; VENTRICULAR MYOCYTES; SKELETAL-MUSCLE; CELL LINE; MODULATION; ISOFORM; ANTIBODIES	The voltage-sensitive Na+ channel is responsible for generating action potentials in the heart which are critical for coordinated cardiac muscle contraction. Cardiac Na+ channels are regulated by cAMP-dependent phosphorylation, but the sites of phosphorylation are not known. Using mammalian cells expressing the rat cardiac Na+ channel (rH1) alpha subunit and site-specific antibodies, we have shown that the a subunit of rat heart Na+ channel is phosphorylated selectively by cAMP-dependent protein kinase (PKA) in vitro and in intact cells. Analysis of the sites of phosphorylation by two-dimensional phosphopeptide mapping and site-directed mutagenesis of fusion proteins revealed that the cardiac a subunit is phosphorylated selectively in vitro by PKA on Ser(526) and Ser(529) in the intracellular loop connecting homologous domains I and II (L(I-II)). These two residues were phosphorylated in intact cells expressing the rH1 alpha subunit when PKA was activated. Our results define a different pattern of phosphorylation of L(I-II) of cardiac and brain Na+ channels and implicate phosphorylation of Ser(526) and Ser(529) in the differential regulation of cardiac and brain Na+ channels by PKA.	UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NHLBI NIH HHS [P01 HL44948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		COHEN SA, 1993, CIRC RES, V73, P735, DOI 10.1161/01.RES.73.4.735; COSTA MRC, 1982, J BIOL CHEM, V257, P7918; COSTA MRC, 1984, J BIOL CHEM, V259, P8210; CRIBBS LL, 1990, FEBS LETT, V275, P195, DOI 10.1016/0014-5793(90)81470-9; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; FROHNWIESER B, 1995, PFLUG ARCH EUR J PHY, V430, P751, DOI 10.1007/BF00386171; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; GERSHON E, 1992, J NEUROSCI, V12, P3743; GORDON D, 1988, BIOCHEMISTRY-US, V27, P7032, DOI 10.1021/bi00418a054; GORDON D, 1987, P NATL ACAD SCI USA, V84, P8682, DOI 10.1073/pnas.84.23.8682; HARDIE DG, 1993, PROTEIN PHOSPHORYLAT, P61; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1992, NEURON, V8, P1151, DOI 10.1016/0896-6273(92)90135-Z; MATSUDA JJ, 1992, CIRC RES, V70, P199, DOI 10.1161/01.RES.70.1.199; MEGGIO F, 1981, BIOCHIM BIOPHYS ACTA, V662, P94, DOI 10.1016/0005-2744(81)90228-X; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MURPHY BJ, 1992, J BIOL CHEM, V267, P16129; MURPHY BJ, 1993, J BIOL CHEM, V268, P27355; ONO K, 1989, AM J PHYSIOL, V256, pC1131, DOI 10.1152/ajpcell.1989.256.6.C1131; ONO K, 1993, CIRC RES, V72, P807, DOI 10.1161/01.RES.72.4.807; QU YS, 1994, P NATL ACAD SCI USA, V91, P3289, DOI 10.1073/pnas.91.8.3289; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; ROSSIE S, 1987, J BIOL CHEM, V262, P12735; SCHREIBMAYER W, 1994, RECEPTOR CHANNEL, V2, P339; SCHUBERT B, 1989, SCIENCE, V245, P516, DOI 10.1126/science.2547248; Smith RD, 1996, J NEUROSCI, V16, P1965; SUNAMI A, 1991, PFLUG ARCH EUR J PHY, V419, P415, DOI 10.1007/BF00371125; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P; WHITE MM, 1991, MOL PHARMACOL, V39, P604; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	32	85	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28837	28843		10.1074/jbc.271.46.28837	http://dx.doi.org/10.1074/jbc.271.46.28837			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910529	hybrid			2022-12-25	WOS:A1996VT05200021
J	Durner, J; Klessig, DF				Durner, J; Klessig, DF			Salicylic acid is a modulator of tobacco and mammalian catalases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC ACQUIRED-RESISTANCE; PLANT-DISEASE RESISTANCE; NADPH-BINDING-SITE; HYDROGEN-PEROXIDE; DEFENSE RESPONSES; MOSAIC-VIRUS; 2,6-DICHLOROISONICOTINIC ACID; LIVER CATALASE; 2 INDUCERS; RAT-LIVER	Salicylic acid (SA) plays a key role in the establishment of resistance to microbial pathogens in many plants. The discovery that SA inhibits catalase from tobacco led us to suggest that H2O2 acts as second messenger to activate plant defenses, Detailed analyses of SA's interaction with tobacco and mammalian catalases indicate that SA acts as an electron donor for the peroxidative cycle of catalase. When H2O2 fluxes were relatively low (1 mu M/min or less), SA inhibited catalase, consistent with its suggested signaling function via H2O2. However, significant inhibition was only observed at 100 mu M SA or more, a level reached in infected, but not in uninfected, leaves. This inhibition was probably due to siphoning catalase into the slow peroxidative reaction. Surprisingly, SA was also able to protect catalase from inactivation by damaging levels of H2O2 (lower millimolar range), which is generally assumed to reflect accumulation of inactive ferro-oxy intermediates. SA did so by supporting or substituting for the protective function of-catalase-bound NADPH. These results add new features to SA's interaction with heme enzymes and its in vivo redox properties. Thus, SA, in addition to its proposed signaling function, may also have an important antioxidant role in containing oxidative processes associated with plant defense responses.	RUTGERS STATE UNIV, WAKSMAN INST, PISCATAWAY, NJ 08855 USA; RUTGERS STATE UNIV, DEPT MOL BIOL & BIOCHEM, PISCATAWAY, NJ 08855 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick								AEBI H, 1984, METHOD ENZYMOL, V105, P121; BI YM, 1995, PLANT J, V8, P235, DOI 10.1046/j.1365-313X.1995.08020235.x; Bonagura CA, 1996, BIOCHEMISTRY-US, V35, P6107, DOI 10.1021/bi960122x; CHEN ZX, 1995, P NATL ACAD SCI USA, V92, P4134, DOI 10.1073/pnas.92.10.4134; CHEN ZX, 1993, SCIENCE, V262, P1883, DOI 10.1126/science.8266079; CHEN ZX, 1993, P NATL ACAD SCI USA, V90, P9533, DOI 10.1073/pnas.90.20.9533; CONRATH U, 1995, P NATL ACAD SCI USA, V92, P7143, DOI 10.1073/pnas.92.16.7143; DANGL JL, 1995, CELL, V80, P363, DOI 10.1016/0092-8674(95)90485-9; DEISSEROTH A, 1970, PHYSIOL REV, V50, P319, DOI 10.1152/physrev.1970.50.3.319; DELUCA DC, 1995, ARCH BIOCHEM BIOPHYS, V320, P129, DOI 10.1006/abbi.1995.1350; DEMPSEY DA, 1995, B I PASTEUR, V93, P167, DOI 10.1016/0020-2452(96)81488-6; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; DOKE N, 1988, PHYSIOL MOL PLANT P, V32, P163, DOI 10.1016/S0885-5765(88)80013-4; DURNER J, 1995, P NATL ACAD SCI USA, V92, P11312, DOI 10.1073/pnas.92.24.11312; ENYEDI AJ, 1992, P NATL ACAD SCI USA, V89, P2480, DOI 10.1073/pnas.89.6.2480; Escobar JA, 1996, FREE RADICAL BIO MED, V20, P285, DOI 10.1016/0891-5849(95)02037-3; FEUERS RJ, 1993, FREE RADICAL BIO MED, V15, P223, DOI 10.1016/0891-5849(93)90063-Z; FITA I, 1985, P NATL ACAD SCI USA, V82, P1604, DOI 10.1073/pnas.82.6.1604; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; GALARIS D, 1988, ARCH BIOCHEM BIOPHYS, V262, P221, DOI 10.1016/0003-9861(88)90184-1; GOLDACRE PL, 1953, ARCH BIOCHEM BIOPHYS, V43, P169, DOI 10.1016/0003-9861(53)90096-4; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; GUAN LQ, 1995, P NATL ACAD SCI USA, V92, P5930, DOI 10.1073/pnas.92.13.5930; HALLIWELL B, 1988, FASEB J, V2, P2867, DOI 10.1096/fasebj.2.13.2844616; HALLIWELL B, 1995, FOOD CHEM TOXICOL, V33, P601, DOI 10.1016/0278-6915(95)00024-V; HAVIR EA, 1987, PLANT PHYSIOL, V84, P450, DOI 10.1104/pp.84.2.450; Havir EA, 1996, PHYTOCHEMISTRY, V41, P699, DOI 10.1016/0031-9422(95)00674-5; HILLAR A, 1994, BIOCHEM J, V300, P531, DOI 10.1042/bj3000531; Hook DWA, 1996, FEBS LETT, V382, P281, DOI 10.1016/0014-5793(96)00134-2; ITOH M, 1962, CAN J BIOCHEM PHYS, V40, P1327; JOUVE HM, 1986, ARCH BIOCHEM BIOPHYS, V248, P71, DOI 10.1016/0003-9861(86)90402-9; KATO S, 1976, Annals of the Phytopathological Society of Japan, V42, P472, DOI 10.3186/jjphytopath.42.472; KETTLE AJ, 1991, BIOCHEM PHARMACOL, V41, P1485, DOI 10.1016/0006-2952(91)90565-M; KIRKMAN HN, 1987, J BIOL CHEM, V262, P660; KITLAR T, 1994, PROTEIN SCI, V3, P696; KONO Y, 1982, J BIOL CHEM, V257, P5751; LEON J, 1995, PLANT PHYSIOL, V108, P1673, DOI 10.1104/pp.108.4.1673; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; LUCK H, 1957, BIOCHEM Z, V328, P411; MALAMY J, 1992, PLANT J, V2, P643, DOI 10.1111/j.1365-313X.1992.tb00133.x; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MEHDY MC, 1994, PLANT PHYSIOL, V105, P467, DOI 10.1104/pp.105.2.467; Metraux J. P., 1991, Advances in molecular genetics of plant-microbe interactions. Vol. 1. Proceedings of the 5th international symposium on the molecular genetics of plant-microbe interactions, Interlaken, Switzerland, September 9-14, 1990., P432; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; MORIKOFERZWEZ S, 1970, EXPERIENTIA, V26, P945, DOI 10.1007/BF02114120; MULLEN RT, 1993, PLANT PHYSIOL, V103, P477, DOI 10.1104/pp.103.2.477; NEUENSCHWANDER U, 1995, PLANT J, V8, P227, DOI 10.1046/j.1365-313X.1995.08020227.x; NI WT, 1991, PLANT CELL, V3, P737, DOI 10.1105/tpc.3.7.737; OGURA Y, 1950, J BIOCHEM-TOKYO, V37, P153, DOI 10.1093/oxfordjournals.jbchem.a126187; ORLANDI EW, 1992, PHYSIOL MOL PLANT P, V40, P173, DOI 10.1016/0885-5765(92)90058-4; OSHINO N, 1973, ARCH BIOCHEM BIOPHYS, V159, P704, DOI 10.1016/0003-9861(73)90510-9; OTTALLAHKOLAC M, 1995, EUR J BIOCHEM, V228, P506; Ou PM, 1996, J BIOCHEM BIOPH METH, V31, P59, DOI 10.1016/0165-022X(95)00039-T; OU PM, 1994, BIOCHEM J, V303, P935, DOI 10.1042/bj3030935; PUPPO A, 1988, PLANTA, V173, P405, DOI 10.1007/BF00401028; Ruffer M, 1995, FEBS LETT, V377, P175, DOI 10.1016/0014-5793(95)01334-2; Russell RB, 1996, PROTEIN ENG, V9, P107, DOI 10.1093/protein/9.2.107; RYALS J, 1994, PLANT PHYSIOL, V104, P1109, DOI 10.1104/pp.104.4.1109; SANCHEZCASAS P, 1994, PLANT PHYSIOL, V106, P1675, DOI 10.1104/pp.106.4.1675; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; Scandalios J. G., 1994, Causes of photooxidative stress and amelioration of defense systems in plants., P275; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; Schonbaum G. R., 1976, ENZYMES, V13, P363, DOI [10.1016/S1874-6047(08)60245-0, DOI 10.1016/S1874-6047(08)60245-0]; SIMINIS CI, 1994, PLANT PHYSIOL, V105, P1375, DOI 10.1104/pp.105.4.1375; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; SUMMERMATTER K, 1995, PLANT PHYSIOL, V108, P1379, DOI 10.1104/pp.108.4.1379; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; WHITE RF, 1979, VIROLOGY, V99, P410, DOI 10.1016/0042-6822(79)90019-9; WILLEKENS H, 1995, MOL BREEDING, V1, P207, DOI 10.1007/BF02277422; YASMINEH WG, 1991, CANCER RES, V51, P3990; ZAMOCKY M, 1995, FEBS LETT, V367, P241, DOI 10.1016/0014-5793(95)00568-T; ZELITCH I, 1991, PLANT PHYSIOL, V97, P1592, DOI 10.1104/pp.97.4.1592	72	224	258	0	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28492	28501		10.1074/jbc.271.45.28492	http://dx.doi.org/10.1074/jbc.271.45.28492			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910477	hybrid			2022-12-25	WOS:A1996VU03300077
J	Li, CH; Ramjeesingh, M; Wang, W; Garami, E; Hewryk, M; Lee, D; Rommens, JM; Galley, K; Bear, CE				Li, CH; Ramjeesingh, M; Wang, W; Garami, E; Hewryk, M; Lee, D; Rommens, JM; Galley, K; Bear, CE			ATPase activity of the cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER OVARY; CFTR CHLORIDE CHANNELS; CL CHANNEL; P-GLYCOPROTEIN; BINDING; CELLS; HYDROLYSIS; PROTEINS; GENE; PURIFICATION	The gene mutated in cystic fibrosis codes for the cystic fibrosis transmembrane conductance regulator (CFTR), a cyclic AMP-activated chloride channel thought to be critical for salt and water transport by epithelial cells. Plausible models exist to describe a role for ATP hydrolysis in CFTR channel activity; however, biochemical evidence that CFTR possesses intrinsic ATPase activity is lacking, In this study, we report the first measurements of the rate of ATP hydrolysis by purified, reconstituted CFTR. The mutation CFTRG551D resides within a motif conserved in many nucleotidases and is known to cause severe human disease. Following reconstitution the mutant protein exhibited both defective ATP hydrolysis and channel gating, providing direct evidence that CFTR utilizes ATP to gate its channel activity.	HOSP SICK CHILDREN,RES INST,DIV CELL BIOL,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,RES INST,DIV GENET,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Rommens, Johanna/AAT-7465-2021	Garami, Elizabeth/0000-0003-1295-4007				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEAR C, 1992, AM J PHYSIOL, V262, pC261; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BIRNBAUMER L, 1983, EUR J BIOCHEM, V136, P107, DOI 10.1111/j.1432-1033.1983.tb07712.x; CARSON MR, 1993, AM J PHYSIOL, V265, pL27, DOI 10.1152/ajplung.1993.265.1.L27; DOUSMANIS AG, 1996, BIOPHYS J, V70, P127; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KO YH, 1995, J BIOL CHEM, V270, P22093, DOI 10.1074/jbc.270.38.22093; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI CH, 1993, NAT GENET, V3, P311, DOI 10.1038/ng0493-311; Li CH, 1996, J BIOL CHEM, V271, P11623, DOI 10.1074/jbc.271.20.11623; MANAVALAN P, 1995, FEBS LETT, V366, P87, DOI 10.1016/0014-5793(95)00463-J; ORIORDAN CR, 1995, J BIOL CHEM, V270, P17033, DOI 10.1074/jbc.270.28.17033; RACKER E, 1985, RECONSTITUTION TRANS, P37; REDDY MM, 1996, AM J PHYSIOL, V40, pC35; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHULTZ BD, 1995, J GEN PHYSIOL, V105, P329, DOI 10.1085/jgp.105.3.329; SCHULTZ BD, 1993, PEDIATR PULM, V9, pR37; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SEIBERT FS, 1995, J BIOL CHEM, V270, P2158, DOI 10.1074/jbc.270.5.2158; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHAROM FJ, 1995, BIOCHEM J, V308, P381, DOI 10.1042/bj3080381; SIGURDSON WJ, 1987, J EXP BIOL, V127, P191; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; TSUI LC, 1995, AM J RESP CRIT CARE, V151, pS47, DOI 10.1164/ajrccm/151.3_Pt_2.S47; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VIGERS GA, 1968, BIOCHEM BIOPH RES CO, V30, P83, DOI 10.1016/0006-291X(68)90716-X; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; WINTER MC, 1994, BIOPHYS J, V66, P1398, DOI 10.1016/S0006-3495(94)80930-0; WOODBURY DJ, 1990, BIOPHYS J, V58, P833, DOI 10.1016/S0006-3495(90)82429-2; Yike I, 1996, PROTEIN SCI, V5, P89	45	218	221	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28463	28468		10.1074/jbc.271.45.28463	http://dx.doi.org/10.1074/jbc.271.45.28463			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910473	hybrid			2022-12-25	WOS:A1996VU03300073
J	Michell, BJ; Stapleton, D; Mitchelhill, KI; House, CM; Katsis, F; Witters, LA; Kemp, BE				Michell, BJ; Stapleton, D; Mitchelhill, KI; House, CM; Katsis, F; Witters, LA; Kemp, BE			Isoform-specific purification and substrate specificity of the 5'-AMP-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; YEAST SNF1; SYNTHETIC PEPTIDES; AMP; PHOSPHORYLATION; ACTIVATION; REDUCTASE; INACTIVATION	The 5'-AMP-activated protein kinase (AMPK) mediates several cellular responses to metabolic stress, Rat liver contains at least two isoforms of this enzyme, either alpha(1) or alpha(2) catalytic subunits together with beta and gamma noncatalytic subunits in a trimeric complex, The alpha(1) isoform is purified using a peptide substrate affinity chromatography column with ADR1 (222-234)P-229 (LKKLTRRPSFSAQ), corresponding to the cAMP-dependent protein kinase phosphorylation site in the yeast transcriptional activator of the ADH2 gene, ADR1, This peptide is phosphorylated at Ser(230) by AMPK alpha(1) with a K-m of 3.8 mu M and a V-max of 4.8 mu mol/min/mg compared to the commonly used rat acetyl-CoA carboxylase (73-87)A(77)R(86-87) peptide substrate, HMRSAMSGLHLVKRR, with a K-m of 33.3 mu M and a V-max of 8.1 mu mol/min/mg. Thus, the AMPK exhibits some overlapping specificity with the cAMP-dependent protein kinase. The rat liver AMPK alpha(1) isoform has a K-cat similar to 250-fold higher than the AMPK alpha(2) isoform isolated from rat liver. The AMPK alpha(1) isoform readily phosphorylates peptides corresponding to the reported AMPK phosphorylation sites in rat, chicken, and yeast acetyl-CoA carboxylase and rat hydroxymethylglutaryl-CoA reductase but not phosphorylase kinase, Based on previous peptide substrate specificity studies (Dale, S., Wilson W. A., Edelman, A. M., and Hardie, G. (1995) FEBS Lett. 361, 191-195) using partially purified enzyme and variants of the peptide AMARAASAAALARRR, it was proposed that the AMPK preferred the phosphorylation site motif Phi(X, beta)XXS/TXXX Phi (Phi, hydrophobic; beta, basic), In good AMPK alpha(1) peptide substrates, a hydrophobic residue at the P-5 position is conserved but not at the P+4 position. Oxidation of the Met residues in the rat acetyl-CoA carboxylase (73-87)A(77)R(86-87) peptide increased the K-m 6-fold and reduced the V-max to 4% of the reduced peptide.	DARTMOUTH COLL SCH MED, DEPT MED, DIV ENDOCRINE METAB, HANOVER, NH 03755 USA; DARTMOUTH COLL SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA	Dartmouth College; Dartmouth College	Michell, BJ (corresponding author), ST VINCENTS INST MED RES, 41 VICTORIA PARADE, FITZROY, VIC 3065, AUSTRALIA.		Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035712] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35712] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIANCHI A, 1990, J BIOL CHEM, V265, P1502; CARLING D, 1989, BIOCHIM BIOPHYS ACTA, V1012, P81, DOI 10.1016/0167-4889(89)90014-1; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; DENIS CL, 1991, J BIOL CHEM, V266, P17932; Gao G, 1996, J BIOL CHEM, V271, P8675, DOI 10.1074/jbc.271.15.8675; GILLESPIE JG, 1992, FEBS LETT, V306, P59, DOI 10.1016/0014-5793(92)80837-7; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; KEMP BE, 1994, PROTEIN KINASES, P30; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT, P265; SATO R, 1993, P NATL ACAD SCI USA, V90, P261; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; STAPLETON D, 1994, J BIOL CHEM, V269, P29343; TIPPER JP, 1982, BIOCHIM BIOPHYS ACTA, V715, P162, DOI 10.1016/0304-4165(82)90354-3; WEEKES J, 1993, FEBS LETT, V334, P335, DOI 10.1016/0014-5793(93)80706-Z; WEEKES J, 1994, EUR J BIOCHEM, V219, P751, DOI 10.1111/j.1432-1033.1994.tb18554.x; WOODGETT JR, 1991, METHOD ENZYMOL, V200, P169; WOODS A, 1994, J BIOL CHEM, V269, P19509	28	83	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28445	28450		10.1074/jbc.271.45.28445	http://dx.doi.org/10.1074/jbc.271.45.28445			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910470	hybrid			2022-12-25	WOS:A1996VU03300070
J	Sharma, S; Gopinathan, KP				Sharma, S; Gopinathan, KP			Transcriptional silencing of a tRNA(1)(Gly) copy from within a multigene family is modulated by distal cia elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA GENE; STABLE COMPLEX-FORMATION; 5' FLANKING REGION; 5'-FLANKING SEQUENCES; INVITRO TRANSCRIPTION; BOMBYX-MORI; POLYMERASE-III; EXPRESSION; SILKWORM; UPSTREAM	Individual copies of tRNA(1)(Gly) from within the multigene family in Bombyx mori could be classified based on in vitro transcription in homologous nuclear extracts into three categories of highly, moderately, or weakly transcribed genes, Segregation of the poorly transcribed gene copies 6 and 7, which are clustered in tandem within 425 base pairs, resulted in enhancement of their individual transcription levels, but the linkage itself had little influence on the transcriptional status, For these gene copies, when fused together generating a single coding region, transcription was barely detectable, which suggested the presence of negatively regulating elements located in the far flanking sequences. They exerted the silencing effect on transcription overriding the activity of positive regulatory elements. Systematic analysis of deletion, chimeric, and mutant constructs revealed the presence of a sequence element TATATAA located beyond 800 nucleotides upstream to the coding region acting as negative modulator, which when mutated resulted in high level transcription. Conversely, a TATATAA motif reintroduced at either far upstream or far downstream flanking regions exerted a negative effect on transcription. The location of cis-regulatory sequences at such farther distances from the coding region and the behavior of TATATAA element as negative regulator reported here are novel. These element(s) could play significant roles in activation or silencing of genes from within a multigene family, by recruitment or sequestration of transcription factors.	INDIAN INST SCI,DEPT MICROBIOL & CELL BIOL,BANGALORE 560012,KARNATAKA,INDIA; INDIAN INST SCI,CTR GENET ENGN,BANGALORE 560012,KARNATAKA,INDIA	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore								ALLISON DS, 1985, EMBO J, V4, P2657, DOI 10.1002/j.1460-2075.1985.tb03984.x; ARNOLD GJ, 1988, DNA-J MOLEC CELL BIO, V7, P87, DOI 10.1089/dna.1988.7.87; CARBON P, 1991, EMBO J, V10, P599, DOI 10.1002/j.1460-2075.1991.tb07987.x; DEFRANCO D, 1981, J BIOL CHEM, V256, P2424; DINGERMANN T, 1982, J BIOL CHEM, V257, P4738; FOURNIER A, 1979, BIOCHIMIE, V61, P283, DOI 10.1016/S0300-9084(79)80073-5; FOURNIER A, 1993, GENE, V134, P183, DOI 10.1016/0378-1119(93)90092-H; GALLI G, 1981, NATURE, V294, P626, DOI 10.1038/294626a0; GAREL JP, 1976, NATURE, V260, P805, DOI 10.1038/260805a0; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; HIPSKIND RA, 1983, CELL, V34, P881, DOI 10.1016/0092-8674(83)90545-7; HOFSTETTER H, 1981, CELL, V24, P573, DOI 10.1016/0092-8674(81)90348-2; HUIBREGTSE JM, 1989, MOL CELL BIOL, V9, P3244, DOI 10.1128/MCB.9.8.3244; JOHNSON JD, 1984, J BIOL CHEM, V259, P5990; LARSON D, 1983, P NATL ACAD SCI-BIOL, V80, P3416, DOI 10.1073/pnas.80.11.3416; LEVEILLARD T, 1993, J BIOL CHEM, V268, P3594; MORRY MJ, 1986, MOL CELL BIOL, V6, P105, DOI 10.1128/MCB.6.1.105; PATEL CV, 1991, INDIAN J BIOCHEM BIO, V28, P521; RAYMOND KC, 1985, EMBO J, V4, P2649, DOI 10.1002/j.1460-2075.1985.tb03983.x; ROONEY RJ, 1988, NUCLEIC ACIDS RES, V16, P2509, DOI 10.1093/nar/16.6.2509; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAACK J, 1984, J BIOL CHEM, V259, P1461; SCHMUTZLER C, 1990, NUCLEIC ACIDS RES, V18, P5001, DOI 10.1093/nar/18.17.5001; Sharma S, 1996, J MOL BIOL, V262, P396, DOI 10.1006/jmbi.1996.0523; SHAW KJ, 1984, MOL CELL BIOL, V4, P657, DOI 10.1128/MCB.4.4.657; SPRAGUE KU, 1980, CELL, V22, P171, DOI 10.1016/0092-8674(80)90165-8; TANEJA R, 1992, P NATL ACAD SCI USA, V89, P1070, DOI 10.1073/pnas.89.3.1070; TAPPING RI, 1993, NUCLEIC ACIDS RES, V21, P4476, DOI 10.1093/nar/21.19.4476; WHITE RJ, 1994, RNA POLYMERASE 3 TRA; YOUNG LS, 1986, P NATL ACAD SCI USA, V83, P374, DOI 10.1073/pnas.83.2.374	30	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28146	28153		10.1074/jbc.271.45.28146	http://dx.doi.org/10.1074/jbc.271.45.28146			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910429	hybrid			2022-12-25	WOS:A1996VU03300029
J	Shum, L; Turck, DW; Derynck, R				Shum, L; Turck, DW; Derynck, R			Cysteines 153 and 154 of transmembrane transforming growth factor-alpha are palmitoylated and mediate cytoplasmic protein association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAIN; TGF-ALPHA; DEVELOPMENTAL EXPRESSION; NUCLEOTIDE-SEQUENCE; LIPID MODIFICATIONS; MENETRIERS DISEASE; SIGNALING PATHWAYS; MOLECULAR-CLONING; TRANSGENIC MICE; FATTY ACYLATION	Transforming growth factor-alpha (TGF-alpha) is synthesized as a transmembrane protein with a highly conserved, short cytoplasmic domain that is rich in cysteines. TGF-alpha is a prototype of a large family of growth factors involved in cell-cell communication. We have shown previously that transmembrane TGF-alpha associates with a kinase activity and two proteins of 106 and 86 kDa. In this study, we have used site-directed mutagenesis of the cytoplasmic domain of TGF-alpha to define the structural requirements for these protein interactions. Whereas the cytoplasmic domain of TGF-alpha was not essential for association with transmembrane p106, deletion of the C-terminal 8 amino acids, including a cysteine pair, abolished the interaction with p86 and greatly reduced the kinase activity associated with transmembrane TGF-alpha. Replacement of these 2 cysteines by serines similarly reduced the association of p86 with transmembrane TGF-alpha. Using a combination of mutational analysis and direct microsequencing, we have determined that this cysteine pair was palmitoylated. We therefore conclude that these cysteines play a critical role in the interaction of TGF-alpha with associated proteins and in the function of this protein complex. The palmitoylation of these cysteines suggests a possibly dynamic role of fatty acid modification in the integrity and function of the transmembrane TGF-alpha complex.	UNIV CALIF SAN FRANCISCO,DEPT GROWTH & DEV,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,INST CARDIOVASC RES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [R01CA054826] Funding Source: NIH RePORTER; NCI NIH HHS [CA54826] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASELGA J, 1993, J BIOL CHEM, V271, P3279; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; CHIANG T, 1991, CARCINOGENESIS, V12, P529; DAUTIGNY A, 1985, FEBS LETT, V188, P33, DOI 10.1016/0014-5793(85)80869-3; DEMPSEY PJ, 1992, GASTROENTEROLOGY, V103, P1950, DOI 10.1016/0016-5085(92)91455-D; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DERYNCK R, 1987, CANCER RES, V47, P707; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GLENN GM, 1993, J VIROL, V67, P1945, DOI 10.1128/JVI.67.4.1945-1952.1993; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HARANO T, 1994, J BIOL CHEM, V269, P20305; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; LEE DC, 1985, MOL CELL BIOL, V5, P3644, DOI 10.1128/MCB.5.12.3644; MACAULAY SL, 1995, BIOCHEM J, V306, P811, DOI 10.1042/bj3060811; MAGEE AI, 1992, BIOCHEM SOC T, V20, P497, DOI 10.1042/bst0200497; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; Sambrook J., 2002, MOL CLONING LAB MANU; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; SCOTT J, 1983, SCIENCE, V221, P236, DOI 10.1126/science.6602382; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; STOFFEL W, 1983, H-S Z PHYSIOL CHEM, V364, P1455, DOI 10.1515/bchm2.1983.364.2.1455; STROOBANT P, 1985, CELL, V42, P383, DOI 10.1016/S0092-8674(85)80133-1; SUTTON R, 1995, COMP BIOCHEM PHYS B, V110, P697, DOI 10.1016/0305-0491(94)00208-C; TAKAGI H, 1992, J CLIN INVEST, V90, P1161, DOI 10.1172/JCI115936; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; Zurfluh LL, 1990, GROWTH FACTORS, V3, P257, DOI 10.3109/08977199009003668	62	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28502	28508		10.1074/jbc.271.45.28502	http://dx.doi.org/10.1074/jbc.271.45.28502			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910478	hybrid			2022-12-25	WOS:A1996VU03300078
J	Gregor, P; Feng, Y; DeCarr, LB; Cornfield, LJ; McCaleb, ML				Gregor, P; Feng, Y; DeCarr, LB; Cornfield, LJ; McCaleb, ML			Molecular characterization of a second mouse pancreatic polypeptide receptor and its inactivated human homologue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROPEPTIDE-Y RECEPTOR; PROTEIN-COUPLED RECEPTOR; PEPTIDE-YY; FUNCTIONAL EXPRESSION; PLASMA-MEMBRANE; CLONING; BINDING; GLUCAGON; SUBTYPE; FAMILY	The family of mammalian neuropeptide Y (NPY)/peptide YY (PW)/pancreatic polypeptide (PP) receptors comprises several G protein-coupled receptors, i.e. Y1, Y2, and Y4/PP1. We now report cloning of a novel member of this family named PP2, The coding region of the mouse PP2 gene reveals no introns and predicts a seven transmembrane domain (TM) receptor of 371 amino acids, Percent identities of the mouse PP2 to mouse Y1, mouse Y4/PP1 and human Y2 receptors are 53, 42, and 31, respectively, The mouse PP2 receptor expressed in COS cells binds rat I-125-PP With high affinity, i.e. IC50 = 65 pM. Pharmacological characterization of I-125-PP binding shows a rank order of potency of PP much greater than PYY greater than or equal to NPY, which is similar to that of the mouse Y4/PP1 receptor. Mouse PP2 transcripts were not detectable by Northern analysis ill adult tissues and in 11-, 15-, and 17-day-old embryos. However, a 9.8-kb PP2 transcript was detectable in 7-day-old mouse embryo, i.e. prior to the organogenesis of pancreas and the onset of PP production. We have also cloned the human homologue of PP2, which is a single copy gene and maps to human chromosome 5q31. Surprisingly, the human PP2 cDNAs and gene sequences display a single base deletion in the coding region. This frameshifting mutation predicts a truncated receptor of 290 amino acids without TM7. Transfection of COS-7 cells with several different human PP2 expression constructs failed to confirm any specific binding of I-125-PP, I-125-PYY, Or I-125-NPY to cell membranes. These data suggest that in mouse there are at least tyro PP receptors, Y4/PP1 and PP2, whereas in humans, PP2 is either functionally inactive or it has acquired a PP-independent function.			Gregor, P (corresponding author), BAYER CORP,DIV PHARMACEUT,METAB DISORDERS RES,B-24,400 MORGAN LANE,W HAVEN,CT 06516, USA.							BALLANTYNE GH, 1993, AM J PHYSIOL, V264, pG848, DOI 10.1152/ajpgi.1993.264.5.G848; BARD JA, 1995, J BIOL CHEM, V270, P26762, DOI 10.1074/jbc.270.45.26762; COX H, 1993, BIOL NEUROPEPTIDE Y, P197; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DUMONT Y, 1992, PROG NEUROBIOL, V38, P125, DOI 10.1016/0301-0082(92)90038-G; EVA C, 1990, FEBS LETT, V271, P80; Gehlert DR, 1996, MOL PHARMACOL, V49, P224; GERALD C, 1995, J BIOL CHEM, V270, P26758, DOI 10.1074/jbc.270.45.26758; GITTES GK, 1992, P NATL ACAD SCI USA, V89, P1128, DOI 10.1073/pnas.89.3.1128; Gregor P, 1996, FEBS LETT, V381, P58, DOI 10.1016/0014-5793(96)00067-1; Grundemar L., 1993, BIOL NEUROPEPTIDE RE, P197, DOI [10.1007/978-1-59259-465-8_5, DOI 10.1007/978-1-59259-465-8_5]; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HAZELWOOD RL, 1993, P SOC EXP BIOL MED, V202, P44; HERRERA PL, 1994, P NATL ACAD SCI USA, V91, P12999, DOI 10.1073/pnas.91.26.12999; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LI XJ, 1992, J BIOL CHEM, V267, P9; LUNDELL I, 1995, J BIOL CHEM, V270, P29123, DOI 10.1074/jbc.270.49.29123; Maniatis T, 1989, DECONTAMINATION DILU; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; NGUYEN TD, 1995, AM J PHYSIOL-GASTR L, V268, pG215, DOI 10.1152/ajpgi.1995.268.2.G215; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OKUMURA T, 1995, GASTROENTEROLOGY, V108, P1517, DOI 10.1016/0016-5085(95)90702-5; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Rimland JM, 1996, MOL PHARMACOL, V49, P387; ROSE PM, 1995, J BIOL CHEM, V270, P22661, DOI 10.1074/jbc.270.39.22661; SCHONEBERG T, 1995, J BIOL CHEM, V270, P18000; Sundler F., 1993, BIOL NEUROPEPTIDE Y, P157, DOI [10.1007/978-1-59259-465-8, DOI 10.1007/978-1-59259-465-8]; TEITELMAN G, 1993, DEVELOPMENT, V118, P1031; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720; UPCHURCH BH, 1994, DEVELOPMENT, V120, P245; WAHLESTEDT C, 1993, ANN REV PHARM TOXICO, V32, P309; WHITCOMB DC, 1990, AM J PHYSIOL, V259, pG687, DOI 10.1152/ajpgi.1990.259.4.G687; Yan H, 1996, P NATL ACAD SCI USA, V93, P4661, DOI 10.1073/pnas.93.10.4661	34	149	154	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27776	27781		10.1074/jbc.271.44.27776	http://dx.doi.org/10.1074/jbc.271.44.27776			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910373	hybrid			2022-12-25	WOS:A1996VQ67900091
J	Huang, SM; Cao, ZY; Chung, DW; Davie, EW				Huang, SM; Cao, ZY; Chung, DW; Davie, EW			The role of beta gamma and alpha gamma complexes in the assembly of human fibrinogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; RECOMBINANT HUMAN FIBRINOGEN; CELL-LINES; CHAIN; HEPATOCYTES; SECRETION; BIOSYNTHESIS; PROTEINS; SUBUNIT	The role of alpha gamma and beta gamma dimers as intermediates in the assembly of fibrinogen was examined in cell fusion experiments using stably transfected baby hamster kidney cell lines expressing one or combinations of fibrinogen chains. Fibrinogen was readily formed and secreted into the culture media when cells co-expressing beta and gamma chains and generating beta gamma complexes were fused with cells expressing only the alpha chain. Likewise, when cells co-expressing alpha and gamma chains and generating alpha gamma complexes were fused with cells expressing only the beta chain, fibrinogen was also formed and secreted. The relative amounts of alpha gamma or beta gamma intermediates observed during fibrinogen biosynthesis were determined by the levels of the component chains; i.e. when the beta chain was limiting the alpha gamma dimer was the predominant intermediate; likewise, when the alpha chain was limiting, the beta gamma complex was the predominant intermediate. The incorporation of preformed alpha gamma and beta gamma complexes into secreted fibrinogen did not require concurrent protein synthesis, as shown by experiments employing cycloheximide. These data strongly support the role of alpha gamma and beta gamma complexes as functional intermediates in the assembly of fibrinogen.			Huang, SM (corresponding author), UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA.		Sessum, Rachel/F-7312-2015	Sessum, Rachel/0000-0002-2444-7056	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016919] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16919] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALVING BM, 1982, ARCH BIOCHEM BIOPHYS, V217, P1, DOI 10.1016/0003-9861(82)90472-6; CHUNG DW, 1990, ADV EXP MED BIOL, V281, P39; DAVIDSON JM, 1977, EUR J BIOCHEM, V81, P349, DOI 10.1111/j.1432-1033.1977.tb11958.x; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P271, DOI 10.1007/BF01538965; DOOLITTLE RF, 1978, J MOL BIOL, V120, P311, DOI 10.1016/0022-2836(78)90070-0; DOOLITTLE RF, 1979, NATURE, V280, P464, DOI 10.1038/280464a0; ERICKSON HP, 1983, ANN NY ACAD SCI, V408, P146, DOI 10.1111/j.1749-6632.1983.tb23242.x; FARRELL DH, 1991, BIOCHEMISTRY-US, V30, P9414, DOI 10.1021/bi00103a004; FORMAN WB, 1964, JAMA-J AM MED ASSOC, V187, P128; FU YP, 1992, BIOCHEMISTRY-US, V31, P11968, DOI 10.1021/bi00163a002; GRIENINGER G, 1984, J BIOL CHEM, V259, P4973; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; HANTGAN RR, 1987, BIOCHIM BIOPHYS ACTA, V927, P55, DOI 10.1016/0167-4889(87)90065-6; HARTWIG R, 1991, J BIOL CHEM, V266, P6578; HENSCHEN A, 1977, H-S Z PHYSIOL CHEM, V358, P1643; HENSCHEN A, 1979, H-S Z PHYSIOL CHEM, V360, P1951; HIROSE S, 1988, BIOCHEM J, V251, P373, DOI 10.1042/bj2510373; HUANG SM, 1993, J BIOL CHEM, V268, P8919; HUANG SM, 1993, BIOCHEM BIOPH RES CO, V190, P488, DOI 10.1006/bbrc.1993.1074; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTTSPEICH F, 1977, HOPPESEYLERS Z PHYSL, V358, P3787; MCKEE PA, 1966, ARCH BIOCHEM BIOPHYS, V116, P271, DOI 10.1016/0003-9861(66)90033-6; MULVIHILL E, 1988, Patent No. 39944; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; PLANT PW, 1986, J BIOL CHEM, V261, P2331; ROY SN, 1991, J BIOL CHEM, V266, P4758; WATT KWK, 1979, BIOCHEMISTRY-US, V18, P68, DOI 10.1021/bi00568a011; YU S, 1984, J BIOL CHEM, V259, P574; YU S, 1983, J BIOL CHEM, V258, P3407	30	56	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27942	27947		10.1074/jbc.271.44.27942	http://dx.doi.org/10.1074/jbc.271.44.27942			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910396	hybrid			2022-12-25	WOS:A1996VQ67900114
J	Riederer, B; Han, M; Keller, U				Riederer, B; Han, M; Keller, U			D-lysergyl peptide synthetase from the ergot fungus Claviceps purpurea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN READING FRAME; POLYACRYLAMIDE GELS; BIOSYNTHESIS; ACTINOMYCIN; PROTEINS; PROTOPLASTS; BINDING; ENZYMES	The ergot fungus Claviceps pzrrpurea produces She medically important ergopeptines, which consist of a cyclol-structured tripeptide and D-lysergic acid linked by an amide bond, Az enzyme activity capable of nonribosomal synthesis of D-lysergyl-L-alanyl-L-phenylalanyl-L-proline lactam, the non-cyclol precursor of the ergopeptine ergotamine, has been purified about 18-fold from the ergotamine-producing C. purpurea strain D1. Analysis of radioactively labeled enzyme-substrate complexes revealed a 370-kDa lysergyl peptide synthetase 1 (LPS 1) carrying the amino acid activation domains for alanine, phenylalanine, and proline. The activation of D-lysergic acid is catalyzed by a 140-kDa peptide synthetase (LPS 2) copurifyimg with LPS 1, LPS 1 and LPS 2 contain 4'-phosphopantetheine and bind their substrates covalently by thioester linkage, Kinetic analysis of the synthesis reaction revealed a K-m of similar to 1.4 mu M for both D-lysergic acid and its structural homolog dihydrolysergic acid, which is one to two orders of magnitude lower than the K-m values for the other amino acids involved, The K-m values for the amino acids reflect their relative concentrations in the cellular pool of C, purpurea, This may indicate that in in vivo conditions D-lysergyl peptide formation is limited by the n-lysergic acid concentration in the cell, lit vitro, the multienzyme preparation catalyzes the formation of several different D-lysergyl peptide lactams according to the amino acids supplied. Specific antiserum was used to detect LPS 1 in various C. pupurea strains, In C, purpurea wild type, the enzyme was expressed at all. stages of cultivation and in different media, suggesting that it is produced constitutively.	TECH UNIV BERLIN,INST BIOCHEM & MOL BIOL,D-10587 BERLIN,GERMANY	Technical University of Berlin								AMICI AM, 1969, APPL MICROBIOL, V18, P464, DOI 10.1128/AEM.18.3.464-468.1969; AMICI AM, 1966, EXPERIENTIA, V22, P415, DOI 10.1007/BF01901174; ANDERSON JA, 1979, J NAT PROD, V42, P271, DOI 10.1021/np50003a004; BASSETT RA, 1973, BIOCHEM J, V134, P1; BELZECKI CM, 1980, J ORG CHEM, V45, P2215, DOI 10.1021/jo01299a035; BILLICH A, 1988, APPL ENVIRON MICROB, V54, P2504, DOI 10.1128/AEM.54.10.2504-2509.1988; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIERKES W, 1993, APPL ENVIRON MICROB, V59, P2029, DOI 10.1128/AEM.59.7.2029-2033.1993; HAESE A, 1993, MOL MICROBIOL, V7, P905, DOI 10.1111/j.1365-2958.1993.tb01181.x; HOFMANN A, 1963, HELV CHIM ACTA, V46, P2306, DOI 10.1002/hlca.19630460650; HOFMANN A, 1963, MUTTERKORNALKALOIDE, P35; KELLER U, 1984, BIOCHEM J, V218, P857, DOI 10.1042/bj2180857; KELLER U, 1987, J BIOL CHEM, V262, P5852; KELLER U, 1980, J GEN MICROBIOL, V118, P485; KELLER U, 1988, BIOCHEMISTRY-US, V27, P6164, DOI 10.1021/bi00416a051; KELLER U, 1983, APPL ENVIRON MICROB, V46, P580, DOI 10.1128/AEM.46.3.580-584.1983; KELLER U, 1984, APPL ENVIRON MICROB, V47, P710, DOI 10.1128/AEM.47.4.710-714.1984; KELLER U, 1992, J BIOL CHEM, V267, P11745; KELLER U, 1995, GENETICS BIOCH ANTIB, P71; KLEINKAUF H, 1990, EUR J BIOCHEM, V192, P1, DOI 10.1111/j.1432-1033.1990.tb19188.x; Kobel H, 1986, BIOTECHNOLOGY, P569, DOI Weinheim; KOBEL H, 1976, Patent No. 577556; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lipmann F, 1980, Adv Microb Physiol, V21, P227; PUGH EL, 1965, J BIOL CHEM, V240, P4727; QUIGLEY FR, 1981, J ORG CHEM, V46, P464, DOI 10.1021/jo00315a051; REHACEK Z, 1991, FOLIA MICROBIOL, V36, P323, DOI 10.1007/BF02814505; ROBBERS JE, 1972, J BACTERIOL, V112, P791, DOI 10.1128/JB.112.2.791-796.1972; SCHLUMBOHM W, 1991, J BIOL CHEM, V266, P23135; SCOTTCRAIG JS, 1992, J BIOL CHEM, V267, P26044; SMITH DJ, 1990, EMBO J, V9, P2743, DOI 10.1002/j.1460-2075.1990.tb07461.x; STACHELHAUS T, 1995, FEMS MICROBIOL LETT, V125, P3, DOI 10.1016/0378-1097(94)00459-5; Stadler P. A., 1984, NATURAL PRODUCTS DRU, P463; STADLER PA, 1982, PLANTA MED, V46, P131, DOI 10.1055/s-2007-970038; STEIN T, 1995, BIOCHEMISTRY-US, V34, P4633, DOI 10.1021/bi00014a017; STINDL A, 1994, BIOCHEMISTRY-US, V33, P9358, DOI 10.1021/bi00197a041; STINDL A, 1993, J BIOL CHEM, V268, P10612; STINDL A, 1993, THESIS TU BERLIN BER; Stoll A., 1943, HELVETICA CHIM ACTA, V26, P1602, DOI 10.1002/hlca.19430260523; STUTZ P, 1973, EXPERIENTIA, V29, P936, DOI 10.1007/BF01930383; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; VOGEL HJ, 1964, AM NAT, V98, P435, DOI 10.1086/282338; WEBER G, 1994, CURR GENET, V26, P120, DOI 10.1007/BF00313798; ZOCHER R, 1982, BIOCHEMISTRY-US, V21, P44	46	57	62	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27524	27530		10.1074/jbc.271.44.27524	http://dx.doi.org/10.1074/jbc.271.44.27524			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910337	hybrid			2022-12-25	WOS:A1996VQ67900055
J	Rojas, M; Yao, SY; Lin, YZ				Rojas, M; Yao, SY; Lin, YZ			Controlling epidermal growth factor (EGF)-stimulated ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; TYROSINE KINASE; SIGNAL-TRANSDUCTION; SH2 DOMAINS; SH2-CONTAINING PROTEINS; ADAPTER PROTEIN; GRB2; BINDS; SOS; ASSOCIATION	Epidermal growth factor (EGF)-stimulated Ras activation involves specific interactions between the EGF receptor (EGFR), the adaptor proteins Grb2 and She, and the nucleotide exchange factor Sos-1. Study and control of these protein-protein interactions in vivo can be greatly promoted by introducing intracellular reagents that mimic EGFR functions, Here, we showed that a synthetic phosphopeptide encompassing the autophosphorylation site 1068 of EGFR formed a complex with endogenous Grb2 after this peptide was delivered into intact cells by a cell-permeable peptide import technique, Consequently, this intracellular peptide inhibited EGF-induced EGFR/Grb2 associations but not EGFR/Shc or Shc/GFb2 associations. Peptide-mediated disruption of the EGF/Grb2/Sos-1 cascade led to reduced Ras activation and mitogen-activated protein kinase activation. These results indicate that the binding of Grb2 to the phosphorylated Tyr-1068 of EGFR is crucial to the EGF-induced Ras/mitogen-activated protein kinase signaling pathway. The application of cell-permeable peptides to this study demonstrates a useful biochemical tool to probe and control various intracellular processes involved in signal transduction and gene transcription.	VANDERBILT UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, NASHVILLE, TN 37232 USA	Vanderbilt University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052500] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM52500] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Lin YZ, 1996, J BIOL CHEM, V271, P5305, DOI 10.1074/jbc.271.10.5305; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SOLER C, 1994, J BIOL CHEM, V269, P12320; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	29	211	241	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27456	27461		10.1074/jbc.271.44.27456	http://dx.doi.org/10.1074/jbc.271.44.27456			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910327	hybrid			2022-12-25	WOS:A1996VQ67900045
J	Steinberg, RA; Symcox, MM; Sollid, S; Ogreid, D				Steinberg, RA; Symcox, MM; Sollid, S; Ogreid, D			Arginine 210 is not a critical residue for the allosteric interactions mediated by binding of cyclic AMP to site A of regulatory (RI alpha) subunit of cyclic AMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE LYMPHOMA-CELLS; NUCLEOTIDE BINDING; CATALYTIC SUBUNIT; CAMP; MUTATIONS; ACTIVATION; DERIVATIVES; AFFINITY; ANALOGS; DOMAINS	The guanidinium groups of conserved arginines in the two intrachain cAMP-binding sites of regulatory (R) subunit of cAMP-dependent protein kinase have been implicated in the allosteric interactions by which cAMP binding leads to kinase activation, We have investigated the functional role of Arg-210, the conserved arginine in site A of murine type I alpha R subunit, by analyzing the effects of nine different substitutions at this residue on cAMP binding and allosteric properties of bacterially expressed RI alpha subunits, All substitutions reduced the cAMP binding affinity of site A, but the magnitude of reduction varied from several hundredfold to 10(6)-fold, The differential effects of the different substitutions could not easily be rationalized by interactions with cAMP and might, in part, reflect interactions with other residues in She unoccupied cAMP-binding pocket, None of the Arg-210 substitutions appeared to disrupt the allosteric interaction by which occupation of site a slows dissociation of cAMP from site B, although the effect was difficult to elicit in full with mutations that had strong effects on cAMP binding, The two weakest substitutions, Arg-210 --> Ile and Arg-210 --> Thr, could be shown to have: essentially no effect on the allosteric interaction by which occupation of site A reduces the affinity of R subunit for the catalytic subunit, The weaker mutations had a smaller effect on kinase activation by the suboptimal activator R(p)-adenosine cyclic 3',5'-phosphorothioate than by cAMP, suggesting that the analog largely bypasses interactions with the guanidinium group of Arg-210.	UNIV BERGEN,CTR MOL MED,HAUKELAND HOSP,N-5021 BERGEN,NORWAY	University of Bergen	Steinberg, RA (corresponding author), UNIV OKLAHOMA,CTR HLTH SCI,DEPT BIOCHEM & MOL BIOL,BMSB-853,POB 26901,OKLAHOMA CITY,OK 73190, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037583, R55DK037583] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37583] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOTELHO LHP, 1988, J BIOL CHEM, V263, P5301; BUBIS J, 1988, J BIOL CHEM, V263, P9668; CAUTHRON RD, 1995, J CELL PHYSIOL, V165, P376, DOI 10.1002/jcp.1041650219; DEWIT RJW, 1982, EUR J BIOCHEM, V122, P95; DEWIT RJW, 1984, EUR J BIOCHEM, V142, P255; DILLS WL, 1975, BIOCHEM BIOPH RES CO, V62, P70, DOI 10.1016/S0006-291X(75)80406-2; DOSKELAND SO, 1988, METHOD ENZYMOL, V159, P147; DOSKELAND SO, 1993, BIOCHIM BIOPHYS ACTA, V1178, P249, DOI 10.1016/0167-4889(93)90201-Y; DOSKELAND SO, 1984, J BIOL CHEM, V259, P2291; DOSTMANN WRG, 1991, BIOCHEMISTRY-US, V30, P8710, DOI 10.1021/bi00099a032; DOSTMANN WRG, 1990, J BIOL CHEM, V265, P10484; GORMAN KB, 1994, SOMAT CELL MOLEC GEN, V20, P801; HOFMANN F, 1980, J BIOL CHEM, V255, P1559; HOUGE G, 1990, J BIOL CHEM, V265, P19507; JASTORFF B, 1979, EUR J BIOCHEM, V101, P555, DOI 10.1111/j.1432-1033.1979.tb19750.x; NEITZEL JJ, 1991, BIOCHEMISTRY-US, V30, P733, DOI 10.1021/bi00217a023; OBRIAN CA, 1982, BIOCHEMISTRY-US, V21, P4371, DOI 10.1021/bi00261a028; OGREID D, 1989, EUR J BIOCHEM, V181, P19; OGREID D, 1988, J BIOL CHEM, V263, P17397; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; STEINBERG RA, 1994, ANAL BIOCHEM, V219, P155, DOI 10.1006/abio.1994.1246; STEINBERG RA, 1991, J BIOL CHEM, V266, P3547; STEINBERG RA, 1992, MOL CELL BIOL, V12, P767, DOI 10.1128/MCB.12.2.767; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; SYMCOX MM, 1994, J BIOL CHEM, V269, P23025; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; YAGURA TS, 1981, BIOCHEMISTRY-US, V20, P879, DOI 10.1021/bi00507a035	28	12	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27630	27636		10.1074/jbc.271.44.27630	http://dx.doi.org/10.1074/jbc.271.44.27630			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910352	hybrid			2022-12-25	WOS:A1996VQ67900070
J	deChateau, M; Holst, E; Bjorck, L				deChateau, M; Holst, E; Bjorck, L			Protein PAB, an albumin-binding bacterial surface protein promoting growth and virulence.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGG-BINDING; STREPTOCOCCUS-PYOGENES; GEL ELECTROPHORESIS; ESCHERICHIA-COLI; CELL-WALL; RECEPTOR; M1-PROTEIN; REGIONS; MAGNUS; MODULE	The anaerobic bacterium Peptostreptococcus magnus is a human commensal and pathogen, Previous work has shown that strains of P. magnus isolated from patients with gynecological disease (vaginosis) frequently express an immunoglobulin (Ig) light chain-binding protein called protein L. Here we report that strains isolated from localized suppurative infections bind human serum albumin (HSA), whereas commensal isolates bind neither Ig nor HSA. The HSA-binding protein PAB was extracted from the bacterial surface or isolated from the culture supernatant of the P. magnus strain ALB8. Protein PAB was shown to have two homologous HSA binding domains, GA and uGA. GA is absent in the sequence of a related protein from another P. magnus strain and shows a high degree of homology to the HSA-binding domains of streptococcal protein G. Therefore GA is believed to have recently been shuffled as a module from genes of other bacterial species into the protein PAB gene, This GA module was shown to exhibit a much higher affinity for HSA than uGA and was also found to be present in all of the isolates tested from localized suppurative infections, indicating a role in virulence, Moreover, when peptostreptococci or streptococci expressing the GA module were grown in the presence of HSA, the growth rate was substantially increased. Thus, the HSA binding activity of the GA module adds selective advantages to the bacteria, which increases their virulence in the case of P. magnus strains.	LUND UNIV,DEPT MED MICROBIOL,S-22100 LUND,SWEDEN	Lund University	deChateau, M (corresponding author), LUND UNIV,DEPT CELL & MOL BIOL,POB 94,S-22100 LUND,SWEDEN.							AKERSTROM B, 1989, J BIOL CHEM, V264, P19740; AKERSTROM B, 1987, J BIOL CHEM, V262, P13388; AKESSON P, 1994, BIOCHEM J, V300, P877, DOI 10.1042/bj3000877; BJORCK L, 1988, J IMMUNOL, V140, P1194; BJORCK L, 1987, MOL IMMUNOL, V24, P1113, DOI 10.1016/0161-5890(87)90080-0; BJORCK L, 1984, J IMMUNOL, V133, P969; BOURGAULT AM, 1980, ANN INTERN MED, V93, P244, DOI 10.7326/0003-4819-93-2-244; BROOK I, 1985, CAN J MICROBIOL, V31, P176, DOI 10.1139/m85-033; DALBOGE H, 1989, GENE, V79, P325, DOI 10.1016/0378-1119(89)90214-X; deChateau M, 1996, P NATL ACAD SCI USA, V93, P8490, DOI 10.1073/pnas.93.16.8490; DECHATEAU M, 1994, J BIOL CHEM, V269, P12147; DECHATEAU M, 1993, SCAND J IMMUNOL, V37, P399; Ezaki T, 1992, PROKARYOTES, V2, P1879; FAHNESTOCK SR, 1986, J BACTERIOL, V167, P870, DOI 10.1128/jb.167.3.870-880.1986; FINEGOLD SM, 1995, ANAEROBE, V1, P3, DOI 10.1016/S1075-9964(95)80340-8; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; FORSGREN A, 1966, J IMMUNOL, V97, P822; FOSTER TJ, 1994, FEMS MICROBIOL LETT, V118, P199, DOI 10.1016/0378-1097(94)90504-5; GUSS B, 1986, EMBO J, V5, P1567, DOI 10.1002/j.1460-2075.1986.tb04398.x; JOHANSSON BG, 1972, SCAND J CLIN LAB INV, V29, P7, DOI 10.3109/00365517209102747; JOHANSSON MU, 1995, FEBS LETT, V374, P257, DOI 10.1016/0014-5793(95)01121-T; JONSSON H, 1994, GENE, V143, P85, DOI 10.1016/0378-1119(94)90609-2; JONSSON H, 1995, INFECT IMMUN, V63, P2968, DOI 10.1128/IAI.63.8.2968-2975.1995; KASTERN W, 1992, J BIOL CHEM, V267, P12820; KASTERN W, 1990, INFECT IMMUN, V58, P1217, DOI 10.1128/IAI.58.5.1217-1222.1990; KEHOE MA, 1994, NEW COMPR BIOCH, V27, P217; Kraulis PJ, 1996, FEBS LETT, V378, P190, DOI 10.1016/0014-5793(95)01452-7; KREPEL CJ, 1992, J CLIN MICROBIOL, V30, P2330, DOI 10.1128/JCM.30.9.2330-2334.1992; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Moore LVH, 1977, VPI ANAEROBE LAB MAN; MURPHY JP, 1994, MOL MICROBIOL, V12, P911, DOI 10.1111/j.1365-2958.1994.tb01079.x; OCKNER RK, 1983, AM J PHYSIOL, V245, pG13, DOI 10.1152/ajpgi.1983.245.1.G13; PATELLA V, 1990, J IMMUNOL, V145, P3054; READER R, 1993, INFECT IMMUN, V61, P3696; REIS KJ, 1984, J IMMUNOL, V132, P3091; RETNONINGRUM DS, 1994, INFECT IMMUN, V62, P2387, DOI 10.1128/IAI.62.6.2387-2394.1994; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT KH, 1990, ZBL BAKT-INT J MED M, V273, P216; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; SJOBRING U, 1992, INFECT IMMUN, V60, P3601; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	41	44	51	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26609	26615		10.1074/jbc.271.43.26609	http://dx.doi.org/10.1074/jbc.271.43.26609			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900134	hybrid			2022-12-25	WOS:A1996VP23300028
J	Nornes, S; Mikkola, I; Krauss, S; Delghandi, M; Perander, M; Johansen, T				Nornes, S; Mikkola, I; Krauss, S; Delghandi, M; Perander, M; Johansen, T			Zebrafish Pax9 encodes two proteins with distinct C-terminal transactivating domains of different potency negatively regulated by adjacent N-terminal sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR BSAP; B-CELL DIFFERENTIATION; PAIRED BOX GENE; SONIC-HEDGEHOG; ALVEOLAR RHABDOMYOSARCOMA; POLARIZING ACTIVITY; EXPRESSION PATTERN; NERVOUS-SYSTEM; DEVELOPING CNS; EYELESS GENE	We describe the isolation of cDNA clones for zebrafish Pax9. Pax9 expression was initiated at the end of the segmentation period in mesenchymal sclerotome cells on both sides of the notochord similarly to the corresponding mouse and chick genes. Two transcripts, Pax9a and -b, are generated by alternative splicing. The gene contains 4 exons with exon 3 being included in the Pax9a transcript and spliced out in the Pax9b transcript. The Pax9a and -b proteins are identical for 212 amino acids from the N terminus but contain distinct C-terminal regions of 131 and 58 amino acids, respectively. The paired domain of Pax9 displayed a binding-site specificity distinct from Pax6 but similar to Pax1 and -2. Both Pax9a and -b activated a promoter containing a paired domain binding site. However, this activation was observed when low amounts of Pax9 expression vectors were used. Higher amounts led to a sharp decrease in the activation and even turned into repression. Both the distinct C-terminal regions of Pax9a and -b harbored transcriptional activating domains of different potency not revealed in the context of the full-length proteins due to a negative influence of the N-terminal region including the paired domain.	UNIV TROMSO, INST MED BIOL, DEPT BIOCHEM, N-9037 TROMSO, NORWAY; UNIV TROMSO, INST MED BIOL, DEPT MOL GENET, N-9037 TROMSO, NORWAY	UiT The Arctic University of Tromso; UiT The Arctic University of Tromso			Johansen, Terje/AAY-1753-2021; Johansen, Terje/N-2971-2015	Johansen, Terje/0000-0003-1451-9578; Johansen, Terje/0000-0003-1451-9578; Perander, Maria/0000-0002-1177-2407; Krauss, Stefan/0000-0001-6992-8091; Mikkola, Ingvild/0000-0001-6442-7626				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; Affolter M, 1990, CURR OPIN CELL BIOL, V2, P485, DOI 10.1016/0955-0674(90)90132-X; BJORKOY G, 1995, J BIOL CHEM, V270, P21299; BOPP D, 1989, EMBO J, V8, P3447, DOI 10.1002/j.1460-2075.1989.tb08509.x; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CARRUTH LM, 1994, J VIROL, V68, P6137, DOI 10.1128/JVI.68.10.6137-6146.1994; CERNY T, 1995, MOL CELL BIOL, V15, P2858; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHALEPAKIS G, 1993, J NEUROBIOL, V24, P1367, DOI 10.1002/neu.480241009; CVEKL A, 1995, MOL CELL BIOL, V15, P653; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DAVIS RJ, 1994, CANCER RES, V54, P2869; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; DEUTSCH U, 1991, SEMIN DEV BIOL, V2, P413; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FICKENSCHER HR, 1993, DNA CELL BIOL, V12, P381, DOI 10.1089/dna.1993.12.381; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HEIN J, 1990, METHOD ENZYMOL, V183, P626; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOLST BD, 1994, J BIOL CHEM, V269, P22245; HOOK AG, 1988, J BIOL CHEM, V263, P2337; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; KHORANA S, 1994, NUCLEIC ACIDS RES, V22, P3425, DOI 10.1093/nar/22.16.3425; KIOUSSI C, 1995, NEURON, V15, P553, DOI 10.1016/0896-6273(95)90144-2; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZMIK Z, 1993, MOL CELL BIOL, V13, P6024, DOI 10.1128/MCB.13.10.6024; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; KRAUSS S, 1991, EMBO J, V10, P3609, DOI 10.1002/j.1460-2075.1991.tb04927.x; KRAUSS S, 1991, DEVELOPMENT, V113, P1193; KRAUSS S, 1992, NATURE, V360, P87, DOI 10.1038/360087a0; KRAUSS S, 1991, NATURE, V353, P267, DOI 10.1038/353267a0; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTIN P, 1992, ONCOGENE, V7, P1721; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; NEUBUSER A, 1995, DEV BIOL, V170, P701, DOI 10.1006/dbio.1995.1248; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; NORTON PA, 1994, J CELL SCI, V107, P1; OKAJIMA T, 1993, ANAL BIOCHEM, V211, P293, DOI 10.1006/abio.1993.1272; PETERS H, 1995, DEV DYNAM, V203, P1, DOI 10.1002/aja.1002030102; PLAZA S, 1993, CELL GROWTH DIFFER, V4, P1041; PUSCHEL AW, 1992, DEVELOPMENT, V114, P643; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAFER BW, 1994, NUCLEIC ACIDS RES, V22, P4574, DOI 10.1093/nar/22.22.4574; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SINGH M, 1993, MOL CELL BIOL, V13, P3611, DOI 10.1128/MCB.13.6.3611; STAMM S, 1994, NUCLEIC ACIDS RES, V22, P1515, DOI 10.1093/nar/22.9.1515; STAPLETON P, 1993, NAT GENET, V3, P292, DOI 10.1038/ng0493-292; STRACHAN T, 1994, CURR OPIN GENE DEV, V4, P427; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; TSUKAMOTO K, 1994, HUM GENET, V93, P270, DOI 10.1007/BF00212021; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WALLIN J, 1993, MAMM GENOME, V4, P354, DOI 10.1007/BF00360584; WALLIN J, 1994, DEVELOPMENT, V120, P1109; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WARD TA, 1994, CELL GROWTH DIFFER, V5, P1015; WISBART DS, 1994, COMPUT APPL BIOSCI, V10, P121; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	84	63	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26914	26923		10.1074/jbc.271.43.26914	http://dx.doi.org/10.1074/jbc.271.43.26914			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900176	hybrid			2022-12-25	WOS:A1996VP23300070
J	Tao, JS; Sanghera, JS; Pelech, SL; Wong, G; Levy, JG				Tao, JS; Sanghera, JS; Pelech, SL; Wong, G; Levy, JG			Stimulation of stress-activated protein kinase and p38 HOG1 kinase in murine keratinocytes following photodynamic therapy with benzoporphyrin derivative	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; C-JUN; PORPHYRIN PHOTOSENSITIZATION; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; MAPKAP KINASE-2; PHOSPHORYLATION; TRANSCRIPTION; INDUCTION	The activation state of the members of the mitogen-activated protein kinase family following photodynamic therapy (PDT) with benzoporphyrin derivative monoacid ring A was investigated using a naturally transformed murine keratinocyte cell line, Pam 212. PDT involves the use of photosensitizer molecules and a specific wavelength of visible light. The process of PDT generates singlet oxygen and other reactive oxygen intermediates (ROIs), and the cytotoxic effect of these ROIs is the basis for the use of PDT to treat cancer and psoriasis. PDT caused a strong dose- and time-dependent activation of both stress-activated protein kinase (SAPK) and p38 HOG1. The maximum activation of SAPK and p38 HOG1 occurred between 20 and 30 min following PDT treatment with 200 ng/ml benzoporphyrin derivative monoacid ring A and 2 J/cm(2) of red light at 690 nm. In our system, PDT did not cause significant activation of extracellularly regulated kinase (ERK) 1 and ERK2. Under the same experimental conditions, ultraviolet light irradiation caused strong activation of SAPK and p38 HOG1 and minimum activation of ERK1 and ERK2 in Pam212 cells. A number of ROI scavengers were tested for their effect on PDT-induced SAPK and p38 HOG1 activation. Both L-histidine and N-acetyl-L-cysteine showed a significant inhibitory effect on PDT-induced SAPK and p38 HOG1 activation. This indicated that PDT-induced SAPK and p38 HOG1 activation may be partially mediated by ROI.	UNIV BRITISH COLUMBIA, DEPT MED, VANCOUVER, BC V6T 1Z3, CANADA; UNIV BRITISH COLUMBIA, DEPT MICROBIOL & IMMUNOL, VANCOUVER, BC V6T 1Z3, CANADA; QLT PHOTOTHERAPEUT INC, VANCOUVER, BC V5Z 4H5, CANADA; KINETEK PHARMACEUT INC, VANCOUVER, BC V5Z 1A1, CANADA; STRESSGEN BIOTECHNOL CORP, VICTORIA, BC V8Z 4B9, CANADA	University of British Columbia; University of British Columbia								AGARWAL ML, 1993, CANCER RES, V53, P5897; AGARWAL ML, 1991, CANCER RES, V51, P5993; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CURRY PM, 1993, PHOTOCHEM PHOTOBIOL, V58, P374, DOI 10.1111/j.1751-1097.1993.tb09577.x; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; EVANS S, 1990, J NATL CANCER I, V82, P34, DOI 10.1093/jnci/82.1.34; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GIROTTI A, 1990, PHOTODYNAMIC THERAPY, V1, P229; GOMER CJ, 1991, CANCER RES, V51, P6574; GOMER CJ, 1991, PHOTOCHEM PHOTOBIOL, V53, P275, DOI 10.1111/j.1751-1097.1991.tb03934.x; GOMER GJ, 1988, LASER SURG MED, V8, P450, DOI 10.1002/lsm.1900080503; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HALLIWELL B, 1989, PROTECTION OXIDANTS, P86; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HENDERSON BW, 1989, CANCER RES, V49, P6896; Karin M, 1991, CURR OPIN CELL BIOL, V3, P467, DOI 10.1016/0955-0674(91)90075-A; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KRUTMANN J, 1989, J BIOL CHEM, V264, P11407; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEGRANDPOELS S, 1995, J BIOL CHEM, V270, P6925, DOI 10.1074/jbc.270.12.6925; LUNA MC, 1994, CANCER RES, V54, P1374; MAI S, 1989, J CELL SCI, V94, P609; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NICKOLOFF BJ, 1993, AM J PATHOL, V143, P325; PELECH SL, 1995, PROTEIN KINASE CIRCU; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RYTER SW, 1993, PHOTOCHEM PHOTOBIOL, V58, P753, DOI 10.1111/j.1751-1097.1993.tb04964.x; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; SUTHERLAND CL, 1996, IN PRESS J IMMUNOL; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	43	97	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27107	27115		10.1074/jbc.271.43.27107	http://dx.doi.org/10.1074/jbc.271.43.27107			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900202	hybrid			2022-12-25	WOS:A1996VP23300096
J	Yamashita, M; Ojima, N; Sakamoto, T				Yamashita, M; Ojima, N; Sakamoto, T			Molecular cloning and cold-inducible gene expression of ferritin H subunit isoforms in rainbow trout cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN; TRANSCRIPTIONAL REGULATION; TRANSFERRIN RECEPTOR; MESSENGER-RNAS; PROTEINS; IRON; IDENTIFICATION; MECHANISM; FIBROBLASTS; HIBERNATION	Cold acclimation of rainbow trout cells is considered to be mediated by alterations in the mRNAs and proteins present in cold-treated cells. A subtracted cDNA library from cold-treated rainbow trout RTG-2 cells was constructed and screened to isolate cDNA induced in the cold-treated cells in order to elucidate which genes are induced by cold acclimation. A set of cDNA clones encoding three members of ferritin H isoforms was isolated as cold-inducible genes, Northern blot analysis and nuclear run-on transcription assay showed that the transcription and accumulation of the ferritin H isoforms mRNA were enhanced by cold acclimation, Furthermore, the ferritin level in the trout cells increased on cold acclimation in response to a temperature shift from 22 degrees C to 4 degrees C. When the trout cells were subjected to 4 degrees C under the condition of a decreased ferritin H level obtained by the addition of an antisense oligonucleotide, cell growth was apparently inhibited. These findings indicate an association between the induction of ferritin H and cellular mechanisms during cold acclimation of trout cells.			Yamashita, M (corresponding author), NATL RES INST FISHERIES SCI, KANAZAWA KU, FUKUURA, YOKOHAMA, KANAGAWA 236, JAPAN.		Ojima, Nobuhiko/I-5377-2016					ANDREWS SC, 1992, J INORG BIOCHEM, V47, P161, DOI 10.1016/0162-0134(92)84062-R; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARRESI R, 1994, GENE, V140, P195, DOI 10.1016/0378-1119(94)90544-4; BEAUMONT C, 1994, J BIOL CHEM, V269, P20281; BEAUMONT C, 1989, J BIOL CHEM, V264, P7498; BEVILACQUA MA, 1992, GENE, V111, P255, DOI 10.1016/0378-1119(92)90696-M; BOYD D, 1984, P NATL ACAD SCI-BIOL, V81, P4751, DOI 10.1073/pnas.81.15.4751; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; COSTANZO F, 1984, EMBO J, V3, P23, DOI 10.1002/j.1460-2075.1984.tb01756.x; COULSON RMR, 1993, P NATL ACAD SCI USA, V90, P7613, DOI 10.1073/pnas.90.16.7613; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; DUMAN J, 1983, ANNU REV PHYSIOL, V45, P261, DOI 10.1146/annurev.ph.45.030183.001401; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; HIROSE S, 1985, J BIOL CHEM, V260, P557; JOHNSTON IA, 1990, PHILOS T R SOC B, V326, P655, DOI 10.1098/rstb.1990.0037; KONDO N, 1992, J BIOL CHEM, V267, P473; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LEVI S, 1988, J BIOL CHEM, V263, P18086; MICHOT B, 1990, EUR J BIOCHEM, V188, P219, DOI 10.1111/j.1432-1033.1990.tb15393.x; MOSSER DD, 1986, J CELL PHYSIOL, V128, P432, DOI 10.1002/jcp.1041280312; MOSSER DD, 1987, J CELL PHYSIOL, V132, P155, DOI 10.1002/jcp.1041320122; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MUNDY J, 1988, EMBO J, V7, P2279, DOI 10.1002/j.1460-2075.1988.tb03070.x; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; RAO K, 1986, MOL CELL BIOL, V6, P236, DOI 10.1128/MCB.6.1.236; ROUAULT TA, 1996, TRANSLATIONAL CONTRO, P335; Sambrook J., 1989, MOL CLONING LAB MANU, V2; TAKAMATSU N, 1993, MOL CELL BIOL, V13, P1516, DOI 10.1128/MCB.13.3.1516; TENEA AL, 1991, P NATL ACAD SCI USA, V88, P10907; THEIL EC, 1990, J BIOL CHEM, V265, P4771; TORTI SV, 1988, J BIOL CHEM, V263, P12638; TREFFRY A, 1992, FEBS LETT, V302, P108, DOI 10.1016/0014-5793(92)80417-F; Yamashita M, 1996, FEBS LETT, V382, P261, DOI 10.1016/0014-5793(96)00172-X; ZAHRINGER J, 1976, P NATL ACAD SCI USA, V73, P857, DOI 10.1073/pnas.73.3.857	38	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26908	26913		10.1074/jbc.271.43.26908	http://dx.doi.org/10.1074/jbc.271.43.26908			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900175	hybrid			2022-12-25	WOS:A1996VP23300069
J	Fornerod, M; Boer, J; vanBaal, S; Morreau, H; Grosveld, G				Fornerod, M; Boer, J; vanBaal, S; Morreau, H; Grosveld, G			Interaction of cellular proteins with the leukemia specific fusion proteins DEK-CAN and SET-CAN and their normal counterpart, the nucleoporin CAN	ONCOGENE			English	Article						DEK-CAN; SET-CAN; can proto-oncogene; nucleoporins; acute leukemia	NUCLEAR-PORE COMPLEX; ACUTE NONLYMPHOCYTIC LEUKEMIA; MYELOID LEUKEMOGENESIS; PUTATIVE ONCOGENE; IDENTIFICATION; LOCALIZATION; EXPRESSION; SEQUENCE; IMPORT; GENE	The recurrent chromosomal translocation (6;9) is associated with acute myeloid leukemia and results in expression of the DER-CAN fusion protein. This oncoprotein consists of almost the entire DEK protein fused to the C-terminal two-thirds of the CAN protein. In much the same way, CAN is fused to SET in a patient with acute undifferentiated leukemia, producing a SET-CAN fusion protein. Interestingly, CAN is associated with the nuclear pore complex (NPC) and we recently established its crucial role in nucleocytoplasmic transport processes and cell cycle progression. As a first step in the biochemical analysis of the oncogenic mechanism associated with translocation (6;9), we set out to identify proteins that interact with CAN and its fusion proteins. We found that two proteins specifically co-immunoprecipitate with CAN. One had a molecular mass of 88 kDa protein (CC88) and was determined to associate with the central region of CAN that contains several protein interaction motifs. A second protein of 112 kDa (CC112) was found to interact with the C-terminal nucleoporin-specific repeat of CAN, a region that is supposed to function in nucleocytoplasmic transport. CC112 also interacts with the DEK-CAN and SET-CAN fusion proteins. This finding suggests that CC112 may contribute an essential function to the leukemogenic effect of DEK-CAN and SET-CAN.	ST JUDE CHILDRENS RES HOSP, DEPT GENET, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital			Fornerod, Maarten/A-7503-2010; Boer, Judith/A-7546-2010	Fornerod, Maarten/0000-0002-6166-3030	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA-21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; BYRD DA, 1994, J CELL BIOL, V127, P1515, DOI 10.1083/jcb.127.6.1515; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; FORNEROD M, 1995, ONCOGENE, V10, P1739; Fornerod M, 1996, BIOTECHNIQUES, V20, P876; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRANDI P, 1995, J CELL BIOL, V130, P1263, DOI 10.1083/jcb.130.6.1263; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HURT EC, 1989, J CELL SCI, P243; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; KOEFFLER HP, 1978, SCIENCE, V200, P1153, DOI 10.1126/science.306682; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; PANTE N, 1994, J CELL BIOL, V126, P603, DOI 10.1083/jcb.126.3.603; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; ROWLEY JD, 1976, BLOOD, V47, P705; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; SOEKARMAN D, 1992, BLOOD, V79, P2990; STARR CM, 1990, J CELL BIOL, V110, P1861, DOI 10.1083/jcb.110.6.1861; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; VANDEURSEN J, 1996, IN PRESS EMBO J; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; VONLINDERN M, 1990, MOL CELL BIOL, V10, P4016, DOI 10.1128/MCB.10.8.4016; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x	39	68	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1801	1808						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895527				2022-12-25	WOS:A1996VM88700026
J	Konstantopoulos, N; Clark, S				Konstantopoulos, N; Clark, S			Reduced cell attachment and phosphorylation of focal adhesion kinase associated with expression of a mutant insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; ACTIN STRESS FIBERS; SWISS 3T3 CELLS; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; INDUCED ACTIVATION; CROSS-TALK; PAXILLIN; BINDING	Insulin signaling results in rapid changes to the cell cytoskeleton, and it has recently been shown that insulin stimulates the dephosphorylation of the cytoskeletal-associated tyrosine kinase, focal adhesion kinase (pp125(FAK)). We report here that mutation of two tryptic cleavage sites (Lys(164) and Lys(582) --> Asn; 2N) in the insulin receptor alpha-subunit results in a cell-line (CHO.2N-10) with altered morphology associated with an increase in cell size, a decrease in cell adhesiveness, and a decrease in pp125(FAK) tyrosine phosphorylation in the absence of insulin (45.2 +/- 9.7% compared to nontransfected Chinese hamster ovary (CHO) cells). In contrast to pp125(FAK) paxillin phosphorylation was similar in all cell Lines despite lower levels (61.0 +/- 10.4% compared to CHO cells) of paxillin protein in CHO.2N-10 cells. We observed comparable protein levels of pp125(FAK) and the structural focal adhesion protein, vinculin, in all cell Lines. Despite underphosphorylation of pp125(FAK) in the basal state, insulin stimulation of CHO.2N-10 cells still resulted in dephosphorylation of pp125(FAK). CHO.2N-10 and CHO.T (overexpress wild-type insulin receptor) cells have similar insulin binding characteristics, insulin-stimulated autokinase and peptide phosphorylation, and insulin-stimulated pp185/IRS-1 phosphorylation. Our results suggest that the insulin receptor may play an important role in cell-matrix interactions, such as modulating cell adhesion and inducing cell architecture changes.	DEAKIN UNIV,INST HUMAN NUTR,MALVERN,VIC 3144,AUSTRALIA; UNIV MELBOURNE,PO ROYAL MELBOURNE HOSP,DEPT MED,PARKVILLE,VIC 3050,AUSTRALIA	Deakin University; Royal Melbourne Hospital; University of Melbourne								AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; BARON V, 1992, J BIOL CHEM, V267, P23290; BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; BENNETT PA, 1993, J CELL SCI, V106, P891; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK S, 1991, BIOCHEM J, V276, P27, DOI 10.1042/bj2760027; Clark S, 1990, Methods Mol Biol, V5, P559, DOI 10.1385/0-89603-150-0:559; CLARK S, 1993, BIOCHEM J, V292, P217, DOI 10.1042/bj2920217; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GILMORE AP, 1995, NATURE, V373, P197, DOI 10.1038/373197a0; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KNIGHT JB, 1995, J BIOL CHEM, V270, P10199, DOI 10.1074/jbc.270.17.10199; Konstantopoulos N, 1996, BIOCHEM J, V314, P387, DOI 10.1042/bj3140387; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P24328; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; Li PM, 1996, J CELL BIOCHEM, V61, P31, DOI 10.1002/(SICI)1097-4644(19960401)61:1<31::AID-JCB5>3.0.CO;2-3; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, J CELL SCI, V108, P225; Paz K, 1996, J BIOL CHEM, V271, P6998, DOI 10.1074/jbc.271.12.6998; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; RANKIN S, 1994, J BIOL CHEM, V269, P704; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SEGER R, 1994, J BIOL CHEM, V269, P25699; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; Ugi S, 1996, J BIOL CHEM, V271, P12595, DOI 10.1074/jbc.271.21.12595; UGI S, 1994, FEBS LETT, V340, P216, DOI 10.1016/0014-5793(94)80141-X; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	54	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28960	28968		10.1074/jbc.271.46.28960	http://dx.doi.org/10.1074/jbc.271.46.28960			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910546	hybrid			2022-12-25	WOS:A1996VT05200038
J	Ohno, H; Fournier, MC; Poy, G; Bonifacino, JS				Ohno, H; Fournier, MC; Poy, G; Bonifacino, JS			Structural determinants of interaction of tyrosine-based sorting signals with the adaptor medium chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; TRANSFERRIN RECEPTOR INTERNALIZATION; CYTOPLASMIC DOMAIN; PLASMA-MEMBRANE; COATED PITS; COMPLEX AP-2; AMINO-ACID; CLATHRIN; PROTEINS; ENDOCYTOSIS	Many integral membrane proteins contain tyrosine-based signals within their cytoplasmic domains that mediate internalization from the cell surface and targeting to lysosomal compartments. internalization depends on an interaction of the tyrosine-based signals with the clathrin-associated adaptor complex AP-2 at the plasma membrane, whereas lysosomal targeting involves interaction of the signals with an analogous complex, AP-1, at the trans-Golgi network. Recent studies have identified the medium chains mu(2) of AP-2 and mu(1) of AP-1 as the recognition molecules for tyrosine-based signals. We have now investigated the structural determinants for interaction of the signals with mu(2) and mu(1). The position of the signals was found to be an important determinant of interactions with mu(2) and mu(1); signals were most effective when present at the carboxyl terminus of a polypeptide sequence. Another important determinant of interactions was the identity of residues surrounding the critical tyrosine residue. Mutation of some residues affected interactions with mu(2) and mu(1) similarly, whereas other mutations had differential effects. These observations suggest that both the position and the exact sequence of tyrosine-based sorting signals are major determinants of selectivity in their interaction with clathrin-associated adaptor complexes.	NICHHD,CELL BIOL & METAB BRANCH,NIH,BETHESDA,MD 20892; NIDDK,GENET & BIOCHEM BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Ohno, Hiroshi/L-7899-2014	Ohno, Hiroshi/0000-0001-8776-9661; Bonifacino, Juan S./0000-0002-5673-6370				BOLL W, 1995, CURR BIOL, V5, P1168, DOI 10.1016/S0960-9822(95)00233-8; BONIFACINO JS, 1996, P ASS AM PHYSIC, V4, P285; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; FAMBROUGH DM, 1988, J CELL BIOL, V106, P61, DOI 10.1083/jcb.106.1.61; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; GILBOA L, 1995, J BIOL CHEM, V270, P7061, DOI 10.1074/jbc.270.13.7061; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HOLNESS CL, 1993, BLOOD, V81, P1607; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KIRCHHAUSEN T, 1991, J BIOL CHEM, V266, P11153; KIRCHHAUSEN T, 1993, CURR OPIN STRUC BIOL, V3, P182, DOI 10.1016/S0959-440X(05)80150-2; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LINDSTEDT R, 1995, IMMUNITY, V3, P561, DOI 10.1016/1074-7613(95)90127-2; MARKS MS, 1995, J CELL BIOL, V131, P351, DOI 10.1083/jcb.131.2.351; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; NAIM HY, 1994, J BIOL CHEM, V269, P3928; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEVSNER J, 1994, GENE, V146, P279, DOI 10.1016/0378-1119(94)90306-9; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOSA MA, 1993, J BIOL CHEM, V268, P12537; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; ZHOU SY, 1995, TRENDS BIOCHEM SCI, V20, P470	45	253	254	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29009	29015		10.1074/jbc.271.46.29009	http://dx.doi.org/10.1074/jbc.271.46.29009			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910552	hybrid			2022-12-25	WOS:A1996VT05200044
J	Siciliano, JC; Toutant, M; Derkinderen, P; Sasaki, T; Girault, JA				Siciliano, JC; Toutant, M; Derkinderen, P; Sasaki, T; Girault, JA			Differential regulation of proline-rich tyrosine kinase 2 cell adhesion kinase beta (PYK2/CAK beta) and pp125(FAK) by glutamate and depolarization in rat hippocampus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; MUTANT MICE; PHOSPHORYLATION; BRAIN; ACID; SYNAPTOSOMES; ASSOCIATION; INHIBITORS; 3-KINASE; SLICES	The mechanisms by which stimuli that raise cytosolic free Ca2+ concentrations in neurons can increase protein tyrosine phosphorylation are not known. Using rat hippocampal slices and cortical synaptosomes, we have examined the regulation of two highly related cytoplasmic tyrosine kinases, pp125 focal adhesion kinase (pp125(FAK)) and proline-rich tyrosine kinase 2/cell adhesion kinase beta (PYK2/CAK beta). Membrane depolarization increased tyrosine phosphorylation of PYK2/CAK beta and pp125(FAK). These effects were blocked by EGTA or by protein kinase C inhibitors (RO31-8220; GF109203X) and mimicked by ionomycin or phorbol 12-myristate 13-acetate, in the case of pp125(FAK), or their combination in the case of PYK2/CAK beta. Glutamate and specific agonists of ionotropic (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate and N-methyl-D-aspartate) or metabotropic (trans-1-aminocyclopentane-1,3,-dicarboxylate) glutamate receptors stimulated the phosphorylation of pp125(FAK), but not of PYK2/CAK beta. Glutamate effects were prevented by GF109203X. Thus, in hippocampal slices, tyrosine phosphorylation of pp125(FAK) and PYK2/CARP are regulated differentially by pathways involving Ca2+ and protein kinase C. pp125(FAK) and PYK2/CAK beta may provide specific links between neuronal activity, increases in cytosolic Ca2+ and protein tyrosine phosphorylation, which may be important for neuronal survival, and synaptic plasticity.	COLL FRANCE,INSERM,CHAIRE NEUROPHARMACOL,U114,F-75231 PARIS 05,FRANCE; FAC MED,DEPT HISTOL,MONTEVIDEO 11800,URUGUAY; SAPPORO MED UNIV,CANC RES INST,DEPT BIOCHEM,SAPPORO,HOKKAIDO 060,JAPAN	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universidad de la Republica, Uruguay; Sapporo Medical University			Girault, Jean-Antoine/F-7518-2013; Derkinderen, Pascal/K-2393-2015	Girault, Jean-Antoine/0000-0002-7900-1705; Siciliano, Julio/0000-0002-9731-2945				AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BENGISGARBER C, 1995, CELL SIGNAL, V7, P721, DOI 10.1016/0898-6568(95)00040-V; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Boxall AR, 1996, NEURON, V16, P805, DOI 10.1016/S0896-6273(00)80100-2; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BURGAYA F, 1995, EUR J NEUROSCI, V7, P1810, DOI 10.1111/j.1460-9568.1995.tb00700.x; Burgaya F, 1996, MOL BRAIN RES, V37, P63, DOI 10.1016/0169-328X(95)00273-U; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Derkinderen P, 1996, SCIENCE, V273, P1719, DOI 10.1126/science.273.5282.1719; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GIRAULT JA, 1990, J NEUROSCI, V10, P1124; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GRANT SGN, 1995, GENE DEV, V9, P1909, DOI 10.1101/gad.9.15.1909; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HAMMERSTAD JP, 1972, BRAIN RES, V47, P401, DOI 10.1016/0006-8993(72)90648-8; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Herzog H, 1996, GENOMICS, V32, P484, DOI 10.1006/geno.1996.0149; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; Menegoz M, 1995, NEUROREPORT, V7, P125, DOI 10.1097/00001756-199512290-00030; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHOEPP D, 1990, TRENDS PHARMACOL SCI, V11, P508, DOI 10.1016/0165-6147(90)90052-A; SICILIANO JC, 1994, J NEUROCHEM, V62, P950; SICILIANO JC, 1992, NEUROPROTOCOLS, V1, P185; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stemmer P, 1991, Curr Opin Neurobiol, V1, P53, DOI 10.1016/0959-4388(91)90010-5; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WOODROW S, 1992, J NEUROCHEM, V59, P857, DOI 10.1111/j.1471-4159.1992.tb08323.x; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	38	129	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28942	28946		10.1074/jbc.271.46.28942	http://dx.doi.org/10.1074/jbc.271.46.28942			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910543				2022-12-25	WOS:A1996VT05200035
J	Smulders, RHPH; Carver, JA; Lindner, RA; vanBoekel, MAM; Bloemendal, H; deJong, WW				Smulders, RHPH; Carver, JA; Lindner, RA; vanBoekel, MAM; Bloemendal, H; deJong, WW			Immobilization of the C-terminal extension of bovine alpha A-crystallin reduces chaperone-like activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; B-CRYSTALLIN; QUATERNARY STRUCTURE; NONLENTICULAR TISSUES; H-1-NMR SPECTROSCOPY; LENS CRYSTALLINS; NMR-SPECTROSCOPY; IDENTIFICATION; EXPRESSION; DISEASE	alpha-Crystallins occur as multimeric complexes, which are able to suppress precipitation of unfolding proteins. Although the mechanism of this chaperone-like activity is unknown, the affinity of alpha-crystallin for aggregation-prone proteins is probably based on hydrophobic interactions. alpha-Crystallins expose a considerable hydrophobic surface to solution, but nevertheless they are very stable and highly soluble. An explanation for this paradox may be that alpha-crystallin subunits have a polar and unstructured C-terminal extension that functions as a sort of solubilizer. In this paper we have described five alpha A-crystallins in which charged and hydrophobic residues were inserted in the C-terminal extension. Introduction of lysine, arginine, and aspartate does not substantially influence chaperone-like activity. In contrast, introduction of a hydrophobic tryptophan greatly diminishes functional activity. CD experiments indicate that this mutant has a normal secondary structure and fluorescence measurements show that the inserted tryptophan is located in a polar environment. However, NMR spectroscopy clearly demonstrates that the presence of the tryptophan residue dramatically reduces the flexibility of the C-terminal extension. Furthermore, the introduction of this tryptophan results in a considerably decreased thermostability of the protein. We conclude that changing the polarity of the C-terminal extension of alpha A-crystallin by insertion of a highly hydrophobic residue can seriously disturb structural and functional integrity.	UNIV NIJMEGEN,DEPT BIOCHEM,NL-6500 HB NIJMEGEN,NETHERLANDS; UNIV WOLLONGONG,DEPT CHEM,WOLLONGONG,NSW 2522,AUSTRALIA	Radboud University Nijmegen; University of Wollongong			Carver, John Adrian/J-3825-2014	Carver, John Adrian/0000-0002-2441-8108	NEI NIH HHS [EY09683] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009683] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BINDELS JG, 1979, OPHTHALMIC RES, V11, P711; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARVER JA, 1992, FEBS LETT, V311, P143, DOI 10.1016/0014-5793(92)81386-Z; CARVER JA, 1995, FEBS LETT, V369, P305, DOI 10.1016/0014-5793(95)00770-A; CARVER JA, 1995, BBA-PROTEIN STRUCT M, V1252, P251, DOI 10.1016/0167-4838(95)00146-L; CARVER JA, 1993, BIOCHIM BIOPHYS ACTA, V1164, P22, DOI 10.1016/0167-4838(93)90107-3; CARVER JA, 1994, EXP EYE RES, V59, P231, DOI 10.1006/exer.1994.1101; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; CHIESI M, 1990, MOL CELL BIOCHEM, V97, P129; CREIGHTON TE, 1993, PROTEINS STRUCTURE M, P270; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; DEJONG WW, 1994, PROG RETIN EYE RES, V13, P391, DOI 10.1016/1350-9462(94)90018-3; DERETIC D, 1994, J BIOL CHEM, V269, P16853; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; GROOTJANS JJ, 1995, J BIOL CHEM, V270, P22855, DOI 10.1074/jbc.270.39.22855; HENDRIKS W, 1988, EUR J BIOCHEM, V174, P133, DOI 10.1111/j.1432-1033.1988.tb14072.x; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1993, AM J PATHOL, V143, P487; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JEENER J, 1979, J CHEM PHYS, V48, P286; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KELLEY MJ, 1993, J BIOL CHEM, V268, P18844; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LeBreton ER, 1996, INT J PEPT PROT RES, V47, P9; LOWE J, 1992, J PATHOL, V166, P61, DOI 10.1002/path.1711660110; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; RAMAN B, 1994, J BIOL CHEM, V269, P27264; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P155, DOI 10.1007/BF00296185; SIEZEN RJ, 1983, BIOCHIM BIOPHYS ACTA, V748, P56, DOI 10.1016/0167-4838(83)90027-4; SINGH K, 1995, FEBS LETT, V372, P283, DOI 10.1016/0014-5793(95)00980-N; SMULDERS RHP, 1995, EUR J BIOCHEM, V232, P854; SMULDERS RHPH, 1995, J BIOL CHEM, V270, P13916, DOI 10.1074/jbc.270.23.13916; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUREWICZ WK, 1995, BIOCHEMISTRY-US, V34, P9655, DOI 10.1021/bi00030a001; TAKEMOTO L, 1994, EXP EYE RES, V59, P239, DOI 10.1006/exer.1994.1103; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; VANDENIJSSEL PRLA, 1994, FEBS LETT, V355, P54, DOI 10.1016/0014-5793(94)01175-3; VANDENOETELAAR PJM, 1989, BIOCHIM BIOPHYS ACTA, V995, P91, DOI 10.1016/0167-4838(89)90238-0; VANNOORT JM, 1995, NATURE, V375, P798, DOI 10.1038/375798a0; VOORTER CEM, 1986, EUR J BIOCHEM, V160, P203; VOORTER CEM, 1992, FEBS LETT, V309, P111, DOI 10.1016/0014-5793(92)81075-W; WALSH MT, 1991, J BIOL CHEM, V266, P20079; WANG KY, 1994, J BIOL CHEM, V269, P13601; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9; WISTOW G, 1993, EXP EYE RES, V56, P729, DOI 10.1006/exer.1993.1090; Wuthrich K, 1986, NMR PROTEINS NUCL AC	60	117	118	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29060	29066		10.1074/jbc.271.46.29060	http://dx.doi.org/10.1074/jbc.271.46.29060			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910559	hybrid, Green Published			2022-12-25	WOS:A1996VT05200051
J	Biessen, EAL; Noorman, F; vanTeijlingen, ME; Kuiper, J; BarrettBergshoeff, M; Bijsterbosch, MK; Rijken, DC; vanBerkel, TJC				Biessen, EAL; Noorman, F; vanTeijlingen, ME; Kuiper, J; BarrettBergshoeff, M; Bijsterbosch, MK; Rijken, DC; vanBerkel, TJC			Lysine-based cluster mannosides that inhibit ligand binding to the human mannose receptor at nanomolar concentration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; RABBIT ALVEOLAR MACROPHAGES; HIGH-AFFINITY BINDING; PLASMINOGEN-ACTIVATOR; CELLS; ENDOCYTOSIS; LIVER; GLYCOPROTEINS; CLEARANCE; LECTINS	In search of synthetic high affinity ligands for the mannose receptor, we synthesized a series of lysine-based oligomannosides containing two (M(2)L) to six (M(6)L(5)) terminal alpha-D-mannose groups that are connected with the backbone by flexible elongated spacers (16 Angstrom). The synthesized cluster mannosides were all able to displace binding of biotinylated ribonuclease B and tissue-type plasminogen activator to isolated human mannose receptor, The affinity of these cluster mannosides for the mannose receptor was continuously enhanced from 18-23 mu M to 0.5-2.6 nM, with mannose valencies increasing from two to six. On average, expansion of the cluster mannoside with an additional alpha-D-mannose group resulted in a 10-fold increase in its affinity for the mannose receptor. M(3)L(2) to M(6)L(5) displayed negative cooperative inhibition of ligand binding to the mannose receptor, suggesting that binding of these mannosides involves multiple binding sites. The nanomolar affinity of the most potent ligand, the hexamannoside M(6)L(5) makes it the most potent synthetic cluster mannoside for the mannose receptor yet developed. As a result of its high affinity and accessible synthesis, M(6)L(5) not only is a powerful tool to study the mechanism of ligand binding by the mannose receptor, but it is also a promising targeting device to accomplish cell-specific delivery of genes and drugs to liver endothelial cells or macrophages in bone marrow, lungs, spleen, and atherosclerotic plaques.	TNO PREVENT & HLTH,GAUBIUS LAB,NL-2301 CE LEIDEN,NETHERLANDS	Netherlands Organization Applied Science Research	Biessen, EAL (corresponding author), LEIDEN UNIV,LEIDEN AMSTERDAM CTR DRUG RES,DIV BIOPHARMACEUT,POB 9503,NL-2300 RA LEIDEN,NETHERLANDS.		Van Berkel, Theo/ABD-7677-2021	Noorman, Femke/0000-0002-4891-2047				BIESSEN EAL, 1994, BIOCHEM J, V299, P291, DOI 10.1042/bj2990291; BIESSEN EAL, 1995, J MED CHEM, V38, P1538, DOI 10.1021/jm00009a014; BIESSEN EAL, 1988, BIOCHEM PHARMACOL, V37, P3959, DOI 10.1016/0006-2952(88)90080-9; BIESSEN EAL, 1996, CIRCULATION, V92, P692; BRUNDA MJ, 1983, INT J CANCER, V31, P373, DOI 10.1002/ijc.2910310319; DERIJKE YB, 1992, J LIPID RES, V33, P1315; DERRIEN D, 1989, GLYCOCONJUGATE J, V6, P241, DOI 10.1007/BF01050652; EZEKOWITZ RAB, 1991, NATURE, V351, P155, DOI 10.1038/351155a0; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HOPPE CA, 1984, BIOCHEMISTRY-US, V23, P1723, DOI 10.1021/bi00303a022; HOPPE CA, 1983, J BIOL CHEM, V258, P4193; JANSEN RW, 1991, J BIOL CHEM, V266, P3343; KATAOKA M, 1984, J HISTOCHEM CYTOCHEM, V32, P1091, DOI 10.1177/32.10.6434628; KERY V, 1992, ARCH BIOCHEM BIOPHYS, V298, P49, DOI 10.1016/0003-9861(92)90092-B; LEE RT, 1991, J BIOL CHEM, V266, P4810; LENNARTZ MR, 1987, J BIOL CHEM, V262, P9942; MAIHOTRA R, 1995, NAT MED, V1, P237; MAYNARD Y, 1981, J BIOL CHEM, V256, P8063; MONSIGNY M, 1983, BIOL CELL, V47, P95; OSHIMI Y, 1988, ARCH BIOCHEM BIOPHYS, V260, P241; OTTER M, 1992, ANN NY ACAD SCI, V667, P431, DOI 10.1111/j.1749-6632.1992.tb51645.x; OTTER M, 1992, HEPATOLOGY, V16, P54, DOI 10.1002/hep.1840160111; OTTER M, 1991, J BIOL CHEM, V266, P13931; OTTER M, 1992, BIOCHEM J, V284, P545, DOI 10.1042/bj2840545; ROBBINS JC, 1981, P NATL ACAD SCI-BIOL, V78, P7294, DOI 10.1073/pnas.78.12.7294; SMEDSROD B, 1990, BIOCHEM J, V271, P345, DOI 10.1042/bj2710345; STAHL PD, 1990, AM J RESP CELL MOL, V2, P317, DOI 10.1165/ajrcmb/2.4.317; STAHL PD, 1980, TRENDS BIOCHEM SCI, V5, P194, DOI 10.1016/0968-0004(80)90238-8; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; TAYLOR ME, 1993, BIOCHEM SOC T, V21, P468, DOI 10.1042/bst0210468	33	69	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28024	28030		10.1074/jbc.271.45.28024	http://dx.doi.org/10.1074/jbc.271.45.28024			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910412	Green Published, hybrid			2022-12-25	WOS:A1996VU03300012
J	Khoo, KH; Douglas, E; Azadi, P; Inamine, JM; Besra, GS; Mikusova, K; Brennan, PJ; Chatterjee, D				Khoo, KH; Douglas, E; Azadi, P; Inamine, JM; Besra, GS; Mikusova, K; Brennan, PJ; Chatterjee, D			Truncated structural variants of lipoarabinomannan in ethambutol drug-resistant strains of Mycobacterium smegmatis - Inhibition of arabinan biosynthesis by ethambutol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOMBARDMENT MASS-SPECTROMETRY; CELL-WALL; NONREDUCING TERMINI; MYCOLIC ACID; BOVIS BCG; TUBERCULOSIS; ARABINOGALACTAN; MACROPHAGES; FEATURES; BIOGENESIS	The anti-tuberculosis drug, ethambutol (Emb), was previously shown to inhibit the synthesis of arabinans of both the cell wall arabinogalactan (AG) and lipoarabinomannan (LAM) of Mycobacterium tuberculosis and other mycobacteria. However, an Emb-resistant mutant, isolated by consecutive passage of the Mycobacterium smegmatis parent strain in media containing increasing concentrations of Emb, while synthesizing a normal version of AG, produced truncated forms of LAM when maintained on 10 mu g/ml Emb (Mikusova, K., Slayden, R. A., Besra, G. S., and Brennan, P. J. (1995) Antimicrob. Agents Chemother. 39, 2482-2489). We have now isolated and characterized the truncated LAMs made by both the resistant mutant and a recombinant strain transfected with a plasmid containing the emb region from Mycobacterium avium which encodes for Emb resistance. By chemical analysis, endoarabinanase digestion, high pH anion exchange chromatography, and mass spectrometry analyses, truncation was demonstrated as primarily a consequence of selective and partial inhibition of the synthesis of the linear arabinan terminal motif, which constitutes a substantial portion of the arabinan termini in LAM but not of AG. However, at higher concentrations, Emb also affected the general biosynthesis of arabinan destined for both AG and LAM, resulting in severely truncated LAM as well as AG with a reduced Ara:Gal ratio. The results suggested that Emb exerts its antimycobacterial effect by inhibiting an array of arabinosyltransferases involved in the biosynthesis of arabinans unique to the mycobacterial cell wall. It was further concluded that the uniquely branched terminal Ara(6) motif common to both AG and LAM is an essential structural entity for a functional cell wall and, consequently, that the biosynthetic machinery responsible for its synthesis is the effective target of Emb in its role as a potent anti-tuberculosis drug.	COLORADO STATE UNIV, DEPT MICROBIOL, FT COLLINS, CO 80523 USA; UNIV GEORGIA, COMPLEX CARBOHYDRATE RES CTR, ATHENS, GA 30602 USA	Colorado State University; University System of Georgia; University of Georgia			Khoo, Kay-Hooi/E-1989-2019; Mikusova, Katarina/I-3622-2014	Khoo, Kay-Hooi/0000-0003-2906-406X; Besra, Gurdyal/0000-0002-5605-0395	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018357, U19AI038087, R01AI018357, R22AI018357] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 18357, AI 38087, AI 01185] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; BESRA GS, 1995, BIOCHEMISTRY-US, V34, P4257, DOI 10.1021/bi00013a015; Besra Gurdyal S., 1994, P285; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; CHAN J, 1991, INFECT IMMUN, V59, P1755, DOI 10.1128/IAI.59.5.1755-1761.1991; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; CHATTERJEE D, 1991, J BIOL CHEM, V266, P9652; CHATTERJEE D, 1993, GLYCOBIOLOGY, V3, P497, DOI 10.1093/glycob/3.5.497; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; DAFFE M, 1993, CARBOHYD RES, V249, P383, DOI 10.1016/0008-6215(93)84102-C; DELL A, 1994, METHOD ENZYMOL, V230, P108; DENG LY, 1995, ANTIMICROB AGENTS CH, V39, P694, DOI 10.1128/AAC.39.3.694; DRAPER P, 1982, BIOL MYCOBACTERIA, V1, P9; FORBES M, 1962, J BACTERIOL, V84, P1099, DOI 10.1128/JB.84.5.1099-1103.1962; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; KAPLAN G, 1987, J IMMUNOL, V138, P3028; KHANOLKAR SR, 1989, J MED MICROBIOL, V28, P157, DOI 10.1099/00222615-28-3-157; KHOO KH, 1995, J BIOL CHEM, V270, P12380, DOI 10.1074/jbc.270.21.12380; KILBURN JO, 1981, ANTIMICROB AGENTS CH, V20, P401, DOI 10.1128/AAC.20.3.401; LEE RE, 1995, J AM CHEM SOC, V117, P11829, DOI 10.1021/ja00153a002; LEOPOLD K, 1993, ANAL BIOCHEM, V208, P57, DOI 10.1006/abio.1993.1008; MCNEIL MR, 1994, GLYCOBIOLOGY, V4, P165, DOI 10.1093/glycob/4.2.165; MCNEIL MR, 1991, RES MICROBIOL, V142, P451, DOI 10.1016/0923-2508(91)90120-Y; MIKUSOVA K, 1995, ANTIMICROB AGENTS CH, V39, P2484, DOI 10.1128/AAC.39.11.2484; MOHR MD, 1995, RAPID COMMUN MASS SP, V9, P808; PAULIN LG, 1985, ANTIMICROB AGENTS CH, V28, P157, DOI 10.1128/AAC.28.1.157; PRINZIS S, 1993, J GEN MICROBIOL, V139, P2649, DOI 10.1099/00221287-139-11-2649; SCHLESINGER LS, 1994, J IMMUNOL, V152, P4070; SIBLEY LD, 1988, INFECT IMMUN, V56, P1232, DOI 10.1128/IAI.56.5.1232-1236.1988; SILVE G, 1993, ANTIMICROB AGENTS CH, V37, P1536, DOI 10.1128/AAC.37.7.1536; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; TAKAYAMA K, 1979, ANTIMICROB AGENTS CH, V16, P240, DOI 10.1128/AAC.16.2.240; TAKAYAMA K, 1989, ANTIMICROB AGENTS CH, V33, P1493, DOI 10.1128/AAC.33.9.1493; THOMAS JP, 1961, AM REV RESPIR DIS, V83, P891; VENISSE A, 1993, J BIOL CHEM, V268, P12401; WINDER FG, 1982, BIOL MYCOBACTERIA, V1, P417; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328	38	98	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28682	28690		10.1074/jbc.271.45.28682	http://dx.doi.org/10.1074/jbc.271.45.28682			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910503	hybrid			2022-12-25	WOS:A1996VU03300103
J	Lin, HC; Gilman, AG				Lin, HC; Gilman, AG			Regulation of dynamin I GTPase activity by G protein beta gamma subunits and phosphatidylinositol 4,5-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; CLATHRIN-COATED VESICLES; HIGH-AFFINITY BINDING; MECHANOCHEMICAL ENZYME; PH DOMAIN; MICROTUBULES; ACTIVATION; KINASE; ENDOCYTOSIS; SHIBIRE	Dynamin I is a 100-kDa GTPase that plays an important role in the recycling of synaptic vesicles. Hydrolysis of GTP by dynamin is thought to be a critical step in fission of coated pits to form coated vesicles. We report that the heterotrimeric G protein beta gamma subunit complex (G(beta gamma)) and phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2) are negative and positive regulators of dynamin GTPase activity, respectively. Furthermore, the apparent affinity of dynamin for G(beta gamma) is substantially enhanced by PtdIns(4,5)P-2. However, the GTPase activity of oligomeric dynamin is unaffected by G(beta gamma). The effects of heterotrimeric G proteins on endocytosis may thus be mediated directly and not involve more remote aspects of their signaling properties.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CHERKSEY B, 1994, NEUROCHEM RES, V19, P1101, DOI 10.1007/BF00968722; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LIU JP, 1994, J BIOL CHEM, V269, P21043; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; SARASTE M, 1995, CURR OPIN STRUC BIOL, V5, P403, DOI 10.1016/0959-440X(95)80104-9; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; SILVA WI, 1991, JPN J PHARMACOL, V56, P97, DOI 10.1254/jjp.56.97; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TUMA PL, 1994, J BIOL CHEM, V269, P30842; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	28	79	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					27979	27982		10.1074/jbc.271.45.27979	http://dx.doi.org/10.1074/jbc.271.45.27979			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910402	hybrid			2022-12-25	WOS:A1996VU03300002
J	Romano, C; Yang, WL; OMalley, KL				Romano, C; Yang, WL; OMalley, KL			Metabotropic glutamate receptor 5 is a disulfide-linked dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPLASMIC BINDING-PROTEINS; LIGAND-BINDING; SMOOTH-MUSCLE; RAT-BRAIN; BETA-2-ADRENERGIC RECEPTOR; MOLECULAR CHARACTERIZATION; AGONIST SELECTIVITY; KINASE ACTIVATION; RESPONSES; AFFINITY	The sequences of the metabotropic glutamate receptors (mGluRs) show Little homology with other members of the G protein-coupled receptor family and exhibit several distinctive features, including a large N-terminal extracellular domain with 17 cysteines in conserved positions. Here we demonstrate that MGluR5, as well as other mGluRs, behave as species approximately twice as large as expected from their sequence, but reducing conditions cause a decrease to the predicted molecular mass. Co-immunoprecipitation experiments using wild type and epitope-tagged receptors demonstrate that this is due to specific, disulfide-dependent dimerization of the receptor. The intermolecular disulfide that mediates dimerization occurs in the extracellular domain, within about 17 kDa from the N terminus.	WASHINGTON UNIV, SCH MED, DEPT VISUAL SCI, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	Romano, C (corresponding author), WASHINGTON UNIV, SCH MED, DEPT OPHTHALMOL & VISUAL SCI, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA.		soler, martha maricel m gomez/L-6025-2014	soler, martha maricel m gomez/0000-0002-4412-8108	NEI NIH HHS [EY02687, EY09370] Funding Source: Medline; NIA NIH HHS [AG11355] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009370, P30EY002687] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG011355] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABE T, 1992, J BIOL CHEM, V267, P13361; ADAMS MD, 1989, J BIOL CHEM, V264, P15739; BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; BONE EA, 1988, PEPTIDES, V9, P373, DOI 10.1016/0196-9781(88)90273-2; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CARMANKRZAN M, 1984, AGENTS ACTIONS, V14, P561; DICKENSON JM, 1994, BIOCHEM PHARMACOL, V48, P1721, DOI 10.1016/0006-2952(94)90457-X; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; DONALDSON J, 1986, BRIT J PHARMACOL, V87, P191, DOI 10.1111/j.1476-5381.1986.tb10171.x; DONALDSON J, 1987, BRIT J PHARMACOL, V90, P263, DOI 10.1111/j.1476-5381.1987.tb16848.x; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; EATON SA, 1993, EUR J NEUROSCI, V5, P186, DOI 10.1111/j.1460-9568.1993.tb00484.x; Gioannini T L, 1989, J Mol Recognit, V2, P44, DOI 10.1002/jmr.300020107; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; ISHII T, 1993, J BIOL CHEM, V268, P2836; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KUSUI T, 1994, BIOCHEMISTRY-US, V33, P12968, DOI 10.1021/bi00248a005; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MICHALAK M, 1992, BIOCHIM BIOPHYS ACTA, V1111, P247, DOI 10.1016/0005-2736(92)90317-F; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NODA K, 1994, J BIOL CHEM, V269, P6743; NOMURA A, 1994, CELL, V77, P361, DOI 10.1016/0092-8674(94)90151-1; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Petralia RS, 1996, NEUROSCIENCE, V71, P949, DOI 10.1016/0306-4522(95)00533-1; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; PIN JP, 1995, BIOCHEM SOC T, V23, P91, DOI 10.1042/bst0230091; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; REYNOLDS IJ, 1990, BRIT J PHARMACOL, V101, P178, DOI 10.1111/j.1476-5381.1990.tb12109.x; ROMANO C, 1995, J COMP NEUROL, V355, P455, DOI 10.1002/cne.903550310; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; Sucher N J, 1990, Neuroreport, V1, P29, DOI 10.1097/00001756-199009000-00009; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TANG LH, 1993, J PHYSIOL-LONDON, V465, P303, DOI 10.1113/jphysiol.1993.sp019678; TERMAN BI, 1986, J BIOL CHEM, V261, P5603; VIGNES M, 1992, NEUROCHEM INT, V21, P229, DOI 10.1016/0197-0186(92)90152-H; WEI JW, 1980, N-S ARCH PHARMACOL, V314, P51, DOI 10.1007/BF00498431; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N	46	428	438	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28612	28616		10.1074/jbc.271.45.28612	http://dx.doi.org/10.1074/jbc.271.45.28612			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910492	hybrid			2022-12-25	WOS:A1996VU03300092
J	Rostovtseva, T; Colombini, M				Rostovtseva, T; Colombini, M			ATP flux is controlled by a voltage-gated channel from the mitochondrial outer membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC POLYANION; NEUROSPORA-CRASSA; VDAC CHANNEL; PORIN; PERMEABILITY; CALCIUM; PROTEIN; MODE	A voltage-gated channel, called VDAC (mitochondrial porin) is known to be responsible for most of the metabolite flux across the mitochondrial outer membrane. Here, direct measurements of ATP flux through VDAC channels reconstituted into planar phospholipid membranes establish that VDAC is sufficient to provide passage for ATP efflux from mitochondria. Further, the gating of the channel can shut down ATP flux completely while, simultaneously, allowing the flow of small ions. Thus, these channels are ideally suited to control ATP flux through the mitochondrial outer membrane and, consequently, mitochondrial function. The block to ATP flow through the closed state is likely to be not steric but electrostatic.	UNIV MARYLAND,DEPT ZOOL,CELL BIOL LABS,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park			Colombini, Marco/A-1540-2014					BENZ R, 1990, BIOCHIM BIOPHYS ACTA, V1022, P311, DOI 10.1016/0005-2736(90)90279-W; BENZ R, 1988, FEBS LETT, V231, P75, DOI 10.1016/0014-5793(88)80706-3; BRDICZKA D, 1994, NATO ASI SERIES H, V83, P297; CHAPPELL JB, 1964, BIOCHEM J, V90, P237, DOI 10.1042/bj0900237; Colombini M, 1980, Ann N Y Acad Sci, V341, P552, DOI 10.1111/j.1749-6632.1980.tb47198.x; Colombini M, 1996, Ion Channels, V4, P169; COLOMBINI M, 1987, METHOD ENZYMOL, V148, P465; COLOMBINI M, 1994, CURR TOP MEMBR, V42, P73, DOI 10.1016/S0070-2161(08)60819-9; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; COLOMBINI M, 1987, BIOCHIM BIOPHYS ACTA, V905, P279, DOI 10.1016/0005-2736(87)90456-1; FEIN A, 1988, NATURE, V331, P437, DOI 10.1038/331437a0; FREITAG H, 1983, METHOD ENZYMOL, V97, P286; GELLERICH FN, 1993, BIOCHIM BIOPHYS ACTA, V1142, P217, DOI 10.1016/0005-2728(93)90150-E; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HOLDEN MJ, 1988, FEBS LETT, V241, P105, DOI 10.1016/0014-5793(88)81040-8; INOUE I, 1991, NATURE, V352, P244, DOI 10.1038/352244a0; LEE AC, 1994, J BIOL CHEM, V269, P30974; LINDEN M, 1984, BIOCHIM BIOPHYS ACTA, V770, P93, DOI 10.1016/0005-2736(84)90077-4; LIU MY, 1992, BIOCHIM BIOPHYS ACTA, V1098, P255, DOI 10.1016/S0005-2728(05)80344-5; MANNELLA CA, 1990, BIOPHYS J, V57, P23, DOI 10.1016/S0006-3495(90)82503-0; MANNELLA CA, 1982, J CELL BIOL, V94, P680, DOI 10.1083/jcb.94.3.680; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; PENG S, 1992, BIOPHYS J, V62, P123, DOI 10.1016/S0006-3495(92)81799-X; SORGATO MC, 1987, NATURE, V330, P498, DOI 10.1038/330498a0; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; ZAMBROWICZ EB, 1993, BIOPHYS J, V65, P1093, DOI 10.1016/S0006-3495(93)81148-2; ZIZI M, 1994, J BIOL CHEM, V269, P1614	27	200	204	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28006	28008		10.1074/jbc.271.45.28006	http://dx.doi.org/10.1074/jbc.271.45.28006			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910409	hybrid			2022-12-25	WOS:A1996VU03300009
J	Verdot, L; Lalmanach, G; Vercruysse, V; Hartmann, S; Lucius, R; Hoebeke, J; Gauthier, F; Vray, B				Verdot, L; Lalmanach, G; Vercruysse, V; Hartmann, S; Lucius, R; Hoebeke, J; Gauthier, F; Vray, B			Cystatins up-regulate nitric oxide release from interferon-gamma-activated mouse peritoneal macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGG-WHITE CYSTATIN; TRYPANOSOMA-CRUZI; CYSTEINE PROTEINASES; ALVEOLAR MACROPHAGES; RESPIRATORY BURST; CHICKEN CYSTATIN; CHAGAS-DISEASE; SYNTHASE GENE; T-KININOGEN; INHIBITORS	Up-regulation of nitric oxide (NO) production by activated murine macrophages was observed during infection by Trypanosoma cruzi, the etiological agent of Chagas' disease. Cell infection by T. cruzi depends at least in part on cruzipain, a membrane-associated papain-related proteinase which is sensitive to inhibition by synthetic inhibitors of cysteine proteinases. Using the natural cysteine proteinase inhibitor chicken cystatin, a representative member of cystatin family 2, to investigate the effect of cruzipain on macrophage infection and NO release, we found that the inhibitor alone up-regulated NO release from interferon-gamma-activated macrophages. A 12-fold increase in NO production was observed in the presence of 1 mu M chicken cystatin. This overproduction was concentration-dependent and could be detected at concentrations as low as 10 nM and remained in the presence of polymyxin B. Representative members of the other cystatin families, i.e. stefin B (family 1), T-kininogen, and its inhibitory domains (family 3), were also able to enhance NO production from interferon-gamma-activated macrophages. Neither E64, an irreversible inhibitor of cysteine proteinases, nor inhibitors of aspartyl and serine proteinases (aprotinin, pepstatin, and soybean trypsin inhibitor) enhanced NO production. Upon complexation with saturating amounts of reduced-alkylated papain, cystatins still remained active in increasing NO production, suggesting that the cystatin inhibitory site was not involved in the mechanism. The results demonstrate that members of all 3 cystatin families share another common property unrelated to their function of cysteine proteinase inhibitors, i.e. upregulation of NO production, which biological significance remains to be elucidated.	FREE UNIV BRUSSELS, FAC MED, EXPT IMMUNOL LAB, B-1070 BRUSSELS, BELGIUM; UNIV TOURS, LAB ENZYMOL & CHIM PROT, F-37032 TOURS, FRANCE; HUMBOLDT UNIV BERLIN, INST BIOL, BERLIN, GERMANY	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite de Tours; Humboldt University of Berlin			Hartmann, Susanne/M-9154-2016	Lalmanach, Gilles/0000-0001-8562-4821				ARAUJO-JORGE T C D, 1989, Memorias do Instituto Oswaldo Cruz, V84, P441; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BJORK I, 1989, BIOCHEM J, V260, P61; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BOGLE RG, 1991, BIOCHEM BIOPH RES CO, V180, P926, DOI 10.1016/S0006-291X(05)81154-4; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; CAZULLO JJ, 1990, BIOCHIM BIOPHYS ACTA, V1037, P186; CAZULLO JJ, 1989, MOL BIOCHEM PARASIT, V33, P33; CHESROWN SE, 1994, BIOCHEM BIOPH RES CO, V200, P126, DOI 10.1006/bbrc.1994.1424; DENG WL, 1993, J IMMUNOL, V151, P322; DENIS M, 1994, J LEUKOCYTE BIOL, V55, P682, DOI 10.1002/jlb.55.5.682; EAKIN AE, 1992, J BIOL CHEM, V267, P7411; ENGH RA, 1993, J MOL BIOL, V234, P1060, DOI 10.1006/jmbi.1993.1659; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GUTMAN N, 1988, EUR J BIOCHEM, V171, P577, DOI 10.1111/j.1432-1033.1988.tb13827.x; HARTH G, 1993, MOL BIOCHEM PARASIT, V58, P17, DOI 10.1016/0166-6851(93)90086-D; JORENS PG, 1992, AGENTS ACTIONS, V36, P243; JORENS PG, 1992, BIOCHEM PHARMACOL, V44, P387, DOI 10.1016/0006-2952(92)90025-E; KILBOURN R, 1990, J IMMUNOL, V144, P1042; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; LEUNGTACK J, 1990, EXP CELL RES, V188, P16, DOI 10.1016/0014-4827(90)90272-C; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LOWENSTEIN CJ, 1994, ANN INTERN MED, V120, P227, DOI 10.7326/0003-4819-120-3-199402010-00009; MACHLEIDT W, 1989, FEBS LETT, V243, P234, DOI 10.1016/0014-5793(89)80135-8; MEIRELLES MNL, 1992, MOL BIOCHEM PARASIT, V52, P175, DOI 10.1016/0166-6851(92)90050-T; METZ G, 1993, PARASITE IMMUNOL, V15, P693, DOI 10.1111/j.1365-3024.1993.tb00584.x; MOREAU T, 1989, J BIOL CHEM, V264, P4298; MURTA ACM, 1990, MOL BIOCHEM PARASIT, V43, P27, DOI 10.1016/0166-6851(90)90127-8; NATHAN C, 1994, J BIOL CHEM, V269, P13725; OSWALD IP, 1994, COMP BIOCHEM PHYS C, V108, P11, DOI 10.1016/1367-8280(94)90083-3; PETRAY P, 1994, PARASITE IMMUNOL, V16, P193, DOI 10.1111/j.1365-3024.1994.tb00340.x; SAKURADA JK, 1992, RES IMMUNOL, V143, P157, DOI 10.1016/S0923-2494(92)80158-H; SCHARFSTEIN J, 1986, J IMMUNOL, V137, P1336; SCHARFSTEIN J, 1995, J IMMUNOL METHODS, V182, P63, DOI 10.1016/0022-1759(95)00023-4; SOUTOPADRON T, 1990, J CELL SCI, V96, P485; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; STUEHR DJ, 1987, J IMMUNOL, V139, P518; TANOWITZ HB, 1992, CLIN MICROBIOL REV, V5, P400, DOI 10.1128/CMR.5.4.400-419.1992; TIFFANY CW, 1989, FEBS LETT, V247, P189, DOI 10.1016/0014-5793(89)81331-6; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; VESPA GNR, 1994, INFECT IMMUN, V62, P5177, DOI 10.1128/IAI.62.11.5177-5182.1994; WEISZ A, 1994, J BIOL CHEM, V269, P8324; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	44	98	101	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28077	28081		10.1074/jbc.271.45.28077	http://dx.doi.org/10.1074/jbc.271.45.28077			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910420	hybrid			2022-12-25	WOS:A1996VU03300020
J	Iwasaki, T; Imai, T; Urushiyama, A; Oshima, T				Iwasaki, T; Imai, T; Urushiyama, A; Oshima, T			Redox-linked ionization of Sulredoxin, an archaeal Rieske-type [2Fe-2S] protein from Sulfolobus sp strain 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; RESONANCE RAMAN-SPECTROSCOPY; MAGNETIC CIRCULAR-DICHROISM; THERMOACIDOPHILIC ARCHAEON; PHTHALATE DIOXYGENASE; ACIDOTHERMOPHILIC ARCHAEBACTERIUM; CYTOCHROME-BC1 COMPLEXES; 2 HISTIDINES; FES CENTER; ACIDOCALDARIUS	''Sulredoxin'' of Sulfolobus sp. strain 7 is an archaeal soluble Rieske-type [2Fe-2S] protein and was initially characterized by several spectroscopic techniques (Iwasaki, T., Isogai, T., Iizuka, T., and Oshima, T. (1995) J. Bacteriol. 177, 2576-2582), It appears to have tightly linked ionization affecting the redox properties of the protein, which is characteristic of the Rieske FeS proteins found as part of the respiratory chain, Sulredoxin had an E(m)(low pH) value of +188 +/- 9 mV, and the slope of pH dependence of the midpoint redox potential indicated two ionization equilibria in the oxidized form with pK(a(ox1)) of 6.23 +/- 0.22 and pK(a(ox2)) of 8.57 +/- 0.20, The absorption, CD, and resonance Raman spectra of oxidized sulredoxin are consistent with the proposed (S2FeS2Fe)-Fe-t-Fe-b[N(His)](t)(2) core structure, and deprotonation of one of the two putative coordinated histidine imidazoles, having the pK(a(ox2)) of 8.57 +/- 0.20, causes a decrease in the midpoint redox potential, the change in the optical and CD spectra, and the appearance of a new Raman transition at 278 cm(-1), without major structural rearrangement of the [2Fe-2S] cluster as well as the overall protein conformation, The redox-linked ionization of sulredoxin is also contributed by local changes involving another ionizable group having the pK(a(ox1)) of 6.23 +/- 0.22, which is probably attributed to a certain positively charged amino acid residue that may not be a ligand by itself but located very close to the cluster. We suggest that sulredoxin provides a new tractable model of the membrane-bound homologue of the respiratory chain, the Rieske FeS proteins of the cytochrome bc(1)-b(6)f complexes.	TOKYO INST TECHNOL, DEPT LIFE SCI, YOKOHAMA, KANAGAWA 226, JAPAN; RIKKYO UNIV, DEPT CHEM, TOSHIMA KU, TOKYO 171, JAPAN; TOKYO UNIV PHARM & LIFE SCI, DEPT MOL BIOL, HACHIOJI, TOKYO 19203, JAPAN	Tokyo Institute of Technology; Rikkyo University; Tokyo University of Pharmacy & Life Sciences	Iwasaki, T (corresponding author), NIPPON MED COLL, DEPT BIOCHEM & MOL BIOL, BUNKYO KU, 1-1-5 SENDAGI, TOKYO 113, JAPAN.			Iwasaki, Toshio/0000-0001-9562-4649				ANEMULLER S, 1994, BIOCHEM BIOPH RES CO, V202, P252, DOI 10.1006/bbrc.1994.1920; ANEMULLER S, 1993, FEBS LETT, V318, P61, DOI 10.1016/0014-5793(93)81328-W; BRITT RD, 1991, BIOCHEMISTRY-US, V30, P1892, DOI 10.1021/bi00221a023; Clark W. M., 1960, OXIDATION REDUCTION; CLINE JF, 1985, J BIOL CHEM, V260, P3251; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3342, DOI 10.1021/bi00128a006; DENDA K, 1990, J BIOL CHEM, V265, P21509; FEE JA, 1984, J BIOL CHEM, V259, P124; FEE JA, 1986, BIOCHIM BIOPHYS ACTA, V853, P153, DOI 10.1016/0304-4173(86)90009-1; FU WG, 1992, J BIOL CHEM, V267, P15502; GURBIEL RJ, 1989, BIOCHEMISTRY-US, V28, P4861, DOI 10.1021/bi00437a051; GURBIEL RJ, 1991, BIOCHEMISTRY-US, V30, P11579, DOI 10.1021/bi00113a013; HAN S, 1989, J AM CHEM SOC, V111, P3496, DOI 10.1021/ja00192a002; HAN S, 1989, J AM CHEM SOC, V111, P3505, DOI 10.1021/ja00192a003; IMAI T, 1995, FEBS LETT, V368, P23, DOI 10.1016/0014-5793(95)00601-5; IWASAKI T, 1995, J BACTERIOL, V177, P2576, DOI 10.1128/jb.177.9.2576-2582.1995; Iwasaki T, 1995, J BIOL CHEM, V270, P30893, DOI 10.1074/jbc.270.52.30893; Iwasaki T, 1995, J BIOL CHEM, V270, P30881, DOI 10.1074/jbc.270.52.30881; IWASAKI T, 1994, J BIOL CHEM, V269, P29444; IWASAKI T, 1995, J BIOL CHEM, V270, P17878, DOI 10.1074/jbc.270.30.17878; Iwasaki T, 1995, J BIOL CHEM, V270, P30902, DOI 10.1074/jbc.270.52.30902; KNAFF DB, 1976, BIOCHIM BIOPHYS ACTA, V430, P244, DOI 10.1016/0005-2728(76)90082-7; KONISHI J, 1987, J BIOCHEM, V102, P1379, DOI 10.1093/oxfordjournals.jbchem.a122184; KUILA D, 1987, J AM CHEM SOC, V109, P1559, DOI 10.1021/ja00239a041; KUILA D, 1992, BIOCHIM BIOPHYS ACTA, V1140, P175, DOI 10.1016/0005-2728(92)90007-O; KUILA D, 1986, J BIOL CHEM, V261, P2768; LIEBL U, 1992, J BIOL CHEM, V267, P14068; LINK TA, 1992, EUR J BIOCHEM, V208, P685, DOI 10.1111/j.1432-1033.1992.tb17235.x; LUBBEN M, 1994, EUR J BIOCHEM, V224, P151, DOI 10.1111/j.1432-1033.1994.tb20006.x; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; MEYER J, 1992, ADV INORG CHEM, V38, P73, DOI 10.1016/S0898-8838(08)60062-8; MEYER J, 1986, BIOCHIM BIOPHYS ACTA, V873, P108, DOI 10.1016/0167-4838(86)90196-2; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; PRINCE RC, 1976, FEBS LETT, V65, P117, DOI 10.1016/0014-5793(76)80634-5; SCHMIDT CL, 1995, FEBS LETT, V359, P239, DOI 10.1016/0014-5793(94)00052-W; SPIRO TG, 1995, METHODS ENZYMOL, V246, P416; STEPHENS PJ, 1978, BIOCHEMISTRY-US, V17, P4770, DOI 10.1021/bi00615a026; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; TRUMPOWER BL, 1981, BIOCHIM BIOPHYS ACTA, V639, P129, DOI 10.1016/0304-4173(81)90008-2; WAKAGI T, 1986, SYST APPL MICROBIOL, V7, P342; WAKAO H, 1987, J BIOCHEM, V102, P255, DOI 10.1093/oxfordjournals.jbchem.a122049; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; Zhang Q, 1996, J BIOCHEM-TOKYO, V120, P587	43	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27659	27663		10.1074/jbc.271.44.27659	http://dx.doi.org/10.1074/jbc.271.44.27659			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910356	hybrid			2022-12-25	WOS:A1996VQ67900074
J	Johanning, K; Mathis, JP; Lindberg, I				Johanning, K; Mathis, JP; Lindberg, I			Processing site blockade results in more efficient conversion of proenkephalin to active opioid peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SPINAL-CORD; MESSENGER-RNA; ATT-20 CELLS; PROHORMONE CONVERTASE-1; DIRECTED MUTAGENESIS; CHROMAFFIN CELLS; BETA-ENDORPHIN; CLEAVAGE; PROOPIOMELANOCORTIN; BIOSYNTHESIS	Prohormones are known to be processed at various cleavage sites in a defined temporal order, suggesting the possibility of sequential unfolding of processing sites. In order to investigate whether sequential processing at predefined sites is in fact required for proper processing, site-directed mutagenesis was performed to block known initial cleavage sites within proenkephalin. Pulse-chase/immunoprecipitation experiments were employed to analyze the fate of mutant and native proenkephalins in stably transfected AtT-20 cells. While processing did not occur at blockaded sites, surprisingly, overall processing of mutant proenkephalins proceeded efficiently, and alternative sites were chosen. When compared with native proenkephalin, processing of mutant proenkephalins occurred more slowly at early stages and more quickly at later stages. Experiments employing endoglycosidase H indicated that the early slow processing of mutant proenkephalins may be due to delays in intracellular transport. Metabolic labeling studies showed that more efficient production of bioactive opioids occurred in all processing site blockade mutants examined; these results were confirmed using several different radioimmunoassays of stored peptide products. We conclude that efficient processing of prohormone precursors does not require a specific temporal order of processing events. The fact that mutant proenkephalins were more fully processed than native proenkephalin may provide a route for more efficient production of opioid peptides in applications for chronic pain treatment.	LOUISIANA STATE UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,NEW ORLEANS,LA 70112	Louisiana State University System			Lindberg, Iris/Q-3825-2019		NATIONAL INSTITUTE ON DRUG ABUSE [R56DA005084, R01DA005084] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA005084, R56 DA005084] Funding Source: Medline; PHS HHS [5084] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BRAKCH N, 1993, BIOCHEMISTRY-US, V32, P4925, DOI 10.1021/bi00069a029; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; DAY NC, 1993, NEUROPEPTIDES, V24, P253, DOI 10.1016/0143-4179(93)90013-Z; DICKERSON IM, 1990, J BIOL CHEM, V265, P2462; DOCHERTY K, 1989, J BIOL CHEM, V264, P18335; DUGUAY SJ, 1995, J BIOL CHEM, V270, P17566, DOI 10.1074/jbc.270.29.17566; GILES N, 1991, MOL ENDOCRINOL, V5, P404; GIRAUD P, 1981, NEUROPEPTIDES, V1, P237, DOI 10.1016/0143-4179(81)90002-0; HAMA AT, 1994, BRAIN RES, V651, P183, DOI 10.1016/0006-8993(94)90696-3; Johanning K, 1996, J NEUROCHEM, V66, P898; JUNG LJ, 1993, J CELL BIOL, V121, P11, DOI 10.1083/jcb.121.1.11; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LINDBERG I, 1984, BRAIN RES, V299, P73, DOI 10.1016/0006-8993(84)90789-3; LINDBERG I, 1991, ENDOCRINOLOGY, V128, P1849, DOI 10.1210/endo-128-4-1849; LINDBERG I, 1994, MOL CELL NEUROSCI, V5, P263, DOI 10.1006/mcne.1994.1030; LINDBERG I, 1986, J BIOL CHEM, V261, P6317; Lindberg I., 1995, METH NEUROSCI, V23, P94; MAINS RE, 1990, FRONT NEUROENDOCRIN, V11, P52; MATHIS JP, 1992, ENDOCRINOLOGY, V131, P2287, DOI 10.1210/en.131.5.2287; MILGRAM SL, 1994, J CELL SCI, V107, P737; MOCCHETI I, 1994, EUR J PHARMACOL, V106, P427; RHODES CJ, 1992, J BIOL CHEM, V267, P22719; ROSTOVTSEV AP, 1994, MOL CELL ENDOCRINOL, V101, P267; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P1; SAGEN J, 1986, P NATL ACAD SCI USA, V83, P7522, DOI 10.1073/pnas.83.19.7522; SAGEN J, 1986, BRAIN RES, V384, P189, DOI 10.1016/0006-8993(86)91238-2; SAITOH Y, 1995, CELL TRANSPLANT, V4, pS13, DOI 10.1016/0963-6897(94)00072-R; Sambrook J., 2002, MOL CLONING LAB MANU; SCHILLER MR, 1995, BIOCHEMISTRY-US, V34, P7988, DOI 10.1021/bi00025a004; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; STOLLER TJ, 1989, J BIOL CHEM, V264, P6922; TAKAHASHI KI, 1995, PEPTIDES, V16, P93; THORNE BA, 1989, J BIOL CHEM, V264, P3545; UDENFRIEND S, 1983, ARCH BIOCHEM BIOPHYS, V221, P309, DOI 10.1016/0003-9861(83)90149-2; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; Wilson S. P., 1995, Society for Neuroscience Abstracts, V21, P1847; WILSON SP, 1991, J NEUROCHEM, V57, P876, DOI 10.1111/j.1471-4159.1991.tb08232.x; WU HH, 1994, J NEUROSCI, V14, P4806; YOSHIKAWA K, 1984, J BIOL CHEM, V259, P4301; ZHOU A, 1994, J BIOL CHEM, V269, P17440; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHOU Y, 1994, J BIOL CHEM, V269, P18408	45	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27871	27878		10.1074/jbc.271.44.27871	http://dx.doi.org/10.1074/jbc.271.44.27871			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910386	hybrid			2022-12-25	WOS:A1996VQ67900104
J	Lee, DH; Goldberg, AL				Lee, DH; Goldberg, AL			Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOLYTIC PATHWAY; UBIQUITIN; YEAST; LACTACYSTIN; CELLS; CFTR	We have studied whether various agents that inhibit purified yeast and mammalian 26 S proteasome can suppress the breakdown of different classes of proteins in Saccharomyces cerevisiae. The degradation of short-lived proteins was inhibited reversibly by peptide aldehyde inhibitors of proteasomes, carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132) and carbobenzoxyl-leucinyl-leucinyl-norvalinal (MG115), in a yeast mutant with enhanced permeability, but not irt wild-type strains, Lactacystin, an irreversible proteasome inhibitor, had no effect, but the beta-lactone derivative of lactacystin, which directly reacts with proteasomes, inhibited the degradation of short-lived proteins, These inhibitors also blocked the rapid ubiquitin-dependent breakdown of a beta-galactosidase fusion protein and caused accumulation of enzymatically active molecules in cells, The degradation of the bulk of cell proteins, which are long-lived molecules, was not blocked by proteasome inhibitors, but could be blocked by phenylmethylsulfonyl fluoride, This agent, which inhibits multiple vacuolar proteases, did not affect the proteasome or breakdown of short-lived proteins, These two classes of inhibitors can thus be. used to distinguish the cytosolic and vacuolar proteolytic pathways and to increase the cellular content of short-lived proteins.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School								AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DESHAIES RJ, 1995, TRENDS CELL BIOL, V5, P428, DOI 10.1016/S0962-8924(00)89102-3; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; DICE JF, 1994, BIOL HEAT SHOCK PROT, P137; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GOLDBERG AL, 1995, CHEM BIOL, V2, P503, DOI 10.1016/1074-5521(95)90182-5; GRAHAM TR, 1993, EMBO J, V12, P869, DOI 10.1002/j.1460-2075.1993.tb05727.x; GRONOSTAJSKI RM, 1985, J BIOL CHEM, V260, P3344; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JONES EW, 1991, METHOD ENZYMOL, V194, P428; Lee DH, 1996, MOL CELL BIOL, V16, P4773; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; OMURA S, 1991, J ANTIBIOT, V44, P117, DOI 10.7164/antibiotics.44.117; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Tawa Nicholas T. Jr., 1995, Surgical Forum, V46, P12; VANDERREST ME, 1995, MICROBIOL REV, V59, P304, DOI 10.1128/MMBR.59.2.304-322.1995; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6	33	340	348	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27280	27284		10.1074/jbc.271.44.27280	http://dx.doi.org/10.1074/jbc.271.44.27280			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910302	hybrid			2022-12-25	WOS:A1996VQ67900020
J	Retzler, C; Gohring, W; Rauch, U				Retzler, C; Gohring, W; Rauch, U			Analysis of neurocan structures interacting with the neural cell adhesion molecule N-CAM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; PROTEIN-TYROSINE-PHOSPHATASE; BRAIN; RECEPTOR; SELECTIN; CLONING; BINDING; LIGAND	Neurocan is a brain-specific chondroitin sulfate proteoglycan, which has been shown to bind to the neural cell adhesion molecule N-CAM and to inhibit its homophilic interaction, To study in more detail the structures of neurocan responsible for this interaction, various recombinant neurocan fragments were generated, The ability of these fragments to interact with N-CAM was investigated in several different in vitro assay systems, enzyme-linked immunosorbent assay-type binding assays, Covasphere-aggregation assays, and assays based on an optical biosensor (BIA-core(TM)) system, The analysis of the hamophilic N-CAM interaction in the BLAcore system revealed a K-D of 64 nM. This homophilic interaction could be reduced by preincubation of soluble N-CAM with neurocan. Direct binding of N-CAM to immobilized neurocan care protein and recombinant neurocan fragments could also be demonstrated, and K-D values behveen 25 and 100 nM were obtained. in addition, direct binding of N-CAM to chondroitin sulfate could be demonstrated Binding of N-CAM to the immobilized neurocan core protein could be inhibited with all recombinant fragments containing chondroitin sulfate or major parts of the mucin-like central region of neurocan. For the inhibition of homophilic N-CAM interactions, however, a combination of globular and extended structures was required.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Max Planck Society								BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; COLE GJ, 1986, NATURE, V320, P445, DOI 10.1038/320445a0; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; HOFFMAN S, 1982, J BIOL CHEM, V257, P7720; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; JONSSON U, 1991, BIOTECHNIQUES, V11, P520; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; RAO Y, 1993, J BIOL CHEM, V268, P20630; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Retzler C, 1996, J BIOL CHEM, V271, P17107, DOI 10.1074/jbc.271.29.17107; RUTISHAUSER U, 1985, J CELL BIOL, V101, P1842, DOI 10.1083/jcb.101.5.1842; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Storms SD, 1996, EXP CELL RES, V223, P385, DOI 10.1006/excr.1996.0093; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354	21	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27304	27310		10.1074/jbc.271.44.27304	http://dx.doi.org/10.1074/jbc.271.44.27304			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910306	hybrid			2022-12-25	WOS:A1996VQ67900024
J	Belden, WJ; Barlowe, C				Belden, WJ; Barlowe, C			Erv25p, a component of COPII-coated vesicles, forms a complex with Emp24p that is required for efficient endoplasmic reticulum to Golgi transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SECRETORY PATHWAY; SACCHAROMYCES-CEREVISIAE; CARBOXYPEPTIDASE-Y; PROTEIN-TRANSPORT; MEMBRANE-PROTEIN; PLASMA-MEMBRANE; SHUTTLE VECTORS; SEC PROTEINS; HOST STRAINS; GENE	COPII-coated endoplasmic reticulum (ER)-derived transport vesicles contain a distinct set of membrane-bound polypeptides. We have obtained the NH2-terminal amino acid sequence of polypeptide constituents found on purified vesicles and in this report investigate the 24- and 25-kDa species. The 24-kDa protein is identical to Emp24p, a type I transmembrane protein that is required for transport of a subset of secretory proteins from the ER to the Golgi complex (Schimmoller, F., Singer-Kruger, B., Schroder, S., Kruger, U., Barlowe, C., and Riezman, H. (1995) EMBO J, 14, 1329-1339). The 25-kDa protein, termed Erv25p (ER vesicle protein of 25 kDa), corresponds to an open reading frame found on chromosome XIII of Saccharomyces cerevisiae, Erv25p shares overall sequence identity with Emp24p, but the two proteins are not functionally interchangeable. Antibodies directed against Erv25p reveal that Emp24p and Erv25p depend on each other for stability and form a protein complex that can be isolated after chemical cross-linking. Yeast strains lacking Erv25p (erv25 Delta) are viable and display the same selective defect in transport of secretory proteins from the ER to Golgi complex as an emp24 Delta strain. A cell-free assay that measures vesicle formation from ER membranes demonstrates that Erv25p and Emp24p are incorporated equally into ER-derived vesicles when COPII-coated budding is reconstituted. Vesicle formation from an erv25 Delta strain, an emp24 Delta strain and a double erv25 Delta emp24 Delta strain proceed at wild-type levels; however, incorporation of the Erv25p or the Emp24p protein into COPII-coated vesicles requires expression of both subunits, A potential model for transport of the Erv25p-Emp24p complex between the ER and Golgi compartments is discussed.	DARTMOUTH COLL, SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA	Dartmouth College					NIGMS NIH HHS [GM52549] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM052549, R01GM052549] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARRELL BG, 1995, Z49810; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; FRANKHAUSER C, 1991, EUR J BIOCHEM, V195, P439; HARLOW E, 1988, ANTIBODIES LABORATOR, P312; HOLTHUIS JCM, 1995, BIOCHEM J, V312, P205, DOI 10.1042/bj3120205; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; PARLATI F, 1995, J BIOL CHEM, V270, P244, DOI 10.1074/jbc.270.1.244; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; QUINN P, 1984, J CELL BIOL, V98, P2142, DOI 10.1083/jcb.98.6.2142; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SALAMA NR, 1995, CURR OPIN CELL BIOL, V7, P536, DOI 10.1016/0955-0674(95)80011-5; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGERKRUGER B, 1993, J BIOL CHEM, V268, P14376; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; STERLING CJ, 1992, MOL BIOL CELL, V3, P129; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WADA I, 1991, J BIOL CHEM, V266, P19599; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469; Yeung T, 1995, J BIOL CHEM, V270, P30567, DOI 10.1074/jbc.270.51.30567	50	170	173	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26939	26946		10.1074/jbc.271.43.26939	http://dx.doi.org/10.1074/jbc.271.43.26939			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900179	hybrid			2022-12-25	WOS:A1996VP23300073
J	Beltman, J; McCormick, F; Cook, SJ				Beltman, J; McCormick, F; Cook, SJ			The selective protein kinase C inhibitor, Ro-31-8220, inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) expression, induces c-Jun expression, and activates Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; CELL-LINE; GROWTH-FACTORS; PHOSPHORYLATION; SPECIFICITY; DOMAIN; FOS; IDENTIFICATION; FIBROBLASTS; INDUCTION	The role of protein kinase C (PKC) in inflammation, mitogenesis, and differentiation has been deduced in part through the use of a variety of PKC inhibitors. Two widely used inhibitors are the structurally related compounds GF109203X and Ro-31-8220, both of which potently inhibit PKC activity and are believed to be highly selective. While using GF109203X and Ro-31-8220 to address the role of PKC in immediate early gene expression, we observed striking differential effects by each of these two compounds. Growth factors induce the expression of the immediate early gene products MAP kinase phosphatase-1 (MKP-1), c-Fos and c-Jun. Ro-31-8220 inhibits growth factor-stimulated expression of MKP-1 and c-Fos but strongly stimulated c-Jun expression, even in the absence of growth factors, GF109203X displays none of these properties. These data suggest that Ro-31-8220 may have other pharmacological actions in addition to PKC inhibition, Indeed, Ro-31-8220 strongly stimulates the stress-activated protein kinase, JNK1. Furthermore, Ro-31-8220 apparently activates JNK in a PKC-independent manner. Neither the down-regulation of PKC by phorbol esters nor the inhibition of PKC by GF109203X affected the ability of Ro-31-8220 to activate JNK1, These data suggest that, in addition to potently inhibiting PKC, Ro-31-8220 exhibits novel pharmacological properties which are independent of its ability to inhibit PKC.			Beltman, J (corresponding author), ONYX PHARMACEUT,3031 RES DR,RICHMOND,CA 94806, USA.				NIGMS NIH HHS [GM16575] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BRADSHAW D, 1993, AGENTS ACTIONS, V38, P135, DOI 10.1007/BF02027225; BUDWORTH J, 1995, FEBS LETT, V362, P139, DOI 10.1016/0014-5793(95)00227-Z; BUHL AM, 1995, J BIOL CHEM, V270, P19828, DOI 10.1074/jbc.270.34.19828; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CHARLES CH, 1992, ONCOGENE, V7, P187; Chen RH, 1996, ONCOGENE, V12, P1493; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COOK SJ, 1991, BIOCHEM J, V280, P431, DOI 10.1042/bj2800431; COOK SJ, 1996, IN PRESS BIOCH J; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; JOHNSON MS, 1993, FEBS LETT, V333, P67, DOI 10.1016/0014-5793(93)80376-6; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MCLEES A, 1995, BIOCHEM J, V307, P743, DOI 10.1042/bj3070743; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MUKAI H, 1995, BBA-GENE STRUCT EXPR, V1261, P296, DOI 10.1016/0167-4781(95)00030-K; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NIXON JS, 1992, BIOCHEM SOC T, V20, P419, DOI 10.1042/bst0200419; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; SAMPSON LE, 1993, BIOCHEM J, V292, P289, DOI 10.1042/bj2920289; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Shapiro PS, 1996, J BIOL CHEM, V271, P5750, DOI 10.1074/jbc.271.10.5750; STANWELL C, 1994, INT J CANCER, V56, P585; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335	43	166	170	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27018	27024		10.1074/jbc.271.43.27018	http://dx.doi.org/10.1074/jbc.271.43.27018			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900190	hybrid			2022-12-25	WOS:A1996VP23300084
J	Doerrler, WT; Ye, JH; Falck, JR; Lehrman, MA				Doerrler, WT; Ye, JH; Falck, JR; Lehrman, MA			Acylation of glucosaminyl phosphatidylinositol revisited - Palmitoyl-CoA dependent palmitoylation of the inositol residue of a synthetic dioctanoyl glucosaminyl phosphatidylinositol by hamster membranes permits efficient mannosylation of the glucosamine residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEINS; TRYPANOSOMA-BRUCEI; GLYCOSYL-PHOSPHATIDYLINOSITOL; MAMMALIAN-CELLS; COENZYME-A; BIOSYNTHESIS; GLYCOSYLPHOSPHATIDYLINOSITOL; ANCHOR; PURIFICATION; GLYCOLIPIDS	Two critical steps in the assembly of yeast and mammalian glycosylphosphatidylinositol (GPI) anchor precursors are palmitoylation of the inositol residue and mannosylation of the glucosamine residue of the glucosaminyl phosphatidylinositol (GlcN alpha-PI) intermediate. Palmitoylation has been reported to be acyl-CoA dependent in yeast membranes (Costello, L. C., and Orlean, P. (1992) J. Biol. Chem. 267, 8599-8603) but strictly acyl-CoA independent in rodent membranes (Stevens, V. L., and Zhang, H. (1994) J. Biol. Chem. 269, 31397-31403), and thus poorly conserved. In addition, it was suggested that acylation must precede mannosylation in both yeast (Costello, L. C., and Orlean, P. (1992) J. Biol. Chem. 276, 8599-8603) and rodent (Urakaze, M., Kamitani, T., DeGasperi, R., Sugiyama, E., Chang, H.-M., Warren, C. D., and Yeh, E. T. H. (1992) J. Biol. Chem. 267, 6459-6462) cells because GlcN alpha-acyl-PI accumulates in vivo when mannosylation is blocked. However, GlcN alpha-acyl-PI accumulation would also be expected if mannosylation and acylation were independent of each other. These issues were addressed by the use of a synthetic dioctanoyl GlcN alpha-PI analogue (GlcN alpha-PI(C8)) as an in vitro substrate for GPI-synthesizing enzymes in Chinese hamster ovary cell membranes. GlcN alpha-PI(C8) was acylated in an manner requiring acyl-CoA. Thus, the process involving acyl-CoA reported for yeast has been conserved in mammals. Furthermore, both GlcN alpha-PI(C8) and GlcN alpha-acyl-PI(C8) could be mannosylated in vitro, but mannosylation of the latter was significantly more efficient. This provides direct support for the earlier suggestion that acylation precedes mannosylation in rodents cells. A similar result was also observed with the Saccharomyces cerevisiae mannosyltransferase. In contrast, it has been reported that mannosylation of endogenous GlcN alpha-PI by Trypansoma brucei membranes occurs without prior acylation. The same result was obtained with GlcN alpha-PI(C8), confirming that the mannosyltransferase of trypanosomes is divergent from those in yeasts and rodents.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT CELL REGULAT GRAD PROGRAM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Falck, John/0000-0002-9219-7845	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278, R01GM038545, R56GM038545] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38545, GM31278] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMAN RA, 1985, J BIOL CHEM, V260, P6966; BREWIS IA, 1995, J BIOL CHEM, V270, P22946, DOI 10.1074/jbc.270.39.22946; CAMP LA, 1993, J BIOL CHEM, V268, P6721; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; DAVITZ MA, 1989, J BIOL CHEM, V264, P13760; DELUCA AW, 1994, GLYCOBIOLOGY, V4, P909, DOI 10.1093/glycob/4.6.909; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1993, LIPID MODIFICATIONS, P191; FIELD MC, 1991, EMBO J, V10, P2731, DOI 10.1002/j.1460-2075.1991.tb07821.x; GARIGAPATI VR, 1993, TETRAHEDRON LETT, V34, P769, DOI 10.1016/0040-4039(93)89007-D; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; GUTHER MLS, 1995, EMBO J, V14, P3080, DOI 10.1002/j.1460-2075.1995.tb07311.x; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; KAMITANI T, 1992, J BIOL CHEM, V267, P24611; LEHRMAN MA, 1988, J BIOL CHEM, V263, P19796; LEMANSKY P, 1991, MOL CELL BIOL, V11, P3879, DOI 10.1128/MCB.11.8.3879; LIU YC, 1989, TETRAHEDRON LETT, V30, P1617, DOI 10.1016/S0040-4039(00)99535-2; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1991, CELL BIOL INT REP, V15, P1007; PENKETH PG, 1991, J PROTOZOOL, V38, P172, DOI 10.1111/j.1550-7408.1991.tb04425.x; PHILLIPS MA, 1988, J BIOL CHEM, V263, P17933; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; Smith TK, 1996, J BIOL CHEM, V271, P6476, DOI 10.1074/jbc.271.11.6476; STEVENS VL, 1994, J BIOL CHEM, V269, P31397; TAYLOR DC, 1990, ANAL BIOCHEM, V184, P311, DOI 10.1016/0003-2697(90)90686-4; URAKAZE M, 1992, J BIOL CHEM, V267, P6459; Ye JH, 1996, BIOORG MED CHEM LETT, V6, P1715	30	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27031	27038		10.1074/jbc.271.43.27031	http://dx.doi.org/10.1074/jbc.271.43.27031			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900192				2022-12-25	WOS:A1996VP23300086
J	Fuller, CM; Ismailov, II; Berdiev, BK; Shlyonsky, VG; Benos, DJ				Fuller, CM; Ismailov, II; Berdiev, BK; Shlyonsky, VG; Benos, DJ			Kinetic interconversion of rat and bovine homologs of the alpha subunit of an amiloride-sensitive Na+ channel by C-terminal truncation of the bovine subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; MOLECULAR-CLONING; EXPRESSION; PROTEINS	We have recently cloned the a subunit of a bovine amiloride-sensitive Na+ channel (alpha bENaC). This subunit shares extensive homology with both rat and human alpha ENaC subunits but shows marked divergence at the C terminus beginning at amino acid 584 of the 697-residue sequence, When incorporated into planar lipid bilayers, alpha bENaC almost exclusively exhibits a main transition to 39 picosiemens (pS) with very rare 13 pS step transitions to one of two subconductance states (26 and 13 pS), In contrast, the alpha subunit of the rat renal homolog of ENaC (alpha rENaC) has a main transition step to 13 pS that is almost constituitively open, with a second stepwise transition of 26 to 39 pS, A deletion mutant of alpha bENaC, encompassing the entire C-terminal region (R567X), converts the kinetic behavior of alpha bENaC to that of alpha rENaC, i.e. a transition to 13 pS followed by a second 26 pS transition to 39 pS, Chemical cross-linking of R567X restores the wild-type alpha bENaC gating pattern, whereas treatment with the reducing agent dithiothreitol produced only 13 pS transitions, In contrast, an equivalent C-terminal truncation of alpha rENaC (R613X) had no effect on the gating pattern of alpha rENaC. These results are consistent with the hypothesis that interactions between the C termini of alpha bENaC account for the different kinetic behavior of this member of the ENaC family of Na+ channels.			Fuller, CM (corresponding author), UNIV ALABAMA, DEPT PHYSIOL & BIOPHYS, BHSB 735, UNIV STN, BIRMINGHAM, AL 35294 USA.		Fuller, Cathy/B-4046-2011	Shlyonsky, Vadim/0000-0003-2999-6553	NIDDK NIH HHS [DK37206] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037206, R56DK037206] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AWAYDA MS, 1995, AM J PHYSIOL-CELL PH, V268, pC1450, DOI 10.1152/ajpcell.1995.268.6.C1450; BRADFORD AL, 1995, AM J PHYSIOL-CELL PH, V269, pC601, DOI 10.1152/ajpcell.1995.269.3.C601; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Cunningham SA, 1995, J BIOL CHEM, V270, P31016, DOI 10.1074/jbc.270.52.31016; FULLER CM, 1995, AM J PHYSIOL-CELL PH, V269, pC641, DOI 10.1152/ajpcell.1995.269.3.C641; Ismailov II, 1996, J BIOL CHEM, V271, P807, DOI 10.1074/jbc.271.2.807; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI XJ, 1995, MOL PHARMACOL, V47, P1133; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; PEREZ G, 1994, BIOPHYS J, V66, P1022, DOI 10.1016/S0006-3495(94)80883-5; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; PUOTI A, 1995, AM J PHYSIOL-CELL PH, V269, pC188, DOI 10.1152/ajpcell.1995.269.1.C188; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411	18	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26602	26608		10.1074/jbc.271.43.26602	http://dx.doi.org/10.1074/jbc.271.43.26602			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900133	hybrid			2022-12-25	WOS:A1996VP23300027
J	Mu, J; Cheng, C; Roach, PJ				Mu, J; Cheng, C; Roach, PJ			Initiation of glycogen synthesis in yeast - Requirement of multiple tyrosine residues for function of the self-glucosylating Glg proteins in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-D-MALTOSIDE; SACCHAROMYCES-CEREVISIAE; BRANCHING ENZYME; XYLOSYL TRANSFER; BIOGENESIS; SYNTHASE; ACCUMULATION; MECHANISM; MUSCLE	The self-glucosylating proteins, G1g1p and G1g2p, are required for glycogen synthesis in Saccharomyces cerevisiae (Cheng, C., Mu., J., Farkas, I., Huang., If,, Goebl M. G., and Roach, P. J. (1995) Mol. Cell. Biol. 15, 6632-6640). G1g2p was shown to be associated with carbohydrate in vivo and was released from the high molecular weight glycogen fraction by treatment with alpha-amylase. In addition, some G1g2p exists as a protein of M(r) similar to 43,000, whose proportion is increased in cells lacking glycogen synthase, Unlike the. mammalian counterpart, glycogenin, the yeast GIg proteins appear to require multiple Tyr residues for functionality. In G1g2p, mutation of both Tyr(230) and Tyr(232) is necessary to suppress self-glucosylation of purified protein in vitro. The mutant protein is still capable of transferring glucose to an exogeneous acceptor, rt-dodecyl beta-D-maltoside. A small COOH-terminal region, conserved between G1g1p and G1g2p, is also important for function; mutation of Tyr(367) Or truncation at:residue 362 impairs the ability of primed G1g2p to be elongated by glycogen synthase. Complete suppression of glycogen accumulation in vivo requires mutation of all three Tyr residues. In G1g1p, two Tyr residues are implicated, Tyr(232), and Tyr(600), mutation of both being required to eliminate glycogen accumulation in vivo.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis				Mu, James/0000-0001-8081-2401	NIDDK NIH HHS [DK42576] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042576] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALONSO MD, 1994, FEBS LETT, V342, P38, DOI 10.1016/0014-5793(94)80580-6; ALONSO MD, 1995, FEBS LETT, V359, P110, DOI 10.1016/0014-5793(95)00018-5; ALONSO MD, 1995, FASEB J, V9, P1126, DOI 10.1096/fasebj.9.12.7672505; ALONSO MD, 1995, J BIOL CHEM, V270, P15315, DOI 10.1074/jbc.270.25.15315; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO YJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P293, DOI 10.1006/abbi.1995.1295; CAO YJ, 1993, J BIOL CHEM, V268, P14687; CHENG C, 1995, MOL CELL BIOL, V15, P6632; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; EIBLE R, 1992, BIOTECHNIQUES, V13, P18; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FARKAS I, 1990, J BIOL CHEM, V265, P20879; Gu J, 1994, BIOTECHNIQUES, V17, P260; HARDY TA, 1994, J BIOL CHEM, V269, P27907; HARDY TA, 1993, J BIOL CHEM, V268, P23799; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; MANZELLA S, 1995, ARCH BIOCHEM BIOPHYS, V320, P361, DOI 10.1016/0003-9861(95)90020-9; MANZELLA SM, 1995, GLYCOBIOLOGY, V5, P263, DOI 10.1093/glycob/5.2.263; MANZELLA SM, 1994, ANAL BIOCHEM, V216, P383, DOI 10.1006/abio.1994.1056; PITCHER J, 1988, EUR J BIOCHEM, V176, P391, DOI 10.1111/j.1432-1033.1988.tb14294.x; RODRIGUEZ IR, 1988, ARCH BIOCHEM BIOPHYS, V260, P628, DOI 10.1016/0003-9861(88)90491-2; Rose MD., 1990, METHODS YEAST GENETI; ROWEN DW, 1992, MOL CELL BIOL, V12, P22, DOI 10.1128/MCB.12.1.22; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMYTHE C, 1991, EUR J BIOCHEM, V200, P625, DOI 10.1111/j.1432-1033.1991.tb16225.x; SMYTHE C, 1988, EMBO J, V7, P2681, DOI 10.1002/j.1460-2075.1988.tb03121.x; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; THON VJ, 1992, J BIOL CHEM, V267, P15224	30	22	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26554	26560		10.1074/jbc.271.43.26554	http://dx.doi.org/10.1074/jbc.271.43.26554			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900126	hybrid			2022-12-25	WOS:A1996VP23300020
J	Takahashi, M; Ilan, Y; Chowdhury, NR; Guida, J; Horwitz, M; Chowdhury, JR				Takahashi, M; Ilan, Y; Chowdhury, NR; Guida, J; Horwitz, M; Chowdhury, JR			Long term correction of bilirubin-UDP-glucuronosyltransferase deficiency in Gunn rats by administration of a recombinant adenovirus during the neonatal period	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II ALLOANTIGENS; GENE-TRANSFER; CELLULAR MECHANISMS; INDUCED TOLERANCE; T-CELLS; EXPRESSION; INDUCTION; COMPLEX; VECTORS; INVIVO	Injection of a recombinant adenovirus expressing human bilirubin-UGT(1) (Ad-hBUGT(1)) (3 x 10(9) plaque-forming units (pfu) intravenously) in adult bilirubin-UDP-glucuronosyltransferase-1 (BUGT(1))-deficient Gunn rats resulted in biliary excretion of bilirubin glucuronides and a 70% reduction of serum bilirubin levels. However, the effect was transient, and. host humoral and cellular immune response prevented transgene expression after subsequent injections. To determine whether injection during the neonatal period would tolerize the host to the recombinant virus, we injected 1 x 10(8) pfu of Ad-hBUGT(1) or Ad-LacZ (a recombinant adenovirus expressing Escherichia coli beta-galactosidase) into 1-3-day-old Gunn rats, Two subsequent injections (3 x 10(9) pfu) were given 56 and 112 days after the initial injection, Injection of Ad-BUGT(1), but not Ad-LacZ, reduced serum bilirubin by 70-76% of the levels in untreated pups (9 +/- 1.3 mg/dl), followed by a gradual increase to 3.25 +/- 0.3 mg/dl in 56 days; similar or greater reductions occurred after the second and third injection. Serum neutralizing antibody titer and cytotoxic lymphocyte activity against adenovirus-infected hepatocytes were low or undetectable. Thus, tolerization by injection of the virus during the neonatal period permits long term gene therapy by repeated injection of the virus.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, MARION BESSIN LIVER RES CTR, DEPT MED & MOL GENET, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041296, R01DK046057, R01DK039137] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30-DK 41296, R01-DK 39137, R01-DK 46057] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BETT AJ, 1993, J VIROL, V67, P5911, DOI 10.1128/JVI.67.10.5911-5921.1993; BOSMA PJ, 1994, J BIOL CHEM, V269, P17960; CHOWDHURY J R, 1981, Hepatology, V1, P622; CHOWDHURY R, 1993, ANIMAL MODELS LIVER, P150; DAI YF, 1995, P NATL ACAD SCI USA, V92, P1401, DOI 10.1073/pnas.92.5.1401; ELAWADY M, 1990, J BIOL CHEM, V265, P10752; EMI Y, 1995, J BIOCHEM, V117, P392, DOI 10.1093/jb/117.2.392; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; HORWITZ MS, 1990, VIROLOGY, P01679; JAFFE HA, 1992, NAT GENET, V1, P372, DOI 10.1038/ng0892-372; Jansen P L, 1995, Prog Liver Dis, V13, P125; Jendrassik L, 1938, BIOCHEM Z, V297, P81; KASSEISLER A, 1994, GENE THER, V1, P395; MATRIANO JA, 1994, J IMMUNOL, V153, P1515; MATRIANO JA, 1994, J IMMUNOL, V153, P1505; MOHLER KM, 1989, TRANSPLANTATION, V47, P633, DOI 10.1097/00007890-198904000-00014; POWELL TJ, 1990, J IMMUNOL, V144, P854; POWELL TJ, 1991, TRANSPLANTATION, V52, P383; PREVEC L, 1989, J GEN VIROL, V70, P429, DOI 10.1099/0022-1317-70-2-429; Raper S E, 1995, Prog Liver Dis, V13, P201; RITTER JK, 1992, J BIOL CHEM, V267, P3257; SENGUPTA K, 1994, HEPATOLOGY, V13, pA320; TAKAHASHI M, 1995, HEPATOLOGY, V22, P453; WILSON JM, 1992, J BIOL CHEM, V267, P11483; WOOD PJ, 1987, J IMMUNOL, V138, P3661; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995	27	100	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26536	26542		10.1074/jbc.271.43.26536	http://dx.doi.org/10.1074/jbc.271.43.26536			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900123	hybrid			2022-12-25	WOS:A1996VP23300017
J	Zhang, X; Chen, ZQ; Wang, ZW; Mohan, W; Tam, SP				Zhang, X; Chen, ZQ; Wang, ZW; Mohan, W; Tam, SP			Protein-DNA interactions at a drug-responsive element of the human apolipoprotein A-I gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; HIGH-DENSITY LIPOPROTEIN; TRANSCRIPTION FACTOR AP-2; CHOLESTEROL-FED RATS; HEPATOMA-CELL LINES; PEROXISOME PROLIFERATORS; GEMFIBROZIL TREATMENT; CONTROL EXPRESSION; NUCLEAR RECEPTOR; TRANSGENIC MICE	Previously, we demonstrated that when two human hepatoma cell lines, Hep3B and HepG2, were exposed to gemfibrozil, a hypolipidemic drug, a 2-fold induction in apolipoprotein A-I (apoA-I) mRNA levels resulted, To determine if mRNA stabilization Nas responsible for the changes in apoA-I mRNA levels, the half-lives for apoA-I mRNA were measured in the presence of actinomycin D with and without gemfibrozil. These experiments revealed no differences in stability, However, nuclear runoff assays indicated that the transcription rate of the apoA-I gene was increased 2-fold in gemfibrozil-treated cells, Transient transfection experiments also indicated that the induction of apoA-I mRNA level in response to gemfibrozil is mediated at the transcriptional level, We have identified two copies of the ''drug-responsive element'' (DRE) in the apoA-I promoter region that may be responsible for the increase in apoA-I transcriptional activity by gemfibrozil, Using gel mobility shift assays with a synthetic DRE oligonucleotide, we have demonstrated that exposure of Hep3B and HepG2 cells to gem fibrozil resulted in strong induction of a protein-DNA complex, The formation of this complex is highly sequence-specific as indicated by the DNA competition experiments, The drug-inducible nuclear proteins bind to the DRE of the human apoA-I gene with an apparent K-d of 4.1 nM. Methylation interference experiments have localized the contact sites of nuclear factors to the DRE region, Southwestern blot analyses have identified two groups of drug-inducible nuclear proteins with molecular masses of approximately 30 and 15 kDa. When a copy of synthetic DRE oligonucleotide was inserted upstream of the thymidine kinase promoter and luciferase reporter construct, a significant 2-fold induction in luciferase activity was observed in the presence of gemfibrozil following transient transfection of two human hepatoma cell lines, HepG2 and Hep3B, However, a plasmid containing one copy of mutated apoA-I-DRE oligomer did not confer responsiveness to gemfibrozil treatment, Furthermore, pGL2 (apoA-I -250 mutant DRE), which carried an internal mutation of the DRE in the human apoA-I proximal promoter region, showed no increase in luciferase activity in response to gemfibrozil, These results implicate protein-DNA interactions at the DRE region in the transcriptional induction of human apoA-I gene expression by gemfibrozil.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA	Queens University - Canada			Zhang, Xia/B-8152-2008	Zhang, Xia/0000-0002-9040-1486				ALVARES K, 1994, CANCER RES, V54, P2303; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALFOUR JA, 1990, DRUGS, V40, P260, DOI 10.2165/00003495-199040020-00007; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BARTALENA L, 1992, MOL ENDOCRINOL, V6, P935, DOI 10.1210/me.6.6.935; BROWN WV, 1987, AM J MED, V84, P85; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CHEN D, 1994, J BIOL CHEM, V269, P5420; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; DELAIGLESIA FA, 1982, ATHEROSCLEROSIS, V43, P19, DOI 10.1016/0021-9150(82)90096-X; DENG TL, 1992, P NATL ACAD SCI USA, V89, P8572, DOI 10.1073/pnas.89.18.8572; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRICK MH, 1987, NEW ENGL J MED, V34, P74; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; Glomset J A, 1980, Adv Intern Med, V25, P91; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTO AM, 1986, METHOD ENZYMOL, V128, P3; GREEN S, 1992, BIOCHEM PHARMACOL, V43, P393, DOI 10.1016/0006-2952(92)90554-V; GRUNDY SM, 1987, AM J MED, V83, P9, DOI 10.1016/0002-9343(87)90866-7; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HAMSTEN A, 1986, ATHEROSCLEROSIS, V60, P199, DOI 10.1016/0021-9150(86)90166-8; HAPGOOD J, 1991, MOL CELL BIOL, V11, P4314, DOI 10.1128/MCB.11.9.4314; INNIS MA, 1990, PCR PROTOCOLS, P13; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; ISSEMANN I, 1993, BIOCHIMIE, V75, P251, DOI 10.1016/0300-9084(93)90084-6; KRAUSE BR, 1986, ATHEROSCLEROSIS, V59, P95, DOI 10.1016/0021-9150(86)90036-5; KRAUSE BR, 1986, ATHEROSCLEROSIS, V61, P245, DOI 10.1016/0021-9150(86)90145-0; KUUSI T, 1987, ARTERIOSCLEROSIS, V7, P421, DOI 10.1161/01.ATV.7.4.421; LARSEN ML, 1993, CURR OPIN LIPIDOL, V4, P34, DOI 10.1097/00041433-199302000-00007; LEIGHTON JK, 1984, J BIOL CHEM, V259, P1165; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; MOLL PP, 1989, AM J HUM GENET, V44, P124; MORRISON HG, 1993, BIOTECHNIQUES, V14, P454; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; ORTON TC, 1982, DRUG METAB DISPOS, V10, P110; PAGANI F, 1990, J LIPID RES, V31, P1371; PALMER CNA, 1994, J BIOL CHEM, V269, P18083; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; *PROM, 1991, GEN PLASM TECHN MAN, P1; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SAKU K, 1985, J CLIN INVEST, V75, P1702, DOI 10.1172/JCI111879; Sambrook J., 2002, MOL CLONING LAB MANU; SASTRY KN, 1988, MOL CELL BIOL, V8, P605, DOI 10.1128/MCB.8.2.605; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; SIGURDSSON G, 1992, ARTERIOSCLER THROMB, V12, P1017, DOI 10.1161/01.ATV.12.9.1017; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SIRTORI CR, 1988, PHARMACOL THERAPEUT, V37, P167, DOI 10.1016/0163-7258(88)90024-1; SMITH JD, 1992, J CLIN INVEST, V89, P1796, DOI 10.1172/JCI115783; SOGAWA K, 1986, P NATL ACAD SCI USA, V83, P8044, DOI 10.1073/pnas.83.21.8044; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; TAM SP, 1992, ALCOHOL CLIN EXP RES, V16, P1021, DOI 10.1111/j.1530-0277.1992.tb00693.x; TAM SP, 1991, ATHEROSCLEROSIS, V91, P51, DOI 10.1016/0021-9150(91)90186-7; TAM SP, 1994, ATHEROSCLEROSIS, V105, P235, DOI 10.1016/0021-9150(94)90054-X; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; VANDENBROUCK Y, 1995, EUR J BIOCHEM, V231, P126, DOI 10.1111/j.1432-1033.1995.tb20678.x; VUDAC N, 1994, J BIOL CHEM, V269, P31012; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541; ZHAO SP, 1994, AM J MED, V96, P49, DOI 10.1016/0002-9343(94)90115-5; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	75	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27152	27160		10.1074/jbc.271.43.27152	http://dx.doi.org/10.1074/jbc.271.43.27152			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900208	hybrid			2022-12-25	WOS:A1996VP23300102
J	Cheng, NC; Beitsma, M; Chan, A; denCamp, IO; Westerveld, A; Pronk, J; Versteeg, R				Cheng, NC; Beitsma, M; Chan, A; denCamp, IO; Westerveld, A; Pronk, J; Versteeg, R			Lack of class I HLA expression in neuroblastoma is associated with high N-myc expression and hypomethylation due to loss of the MEMO-1 locus	ONCOGENE			English	Article						class I HLA; MEMO-1; methylation; neuroblastoma; N-myc; tumour suppressor gene	BLASTOMA CELL-LINES; NEURO-BLASTOMA; ANTIGEN EXPRESSION; LEUKOCYTE ANTIGEN; DNA METHYLATION; C-MYC; GENE; AMPLIFICATION; TUMOR; SEQUENCE	Class I HLA expression is low in neuroblastoma tumours and cell lines. We have recently mapped a modifier of methylation for HLA-C (MEMO-1) to chromosomal bands 1p35-36.1, a region deleted in many neuroblastomas. Hypomethylation of HLA-C is strongly correlated with allelic loss of the MEMO-1 locus. Here, we show that loss of MEMO-1 is associated with hypomethylation of both the 5' and 3' regions of class I KLA loci. We next investigated the relationship between methylation and expression of class I HLA in 28 cell lines of neuroectodermal tumours. Cell lines with hypermethylated HLA-C and HLA-A loci have relatively high expression, while most cell lines with hypomethylated loci have no or a reduced expression. It was reported earlier that high expression of c- or N-myc can suppress class I HLA expression. Remarkably, also N-myc amplification in neuroblastomas is associated with allelic loss of 1p35-36. Therefore, we have analysed the relationships between allelic loss of the MEMO-1 locus, class I HLA methylation and expression, and N-myc amplification and expression. This study shows a tight inter-relationship between these phenomena. Our data suggest a model in which hypomethylation of class I HLA due to loss of the MEMO-1 locus and high N-myc expression could collaborate in the down-regulation of class I HLA expression.	UNIV AMSTERDAM,ACAD MED CTR,DEPT HUMAN GENET,NL-1100 DE AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam			Versteeg, Rogier/AAQ-1765-2020	Versteeg, Rogier/0000-0001-7172-0388				BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BRODEUR GM, 1981, CANCER RES, V41, P4678; CAMPBELL RD, 1993, IMMUNOL TODAY, V14, P349, DOI 10.1016/0167-5699(93)90234-C; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; CHENG NC, 1995, ONCOGENE, V10, P291; Cheng NC, 1996, HUM MOL GENET, V5, P309, DOI 10.1093/hmg/5.3.309; COOPER MJ, 1990, CANCER RES, V50, P3694; DAAR AS, 1984, TRANSPLANTATION, V38, P287, DOI 10.1097/00007890-198409000-00018; EMMOUR J, 1991, IMMUNOBIOLOGY, V187, P70; FAVROT MC, 1991, INT J CANCER, V48, P502, DOI 10.1002/ijc.2910480405; FELTNER DE, 1989, J IMMUNOL, V143, P4292; GILBERT F, 1984, CANCER RES, V44, P5444; GROSS N, 1994, INT J CANCER, V59, P141, DOI 10.1002/ijc.2910590124; GUSSOW D, 1987, IMMUNOGENETICS, V25, P313, DOI 10.1007/BF00404424; KOLLER BH, 1985, J IMMUNOL, V134, P2727; LAMPSON LA, 1983, J IMMUNOL, V130, P2471; NEEFJES JJ, 1986, HUM IMMUNOL, V16, P169, DOI 10.1016/0198-8859(86)90046-7; REIN RS, 1987, J IMMUNOL, V138, P1178; REYNOLDS CP, 1988, ADV NEUROBLASTOMA RE, V2, P291; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SODOYER R, 1984, EMBO J, V3, P879, DOI 10.1002/j.1460-2075.1984.tb01900.x; SUMMERS CW, 1993, EUR J IMMUNOGENET, V20, P201, DOI 10.1111/j.1744-313X.1993.tb00111.x; TANAKA K, 1986, P NATL ACAD SCI USA, V83, P7598, DOI 10.1073/pnas.83.20.7598; TANAKA K, 1983, CELL, V35, P457, DOI 10.1016/0092-8674(83)90179-4; VANTVEER LJ, 1993, EMBO J, V12, P195, DOI 10.1002/j.1460-2075.1993.tb05645.x; VERSTEEG R, 1988, EMBO J, V7, P1023, DOI 10.1002/j.1460-2075.1988.tb02909.x; VERSTEEG R, 1989, J EXP MED, V170, P621, DOI 10.1084/jem.170.3.621; VERSTEEG R, 1990, MOL CELL BIOL, V10, P5416, DOI 10.1128/MCB.10.10.5416	29	27	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1737	1744						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895520				2022-12-25	WOS:A1996VM88700019
J	Kimble, RB; Srivastava, S; Ross, FP; Matayoshi, A; Pacifici, R				Kimble, RB; Srivastava, S; Ross, FP; Matayoshi, A; Pacifici, R			Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1- and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MARROW CULTURES; RECEPTOR ANTAGONIST; GENE-EXPRESSION; UP-REGULATION; FACTOR-I; DIFFERENTIATION; PROLIFERATION; RESORPTION; PROMOTER; BINDING	To analyze how estrogen blocks osteoclastogenesis, we investigated the effects of ovariectomy on osteoclast (OC) formation in co-cultures of purified OC precursors and purified stromal cells (SC). OC formation was higher in co-cultures containing SC from ovariectomized mice than in those containing SC from sham-operated mice, thus suggesting that estrogen regulates osteoclastogenesis by targeting SC. Ovariectomy also increased the mononuclear cell secretion of interleukin (IL)-1) and tumor necrosis factor (TNF) and the SC production of macrophage colony-stimulating factor (M-CSF), Osteoclastogenesis and SC production of M-CSF were not blocked by in vitro estrogen treatment but were decreased by in viva treatment of donor mice with either estrogen or a combination of the IL-1 inhibitor, IL-1 receptor antagonist, and the TNF inhibitor, TNF binding protein. IL-1 and TNF production were also blocked by in vivo estrogen treatment, demonstrating that the increased bone marrow levels of IL-1 and TNF characteristic of ovariectomized mice induce the formation of a SC population characterized by a high production of M-CSF and increased pro-osteoclastogenic activity. Since in co-cultures of SC and OC precursors M-CSF levels correlated with OC production (r = 0.7, p < 0.0001), the data also indicate that the pro-osteoclastogenic activity of SC is proportional to their secretion of M-CSF. The ability of estrogen to decrease SC production of M-CSF and the pro-osteoclastogenic activity of these cells by regulating IL-1 and TNF production is a previously undescribed mechanism by which estrogen do cvn-regulates osteoclastogenesis.	BARNES JEWISH HOSP, DIV BONE & MINERAL DIS, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL)					NIAMS NIH HHS [AR 41412, AR 42404] Funding Source: Medline; NIA NIH HHS [AG 13534] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042404, R01AR041412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013534] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABBOUD SL, 1991, BLOOD, V78, P103; ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; BELLIDO T, 1993, ENDOCRINOLOGY, V133, P553, DOI 10.1210/en.133.2.553; BRAITMAN LE, 1983, ANN INTERN MED, V99, P269, DOI 10.7326/0003-4819-99-2-269; CHAPLIN DD, 1992, TUMOR NECROSIS FACTO, P197; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOHISY DR, 1987, J BIOL CHEM, V262, P15922; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; DEXTER TM, 1990, MOL CONTROL HAEMOPOI, P86; DINARELLO CA, 1991, BLOOD, V77, P1627; FALKENBURG JHF, 1991, BLOOD, V78, P658; FIORELLI G, 1995, P NATL ACAD SCI USA, V92, P2672, DOI 10.1073/pnas.92.7.2672; GAZIT D, 1994, J BONE MINER RES, V9; GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130; GUILBERT LJ, 1986, J BIOL CHEM, V261, P4024; GULSHAN S, 1990, SCAND J IMMUNOL, V31, P691, DOI 10.1111/j.1365-3083.1990.tb02820.x; HARRINGTON MA, 1991, GENE, V102, P165, DOI 10.1016/0378-1119(91)90074-L; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HART DM, 1993, J NIH RES, V5, P66; HOROWITZ MC, 1993, SCIENCE, V260, P626, DOI 10.1126/science.8480174; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; KALU DN, 1990, P SOC EXP BIOL MED, V195, P70; KIMBLE RB, 1995, ENDOCRINOLOGY, V136, P3054, DOI 10.1210/en.136.7.3054; KIMBLE RB, 1994, J CLIN INVEST, V93, P1959, DOI 10.1172/JCI117187; KITAZAWA R, 1994, J CLIN INVEST, V94, P2397, DOI 10.1172/JCI117606; LADNER MB, 1988, P NATL ACAD SCI USA, V85, P6706, DOI 10.1073/pnas.85.18.6706; LOKESHWAR BL, 1988, J IMMUNOL, V141, P483; MACDONALD BR, 1986, J BONE MINER RES, V1, P227; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; MODDERMAN WE, 1994, EXP HEMATOL, V22, P194; OURSLER MJ, 1991, P NATL ACAD SCI USA, V88, P6613, DOI 10.1073/pnas.88.15.6613; OURSLER MJ, 1993, ENDOCRINOLOGY, V132, P1373, DOI 10.1210/en.132.3.1373; PASSERI G, 1993, ENDOCRINOLOGY, V133, P822, DOI 10.1210/en.133.2.822; Perkins SL, 1995, AM J PHYSIOL-ENDOC M, V269, pE1024, DOI 10.1152/ajpendo.1995.269.6.E1024; PFEILSCHIFTER J, 1989, J BONE MINER RES, V4, P113, DOI 10.1002/jbmr.5650040116; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; SUVA LJ, 1991, MOL ENDOCRINOL, V5, P829, DOI 10.1210/mend-5-6-829; TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461; VANDERPLUIJM G, 1991, ENDOCRINOLOGY, V129, P1596; WEUSTEN JJAM, 1986, ACTA ENDOCRINOL-COP, V112, P409, DOI 10.1530/acta.0.1120409	44	217	241	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28890	28897		10.1074/jbc.271.46.28890	http://dx.doi.org/10.1074/jbc.271.46.28890			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910536	hybrid			2022-12-25	WOS:A1996VT05200028
J	Kuhn, FJP; Knopf, CW				Kuhn, FJP; Knopf, CW			Herpes simplex virus type 1 DNA polymerase - Mutational analysis of the 3'-5'-exonuclease domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXONUCLEASE ACTIVE-SITE; 3'-5' EXONUCLEASE; ESCHERICHIA-COLI; AMINO-ACID; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; CATALYTIC SUBUNIT; UL42 PROTEIN; STRAIN ANGELOTTI; GENE	Like true DNA replicases, herpes simplex virus type 1 DNA polymerase is equipped with a proofreading 3'-5'-exonuclease, In order to assess the functional significance of conserved residues in the putative exonuclease domain, we introduced point mutations as well as deletions within and near the conserved motifs' exonuclease (Exo) I, II, and III of the DNA polymerase gene from a phosphonoacetic acid-resistant derivative of herpes simplex virus-1 strain ANG. We examined the catalytic activities of the partially purified enzymes after overexpression by recombinant baculovirus. Mutations of the motifs' Exo I (D368A, E370A) and Exo III (Y577F, D581A) yielded enzymes without detectable and severely impaired 3'-5'-exonuclease activities, respectively. Except for the Exo I mutations, all other Exo mutations examined affected both exonuclease and polymerization activities. Mutant enzymes D368A, E370A, Y557S, and D581A showed a significant ability to extend mispaired primer termini. Mutation Y557S resulted in a strong reduction of the 3'-5'-exonuclease activity and in a polymerase activity that was hyperresistant to phosphonoacetic acid. The results of the mutational analysis provide evidence for a tight linkage of polymerase and 3'-5'-exonuclease activity in the herpesviral enzyme.	DEUTSCH KREBSFORSCHUNGSZENTRUM,DEPT GENOMFORSCH & BIOINFORMAT 0841,D-69120 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)			Kuehn, Frank JP/H-5889-2018					BARNES MH, 1992, GENE, V111, P43, DOI 10.1016/0378-1119(92)90601-K; BAYER S, 1990, THESIS U HEIDELBERG; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BLANCO L, 1992, GENE, V112, P139, DOI 10.1016/0378-1119(92)90316-H; BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; BROWN M, 1977, J GEN VIROL, V36, P361, DOI 10.1099/0022-1317-36-2-361; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHUNG DW, 1991, P NATL ACAD SCI USA, V88, P11197, DOI 10.1073/pnas.88.24.11197; COEN DM, 1991, ANTIVIR RES, V15, P287, DOI 10.1016/0166-3542(91)90010-O; CRUTE JJ, 1989, J BIOL CHEM, V264, P19266; CULLMANN G, 1993, GENE, V134, P191, DOI 10.1016/0378-1119(93)90093-I; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DIGARD P, 1993, J VIROL, V67, P1159, DOI 10.1128/JVI.67.3.1159-1168.1993; DOWNEY KM, 1990, BIOESSAYS, V12, P231, DOI 10.1002/bies.950120507; FREEMONT P S, 1986, Proteins Structure Function and Genetics, V1, P66, DOI 10.1002/prot.340010111; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GALLO ML, 1989, J VIROL, V63, P5023, DOI 10.1128/JVI.63.12.5023-5029.1989; GIBBS JS, 1991, MOL CELL BIOL, V11, P4786, DOI 10.1128/MCB.11.9.4786; GOTTLIEB J, 1990, J VIROL, V64, P5976, DOI 10.1128/JVI.64.12.5976-5987.1990; HAFFEY ML, 1990, J VIROL, V64, P5008, DOI 10.1128/JVI.64.10.5008-5018.1990; HALL JD, 1995, J GEN VIROL, V76, P2999, DOI 10.1099/0022-1317-76-12-2999; HALL JD, 1989, NUCLEIC ACIDS RES, V17, P9231, DOI 10.1093/nar/17.22.9231; HART GJ, 1992, FEBS LETT, V305, P97, DOI 10.1016/0014-5793(92)80872-E; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; ISHINO Y, 1994, J BIOL CHEM, V269, P14655; JOYCE CM, 1982, J BIOL CHEM, V257, P1958; JOYCE JM, 1994, ANN REV BIOCH, V63, P777; KNOPF CW, 1990, EUR J BIOCHEM, V191, P263, DOI 10.1111/j.1432-1033.1990.tb19119.x; KNOPF CW, 1988, BIOCHIM BIOPHYS ACTA, V951, P298, DOI 10.1016/0167-4781(88)90100-5; KNOPF CW, 1986, NUCLEIC ACIDS RES, V14, P8225, DOI 10.1093/nar/14.20.8225; KNOPF CW, 1987, J GEN VIROL, V68, P1429, DOI 10.1099/0022-1317-68-5-1429; KNOPF HW, 1988, THESIS U HEIDELBERG; KNOPF KW, 1979, EUR J BIOCHEM, V98, P231, DOI 10.1111/j.1432-1033.1979.tb13181.x; KNOPF KW, 1981, J VIROL, V39, P746, DOI 10.1128/JVI.39.3.746-757.1981; KNOPF KW, 1994, FRONTIERS VIROLOGY, V3, P87; KUHN FJP, 1995, THESIS U HEIDELBERG; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MORRISON A, 1992, NUCLEIC ACIDS RES, V20, P375, DOI 10.1093/nar/20.2.375; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; MULLEN GP, 1990, J BIOL CHEM, V265, P14327; ODONNELL ME, 1987, J BIOL CHEM, V262, P4252; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Possee RD., 1992, BACULOVIRUS EXPRESSI; REHAKRANTZ LJ, 1993, J BIOL CHEM, V268, P27100; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; RUSCITTI T, 1992, J BIOL CHEM, V267, P16806; Sambrook J., 2002, MOL CLONING LAB MANU; SAWADOGO M, 1991, NUCLEIC ACIDS RES, V19, P674, DOI 10.1093/nar/19.3.674; SHANAFELT AB, 1991, BIOTECHNIQUES, V11, P330; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; SO AG, 1992, CRIT REV BIOCHEM MOL, V27, P129, DOI 10.3109/10409239209082561; SOENGAS MS, 1992, EMBO J, V11, P4227, DOI 10.1002/j.1460-2075.1992.tb05517.x; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; STOCKI SA, 1995, J MOL BIOL, V254, P15, DOI 10.1006/jmbi.1995.0595; STRICK R, 1993, THESIS U HEIDELBERG; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WANG X, 1983, J GEN VIROL, V64, P2229, DOI 10.1099/0022-1317-64-10-2229; WANG Y, 1992, J VIROL, V66, P1814, DOI 10.1128/JVI.66.3.1814-1816.1992; WEISSBACH A, 1973, J BIOL CHEM, V248, P6270; WEISSHART K, 1988, EUR J BIOCHEM, V174, P707, DOI 10.1111/j.1432-1033.1988.tb14155.x; WEISSHART K, 1994, J BIOL CHEM, V269, P22788; ZHANG J, 1991, BIOCHEMISTRY-US, V30, P11742, DOI 10.1021/bi00115a002; ZHU WG, 1994, NUCLEIC ACIDS RES, V22, P5177, DOI 10.1093/nar/22.24.5177	67	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29245	29254						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910584				2022-12-25	WOS:A1996VT05200076
J	Ogata, Y; Mizushima, T; Kataoka, K; Kita, K; Miki, T; Sekimizu, K				Ogata, Y; Mizushima, T; Kataoka, K; Kita, K; Miki, T; Sekimizu, K			DnaK heat shock protein of Escherichia coli maintains the negative supercoiling of DNA against thermal stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEX FACTOR-F; RNA-POLYMERASE; SIGMA-32 SYNTHESIS; ATPASE ACTIVITY; TRANSCRIPTIONAL CONTROL; ENZYMATIC REPLICATION; BACTERIOPHAGE-LAMBDA; SUPERHELICAL TURNS; REGULATORY GENE; PLASMID DNA	Plasmid DNA in exponentially growing Escherichia coli immediately relaxes after heat shock, and the relaxed state of DNA rapidly reverts to the original state with exposure to conditions of heat shock. We have now obtained genetic and biochemical evidence indicating that DnaK heat shock protein off. coli, a prokaryotic homologue of hsp70, is involved in this re-supercoiling of DNA. As re-supercoiling of DNA did not occur in an rpoH amber mutant, it seems likely that heat shock proteins are required for this reaction, Plasmid DNA in a dnaK deletion mutant relaxed excessively after temperature shift-up, and the re-supercoiling of DNA was not observed. DNAs incubated with a crude cell extract prepared from the dnaK mutant were more relaxed than seen with the extract from its isogenic wild-type strain, and the addition of purified DnaK protein to the mutant extract led to an increase in the negative supercoiling of DNA. Moreover, reaction products of purified DNA gyrase more negatively supercoiled in the presence of DnaK protein, Based on these results, we propose that DnaK protein plays a role in maintaining the negative supercoiling of DNA against thermal stress.	KYUSHU UNIV, FAC PHARMACEUT SCI, DEPT MICROBIOL, HIGASHI KU, FUKUOKA 81282, JAPAN; UNIV TOKYO, INST MED SCI, DEPT PARASITOL, MINATO KU, TOKYO 108, JAPAN	Kyushu University; University of Tokyo				Kita, Kiyoshi/0000-0002-0426-4308; Ogata, Yasuyuki/0000-0003-0316-0109				Ashburner M., 1982, HEAT SHOCK BACTERIA, P1; BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; BALKE VL, 1987, J BACTERIOL, V169, P4499, DOI 10.1128/jb.169.10.4499-4506.1987; BLASZCZAK A, 1995, EMBO J, V14, P5085, DOI 10.1002/j.1460-2075.1995.tb00190.x; BUKAU B, 1990, EMBO J, V9, P4027, DOI 10.1002/j.1460-2075.1990.tb07624.x; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; DRLICA K, 1984, MICROBIOL REV, V48, P273, DOI 10.1128/MMBR.48.4.273-289.1984; FUJITA N, 1987, MOL GEN GENET, V210, P10, DOI 10.1007/BF00337752; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; FUNNELL BE, 1986, J BIOL CHEM, V261, P5616; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDSTEIN E, 1984, P NATL ACAD SCI-BIOL, V81, P4046, DOI 10.1073/pnas.81.13.4046; GROSSMAN AD, 1987, GENE DEV, V1, P179, DOI 10.1101/gad.1.2.179; HILL CW, 1981, P NATL ACAD SCI-BIOL, V78, P7069, DOI 10.1073/pnas.78.11.7069; HUPP TR, 1993, J BIOL CHEM, V268, P13137; HUPP TR, 1993, J BIOL CHEM, V268, P13143; HWANG DS, 1990, J BIOL CHEM, V265, P19244; KAMATHLOEB AS, 1991, J BACTERIOL, V173, P3904, DOI 10.1128/JB.173.12.3904-3906.1991; Kaneko T, 1996, MOL GEN GENET, V250, P593; Kataoka K, 1996, J BIOL CHEM, V271, P24806, DOI 10.1074/jbc.271.40.24806; KAWASAKI Y, 1990, MOL GEN GENET, V220, P277; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T, 1989, MOL CLONING; MARGER WH, 1995, MICROBIOL REV, V59, P506; MCCARTY JS, 1994, J BACTERIOL, V176, P764, DOI 10.1128/jb.176.3.764-780.1994; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; MIKI T, 1988, J MOL BIOL, V201, P327, DOI 10.1016/0022-2836(88)90141-6; MIKI T, 1992, J MOL BIOL, V225, P39, DOI 10.1016/0022-2836(92)91024-J; MIZUSHIMA T, 1993, MOL GEN GENET, V238, P1; MIZUSHIMA T, 1994, FEMS MICROBIOL LETT, V121, P333, DOI 10.1016/0378-1097(94)90313-1; MIZUUCHI K, 1984, J BIOL CHEM, V259, P9199; MORIMOTO R I, 1990, P1; NAGAI H, 1991, P NATL ACAD SCI USA, V88, P10515, DOI 10.1073/pnas.88.23.10515; NEIDHARDT FC, 1981, BIOCHEM BIOPH RES CO, V100, P894, DOI 10.1016/S0006-291X(81)80257-4; NEIDHARDT FC, 1984, ANNU REV GENET, V18, P295, DOI 10.1146/annurev.ge.18.120184.001455; OGATA Y, 1994, MOL GEN GENET, V244, P451, DOI 10.1007/BF00583895; OGATA Y, 1993, BIOCHEM BIOPH RES CO, V197, P34, DOI 10.1006/bbrc.1993.2437; PAEK KH, 1987, J BACTERIOL, V169, P283, DOI 10.1128/jb.169.1.283-290.1987; PANAGIOTIDIS CA, 1994, J BIOL CHEM, V269, P16643; POLISSI A, 1995, FEMS MICROBIOL REV, V17, P159; PRUSS GJ, 1989, CELL, V56, P521, DOI 10.1016/0092-8674(89)90574-6; SAKAKIBARA Y, 1988, J BACTERIOL, V170, P972, DOI 10.1128/jb.170.2.972-979.1988; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; STRAUS DB, 1987, NATURE, V329, P348, DOI 10.1038/329348a0; TAYLOR WE, 1984, CELL, V38, P371, DOI 10.1016/0092-8674(84)90492-6; TILLY K, 1983, CELL, V34, P641, DOI 10.1016/0092-8674(83)90396-3; TILLY K, 1986, J BACTERIOL, V168, P1155, DOI 10.1128/jb.168.3.1155-1158.1986; TOBE T, 1984, MOL GEN GENET, V195, P10, DOI 10.1007/BF00332716; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG JY, 1992, MOL MICROBIOL, V6, P1861, DOI 10.1111/j.1365-2958.1992.tb01358.x; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; YAMAMORI T, 1982, P NATL ACAD SCI-BIOL, V79, P860, DOI 10.1073/pnas.79.3.860; YAMAMORI T, 1980, J BACTERIOL, V142, P843, DOI 10.1128/JB.142.3.843-851.1980; YURA T, 1993, ANNU REV MICROBIOL, V47, P321, DOI 10.1146/annurev.mi.47.100193.001541; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437	67	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29407	29414		10.1074/jbc.271.46.29407	http://dx.doi.org/10.1074/jbc.271.46.29407			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910606	hybrid			2022-12-25	WOS:A1996VT05200098
J	Skripkin, E; Paillart, JC; Marquet, R; Blumenfeld, M; Ehresmann, B; Ehresmann, C				Skripkin, E; Paillart, JC; Marquet, R; Blumenfeld, M; Ehresmann, B; Ehresmann, C			Mechanisms of inhibition of in vitro dimerization of HIV type I RNA by sense and antisense oligonucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SEQUENCE-SPECIFIC INHIBITION; REVERSE TRANSCRIPTION; INFECTED-CELLS; GENOMIC RNA; TARGET RNA; REPLICATION; COMPLEMENTARY; RECOMBINATION; PROTEIN	Retroviruses display a strong selective pressure to maintain the dimeric nature of their genomic RNAs, suggesting that dimerization is essential for viral replication. Recently, we identified the cis-element required for initiation of human immunodeficiency virus type I (HIV-I) RNA dimerization in vitro. The dimerization initiation site (DIS) is a hairpin structure containing a self complementary sequence in the loop. We proposed that dimerization is initiated by a loop-loop kissing interaction involving the self-complementary sequence present in each monomer. We tested the ability of sense and antisense oligonucleotides targeted against the DIS to interfere with a preformed viral RNA dimer. Self-dimerization and inhibition properties of the tested oligonucleotides are dictated by the nature of the loop. An RNA loop is absolutely required in the case of sense oligonucleotides, whereas the nature and the sequence of the stem is not important. They form reversible loop-loop interactions and act as competitive inhibitors. Antisense oligonucleotides are less efficient in self-dimerization and are more potent inhibitors than sense oligonucleotides. They are less sensitive to the nature of the loop than the antisense oligonucleotides. Antisense hairpins with either RNA or DNA stems are able to form highly stable and irreversible complexes with viral RNA, resulting from complete extension of base pairing initiated by loop-loop interaction.	INST BIOL MOL & CELLULAIRE, CNRS, UNITE PROPRE RECH 9002, F-67084 STRASBOURG, FRANCE; GENSET, F-75011 PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Paillart, Jean-Christophe/A-4171-2010	Paillart, Jean-Christophe/0000-0003-1647-8917; Marquet, Roland/0000-0002-4209-3976				Agrawal S, 1992, Antisense Res Dev, V2, P261; AGRAWAL S, 1989, P NATL ACAD SCI USA, V86, P7790, DOI 10.1073/pnas.86.20.7790; AGRAWAL S, 1988, P NATL ACAD SCI USA, V85, P7079, DOI 10.1073/pnas.85.19.7079; Agrawal S., 1994, J BIOTECH HEALTHCARE, V1, P167; ANAZODO MI, 1995, J VIROL, V69, P1794, DOI 10.1128/JVI.69.3.1794-1801.1995; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; BERKHOUT B, 1995, ANTIVIR RES, V26, P101, DOI 10.1016/0166-3542(94)00068-J; BERTRAND EL, 1994, EMBO J, V13, P2904, DOI 10.1002/j.1460-2075.1994.tb06585.x; BIETH E, 1990, NUCLEIC ACIDS RES, V18, P119, DOI 10.1093/nar/18.1.119; BORDIER B, 1995, P NATL ACAD SCI USA, V92, P9383, DOI 10.1073/pnas.92.20.9383; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; EGUCHI Y, 1991, J MOL BIOL, V220, P831, DOI 10.1016/0022-2836(91)90356-B; EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215; GOODCHILD J, 1988, P NATL ACAD SCI USA, V85, P5507, DOI 10.1073/pnas.85.15.5507; GORELICK RJ, 1990, ADV MOL BIOL TARGETE, P257; GRAHAM GJ, 1990, P NATL ACAD SCI USA, V87, P5817, DOI 10.1073/pnas.87.15.5817; GREGORIAN RS, 1995, J MOL BIOL, V248, P968, DOI 10.1006/jmbi.1995.0275; Haddrick M, 1996, J MOL BIOL, V259, P58, DOI 10.1006/jmbi.1996.0301; HOMANN M, 1993, J MOL BIOL, V233, P7, DOI 10.1006/jmbi.1993.1480; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; KIM HJ, 1994, VIROLOGY, V198, P336, DOI 10.1006/viro.1994.1037; KITTLE JD, 1989, J MOL BIOL, V210, P561, DOI 10.1016/0022-2836(89)90132-0; LAUGHREA M, 1994, BIOCHEMISTRY-US, V33, P13464, DOI 10.1021/bi00249a035; Laughrea M, 1996, BIOCHEMISTRY-US, V35, P1589, DOI 10.1021/bi951838f; LISZIEWICZ J, 1994, P NATL ACAD SCI USA, V91, P7942, DOI 10.1073/pnas.91.17.7942; LISZIEWICZ J, 1993, P NATL ACAD SCI USA, V90, P3860, DOI 10.1073/pnas.90.9.3860; MARQUET R, 1994, NUCLEIC ACIDS RES, V22, P145, DOI 10.1093/nar/22.2.145; MARQUET R, 1991, NUCLEIC ACIDS RES, V19, P2349, DOI 10.1093/nar/19.9.2349; McBride MS, 1996, J VIROL, V70, P2963, DOI 10.1128/JVI.70.5.2963-2973.1996; MIRABELLI CK, 1993, ANTISENSE RES APPL, P7; MURIAUX D, 1995, J BIOL CHEM, V270, P8209, DOI 10.1074/jbc.270.14.8209; MYERS G, 1995, HUMAN RETROVIRUSES A, pIA2; PAILLART JC, 1994, J BIOL CHEM, V269, P27486; Paillart JC, 1996, P NATL ACAD SCI USA, V93, P5572, DOI 10.1073/pnas.93.11.5572; PAILLART JC, 1996, IN PRESS J VIROL; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PERSSON C, 1990, EMBO J, V9, P3767, DOI 10.1002/j.1460-2075.1990.tb07590.x; Riesner D., 1991, ADV ELECTROPHORESIS, V4, P169; SCZAKIEL G, 1992, ANN NY ACAD SCI, V660, P268, DOI 10.1111/j.1749-6632.1992.tb21080.x; SIMONS RW, 1993, ANTISENSE RES APPLIC, P97; SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945; STUHLMANN H, 1992, J VIROL, V66, P2378, DOI 10.1128/JVI.66.4.2378-2388.1992; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; TAKAYAMA KM, 1990, CRIT REV BIOCHEM MOL, V25, P155, DOI 10.3109/10409239009090608; TEMIN HM, 1993, P NATL ACAD SCI USA, V90, P6900, DOI 10.1073/pnas.90.15.6900; TOMIZAWA J, 1990, J MOL BIOL, V212, P683, DOI 10.1016/0022-2836(90)90230-J; VICKERS T, 1991, NUCLEIC ACIDS RES, V19, P3359, DOI 10.1093/nar/19.12.3359; WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433	49	36	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28812	28817		10.1074/jbc.271.46.28812	http://dx.doi.org/10.1074/jbc.271.46.28812			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910525	hybrid			2022-12-25	WOS:A1996VT05200017
J	Liao, YF; Lal, A; Moremen, KW				Liao, YF; Lal, A; Moremen, KW			Cloning, expression, purification, and characterization of the human broad specificity lysosomal acid alpha-mannosidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; GLYCOPROTEIN-BIOSYNTHESIS; DICTYOSTELIUM-DISCOIDEUM; SACCHAROMYCES-CEREVISIAE; SUBSTRATE-SPECIFICITY; MOLECULAR-CLONING; PICHIA-PASTORIS; COMPLEX GLYCANS; GOLGI; GENE	We have cloned and expressed two cDNAs encoding the human lysosomal alpha-mannosidase (EC 3.2.1.24) by RT-PCB of human spleen mRNk This enzyme is required for the degradation of N-Linked carbohydrates during glycoprotein catabolism in eucaryotic cells, The shorter of the two cDNAs (3 kilobases (kb)) was found to encode an open reading frame of 2964 base pairs and, when expressed in Pichia pastoris, was found to encode an enzyme that could cleave high mannose oligosaccharides, oligosaccharides isolated from alpha-mannosidosis fibroblasts, and p-nitrophenyl-alpha-D-mannopyranoside substrates, In addition, the Pichia-expressed enzyme was inhibited by swainsonine, and had a pH optimum, K-m, and V-max characteristic of the enzyme purified previously from human liver. The second, larger RT-PCR product (3.6 kb) was found to contain an insertion and a deletion relative to the 3-kb spleen amplimer and encoded a truncated coding region, indicating that it resulted from alternate transcript splicing, No alpha-mannosidase activity could be detected in Pichia transformants containing this coding region, indicating that it did not encode a functional enzyme, Antiserum raised to the recombinant product of the 3-kb alpha-mannosidase cDNA immunoprecipitated lysosomal alpha-mannosidase activity from human fibroblast extracts, Northern blots identified a 3-kb RNA transcript in all human tissues tested, including alpha-mannosidosis fibroblasts, while minor transcripts of 3.6 kb were also present in several adult tissues, Human chromosome mapping of the mannosidase gene confirmed that the functional gene maps to the MANB locus on chromosome 19, Sequence comparisons were made to preciously published human cDNA sequences encoding a putative lysosomal alpha-mannosidase (Nebes, V, L., and Schmidt, M. C. (1994) Biochem. Biophys. Res, Commun. 200, 289-245) and several differences were found relative to the functional lysosomal alpha-mannosidase encoded by the 3-kb spleen cDNA.	UNIV GEORGIA,DEPT BIOCHEM & MOL BIOL,ATHENS,GA 30602; UNIV GEORGIA,COMPLEX CARBOHYDRATE RES CTR,ATHENS,GA 30602	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia			Moremen, Kelley/AAD-4661-2019; Liao, Yung-Feng/A-9761-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047533] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05351] Funding Source: Medline; NIGMS NIH HHS [GM47533] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDAHER S, 1991, BIOCHEM J, V277, P743, DOI 10.1042/bj2770743; ARONSON NN, 1989, FASEB J, V3, P2615, DOI 10.1096/fasebj.3.14.2531691; BAUSE E, 1993, EUR J BIOCHEM, V217, P535, DOI 10.1111/j.1432-1033.1993.tb18274.x; BENNET JK, 1995, AM J MED GENET, V55, P21, DOI 10.1002/ajmg.1320550108; BISCHOFF J, 1990, J BIOL CHEM, V265, P17110; CAMIRAND A, 1991, J BIOL CHEM, V266, P15120; CARROLL M, 1972, BIOCHEM BIOPH RES CO, V49, P579, DOI 10.1016/0006-291X(72)90450-0; CHAMPION MJ, 1978, CYTOGENET CELL GENET, V22, P186, DOI 10.1159/000130932; CHAMPION MJ, 1977, P NATL ACAD SCI USA, V74, P2968, DOI 10.1073/pnas.74.7.2968; CHENG SH, 1986, BIOCHEM J, V233, P65, DOI 10.1042/bj2330065; CREGG JM, 1985, MOL CELL BIOL, V5, P3376, DOI 10.1128/MCB.5.12.3376; DANIEL PF, 1994, GLYCOBIOLOGY, V4, P551, DOI 10.1093/glycob/4.5.551; DANIEL PF, 1992, GLYCOBIOLOGY, V2, P327, DOI 10.1093/glycob/2.4.327; DEGASPERI R, 1991, J BIOL CHEM, V266, P16556; DEGASPERI R, 1992, J BIOL CHEM, V267, P9706; Desnick R J, 1976, Adv Exp Med Biol, V68, P277; DESNICK RJ, 1976, PEDIATR RES, V10, P985, DOI 10.1203/00006450-197612000-00008; EMILIANI C, 1995, BIOCHEM J, V305, P363, DOI 10.1042/bj3050363; HASE S, 1994, METHOD ENZYMOL, V230, P225; HASE S, 1988, J CHROMATOGR-BIOMED, V434, P51, DOI 10.1016/0378-4347(88)80061-6; HERSCOVICS A, 1994, J BIOL CHEM, V269, P9864; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; INGRAM PH, 1977, BIOCHEM GENET, V15, P455, DOI 10.1007/BF00520191; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAL A, 1994, J BIOL CHEM, V269, P9872; LIPARI F, 1995, BIOCHEM BIOPH RES CO, V209, P322, DOI 10.1006/bbrc.1995.1506; LIS H, 1966, J BIOL CHEM, V241, P684; MARTINIUK F, 1985, HUM GENET, V69, P109, DOI 10.1007/BF00293278; MERKLE RK, 1994, GLYCOBIOLOGY, V4, P734; MICHALSKI JC, 1990, EUR J BIOCHEM, V189, P369, DOI 10.1111/j.1432-1033.1990.tb15498.x; MIERENDORF RC, 1983, J BIOL CHEM, V258, P5878; MOREMEN KW, 1991, J CELL BIOL, V115, P1521, DOI 10.1083/jcb.115.6.1521; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; MOREMEN KW, 1989, P NATL ACAD SCI USA, V86, P5276, DOI 10.1073/pnas.86.14.5276; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; NEBES VL, 1994, BIOCHEM BIOPH RES CO, V200, P239, DOI 10.1006/bbrc.1994.1440; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; OKUMURA T, 1973, J BIOCHEM, V73, P131; OPHEIM DJ, 1978, J BIOL CHEM, V253, P1017; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PHILLIPS NC, 1976, BIOCHEM J, V153, P579, DOI 10.1042/bj1530579; PHILLIPS NC, 1977, BIOCHEM J, V163, P269, DOI 10.1042/bj1630269; POHLMANN R, 1983, BIOCHEM BIOPH RES CO, V115, P1083, DOI 10.1016/S0006-291X(83)80046-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZLE J, 1992, J BIOL CHEM, V267, P4000; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; STADEN R, 1987, NUCLEIC ACID PROTEIN, P173; TAYLOR HA, 1975, CLIN CHIM ACTA, V59, P93, DOI 10.1016/0009-8981(75)90223-5; TSAY GC, 1975, J CLIN INVEST, V56, P711, DOI 10.1172/JCI108142; Tschopp J F, 1991, Biotechnology, V18, P305; TSCHOPP JF, 1987, NUCLEIC ACIDS RES, V15, P3859, DOI 10.1093/nar/15.9.3859; TULSIANI DRP, 1989, J CELL BIOL, V109, P1257, DOI 10.1083/jcb.109.3.1257; TULSIANI DRP, 1995, DEV BIOL, V167, P584, DOI 10.1006/dbio.1995.1050; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; YAMASHITA K, 1980, J BIOL CHEM, V255, P5126	55	104	128	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28348	28358		10.1074/jbc.271.45.28348	http://dx.doi.org/10.1074/jbc.271.45.28348			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910458	hybrid			2022-12-25	WOS:A1996VU03300058
J	Louie, DF; Resing, KA; Lewis, TS; Ahn, NG				Louie, DF; Resing, KA; Lewis, TS; Ahn, NG			Mass spectrometric analysis of 40 S ribosomal proteins from rat-1 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLISION-INDUCED DISSOCIATION; MAP KINASE KINASE; ELECTROSPRAY-IONIZATION; SACCHAROMYCES-CEREVISIAE; PHOSPHORYLATION SITES; LOCALIZATION; RNA; LIVER; NUCLEOLIN; PEPTIDES	Although sequences of most mammalian ribosomal proteins are available, little is known about the posttranslational processing of ribosomal proteins. To exam ine their post-translational modifications, 40 S subunit proteins purified from Rat-1 fibroblasts and their peptides were analyzed by Liquid chromatography coupled with electrospray mass spectrometry. Of 41 proteins observed, 36 corresponded to the 32 rat 40 S ribosomal proteins with known sequences (S3, S5, S7, and S24 presented in two forms). The observed masses of S4, S6-S8, S13, S15a, S16, S17, S19, S27a, S29, and S30 matched those predicted. Sa, S3a, S5, S11, S15, S18, S20, S21, S24, S26-S28, and an 57 variant showed changes in mass that were consistent with N-terminal demethionylation and/or acetylation (S5 and S27 also appeared to be internally formylated and acetylated, respectively). S23 appeared to be internally hydroxylated or methylated. S2, S3, S9, S10, S12, S14, and S25 showed changes in mass inconsistent with known covalent modifications (+220, -75, +86, +56, -100, -117, and -103 Da, respectively), possibly representing novel post-translational modifications or allelic sequence variation. Five unidentified proteins (12,084, 13,706, 13,741, 13,884, and 34,987 Da) were observed; for one, a sequence tag (PPGPPP), absent in any known ribosomal proteins, was determined, suggesting that it is a previously undescribed ribosome-associated protein. This study establishes a powerful method to rapidly analyze protein components of large biological complexes and their covalent modifications.	UNIV COLORADO,HOWARD HUGHES MED INST,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Louie, DF (corresponding author), UNIV COLORADO,DEPT CHEM & BIOCHEM,CAMPUS BOX 215,BOULDER,CO 80309, USA.				NIAMS NIH HHS [AR39730] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039730] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; ASHTON DS, 1994, FEBS LETT, V342, P1, DOI 10.1016/0014-5793(94)80572-5; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; BIEMANN K, 1990, METHOD ENZYMOL, V193, P455, DOI 10.1016/0076-6879(90)93433-L; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOISSEL JP, 1988, J BIOL CHEM, V263, P8443; BURLINGAME AL, 1994, ANAL CHEM, V66, pR634; CHAN YL, 1993, BIOCHEM BIOPH RES CO, V193, P106, DOI 10.1006/bbrc.1993.1596; CHAN YL, 1994, BIOCHEM BIOPH RES CO, V200, P1498, DOI 10.1006/bbrc.1994.1620; CHAN YL, 1990, FEBS LETT, V263, P85, DOI 10.1016/0014-5793(90)80711-Q; CHAN YL, 1995, BIOCHEM BIOPH RES CO, V215, P682, DOI 10.1006/bbrc.1995.2518; CHAN YL, 1987, NUCLEIC ACIDS RES, V15, P9451, DOI 10.1093/nar/15.22.9451; CHAN YL, 1993, NUCLEIC ACIDS RES, V21, P649, DOI 10.1093/nar/21.3.649; CHAN YL, 1988, J BIOL CHEM, V263, P2891; Cooks R.G., 1978, COLLISION SPECTROSCO; CREANCIER L, 1993, MOL BIOL CELL, V4, P1239, DOI 10.1091/mbc.4.12.1239; DEVI KRG, 1989, BIOCHIM BIOPHYS ACTA, V1008, P258; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; HILL WE, 1990, RIBOSOMES STRUCTURE; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; ITOH T, 1985, BIOCHEMISTRY-US, V24, P7418, DOI 10.1021/bi00346a058; JACKSON R, 1970, NATURE, V227, P672, DOI 10.1038/227672a0; JONG AYS, 1987, MOL CELL BIOL, V7, P2947, DOI 10.1128/MCB.7.8.2947; JORNVALL H, 1975, J THEOR BIOL, V55, P1, DOI 10.1016/S0022-5193(75)80105-6; KATTA V, 1991, ANAL CHEM, V63, P174, DOI 10.1021/ac00002a016; KITAGAWA M, 1991, FEBS LETT, V283, P210, DOI 10.1016/0014-5793(91)80590-Y; KITAOKA Y, 1994, BIOCHEM BIOPH RES CO, V202, P314, DOI 10.1006/bbrc.1994.1929; KRISHNA RG, 1993, ADV ENZYMOL RAMB, V67, P265; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; LOO JA, 1993, ANAL CHEM, V65, P425, DOI 10.1021/ac00052a020; LUTSCH G, 1979, MOL GEN GENET, V176, P281, DOI 10.1007/BF00273223; MADEN BEH, 1995, BIOCHIMIE, V77, P22, DOI 10.1016/0300-9084(96)88100-4; MANN M, 1995, TRENDS BIOCHEM SCI, V20, P219, DOI 10.1016/S0968-0004(00)89019-2; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MUSATOV A, 1994, BIOCHEMISTRY-US, V33, P10561, DOI 10.1021/bi00201a001; NAKANISHI O, 1985, GENE, V35, P289; OLVERA J, 1993, J BIOL CHEM, V268, P17967; PALMITER RD, 1978, P NATL ACAD SCI USA, V75, P94, DOI 10.1073/pnas.75.1.94; RESING KA, 1993, BIOCHEMISTRY-US, V32, P10036, DOI 10.1021/bi00089a020; RESING KA, 1995, BIOCHEMISTRY-US, V34, P2610, DOI 10.1021/bi00008a027; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; SHERTON CC, 1972, J BIOL CHEM, V247, P4460; STEWART MJ, 1994, BIOESSAYS, V16, P809, DOI 10.1002/bies.950161107; SUZUKI K, 1990, FEBS LETT, V271, P51, DOI 10.1016/0014-5793(90)80369-T; SUZUKI K, 1990, BIOCHIMIE, V72, P299, DOI 10.1016/0300-9084(90)90088-X; SUZUKI K, 1991, J BIOL CHEM, V266, P20007; SUZUKI K, 1990, BIOCHEM BIOPH RES CO, V117, P519; TERAO K, 1970, BIOCHEM BIOPH RES CO, V38, P80, DOI 10.1016/0006-291X(70)91086-7; WAGNER R, 1994, ARCH MICROBIOL, V161, P100, DOI 10.1007/s002030050028; WEIR MS, 1994, TECHNIQUES PROTEIN C, V5, P115; WOOL IG, 1979, ANNU REV BIOCHEM, V48, P719, DOI 10.1146/annurev.bi.48.070179.003443; Wool IG, 1995, BIOCHEM CELL BIOL, V73, P933, DOI 10.1139/o95-101	53	48	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28189	28198		10.1074/jbc.271.45.28189	http://dx.doi.org/10.1074/jbc.271.45.28189			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910435	hybrid			2022-12-25	WOS:A1996VU03300035
J	Wang, YY; Rasnick, D; Klaus, J; Payan, D; Bromme, D; Anderson, DC				Wang, YY; Rasnick, D; Klaus, J; Payan, D; Bromme, D; Anderson, DC			Nucleophile labeling of cysteine and serine protease substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; SPECIFICITY; INHIBITORS; AMINOLYSIS; SURFACE	Dipeptides containing fluorescein or biotin have been incorporated into proteolytic substrate cleavage products of bovine serum albumin generated by human cathepsin S or neutrophil elastase and into a fragment of the 31-kDa interleukin 1 beta precursor by human interleukin 1 beta-converting enzyme, Incorporation of the nucleophile is blocked by prior inhibition of the enzymes, and is not seen when proteolysis occurs in the absence of label, and the protease is then inhibited before the addition of label, Labeling is dependent on the pH, the time of reaction, and the concentrations of the nucleophile and substrate. Labeling of proteins can be readily detected by SDS-polyacrylamide gel electrophoresis. The pattern of elastase-labeled bovine serum albumin bands differs among P-1' Phe, Ala, and Gly, suggesting that nucleophilic attack on acyl enzyme intermediates derived from a large protein may differ from attack on small intermediates, The only observed labeled fragment catalyzed by interleukin 1 beta-converting enzyme is fragment 28-116 from the interleukin 1 beta precursor, suggesting that the cleavage between residues 27 and 28 is at least as efficient as between residues 116 and 117, This labeling method does not require organic solvent or nonphysiological pH values and thus may be useful for the discovery of novel protease substrates in cells or other in vivo systems or for diagnostic applications.	KHEPRI PHARMACEUT, San Francisco, CA 94080 USA									BROMME D, 1993, FEBS LETT, V322, P211, DOI 10.1016/0014-5793(93)81571-G; Chen Wen-Tien, 1992, Current Opinion in Cell Biology, V4, P802; DUFFY MJ, 1992, CLIN EXP METASTAS, V10, P145, DOI 10.1007/BF00132746; FOX JEB, 1994, BLOOD COAGUL FIBRIN, V5, P291, DOI 10.1097/00001721-199404000-00020; GROMOV PS, 1989, INT J BIOCHEM, V21, P941, DOI 10.1016/0020-711X(89)90296-6; HOOK VYH, 1994, FASEB J, V8, P1269, DOI 10.1096/fasebj.8.15.8001739; Klenk Hans-Dieter, 1994, Trends in Microbiology, V2, P39, DOI 10.1016/0966-842X(94)90123-6; Knop M, 1993, CURR OPIN CELL BIOL, V5, P990, DOI 10.1016/0955-0674(93)90082-2; KRUFT V, 1991, BIOCHEMISTRY-US, V30, P11781, DOI 10.1021/bi00115a007; KULLMAN W, 1987, ENZYMATIC PEPTIDE SY; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MENARD R, 1993, FEBS LETT, V328, P107, DOI 10.1016/0014-5793(93)80975-Z; SCHELLENBERGER V, 1993, BIOCHEMISTRY-US, V32, P4349, DOI 10.1021/bi00067a026; SCHUSTER M, 1992, BIOCHIM BIOPHYS ACTA, V1121, P207, DOI 10.1016/0167-4838(92)90356-I; SMEEKENS SP, 1993, BIO-TECHNOL, V11, P182, DOI 10.1038/nbt0293-182; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; SORENSEN SB, 1995, J AM CHEM SOC, V117, P5944, DOI 10.1021/ja00127a006; STEIN RL, 1987, BIOCHEMISTRY-US, V26, P2238, DOI 10.1021/bi00382a025; THORNBERRY NA, 1995, PROTEIN SCI, V4, P3; THORNBERRY NA, 1994, METHOD ENZYMOL, V244, P615	21	0	0	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28399	28406		10.1074/jbc.271.45.28399	http://dx.doi.org/10.1074/jbc.271.45.28399			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910464	hybrid			2022-12-25	WOS:A1996VU03300064
J	Yuan, CS; AultRiche, DB; Borchardt, RT				Yuan, CS; AultRiche, DB; Borchardt, RT			Chemical modification and site-directed mutagenesis of cysteine residues in human placental S-adenosylhomocysteine hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-HOMOCYSTEINE; AMINO-ACID SEQUENCE; RAT-LIVER; ANTIVIRAL AGENTS; CDNA SEQUENCE; INACTIVATION; MECHANISM; TARGET; CHEMOTHERAPY; SYNTHETASE	Human placental S-adenosylhomocysteine (AdoHcy) hydrolase (EC 3.3.1.1) was inactivated by 5',5-dithio-bis(2-nitrobenzoic acid) following pseudo first-order kinetics. Modification of three of the 10 cysteine residues per enzyme subunit resulted in complete inactivation of the enzyme, The three modified cysteine residues were identified as Cys(113), Cys(195), and Cys(421), respectively by protein sequencing after modification with [1-C-14]iodoacetamide. Of the three modifiable cysteines, Cys(113) and Cys(195) could be protected from modification in the presence of the substrate adenosine (Ado), which also protected the enzyme from inactivation. On the other hand, Cys(421) was not protected by Ado, and modification of Cys(421) alone did not affect the enzyme activity. To verify whether some of these cysteine residues are important for the enzyme catalysis, these three cysteine residues were replaced by either serine or aspartic acid using site-directed mutagenesis. Mutants of both Cys(113) (C113S and C113D) and Cys(421) (C421S and C421D) had enzyme activities similar to that of the wild type enzyme, and only slight changes were observed in the steady-state kinetics measured in both the synthetic and hydrolytic directions. However, mutants of Cys(195) (C195D and C195S) displayed drastically reduced enzyme activities, and k(cat) values were only 7 and 12% of that of the wild-type enzyme, respectively, resulting in a calculated loss in binding energy (Delta Delta G) of approximate 1 Kcal/mol. The Cys(195) mutants were capable of catalyzing both the 3'-oxidative and 5'-hydrolytic reactions, as evidenced by the reduction of E . NAD(+) to NADH and formation of the 5'-hydrolytic product when incubated with (E)-5',6'-didehydro-6'-deoxy-6'-chlorohomoadenosine at rates comparable with those catalyzed by the wild-type enzyme. However, mutations of the Cys(195) Severely altered the 3'-reduction potential as evidenced by the drastic reduction in the rate of [2,8-H-3]Ado release from the E(-NADH).[2,8-H-3]3'-keto-Ado complex. Circular dichroism studies of the Cys(195) mutants confirmed that the observed effects are not due to changes in secondary structure, These results suggested that the Cys(195) is involved in the catalytic center and may play an important role in maintaining the 3'-reduction potential for effective release of the reaction products and regeneration of the active form (NAD(+) form) of the enzyme; the Cys(113) is located in or near the substrate binding site, but plays no role beneficial to the catalysis; and the Cys(421) is a nonessential residue, which also explains why Cys(421) does not occur in any other known AdoHcy hydrolases.	UNIV KANSAS, DEPT BIOCHEM, LAWRENCE, KS 66047 USA	University of Kansas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029332] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29332] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKSAMIT RR, 1994, J BIOL CHEM, V269, P4084; AULTRICHE DB, 1994, J BIOL CHEM, V269, P31472; AULTRICHE DB, 1993, MOL PHARMACOL, V43, P989; BITONTI AJ, 1990, BIOCHEM PHARMACOL, V40, P601, DOI 10.1016/0006-2952(90)90562-Y; BORCHARDT RT, 1980, J MED CHEM, V23, P347, DOI 10.1021/jm00178a001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COULTERKARIS DE, 1989, ANN HUM GENET, V53, P169, DOI 10.1111/j.1469-1809.1989.tb01781.x; CREEDON KA, 1994, J BIOL CHEM, V269, P16364; DECLERCQ E, 1987, BIOCHEM PHARMACOL, V36, P2567, DOI 10.1016/0006-2952(87)90533-8; DELAHABA G, 1959, J BIOL CHEM, V234, P603; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FREY MN, 1973, ACTA CRYSTALLOGR B, VB 29, P876, DOI 10.1107/S0567740873003481; GOMI T, 1986, J BIOL CHEM, V261, P3422; GOMI T, 1982, BIOCHEMISTRY-US, V21, P4171, DOI 10.1021/bi00260a039; GOMI T, 1985, J BIOL CHEM, V260, P2789; GOMI T, 1983, BIOCHEMISTRY-US, V22, P137, DOI 10.1021/bi00270a020; GUPTA RA, 1995, ARCH BIOCHEM BIOPHYS, V319, P365, DOI 10.1006/abbi.1995.1306; HENDERSON DM, 1992, MOL BIOCHEM PARASIT, V53, P169, DOI 10.1016/0166-6851(92)90019-G; KASIR J, 1988, BIOCHEM BIOPH RES CO, V153, P359, DOI 10.1016/S0006-291X(88)81231-2; KAWALLECK P, 1992, P NATL ACAD SCI USA, V89, P4713, DOI 10.1073/pnas.89.10.4713; KELER BT, 1988, ANTIVIRAL DRUG DEV, P123; KERR KA, 1975, ACTA CRYSTALLOGR B, V31, P2022, DOI 10.1107/S0567740875006772; LIU S, 1992, ANTIVIR RES, V19, P247, DOI 10.1016/0166-3542(92)90083-H; OGAWA H, 1987, P NATL ACAD SCI USA, V84, P719, DOI 10.1073/pnas.84.3.719; PALMER JL, 1979, J BIOL CHEM, V254, P1217; PORTER DJT, 1992, J BIOL CHEM, V267, P3205; PRASAD SS, 1993, GENOME, V36, P57, DOI 10.1139/g93-008; SGANGA MW, 1992, P NATL ACAD SCI USA, V89, P6328, DOI 10.1073/pnas.89.14.6328; TAKATA Y, 1983, J BIOL CHEM, V258, P7374; TAKATA Y, 1985, ARCH BIOCHEM BIOPHYS, V240, P827, DOI 10.1016/0003-9861(85)90092-X; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; WOLFE MS, 1991, J MED CHEM, V34, P1521, DOI 10.1021/jm00109a001; WOLOS JA, 1993, J IMMUNOL, V151, P526; YUAN CS, 1995, J BIOL CHEM, V270, P16140, DOI 10.1074/jbc.270.27.16140; YUAN CS, 1993, J BIOL CHEM, V268, P17030; YUAN CS, 1994, BIOCHEMISTRY-US, V33, P3758, DOI 10.1021/bi00178a036; YUAN CS, 1994, BIOCHEMISTRY-US, V33, P12305, DOI 10.1021/bi00206a038	38	39	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28009	28016		10.1074/jbc.271.45.28009	http://dx.doi.org/10.1074/jbc.271.45.28009			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910410	hybrid			2022-12-25	WOS:A1996VU03300010
J	Lin, HH; Tu, ZJ; Ann, DK				Lin, HH; Tu, ZJ; Ann, DK			Involvement of nuclear orphan receptor NGFI-B in transcriptional activation of salivary-specific R15 gene by cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH PROTEIN; PAROTID-GLANDS; BINDING PROTEINS; TRANSGENIC MICE; DNA-BINDING; MULTIGENE FAMILY; CONTROL REGION; AMYLASE GENES; RP4 GENE; EXPRESSION	Proline rich proteins (PRPs) are selectively expressed in the acinar cells of the salivary glands and are inducible by beta-agonist isoproterenol and dietary tannins, In the previous studies of rat PRP gene, R15, the 5'-flanking region up to -1.7 kilobase pairs (kb), which was thought to contain the necessary proximal regulatory elements, failed to confer the catecholamine isoproterenol and dietary tannin inducibility to the transgene expression in the salivary glands of transgenic mice, Here we analyzed distal 5'-flanking region of R15 in order to understand the mechanisms of tissue-specific and inducible gene regulation, An upstream regulatory region located between -2.4 and -1.7 kb of the R15 5'-flanking region is demonstrated to be indispensable for the salivary-specific and inducible reporter gene expression in vivo, by transgenic approach, Element(s) within the 0.7-kb (-2.4 to -1.7) region that is able to cis-activate the expression of a heterologous reporter gene expression is further elucidated by transient transfection assays in vitro. Three distinct nuclear orphan receptor NGFI-B regulatory sequences are identified within a 184-base pair (bp) minimal control region extended from -1995 to -1812 nucleotides relative to the transcription start site. When reporter gene containing this 184-bp control region and heterologous promoter was cotransfected with the NGFI-B expression construct, a transactivation that mimics the effect of cAMP is observed in the parotid cells, Finally, mutations on all three identified NGFI-B binding sites and coexpression of a dominant negative mutant construct, pCMV-NGFI-B(Delta 25-195), abolish this transactivation mediated by NGFI-B. In summary, these data suggest that the inducible nuclear orphan receptor NGFI-B may participate in the regulation of salivary acinar cell-specific and inducible expression of the rat R15 gene via three distinct distal NGFI-B sites.	UNIV SO CALIF,DEPT MOL PHARMACOL & TOXICOL,LOS ANGELES,CA 90033	University of Southern California					NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010742] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01-DE10742] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANN DK, 1987, J BIOL CHEM, V262, P899; ANN DK, 1985, J BIOL CHEM, V260, P5863; BEIMLING P, 1992, ONCOGENE, V7, P257; CRAWFORD PA, 1995, MOL CELL BIOL, V15, P4331; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; DAVIS IJ, 1994, MOL CELL BIOL, V14, P3469, DOI 10.1128/MCB.14.5.3469; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; KARIN M, 1990, MOL ASPECTS CELLULAR, V6, P143; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KOUSVELARI E, 1996, STUDIES STOMATOLOGY, P85; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAYFIELD R, 1992, EUR J BIOCHEM, V204, P591, DOI 10.1111/j.1432-1033.1992.tb16672.x; LAZOWSKI KW, 1992, DIFFERENTIATION, V51, P225, DOI 10.1111/j.1432-0436.1992.tb00700.x; Lin H. Helen, 1992, Gene Expression, V2, P365; LIN HH, 1991, GENOMICS, V10, P102, DOI 10.1016/0888-7543(91)90490-6; LIN HH, 1991, GENE, V104, P219, DOI 10.1016/0378-1119(91)90253-8; LIN HH, 1993, J BIOL CHEM, V268, P10214; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MEHANSHO H, 1983, P NATL ACAD SCI-BIOL, V80, P3948, DOI 10.1073/pnas.80.13.3948; MEHANSHO H, 1987, J BIOL CHEM, V262, P12344; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUENZER J, 1979, J BIOL CHEM, V254, P5623; ONATE SA, 1995, SCIENCE, V270, P1354; PACKAGE WSA, 1995, RELEASE 8; PAULSEN RE, 1992, J BIOL CHEM, V267, P16491; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; REDMAN R S, 1987, P1; ROBERTS SGE, 1991, NUCLEIC ACIDS RES, V19, P5205, DOI 10.1093/nar/19.19.5205; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Tu Zheng-Jin, 1993, Gene Expression, V3, P289; WILKIE TM, 1986, DEV BIOL, V118, P9, DOI 10.1016/0012-1606(86)90068-0; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; WRIGHT PS, 1990, J MOL ENDOCRINOL, V4, P81, DOI 10.1677/jme.0.0040081; WRIGHT PS, 1988, FASEB J, V2, P3104, DOI 10.1096/fasebj.2.15.2847950; YAN C, 1995, J BIOL CHEM, V270, P24852, DOI 10.1074/jbc.270.42.24852	43	24	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27637	27644		10.1074/jbc.271.44.27637	http://dx.doi.org/10.1074/jbc.271.44.27637			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910353	hybrid			2022-12-25	WOS:A1996VQ67900071
J	Varoqui, H; Erickson, JD				Varoqui, H; Erickson, JD			Active transport of acetylcholine by the human vesicular acetylcholine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TORPEDO SYNAPTIC VESICLES; H-3 VESAMICOL BINDING; CLONAL CELL LINE; CHOLINE-ACETYLTRANSFERASE; CAENORHABDITIS-ELEGANS; MONOAMINE TRANSPORTER; FUNCTIONAL IDENTIFICATION; ALZHEIMERS-DISEASE; MOLECULAR-CLONING; RAT STRIATUM	The characteristics of ATP dependent transport of acetylcholine (ACh) in homogenates of pheochromocytoma (PC-12) cells stably transfected with the human vesicular acetylcholine transporter (VAChT) cDNA are described. The human VAChT protein was abundantly expressed in this line and appeared as a diffuse band with a molecular mass of similar to 75 kDa on Western blots, Vesicular [H-3]ACh accumulation increased similar to 20 times over levels attained by the endogenous rat VAChT, expressed at low levels in control PC-12 cells, The transport of [H-3]ACh by human VAChT was dependent upon the addition of exogenous ATP at 37 degrees C. Uptake was abolished by low temperature (4 degrees C), the proton ionophore carbonyl cyanide p-trifluoromethoxyphenylhydrazone (2.5 mu M) and bafilomycin A(1) (1 mu M), a specific inhibitor of the vesicular H+-ATPase, The kinetics of [H-3]ACh uptake by human VAChT were saturable, exhibiting an apparent K-m of 0.97 +/- 0.1 mM and V-max of 0.58 +/- 0.04 nmol/min/mg, Maximal steady-state levels of vesicular [H-3]ACh accumulation were directly proportional to the concentration of substrate present in the medium with saturation occurring at similar to 4 mM. Uptake was stereospecifically inhibited by L-vesamicol with an IC50 of 14.7 +/- 1.5 nM. The apparent affinity (K-d) of [H-3] vesamicol for human VAChT was 4.1 +/- 0.5 nM, and the B-max was 8.9 +/- 0.6 pmol/mg. The turnover (VmaxBmax) of the human VAChT was similar to 65/min. This expression system should prove useful for the structure/function analysis of VAChT.	NIMH, CELL BIOL LAB, MOL NEUROSCI SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)								ALFONSO A, 1994, J MOL BIOL, V241, P627, DOI 10.1006/jmbi.1994.1538; ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; BAHR BA, 1986, P NATL ACAD SCI USA, V83, P2267, DOI 10.1073/pnas.83.7.2267; BAHR BA, 1986, J NEUROCHEM, V46, P1214, DOI 10.1111/j.1471-4159.1986.tb00640.x; BAUERFEIND R, 1993, NEURON, V11, P105, DOI 10.1016/0896-6273(93)90275-V; BEJANIN S, 1994, J BIOL CHEM, V269, P21944; BERRARD S, 1995, J NEUROCHEM, V65, P939; BERSE B, 1995, J BIOL CHEM, V270, P22101, DOI 10.1074/jbc.270.38.22101; BLUMBERG D, 1992, J NEUROCHEM, V58, P801, DOI 10.1111/j.1471-4159.1992.tb09328.x; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIEBLER MF, 1989, J NEUROCHEM, V52, P813, DOI 10.1111/j.1471-4159.1989.tb02526.x; ERICKSON JD, 1993, J NEUROCHEM, V61, P2314, DOI 10.1111/j.1471-4159.1993.tb07476.x; Erickson JD, 1996, P NATL ACAD SCI USA, V93, P5166, DOI 10.1073/pnas.93.10.5166; ERICKSON JD, 1990, BRAIN RES, V516, P155, DOI 10.1016/0006-8993(90)90912-U; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GALLAGHER M, 1995, CURR OPIN NEUROBIOL, V5, P161, DOI 10.1016/0959-4388(95)80022-0; Gilmor ML, 1996, J NEUROSCI, V16, P2179; GREENE LA, 1977, NATURE, V268, P349, DOI 10.1038/268349a0; GREENE LA, 1977, BRAIN RES, V129, P247, DOI 10.1016/0006-8993(77)90005-1; HAIGH JR, 1994, NEUROREPORT, V5, P773, DOI 10.1097/00001756-199403000-00009; HARTINGER J, 1993, J BIOL CHEM, V268, P23122; KISH SJ, 1990, NEUROSCI LETT, V117, P347, DOI 10.1016/0304-3940(90)90689-7; KOSHIMURA K, 1990, J NEUROCHEM, V54, P533, DOI 10.1111/j.1471-4159.1990.tb01904.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MELEGA WP, 1981, BIOCHEMISTRY-US, V20, P4477, DOI 10.1021/bi00518a036; MISAWA H, 1995, NEUROREPORT, V6, P965, DOI 10.1097/00001756-199505090-00004; Misawa H., 1994, Society for Neuroscience Abstracts, V20, P890; PARSONS SM, 1993, INT REV NEUROBIOL, V35, P279, DOI 10.1016/S0074-7742(08)60572-3; PETER D, 1994, J BIOL CHEM, V269, P7231; REBOIS RV, 1980, BIOCHEMISTRY-US, V19, P1240, DOI 10.1021/bi00547a031; ROGHANI A, 1994, P NATL ACAD SCI USA, V91, P10620, DOI 10.1073/pnas.91.22.10620; RUBERG M, 1990, NEUROSCIENCE, V35, P327, DOI 10.1016/0306-4522(90)90086-J; SALVATERRA PM, 1989, INT REV NEUROBIOL, V31, P81; SCHAFER MKH, 1994, J MOL NEUROSCI, V5, P1, DOI 10.1007/BF02736691; Schafer MKH, 1995, J MOL NEUROSCI, V6, P225, DOI 10.1007/BF02736782; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P5184, DOI 10.1073/pnas.74.11.5184; SLOTKIN TA, 1994, J CLIN INVEST, V94, P696, DOI 10.1172/JCI117387; STRADA O, 1992, P NATL ACAD SCI USA, V89, P9549, DOI 10.1073/pnas.89.20.9549; TABB JS, 1992, J BIOL CHEM, V267, P15412; TOLL L, 1980, J BIOL CHEM, V255, P1787; Tuek S., 1988, HDB EXPT PHARM, P125; USDIN TB, 1995, TRENDS NEUROSCI, V18, P218, DOI 10.1016/0166-2236(95)93906-E; VAROQUI H, 1994, FEBS LETT, V342, P97, DOI 10.1016/0014-5793(94)80592-X; Varoqui H, 1996, PROG BRAIN RES, V109, P83; WEIHE E, 1994, J MOL NEUROSCI, V5, P149, DOI 10.1007/BF02736730; Weihe E, 1996, P NATL ACAD SCI USA, V93, P3547, DOI 10.1073/pnas.93.8.3547; WHITTAKER VP, 1988, HDB EXP PHARM, V86, P3; WU DH, 1994, J NEUROCHEM, V62, P1653; WURTMAN RJ, 1992, TRENDS NEUROSCI, V15, P117, DOI 10.1016/0166-2236(92)90351-8	53	94	99	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27229	27232		10.1074/jbc.271.44.27229	http://dx.doi.org/10.1074/jbc.271.44.27229			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910293	hybrid			2022-12-25	WOS:A1996VQ67900011
J	Aparicio, JG; Applebury, ML				Aparicio, JG; Applebury, ML			The photoreceptor guanylate cyclase is an autophosphorylating protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATRIURETIC-PEPTIDE RECEPTOR; ROD OUTER SEGMENTS; CRYSTAL-STRUCTURE; ADENINE-NUCLEOTIDES; CATALYTIC SUBUNIT; ACTIVATION; PURIFICATION; CALCIUM; DOMAIN; FAMILY	The photoreceptor membrane guanylate cyclase is a member of a family of proteins with a set of four structural motifs: an extracellular ligand binding domain, a transmembrane domain, an intracellular protein kinase-like domain, and an intracellular catalytic domain. Purified preparations of the photoreceptor guanylate cyclase have allowed us to explore the function of the protein kinase-like domain. ATP enhances the guanylate cyclase activity 2-fold in membranes stripped of peripheral proteins, The stimulation can be mimicked by ATP gamma S (adenosine 5'-O-(3-thiotriphosphate)), AMPPNP (5'-adenylyl beta,gamma-imidodiphosphate), and ADP, but not AMP. While this effect is lost by solubilizing guanylate cyclase, ATP binds the purified, solubilized enzyme in a site distinct from the catalytic GTP site as shown by specific labeling with 8-N-3[alpha-P-32]ATP. The enzyme has a protein kinase activity that is Mg2+-dependent and autophosphorylates serine residues. Myelin basic protein serves as a substrate for the kinase and enables further characterization of the kinase properties. The K-m for ATP is 81 mu M. The kinase activity is unaffected by calcium, cyclic nucleotides, and phorbol 12-myristate 13-acetate/L-alpha-phosphatidylserine/Ca2+ and is inhibited by high concentrations of staurosporine. These properties are distinct from other Ser/Thr kinases identified in rod outer segment preparations including protein kinase A, protein kinase C, and rhodopsin kinase. The observations offer the first biochemical evidence that a member of the receptor guanylate cyclase family has intrinsic protein kinase activity.	UNIV CHICAGO, COMM NEUROBIOL, CHICAGO, IL 60637 USA	University of Chicago				Aparicio, Jennifer/0000-0002-6442-3032	NEI NIH HHS [EY04810] Funding Source: Medline; NIMH NIH HHS [MH1-164] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY004810] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		APARICIO JG, 1995, PROTEIN EXPRES PURIF, V6, P501, DOI 10.1006/prep.1995.1067; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHANG CH, 1990, BIOCHIM BIOPHYS ACTA, V1052, P159, DOI 10.1016/0167-4889(90)90071-K; CHINKERS M, 1991, ANNU REV BIOCHEM, V60, P553, DOI 10.1146/annurev.bi.60.070191.003005; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; Czarnecki J, 1979, Methods Enzymol, V56, P642; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; DUDA T, 1993, BIOCHEMISTRY-US, V32, P1391, DOI 10.1021/bi00057a001; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GAZZANO H, 1991, INFECT IMMUN, V59, P1552, DOI 10.1128/IAI.59.4.1552-1557.1991; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GORACZNIAK RM, 1994, BIOCHEM J, V302, P455, DOI 10.1042/bj3020455; GORCZYCA WA, 1994, BIOCHEMISTRY-US, V33, P3217, DOI 10.1021/bi00177a011; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; HALEY BE, 1989, ICN BIOSCOPE, V1, P3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEBDON GM, 1981, P NATL ACAD SCI-BIOL, V78, P120, DOI 10.1073/pnas.78.1.120; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KAUPP UB, 1992, ANNU REV PHYSIOL, V54, P153; KELLEHER DJ, 1985, J CYCLIC NUCL PROT, V10, P579; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; KOLLER KJ, 1993, J BIOL CHEM, V268, P5997; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; KUROSE H, 1987, FEBS LETT, V219, P375, DOI 10.1016/0014-5793(87)80256-9; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; POZDNYAKOV N, 1995, BIOCHEMISTRY-US, V34, P14279, DOI 10.1021/bi00044a002; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; SITARAMAYYA A, 1991, BIOCHEMISTRY-US, V30, P6742, DOI 10.1021/bi00241a016; STRYER L, 1991, J BIOL CHEM, V266, P10711; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; WOLBRING G, 1995, BIOCHEMISTRY-US, V34, P4689, DOI 10.1021/bi00014a024; Wong SKF, 1995, J BIOL CHEM, V270, P30818, DOI 10.1074/jbc.270.51.30818; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2490, DOI 10.1021/bi00789a010; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193	49	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27083	27089		10.1074/jbc.271.43.27083	http://dx.doi.org/10.1074/jbc.271.43.27083			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900199	hybrid			2022-12-25	WOS:A1996VP23300093
J	Palmer, M; Saweljew, P; Vulicevic, I; Valeva, A; Kehoe, M; Bhakdi, S				Palmer, M; Saweljew, P; Vulicevic, I; Valeva, A; Kehoe, M; Bhakdi, S			Membrane-penetrating domain of streptolysin O identified by cysteine scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-ACTIVATED TOXIN; PNEUMOLYSIN; CYTOLYSIN; REQUIRE	Streptolysin O (SLO), a polypeptide of 571 amino acids, belongs to a family of highly homologous toxins that bind to cell membranes containing cholesterol and then polymerize to form large transmembrane pores. A conserved region close to the C terminus contains the single cysteine residue of SLO and has been implicated in membrane binding, which has been the only clear assignment of function to a part of the sequence. We have used a cysteine-less active mutant of SLO to introduce single cysteine residues at 19 positions distributed throughout the sequence. The cysteines were derivatized with the polarity-sensitive fluorophore acrylodan, and the fluorescence emission of the label was examined. at the different stages of SLO pore assembly. With several mutants, oligomerization on membranes was accompanied by emission blue-shifts, indicating movement of the label into a more hydrophobic environment, These effects were essentially confined to the range of amino acids 213-305. With oligomeric mutants L274C, S286C, and S305C, additional environmental alterations were induced when different nondenaturing detergents were used to dislodge the membrane lipids from the oligomers. The corresponding amino acid residues thus insert. into the lipid bilayer during pore formation. Conversely, the spectra of oligomeric mutants A213C and T245C were not affected by detergents, Devoid of contact with the lipid bilayer, these amino acid residues probably participate in the interaction of SLO molecules within the oligomer.	UNIV NEWCASTLE UPON TYNE, SCH MED, DEPT MICROBIOL, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND	Newcastle University - UK	Palmer, M (corresponding author), UNIV MAINZ, INST MED MICROBIOL, AUGUSTUSPL, D-55101 MAINZ, GERMANY.							Alouf JE, 1991, SOURCEBOOK BACTERIAL, P147; BHAKDI S, 1985, INFECT IMMUN, V47, P52; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; CORMACK B, 1987, CURRENT PROTOCOLS MO; DELOSTOYOS JR, 1996, INFECT IMMUN, V64, P40; DUNCAN JL, 1975, J CELL BIOL, V67, P160, DOI 10.1083/jcb.67.1.160; FUESSLE R, 1981, Journal of Cell Biology, V91, P83; HILL J, 1994, INFECT IMMUN, V62, P757, DOI 10.1128/IAI.62.2.757-758.1994; HUGO F, 1986, INFECT IMMUN, V54, P641, DOI 10.1128/IAI.54.3.641-645.1986; IWAMOTO M, 1987, EUR J BIOCHEM, V167, P425, DOI 10.1111/j.1432-1033.1987.tb13355.x; KEHOE MA, 1987, INFECT IMMUN, V55, P3228, DOI 10.1128/IAI.55.12.3228-3232.1987; LAKEY JH, 1991, EUR J BIOCHEM, V196, P599, DOI 10.1111/j.1432-1033.1991.tb15855.x; OHNOIWASHITA Y, 1991, J BIOCHEM-TOKYO, V110, P369, DOI 10.1093/oxfordjournals.jbchem.a123588; PALMER M, 1995, EUR J BIOCHEM, V231, P388, DOI 10.1111/j.1432-1033.1995.tb20711.x; PINKNEY M, 1989, INFECT IMMUN, V57, P2553, DOI 10.1128/IAI.57.8.2553-2558.1989; PINKNEY M, 1995, INFECT IMMUN, V63, P2776, DOI 10.1128/IAI.63.7.2776-2779.1995; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; SAUNDERS FK, 1989, INFECT IMMUN, V57, P2547, DOI 10.1128/IAI.57.8.2547-2552.1989; SEKIYA K, 1993, J BACTERIOL, V175, P5953, DOI 10.1128/JB.175.18.5953-5961.1993; Valeva A, 1996, EMBO J, V15, P1857, DOI 10.1002/j.1460-2075.1996.tb00536.x; WARD RJ, 1994, BIOCHEMISTRY-US, V33, P7477, DOI 10.1021/bi00189a056; Weller U, 1996, EUR J BIOCHEM, V236, P34, DOI 10.1111/j.1432-1033.1996.00034.x	22	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26664	26667		10.1074/jbc.271.43.26664	http://dx.doi.org/10.1074/jbc.271.43.26664			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900142	hybrid			2022-12-25	WOS:A1996VP23300036
J	Petrova, TV; Takagi, T; Cox, JA				Petrova, TV; Takagi, T; Cox, JA			Phosphorylation of the IQ domain regulates the interaction between Ca2+-vector protein and its target in amnphioxus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM VECTOR PROTEIN; LIGHT CHAIN KINASE; CALMODULIN-BINDING-PROTEIN; SKELETAL-MUSCLE; MYOSIN-BINDING; TROPONIN-C; IDENTIFICATION; AMPHIOXUS; PURIFICATION; NEUROMODULIN	Calcium vector protein target (CaVPT) a 26-kDa endogenous target of calcium vector protein from Amphioxus (CaVP), contains three distinct regions: a N-terminal Pro-Ala-Lys-rich motif segment 36-50 displaying sequence similarity to the calmodulin-binding site in neuromodulin and neurogranin where they are designated as the IQ domain; and two immunoglobulinlike folds. The phosphorylation by protein kinase C of Ser-43 in the IQ domain drastically decreases the affinity of CaVPT for CaVP and CaVP protects CaVPT from phosphorylation. Phosphorylation by the catalytic subunit of cyclic AMP-dependent protein kinase has a similar effect, but in addition to Ser 43 four other phosphorylated sites were identified. Removal of the Pro-Ala-Lys-rich region and the IQ domain in CaVPT by trypsin leads to the loss of binding to CaVP, whereas the chymotryptic fragment, containing these regions and first immunoglobulin-like domain, retained the ability to interact with CaVP. A synthetic IQ domain alone interacts strongly with calmodulin, but not with CaVP. Two main conclusions can be drawn from this study: 1) the regulation of interaction between CaVP and CaVPT is very similar to the mechanism observed in the complex between neuromodulin or neurogranin and calmodulin; 2) in spite of this similarity the entire CaVP-binding site is not restricted to the IQ domain; in addition the Pro-Ala-Lys-rich motif may he necessary for high affinity binding to CaVP.	UNIV GENEVA,DEPT BIOCHEM,CH-1211 GENEVA 4,SWITZERLAND; TOHOKU UNIV,FAC SCI,INST BIOL,SENDAI,MIYAGI 980,JAPAN	University of Geneva; Tohoku University								ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BRONSTEIN I, 1990, BIOTECHNIQUES, V8, P310; BUELT MK, 1994, J BIOL CHEM, V269, P29367; CHENEY RE, 1991, J CELL BIOL, V115, P432; COX JA, 1986, J BIOL CHEM, V261, P3173; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DURUSSEL I, 1993, BIOCHEMISTRY-US, V32, P2394, DOI 10.1021/bi00060a034; Edlund M, 1996, J BIOL CHEM, V271, P1393, DOI 10.1074/jbc.271.3.1393; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; FURST DO, 1992, J CELL SCI, V102, P769; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HEAD JF, 1974, BIOCHEM J, V137, P145, DOI 10.1042/bj1370145; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; ITO M, 1989, J BIOL CHEM, V264, P13971; LABEIT S, 1992, EMBO J, V11, P1711, DOI 10.1002/j.1460-2075.1992.tb05222.x; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NOGUCHI J, 1992, J BIOL CHEM, V267, P20302; OBERMANN WMJ, 1995, EUR J BIOCHEM, V233, P110, DOI 10.1111/j.1432-1033.1995.110_1.x; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PETROVA TV, 1995, BIOCHEMISTRY-US, V34, P312, DOI 10.1021/bi00001a038; PETROVA TV, 1995, 9 INT S CALC BIND PR; PFUHL M, 1995, J BIOMOL NMR, V6, P48, DOI 10.1007/BF00417491; ROSE K, 1994, J AM CHEM SOC, V116, P30, DOI 10.1021/ja00080a004; TAKAGI T, 1990, J BIOL CHEM, V265, P19721; TAKAGI T, 1994, EUR J BIOCHEM, V221, P537, DOI 10.1111/j.1432-1033.1994.tb18766.x; VALETTETALBI L, 1993, HISTOCHEMISTRY, V100, P73, DOI 10.1007/BF00268880; VAUGHAN KT, 1993, J BIOL CHEM, V268, P3670; VONDERHAAR F, 1976, BIOCHEM BIOPH RES CO, V70, P1009, DOI 10.1016/0006-291X(76)90692-6; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WOLENSKI JS, 1995, TRENDS CELL BIOL, V5, P310, DOI 10.1016/S0962-8924(00)89053-4	36	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26646	26652		10.1074/jbc.271.43.26646	http://dx.doi.org/10.1074/jbc.271.43.26646			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900139	hybrid			2022-12-25	WOS:A1996VP23300033
J	Watanabe, R; Kinoshita, T; Masaki, R; Yamamoto, A; Takeda, J; Inoue, N				Watanabe, R; Kinoshita, T; Masaki, R; Yamamoto, A; Takeda, J; Inoue, N			PIG-A and PIG-H, which participate in glycosylphosphatidylinositol anchor biosynthesis, from a protein complex in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; GPI-ANCHOR; GENE; PHOSPHATIDYLINOSITOL; CLONING; IDENTIFICATION; EXPRESSION; COMPONENT; MUTATIONS; MUTANTS	Many eukaryotic cell surface proteins are bound to the membrane via a glycosylphosphatidylinositol (GPI) anchor. Assembly of the GPI anchor precursor is a sequential addition of components to phosphatidylinositol (PI) in the endoplasmic reticulum (ER). The first step is the transfer of N-acetylglucosamine (GlcNAc) to PI from UDB-GlcNAc to generate GlcNAc-PI. This simple step, however, is regulated by at least three genes because in both mammals and yeasts, there ape three mutants of different complementation classes. To clarify this complexity we analyzed the products of two cloned human genes, PIG-A and PIG-H. Here we demonstrate 1) that PIG-A is an ER transmembrane protein with a large cytoplasmic domain that has homology to a bacterial GlcNAc transferase and a small lumenal domain; 2) that PIG-H is a cytoplasmically oriented, ER-associated protein; and 3) that they form a protein complex. We also show that part of the small lumenal domain of PIG-A plays an essential functional role in targeting itself to the rough ER. Taken together with the cytoplasmic orientation of GlcNAc-PI, these results indicated that PIG-A and PIG-H are subunits of the GPI GlcNAc transferase that transfers GlcNAc to PI on the cytoplasmic side of the ER.	OSAKA UNIV, MICROBIAL DIS RES INST, DEPT IMMUNOREGULAT, SUITA, OSAKA 565, JAPAN; KANSAI MED UNIV, DEPT PHYSIOL, MORIGUCHI, OSAKA 570, JAPAN; KANSAI MED UNIV, LIVER RES CTR, DIV CELL BIOL, MORIGUCHI, OSAKA 570, JAPAN	Osaka University; Kansai Medical University; Kansai Medical University			Kinoshita, Taroh/C-7353-2009	Watanabe, Reika/0000-0002-7427-7702				BENGHEZAL M, 1995, J CELL BIOL, V130, P1333, DOI 10.1083/jcb.130.6.1333; BESSLER M, 1994, EMBO J, V13, P110, DOI 10.1002/j.1460-2075.1994.tb06240.x; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; HOLLANDER N, 1988, J IMMUNOL, V141, P4283; HYMAN R, 1988, TRENDS GENET, V4, P5, DOI 10.1016/0168-9525(88)90120-5; INOUE N, 1993, J BIOL CHEM, V268, P6882; KAMITANI T, 1993, J BIOL CHEM, V268, P20733; KAWAGOE K, 1994, GENOMICS, V23, P566, DOI 10.1006/geno.1994.1544; Kinoshita T, 1995, ADV IMMUNOL, V60, P57, DOI 10.1016/S0065-2776(08)60584-2; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; LEIDICH SD, 1994, J BIOL CHEM, V269, P10193; LEIDICH SD, 1995, J BIOL CHEM, V270, P13029, DOI 10.1074/jbc.270.22.13029; MASAKI R, 1994, J CELL BIOL, V126, P1407, DOI 10.1083/jcb.126.6.1407; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; MOHNEY RP, 1994, J BIOL CHEM, V269, P6536; OMURA T, 1970, J BIOCHEM-TOKYO, V67, P249, DOI 10.1093/oxfordjournals.jbchem.a129248; OSTENDORF T, 1995, BLOOD, V85, P1640, DOI 10.1182/blood.V85.6.1640.bloodjournal8561640; ROSSE WF, 1995, BLOOD, V86, P3277, DOI 10.1182/blood.V86.9.3277.bloodjournal8693277; SCHONBACHLER M, 1995, EMBO J, V14, P1637, DOI 10.1002/j.1460-2075.1995.tb07152.x; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333; VOSSEN JH, 1995, BBA-GEN SUBJECTS, V1243, P549, DOI 10.1016/0304-4165(95)00002-S; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8	29	76	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26868	26875		10.1074/jbc.271.43.26868	http://dx.doi.org/10.1074/jbc.271.43.26868			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900170	hybrid			2022-12-25	WOS:A1996VP23300064
J	Reddy, UR; Phatak, S; Pleasure, D				Reddy, UR; Phatak, S; Pleasure, D			Human neural tissues express a truncated Ror1 receptor tyrosine kinase, lacking both extracellular and transmembrane domains	ONCOGENE			English	Article						splicing; truncated-Ror1; neural tissues	GROWTH-FACTOR RECEPTOR; HUMAN CELL-LINE; NTERA-2 CELLS; FAMILY; GENE; RNA	Human heart, lung and kidney express a 6 kb mRNA encoding Ror1, a member of the receptor tyrosine kinase (RTK) family with as yet unknown ligand specificity. We used a Ror1 cDNA probe to screen a cDNA library prepared from the human neuronogenic teratocarcinoma line, NTera2, and cloned a 2373 nucleotide transcript, This transcript contains an open reading frame that encodes a 388 amino acid protein identical with the cytosolic, C-terminal region of ror1 but lacking the ror1 transmembrane and entire extracellular domains, Northern blots demonstrate that mRNA encoding this truncated Ror1 ('t-Ror1') is abundantly expressed in fetal and adult human CNS, in human leukemia, lymphoma cell. lines, and in a variety of human cancers derived from neuroectoderm. While previous studies have documented alternative splicing patterns within 5' and 3' regions of mRNAs encoding various RTKs altering their ligand binding specificity or their intracellular signaling, the present report is the first to demonstrate tissue-specific alternative mRNA splicing causing loss of the entire extracellular and transmembrane regions of an RTK.	UNIV PENN,DEPT NEUROL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PEDIAT,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	Reddy, UR (corresponding author), CHILDRENS HOSP PHILADELPHIA,DIV NEUROL RES,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS008075, P20NS031102, R01NS025044, P50NS008075] Funding Source: NIH RePORTER; NINDS NIH HHS [NS08075, NS31102, NS25044] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAKER DL, 1989, CANCER RES, V49, P4142; BARKER PA, 1993, J BIOL CHEM, V268, P15150; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WILSON C, 1993, P NATL ACAD SCI USA, V90, P7109, DOI 10.1073/pnas.90.15.7109; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOUNKIN DP, 1993, P NATL ACAD SCI USA, V90, P2174, DOI 10.1073/pnas.90.6.2174	18	27	34	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1555	1559						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875995				2022-12-25	WOS:A1996VL38400022
J	Roenneberg, T; Rehman, J				Roenneberg, T; Rehman, J			Nitrate, a nonphotic signal for the circadian system	FASEB JOURNAL			English	Article						dinoflagellates; nitrate metabolism; circadian rhythms; multioscillator model; algal blooms	GONYAULAX-POLYEDRA; ACTIVITY RHYTHMS; PHASE RESPONSES; HOUSE SPARROWS; CLOCK; LIGHT; FREQUENCY; PERIOD; AUTOREGULATION; OSCILLATORS	Recent advances in circadian biology have brought insights into the molecular mechanisms involved in the generation of circadian rhythmicity. However, Little is known about the relationship between these molecular oscillators and the organism's temporal adaptation to complex daily environmental changes. We have studied the effects of nutrients on the circadian system of a marine unicellular alga and found that nitrate influences all three canonical properties of circadian rhythmicity: amplitude, phase, and period. The effects of nitrate are part of a complex feedback loop involving both circadian input and output. These new aspects of circadian nutrient metabolism have important implications for our understanding of the ecological significance of circadian programs.			Roenneberg, T (corresponding author), UNIV MUNICH,INST MED PSYCHOL,D-80336 MUNICH,GERMANY.		Rehman, Jalees/J-8258-2012; Rehman, Jalees/B-8064-2009; Rehman, Jalees/GVU-1981-2022	Rehman, Jalees/0000-0002-2787-9292; Rehman, Jalees/0000-0002-2787-9292				ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; ASCHOFF J, 1987, COMP ASPECTS CIRCADI, P19; Broda H., 1986, Journal of Biological Rhythms, V1, P251, DOI 10.1177/074873048600100307; BYRNE TE, 1992, PLANT PHYSIOL, V98, P879, DOI 10.1104/pp.98.3.879; CHABOT CC, 1992, J BIOL RHYTHM, V7, P287, DOI 10.1177/074873049200700403; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; DAAN S, 1984, J COMP PHYSIOL A, V154, P669; EBIHARA S, 1992, J COMP PHYSIOL A, V171, P63; EPPLEY RW, 1968, J PHYCOL, V4, P333, DOI 10.1111/j.1529-8817.1968.tb04704.x; FLEISSNER G, 1996, IN PRESS SCORPION BI; GUILLARD RR, 1962, CAN J MICROBIOL, V8, P229, DOI 10.1139/m62-029; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; HARRISON PJ, 1979, J EXP MAR BIOL ECOL, V21, P199; HASTINGS JW, 1961, J GEN PHYSIOL, V45, P69, DOI 10.1085/jgp.45.1.69; HASTINGS JW, 1958, BIOL BULL, V115, P440, DOI 10.2307/1539108; HASTINGS JW, 1964, PHOTOPHYSIOLOGY, P333; HAU M, 1992, J COMP PHYSIOL A, V170, P403; JILGE B, 1991, PHYSIOL BEHAV, V51, P157; JOHNSON CH, 1989, J BIOL RHYTHM, V4, P417, DOI 10.1177/074873048900400403; KENNEDY GA, 1991, AM J PHYSIOL, V261, pR819, DOI 10.1152/ajpregu.1991.261.4.R819; Kleinhofs A., 1990, BIOCH PLANTS, P89, DOI [DOI 10.1016/B978-0-08-092616-2.50009-7, 10.1016/B978-0-08-092616-2.50009-7]; MORSE D, 1994, J BIOL RHYTHM, V9, P263, DOI 10.1177/074873049400900307; MROSOVSKY N, 1992, J BIOL RHYTHM, V7, P41, DOI 10.1177/074873049200700104; PILGRIM ML, 1993, PLANT MOL BIOL, V23, P349, DOI 10.1007/BF00029010; RAMALHO CB, 1995, PLANT PHYSIOL, V107, P225, DOI 10.1104/pp.107.1.225; ROENNEBERG T, 1989, J BIOL RHYTHM, V4, P201, DOI 10.1177/074873048900400208; ROENNEBERG T, 1991, PHOTOCHEM PHOTOBIOL, V53, P525, DOI 10.1111/j.1751-1097.1991.tb03665.x; ROENNEBERG T, 1988, NATURWISSENSCHAFTEN, V75, P206, DOI 10.1007/BF00735584; ROENNEBERG T, 1993, NATURE, V362, P362, DOI 10.1038/362362a0; ROENNEBERG T, 1994, J BIOL RHYTHM, V9, P1, DOI 10.1177/074873049400900101; ROENNEBERG T, 1994, NATURWISSENSCHAFTEN, V81, P343; ROENNEBERG T, 1992, OSCILLATIONS MORPHOG, P399; Roenneberg T, 1994, EVOLUTION CIRCADIAN, P3; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; STEPHAN FK, 1992, PHYSIOL BEHAV, V52, P997, DOI 10.1016/0031-9384(92)90382-C; STEPHAN FK, 1992, PHYSIOL BEHAV, V52, P985, DOI 10.1016/0031-9384(92)90381-B; SWEENEY BM, 1984, PLANT PHYSIOL, V75, P242, DOI 10.1104/pp.75.1.242; VANREETH O, 1994, AM J PHYSIOL, V266, pE964, DOI 10.1152/ajpendo.1994.266.6.E964; WEAVER DR, 1989, DEV BRAIN RES, V46, P291, DOI 10.1016/0165-3806(89)90292-7	39	45	45	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1996	10	12					1443	1447		10.1096/fasebj.10.12.8903515	http://dx.doi.org/10.1096/fasebj.10.12.8903515			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	VP485	8903515				2022-12-25	WOS:A1996VP48500010
J	Kimura, K; Suzuki, H; Daiho, T; Yamasaki, K; Kanazawa, T				Kimura, K; Suzuki, H; Daiho, T; Yamasaki, K; Kanazawa, T			Identification of arginyl residues located at the ATP binding site of sarcoplasmic reticulum Ca2+-ATPase - Modification with 1,2-cyclohexanedione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PROTON-TRANSLOCATING ATPASE; PLASMA-MEMBRANE ATPASE; ACTIVE-SITE; ADENOSINE-TRIPHOSPHATASE; FUNCTIONAL CONSEQUENCES; CONFORMATIONAL CHANGE; FLUORESCEIN ISOTHIOCYANATE; CA-2+-TRANSPORTING ATPASE; MECHANISTIC IMPLICATIONS	Sarcoplasmic reticulum vesicles were treated with 1,2-cyclohexanedione (CHD) in sodium berate (pH 8.0), The Ca2+-ATPase activity was completely inhibited, Inhibition of Mg . ATP and Mg . ADP binding to the high affinity ATP binding site as well as inhibition of phosphorylation with ATP occurred simultaneously with the inhibition of the Ca2+-ATPase activity. Phosphorylation with acetyl phosphate was not inhibited, The Ca2+-ATPase was strongly protected by Mg . ATP, Mg . ADP, and Mg . AMP against this inhibition, Binding of acetyl phosphate or P-i to the enzyme gave no protection, Phosphorylation with acetyl phosphate also had no protective effect, Peptide mapping of the tryptic digests, detection of peptides containing CHD-modified arginyl residues with Girard's reagent T, and sequencing revealed that Arg-489, Arg-505, and Arg-678 were modified with CHD. Arg-489 and Arg-678 were almost completely protected by Mp . ATP against this modification, but partially protected by prelabeling with fluorescein 5-isothiocyanate, which occupies the adenosine binding region in the ATP binding site, In contrast, Arg-505 was slightly protected by Mg . ATP and almost completely protected by prelabeling with fluorescein 5-isothiocyanate, Taken together, these findings suggest that Arg-489 and Arg-678 are located in or near the region occupied by the triphosphate moiety of ATP, either or both of these residues being in or close to the region occupied by the alpha-phosphoryl group in the high affinity ATP binding site and involved in the CHD-induced inhibition of this enzyme and that Arg-505 is very close to (but slightly out of) the adenosine binding region in the ATP binding site. The acetyl phosphatase activity and phosphorylation with P-i were also inhibited by the CHD treatment, but the inhibitions were considerably slower than those described above, This suggests that the arginyl residues involved in these inhibitions are distinct from that involved in the inhibition of the Ca2+-ATPase activity.	ASAHIKAWA MED COLL,DEPT BIOCHEM,ASAHIKAWA,HOKKAIDO 078,JAPAN; ASAHIKAWA MED COLL,DEPT INTERNAL MED 3,ASAHIKAWA,HOKKAIDO 078,JAPAN	Asahikawa Medical College; Asahikawa Medical College								ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALLEN G, 1976, FEBS LETT, V63, P188, DOI 10.1016/0014-5793(76)80223-2; ANDERSEN JP, 1985, J MEMBRANE BIOL, V88, P187, DOI 10.1007/BF01868432; ARAV R, 1983, J BIOL CHEM, V258, P433; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BASTIDE F, 1973, Journal of Biological Chemistry, V248, P8385; BISHOP JE, 1989, BIOPHYS J, V55, pA204; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; COHN WE, 1957, METHOD ENZYMOL, V3, P867, DOI 10.1016/S0076-6879(57)03464-3; DAIHO T, 1994, J BIOL CHEM, V269, P11060; DAIHO T, 1993, BIOCHEMISTRY-US, V32, P10021, DOI 10.1021/bi00089a018; DEGANI C, 1973, J BIOL CHEM, V248, P8222; DUPONT Y, 1978, NATURE, V273, P396, DOI 10.1038/273396a0; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; EVANS PR, 1979, NATURE, V279, P500, DOI 10.1038/279500a0; Fersht A., 1985, ENZYME STRUCTURE MEC; FLETTERICK RJ, 1975, P NATL ACAD SCI USA, V72, P38, DOI 10.1073/pnas.72.1.38; FRIEDMAN Z, 1970, FEBS LETT, V11, P69, DOI 10.1016/0014-5793(70)80494-X; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GREEN NM, 1986, CIBA F SYMP, V122, P93; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; HEGYVARY C, 1971, J BIOL CHEM, V246, P5234; HESSE JE, 1984, P NATL ACAD SCI-BIOL, V81, P4746, DOI 10.1073/pnas.81.15.4746; IMAMURA Y, 1984, J BIOCHEM, V95, P1305, DOI 10.1093/oxfordjournals.jbchem.a134736; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KOLAND JG, 1986, J BIOL CHEM, V261, P5936; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; LACAPERE JJ, 1993, BIOCHEMISTRY-US, V32, P3414, DOI 10.1021/bi00064a027; LIPMANN F, 1945, J BIOL CHEM, V159, P21; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MAEDA M, 1990, J BIOL CHEM, V265, P9027; MAKINOSE M, 1967, PFLUG ARCH GES PHYS, V294, pR82; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MCINTOSH DB, 1992, J BIOL CHEM, V267, P22328; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; MISSIAEN L, 1989, BIOCHEM J, V264, P609, DOI 10.1042/bj2640609; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MUALEM S, 1979, NATURE, V277, P238, DOI 10.1038/277238a0; MURPHY AJ, 1976, BIOCHEM BIOPH RES CO, V70, P1048, DOI 10.1016/0006-291X(76)91008-1; NAKAMURA S, 1994, J BIOL CHEM, V269, P16015; PATTHY L, 1975, J BIOL CHEM, V250, P557; PATTHY L, 1979, EUR J BIOCHEM, V99, P309, DOI 10.1111/j.1432-1033.1979.tb13258.x; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; PUCELL A, 1971, J BIOL CHEM, V246, P3389; RAESS BU, 1985, MOL PHARMACOL, V27, P444; RIORDAN JF, 1979, MOL CELL BIOCHEM, V26, P71; ROSS DC, 1991, J BIOL CHEM, V266, P4613; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SIEBERS A, 1992, J BIOL CHEM, V267, P12717; STADTMAN ER, 1957, METHOD ENZYMOL, V3, P228, DOI 10.1016/S0076-6879(57)03379-0; STEFANOVA HI, 1993, BIOCHEMISTRY-US, V32, P356, DOI 10.1021/bi00052a044; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VILSEN B, 1991, J BIOL CHEM, V266, P16157; WALLMARK B, 1980, J BIOL CHEM, V255, P5313; WASSARMAN PM, 1971, J MOL BIOL, V60, P509, DOI 10.1016/0022-2836(71)90185-9; WELLS TNC, 1994, BIOCHEMISTRY-US, V33, P5777, DOI 10.1021/bi00185a015; YAMAGATA K, 1993, J BIOL CHEM, V268, P20930; YAMAMOTO H, 1988, J BIOCHEM-TOKYO, V103, P452, DOI 10.1093/oxfordjournals.jbchem.a122291; YAMAMOTO H, 1989, J BIOCHEM-TOKYO, V106, P1121, DOI 10.1093/oxfordjournals.jbchem.a122976; YAMAMOTO T, 1967, J BIOCHEM-TOKYO, V62, P558, DOI 10.1093/oxfordjournals.jbchem.a128706; YAMASAKI K, 1994, J BIOL CHEM, V269, P4129	71	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28933	28941		10.1074/jbc.271.46.28933	http://dx.doi.org/10.1074/jbc.271.46.28933			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910542	hybrid			2022-12-25	WOS:A1996VT05200034
J	Song, LX; Fricker, LD				Song, LX; Fricker, LD			Tissue distribution and characterization of soluble and membrane-bound forms of metallocarboxypeptidase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYPEPTIDASE-E; FURIN; VESICLES; ENZYME; GENE; RAT; PH; PURIFICATION; ENDOPROTEASE; INHIBITION	Metallocarboxypeptidase D (CPD) is a recently discovered 180-kDa membrane-bound carboxypeptidase E-like enzyme (Song, L. and Fricker, L. D. (1995) J. Biol. Chem. 270, 25007-25013). In the present study, a soluble CPD-like activity has been purified to homogeneity and characterized. On denaturing polyacrylamide gels, the soluble enzyme from bovine pituitary glands appears as two bands of 170 and 135 kDa which are converted to 155 and 115 kDa by endoglycosidase F. Both of the soluble forms of CPD are recognized by an antisera raised against CPD purified from rat brain membranes. The partial N-terminal amino acid sequences of the two soluble forms are identical to each other and to the predicted N terminus of duck gp180. The soluble and membrane forms of CPD have similar pH optima, inhibitor specificities, and kinetic parameters for substrate hydrolysis. CPD-Like enzymatic activity is detected in all rat tissues examined, with highest levels in pituitary, brain, and adrenal. Western blot analysis indicates that both soluble and membrane forms of CPD are present in rat brain, heart, Liver, and kidney. At least four distinct 100-180-kDa forms of CPD are detected on Western blots, although an antiserum raised against the C-terminal region of rat CPD recognizes only the 180-kDa membrane-bound form. The finding that CPD is widely distributed suggests a broad role for this enzyme in the processing of proteins that transit the secretory pathway.	ALBERT EINSTEIN COLL MED,DEPT MOL PHARMACOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NIDA NIH HHS [DA-04494, DA-00194] Funding Source: Medline; NIDDK NIH HHS [DK-51271] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K02DA000194, R01DA004494] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; [Anonymous], 1995, METH NEUROSCI; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; EIPPER BA, 1992, J BIOL CHEM, V267, P4008; EIPPER BA, 1988, ANNU REV PHYSIOL, V50, P333, DOI 10.1146/annurev.ph.50.030188.002001; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FRICKER LD, 1989, MOL ENDOCRINOL, V3, P666, DOI 10.1210/mend-3-4-666; FRICKER LD, 1991, PEPTIDE BIOSYNTHESIS, P199; GARTEN W, 1994, BIOCHIMIE, V76, P217, DOI 10.1016/0300-9084(94)90149-X; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; JOHNSON RG, 1976, J BIOL CHEM, V251, P2189; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; KUROKI K, 1995, J BIOL CHEM, V270, P15022, DOI 10.1074/jbc.270.25.15022; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; Rovere C, 1996, ENDOCRINOLOGY, V137, P2954, DOI 10.1210/en.137.7.2954; RUSSELL JT, 1984, J BIOL CHEM, V259, P9496; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; SETTLE SH, 1995, P NATL ACAD SCI USA, V92, P9470, DOI 10.1073/pnas.92.21.9470; SKIDGEL RA, 1988, TRENDS PHARMACOL SCI, V9, P299, DOI 10.1016/0165-6147(88)90015-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONG LX, 1995, J BIOL CHEM, V270, P25007, DOI 10.1074/jbc.270.42.25007; STEINER DF, 1992, J BIOL CHEM, V267, P23435; Varlamov O, 1996, J BIOL CHEM, V271, P13981, DOI 10.1074/jbc.271.24.13981; VARLAMOV O, UNPUB; ZHENG M, 1994, J NEUROSCI, V14, P4656	30	65	66	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28884	28889		10.1074/jbc.271.46.28884	http://dx.doi.org/10.1074/jbc.271.46.28884			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910535				2022-12-25	WOS:A1996VT05200027
J	Trapaidze, N; Keith, DE; Cvejic, S; Evans, CJ; Devi, LA				Trapaidze, N; Keith, DE; Cvejic, S; Evans, CJ; Devi, LA			Sequestration of the delta opioid receptor - Role of the C terminus in agonist-mediated internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; COATED PIT FORMATION; SEQUENCE; PHOSPHORYLATION; ENDOCYTOSIS; EXPRESSION	The primary structure of the opioid receptors have revealed that many of the structural features that are conserved in other G protein-coupled receptors are also conserved in the opioid receptors. Upon exposure to agonists, some G protein-coupled receptors internalize rapidly, whereas other structurally homologous G protein-coupled receptors do not. It is not known whether opioid receptors are regulated by rapid endocytosis. In transfected Chinese hamster ovary cells expressing the epitope-tagged wild type delta opioid receptor, exposure to 100 nM [D-Ala(2),D-Leu(5)]enkephalin causes internalization of the receptor within 30 min as determined by confocal microscopy, The rate of internalization of the wild type receptor is rapid with a half-maximal reduction by about 10 min, as determined by the reduction in mean surface receptor fluorescence intensity measured using flow cytometry. In contrast, the cells expressing receptors lacking the C-terminal 15 or 37 amino acids exhibit a substantially slower rate of internalization. Furthermore, the cells expressing receptors with point mutations of any of the Ser/Thr between Ser(344) and Ser(363) in the C-terminal tail exhibit a significant reduction in the rate of receptor internalization. These results suggest that a portion of the C-terminal tail is involved in receptor internalization. Agents that block the formation of clathrin-coated pits considerably reduce the extent of agonist-mediated internalization of the wild type receptor. Taken together, these results suggest that the mild type opioid receptor undergoes rapid agonist-mediated internalization via a classic endocytic pathway and that a portion of the C-terminal tail plays an important role in this internalization process.	NYU,SCH MED,DEPT PHARMACOL,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN COMPREHENS CANC CTR,NEW YORK,NY 10016; UNIV CALIF LOS ANGELES,DEPT PSYCHIAT & BEHAV SCI,LOS ANGELES,CA 90024	New York University; New York University; University of California System; University of California Los Angeles			Devi P, Lakshmi/GXM-5982-2022	Devi P, Lakshmi/0000-0001-9274-4776	NATIONAL INSTITUTE ON DRUG ABUSE [R56DA008863, P50DA005010, R01DA008863, R37DA008863] Funding Source: NIH RePORTER; NIDA NIH HHS [DA08863, P50 DA005010, DA05010, R01 DA008863] Funding Source: Medline; NINDS NIH HHS [NS1788] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARDEN JR, 1995, J NEUROCHEM, V65, P1636; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; CHENG PY, 1995, J NEUROSCI, V15, P5976; CHEUNG AH, 1988, MOL PHARMACOL, V34, P128; Cvejic S, 1996, J BIOL CHEM, V271, P4073; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; ELDE R, 1995, ANN NY ACAD SCI, V757, P390, DOI 10.1111/j.1749-6632.1995.tb17497.x; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P1979; Hermans E, 1996, MOL PHARMACOL, V49, P365; Herz A., 1993, OPIOIDS; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; Jockers R, 1996, J BIOL CHEM, V271, P9355, DOI 10.1074/jbc.271.16.9355; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; NANTEL F, 1993, MOL PHARMACOL, V43, P548; PEI G, 1995, MOL PHARMACOL, V48, P173; PETANCESKA S, 1992, J BIOL CHEM, V267, P26038; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; SCHMID I, 1988, CYTOMETRY, V9, P533, DOI 10.1002/cyto.990090605; SLICE LW, 1994, J BIOL CHEM, V269, P21755; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; UHL GR, 1994, TRENDS NEUROSCI, V17, P89, DOI 10.1016/0166-2236(94)90110-4; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; YU SS, 1993, J BIOL CHEM, V268, P337; ZHANG J, J BIOL CHEM, V271, P18302	30	149	151	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29279	29285		10.1074/jbc.271.46.29279	http://dx.doi.org/10.1074/jbc.271.46.29279			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910588	hybrid, Green Accepted			2022-12-25	WOS:A1996VT05200080
J	Habib, S; Hasnain, SE				Habib, S; Hasnain, SE			A 38-kDa host factor interacts with functionally important motifs within the Autographa californica multinucleocapsid nuclear polyhedrosis virus homologous region (hr1) DNA sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION FACTOR GENES; 30-KDA PROTEIN-BINDING; ENHANCER ELEMENTS; PUTATIVE ORIGINS; REPLICATION; TRANSCRIPTION; IE1; TRANSACTIVATOR; PROMOTER; REPEAT	We recently demonstrated that the Autographa californica multinucleocapsid nuclear polyhedrosis virus homologous region (hr1) enhances transcription from the viral polyhedrin promoter and also functions as a putative origin of replication (ori). Hr1, carrying five 28-base pair core palindrome units, has also been mapped with respect to its enhancer and ori functions (Habib, S., Pandey, S., Chatterji, U., Burma, S., Ahmad, R., Jain, A., and Hasnain, S. E. (1996) DNA Cell Biol. 15, 737-747). A 38-kDa host factor termed hr1-binding protein (hr1-BP) binds with high specificity and affinity (K-d similar to 6.5 x 10(-11) M) to functionally important motifs within hr1. The core palindrome as well as sequences immediately flanking it are required for this interaction. Divalent cations are not essential, and ionic interactions play only a minor role in complex formation. hr1-BP binds through the minor groove of the double helix to multiple sites within hr1, and binding occurs as a function of the number of modules within hr1. Phosphorylation of hr1-BP is important for host factor-hr1 interaction. Hr1-BP differs in several respects from the other host factor, polyhedrin promoter-binding protein described previously (Burma, S., Mukherjee, B., Jain, A., Habib, S., and Hasnain, S. E. (1994) J. Biol. Chem 269, 2750-2757). When hr1-BP was sequestered out, in vivo, by a plasmid carrying hr1 alone, the hr1-mediated enhancement of reporter expression was abolished, demonstrating that the binding of hr1-BP may be crucial for the enhancer activity of the dual function hr1 element.	NATL INST IMMUNOL,EUKARYOT GENE EXPRESS LAB,NEW DELHI 110067,INDIA	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)			HASNAIN, SEYED/C-1492-2009	Hasnain, Seyed/0000-0002-2967-0791				AHRENS CH, 1996, IN PRESS DNA REPLICA; BURMA S, 1994, J BIOL CHEM, V269, P2750; CARSON DD, 1991, J VIROL, V65, P945, DOI 10.1128/JVI.65.2.945-951.1991; CHOI J, 1995, VIROLOGY, V209, P99, DOI 10.1006/viro.1995.1234; CHOI J, 1995, J VIROL, V69, P4548, DOI 10.1128/JVI.69.7.4548-4551.1995; COPENHAVER GP, 1994, NUCLEIC ACIDS RES, V22, P2651, DOI 10.1093/nar/22.13.2651; DAVID E, 1995, J BIOL CHEM, V270, P8353, DOI 10.1074/jbc.270.14.8353; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GUARINO LA, 1986, J VIROL, V60, P224, DOI 10.1128/JVI.60.1.224-229.1986; GUARINO LA, 1991, J VIROL, V65, P3676, DOI 10.1128/JVI.65.7.3676-3680.1991; GUARINO LA, 1986, J VIROL, V60, P215, DOI 10.1128/JVI.60.1.215-223.1986; GUARINO LA, 1994, VIROLOGY, V200, P328, DOI 10.1006/viro.1994.1197; Habib S, 1996, DNA CELL BIOL, V15, P737, DOI 10.1089/dna.1996.15.737; HASNAIN SE, 1995, METHODS ENZYMOLOGY R, P20; Jain A, 1996, EUR J BIOCHEM, V239, P384, DOI 10.1111/j.1432-1033.1996.0384u.x; KANDALA JC, 1994, VIROLOGY, V198, P514, DOI 10.1006/viro.1994.1062; KIM SK, 1993, FEBS LETT, V315, P61, DOI 10.1016/0014-5793(93)81133-K; KOOL M, 1993, J GEN VIROL, V74, P2661, DOI 10.1099/0022-1317-74-12-2661; KOOL M, 1993, VIROLOGY, V192, P94, DOI 10.1006/viro.1993.1011; KOOL M, 1995, J GEN VIROL, V76, P2103, DOI 10.1099/0022-1317-76-9-2103; LEISY DJ, 1995, VIROLOGY, V208, P742, DOI 10.1006/viro.1995.1206; LEISY DJ, 1993, VIROLOGY, V196, P722, DOI 10.1006/viro.1993.1529; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; LU A, 1995, J VIROL, V69, P975, DOI 10.1128/JVI.69.2.975-982.1995; LU A, 1995, J VIROL, V69, P6265, DOI 10.1128/JVI.69.10.6265-6272.1995; MUKHERJEE B, 1995, J BIOL CHEM, V270, P4405, DOI 10.1074/jbc.270.9.4405; OSTAPCHUK P, 1986, P NATL ACAD SCI USA, V83, P8550, DOI 10.1073/pnas.83.22.8550; PAPAVASSILIOU AG, 1992, ANAL BIOCHEM, V203, P302, DOI 10.1016/0003-2697(92)90317-Z; PARTHUN MR, 1992, MOL CELL BIOL, V12, P4981, DOI 10.1128/MCB.12.11.4981; PEARSON M, 1992, SCIENCE, V257, P1382, DOI 10.1126/science.1529337; RODEMS SM, 1995, J VIROL, V69, P5368, DOI 10.1128/JVI.69.9.5368-5375.1995; RYDEN TA, 1993, J VIROL, V67, P2862, DOI 10.1128/JVI.67.5.2862-2870.1993; SUMMERS MD, 1987, B TEXAS AGR EXPT STA, V1555, P10	35	25	26	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28250	28258		10.1074/jbc.271.45.28250	http://dx.doi.org/10.1074/jbc.271.45.28250			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910443	hybrid			2022-12-25	WOS:A1996VU03300043
J	Yang, YZ; BurgosTrinidad, M; Wu, YF; Koenig, RJ				Yang, YZ; BurgosTrinidad, M; Wu, YF; Koenig, RJ			Thyroid hormone receptor variant alpha 2 - Role of the ninth heptad in DNA binding, heterodimerization with retinoid X receptors, and dominant negative activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSE ELEMENTS; TARGET GENES; TRANS-ACTIVATION; DIRECT REPEAT; CO-REPRESSOR; VITAMIN-D; V-ERBA; DIMERIZATION; RESISTANCE; SEQUENCES	Thyroid hormone receptors bind DNA with highest affinity as heterodimers with retinoid X receptors, and such heterodimers generally are thought to be the biological mediators of thyroid hormone action. An alternative splice product of the thyroid hormone receptor cu gene, thyroid hormone receptor variant alpha 2, does not bind thyroid hormone and functions as a weak dominant negative inhibitor of thyroid hormone action, Thyroid hormone receptor variant alpha 2 is missing one-half of the ninth heptad, a region of the bona fide receptor thought to be important for heterodimerization with retinoid X receptors, The role of the ninth heptad in heterodimerization has been evaluated further, Thyroid hormone receptor variant alpha 2-retinoid X receptor heterodimers form on a subset of direct repeat response elements but not on palindromic or inverted palindromic elements, Restoration of the missing ninth heptad sequence is critical for restoring heterodimerization on the palindromic DNA, but either the ninth heptad amino acids or a stretch of alanines is equally able to restore heterodimerization on the inverted palindrome, Thus, the role of the ninth heptad in heterodimerization differs on direct repeat, palindromic, and inverted palindromic response elements, suggesting that the protein-protein interactions differ on each of these elements, The dominant negative activity of thyroid hormone receptor variant alpha 2 requires DNA binding, but the relatively weak nature of the dominant negative activity is only partially explained by the weak DNA binding.	UNIV MICHIGAN,MED CTR,DIV ENDOCRINOL & METAB,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044155] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44155] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BRENT GA, 1992, MOL ENDOCRINOL, V6, P502, DOI 10.1210/me.6.4.502; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; CAI Z, 1990, BIOTECHNIQUES, V8, P528; CHATTERJEE VKK, 1991, J CLIN INVEST, V87, P1977; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; COLLINGWOOD TN, 1994, MOL ENDOCRINOL, V8, P1262, DOI 10.1210/me.8.9.1262; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; FARSETTI A, 1992, J BIOL CHEM, V267, P15784; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; KATZ D, 1993, J BIOL CHEM, V268, P20904; KATZ D, 1992, MOL ENDOCRINOL, V6, P805, DOI 10.1210/me.6.5.805; KATZ D, 1995, MOL CELL BIOL, V15, P2341; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KATZ RW, 1994, J BIOL CHEM, V269, P9500; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIU RT, 1995, MOL ENDOCRINOL, V9, P86, DOI 10.1210/me.9.1.86; MOORE DD, 1986, GENE AMST, V45, P107; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGAYA T, 1992, J BIOL CHEM, V267, P13014; NAGAYA T, 1993, J BIOL CHEM, V268, P24278; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; ODONNELL AL, 1990, MOL ENDOCRINOL, V4, P715, DOI 10.1210/mend-4-5-715; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PROST E, 1988, NUCLEIC ACIDS RES, V16, P6248, DOI 10.1093/nar/16.13.6248; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; RIBEIRO RCJ, 1995, ANNU REV MED, V46, P443, DOI 10.1146/annurev.med.46.1.443; ROSEN ED, 1993, J BIOL CHEM, V268, P11534; SPANJAARD RA, 1991, P NATL ACAD SCI USA, V88, P8587, DOI 10.1073/pnas.88.19.8587; SUBAUSTE JS, 1995, J BIOL CHEM, V270, P7957, DOI 10.1074/jbc.270.14.7957; SUBAUSTE JS, 1994, J BIOL CHEM, V269, P30232; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WILLIAMS GR, 1994, ENDOCRINOLOGY, V134, P1888, DOI 10.1210/en.134.4.1888; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	42	41	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28235	28242		10.1074/jbc.271.45.28235	http://dx.doi.org/10.1074/jbc.271.45.28235			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910441	hybrid			2022-12-25	WOS:A1996VU03300041
J	Hawley, SA; Davison, M; Woods, A; Davies, SP; Beri, RK; Carling, D; Hardie, DG				Hawley, SA; Davison, M; Woods, A; Davies, SP; Beri, RK; Carling, D; Hardie, DG			Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; YEAST SNF1; SKELETAL-MUSCLE; PURIFICATION; REDUCTASE; GENE; PHOSPHATASE-1; HEPATOCYTES; SPECIFICITY; QUANTITIES	We have developed a sensitive assay for the AMP-activated protein kinase kinase, the upstream component in the AMP-activated protein kinase cascade. Phosphorylation and activation of the downstream kinase by the upstream kinase absolutely requires AMP and is antagonized by high (millimolar) concentrations of ATP. We have purified the upstream kinase >1000-fold from rat liver; a variety of evidence indicates that the catalytic subunit may be a polypeptide of 58 kDa. The physical properties of the downstream and upstream kinases, e.g. catalytic subunit masses (63 versus 58 kDa) and native molecular masses (190 versus 195 kDa), are very similar, However, unlike the downstream kinase, the upstream kinase is not inactivated by protein phosphatases. The upstream kinase phosphorylates the downstream kinase at a single major site on the a subunit, i.e. threonine 172, which lies in the ''activation segment'' between the DFG and APE motifs. This site aligns with activating phosphorylation sites on many other protein kinases, including Thr(177) on calmodulin-dependent protein kinase I. As well as suggesting a mechanism of activation of AMP-activated protein kinase, this finding is consistent with our recent report that the AMP-activated protein kinase kinase can slowly phosphorylate and activate calmodulin-dependent protein kinase I, at least in vitro (Hawley, S. A., Selbert, M. A., Goldstein, E. G., Edelman, A. M., Carling, D., and Hardie, D. G. (1995) J. Biol. Chem. 270, 27186-27191).	UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND; ZENECA PHARMACEUT,MACCLESFIELD SK10 4TG,CHESHIRE,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,MOL MED GRP,LONDON W12 0NN,ENGLAND	University of Dundee; Imperial College London			Hardie, David/Z-1979-2019; Carling, David/F-1943-2014	Carling, David/0000-0002-2316-1830; Hardie, Grahame/0000-0002-8373-7379	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; BERI RK, 1994, FEBS LETT, V356, P117, DOI 10.1016/0014-5793(94)01247-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLING D, 1989, BIOCHIM BIOPHYS ACTA, V1012, P81, DOI 10.1016/0167-4889(89)90014-1; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CARLING D, 1994, J BIOL CHEM, V269, P11442; CELENZA JL, 1989, MOL CELL BIOL, V9, P5045, DOI 10.1128/MCB.9.11.5045; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CLARKE PR, 1990, EMBO J, V9, P2439, DOI 10.1002/j.1460-2075.1990.tb07420.x; COHEN P, 1988, METHOD ENZYMOL, V159, P390; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; COULL J M, 1990, Journal of Protein Chemistry, V9, P259; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7; DAVIES SP, 1994, EUR J BIOCHEM, V223, P351, DOI 10.1111/j.1432-1033.1994.tb19001.x; DAVIES SP, 1992, EUR J BIOCHEM, V203, P615, DOI 10.1111/j.1432-1033.1992.tb16591.x; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; ESTRUCH F, 1992, GENETICS, V132, P639; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAO G, 1995, BBA-MOL CELL RES, V1266, P73, DOI 10.1016/0167-4889(94)00222-Z; GILLESPIE JG, 1992, FEBS LETT, V306, P59, DOI 10.1016/0014-5793(92)80837-7; HANKS SK, 1995, PROTEIN KINASE FACTS, V1, P7; Hardie D. Grahame, 1994, Seminars in Cell Biology, V5, P409, DOI 10.1006/scel.1994.1048; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; HAYSTEAD CMM, 1993, EUR J BIOCHEM, V214, P459, DOI 10.1111/j.1432-1033.1993.tb17942.x; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; MUNDAY MR, 1988, EUR J BIOCHEM, V175, P331, DOI 10.1111/j.1432-1033.1988.tb14201.x; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SIM ATR, 1988, FEBS LETT, V233, P294, DOI 10.1016/0014-5793(88)80445-9; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; STAPLETON D, 1994, J BIOL CHEM, V269, P29343; STREULI M, 1988, J EXP MED, V168, P1553; WEEKES J, 1994, EUR J BIOCHEM, V219, P751, DOI 10.1111/j.1432-1033.1994.tb18554.x; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; WOODS A, 1994, J BIOL CHEM, V269, P19509; YANG XL, 1994, EMBO J, V13, P5878, DOI 10.1002/j.1460-2075.1994.tb06933.x; YANG XO, 1992, SCIENCE, V257, P680, DOI 10.1126/science.1496382; ZOLLER MJ, 1981, J BIOL CHEM, V256, P837	46	970	1003	2	58	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27879	27887		10.1074/jbc.271.44.27879	http://dx.doi.org/10.1074/jbc.271.44.27879			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910387	hybrid			2022-12-25	WOS:A1996VQ67900105
J	Severinov, K; Mustaev, A; Kukarin, A; Muzzin, O; Bass, I; Darst, SA; Goldfarb, A				Severinov, K; Mustaev, A; Kukarin, A; Muzzin, O; Bass, I; Darst, SA; Goldfarb, A			Structural modules of the large subunits of RNA polymerase - Introducing archaebacterial and chloroplast split sites in the beta and beta' subunits Escherichia coli RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOLYDIGIN-RESISTANT MUTANTS; ACTIVE-CENTER; 3-DIMENSIONAL STRUCTURE; RIFAMPICIN-RESISTANT; DNA-SEQUENCE; TRANSCRIPTION; PROMOTER; GENES; ENZYME; ELONGATION	The beta and beta' subunits of Escherichia coli DNA-dependent RNA polymerase are highly conserved throughout eubacterial and eukaryotic kingdoms. However, in some archaebacteria and chloroplasts, the corresponding sequences are ''split'' into smaller polypeptides that are encoded by separate genes. To test if such split sites can be accommodated into E. coli RNA polymerase, subunit fragments encoded by the segments of E. coli rpoB and rpoC genes corresponding to archaebacterial and chloroplast split subunits were individually overexpressed. The purified fragments, when mixed in vitro with complementing intact RNA polymerase subunits, yielded an active enzyme capable of catalyzing the phosphodiester bond formation. Thus, the large subunits of eubacteria and eukaryotes are composed of independent structural modules corresponding to the smaller subunits of archaebacteria and chloroplasts.	PUBL HLTH RES INST,NEW YORK,NY 10016; RUSSIAN ACAD SCI,INST MOL GENET,MOSCOW 123182,RUSSIA	Russian Academy of Sciences	Severinov, K (corresponding author), ROCKEFELLER UNIV,BOX 224,1230 YORK AVE,NEW YORK,NY 10021, USA.		Severinov, Konstantin/C-8545-2016		NIGMS NIH HHS [GM30717, GM53759] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053759, R01GM030717] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ARMSTRONG VW, 1979, BIOCHEMISTRY-US, V18, P5117, DOI 10.1021/bi00590a014; BERGHOFER B, 1988, NUCLEIC ACIDS RES, V16, P8113, DOI 10.1093/nar/16.16.8113; BERGSLAND KJ, 1991, J BACTERIOL, V173, P3446, DOI 10.1128/jb.173.11.3446-3455.1991; BIGGS J, 1985, CELL, V42, P611, DOI 10.1016/0092-8674(85)90118-7; BOOR KJ, 1995, J BIOL CHEM, V270, P20329, DOI 10.1074/jbc.270.35.20329; BORUKHOV S, 1991, J BIOL CHEM, V266, P23921; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BORUKHOV S, 1993, PROTEIN EXPRES PURIF, V4, P503, DOI 10.1006/prep.1993.1066; BORUKHOV S, 1991, J BIOL CHEM, V266, P23932; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; DANILKOVICH AV, 1988, DOKL AKAD NAUK SSSR+, V303, P241; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; GRACHEV MA, 1986, BIOORG KHIM+, V12, P1678; GRACHEV MA, 1987, EUR J BIOCHEM, V163, P113, DOI 10.1111/j.1432-1033.1987.tb10743.x; HEISLER LM, 1993, J BIOL CHEM, V268, P25369; HEUMANN H, 1987, BIOCHIM BIOPHYS ACTA, V909, P126, DOI 10.1016/0167-4781(87)90034-0; HONORE N, 1993, MOL MICROBIOL, V7, P207, DOI 10.1111/j.1365-2958.1993.tb01112.x; HU J, 1990, P NATL ACAD SCI USA, V87, P1531, DOI 10.1073/pnas.87.4.1531; IGLOI GL, 1990, MOL GEN GENET, V221, P379, DOI 10.1007/BF00259403; Ishihama A, 1981, Adv Biophys, V14, P1; IWABE N, 1991, J MOL EVOL, V32, P70, DOI 10.1007/BF02099931; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KOLODZIEJ PA, 1991, MOL CELL BIOL, V11, P4669, DOI 10.1128/MCB.11.9.4669; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LEFFERS H, 1989, J MOL BIOL, V206, P1, DOI 10.1016/0022-2836(89)90519-6; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; MUSTAEV A, 1994, P NATL ACAD SCI USA, V91, P12036, DOI 10.1073/pnas.91.25.12036; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; OHME M, 1986, FEBS LETT, V200, P87, DOI 10.1016/0014-5793(86)80516-6; OVCHINNIKOV YA, 1981, MOL GEN GENET, V184, P536, DOI 10.1007/BF00352535; PALM P, 1993, NUCLEIC ACIDS RES, V21, P4904, DOI 10.1093/nar/21.21.4904; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; REITER WD, 1990, P NATL ACAD SCI USA, V87, P9509, DOI 10.1073/pnas.87.24.9509; SCHNEIDER GJ, 1987, J BIOL CHEM, V262, P14633; SCHULTZ P, 1993, EMBO J, V12, P2601, DOI 10.1002/j.1460-2075.1993.tb05920.x; SCHYNS G, 1994, MOL MICROBIOL, V13, P887, DOI 10.1111/j.1365-2958.1994.tb00480.x; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; SEVERINOV K, 1995, J BIOL CHEM, V270, P29428, DOI 10.1074/jbc.270.49.29428; SEVERINOV K, 1994, J BIOL CHEM, V269, P14254; SEVERINOV K, 1995, P NATL ACAD SCI USA, V92, P4591, DOI 10.1073/pnas.92.10.4591; SEVERINOV K, 1994, MOL GEN GENET, V244, P120, DOI 10.1007/BF00283512; SEVERINOV K, 1995, J BIOL CHEM, V270, P23926, DOI 10.1074/jbc.270.41.23926; SEVERINOV K, 1994, J BIOL CHEM, V269, P31701; SEVERINOV K, 1992, J BIOL CHEM, V267, P12813; SHIMADA H, 1990, MOL GEN GENET, V221, P395, DOI 10.1007/BF00259404; SWOETSER D, 1987, P NATL ACAD SCI USA, V84, P1192; TANG H, 1995, P NATL ACAD SCI USA, V92, P4902, DOI 10.1073/pnas.92.11.4902; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; XIE WQ, 1989, J BACTERIOL, V171, P1967, DOI 10.1128/jb.171.4.1967-1973.1989; YANG XF, 1995, J BIOL CHEM, V270, P23930, DOI 10.1074/jbc.270.41.23930; ZILLIG W, 1986, RNA POLYMERASE REGUL, P17	57	68	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27969	27974		10.1074/jbc.271.44.27969	http://dx.doi.org/10.1074/jbc.271.44.27969			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910400	hybrid			2022-12-25	WOS:A1996VQ67900118
J	Kennedy, MT; Brockman, H; Rusnak, F				Kennedy, MT; Brockman, H; Rusnak, F			Contributions of myristoylation to calcineurin structure/function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; NITRIC-OXIDE SYNTHASE; NH2-TERMINAL BLOCKING GROUP; SUBCELLULAR-LOCALIZATION; CATALYTIC SUBUNIT; PHOSPHOLIPID-VESICLES; TRANSFORMING PROTEIN; PHOSPHATASE-ACTIVITY; PHASE-TRANSITIONS; MEMBRANE-BINDING	Calcineurin is a serine/threonine protein phosphatase composed of a catalytic subunit, calcineurin A (58 kDa), and a NH2-terminal myristoylated regulatory subunit, calcineurin B (19 kDa). In order to study the effect of myristoylation on calcineurin structure/function, a dual plasmid transfection system was used to generate myristoylated and nonmyristoylated calcineurin B. Both metabolic labeling of calcineurin B with radiolabeled myristic acid and electrospray mass spectral analysis confirmed that myristic acid was covalently and stoichiometrically linked to calcineurin B, Myristoyl and non-myristoyl calcineurin B were reconstituted with recombinant calcineurin A to form native-like heterodimers, and the properties of the two calcineurin forms were examined. Myristoylation had no effect on enzymatic activity, calcineurin-immunosuppressant/immunophilin interactions, or Ca2+ binding, Surprisingly, myristoylation also had no effect on calcineurin heterodimer association with phospholipid monolayers. Fatty acylation, however, significantly influenced the thermal stability of calcineurin, with an approximate 10 degrees C increase in t(1/2) observed for myristoyl calcineurin when compared to the non-myristoyl form. Myristoylation of calcineurin B therefore appears to provide structural stability to the calcineurin heterodimer.	MAYO CLIN & MAYO FDN,HEMATOL RES SECT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905; UNIV MINNESOTA,HORMEL INST,AUSTIN,MN 55912	Mayo Clinic; Mayo Clinic; University of Minnesota System					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046865] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49180] Funding Source: Medline; NIGMS NIH HHS [GM46865] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AITKEN A, 1982, FEBS LETT, V150, P314, DOI 10.1016/0014-5793(82)80759-X; ALEXANDER DR, 1988, BIOCHEM J, V256, P885, DOI 10.1042/bj2560885; ALLAND L, 1994, J BIOL CHEM, V269, P16701; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; Ames JB, 1995, J BIOL CHEM, V270, P30909, DOI 10.1074/jbc.270.52.30909; APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; BLUME A, 1979, BIOCHIM BIOPHYS ACTA, V557, P32, DOI 10.1016/0005-2736(79)90087-7; BROCKMAN HL, 1984, J PHYS E SCI INSTRUM, V17, P351, DOI 10.1088/0022-3735/17/5/006; BUSCONI L, 1994, J BIOL CHEM, V269, P25016; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CALVERT PD, 1995, J BIOL CHEM, V270, P24127, DOI 10.1074/jbc.270.41.24127; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; GREENHUT SF, 1985, J BIOL CHEM, V260, P5883; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HADDY A, 1992, FEBS LETT, V314, P37, DOI 10.1016/0014-5793(92)81456-V; HAO R, 1993, PROTIEN SCI, V2, P122; HECKER M, 1994, J NEUROCHEM, V62, P1524; HUBBARD MJ, 1991, MOL NEUROBIOL, P135; JONES MN, 1995, MICELLES MONOLAYERS, P59; JOSEPH M, 1995, J BIOL CHEM, V270, P16749, DOI 10.1074/jbc.270.28.16749; KAKALIS LT, 1995, FEBS LETT, V362, P55, DOI 10.1016/0014-5793(95)00207-P; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; LUAN S, 1993, P NATL ACAD SCI USA, V90, P2202, DOI 10.1073/pnas.90.6.2202; MACDONALD RC, 1988, J BIOL CHEM, V263, P10052; MOMSEN WE, 1990, J COLLOID INTERF SCI, V135, P547, DOI 10.1016/0021-9797(90)90025-J; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NADLER MJS, 1993, BIOCHEMISTRY-US, V32, P9250, DOI 10.1021/bi00086a034; NAGLE JF, 1976, J MEMBRANE BIOL, V27, P233, DOI 10.1007/BF01869138; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; PERRINO BA, 1992, J BIOL CHEM, V267, P15965; PHILLIPS MC, 1986, METHOD ENZYMOL, V128, P387; POLITINO M, 1990, J BIOL CHEM, V265, P7619; POLITINO M, 1987, J BIOL CHEM, V262, P10109; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SAITOH Y, 1991, BIOMED RES-TOKYO, V12, P215, DOI 10.2220/biomedres.12.215; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SEELIG A, 1987, BIOCHIM BIOPHYS ACTA, V899, P196, DOI 10.1016/0005-2736(87)90400-7; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; SIKKINK R, 1995, BIOCHEMISTRY-US, V34, P8348, DOI 10.1021/bi00026a016; TALLANT EA, 1983, BIOCHEMISTRY-US, V22, P3630, DOI 10.1021/bi00284a014; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; ZHU DH, 1995, J BIOL CHEM, V270, P24831, DOI 10.1074/jbc.270.42.24831; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	58	43	45	3	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26517	26521		10.1074/jbc.271.43.26517	http://dx.doi.org/10.1074/jbc.271.43.26517			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900120	hybrid			2022-12-25	WOS:A1996VP23300014
J	Kessler, MM; Zhao, J; Moore, CL				Kessler, MM; Zhao, J; Moore, CL			Purification of the Saccharomyces cerevisiae cleavage/polyadenylation factor I - Separation into two components that are required for both cleavage and polyadenylation of mRNA 3' ends	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; POLY(A) POLYMERASE; SPECIFICITY FACTOR; SUBUNIT; GENE; CLONING; PROTEIN; BINDING; SITE; EXPRESSION	The cleavage/polyadenylation factor I (CF I) is one of four factors required for mRNA 3' end formation in the yeast Saccharomyces cerevisiae, Here we describe the purification of CF I and its separation into two components, CF IA and CF IB, Both components are needed to reconstitute CF I activity in cleavage and poly(A) addition, CF IA consists of a complex of four polypeptides of 76, 70, 50, and 38 kDa, and CF IB is a single 73-kDa polypeptide. The 76- and 38-kDa subunits of CF IA correspond to the previously identified RNA14 and RNA15 proteins, The RNA14 protein, but not the 70- or 50-kDa proteins, coimmunoprecipitates with the RNA15 protein, indicating that RNA14 and RNA15 proteins exist in a tight complex, RNA15 is the only subunit of CF I that can be cross-linked to pre-mRNA.	TUFTS UNIV,SCH MED,DEPT MOL BIOL & MICROBIOL,BOSTON,MA 02111	Tufts University					NIGMS NIH HHS [R01 GM417S2] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE A, 1990, EMBO J, V9, P3691, DOI 10.1002/j.1460-2075.1990.tb07581.x; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; BONNEAUD N, 1994, J CELL SCI, V107, P913; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GOTTLIEB M, 1987, ANAL BIOCHEM, V165, P33, DOI 10.1016/0003-2697(87)90197-7; GUO ZJ, 1995, MOL CELL BIOL, V15, P5983; Guo ZJ, 1996, MOL CELL BIOL, V16, P2772; Harlow E., 1988, ANTIBODIES LAB MANUA; Huang YQ, 1996, MOL CELL BIOL, V16, P1534; JENNY A, 1994, MOL CELL BIOL, V14, P8183, DOI 10.1128/MCB.14.12.8183; JENNY A, 1995, NUCLEIC ACIDS RES, V23, P2629, DOI 10.1093/nar/23.14.2629; Jha PK, 1996, BIOCHEMISTRY-US, V35, P11026, DOI 10.1021/bi960406h; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KESSLER MM, 1995, BIOCHEMISTRY-US, V34, P1750, DOI 10.1021/bi00005a032; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; LINGNER J, 1991, J BIOL CHEM, V266, P8741; MACDONALD CC, 1994, MOL CELL BIOL, V14, P6647, DOI 10.1128/MCB.14.10.6647; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; NEMETH A, 1995, NUCLEIC ACIDS RES, V23, P4034, DOI 10.1093/nar/23.20.4034; PATEL D, 1992, MOL CELL BIOL, V12, P3297, DOI 10.1128/MCB.12.7.3297; PREKER PJ, 1995, CELL, V81, P379, DOI 10.1016/0092-8674(95)90391-7; Ruegsegger U, 1996, J BIOL CHEM, V271, P6107; RUSSO P, 1993, MOL CELL BIOL, V13, P7836, DOI 10.1128/MCB.13.12.7836; Sambrook J., 2002, MOL CLONING LAB MANU; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; WAHLE E, 1995, BBA-GENE STRUCT EXPR, V1261, P183, DOI 10.1016/0167-4781(94)00248-2; ZHELKOVSKY AM, 1995, J BIOL CHEM, V270, P26715, DOI 10.1074/jbc.270.44.26715	36	79	83	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27167	27175		10.1074/jbc.271.43.27167	http://dx.doi.org/10.1074/jbc.271.43.27167			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900210	hybrid			2022-12-25	WOS:A1996VP23300104
J	Kishi, K; Hayashi, H; Wang, LH; Kamohara, S; Tamaoka, K; Shimizu, T; Ushikubi, F; Narumiya, S; Ebina, Y				Kishi, K; Hayashi, H; Wang, LH; Kamohara, S; Tamaoka, K; Shimizu, T; Ushikubi, F; Narumiya, S; Ebina, Y			G(q)-coupled receptors transmit the signal for GLUT4 translocation via an insulin-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE GLUCOSE-TRANSPORTER; ACTIVATING-FACTOR RECEPTOR; GROWTH-FACTOR TRIGGERS; RAT SKELETAL-MUSCLE; MOLECULAR-CLONING; PLASMA-MEMBRANE; PHOSPHOLIPASE-C; G-PROTEINS; FAT-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE	Guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) induces the translocation of glucose transporter type 4 (GLUT4) from an intracellular pool to the cell surface and increases glucose uptake in adipocytes. The GTP-binding protein(s) responsible for the translocation has remained to be identified. Using a sensitive and quantitative method to assess the translocation of c-MYC epitope tagged GLUT4, we obtained evidence that the activation of receptor-coupled G(q) (neither G(i) nor G(s)) triggered GLUT4 translocation In cells, independently of insulin signaling pathway(s). Platelet-activating factor (PAF) induced GLUT4 translocation in the cells expressing the Gi and G(q)-coupled PAF receptor, but the translocation was induced even after pretreatment with wortmannin, an islet-activating protein and phorbol 12,13-dibutyrate. Norepinephrine triggered GLUT4 translocation in cells expressing the G(q) coupled alpha(1)-adrenergic receptor, but prostaglandin E(2) did not cause GLUT4 translocation in cells expressing the G(s)-coupled EP4 receptor or the G(i)-coupled EP3 alpha receptor. The nor epinephrine-stimulated GLUT4 translocation and glucose uptake via G(q) may possibly contribute to the fuel supply required for thermogenesis in brown adipocytes and for the enhanced contractility in cardiomyocytes, both of which have an abundant endogenous GLUT4.	UNIV TOKUSHIMA,INST ENZYME RES,DEPT ENZYME GENET,TOKUSHIMA 770,JAPAN; AOBA OKA HOSP,TONDABAYASHI,OSAKA 584,JAPAN; UNIV TOKYO,FAC MED,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN	Tokushima University; University of Tokyo; Kyoto University				Hayashi, Hideki/0000-0003-4585-6542; Kamohara, Seika/0000-0002-2482-6611				BALDINI G, 1991, J BIOL CHEM, V266, P4037; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BROZINICK JT, 1994, BIOCHEM J, V297, P539, DOI 10.1042/bj2970539; CLARK AE, 1990, BIOCHEM J, V269, P615, DOI 10.1042/bj2690615; CORMONT M, 1991, ENDOCRINOLOGY, V129, P3343, DOI 10.1210/endo-129-6-3343; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1995, ANNU REV NUTR, V15, P441, DOI 10.1146/annurev.nu.15.070195.002301; DELISLE RC, 1986, ANNU REV PHYSIOL, V48, P225; Dietze GJ, 1996, DIABETES, V45, pS110, DOI 10.2337/diab.45.1.S110; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; Fischer Y, 1996, AM J PHYSIOL-CELL PH, V270, pC1204, DOI 10.1152/ajpcell.1996.270.4.C1204; GARFINKEL D, 1971, COMPUT BIOMED RES, V4, P1, DOI 10.1016/0010-4809(71)90044-9; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HONDA A, 1993, J BIOL CHEM, V268, P7759; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HORIE K, 1994, EUR J PHARM-MOLEC PH, V268, P399, DOI 10.1016/0922-4106(94)90065-5; ISHII K, 1994, BIOCHEM BIOPH RES CO, V205, P857, DOI 10.1006/bbrc.1994.2743; ISHII K, 1995, BIOCHEM J, V309, P813, DOI 10.1042/bj3090813; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAMOHARA S, 1995, P NATL ACAD SCI USA, V92, P1077, DOI 10.1073/pnas.92.4.1077; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KANAI F, 1993, J BIOL CHEM, V268, P14523; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MENKE JG, 1994, J BIOL CHEM, V269, P21583; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; MUHLBACHER C, 1988, BIOCHEM J, V249, P865; NAKAMURA M, 1992, FEBS LETT, V314, P125, DOI 10.1016/0014-5793(92)80957-I; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OBERMAIERKUSSER B, 1988, BIOCHEM J, V256, P515, DOI 10.1042/bj2560515; OKADA T, 1994, J BIOL CHEM, V269, P3568; OMATSUKANBE M, 1992, FEBS LETT, V314, P246, DOI 10.1016/0014-5793(92)81481-Z; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; QUON MJ, 1994, P NATL ACAD SCI USA, V91, P5587, DOI 10.1073/pnas.91.12.5587; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHROER DW, 1986, BIOCHIM BIOPHYS ACTA, V885, P317, DOI 10.1016/0167-4889(86)90247-8; SCHWINN DA, 1990, J BIOL CHEM, V265, P8183; SHIBATA K, 1995, MOL PHARMACOL, V48, P250; SHIMIZU Y, 1994, BIOCHEM BIOPH RES CO, V202, P660, DOI 10.1006/bbrc.1994.1981; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; Todaka M, 1996, BIOCHEM J, V315, P875, DOI 10.1042/bj3150875; VILARO S, 1989, NATURE, V342, P798, DOI 10.1038/342798a0; VOGT B, 1991, BIOCHEM J, V275, P597, DOI 10.1042/bj2750597; VONMOLLARD GF, 1994, TRENDS BIOCHEM SCI, V19, P164, DOI 10.1016/0968-0004(94)90278-X; WU DQ, 1992, J BIOL CHEM, V267, P25798; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107	64	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26561	26568		10.1074/jbc.271.43.26561	http://dx.doi.org/10.1074/jbc.271.43.26561			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900127	hybrid			2022-12-25	WOS:A1996VP23300021
J	Liu, J; Shworak, NW; Fritze, LMS; Edelberg, JM; Rosenberg, RD				Liu, J; Shworak, NW; Fritze, LMS; Edelberg, JM; Rosenberg, RD			Purification of heparan sulfate D-glucosaminyl 3-O-sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITHROMBIN-BINDING SEQUENCE; ENDOTHELIAL-CELLS; CHONDROITIN 6-SULFOTRANSFERASE; HEPARINLIKE MOLECULES; CULTURE-MEDIUM; HIGH-AFFINITY; BIOSYNTHESIS; SULFOTRANSFERASE; IDENTIFICATION; MASTOCYTOMA	The cellular generation of proteoglycans with anticoagulant heparan sulfate (HSPG(act)) is determined by microsomal ''HSact conversion activity'' that functions in concert with the sulfate doctor 3'-phosphoadenosine 5'phosphosulfate (PAPS) to convert nonanticoagulant heparan sulfate (HSinact) to anticoagulant heparan sulfate (HSact) (Shworak, N. W., Fritze, L. M., S., Liu, J., Butler, L. D., and Rosenberg, R. D. (1996) J. Biol. Chem. 271, 27063-27071), Suspension cultures of L-33(+) cells in serum-free medium produce HSPG(act) and secrete HSact conversion activity, The secreted protein exhibiting HSact conversion activity was isolated by subjecting large volumes of conditioned suspension culture medium to heparin-AF Toyopearl affinity chromatography, Mono Q-FPLC, TSK SW3000-HPLC, and 3',5'-ADP-agarose affinity chromatography. The final product was purified similar to 700,000-fold relative to cellular material with a 5% overall recovery of HSact conversion activity, The isolated protein migrated. on SDS-polyacrylamide gel electrophoresis as a broad band of M(r) = 46,000 and co-migrated on nondenaturing acidic pH gel electrophoresis with HSact conversion activity, The purified component was identified as heparan sulfate D-glucosaminyl 3-O-sulfotransferase because it transferred sulfate from [S-35]PAPS to the 3-O-position of D-glucosamine and D-glucosamine 6-O-sulfate of HSact precursor and HSinact precursor to produce nearly equivalent amounts of labeled HSact and HSinact. The exhaustive modification of wild-type LTA cell [S-35]HS with either microsomal HSact conversion activity or purified enzyme increased HSact content from 9 to similar to 36%, which indicates that microsomal HSact conversion activity predominantly reflects the level of a 3-O-sulfotransferase that converts HSact precursor into HSact, The kinetic parameters of purified 3-O-sulfotransferase were determined for modification of HSact precursor and HSinact precursor, The apparent K*(M)--- and V*(max)---, with respect to PAPS concentration for sulfation of HSact precursor and HSinact precursor were 2.4 mu M and 23 fmol of sulfate/min/ng of enzyme and 2.1 mu M and 38 fmol of sulfate/min/ng of enzyme, respectively, There was substrate inhibition of the sulfation reaction at elevated HS concentration, The apparent K*(M)--- and V*(max)--- with respect to GAG concentration or sulfation of HSact precursor and HSinact precursor were 16 nM and 120 fmol of sulfate/min/ng of enzyme and 17 nM and 240 fmol of sulfate/min/ng of enzyme, respectively The observation that purified 3-O-sulfotransferase catalyzes sulfation of HSact precursor and HSinact precursor in conjunction with a documented discordant regulation of 3-O-sulfate content in HSinact and HSact suggests that two discrete forms of the enzyme may exist.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634	NHLBI NIH HHS [HL-41484, HL-33014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484, P01HL033014] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; CASU B, 1981, BIOCHEM J, V197, P599, DOI 10.1042/bj1970599; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; CHOAY J, 1980, THROMB RES, V18, P573, DOI 10.1016/0049-3848(80)90356-4; CLELAND WW, 1970, ENZYMES, V2, P35; CLEVELAND WL, 1983, J IMMUNOL METHODS, V56, P221; COLLIECJOUAULT S, 1994, J BIOL CHEM, V269, P24953; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; DANISHEFSKY I, 1969, J BIOL CHEM, V244, P1741; DELANEY SR, 1980, ANAL BIOCHEM, V100, P253; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; HAMILTON W, 1977, IN VITRO, V9, P537; Kobayashi M, 1996, J BIOL CHEM, V271, P7645, DOI 10.1074/jbc.271.13.7645; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KUSCHE M, 1988, J BIOL CHEM, V263, P15474; LAM LH, 1976, BIOCHEM BIOPH RES CO, V69, P570, DOI 10.1016/0006-291X(76)90558-1; LEDER IG, 1980, BIOCHEM BIOPH RES CO, V94, P1183, DOI 10.1016/0006-291X(80)90544-6; LIND T, 1993, J BIOL CHEM, V268, P20705; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LINDAHL U, 1987, BIOL PROTEOGLYCANS, P59; MARCUM JA, 1985, BIOCHEM BIOPH RES CO, V126, P365, DOI 10.1016/0006-291X(85)90615-1; MARCUM JA, 1984, J CLIN INVEST, V74, P341, DOI 10.1172/JCI111429; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MARCUM JA, 1986, AM J PHYSIOL, V250, pH879, DOI 10.1152/ajpheart.1986.250.5.H879; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MONTGOMERY RI, 1992, P NATL ACAD SCI USA, V89, P11327, DOI 10.1073/pnas.89.23.11327; MORAWITZ P, 1959, CHEM BLOOD COAGULATI; OOSTA GM, 1981, P NATL ACAD SCI-BIOL, V78, P829, DOI 10.1073/pnas.78.2.829; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; RAZI N, 1995, J BIOL CHEM, V270, P11267, DOI 10.1074/jbc.270.19.11267; ROSENBERG RD, 1979, P NATL ACAD SCI USA, V76, P1218, DOI 10.1073/pnas.76.3.1218; ROSENBERG RD, 1978, P NATL ACAD SCI USA, V75, P3065, DOI 10.1073/pnas.75.7.3065; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; Shworak NW, 1996, J BIOL CHEM, V271, P27063, DOI 10.1074/jbc.271.43.27063; STONE AL, 1982, P NATL ACAD SCI-BIOL, V79, P7190, DOI 10.1073/pnas.79.23.7190; SUGUMARAN G, 1995, J BIOL CHEM, V270, P22483, DOI 10.1074/jbc.270.38.22483; WLAD H, 1994, J BIOL CHEM, V269, P24538	47	101	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27072	27082		10.1074/jbc.271.43.27072	http://dx.doi.org/10.1074/jbc.271.43.27072			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900198	hybrid			2022-12-25	WOS:A1996VP23300092
J	Nett, JH; Trumpower, BL				Nett, JH; Trumpower, BL			Dissociation of import of the Rieske iron-sulfur protein into Saccharomyces cerevisiae mitochondria from proteolytic processing of the presequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST MITOCHONDRIA; MUTATIONAL ANALYSIS; COMPLEX; PEPTIDASE; PRECURSOR; CLEAVAGE	The correlation between the import of the Rieske iron-sulfur protein into the mitochondrial matrix and processing of the precursor protein by matrix processing peptidase was investigated using high concentrations of metal chelators and iron sulfur protein in which the recognition site for the matrix processing peptidase was destroyed by site-directed mutagenesis. High concentrations of EDTA and o-phenanthroline inhibit import of iron-sulfur protein into the matrix. The non-chelating structural isomers m-phenanthroline and p-phenan-throline inhibit import similar to o-phenanthroline, indicating that inhibition of import is mainly independent of the metal chelating ability of the compounds. Iron-sulfur protein in which the recognition site for the matrix processing peptidase had been destroyed by a point mutation was efficiently imported into the matrix space. Import of this mutant iron-sulfur protein was inhibited by the same concentrations of EDTA and o-phenanthroline which inhibit import of the wild-type protein. These results indicate that import of the iron-sulfur protein into the mitochondrial matrix is independent of proteolytic processing of the presequence, and that o-phenanthroline together with EDTA inhibits import of iron-sulfur protein into the matrix space of mitochondria by inhibiting a step other than proteolysis of the presequence.	DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755	Dartmouth College					NIGMS NIH HHS [GM 20379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020379, R01GM020379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRETZ M, 1994, J BIOL CHEM, V269, P4959; FU W, 1991, J BIOL CHEM, V266, P16212; FU W, 1990, J BIOL CHEM, V265, P16541; GRAHAM LA, 1993, J BIOENERG BIOMEMBR, V25, P245, DOI 10.1007/BF00762586; GRAHAM LA, 1991, J BIOL CHEM, V266, P22485; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P631; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HORWICH AL, 1986, CELL, V44, P451, DOI 10.1016/0092-8674(86)90466-6; KALOUSEK F, 1992, EMBO J, V11, P2803, DOI 10.1002/j.1460-2075.1992.tb05347.x; MCADA PC, 1982, J BIOL CHEM, V257, P3177; RAMABADRAN RS, 1992, ARCH BIOCHEM BIOPHYS, V296, P279, DOI 10.1016/0003-9861(92)90573-F; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535	15	12	12	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26713	26716		10.1074/jbc.271.43.26713	http://dx.doi.org/10.1074/jbc.271.43.26713			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900149	hybrid			2022-12-25	WOS:A1996VP23300043
J	Washington, MT; Rosenberg, AH; Griffin, K; Studier, FW; Patel, SS				Washington, MT; Rosenberg, AH; Griffin, K; Studier, FW; Patel, SS			Biochemical analysis of mutant T7 primase/helicase proteins defective in DNA binding, nucleotide hydrolysis, and the coupling of hydrolysis with DNA unwinding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE PREDICTION; SINGLE-STRANDED-DNA; COLI RECA PROTEIN; BACTERIOPHAGE-T7 DEOXYRIBONUCLEIC-ACID; PRIMASE-HELICASE PROTEIN; GENE-4 PROTEIN; RNA-POLYMERASE; CLONED GENES; REPLICATION; SEQUENCE	We characterized nine helicase-deficient mutants of bacteriophage T7 helicase-primase protein (4A') prepared by random mutagenesis as reported in the accompanying paper (Rosenberg, A, H., Griffin, K., Washington, A. T., Patel, S. S., and Studier, F. W. (1996) J. Biol. Chem. 271, 26819-26824). Mutants were selected from each of the helicase-conserved motifs for detailed analysis to understand better their function. In agreement with the in vivo results, the mutants were defective in helicase activity but were active in primase function, dTTP hydrolysis, DNA binding, and hexamer formation were examined, Three classes of defective mutants were observed, Group A mutants (E348K, D424N, and S496F), defective in dTTP hydrolysis, lie in motifs 1a, 2, and 4 and are possibly involved in NTP binding/hydrolysis, Group B mutants (R487C and G488D), defective in DNA binding, lie in motif 4 and are responsible directly or indirectly for DNA binding, Group C mutants (G116D, A257T, S345F, and G451E) were not defective in any of the activities except the helicase function, These mutants, scattered throughout the protein, appear defective in coupling dTTPase activity to helicase function, Secondary structural predictions of 4A' and DnaB helicases resemble the known structures of RecA and F-1-ATPase enzymes, Alignment shows a striking correlation in the positions of the amino acids that interact with NTP and DNA.	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	University System of Ohio; Ohio State University; United States Department of Energy (DOE); Brookhaven National Laboratory				Washington, Todd/0000-0001-8680-2992				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; DUNN JJ, 1981, J MOL BIOL, V148, P303, DOI 10.1016/0022-2836(81)90178-9; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; FULLER CW, 1985, J BIOL CHEM, V260, P3185; GARDNER RV, 1995, EUR J BIOCHEM, V233, P419, DOI 10.1111/j.1432-1033.1995.419_2.x; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; GEOURJON C, 1995, IN PRESS COMP APPL B; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; Hingorani MM, 1996, BIOCHEMISTRY-US, V35, P2218, DOI 10.1021/bi9521497; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; KOLODNER R, 1978, J BIOL CHEM, V253, P566; LEVIN JM, 1986, FEBS LETT, V205, P303, DOI 10.1016/0014-5793(86)80917-6; MALKOV VV, 1995, J BIOL CHEM, V270, P30230; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MILLER H, 1987, METHOD ENZYMOL, V152, P145; MIWA Y, 1995, J MOL BIOL, V254, P816; NAKAI H, 1986, J BIOL CHEM, V261, P5208; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; NOTARNICOLA SM, 1995, J BIOL CHEM, V270, P20215, DOI 10.1074/jbc.270.34.20215; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Pereira S, 1995, J BIOL CHEM, V270, P30401, DOI 10.1074/jbc.270.51.30401; Rosenberg AH, 1996, J BIOL CHEM, V271, P26819, DOI 10.1074/jbc.271.43.26819; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Sambrook J., 2002, MOL CLONING LAB MANU; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	42	87	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26825	26834		10.1074/jbc.271.43.26825	http://dx.doi.org/10.1074/jbc.271.43.26825			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900164	hybrid			2022-12-25	WOS:A1996VP23300058
J	Zimmermann, G; Taussig, R				Zimmermann, G; Taussig, R			Protein kinase C alters the responsiveness of adenylyl cyclases to G protein alpha and beta gamma subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BOVINE BRAIN; RAT-BRAIN; EXPRESSION; STIMULATION; PURIFICATION; INHIBITION; ACTIVATION; CLONING; CELLS	The ability of protein kinase C (PKC) to regulate the responsiveness of adenylyl cyclase to different activators was assessed, Membranes prepared from Sf9 cells infected with recombinant baculoviruses encoding either type II or IV adenylyl cyclase were incubated with recombinant PKC alpha (purified from Sf9 cells), and the effects on adenylyl cyclase activity were measured after reconstitution with G(s alpha), G beta gamma, or forskolin, PKC alpha treatment of type II adenylyl cyclase leads to increases in basal, forskolin-stimulated, and beta gamma-stimulated activities and greater sensitivity to stimulation by G(s alpha). Paradoxically, most of the beta gamma potentiation of G(s alpha)-stimulated activity is eliminated by pretreatment with PKC alpha, By contrast, treatment of type IV adenylyl cyclase with PKC alpha has little effect on the basal, forskolin-stimulated, or beta gamma-stimulated activities but markedly reduces the G(s alpha)-stimulated and beta gamma-potentiated activity of this isoform. These studies demonstrate that protein kinases can alter both the activity of adenylyl cyclase isoforms and their responsiveness to G protein regulation, thereby altering the ability of adenylyl cyclases to integrate signals derived from multiple hormonal inputs.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIDDK NIH HHS [5 P60 DK20572-19, P30 DK34933] Funding Source: Medline; NIGMS NIH HHS [GM53645-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572, P30DK034933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053645] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHOI EJ, 1993, BIOCHEMISTRY-US, V32, P1891, DOI 10.1021/bi00059a001; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GIRARD PR, 1985, P NATL ACAD SCI USA, V82, P3030, DOI 10.1073/pnas.82.9.3030; Gorman R R, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17B, P963; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; GUSOVSKY F, 1991, MOL PHARMACOL, V39, P124; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HELLEVUO K, 1995, J BIOL CHEM, V270, P11581, DOI 10.1074/jbc.270.19.11581; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; LEE E, 1994, METHOD ENZYMOL, V237, P146; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; SUMMERS MD, 1987, TEX AGR EXP STN B, V155, P1; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAUSSIG R, 1994, METHOD ENZYMOL, V238, P95; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Tsu RC, 1996, J NEUROSCI, V16, P1317; WAYMAN GA, 1995, J BIOL CHEM, V270, P21480, DOI 10.1074/jbc.270.37.21480; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; YEAGER RE, 1985, J NEUROCHEM, V44, P818, DOI 10.1111/j.1471-4159.1985.tb12889.x; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604	39	116	118	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27161	27166		10.1074/jbc.271.43.27161	http://dx.doi.org/10.1074/jbc.271.43.27161			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900209	hybrid			2022-12-25	WOS:A1996VP23300103
J	Nikiforov, MA; Hagen, K; Ossovskaya, VS; Connor, TMF; Lowe, SW; Deichman, GI; Gudkov, AV				Nikiforov, MA; Hagen, K; Ossovskaya, VS; Connor, TMF; Lowe, SW; Deichman, GI; Gudkov, AV			p53 Modulation of anchorage independent growth and experimental metastasis	ONCOGENE			English	Article						anchorage dependence; apoptosis; metastasis; p53	TUMOR-SUPPRESSOR GENES; WILD-TYPE P53; DRUG-RESISTANCE; EXTRACELLULAR-MATRIX; ADHESION MOLECULES; BREAST-CARCINOMA; BCL-2 EXPRESSION; CANCER; APOPTOSIS; CELLS	Death in circulation is one of the natural barriers preventing dissemination of tumor cells and formation of metastases. One of the negative factors acting in circulation is the loss of cell contact with natural substrate which can be imitated in vitro by the incubation of cells in suspension or in semi-solid media. Normal mouse fibroblasts (MEFs) stay viable in suspension and undergo p53-independent G(1) growth arrest. Transformation with Ela and ras oncogenes leads to the abrogation of this arrest and to the p53-dependent apoptosis occurring in G, phase of the cell cycle. Suppression of apoptosis by p53 gene knock-out, transduction of dominant negative p53 mutant or bcl-2 prevents death in suspension and greatly induces frequency of colony formation in semi-solid media. The ability of cells to undergo apoptosis does not correlate with their tumorigenicity in nude mice but does correlate with their ability to survive in lungs of intravenously injected mice and to form experimental metastases. We suggest that abrogation of a p53-mediated apoptosis facilitates experimental metastasis by promoting survival of tumor cells in circulation.	UNIV ILLINOIS, DEPT GENET, CHICAGO, IL 60607 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; CTR CANC RES, INST CARCINOGENESIS, MOSCOW 115478, RUSSIA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cold Spring Harbor Laboratory				Gudkov, Andrei/0000-0003-2548-0154	FOGARTY INTERNATIONAL CENTER [R03TW000475] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R21CA062045, R01CA060730] Funding Source: NIH RePORTER; FIC NIH HHS [R03TW00475] Funding Source: Medline; NCI NIH HHS [R01-CA60730, R21CA62045] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN TI, 1993, BRIT J CANCER, V68, P540, DOI 10.1038/bjc.1993.383; BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; BENZEEV A, 1980, CELL, V21, P365, DOI 10.1016/0092-8674(80)90473-0; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; BERTORELLE R, 1995, AM J SURG PATHOL, V19, P463, DOI 10.1097/00000478-199504000-00008; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HAGUE A, 1994, ONCOGENE, V9, P3367; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAYES DF, 1995, SEMIN ONCOL, V22, P5; HELLMAN K, 1991, MICROCIRCULATION CAN, P67; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; HOFFMAN B, 1994, ONCOGENE, V9, P1807; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KASTRINAKIS WV, 1995, ONCOGENE, V11, P647; KERBEL RS, 1994, INVAS METAST, V14, P50; KERBEL RS, 1994, J CELL BIOCHEM, V56, P37, DOI 10.1002/jcb.240560108; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Lafrenie R M, 1993, Cell Biophys, V23, P3; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARCHETTI A, 1993, CANCER RES, V53, P2846; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MYERS RB, 1994, PROSTATE, V25, P243, DOI 10.1002/pros.2990250504; NEIMAN PE, 1994, MOL BIOL CELL, V5, P763, DOI 10.1091/mbc.5.7.763; NOONAN KD, 1977, J CELL PHYSIOL, V91, P201, DOI 10.1002/jcp.1040910206; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERRY ME, 1992, MUTAT RES, V276, P189, DOI 10.1016/0165-1110(92)90008-W; POUPON MF, 1992, AIDS RES HUM RETROV, V8, P796; PROSS HF, 1993, NAT IMMUN, V12, P279; SIERRA A, 1995, INT J CANCER, V60, P54, DOI 10.1002/ijc.2910600108; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; THOMPSON TC, 1995, ONCOGENE, V10, P869; UHLMAN DL, 1994, J NATL CANCER I, V86, P1470, DOI 10.1093/jnci/86.19.1470; ULBRIGHT TM, 1994, MODERN PATHOL, V7, P64; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; WEISS L, 1989, CLIN EXP METASTAS, V7, P127, DOI 10.1007/BF01787020; WEISS L, 1994, INVAS METAST, V14, P192; Weiss L., 1985, PRINCIPLES METASTASI; WHITESIDE TL, 1994, IMMUNOL SER, V61, P159; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YOKOYAMA M, 1994, ANTICANCER RES, V14, P2477; YUSPA SH, 1994, J INVEST DERMATOL, V103, pS90, DOI 10.1111/1523-1747.ep12399255	57	73	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1709	1719						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895517				2022-12-25	WOS:A1996VM88700016
J	Burikhanov, R; Coulonval, K; Pirson, I; Lamy, F; Dumont, JE; Roger, PP				Burikhanov, R; Coulonval, K; Pirson, I; Lamy, F; Dumont, JE; Roger, PP			Thyrotropin via cyclic AMP induces insulin receptor expression and insulin co-stimulation of growth and amplifies insulin and insulin-like growth factor signaling pathways in dog thyroid epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTORS; DEOXYRIBONUCLEIC-ACID SYNTHESIS; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; GLUCOCORTICOID REGULATION; FOLLICULAR CELL; PHORBOL ESTER; SOMATOMEDIN-C; FRTL-5 CELLS	Despite the similarity of their receptors and signal transduction pathways, insulin is regarded as a regulator of glucose, protein, and lipid metabolism, whereas insulin-like growth factors (IGF-I and IGF-II) mainly act as mitogenic hormones. In the dog thyroid primary culture model, the triggering of DNA synthesis by thyrotropin (TSH) through cAMP, or by cAMP-independent factors including epidermal growth factor, hepatocyte growth factor and phorbol esters, requires insulin or IGFs as comitogenic factors. In the present study, in TSH-treated cells, IGF-I receptors and insulin receptors were paradoxically equivalent in their capacity to elicit the comitogenic pathway, which, however, was mediated only by IGF-I receptors in dog thyroid cells stimulated by cAMP-independent mitogens. Moreover, prior cell exposure to TSH or forskolin increased their responsiveness to insulin, IGF-I, and IGF-II, as seen on DNA synthesis and activation of a common insulin/IGF signaling pathway. To understand these observations, binding characteristics and expression of insulin and IGF-I receptors were examined. To analyze IGF-I receptor characteristics, the unexpected interference of a huge presence of IGF-binding proteins at the cell membrane was avoided using labeled Long R(3) IGF-I instead of IGF-I, Strikingly, TSH, through cAMP, time-dependently induced insulin binding and insulin receptor mRNA and protein accumulation without any effect on IGF-I receptors. These findings constitute a first example of an induction of insulin receptor gene expression by a cAMP-mediated hormone, In dog thyroid cells, this allows low physiological insulin concentrations to act as a comitogenic factor and might explain in part the enhanced responsiveness to IGFs in response to TSH. This raises the possibility that TSH-insulin interactions may play a role in the regulation of thyroid growth and function in vivo.	FREE UNIV BRUSSELS,INST INTERDISCIPLINARY RES,B-1070 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel				Roger, Pierre/0000-0002-5812-1783				ADASHI EY, 1986, J BIOL CHEM, V261, P3923; BAGCHI N, 1981, ENDOCRINOLOGY, V109, P1428, DOI 10.1210/endo-109-5-1428; BAPTIST M, 1995, EXP CELL RES, V221, P160, DOI 10.1006/excr.1995.1363; BARON V, 1991, BIOCHEMISTRY-US, V30, P9365, DOI 10.1021/bi00102a033; BASERGA R, 1994, CELL PROLIFERAT, V27, P63, DOI 10.1111/j.1365-2184.1994.tb01406.x; BRIATA P, 1990, BIOCHEM BIOPH RES CO, V170, P1184, DOI 10.1016/0006-291X(90)90518-R; CONDORELLI G, 1992, ENDOCRINOLOGY, V130, P1615, DOI 10.1210/en.130.3.1615; CONOVER A, 1989, HORM METAB RES, V21, P59, DOI 10.1055/s-2007-1009151; CONTOR L, 1988, MOL CELL BIOL, V8, P2494, DOI 10.1128/MCB.8.6.2494; DEMEYTS P, 1994, HORM RES, V42, P152, DOI 10.1159/000184188; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; DESHUQUOIS B, 1993, ANN ENEODRINOL PARIS, V54, P373; DREMIER S, 1994, ENDOCRINOLOGY, V135, P135, DOI 10.1210/en.135.1.135; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; FRANCIS GL, 1992, J MOL ENDOCRINOL, V8, P213, DOI 10.1677/jme.0.0080213; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GIORGINO F, 1993, J CLIN INVEST, V91, P2020, DOI 10.1172/JCI116424; HOFMANN C, 1989, J BIOL CHEM, V264, P8606; IshShalom D, 1995, ANN NY ACAD SCI, V766, P409, DOI 10.1111/j.1749-6632.1995.tb26690.x; JOLIN T, 1970, ENDOCRINOLOGY, V87, P99, DOI 10.1210/endo-87-1-99; KING GL, 1980, J CLIN INVEST, V66, P130, DOI 10.1172/JCI109826; KLINMAN D, 1995, ENDOCRINOLOGY, V136, P2531; KOONTZ JW, 1981, SCIENCE, V211, P947, DOI 10.1126/science.7008195; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LAMY F, 1993, J BIOL CHEM, V268, P8398; LEE JK, 1994, MOL ENDOCRINOL, V8, P625, DOI 10.1210/me.8.5.625; LEROITH D, 1994, HORM RES, V41, P74, DOI 10.1159/000183964; LI SL, 1993, BIOCHEM BIOPH RES CO, V196, P92, DOI 10.1006/bbrc.1993.2220; MACIEL RMB, 1988, J CLIN INVEST, V82, P1546, DOI 10.1172/JCI113764; MAMULA PW, 1990, DIABETES CARE, V13, P288, DOI 10.2337/diacare.13.3.288; MASTICK CC, 1994, ENDOCRINOLOGY, V135, P214, DOI 10.1210/en.135.1.214; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MCKEON C, 1994, ADV EXP MED BIOL MCK, V343, P79; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; OSTEROP APRM, 1994, BIOCHEMISTRY-US, V33, P7453, DOI 10.1021/bi00189a053; PAPA V, 1990, CANCER RES, V50, P7858; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PERICAS I, 1977, ACTA ENDOCRINOL-COP, V86, P128, DOI 10.1530/acta.0.0860128; PIETRZKOWSKI Z, 1992, CANCER RES, V52, P6447; POHL V, 1990, J CELL BIOL, V111, P663, DOI 10.1083/jcb.111.2.663; RANDAZZO PA, 1990, EXP CELL RES, V190, P31, DOI 10.1016/0014-4827(90)90140-6; REUSE S, 1991, EXP CELL RES, V196, P210, DOI 10.1016/0014-4827(91)90253-Q; ROGER P, 1988, J CLIN ENDOCR METAB, V66, P1158, DOI 10.1210/jcem-66-6-1158; ROGER PP, 1987, EXP CELL RES, V172, P282, DOI 10.1016/0014-4827(87)90387-9; ROGER PP, 1987, J CELL PHYSIOL, V130, P58, DOI 10.1002/jcp.1041300110; Roger PP, 1995, VITAM HORM, V51, P59, DOI 10.1016/S0083-6729(08)61038-9; ROGER PP, 1983, FEBS LETT, V157, P323, DOI 10.1016/0014-5793(83)80569-9; ROGER PP, 1986, CANCER RES, V46, P895; ROHLIK QT, 1987, BIOCHEM BIOPH RES CO, V149, P276, DOI 10.1016/0006-291X(87)91635-4; RUSSELL WE, 1984, P NATL ACAD SCI-BIOL, V81, P2389, DOI 10.1073/pnas.81.8.2389; SAAD MJA, 1994, MOL ENDOCRINOL, V8, P545, DOI 10.1210/me.8.5.545; SIDDLE K, 1994, HORM RES, V41, P56, DOI 10.1159/000183962; SMITH P, 1986, ENDOCRINOLOGY, V119, P1439, DOI 10.1210/endo-119-4-1439; STADTMAUER L, 1986, J BIOL CHEM, V261, P3402; TAKADA K, 1990, J CLIN INVEST, V86, P1548, DOI 10.1172/JCI114874; TAKAHASHI S, 1990, ENDOCRINOLOGY, V126, P736, DOI 10.1210/endo-126-2-736; TAKAHASHI SI, 1991, J BIOL CHEM, V266, P7834; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TANTI JF, 1987, BIOCHEM J, V245, P19, DOI 10.1042/bj2450019; THOMAS GA, 1994, J PATHOL, V173, P355, DOI 10.1002/path.1711730411; TONG ZQ, 1994, GEN COMP ENDOCR, V94, P374, DOI 10.1006/gcen.1994.1093; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P133, DOI 10.1210/endo-122-1-133; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P127, DOI 10.1210/endo-122-1-127; VANOBBERGHENSCHILLING E, 1983, EXP CELL RES, V147, P369, DOI 10.1016/0014-4827(83)90219-7; WERNER H, 1994, VITAM HORM, V48, P1, DOI 10.1016/S0083-6729(08)60495-1; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILLIAMS DW, 1989, MOL CELL ENDOCRINOL, V61, P139, DOI 10.1016/0303-7207(89)90199-8; XU B, 1995, J BIOL CHEM, V270, P29825	68	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29400	29406		10.1074/jbc.271.46.29400	http://dx.doi.org/10.1074/jbc.271.46.29400			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910605	hybrid			2022-12-25	WOS:A1996VT05200097
J	Fiedler, B; ScheinerBobis, G				Fiedler, B; ScheinerBobis, G			Transmembrane topology of alpha- and beta-subunits of Na+,K+-ATPase derived from beta-galactosidase fusion proteins expressed in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SITE-DIRECTED MUTAGENESIS; ATP BINDING-SITE; NA+/K+-ATPASE; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; SODIUM-PUMP; NA/K-ATPASE; IMMUNOELECTRON MICROSCOPY; EXTRACELLULAR DOMAIN	Various models of the transmembrane topology of the Na+,KC-ATPase predict either 8 or 10 membrane spans for the alpha-subunit and one to three membrane spans for the beta-subunit. Structure/function analysis, however, requires precise knowledge about the folding of enzymes. Therefore, the intention of this work was to establish a transmembrane topology model for the subunits of Na+,K+-ATPase. The bacterial enzyme beta-galactosidase was fused to the C termini of truncated alpha- and beta-subunits of Na+,K+-ATPase. Fusions were generated at Arg(60) (LTTAR(60)), Glu(116) (AATEE(116)), Ala(247) (VEGTA(247)), Leu(311) (YTWEL(311)), Ala(444) (VAGDA(444)), Ala(789) (IFIIA(789)) Met(809) (LGTDM(809)), Asp(884) (RVTWD(884)), IIe(946) (MKNKI(946)), and Arg(972) (GVALR(972)) of the sheep alpha(1)-subunit and at Pro(236) (LGGYP(236)) of the dog beta-subunit. The fusion constructs were expressed in yeast cells for studies on the localization of the fused reporter enzyme. Activity measurements of the reporter enzyme revealed that only intracellular fusion sites lead to active beta-galactosidase. Indirect immunofluorescence microscopy with cells expressing alpha(1)/beta-galacosidase and beta/beta-galactosidase hybrid proteins demonstrated that inactive beta-galactosidase is associated with the yeast plasma membrane and can be detected from the extracellular side. The data obtained suggest that Pro(236) of the beta-subunit is located on the extracellular surface, corresponding to a model with one transmembrane segment, and that the alpha-subunit of the Na+,K+-ATPase consists of 10 membrane-associated spans, They also suggest that a stretch of the alpha(1)-subunit between membrane spans M7 and M8 might be hidden within the membrane, surrounded by the other hydrophobic spans, in analogy to the P-loop of Na+ or K+ channels and to the ''hourglass'' structure of water channels.	UNIV GIESSEN,INST BIOCHEM & ENDOKRINOL,FACHBEREICH VET MED,D-35392 GIESSEN,GERMANY	Justus Liebig University Giessen								ANDERBERG SJ, 1995, BIOCHEMISTRY-US, V34, P9508, DOI 10.1021/bi00029a027; ANTOLOVIC R, 1991, EUR J BIOCHEM, V199, P195, DOI 10.1111/j.1432-1033.1991.tb16109.x; ARYSTARKHOVA E, 1995, J BIOL CHEM, V270, P8785, DOI 10.1074/jbc.270.15.8785; ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; BAYER R, 1990, BIOCHEMISTRY-US, V29, P2251, DOI 10.1021/bi00461a007; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CANFIELD VA, 1993, BIOCHEMISTRY-US, V32, P13782, DOI 10.1021/bi00213a005; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CHEN CY, 1984, NUCLEIC ACIDS RES, V12, P8951, DOI 10.1093/nar/12.23.8951; EAKLE KA, 1995, J BIOL CHEM, V270, P13937, DOI 10.1074/jbc.270.23.13937; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FAGAN MJ, 1994, J MOL EVOL, V38, P57; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; FROSHAUER S, 1988, J MOL BIOL, V200, P501, DOI 10.1016/0022-2836(88)90539-6; GLYNN IM, 1993, J PHYSIOL-LONDON, V462, P1; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; GREEN NM, 1989, BIOCHEM SOC T, V17, P972, DOI 10.1042/bst0170972; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HAMRICK M, 1993, J BIOL CHEM, V268, P24367; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACOBSON RH, 1992, J MOL BIOL, V223, P1177, DOI 10.1016/0022-2836(92)90269-P; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JORGENSEN PL, 1982, J BIOL CHEM, V257, P7435; JUNG JS, 1994, J BIOL CHEM, V269, P14648; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KARLISH SJD, 1992, ACTA PHYSIOL SCAND, V146, P69; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KIRSCH GE, 1995, BIOPHYS J, V68, P1804, DOI 10.1016/S0006-3495(95)80357-7; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LIN JL, 1995, J BIOL CHEM, V270, P6942, DOI 10.1074/jbc.270.12.6942; LINGREL JB, 1992, J BIOENERG BIOMEMBR, V24, P263; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; MILLER RP, 1988, BIOCHIM BIOPHYS ACTA, V954, P50, DOI 10.1016/0167-4838(88)90054-4; MOHRAZ M, 1994, J BIOL CHEM, V269, P2929; NING G, 1993, FEBS LETT, V336, P521, DOI 10.1016/0014-5793(93)80868-U; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P230, DOI 10.1016/0014-5793(88)80904-9; POST RL, 1965, J BIOL CHEM, V240, P1437; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Sambrook J, 1989, MOL CLONING LAB MANU, V1-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEINERBOBIS G, 1994, MOL PHARMACOL, V45, P1132; SCHEINERBOBIS G, 1994, BBA-BIOMEMBRANES, V1193, P226, DOI 10.1016/0005-2736(94)90157-0; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SKOU JC, 1992, J BIOENERG BIOMEMBR, V24, P249; SKOU JC, 1988, METHOD ENZYMOL, V156, P1; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; TOMASELLI GF, 1995, BIOPHYS J, V68, P1814, DOI 10.1016/S0006-3495(95)80358-9; TRAN CM, 1994, J BIOL CHEM, V269, P6558; TRAN CM, 1994, BIOCHEMISTRY-US, V33, P4140, DOI 10.1021/bi00180a006; VLADIMIROVA NM, 1995, BBA-BIOMEMBRANES, V1233, P175, DOI 10.1016/0005-2736(94)00247-M; Xie YH, 1996, J BIOL CHEM, V271, P2563, DOI 10.1074/jbc.271.5.2563; YOON KL, 1994, J BIOL CHEM, V269, P28249; ZHANG YZ, 1991, FASEB J, V5, P3108, DOI 10.1096/fasebj.5.15.1720751	69	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29312	29320		10.1074/jbc.271.46.29312	http://dx.doi.org/10.1074/jbc.271.46.29312			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910592	hybrid			2022-12-25	WOS:A1996VT05200084
J	Iynedjian, PB; Marie, S; Wang, HY; Gjinovci, A; Nazaryan, K				Iynedjian, PB; Marie, S; Wang, HY; Gjinovci, A; Nazaryan, K			Liver-specific enhancer of the glucokinase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; POLYMERASE CHAIN-REACTION; PANCREATIC BETA-CELL; HYPERSENSITIVE SITES; MESSENGER-RNA; RAT-LIVER; EXPRESSION; PROMOTER; INSULIN; TRANSCRIPTION	Glucokinase gene regions that are important for liver specific expression of the enzyme have been functionally identified using transient transfection of rat hepatocytes. Maximal luciferase activity was elicited by a reporter plasmid with 3.4 kilobase pairs of genomic DNA flanking the liver glucokinase promoter. Deletion of a gene fragment between -1000 and -600 with respect to the start of transcription resulted in a 60% decrease in luciferase activity. Further reduction, close to background level, occurred upon deletion of a 90-base pair sequence between -123 and -34. Reporter plasmids with the liver glucokinase promoter and any length of flanking sequence were minimally active in INS-1 insulinoma cells, and conversely reporters with the beta-cell-specific promoter were ineffective in primary hepatocytes. In FTO-2B hepatoma cells, a differentiated line expressing many liver-specific traits but not the endogenous glucokinase gene, the promoter proximal region between -123 and -34 markedly stimulated the expression of transfected plasmids above background. However, addition of the flanking region up to -1000 inhibited luciferase expression. The gene fragment from -1003 to -707 was shown to be a bona fide, hepatocyte-specific enhancer by the following criteria: 1) it stimulated reporter expression by more than 10- and 5-fold when inserted directly upstream of the glucokinase TATA box or complete promoter, respectively, regardless of orientation; 2) it stimulated gene expression from the heterologous SV 40 promoter 4-fold; 3) it was also effective from a downstream position; and 4) in contrast to the enhancer effect in primary hepatocytes, the sequence acted as a silencer in FTO-2B cells and was neutral in INS-1 cells. Both the promoter proximal and the enhancer regions were marked by DNase I hypersensitive sites in the chromatin of primary hepatocytes but not hepatoma or insulinoma cells. Seven footprinted elements termed A through G were mapped in the enhancer by the in vitro DNase I protection assay. Elements A-C may bind liver enriched factors, because they were not protected by spleen nuclear extract. In hepatocyte transfection, the downstream half of the enhancer containing elements A-C was about half as effective as the complete enhancer in stimulating glucokinase promoter activity. Site-directed mutagenesis of element A virtually abrogated the activity of the half enhancer, whereas mutation of element C had a more moderate effect. The sequence between -732 and -578 upstream of the liver start of transcription in the human glucokinase gene displays 79% sequence identity with the downstream half of the rat enhancer. The human gene fragment ligated to the minimal rat liver glucokinase promoter was shown to work as an enhancer in the hepatocyte transfection system.	UNIV GENEVA,SCH MED,DIV CLIN BIOCHEM & DIABET RES,CH-1211 GENEVA,SWITZERLAND	University of Geneva				Nazaryan, Karen/0000-0002-5231-3928				ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BOSSARD P, 1993, EUR J BIOCHEM, V215, P883, DOI 10.1111/j.1432-1033.1993.tb18106.x; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BURCH JBE, 1983, CELL, V33, P65, DOI 10.1016/0092-8674(83)90335-5; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; IYNEDJIAN PB, 1988, J BIOL CHEM, V263, P740; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; IYNEDJIAN PB, 1987, J BIOL CHEM, V262, P6032; IYNEDJIAN PB, 1995, J CLIN INVEST, V95, P1966, DOI 10.1172/JCI117880; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; JETTON TL, 1994, J BIOL CHEM, V269, P3641; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; KINGSTON RE, 1990, CURRENT PROTOCOLS MO; KLIMEK F, 1993, CARCINOGENESIS, V14, P1857, DOI 10.1093/carcin/14.9.1857; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MARIE S, 1993, J BIOL CHEM, V268, P23881; Parsa R, 1996, EUR J BIOCHEM, V236, P214, DOI 10.1111/j.1432-1033.1996.00214.x; PERRIN S, 1990, NUCLEIC ACIDS RES, V18, P7433, DOI 10.1093/nar/18.24.7433; *PROM CORP, 1993, TECHN B PROM CORP, V101; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; SALAVERT A, 1982, J BIOL CHEM, V257, P13404; Sambrook J., 2002, MOL CLONING LAB MANU; SHELTON KD, 1992, MOL CELL BIOL, V12, P4578, DOI 10.1128/MCB.12.10.4578; Sladek FM, 1992, CURR OPIN GENET DEV, V2, P256, DOI 10.1016/S0959-437X(05)80282-5; STEWART AF, 1991, NUCLEIC ACIDS RES, V19, P3157, DOI 10.1093/nar/19.11.3157; TANIZAWA Y, 1992, MOL ENDOCRINOL, V6, P1070, DOI 10.1210/me.6.7.1070	35	23	23	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29113	29120		10.1074/jbc.271.46.29113	http://dx.doi.org/10.1074/jbc.271.46.29113			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910567	hybrid			2022-12-25	WOS:A1996VT05200059
J	vandenBerg, MA; deJongGubbels, P; Kortland, CJ; vanDijken, JP; Pronk, JT; Steensma, HY				vandenBerg, MA; deJongGubbels, P; Kortland, CJ; vanDijken, JP; Pronk, JT; Steensma, HY			The two acetyl-coenzyme A synthetases of Saccharomyces cerevisiae differ with respect to kinetic properties and transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A SYNTHETASE; CHEMOSTAT CULTURES; METABOLIC FLUXES; GLUCOSE; YEASTS; GENE; PHYSIOLOGY; ACETATE; ETHANOL; GROWTH	Saccharomyces cerevisiae contains two structural genes, ACS1 and ACS2, each encoding an active acetyl-coenzyme A synthetase. Characterization of enzyme activities in cell-free extracts from strains expressing either of the two genes revealed differences in the catalytic properties of the two enzymes, The K-m for ac etate of Acs1p was about 30-fold lower than that of Acs2p and Acs1p, but not Acs2p, could use propionate as a substrate, Enzyme activity measurements and mRNA analyses showed that ACS1 and ACS2 were both expressed during carbon-limited growth on glucose, ethanol, and acetate in aerobic chemostat cultures, In anaerobic glucose-limited cultures, only the ACS2 gene was expressed, Based on these facts, the products of the ACS1 and ACS2 genes were identified as the previously described ''aerobic'' and ''non-aerobic'' forms of acetyl-coenzyme A synthetase, respectively, Batch and glucose-pulse experiments revealed that transcription of ACS1 is subject to glucose repression, A mutant strain lacking Acs2p was unable to grow on glucose in batch cultures, but grew readily in aerobic glucose limited chemostat cultures, in which the low residual glucose concentration alleviated glucose repression. Experiments in which ethanol was pulsed to aerobic ethanol-limited chemostat cultures indicated that, in addition to glucose, ethanol also repressed ACS1 transcription, although to a lesser extent, In contrast, transcription of ACS2 was slightly induced by ethanol and glucose, Absence of ACS2 prevented complete glucose repression of ACS1, indicating that ACS2 (in)directly is involved in the transcriptional regulation of ACS1.	DELFT UNIV TECHNOL,KLUYVER LAB BIOTECHNOL,NL-2628 BC DELFT,NETHERLANDS; LEIDEN UNIV,INST MOL PLANT SCI,NL-2333 AL LEIDEN,NETHERLANDS	Delft University of Technology; Leiden University; Leiden University - Excl LUMC				Pronk, Jack/0000-0002-5617-4611				DEJONGGUBBELS P, 1995, YEAST, V11, P407, DOI 10.1002/yea.320110503; DEVICENZI DL, 1970, FED PROC, V3551, P872; DEVIRGILIO C, 1992, YEAST, V8, P1043, DOI 10.1002/yea.320081207; Flikweert MT, 1996, YEAST, V12, P247, DOI 10.1002/(SICI)1097-0061(19960315)12:3<247::AID-YEA911>3.0.CO;2-I; FRENKEL EP, 1977, J BIOL CHEM, V252, P504; GRUNDY FJ, 1993, MOL MICROBIOL, V10, P259, DOI 10.1111/j.1365-2958.1993.tb01952.x; HOLZER H, 1957, BIOCHEM Z, V329, P175; KLEIN HP, 1979, J BACTERIOL, V137, P179, DOI 10.1128/JB.137.1.179-184.1979; KLEIN HP, 1971, J BACTERIOL, V106, P596, DOI 10.1128/JB.106.2.596-602.1971; KRATZER S, 1995, GENE, V161, P75, DOI 10.1016/0378-1119(95)00289-I; LOMBARDO A, 1992, MOL CELL BIOL, V12, P2941, DOI 10.1128/MCB.12.7.2941; MERCADO JJ, 1994, EUR J BIOCHEM, V224, P473, DOI 10.1111/j.1432-1033.1994.00473.x; PETRIK M, 1983, J GEN MICROBIOL, V135, P43; POSTMA E, 1989, APPL ENVIRON MICROB, V53, P468; PRONK JT, 1994, MICROBIOL-SGM, V140, P601, DOI 10.1099/00221287-140-3-601; PRONK JT, 1994, MICROBIOL-UK, V140, P717, DOI 10.1099/00221287-140-4-717; SATYANAR.T, 1973, J BACTERIOL, V115, P600, DOI 10.1128/JB.115.2.600-606.1973; SATYANARAYANA T, 1974, BIOCHIM BIOPHYS ACTA, V341, P396, DOI 10.1016/0005-2744(74)90232-0; SATYANARAYANA T, 1976, ARCH BIOCHEM BIOPHYS, V174, P480, DOI 10.1016/0003-9861(76)90376-3; SATYANARAYANA T, 1974, P 4 INT S YEASTS VIE; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SIERKSTRA LN, 1992, YEAST, V8, P1077, DOI 10.1002/yea.320081210; VANDENBERG MA, 1995, EUR J BIOCHEM, V231, P704; VANURK H, 1990, APPL ENVIRON MICROB, V56, P281, DOI 10.1128/AEM.56.1.281-287.1990; VANURK H, 1988, YEAST, V4, P283, DOI 10.1002/yea.320040406; VERDUYN C, 1991, ANTON LEEUW INT J G, V60, P325, DOI 10.1007/BF00430373; VERDUYN C, 1990, J GEN MICROBIOL, V136, P395, DOI 10.1099/00221287-136-3-395; VERDUYN C, 1992, YEAST, V8, P501, DOI 10.1002/yea.320080703; ZONNEVELD BJM, 1986, J MICROBIOL METH, V4, P287, DOI 10.1016/0167-7012(86)90040-0	29	183	195	3	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28953	28959		10.1074/jbc.271.46.28953	http://dx.doi.org/10.1074/jbc.271.46.28953			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910545	hybrid, Green Published			2022-12-25	WOS:A1996VT05200037
J	Waterhouse, N; Kumar, S; Song, QH; Strike, P; Sparrow, L; Dreyfuss, G; Alnemri, ES; Litwack, G; Lavin, M; Watters, D				Waterhouse, N; Kumar, S; Song, QH; Strike, P; Sparrow, L; Dreyfuss, G; Alnemri, ES; Litwack, G; Lavin, M; Watters, D			Heteronuclear ribonucleoproteins C1 and C2, components of the spliceosome, are specific targets of interleukin 1 beta-converting enzyme-like proteases in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; HETEROGENEOUS NUCLEAR-RNA; ICE-LIKE PROTEASES; CONVERTING-ENZYME; POLY(ADP-RIBOSE) POLYMERASE; BINDING-PROTEINS; PREMESSENGER RNA; GENE CED-3; IL-1-BETA-CONVERTING ENZYME; MAMMALIAN HOMOLOG	Apoptosis induced by a variety of agents results in the proteolytic cleavage of a number of cellular substrates by enzymes related to interleukin 1 beta-converting enzyme (ICE). A small number of substrates for these enzymes have been identified to date, including enzymes involved in DNA repair processes: poly(ADP-ribose) polymerase and DNA-dependent protein kinase. We describe here for the first time the specific cleavage of the heteronuclear ribonucleoproteins (hnRNPs) C1 and C2 in apoptotic cells induced to undergo apoptosis by a variety of stimuli, including ionizing radiation, etoposide, and ceramide. No cleavage was observed in cells that are resistant to apoptosis induced by ionizing radiation. Protease inhibitor data implicate the involvement of an ICE-like protease in the cleavage of hnRNP C. Using recombinant ICE-like proteases and purified hnRNP C proteins in. vitro, we show that the C proteins are cleaved by Mch3 alpha and CPP32 and, to a lesser extent, by Mch2 alpha, but not by ICE, Nedd2, Tx, or the cytotoxic T-cell protease granzyme B. The results described here demonstrate that the hnRNP C proteins, abundant nuclear proteins thought to be involved in RNA splicing, belong to a critical set of protein substrates that are cleaved by ICE-like proteases during apoptosis.	QUEENSLAND INST MED RES, PO ROYAL BRIBANE HOSP, QUEENSLAND CANC FUND RES UNIT, BRISBANE, QLD 4029, AUSTRALIA; UNIV QUEENSLAND, DEPT SURG, ST LUCIA, QLD 4072, AUSTRALIA; HANSON CTR CANC RES, ADELAIDE, SA 5000, AUSTRALIA; CSIRO, DIV BIOMOL ENGN, PARKVILLE, VIC 3052, AUSTRALIA; UNIV PENN, SCH MED,HOWARD HUGHES MED INST,RES LABS, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA; THOMAS JEFFERSON UNIV, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, PHILADELPHIA, PA 19107 USA	QIMR Berghofer Medical Research Institute; University of Queensland; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Howard Hughes Medical Institute; University of Pennsylvania; Jefferson University; Jefferson University			Lavin, Martin F/F-5961-2014; Waterhouse, Nigel/I-9813-2016; Dreyfuss, Gideon/D-1218-2013; Kumar, Sharad/AAX-7787-2020; Watters, Dianne J/E-6007-2010	Lavin, Martin F/0000-0002-5940-4769; Dreyfuss, Gideon/0000-0001-8129-8774; Kumar, Sharad/0000-0001-7126-9814; Watters, Dianne J/0000-0002-2555-5825				Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; COMPTON MM, 1987, J BIOL CHEM, V262, P8288; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GORLACH M, 1994, J BIOL CHEM, V269, P23074; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; HOLCOMB ER, 1984, J BIOL CHEM, V259, P31; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Khanna KK, 1996, CELL DEATH DIFFER, V3, P315; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MAYRAND SH, 1993, P NATL ACAD SCI USA, V90, P7764, DOI 10.1073/pnas.90.16.7764; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOORE CL, 1988, EMBO J, V7, P3159, DOI 10.1002/j.1460-2075.1988.tb03183.x; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; PINOLROMA S, 1993, MOL CELL BIOL, V13, P5762, DOI 10.1128/MCB.13.9.5762; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Song QZ, 1996, J EXP MED, V184, P619, DOI 10.1084/jem.184.2.619; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SWANSON MS, 1987, MOL CELL BIOL, V7, P1731, DOI 10.1128/MCB.7.5.1731; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; TEH BS, 1991, INT J IMMUNOPHARMACO, V13, P1117, DOI 10.1016/0192-0561(91)90163-2; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1995, J BIOL CHEM, V270, P18044, DOI 10.1074/jbc.270.30.18044; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Whyte M, 1996, TRENDS CELL BIOL, V6, P245, DOI 10.1016/0962-8924(96)20025-X; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1995, CURR OPIN CELL BIOL, V7, P211, DOI 10.1016/0955-0674(95)80030-1	62	103	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29335	29341		10.1074/jbc.271.46.29335	http://dx.doi.org/10.1074/jbc.271.46.29335			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910595	hybrid			2022-12-25	WOS:A1996VT05200087
J	Chandrasekaran, C; Coopersmith, CM; Gordon, JI				Chandrasekaran, C; Coopersmith, CM; Gordon, JI			Use of normal and transgenic mice to examine the relationship between terminal differentiation of intestinal epithelial cells and accumulation of their cell cycle regulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SMALL INTESTINE; RETINOBLASTOMA SUSCEPTIBILITY GENE; HUMAN-DIPLOID FIBROBLASTS; SV40 T-ANTIGEN; G(1) CYCLINS; IN-VIVO; S-PHASE; PROTEIN; EXPRESSION; DNA	A spatially well organized continuum of proliferation, differentiation, and death is displayed along crypt-villus units in the adult mouse small intestine, This continuum provides an opportunity to examine in vivo the mechanisms by which proliferative status changes as a function of cellular differentiation. Immunohistochemical studies of normal FVB/N mice revealed that as epithelial cells complete their terminal differentiation during a 48-72-h migration up villi, there is a marked and rapid fall in the levels of two important regulators of the G(1)/S transition, cyclin D-1 and cyclin-dependent kinase (cdk) 2, However, cellular levels of their partners, cdk4 and cyclin E, remain unchanged as does the level of pRB, Adult FVB/N transgenic mice were studied that contained an intestinal fatty acid binding protein gene promoter (Fabpi) linked to wild type Simian virus 40 large T antigen (SV40 TAgWt) or a mutant TAg with Lys for Glu substitutions at residues 107 and 108 (SV40 TAgK107/8) that fails to bind pRB and related pocket proteins, Both transgenes are expressed only in villus enterocytes, SV40 TAgWt causes these terminally differentiated cells to re-enter the cycle, Re-entry is accompanied by a reduction in un/hypophosphorylated pRB, an induction of cyclin D-1 and cdk2, but no change in cdk4, cyclin E, or E2F-1. In contrast, SV40 TAgK107/8 fails to induce reentry and does not produce changes in un/hypophosphorylated pRB, cyclin D-1, or cdk2 accumulation, These results suggest that un/hypophosphorylated pRB is an important mediator of the cell cycle arrest that normally occurs as enterocytes exit the crypt and complete their differentiation. Fabpi-directed expression of E2F-1 does not cause villus enterocytes to return to the cell cycle, alter their suppression of cyclin D-1 or cdk2, or affect their state of differentiation emphasizing the insensitivity of these cells to the effects of E2F-1, Analyses of p53(-/-) and p58(+/+) mice containing Fabpi-SV40 TAgWt and Fabpi-SV40 TAgK107/8 established that the proliferation induced by SV40 TAgWt does not require p53 and is associated with increased (p53-independent) apoptosis, The presence of cyclin E and cdk4 in differentiating villus enterocytes emphasizes that these cells retain part of their proliferative heritage expressed 24-72 h earlier in the crypt, The data suggest that down-regulation of cdk2 and/or cyclin D-1 expression may be important for control of proliferative status and/or execution of terminal differentiation.	WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT SURG,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NIDDK NIH HHS [DK30292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030292, R37DK030292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATES S, 1994, ONCOGENE, V9, P1633; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BRY L, 1994, P NATL ACAD SCI USA, V91, P10335, DOI 10.1073/pnas.91.22.10335; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHENG H, 1974, AM J ANAT, V141, P481, DOI 10.1002/aja.1001410404; CHENG H, 1974, AM J ANAT, V141, P503, DOI 10.1002/aja.1001410405; CHENG H, 1974, AM J ANAT, V141, P521, DOI 10.1002/aja.1001410406; COHN SM, 1984, J BIOL CHEM, V259, P2456; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; FALK P, 1994, AM J PHYSIOL, V266, pG987, DOI 10.1152/ajpgi.1994.266.6.G987; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Fromm L, 1996, ONCOGENE, V12, P69; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; HAGEMANN RF, 1970, AM J ANAT, V129, P41, DOI 10.1002/aja.1001290104; HALL PA, 1994, J CELL SCI, V107, P3569; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; Hermiston ML, 1996, GENE DEV, V10, P985, DOI 10.1101/gad.10.8.985; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HOGAN B, 1986, MANIPULATING MOUSE E; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; JIANG D, 1993, ONCOGENE, V8, P2805; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LATHANGUE NB, 1994, TRENDS BIOL SCI, V19, P443; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; LOEFFLER M, 1993, J THEOR BIOL, V160, P471, DOI 10.1006/jtbi.1993.1031; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; SAKAMOTO K, 1993, ONCOGENE, V8, P1887; Sambrook J., 2002, MOL CLONING LAB MANU; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tevosian SG, 1996, CELL GROWTH DIFFER, V7, P43; WICE BM, 1992, J CELL BIOL, V116, P405, DOI 10.1083/jcb.116.2.405; WIMAN KG, 1993, FASEB J, V7, P841, DOI 10.1096/fasebj.7.10.8393817; WRIGHT NA, 1982, P NATL ACAD SCI USA, V91, P3602; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	70	67	70	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28414	28421		10.1074/jbc.271.45.28414	http://dx.doi.org/10.1074/jbc.271.45.28414			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910466	hybrid			2022-12-25	WOS:A1996VU03300066
J	ElMezgueldi, M; Marston, SB				ElMezgueldi, M; Marston, SB			The effects of smooth muscle calponin on the strong and weak myosin binding sites of F-actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITRO MOTILITY ANALYSIS; ATPASE ACTIVITY; TROPONIN-TROPOMYOSIN; HEAVY-MEROMYOSIN; SKELETAL-MUSCLE; IN-VITRO; ACTOMYOSIN MGATPASE; THIN-FILAMENTS; CALDESMON; INHIBITION	We have investigated the mechanism of inhibition of the actomyosin MgATPase by the smooth muscle protein calponin. We have shown previously the specific interaction of calponin with Glu(334) of actin (EL-Mezgueldi, M., Fattoum, A., Derancourt, J., and Hassab, R. (1992) J. Biol. Chem. 267, 15943-15951). This residue is within the sequence 332-334, which has been proposed to be an important part of the strong myosin binding site (Rayment, L., Holden, H. M., Whittaker, M., Yohn, C. B., Lorenz, M., Holmes, K. C., and Milligan, R. A. (1993) Science 261, 58-65), Therefore, we suggested that calponin will affect the strong binding actin-myosin interaction, To test this hypothesis we have investigated the effect of calponin on the strong binding of S-1 . MgAMP-PNP (5'-adenylyl imidodiphosphate) and on the weak binding of S-1 . MgADP . P-i to actin, We found that an inhibitory concentration of calponin decreased the binding of S-1 . MgAMP-PNP to actin but had no effect on the binding of S-1 . MgADP . P-i. Similar results were obtained with skeletal muscle and smooth muscle S-1. In competition experiments calponin was found to displace S-1 . MgAMP-PNP and S-1 . MgADP but not S-1 . MgADP . P-i from the actin filament, S-1 displaced calponin from actin in the rigor state, in the presence of MgADP, and in the presence of MgAMP-PNP. We conclude that calponin inhibits the actin activated S-1 ATPase by blocking a strong S-1 binding site on actin and does not block the weak binding site.			ElMezgueldi, M (corresponding author), NATL HEART & LUNG INST,UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,SCH MED,DEPT CARDIAC MED,LONDON SW3 6LY,ENGLAND.			Marston, Steven/0000-0001-6054-6070	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABE M, 1990, J BIOCHEM-TOKYO, V108, P835, DOI 10.1093/oxfordjournals.jbchem.a123289; BARANY M, 1991, BIOCH SMOOTH MUSCLE, P321; BERTRAND R, 1989, EUR J BIOCHEM, V181, P747, DOI 10.1111/j.1432-1033.1989.tb14787.x; BONETKERRACHE A, 1995, BIOCHEM BIOPH RES CO, V206, P127, DOI 10.1006/bbrc.1995.1018; CHALOVICH JM, 1987, J BIOL CHEM, V262, P5711; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; ELMEZGUELDI M, 1992, J BIOL CHEM, V267, P15943; ELMEZGUELDI M, 1996, BIOCHEMISTRY-US, V35, P365; ELMEZGUELDI M, 1995, J BIOL CHEM, V270, P8867; FRASER IDC, 1995, J BIOL CHEM, V270, P19688, DOI 10.1074/jbc.270.34.19688; FRASER IDC, 1995, J BIOL CHEM, V270, P7836, DOI 10.1074/jbc.270.14.7836; GREENE L, 1982, J BIOL CHEM, V257, P3993; GREENE LE, 1983, BIOCHEMISTRY-US, V22, P530, DOI 10.1021/bi00272a002; HOLMES KC, 1995, BIOPHYS J, V68, pS2; HORIUCHI KY, 1991, BIOCHEM BIOPH RES CO, V176, P1487, DOI 10.1016/0006-291X(91)90455-G; JAWOROWSKI A, 1995, FEBS LETT, V365, P167, DOI 10.1016/0014-5793(95)00451-E; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KING RT, 1985, BIOCHEMISTRY-US, V24, P7009, DOI 10.1021/bi00345a039; KOLAKOWSKI J, 1995, BIOCHEM J, V306, P199; LASH JA, 1986, J BIOL CHEM, V261, P6155; LU FWM, 1995, BIOCHEMISTRY-US, V34, P11864, DOI 10.1021/bi00037a026; Mabuchi K, 1996, J MUSCLE RES CELL M, V17, P243, DOI 10.1007/BF00124246; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MARSTON S, 1975, BIOCHEMISTRY-US, V14, P3868, DOI 10.1021/bi00688a021; MARSTON S, 1995, INT J BIOCHEM CELL B, V27, P97, DOI 10.1016/1357-2725(94)00080-U; MARSTON SB, 1991, FEBS LETT, V292, P179, DOI 10.1016/0014-5793(91)80862-W; MARSTON SB, 1994, J BIOL CHEM, V269, P32104; MARSTON SB, 1992, J BIOL CHEM, V267, P16796; MARSTON SB, 1991, BIOCHEM J, V279, P1; MARSTON SB, 1993, J BIOL CHEM, V268, P12317; MARSTON SB, 1980, J MOL BIOL, V139, P573, DOI 10.1016/0022-2836(80)90050-9; MARSTON SB, 1976, J MOL BIOL, V104, P263, DOI 10.1016/0022-2836(76)90012-7; MIKI M, 1992, BIOCHEM BIOPH RES CO, V187, P867, DOI 10.1016/0006-291X(92)91277-W; Milligan RA, 1996, P NATL ACAD SCI USA, V93, P21, DOI 10.1073/pnas.93.1.21; NORTH AJ, 1994, J CELL SCI, V107, P437; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; SCHWYTER D, 1989, BIOCHEMISTRY-US, V28, P5889, DOI 10.1021/bi00440a027; SELLERS JR, 1982, J BIOL CHEM, V257, P3880; SHIRINSKY VP, 1992, J BIOL CHEM, V267, P15886; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; Straub FB, 1942, STUD I MED CHEM U SZ, V2, P3; SZYMANSKI PT, 1993, FEBS LETT, V331, P256, DOI 10.1016/0014-5793(93)80348-X; TAKAHASHI K, 1988, HYPERTENSION, V11, P620, DOI 10.1161/01.HYP.11.6.620; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; VANCOMPERNOLLE K, 1990, FEBS LETT, V274, P146, DOI 10.1016/0014-5793(90)81350-W; WILLS FL, 1993, BIOCHEMISTRY-US, V32, P2321, DOI 10.1021/bi00060a025; WILLS FL, 1994, BIOCHEMISTRY-US, V33, P5562, DOI 10.1021/bi00184a027; WINDER SJ, 1993, BIOCHEM J, V296, P827, DOI 10.1042/bj2960827; WINDER SJ, 1990, J BIOL CHEM, V265, P10148; WINDER SJ, 1992, JPN J PHARMACOL, V58, pP29; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	52	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28161	28167		10.1074/jbc.271.45.28161	http://dx.doi.org/10.1074/jbc.271.45.28161			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910431	hybrid			2022-12-25	WOS:A1996VU03300031
J	Hollenberg, AN; Monden, T; Madura, JP; Lee, K; Wondisford, FE				Hollenberg, AN; Monden, T; Madura, JP; Lee, K; Wondisford, FE			Function of nuclear co-repressor protein on thyroid hormone response elements is regulated by the receptor A/B domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTOR; BETA-SUBUNIT GENE; ONCOGENE PRODUCT; X RECEPTOR; V-ERBA; LIGAND; TRANSCRIPTION; BINDING; PLASMID; ALPHA	Recently, a family of nuclear co-repressor proteins (TRACs) have been identified that interact with thyroid hormone (TR) and retinoic acid receptors to mediate Ligand-independent repression of gene transcription. In this report, we have cloned and characterized a human TRAC, which when expressed as a truncated protein lacking its repressing domains, can abolish endogenous cellular TRAC activity. Use of this inhibitor has uncovered a differential function of TRACs on negative versus positive thyroid hormone response elements and has demonstrated the importance of the TR A/B domain in modulating TRAC function. Thus, isoform-specific functions of the TR may be mediated by their functional interaction with co-repressor proteins.	BETH ISRAEL HOSP, DEPT MED, THYROID UNIT, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK-43653, DK-49126, DK-02354] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049126, R29DK043653, K08DK002354] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BIGLER J, 1995, EMBO J, V14, P5710, DOI 10.1002/j.1460-2075.1995.tb00258.x; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; HOLLENBERG AN, 1995, J BIOL CHEM, V270, P14274, DOI 10.1074/jbc.270.24.14274; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HSU JH, 1995, ENDOCRINOLOGY, V136, P421, DOI 10.1210/en.136.2.421; KAISER P, 1993, BIOTECHNIQUES, V14, P552; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKHAM BE, 1990, J BIOL CHEM, V265, P6489; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; SJOBERG M, 1995, MOL CELL BIOL, V15, P4718; TomicCanic M, 1996, J BIOL CHEM, V271, P1416, DOI 10.1074/jbc.271.3.1416; Tong GX, 1996, MOL CELL BIOL, V16, P1909; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WONDISFORD FE, 1989, J BIOL CHEM, V264, P14601; WONDISFORD FE, 1993, J BIOL CHEM, V268, P2749; Wood WM, 1989, J BIOL CHEM, V61, P497; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	38	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28516	28520		10.1074/jbc.271.45.28516	http://dx.doi.org/10.1074/jbc.271.45.28516			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910480	hybrid			2022-12-25	WOS:A1996VU03300080
J	Nicholson, AC; Nachman, RL; Altieri, DC; Summers, BD; Ruf, W; Edgington, TS; Hajjar, DP				Nicholson, AC; Nachman, RL; Altieri, DC; Summers, BD; Ruf, W; Edgington, TS; Hajjar, DP			Effector cell protease receptor-1 is a vascular receptor for coagulation factor Xa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VEIN ENDOTHELIAL-CELLS; TISSUE-PLASMINOGEN ACTIVATOR; SMOOTH-MUSCLE; FACTOR-VA; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; COS-1 CELLS; FACTOR VIIA; ANNEXIN-II; THROMBIN	The binding and assembly of the coagulation proteases on the endothelial cell surface are important steps not only in the generation of thrombin and thrombogenesis, but also in vascular cell signaling. Effector cell protease receptor (EPR-1) was identified as a novel leukocyte cell surface receptor recognizing the coagulation serine protease Factor Xa but not the precursor Factor X. We now demonstrate that EPR-1 is expressed on vascular endothelial cells and smooth muscle cells. Northern blots of endothelial and smooth muscle cells demonstrated three abundant mRNA bands of 3.0, 1.8, and 1.3 kDa. I-125-Labeled Factor Xa bound to endothelial cells in a dose-dependent saturable manner, and the binding was inhibited by antibody to EPR-1. No specific binding was observed with a recombinant mutant Factor X in which the activation site was substituted by Arg(196) --> Gln to prevent the proteolytic conversion to Xa. EPR-1 was identified immunohistochemically on microvascular endothelial and smooth muscle cells. Functionally, exposure of smooth muscle cells or endothelial cells to Factor Xa induced a 3-fold and a 8-fold increase in [H-3]thymidine uptake, respectively. However, receptor occupancy alone is insufficient for mitogenic signaling because the active site of the enzyme is required for mitogenesis. Thus, EPR-1 represents a site of specific protease-receptor complex assembly, which during local initiation of the coagulation cascade could mediate cellular signaling and responses of the vessel wall.	CORNELL UNIV, COLL MED, DEPT BIOCHEM A626, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT PATHOL, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT MED, NEW YORK, NY 10021 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06536 USA	Cornell University; Cornell University; Cornell University; Scripps Research Institute; Yale University					NHLBI NIH HHS [HL 46403, HL-18828, HL-43773] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043773, P50HL018828, P01HL046403] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1994, BIOCHEMISTRY-US, V33, P13848, DOI 10.1021/bi00250a039; ALTIERI DC, 1994, J BIOL CHEM, V269, P3139; ALTIERI DC, 1994, CELL IMMUNOL, V155, P372, DOI 10.1006/cimm.1994.1130; ALTIERI DC, 1990, J IMMUNOL, V145, P246; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ALTIERI DC, 1988, P NATL ACAD SCI USA, V85, P7462, DOI 10.1073/pnas.85.20.7462; Ambrosini G, 1996, J BIOL CHEM, V271, P1243, DOI 10.1074/jbc.271.2.1243; ANNAMALAI AE, 1986, ARTERIOSCLEROSIS, V6, P196, DOI 10.1161/01.ATV.6.2.196; BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310; BOUCHARD B, 1995, BLOOD S, V86, P450; CERVENY TJ, 1984, BLOOD, V63, P1467; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; CHEN LB, 1976, EXP CELL RES, V101, P41, DOI 10.1016/0014-4827(76)90409-2; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; COUGHLIN SR, 1993, THROMB HAEMOSTASIS, V70, P184; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; DOI T, 1993, J BIOL CHEM, V268, P2126; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; FAIR DS, 1979, J CLIN INVEST, V64, P884, DOI 10.1172/JCI109554; GAJDUSEK C, 1986, J CELL BIOL, V103, P419, DOI 10.1083/jcb.103.2.419; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; MARMUR JD, 1993, J CLIN INVEST, V91, P2253, DOI 10.1172/JCI116452; MARUYAMA I, 1984, J CLIN INVEST, V74, P224, DOI 10.1172/JCI111405; MESSIER TL, 1991, GENE, V99, P291, DOI 10.1016/0378-1119(91)90141-W; MORRISSEY JH, 1988, THROMB RES, V52, P247, DOI 10.1016/0049-3848(88)90084-9; MULLER WA, 1992, J EXP MED, V175, P1401, DOI 10.1084/jem.175.5.1401; NAKANO T, 1995, J BIOL CHEM, V270, P5702, DOI 10.1074/jbc.270.11.5702; RODGERS GM, 1985, BIOCHIM BIOPHYS ACTA, V844, P320, DOI 10.1016/0167-4889(85)90133-8; ROTTINGEN JA, 1995, J BIOL CHEM, V270, P4650, DOI 10.1074/jbc.270.9.4650; RUF W, 1994, BIOCHEMISTRY-US, V33, P11631, DOI 10.1021/bi00204a026; RUF W, 1991, THROMB HAEMOSTASIS, V66, P529; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1994, FASEB J, V8, P385, DOI 10.1096/fasebj.8.6.8168689; SAKAI T, 1990, J BIOL CHEM, V265, P9105; STERN DM, 1984, J CLIN INVEST, V74, P1910, DOI 10.1172/JCI111611; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; SUGO T, 1995, J BIOCHEM-TOKYO, V117, P244, DOI 10.1093/jb/117.2.244; TRACY PB, 1992, METHOD ENZYMOL, V215, P329; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V	46	76	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28407	28413		10.1074/jbc.271.45.28407	http://dx.doi.org/10.1074/jbc.271.45.28407			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910465	hybrid			2022-12-25	WOS:A1996VU03300065
J	Tang, WM; Wo, YYP; Stewart, J; Hawkins, AL; Griffin, CA; Sutter, TR; Greenlee, WF				Tang, WM; Wo, YYP; Stewart, J; Hawkins, AL; Griffin, CA; Sutter, TR; Greenlee, WF			Isolation and characterization of the human cytochrome p450 CYP1B1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AROMATIC HYDROCARBON METABOLISM; PHENOL-CHLOROFORM EXTRACTION; DIOXIN-RESPONSIVE ENHANCER; PROTEIN-DNA INTERACTIONS; SINGLE-STEP METHOD; AH-RECEPTOR; MESSENGER-RNA; ADRENAL CYTOCHROME-P450; INSITU HYBRIDIZATION; RAT CYP1B1	Previously, we identified a novel human cytochrome P450 cDNA that is inducible by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and represents the first member of a new subfamily designated cytochrome P4501B1 (CYP1B1; Sutter, T. R.,, Tang, Y. M., Hayes, C. L., Wo, Y. P., Jabs, E. W., Li, X., Yin, H., Cody, C. W., and Greenlee, W. F. (1994) J. Biol. Chem 269, 13092-13099). Here, we report on the isolation and initial characterization of the CYP1B1 gene. The CYP1B1 gene maps to human chromosome 2 at 2p21-22 and contains three exons and two introns. The putative open reading frame starts in the second exon and is 1629 base pairs in length. Southern analysis using DNA probes directed to each of the three exons confirmed that CYP1B1 is a single copy gene, Human CYP1B1 differs from its two most closely related members of the cytochrome P450 superfamily, CYP1A1 and CYP1A2, in the number of exons (3 versus 7) and chromosome location (2 versus 15). A single transcription initiation site was identified by primer extension analysis and S1 nuclease mapping, Based on nucleotide sequence analysis, the CYP1B1 gene lacks a consensus TATA box in the promoter region and contains nine TCDD-responsive enhancer core binding motifs (5'-GCGTG-3') located within a 2,5-kilobase pair genomic fragment 5'-ward of the transcription initiation start site, Deletion analysis of chloramphenicol acetyltransferase reporter gene constructs containing 5' CYP1B1 genomic fragments indicates that a region from -1022 to -835 containing three of the nine core binding moths contributes to the TCDD-inducible expression of CYP1B1.	UNIV MASSACHUSETTS,MED CTR,DEPT PHARMACOL & MOL TOXICOL,WORCESTER,MA 01655; PURDUE UNIV,DEPT PHARMACOL & TOXICOL,W LAFAYETTE,IN 47907; JOHNS HOPKINS MED INST,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT ONCOL,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT ENVIRONM HLTH SCI,BALTIMORE,MD 21205	University of Massachusetts System; University of Massachusetts Worcester; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007009, P30ES003819, R29ES006071] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06071, ES07009, ES03819] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BHATT B, 1988, NUCLEIC ACIDS RES, V16, P3951, DOI 10.1093/nar/16.9.3951; BHATTACHARYYA KK, 1995, J BIOL CHEM, V270, P11595, DOI 10.1074/jbc.270.19.11595; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CHISHOLM D, 1989, BIOTECHNIQUES, V7, P21; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRISE B, 1990, J VIROL, V64, P5585, DOI 10.1128/JVI.64.11.5585-5593.1990; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; FISHER JM, 1990, J BIOL CHEM, V265, P9676; GONZALEZ FJ, 1990, PHARMACOL THERAPEUT, V45, P1, DOI 10.1016/0163-7258(90)90006-N; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GREENLEE WF, 1994, PROG CLIN BIOL RES, V387, P47; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; KAWAJIRI K, 1984, P NATL ACAD SCI-BIOL, V81, P1649, DOI 10.1073/pnas.81.6.1649; KELLER W, 1984, CELL, V39, P423, DOI 10.1016/0092-8674(84)90449-5; KELLY RB, 1970, J BIOL CHEM, V245, P39; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; LANG D, 1992, NUCLEIC ACIDS RES, V20, P3287, DOI 10.1093/nar/20.13.3287; LEWIN B, 1980, CELL, V22, P324, DOI 10.1016/0092-8674(80)90340-2; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; NELSON DR, 1987, MOL BIOL EVOL, V4, P572; OTTO S, 1992, ENDOCRINOLOGY, V131, P3067, DOI 10.1210/en.131.6.3067; OTTO S, 1991, ENDOCRINOLOGY, V129, P970, DOI 10.1210/endo-129-2-970; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; QUATTROCHI LC, 1986, P NATL ACAD SCI USA, V83, P6731, DOI 10.1073/pnas.83.18.6731; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; REZNIKOFF WS, 1985, ANNU REV GENET, V19, P335; ROBIDOUX S, 1992, MOL CELL BIOL, V12, P3796, DOI 10.1128/MCB.12.9.3796; ROUET P, 1992, BIOTECHNIQUES, V13, P700; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAS U, 1994, J BIOL CHEM, V269, P14905; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHEN ZY, 1993, P NATL ACAD SCI USA, V90, P11483, DOI 10.1073/pnas.90.24.11483; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SPINK DC, 1994, J STEROID BIOCHEM, V51, P251, DOI 10.1016/0960-0760(94)90037-X; SPINK DC, 1990, P NATL ACAD SCI USA, V87, P6917, DOI 10.1073/pnas.87.17.6917; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; SUTTER TR, 1994, J BIOL CHEM, V269, P13092; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; WALKER NJ, 1995, CARCINOGENESIS, V16, P1319, DOI 10.1093/carcin/16.6.1319; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251	46	178	191	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28324	28330		10.1074/jbc.271.45.28324	http://dx.doi.org/10.1074/jbc.271.45.28324			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910454	hybrid			2022-12-25	WOS:A1996VU03300054
J	Goalstone, ML; Draznin, B				Goalstone, ML; Draznin, B			Effect of insulin on farnesyltransferase activity in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL-PROTEIN TRANSFERASE; TGF-BETA-RECEPTOR; GROWTH-FACTOR; RAS PROTEINS; SELECTIVE-INHIBITION; P21RAS; ACTIVATION; EXPRESSION; P21(RAS); CELLS	Activation of p21(ras) by GTP loading is a critical step in a cascade of intracellular insulin signaling. Farnesylation of p21(ras) protein is an obligatory event that facilitates Ras migration to the plasma membrane and subsequent activation. Farnesyltransferase (FTase) is a ubiquitous enzyme that catalyzes the lipid modification of p21(ras) by the addition of farnesyl to the C-terminal ''CAAX'' motif. In vitro and in vivo FTase activities were studied in 3T3-L1 adipocytes in response to insulin challenge. Insulin exerted a biphasic stimulatory effect on FTase activity measured in vitro with a 31% increase at 5 min and a 130% increase at 60 min. Insulin-stimulated farnesylation of p21(ras) pools in vivo correlated with FTase activity seen in vitro by displaying an increase in farnesylated p21(ras) from 40% of total cellular Ras in control cells to 63% by 5 min and 80% by 60 min (p < 0.05) in insulin-treated cells. Insulin challenge of 3T3-L1 adipocytes increased incorporation of tritiated mevalonic acid in p21(ras) in a dose-dependent manner and stimulated a a-fold increase in phosphorylation of the alpha-subunit of FTase at 5 min and a 4-fold increase at 60 min.	VET AFFAIRS MED CTR,MED RES SERV,DENVER,CO; VET AFFAIRS MED CTR,DEPT MED,DENVER,CO; UNIV COLORADO,CTR HLTH SCI,DENVER,CO 80220	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								ANDRES DA, 1993, J BIOL CHEM, V268, P1383; ARMSTRONG SA, 1995, J BIOL CHEM, V270, P7864, DOI 10.1074/jbc.270.14.7864; Bishop WR, 1995, J BIOL CHEM, V270, P30611, DOI 10.1074/jbc.270.51.30611; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; Goalstone ML, 1996, BIOL REPROD, V54, P675, DOI 10.1095/biolreprod54.3.675; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JHUN BH, 1994, J BIOL CHEM, V269, P5699; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MENDOLA CE, 1990, CELL GROWTH DIFFER, V1, P499; MOORES SL, 1991, J BIOL CHEM, V266, P14603; NIGAM M, 1993, J BIOL CHEM, V268, P20695; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; PRENDERGAST GC, 1993, CELL GROWTH DIFFER, V4, P707; QIAN YM, 1994, J BIOL CHEM, V269, P12410; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; REUSCH JEB, 1995, J BIOL CHEM, V270, P2036, DOI 10.1074/jbc.270.5.2036; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	37	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27585	27589		10.1074/jbc.271.44.27585	http://dx.doi.org/10.1074/jbc.271.44.27585			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910345	hybrid			2022-12-25	WOS:A1996VQ67900063
J	Huber, M; Pelletier, JG; Torossian, K; Dionne, P; Gamache, I; CharestGaudreault, R; Audette, M; Poulin, R				Huber, M; Pelletier, JG; Torossian, K; Dionne, P; Gamache, I; CharestGaudreault, R; Audette, M; Poulin, R			2,2'-Dithiobis(N-ethyl-spermine-5-carboxamide) is a high affinity, membrane-impermeant antagonist of the mammalian polyamine transport system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; L1210 LEUKEMIA-CELLS; GLUCOSE-TRANSPORTER; ORNITHINE DECARBOXYLASE; BIOLOGICAL PROPERTIES; SPERMINE SYNTHASE; TUMOR-GROWTH; AMINO-ACIDS; BINDING; PROTEIN	We have synthesized 2,2'-dithiobis(N-ethyl-spermine-5-carboxamide) (DESC), its thiol monomer (MESC), and the mixed MESC-cysteamine disulfide (DEASC) as potential inhibitors of polyamine transport in mammalian cells, DESC was the most potent antagonist; of spermine transport in ZR-75-1 human breast cancer cells, with K-i values of 5.0 +/- 0.7, 80 +/- 31, and 16 +/- 3 mu m for DESC, MESC, and DEASC, respectively. DESC also strongly blocked putrescine and spermidine uptake in ZR-75-1 cells (K-i = 1.6 +/- 0.5 and 2.7 +/- 1.1 mu M, respectively). While DESC and MESC were purely competitive inhibitors of putrescine transport, DEASC was a mixed competitive/ noncompetitive antagonist, Remarkably, DESC was virtually impermeant in ZR-75-1 cells despite its low K-i toward polyamine transport, The marked difference in affinity between DESC and MESC was essentially due to the tail-to-tail juxtaposition of two spermine-like structures, suggesting that dimeric ligands of the polyamine transporter might simultaneously interact with more than one binding site. While DESC strongly decreased the initial rate of [H-3]spermidine transport, even a 40-fold molar excess of antagonist could not completely abolish intracellular spermidine accumulation Moreover, as little as 0.3 mu M spermidine fully restored growth in ZR-75-1 cells treated with an inhibitor of polyamine biosynthesis in the presence of 50 mu M DESC, thus emphasizing the importance of uptake of trace amounts of exogenous polyamines. Thus, reducing the exogenous supply of polyamines with a patent competitive inhibitor mag be kinetically inadequate to block; replenishment of the polyamine pool in polyamine-depleted tumor cells that display high transport capacity. These results demonstrate that polyamine analogues cross-linked into a dimeric structure such as DESC interact with high affinity with the mammalian polyamine carrier without being used as substrates. These novel properties provide a framework for the design of specific irreversible inhibitors of the polyamine transporter, which should present advantages over competitive antagonists for an efficient blockade of polyamine transport in tumor cells.	UNIV LAVAL,MED RES CTR,MOL ENDOCRINOL LAB,ST FOY,PQ G1V 4G2,CANADA; HOP ST FRANCOIS ASSISE,RES CTR,QUEBEC CITY,PQ G1L 3L5,CANADA	Laval University; Laval University								ASK A, 1992, CANCER LETT, V66, P29, DOI 10.1016/0304-3835(92)90276-2; AZIZ SM, 1995, J PHARMACOL EXP THER, V274, P181; BACHRACH U, 1989, PHYSL POLYAMINES, V2, P235; BASU HS, 1989, CANCER RES, V49, P5591; BEHR JP, 1989, J CHEM SOC CHEM COMM, P101, DOI 10.1039/c39890000101; BERGERON RJ, 1986, BIOORG CHEM, V14, P345, DOI 10.1016/0045-2068(86)90001-5; BERGERON RJ, 1984, SYNTHESIS-STUTTGART, P782; BLASCHKO H, 1959, J PHYSIOL-LONDON, V145, P124, DOI 10.1113/jphysiol.1959.sp006132; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNE B, 1991, EXP CELL RES, V195, P323, DOI 10.1016/0014-4827(91)90380-D; BRUNTON VG, 1990, BIOCHEM PHARMACOL, V40, P1893, DOI 10.1016/0006-2952(90)90371-Q; BYERS TL, 1990, J CELL PHYSIOL, V143, P460, DOI 10.1002/jcp.1041430309; CAVALLINI D, 1956, EXPERIENTIA, V12, P377, DOI 10.1007/BF02157276; CLARK AE, 1990, BIOCHEM J, V269, P615, DOI 10.1042/bj2690615; COOPER AJL, 1983, ANNU REV BIOCHEM, V52, P187, DOI 10.1146/annurev.bi.52.070183.001155; Dixon M., 1976, ENZYMES; FELSCHOW DM, 1995, J BIOL CHEM, V270, P28705, DOI 10.1074/jbc.270.48.28705; GORDONSMITH RH, 1983, BIOCHEM PHARMACOL, V32, P3701, DOI 10.1016/0006-2952(83)90138-7; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HEBERT DN, 1992, J BIOL CHEM, V267, P23829; HESSELS J, 1989, INT J CANCER, V43, P1115; HOLLEY JL, 1992, CANCER RES, V52, P4190; HUBER M, 1995, CANCER RES, V55, P934; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P44; KAKINUMA Y, 1988, EUR J BIOCHEM, V176, P409, DOI 10.1111/j.1432-1033.1988.tb14297.x; KAWASE M, 1982, BIOCHEM PHARMACOL, V31, P2983, DOI 10.1016/0006-2952(82)90273-8; LESSARD M, 1995, J BIOL CHEM, V270, P1685, DOI 10.1074/jbc.270.4.1685; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAMONT PS, 1978, BIOCHEM BIOPH RES CO, V81, P58, DOI 10.1016/0006-291X(78)91630-3; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MINCHIN RF, 1989, BIOCHEM J, V262, P391, DOI 10.1042/bj2620391; MITCHELL JLA, 1992, BIOCHEM BIOPH RES CO, V186, P81, DOI 10.1016/S0006-291X(05)80778-8; Morgan D. M., 1989, PHYSL POLYAMINES, V1, P203; MOULINOUX JP, 1991, CELL MOL BIOL, V37, P773; PEGG AE, 1995, INT J BIOCHEM CELL B, V27, P425, DOI 10.1016/1357-2725(95)00007-C; PEGG AE, 1989, BIOCHEMISTRY-US, V28, P8446, DOI 10.1021/bi00447a026; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; PEGG AE, 1991, BIOCHEM J, V274, P167, DOI 10.1042/bj2740167; PEGG AE, 1989, J BIOL CHEM, V264, P11744; PERSSON L, 1988, CANCER RES, V48, P4807; PONNUSAMY E, 1986, SYNTHESIS-STUTTGART, P48; PORTER CW, 1985, CANCER RES, V45, P2050; PORTER CW, 1991, CANCER RES, V51, P3715; PORTER CW, 1982, CANCER RES, V42, P4072; PORTER CW, 1983, SCIENCE, V219, P1083, DOI 10.1126/science.6823570; POULIN R, 1992, J BIOL CHEM, V267, P150; RANNELS DE, 1985, AM J PHYSIOL, V249, pE506, DOI 10.1152/ajpendo.1985.249.5.E506; REMY JS, 1995, P NATL ACAD SCI USA, V92, P1744, DOI 10.1073/pnas.92.5.1744; SARHAN S, 1989, ANTICANCER RES, V9, P215; SCALABRINO G, 1981, ADV CANCER RES, V36, P1; SEILER N, 1990, CANCER RES, V50, P5077; SEILER N, 1990, INT J BIOCHEM, V22, P211, DOI 10.1016/0020-711X(90)90332-W; Seiler N., 1987, INHIBITION POLYAMINE, P49; SIMARD J, 1990, ENDOCRINOLOGY, V126, P3223, DOI 10.1210/endo-126-6-3223; SMITH LL, 1981, BIOCHEM PHARMACOL, V30, P1053, DOI 10.1016/0006-2952(81)90441-X; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Torossian K, 1996, BIOCHEM J, V319, P21, DOI 10.1042/bj3190021; [No title captured]	59	28	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27556	27563		10.1074/jbc.271.44.27556	http://dx.doi.org/10.1074/jbc.271.44.27556			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910341	hybrid			2022-12-25	WOS:A1996VQ67900059
J	Uozumi, N; Yanagidani, S; Miyoshi, E; Ihara, Y; Sakuma, T; Gao, CX; Teshima, T; Fujii, S; Shiba, T; Taniguchi, N				Uozumi, N; Yanagidani, S; Miyoshi, E; Ihara, Y; Sakuma, T; Gao, CX; Teshima, T; Fujii, S; Shiba, T; Taniguchi, N			Purification and cDNA cloning of porcine brain GDP-L-Fuc:N-acetyl-beta-D-glucosaminide alpha 1->6fucasyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; HAMSTER-KIDNEY CELLS; SIALYL-LEWIS-X; ALPHA-FETOPROTEIN; MOLECULAR-CLONING; ACETYLGLUCOSAMINYLTRANSFERASE-V; GENE FAMILY; HEPATOCELLULAR-CARCINOMA; MEMBRANE-GLYCOPROTEINS; ENZYMATIC BASIS	GDP-L-Fuc:N-acetyl-beta-D-glucosaminide alpha 1 --> 6fucosyl-transferase (alpha 1-6FucT; EC 2.4.1.68), which catalyzes the transfer of fucose from GDP-Fuc to N-linked type complex glycopeptides, was purified from a Triton X-100 extract of porcine brain microsomes. The purification procedures included sequential affinity chromatographies on GlcNAc beta 1-2Man alpha 1-6(GlcNAc beta 1-2Man alpha 1-2)-Man beta 1-4GlcNAc beta 1-4GlcNAc-Asn-Sepharose 4B and synthetic GDP-hexanolamine-Sepharose 4B columns. The enzyme was recovered in a 12% final yield with a 440,000-fold increase in specific activity. SDS-polyacrylamide gel electrophoresis of the purified enzyme gave a major band corresponding to an apparent molecular mass of 58 kDa, The alpha 1-6FucT has 575 amino acids and no putative N-glycosylation sites. The cDNA was cloned in to pSVK3 and was then transiently transfected into COS-l cells. alpha 1-6FucT activity was found to be high in the transfected cells, as compared with non- or mock-transfected cells. Northern blotting analyses of rat adult tissues showed that alpha 1-6FucT was highly expressed in brain. No sequence homology was found with other previously cloned fucosyltransferases, but the enzyme appears to be a type II transmembrane protein like the other glycosyltransferases.	OSAKA UNIV,SCH MED,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN; KANSAI MED UNIV,CHEM LAB,HIRAKATA,OSAKA 573,JAPAN; PROT RES FDN,PEPTIDE INST,OSAKA 562,JAPAN	Osaka University; Kansai Medical University			Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968; Sakuma, Takahiko/0000-0002-9477-2196				AOYAGI Y, 1993, CANCER-AM CANCER SOC, V72, P615, DOI 10.1002/1097-0142(19930715)72:2<615::AID-CNCR2820720246>3.0.CO;2-T; AOYAGI Y, 1985, BIOCHIM BIOPHYS ACTA, V830, P217, DOI 10.1016/0167-4838(85)90277-8; ARAR C, 1995, J BIOL CHEM, V270, P3551, DOI 10.1074/jbc.270.8.3551; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BOLSCHER JGM, 1986, CANCER RES, V46, P4080; BOLSCHER JGM, 1988, EMBO J, V7, P3361, DOI 10.1002/j.1460-2075.1988.tb03208.x; BOURNE Y, 1994, STRUCTURE, V2, P209, DOI 10.1016/S0969-2126(00)00022-8; CUMMINGS RD, 1988, J BIOL CHEM, V263, P511; DESOUSA CBP, 1993, ACTA TROP, V53, P59, DOI DOI 10.1016/0001-706X(93)90006-W; EASTON EW, 1991, J BIOL CHEM, V266, P21674; FENDERSON BA, 1986, DEV BIOL, V114, P12, DOI 10.1016/0012-1606(86)90379-9; FIELD MC, 1995, GLYCOBIOLOGY, V5, P463, DOI 10.1093/glycob/5.5.463; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; GUY RA, 1993, INFECT IMMUN, V61, P1553, DOI 10.1128/IAI.61.4.1553-1558.1993; HAGEN FK, 1993, J BIOL CHEM, V268, P18963; HALL SE, 1994, J IMMUNOL, V153, P3218; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HUBBARD SC, 1987, J BIOL CHEM, V262, P16403; HUCHINSON WL, 1991, HEPATOLOGY, V13, P683; KAPADIA A, 1981, EXP CELL RES, V131, P185, DOI 10.1016/0014-4827(81)90418-3; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOSCIELAK J, 1987, GLYCOCONJUGATE J, V4, P43, DOI 10.1007/BF01048443; Koscielak Jerzy, 1995, Acta Biochimica Polonica, V42, P35; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RT, 1994, J BIOL CHEM, V269, P19617; LEHRMAN MA, 1986, J BIOL CHEM, V261, P7412; LIN AI, 1994, GLYCOBIOLOGY, V4, P895, DOI 10.1093/glycob/4.6.895; LONGMORE GD, 1982, CARBOHYD RES, V100, P365, DOI 10.1016/S0008-6215(00)81049-6; MIYOSHI E, 1995, J BIOL CHEM, V270, P6216, DOI 10.1074/jbc.270.11.6216; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; NUNEZ HA, 1981, CAN J CHEM, V59, P2086, DOI 10.1139/v81-304; OHNO M, 1992, INT J CANCER, V51, P315, DOI 10.1002/ijc.2910510223; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PIERCE M, 1986, J BIOL CHEM, V261, P772; SAITO H, 1994, BIOCHEM BIOPH RES CO, V198, P318, DOI 10.1006/bbrc.1994.1045; SANTER UV, 1984, CANCER RES, V44, P3730; SANTER UV, 1987, BIOCHEMISTRY-US, V18, P2533; SCHACHTER H, 1983, CAN J BIOCHEM CELL B, V61, P1049, DOI 10.1139/o83-134; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SHINLER R, 1993, EUR J CELL BIOL, V61, P1; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STAHL P, 1982, J CELL BIOL, V93, P49, DOI 10.1083/jcb.93.1.49; TAKETA K, 1990, GASTROENTEROLOGY, V99, P508, DOI 10.1016/0016-5085(90)91034-4; TAKETA K, 1990, HEPATOLOGY, V12, P1420, DOI 10.1002/hep.1840120625; TANIGUCHI N, 1995, GLYCOCONJUGATE J, V12, P733, DOI 10.1007/BF00731232; Uozumi N, 1996, J BIOCHEM, V120, P385; VANBEEK WP, 1977, BRIT J CANCER, V36, P157, DOI 10.1038/bjc.1977.172; VOYNOW JA, 1991, J BIOL CHEM, V266, P21572; VOYNOW JA, 1988, ANAL BIOCHEM, V169, P367; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEN DX, 1992, J BIOL CHEM, V267, P21011; WESTON BW, 1992, J BIOL CHEM, V267, P24575; WILSON JR, 1976, BIOCHEM BIOPH RES CO, V72, P909, DOI 10.1016/S0006-291X(76)80218-5; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; YAMASHITA K, 1984, J BIOL CHEM, V259, P834	58	159	170	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27810	27817		10.1074/jbc.271.44.27810	http://dx.doi.org/10.1074/jbc.271.44.27810			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910378	hybrid			2022-12-25	WOS:A1996VQ67900096
J	Sugahara, K; Tanaka, Y; Yamada, S; Seno, N; Kitagawa, H; Haslam, SM; Morris, HR; Dell, A				Sugahara, K; Tanaka, Y; Yamada, S; Seno, N; Kitagawa, H; Haslam, SM; Morris, HR; Dell, A			Novel sulfated oligosaccharides containing 3-O-sulfated glucuronic acid from king crab cartilage chondroitin sulfate K - Unexpected degradation by chondroitinase ABC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNANCEJA-HORRIDA VENOM; HNK-1 EPITOPE; IGM PARAPROTEINS; HEPARAN-SULFATE; PROTEOGLYCANS; GLYCOLIPIDS; TETRASACCHARIDES; HYALURONIDASE; CARBOHYDRATE; NEUROPATHY	We prepared a series of oligosaccharides from king crab cartilage chondroitin sulfate K after exhaustive digestion with testicular hyaluronidase, and determined the structures of four tetrasaccharides and a pentasaccharide by fast atom bombardment mass spectrometry, high performance liquid chromatography analysis of chondroitinase AC-II digests, and 500-MHz H-1 NMR spectroscopy. The tetrasaccharides shared the common core structure GlcA beta 1-3GalNAc beta 1-4GlcA beta 1-3GalNAc with various sulfation profiles. One structure was GlcA beta 1-3GalNAc(4S)beta 1-4GlcA beta 1-3GalNAc(4S), whereas three of them have the following hitherto unreported structures including a novel glucuronate 3-O-sulfate: GlcA(3S)beta 1-3GalNAc(4S)beta 1-4GlcA beta 1-3GalNAc(4S), GlcA beta 1-3GalNAc(4S)beta 1-4GlcA(3S)beta 1-3GalNAc(4S), and GlcA (3S)beta 1-3GalNAc(4S)beta 1-4GlcA(3S)beta 1-3GalNAc(4S) where 3S or 4S represents 3-O- or 4-O-sulfate, respectively. The structure of the pentasaccharide was determined as GlcA(3S)beta 1-3GalNAc(4S)beta 1-4GlcA(3S)beta 1-3GalNAc(4S)beta 1-4GlcA. Chondroitinase ABC digestion of the tetrasaccharides with GlcA(3S) at the internal position destroyed the disaccharide unit containing GlcA(3S) derived from the reducing side and resulted in only the disaccharide unit from the non-reducing side. In contrast, these tetrasaccharides remained totally resistant to chondroitinase AC-II. The results indicated that it is necessary to reevaluate the disaccharide composition of chondroitin sulfate poly- or oligosaccharides purified from various biological sources, since they were usually determined after chondroitinase ABC digestion, It is probable that the structures containing GlcA(3S) would not have been detected.	OCHANOMIZU UNIV, DEPT CHEM, TOKYO 112, JAPAN; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AZ, ENGLAND	Ochanomizu University; Imperial College London	Sugahara, K (corresponding author), KOBE PHARMACEUT UNIV, DEPT BIOCHEM, HIGASHINADA KU, KOBE 658, JAPAN.		Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARIGA T, 1987, J BIOL CHEM, V262, P848; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CHOU DKH, 1991, J NEUROCHEM, V57, P852, DOI 10.1111/j.1471-4159.1991.tb08229.x; DIFERRANTE N, 1956, J BIOL CHEM, V220, P303; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; GOTO F, 1994, BIOORG MED CHEM LETT, V4, P619, DOI 10.1016/S0960-894X(01)80166-9; GOWDA DC, 1989, BIOCHEMISTRY-US, V28, P4468, DOI 10.1021/bi00436a052; HARRIS MJ, 1970, CARBOHYD RES, V15, P57, DOI 10.1016/S0008-6215(00)80294-3; ILYAS AA, 1986, BRAIN RES, V385, P1, DOI 10.1016/0006-8993(86)91540-4; KARAMANOS NK, 1994, BIOCHIMIE, V76, P79, DOI 10.1016/0300-9084(94)90066-3; KRESSE H, 1987, ADV ENZYMOL RAMB, V60, P217; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; MARGOLIS RK, 1987, BIOCHEM BIOPH RES CO, V145, P1142, DOI 10.1016/0006-291X(87)91556-7; MEYER K, 1958, FED PROC, V17, P1075; Meyer K., 1971, ENZYMES, V5, P307; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; POH CH, 1992, COMP BIOCHEM PHYS B, V101, P159, DOI 10.1016/0305-0491(92)90172-N; POOLE AR, 1986, BIOCHEM J, V236, P1; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAITOH H, 1995, J BIOL CHEM, V270, P3741, DOI 10.1074/jbc.270.8.3741; SENO N, 1974, BIOCHIM BIOPHYS ACTA, V343, P423, DOI 10.1016/0304-4165(74)90107-X; SENO N, 1982, CARBOHYD RES, V103, P190; SENO N, 1974, BIOCHIM BIOPHYS ACTA, V362, P290, DOI 10.1016/0304-4165(74)90221-9; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; SUGAHARA K, 1992, BIOCHEM J, V283, P99, DOI 10.1042/bj2830099; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; Sugahara K, 1996, GLYCOCONJUGATE J, V13, P609, DOI 10.1007/BF00731449; SUGAHARA K, 1994, CARBOHYD RES, V255, P165, DOI 10.1016/S0008-6215(00)90977-7; SUGAHARA K, 1994, INT S CART MET NOV 1, P12; SUZUKI S, 1968, J BIOL CHEM, V243, P1543; SUZUKI S, 1960, J BIOL CHEM, V235, P3580; VIEIRA RP, 1991, J BIOL CHEM, V266, P13530; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WEISSMANN B, 1955, J BIOL CHEM, V216, P783; YAMADA S, 1992, J BIOCHEM-TOKYO, V112, P440, DOI 10.1093/oxfordjournals.jbchem.a123919; YAMADA SH, 1993, J BIOL CHEM, V268, P4780	38	92	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26745	26754		10.1074/jbc.271.43.26745	http://dx.doi.org/10.1074/jbc.271.43.26745			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900154	hybrid			2022-12-25	WOS:A1996VP23300048
J	Sugiyama, N; Boyd, AE; Taylor, P				Sugiyama, N; Boyd, AE; Taylor, P			Anionic residue in the alpha-subunit of the nicotinic acetylcholine receptor contributing to subunit assembly and ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; AMINO-ACID-RESIDUES; MOLECULAR DISSECTION; DELTA-SUBUNIT; IDENTIFICATION; AFFINITY; SNAKE; DETERMINANTS; ANTAGONISTS; SELECTIVITY	To ascertain the anionic sites on the nicotinic receptor to which acetylcholine and other quaternary ammonium ligands bind, we have examined the role of an aspartyl residue (Asp-152) in the alpha-subunit. Prior photolytic labeling with agonist analogues of the neighboring residues Trp-149 and Try-151 suggests that their side chains reside on the binding face (also termed the (+)- or counterclockwise face) of the alpha-subunit. Asp-152 presents an anionic charge in the vicinity of these aromatic residues. Modification of the aspartate to asparagine (D152N) creates a glycosylation signal (Asn-152-Gly-Ser), and we find, on the basis of altered electrophoretic migration, that glycosylation occurs at this position upon cotransfection of the mutant alpha-subunit with beta-, gamma-, and delta-subunits. Glycosylation results in a reduction in the capacity of the receptor to assemble; this reduction is manifest in the initial step of dimer formation between the alpha gamma- and alpha delta-subunits. The alpha-subunit mutant receptor reaching the assembled pentamer exhibits an altered selectivity for certain ligands, Little reduction in alpha-bungarotoxin binding is observed, whereas affinities for agonists and competitive alkaloid antagonists are reduced substantially. Separation of the contributions of charge removal and glycosylation addition shows that both factors affect agonist affinity, with the charge influence being far more predominant. These findings raise the possibility that a component of the coulombic attraction stabilizing the binding of agonists comes from the aspartyl residue at position 152 in the alpha-subunit.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NIGMS NIH HHS [GM18360] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360, R01GM018360] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON SN, 1991, J MED CHEM, V34, P1798, DOI 10.1021/jm00110a007; ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; AMRTIN M, 1996, J BIOL CHEM, V271, P13497; BARCHAN D, 1992, P NATL ACAD SCI USA, V89, P7717, DOI 10.1073/pnas.89.16.7717; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; BULLER AL, 1994, MOL PHARMACOL, V46, P858; CHIARA D C, 1992, Biophysical Journal, V61, pA106; COHEN JB, 1991, J BIOL CHEM, V266, P23354; CORRINGER PJ, 1995, J BIOL CHEM, V270, P11749, DOI 10.1074/jbc.270.20.11749; CRAJKOWSKI C, 1995, J BIOL CHEM, V270, P3160; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; GALZI JL, 1994, CURR OPIN STRUC BIOL, V4, P554, DOI 10.1016/S0959-440X(94)90218-6; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; GU Y, 1991, NEURON, V6, P879, DOI 10.1016/0896-6273(91)90228-R; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; KAO PN, 1984, J BIOL CHEM, V259, P1662; KAO PN, 1986, J BIOL CHEM, V261, P8085; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KARLIN A, 1969, J GEN PHYSIOL, V54, pS245; KELLER SH, 1995, J BIOL CHEM, V270, P4165, DOI 10.1074/jbc.270.8.4165; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; MISHINA M, 1985, NATURE, V313, P364, DOI 10.1038/313364a0; NEUMANN D, 1989, P NATL ACAD SCI USA, V86, P7255, DOI 10.1073/pnas.86.18.7255; OLEARY ME, 1994, AM J PHYSIOL, V266, pC648, DOI 10.1152/ajpcell.1994.266.3.C648; OLEARY ME, 1992, J BIOL CHEM, V267, P8360; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; SEGAL DM, 1974, P NATL ACAD SCI USA, V71, P4298, DOI 10.1073/pnas.71.11.4298; SINE S, 1979, J BIOL CHEM, V254, P3315; SINE SM, 1995, NEURON, V15, P229, DOI 10.1016/0896-6273(95)90080-2; SINE SM, 1991, J BIOL CHEM, V266, P19369; SINE SM, 1994, J BIOL CHEM, V269, P8808; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362	43	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26575	26581		10.1074/jbc.271.43.26575	http://dx.doi.org/10.1074/jbc.271.43.26575			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900129	hybrid			2022-12-25	WOS:A1996VP23300023
J	Miyazaki, Y; Sun, X; Uchida, H; Zhang, J; Nimer, S				Miyazaki, Y; Sun, X; Uchida, H; Zhang, J; Nimer, S			MEF, a novel transcription factor with an Elf-1 like DNA binding domain but distinct transcriptional activating properties	ONCOGENE			English	Article						transcriptional activator; ets protein; cytokine genes	STIMULATING FACTOR PROMOTER; ETS ONCOGENE FAMILY; EWINGS-SARCOMA TRANSLOCATION; T-CELLS; FACTOR PU.1; GM-CSF; RESTRICTED EXPRESSION; MOLECULAR-CLONING; NUCLEAR FACTORS; TEL GENE	To isolate novel ETS genes expressed in hematopoietic cells we used a nested, degenerate oligonucleotide PCR based technique to obtain a cDNA fragment that encodes an ETS domain from a human megakaryocytic cell line. This fragment was used to isolate a full length, 4.2 kb cDNA that encodes a 663 amino acid protein which we call MEF (myeloid elf-1-like factor). MEF contains a central ETS domain and is expressed in a variety of myeloid leukemia cell lines and in normal adult hematopoietic tissue such as spleen, thymus and peripheral blood, as well as non-hematopoietic tissue such as ovary, placenta and colon. Using an oligonucleotide binding selection assay, and bacterially expressed MEF, we demonstrated that MEF recognizes a consensus DNA binding sequence nearly identical to elf-1 (..WGGA..) and then showed that MEF specifically bound to known elf-1 binding sites in the human GMCSF and IL-3 promoters. To characterize the functional effect of MEF on transcription, we performed cotransfection experiments in myeloid cells, and T cells, and demonstrated transactivation of both promoters by MEF, but not by elf-1. MEF is a new member of the elf-1/E74 family of ETS proteins, that has DNA binding properties similar to elf-1 but distinct transcriptional activating effects in several hematopoietic cell lineages.	MEM SLOAN KETTERING CANC CTR, SLOAN KETTERING INST CANC RES, LAB MOL ASPECTS HEMATOPOIESIS, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEPT MED, DIV HEMATOL ONCOL, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043025] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 43025] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BORLES JC, 1995, NATURE, V377, P635; BUIJS A, 1995, ONCOGENE, V10, P1511; Chomczynski P, 1987, ANAL BIOCH, V162, P156; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; FRASER JK, 1994, BLOOD, V84, P2523; FRASER JK, 1994, MOL CELL BIOL, V14, P2213, DOI 10.1128/MCB.14.3.2213; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GOTTSCHALK LR, 1993, J EXP MED, V178, P1681, DOI 10.1084/jem.178.5.1681; HROMAS R, 1994, INT J HEMATOL, V59, P257; HROMAS R, 1993, BLOOD, V82, P2998; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; INABA T, 1994, MOL CELL BIOL, V14, P3403, DOI 10.1128/MCB.14.5.3403; JEON IS, 1995, ONCOGENE, V10, P1229; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; MIGNOTTE V, 1994, GENOMICS, V20, P5, DOI 10.1006/geno.1994.1120; MIYATAKE S, 1991, MOL CELL BIOL, V11, P5894, DOI 10.1128/MCB.11.12.5894; MONTE D, 1994, ONCOGENE, V9, P1397; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NIMER S, 1990, MOL CELL BIOL, V10, P6084, DOI 10.1128/MCB.10.11.6084; Nimer SD, 1996, BLOOD, V87, P3694, DOI 10.1182/blood.V87.9.3694.bloodjournal8793694; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OVAL J, 1990, BLOOD, V76, P1369; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; SATO T, 1989, BRIT J HAEMATOL, V72, P184, DOI 10.1111/j.1365-2141.1989.tb07681.x; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; THOMAS RS, 1995, ONCOGENE, V11, P2135; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WOLIN M, 1993, ONCOGENE, V8, P1905; WURSTER AL, 1994, MOL CELL BIOL, V14, P6452, DOI 10.1128/MCB.14.10.6452; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	47	64	67	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1721	1729						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895518				2022-12-25	WOS:A1996VM88700017
J	Chou, DKH; Jungalwala, FB				Chou, DKH; Jungalwala, FB			N-acetylglucosaminyl transferase regulates the expression of the sulfoglucuronyl glycolipids in specific cell types in cerebellum during development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; CHONDROITIN SULFATE PROTEOGLYCANS; NERVOUS-SYSTEM; HNK-1-REACTIVE ANTIGENS; HNK-1 ANTIBODY; L2/HNK-1 CARBOHYDRATE; MOUSE CEREBELLUM; GLUCURONIC-ACID; MONOCLONAL IGM; MURINE MUTANTS	In the adult cerebellum, sulfoglucuronyl glycolipids (SGGLs) are specifically localized in Purkinje cells and their dendrites in the molecular layer. Other major cell types such as granule neurons and glial cells lack SGGLs. To explain the cell specific localization and the known biphasic expression of SGGLs, enzymic activities of four glycosyltransferases involved in the biosynthesis of SGGLs were studied in murine cerebellar mutants, in distinct cellular layers of rat cerebellum, and in isolated granule neurons during development. The enzymes studied were lactosylceramide: N-acetylglucosaminyl transferase (GlcNAc-Tr), lactotriaosylceramide:galactosyltransferase, neolactotetraosylceramide:glucuronyltransferase, and glucuronylglycolipid:sulfotransferase. In the cerebellum of Purkinje cell-deficient mutants, such as (pcd/pcd) and lurcher (Lc/+) where Purkinje cells are lost, GlcNAc-Tr was absent, but the other three glycosyltransferase were not severely affected. This indicated that the latter three enzymes were localized in other cell types, such as in mature granule neurons and glial cells, in addition to that in Purkinje cells, and the lack of SGGLs in these mutants was due to absence of GlcNAc-Tr. Analyses of the enzymes in the specific micro-dissected cellular layers also showed that Purkinje cell layer and molecular layer (where Purkinje cell dendrites are localized) contained all four enzymes. However, granule neurons and glial cells in the white matter lacked GlcNAc-Tr, but expressed the other three enzymes. It was concluded that the absence of SGGLs in adult granule neurons and glial cells was due to specific deficiency of the GlcNAc-Tr. Although adult granule neurons lacked GlcNAc-Tr and therefore SGGLs, isolated granule neurons from the neonatal cerebellum contained all four enzymes necessary for the synthesis of SGGLs. With development, the activity of GlcNAc-Tr in the isolated granule neurons declined but the other enzymes were not as affected, indicating that immature granule neurons were capable of synthesizing SGGLs and with maturation the synthesis was down-regulated. This also explains the biphasic expression of SGGLs in the developing cerebellum.	EUNICE KENNEDY SHRIVER CTR MENTAL RETARDAT INC, DEPT BIOCHEM, WALTHAM, MA 02254 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School					NICHD NIH HHS [P01-HD05505] Funding Source: Medline; NINDS NIH HHS [R01-NS 24405] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024405] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLENDOERFER KL, 1995, MOL CELL NEUROSCI, V6, P381, DOI 10.1006/mcne.1995.1029; ARIGA T, 1987, J BIOL CHEM, V262, P848; BRAUN PE, 1982, J NEUROCHEM, V39, P1261, DOI 10.1111/j.1471-4159.1982.tb12563.x; Chou DKH, 1996, GLYCOCONJUGATE J, V13, P295, DOI 10.1007/BF00731504; CHOU DKH, 1990, J NEUROCHEM, V54, P1598, DOI 10.1111/j.1471-4159.1990.tb01210.x; CHOU DKH, 1993, J BIOL CHEM, V268, P21727; CHOU DKH, 1987, J NEUROCHEM, V49, P865, DOI 10.1111/j.1471-4159.1987.tb00974.x; CHOU DKH, 1994, J NEUROCHEM, V62, P307; CHOU DKH, 1991, J BIOL CHEM, V266, P17941; CHOU DKH, 1988, J NEUROCHEM, V50, P1655, DOI 10.1111/j.1471-4159.1988.tb03056.x; CHOU DKH, 1990, J NEUROCHEM, V54, P1589, DOI 10.1111/j.1471-4159.1990.tb01209.x; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CHOU DKH, 1993, J BIOL CHEM, V268, P330; CHOU DKH, 1991, J NEUROCHEM, V57, P852, DOI 10.1111/j.1471-4159.1991.tb08229.x; CHOU DKH, 1994, T AM SOC NEUROCHEM, V25, P127; CHOU DKH, 1994, J NEUROCHEM S, V64, P562; CHOU KH, 1985, BIOCHEM BIOPH RES CO, V128, P383, DOI 10.1016/0006-291X(85)91690-0; DIEPERINK ME, 1992, J NEUROSCI, V12, P2177; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; HOLLEY JA, 1987, DEV NEUROSCI-BASEL, V9, P105, DOI 10.1159/000111613; HOLMES EH, 1991, ARCH BIOCHEM BIOPHYS, V288, P87, DOI 10.1016/0003-9861(91)90168-I; HOLMES EH, 1987, J BIOL CHEM, V262, P15649; ILYAS AA, 1990, J NEUROCHEM, V55, P594, DOI 10.1111/j.1471-4159.1990.tb04175.x; JESSELL TM, 1990, ANNU REV NEUROSCI, V13, P227, DOI 10.1146/annurev.ne.13.030190.001303; JUNGALWALA FB, 1994, NEUROCHEM RES, V19, P945, DOI 10.1007/BF00968704; KROG L, 1992, APMIS, V100, P53; KRUEGER RC, 1992, J BIOL CHEM, V267, P12149; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; LOWRY OH, 1953, J HISTOCHEM CYTOCHEM, V1, P420, DOI 10.1177/1.6.420; MARGOLIS RK, 1987, BIOCHEM BIOPH RES CO, V145, P1142, DOI 10.1016/0006-291X(87)91556-7; MCGARRY RC, 1983, NATURE, V306, P376, DOI 10.1038/306376a0; NAIR SM, 1993, J COMP NEUROL, V332, P282, DOI 10.1002/cne.903320303; PRASADARAO N, 1990, J HISTOCHEM CYTOCHEM, V38, P1193, DOI 10.1177/38.8.1694876; PRASADARAO N, 1990, J NEUROCHEM, V55, P2024, DOI 10.1111/j.1471-4159.1990.tb05791.x; SCHACHNER M, 1989, CIBA F SYMP, V145, P156; SCHMITZ B, 1994, GLYCOCONJUGATE J, V11, P345, DOI 10.1007/BF00731208; SCHWARTING GA, 1987, DEV BIOL, V120, P65, DOI 10.1016/0012-1606(87)90104-7; STULTS CLM, 1993, ARCH BIOCHEM BIOPHYS, V303, P125, DOI 10.1006/abbi.1993.1263; Svennerholm L, 1980, Adv Exp Med Biol, V125, P11; VOGEL M, 1991, BIOCHEM J, V278, P199, DOI 10.1042/bj2780199; WERNECKE H, 1985, J NEUROIMMUNOL, V9, P115, DOI 10.1016/S0165-5728(85)80012-6; YAMAMOTO M, 1985, P NATL ACAD SCI USA, V82, P3045, DOI 10.1073/pnas.82.9.3045	42	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28868	28874		10.1074/jbc.271.46.28868	http://dx.doi.org/10.1074/jbc.271.46.28868			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910533	hybrid			2022-12-25	WOS:A1996VT05200025
J	Karoor, V; Malbon, CC				Karoor, V; Malbon, CC			Insulin-like growth factor receptor-1 stimulates phosphorylation of the beta(2)-adrenergic receptor in vivo on sites distinct from those phosphorylated in response to insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-MEDIATED PATHWAYS; BETA-ADRENERGIC-RECEPTOR; MASS-SPECTROMETRY; CROSS-REGULATION; TYROSINE KINASE; SIGNAL	G-protein-linked receptors have been shown to be substrates for growth factor receptors with intrinsic tyrosine kinase activity typified by the ability of insulin to both phosphorylate tyrosyl residues in the C terminus of and to counter-regulate the action of the beta(2)-adrenergic receptor (Karoor, V., Baltensperger, K., Paul, H., Czech, M. P., and Malbon, C, C, (1995) J. Biol. Chem, 270, 25305-25308). Insulin-like growth factor-1 (IGF-1), another member of the growth factor family operating via receptors with intrinsic tyrosine kinase, is shown in the present work to stimulate in vivo the phosphorylation of the beta(2)-adrenergic receptor. Analysis of tryptic digests prepared from phosphorylated beta(2)-adrenergic receptors of IGF-1-treated, metabolically labeled smooth muscle cells was performed using reversed-phase high performance liquid chromatography, two-dimensional peptide mapping, and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The results of these separate analyses reveal that IGF-1 stimulates phosphorylation predominantly on tyrosyl residues Y132/141 of the second intracellular loop of the beta(2)-adrenergic receptor rather than the C-terminal region targeted by the activated insulin receptor (Y350/354, Y364), although both growth factors block beta-adrenergic agonist action. These data demonstrate selective phosphorylation of a G-protein-linked receptor by receptor tyrosine kinases for insulin and IGF-1 mapping to spatially distinct regions of this heptihelical membrane receptor.	SUNY STONY BROOK, SCH MED, DIABET & METAB DIS RES CTR, DEPT MOL PHARMACOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			malbon, craig/ABF-3604-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025410] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25410] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baltensperger K, 1996, J BIOL CHEM, V271, P1061, DOI 10.1074/jbc.271.2.1061; BALTENSPERGER K, 1992, P NATL ACAD SCI USA, V89, P7885, DOI 10.1073/pnas.89.17.7885; CROUCH MF, 1991, FASEB J, V5, P200, DOI 10.1096/fasebj.5.2.1900794; CZECH MP, 1980, J CLIN INVEST, V66, P574, DOI 10.1172/JCI109889; ENGLAND PJ, 1976, ANAL BIOCHEM, V75, P429, DOI 10.1016/0003-2697(76)90096-8; GEAHLEN RL, 1989, PEPTIDES PROTEIN PHO, P239; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; HADCOCK JR, 1992, J BIOL CHEM, V267, P26017; HADCOCK JR, 1990, J BIOL CHEM, V265, P14784; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Karoor V, 1996, PROG NEUROBIOL, V48, P555, DOI 10.1016/0301-0082(96)00004-4; KAROOR V, 1995, J BIOL CHEM, V270, P25305, DOI 10.1074/jbc.270.43.25305; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; LIAO PC, 1994, ANAL BIOCHEM, V219, P9, DOI 10.1006/abio.1994.1224; Liu WW, 1996, P NATL ACAD SCI USA, V93, P8258, DOI 10.1073/pnas.93.16.8258; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PORT JD, 1992, J BIOL CHEM, V267, P8468; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YIP TT, 1992, FEBS LETT, V308, P149, DOI 10.1016/0014-5793(92)81264-M; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	23	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29347	29352		10.1074/jbc.271.46.29347	http://dx.doi.org/10.1074/jbc.271.46.29347			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910597	hybrid			2022-12-25	WOS:A1996VT05200089
J	Levin, G; Chikvashvili, D; SingerLahat, D; Peretz, T; Thornhill, WB; Lotan, I				Levin, G; Chikvashvili, D; SingerLahat, D; Peretz, T; Thornhill, WB; Lotan, I			Phosphorylation of a K+ channel alpha subunit modulates the inactivation conferred by a beta subunit - Involvement of cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; POTASSIUM CHANNELS; DENDROTOXIN ACCEPTOR; BINDING-PROPERTIES; XENOPUS-OOCYTES; PROTEIN-KINASE; RAT-BRAIN; DIVERSITY; PURIFICATION; ASSOCIATION	Voltage-gated K+ channels isolated from mammalian brain are composed of alpha and beta subunits. Interaction between coexpressed K(V)1.1 (alpha) and K-V beta 1.1 (beta) subunits confers rapid inactivation on the delayed rectifier-type current that is observed when alpha subunits are expressed alone. Integrating electrophysiological and biochemical analyses, we show that the inactivation of the alpha beta current is not complete even when alpha is saturated with beta, and the alpha beta current has an inherent sustained compo nent, indistinguishable from a pure alpha current. We further show that basal and protein kinase A-induced phosphorylations at Ser-446 of the alpha protein increase the extent, but not the rate, of inactivation of the alpha beta channel, without affecting the association between alpha and beta. In addition, the extent of inactivation is increased by agents that lead to microfilament depolymerization. The effects of phosphorylation and of microfilament depolymerization are not additive. Taken together, we suggest that phosphorylation, via a mechanism that involves the interaction of the alpha beta channel with microfilaments, enhances the extent of inactivation of the channel. Furthermore, phosphorylation at Ser-446 also increases current amplitudes of the alpha beta channel as was shown before for the alpha channel. Thus, phosphorylation enhances in concert inactivation and current amplitudes, thereby leading to a substantial increase in A-type activity.	TEL AVIV UNIV,SACKLER SCH MED,DEPT PHYSIOL & PHARMACOL,IL-69978 RAMAT AVIV,ISRAEL; MT SINAI HOSP,MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029	Tel Aviv University; Sackler Faculty of Medicine; Icahn School of Medicine at Mount Sinai								ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; CROW T, 1988, TRENDS NEUROSCI, V11, P136, DOI 10.1016/0166-2236(88)90138-5; Dascal N., 1992, METHODS MOL BIOL VOL, VVolume 13, P205; DRAIN P, 1994, NEURON, V12, P1097, DOI 10.1016/0896-6273(94)90317-4; FUKODA J, 1981, NATURE, V294, P82; Heinemann SH, 1995, FEBS LETT, V377, P383, DOI 10.1016/0014-5793(95)01377-6; Heinemann SH, 1996, J PHYSIOL-LONDON, V493, P625, DOI 10.1113/jphysiol.1996.sp021409; HONORE E, 1992, EMBO J, V11, P2465, DOI 10.1002/j.1460-2075.1992.tb05311.x; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; JOHNSON BD, 1993, NEURON, V10, P797, DOI 10.1016/0896-6273(93)90196-X; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; LEVIN G, 1995, J BIOL CHEM, V270, P14611, DOI 10.1074/jbc.270.24.14611; LOPATIN AN, 1994, J GEN PHYSIOL, V103, P203, DOI 10.1085/jgp.103.2.203; MANGEAT P, 1984, J CELL BIOL, V99, pS95, DOI 10.1083/jcb.99.1.95s; MORALES MJ, 1995, J BIOL CHEM, V270, P6272, DOI 10.1074/jbc.270.11.6272; Nakahira K, 1996, J BIOL CHEM, V271, P7084, DOI 10.1074/jbc.271.12.7084; PARCEJ DN, 1989, BIOCHEM J, V257, P899, DOI 10.1042/bj2570899; Peretz T, 1996, FEBS LETT, V381, P71, DOI 10.1016/0014-5793(96)00085-3; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; REHM H, 1989, FEBS LETT, V249, P224, DOI 10.1016/0014-5793(89)80628-3; REHM H, 1988, BIOCHEM BIOPH RES CO, V153, P231, DOI 10.1016/S0006-291X(88)81213-0; RETTIG J, 1992, EMBO J, V11, P2473, DOI 10.1002/j.1460-2075.1992.tb05312.x; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RHODES KJ, 1995, J NEUROSCI, V15, P5360; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SCHREIBMAYER W, 1994, PFLUG ARCH EUR J PHY, V426, P453, DOI 10.1007/BF00388310; SCOTT VES, 1990, J BIOL CHEM, V265, P20094; SEWING S, 1996, NEURON, V16, P1; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; STUHMER W, 1991, ANNU REV BIOPHYS BIO, V20, P65, DOI 10.1146/annurev.biophys.20.1.65; UNDROVINAS AI, 1995, AM J PHYSIOL-HEART C, V269, pH203, DOI 10.1152/ajpheart.1995.269.1.H203; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8	39	65	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29321	29328		10.1074/jbc.271.46.29321	http://dx.doi.org/10.1074/jbc.271.46.29321			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910593	hybrid			2022-12-25	WOS:A1996VT05200085
J	Prassl, R; Chapman, JM; Nigon, F; Sara, M; Eschenburg, S; Betzel, C; Saxena, A; Laggner, P				Prassl, R; Chapman, JM; Nigon, F; Sara, M; Eschenburg, S; Betzel, C; Saxena, A; Laggner, P			Crystallization and preliminary x-ray analysis of a low density lipoprotein from human plasma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APOLIPOPROTEIN-B-100; RECEPTOR; SEQUENCE; SCATTERING; MICROSCOPY; PATHWAY; DOMAINS	Single crystals of human plasma low density lipoprotein (LDL), the major transport vehicle for cholesterol in blood, have been produced with a view to analysis of the three-dimensional structure by x-ray crystallography. Crystals with dimensions of approximately 200 x 100 x 50 mu m have been reproducibly obtained from highly homogeneous LDL particle subspecies, isolated in the density ranges d = 1.0271-1.0297 g/ml and d = 1.0297-1.0327 g/ml. Electron microscopic imaging of ultrathin-sectioned preparations of the crystals confirmed the existence of a regular, quasihexagonal arrangement of spherical particles of approximately 18 nn in diameter, thereby resembling the dimensions characteristic of LDL after dehydration and fixation. X-ray diffraction with synchrotron radiation under cryogenic conditions revealed the presence of well resolved diffraction spots, to a resolution of about 29 Angstrom. The diffraction patterns are indexed in terms of a triclinic lattice with unit cell dimensions of a = 16.1 nm, b = 39.0 nm, c = 43.9 nm; alpha 96.2 degrees, beta = 92.1 degrees, gamma = 102 degrees, and with space group P1.	AUSTRIAN ACAD SCI, INST BIOPHYS & XRAY STRUCTURE RES, A-8010 GRAZ, AUSTRIA; INSERM, U321, F-75651 PARIS, FRANCE; AGR UNIV VIENNA, CTR ULTRASTRUCT RES, A-1010 VIENNA, AUSTRIA; DESY, EMBL OUTSTN, D-22603 HAMBURG, GERMANY	Austrian Academy of Sciences; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Natural Resources & Life Sciences, Vienna; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)			Prassl, Ruth/AAE-1523-2021; Betzel, Christian/G-8105-2018	Betzel, Christian/0000-0002-3879-5019; Prassl, Ruth/0000-0002-1010-9494				ATKINSON D, 1977, P NATL ACAD SCI USA, V74, P1042, DOI 10.1073/pnas.74.3.1042; BANUELOS S, 1995, J BIOL CHEM, V270, P29910, DOI 10.1074/jbc.270.50.29910; BAUMSTARK M, 1983, BIOCHIM BIOPHYS ACTA, V751, P108, DOI 10.1016/0005-2760(83)90262-X; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHAPMAN MJ, 1988, J LIPID RES, V29, P442; CHEN SH, 1986, J BIOL CHEM, V261, P2918; DECKELBAUM RJ, 1977, J BIOL CHEM, V252, P744; DECKELBAUM RJ, 1975, SCIENCE, V190, P392, DOI 10.1126/science.170681; DEJAGER S, 1993, J LIPID RES, V34, P295; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GULIKKRZYWICKI T, 1979, J MOL BIOL, V131, P475, DOI 10.1016/0022-2836(79)90003-2; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; LAGGNER P, 1978, EUR J BIOCHEM, V84, P227, DOI 10.1111/j.1432-1033.1978.tb12160.x; LAGGNER P, 1995, NATO ADV SCI INST SE, V451, P371; LAGGNER P, 1981, J BIOL CHEM, V256, P1832; LUZZATI V, 1979, J MOL BIOL, V131, P435, DOI 10.1016/0022-2836(79)90002-0; MARGOLIS S, 1966, J BIOL CHEM, V241, P485; MEYER DF, 1995, BIOCHEM J, V310, P407, DOI 10.1042/bj3100407; MULLER K, 1978, EUR J BIOCHEM, V82, P73, DOI 10.1111/j.1432-1033.1978.tb11998.x; NIGON F, 1991, J LIPID RES, V32, P1741; OTWINOWSKY Z, 1991, DENZO FILM PROCESSIN; RODGERS DW, 1994, STRUCTURE, V2, P1135, DOI 10.1016/S0969-2126(94)00116-2; SCHUSTER B, 1995, P NATL ACAD SCI USA, V92, P2059; SPIN JM, 1995, BIOPHYS J, V68, P2115, DOI 10.1016/S0006-3495(95)80392-9; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; STUHRMANN HB, 1975, P NATL ACAD SCI USA, V72, P2270, DOI 10.1073/pnas.72.6.2270; TRIPLETT RB, 1978, J LIPID RES, V19, P478; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0	29	16	16	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28731	28733		10.1074/jbc.271.46.28731	http://dx.doi.org/10.1074/jbc.271.46.28731			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910510	hybrid			2022-12-25	WOS:A1996VT05200002
J	Shen, H; Dowhan, W				Shen, H; Dowhan, W			Reduction of CDP-diacylglycerol synthase activity results in the excretion of inositol by Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PHOSPHOLIPID BIOSYNTHESIS; PHOSPHATIDYLSERINE SYNTHASE; ESCHERICHIA-COLI; MOLECULAR-CLONING; YEAST; GENE; DNA; EXPRESSION; ENZYMES	A yeast mutant, cdg1, was isolated on the basis of an inositol excretion phenotype. This mutant exhibited pleiotropic deficiencies in phospholipid biosynthesis, including reduced levels of CDP-diacylglycerol (DAG) synthase activity (KIig, L. S., Homann, M. J., Kohlwein, S. D. Kelley, M. J., Henry, S. A., and Carman, G. M. (1988) J. Bacteriol. 170, 1878-1886). In this study we present evidence that the molecular basis for the inositol excretion phenotype is a G(305)/A(305) point mutation (Cys(102) --> Tyr substitution) within the CDS1 gene (encodes CDP-DAG synthase) of this mutant. Expression of CDP-DAG synthase activity from a plasmid-borne copy of the CDS1 gene in the cdg1 mutant was not down-regulated, and this expression also corrected the inositol excretion phenotype. Introduction of the above mutated gene (CDS1*) controlled by its endogenous promoter on a single copy plasmid into a cds1-null background reconstituted a transformant with the cdg1 phenotype, including reduced CDP-DAG synthase activity, elevated phosphatidylserine synthase activity, and inositol excretion into the growth medium. Expression of CDS1* in a single copy in the cdg1 mutant raised CDP-DAG synthase activity from 15 to 30% of derepressed wild-type yeast levels but still did not correct the inositol excretion phenotype, CDP-DAG synthase activity was not regulated in response to precursors of phospholipid biosynthesis in the cdg1 mutant either with or without a transcopy of the CDS1* gene. An open reading frame was identified 5' to the CDS1 locus, YBR0314, which also resulted in inositol excretion when present in trans in multiple copies.	UNIV TEXAS, SCH MED, DEPT BIOCHEM & MOL BIOL, HOUSTON, TX 77225 USA	University of Texas System								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASHBURNER BP, 1995, MOL CELL BIOL, V15, P1709; BONNER JJ, 1991, GENE, V104, P113, DOI 10.1016/0378-1119(91)90475-Q; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; CARMAN GM, 1992, METHOD ENZYMOL, V209, P242; CARMAN GM, 1992, METHOD ENZYMOL, V209, P298; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CARMAN GM, 1992, METHOD ENZYMOL, V209, P305; CULBERTSON MR, 1975, GENETICS, V80, P23; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIFCO, 1984, DEH CULT MED REAG MI, V10th; Dowhan W, 1995, ADV CELL MOL BIOL M, V4, P189, DOI [10.1016/S1874-5172(06)80013-1, DOI 10.1016/S1874-5172(06)80013-1]; FERBEYRE G, 1993, BIOTECHNIQUES, V14, P386; FUJIMURA HA, 1993, BIOTECHNIQUES, V14, P538; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; HENRY SA, 1984, ANNU REV GENET, V18, P207; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; HOMANN MJ, 1985, J BACTERIOL, V163, P1265, DOI 10.1128/JB.163.3.1265-1266.1985; HROMY MJ, 1986, J BIOL CHEM, V261, P15572; ICHO T, 1985, J BIOL CHEM, V260, P2078; Innis MA, 1990, PCR PROTOCOLS GUIDE; JANITOR M, 1993, CURR GENET, V24, P307, DOI 10.1007/BF00336781; KELLEY MJ, 1987, J BIOL CHEM, V262, P14563; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KINNEY AJ, 1990, J BACTERIOL, V172, P4115, DOI 10.1128/jb.172.7.4115-4117.1990; KINNEY AJ, 1988, P NATL ACAD SCI USA, V85, P7962, DOI 10.1073/pnas.85.21.7962; KINNEY AJ, 1990, J BACTERIOL, V172, P1133, DOI 10.1128/jb.172.2.1133-1136.1990; KLIG LS, 1988, J BACTERIOL, V170, P1878, DOI 10.1128/jb.170.4.1878-1886.1988; KUCHLER K, 1986, J BACTERIOL, V165, P901, DOI 10.1128/jb.165.3.901-910.1986; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAI K, 1994, J BIOL CHEM, V269, P2245; LETTS VA, 1985, J BACTERIOL, V163, P560, DOI 10.1128/JB.163.2.560-567.1985; MCGEE TP, 1994, J BACTERIOL, V176, P6861, DOI 10.1128/JB.176.22.6861-6868.1994; NICKELS JT, 1994, J BIOL CHEM, V269, P11018; NIKOLOFF DM, 1994, J BIOL CHEM, V269, P7402; NIKOLOFF DM, 1991, ANNU REV GENET, V25, P559; PRESUTTI C, 1991, EMBO J, V10, P2215, DOI 10.1002/j.1460-2075.1991.tb07757.x; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; RALEIGH EA, 1989, CURRENT PROTOCOLS MO, V1; RINE J, 1991, METHOD ENZYMOL, V194, P239; Shen HF, 1996, J BIOL CHEM, V271, P789, DOI 10.1074/jbc.271.2.789; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SMITS PHM, 1994, YEAST, V10, pS75, DOI 10.1002/yea.320100010; WU L, 1995, NATURE, V373, P216, DOI 10.1038/373216a0	48	21	22	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29043	29048		10.1074/jbc.271.46.29043	http://dx.doi.org/10.1074/jbc.271.46.29043			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910557	hybrid			2022-12-25	WOS:A1996VT05200049
J	Hofer, G; Grimmer, C; Sukhatme, VP; Sterzel, RB; Rupprecht, HD				Hofer, G; Grimmer, C; Sukhatme, VP; Sterzel, RB; Rupprecht, HD			Transcription factor Egr-1 regulates glomerular mesangial cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENTS; ZINC FINGER PROTEIN; C-FOS; ANTISENSE OLIGONUCLEOTIDES; GROWTH-FACTOR; EPITHELIAL-CELL; 3T3 CELLS; GENE; EXPRESSION; DIFFERENTIATION	Increase of glomerular mesangial cells (MCs) is a prominent histopathological finding in many types of glomerulonephritis. We have shown previously that expression of the zinc-finger transcription factor, early growth response gene-1 (egr-1), is closely correlated with the proliferation of cultured MCs. To elucidate whether Egr-1 is required for MC proliferation, we inhibited serum-induced Egr-1 expression by phosphothioate-modified antisense oligonucleotides (ODNs), Uptake of antisense ODNs into ASCs was demonstrated, and five different egr-1 antisense ODNs were tested for their impact on serum-induced egr-1 mRNA and protein levels and on MC growth. The most potent egr-1 antisense ODN inhibited serum-induced egr-1 mRNA by 68%, protein induction by 58%, and MC replication as measured by [H-3]thymidine uptake and cell counts by 78 and 46%, respectively. The effects of antisense ODNs on MC growth correlated closely with their ability to inhibit Egr-1 protein, ODNs acted in a dose-dependent manner, the minimal effective concentration being 1 mu M. Control ODNs had no significant effects. In addition, antisense ODNs against egr-1 potently inhibited endothelin-1-induced Egr-1 expression and MC growth, Heparin, a known inhibitor of MC growth, suppressed serum-induced [H-3]thymidine uptake by 39% and egr-1 mRNA expression by 44%. We conclude that Egr-1 is an essential part of the mitogenic signal transduction cascade in cultured MCs.	BETH ISRAEL HOSP,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Hofer, G (corresponding author), UNIV ERLANGEN NURNBERG,MED KLIN 4,NEPHROL FORSCHUNGSLAB,LOSCHGESTR 8,D-91054 ERLANGEN,GERMANY.		Sukhatme, Vikas/W-2776-2019					ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; AKAI Y, 1994, AM J PHYSIOL, V267, pC482, DOI 10.1152/ajpcell.1994.267.2.C482; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CASTELLOT JJ, 1985, AM J PATHOL, V120, P427; CHENG T, 1994, J BIOL CHEM, V269, P30848; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; FISHER TL, 1993, NUCLEIC ACIDS RES, V21, P3857, DOI 10.1093/nar/21.16.3857; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HU RM, 1994, J CLIN INVEST, V93, P1820, DOI 10.1172/JCI117167; HUANG RP, 1994, ONCOGENE, V9, P1367; KINANE TB, 1994, J BIOL CHEM, V269, P27503; LAPTEV AV, 1994, BIOCHEMISTRY-US, V33, P11033, DOI 10.1021/bi00202a024; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013; MCMAHON AP, 1990, DEVELOPMENT, V108, P281; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; MUTERO A, 1995, J BIOL CHEM, V270, P1866, DOI 10.1074/jbc.270.40.23511; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PEREZCASTILLO A, 1993, J BIOL CHEM, V268, P19445; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; RICKER RD, 1992, FEBS LETT, V309, P363, DOI 10.1016/0014-5793(92)80808-T; RUPPRECHT HD, 1992, AM J PHYSIOL, V263, pF623, DOI 10.1152/ajprenal.1992.263.4.F623; RUPPRECHT HD, 1993, AM J PHYSIOL, V265, pF351, DOI 10.1152/ajprenal.1993.265.3.F351; RUPPRECHT HD, 1994, J CELL PHYSIOL, V159, P311, DOI 10.1002/jcp.1041590214; SANKAR S, 1989, EUR J BIOCHEM, V184, P39, DOI 10.1111/j.1432-1033.1989.tb14987.x; SELLS SF, 1995, MOL CELL BIOL, V15, P682; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0	40	56	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28306	28310		10.1074/jbc.271.45.28306	http://dx.doi.org/10.1074/jbc.271.45.28306			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910451	hybrid			2022-12-25	WOS:A1996VU03300051
J	Jimenez, EC; Olivera, BM; Gray, WR; Cruz, LJ				Jimenez, EC; Olivera, BM; Gray, WR; Cruz, LJ			Contryphan is a D-tryptophan-containing Conus peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-AMINO-ACID; ACHATINA-FULICA; AMPHIBIAN SKIN; D-SERINE; RESIDUE; DERMORPHIN; NEUROPEPTIDE; PRECURSOR; SEQUENCE; AFFINITY	In this report, we document for the first time the occurrence of D-tryptophan in a normally translated polypeptide, contryphan. The peptide, isolated from the venom of the fish-hunting marine snail Conus radiatus, produces the ''stiff-tail'' syndrome in mice. Characterization of the octapeptide gave the following sequence, Gly-Cys-Hyp-D-Trp-Glu-Pro-Trp-Cys-NH2 SEQUENCE 1 where Hyp = 4-trans-hydroxyproline. The presence of D-tryptophan in position 4 of contryphan was confirmed by chemical synthesis. The posttranslational epimerization in all other D-amino acid-containing small peptides characterized previously from vertebrates and molluscan systems is in position 2.	UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112; UNIV PHILIPPINES,INST MARINE SCI,QUEZON 1101,PHILIPPINES	Utah System of Higher Education; University of Utah; University of the Philippines System; University of the Philippines Diliman			Jimenez, Elsie/AAA-7347-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48677] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CRUZ L J, 1976, Veliger, V18, P302; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; FUJISAWA Y, 1992, COMP BIOCHEM PHYS C, V102, P91, DOI 10.1016/0742-8413(92)90049-D; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; Heck SD, 1996, P NATL ACAD SCI USA, V93, P4036, DOI 10.1073/pnas.93.9.4036; HECK SD, 1994, J AM CHEM SOC, V116, P10426, DOI 10.1021/ja00102a009; HECK SD, 1994, SCIENCE, V266, P1065, DOI 10.1126/science.7973665; HOCHLOWSKI JE, 1994, J ANTIBIOT, V47, P528, DOI 10.7164/antibiotics.47.528; KAMATANI Y, 1989, BIOCHEM BIOPH RES CO, V160, P1015, DOI 10.1016/S0006-291X(89)80103-2; KREIL G, 1994, J BIOL CHEM, V269, P10967; KREIL G, 1989, EUR J PHARMACOL, V162, P123, DOI 10.1016/0014-2999(89)90611-0; KUWADA M, 1994, MOL PHARMACOL, V46, P587; MONTECUCCHI PC, 1981, INT J PEPT PROT RES, V17, P275; MOR A, 1989, FEBS LETT, V255, P269, DOI 10.1016/0014-5793(89)81104-4; OHTA N, 1991, BIOCHEM BIOPH RES CO, V178, P486, DOI 10.1016/0006-291X(91)90133-R; RICHTER K, 1990, P NATL ACAD SCI USA, V87, P4836, DOI 10.1073/pnas.87.12.4836; RICHTER K, 1987, SCIENCE, V238, P200, DOI 10.1126/science.3659910; SHIKATA Y, 1995, J BIOL CHEM, V270, P16719, DOI 10.1074/jbc.270.28.16719; SOYEZ D, 1994, J BIOL CHEM, V269, P18295; Terlau H, 1996, NATURE, V381, P148, DOI 10.1038/381148a0; YASUDAKAMATANI Y, 1995, J NEUROCHEM, V64, P2248	21	125	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28002	28005		10.1074/jbc.271.45.28002	http://dx.doi.org/10.1074/jbc.271.45.28002			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910408	hybrid			2022-12-25	WOS:A1996VU03300008
J	Paulssen, RH; Woodson, J; Liu, Z; Ross, EM				Paulssen, RH; Woodson, J; Liu, Z; Ross, EM			Carboxyl-terminal fragments of phospholipase C-beta 1 with intrinsic G(q) GTPase-activating protein (GAP) activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; GUANINE-NUCLEOTIDE-BINDING; ALPHA-SUBUNIT; DEPENDENT ACTIVATION; C ISOZYMES; GQ-ALPHA; PURIFICATION; STIMULATION; RECEPTORS; CLONING	Fragments of the similar to 50 kDa COOH-terminal region of phospholipase C-beta 1 (PLC-beta 1(1)), ranging in size from 14 to 38 kDa, were expressed in Escherichia coli, purified, and tested for their regulatory activities. As expected, none of the fragments had phospholipase activity, Several fragments, referred to as PLC tails, displayed GTPase-activating protein (GAP) activity for G(q), the G protein class that stimulates the PLC-beta s in response to receptors, G(q) GAP activity is characteristic of intact PLC-beta s. In reconstituted phospholipid vesicles that contained purified G(q) and m1 muscarinic cholinergic receptors, the most active tails increased agonist-stimulated, steady-state GTPase activity over 4-fold. Stimulation of steady-state GTPase by the tails depended on receptors for facilitation of GDP-GTP exchange, suggesting that the tails act by accelerating hydrolysis of bound GTP, In addition to intrinsic GAP activity, one tail with high GAP activity and others with low or minimal activity potentiated the GAP activity of intact PLC-beta 1. Other tails inhibited PLC-beta 1s GAP effect, Both intrinsic GAP activity and potentiation of the PLC-beta 1 GAP effect were often biphasic, with maxima as low as 100 nm tail and declining activities at higher concentrations, Several tails inhibited either the phospholipase activity of PLC-beta 1, beta 1, its stimulation by G(q), or both. The tails thus define the region of PLC-beta 1 that has G(q) GAP activity and suggest a mechanism of action in which the COOH terminus of PLC-beta s can interact with G(q) and with other PLC-beta 1 molecules.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030355, R37GM030355] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30355] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; BLANK JL, 1991, J BIOL CHEM, V266, P18206; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; JHON DY, 1993, J BIOL CHEM, V268, P6654; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEE CW, 1994, J BIOL CHEM, V269, P25335; LEE E, 1994, METHOD ENZYMOL, V237, P146; MARTELL AE, 1952, CHEM METAL CHELATE C; PARK DG, 1993, J BIOL CHEM, V268, P3710; PARKER EM, 1991, J BIOL CHEM, V266, P519; PATERSON A, 1995, CELL SIGNAL, V7, P709, DOI 10.1016/0898-6568(95)00039-R; PEDERSEN SE, 1985, J BIOL CHEM, V260, P4150; ROSS EM, 1995, RECENT PROG HORM RES, V50, P207; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, J BIOL CHEM, V263, P14497; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1993, J BIOL CHEM, V268, P3704	31	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26622	26629		10.1074/jbc.271.43.26622	http://dx.doi.org/10.1074/jbc.271.43.26622			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900136	hybrid			2022-12-25	WOS:A1996VP23300030
J	Somasundaram, R; Schuppan, D				Somasundaram, R; Schuppan, D			Type I, II, III, IV, V, and VI collagens serve as extracellular ligands for the isoforms of platelet-derived growth factor (AA, BB, and AB)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA; PLASMINOGEN-ACTIVATOR; MATRIX INTERACTIONS; BINDING DOMAINS; BODY-FLUIDS; PDGF; PROTEIN; TISSUE; CELLS; LIVER	The biological activities of several growth factors/cytokines have been shown to be modulated by binding to molecules of the extracellular matrix. Here, the interactions of PDGF (isoforms AA, BB, and AB), a potent mitogen for mesenchymal cells, with collagens were investigated. All radiolabeled PDGF isoforms specifically interacted with type I, II, III, IV, V, and VI collagens (preferential binding to types III, I, VI, and IV) and their constituent chains, either when immobilized on polystyrene or blotted to nitrocellulose. PDGF-collagen interactions were of medium affinity (K-D between 4 and 22 nM) and were inhibited by different soluble collagen chains suggesting a collagenous consensus binding site(s) for the PDGF isoforms investigated. Scatchard analysis revealed molar ratios of up to 3-4 PDGF molecules bound/triple-helical (native) collagen. Biological activity of collagen-bound PDGF was demonstrated by a 1.5-3-fold stimulation of proliferation of human fibroblasts and mouse 3T3 cells. Furthermore, a preferential association of PDGF with the collagenous extracellular matrix of cirrhotic liver could be shown by immunostaining. Our data are in accord with previous studies that localized PDGF in the extracellular matrix of fibroproliferative lesions and suggest that binding of PDGF to collagens may localize and modulate its biological activities.	FREE UNIV BERLIN, UNIV KLINIKUM BENJAMIN FRANKLIN, GASTROENTEROL & HEPATOL ABT, D-12200 BERLIN, GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin				Somasundaram, Rajan/0000-0003-3461-3326				ABBOUD HE, 1992, KIDNEY INT, V41, P581, DOI 10.1038/ki.1992.86; ALON R, 1994, J IMMUNOL, V152, P1304; BECKER J, 1986, J HISTOCHEM CYTOCHEM, V34, P1417, DOI 10.1177/34.11.3772076; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DALLAS SL, 1995, J CELL BIOL, V131, P539, DOI 10.1083/jcb.131.2.539; ELNAHAS AM, 1992, KIDNEY INT, V41, pS15; FLOEGE J, 1992, KIDNEY INT, V41, P297, DOI 10.1038/ki.1992.42; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; GAY S, 1989, J INVEST DERMATOL, V92, P301, DOI 10.1111/1523-1747.ep12276895; GAY S, 1992, ARTHRITIS RHEUM, V35, P304, DOI 10.1002/art.1780350309; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HERSHKOVIZ R, 1994, J IMMUNOL, V153, P554; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; KELLY JL, 1993, J CELL BIOL, V121, P1153, DOI 10.1083/jcb.121.5.1153; KHAGIGIAN LM, 1994, PEPTIDES, V15, P133; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; LEVESQUE JP, 1991, IMMUNOL TODAY, V12, P258, DOI 10.1016/0167-5699(91)90122-A; LORTAT-JACOB H, 1991, J CLIN INVEST, V87, P878, DOI 10.1172/JCI115093; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; MOORADIAN DL, 1989, J CELL BIOCHEM, V41, P189, DOI 10.1002/jcb.240410404; MOSER TL, 1993, J BIOL CHEM, V268, P18917; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; NUGENT MA, 1989, J BIOL CHEM, V264, P18060; PARALKAR VM, 1991, DEV BIOL, V143, P303, DOI 10.1016/0012-1606(91)90081-D; PIERCE GF, 1991, J CELL BIOCHEM, V45, P319, DOI 10.1002/jcb.240450403; PINZANI M, 1989, J CLIN INVEST, V84, P1786, DOI 10.1172/JCI114363; Pollock RA, 1992, GROWTH FACTORS, V7, P267, DOI 10.3109/08977199209046409; RAGHOW R, 1994, FASEB J, V8, P823, DOI 10.1096/fasebj.8.11.8070631; RAINES EW, 1992, P NATL ACAD SCI USA, V89, P1281, DOI 10.1073/pnas.89.4.1281; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RAINES EW, 1990, PEPTIDE GROWTH FACTO, V1, P173; RAMSDEN L, 1992, EUR J IMMUNOL, V22, P3027, DOI 10.1002/eji.1830221139; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUOSLAHTI E, 1992, BRIT J CANCER, V66, P239, DOI 10.1038/bjc.1992.250; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schubert D, 1992, Trends Cell Biol, V2, P63, DOI 10.1016/0962-8924(92)90057-T; SCHUPPAN D, 1990, J BIOL CHEM, V265, P8823; SCHUPPAN D, 1985, ANAL BIOCHEM, V149, P238, DOI 10.1016/0003-2697(85)90501-9; SCHUPPAN D, 1986, J CLIN INVEST, V78, P241, DOI 10.1172/JCI112557; SCHUPPAN D, 1986, CELL TISSUE RES, V243, P535; SOMASUNDARAM R, 1993, GASTROENTEROLOGY, V104, pA988; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; WALZOG B, 1995, EXP CELL RES, V218, P28, DOI 10.1006/excr.1995.1127; WESTERMARK B, 1990, ACTA ENDOCRINOL-COP, V123, P131, DOI 10.1530/acta.0.1230131; WHITBY DJ, 1991, DEV BIOL, V147, P207, DOI 10.1016/S0012-1606(05)80018-1; WILCOX JN, 1990, GROWTH FACTORS DIFFE, P305; WONG P, 1995, J BIOL CHEM, V270, P25805, DOI 10.1074/jbc.270.43.25805; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	58	99	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26884	26891		10.1074/jbc.271.43.26884	http://dx.doi.org/10.1074/jbc.271.43.26884			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900172	hybrid			2022-12-25	WOS:A1996VP23300066
J	Bosher, JM; Totty, NF; Hsuan, JJ; Williams, T; Hurst, HC				Bosher, JM; Totty, NF; Hsuan, JJ; Williams, T; Hurst, HC			A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma	ONCOGENE			English	Article						c-erbB-2; AP-2; transcription; mammary carcinoma	TRANSCRIPTION FACTOR AP-2; POSITIVE BREAST-CANCER; RNA POLYMERASE-II; NEU ONCOGENE; DNA-BINDING; RECEPTOR; OVEREXPRESSION; ACTIVATION; AMPLIFICATION; EMBRYOGENESIS	The proto-oncogene c-erbB-2 is overexpressed in 25-30% of breast cancers through increased transcription and amplification of the gene, We have previously described a factor, OB2-1 which upregulates c-erbB-2 transcription and which is closely related to the developmentally regulated transcription factor, AP-2. Further analysis of affinity purified OB2-1 has now shown that it is in fact a combination of proteins from three AP-2-related genes, the previously described AP-2 alpha gene and two new human family members, AP-2 beta and AP-2 gamma whose cloning and characterisation are described here. All three AP-2 proteins show a high degree of homology and are capable of binding to the c-erbB-2 promoter as homo- or heterodimers. The three proteins can also activate a c-erbB-2 reporter construct, but AP-2 alpha and AP-2 gamma are 3-4 times more active in this regard than AP-2 beta. In addition both AP-2 alpha and AP-2 gamma are expressed at elevated levels in the majority of c-erbB-2 overexpressing mammary tumour lines examined. Mechanisms which may have led to the increased AP-2 levels in these cells are discussed.	HAMMERSMITH HOSP,IMPERIAL CANC RES FUND,ONCOL UNIT,GENE TRANSPORTAT LAB,LONDON W12 0NN,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOL BIOL,LONDON WC1E 6BT,ENGLAND; YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520	Cancer Research UK; Imperial College London; Ludwig Institute for Cancer Research; University of London; University College London; Yale University			Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564	NIGMS NIH HHS [GM46770] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046770] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUER R, 1994, NUCLEIC ACIDS RES, V22, P1413, DOI 10.1093/nar/22.8.1413; BORG A, 1994, CANCER LETT, V81, P137, DOI 10.1016/0304-3835(94)90194-5; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chazaud C, 1996, MECH DEVELOP, V54, P83, DOI 10.1016/0925-4773(95)00463-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DSOUZA B, 1993, ONCOGENE, V8, P1797; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HOLLYWOOD DP, 1995, BRIT J CANCER, V71, P753, DOI 10.1038/bjc.1995.146; HUDSON DL, 1992, HYBRIDOMA, V11, P367, DOI 10.1089/hyb.1992.11.367; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MARCHIONNI MA, 1995, NATURE, V378, P334, DOI 10.1038/378334a0; MEIER P, 1995, DEV BIOL, V169, P1, DOI 10.1006/dbio.1995.1121; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOSER M, 1995, DEVELOPMENT, V121, P2779; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLATTERY E, 1983, J BIOL CHEM, V258, P5955; SNAPE AM, 1991, DEVELOPMENT, V113, P283; TETU B, 1994, CANCER, V73, P2359, DOI 10.1002/1097-0142(19940501)73:9<2359::AID-CNCR2820730919>3.0.CO;2-9; TOTTY NF, 1972, SCIENCE, V1, P1215; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Williamson JA, 1996, GENOMICS, V35, P262, DOI 10.1006/geno.1996.0351; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	34	204	210	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1701	1707						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895516				2022-12-25	WOS:A1996VM88700015
J	Cook, DM; Hinkes, MT; Bernfield, M; Rauscher, FJ				Cook, DM; Hinkes, MT; Bernfield, M; Rauscher, FJ			Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1	ONCOGENE			English	Article						Wilms' tumor; DNA-binding protein; zincfinger; WT1; kidney development; syndecan-1	ZINC FINGER PROTEIN; GENE-PRODUCT; KIDNEY DEVELOPMENT; SUPPRESSOR WT1; MAMMALIAN-CELLS; DNA-BINDING; EXPRESSION; REPRESSION; GROWTH; LOCUS	The Wilms' tumor suppressor gene (wt1) encodes a zinc finger DNA binding protein (WT1) which functions as a transcriptional regulator and is essential for normal urogenital development. WT1 has previously been shown to repress the transcription of a variety of target genes whose products stimulate growth, such as growth factors, growth factor receptors and other transcription factors. In this study, we identify syndecan-1 as a target gene for WT1-mediated activation. Syndecan-1 is a cell surface proteoglycan whose induction is coincident with epithelial differentiation during kidney development and whose loss of expression is correlated with the loss of the epithelial phenotype and malignant transformation. The murine syndecan-1 promoter contains several potential binding sites for WT1. We demonstrate that both WT1 (-KTS) and WT1 (+KTS) isoforms bind to multiple sites in this highly G+C-rich region, as detected by gel-shift analyses. These WT1 isoforms function as transcriptional activators of syndecan-1 expression in transient transfection assays. Activation of syndecan-1 by WT1 is dependent on an intact zinc-finger region as well as a 179 amino acid proline-rich region in the amino terminus of the protein. Moreover, the endogenous syndecan-1 gene is activated by WT1 in a novel inducible cell line based upon the sheep metallothionein promoter. These results highlight an emerging role for WT1 as an activator of genes like syndecan-1 which may potentiate epithelial differentiation and maintenance in the developing kidney.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; HARVARD UNIV,SCH MED,JOINT PROGRAM NEONATOL,BOSTON,MA 02115	The Wistar Institute; Harvard University; Harvard Medical School					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD006763, R01HD006763] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA028735] Funding Source: NIH RePORTER; NCI NIH HHS [CA09171, CA28735] Funding Source: Medline; NICHD NIH HHS [HD06763] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHOO KH, 1986, DNA-J MOLEC CELL BIO, V5, P529, DOI 10.1089/dna.1.1986.5.529; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GOODYER P, 1995, ONCOGENE, V10, P1125; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABER DA, 1992, ADV CANCER RES, V59, P41, DOI 10.1016/S0065-230X(08)60302-4; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HINKES MT, 1993, J BIOL CHEM, V268, P11440; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; INKI P, 1991, AM J PATHOL, V139, P1333; JALKANEN M, 1991, BIOCHEM SOC T, V19, P1069, DOI 10.1042/bst0191069; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KATO M, 1995, MOL CELL BIOL, V6, P554; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LELONGT B, 1988, DEV BIOL, V128, P256, DOI 10.1016/0012-1606(88)90289-8; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; MADDEN SL, 1993, ONCOGENE, V8, P1713; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MORRIS JF, 1991, ONCOGENE, V6, P2339; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; PARK S, 1993, CANCER RES, V53, P457; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; ROBERTS SGE, 1995, NATURE, V375, P105, DOI 10.1038/375105a0; ROTHSTEIN JL, 1992, GENE DEV, V6, P1190, DOI 10.1101/gad.6.7.1190; RYAN G, 1995, DEVELOPMENT, V121, P867; Sambrook J., 2002, MOL CLONING LAB MANU; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; Saxen L., 1987, ORGANOGENESIS KIDNEY; SPAETE RR, 1985, J VIROL, V56, P136; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; VAINIO S, 1989, DEV BIOL, V134, P382, DOI 10.1016/0012-1606(89)90110-3; VAINIO S, 1992, DEV BIOL, V152, P221, DOI 10.1016/0012-1606(92)90130-9; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1992, P NATL ACAD SCI USA, V89, P10984; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; ZHOU P, 1995, ONCOGENE, V11, P571	57	90	90	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1789	1799						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895526				2022-12-25	WOS:A1996VM88700025
J	Aman, MJ; Tayebi, N; Obiri, NI; Puri, RK; Modi, WS; Leonard, WJ				Aman, MJ; Tayebi, N; Obiri, NI; Puri, RK; Modi, WS; Leonard, WJ			cDNA cloning and characterization of the human interleukin 13 receptor alpha chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE CLEAVAGE SITES; LIGAND-BINDING; GAMMA-CHAIN; B-CELLS; CYTOKINE; EXPRESSION; MONOCYTES; SUBUNITS; IL-4	We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13R alpha). The protein has 76% homology to murine IL-13R alpha, with 95% amino acid identity in the cytoplasmic domain. Only weak IL-13 binding activity was found in cells transfected with only IL-13R alpha; however, the combination of both IL-13R alpha and IL-4R alpha resulted in substantial binding activity, with a K-d of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor. Whereas IL-13R alpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gamma(c)) for IL-4 signaling, it could not replace the function of gamma(c) in allowing enhanced IL-2 binding activity. Nevertheless, the overall size and length of the cytoplasmic domain of IL-13R alpha and gamma(c) are similar, and like gamma(c), IL-13R alpha is located on chromosome X.	NHLBI,LAB MOL IMMUNOL,NIH,BETHESDA,MD 20892; NIMH,CLIN NEUROSCI BRANCH,NIH,BETHESDA,MD 20892; US FDA,CTR BIOL EVALUAT & RES,DIV CELLULAR & GENE THERAPIES,BETHESDA,MD 20892; NCI,FREDERICK CANC RES & DEV CTR,SCI APPLICAT INT CORP,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Leonard, Warren/AAA-1397-2022					BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Chaouchi N, 1996, BLOOD, V87, P1022, DOI 10.1182/blood.V87.3.1022.bloodjournal8731022; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; JOHNSON K, 1994, EUR CYTOKINE NETW, V5, P23; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; LOWENTHAL JW, 1987, J EXP MED, V166, P1156, DOI 10.1084/jem.166.4.1156; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Murata T, 1995, J BIOL CHEM, V270, P30829, DOI 10.1074/jbc.270.51.30829; MUZIO M, 1994, BLOOD, V83, P1738, DOI 10.1182/blood.V83.7.1738.bloodjournal8371738; OBIRI NI, 1995, J BIOL CHEM, V270, P13869; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SANA TR, 1994, BIOCHEMISTRY-US, V17, P5838; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; VITA N, 1995, J BIOL CHEM, V270, P3512, DOI 10.1074/jbc.270.8.3512; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WANG HM, 1987, J EXP MED, V166, P1055, DOI 10.1084/jem.166.4.1055; WLOWAWER A, 1993, PROTEIN SCI, V2, P1373; WU ZN, 1995, J BIOL CHEM, V270, P16045, DOI 10.1074/jbc.270.27.16045; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	28	267	305	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29265	29270		10.1074/jbc.271.46.29265	http://dx.doi.org/10.1074/jbc.271.46.29265			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910586	hybrid			2022-12-25	WOS:A1996VT05200078
J	Burden, DA; Kingma, PS; FroelichAmmon, SJ; Bjornsti, MA; Patchan, MW; Thompson, RB; Osheroff, N				Burden, DA; Kingma, PS; FroelichAmmon, SJ; Bjornsti, MA; Patchan, MW; Thompson, RB; Osheroff, N			Topoisomerase II etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPLOITING MECHANISTIC DIFFERENCES; DROSOPHILA-MELANOGASTER; SEQUENCE SPECIFICITY; ANTINEOPLASTIC DRUGS; RELIGATION REACTION; INTERACTION DOMAINS; INHIBITORS; YEAST; RESISTANCE; BINDING	Topoisomerase II is the target for several highly active anticancer drugs that induce cell death by enhancing enzyme-mediated DNA scission. Although these agents dramatically increase levels of nucleic acid cleavage in a site-specific fashion, little is understood regarding the mechanism by which they alter the DNA site selectivity of topoisomerase II. Therefore, a series of kinetic and binding experiments were carried out to determine the mechanistic basis by which the anticancer drug, etoposide, enhances cleavage complex formation at 22 specific nucleic acid sequences. In general, maximal levels of DNA scission (i.e. C-max) varied over a considerably larger range than did the apparent affinity of etoposide (i.e. K-m) for these sites, and there was no correlation between these two kinetic parameters. Furthermore, enzyme drug binding and order of addition experiments indicated that etoposide and topoisomerase II form a kinetically competent complex in the absence of DNA. These findings suggest that etoposide topoisomerase II (rather than etoposide DNA) interactions mediate cleavage complex formation. Finally, rates of religation at specific sites correlated inversely with C-max values, indicating that maximal levels of etoposide-induced scission reflect the ability of the drug to inhibit religation at specific sequences rather than the affinity of the drug for site-specific enzyme-DNA complexes.	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT MED,NASHVILLE,TN 37232; THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOL BIOL,PHILADELPHIA,PA 19107; UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201	Vanderbilt University; Vanderbilt University; Jefferson University; University System of Maryland; University of Maryland Baltimore				Patchan, Marcia/0000-0002-0485-0403	NCI NIH HHS [CA58755, 5 T32 CA09582] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009582, R01CA058755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RD, 1994, MUTAT RES-FUND MOL M, V309, P109, DOI 10.1016/0027-5107(94)90048-5; BECK WT, 1993, ADV ENZYME REGUL, V33, P113; BELANI CP, 1994, CANCER CHEMOTH PHARM, V34, pS118, DOI 10.1007/BF00684875; Berger JM, 1996, CURR OPIN STRUC BIOL, V6, P84, DOI 10.1016/S0959-440X(96)80099-6; BIGIONI M, 1996, BIOCHEMISTRY-US, V35, P1153; CAPRANICO G, 1992, EUR J CANCER, V28A, P2055, DOI 10.1016/0959-8049(92)90255-Z; CAPRANICO G, 1994, J BIOL CHEM, V269, P25004; CAPRANICO G, 1993, BIOCHEMISTRY-US, V32, P3038, DOI 10.1021/bi00063a015; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P6611, DOI 10.1093/nar/18.22.6611; CAPRANICO G, 1994, J MOL BIOL, V235, P1218, DOI 10.1006/jmbi.1994.1075; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHOW KC, 1988, MOL PHARMACOL, V34, P467; CORBETT AH, 1992, J BIOL CHEM, V267, P683; CORBETT AH, 1993, J BIOL CHEM, V268, P14394; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; Cozzarelli N.R., 1990, DNA TOPOLOGY ITS BIO; COZZARELLI NR, 1980, CELL, V22, P327, DOI 10.1016/0092-8674(80)90341-4; DEVORE R, 1992, SEMIN ONCOL, V19, P40; DILLEHAY LE, 1989, MUTAT RES, V215, P15, DOI 10.1016/0027-5107(89)90213-3; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; FERGUSON LR, 1994, ENVIRON MOL MUTAGEN, V24, P245, DOI 10.1002/em.2850240402; FREUDENREICH CH, 1993, EMBO J, V12, P2085, DOI 10.1002/j.1460-2075.1993.tb05857.x; FREUDENREICH CH, 1994, P NATL ACAD SCI USA, V91, P11007, DOI 10.1073/pnas.91.23.11007; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P14998, DOI 10.1074/jbc.270.25.14998; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P28018; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GALE KC, 1990, BIOCHEMISTRY-US, V29, P9538, DOI 10.1021/bi00493a007; GEWIRTZ DA, 1991, BIOCHEM PHARMACOL, V42, P2253, DOI 10.1016/0006-2952(91)90227-V; GOTO T, 1984, CELL, V36, P1073, DOI 10.1016/0092-8674(84)90057-6; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HIGGINS NP, 1982, NUCLEIC ACIDS RES, V10, P6833, DOI 10.1093/nar/10.21.6833; HOLDEN JA, 1995, AM J CLIN PATHOL, V104, P54, DOI 10.1093/ajcp/104.1.54; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HSIANG YH, 1988, CANCER RES, V48, P3230; KNAB AM, 1993, J BIOL CHEM, V268, P22322; LIU LF, 1994, ADV PHARM, V29; NELSON WG, 1987, CANCER RES, V47, P3246; Nitiss J L, 1994, Adv Pharmacol, V29A, P103; NITISS JL, 1993, CANCER RES, V53, P89; OSHEROFF N, 1994, CANCER CHEMOTH PHARM, V34, pS19, DOI 10.1007/BF00684859; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; POMMIER Y, 1991, NUCLEIC ACIDS RES, V19, P5973, DOI 10.1093/nar/19.21.5973; POMMIER Y, 1994, CANCER INVEST, V12, P530, DOI 10.3109/07357909409021413; Pommier Y., 1996, CANC CHEMOTHERAPY BI, P435; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROSE D, 1990, CELL, V60, P1009, DOI 10.1016/0092-8674(90)90349-J; Sambrook J., 2002, MOL CLONING LAB MANU; SANDER M, 1987, J MOL BIOL, V194, P219, DOI 10.1016/0022-2836(87)90370-6; SANDER M, 1983, J BIOL CHEM, V258, P8421; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Segel I.H., 1975, ENZYME KINETICS; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SINHA BK, 1995, DRUGS, V49, P11, DOI 10.2165/00003495-199549010-00002; SPITZNER JR, 1995, MOL PHARMACOL, V48, P238; SULLIVAN DM, 1987, CANCER RES, V47, P3973; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014	65	129	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29238	29244		10.1074/jbc.271.46.29238	http://dx.doi.org/10.1074/jbc.271.46.29238			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910583	hybrid			2022-12-25	WOS:A1996VT05200075
J	Hodder, AN; Crewther, PE; Matthew, MLSM; Reid, GE; Moritz, RL; Simpson, RJ; Anders, RF				Hodder, AN; Crewther, PE; Matthew, MLSM; Reid, GE; Moritz, RL; Simpson, RJ; Anders, RF			The disulfide bond structure of Plasmodium apical membrane antigen-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; SEQUENCE-ANALYSIS; LIQUID-CHROMATOGRAPHY; MEROZOITE ANTIGEN; SURFACE-ANTIGEN; I AMA-1; FALCIPARUM; SUPERFAMILY; PREDICTION; PEPTIDES	Apical membrane antigen-1 (AMA-1) of Plasmodium falciparum is one of the leading asexual blood stage antigens being considered for inclusion in a malaria vaccine. The ability of this molecule to induce a protective immune response has been shown to be dependent upon a conformation stabilized by disulfide bonds. In this study we have utilized the reversed-phase high performance liquid chromatography of dithiothreitol-reduced and nonreduced tryptic digests of Plasmodium chabaudi AMA-1 secreted from baculovirus-infected insect cells, in conjunction with N-terminal sequencing and electrospray-ionization mass spectrometry, to identify and assign disulfide-linked peptides. All 16 cysteine residues that are conserved in all known sequences of AMA-1 are incorporated into intramolecular disulfide bonds. Six of the eight bonds have been assigned unequivocally, whereas the two unassigned disulfide bonds connect two Cys-Xaa-Cys sequences separated by 14 residues. The eight disulfide bonds fall into three nonoverlapping groups that define three possible subdomains within the AMA-1 ectodomain. Although the pattern of disulfide bonds within subdomain III has not been fully elucidated, one of only two possible linkage patterns closely resembles the cystine knot motif found in growth factors. Sites of amino acid substitutions in AMA-1 that are well separated in the primary sequence are clustered by the disulfide bonds in subdomains II and III. These findings are consistent with the conclusion that these amino acid substitutions are defining conformational disulfide bond-dependent epitopes that are recognized by protective immune responses.	WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,COOPERAT RES CTR VACCINE TECHNOL,MELBOURNE,VIC 3052,AUSTRALIA; UNIV MELBOURNE,DEPT MICROBIOL,MELBOURNE,VIC 3052,AUSTRALIA; LUDWIG INST CANC RES,JOINT PROT STRUCT LAB,MELBOURNE BRANCH,MELBOURNE,VIC 3050,AUSTRALIA	Walter & Eliza Hall Institute; University of Melbourne; University of Melbourne; Ludwig Institute for Cancer Research	Hodder, AN (corresponding author), COOPERAT RES CTR VACCINE TECHNOL,PO ROYAL MELBOURNE HOSP,MELBOURNE,VIC 3050,AUSTRALIA.		Moritz, Robert L/B-9222-2011	Anders, Robin/0000-0002-0693-4547; Reid, Gavin/0000-0002-9675-1444; Simpson, Richard/0000-0002-9834-0796				ANDERS RF, 1993, MOL IMMUNOLOGICAL CO, P169; CHENG Q, 1994, MOL BIOCHEM PARASIT, V65, P183, DOI 10.1016/0166-6851(94)90127-9; COLLINS WE, 1994, AM J TROP MED HYG, V51, P711, DOI 10.4269/ajtmh.1994.51.711; DEANS JA, 1984, MOL BIOCHEM PARASIT, V11, P189, DOI 10.1016/0166-6851(84)90065-3; DEANS JA, 1988, PARASITE IMMUNOL, V10, P535, DOI 10.1111/j.1365-3024.1988.tb00241.x; DUTTA S, 1995, MOL BIOCHEM PARASIT, V73, P267, DOI 10.1016/0166-6851(95)00112-E; ISAACS NW, 1995, CURR OPIN STRUC BIOL, V5, P391, DOI 10.1016/0959-440X(95)80102-2; KRISHNA RG, 1993, METHODS IN PROTEIN SEQUENCE ANALYSIS, P167; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Marshall VM, 1996, MOL BIOCHEM PARASIT, V77, P109, DOI 10.1016/0166-6851(96)02583-2; MARSHALL VM, 1989, MOL BIOCHEM PARASIT, V37, P281, DOI 10.1016/0166-6851(89)90160-6; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MORITZ RL, 1992, J CHROMATOGR, V599, P119; MORITZ RL, 1995, TECH PROT CHEM, V6, P311, DOI 10.1016/S1080-8914(06)80039-6; MORITZ RL, 1992, J MICROCOLUMN SEP, V4, P485, DOI 10.1002/mcs.1220040604; Moritz Robert L., 1994, Methods (Orlando), V6, P213, DOI 10.1006/meth.1994.1024; NARUM DL, 1994, MOL BIOCHEM PARASIT, V67, P59, DOI 10.1016/0166-6851(94)90096-5; PETERSON MG, 1989, MOL CELL BIOL, V9, P3151, DOI 10.1128/MCB.9.7.3151; PETERSON MG, 1990, MOL BIOCHEM PARASIT, V39, P279, DOI 10.1016/0166-6851(90)90067-V; REID GE, 1995, ELECTROPHORESIS, V16, P1120, DOI 10.1002/elps.11501601189; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; THOMAS AW, 1990, MOL BIOCHEM PARASIT, V42, P285, DOI 10.1016/0166-6851(90)90172-I; THOMAS AW, 1984, MOL BIOCHEM PARASIT, V13, P187, DOI 10.1016/0166-6851(84)90112-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATERS AP, 1991, MOL BIOCHEM PARASIT, V44, P141, DOI 10.1016/0166-6851(91)90230-4	28	220	230	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29446	29452		10.1074/jbc.271.46.29446	http://dx.doi.org/10.1074/jbc.271.46.29446			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910611				2022-12-25	WOS:A1996VT05200103
J	Hoyal, CR; Thomas, AP; Forman, HJ				Hoyal, CR; Thomas, AP; Forman, HJ			Hydroperoxide-induced increases in intracellular calcium due to annexin VI translocation and inactivation of plasma membrane Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ALVEOLAR MACROPHAGES; RESPIRATORY BURST; HYDROGEN-PEROXIDE; BUTYL HYDROPEROXIDE; MITOCHONDRIA; PROTEIN; PHOSPHOLIPASE-A2; LIPOCORTINS; INHIBITION; OXIDATION	Oxidative stress can cause changes in intracellular free calcium concentration ([Ca2+](i)) that resemble those occurring under normal cell signaling. In the alveolar macrophage, hydroperoxide-induced elevation of [Ca2+](i) modulates the respiratory burst and other important physiologic functions. The source of Ca2+ released by hydroperoxide is intracellular but separate from the endoplasmic reticulum pool released by receptor-mediated stimuli (Hoyal, C. R., Gozal, E., Zhou, H., Foldenauer, K., and Forman, H. J. (1996) Arch. Biochem. Biophys. 326, 166-171). Previous studies in other cells have suggested that mitochondria are a potential source of oxidant-induced [Ca2+](i) elevation. In this study we have identified another potential source of hydroperoxide-releasable intracellular calcium, that bound to annexin VI on the inner surface of the plasma membrane. Translocation of annexin VI from the membrane during exposure to t-butyl hydroperoxide matched elevation of [Ca2+](i) as a function of time and t-butyl hydroperoxide concentration. The translocation was possibly due to a combination of ATP depletion and oxidative modification of membrane lipids and proteins, A sustained increase in [Ca2+](i) occurring > 50 pmol/10(6) cells (50 mu M under these conditions) appeared to be a consequence of membrane Ca2+-ATPase dysfunction. These results suggest that exposure to oxidative stress results in early alterations to the plasma membrane and concomitant release of Ca2+ into the cytosol. In addition it suggests a mechanism for participation of annexin VI translocation that may underlie the alterations in macrophage function by oxidative stress.	UNIV SO CALIF,SCH PHARM,DEPT MOL PHARMACOL & TOXICOL,LOS ANGELES,CA 90033; UNIV SO CALIF,DEPT PATHOL,LOS ANGELES,CA 90033; THOMAS JEFFERSON UNIV,DEPT ANAT PATHOL & CELL BIOL,PHILADELPHIA,PA 19107	University of Southern California; University of Southern California; Jefferson University			Thomas, Andrew/C-6755-2013	Thomas, Andrew/0000-0002-9026-7467; Forman, Henry Jay/0000-0001-5838-2791	NHLBI NIH HHS [HL37556] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037556] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELLOMO G, 1984, EUR J BIOCHEM, V140, P1, DOI 10.1111/j.1432-1033.1984.tb08058.x; BOWLES AL, 1979, AM REV RESPIR DIS, V120, P541; COMERA C, 1990, EUR J BIOCHEM, V188, P139, DOI 10.1111/j.1432-1033.1990.tb15381.x; CROMPTON MR, 1988, EMBO J, V7, P21, DOI 10.1002/j.1460-2075.1988.tb02779.x; CROWELL RE, 1995, AM J RESP CELL MOL, V12, P190, DOI 10.1165/ajrcmb.12.2.7865216; DAVIDSON FF, 1989, BIOCHEM PHARMACOL, V38, P3645, DOI 10.1016/0006-2952(89)90567-4; DAVIDSON FF, 1990, J BIOL CHEM, V265, P5602; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; EDWARDS HC, 1995, MOL CELL BIOCHEM, V149, P293, DOI 10.1007/BF01076591; FORMAN HJ, 1980, J BIOL CHEM, V255, P9879; FORMAN HJ, 1982, J APPL PHYSIOL, V53, P685, DOI 10.1152/jappl.1982.53.3.685; FORMAN HJ, 1993, ACTIVE OXYGENS, LIPID PEROXIDES, AND ANTIOXIDANTS, P149; GAMALEY IA, 1994, CELL SIGNAL, V6, P949, DOI 10.1016/0898-6568(94)90028-0; GEISOW MJ, 1986, TRENDS BIOCHEM SCI, V11, P420, DOI 10.1016/0968-0004(86)90176-3; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hofer AM, 1996, FASEB J, V10, P302, DOI 10.1096/fasebj.10.2.8641563; Hoyal CR, 1996, ARCH BIOCHEM BIOPHYS, V326, P166, DOI 10.1006/abbi.1996.0061; KAETZEL MA, 1995, NEWS PHYSIOL SCI, V10, P171; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; LIVINGSTON FR, 1992, ARCH BIOCHEM BIOPHYS, V299, P83, DOI 10.1016/0003-9861(92)90247-T; LU Y, 1995, BIOCHEMISTRY-US, V34, P10777, DOI 10.1021/bi00034a010; MOORE RB, 1992, BLOOD, V79, P1334; MURPHY JK, 1995, FREE RADICAL BIO MED, V18, P37, DOI 10.1016/0891-5849(94)00101-O; MURPHY JK, 1993, AM J RESP CELL MOL, V9, P505, DOI 10.1165/ajrcmb/9.5.505; OOSTING RS, 1990, AM J PHYSIOL, V259, pL87, DOI 10.1152/ajplung.1990.259.2.L87; OWENS RJ, 1984, EMBO J, V3, P945, DOI 10.1002/j.1460-2075.1984.tb01912.x; RAO GN, 1995, BBA-MOL CELL RES, V1265, P67, DOI 10.1016/0167-4889(95)91997-Z; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; ROBISON TW, 1995, ARCH BIOCHEM BIOPHYS, V318, P215, DOI 10.1006/abbi.1995.1223; ROHN TT, 1993, BIOCHEM PHARMACOL, V46, P525, DOI 10.1016/0006-2952(93)90530-A; ROHN TT, 1993, BIOCHIM BIOPHYS ACTA, V1153, P67, DOI 10.1016/0005-2736(93)90277-7; SMITH PD, 1994, P NATL ACAD SCI USA, V91, P2713, DOI 10.1073/pnas.91.7.2713; SOMLYO AP, 1985, NATURE, V314, P622, DOI 10.1038/314622a0; SUDHOF TC, 1988, P NATL ACAD SCI USA, V85, P664, DOI 10.1073/pnas.85.3.664; TAGOE CE, 1994, BIOCHIM BIOPHYS ACTA, P272; VILE G, 1990, BIOCHEM PHARMACOL, V39, P769, DOI 10.1016/0006-2952(90)90157-G; YOSHIZAKI H, 1990, J BIOCHEM-TOKYO, V107, P43, DOI 10.1093/oxfordjournals.jbchem.a123009	40	66	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29205	29210		10.1074/jbc.271.46.29205	http://dx.doi.org/10.1074/jbc.271.46.29205			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910578	hybrid			2022-12-25	WOS:A1996VT05200070
J	Huang, YD; Schwendner, SW; Rall, SC; Mahley, RW				Huang, YD; Schwendner, SW; Rall, SC; Mahley, RW			Hypolipidemic and hyperlipidemic phenotypes in transgenic mice expressing human apolipoprotein E2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; III HYPERLIPOPROTEINEMIA; FAMILIAL DYSBETALIPOPROTEINEMIA; HEPATIC LIPASE; PLASMA-LIPOPROTEINS; MARKED REDUCTION; E DEFICIENCY; A-I; DIET; ATHEROSCLEROSIS	Transgenic mice mere produced that expressed different plasma levels (3-60 mg/dl) of human apolipoprotein (ape) E2(Arg(158) --> Cys), which is associated with the recessive form of human type III hyperlipoproteinemia (HLP). In transgenic mice fed a normal chow diet, low levels of apoE2 (< 10 mg/dl) did not significantly alter the lipid phenotype. Mice expressing intermediate levels of apoE2 (10-30 mg/dl) had a 50-60% decrease in total cholesterol compared with nontransgenic mice. The decrease was almost entirely due to a reduction in high density lipoprotein (HDL) cholesterol. These hypolipidemic apoE2 transgenic mice were cross-bred with human apoB transgenic mice, which have increased total cholesterol and low density Lipoprotein (LDL) levels. The apoE2/apoB double transgenics revealed that expression of apoE2 on the background of human apoB overexpression resulted in a substantial decrease in LDL and HDL cholesterol and a corresponding accumulation of very low density Lipoproteins (VLDL) and intermediate density lipoproteins (mt). Thus, the double transgenics had a lipid phenotype resembling human type III HLP. In contrast to the hypolipidemic mice, mice expressing high levels of apoE2 (>50 mg/dl) were hyperlipidemic. The VLDL and IDL in these mice were significantly increased and cholesterol-enriched and had other characteristics of remnant lipoproteins. Upon agarose gel electrophoresis, the VLDL and IDL from both intermediate and high expressers migrated more slowly toward the beta position compared with the pre-beta-mobility of nontransgenic mouse VLDL and IDL. Thus, depending on plasma apoE2 levels, the expression of human apoE2 in the transgenic mice leads to either a hypolipidemic or hyperlipidemic phenotype. This animal model provides the opportunity to study the factors that cause hypolipidemia and those that precipitate the hyperlipidemia of type III HLP.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL47660] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; DEKNIJFF P, 1991, J CLIN INVEST, V88, P643, DOI 10.1172/JCI115349; DESILVA HV, 1994, J LIPID RES, V35, P1297; DESILVA HV, 1994, J BIOL CHEM, V269, P2324; DONG LM, 1994, J BIOL CHEM, V269, P22358; FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724; FAZIO S, 1994, ARTERIOSCLER THROMB, V14, P1873, DOI 10.1161/01.ATV.14.11.1873; FAZIO S, 1992, J BIOL CHEM, V267, P6941; FAZIO S, 1993, J CLIN INVEST, V92, P1497, DOI 10.1172/JCI116728; GOLDERNOVOSELSKY E, 1992, J BIOL CHEM, V267, P20787; HAVEL RJ, 1983, J CLIN INVEST, V72, P379, DOI 10.1172/JCI110978; HAVEL RJ, 1980, J CLIN INVEST, V66, P1351, DOI 10.1172/JCI109988; HORIE Y, 1992, J BIOL CHEM, V267, P1962; JI ZS, 1994, J BIOL CHEM, V269, P13421; MABUCHI H, 1989, METABOLISM, V38, P115, DOI 10.1016/0026-0495(89)90249-7; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MAHLEY RW, 1994, ANN NY ACAD SCI, V737, P39, DOI 10.1111/j.1749-6632.1994.tb44300.x; MAHLEY RW, 1984, ADV INTERNAL MED, V29, P385; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1990, CURRENT OPINION LIPI, V1, P87; MAHLEY RW, 1995, METABOLIC MOL BASES, P1953; MCLEAN JW, 1984, J BIOL CHEM, V259, P6498; MORGANROTH J, 1975, ANN INTERN MED, V82, P158, DOI 10.7326/0003-4819-82-2-158; MORTIMER BC, 1994, ARTERIOSCLER THROMB, V14, P1542, DOI 10.1161/01.ATV.14.10.1542; PETERSON J, 1986, BIOCHIM BIOPHYS ACTA, V878, P65, DOI 10.1016/0005-2760(86)90344-9; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; RALL SC, 1989, J CLIN INVEST, V83, P1095, DOI 10.1172/JCI113988; RALL SC, 1992, J INTERN MED, V231, P653, DOI 10.1111/j.1365-2796.1992.tb01254.x; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SCOTT J, 1990, CURRENT OPINION LIPI, V1, P96; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; THUREN T, 1992, BIOCHEMISTRY-US, V31, P2332, DOI 10.1021/bi00123a018; THUREN T, 1991, J BIOL CHEM, V266, P4853; UTERMANN G, 1979, CLIN GENET, V15, P37; UTERMANN G, 1977, NATURE, V269, P604, DOI 10.1038/269604a0; UTERMANN G, 1985, DIABETES OBESITY HYP, V3, P11; VANDENMAAGDENBERG AMJM, 1993, J BIOL CHEM, V268, P10540; VANVLIJMEN BJM, 1994, J CLIN INVEST, V93, P1403, DOI 10.1172/JCI117117; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518; ZHAO SP, 1994, ARTERIOSCLER THROMB, V14, P1705, DOI 10.1161/01.ATV.14.11.1705; ZHAO SP, 1994, CLIN CHEM, V40, P1559	43	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29146	29151		10.1074/jbc.271.46.29146	http://dx.doi.org/10.1074/jbc.271.46.29146			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910571	hybrid			2022-12-25	WOS:A1996VT05200063
J	Jarvis, TC; Wincott, FE; Alby, LJ; McSwiggen, JA; Beigelman, L; Gustofson, J; DiRenzo, A; Levy, K; Arthur, M; MatulicAdamic, J; Karpeisky, A; Gonzalez, C; Woolf, TM; Usman, N; Stinchcomb, DT				Jarvis, TC; Wincott, FE; Alby, LJ; McSwiggen, JA; Beigelman, L; Gustofson, J; DiRenzo, A; Levy, K; Arthur, M; MatulicAdamic, J; Karpeisky, A; Gonzalez, C; Woolf, TM; Usman, N; Stinchcomb, DT			Optimizing the cell efficacy of synthetic ribozymes - Site selection and chemical modifications of ribozymes targeting the proto-oncogene c-myb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; HAMMERHEAD RIBOZYMES; IN-VIVO; ANTISENSE OLIGODEOXYNUCLEOTIDES; NUCLEOTIDE-SEQUENCE; CATALYTIC ACTIVITY; MESSENGER-RNA; EXPRESSION; PROTOONCOGENE; INHIBITION	Expression of the proto-oncogene c-myb is necessary for proliferation of vascular smooth muscle cells. We have developed synthetic hammerhead ribozymes that recognize and cleave c-myb RNA, thereby inhibiting cell proliferation. Herein, we describe a method for the selection of hammerhead ribozyme cleavage sites and optimization of chemical modifications that maximize cell efficacy. In vitro assays were used to determine the relative accessibility of the ribozyme target sites for binding and cleavage. Several ribozymes thus identified showed efficacy in inhibiting smooth muscle cell proliferation relative to catalytically inactive controls. A combination of modifications including several phosphorothioate linkages at the 5'-end of the ribozyme and an extensively modified catalytic core resulted in substantially increased cell efficacy. A variety of different 2'-modifications at positions U4 and U7 that confer nuclease resistance gave comparable levels of cell efficacy. The lengths of the ribozyme binding arms were varied; optimal cell efficacy was observed with relatively short sequences (13-15 total nucleotides). These synthetic ribozymes have potential as therapeutics for hyperproliferative disorders such as restenosis and cancer. The chemical moths that give optimal ribozyme activity in smooth muscle cell assays may be applicable to other cell types and other molecular targets.			Jarvis, TC (corresponding author), RIBOZYME PHARMACEUT INC,BOULDER,CO 80301, USA.			Stinchcomb, Dan/0000-0002-3634-7503; Karpeisky, Alexander/0000-0002-9226-8789				BEIGELMAN L, 1995, NUCLEOS NUCLEOT, V14, P907, DOI 10.1080/15257779508012499; BEIGELMAN L, 1995, J BIOL CHEM, V270, P25702, DOI 10.1074/jbc.270.43.25702; BEIGELMAN L, 1995, NUCLEOS NUCLEOT, V14, P895, DOI 10.1080/15257779508012497; BROWN KE, 1992, J BIOL CHEM, V267, P4625; BROWN S, 1996, IN PRESS RIBOZYME PR; CECH TR, 1992, CURR OPIN STRUC BIOL, V2, P605, DOI DOI 10.1016/0959-440X(92)90093-M; CHRISTOFFERSEN RE, 1994, J MOL STRUC-THEOCHEM, V311, P273; FEDOR MJ, 1990, P NATL ACAD SCI USA, V87, P1668, DOI 10.1073/pnas.87.5.1668; Flory CM, 1996, P NATL ACAD SCI USA, V93, P754, DOI 10.1073/pnas.93.2.754; FORRESTER JS, 1991, J AM COLL CARDIOL, V17, P758, DOI 10.1016/S0735-1097(10)80196-2; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; HIJIYA N, 1994, P NATL ACAD SCI USA, V91, P4499, DOI 10.1073/pnas.91.10.4499; JACKSON CL, 1992, HYPERTENSION, V20, P713, DOI 10.1161/01.HYP.20.6.713; Jarvis TC, 1996, RNA, V2, P419; KIEHNTOPF M, 1994, EMBO J, V13, P4645, DOI 10.1002/j.1460-2075.1994.tb06787.x; KINDY MS, 1986, J BIOL CHEM, V261, P2865; LANDAU C, 1994, NEW ENGL J MED, V330, P981, DOI 10.1056/NEJM199404073301407; LANGE W, 1993, LEUKEMIA, V7, P1786; LYNGSTADAAS SP, 1995, EMBO J, V14, P5224, DOI 10.1002/j.1460-2075.1995.tb00207.x; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MELANI C, 1991, CANCER RES, V51, P2897; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P11823, DOI 10.1073/pnas.89.24.11823; SARMIENTO UM, 1994, ANTISENSE RES DEV, V4, P99, DOI 10.1089/ard.1994.4.99; SELIGER H, 1994, NEW DEV FIELD ANTISE, P681; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SIOUD M, 1994, J MOL BIOL, V242, P619, DOI 10.1006/jmbi.1994.1612; SNYDER DS, 1993, BLOOD, V82, P600; SYMONS RH, 1994, CURR OPIN STRUC BIOL, V4, P322, DOI 10.1016/S0959-440X(94)90099-X; TUSCHL T, 1995, CURR OPIN STRUC BIOL, V5, P296, DOI 10.1016/0959-440X(95)80090-5; UHLMANN E, 1990, CHEM REV, V90, P544; USMAN N, 1995, CATALYTIC RNA RIBOZY, P285; WINCOTT F, 1995, NUCLEIC ACIDS RES, V23, P2677, DOI 10.1093/nar/23.14.2677	32	71	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29107	29112		10.1074/jbc.271.46.29107	http://dx.doi.org/10.1074/jbc.271.46.29107			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910566				2022-12-25	WOS:A1996VT05200058
J	Smart, EJ; Ying, YS; Donzell, WC; Anderson, RGW				Smart, EJ; Ying, YS; Donzell, WC; Anderson, RGW			A role for caveolin in transport of cholesterol from endoplasmic reticulum to plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED-CELLS; MA104 CELLS; RECEPTOR; PROTEIN; FOLATE; INTERNALIZATION; PALMITOYLATION; LOCALIZATION; PROGESTERONE; POTOCYTOSIS	Caveolin is a 22-kDa membrane protein found associated with a coat material decorating the inner membrane surface of caveolae. A remarkable feature of this protein is its ability to migrate from caveolae directly to the endoplasmic reticulum (ER) when membrane cholesterol is oxidized. We now present evidence caveolin is involved in transporting newly synthesized cholesterol from the ER directly to caveolae. MA104 cells and normal human fibroblasts transported new cholesterol to caveolae with a half-time of similar to 10 min. The cholesterol then rapidly flowed from caveolae to non-caveolae membrane. Cholesterol moved out of caveolae even when the supply of fresh cholesterol from the ER was interrupted. Treatment of cells with 10 mu g/ml progesterone blocked cholesterol movement from ER to caveolae. Simultaneously, caveolin accumulated in the lumen of the ER, suggesting cholesterol transport is linked to caveolin movement. Caveolae fractions from cells expressing caveolin were enriched in cholesterol 3-4-fold, while the same fractions from cells lacking caveolin were not enriched. Cholesterol transport to the cell surface was nearly 4 times more rapid in cells expressing caveolin than in matched cells lacking caveolin.	UNIV TEXAS, SW MED CTR, DEPT CELL BIOL & NEUROSCI, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NHLBI NIH HHS [HL 20948] Funding Source: Medline; NIGMS NIH HHS [GM 43169, GM 15631] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043169, F32GM015631] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BERGERON M, 1994, CELL TISSUE RES, V277, P297, DOI 10.1007/s004410050156; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CONRAD PA, 1995, J CELL BIOL, V131, P1424; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; FAN JG, 1991, J BIOL CHEM, V266, P14862; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; KAMEN BA, 1986, P NATL ACAD SCI USA, V83, P5983, DOI 10.1073/pnas.83.16.5983; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE Y, 1985, J BIOL CHEM, V260, P5592; LANGE Y, 1994, J BIOL CHEM, V269, P3411; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Metherall JE, 1996, J BIOL CHEM, V271, P2627, DOI 10.1074/jbc.271.5.2627; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; PALADE GE, 1968, J CELL BIOL, V37, P633, DOI 10.1083/jcb.37.3.633; PALADE GE, 1953, J APPL PHYS, V24, P1424; PANINI SR, 1987, J BIOL CHEM, V262, P14435; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Smart EJ, 1995, COLD SPRING HARB SYM, V60, P243, DOI 10.1101/SQB.1995.060.01.028; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1996, J CELL BIOL, V134, P1169, DOI 10.1083/jcb.134.5.1169; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; TRIGATTI BL, 1991, J BIOL CHEM, V266, P22621; URBANI L, 1990, J BIOL CHEM, V265, P1919; VANDENBERG CW, 1995, J CELL BIOL, V131, P669, DOI 10.1083/jcb.131.3.669; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445	43	475	487	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29427	29435		10.1074/jbc.271.46.29427	http://dx.doi.org/10.1074/jbc.271.46.29427			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910609	hybrid			2022-12-25	WOS:A1996VT05200101
J	Chen, CJ; Lin, TT; Shively, JE				Chen, CJ; Lin, TT; Shively, JE			Role of interferon regulatory factor-1 in the induction of biliary glycoprotein (cell CAM-1) by interferon-gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOEMBRYONIC ANTIGEN CEA; CROSS-REACTING ANTIGEN; LIGATION-MEDIATED PCR; IFN-INDUCIBLE GENES; FACTOR-I IRF-1; NF-KAPPA-B; ADHESION MOLECULE; TRANSCRIPTION FACTOR; ESCHERICHIA-COLI; MONOCLONAL-ANTIBODIES	Biliary glycoprotein (BGP), also known as C-CAM-1, has been shown to be down-regulated in colon and prostate tumors. Previously, we demonstrated that BGP mRNA is up-regulated by interferon-gamma (IFN-gamma) in colon cancer cell lines (Takahashi, H., Okai, Y., Paxton, R. J., Hefta, L. J. F., and Shivery, J. E. (1993) Cancer Res. 53, 1612-1619). We now show that the BGP promoter contains an interferon-sensitive response element (ISRE) that is specifically protected in in vivo footprints. Interferon regulatory factor-1 (IRF-1) was identified as the ISRE-binding factor by electrophoretic mobility shift assays. The induction of IRF-1 mRNA by IFN-gamma in HT-29 cells reaches a maximum at 6 h and is superinduced by cycloheximide. Four mRNA species for BGP are induced by IFN-gamma, the major band of which is inhibited by cycleheximide. Transfection of HT-29 cells with an IRF-1 expression plasmid (pAct-1) transactivates a BGP promoter reporter gene containing wild-type (but not mutant) ISRE. Electrophoretic mobility shift assay analysis of a second footprint reveals the binding of Sp1, an Sp1-like protein, and upstream stimulatory factor. The Sp1-like complex wits also induced by IFN-gamma treatment of HT-29 cells and may be a second point of transcriptional control for the BGP gene.	BECKMAN RES INST CITY HOPE,DIV IMMUNOL,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope					NATIONAL CANCER INSTITUTE [R01CA037808] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37808, CA 65767] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1992, BIOCHIM BIOPHYS ACTA, V1134, P46, DOI 10.1016/0167-4889(92)90026-8; AURIVILLIUS M, 1990, FEBS LETT, V264, P267, DOI 10.1016/0014-5793(90)80264-J; BARANOV V, 1994, CANCER RES, V54, P3305; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; CHANG CH, 1992, IMMUNOGENETICS, V35, P378; CHEN CJ, 1995, CANCER RES, V55, P3873; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIGMAN JD, 1983, METHOD ENZYMOL, V101, P582; DVESKSLER GS, 1993, J VIROL, V67, P1; FRANGSMYR L, 1995, CANCER RES, V55, P2963; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GAO E, 1993, J BIOL CHEM, V268, P19697; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HAUCK W, 1994, EUR J BIOCHEM, V223, P529, DOI 10.1111/j.1432-1033.1994.tb19022.x; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; HIRADA H, 1990, CELL, V63, P303; HSEIH JT, 1995, CANCER RES, V55, P190; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KLEINERMAN DI, 1995, CANCER RES, V55, P2831; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; LEUSCH HG, 1990, FEBS LETT, V261, P405, DOI 10.1016/0014-5793(90)80603-G; MARGOLIS RN, 1990, BIOCHEM BIOPH RES CO, V166, P52; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MCCUAIG K, 1992, CELL GROWTH DIFFER, V3, P195; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MUELLER PR, 1994, CURRENT PROTOCOLS MO; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NAEVE GS, 1992, CELL GROWTH DIFFER, V3, P919; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; OLSEN A, 1994, GENOMICS, V23, P659, DOI 10.1006/geno.1994.1555; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; QUERSHI SA, 1995, P NATL ACAD SCI USA, V92, P3829; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; ROSENBERG M, 1993, CANCER RES, V53, P4938; SANCEAU J, 1995, J BIOL CHEM, V270, P27920, DOI 10.1074/jbc.270.46.27920; SAUTER SL, 1991, INFECT IMMUN, V59, P2485, DOI 10.1128/IAI.59.7.2485-2493.1991; SAUTER SL, 1993, J BIOL CHEM, V268, P15510; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SKUBITZ KM, 1992, J IMMUNOL, V148, P852; SVENBERG T, 1976, INT J CANCER, V17, P588, DOI 10.1002/ijc.2910170506; SVENBERG T, 1979, CLIN EXP IMMUNOL, V36, P436; TAKAHASHI H, 1993, CANCER RES, V53, P1612; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TEGLUND S, 1994, GENOMICS, V23, P669, DOI 10.1006/geno.1994.1556; THOMPSON J, 1992, GENOMICS, V12, P761, DOI 10.1016/0888-7543(92)90307-E; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; TURBIDE C, 1991, J BIOL CHEM, V266, P309; TYNAN K, 1992, NUCLEIC ACIDS RES, V20, P1629, DOI 10.1093/nar/20.7.1629; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421	57	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28181	28188		10.1074/jbc.271.45.28181	http://dx.doi.org/10.1074/jbc.271.45.28181			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910434	hybrid			2022-12-25	WOS:A1996VU03300034
J	Cheng, F; Heinegard, D; Fransson, LA; Bayliss, M; Bielicki, J; Hopwood, J; Yoshida, K				Cheng, F; Heinegard, D; Fransson, LA; Bayliss, M; Bielicki, J; Hopwood, J; Yoshida, K			Variations in the chondroitin sulfate-protein linkage region of aggrecans from bovine nasal and human articular cartilages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWARM RAT CHONDROSARCOMA; TRYPSIN-INHIBITOR; SEQUENCE-ANALYSIS; DERMATAN SULFATE; SHARK CARTILAGE; PROTEOGLYCANS; OLIGOSACCHARIDES; FIBROBLASTS; RESIDUES; CHAINS	Aggrecan-derived chondroitin sulfate (CS) chains, released by beta-elimination, were derivatized with p-aminobenzoic acid or p-aminophenol; radioiodinated; and subjected to graded or complete degradations by chondroitin ABC lyase to generate linkage region fragments of the basic structure Delta GlyUA-GalNAc-GlcUA-Gal-Gal-Xyl-R (where Delta GlyUA represents 4,5-unsaturated glycuronic acid, and R is the adduct), by chondroitin AC lyase to generate the shorter fragment Delta GlyUA-Gal-Gal-Xyl-R, or by chondroitin C lyase to generate the same fragment when it was linked to a 6-O-sulfated or unsulfated GalNac at the nonreducing end. Fragments were separated by size using gel chromatography, by charge using ion-exchange chromatography, and by size/charge using electrophoresis and then characterized by stepwise degradations from the nonreducing end by using mercuric acetate to remove all terminal Delta GlyUA, by bacterial glycuronidase to remove the same residue when linked to unsulfated or 6-O-sulfated GalNAc/Gal, by mammalian 4-sulfatase to remove sulfate from terminal GalNAc 4-O-sulfate, by chondro-4-sulfatase to remove 4-O-sulfate from other GalNAc/Gal residues, and by beta-galactosidase to remove terminal Gal. Results with CS from bovine nasal cartilage aggrecan show that, in nearly all chains, Xyl and probably also the first Gal are unsubstituted, whereas the second Gal is 4-O-sulfated in one CS chain out of five. The first disaccharide repeat is sulfated at C-4 of GalNAc in one chain out of three and unsulfated in the other two. A sulfated first disaccharide is always joined to an unsulfated GlcUA-Gal-Gal sequence. In contrast, CS from human articular cartilage usually has a sulfated first disaccharide repeat. In CS from young human cartilage, sulfate groups are mostly at C-4 of GalNAc in the major part of the chain, but at C-6 in the nonreducing distal portion. In CS from old cartilage, sulfation at C-6 of GalNAc is a major feature from the nonreducing end down to approximately positions 4 and 5 from the linkage region, where GalNAc 4-O-sulfate is common.	KENNEDY INST,LONDON W6 7DW,ENGLAND; ADELAIDE CHILDRENS HOSP INC,DEPT CHEM PATHOL,ADELAIDE,SA 5006,AUSTRALIA; SEIKAGAKU CORP,TOKYO RES INST,HIGASHIYAMATO,TOKYO 207,JAPAN	University of Oxford; Seikagaku Corporation	Cheng, F (corresponding author), LUND UNIV,DEPT CELL & MOL BIOL,SECT CELL & MATRIX BIOL,POB 94,S-22100 LUND,SWEDEN.							ANSON DS, 1992, BIOCHEM J, V284, P789, DOI 10.1042/bj2840789; BAYLISS MT, 1978, BIOCHEM J, V176, P683, DOI 10.1042/bj1760683; Bayliss MT, 1995, ACTA ORTHOP SCAND, V66, P22, DOI 10.3109/17453679509157642; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; CHENG F, 1994, GLYCOBIOLOGY, V4, P685, DOI 10.1093/glycob/4.5.685; CHENG F, 1992, GLYCOBIOLOGY, V2, P553, DOI 10.1093/glycob/2.6.553; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DEWAARD P, 1992, J BIOL CHEM, V267, P6036; FRANSSON LA, 1990, BIOCHEM J, V269, P381, DOI 10.1042/bj2690381; FRANSSON LA, 1985, J BIOL CHEM, V260, P4722; FRANSSON LA, 1992, BIOCHIM BIOPHYS ACTA, V1137, P287, DOI 10.1016/0167-4889(92)90149-6; HABUCHI O, 1977, J BIOL CHEM, V252, P4570; HEINEGARD D, 1987, METHOD ENZYMOL, V144, P319; Heinegard Dick, 1993, P189; KAPLAN D, 1959, NATURE, V183, P1267, DOI 10.1038/1831267a0; KARAMANOS NK, 1995, ANAL BIOCHEM, V225, P220, DOI 10.1006/abio.1995.1147; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LAINE RA, 1994, GLYCOBIOLOGY, V4, P759, DOI 10.1093/glycob/4.6.759; Liu J, 1995, GLYCOBIOLOGY, V5, P765, DOI 10.1093/glycob/5.8.765; LUDWIGS U, 1987, BIOCHEM J, V245, P795, DOI 10.1042/bj2450795; MATHEWS MB, 1966, J CLIN INVEST, V45, P1103, DOI 10.1172/JCI105416; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; OTOTANI N, 1987, CARBOHYD RES, V159, P25, DOI 10.1016/S0008-6215(00)90003-X; Roden L., 1972, METHODS ENZYMOLOGY, V28, P73; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; SHIBATA S, 1992, J BIOL CHEM, V267, P6548; SUGAHARA K, 1991, EUR J BIOCHEM, V202, P805, DOI 10.1111/j.1432-1033.1991.tb16436.x; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; SUZUKI S, 1968, J BIOL CHEM, V243, P3580; YAMADA S, 1995, GLYCOBIOLOGY, V5, P335, DOI 10.1093/glycob/5.3.335; YAMADA S, 1995, EUR J BIOCHEM, V233, P687, DOI 10.1111/j.1432-1033.1995.687_2.x; Yoshida K., 1993, DERMATAN SULFATE PRO, P55	33	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28572	28580		10.1074/jbc.271.45.28572	http://dx.doi.org/10.1074/jbc.271.45.28572			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910487	hybrid			2022-12-25	WOS:A1996VU03300087
J	Porter, JE; Hwa, J; Perez, DM				Porter, JE; Hwa, J; Perez, DM			Activation of the alpha(1b)-adrenergic receptor is initiated by disruption of an interhelical salt bridge constraint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-ADRENERGIC RECEPTOR; LIGAND-BINDING; SITE; IDENTIFICATION; EXPRESSION; RHODOPSIN; SUBTYPES; MUTATION; CLONING; CDNA	Rhodopsin receptor activation in involves the disruption of a salt bridge constraint between glutamic acid 113 on transmembrane 3 and a lysine 296 in transmembrane 7, which forms a Schiffs base with retinal, Light-induced isomerization of cis-retinal to the all trans form breaks this rhodopsin salt bridge leading to receptor activation, The analogous residues in alpha(1b)-adrenergic receptors, aspartic acid 125 and lysine 331, also have the potential of forming a constraining salt bridge holding the receptor to an inactive protein configuration, This alpha(1b)-adrenergic receptor salt bridge constraint is then released upon binding by the receptor agonist. To test this hypothesis, site-directed mutagenesis was used to eliminate the positive charge at position 331 by substitution of an alanine, The expressed alpha(1b)-adrenergic receptor mutant demonstrated a 6-fold increased epinephrine binding affinity with no alterations of affinity values for selective adrenergic receptor antagonists, Furthermore, an increased epinephrine potency for total soluble inositol phosphate production along with an elevated basal inositol triphosphate level was observed in COS-1 cells transfected with mutant versus wild-type alpha(1b)-adrenergic receptors, Similar results were obtained for a lysine to a glutamic acid alpha(1b)-adrenergic receptor mutation. In addition, increased basal inositol triphosphate levels were also observed for two aspartic acid 125 alpha(1b)-adrenergic receptor mutations, consistent with this residue's role as the counterion of the salt bridge, Taken together, these alpha(1b)-adrenergic receptor mutations suggest a molecular mechanism by which the positively charged lysine 331 stabilizes the negatively charged aspartic acid 125 via a salt bridge constraint until bound by the receptor agonist.	CLEVELAND CLIN FDN,RES INST,DEPT MOL CARDIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NHLBI NIH HHS [R01HL52544] Funding Source: Medline; NIDCR NIH HHS [F32-DE05646] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [F32DE005646] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABEL PW, 1995, PHARM COMMUN, V6, P29; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYLUND DB, 1992, FASEB J, V6, P832, DOI 10.1096/fasebj.6.3.1346768; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; HO BY, 1992, FEBS LETT, V312, P259, DOI 10.1016/0014-5793(92)80948-G; Hwa J, 1996, J BIOL CHEM, V271, P7956, DOI 10.1074/jbc.271.14.7956; Hwa J, 1996, J BIOL CHEM, V271, P6322, DOI 10.1074/jbc.271.11.6322; HWA J, 1995, J BIOL CHEM, V270, P23189, DOI 10.1074/jbc.270.39.23189; HWA J, 1996, AUTONOMIC NERVOUS SY, V8, P49; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P188, DOI 10.1016/S0165-6147(00)89020-3; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; MINNEMAN KP, 1988, PHARMACOL REV, V40, P87; MULTULSKY HJ, 1987, FASEB J, V1, P365; Perez DM, 1996, MOL PHARMACOL, V49, P112; PEREZ DM, 1994, MOL PHARMACOL, V46, P823; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; Piascik MT, 1995, J PHARMACOL EXP THER, V275, P1583; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; RUFFOLO RR, 1991, PHARMACOL REV, V43, P475; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Sambrook J., 2002, MOL CLONING LAB MANU; STRADER CD, 1991, J BIOL CHEM, V266, P5; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; WANG CD, 1991, MOL PHARMACOL, V40, P168	25	107	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28318	28323		10.1074/jbc.271.45.28318	http://dx.doi.org/10.1074/jbc.271.45.28318			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910453	hybrid			2022-12-25	WOS:A1996VU03300053
J	Tang, NM; Ho, CY; Katze, MG				Tang, NM; Ho, CY; Katze, MG			The 58-kDa cellular inhibitor of the double stranded RNA-dependent protein kinase requires the tetratricopeptide repeat 6 and DnaJ motifs to stimulate protein synthesis in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-II; ADENOVIRUS VAI RNA; TRANSLATIONAL CONTROL; MESSENGER-RNA; MALIGNANT TRANSFORMATION; MOLECULAR CHAPERONES; GENE-EXPRESSION; ALPHA-SUBUNIT; P68 KINASE; SNAP HELIX	Double stranded RNA-dependent protein kinase (PKR) is a double stranded RNA-activated, interferon-induced serine-threonine kinase that participates in both the antiviral and antiproliferative properties of interferon. We previously found that influenza virus inhibited PKR function by recruiting or activating a cellular inhibitor termed P58(IPK). The present study was undertaken to complement our earlier analyses, which demonstrated that P58(IPK) efficiently inhibited PKR autophosphorylation and activity in vitro. We now report that P58(IPK) down-regulates PKR and, in turn, stimulates protein synthetic rates inside the cell. Using transfection analysis, we show that P58(IPK) stimulates translation of secreted embryonic alkaline phosphatase reporter gene mRNA. Furthermore, we found that at least two regions of the P58(IPK) molecule were required for PKR inhibitory activity in COS-1 cells: (i) the DnaJ similarity region at the carboxyl terminus (amino acids 391-504); and (ii) the tetratricopeptide repeat 6 (TPR6) domain (amino acids 222-255) located in the middle of the P58(IPK) protein and within the eukaryotic protein synthesis initiation factor 2 alpha homology region. P58(IPK) variants lacking either one of these regions were unable to stimulate secreted embryonic alkaline phosphatase protein synthetic rates. Consistent with this data is the observation that the Delta TPR6 mutant (the P58(IPK) variant lacking the TPR6 motif) failed to block PKR activity in vitro. Based on these data and our earlier in vitro functional and PKR-P58(IPK) binding analyses, a revised model of PKR regulation by P58(IPK) is presented.	UNIV WASHINGTON, DEPT MICROBIOL, SCH MED, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00166] Funding Source: Medline; NIAID NIH HHS [AI 22646] Funding Source: Medline; NIGMS NIH HHS [T32 GM07270] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BLACK TL, 1989, J VIROL, V63, P2244, DOI 10.1128/JVI.63.5.2244-2251.1989; CARROLL K, 1993, J BIOL CHEM, V268, P12837; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; COLTHURST DR, 1987, EUR J BIOCHEM, V166, P357, DOI 10.1111/j.1432-1033.1987.tb13523.x; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; Davis S, 1996, P NATL ACAD SCI USA, V93, P508, DOI 10.1073/pnas.93.1.508; EDERY I, 1989, CELL, V56, P303, DOI 10.1016/0092-8674(89)90904-5; GALABRU J, 1987, J BIOL CHEM, V262, P15538; Gale M, 1996, MOL CELL BIOL, V16, P4172; GHADGE GD, 1991, P NATL ACAD SCI USA, V88, P7140, DOI 10.1073/pnas.88.16.7140; GIANTINI M, 1989, J VIROL, V63, P2415, DOI 10.1128/JVI.63.6.2415-2421.1989; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HOHFELD J, 1995, CELL, V83, P589; HOVANESSIAN AG, 1991, J INTERFERON RES, V11, P199, DOI 10.1089/jir.1991.11.199; JARAMILLO ML, 1995, CANCER INVEST, V13, P327, DOI 10.3109/07357909509094468; KATZE MG, 1987, EMBO J, V6, P689, DOI 10.1002/j.1460-2075.1987.tb04809.x; KATZE MG, 1996, TRANSLATIONAL CONTRO, P607; Katze Michael G., 1995, Trends in Microbiology, V3, P75, DOI 10.1016/S0966-842X(00)88880-0; KAUFMAN RJ, 1985, P NATL ACAD SCI USA, V82, P689, DOI 10.1073/pnas.82.3.689; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KEMP BE, 1991, METHOD ENZYMOL, V201, P287; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Korth MJ, 1996, GENE, V170, P181, DOI 10.1016/0378-1119(95)00883-7; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331; LEE TG, 1992, J BIOL CHEM, V267, P14238; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LI JH, 1991, EUR J BIOCHEM, V195, P41, DOI 10.1111/j.1432-1033.1991.tb15673.x; LLOYD RM, 1992, J VIROL, V66, P6878, DOI 10.1128/JVI.66.12.6878-6884.1992; MATHEWS MB, 1996, TRANSLATIONAL CONTRO, P505; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; OHKI M, 1986, J BIOL CHEM, V261, P1778; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; Polyak SJ, 1996, J BIOL CHEM, V271, P1702, DOI 10.1074/jbc.271.3.1702; RICE AP, 1985, J VIROL, V54, P894, DOI 10.1128/JVI.54.3.894-898.1985; SCHNEIDER RJ, 1996, TRANSLATIONAL CONTRO, P575; SELIGER LS, 1992, VIROLOGY, V187, P202, DOI 10.1016/0042-6822(92)90308-C; SIKORSKI RS, 1993, MOL CELL BIOL, V13, P1212, DOI 10.1128/MCB.13.2.1212; SIKORSKI RS, 1991, COLD SH Q B, V56, P663; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; SMITH RL, 1995, GENE DEV, V9, P2903, DOI 10.1101/gad.9.23.2903; SVENSSON C, 1984, MOL CELL BIOL, V4, P736, DOI 10.1128/MCB.4.4.736; SVENSSON C, 1985, EMBO J, V4, P957, DOI 10.1002/j.1460-2075.1985.tb03724.x; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TZAMARIAS D, 1988, EMBO J, V7, P3547, DOI 10.1002/j.1460-2075.1988.tb03231.x; WILLIAMS BRG, 1995, SEMIN VIROL, V6, P191, DOI 10.1006/smvy.1995.0024; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	64	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28660	28666		10.1074/jbc.271.45.28660	http://dx.doi.org/10.1074/jbc.271.45.28660			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910500	hybrid			2022-12-25	WOS:A1996VU03300100
J	Zhong, XT; Kolter, R; Tai, PC				Zhong, XT; Kolter, R; Tai, PC			Processing of colicin V-1, a secretable marker protein of a bacterial ATP binding cassette export system, requires membrane integrity, energy, and cytosolic factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; MULTIDRUG RESISTANCE; GENETIC-ANALYSIS; TRANSPORT PROTEINS; ABC TRANSPORTERS; OUTER-MEMBRANE; P-GLYCOPROTEIN; HEMOLYSIN; SECRETION	Extracellular secretion of the peptide antibiotic colicin V (ColV) in Escherichia coli is mediated by a dedicated exporter system consisting of host TolC protein and the products of two specific genes, cvaA and cvaB, the latter being a member of the ATP binding cassette (ABC) superfamily. An amino-terminal export signal of ColV is specific for the CvaA-CvaE-TolC exporter and is processed concomitant with secretion. In this study, we attempt to characterize this processing with a secretable marker protein, ColV-1, using a newly developed in vitro assay. Processing is found to be dependent on both CvaA-CvaB transporters and the TolC protein and to require membrane integrity. An additional cytoplasmic soluble factor(s) is also necessary for the processing. Although the sequence of the cleavage site suggests it could be a substrate, ColV-1 cannot be processed in vitro by the purified leader peptidase I. Moreover, ColV-1 processing is inhibited by antipain and N-ethylmaleimide. Furthermore, the processing requires energy in the form of nucleotide hydrolysis. These results indicate that the processing of ColV-1 is specific and more complex than expected, requiring the CvaA-CvaB-TolC transporter intact in the membrane, energy, and cytosolic factors for rapid cleavage.	GEORGIA STATE UNIV, DEPT BIOL, ATLANTA, GA 30303 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOL GENET, BOSTON, MA 02115 USA	University System of Georgia; Georgia State University; Harvard University; Harvard Medical School								AMES GFL, 1990, J BACTERIOL, V172, P4133, DOI 10.1128/jb.172.8.4133-4137.1990; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; FATH MJ, 1994, BIOCHEMISTRY-US, V33, P6911, DOI 10.1021/bi00188a021; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; FATH MJ, 1993, THESIS HARVARD U CAM; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; FELMLEE T, 1988, P NATL ACAD SCI USA, V85, P5269, DOI 10.1073/pnas.85.14.5269; GARRIDO MD, 1988, EMBO J, V7, P1853, DOI 10.1002/j.1460-2075.1988.tb03018.x; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; Gething M, 1985, PROTEIN TRANSPORT SE, P103; GILSON L, 1987, J BACTERIOL, V169, P2466, DOI 10.1128/jb.169.6.2466-2470.1987; GILSON L, 1990, EMBO J, V9, P3875, DOI 10.1002/j.1460-2075.1990.tb07606.x; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GRAY L, 1986, MOL GEN GENET, V205, P127, DOI 10.1007/BF02428042; GRAY L, 1989, J CELL SCI, P45; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HAVARSTEIN LS, 1995, MOL MICROBIOL, V16, P229, DOI 10.1111/j.1365-2958.1995.tb02295.x; HAVARSTEIN LS, 1994, MICROBIOL-SGM, V140, P2383, DOI 10.1099/13500872-140-9-2383; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOLLAND IB, 1990, J BIOENERG BIOMEMBR, V22, P473, DOI 10.1007/BF00763178; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; KLAENHAMMER TR, 1993, FEMS MICROBIOL REV, V12, P39, DOI 10.1111/j.1574-6976.1993.tb00012.x; KLAENHAMMER TR, 1992, BACTERIOCINS MICROCI, P37; KOLTER R, 1992, ANNU REV MICROBIOL, V46, P141, DOI 10.1146/annurev.mi.46.100192.001041; Koronakis V, 1993, Semin Cell Biol, V4, P7, DOI 10.1006/scel.1993.1002; KORONAKIS V, 1989, EMBO J, V8, P595, DOI 10.1002/j.1460-2075.1989.tb03414.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOFFE S, 1990, EMBO J, V9, P1375, DOI 10.1002/j.1460-2075.1990.tb08252.x; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MIMMACK ML, 1989, P NATL ACAD SCI USA, V86, P8257, DOI 10.1073/pnas.86.21.8257; OROPEZAWEKERLE RL, 1990, J BACTERIOL, V172, P3711, DOI 10.1128/jb.172.7.3711-3717.1990; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; TAI PC, 1991, METHOD CELL BIOL, V34, P167; TSCHANTZ WR, 1994, METHOD ENZYMOL, V244, P285; VENEMA K, 1995, MOL MICROBIOL, V17, P515, DOI 10.1111/j.1365-2958.1995.mmi_17030515.x; WAGNER W, 1983, J BACTERIOL, V154, P200, DOI 10.1128/JB.154.1.200-210.1983; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WANDERSMAN C, 1990, P NATL ACAD SCI USA, V87, P4776, DOI 10.1073/pnas.87.12.4776; WANG RC, 1991, J MOL BIOL, V217, P441, DOI 10.1016/0022-2836(91)90748-U; WATERS VL, 1991, MICROBIOL REV, V55, P437, DOI 10.1128/MMBR.55.3.437-450.1991; WOLIN SL, 1994, CELL, V77, P787, DOI 10.1016/0092-8674(94)90124-4; YANG CC, 1984, J BACTERIOL, V158, P757, DOI 10.1128/JB.158.2.757-759.1984; ZHANG LH, 1995, GENETICS, V141, P25; ZHONG X, UNPUB	51	24	24	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28057	28063		10.1074/jbc.271.45.28057	http://dx.doi.org/10.1074/jbc.271.45.28057			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910417	hybrid			2022-12-25	WOS:A1996VU03300017
J	Karsan, A; Yee, E; Harlan, JM				Karsan, A; Yee, E; Harlan, JM			Endothelial cell death induced by tumor necrosis factor-alpha is inhibited by the Bcl-2 family member, A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-MEDIATED CYTOTOXICITY; CERAMIDE-INDUCED APOPTOSIS; GROWTH-FACTOR; RETROVIRAL VECTORS; GENE-TRANSFER; PROTEIN; EXPRESSION; INTERLEUKIN-1; ACTIVATION; RESISTANCE	Endothelial cells play a central role in the inflammatory process, Tumor necrosis factor-cy (TNF) is a multifunctional cytokine which elicits many of the inflammatory responses of endothelial cells, While TNF directly causes apoptosis of tumor cells and virally infected cells, normal cells are generally resistant. However, most resistant cells, including human endothelial cells, can be rendered susceptible to TNF by inhibiting RNA or protein synthesis. This finding suggests that TNF provides a cell survival signal in addition to a death signal. We have previously cloned a human Bcl-2 homologue, Al, and shown that it is specifically induced by proinflammatory cytokines but not by endothelial growth factors. In this study, we show that retroviral-mediated transfer of the Al cDNA to a human microvascular endothelial cell line provides protection against cell death initiated by TNF in the presence of actinomycin D. The induction of Al by TNF in this system is mediated via a protein kinase C pathway, Since TNF signaling has also been shown to proceed via ceramides, we tested whether exogenous ceramides could induce Al, Our findings indicate that ceramides do not induce Al but do up-regulate c-jun and induce endothelial death. Ceramide-activated endothelial death is also inhibited by Al, suggesting that TNF may initiate divergent survival and death pathways via separate lipid second messengers.			Karsan, A (corresponding author), UNIV WASHINGTON,DIV HEMATOL,BOX 357710,SEATTLE,WA 98195, USA.		Karsan, Aly/K-2067-2015		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL047151] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47151] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; ARAKI S, 1990, BIOCHEM BIOPH RES CO, V168, P1194, DOI 10.1016/0006-291X(90)91155-L; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; CARMICHAEL J, 1987, CANCER RES, V47, P943; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; FANG W, 1995, J IMMUNOL, V155, P66; HAIMOVITZFRIEDMAN A, 1994, CANCER RES, V54, P2591; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HENNET T, 1993, CANCER RES, V53, P1456; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; JAATTELA M, 1995, ONCOGENE, V10, P2297; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; Karsan A, 1996, BLOOD, V87, P3089, DOI 10.1182/blood.V87.8.3089.bloodjournal8783089; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; KUMAR S, 1991, J BIOL CHEM, V266, P20960; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; Masamune A, 1996, J BIOL CHEM, V271, P9368, DOI 10.1074/jbc.271.16.9368; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; POHLMAN TH, 1989, CELL IMMUNOL, V119, P41, DOI 10.1016/0008-8749(89)90222-0; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; SCHUTZE S, 1994, J LEUKOCYTE BIOL, V56, P533, DOI 10.1002/jlb.56.5.533; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wallach D, 1986, Interferon, V7, P89; WALLACH D, 1984, J IMMUNOL, V132, P2464; WEPSIC HT, 1989, IMMUNOPHARM IMMUNOT, V11, P81, DOI 10.3109/08923978909082144; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	51	207	214	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27201	27204		10.1074/jbc.271.44.27201	http://dx.doi.org/10.1074/jbc.271.44.27201			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910286	hybrid			2022-12-25	WOS:A1996VQ67900004
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			The minimum functional unit of human P-glycoprotein appears to be a monomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED ATPASE ACTIVITY; NUCLEOTIDE-BINDING SITES; MEMBRANE-PROTEIN; CELLS; MUTANTS; GENE; RECONSTITUTION; PURIFICATION; MUTATIONS; TOPOLOGY	Several studies have demonstrated the presence of oligomers of P-glycoprotein in multidrug-resistant cells. The minimum functional unit of P-glycoprotein, however, is not known. In order to determine whether the functional unit is an oligomer, we tested for associations between P-glycoproteins containing either a histidine tag or the epitope tag for monoclonal antibody A52 at the COOH-terminal end of the molecule. Both tagged molecules were active and had indistinguishable drug resistance profiles. The tagged P-glycoprotin were expressed contemporaneously in HEK 293 cells, purified by nickel-chelate chromatography followed by immuno-blot analysis. We found that P-glycoprotein-A52 did not copurify with functionally active P-glycoprotein-(His)(10), even when the former was overexpressed relative to the histidine-tagged protein. Similar results were obtained with phosphorylation-deficient mutants of P-glycoprotein. By contrast, we could purify and reconstitute drug-stimulated ATPase activity when the half-molecules NH2-terminal half-(His)(10)/COOH-terminal half-A52 or NH2-terminal half-A52/COOH-terminal half-(His)(10) were coexpressed in HEK 293 cells. These results suggest that nickel-chelate chromatography may be a suitable method for studying protein-protein interactions in membrane proteins and that the minimal functional unit of P-glycoprotein is likely to be a monomer.	UNIV TORONTO,DEPT MED,MRC,GRP MEMBRANE BIOL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University of Toronto			Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BOSCOBOINIK D, 1990, BIOCHIM BIOPHYS ACTA, V1027, P225, DOI 10.1016/0005-2736(90)90311-B; CASEY JR, 1993, BIOCHEMISTRY-US, V32, P1172, DOI 10.1021/bi00055a023; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GEORGES E, 1993, J BIOL CHEM, V268, P1792; Germann UA, 1996, J BIOL CHEM, V271, P1708, DOI 10.1074/jbc.271.3.1708; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1994, J BIOL CHEM, V269, P28683; NAITO M, 1992, BIOCHEM BIOPH RES CO, V185, P284, DOI 10.1016/S0006-291X(05)80988-X; PORUCHYNSKY MS, 1994, BIOCHEMISTRY-US, V33, P4163, DOI 10.1021/bi00180a009; REITHMEIER RAF, 1994, CURR OPIN CELL BIOL, V6, P583, DOI 10.1016/0955-0674(94)90080-9; SCHINKEL AH, 1995, EUR J CANCER, V31A, P1295, DOI 10.1016/0959-8049(95)00130-B; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Schuetz EG, 1996, P NATL ACAD SCI USA, V93, P4001, DOI 10.1073/pnas.93.9.4001; SEKLER I, 1995, J BIOL CHEM, V270, P21028, DOI 10.1074/jbc.270.36.21028; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	27	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27488	27492		10.1074/jbc.271.44.27488	http://dx.doi.org/10.1074/jbc.271.44.27488			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910332	hybrid			2022-12-25	WOS:A1996VQ67900050
J	Nakahara, H; Nomizu, M; Akiyama, SK; Yamada, Y; Yeh, YY; Chen, WT				Nakahara, H; Nomizu, M; Akiyama, SK; Yamada, Y; Yeh, YY; Chen, WT			A mechanism for regulation of melanoma invasion - Ligation of alpha(6)beta(1) integrin by laminin G peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CELL-ADHESION; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; SYNTHETIC PEPTIDES; BETA-1 INTEGRINS; IV COLLAGENASE; SCATTER FACTOR; A CHAIN; FIBRONECTIN	Invasion of LOX human melanoma cells involves extracellular matrix (ECM) degradation and formation of cell surface invadopodia. Here we show that the ligation of alpha(6) beta(1) by two peptides derived from the COOH-terminal globular domain of laminin-1 alpha(1) chain (laminin G peptides), designated AG-10 (NPWHSIYITRFG) and AG-32 (TWYKIAFQRNRK), and antibodies against alpha(6) and beta(1) integrins promoted invasiveness. AG-10 and AG-SB inhibited cell adhesion on laminin, and the antibodies blocked cell adhesion on immobilized AG-10 and AG-32, suggesting that the peptides interact primarily with alpha(6) beta(1) integrin. These soluble peptides and integrin antibodies induced invasiveness by causing an 2-3-fold increase in ECM degradation and invadopodial activity independently of adhesion activity of integrins that were prebound to ECM. The induced ECM degradation and invasion was associated with an increased surface expression of the 170-kDa membrane-bound gelatinase, seprase, as well as its intense localization at invadopodia but not at focal adhesions. However, the total expression levels of seprase, gelatinase A and beta(1) integrins were not altered. We suggest that laminin G peptides act on the alpha(6) beta(1) integrin signaling of invasion by stimulating invadopodial activities, which is distinct from their direct effects on cell adhesion on immobilized ECM.	GEORGETOWN UNIV,MED CTR,LOMBARDI CANC CTR,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT CELL BIOL,WASHINGTON,DC 20007; NIDR,DEV BIOL LAB,NIH,BETHESDA,MD 20892	Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)					NCI NIH HHS [R01 CA-39077] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039077] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; AOYAMA A, 1990, P NATL ACAD SCI USA, V87, P8296, DOI 10.1073/pnas.87.21.8296; Chen Wen-Tien, 1994, Journal of Tissue Culture Methods, V16, P177, DOI 10.1007/BF01540646; CHEN WT, 1994, BREAST CANCER RES TR, V31, P217, DOI 10.1007/BF00666155; CHEN WT, 1986, J CELL BIOL, V103, P1649, DOI 10.1083/jcb.103.5.1649; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; KANEMOTO T, 1990, P NATL ACAD SCI USA, V87, P2279, DOI 10.1073/pnas.87.6.2279; KELLY T, 1994, J CELL PHYSIOL, V158, P299, DOI 10.1002/jcp.1041580212; KIKKAWA Y, 1994, J BIOCHEM-TOKYO, V116, P862, DOI 10.1093/oxfordjournals.jbchem.a124608; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; MACKAY AR, 1994, LAB INVEST, V70, P800; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MIYAZAKI K, 1993, P NATL ACAD SCI USA, V90, P11767, DOI 10.1073/pnas.90.24.11767; MONSKY WL, 1994, CANCER RES, V54, P5702; MUELLER SC, 1991, J CELL SCI, V99, P213; MUELLER SC, 1992, J CELL BIOL, V119, P1309, DOI 10.1083/jcb.119.5.1309; MUELLER SC, 1989, J CELL BIOL, V109, P3455, DOI 10.1083/jcb.109.6.3455; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; RAMOS DM, 1990, CANCER RES, V50, P728; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; SEFTOR REB, 1993, CANCER RES, V53, P3411; STACK MS, 1993, CANCER RES, V53, P1998; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; TURPEENNIEMIHUJANEN T, 1986, J BIOL CHEM, V261, P1883; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; YAMAMURA K, 1993, CANCER RES, V53, P423	30	102	105	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27221	27224		10.1074/jbc.271.44.27221	http://dx.doi.org/10.1074/jbc.271.44.27221			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910291	hybrid			2022-12-25	WOS:A1996VQ67900009
J	Saftig, P; Peters, C; vonFigura, K; Craessaerts, K; VanLeuven, F; DeStrooper, B				Saftig, P; Peters, C; vonFigura, K; Craessaerts, K; VanLeuven, F; DeStrooper, B			Amyloidogenic processing of human amyloid precursor protein in hippocampal neurons devoid of cathepsin D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; CANINE KIDNEY-CELLS; BETA-PROTEIN; CLEAVAGE; MUTATION; PATHWAY; EXPRESSION; IDENTIFICATION; PROTEASES; FRAGMENTS	beta A4-Amyloid peptide, the main component of the amyloid plaques in the brain of Alzheimer's disease patients is produced from amyloid precursor protein (APP) by proteolytical processing. Several lines of evidence suggest a direct role for cathepsin D, the major endosomal/lysosomal aspartic endopeptidase, in beta A4-amyloid peptide generation, Here we tested this hypothesis using primary cultures of hippocampal neurons derived from cathepsin D-deficient (knock out) mice and expressing wild-type human APP and two clinical APP variants via recombinant Semliki Forest virus. We demonstrate APP secretory processing, production of carboxyl-terminal amyloid fragments, and secretion of the beta A4-amyloid peptide in the complete absence of cathepsin D. The results rule out cathepsin D as a critical component of alpha-, beta-, or gamma-secretase and therefore as a primary target for drugs aimed at decreasing the beta A4-amyloid peptide burden in Alzheimer's disease.	UNIV HOSP GASTHUISBERG,CTR HUMAN GENET,EXPT GENET GRP,B-3000 LOUVAIN,BELGIUM; UNIV GOTTINGEN,ZENTRUM BIOCHEM & MOL ZELLBIOL,BIOCHEM ABT 2,D-37073 GOTTINGEN,GERMANY	KU Leuven; University Hospital Leuven; University of Gottingen			de+Strooper, Bart/Z-1638-2019; De Strooper, Bart/F-6507-2012; Saftig, Paul/A-7966-2010	De Strooper, Bart/0000-0001-5455-5819; 				CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CATALDO AM, 1994, BRAIN RES, V640, P68, DOI 10.1016/0006-8993(94)91858-9; CATALDO AM, 1991, P NATL ACAD SCI USA, V88, P10998, DOI 10.1073/pnas.88.24.10998; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; CATALDO AM, 1995, NEURON, V14, P671, DOI 10.1016/0896-6273(95)90324-0; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; DESTROOPER B, 1995, J BIOL CHEM, V270, P4058, DOI 10.1074/jbc.270.8.4058; DIEDRICH JF, 1991, J VIROL, V65, P4759, DOI 10.1128/JVI.65.9.4759-4768.1991; DIMENT S, 1989, J BIOL CHEM, V264, P13403; DIMENT S, 1985, J BIOL CHEM, V260, P5311; DREYER RN, 1994, EUR J BIOCHEM, V224, P265, DOI 10.1111/j.1432-1033.1994.00265.x; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Essalmani R, 1996, BIOCHEM BIOPH RES CO, V218, P89, DOI 10.1006/bbrc.1996.0017; EVIN G, 1995, BIOCHEMISTRY-US, V34, P14185, DOI 10.1021/bi00043a024; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Goslin K., 1991, CULTURING NERVE CELL, P251; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; KOHNKEN RE, 1995, EXP NEUROL, V133, P105, DOI 10.1006/exnr.1995.1013; KONIG G, 1992, J BIOL CHEM, V267, P10804; KOO EH, 1994, J BIOL CHEM, V269, P17386; KUENTZEL SL, 1993, BIOCHEM J, V295, P367, DOI 10.1042/bj2950367; LADROR US, 1994, J BIOL CHEM, V269, P18422; LO ACY, 1994, J BIOL CHEM, V269, P30966; LOWERY DE, 1991, J BIOL CHEM, V266, P19842; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; REID WA, 1986, J CLIN PATHOL, V39, P1323, DOI 10.1136/jcp.39.12.1323; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; SCHWAGERL AL, 1995, J NEUROCHEM, V64, P443; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SIMAN R, 1993, J BIOL CHEM, V268, P16602; Simons M, 1996, J NEUROSCI, V16, P899; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; VANNOORT JM, 1994, EUR J IMMUNOL, V24, P2175, DOI 10.1002/eji.1830240936; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	45	76	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27241	27244		10.1074/jbc.271.44.27241	http://dx.doi.org/10.1074/jbc.271.44.27241			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910296	hybrid			2022-12-25	WOS:A1996VQ67900014
J	Singh, US; Cerione, RA				Singh, US; Cerione, RA			Biochemical effects of retinoic acid on GTP-binding protein transglutaminases in HeLa cells - Stimulation of GTP-binding and transglutaminase activity, membrane association, and phosphatidylinositol lipid turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG LIVER TRANSGLUTAMINASE; TISSUE TRANSGLUTAMINASE; KERATINOCYTE TRANSGLUTAMINASE; FACTOR-XIII; ALPHA-1-ADRENERGIC RECEPTOR; ANCHORAGE REGION; EPIDERMAL-CELLS; IDENTIFICATION; EXPRESSION; DIFFERENTIATION	Treatment of HeLa cells with retinoic acid (RA) gives rise to a marked stimulation in the incorporation of [alpha-P-32]GTP into an similar to 87-kDa cytosolic protein that cross reacts with a monoclonal antibody raised against tissue transglutaminases. In the absence of RA treatment, the transglutaminase immunoreactivity elutes from a gel filtration column with an apparent size of similar to 600 kDa (designated TGa), whereas following RA treatment, a second peak of transglutaminase immunoreactivity (described TGb) is detected with an apparent size of similar to 150 kDa, The TGa fractions show little or no GTP-binding or GTP hydrolytic activity and very little transglutaminase activity, However, the TGb fractions show all three activities. Retinoic acid treatment also promotes the association of the GTP-binding protein/transglutaminase with membrane fractions, as detected by Western blotting and photoaffinity cross-linking with [alpha-P-32]GTP. In addition, the TGb fraction shows a markedly enhanced ability (relative to TGa) to associate with membranes from control (non-RA-treated) cells. The ability of the GTP-binding protein/transglutaminase to bind to membranes is correlated with the stimulation of a membrane-associated phospholipase C activity, Thus, these findings indicate that RA treatment results ill a number of changes in the biochemical properties of a GTP-binding protein/transglutaminase which strongly enhance its ability to bind GTP, associate with plasma membranes, and stimulate phosphoinositide Lipid turnover.	CORNELL UNIV,CTR VET MED,DEPT PHARMACOL,ITHACA,NY 14853	Cornell University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40654] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; BERTRAM JS, 1983, CANCER SURV, V2, P243; CARIELLO L, 1984, BIOCHEMISTRY-US, V23, P6843, DOI 10.1021/bi00321a087; CERLONE RA, 1984, BIOCHEMISTRY-US, V23, P4519; CHAKRAVARTY R, 1990, BIOCHEM J, V271, P25, DOI 10.1042/bj2710025; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; CHEN R, 1970, P NATL ACAD SCI USA, V66, P472, DOI 10.1073/pnas.66.2.472; CHIOCCA EA, 1988, J BIOL CHEM, V263, P11584; CHUNG SI, 1972, ANN NY ACAD SCI, V202, P240, DOI 10.1111/j.1749-6632.1972.tb16338.x; DIVECHA N, 1993, BIOCHEM J, V289, P617, DOI 10.1042/bj2890617; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GENTILE V, 1991, J BIOL CHEM, V266, P478; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P4633, DOI 10.1021/bi00364a027; IM MJ, 1990, J BIOL CHEM, V265, P18952; IM MJ, 1990, J BIOL CHEM, V265, P18944; KIM HC, 1990, J BIOL CHEM, V265, P21971; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; LICHTI U, 1985, J BIOL CHEM, V260, P1422; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; NARA K, 1989, J BIOL CHEM, V264, P19308; PIACENTINI M, 1991, EUR J CELL BIOL, V54, P246; RAGSDALE CW, 1989, NATURE, V341, P654, DOI 10.1038/341654a0; RICE RH, 1990, BIOCHEM J, V265, P351, DOI 10.1042/bj2650351; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; SPORN MB, 1983, CANCER RES, V43, P3034; TAKAGI T, 1974, BIOCHEMISTRY-US, V13, P750, DOI 10.1021/bi00701a018; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; UUSPA SH, 1982, J BIOL CHEM, V257, P9906; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	36	39	39	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27292	27298		10.1074/jbc.271.44.27292	http://dx.doi.org/10.1074/jbc.271.44.27292			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910304	hybrid			2022-12-25	WOS:A1996VQ67900022
J	Takahashi, M; Hood, DA				Takahashi, M; Hood, DA			Protein import into subsarcolemmal and intermyofibrillar skeletal muscle mitochondria - Differential import regulation in distinct subcellular regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE TRANSCARBAMYLASE PRECURSOR; RAT CARDIAC-MUSCLE; MALATE-DEHYDROGENASE; INNER MEMBRANE; MAMMALIAN MITOCHONDRIA; INTERFIBRILLAR MITOCHONDRIA; OXIDATIVE-PHOSPHORYLATION; INTERMEMBRANE SPACE; YEAST MITOCHONDRIA; TRANSIT PEPTIDE	To date, no studies have described the import of proteins in mitochondria obtained from skeletal muscle. In this tissue, mitochondria consist of the functionally and biochemically distinct intermyofibrillar (IMF) and subsarcolemmal (SS) subfractions, which are localized in specialized cellular compartments, This mitochondrial heterogeneity in muscle could be due, in part, to differential rates of protein import, To evaluate this possibility, the import of precursor malate dehydrogenase and ornithine carbamyltransferase proteins was investigated in isolated IMF and SS mitochondria in vitro, Import of these was 3-4-fold greater in IMF compared with SS mitochondria as a function of time, This could account for the higher malate dehydrogenase enzyme activity in IMF mitochondria, Divergent import rates in IMF and SS mitochondria likely result from a differential reliance on various components of the import pathway, SS mitochondria possess a greater content of the molecular chaperones hsp60 and Grp75, yet import is lower than in IMF mitochondria, On the other hand, adriamycin inhibition studies illustrated a greater reliance on acidic phospholipids (i.e. cardiolipin) for the import process in SS mitochondria, Matrix ATP levels were 3-fold higher in IF mitochondria, but experiments in which ATP depletion was performed with atractyloside and oligomycin illustrated a dissociation between import rates and levels of ATP, In contrast, a close relationship was found between the rate of ATP production (i.e. mitochondrial respiration) and protein import, When respiratory rates in IMF and SS mitochondria were equalized, import rates in both subfractions were similar, These data indicate that 1) import rates are more closely related to the rate of ATP production than the steady state ATP level, 2) import into IMF and SS mitochondrial subfractions is regulated differently, and 3) mitochondrial heterogeneity within a cell type can be due to differences in the rates of protein import, suggesting that this step is a potentially regulatable event in determining the final mitochondrial phenotype.	YORK UNIV,DEPT BIOL,N YORK,ON M3J 1P3,CANADA; YORK UNIV,DEPT KINESIOL,N YORK,ON M3J 1P3,CANADA	York University - Canada; York University - Canada								ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BEASLEY E M, 1992, Current Opinion in Cell Biology, V4, P646, DOI 10.1016/0955-0674(92)90084-P; CASCARANO J, 1995, HEPATOLOGY, V22, P837, DOI 10.1016/0270-9139(95)90306-2; CHIEN SM, 1984, J BIOL CHEM, V259, P3633; CHU TW, 1987, J BIOL CHEM, V262, P12806; CHU TW, 1989, J BIOL CHEM, V264, P9552; COGSWELL AM, 1993, AM J PHYSIOL, V264, pC383, DOI 10.1152/ajpcell.1993.264.2.C383; CONBOY JG, 1982, BIOCHEM BIOPH RES CO, V105, P1, DOI 10.1016/S0006-291X(82)80002-8; Cossarizza A, 1996, EXP CELL RES, V222, P84, DOI 10.1006/excr.1996.0011; COTE C, 1990, BIOCHEM BIOPH RES CO, V170, P1273, DOI 10.1016/0006-291X(90)90531-Q; DECERQUEIRA CM, 1995, ARCH BIOCHEM BIOPHYS, V324, P9; DEMEL RA, 1989, J BIOL CHEM, V264, P3988; DUAN JM, 1989, CAN J PHYSIOL PHARM, V67, P704, DOI 10.1139/y89-114; DUAN JM, 1989, MOL CELL BIOCHEM, V90, P47; EILERS M, 1989, J BIOL CHEM, V264, P2945; ELANDER A, 1985, CLIN SCI, V69, P153, DOI 10.1042/cs0690153; ENDO T, 1988, EMBO J, V7, P1153, DOI 10.1002/j.1460-2075.1988.tb02925.x; Essig D A, 1996, Exerc Sport Sci Rev, V24, P289; GILLESPIE LL, 1985, J BIOL CHEM, V260, P6045; GLICK BS, 1993, PROTEIN SCI, V2, P1901, DOI 10.1002/pro.5560021112; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GOGLIA F, 1988, BIOCHEM BIOPH RES CO, V151, P1241, DOI 10.1016/S0006-291X(88)80499-6; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; HARTMANN CM, 1991, BIOCHEM BIOPH RES CO, V174, P1232, DOI 10.1016/0006-291X(91)91553-O; HOOD DA, 1989, FEBS LETT, V247, P471, DOI 10.1016/0014-5793(89)81393-6; HOOD DA, 1994, CAN J APPL PHYSIOL, V19, P12, DOI 10.1139/h94-002; HOOD DA, 1992, COMP BIOCHEM PHYS A, V101, P597, DOI 10.1016/0300-9629(92)90514-Q; HOPPEL CL, 1982, J BIOL CHEM, V257, P1540; HOWALD H, 1985, PFLUG ARCH EUR J PHY, V403, P369, DOI 10.1007/BF00589248; Komiya T, 1996, EMBO J, V15, P399, DOI 10.1002/j.1460-2075.1996.tb00370.x; KONDO H, 1990, P SOC EXP BIOL MED, V196, P83; KRIEGER DA, 1980, J APPL PHYSIOL, V48, P23, DOI 10.1152/jappl.1980.48.1.23; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; LAI JCK, 1977, J NEUROCHEM, V28, P625, DOI 10.1111/j.1471-4159.1977.tb10434.x; Leenhouts JM, 1995, BIOCHEM SOC T, V23, P968, DOI 10.1042/bst0230968; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; LOPEZMEDIAVILLA C, 1989, FEBS LETT, V254, P115, DOI 10.1016/0014-5793(89)81020-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLACHLAN LK, 1994, BIOCHEM J, V303, P657, DOI 10.1042/bj3030657; MAINWOOD GW, 1982, CAN J PHYSIOL PHARM, V60, P98, DOI 10.1139/y82-016; MANDIEAU V, 1995, FEBS LETT, V368, P15, DOI 10.1016/0014-5793(95)00577-V; MARTIN TP, 1987, COMP BIOCHEM PHYS B, V88, P273, DOI 10.1016/0305-0491(87)90113-1; MARTINUS RD, 1995, FASEB J, V9, P371, DOI 10.1096/fasebj.9.5.7896006; MCMILLINWOOD J, 1980, BIOCHIM BIOPHYS ACTA, V591, P251, DOI 10.1016/0005-2728(80)90157-7; MILLER AD, 1993, BIOCHEM J, V291, P139, DOI 10.1042/bj2910139; NEUPERT NW, 1993, MOL CHAPERONES, P99; NGUYEN M, 1986, J BIOL CHEM, V261, P800; OGATA T, 1985, CELL TISSUE RES, V241, P251, DOI 10.1007/BF00217168; ORNATSKY OI, 1995, BIOCHEM J, V311, P119, DOI 10.1042/bj3110119; OU WJ, 1988, J BIOCHEM-TOKYO, V103, P589, DOI 10.1093/oxfordjournals.jbchem.a122312; PALMER JW, 1977, J BIOL CHEM, V252, P8731; PALMER JW, 1985, ARCH BIOCHEM BIOPHYS, V236, P691, DOI 10.1016/0003-9861(85)90675-7; PFANNER N, 1986, FEBS LETT, V209, P152, DOI 10.1016/0014-5793(86)81101-2; PINSKY WW, 1981, AM J PHYSIOL, V240, pH326, DOI 10.1152/ajpheart.1981.240.3.H326; RALSTON E, 1992, J CELL BIOL, V119, P1063, DOI 10.1083/jcb.119.5.1063; RILEY DA, 1990, FASEB J, V4, P84, DOI 10.1096/fasebj.4.1.2153085; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWARZ E, 1994, BBA-BIOENERGETICS, V1187, P270, DOI 10.1016/0005-2728(94)90125-2; SHORE GC, 1983, METHOD ENZYMOL, V97, P396; SHORE GC, 1995, EUR J BIOCHEM, V227, P9, DOI 10.1111/j.1432-1033.1995.tb20354.x; SKERJANC I, 1987, EMBO J, V6, P6117; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; SZTUL ES, 1989, J CELL SCI, V94, P695; SZTUL ES, 1987, J CELL BIOL, V105, P2631, DOI 10.1083/jcb.105.6.2631; TAKAHASHI M, 1993, J APPL PHYSIOL, V74, P934, DOI 10.1152/jappl.1993.74.2.934; TERADA K, 1995, MOL CELL BIOL, V15, P3708; THOMPSON LM, 1989, J BIOL CHEM, V264, P12091; VERNER K, 1987, EMBO J, V6, P2449, DOI 10.1002/j.1460-2075.1987.tb02524.x; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WANG Y, 1994, BIOCHEMISTRY-US, V33, P12860, DOI 10.1021/bi00209a018; WEBSTER TJ, 1994, DNA CELL BIOL, V13, P1213, DOI 10.1089/dna.1994.13.1213; WEINSTEIN ES, 1985, ARCH SURG-CHICAGO, V120, P332; WINDER W, 1980, PLASTICITY MUSCLE, P581; ZARA V, 1992, J BIOL CHEM, V267, P12077	77	102	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27285	27291		10.1074/jbc.271.44.27285	http://dx.doi.org/10.1074/jbc.271.44.27285			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910303	hybrid			2022-12-25	WOS:A1996VQ67900021
J	Tsuboi, S; Isogai, Y; Hada, N; King, JK; Hindsgaul, O; Fukuda, M				Tsuboi, S; Isogai, Y; Hada, N; King, JK; Hindsgaul, O; Fukuda, M			6'-sulfo sialyl Le(x) but not 6-sulfo sialyl Le(x) expressed on the cell surface supports L-selectin-mediated adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTINCT METASTATIC POTENTIALS; ENDOTHELIAL-DERIVED LIGAND; HAMSTER OVARY CELLS; MAJOR CAPPING GROUP; FUCOSYL-TRANSFERASE; LEWIS-X; O-GLYCANS; LINKED OLIGOSACCHARIDES; CARBOHYDRATE LIGAND; MOLECULAR-CLONING	In order to determine if a sulfated oligosaccharide on the cell surface can function as an L-selectin ligand, a novel approach for in vitro transfer of oligosaccharides was utilized (Srivastava, G., Kaun, K. J., Hindsgaul, O., and Palcic, M. M. (1992) J. Biol. Chem. 267, 22356-22361). CHO cells were incubated with synthetic 6'-sulfo sialyl Le(x), NeuNAc alpha 2-->3(sulfate-6)Gal beta 1-->4(Fuc alpha 1-->3)GlcNAc or 6-sulfo sialyl Le(x), NeuNAc alpha 2-->3Gal beta 1-->4[(Fuc-alpha 1-->3)sulfate-->6GlcNAc] oligosaccharide linked to C-6 of a fucose residue in GDP-fucose and a milk fucosyltransferase, The resultant CHO cells expressing 6'-sulfo sialyl Le(x) or 6-sulfo sialyl Le(x) on their cell surface were tested for adhesion to E-selectin and L-selectin chimeric proteins coated on plates, The results indicate that 6'-sulfo sialyl Le(x) supports L-selectin-mediated adhesion much better than sialyl Le(x) similarly tagged on the cell surface, In contrast, 6 sulfo sialyl Le(x) containing a sulfate group on the N-acetylglucosamine residue did not support adhesion with either selectin, These combined results suggest that 6'-sulfo sialyl Lex is a much better ligand than sialyl Le(x) oligosaccharide for L-selectin.	BURNHAM INST,LA JOLLA CANC RES CTR,GLYCOBIOL PROGRAM,LA JOLLA,CA 92037; UNIV ALBERTA,DEPT CHEM,EDMONTON,AB T6G 2G2,CANADA	Sanford Burnham Prebys Medical Discovery Institute; University of Alberta					NATIONAL CANCER INSTITUTE [P01CA071932, R01CA048737, R37CA033000] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA33000, P01 CA71932, R01 CA48737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BERTOZZI CR, 1995, BIOCHEMISTRY-US, V34, P14271, DOI 10.1021/bi00044a001; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; HALLGREN C, 1995, J CARBOHYD CHEM, V14, P453, DOI 10.1080/07328309508005350; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HO MK, 1983, J BIOL CHEM, V258, P636; IMAI Y, 1993, NATURE, V361, P555; JAIN RK, 1994, J AM CHEM SOC, V116, P12123, DOI 10.1021/ja00105a091; JOHNSON PH, 1982, BIOCHEM SOC T, V10, P445; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SASAKI H, 1987, J BIOL CHEM, V262, P12059; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SAWADA R, 1994, J BIOL CHEM, V269, P1425; SCUDDER PR, 1994, GLYCOBIOLOGY, V4, P929, DOI 10.1093/glycob/4.6.929; SIMMONS DL, 1992, J IMMUNOL, V148, P267; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SRIVASTAVA G, 1992, J BIOL CHEM, V267, P22356; STOOLMAN LM, 1984, J CELL BIOL, V99, P1535, DOI 10.1083/jcb.99.4.1535; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P770, DOI 10.1021/bi952461g; SUEYOSHI S, 1994, J BIOL CHEM, V269, P32342; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WANG WC, 1988, J BIOL CHEM, V263, P4576; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0	43	80	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27213	27216		10.1074/jbc.271.44.27213	http://dx.doi.org/10.1074/jbc.271.44.27213			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910289	hybrid			2022-12-25	WOS:A1996VQ67900007
J	Anderson, MS; Lopes, JM				Anderson, MS; Lopes, JM			Carbon source regulation of PIS1 gene expression in Saccharomyces cerevisiae involves the MCM1 gene and the two-component regulatory gene, SLN1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHESIS; TRANSCRIPTION FACTOR; PHOSPHATIDYLINOSITOL SYNTHASE; 2-COMPONENT REGULATORS; STRUCTURAL GENE; INO1 PROMOTER; CELL-WALL; YEAST; INOSITOL; IDENTIFICATION	The Saccharomyces cerevisiae PISI gene encodes phosphatidylinositol synthase. The amount of phosphatidylinositol synthase is not affected by the presence of inositol and choline in the growth medium. This is unusual because the amounts and/or activities of other phospholipid biosynthetic enzymes are affected by these precursors, and the promoter of the PIS1 gene contains a sequence resembling the regulatory element that coordinates the inositol-mediated regulation (UAS(INO)). We found that transcription of the PIS1 gene was insensitive to inositol and choline and did not require the putative UAS(INO) regulatory sequence or the cognate regulatory genes (INO2 and OPI1). The PIS1 promoter includes sequences (MCEs) that hind the Mcm1 protein. Because the Mcm1 protein interacts with both the Sln1 and the Gal11 regulatory proteins, we examined the effect of mutant alleles of the MCMI and SLN1 genes and carbon source on expression of the PISI. gene. We found that expression of the PIS1 gene was reduced when cells were grown in a medium containing glycerol and increased when grown in a medium containing galactose relative to cells grown in a glucose medium. The glycerol-mediated repression of PIS1 gene expression required both the MCM1 gene and the MCEs, whereas the SLN1 gene was required for full galactose-mediated induction of a PIS1-lacZ reporter gene. Thus, PISI gene expression is unique among the phospholipid biosynthetic structural genes because it is uncoupled from the inositol response and regulated in response to the carbon source. This is the first example in yeast of a complete circuit linking a stimulus (carbon source) to gene regulation (PIS1) using a two-component regulator (SLN1).	LOYOLA UNIV,DEPT MOL & CELLULAR BIOL,PROGRAM MOL BIOL,MAYWOOD,IL 60153	Loyola University Chicago								AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; ASHBURNER BP, 1995, MOL CELL BIOL, V15, P1709; BACCHAWAT N, 1995, J BIOL CHEM, V270, P25087; BAILIS AM, 1992, NUCLEIC ACIDS RES, V20, P1411, DOI 10.1093/nar/20.6.1411; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; BROWN JL, 1993, J BACTERIOL, V175, P6908, DOI 10.1128/jb.175.21.6908-6915.1993; BUTLER G, 1988, CURR GENET, V14, P405, DOI 10.1007/BF00521261; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CHAMBERS A, 1989, MOL CELL BIOL, V9, P5516, DOI 10.1128/MCB.9.12.5516; CULBERTSON MR, 1976, J BACTERIOL, V126, P232, DOI 10.1128/JB.126.1.232-242.1976; DENIS CL, 1983, J BIOL CHEM, V258, P1165; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; ELBLE R, 1991, P NATL ACAD SCI USA, V88, P10966, DOI 10.1073/pnas.88.23.10966; ELION EA, 1984, CELL, V39, P663, DOI 10.1016/0092-8674(84)90473-2; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; GAYNOR PM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P326, DOI 10.1016/0167-4781(91)90197-T; Greenberg ML, 1996, MICROBIOL REV, V60, P1; HENRY SA, 1977, J BACTERIOL, V130, P472, DOI 10.1128/JB.130.1.472-484.1977; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOSAKA K, 1990, J BACTERIOL, V172, P2005, DOI 10.1128/jb.172.4.2005-2012.1990; Jackson JC, 1996, NUCLEIC ACIDS RES, V24, P1322, DOI 10.1093/nar/24.7.1322; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, V2, P193; KELLY BL, 1990, BIOCHIM BIOPHYS ACTA, V1046, P144, DOI 10.1016/0005-2760(90)90181-V; KODAKI T, 1991, J BIOCHEM-TOKYO, V109, P276; KOIPALLY J, 1996, IN PRESS YEAST; KUCHLER K, 1986, J BACTERIOL, V165, P901, DOI 10.1128/jb.165.3.901-910.1986; KUO MH, 1994, MOL CELL BIOL, V14, P348, DOI 10.1128/MCB.14.1.348; LAWTHER RP, 1990, J BACTERIOL, V172, P2320, DOI 10.1128/jb.172.5.2320-2327.1990; LI ZY, 1993, MOL GEN GENET, V241, P680, DOI 10.1007/BF00279911; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MEYERS AM, 1986, GENE, V45, P299; MORGAN BA, 1995, EMBO J, V14, P5679, DOI 10.1002/j.1460-2075.1995.tb00255.x; NIKAWA J, 1984, EUR J BIOCHEM, V143, P251, DOI 10.1111/j.1432-1033.1984.tb08366.x; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; NIKAWA JI, 1982, EUR J BIOCHEM, V125, P445, DOI 10.1111/j.1432-1033.1982.tb06703.x; NIKAWA JI, 1988, J BACTERIOL, V170, P4727, DOI 10.1128/jb.170.10.4727-4731.1988; NIKOLOFF DM, 1994, J BIOL CHEM, V269, P7402; NISHIZAWA M, 1989, MOL CELL BIOL, V9, P442, DOI 10.1128/MCB.9.2.442; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; PAPCIAK SM, 1992, MOL GEN GENET, V234, P22, DOI 10.1007/BF00272341; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; SCHULLER HJ, 1995, FEBS LETT, V370, P149, DOI 10.1016/0014-5793(95)00818-T; SCHWANK S, 1995, NUCLEIC ACIDS RES, V23, P230, DOI 10.1093/nar/23.2.230; SWIFT S, 1995, NUCLEIC ACIDS RES, V23, P1426, DOI 10.1093/nar/23.8.1426; WHITE MJ, 1991, J BIOL CHEM, V266, P863; YU GY, 1995, J BIOL CHEM, V270, P8739, DOI 10.1074/jbc.270.15.8739; YU GY, 1993, MOL CELL BIOL, V13, P63, DOI 10.1128/MCB.13.1.63	50	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26596	26601		10.1074/jbc.271.43.26596	http://dx.doi.org/10.1074/jbc.271.43.26596			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900132	hybrid			2022-12-25	WOS:A1996VP23300026
J	Hartland, RP; Fontaine, T; Debeaupuis, JP; Simenel, C; Delepierre, M; Latge, JP				Hartland, RP; Fontaine, T; Debeaupuis, JP; Simenel, C; Delepierre, M; Latge, JP			A novel beta-(1-3)-glucanosyltransferase from the cell wall of Aspergillus fumigatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CANDIDA-ALBICANS; BETA-GLUCAN; ENZYMATIC-SYNTHESIS; BGL2 GENE; CHITIN; YEAST; TRANSGLYCOSYLATION; OLIGOSACCHARIDES; XYLOGLUCAN	Cell wall transferases utilizing beta-(1-3)-glucan chains as substrates may play important roles in cell wall assembly and rearrangement, as beta-(1-3)-glucan is a major structural component of the cell wall of many fungi, A novel beta-(1-3)-glucanosyltransferase was purified to apparent homogeneity from an autolysate of the cell wall of Aspergillus fumigatus. The enzyme had a molecular mass of 49 kDa and contained approximately 5 kDa of N-linked carbohydrate. The enzyme catalyzed an initial endo-type splitting of a beta-(1-3) glucan molecule, followed by linkage of the newly generated reducing end to the nonreducing end of another beta-(13)-glucan molecule, Laminarioligosaccharides of size G(10) and greater were donor substrates for the transferase, Laminarioligosaccharides of size G(5) and greater formed accepters. The enzyme was able to reuse initial transferase products as donors and accepters in extended incubations, resulting in the formation of increasingly larger transferase products until they became insoluble. The major initial products from an incubation of the transferase with borohydride-reduced G(11) (rG(11)) were rG(6) and rG(16). H-1 MMR analysis of the rG(16) transferase product showed it was a laminarioligosaccharide, indicating that the enzyme forms a beta-(1-3)-linkage during transfer. The enzyme may have a key function in vivo by allowing the integration of newly synthesized glucan into the wall and promoting cell wall expansion during cell growth.	INST PASTEUR, ASPERGILLUS LAB, F-75724 PARIS 15, FRANCE; INST PASTEUR, LAB NUCL MAGNET RESONANCE, F-75724 PARIS 15, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Fontaine, thierry/Q-2201-2018; Fontaine, Thierry/F-8227-2011; latge, jean paul/F-3581-2011; Latge, Jean Paul/C-9846-2014; Debeaupuis, Jean-Paul/A-2035-2012	Fontaine, thierry/0000-0002-8184-789X; 				Ashwell G., 1966, METHODS ENZYMOLOGY, V8, P85; CABIB E, 1983, P NATL ACAD SCI-BIOL, V80, P3318, DOI 10.1073/pnas.80.11.3318; CABIB E, 1988, MICROBIOL SCI, V5, P370; COEN ML, 1994, MICROBIOL-SGM, V140, P2229, DOI 10.1099/13500872-140-9-2229; Fleet G.H., 1991, YEASTS, VVol. 4, P199, DOI [10.1002/jobm.19720120411, DOI 10.1002/JOBM.19720120411]; FRY SC, 1992, BIOCHEM J, V282, P821, DOI 10.1042/bj2820821; FRY SC, 1989, PHYSIOL PLANTARUM, V75, P532, DOI 10.1111/j.1399-3054.1989.tb05620.x; FRY SC, 1989, J EXP BOT, V40, P1, DOI 10.1093/jxb/40.1.1; GOLDMAN RC, 1995, EUR J BIOCHEM, V227, P372, DOI 10.1111/j.1432-1033.1995.tb20399.x; GOODAY GW, 1993, J APPL BACTERIOL, V74, pS12, DOI 10.1111/j.1365-2672.1993.tb04338.x; HARTLAND RP, 1991, P ROY SOC B-BIOL SCI, V246, P155, DOI 10.1098/rspb.1991.0138; HARTLAND RP, 1994, YEAST, V10, P1591, DOI 10.1002/yea.320101208; HEARN VM, 1994, MICROBIOL-UK, V140, P789, DOI 10.1099/00221287-140-4-789; KAPTEYN JC, 1995, J BACTERIOL, V177, P3788, DOI 10.1128/jb.177.13.3788-3792.1995; KLEBL F, 1989, J BACTERIOL, V171, P6259, DOI 10.1128/jb.171.11.6259-6264.1989; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; KOLLAR R, 1995, J BIOL CHEM, V270, P1170, DOI 10.1074/jbc.270.3.1170; KOPECKA M, 1986, ARCH MICROBIOL, V143, P387, DOI 10.1007/BF00412807; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATGE JP, 1994, INFECT IMMUN, V62, P5424; MATSUI I, 1991, BIOCHIM BIOPHYS ACTA, V1077, P416, DOI 10.1016/0167-4838(91)90560-M; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MRSA V, 1993, J BACTERIOL, V175, P2102, DOI 10.1128/JB.175.7.2102-2106.1993; NAKAMURA A, 1994, FEBS LETT, V337, P66, DOI 10.1016/0014-5793(94)80631-4; NILSSON KGI, 1988, TRENDS BIOTECHNOL, V6, P256, DOI 10.1016/0167-7799(88)90058-3; NISHITANI K, 1992, J BIOL CHEM, V267, P21058; Peberdy J., 1990, BIOCH CELL WALLS MEM, P5, DOI [10.1007/978-3-642-74215-6_2, DOI 10.1007/978-3-642-74215-6_2]; RAM SP, 1988, LIFE SCI ADV, V7, P379; RUIZHERRERA J, 1991, ANTON LEEUW INT J G, V60, P73, DOI 10.1007/BF00572695; SAITO H, 1990, BIOPOLYMERS, V29, P1689, DOI 10.1002/bip.360291402; SANZ P, 1985, J GEN MICROBIOL, V131, P2925; SHAW JA, 1991, J CELL BIOL, V114, P111, DOI 10.1083/jcb.114.1.111; SHEMATEK EM, 1980, J BIOL CHEM, V255, P888; SIETSMA JH, 1979, J GEN MICROBIOL, V114, P99, DOI 10.1099/00221287-114-1-99; SINNOT ML, 1989, ENZYME MECH, P259; SMITH RC, 1991, BIOCHEM J, V279, P529, DOI 10.1042/bj2790529; STONE BA, 1992, CHEM BIOL 1 3 BETA G, P1; SULLIVAN PA, 1991, FEMS SYMP, V50, P35; SURARIT R, 1988, J GEN MICROBIOL, V134, P1723; USUI T, 1990, CARBOHYD RES, V203, P65, DOI 10.1016/0008-6215(90)80046-6; VANRINSUM J, 1991, YEAST, V7, P717, DOI 10.1002/yea.320070707; WESSELS JGH, 1990, TIP GROWTH PLANT FUN, P1; YU LP, 1993, J BIOMOL NMR, V3, P429	43	95	100	0	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26843	26849		10.1074/jbc.271.43.26843	http://dx.doi.org/10.1074/jbc.271.43.26843			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900166	hybrid			2022-12-25	WOS:A1996VP23300060
J	Huang, K; Sommers, CL; Grinberg, A; Kozak, CA; Love, PE				Huang, K; Sommers, CL; Grinberg, A; Kozak, CA; Love, PE			Cloning and characterization of PTP-K1, a novel nonreceptor protein tyrosine phosphatase highly expressed in bone marrow	ONCOGENE			English	Article						protein tyrosine phosphatase; cDNA cloning; signal transduction	NUCLEAR-LOCALIZATION; SIGNAL-TRANSDUCTION; SEQUENCE HOMOLOGY; RICH SEQUENCES; PROLINE-RICH; RECEPTOR; FAMILY; CDNA; IDENTIFICATION; DOMAINS	A novel nonreceptor protein tyrosine phosphatase (PTP), PTP-K1, was identified using a consensus polymerase chain reaction-based approach, The full length cDNA encompasses an open reading frame of 1362 base pairs, predicting a protein of 453 amino acid residues with a molecular mass of 54 kDa, The PTP domain is located in the N-terminal portion of the molecule and shares similar to 50% amino acid identify with two other nonreceptor PTPs: PEP and PTP-PEST, PTP-K1 is preferentially expressed in mouse bone marrow with transcripts of 1.7 kb, 1.9 kb and 3.5 kb, The 1.7 kb transcript was also detected in kidney, lung and ovary, The PTP domain of PTP-K1 was expressed as a fusion protein in bacteria and had intrinsic PTP catalytic activity, Indirect immunofluorescence microscopy in COS-7 cells showed that PTP-K1 was localized to the cytoplasm, Ptp-k1 was mapped to mouse chromosome 1, and was closely linked to the interleukin-1 receptor gene, The high level expression of PTP-K1 mRNA in bone marrow suggests that PTP-K1 may be involved in signal transduction in growth and differentiation of hematopoietic cells.	NICHHD,NIH,LAB MAMMALIAN GENES & DEV,BETHESDA,MD 20892; NIAID,MOL MICROBIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								Adachi M, 1996, CELL, V85, P15; ADAMSON MC, 1991, VIROLOGY, V183, P778, DOI 10.1016/0042-6822(91)91010-E; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; CHANG HL, 1991, J IMMUNOL, V147, P1687; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; DENHERTOG J, 1992, BIOCHEM BIOPH RES CO, V184, P1241, DOI 10.1016/S0006-291X(05)80015-4; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FLORES E, 1994, MOL CELL BIOL, V14, P4938, DOI 10.1128/MCB.14.7.4938; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; Green EL, 1981, GENETICS PROBABILITY, P77; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HIGASHITSUJI H, 1995, ONCOGENE, V10, P407; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; KOZAK CA, 1994, GENOMICS, V21, P659, DOI 10.1006/geno.1994.1331; KOZAK CA, 1990, GENOMICS, V8, P519, DOI 10.1016/0888-7543(90)90039-W; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MIYASAKA H, 1992, BIOCHEM BIOPH RES CO, V185, P818, DOI 10.1016/0006-291X(92)91700-Z; MIZUNO K, 1993, MOL CELL BIOL, V13, P5513, DOI 10.1128/MCB.13.9.5513; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; MOUREY RJ, 1994, CURR OPIN GENET DEV, V4, P31, DOI 10.1016/0959-437X(94)90088-4; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAGA Y, 1986, P NATL ACAD SCI USA, V83, P6940, DOI 10.1073/pnas.83.18.6940; SCHEPENS J, 1992, MOL BIOL REP, V16, P241, DOI 10.1007/BF00419663; SELDIN MF, 1994, MAMM GENOME, V5, pS1; SOMMERS CL, 1995, ONCOGENE, V11, P245; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TONKS NK, 1992, COLD SPRING HARB SYM, V57, P87, DOI 10.1101/SQB.1992.057.01.012; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; ZANKE B, 1992, EUR J IMMUNOL, V22, P235, DOI 10.1002/eji.1830220134	41	16	19	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1567	1573						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875997				2022-12-25	WOS:A1996VL38400024
J	Tisdale, EJ; Balch, WE				Tisdale, EJ; Balch, WE			Rab2 is essential for the maturation of pre-Golgi intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEINS; STOMATITIS-VIRUS GLYCOPROTEIN; N-TERMINAL DOMAIN; SEMI-INTACT CELLS; ENDOPLASMIC-RETICULUM; VESICULAR TRANSPORT; SECRETORY PATHWAY; RNA-POLYMERASE; IN-VITRO; COMPARTMENTS	The small GTPase Rab2 is a resident of pre-Golgi intermediates and required for protein transport from the endoplasmic reticulum (ER) to the Golgi complex (Tisdale, E. J., Bourne, J. R,, Khosravi-Far, R., Der, C, J,, and Balch, W. E, (1992) J. Cell Biol. 119, 749-761). The Rab2 protein, Like all small GTPases, contains conserved GTP-binding domains as well as hypervariable carboxyl-terminal and amino-terminal domains. While the role of the carboxyl terminus in specific membrane localization is well recognized, the potential role of the variable NR,terminus remains to be clarified. To determine whether the NH, terminus of Rab2 was required for its activity in vivo, a trans dominant mutant of Rab2 that inhibits ER to Golgi transport was progressively truncated and analyzed for its effect on vesicular stomatitis virus glycoprotein transport in a vaccinia-based transient expression system. Deletion of the first 14 aminoterminal residues resulted in the loss of the inhibitory properties of the mutant without affecting its posttranslational processing or membrane association. To assess the potential role of the NH, terminus in Rab2 function, a peptide corresponding to the first 13 amino acids following the initiator methionine was introduced into an in vitro assay that efficiently reconstitutes transport of vesicular stomatitis virus glycoprotein from the ER to the Golgi stack. This peptide was a potent inhibitor of transport. Biochemical and morphological studies revealed that the peptide strongly interfered with assembly of pre-Golgi intermediates which mediate segregation of anterograde and retrograde transported proteins en route to the Golgi. The combined results suggest that the NH2, terminus of Rab2 is required for its function and for direct interaction with components of the transport machinery involved in the maturation of pre-Golgi intermediates.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NCI NIH HHS [CA 58689] Funding Source: Medline; NCRR NIH HHS [RR07273] Funding Source: Medline; NIGMS NIH HHS [GM 42336] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR007273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Balch W. E., 1993, Methods (Orlando), V5, P258, DOI 10.1006/meth.1993.1032; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BANNYKH S, 1996, IN PRESS J CELL BIOL, V135; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BECKERS CJM, 1990, J BIOL CHEM, V265, P18298; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CASEY PJ, 1992, J LIPID RES, V33, P1; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; FABBRI M, 1994, J BIOL CHEM, V269, P26848; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OKA T, 1994, J CELL BIOL, V124, P425, DOI 10.1083/jcb.124.4.425; PETER F, 1994, J CELL BIOL, V126, P1393, DOI 10.1083/jcb.126.6.1393; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; SANFORD JC, 1995, MOL BIOL CELL, V6, P71, DOI 10.1091/mbc.6.1.71; SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021; SARASTE J, 1995, J CELL SCI, V108, P1541; SARASTE J, 1991, J CELL SCI, V100, P415; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SIMONS K, 1993, NEURON, V5, P613; STEELEMORTIMER O, 1994, EMBO J, V13, P34, DOI 10.1002/j.1460-2075.1994.tb06232.x; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WEIDMAN PJ, 1994, J CELL BIOL, V127, P1815, DOI 10.1083/jcb.127.6.1815; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	44	106	108	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29372	29379		10.1074/jbc.271.46.29372	http://dx.doi.org/10.1074/jbc.271.46.29372			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910601				2022-12-25	WOS:A1996VT05200093
J	Bolgar, MS; Yang, CY; Gaskell, SJ				Bolgar, MS; Yang, CY; Gaskell, SJ			First direct evidence for lipid/protein conjugation in oxidized human low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-B; MASS-SPECTROMETRY; PROTEIN ADDUCTS; OXIDATION; SEQUENCE; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; ALDEHYDES; RESIDUES; DOMAINS; LYSINE	It has been postulated that lipids incorporated in atherosclerotic plaques are derived from the uptake of oxidized low density lipoprotein (LDL) by a macrophage-bound receptor. In vitro studies of LDL oxidation have established that reactive lipids are formed and that the exposure of native LDL to these products leads to modified protein with physical properties similar to oxidized LDL. Here we describe the application of highly specific tandem mass spectrometric techniques to the first characterization of lipid modified LDL by demonstrating the addition of 4-hydroxy-2-nonenal to histidine residues of apolipoprotein B-100, following oxidation of LDL. The modified residues have been assigned to specific locations that have been previously shown to reside on the surface of the LDL particle.	UNIV MANCHESTER,INST SCI & TECHNOL,MICHAEL BARBER CTR MASS SPECT,MANCHESTER M60 1QD,LANCS,ENGLAND; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	University of Manchester; Baylor College of Medicine								BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; Bolgar MS, 1996, ANAL CHEM, V68, P2325, DOI 10.1021/ac9601021; BRUENNER BA, 1995, CHEM RES TOXICOL, V8, P552, DOI 10.1021/tx00046a009; CHEN SH, 1986, J BIOL CHEM, V261, P2918; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1987, J LIPID RES, V28, P495; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; JURGENS G, 1986, BIOCHIM BIOPHYS ACTA, V875, P103, DOI 10.1016/0005-2760(86)90016-0; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; SZWEDA LI, 1993, J BIOL CHEM, V268, P3342; UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P4544, DOI 10.1073/pnas.89.10.4544; UCHIDA K, 1994, BIOCHEMISTRY-US, V33, P12487, DOI 10.1021/bi00207a016; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96	19	61	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					27999	28001		10.1074/jbc.271.45.27999	http://dx.doi.org/10.1074/jbc.271.45.27999			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910407	hybrid			2022-12-25	WOS:A1996VU03300007
J	Swope, DL; Mueller, CL; Chrivia, JC				Swope, DL; Mueller, CL; Chrivia, JC			CREB-binding protein activates transcription through multiple domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; TRANSACTIVATION DOMAIN; SOMATOSTATIN GENE; ADENOVIRUS E1A; CAMP; PHOSPHORYLATION; ELEMENT; CBP; INTERACTS; P300	CREB-binding protein (CBP) functions as a coactivator molecule for a number of transcription factors including CREB, c-Fos, c-Jun, c-Myb, and several nuclear receptors. Although binding sites for these factors within CBP have been identified, the regions of CBP responsible for transcriptional activation are unknown. In this report, we show that the N-terminal half of CBP is sufficient for activation of CREB-mediated transcription and that this region contains a strong transcriptional activation domain (TAD). Both deletion of this TAD or sequestering of factors that the TAD binds using a squelching assay were found to greatly decrease the ability of CBP to activate CREB-mediated transcription, In vivo studies by others have shown that p300/CBP associates with TBP; using an in vitro approach, we show the N-terminal TAD binds TBP. We also examined the ability of the C terminus of CBP to activate transcription using GAL-CBP chimeras, With this approach, we identified two C-terminal TADs located adjacent to the c-Fos binding site, In previous studies, cAMP-dependent protein kinase A (PKA) increased the transcriptional activity of a GAL full-length CBP chimera in F9 cells, and of the C terminus in PC-12 cells. Here, we demonstrate that PKA also increased the ability of the N-terminal TADs of CBP to activate transcription in PC-12 but not F9 or COS-7 cells, suggesting that this PKA-responsiveness is cell type-specific.	ST LOUIS UNIV,SCH MED,DEPT PHARMACOL & PHYSIOL SCI,ST LOUIS,MO 63104	Saint Louis University								ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ADLER V, 1992, J BIOL CHEM, V267, P17001; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BANNISTER AJ, 1996, ONCOGENE, V11, P2510; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINDLE P, 1995, P NATL ACAD SCI USA, V92, P10521, DOI 10.1073/pnas.92.23.10521; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HOEFFLER JP, 1988, SCIENCE, V242, P1428; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KEEGAN L, 1986, SCIENCE, V231, P669; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LUNDBLAD JR, 1995, NATURE, V374, P77; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Sambrook J., 2002, MOL CLONING LAB MANU; SAUER F, 1995, SCIENCE, V270, P1825, DOI 10.1126/science.270.5243.1825; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN PQ, 1995, J BIOL CHEM, V270, P7041, DOI 10.1074/jbc.270.13.7041; WALTON KM, 1992, MOL NEUROBIOL, V4, P197; XING LP, 1995, J BIOL CHEM, V270, P17488, DOI 10.1074/jbc.270.29.17488	46	153	156	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28138	28145		10.1074/jbc.271.45.28138	http://dx.doi.org/10.1074/jbc.271.45.28138			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910428	hybrid			2022-12-25	WOS:A1996VU03300028
J	Berman, DM; Kozasa, T; Gilman, AG				Berman, DM; Kozasa, T; Gilman, AG			The GTPase-activating protein RGS4 stabilizes the transition state for nucleotide hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FACTOR PHEROMONES; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; HUMAN GENE; G1 ARREST; SF9 CELLS; A-FACTOR; SUBUNITS; TRANSDUCIN; PHOSPHODIESTERASE	RGS proteins constitute a newly appreciated group of negative regulators of G protein Signaling. Discovered by genetic screens in yeast, worms, and other organisms, two mammalian RGS proteins, RGS4 and GAIP, act as GTPase-activating proteins for members of the G(i) family of G protein alpha subunits. We have purified recombinant RGS4 to homogeneity and demonstrate that it acts catalytically to stimulate GTP hydrolysis by G(i) proteins. Furthermore, RGS4 stabilizes the transition state for GTP hydrolysis, as evidenced by its high affinity for the GDP-AlF4--bound forms of G(o alpha) and G(i alpha) and its relatively low affinity for the GTP gamma S- and GDP-bound forms of these proteins. Consequently, RGS4 is most likely not a downstream effector for activated G(alpha) subunits. All members of the G(i) subfamily of proteins tested are substrates for RGS4 (including G(t alpha) and G(z alpha)); the protein has lower affinity for G(q alpha), and it does not stimulate the GTPase activity of G(s alpha) or G(12 alpha).	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062, R01GM034497, R37GM034497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07062, GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HONG JX, 1993, J IMMUNOL, V150, P3895; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LEE E, 1994, METHOD ENZYMOL, V237, P146; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; NEWTON JS, 1993, BIOCHIM BIOPHYS ACTA, V1216, P314, DOI 10.1016/0167-4781(93)90163-8; PAGES F, 1993, J BIOL CHEM, V268, P26358; ROSS EM, 1995, RECENT PROG HORM RES, V50, P207; Roush W, 1996, SCIENCE, V271, P1056, DOI 10.1126/science.271.5252.1056; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WEINER JL, 1993, J BIOL CHEM, V268, P8070; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207	29	293	296	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27209	27212		10.1074/jbc.271.44.27209	http://dx.doi.org/10.1074/jbc.271.44.27209			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910288	hybrid			2022-12-25	WOS:A1996VQ67900006
J	Heath, RJ; Rock, CO				Heath, RJ; Rock, CO			Roles of the FabA and FabZ beta-hydroxyacyl-acyl carrier protein dehydratases in Escherichia coli fatty acid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYDECANOYL THIOESTER DEHYDRASE; THIOL ESTER DEHYDRASE; SYNTHETASE; INVIVO	There are two genes, fabA and fabZ, encoding beta-hydroxyacyl-acyl carrier protein (ACP) dehydratases that function in the dissociated, type II fatty acid synthase system of Escherichia coli. We have investigated their roles in fatty acid synthesis by purifying the two proteins and reconstituting cycles of fatty acid synthesis in vitro using five other purified proteins. FabA and FabZ exhibited broad, overlapping chain length specificities, The FabZ dehydratase efficiently catalyzed the dehydration of short chain beta-hydroxyacyl-ACPs and long chain saturated and unsaturated beta-hydroxyacyl-ACPs. FabA was most active on intermediate chain length beta-hydroxyacyl-ACPs and also possessed significant activity toward both short and long chain saturated beta-hydroxyacyl-ACPs. Significantly, FabA was virtually inactive in the dehydration of long chain unsaturated beta-hydroxyacyl-ACP. The introduction of the double bond at the 10-carbon stage of fatty acid synthesis by FabA was only detected in the presence of beta-ketoacyl-ACP synthase I (FabB). A yeast two-hybrid analysis failed to detect an interaction between FabA and FabB, therefore the channeling of intermediates toward unsaturated fatty acid synthesis by FabB was attributed to the affinity of the condensing enzyme for cis-decenoyl-ACP. The broad substrate specificity of FabZ coupled with the inactivity of FabA toward a long chain unsaturated p hydroxyacyl-ACP provides a biochemical explanation for the phenotypes of cells with genetically altered levels of the two dehydratases.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center				Heath, Richard/0000-0002-1795-1254	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AW, 1972, J BIOL CHEM, V247, P3190; ANNAND RR, 1993, J AM CHEM SOC, V115, P1088, DOI 10.1021/ja00056a038; BIRGE CH, 1972, J BIOL CHEM, V247, P4930; BIRGE CH, 1967, BIOCHEM BIOPH RES CO, V26, P808; BLOCH K, 1971, ENZYMES, P441; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCK DJH, 1967, J BIOL CHEM, V242, P4432; CLARK DP, 1983, BIOCHEMISTRY-US, V22, P5897, DOI 10.1021/bi00294a032; CRONAN JE, 1988, J BIOL CHEM, V263, P4641; CRONAN JE, 1973, J BIOL CHEM, V248, P1188; CRONAN JE, 1969, J BACTERIOL, V100, P601, DOI 10.1128/JB.100.2.601-604.1969; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; ENDO K, 1970, J BIOL CHEM, V245, P4293; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; GUERRA DJ, 1990, ARCH BIOCHEM BIOPHYS, V280, P336, DOI 10.1016/0003-9861(90)90339-Z; Heath RJ, 1996, J BIOL CHEM, V271, P1833, DOI 10.1074/jbc.271.4.1833; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Heath RJ, 1996, J BIOL CHEM, V271, P10996, DOI 10.1074/jbc.271.18.10996; HELMKAMP GM, 1969, J BIOL CHEM, V244, P6014; HELMKAMP GM, 1968, J BIOL CHEM, V243, P3229; JACKOWSKI S, 1992, METHOD ENZYMOL, V209, P111; KASS LR, 1967, J BIOL CHEM, V242, P4418; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Miller J.H., 1972, EXPT MOL GENETICS; MOHAN S, 1994, J BIOL CHEM, V269, P32896; MORISAKI M, 1971, Bioorganic Chemistry, V1, P188, DOI 10.1016/0045-2068(71)90015-0; NUNN WD, 1983, J BACTERIOL, V154, P554, DOI 10.1128/JB.154.2.554-560.1983; OHLROGGE JB, 1982, TRENDS BIOCHEM SCI, V7, P386, DOI 10.1016/0968-0004(82)90176-1; PETTY KJ, 1994, CURRENT PROTOCOLS MO; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; RANDO RR, 1968, J BIOL CHEM, V243, P5627; RAWLINGS M, 1992, J BIOL CHEM, V267, P5751; ROCK CO, 1979, J BIOL CHEM, V254, P7123; ROCK CO, 1982, J BIOL CHEM, V257, P10759; ROSENFELD IS, 1973, J BIOL CHEM, V248, P2452; SCHWAB JM, 1985, ANAL BIOCHEM, V150, P121, DOI 10.1016/0003-2697(85)90449-X; SCHWAB JM, 1986, J AM CHEM SOC, V108, P5304, DOI 10.1021/ja00277a040; SCHWAB JM, 1984, J AM CHEM SOC, V106, P7217, DOI 10.1021/ja00335a060; SHARMA A, 1990, J BIOL CHEM, V265, P5110; SILBERT DF, 1967, P NATL ACAD SCI USA, V58, P1579, DOI 10.1073/pnas.58.4.1579; TOOMEY RE, 1966, BIOCHIM BIOPHYS ACTA, V116, P189, DOI 10.1016/0005-2760(66)90001-4; VALLARI DS, 1987, J BIOL CHEM, V262, P2468	45	196	231	5	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27795	27801		10.1074/jbc.271.44.27795	http://dx.doi.org/10.1074/jbc.271.44.27795			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910376	hybrid			2022-12-25	WOS:A1996VQ67900094
J	McHugh, TE; Atkins, WM; Racha, JK; Kunze, KL; Eaton, DL				McHugh, TE; Atkins, WM; Racha, JK; Kunze, KL; Eaton, DL			Binding of the aflatoxin-glutathione conjugate to mouse glutathione S-transferase A3-3 is saturated at only one ligand per dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; HEPATIC GLUTATHIONE; COMPLEX; RAT; RESOLUTION; PRODUCT; MECHANISM; SUBUNITS; SITE; DNA	The binding of two different reaction products (p-nitrobenzyl glutathione and the aflatoxin-glutathione conjugate) to mouse glutathione S-transferase A3-3 (mGSTA3-3) has been measured using equilibrium dialysis and a direct fluorescence quenching technique, As expected, p-nitrobenzyl glutathione was found to bind with a stoichiometry of 2.24 +/- 0.17 mol/mol of dimeric enzyme. However, the much larger aflatoxin-glutathione conjugate, 8,9-dihydro-S-(S-glutathionyl)-9-hydroxyl-aflatoxin B-1 (AFB-GSH), was found to bind with a stoichiometry of 1.12 +/- 0.08 mol/mol of dimeric enzyme. p-Nitrobenzyl glutathione bound mGSTA3-3 with a dissociation constant (K-d) of 59 +/- 17 mu M while the aflatoxin-glutathione conjugate bound the enzyme with a K-d of 0.86 +/- 0.19 mu M. Glutathione competitively inhibited binding of AFB-GSH to mGSTA3-3 with a K-i of 1.5 mM, suggesting that AFB-GSH was binding to the enzyme active site. Although AFB-GSH bound to mGSTA3-3 with a stoichiometry of 1 mol/mol of dimeric enzyme, AFB-GSH completely inhibited activity toward 1-chloro-2,4-dinitrobenzene, indicating that AFB-GSH binding to one active site alters affinity for 1-chloro-2,4-dinitrobenzene ill the active site of the other subunit. To our knowledge, this is the first report of a glutathione S-transferase reaction product which binds to the enzyme with a stoichiometry of 1 mol/mol of dimer.	UNIV WASHINGTON,CTR ECOGENET & ENVIRONM HLTH,SCH PUBL HLTH & COMMUNITY MED,SEATTLE,WA 98105; UNIV WASHINGTON,DEPT ENVIRONM HLTH,SCH PUBL HLTH & COMMUNITY MED,SEATTLE,WA 98105; UNIV WASHINGTON,SCH PHARM,DEPT MED CHEM,SEATTLE,WA 98105	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Eaton, David/AAO-1832-2020		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033, R01ES005780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048750] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES-05780, P30 ES-07033] Funding Source: Medline; NIGMS NIH HHS [GM 48750] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENSON AM, 1978, CANCER RES, V38, P4486; BUETLER TM, 1992, CANCER RES, V52, P314; BUETLER TM, 1992, BIOCHEM BIOPH RES CO, V188, P597, DOI 10.1016/0006-291X(92)91098-B; CAMERON AD, 1995, STRUCTURE, V3, P717, DOI 10.1016/S0969-2126(01)00206-4; DANIELSON UH, 1985, BIOCHEM J, V231, P263, DOI 10.1042/bj2310263; EATON DL, 1994, ANNU REV PHARMACOL, V34, P135, DOI 10.1146/annurev.pa.34.040194.001031; GARCIASAEZ I, 1994, J MOL BIOL, V237, P298, DOI 10.1006/jmbi.1994.1232; Habig W H, 1981, Methods Enzymol, V77, P398; Hall A. J., 1994, TOXICOLOGY AFLATOXIN, P233; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HAYES JD, 1981, BIOCHEM J, V197, P491, DOI 10.1042/bj1970491; IVANETICH KM, 1990, BIOCHEM PHARMACOL, V39, P1999, DOI 10.1016/0006-2952(90)90621-Q; JAKOBSON I, 1979, J BIOL CHEM, V254, P7085; JI XH, 1994, BIOCHEMISTRY-US, V33, P1043, DOI 10.1021/bi00171a002; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KITAHARA A, 1981, BIOCHEM BIOPH RES CO, V103, P943, DOI 10.1016/0006-291X(81)90901-3; KLOTZ IM, 1990, PROTEIN FUNCTION PRA, P25; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P342; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MCTIGUE MA, 1995, J MOL BIOL, V246, P21, DOI 10.1006/jmbi.1994.0061; MONROE DH, 1988, TOXICOL APPL PHARM, V94, P118, DOI 10.1016/0041-008X(88)90342-0; MOSS EJ, 1983, BIOCHEM J, V210, P227, DOI 10.1042/bj2100227; RANEY KD, 1992, CHEM RES TOXICOL, V5, P333, DOI 10.1021/tx00027a002; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHRAMM VL, 1984, J BIOL CHEM, V259, P714; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; VANDERJAGT DL, 1982, J BIOL CHEM, V257, P1997; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x	30	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27470	27474		10.1074/jbc.271.44.27470	http://dx.doi.org/10.1074/jbc.271.44.27470			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910329	hybrid			2022-12-25	WOS:A1996VQ67900047
J	Ohyama, T				Ohyama, T			Bent DNA in the human adenovirus type 2 E1A enhancer is an architectural element for transcription stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PROMOTER; CURVED DNA; INVITRO TRANSCRIPTION; UPSTREAM ACTIVATION; INTRINSIC CURVATURE; BACILLUS-SUBTILIS; SEQUENCES; BINDING; REGIONS; INITIATION	The upstream half of the human adenovirus type 2 enhancer adopts a curved DNA structure. Most of the enhancer elements are within the curvature, suggesting that this unusual structure is linked to enhancer function. To verify this experimentally, I constructed in vitro transcription assay systems which could distinguish any effects generated by conformational changes in a DNA template, The curved DNA conformation in the enhancer clearly affected the extent of the stimulation of the E1A gene transcription: assays using the wildtype DNA template showed that the moderately curved enhancer was superior to the highly curved enhancer in transcriptional stimulation. In additional experiments, the enhancer region was substituted with a curved DNA derived from the bacteriophage lambda origin of replication, Assays using this mutant revealed that this curved segment could also act as an enhancer when it had the proper conformation. Consequently, DNA conformation may play a general role in transcriptional stimulation.	MEIJI INST HLTH SCI,DIV MOL BIOL,ODAWARA 250,JAPAN; RES INST INNOVAT TECHNOL EARTH,ODAWARA 250,JAPAN	Research Institute of Innovative Technology for the Earth								AUGEREAU P, 1986, EMBO J, V5, P1791, DOI 10.1002/j.1460-2075.1986.tb04428.x; BOSSI L, 1984, CELL, V39, P643, DOI 10.1016/0092-8674(84)90471-9; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; CALLADINE CR, 1988, J MOL BIOL, V201, P127, DOI 10.1016/0022-2836(88)90444-5; COLLIS CM, 1989, NUCLEIC ACIDS RES, V17, P9447, DOI 10.1093/nar/17.22.9447; DIEKMANN S, 1987, NUCLEIC ACIDS RES, V15, P247, DOI 10.1093/nar/15.1.247; ESPINOSAURGEL M, 1993, NUCLEIC ACIDS RES, V21, P3667; GARTENBERG MR, 1991, J MOL BIOL, V219, P217, DOI 10.1016/0022-2836(91)90563-L; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; HEARING P, 1986, CELL, V45, P229, DOI 10.1016/0092-8674(86)90387-9; HIROTA Y, 1995, J MOL BIOL, V254, P566, DOI 10.1006/jmbi.1995.0639; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; INOKUCHI K, 1988, NUCLEIC ACIDS RES, V16, P6693, DOI 10.1093/nar/16.14.6693; KAWAMOTO T, 1989, NUCLEIC ACIDS RES, V17, P523, DOI 10.1093/nar/17.2.523; KIM J, 1995, J BIOL CHEM, V270, P1282, DOI 10.1074/jbc.270.3.1282; LAVIGNE M, 1992, J MOL BIOL, V224, P293, DOI 10.1016/0022-2836(92)90995-V; LOZINSKI T, 1991, NUCLEIC ACIDS RES, V19, P2947, DOI 10.1093/nar/19.11.2947; MCALLISTER CF, 1988, J BIOL CHEM, V263, P11743; MCALLISTER CF, 1989, J BIOL CHEM, V264, P10451; MIZUNO T, 1987, GENE, V54, P57, DOI 10.1016/0378-1119(87)90347-7; OHYAMA T, 1992, NUCLEIC ACIDS RES, V20, P1617, DOI 10.1093/nar/20.7.1617; OHYAMA T, 1989, NUCLEIC ACIDS RES, V17, P3845, DOI 10.1093/nar/17.10.3845; PLASKON RR, 1987, NUCLEIC ACIDS RES, V15, P785, DOI 10.1093/nar/15.2.785; RAMSTEIN J, 1988, P NATL ACAD SCI USA, V85, P7231, DOI 10.1073/pnas.85.19.7231; Sambrook J., 2002, MOL CLONING LAB MANU; SASSONECORSI P, 1984, P NATL ACAD SCI-BIOL, V81, P308, DOI 10.1073/pnas.81.2.308; SCHOLER HR, 1985, EMBO J, V4, P3005, DOI 10.1002/j.1460-2075.1985.tb04036.x; SCHROTH GP, 1992, J BIOL CHEM, V267, P9958; TRAVERS A, 1989, NATURE, V341, P184, DOI 10.1038/341184a0; WILDEMAN AG, 1984, EMBO J, V3, P3129, DOI 10.1002/j.1460-2075.1984.tb02269.x; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZAHN K, 1985, NATURE, V317, P451, DOI 10.1038/317451a0	32	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27823	27828						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910380				2022-12-25	WOS:A1996VQ67900098
J	Wang, WH; Duan, JX; Vu, TH; Hoffman, AR				Wang, WH; Duan, JX; Vu, TH; Hoffman, AR			Increased expression of the insulin-like growth factor-II gene in Wilms' tumor is not dependent on loss of genomic imprinting or loss of heterozygosity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN H19 GENE; HUMAN EMBRYOGENESIS; IGF2; CANCER; LOCUS; CHROMOSOME-11; RELAXATION; SUSCEPTIBILITY; METHYLATION; ACTIVATION	Loss of imprinting of insulin-like growth factor-II gene (IGF2) and/or loss of heterozygosity at the 11p15 loci have been postulated to be responsible for IGF2 overexpression in Wilms' tumor. In order to delineate the mechanism of IGF2 overexpression in Wilms' tumors, we have genotyped the 11p15-11p13 chromosomal region and determined allelic expression of IGF2 and H19 in both tumor tissue and in normal adjacent kidney tissue from 40 patients with Wilms' tumor. In five of the eight subjects informative for the ApaI IGF2 polymorphism, loss of imprinting of IGF2 was observed in both normal and tumor tissues. A significant increase (>5-fold) in IGF2 expression in tumor tissues compared to the normal adjacent kidney tissue was observed regardless of the IGF2 imprinting or the chromosome 11p15 heterozygosity status. In each case, the overexpression of IGF2 in the tumors was accompanied by activation of all four IGF2 promoters. Our data indicate that alterations of IGF2 imprinting occurred in normal adjacent kidney tissue before tumorigenesis and that the IGF2 overexpression in Wilms' tumor tissue occurs through a loss of heterozygosity- or loss of imprinting-independent process.	VET AFFAIRS MED CTR,MED SERV 111,PALO ALTO,CA 94304; VET AFFAIRS MED CTR,GRECC,PALO ALTO,CA 94304; STANFORD UNIV,SCH MED,DEPT MED,PALO ALTO,CA 94304	US Department of Veterans Affairs; Veterans Health Administration (VHA); Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036054] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36054] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL GI, 1980, NATURE, V284, P26, DOI 10.1038/284026a0; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; COPPES MJ, 1992, GENE CHROMOSOME CANC, V5, P326, DOI 10.1002/gcc.2870050408; CULLEN KJ, 1992, MOL ENDOCRINOL, V6, P91, DOI 10.1210/me.6.1.91; DAUGHADAY WH, 1990, ENDOCRINOLOGY, V127, P1; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; GOSHEN R, 1993, MOL REPROD DEV, V34, P374, DOI 10.1002/mrd.1080340405; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HEARNE CM, 1992, TRENDS GENET, V8, P288, DOI 10.1016/0168-9525(92)90256-4; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; HOBAN PR, 1990, NUCLEIC ACIDS RES, V19, P1164; HU JF, 1995, MOL ENDOCRINOL, V9, P628, DOI 10.1210/me.9.5.628; Hu JF, 1996, J BIOL CHEM, V271, P18253, DOI 10.1074/jbc.271.30.18253; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; JUNIEN C, 1994, KIDNEY INT, V46, P1264, DOI 10.1038/ki.1994.394; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; LITTLE MH, 1991, NATURE, V7, P635; LUCASSEN AM, 1993, NAT GENET, V4, P305, DOI 10.1038/ng0793-305; MANNENS M, 1990, CANCER RES, V50, P3279; Morison IM, 1996, NAT MED, V2, P311, DOI 10.1038/nm0396-311; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1994, DEVELOPMENT, V120, P361; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; PritchardJones K, 1995, EUR J CANCER, V31A, P2138, DOI 10.1016/0959-8049(95)00558-7; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7280; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SUSSENBACH JS, 1992, GROWTH REGULAT, V2, P1; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; TANIGUCHI T, 1995, ONCOGENE, V11, P751; TYCKO B, 1994, AM J PATHOL, V144, P431; VANGURP RJHLM, 1994, JNCI-J NATL CANCER I, V86, P1070, DOI 10.1093/jnci/86.14.1070; VU TH, 1995, J CLIN ENDOCR METAB, V80, P1670, DOI 10.1210/jc.80.5.1670; Vu TH, 1996, J BIOL CHEM, V271, P9014, DOI 10.1074/jbc.271.15.9014; Weksberg R, 1996, NAT GENET, V12, P225, DOI 10.1038/ng0396-225; Yballe CM, 1996, J CLIN ENDOCR METAB, V81, P1607, DOI 10.1210/jc.81.4.1607; ZHAN SL, 1995, J BIOL CHEM, V270, P27983; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344; Zhang LJ, 1996, CANCER RES, V56, P1367; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	51	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27863	27870		10.1074/jbc.271.44.27863	http://dx.doi.org/10.1074/jbc.271.44.27863			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910385	hybrid			2022-12-25	WOS:A1996VQ67900103
J	Xiang, BS; Markham, GD				Xiang, BS; Markham, GD			The conformation of inosine 5'-monophosphate (IMP) bound to IMP dehydrogenase determined by transferred nuclear Overhauser effect spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE CONFORMATIONS; MYCOPHENOLIC-ACID; KINASE COMPLEXES; ACTIVE-SITE; INHIBITOR; PURIFICATION; ENHANCEMENT; TIAZOFURIN; SYNTHETASE; MECHANISM	IMP dehydrogenase (IMPDH) catalyzes the NAD-dependent synthesis of xanthosine 5'-monophosphate which is the rate-limiting step in guanine nucleotide biosynthesis. Although IMPDH is the target of numerous chemotherapeutic agents, nothing has been known about the conformation of the enzyme-bound substrates. The conformation of IMP bound to human type II IMP dehydrogenase has been determined by two-dimensional transferred nuclear Overhauser effect NMR spectroscopy at 600 MHz. NOE buildup rates were determined by recording NOESY spectra at numerous mixing times. The cross-relaxation rates determined from the initial NOE build-up rates were used to calculate interproton distances of bound IMP. The conformation of the enzyme-bound IMP was obtained by molecular modeling with energy minimization using the experimentally determined inter-proton distance constraints. The glycosidic torsion angle of the bound nucleotide is anti and the sugar is in the C-2-endo-conformation. This conformation places H-2 of IMP, which is transferred to NAD in the reaction, in a position clear of the rest of the molecule in order to facilitate the reaction.	FOX CHASE CANC CTR, CANC RES INST, PHILADELPHIA, PA 19111 USA	Fox Chase Cancer Center					NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927] Funding Source: Medline; NIGMS NIH HHS [GM-51481] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTONA C, 1972, J AM CHEM SOC, V94, P8205, DOI 10.1021/ja00778a043; ANTONINO LC, 1994, BIOCHEMISTRY-US, V33, P1760, DOI 10.1021/bi00173a019; ANTONINO LC, 1994, BIOCHEMISTRY-US, V33, P1753, DOI 10.1021/bi00173a018; BALZARINI J, 1993, J BIOL CHEM, V268, P24591; BUNDLE DR, 1994, BIOCHEMISTRY-US, V33, P5183, DOI 10.1021/bi00183a023; CAMPBELL AP, 1993, ANNU REV BIOPH BIOM, V22, P99, DOI 10.1146/annurev.bb.22.060193.000531; CARR SF, 1993, J BIOL CHEM, V268, P27286; CLORE GM, 1983, J MAGN RESON, V53, P423, DOI 10.1016/0022-2364(83)90215-9; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; EHRLICH RS, 1990, BIOCHEMISTRY-US, V29, P5179, DOI 10.1021/bi00473a026; FRANCHETTI P, 1995, J MED CHEM, V38, P3829, DOI 10.1021/jm00019a013; GHAREHBAGHI K, 1994, INT J CANCER, V56, P892, DOI 10.1002/ijc.2910560623; HEDSTROM L, 1990, BIOCHEMISTRY-US, V29, P849, DOI 10.1021/bi00456a001; HUPE DJ, 1986, J BIOL CHEM, V261, P8363; JACKSON RC, 1977, BIOCHEM J, V166, P1; JACKSON RC, 1975, NATURE, V256, P331, DOI 10.1038/256331a0; JARORI GK, 1995, EUR J BIOCHEM, V230, P517; JARORI GK, 1994, BIOCHEMISTRY-US, V33, P6784, DOI 10.1021/bi00188a006; KOBLAN KS, 1995, PROTEIN SCI, V4, P681; LANGMAN LJ, 1995, CLIN CHEM, V41, P295; Link JO, 1996, J AM CHEM SOC, V118, P2091, DOI 10.1021/ja9534056; MAGASANIK B, 1957, J BIOL CHEM, V226, P339; MATSUNAGA TO, 1993, BIOCHEMISTRY-US, V32, P13180, DOI 10.1021/bi00211a029; MURALI N, 1993, BIOCHEMISTRY-US, V32, P12941, DOI 10.1021/bi00210a049; MURALI N, 1994, BIOCHEMISTRY-US, V33, P14227, DOI 10.1021/bi00251a035; NI F, 1994, PROG NUCL MAG RES SP, V26, P517, DOI 10.1016/0079-6565(94)90000-0; OKADA A, 1994, BIOCHEMISTRY-US, V33, P9438, DOI 10.1021/bi00198a009; OTTING G, 1986, J MAGN RESON, V66, P187, DOI 10.1016/0022-2364(86)90122-8; PERLMAN ME, 1994, BIOCHEMISTRY-US, V33, P7547, DOI 10.1021/bi00190a007; PLESNIAK LA, 1995, BIOCHEMISTRY-US, V34, P4943, DOI 10.1021/bi00015a005; ROSEVEAR PR, 1989, METHOD ENZYMOL, V177, P333; ROSEVEAR PR, 1983, BIOCHEMISTRY-US, V22, P3439, DOI 10.1021/bi00283a021; Saenger W., 1984, PRINCIPLES NUCLEIC A, P9; SEELIG GF, 1995, J BIOL CHEM, V270, P9241, DOI 10.1074/jbc.270.16.9241; Sintchak MD, 1996, CELL, V85, P921, DOI 10.1016/S0092-8674(00)81275-1; SONG S, 1994, BIOCHEMISTRY-US, V33, P693, DOI 10.1021/bi00169a010; STEWART JMM, 1989, BIOCHEMISTRY-US, V28, P4695, DOI 10.1021/bi00437a028; STREETER DG, 1973, P NATL ACAD SCI USA, V70, P1174, DOI 10.1073/pnas.70.4.1174; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; VERHAM R, 1987, MOL BIOCHEM PARASIT, V24, P1, DOI 10.1016/0166-6851(87)90110-1; Wang W, 1996, BIOCHEMISTRY-US, V35, P95, DOI 10.1021/bi951499q; WANG ZL, 1993, BIOCHEMISTRY-US, V32, P13991, DOI 10.1021/bi00213a032; Whitby FG, 1995, PROTEINS, V23, P598, DOI 10.1002/prot.340230417; WU JC, 1995, FASEB J, V9, pA1337; Xiang BS, 1996, J BIOL CHEM, V271, P1435, DOI 10.1074/jbc.271.3.1435; YAMADA Y, 1988, BIOCHEMISTRY-US, V27, P2193, DOI 10.1021/bi00406a057; 1983, EUR J BIOCHEM, V131, P9	47	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27531	27535		10.1074/jbc.271.44.27531	http://dx.doi.org/10.1074/jbc.271.44.27531			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910338	hybrid			2022-12-25	WOS:A1996VQ67900056
J	Eissa, NT; Strauss, AJ; Haggerty, CM; Choo, EK; Chu, SC; Moss, J				Eissa, NT; Strauss, AJ; Haggerty, CM; Choo, EK; Chu, SC; Moss, J			Alternative splicing of human inducible nitric-oxide synthase mRNA - Tissue-specific regulation and induction by cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL DIVERSITY; MOLECULAR-CLONING; MESSENGER-RNA; GENE; EXPRESSION; CALMODULIN; BINDING; TETRAHYDROBIOPTERIN; MACROPHAGES; EPITHELIUM	Human inducible nitric-oxide synthase (iNOS) is responsible for nitric oxide synthesis in response to inflammatory mediators. The human iNOS gene, containing 26 exons, encodes a protein of 131 kDa. This study was aimed at investigating the presence of alternative splicing of human iNOS mRNA. Total RNA from human alveolar macrophages, nasal and bronchial epithelial cells, and several human tissues was transcribed to cDNA and analyzed using polymerase chain reaction with specific primers for segmental analysis of the iNOS gene, Four sites of alternative splicing were identified by sequence analysis; these included deletion of: (i) exon 5; (ii) exons 8 and 9; (iii) exons 9, 10, and 11; and (iv) exons 15 and 16. The deduced amino acid sequences of the novel iNOS cDNAs predict one truncated protein (resulting from exon 5 deletion) and three iNOS proteins with in-frame deletions, Southern analyses of polymerase chain reaction products were consistent with tissue-specific regulation of alternative splicing, In cultured cells, iNOS induction by cytokines and lipopolysaccharide was associated with an increase in alternatively spliced mRNA transcripts, Because iNOS is active as a dimer, the novel forms of alternatively spliced iNOS may be involved in regulation of nitric oxide synthesis.			Eissa, NT (corresponding author), NHLBI,NIH,PULM CRIT CARE MED BRANCH,10 CTR DR,MSC 1590,RM 6D03,BLDG 10,BETHESDA,MD 20892, USA.			Haggerty, Cynthia/0000-0002-6019-2724; Choo, Esther/0000-0001-8847-5745				ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CHO HJ, 1995, P NATL ACAD SCI USA, V92, P11514, DOI 10.1073/pnas.92.25.11514; CHU SC, 1995, J BIOL CHEM, V270, P10625, DOI 10.1074/jbc.270.18.10625; EISSA NT, 1994, HUM GENE THER, V5, P1105, DOI 10.1089/hum.1994.5.9-1105; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; GUO FH, 1995, P NATL ACAD SCI USA, V92, P7809, DOI 10.1073/pnas.92.17.7809; HALL AV, 1994, J BIOL CHEM, V269, P33082; LEE CM, 1995, J BIOL CHEM, V270, P27403, DOI 10.1074/jbc.270.46.27403; MEDFORD RM, 1984, CELL, V38, P409, DOI 10.1016/0092-8674(84)90496-3; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; OGURA T, 1993, BIOCHEM BIOPH RES CO, V193, P1014, DOI 10.1006/bbrc.1993.1726; REGULSKI M, 1995, P NATL ACAD SCI USA, V92, P9072, DOI 10.1073/pnas.92.20.9072; SALTINI C, 1984, AM REV RESPIR DIS, V130, P650; Skerjanc IS, 1996, J BIOL CHEM, V271, P3555, DOI 10.1074/jbc.271.7.3555; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; XIE QW, 1994, J BIOL CHEM, V269, P28500; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	23	91	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27184	27187		10.1074/jbc.271.43.27184	http://dx.doi.org/10.1074/jbc.271.43.27184			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900212	hybrid			2022-12-25	WOS:A1996VP23300106
J	Li, YK; Davis, KL; Sytkowski, AJ				Li, YK; Davis, KL; Sytkowski, AJ			Protein kinase C-epsilon is necessary for erythropoietin's up-regulation of c-myc and for factor-dependent DNA synthesis - Evidence for discrete signals for growth and differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE ERYTHROLEUKEMIA-CELLS; ERYTHROID-DIFFERENTIATION; PHOSPHATIDYLINOSITOL 3-KINASE; MESSENGER-RNA; EXPRESSION; RECEPTOR; ACTIVATION; PHOSPHORYLATION; ASSOCIATION; RAUSCHER	Erythropoietin regulates the transcription of the protooncogenes c-myc and c-myb by discrete protein kinase C (PKC)-dependent and protein serine/threonine phosphatase-dependent pathways, respectively (Spangler, R., Bailey, S. C., and Sytkowski, A. J. (1991) J. Biol. Chem. 266, 681-684; Patel H. R. Choi H.-S, and Sytkowski A. J. (1992) J. Biol. Chem. 267, 21300-21302), In the present study we demonstrate that up-regulation of c-myc requires the PKC-epsilon isoform and that this pathway is required for erythropoietin-induced DNA synthesis (growth) but apparently not for beta-globin expression (differentiation), Treatment of Rauscher murine erythroleukemia cells resulted in phosphorylation of phospholipase C-gamma 1 and activation of PKC-epsilon as evidenced by its translocation from soluble to particulate subcellular fractions, Artificial down-regulation of PKC-epsilon with anti-sense oligodeoxynucleotides blocked erythropoietin's up-regulation of c-myc in a concentration-dependent manner, In contrast, antisense oligodeoxynucleotides to PKC-alpha, -beta, -gamma, -delta, and -zeta had no effect, Although down-regulation of PKC-epsilon blocked the increase in c-myc expression, it did not inhibit erythropoietin induction of beta-globin expression, a marker of erythroid differentiation, However, down-regulation of PKC-epsilon did block factor-dependent DNA synthesis quantified by measurement of [H-3]thymidine incorporation into newly synthesized DNA of normal murine erythroid cells, The results are consistent with discrete intracellular signals regulating erythroid cell growth and differentiation.	HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT MED,DIV HEMATOL & ONCOL,BOSTON,MA 02215	Harvard University; Harvard Medical School					NIDDK NIH HHS [1 F32 DK09118, DK38841] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009118, R01DK038841] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY SC, 1991, J BIOL CHEM, V266, P24121; BECKMAN BS, 1992, EXP HEMATOL, V20, P324; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CHALLBERG MD, 1979, P NATL ACAD SCI USA, V76, P655, DOI 10.1073/pnas.76.2.655; CHERN Y, 1991, BLOOD, V78, P1; CHERN YJ, 1991, J BIOL CHEM, V266, P2009; CHOI HS, 1987, J BIOL CHEM, V262, P2933; CHOI HS, 1990, J BIOL CHEM, V265, P4143; CLARK KJ, 1995, J BIOL CHEM, V270, P7097, DOI 10.1074/jbc.270.13.7097; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DAMEN JE, 1993, BLOOD, V81, P3204; DANDREA A, 1990, NATURE, V343, P762; de Both N J, 1978, Nature, V272, P626, DOI 10.1038/272626a0; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KRYSTAL G, 1983, EXP HEMATOL, V11, P649; KRYSTAL G, 1994, J EXP MED, V180, P851, DOI 10.1084/jem.180.3.851; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LENG L, 1993, CANCER RES, V53, P5554; MAY WS, 1994, J BIOL CHEM, V269, P26865; MAYEUX P, 1993, EUR J BIOCHEM, V216, P821, DOI 10.1111/j.1432-1033.1993.tb18203.x; MELLONI E, 1990, P NATL ACAD SCI USA, V87, P4417, DOI 10.1073/pnas.87.12.4417; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MIURA O, 1994, J BIOL CHEM, V269, P614; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PATEL HR, 1992, J BIOL CHEM, V267, P21300; POWELL CT, 1992, P NATL ACAD SCI USA, V89, P147, DOI 10.1073/pnas.89.1.147; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; REN HY, 1994, J BIOL CHEM, V269, P19633; Sambrook J., 2002, MOL CLONING LAB MANU; SPANGLER R, 1991, J BIOL CHEM, V266, P681; SPANGLER R, 1992, BLOOD, V79, P52; SPIVAK JL, 1991, BLOOD, V77, P1228; SYTKOWSKI AJ, 1980, SCIENCE, V210, P74, DOI 10.1126/science.6932101; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	41	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27025	27030		10.1074/jbc.271.43.27025	http://dx.doi.org/10.1074/jbc.271.43.27025			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900191	hybrid			2022-12-25	WOS:A1996VP23300085
J	Tsygankov, AY; Mahajan, S; Fincke, JE; Bolen, JB				Tsygankov, AY; Mahajan, S; Fincke, JE; Bolen, JB			Specific association of tyrosine-phosphorylated c-Cbl with Fyn tyrosine kinase in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; SRC FAMILY; SH3 DOMAIN; PROTEIN-KINASES; IN-VIVO; PROTOONCOGENE PRODUCT; CROSS-LINKING; JURKAT CELLS; V-CBL	Fyn is a Src family protein tyrosine kinase functionally associated with the T-cell antigen receptor (TcR)/CD3 receptor complex. We have demonstrated earlier that the TcR/CD3-induced activation of Fyn results in tyrosine phosphorylation of several Fyn-associated proteins, including a protein of 116 kDa. In this resort, we identify the Fyn-associated 116-kDa phosphoprotein (p116) as c-Cbl. The identity of p116 has been demonstrated by its specific reactivity with anti-Cbl and similarity of phosphopeptides generated by V8 proteolysis of phospho-Cbl and p116. We demonstrate here that the association of Fyn and c-Cbl is direct and does not require the presence of other proteins. We also demonstrate that Fyn is the Src family kinase that preferentially inter acts with c-Cbl in T cells. The fraction of c-Cbl capable of coprecipitating with Fyn is increased by TcR/CD3 ligation. This increase is likely due to the involvement of Fyn SH2 in the interactions between Fyn and tyrosine-phosphorylated c-Cbl.	UNIV MINNESOTA,SCH MED,BIOTHERAPY PROGRAM,ROSEVILLE,MN 55113; DNAX RES INST MOL & CELLULAR BIOL INC,PALO ALTO,CA 94304	University of Minnesota System; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Tsygankov, AY (corresponding author), TEMPLE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,KRESGE BLDG,RM 506,3400 BROAD ST,PHILADELPHIA,PA 19140, USA.		Tsygankov, Alexander Y/K-6205-2017					ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DASILVA AJ, 1992, MOL IMMUNOL, V29, P1417, DOI 10.1016/0161-5890(92)90215-J; DASILVA AJ, 1993, J EXP MED, V178, P2107, DOI 10.1084/jem.178.6.2107; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DESEAU V, 1987, J CELL BIOCHEM, V35, P113, DOI 10.1002/jcb.240350205; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; Fusaki N, 1996, J IMMUNOL, V156, P1369; GASSMANN M, 1992, EUR J IMMUNOL, V22, P283, DOI 10.1002/eji.1830220142; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; Ribon V, 1996, MOL CELL BIOL, V16, P45; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TSYGANKOV AY, 1994, J LEUKOCYTE BIOL, V55, P289, DOI 10.1002/jlb.55.3.289; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; TSYGANKOV AY, 1992, CELL IMMUNOL, V140, P97, DOI 10.1016/0008-8749(92)90179-S; TSYGANKOV AY, 1993, STEM CELLS, V11, P371, DOI 10.1002/stem.5530110504; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEIL R, 1995, J BIOL CHEM, V270, P2791, DOI 10.1074/jbc.270.6.2791	45	69	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27130	27137		10.1074/jbc.271.43.27130	http://dx.doi.org/10.1074/jbc.271.43.27130			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900205	hybrid			2022-12-25	WOS:A1996VP23300099
J	Wang, XD; Russell, RM; Liu, C; Stickel, F; Smith, DE; Krinsky, NI				Wang, XD; Russell, RM; Liu, C; Stickel, F; Smith, DE; Krinsky, NI			beta-oxidation in rabbit liver in vitro and in the perfused ferret liver contributes to retinoic acid biosynthesis from beta-apacarotenoic acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-MERCAPTOPROPIONIC ACID; ENZYMATIC CONVERSION; 9-CIS-RETINOIC ACID; INTESTINAL-MUCOSA; VITAMIN-A; RAT-LIVER; CAROTENE; METABOLISM; ABSORPTION; 9-CIS-BETA-CAROTENE	The biosynthesis of retinoic acid from beta-apocarotenoic acids was examined for a beta-oxidation-like process using both rabbit liver mitochondrial fractions with various beta-apocarotenoic acids (beta-apo-14'-, beta-apo-12'-, and beta-apo-8'-carotenoic acid) and perfusion in ferret liver through the portal vein with beta-apo-8'-carotenoic acid. The in vitro incubation of beta-apo-8', beta-apo-12'-, and beta-apo-14'-carotenoic acids gave rise Co shorter chain beta-apocarotenoic acids as well as retinoic acid, The rate of retinoic acid synthesis from 10 mu M beta-apo-8', beta-apo-12'-, and beta-apo-14'-carotenoic acids was 11 +/- 2, IS +/- 3, and 30 +/- 7 pmol/h/mg of protein, respectively, The stepwise oxidation of beta-apocarotenoic acid in mitochondria was dose-related to both protein concentration and substrate concentration beta-Apocarotenoic acid oxidation was inhibited in a dose dependent manlier when it was co-incubated with oleoyl CoA. The in vivo perfusion of ferret liver with beta-apo-8'-carotenoic acid resulted in a linear increase in the retinoic acid concentration of bile, which was completely abolished by co-perfusion of 3-mercaptopropionic acid, an inhibitor of long chain acyl-CoA dehydrogenase, and partially inhibited by 2-tetradecylglycidic acid, an inhibitor of carnitine-palmitoyl-CoA transferase I. However, the formation of retinoic acid from the beta-apocarotenoic acids was not inhibited, either in vitro or in vivo, by citral, an inhibitor of retinal oxidase. Thus, the formation of retinoic acid was not occurring by the central cleavage pathway. These data suggest that the oxidation of intermediate compounds between beta-carotene and retinoic acid may undergo a type of beta-oxidative process to form retinoic acid, which is reminiscent of mitochondrial fatty acid beta-oxidation. This pathway may play an important role in the biosynthesis of retinoic acid from beta-carotene.	TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA	Tufts University	Wang, XD (corresponding author), TUFTS UNIV, USDA, HUMAN NUTR RES CTR AGING, GASTROINTESTINAL NUTR LAB, 711 WASHINGTON ST, BOSTON, MA 02111 USA.				NATIONAL CANCER INSTITUTE [R01CA049195] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA49195-04A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baginski ES, 1974, METH ENZYMOL; BARUA AB, 1990, METHOD ENZYMOL, V189, P136; BARUA AB, 1969, BIOCHEM J, V113, P447, DOI 10.1042/bj1130447; CONNOR MJ, 1987, BIOCHEM J, V244, P489, DOI 10.1042/bj2440489; CRAIN FD, 1967, J LIPID RES, V8, P249; DMITROVSKI AA, 1991, NEW TRENDS BIOL CHEM, P297; FALES HM, 1973, ANAL CHEM, V45, P2302, DOI 10.1021/ac60335a020; FOX JG, 1992, BIOL DIS FERRET, P1; FRITZ IB, 1967, PERSPECT BIOL MED, V10, P643; Ganguly J., 1985, World Review of Nutrition and Dietetics, V45, P198; GLOVER J, 1960, VITAM HORM, V18, P371; GOODMAN DS, 1965, SCIENCE, V149, P879, DOI 10.1126/science.149.3686.879; HEBUTERNE X, 1995, J LIPID RES, V36, P1264; Hebuterne X, 1996, J LIPID RES, V37, P482; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KIORPES TC, 1984, J BIOL CHEM, V259, P9750; LAKSHMAN MR, 1989, P NATL ACAD SCI USA, V86, P9124, DOI 10.1073/pnas.86.23.9124; LAKSHMAN.MR, 1972, J LIPID RES, V13, P477; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; NAPOLI JL, 1988, J BIOL CHEM, V263, P17372; OLSON JA, 1965, P NATL ACAD SCI USA, V54, P1364, DOI 10.1073/pnas.54.5.1364; OLSON JA, 1969, AM J CLIN NUTR, V22, P953; PETKOVICH M, 1992, ANNU REV NUTR, V12, P443, DOI 10.1146/annurev.nu.12.070192.002303; SABBAGH E, 1985, J BIOL CHEM, V260, P7337; SHARMA RV, 1976, BIOCHEM J, V158, P377, DOI 10.1042/bj1580377; SHARMA RV, 1977, BIOCHIM BIOPHYS ACTA, V486, P183, DOI 10.1016/0005-2760(77)90083-2; SILVA DP, 1982, BIOCHEM J, V206, P33, DOI 10.1042/bj2060033; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TANG GW, 1991, BIOCHEMISTRY-US, V30, P9829, DOI 10.1021/bi00105a003; WANG XD, 1994, ARCH BIOCHEM BIOPHYS, V313, P150, DOI 10.1006/abbi.1994.1371; WANG XD, 1992, ARCH BIOCHEM BIOPHYS, V293, P298, DOI 10.1016/0003-9861(92)90399-H; WANG XD, 1991, ARCH BIOCHEM BIOPHYS, V285, P8, DOI 10.1016/0003-9861(91)90322-A; WANG XD, 1993, BIOCHIM BIOPHYS ACTA, V1167, P159, DOI 10.1016/0005-2760(93)90157-5; WANG XD, 1992, AM J PHYSIOL, V263, pG480, DOI 10.1152/ajpgi.1992.263.4.G480; WANG XD, 1994, J AM COLL NUTR, V13, P314, DOI 10.1080/07315724.1994.10718416; YAMAMOTO M, 1994, GASTROENTEROLOGY, V107, P517, DOI 10.1016/0016-5085(94)90179-1; YEUM KJ, 1995, ARCH BIOCHEM BIOPHYS, V321, P167, DOI 10.1006/abbi.1995.1382; ZENG SH, 1992, AM J CLIN NUTR, V56, P433, DOI 10.1093/ajcn/56.2.433	38	83	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26490	26498		10.1074/jbc.271.43.26490	http://dx.doi.org/10.1074/jbc.271.43.26490			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900117	hybrid			2022-12-25	WOS:A1996VP23300011
J	Davies, MPA; Rudland, PS; Robertson, L; Parry, EW; Jolicoeur, P; Barraclough, R				Davies, MPA; Rudland, PS; Robertson, L; Parry, EW; Jolicoeur, P; Barraclough, R			Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV-neu transgenic mice induces metastasis of mammary tumours	ONCOGENE			English	Article						p9Ka; S100A4; c-neu; breast cancer; metastasis; transgenic mice	HUMAN-BREAST-CANCER; NONMUSCLE MYOSIN; CELL-LINES; GENE; RAT; ONCOGENE; INDUCTION; MTS1; TUMORS; ADENOCARCINOMA	Increased levels of S100A4 (p9Ka) confer metastatic ability on a normally non-metastatic epithelial cell line. To find out whether S100A4 can induce metastasis in vivo, transgenic mice expressing high levels of S100A4, but which show no phenotypic effect, have been mated with MMTV-neu transgenic mice which succumb to stochastic mammary neoplasia related to expression of the MMTV-neu transgene. Resultant bitransgenic, multiparous, female progeny expressing both S100A4 and Neu have a slightly earlier incidence of palpable mammary tumours than the MMTV-neu offspring and specifically exhibit macroscopic metastatic lesions in the lungs. The S100A4 transgene is expressed in primary and secondary lesions of bitransgenic offspring and its expression is particularly associated with regions of invasion of primary lesions and metastases.	UNIV LIVERPOOL,DEPT BIOCHEM,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,DEPT HUMAN ANAT & CELL BIOL,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; CLIN RES INST MONTREAL,MONTREAL,PQ H2W 1R7,CANADA	University of Liverpool; University of Liverpool; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Davies, Michael/GWV-2527-2022; Barraclough, Roger/AAH-6516-2020	Davies, Michael Peter Alan/0000-0002-7609-4977; Barraclough, Roger/0000-0002-7203-1194				BARRACLOUGH R, 1987, J CELL PHYSIOL, V131, P393, DOI 10.1002/jcp.1041310311; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BARRACLOUGH R, 1994, EUR J CANCER, V30A, P1570, DOI 10.1016/0959-8049(94)00320-5; BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V21, P8097; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOMBS LM, 1990, ANAL BIOCHEM, V188, P338, DOI 10.1016/0003-2697(90)90617-I; DAVIES BR, 1993, ONCOGENE, V8, P999; DAVIES M, 1995, DNA CELL BIOL, V14, P825, DOI 10.1089/dna.1995.14.825; DAVIES MPA, 1993, THESIS U LIVERPOOL; DEVOUGE MW, 1992, ONCOGENE, V7, P109; DUNNINGTON DJ, 1984, CANCER RES, V44, P5338; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; FORD HL, 1995, ONCOGENE, V11, P2067; FORD HL, 1995, ONCOGENE, V10, P1597; GIBBS FEM, 1995, J HISTOCHEM CYTOCHEM, V43, P169, DOI 10.1177/43.2.7822773; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GRIGORIAN MS, 1993, GENE, V135, P229, DOI 10.1016/0378-1119(93)90070-J; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HOGAN B, 1986, MANIPULATING MOUSE E; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; LAEMMLI UK, 1970, NATURE, V227, P2678; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PEDROCCHI M, 1994, INT J CANCER, V57, P684, DOI 10.1002/ijc.2910570513; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TAKENAGA K, 1994, JPN J CANCER RES, V85, P831, DOI 10.1111/j.1349-7006.1994.tb02955.x; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D	32	180	184	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1631	1637						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895508				2022-12-25	WOS:A1996VM88700007
J	Maity, A; Hwang, A; Janss, A; Phillips, P; McKenna, WG; Muschel, RJ				Maity, A; Hwang, A; Janss, A; Phillips, P; McKenna, WG; Muschel, RJ			Delayed cyclin B1 expression during the G2 arrest following DNA damage	ONCOGENE			English	Article						DNA damage; G2 delay; cyclin B1	CELL-CYCLE; IONIZING-RADIATION; HELA-CELLS; GENE-EXPRESSION; MESSENGER-RNA; NITROGEN-MUSTARD; ANTITUMOR DRUGS; TOPOISOMERASE-I; MAMMALIAN-CELLS; CDC25 PROTEIN	Exposure of cells to DNA damaging agents results in a G2 arrest. Exposure of HeLa cells to camptothecin, etoposide or nitrogen mustard for 1 h in S phase resulted in delayed expression of cyclin B1 mRNA during the G2 arrest. Initially the levels of cyclin B1 protein were low as well; however, with extended time the cells blocked in G2 regained higher levels of cyclin B1 protein. In the case of cells treated with nitrogen mustard the higher levels coincided with cells exiting the G2 block into G1. However, with camptothecin or etoposide treatment, while the accumulation of cyclin B1 protein was delayed, its levels eventually surpassed peak levels seen in control cells, in spite of the fact that cells were still blocked in G2. These cells did not continue to progress through the cell cycle indicating further complexity to the mechanisms underlying the G2 block. Decreased transcription and stability of cyclin B1 mRNA were shown to occur after treatment with these DNA damaging agents. These results indicate that suppression of cyclin B1 mRNA expression is one consequence of DNA damage in HeLa cells.	UNIV PENN, SCH MED, DEPT RADIAT ONCOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP PHILADELPHIA, DIV ONCOL, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP PHILADELPHIA, DIV NEUROL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Childrens Hospital of Philadelphia				Maity, Amit/0000-0001-7151-2845	NATIONAL CANCER INSTITUTE [R01CA064227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047439] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64227] Funding Source: Medline; NIGMS NIH HHS [GM 47439] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU CF, 1994, J CELL SCI, V107, P1833; DATTA R, 1992, CELL GROWTH DIFFER, V3, P637; DEAN SW, 1984, MUTAT RES, V132, P63, DOI 10.1016/0167-8817(84)90067-1; DELBINO G, 1990, CANCER RES, V50, P5746; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; GAZITT Y, 1993, CANCER RES, V53, P1899; GONG JP, 1995, CELL GROWTH DIFFER, V6, P1485; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HENKEL AW, 1994, ANAL BIOCHEM, V223, P329, DOI 10.1006/abio.1994.1595; HERZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629; HORWITZ SB, 1971, MOL PHARMACOL, V7, P632; HSIANG YH, 1989, CANCER RES, V49, P5077; HWANG A, 1995, J BIOL CHEM, V270, P28419; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; KAN ZY, 1995, MOL CELL BIOL, V15, P5849; KASTAN MB, 1991, CANCER RES, V51, P6304; KATAYOSE D, 1995, BIOCHEM BIOPH RES CO, V215, P446, DOI 10.1006/bbrc.1995.2485; KOHN KW, 1994, J CELL BIOCHEM, V54, P440, DOI 10.1002/jcb.240540411; KRISHAN A, 1975, J CELL BIOL, V66, P521, DOI 10.1083/jcb.66.3.521; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LI LH, 1972, CANCER RES, V32, P2643; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LOCK RB, 1993, INT J ONCOL, V3, P33; LOCK RB, 1994, CANCER RES, V54, P4933; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; MARKIEWICZ DA, 1994, INT J RADIAT ONCOL, V28, P135, DOI 10.1016/0360-3016(94)90151-1; MATEOS S, 1994, MUTAT RES-DNA REPAIR, V315, P181, DOI 10.1016/0921-8777(94)90017-5; McKenna WG, 1996, ONCOGENE, V12, P237; MEYUHAS O, 1980, GENE, V10, P113, DOI 10.1016/0378-1119(80)90129-8; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; MUSCHEL RJ, 1993, CANCER RES, V53, P1128; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RYAN AJ, 1991, NUCLEIC ACIDS RES, V19, P3295, DOI 10.1093/nar/19.12.3295; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SMEETS MFMA, 1994, RADIOTHER ONCOL, V33, P217, DOI 10.1016/0167-8140(94)90357-3; STEWART N, 1995, ONCOGENE, V10, P109; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; TOBEY RA, 1972, CANCER RES, V32, P2720; TODD DG, 1994, CANCER RES, V54, P5224; TSAO YP, 1992, CANCER RES, V52, P1823; VINDELOV LL, 1990, CYTOMETRY, V11, P753, DOI 10.1002/cyto.990110702; WARD JF, 1994, INT J RADIAT BIOL, V66, P427, DOI 10.1080/09553009414551401; WOZNIAK AJ, 1983, CANCER RES, V43, P120; WU RS, 1971, P NATL ACAD SCI USA, V68, P3009, DOI 10.1073/pnas.68.12.3009	56	57	61	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1647	1657						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895510				2022-12-25	WOS:A1996VM88700009
J	Rachmilewitz, J; Elkin, M; Looijenga, LHJ; Verkerk, AJMH; Gonik, B; Lustig, G; Werner, D; deGroot, N; Hochberg, A				Rachmilewitz, J; Elkin, M; Looijenga, LHJ; Verkerk, AJMH; Gonik, B; Lustig, G; Werner, D; deGroot, N; Hochberg, A			Characterization of the imprinted IPW gene: Allelic expression in normal and tumorigenic human tissues	ONCOGENE			English	Article						IPW; imprinted genes; bi-allelic expression; testicular germ cell tumors; bladder carcinoma	GROWTH FACTOR-II; HUMAN H19 GENE; RELAXATION; INVITRO; REGION; LINE; IGF2	IPW (Imprinted gene in the Prader-Willi syndrome region) is a recently identified paternally expressed gene, Previous work has demonstrated IPW expression in the human fetus and adult, with monoallelic expression in adult lymphoblasts and fibroblasts, and in fetal tissues. To further examine the expression of IPW, a series of experiments were carried out using RT-PCR to measure IPW expression in placentae and various fetal and tumor tissues, Biallelic expression of IPW was found in testicular germ cell tumor and bladder cancer cells, suggesting loss of imprinting in the latter case. Both H19 and Insulin-like growth Factor 2 (IGF2), two additional imprinted genes, also showed biallelic expression in those same tumors that demonstrated IPW biallelic expression. Of note, the naturally occurring parthenogenetic-derived mature teratoma unexpectedly expressed large amounts of IPW, Lastly, the pluripotent embryonal cancer cell line Tera-2 expressed IPW at the same level before and after differentiation induced by retinoic acid, suggesting that this gene functions in a 'housekeeping' capacity throughout cell growth. This was in contradistinction to H19 and IGF2, both of which showed significant transcriptional upregulation after Tera-2 cell differentiation.	HEBREW UNIV JERUSALEM,SILBERMAN INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL; UNIV ROTTERDAM HOSP,DR DANIEL DEN HOED CANC CTR,LAB EXPT PATHOONCOL,NL-3075 EA ROTTERDAM,NETHERLANDS; WAYNE STATE UNIV,SCH MED,GRACE HOSP,DEPT OBSTET & GYNECOL,DETROIT,MI; GERMAN CANC RES CTR,D-69120 HEIDELBERG,GERMANY	Hebrew University of Jerusalem; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Wayne State University; Helmholtz Association; German Cancer Research Center (DKFZ)			Looijenga, Leendert/B-8145-2019	Looijenga, Leendert/0000-0002-8146-1911; Verkerk, Annemieke JMH/0000-0002-7523-3656				ANDREWS PW, 1984, LAB INVEST, V50, P147; ARIEL I, 1994, GYNECOL ONCOL, V53, P212, DOI 10.1006/gyno.1994.1118; Ausubel F. M., 1993, CURRENT PROTOCOLS MO, V1; DoucRasy S, 1996, ONCOGENE, V12, P423; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LINDER D, 1975, NEW ENGL J MED, V292, P63, DOI 10.1056/NEJM197501092920202; MCDONALD RJ, 1987, METHOD ENZYMOL, V152, P221; MOSSELMAN S, 1994, CANCER RES, V54, P220; MOSTOFI FK, 1987, SEMIN DIAGN PATHOL, V4, P320; MUTTER GL, 1993, AM J HUM GENET, V53, P1096; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; POIRIER F, 1991, DEVELOPMENT, V113, P1105; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; SOLTER D, 1988, ANNU REV GENET, V22, P127; SURANI MAH, 1987, BIOL REPROD, V36, P1, DOI 10.1095/biolreprod36.1.1; SZABO PE, 1995, GENE DEV, V9, P1857, DOI 10.1101/gad.9.15.1857; SZULMAN AE, 1987, GESTATIONAL TROPHOBL, P27; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; TYCKO B, 1994, AM J PATHOL, V144, P431; VANGURP RJH, 1994, JNCI-J NATL CANCER I, V14, P1070; VILLAR AJ, 1995, DEV BIOL, V172, P264, DOI 10.1006/dbio.1995.0021; WALSH C, 1994, MECH DEVELOP, V46, P55, DOI 10.1016/0925-4773(94)90037-X; WEVRICK R, 1994, HUM MOL GENET, V3, P1877, DOI 10.1093/hmg/3.10.1877; Zhan SL, 1995, ONCOGENE, V11, P2503; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	27	26	27	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1687	1692						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895514				2022-12-25	WOS:A1996VM88700013
J	Sala, A; DeLuca, A; Giordano, A; Peschle, C				Sala, A; DeLuca, A; Giordano, A; Peschle, C			The retinoblastoma family member p107 binds to B-MYB and suppresses its autoregulatory activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINES; PROLIFERATION; EXPRESSION; REQUIREMENT; ACTIVATION; INHIBITION; GROWTH	It was recently reported that B-MYB can overcome p107-induced growth arrest. Here we show that B-MYB autoregulation of its own transcription is specifically suppressed by p107 and transient transfection assays with p107 deletion constructs determined that the carboxyl terminus of the protein, containing the major pocket region, was associated with inhibition of B-MYB-dependent transactivation. Consistent with these results, co-immunoprecipitation studies showed that p107 interacted in vivo with B-MYB through its pocket and carboxyl terminus domain. Thus, B-MYB-dependent promotion of cell proliferation and gene transactivation might be specifically repressed by the growth suppressor p107 through direct interaction with B-MYB.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PATHOL ANAT & CELL BIOL,PHILADELPHIA,PA 19107; IST SUPER SANITA,LAB EMATOL ONCOL,I-00161 ROME,ITALY	Jefferson University; Istituto Superiore di Sanita (ISS)	Sala, A (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MICROBIOL & IMMUNOL,KIMMEL CANC INST,BLSB BLDG,PHILADELPHIA,PA 19107, USA.		sala, arturo/C-4959-2008; De Luca, Antonio/AAD-9562-2020; Giordano, Antonio/F-1927-2010	De Luca, Antonio/0000-0002-3905-6154; Giordano, Antonio/0000-0002-5959-016X; Sala, Arturo/0000-0002-2841-7866	NATIONAL CANCER INSTITUTE [R01CA060999] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA60999-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARSURA M, 1992, BLOOD, V79, P2708; ARSURA M, 1994, BLOOD, V83, P1778, DOI 10.1182/blood.V83.7.1778.bloodjournal8371778; Bies J, 1996, ONCOGENE, V12, P355; CLAUDIO PP, 1994, CANCER RES, V54, P5556; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GOLAY J, 1991, BLOOD, V77, P149; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; Marhamati DJ, 1996, J BIOL CHEM, V271, P3359; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; SATTERWHITE DJ, 1994, CELL GROWTH DIFFER, V5, P789; Sitzmann J, 1996, ONCOGENE, V12, P1889; TASHIRO S, 1995, ONCOGENE, V10, P1699; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	16	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28738	28740		10.1074/jbc.271.46.28738	http://dx.doi.org/10.1074/jbc.271.46.28738			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910512	hybrid			2022-12-25	WOS:A1996VT05200004
J	Li, SW; Song, KS; Koh, SS; Kikuchi, A; Lisanti, MP				Li, SW; Song, KS; Koh, SS; Kikuchi, A; Lisanti, MP			Baculovirus-based expression of mammalian caveolin in Sf21 insect cells A model system for the biochemical and morphological study of caveolae biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH MEMBRANE DOMAINS; TRANS-GOLGI-NETWORK; PLASMA-MEMBRANE; TRANSFORMED-CELLS; PROTEIN-COMPONENT; VESICLES; VIP21-CAVEOLIN; TYROSINE; SEQUENCE; SURFACE	Caveolae were originally defined morphologically as 50-100 nm noncoated vesicular organelles located at or near the plasma membrane. Caveolin, a vesicular integral membrane protein of 21 kDa, is a principal protein component of caveolae membranes in vivo. Caveolin interacts with itself to form high molecular mass oligomers, suggesting that it might play a structural role in the formation of caveolae membranes. However, it remains controversial whether recombinant expression of caveolin is necessary or sufficient to generate caveolae membranes in vivo. To directly address this issue, we have taken a different experimental approach by exploiting a heterologous expression system. Here, we have recombinantly expressed mammalian caveolin in Sf21 insect cells using baculovirus-based vectors. Two isoforms of caveolin have been identified that differ at their extreme N terminus; alpha-caveolin contains residues 1-178, and beta-caveolin contains residues 32-178. After recombinant expression in Sf21 insect cells, both alpha- and beta-caveolin formed SDS-resistant high molecular mass oligomers of the same size as native caveolin. Morphologically, expression of either caveolin isoform resulted in the intracellular accumulation of a homogeneous population of caveolae-sized vesicles with a diameter between 50 and 120 nm (80.3 +/- 14.8 nm). This indicates that each caveolin isoform can independently generate these structures and that caveolin residues 1-31 are not required for this process. Using caveolin as a marker protein and a detergent-free procedure to purify caveolae from mammalian cells, we purified these recombinant caveolin-induced vesicles from insect cells. These purified recombinant vesicles: (i) have the same buoyant density as mammalian caveolae; (ii) appear as similar to 50-100 nm membranous structures by whole mount electron microscopy; and (iii) contain similar to 95% of the recombinantly expressed caveolin protein by Western blotting. Immuno-labeling of these structures with anti-caveolin IgG confirmed that they contain caveolin. Thus, ectopic overexpression of caveolin in this heterologous system is sufficient to drive th formation of caveolae-like vesicles. Further functional analysis demonstrated that caveolin was capable of interacting with a known caveolin-interacting protein, Ha-Ras, when coexpressed in insect cells by co-infection with two recombinant baculoviruses. Taken together, our results demonstrate that baculovirus-based expression of caveolin in insect cells provides an attractive experimental system for studying the biogenesis of caveolae.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; HIROSHIMA UNIV, SCH MED, MINAMI KU, HIROSHIMA 734, JAPAN	Massachusetts Institute of Technology (MIT); Whitehead Institute; Hiroshima University			Li, Shengwen Calvin/H-1725-2012; Lisanti, Michael P/C-6866-2013; Lisanti, Michael/B-6131-2018	Li, Shengwen Calvin/0000-0002-9699-9204; Lisanti, Michael/0000-0003-2034-1382	NCI NIH HHS [F32 CA071326, CA-71326] Funding Source: Medline; NIGMS NIH HHS [GM-50443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA071326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FAN JY, 1983, J CELL SCI, V61, P219; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; GIMPL G, 1995, BIOCHEMISTRY-US, V34, P13794, DOI 10.1021/bi00042a010; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; IZUMI T, 1988, ANAT REC, V220, P225, DOI 10.1002/ar.1092200302; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P3863; Lisanti Michael P., 1995, Seminars in Developmental Biology, V6, P47, DOI 10.1016/S1044-5781(06)80084-8; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; PARK S, 1992, J BIOL CHEM, V267, P11612; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SEVERS NJ, 1988, J CELL SCI, V90, P341; SIMIONESCU N, 1975, J CELL BIOL, V64, P586, DOI 10.1083/jcb.64.3.586; SIMIONESCU N, 1983, HISTOLOGY CELL TISSU, P371; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445	44	122	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28647	28654		10.1074/jbc.271.45.28647	http://dx.doi.org/10.1074/jbc.271.45.28647			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910498	hybrid			2022-12-25	WOS:A1996VU03300098
J	Ryuto, M; Ono, M; Izumi, H; Yoshida, S; Weich, HA; Kohno, K; Kuwano, M				Ryuto, M; Ono, M; Izumi, H; Yoshida, S; Weich, HA; Kohno, K; Kuwano, M			Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells - Possible roles of SP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MESSENGER-RNA; HUMAN CANCER-CELLS; PERMEABILITY FACTOR; TRANSCRIPTION FACTOR; GENE-EXPRESSION; GLIOBLASTOMA-MULTIFORME; LESS PROMOTER; JUN ENCODES; KAPPA-B; ANGIOGENESIS	The expression of vascular endothelial growth factor (VEGF) has been implicated in brain tumor angiogenesis, and the promoter region for the VEGF gene contains several SP-1 and AP-1 (c-Fos and c-Jun) binding motifs. Among eight human glioma cell lines, cellular mRNA levels of transcription factors SP-T and AP-1 (c-Fos and c-Jun) were found to be closely correlated with those of VEGF. VEGF expression appears to be highly susceptible to hypoxia or exogenous cytokines and growth factors. Of various cytokines and growth factors, basic fibroblast growth factor (bFGF), tumor necrosis factor alpha (TNF-alpha), and interleukin 1 most potently enhanced VEGF mRNA levels of a glioma cell line, U251, Incubation of the glioma cells with bFGF or TNF-alpha increased both VEGF and SP-1 mRNA at 30 min and c-Fos mRNA at 1-3 h, over 5-fold. Nuclear run-on assays showed an apparent increase of the transcription of the VEGF gene as well as the SP-1 gene by bFGF or TNF-alpha. Gel mobility shift assays demonstrated that only SP-1 binding activity was increased 1 h after exposure to bFGF or TNF-alpha, and also that AP-1, but not SP-1, activity was significantly activated by hypoxia. Mithramycin, an inhibitor of SP-1, at 1-10 nM inhibited activation of the VEGF gene by bFGF or TNF-alpha but not that by hypoxia. Western blot analysis also demonstrated an increase in cellular amounts of VEGF by TNF-alpha and a decrease by co-administration with mithramycin. The promoter activity of the VEGF gene, which contains five SP-1 binding sites and one AP-1 binding site but not hypoxia regulatory elements, was enhanced by bFGF or TNF-alpha but not by hypoxia. The chloramphenicol acetyltransferase assay with VEGF promoter deletion constructs demonstrated that four clusterized SP-1 binding sites in the proximal promoter were essential for the basal transcription and the TNF-alpha-dependent activation. These data indicated that the expression of the VEGF gene enhanced by bFGF or TNF-alpha appeared to be mediated in part through the transcription factor SP-1, suggesting a different mechanism from that for hypoxia-induced activation of the VEGF gene.	KYUSHU UNIV,SCH MED,DEPT BIOCHEM,FUKUOKA 81282,JAPAN; NATL BIOTECHNOL RES CTR,DEPT GENE EXPRESS,D-318124 BRAUNSCHWEIG,GERMANY; UNIV OCCUPAT & ENVIRONM HLTH,DEPT MOL BIOL,KITAKYUSHU,FUKUOKA 807,JAPAN	Kyushu University; University of Occupational & Environmental Health - Japan				Yoshida, Shigeo/0000-0003-1049-8909				ABE T, 1993, J CLIN INVEST, V92, P54, DOI 10.1172/JCI116599; ABE T, 1994, CLIN EXP METASTAS, V12, P296, DOI 10.1007/BF01753836; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASAKUNO K, 1995, BRAIN RES, V702, P23, DOI 10.1016/0006-8993(95)00880-8; BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; Brandford M.M., 1976, ANAL BIOCHEM, V72, P248; CHEN XR, 1992, ONCOGENE, V7, P1805; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DOLECKI GJ, 1991, BIOCHEM BIOPH RES CO, V180, P572, DOI 10.1016/S0006-291X(05)81103-9; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FIEDLER IJ, 1994, CELL, V79, P185; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; FINKENZELLER G, 1992, CANCER RES, V52, P4821; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDMAN CK, 1993, MOL BIOL CELL, V4, P121, DOI 10.1091/mbc.4.1.121; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; HARDENBOL P, 1992, BIOCHEM BIOPH RES CO, V185, P553, DOI 10.1016/0006-291X(92)91660-I; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; IZUMI H, 1994, EXP CELL RES, V214, P654, DOI 10.1006/excr.1994.1303; JOLLIFF K, 1991, NUCLEIC ACIDS RES, V19, P2267, DOI 10.1093/nar/19.9.2267; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KOHNO K, 1993, EXP CELL RES, V208, P498, DOI 10.1006/excr.1993.1272; KOHNO K, 1994, J BIOL CHEM, V269, P20503; KONDO S, 1993, BIOCHEM BIOPH RES CO, V194, P1234, DOI 10.1006/bbrc.1993.1955; KOONG AC, 1994, CANCER RES, V54, P1425; KUBO T, 1995, CANCER RES, V55, P3860; KUWANO M, 1994, GANN MONOGR CANC RES, V42, P113; LEE JK, 1992, J BIOL CHEM, V267, P4638; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MA L, 1992, NUCLEIC ACIDS RES, V20, P217, DOI 10.1093/nar/20.2.217; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; OKAMURA K, 1991, J BIOL CHEM, V266, P19162; Okimoto T, 1996, ONCOGENE, V12, P1625; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; RAY R, 1989, J CLIN INVEST, V83, P2003, DOI 10.1172/JCI114110; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; SAMOTO K, 1995, CANCER RES, V55, P1189; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHIBUYA M, 1990, ONCOGENE, V5, P519; Shono T, 1996, MOL CELL BIOL, V16, P4231; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STEFANIK DF, 1991, CANCER RES, V51, P5760; Stoltz RA, 1996, P NATL ACAD SCI USA, V93, P2832, DOI 10.1073/pnas.93.7.2832; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VRIES CD, 1992, SCIENCE, V255, P989; WAKABAYASHI M, 1995, JPN J CANC RES, V86, P1189; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4; YAMANE A, 1994, ONCOGENE, V9, P2683; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997; YOKOMIZO A, 1995, J BIOL CHEM, V270, P19451, DOI 10.1074/jbc.270.33.19451; ZAGZAG D, 1990, CANCER RES, V50, P7393	72	421	440	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28220	28228		10.1074/jbc.271.45.28220	http://dx.doi.org/10.1074/jbc.271.45.28220			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910439	hybrid			2022-12-25	WOS:A1996VU03300039
J	Chun, RF; Jeang, KT				Chun, RF; Jeang, KT			Requirements for RNA polymerase II carboxyl-terminal domain for activated transcription of human retroviruses human T-cell lymphotropic virus I and HIV-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; MAJOR LATE PROMOTER; LARGEST SUBUNIT; MAMMALIAN-CELLS; NONPHOSPHORYLATED FORM; PREINITIATION COMPLEX; TRANS-ACTIVATION; TAX PROTEIN; PHOSPHORYLATION; ENHANCER	The carboxyl-terminal domain (CTD) of RNA polymerase (RNAP) II contains multiple repeats with a heptapeptide consensus: Tyr-Ser-Pro-Thr-Ser-Pro-Ser. It has been proposed that phosphorylation of this CTD facilitates clearance and elongation of transcription complexes initiated at the promoters. However, not all transcribed promoters require RNAP II with full-length CTD. Furthermore, different activators can promote capably the transcriptional activity of polymerase II mutants deleted in the CTD. Thus, the role of the RNAP II CTD in transcription and in response to activators remains incompletely understood. To study the role of CTD in the regulated transcription of human retroviruses human-T cell lymphotropic virus I and human immunodeficiency virus 1, we used an alpha-amanitin-resistant system developed previously (Gerber, H. P., Hagmann, M., Seipel, K., Georgiev, O., West, M. A., Litingtung, Y., Schaffner, W., and Corden, J. L. (1995) Nature 374, 660-662). We found that transcription directed by the human T-cell lymphotropic virus I activator protein Tax was strongly promoted by CTD-deficient RNA polymerase II. By contrast, the human immunodeficiency virus 1 activator Tat, which is recruited to the promoter by tethering to a nascent leader RNA, requires CTD-containing polymerase II for transcriptional activity. Biochemically, we characterized that Tat associated with a cellular CTD kinase activity, whereas Tax did not. Concordantly, we found that cellular transcription factor Sp1, which can activate CTD-deficient polymerase II with an efficiency similar to Tax, also failed to bind a CTD kinase. Taken together, these observations address mechanistic corollaries between activators with(out) a linked CTD kinase and regulated transcription by RNA polymerase II moieties with(out) a CTD.	NIAID,MOL VIROL SECT,MOL MICROBIOL LAB,NATL INST HLTH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Jeang, Kuan-Teh/A-2424-2008; Chun, Rene/A-9415-2010	Chun, Rene/0000-0002-0190-0807				BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BERAUD C, 1991, EMBO J, V10, P3795, DOI 10.1002/j.1460-2075.1991.tb04949.x; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; BURATOWSKI S, 1990, MOL CELL BIOL, V10, P5562, DOI 10.1128/MCB.10.10.5562; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CARROLL R, 1992, J VIROL, V66, P2000, DOI 10.1128/JVI.66.4.2000-2007.1992; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; CONAWAY RC, 1992, J BIOL CHEM, V267, P8464; CORDEN JL, 1993, CURR OPIN GENET DEV, V3, P213, DOI 10.1016/0959-437X(93)90025-K; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DAHMUS ME, 1995, BBA-GENE STRUCT EXPR, V1261, P171, DOI 10.1016/0167-4781(94)00233-S; Demarchi F, 1996, J VIROL, V70, P4427, DOI 10.1128/JVI.70.7.4427-4437.1996; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FONTES JD, 1993, J VIROL, V67, P4436, DOI 10.1128/JVI.67.7.4436-4441.1993; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; FUJII M, 1991, ONCOGENE, V6, P2349; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; GOREN I, 1995, J VIROL, V69, P5806, DOI 10.1128/JVI.69.9.5806-5811.1995; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; Jeang K T, 1991, AIDS, V5 Suppl 2, pS3, DOI 10.1097/00002030-199101001-00002; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JEANG KT, 1992, J BIOL CHEM, V267, P17891; JEANG KT, 1988, P NATL ACAD SCI USA, V85, P8291, DOI 10.1073/pnas.85.21.8291; JEANG KT, 1991, VIROLOGY, V181, P218, DOI 10.1016/0042-6822(91)90487-V; JEANG KT, 1994, HUMAN RETROVIRUSES A; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KIM WY, 1989, J BIOL CHEM, V264, P3169; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MATTHEWS MAH, 1992, MOL CELL BIOL, V12, P1986, DOI 10.1128/MCB.12.5.1986; MCMILLAN NAJ, 1995, VIROLOGY, V213, P413, DOI 10.1006/viro.1995.0014; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; PAYNE JM, 1993, J BIOL CHEM, V268, P80; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; ROY R, 1994, J BIOL CHEM, V269, P9826; SEELER JS, 1993, VIROLOGY, V196, P442, DOI 10.1006/viro.1993.1500; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SEIPEL K, 1993, NUCLEIC ACIDS RES, V21, P5606; SEMMES OJ, 1995, J VIROL, V69, P1827, DOI 10.1128/JVI.69.3.1827-1833.1995; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; XIAO H, 1994, NUCLEIC ACIDS RES, V22, P1966, DOI 10.1093/nar/22.11.1966; XIAO H, 1994, MOL CELL BIOL, V14, P7507, DOI 10.1128/MCB.14.11.7507; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZEHRING WA, 1990, J BIOL CHEM, V265, P8351; ZHANG J, 1991, J BIOL CHEM, V266, P2297; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	64	93	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27888	27894		10.1074/jbc.271.44.27888	http://dx.doi.org/10.1074/jbc.271.44.27888			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910388	hybrid			2022-12-25	WOS:A1996VQ67900106
J	Gao, M; Loe, DW; Grant, CE; Cole, SPC; Deeley, RG				Gao, M; Loe, DW; Grant, CE; Cole, SPC; Deeley, RG			Reconstitution of ATP-dependent leukotriene C-4 transport by co-expression of both half-molecules of human multidrug resistance protein in insect cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMAN TUMOR-CELLS; CYSTIC-FIBROSIS; P-GLYCOPROTEIN; MONOCLONAL-ANTIBODIES; ENDOPLASMIC-RETICULUM; GENE OVEREXPRESSION; TOPOISOMERASE-II; DRUG-EFFLUX; MRP	Multidrug resistance protein (MRP) confers a multidrug resistance phenotype similar to that associated with overexpression of P-glycoprotein. Unlike P-glycoprotein, MRP has also been shown to be a primary active ATP-dependent transporter of conjugated organic anions, The mechanism(s) by which MRP transports these compounds and increases resistance to natural product drugs is unknown, To facilitate studies on the structure and function of MRP, we have determined whether a baculovirus expression system can be used to produce active protein, Full-length MRP as well as molecules corresponding to either the NH2- or COOH-proximal halves of the protein were expressed individually and in combination in Spodoptera frugiperda Sf21 cells, High levels of intact and half-length proteins were detected in membrane vesicles from infected cells. Although underglycosylated, the full-length protein transported leukotriene C-4 (LTC(4)) with kinetic parameters very similar to those of MRP produced in transfected HeLa cells, Neither half-molecule was able to transport LTC(4). However, a functional transporter with characteristics similar to those ofintact protein could be reconstituted vvhen both half-molecules were co expressed. Transport of LTC(4) by Sf21 membrane vesicles containing either intact or reconstituted MRP was competitively inhibited by both S-decylglutathione and 17 beta-estradiol 17-(beta-a-glucuronide), with K-i values similar to those reported previously for MRP expressed in HeLa cells (Loe, D. W., Almquist, K. C., Deeley, R. G., and Cole, S. P. C. (1996) J. Biol. Chem. 271, 9675-9682; Loe, D. W., Almquist, K. C., Cole, S. P. C., and Deeley, R. G. (1996) J. Biol. Chem. 271, 9683-9689), These studies demonstrate that human MRP produced in insect cells can function as an active transporter of LTC(4) and that the NH2- and COOH-proximal halves of the protein can assemble efficiently to form a transporter with functional characteristics similar to those of the intact protein.	QUEENS UNIV, CANC RES LABS, KINGSTON, ON K7L 3N6, CANADA; QUEENS UNIV, DEPT PATHOL, KINGSTON, ON K7L 3N6, CANADA	Queens University - Canada; Queens University - Canada			Deeley, Roger/J-4828-2012; Cole, Susan P.C./I-6389-2017	Cole, Susan P.C./0000-0001-6571-6884				AHMAD S, 1994, BIOCHEMISTRY-US, V33, P10313, DOI 10.1021/bi00200a011; ALMQUIST KC, 1995, CANCER RES, V55, P102; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BINASCHI M, 1995, INT J CANCER, V62, P84, DOI 10.1002/ijc.2910620116; BREUNINGER LM, 1995, CANCER RES, V55, P5342; BROCK I, 1995, CANCER RES, V55, P459; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; COLEY HM, 1991, BRIT J CANCER, V63, P351, DOI 10.1038/bjc.1991.84; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; FLENS MJ, 1994, CANCER RES, V54, P4557; Gartner J, 1993, Semin Cell Biol, V4, P45, DOI 10.1006/scel.1993.1006; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRANT CE, 1994, CANCER RES, V54, P357; HASEGAWA S, 1995, BRIT J CANCER, V71, P907, DOI 10.1038/bjc.1995.177; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hipfner DR, 1996, CANCER RES, V56, P3307; HIPFNER DR, 1994, CANCER RES, V54, P5788; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Jedlitschky G, 1996, CANCER RES, V56, P988; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; Koronakis V, 1993, Semin Cell Biol, V4, P7, DOI 10.1006/scel.1993.1002; KRISHNAMACHARY N, 1993, CANCER RES, V53, P3658; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee DW, 1996, EUR J CANCER, V32A, P945, DOI 10.1016/0959-8049(96)00046-9; LEIER I, 1994, EUR J BIOCHEM, V220, P599, DOI 10.1111/j.1432-1033.1994.tb18661.x; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; LEIER I, 1994, J BIOL CHEM, V269, P27807; LI CH, 1993, NAT GENET, V3, P311, DOI 10.1038/ng0493-311; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; MARSH W, 1986, CANCER RES, V46, P4053; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; PIND S, 1994, J BIOL CHEM, V269, P12784; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474; SCHNEIDER E, 1994, CANCER RES, V54, P152; Shen HX, 1996, BIOCHEMISTRY-US, V35, P5719, DOI 10.1021/bi960098n; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; SLAPAK CA, 1994, BLOOD, V84, P3113, DOI 10.1182/blood.V84.9.3113.bloodjournal8493113; Stride BD, 1996, MOL PHARMACOL, V49, P962; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; vanKuijck MA, 1996, P NATL ACAD SCI USA, V93, P5401, DOI 10.1073/pnas.93.11.5401; WARD CL, 1994, J BIOL CHEM, V269, P25710; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822	54	84	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27782	27787		10.1074/jbc.271.44.27782	http://dx.doi.org/10.1074/jbc.271.44.27782			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910374	hybrid			2022-12-25	WOS:A1996VQ67900092
J	Lipari, F; Herscovics, A				Lipari, F; Herscovics, A			Role of the cysteine residues in the alpha 1,2-mannosidase involved in N-glycan biosynthesis in Saccharomyces cerevisiae - The conserved Cys(340) and Cys(385) residues form an essential disulfide bond	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; PROCESSING ALPHA-MANNOSIDASE; MOLECULAR-CLONING; 1,2-ALPHA-D-MANNOSIDASE GENE; GLYCOPROTEIN-BIOSYNTHESIS; NUCLEOTIDE-SEQUENCE; PROTEINS; PURIFICATION; YEAST; POLYPEPTIDES	The Saccharomyces cerevisiae alpha 1,2-mannosidase, which removes one specific mannose residue from Man(9)GlcNAc(2) to form Man(8)GlcNAc(2), is a member of a family of alpha 1,2-mannosidases with similar amino acid sequences. The yeast alpha 1,2-mannosidase contains five cysteine residues, three of which are conserved, Recombinant yeast alpha 1,2-mannosidase, produced as the soluble catalytic domain, was shown to contain two disulfide bonds and one free thiol group using 2-nitro-5-thiosulfobenzoate and 5,5'-dithiobis(2-nitrobenzoate), respectively, Cys485 contains the free thiol group, as demonstrated by sequencing of labeled peptides following modification with [H-3]ICH2COOH and by high performance liquid chromatography/mass spectrometry tryptic peptide mapping, A Cys(340)-Cys(385) disulfide was demonstrated by sequencing a purified peptide containing this disulfide and by tryptic peptide mapping, Cys(468) and Cys(471) were not labeled with [H-3]ICH2COOH and a peptide containing these two residues was identified in the tryptic peptide map, showing that Cys468 and Cys471 form the second disulfide bond, The alpha 1,alpha-mannosidase loses its activity in the presence of dithiothreitol with first order kinetics, suggesting that at least one disulfide bond is essential for activity, Mutagenesis of each cysteine residue to serine showed that Cys(340) and Cys(385) are essential for production of recombinant enzyme, whereas Cys468, Cys(471), and Cys485 are not re quired for production and enzyme activity, These results indicate that the sensitivity to dithiothreitol is due to reduction of the Cys(340)-Cys(385) disulfide, Since Cys(340) and Cys(385) are conserved residues, it is likely that this disulfide bond is important to maintain the correct structure in the other members of the alpha 1,2-mannosidase family.	MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA	McGill University					NIGMS NIH HHS [GM 31265] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUSE E, 1993, EUR J BIOCHEM, V217, P535, DOI 10.1111/j.1432-1033.1993.tb18274.x; Burke J, 1996, EUR J CELL BIOL, V70, P298; CAMIRAND A, 1991, J BIOL CHEM, V266, P15120; CARR SA, 1990, METHOD ENZYMOL, V193, P508; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FORSEE WT, 1989, J BIOL CHEM, V264, P3869; GRONDIN B, 1992, GLYCOBIOLOGY, V2, P369, DOI 10.1093/glycob/2.4.369; Gros E., 1967, METHOD ENZYMOL, V11, P238; HERSCOVICS A, 1994, J BIOL CHEM, V269, P9864; INOUE T, 1995, BBA-PROTEIN STRUCT M, V1253, P141, DOI 10.1016/0167-4838(95)00195-6; JELINEKKELLY S, 1988, J BIOL CHEM, V263, P14757; JELINEKKELLY S, 1985, J BIOL CHEM, V260, P2253; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P44; KERSCHER S, 1995, DEV BIOL, V168, P613, DOI 10.1006/dbio.1995.1106; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAL A, 1994, J BIOL CHEM, V269, P9872; LIPARI F, 1995, BIOCHEM BIOPH RES CO, V209, P322, DOI 10.1006/bbrc.1995.1506; LIPARI F, 1994, GLYCOBIOLOGY, V4, P697, DOI 10.1093/glycob/4.5.697; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Markwell M A, 1981, Methods Enzymol, V72, P296; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; ROBERTSON JG, 1994, BIOCHEMISTRY-US, V33, P11563, DOI 10.1021/bi00204a019; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scaman CH, 1996, GLYCOBIOLOGY, V6, P265, DOI 10.1093/glycob/6.3.265; SCHMELZER CH, 1993, ARCH BIOCHEM BIOPHYS, V302, P484, DOI 10.1006/abbi.1993.1243; SORENSEN SB, 1991, FEBS LETT, V294, P195, DOI 10.1016/0014-5793(91)80667-R; THANNHAUSER TW, 1984, ANAL BIOCHEM, V138, P181, DOI 10.1016/0003-2697(84)90786-3; VILLA S, 1989, ANAL BIOCHEM, V177, P161, DOI 10.1016/0003-2697(89)90032-8; WANG QP, 1994, J AM CHEM SOC, V116, P11594, DOI 10.1021/ja00104a060; YOSHIDA T, 1995, BBA-GENE STRUCT EXPR, V1263, P159, DOI 10.1016/0167-4781(95)00101-L; ZIEGLER F D, 1991, Glycobiology, V1, P605, DOI 10.1093/glycob/1.6.605	31	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27615	27622		10.1074/jbc.271.44.27615	http://dx.doi.org/10.1074/jbc.271.44.27615			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910350	hybrid			2022-12-25	WOS:A1996VQ67900068
J	Rajaraman, K; Raman, B; Rao, CM				Rajaraman, K; Raman, B; Rao, CM			Molten-globule state of carbonic anhydrase binds to the chaperone-like alpha-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; B-CRYSTALLIN; MOLECULAR CHAPERONE; STRUCTURAL CHARACTERIZATION; INTERMEDIATE; LYSOZYME; LACTALBUMIN; EXPRESSION; LENS; DENATURATION	alpha-Crystallin, a multimeric protein, exhibits chaperone-like activity in preventing aggregation of several proteins, We have studied the chaperone-like activity of alpha-crystallin toward heat-induced aggregation of bovine and human carbonic anhydrase, Human carbonic anhydrase aggregates at 60 degrees C, while bovine carbonic anhydrase does not aggregate significantly at this temperature, Removal of the enzyme-bound metal ion, Zn2+, by EDTA modulates the aggregation behavior of bovine carbonic anhydrase, Fluorescence and circular dichroism studies show that removal of the metal ion from the bovine carbonic anhydrase by a chelator such as EDTA enhances the propensity of the enzyme to adopt the molten-globule state, alpha-Crystallin binds to this state of the enzyme and prevents aggregation, Fluorescence and circular dichroism studies on the alpha-crystallin enzyme complexes show that the enzymes in the complex are in the molten-globule state, These results are of relevance to the interaction of chaperones with the partially unfolded states of target proteins.	CTR CELLULAR & MOL BIOL, HYDERABAD 500007, ANDHRA PRADESH, INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)				Krishnan, Rajaraman/0000-0002-5189-4097				AOYAMA A, 1993, INT J CANCER, V55, P760, DOI 10.1002/ijc.2910550511; BALDWIN RL, 1993, CURR OPIN STRUC BIOL, V3, P84, DOI 10.1016/0959-440X(93)90206-Z; BARRICK D, 1994, J MOL BIOL, V237, P588, DOI 10.1006/jmbi.1994.1257; BARRICK D, 1993, PROTEIN SCI, V2, P869, DOI 10.1002/pro.5560020601; BOYLE D, 1993, BIOCHEM BIOPH RES CO, V192, P1147, DOI 10.1006/bbrc.1993.1536; BUCK M, 1993, BIOCHEMISTRY-US, V32, P669, DOI 10.1021/bi00053a036; BYCHKOVA VE, 1988, FEBS LETT, V238, P231, DOI 10.1016/0014-5793(88)80485-X; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; CHERIAN M, 1995, BIOCHEM BIOPH RES CO, V208, P675, DOI 10.1006/bbrc.1995.1391; DAS KP, 1995, BIOCHEM J, V311, P367, DOI 10.1042/bj3110367; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; DEJONG WW, 1988, J BIOL CHEM, V263, P5141; DOLGIKH DA, 1984, FEBS LETT, V165, P88, DOI 10.1016/0014-5793(84)80020-4; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; FINK AL, 1995, ANNU REV BIOPH BIOM, V24, P495, DOI 10.1146/annurev.bb.24.060195.002431; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; IKEGUCHI M, 1986, J BIOCHEM-TOKYO, V99, P1191, DOI 10.1093/oxfordjournals.jbchem.a135582; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAGANNADHAM MV, 1985, FEBS LETT, V188, P326, DOI 10.1016/0014-5793(85)80396-3; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KELLEY MJ, 1993, J BIOL CHEM, V268, P18844; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KUWAJIMA K, 1986, INT J PEPT PROT RES, V27, P18; KUWAJIMA K, 1985, BIOCHEMISTRY-US, V24, P874, DOI 10.1021/bi00325a010; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MULDERS JWM, 1985, EUR J BIOCHEM, V152, P721, DOI 10.1111/j.1432-1033.1985.tb09253.x; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; NYMAN PO, 1968, EUR J BIOCHEM, V6, P172, DOI 10.1111/j.1432-1033.1968.tb00435.x; PARDON E, 1995, J BIOL CHEM, V270, P10514, DOI 10.1074/jbc.270.18.10514; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; Raman B, 1996, J BIOL CHEM, V271, P17067, DOI 10.1074/jbc.271.29.17067; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; RAMAN B, 1994, J BIOL CHEM, V269, P27264; RAMAN B, 1995, J BIOL CHEM, V270, P19888, DOI 10.1074/jbc.270.34.19888; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P155, DOI 10.1007/BF00296185; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; SUNDARI CS, 1991, BIOCHIM BIOPHYS ACTA, V1065, P35; VANDAEL H, 1993, BIOCHEMISTRY-US, V32, P11886, DOI 10.1021/bi00095a018; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; WANG KY, 1994, J BIOL CHEM, V269, P13601; WARD RL, 1970, BIOCHEMISTRY-US, V9, P2447, DOI 10.1021/bi00814a009; WHITNEY PL, 1967, J BIOL CHEM, V242, P4206; WONG KP, 1973, J BIOL CHEM, V248, P8518	54	93	93	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27595	27600		10.1074/jbc.271.44.27595	http://dx.doi.org/10.1074/jbc.271.44.27595			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910347	hybrid			2022-12-25	WOS:A1996VQ67900065
J	Wang, ZZ; Hardy, SF; Hall, ZW				Wang, ZZ; Hardy, SF; Hall, ZW			Assembly of the nicotinic acetylcholine receptor - The first transmembrane domains of truncated alpha and delta subunits are required for heterodimer formation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFECTED COS CELLS; ENDOPLASMIC-RETICULUM; BINDING-SITES; TERMINAL DOMAINS; EPSILON SUBUNIT; ION CHANNELS; MUSCLE-CELLS; MOUSE; PROTEIN; IDENTIFICATION	To investigate the mechanism of assembly of the mouse muscle acetylcholine receptor, we have expressed truncated N-terminal fragments of the alpha and delta subunits in COS cells and have examined their ability to fold, to associate into heterodimers, and to form a ligand-binding site, Truncated fragments of the alpha subunit that include all, part, or none of the first transmembrane domain (M1) folded to acquire cu-bungarotoxin binding activity, Neither the full-length alpha subunit nor any of the fragments were expressed on the cell surface, although the shortest folded fragment lacking a transmembrane domain was secreted into the medium, When coexpressed with the delta subunit, the alpha subunit fragment possessing M1 formed a heterodimer containing a ligand-binding site, but shorter fragments, which lack transmembrane segments, did not associate with the delta subunit, N-terminal delta subunit fragments gave similar results. An N-terminal delta subunit fragment that contains M1 associated with the alpha subunit to form a heterodimer, while a fragment lacking M1 did not. These results show that a complete M1 domain is necessary for association of truncated N-terminal alpha and delta subunits into a heterodimer with high affinity ligand binding activity.	UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; NIMH, CELL BIOL LAB, BETHESDA, MD 20892 USA	University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)								ANDERSON DJ, 1981, P NATL ACAD SCI-BIOL, V78, P5598, DOI 10.1073/pnas.78.9.5598; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; BUONANNO A, 1986, J BIOL CHEM, V261, P6451; CARLIN BE, 1987, PROTEIN COMPARTMENTA, P71; CHAVEZ RA, 1992, J BIOL CHEM, V267, P23028; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; FORSAYETH JR, 1992, J CELL BIOL, V117, P841, DOI 10.1083/jcb.117.4.841; FORSAYETH JR, 1994, BIOTECHNIQUES, V17, P354; FROEHNER SC, 1983, J BIOL CHEM, V258, P7112; FU DX, 1994, J BIOL CHEM, V269, P26152; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; GU Y, 1991, NEURON, V6, P879, DOI 10.1016/0896-6273(91)90228-R; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; GUILLICK W, 1983, BICOHEMISTRY, V22, P3312; Hall Z W, 1992, Trends Cell Biol, V2, P66, DOI 10.1016/0962-8924(92)90058-U; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; ISENBERG KE, 1986, NUCLEIC ACIDS RES, V14, P5111, DOI 10.1093/nar/14.12.5111; KARLIN A, 1991, HARVEY LECT, V85, P71; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPOLLA RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7970, DOI 10.1073/pnas.81.24.7970; MERLIE JP, 1982, J BIOL CHEM, V257, P2694; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; NOMOTO H, 1986, EUR J BIOCHEM, V157, P233, DOI 10.1111/j.1432-1033.1986.tb09661.x; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; RATNAM M, 1986, BIOCHEMISTRY-US, V25, P2621, DOI 10.1021/bi00357a051; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; Shtrom SS, 1996, J BIOL CHEM, V271, P25506, DOI 10.1074/jbc.271.41.25506; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SMITH MM, 1987, J BIOL CHEM, V262, P4367; SUMIKAWA K, 1989, MOL BRAIN RES, V5, P183, DOI 10.1016/0169-328X(89)90034-X; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WILSON PT, 1988, MOL PHARMACOL, V34, P643; YONG G, 1989, J CELL BIOL, V109, P729, DOI 10.1083/jcb.109.2.729; YU XM, 1991, NATURE, V352, P64, DOI 10.1038/352064a0; YU XM, 1994, MOL PHARMACOL, V46, P964	52	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27575	27584		10.1074/jbc.271.44.27575	http://dx.doi.org/10.1074/jbc.271.44.27575			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910344	hybrid			2022-12-25	WOS:A1996VQ67900062
J	Yamaguchi, Y; Ikenaka, K; Niinobe, M; Yamada, H; Mikoshiba, K				Yamaguchi, Y; Ikenaka, K; Niinobe, M; Yamada, H; Mikoshiba, K			Myelin proteolipid protein (PLP), but not DM-20, is an inositol hexakisphosphate-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVOUS-SYSTEM MYELIN; JIMPY MUTANT MOUSE; RAT-BRAIN; POLYPHOSPHATE RECEPTOR; SYNAPTIC FUNCTION; CLATHRIN BINDING; GOLGI-APPARATUS; MESSENGER-RNAS; GENE FAMILY; CNS MYELIN	Myelin proteolipid protein (PLP) and its alternatively spliced isoform, DM-20, are the major integral membrane proteins of central nervous system myelin. It is known that PLP and DM-20 are delivered to myelin by a finely regulated vesicular transport system in oligodendrocytes. Evolutionarily, it is believed that ancestral DM-20 acquired a PLP-specific exon to create PLP, after which PLP/DM-20 became a major component of central nervous system myelin. We purified PLP as an inositol 1,3,4,5-tetrakisphosphate-binding protein after solubilization in a non-organic solvent. However, under the Isotonic condition, PLP binds inositol hexakisphosphate (InsP(6)) significantly, not inositol 1,3,4,5-tetrakisphosphate. Most of the InsP(6)-binding proteins are involved in vesicular transport, suggesting the involvement of PLP in vesicular transport. We separated DM-20 from PLP by CM-52 chromatography and showed that DM-20 has no InsP(6) binding activity. These findings indicate that the PLP-specific domain confers the InsP(6) binding activity and this interaction may be important for directing PLP transport to central nervous system myelin.	OKAZAKI NATL RES INST,NATL INST PHYSIOL SCI,LAB NEURAL INFORMAT,OKAZAKI,AICHI 444,JAPAN; OSAKA UNIV,INST PROT RES,DIV REGULAT MACROMOL FUNCT,SUITA,OSAKA 565,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOL NEUROBIOL LAB,TSUKUBA,IBARAKI 305,JAPAN; UNIV TOKYO,INST MED SCI,DEPT MOL NEUROBIOL,MINATO KU,TOKYO 108,JAPAN	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Okazaki Institute for Integrative Bioscience (OIIB); Osaka University; RIKEN; University of Tokyo			Mikoshiba, Katsuhiko/N-7943-2015	Yamaguchi, Yoshihide/0000-0002-5686-9325				BECK KA, 1991, J BIOL CHEM, V266, P4442; BENJAMINS JA, 1978, J NEUROCHEM, V31, P1077, DOI 10.1111/j.1471-4159.1978.tb00150.x; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; CHADWICK CC, 1992, J BIOL CHEM, V267, P3473; COLMAN DR, 1982, J CELL BIOL, V95, P598, DOI 10.1083/jcb.95.2.598; DIEHL HJ, 1986, P NATL ACAD SCI USA, V83, P9807, DOI 10.1073/pnas.83.24.9807; FLEISCHER B, 1994, J BIOL CHEM, V269, P17826; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; GARDINIER MV, 1986, MOL CELL BIOL, V6, P3755, DOI 10.1128/MCB.6.11.3755; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HUDSON LD, 1987, P NATL ACAD SCI USA, V84, P1454, DOI 10.1073/pnas.84.5.1454; Hudson Lynn D., 1992, P677; IKENAKA K, 1988, J MOL BIOL, V199, P587, DOI 10.1016/0022-2836(88)90303-8; KAGAWA T, 1994, NEURON, V13, P427, DOI 10.1016/0896-6273(94)90358-1; KITAGAWA K, 1993, NEURON, V11, P433, DOI 10.1016/0896-6273(93)90148-K; KOPPITZ B, 1986, EUR J BIOCHEM, V161, P421, DOI 10.1111/j.1432-1033.1986.tb10462.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lees Marjorie B., 1992, P237; LUCAS AH, 1994, FEBS LETT, V347, P273; MACKLIN WB, 1987, J NEUROSCI RES, V18, P383, DOI 10.1002/jnr.490180302; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MENNITI FS, 1993, TRENDS BIOCHEM SCI, V18, P53, DOI 10.1016/0968-0004(93)90053-P; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; MILNER RJ, 1985, CELL, V42, P931, DOI 10.1016/0092-8674(85)90289-2; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; NAISMITH AL, 1985, NUCLEIC ACIDS RES, V13, P7413, DOI 10.1093/nar/13.20.7413; NAKAO J, 1995, J NEUROCHEM, V64, P2396; NAVE KA, 1987, P NATL ACAD SCI USA, V84, P5665, DOI 10.1073/pnas.84.16.5665; NAVE KA, 1986, P NATL ACAD SCI USA, V83, P9264, DOI 10.1073/pnas.83.23.9264; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; NUSSBAUM JL, 1983, CELL TISSUE RES, V234, P547; PERIN MS, 1991, J BIOL CHEM, V266, P615; Pfeiffer Steve E., 1993, Trends in Cell Biology, V3, P191, DOI 10.1016/0962-8924(93)90213-K; POPOT JL, 1991, J MEMBRANE BIOL, V120, P233, DOI 10.1007/BF01868534; PUCKETT C, 1987, J NEUROSCI RES, V18, P511, DOI 10.1002/jnr.490180402; READHEAD C, 1994, NEURON, V12, P583, DOI 10.1016/0896-6273(94)90214-3; ROUSSEL G, 1987, J NEUROCYTOL, V16, P195, DOI 10.1007/BF01795303; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SASAKAWA N, 1995, BIOCHEM PHARMACOL, V50, P137, DOI 10.1016/0006-2952(95)00059-9; SCHWOB VS, 1985, J NEUROCHEM, V45, P559, DOI 10.1111/j.1471-4159.1985.tb04024.x; Skoff Robert P., 1992, P653; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; STOFFEL W, 1984, P NATL ACAD SCI-BIOL, V81, P5012, DOI 10.1073/pnas.81.16.5012; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; TIMERMAN AP, 1992, P NATL ACAD SCI USA, V89, P8976, DOI 10.1073/pnas.89.19.8976; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; WEIMBS T, 1992, BIOCHEMISTRY-US, V31, P12289, DOI 10.1021/bi00164a002; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; YAMAMURA T, 1991, J NEUROCHEM, V57, P1671, DOI 10.1111/j.1471-4159.1991.tb06367.x; YE WL, 1995, J BIOL CHEM, V270, P10933, DOI 10.1074/jbc.270.18.10933; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564	57	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27838	27846		10.1074/jbc.271.44.27838	http://dx.doi.org/10.1074/jbc.271.44.27838			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910382	hybrid			2022-12-25	WOS:A1996VQ67900100
J	Erickson, JW; Zhang, CJ; Kahn, RA; Evans, T; Cerione, RA				Erickson, JW; Zhang, CJ; Kahn, RA; Evans, T; Cerione, RA			Mammalian Cdc42 is a brefeldin A-sensitive component of the Golgi apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; GUANINE-NUCLEOTIDE EXCHANGE; SACCHAROMYCES-CEREVISIAE GENE; ADP-RIBOSYLATION FACTOR; DBL ONCOGENE PRODUCT; ACTIN STRESS FIBERS; CELL POLARITY; MONOCLONAL-ANTIBODY; MEMBRANE-PROTEIN; PHOSPHOLIPASE-D	In this study, we have used immunocytochemical and fractionation approaches to provide a description oft he localization of the mammalian Cdc42 protein (designated Cdc42Hs) in vivo. A specific anti-peptide antibody was generated against the C-terminal region of Cdc42Hs. Using affinity-purified preparations of this antibody in indirect immunofluorescence experiments, Cdc42Hs was found to be localized to the Golgi apparatus, Similar to the well-characterized non-clathrin coat proteins ADP-ribosylation factor (ARF) and beta-COP, the perinuclear clustering of Cdc42Hs is rapidly dispersed upon exposure of the cells to the drug brefeldin A, suggesting that it too may play a role in the processes of intracellular lipid and protein transport, Employing cell lines possessing inducible forms of ARF, we demonstrate here a tight coupling of the nucleotide bound state of ARF and the subcellular localization of Cdc42Hs. Specifically, the expression of wild-type ARF had no effect on the brefeldin A sensitivity of Cdc42Hs while, as is the case for ARF and P-COP, expression of a GTPase-deficient form of ARF (ArF(Q71L)) renders these Golgi-localized proteins resistant to brefeldin A treatment (Teal et al., 1994; Zhang et al,, 1994). Moreover, the induced expression of a mutant form of ARF with a low affinity for nucleotide resulted in constitutive redistribution of Cdc42Hs in the absence of brefeldin A treatment. These results suggest that Cdc42Hs may play a role in cell morphogenesis by acting on targets in the Golgi that direct polarized growth at the plasma membrane.	NCI,BIOL CHEM LAB,DEV THERAPEUT PROGRAM,DIV CANC TREATMENT,NIH,BETHESDA,MD 20892; ONYX PHARMACEUT,RICHMOND,CA 94806	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Erickson, JW (corresponding author), CORNELL UNIV,COLL VET MED,DEPT PHARMACOL,ITHACA,NY 14853, USA.		Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601	NIGMS NIH HHS [GM47458] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BARON MD, 1990, J BIOL CHEM, V265, P19928; BERSHADSKY AD, 1994, P NATL ACAD SCI USA, V91, P5686, DOI 10.1073/pnas.91.12.5686; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BURKE B, 1982, EMBO J, V1, P1621, DOI 10.1002/j.1460-2075.1982.tb01364.x; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LEONARD D, 1992, J BIOL CHEM, V267, P22860; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; ORCI L, 1991, CELL, V64, P1183; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TEAL SB, 1994, J BIOL CHEM, V269, P3135; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; ZIMAN M, 1991, MOL CELL BIOL, V11, P3537, DOI 10.1128/MCB.11.7.3537	41	165	170	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26850	26854		10.1074/jbc.271.43.26850	http://dx.doi.org/10.1074/jbc.271.43.26850			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900167	hybrid			2022-12-25	WOS:A1996VP23300061
J	Lee, AC; Xu, XF; Colombini, M				Lee, AC; Xu, XF; Colombini, M			The role of pyridine dinucleotides in regulating the permeability of the mitochondrial outer membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT-MITOCHONDRIA; NAD(P)H DEHYDROGENASES; SYNTHETIC POLYANION; INTERMEMBRANE SPACE; RAT-HEART; CHANNEL; VDAC; PROTEIN; MUSCLE; NUCLEOTIDES	Both NADH and NADPH reduce the permeability of the mitochondrial outer membrane to ADP. This is specific for the outer membrane and uncorrelated with the respiratory control ratio, This could result in a 7-fold difference between the concentration of ADP in the intermembrane space and that in the external environment, (at 5 mu M ADP). in both cases the permeability declines by a factor of 5, but NADH is more potent: K-D = 86 mu M for NADH versus 580 mu M for NADPH. The lower apparent affinity for NADPH is partly explained by Mg2+-NADPH being the active species, and under our conditions only 30% of the NADPH is in this form. The corrected K-D is 184 mu M. Free NADH has the same charge as the Mg2+-NADPH complex, and thus both likely bind to the same site, The ability of NADH and NADPH to induce the closure of reconstituted VDAC channels is consistent with VDAC being the main pathway for metabolite flow across the outer membrane, Oncotic pressure, effective at inducing VDAC closure, also decreases the enter membrane permeability. Thus, in the presence of cytosolic colloidal osmotic pressure NAD(P)H may inhibit mitochondrial catabolic pathways and divert reducing equivalents to anabolic pathways.	UNIV MARYLAND, DEPT ZOOL, CELL BIOL LABS, COLLEGE PK, MD 20742 USA	University System of Maryland; University of Maryland College Park			Colombini, Marco/A-1540-2014		NIGMS NIH HHS [GM 35759] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPS DK, 1973, BIOCHIM BIOPHYS ACTA, V320, P379, DOI 10.1016/0304-4165(73)90319-X; ARRON GP, 1980, PLANT PHYSIOL, V65, P591, DOI 10.1104/pp.65.4.591; BELL CF, 1977, OXFORD CHEM SERIES, P86; BENZ R, 1988, FEBS LETT, V231, P75, DOI 10.1016/0014-5793(88)80706-3; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BRINDLE KM, 1989, BIOCHEMISTRY-US, V28, P4887, DOI 10.1021/bi00437a054; CANEPA L, 1991, BIOCHIM BIOPHYS ACTA, V1074, P101, DOI 10.1016/0304-4165(91)90046-J; COLOMBINI M, 1987, METHOD ENZYMOL, V148, P465; COLOMBINI M, 1987, BIOCHIM BIOPHYS ACTA, V905, P279, DOI 10.1016/0005-2736(87)90456-1; DOUCE R, 1987, METHOD ENZYMOL, V148, P403; FREITAG H, 1983, METHOD ENZYMOL, V97, P286; GELLERICH FN, 1993, BIOCHIM BIOPHYS ACTA, V1142, P217, DOI 10.1016/0005-2728(93)90150-E; GELLERICH FN, 1987, BIOCHIM BIOPHYS ACTA, V890, P117, DOI 10.1016/0005-2728(87)90012-0; GELLERICH FN, 1989, ANION CARRIERS OF MITOCHONDRIAL MEMBRANES, P349; GOTTSCHALK ME, 1981, BIOCHEMISTRY-US, V20, P2245, DOI 10.1021/bi00511a027; HARVEY AE, 1953, ANAL CHEM, V25, P498, DOI 10.1021/ac60075a031; HOLDEN MJ, 1993, BIOCHIM BIOPHYS ACTA, V1144, P396, DOI 10.1016/0005-2728(93)90126-Z; HOLDEN MJ, 1988, FEBS LETT, V241, P105, DOI 10.1016/0014-5793(88)81040-8; INCE C, 1992, OXYGEN TRANSPORT TIS, V14; LEE AC, 1994, J BIOL CHEM, V269, P30974; LIU MY, 1992, BIOCHIM BIOPHYS ACTA, V1098, P255, DOI 10.1016/S0005-2728(05)80344-5; MOLLER IM, 1986, ANNU REV PLANT PHYS, V37, P309, DOI 10.1146/annurev.arplant.37.1.309; MOLLER IM, 1993, J BIOENERG BIOMEMBR, V25, P377, DOI 10.1007/BF00762463; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; NUUTINEN EM, 1984, BASIC RES CARDIOL, V79, P49, DOI 10.1007/BF01935806; PALMER JM, 1982, TRENDS BIOCHEM SCI, V7, P258, DOI 10.1016/0968-0004(82)90039-1; Parsegian VA, 1995, METHOD ENZYMOL, V259, P43; PROUTY MS, 1985, J MOL BIOL, V184, P517, DOI 10.1016/0022-2836(85)90298-0; ROTH K, 1991, MAGNET RESON MED, V22, P505, DOI 10.1002/mrm.1910220258; SCHWITZGUEBEL JP, 1984, PLANT PHYSIOL, V75, P670, DOI 10.1104/pp.75.3.670; Song JM, 1996, J BIOENERG BIOMEMBR, V28, P153, DOI 10.1007/BF02110646; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a; VELOSO D, 1973, J BIOL CHEM, V248, P4811; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WAN B, 1993, AM J PHYSIOL, V265, pH453, DOI 10.1152/ajpheart.1993.265.2.H453; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; YOUNG A, 1955, ANAL CHEM, V27, P418, DOI 10.1021/ac60099a026; ZIMMERBERG J, 1986, NATURE, V323, P36, DOI 10.1038/323036a0; ZIZI M, 1994, J BIOL CHEM, V269, P1614	40	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26724	26731		10.1074/jbc.271.43.26724	http://dx.doi.org/10.1074/jbc.271.43.26724			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900151	hybrid			2022-12-25	WOS:A1996VP23300045
J	Pahwa, GS; Maher, LJ; Hollingsworth, MA				Pahwa, GS; Maher, LJ; Hollingsworth, MA			A potential H-DNA element in the MUC1 promoter does not influence transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR GENE; UPSTREAM	A purine/pyrimidine mirror repeat element (M-PMR3) in the MUC1 promoter has been shown to form H-DNA under in vitro conditions, We investigated this element for biological function in the regulation of transcription of this gene. Chloramphenicol acetyltransferase reporter-promoter constructs were prepared in which the mirror repeat element (PMR3) was intact, deleted, or modified, and their activities were evaluated by transient transfection assays into the cell lines Capan-2, PANC1, and HT-29. Deletion or modification of M-PMR3 increased expression of chloramphenicol acetyltransferase activity in MUC1-expressing cells; however, a role for an H-DNA structure in this activity was not supported by the results.	UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC & ALLIED DIS, OMAHA, NE 68198 USA; MAYO CLIN & MAYO FDN, DEPT BIOCHEM & MOL BIOL, ROCHESTER, MN 55905 USA	University of Nebraska System; University of Nebraska Medical Center; Mayo Clinic					NATIONAL CANCER INSTITUTE [R01CA057362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046589, R01DK044762] Funding Source: NIH RePORTER; NCI NIH HHS [CA57362] Funding Source: Medline; NIDDK NIH HHS [DK46589, DK44762] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE M, 1993, P NATL ACAD SCI USA, V90, P282, DOI 10.1073/pnas.90.1.282; AUSUBEL MF, 1992, SHORT PROTOCOLS MOL; FARR A, 1992, NUCLEIC ACIDS RES, V20, P920, DOI 10.1093/nar/20.4.920; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; HOLLINGSWORTH MA, 1994, NUCLEIC ACIDS RES, V22, P1138, DOI 10.1093/nar/22.7.1138; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; MA YG, 1992, DEV BIOL, V154, P45, DOI 10.1016/0012-1606(92)90046-J; MAXWELL IH, 1993, HUM GENE THER, V4, P441, DOI 10.1089/hum.1993.4.4-441; MCDONALD CD, 1994, GENE, V150, P267, DOI 10.1016/0378-1119(94)90436-7; Nelson KL, 1996, J BIOL CHEM, V271, P18061, DOI 10.1074/jbc.271.30.18061; PEAT N, 1992, CANCER RES, V52, P1954; RAGHU G, 1994, NUCLEIC ACIDS RES, V22, P3271, DOI 10.1093/nar/22.16.3271; WYNSHAW-BORIS A, 1986, Biotechniques, V4, P104; XU L, 1993, VIROLOGY, V194, P10	14	10	10	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26543	26546		10.1074/jbc.271.43.26543	http://dx.doi.org/10.1074/jbc.271.43.26543			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900124	hybrid			2022-12-25	WOS:A1996VP23300018
J	Waldburger, CD; Sauer, RT				Waldburger, CD; Sauer, RT			Signal detection by the PhoQ sensor-transmitter - Characterization of the sensor domain and a response-impaired mutant that identfies ligand-binding determinants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ASPARTATE RECEPTOR; MOLECULAR ANALYSIS; DNA-BINDING; TRANSDUCTION; GENE; REPRESSOR; INHIBITION; PROTEINS	The PhoP-PhoQ two-component system is required for virulence and/or regulatory stress responses in enteric bacteria, The PhoQ protein responds to low concentrations of extracellular divalent cations by activating PhoP mediated transcription of a set of genes. PhoQ is a member of a family of transmembrane proteins that contain a periplasmic sensor domain coupled to a cytoplasmic transmitter domain. Here, we describe the cloning, purification, and properties of a fragment of Escherichia coli PhoQ corresponding to the sensor domain, This fragment is monomeric in solution and has a circular dichroism spectrum indicative of a mixture of alpha-helix and beta-sheet. Divalent cations do not affect the oligomeric state, circular dichroism spectrum, or fluorescence spectrum of the sensor domain but do stabilize this domain to denaturation in a fashion expected for a direct binding model. We have also constructed a mutant in which a cluster of acidic amino acids (ED-DDDAE) in the sensor domain is replaced with conservative, uncharged residues (QNNNNAQ). The mutant sensor domain is indistinguishable from wild type in terms of oligomeric form and spectral properties but. differs in being substantially more stable to urea denaturation, showing no additional stabilization in the presence of divalent, cations, and showing little activation of PhoP-mediated transcription in response to divalent-cation starvation in vivo. These data are consistent with a model in which divalent cations bind to the acidic cluster of the wild-type sensor domain and stabilize a conformation that; is inactive in signaling, Substituting uncharged residues for the acidic cluster appears to mimic the effect of divalent-cation binding by stabilizing the inactive conformation.			Waldburger, CD (corresponding author), MIT,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.			Sauer, Robert/0000-0002-1719-5399	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016892] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-16892] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADES SE, 1994, BIOCHEMISTRY-US, V33, P9187, DOI 10.1021/bi00197a022; ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; AMMAN E, 1983, GENE, V25, P167; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BRENSTEIN RJ, 1989, ROBELKO SOFTWARE VER; CHURCHWARD G, 1984, GENE, V31, P165, DOI 10.1016/0378-1119(84)90207-5; DELORENZO V, 1990, J BACTERIOL, V172, P6568, DOI 10.1128/jb.172.11.6568-6572.1990; Doty SL, 1996, J BACTERIOL, V178, P961, DOI 10.1128/jb.178.4.961-970.1996; DZIEJMAN M, 1995, 2 COMPONENT SIGNAL T, P305; Eisenhaber F, 1996, PROTEINS, V25, P157, DOI 10.1002/(SICI)1097-0134(199606)25:2<157::AID-PROT2>3.0.CO;2-F; FASMAN GD, 1975, HDB BIOCH MOL BIOL, V1, P187; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; JOHNSON BH, 1994, BIO-TECHNOL, V12, P1357, DOI 10.1038/nbt1294-1357; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KASAHARA M, 1991, J BACTERIOL, V173, P6760, DOI 10.1128/jb.173.21.6760-6765.1991; KASAHARA M, 1992, J BACTERIOL, V174, P492, DOI 10.1128/jb.174.2.492-498.1992; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; Miller JH., 1972, EXPT MOL GENETICS; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; NELSON DL, 1971, J BIOL CHEM, V246, P3042; PACE C N, 1975, Critical Reviews in Biochemistry, V3, P1, DOI 10.3109/10409237509102551; PAN SQ, 1993, P NATL ACAD SCI USA, V90, P9939, DOI 10.1073/pnas.90.21.9939; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; ROBINSON CR, 1996, IN PRESS BIOCHEMISTR; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SILVA JL, 1992, J MOL BIOL, V223, P545, DOI 10.1016/0022-2836(92)90669-B; SUSSKIND MM, 1980, J MOL BIOL, V138, P685, DOI 10.1016/0022-2836(80)90060-1; TEALE FWJ, 1960, BIOCHEM J, V76, P381, DOI 10.1042/bj0760381; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; UTSUMI R, 1989, SCIENCE, V245, P1246, DOI 10.1126/science.2476847; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; WALDBURGER CD, 1995, BIOCHEMISTRY-US, V34, P13109, DOI 10.1021/bi00040a023; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057	38	51	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26630	26636		10.1074/jbc.271.43.26630	http://dx.doi.org/10.1074/jbc.271.43.26630			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900137	hybrid			2022-12-25	WOS:A1996VP23300031
J	Jault, JM; Dou, C; Grodsky, NB; Matsui, T; Yoshida, M; Allison, WS				Jault, JM; Dou, C; Grodsky, NB; Matsui, T; Yoshida, M; Allison, WS			The alpha(3)beta(3)gamma subcomplex of the F-1-ATPase from the thermophilic Bacillus PS3 with the beta T165S substitution does not entrap inhibitory MgADP in a catalytic site during turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; NUCLEOTIDE-BINDING-SITES; GLYCINE-RICH SEQUENCE; STEADY-STATE KINETICS; ESCHERICHIA-COLI; ATP HYDROLYSIS; NONCATALYTIC SITES; BETA-SUBUNIT; F1 ATPASE; ALPHA-3-BETA-3 COMPLEX	The hydrolytic properties of the mutant alpha(3)(beta T165S)(3) gamma and wild-type alpha(3) beta(3) gamma subcomplexes of TF1 have been compared. Whereas the wild-type complex hydrolyzes 50 mu M ATP in three kinetic phases, the mutant complex hydrolyzes 50 mu M ATP with a linear rate. After incubation with a slight excess of ADP in the presence of Mg2+, the wild-type complex hydrolyzes 2 mM ATP with a long lag. In contrast, prior incubation of the mutant complex under these conditions does not affect the kinetics of ATP hydrolysis. The ATPase activity of the wild-type complex is stimulated 4-fold by 0.1% lauryl dimethylamine oxide, whereas this concentration of lauryl dimethylamine oxide inhibits the mutant complex by 25%. Compared with the wild-type complex, the activity of the mutant complex is much less sensitive to turnover-dependent inhibition by azide. This comparison suggests that the mutant complex does not-entrap substantial inhibitory MgADP in a catalytic site during turnover, which is supported by the following observations. ATP hydrolysis catalyzed by the wild-type complex is progressively inhibited by increasing concentrations of Mg2+ in the assay medium, whereas the mutant complex is insensitive to increasing concentrations of Mg2+. A Lineweaver-Burk plot constructed from rates of hydrolysis of 20-2000 mu M ATP by the wild-type complex is biphasic, exhibiting apparent K-m values of 30 Cur and 470 mu M with corresponding k(cat) values of 26 and 77 s(-1). In contrast; a Lineweaver-Burk plot for the mutant complex is linear in this range of ATP concentration, displaying a K-m of 133 mu M and a k(cat) of 360 s(-1).	UNIV CALIF SAN DIEGO, SCH MED, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA; TOKYO INST TECHNOL, RESOURCES UTILIZAT RES LAB, YOKOHAMA, KANAGAWA 227, JAPAN	University of California System; University of California San Diego; Tokyo Institute of Technology			jault, jean-michel/G-2086-2012	jault, jean-michel/0000-0003-1743-2777	NIGMS NIH HHS [GM-16974] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Allison WS, 1995, BIOCHEM SOC T, V23, P752, DOI 10.1042/bst0230752; ALLISON WS, 1992, J BIOENERG BIOMEMBR, V24, P469, DOI 10.1007/BF00762364; AMANO T, 1994, FEBS LETT, V351, P1, DOI 10.1016/0014-5793(94)00796-9; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULYGIN VV, 1991, BIOCHEM J, V276, P149, DOI 10.1042/bj2760149; Cross RL, 1992, MOL MECHANISMS BIOEN, P317; DROBINSKAYA IY, 1985, FEBS LETT, V182, P419, DOI 10.1016/0014-5793(85)80346-X; EBEL RE, 1975, J BIOL CHEM, V250, P191; GRESSER MJ, 1982, J BIOL CHEM, V257, P2030; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; GUERRERO KJ, 1990, J BIOL CHEM, V265, P16280; Guggenheim EA, 1926, PHILOS MAG, V2, P538; HATEFI Y, 1993, EUR J BIOCHEM, V218, P759, DOI 10.1111/j.1432-1033.1993.tb18431.x; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; Jault JM, 1995, BIOCHEMISTRY-US, V34, P16412, DOI 10.1021/bi00050a023; JAULT JM, 1993, J BIOL CHEM, V268, P1558; JAULT JM, 1994, J BIOL CHEM, V269, P319; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KAGAWA Y, 1989, FEBS LETT, V249, P67, DOI 10.1016/0014-5793(89)80017-1; KASHO VN, 1984, J BIOENERG BIOMEMBR, V16, P407, DOI 10.1007/BF00743235; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; MILGROM YM, 1989, BIOCHIM BIOPHYS ACTA, V975, P50, DOI 10.1016/S0005-2728(89)80200-2; MILGROM YM, 1991, J BIOL CHEM, V266, P11551; MIWA K, 1989, P NATL ACAD SCI USA, V86, P6484, DOI 10.1073/pnas.86.17.6484; MUELLER DM, 1994, EUR J BIOCHEM, V222, P991, DOI 10.1111/j.1432-1033.1994.tb18950.x; MUELLER DM, 1989, J BIOL CHEM, V264, P16552; MURATALIEV MB, 1991, BIOCHEMISTRY-US, V30, P8305, DOI 10.1021/bi00098a004; MURATALIEV MB, 1992, BIOCHEMISTRY-US, V31, P12885, DOI 10.1021/bi00166a025; OMOTE H, 1992, J BIOL CHEM, V267, P20571; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PAIK SR, 1994, BIOCHEMISTRY-US, V33, P126, DOI 10.1021/bi00167a016; PAIK SR, 1993, J BIOENERG BIOMEMBR, V25, P679; PAIK SR, 1994, BIOCHEMISTRY-US, V33, P125; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RECKTENWALD D, 1977, FEBS LETT, V76, P25, DOI 10.1016/0014-5793(77)80113-0; ROVERI OA, 1985, FEBS LETT, V192, P123, DOI 10.1016/0014-5793(85)80056-9; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SAUGER F, 1980, J MOL BIOL, V143, P161; SCHUSTER SM, 1975, J BIOL CHEM, V250, P7848; SHEN HG, 1994, J BIOL CHEM, V269, P9424; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; TAKEYAMA M, 1990, J BIOL CHEM, V265, P21279; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; VASILYEVA EA, 1982, BIOCHEM J, V202, P9, DOI 10.1042/bj2020009; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBER J, 1993, J BIOL CHEM, V268, P20126; Weber J, 1996, J BIOL CHEM, V271, P3474; WONG SY, 1984, BIOCHEMISTRY-US, V23, P5004, DOI 10.1021/bi00316a027; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21837; YOSHIDA M, 1981, J BIOL CHEM, V256, P148; YOSHIDA M, 1983, J BIOL CHEM, V258, P4407; YOSHIDA M, 1986, J BIOL CHEM, V261, P5714; ZHOU JM, 1988, BIOCHEMISTRY-US, V27, P5129, DOI 10.1021/bi00414a027	58	62	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28818	28824		10.1074/jbc.271.46.28818	http://dx.doi.org/10.1074/jbc.271.46.28818			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910526	hybrid			2022-12-25	WOS:A1996VT05200018
J	Laughlin, MR; Thompson, D				Laughlin, MR; Thompson, D			The regulatory role for magnesium in glycolytic flux of the human erythrocyte	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODEL; CELL	P-31 NMR was used to measure the intracellular free magnesium concentration ([Mg2+](i)) in human erythrocytes while [Mg2+](i) was changed between 0.01 and 1.2 mM using the divalent cationophore A23187. C-13 NMR and [2-C-13]glucose were used to determine the kinetic effects of [Mg2+](i) by measuring the flux through several parts of the glucose pathway. Glucose utilization was strongly dependent on [Mg2+](i), With half-maximal flux occurring at 0.03 mM. The rate-limiting step was most likely at phosphofructokinase, which has a K-m(Mg2+) Of 0.025 mM in the purified enzyme, Phosphorylated glycolytic intermediate concentration was also strongly dependent on [Mg2+](i) and [MgATP], and glucose transport plus hexokinase may have been partially rate-determining at [Mg2+](i) below similar to 0.1 mM. The pentose phosphate shunt activity was too low to determine the dependence on [Mg2+](i). Phosphoglycerate kinase and 2,3-diphosphoglycerate mutase fluxes were also measured, but were not rate-limiting for glycolysis and showed no Mg2+ dependence. Human erythrocyte [Mg2+](i) varies between 0.2 mM (oxygenated) and 0.6 an (deoxygenated), well above the measured [Mg2+](i(1/2)). It is unlikely, then, that [Mg2+](i) plays a regulatory role in normal erythrocyte glycolysis.			Laughlin, MR (corresponding author), GEORGE WASHINGTON UNIV,MED CTR,DEPT SURG,ROSS HALL 550,2300 EYE ST NW,WASHINGTON,DC 20037, USA.							ENGSTROM I, 1993, SCAND J CLIN LAB INV, V53, P239, DOI 10.3109/00365519309088415; ENGSTROM I, 1993, CLIN CHIM ACTA, V219, P113, DOI 10.1016/0009-8981(93)90202-F; FERREIRA HG, 1976, NATURE, V259, P47, DOI 10.1038/259047a0; FLATMAN P, 1977, NATURE, V267, P360, DOI 10.1038/267360a0; GERBER G, 1974, EUR J BIOCHEM, V45, P39, DOI 10.1111/j.1432-1033.1974.tb03527.x; GEVEN WB, 1991, CLIN CHEM, V37, P206; GRIMES AJ, 1960, ANAEROBIC GLYCOLYSIS; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; MINAKAMI S, 1966, J BIOCHEM, V59, P145, DOI 10.1093/oxfordjournals.jbchem.a128275; MOSHER TJ, 1992, MAGNET RESON MED, V24, P163, DOI 10.1002/mrm.1910240117; MURPHY JR, 1960, J LAB CLIN MED, V55, P286; OTTO M, 1974, EUR J BIOCHEM, V49, P169, DOI 10.1111/j.1432-1033.1974.tb03822.x; PALSSON BO, 1989, RED CELL 7 ANN ARB C, P133; PONCE J, 1971, BIOCHIM BIOPHYS ACTA, V250, P63, DOI 10.1016/0005-2744(71)90120-3; RUDE RK, 1991, MAGNESIUM TRACE ELEM, V92, P117; SCHRADER MC, 1993, BIOCHIM BIOPHYS ACTA, V1182, P162, DOI 10.1016/0925-4439(93)90138-Q; TILTON WM, 1991, J LAB CLIN MED, V118, P146; TONGYAI S, 1989, AM J PHYSIOL, V257, pC270, DOI 10.1152/ajpcell.1989.257.2.C270	18	39	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28977	28983		10.1074/jbc.271.46.28977	http://dx.doi.org/10.1074/jbc.271.46.28977			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910548	hybrid			2022-12-25	WOS:A1996VT05200040
J	Mazzorana, M; Snellman, A; Kivirikko, KI; vanderRest, M; Pihlajaniemi, T				Mazzorana, M; Snellman, A; Kivirikko, KI; vanderRest, M; Pihlajaniemi, T			Involvement of prolyl 4-hydroxylase in the assembly of trimeric minicollagen XII - Study in a baculovirus expression system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; SITE-DIRECTED MUTAGENESIS; BETA-SUBUNIT; HISTIDINE-RESIDUES; MOLECULAR-CLONING; ALPHA-SUBUNIT; COLLAGEN-XIV; PROCOLLAGEN; IDENTIFICATION; HYDROXYLATION	We have shown previously that hydroxylation played a critical role in the trimer assembly and disulfide bonding of the three constituent alpha chains of a minicollagen composed of the extreme C-terminal collagenous (COL1) and noncollagenous (NC1) domains of type XII collagen in HeLa cells (Mazzorana, M., Gruffat, H., Sergeant, A., and van der Rest, M. (1993) J. Biol. Chem. 268, 3029-3032). We have further characterized the involvement of prolyl 4-hydroxylase in the assembly of the three alpha chains to form trimeric disulfide-bonded type XII minicollagen in an insect cell expression system. For this purpose, type XII minicollagen was produced in insect cells from baculovirus vectors, alone or together with wild-type human prolyl 4-hydroxylase or with the human enzyme mutated in the catalytic site of its alpha or beta subunits or with the individual alpha or beta subunits. When type XII minicollagen was produced alone, negligible amounts of disulfide-bonded trimers were found to be produced by the cells. However, coproduction of the collagen with the two subunits of the wild-type human enzyme dramatically increased the amount of disulfide-bonded trimeric type XII minicollagen molecules. In contrast, coproduction of the collagen with alpha subunits that had a mutation completely inactivating the human enzyme failed to enhance the trimer assembly. These results directly show that an active prolyl 4-hydroxylase is required for the assembly of disulfide-bonded trimers of type XII minicollagen.	UNIV OULU, BIOCTR, COLLAGEN RES UNIT, FIN-90220 OULU, FINLAND; UNIV OULU, DEPT MED BIOCHEM, FIN-90220 OULU, FINLAND	University of Oulu; University of Oulu	Mazzorana, M (corresponding author), INST BIOL & CHIM PROT, CNRS, UPR 412, 7 PASSAGE VERCORS, F-69367 LYON 07, FRANCE.			Pihlajaniemi, Taina/0000-0002-1664-9045; MAZZORANA, Marlene/0000-0002-3956-4319				BACHINGER HP, 1981, J BIOL CHEM, V256, P3193; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; BROWN JC, 1994, MATRIX BIOL, V14, P287, DOI 10.1016/0945-053X(94)90194-5; BROWN JC, 1993, J CELL BIOL, V120, P557, DOI 10.1083/jcb.120.2.557; BROWN M, 1977, J GEN VIROL, V36, P361, DOI 10.1099/0022-1317-36-2-361; BRUCKNER P, 1981, EUR J BIOCHEM, V118, P607, DOI 10.1111/j.1432-1033.1981.tb05562.x; BRUCKNER P, 1984, EUR J BIOCHEM, V140, P391, DOI 10.1111/j.1432-1033.1984.tb08114.x; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; DUBLET B, 1987, J BIOL CHEM, V262, P17724; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FESSLER LI, 1974, J BIOL CHEM, V249, P7637; FONT B, 1993, J BIOL CHEM, V268, P25015; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; FUKAI N, 1994, METHOD ENZYMOL, V245, P3; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GORDON MK, 1987, P NATL ACAD SCI USA, V84, P6040, DOI 10.1073/pnas.84.17.6040; GRUENWALD S, 1993, BACULOVIRUS VECTOR E, P1; KEENE DR, 1991, J CELL BIOL, V113, P971, DOI 10.1083/jcb.113.4.971; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; KOIVU J, 1987, J BIOL CHEM, V262, P6447; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERG A, 1995, J BIOL CHEM, V270, P9926, DOI 10.1074/jbc.270.17.9926; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; LUNSTRUM GP, 1992, J BIOL CHEM, V267, P20087; MALITSCHEK B, 1991, BIOTECHNIQUES, V11, P177; Mayne R, 1993, CURR OPIN CELL BIOL, V5, P883, DOI 10.1016/0955-0674(93)90039-S; MAZZORANA M, 1993, J BIOL CHEM, V268, P3029; MAZZORANA M, 1995, MATRIX BIOL, V14, P583, DOI 10.1016/S0945-053X(05)80007-1; MYLLYLA R, 1992, BIOCHEM J, V286, P923, DOI 10.1042/bj2860923; NISHIYAMA T, 1994, J BIOL CHEM, V269, P28193; PARKKONEN T, 1988, BIOCHEM J, V256, P1005, DOI 10.1042/bj2561005; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; SUGRUE SP, 1989, J CELL BIOL, V109, P939, DOI 10.1083/jcb.109.2.939; SUGRUE SP, 1991, INVEST OPHTH VIS SCI, V32, P1876; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; VANDERPLAATS GN, 1993, STRUCT OPTIMIZATION, V6, P1, DOI 10.1007/BF01743168; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; VEIJOLA J, 1994, J BIOL CHEM, V269, P26746; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; WATT SL, 1992, J BIOL CHEM, V267, P20093; Wickham T J, 1995, Methods Mol Biol, V39, P385	47	18	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29003	29008		10.1074/jbc.271.46.29003	http://dx.doi.org/10.1074/jbc.271.46.29003			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910551	hybrid			2022-12-25	WOS:A1996VT05200043
J	Schulein, R; Rutz, C; Rosenthal, W				Schulein, R; Rutz, C; Rosenthal, W			Membrane targeting and determination of transmembrane topology of the human vasopressin V2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN; TRANSLOCATION; ORIENTATION; INSERTION; REQUIRES; CLONING	The human vasopressin V2 receptor belongs to the large family of G-protein-coupled receptors, which possess seven transmembrane helices, an extracellular N terminus and an intracellular C terminus. We have determined the sequence requirements of the V2 receptor for membrane insertion and correct topology for the inner membrane of Escherichia coli with the PhoA/LacZ gene fusion system. In addition, we have studied the signals for ifs membrane insertion and correct topology for the membrane of the endoplasmic reticulum of the authentic eucaryotic transport system. To this end, we have extended the PhoA/LacZ gene fusion system for the first time to eucaryotic cells, i.e. transiently transfected COS.M6 cells. Truncated V2 receptor sequences were fused to PhoA and LacZ and expressed in both E. coli and COS.M6 cells. Cells were fractionated, and LacZ/PhoA activity assays and immunoblots were performed. We show here that a V2 receptor fragment consisting of the N terminus, the first transmembrane segment and the first cytoplasmic loop (71 amino acids) provided sufficient information for membrane insertion and correct orientation (extracellular N terminus) in both procaryotic and eucaryotic cells. Our data differ substantially from those obtained for the human Pz-adrenergic receptor expressed in E. coli (Lacatena, R. M., Cellini, A. Scavizzi, F., and Tocchini-Valentini, G. P. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 10521-10525). To establish correct topology, the beta(2)-adrenergic receptor requires a larger receptor portion, including the three N-terminal transmembrane segments and/or parts of the second cytoplasmic loop. The present data show that the observations made for the beta(2)-adrenergic receptor cannot be applied to G-protein-coupled receptors generally.	UNIV GIESSEN,RUDOLF BUCHHEIM INST PHARMAKOL,D-35392 GIESSEN,GERMANY; FORSCHUNGSINST MOL PHARMAKOL,D-10315 BERLIN,GERMANY	Justus Liebig University Giessen								ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; DRIESSEN AJM, 1994, J MEMBRANE BIOL, V142, P145; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HENN DK, 1995, P NATL ACAD SCI USA, V92, P7425, DOI 10.1073/pnas.92.16.7425; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; HIGH S, 1992, Current Opinion in Cell Biology, V4, P581, DOI 10.1016/0955-0674(92)90075-N; JUNGNICKEL B, 1994, FEBS LETT, V346, P73, DOI 10.1016/0014-5793(94)00367-X; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; KOSHLAND D, 1980, CELL, V20, P749, DOI 10.1016/0092-8674(80)90321-9; LACATENA RM, 1994, P NATL ACAD SCI USA, V91, P10521, DOI 10.1073/pnas.91.22.10521; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; MARULLO S, 1988, P NATL ACAD SCI USA, V85, P7551, DOI 10.1073/pnas.85.20.7551; Miller JH., 1972, EXPT MOL GENETICS; Perbal B., 1988, PRACTICAL GUIDE MOL; SAMBROOK J, 1989, MOL CLINING LAB MANU; SCHULEIN R, 1992, MOL GEN GENET, V234, P155; Schulein R, 1996, BIOCHEM J, V313, P611, DOI 10.1042/bj3130611; SPIESS M, 1995, FEBS LETT, V369, P76, DOI 10.1016/0014-5793(95)00551-J; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8	25	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28844	28852		10.1074/jbc.271.46.28844	http://dx.doi.org/10.1074/jbc.271.46.28844			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910530	hybrid			2022-12-25	WOS:A1996VT05200022
J	Watts, SD; Tang, CL; Capaldi, RA				Watts, SD; Tang, CL; Capaldi, RA			The stalk region of the Escherichia coli ATP synthase - Tyrosine 205 of the gamma subunit is in the interface between the F-1 and F-0 parts and can interact with both the epsilon and c oligomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F1 ADENOSINE-TRIPHOSPHATASE; CRYOELECTRON MICROSCOPY; CATALYTIC SITES; MONOCLONAL-ANTIBODIES; ELECTRON-MICROSCOPY; CYSTEINE RESIDUES; LOOP REGION; POLAR LOOP; F1-ATPASE; BINDING	The soluble portion of the Escherichia coli F1F0 ATP synthase (ECF(1)) and E. coli F1F0 ATP synthase (ECF(1)F(0)) have been isolated hom a novel mutant gamma Y205C. ECF(1) isolated from this mutant had an ATPase activity 3.5-fold higher than that of wild-type enzyme and could be activated further by maleimide modification of the introduced cysteine. This effect was not seen in ECF(1)F(0). The mutation partly disrupts the F-1 to F-0 interaction, as indicated by a reduced efficiency of proton pumping, ECF(1) containing the mutation gamma Y205C was bound to the membrane-bound portion of the E. coli F1F0 ATP synthase (ECF(0)) isolated from mutants cA39C, cQ42C, cP43C, and cD44C to reconstitute hybrid enzymes, Cu2+ treatment or reaction with 5,5'-dithio-bis(2-nitro-benzoic acid) induced disulfide bond formation between the Cys at gamma position 205 and a Cys residue at positions 42, 43, or 44 in the c subunit but not at position 39, Using Cu2+ treatment, this covalent cross-linking was obtained in yields as high as 95% in the hybrid ECF(1) gamma Y205C/cQ42C and in ECF(1)F(0) isolated from the double mutant of the same composition, The covalent linkage of the gamma to a c subunit had little effect on ATPase activity, However, ATP hydrolysis linked proton translocation was lost, by modification of both gamma Cys-205 and c Cys-42 by bulky reagents such as 5,5'-dithio-bis (2 nitro-benzoic acid) or benzophenone-4-maleimide. In both ECF(1) and ECF(1)F(0) containing a Cys at gamma 205 and a Cys in the epsilon subunit (at position 38 or 43), cross linking of the gamma to the epsilon subunit was induced in high yield by Cu2+, NO cross-linking was observed in hybrid enzymes in which the Cys was at position 10, 65, or 108 of the epsilon subunit, Cross-linking of gamma to epsilon had only a minimal effect on ATP hydrolysis, The reactivity of the Cys at gamma 205 showed a nucleotide dependence of reactivity to maleimides in both ECF(1) and ECF(1)F(0), which was lost in ECF(1) when the epsilon subunit was removed, Our results show that there is close interaction of the gamma and a subunits for the full-length of the stalk region in ECF(1)F(0). We argue that this interaction controls the coupling between nucleotide binding sites and the proton channel in ECF(1)F(0).	UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403	University of Oregon					NHLBI NIH HHS [HL 24526] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1990, BIOCHEMISTRY-US, V29, P10387, DOI 10.1021/bi00497a013; AGGELER R, 1993, J BIOL CHEM, V268, P20831; AGGELER R, 1992, J BIOL CHEM, V267, P21355; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; AGGELER R, 1995, BBA-BIOENERGETICS, V1230, P62, DOI 10.1016/0005-2728(95)00040-P; AGGELER R, 1987, BIOCHEMISTRY-US, V26, P7107, DOI 10.1021/bi00396a036; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Feng ZY, 1996, J BIOL CHEM, V271, P17986, DOI 10.1074/jbc.271.30.17986; GIRVIN ME, 1989, BIOCHEMISTRY-US, V28, P4340, DOI 10.1021/bi00436a032; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; LAEMMLI UK, 1970, BIOCHEMISTRY-US, V9, P4620; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; LUNSDORF H, 1984, J MOL BIOL, V173, P131, DOI 10.1016/0022-2836(84)90408-X; MUSIER KM, 1987, BIOCHEMISTRY-US, V26, P5982, DOI 10.1021/bi00393a006; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; TANG CL, 1994, J BIOL CHEM, V269, P4467; TURINA P, 1994, J BIOL CHEM, V269, P13465; WALKER JE, 1984, BIOCHEM J, V224, P799, DOI 10.1042/bj2240799; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; WISE JG, 1981, J BIOL CHEM, V256, P383; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609; ZHANG Y, 1994, J BIOL CHEM, V269, P10221	36	80	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28341	28347		10.1074/jbc.271.45.28341	http://dx.doi.org/10.1074/jbc.271.45.28341			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910457	hybrid			2022-12-25	WOS:A1996VU03300057
J	Denisenko, ON; ONeill, B; Ostrowski, J; VanSeuningen, I; Bomsztyk, K				Denisenko, ON; ONeill, B; Ostrowski, J; VanSeuningen, I; Bomsztyk, K			Zik1, a transcriptional repressor that interacts with the heterogeneous nuclear ribonucleoprotein particle K protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEINS; MAMMALIAN-CELLS; IL-1-RESPONSIVE KINASE; IN-VITRO; EXPRESSION; DOMAIN; DNA; IDENTIFICATION; COMPLEX; INVITRO	The heterogeneous nuclear ribonucleoprotein particle (hnRNP) K protein is comprised of multiple modular domains that serve to engage a diverse group of molecular partners including DNA, RNA, the product of the proto-oncogene vav, and tyrosine and serine/threonine kinases. To identify additional K protein molecular partners and to further understand its function, we used a fragment of K protein as a bait in the yeast two-hybrid screen. The deduced primary structure of one of the positive clones revealed a novel zinc finger protein, hereby denoted as Zik1. In addition to the nine contiguous zinc fingers in the C terminus, Zik1 contains a KRAB-A domain thought to be involved in transcriptional repression, Zik1 and K protein bound in vitro and co-immunoprecipitated from cell extracts indicating that in vivo their interaction is direct. Expression of Gal4 DNA-binding domain-Zik1 fusion protein repressed a gene promoter bearing Gal4-binding elements, indicating that from cognate DNA elements Zik1 is a transcriptional repressor. The known diverse nature of K protein molecular interactions and now the identification of a K protein partner that is a transcriptional repressor lends support to the notion that K protein is a remarkably versatile molecule that may be acting as a docking platform to facilitate communication among molecules involved in signal transduction and gene expression.	INST PROT RES,PUSHCHINO 142292,RUSSIA		Denisenko, ON (corresponding author), UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195, USA.		VAN SEUNINGEN, Isabelle/N-6176-2016	VAN SEUNINGEN, Isabelle/0000-0002-3131-2694; Ostrowski, Jerzy/0000-0003-1363-3766	NIDDK NIH HHS [DK45978] Funding Source: Medline; NIGMS NIH HHS [GM45134, GM42508] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045978, R01DK045978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045134, P01GM042508] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLARD DW, 1988, J BIOL CHEM, V263, P8450; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BIRD TA, 1989, J IMMUNOL, V142, P126; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAILLARD C, 1994, NUCLEIC ACIDS RES, V22, P4183, DOI 10.1093/nar/22.20.4183; GAILLARD C, 1990, J MOL BIOL, V215, P245, DOI 10.1016/S0022-2836(05)80343-2; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HOBERT O, 1994, J BIOL CHEM, V269, P20225; JOHNSON RJ, 1991, J CLIN INVEST, V87, P847, DOI 10.1172/JCI115089; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KILEDJIAN M, 1995, EMBO J, V14, P4357, DOI 10.1002/j.1460-2075.1995.tb00110.x; KLUXEN FW, 1993, ANAL BIOCHEM, V208, P352, DOI 10.1006/abio.1993.1060; Lee MH, 1996, J BIOL CHEM, V271, P3420; MATUNIS MJ, 1994, NUCLEIC ACIDS RES, V22, P1059, DOI 10.1093/nar/22.6.1059; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; OSTROWSKI J, 1994, J BIOL CHEM, V269, P17626; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; PAIGE CJ, 1978, J IMMUNOL, V121, P641; RICHARDSON CA, 1995, AM J PHYSIOL-RENAL, V268, pF273, DOI 10.1152/ajprenal.1995.268.2.F273; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Sambrook J., 2002, MOL CLONING LAB MANU; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; THIESEN H-J, 1990, New Biologist, V2, P363; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; VANSEUNINGEN I, 1995, BIOCHEMISTRY-US, V34, P5644, DOI 10.1021/bi00016a040; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; VANSEUNINGEN I, 1994, J AM SOC NEPHROL, V5, P735; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WITZGALL R, 1993, MOL CELL BIOL, V13, P1933, DOI 10.1128/MCB.13.3.1933; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514	37	69	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27701	27706		10.1074/jbc.271.44.27701	http://dx.doi.org/10.1074/jbc.271.44.27701			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910362	hybrid			2022-12-25	WOS:A1996VQ67900080
J	Muda, M; Theodosiou, A; Rodrigues, N; Boschert, U; Camps, M; Gillieron, C; Davies, K; Ashworth, A; Arkinstall, S				Muda, M; Theodosiou, A; Rodrigues, N; Boschert, U; Camps, M; Gillieron, C; Davies, K; Ashworth, A; Arkinstall, S			The dual specificity phosphatases M3/6 and MKP-3 are highly selective for inactivation of distinct mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; IMMEDIATE-EARLY GENE; MAP KINASE; HEAT-SHOCK; TYROSINE-PHOSPHATASE; MAMMALIAN-CELLS; RAS; STRESS; TRANSFORMATION; EXPRESSION	The mitogen-activated protein (MAP) kinase family includes extracellular signal regulated kinase (ERK), c-Jun NH2-terminal kinase/stress-activated protein kinase (JNK/SAPK) and p38/RK/CSBP (p38) as structurally and functionally distinct enzyme classes. Here we describe two new dual specificity phosphatases of the CL100/MKP-1 family that are selective for inactivating ERK or JNK/SAPK and p38 MAP kinases when expressed in COS-7 cells. M3/6 is the first phosphatase of this family to display highly specific inactivation of JNK/SAPK and p38 MAP kinases. Although stress-induced activation of p54 SAPK beta, p46 SAPK gamma (JNK1) or p38 MAP kinases is abolished upon co-transfection with increasing amounts of M3/6 plasmid, epidermal growth factor-stimulated ERK1 is remarkably insensitive even to the highest levels of M3/6 expression obtained. In contrast to M3/6, the dual specificity phosphatase MKP-3 is selective for inactivation of ERK family MAP kinases. Low level expression of MKP-3 blocks totally epidermal growth factor-stimulated ERK1, whereas stress-induced activation of p54 SAPK beta and p38 MAP kinases is inhibited only partially under identical conditions. Selective regulation by M3/6 and MKP-3 was also observed upon chronic MAP kinase activation by constitutive p21(ras) GTPases. Hence, although M3/6 expression effectively blocked p54 SAPK beta activation by p21(rac) (G12V), ERK1 activated by p21(ras) (G12V) was insensitive to this phosphatase. ERK1 activation by oncogenic p21(ras) was, however, blocked totally by co-expression of MKP-3. This is the first report demonstrating reciprocally selective inhibition of different MAP kinases by two distinct dual specificity phosphatases.	GLAXO WELLCOME RES & DEV LTD,GENEVA BIOMED RES INST,CH-1228 PLAN LES OUATES,GENEVA,SWITZERLAND; UNIV OXFORD,DEPT BIOCHEM,GENET LAB,OXFORD OX1 3QU,ENGLAND; INST CANC RES,CHESTER BEATTY LABS,CANC RES CAMPAIGN,CTR CELL & MOL BIOL,LONDON SW3 6JB,ENGLAND	GlaxoSmithKline; University of Oxford; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK				Camps, Montserrat/0000-0002-9849-8657	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALESSI DR, 1993, ONCOGENE, V8, P2015; BERETTA L, 1995, EUR J BIOCHEM, V227, P388, DOI 10.1111/j.1432-1033.1995.tb20401.x; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHARLES CH, 1992, ONCOGENE, V7, P187; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; King AG, 1995, ONCOGENE, V11, P2553; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P4319; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; THEODOSIOU AM, 1996, HUM MOL GENET, V96, P675; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; XIA A, 1996, SCIENCE, V270, P1326; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	49	312	319	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27205	27208		10.1074/jbc.271.44.27205	http://dx.doi.org/10.1074/jbc.271.44.27205			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910287	hybrid			2022-12-25	WOS:A1996VQ67900005
J	Seibert, FS; Linsdell, P; Loo, TW; Hanrahan, JW; Riordan, JR; Clarke, DM				Seibert, FS; Linsdell, P; Loo, TW; Hanrahan, JW; Riordan, JR; Clarke, DM			Cytoplasmic loop three of cystic fibrosis transmembrane conductance regulator contributes to regulation of chloride channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CL CHANNEL; ATP HYDROLYSIS; CFTR GENE; R-DOMAIN; PHOSPHORYLATION; MUTATIONS; IDENTIFICATION; BINDING; CELLS; DYSFUNCTION	To examine the contribution of the large cytoplasmic loops of the cystic fibrosis transmembrane conductance regulator (CFTR) to channel activity, the three point-mutations (S945L, H949Y, G970R) were characterized that have been detected in the third cytoplasmic loop (CL3, residues 933-990) in patients with cystic fibrosis, Chinese hamster ovary cell lines stably expressing wildtype CFTR or mutant G970R-CFTR yielded polypeptides with apparent masses of 170 kDa as the major products, whereas the major products of mutants S945L-CFTR and H949Y-CFTR had apparent masses of 150 kDa. The 150-kDa forms of CFTR were sensitive to endoglycosidase H digestion, indicating that these mutations interfered with maturation of the protein, Increased levels of mature CFTR (170 kDa) could be obtained for mutant H949Y when cells were grown at a lower temperature (26 degrees C) or incubated in the presence of 10% glycerol, For all mutants, the open probability (P-0) of the CFTR channels was significantly altered, S945L-CFTR and G970R-CFTR showed a severe reduction in the P-0, whereas the H949Y mutation doubled the P-0 relative to wild type. The changes in P-0 predominantly resulted from an alteration of the mean burst durations which suggests that CL3 is involved in obtaining and/or maintaining stability of the open state. In addition, mutants S945L and G970R had current-voltage relationships that were not completely linear over the range +/-80 mV, but showed slight outward rectification, The fact that CL3 mutations can have subtle effects on channel conductance indicates that this region may be physically close to the inner mouth of the pore.	UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA; MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3G 1Y6,CANADA; MAYO CLIN SCOTTSDALE,SC JOHNSON MED RES CTR,MAYO GRAD SCH MED,SCOTTSDALE,AZ 85259; MAYO CLIN SCOTTSDALE,SC JOHNSON MED RES CTR,DEPT BIOCHEM & MOL BIOL,SCOTTSDALE,AZ 85259	University of Toronto; McGill University; Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son; Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son	Seibert, FS (corresponding author), UNIV TORONTO,DEPT MED,MRC,GRP MEMBRANE BIOL,TORONTO,ON M5S 1A8,CANADA.		Hanrahan, John/AGG-1926-2022; Clarke, David M./A-1112-2008	Hanrahan, John/0000-0001-9080-2039; Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188; Linsdell, Paul/0000-0001-6257-6273				ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BAYER EA, 1988, ANAL BIOCHEM, V170, P271, DOI 10.1016/0003-2697(88)90631-8; BECQ F, 1994, P NATL ACAD SCI USA, V91, P9160, DOI 10.1073/pnas.91.19.9160; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; Carson MR, 1995, BIOPHYS J, V69, P2443, DOI 10.1016/S0006-3495(95)80113-X; CHAMPIGNY G, 1995, EMBO J, V14, P2417, DOI 10.1002/j.1460-2075.1995.tb07239.x; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CLAUSTRES M, 1993, HUM MOL GENET, V2, P1209, DOI 10.1093/hmg/2.8.1209; CUPPENS H, 1993, GENOMICS, V18, P693, DOI 10.1016/S0888-7543(05)80376-3; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DIAMOND G, 1991, J BIOL CHEM, V266, P22761; GHANEM N, 1994, GENOMICS, V21, P434, DOI 10.1006/geno.1994.1290; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; LOO TW, 1994, J BIOL CHEM, V269, P28683; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; PRINCE LS, 1994, P NATL ACAD SCI USA, V91, P5192, DOI 10.1073/pnas.91.11.5192; RICH DP, 1993, J BIOL CHEM, V268, P20259; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROSENFELD MA, 1994, HUM GENE THER, V5, P1121, DOI 10.1089/hum.1994.5.9-1121; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Seibert FS, 1996, J BIOL CHEM, V271, P15139, DOI 10.1074/jbc.271.25.15139; SHEPPARD DN, 1995, EMBO J, V14, P876, DOI 10.1002/j.1460-2075.1995.tb07069.x; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TABCHARANI JA, 1992, BIOPHYS J, V62, P1, DOI 10.1016/S0006-3495(92)81759-9; Tao T, 1996, BIOPHYS J, V70, P743, DOI 10.1016/S0006-3495(96)79614-5; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Wilkinson DJ, 1996, J GEN PHYSIOL, V107, P103, DOI 10.1085/jgp.107.1.103; WINTER MC, 1994, BIOPHYS J, V66, P1398, DOI 10.1016/S0006-3495(94)80930-0; XIE JX, 1995, J BIOL CHEM, V270, P28084	41	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27493	27499		10.1074/jbc.271.44.27493	http://dx.doi.org/10.1074/jbc.271.44.27493			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910333	hybrid			2022-12-25	WOS:A1996VQ67900051
J	Yruela, I; Pueyo, JJ; Alonso, PJ; Picorel, R				Yruela, I; Pueyo, JJ; Alonso, PJ; Picorel, R			Photoinhibition of photosystem II from higher plants - Effect of copper inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU(II)-INHIBITORY BINDING-SITE; SINGLET OXYGEN PRODUCTION; REACTION CENTERS; EPR SPECTROSCOPY; DONOR-SIDE; THYLAKOID MEMBRANES; ELECTRON-TRANSPORT; LIPID-PEROXIDATION; 2 SITES; DEGRADATION	Strong illumination of Cu(II)-inhibited photosystem II membranes resulted in a faster loss of oxygen evolution activity compared with that of the intact samples. The phenomenon was oxygen- and temperature-dependent, However, D1 protein degradation rate was similar in both preparations and slower than that found in non-oxygen evolving PSII particles (i.e., Mn-depleted photosystem II), These results seem to indicate that during illumination Cu(II)-inhibited samples do not behave as a typical non-oxygen evolving photosystem II, Cytochrome b(559) was functional in the presence of Cu(II). The effect of Cu(II) inhibition decreased the amount of photoreduced cytochrome b(559) and slowed down the rate of its photoreduction, The presence of Cu(II) during illumination seems to protect P680 against photodamage as occurs in photosystem II reaction centers when the acceptor side is protected, The data were consistent with the finding that production of singlet oxygen was highly reduced in the preparations treated with Cu(II). EPR. spin trapping experiments showed that inactivation of Cu(II)-treated samples was dominated by hydroxyl radical, and the loss of oxygen evolution activity was diminished by the presence of superoxide dismutase and catalase, These results indicate that the rapid loss of oxygen evolution activity in the presence of Cu(II) is mainly due to the formation of (OH)-O-. radicals from superoxide ion via a Cu(II)-catalyzed Haber-Weiss mechanism, Considering that this inactivation process was oxygen-dependent, we propose that the formation of superoxide occurs in the acceptor side of photosystem II by interaction of molecular oxygen with reduced electron acceptor species, and thus, the primarily Cu(II)inhibitory site in photosystem II is on the acceptor side.	CSIC, ESTAC EXPT AULA DEI, E-50080 ZARAGOZA, SPAIN; UNIV ZARAGOZA, CSIC, INST CIENCIA MAT ARAGON, ZARAGOZA 50009, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental de Aula Dei (EEAD); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Quimica y Materiales de Aragon (CEQMA); CSIC - Instituto de Ciencia de Materiales de Aragon (ICMA); University of Zaragoza			Alonso, Pablo J/L-2759-2014; PICOREL, RAFAEL/K-7930-2014; Pueyo, José J./D-8993-2016; Yruela, Inmaculada/A-9330-2015; Yruela, Inmaculada/T-1239-2019	Alonso, Pablo J/0000-0003-3449-4929; PICOREL, RAFAEL/0000-0003-3791-129X; Pueyo, José J./0000-0003-0337-4078; Yruela, Inmaculada/0000-0003-3608-4720; Yruela, Inmaculada/0000-0003-3608-4720				ALFONSO M, 1994, BIOCHEMISTRY-US, V33, P10494, DOI 10.1021/bi00200a034; ALLAKHVERDIEV SI, 1994, BIOCHEMISTRY-US, V33, P12210, DOI 10.1021/bi00206a025; ANDERSON IC, 1960, PLANT PHYSIOL, V35, P531, DOI 10.1104/pp.35.4.531; ANDERSSON B., 1991, CURR TOP BIOENERG, V16, P1; AOSHIMA H, 1986, AGR BIOL CHEM TOKYO, V50, P1777, DOI 10.1080/00021369.1986.10867648; ARELLANO JB, 1995, PHOTOSYNTH RES, V45, P127, DOI 10.1007/BF00032584; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; ASADA K, 1987, TOPICS PHOTOSYNTHESI, V9, P227; BARBER J, 1987, FEBS LETT, V220, P67, DOI 10.1016/0014-5793(87)80877-3; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BARENYI B, 1985, PLANTA, V163, P218, DOI 10.1007/BF00393510; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BUSER CA, 1992, BIOCHEMISTRY-US, V31, P11449, DOI 10.1021/bi00161a025; CHAMULITRAT W, 1991, ARCH BIOCHEM BIOPHYS, V290, P153, DOI 10.1016/0003-9861(91)90601-E; CHEN GX, 1992, BIOCHEMISTRY-US, V31, P11072, DOI 10.1021/bi00160a017; COGDELL RJ, 1987, BIOCHIM BIOPHYS ACTA, V895, P63, DOI 10.1016/S0304-4173(87)80008-3; DAVIES MJ, 1987, BIOCHEM J, V245, P167, DOI 10.1042/bj2450167; DELASRIVAS J, 1992, FEBS LETT, V301, P246, DOI 10.1016/0014-5793(92)80250-K; DURRANT JR, 1990, BIOCHIM BIOPHYS ACTA, V1017, P167, DOI 10.1016/0005-2728(90)90148-W; ECKERT HJ, 1991, PHOTOSYNTH RES, V27, P97, DOI 10.1007/BF00033249; ELSTNER EF, 1982, ANNU REV PLANT PHYS, V33, P73, DOI 10.1146/annurev.pp.33.060182.000445; FINKELSTEIN E, 1980, ARCH BIOCHEM BIOPHYS, V200, P1, DOI 10.1016/0003-9861(80)90323-9; GRIFFITHS M, 1955, NATURE, V176, P1211, DOI 10.1038/1761211a0; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HIDEG E, 1994, PHOTOSYNTH RES, V39, P191, DOI 10.1007/BF00029386; HIDEG E, 1994, BBA-BIOENERGETICS, V1186, P143, DOI 10.1016/0005-2728(94)90173-2; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; JEGERSCHOLD C, 1995, BIOCHEMISTRY-US, V34, P12747, DOI 10.1021/bi00039a034; JEGERSCHOLD C, 1991, FEBS LETT, V280, P87, DOI 10.1016/0014-5793(91)80210-T; JEGERSCHOLD C, 1990, BIOCHEMISTRY-US, V29, P6179, DOI 10.1021/bi00478a010; KIRILOVSKY D, 1994, BIOCHEMISTRY-US, V33, P3087, DOI 10.1021/bi00176a043; KIRILOVSKY DL, 1990, BIOCHEMISTRY-US, V29, P8100, DOI 10.1021/bi00487a016; KLIMOV VV, 1990, PHOTOSYNTH RES, V23, P59, DOI 10.1007/BF00030063; KOKA P, 1978, PHOTOCHEM PHOTOBIOL, V28, P509, DOI 10.1111/j.1751-1097.1978.tb06959.x; KYLE DJ, 1987, TOPICS PHOTOSYNTHESI, V9, P196; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LION Y, 1976, NATURE, V263, P442, DOI 10.1038/263442a0; MACPHERSON AN, 1993, BIOCHIM BIOPHYS ACTA, V1143, P301, DOI 10.1016/0005-2728(93)90201-P; MATHEWS MM, 1964, NATURE, V20, P1092; MISHRA NP, 1994, BBA-BIOENERGETICS, V1186, P81, DOI 10.1016/0005-2728(94)90138-4; MISHRA NP, 1993, J PHOTOCH PHOTOBIO B, V19, P19, DOI 10.1016/1011-1344(93)80088-Q; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; RENGER G, 1992, TOPICS PHOTOSYNTHESI, V11, P45; SAGER R, 1958, NATURE, V182, P98, DOI 10.1038/182098a0; SANDMANN G, 1980, PLANT PHYSIOL, V66, P797, DOI 10.1104/pp.66.5.797; SCHRODER WP, 1994, J BIOL CHEM, V269, P32865; SHIPTON CA, 1991, P NATL ACAD SCI USA, V88, P6691, DOI 10.1073/pnas.88.15.6691; TAOKA S, 1993, PHOTOSYNTH RES, V38, P425, DOI 10.1007/BF00046770; TELFER A, 1991, BIOCHIM BIOPHYS ACTA, V1060, P106, DOI 10.1016/S0005-2728(05)80125-2; TELFER A, 1989, FEBS LETT, V246, P223, DOI 10.1016/0014-5793(89)80287-X; TELFER A, 1990, BIOCHIM BIOPHYS ACTA, V1017, P143, DOI 10.1016/0005-2728(90)90145-T; TELFER A, 1994, J BIOL CHEM, V266, P1; TOMASI A, 1993, BIOL MAGN RESON, V13, P353; VASS I, 1993, BIOCHIM BIOPHYS ACTA, V1183, P388, DOI 10.1016/0005-2728(93)90244-A; VASS I, 1992, P NATL ACAD SCI USA, V89, P1408, DOI 10.1073/pnas.89.4.1408; YRUELA I, 1992, PHOTOSYNTH RES, V33, P227, DOI 10.1007/BF00030033; YRUELA I, 1991, J BIOL CHEM, V266, P22847; Yruela I, 1996, BIOCHEMISTRY-US, V35, P9469, DOI 10.1021/bi951667e; YRUELA I, 1993, J BIOL CHEM, V268, P1684; [No title captured]	61	89	93	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27408	27415		10.1074/jbc.271.44.27408	http://dx.doi.org/10.1074/jbc.271.44.27408			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910320	hybrid			2022-12-25	WOS:A1996VQ67900038
J	Eliasson, R; Pontis, E; Jordan, A; Reichard, P				Eliasson, R; Pontis, E; Jordan, A; Reichard, P			Allosteric regulation of the third ribonucleotide reductase (NrdEF enzyme) from enterobacteriaceae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CLONING; EXPRESSION	Enterobacteriaceae contain genes for three separate ribonucleotide reductases: nrdAB code for a class Ia enzyme, active during aerobiosis, nrdDG for a class III enzyme, active during anaerobiosis, and nrdEF for a cryptic class Ib enzyme. The NrdEF enzyme provides the active reductase in other, widely different bacteria. Here, we describe the allosteric regulation of the Salmonella, typhimurium NrdEF enzyme. It consists of two tightly bound homodimeric proteins, R1E and R2F. Nucleoside triphosphates (ATP, dATP, dGTP, and dTTP) regulate the substrate specificity by binding to a single site af the R1E protein (one nucleotide per polypeptide). Regulation is similar to that of the NrdAB enzyme, with one major exception: dATP stimulates reduction of CDP (and UDP) under conditions when dATP strongly inhibits all activity of the NrdAB enzyme. The nrdA-coded RI protein contains a second binding site for dATP (and ATP) that controls general enzyme activity. All known R1E proteins lack the 50 N-terminal amino acids of R1, and we propose that the activity site is located in this area of the protein. The more sophisticated regulation of NrdAB enzymes of eukaryotes provides protection against the possibly harmful overproduction of dNTPs.	KAROLINSKA INST, DEPT BIOCHEM 1, MED NOBEL INST, MBB, S-17177 STOCKHOLM, SWEDEN; AUTONOMOUS UNIV BARCELONA, DEPT GENET & MICROBIOL, FAC SCI, BELLATERRA 08193, BARCELONA, SPAIN	Karolinska Institutet; Autonomous University of Barcelona			jordan, albert/K-4678-2014; jordan, albert/ABC-8229-2020	jordan, albert/0000-0002-3970-8693; jordan, albert/0000-0002-3970-8693				ABERG A, 1989, J BIOL CHEM, V264, P12249; BLAKLEY RL, 1964, BIOCHEM BIOPH RES CO, V16, P391, DOI 10.1016/0006-291X(64)90363-8; BOOKER S, 1993, P NATL ACAD SCI USA, V90, P8352, DOI 10.1073/pnas.90.18.8352; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN NC, 1969, J MOL BIOL, V46, P25, DOI 10.1016/0022-2836(69)90055-2; BROWN NC, 1969, J MOL BIOL, V46, P39, DOI 10.1016/0022-2836(69)90056-4; CARAS IW, 1988, MOL CELL BIOL, V8, P2698, DOI 10.1128/MCB.8.7.2698; CHEN AK, 1974, BIOCHEMISTRY-US, V13, P654, DOI 10.1021/bi00701a004; ELIASSON R, 1994, J BIOL CHEM, V269, P26052; FONTECAVE M, 1992, ADV ENZYMOL RAMB, V65, P147; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Jordan A, 1996, J BIOL CHEM, V271, P8779, DOI 10.1074/jbc.271.15.8779; JORDAN A, 1994, J BACTERIOL, V176, P3420, DOI 10.1128/jb.176.11.3420-3427.1994; JORDAN A, 1994, P NATL ACAD SCI USA, V91, P12892, DOI 10.1073/pnas.91.26.12892; KIM JJ, 1977, ARCH BIOCHEM BIOPHYS, V182, P674, DOI 10.1016/0003-9861(77)90548-3; KUNZ BA, 1994, MUTAT RES-REV GENET, V318, P1, DOI 10.1016/0165-1110(94)90006-X; MAO SS, 1989, P NATL ACAD SCI USA, V86, P1485, DOI 10.1073/pnas.86.5.1485; Ollagnier S, 1996, J BIOL CHEM, V271, P9410, DOI 10.1074/jbc.271.16.9410; ORMO M, 1990, ANAL BIOCHEM, V182, P674; REICHARD P, 1993, J BIOL CHEM, V268, P8383; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; YANG FD, 1994, J BACTERIOL, V176, P6738, DOI 10.1128/JB.176.21.6738-6743.1994	24	41	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26582	26587		10.1074/jbc.271.43.26582	http://dx.doi.org/10.1074/jbc.271.43.26582			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900130	hybrid			2022-12-25	WOS:A1996VP23300024
J	Liang, YL; Ackerman, SH				Liang, YL; Ackerman, SH			Characterization of mutations in the beta subunit of the mitochondrial F-1-ATPase that produce defects in enzyme catalysis and assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; BOVINE HEART-MITOCHONDRIA; SACCHAROMYCES-CEREVISIAE; ATP-SYNTHASE; DIRECTED MUTAGENESIS; SHUTTLE VECTORS; H+-ATPASE; YEAST; GENES; SEQUENCE	The ATP2 gene, coding for the beta subunit of the mitochondrial F-1-ATPase, was cloned from nine independent isolates of chemically mutagenized yeast. Seven different mutant alleles were identified. In one case the mutation occurs in the mitochondrial targeting sequence (M1I). The remaining six mutations map to the mature part of the beta subunit protein and alter amino acids that are conserved in the bovine heart mitochondrial and Escherichia coli beta subunit proteins. Biochemical analysis of the yeast atp2 mutants identified two different phenotypes. The G133D, P179L, and G227D mutations correlate with an assembly-defective phenotype that is characterized by the accumulation of the F-1 alpha and beta subunits in large protein aggregates. Strains harboring the A192V, E222K, or R293K mutations assemble an F-1 of normal size that is none-the-less catalytically inactive. The effect of the atp2 mutations was also analyzed in diploids formed by Grossing the mutants to wild type yeast. Hybrid enzymes formed with beta subunits containing either the G133D, E222K, or R293K mutations are compromised for steady-state ATPase activity. The display of partial dominance confirms the importance of Gly(133) for structural stability and of Glu(222) and Arg(293) for catalytic cooperativity.	WAYNE STATE UNIV, SCH MED, DEPT SURG, DETROIT, MI 48201 USA; WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, DETROIT, MI 48201 USA	Wayne State University; Wayne State University					NIGMS NIH HHS [GM48157] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048157] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ACKERMAN SH, 1987, J BIOL CHEM, V262, P13765; ACKERMAN SH, 1992, J BIOL CHEM, V267, P7386; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; ALSHAWI MK, 1989, J BIOL CHEM, V264, P15376; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BULLOUGH DA, 1986, J BIOL CHEM, V261, P14171; COLLINSON IR, 1994, BIOCHEMISTRY-US, V33, P7971, DOI 10.1021/bi00191a026; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FUTAI M, 1988, J BIOENERG BIOMEMBR, V20, P41, DOI 10.1007/BF00762137; FUTAI M, 1983, MICROBIOL REV, V47, P285, DOI 10.1128/MMBR.47.3.285-312.1983; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HSU SY, 1987, FEBS LETT, V218, P222, DOI 10.1016/0014-5793(87)81050-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MUELLER DM, 1989, BIOCHEM BIOPH RES CO, V164, P381, DOI 10.1016/0006-291X(89)91730-0; MUELLER DM, 1988, J BIOL CHEM, V263, P5634; MUELLER DM, 1989, J BIOL CHEM, V264, P16552; MUKHOPADHYAY A, 1994, FEBS LETT, V343, P160, DOI 10.1016/0014-5793(94)80310-2; NOUMI T, 1986, J BIOL CHEM, V261, P9196; PARSONAGE D, 1988, ARCH BIOCHEM BIOPHYS, V261, P222, DOI 10.1016/0003-9861(88)90121-X; PARSONAGE D, 1987, J BIOL CHEM, V262, P6301; PENEFSKY HS, 1991, ADV ENZYMOL RAMB, V64, P173; RAO R, 1987, J BIOL CHEM, V262, P17450; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; SHEN HG, 1994, J BIOL CHEM, V269, P9424; SIKORSKI RS, 1989, GENETICS, V122, P19; TAKEDA M, 1994, YEAST, V10, P1531, DOI 10.1002/yea.320101118; TAKEDA M, 1985, J BIOL CHEM, V260, P5458; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WALPOLE RE, 1978, PROBABILITY STAT ENG, P12; Wang ZG, 1996, J BIOL CHEM, V271, P4887	45	11	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26522	26528		10.1074/jbc.271.43.26522	http://dx.doi.org/10.1074/jbc.271.43.26522			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900121				2022-12-25	WOS:A1996VP23300015
J	Liu, Y; Arshavsky, VY; Ruoho, AE				Liu, Y; Arshavsky, VY; Ruoho, AE			Interaction sites of the COOH-terminal region of the gamma subunit of cGMP phosphodiesterase with the GTP-bound alpha subunit of transducin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; ROD OUTER SEGMENTS; AMINO-ACID-SEQUENCE; G-PROTEIN; INHIBITORY SUBUNIT; SYNTHETIC PEPTIDES; BINDING PROTEIN; ACTIVATION MECHANISM; STRUCTURAL-ANALYSIS; CATALYTIC SUBUNITS	In photoreceptor cells, visual transduction occurs through photoexcitation of rhodopsin, GTP activation of the alpha subunit of transducin, and interaction between GTP-bound transducin alpha subunit and the inhibitory gamma subunit of phosphodiesterase. The gamma subunit of phosphodiesterase, in turn, accelerates the hydrolysis of GTP on the alpha subunit if transducin. Within the COOH-terminal residues (46-87) of the phosphodiesterase gamma subunit, Trp-70 has been implicated in phosphodiesterase activation, transducin alpha subunit-phosphodiesterase gamma subunit, interaction, and the GTP hydrolysis accelerating activity. We have derivatized the phosphodiesterase gamma subunit with a reversible photoactivatable reagent, [I-125]N-[(3-iodo-4-azidophenylpropionamido-S-(2-thiopyridyl)] cysteine ([I-125]ACTP), at cysteine (Cys-68). A light-dependent, cross-linked complex of guanosine 5'-(gamma-thio)-triphosphate-bound transducin alpha subunit and ACTP-derivatized phosphodiesterase gamma subunit formed after photolysis of a 1:1 stoichiometric complex of the two proteins. The specificity of complex formation between the transducin alpha subunit and the phosphodiesterase gamma subunit was demonstrated by specific protection by the C68A mutant of the phosphodiesterase gamma subunit. The cross-linked complex was treated with beta-mercaptoethanol to transfer the I-125 photomoiety from the phosphodiesterase gamma subunit to the transducin alpha subunit. Combined techniques involving electrophoresis, chemical and enzymatic cleavage, and chemical and radiosequencing were based to identify photoinsertion sites on the alpha(3) and alpha(4)/beta(6) regions of the transducin alpha subunit. Three photo-labeled residues, His-244 (alpha(3) helix), Met-308, and Arg-310 (alpha(4)/beta(6) interface), were specifically identified as photoinsertion sites. Utilizing the crystal structure coordinates of the GTP-bound transducin alpha subunit and molecular modeling, we conclude that Cys-68 of the phosphodiesterase gamma subunit is located at a position between the exposed face of the alpha(3) and alpha(4), helices of the transducin alpha subunit. We propose that the phosphodiesterase gamma subunit interacts with GTP-bound transducin alpha subunit at multiple sites in which the cysteine 68 to tryptophan 70 sequence of the phosphodiesterase gamma subunit, which is critical for GTP hydrolysis accelerating activity, interacts in the alpha(3)/alpha(4)/beta(6) region of GTP-bound transducin alpha subunit.	UNIV WISCONSIN, SCH MED, DEPT PHARMACOL, MADISON, WI 53706 USA; HARVARD UNIV, MASSACHUSETTS EYE & EAR INFIRM, SCH MED, BOSTON, MA 02114 USA	University of Wisconsin System; University of Wisconsin Madison; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary					NATIONAL EYE INSTITUTE [R01EY010336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033138] Funding Source: NIH RePORTER; NEI NIH HHS [EY-10336] Funding Source: Medline; NIGMS NIH HHS [GM33138] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARKINSTALL S, 1995, FEBS LETT, V364, P45, DOI 10.1016/0014-5793(95)00351-9; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; ARTEMYEV NO, 1993, J BIOL CHEM, V268, P23611; BENNETT N, 1989, BIOCHEMISTRY-US, V28, P7418, DOI 10.1021/bi00444a040; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BORNSTEIN P, 1977, METHOD ENZYMOL, V47, P133; BOURNE HR, 1992, NATURE, V358, P541, DOI 10.1038/358541a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CRIMMINS DL, 1990, ANAL BIOCHEM, V187, P27, DOI 10.1016/0003-2697(90)90412-3; CUNNICK J, 1994, BIOCHEM J, V297, P87, DOI 10.1042/bj2970087; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; DHANASEKARAN N, 1988, J BIOL CHEM, V263, P17942; ERICKSON JW, 1995, BIOCHEMISTRY-US, V34, P8693, DOI 10.1021/bi00027a019; Fontana A, 1972, Methods Enzymol, V25, P419, DOI 10.1016/S0076-6879(72)25037-6; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; FUNG BKK, 1983, J BIOL CHEM, V258, P503; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; JOHNSON GL, 1991, J CELL BIOCHEM, V47, P136, DOI 10.1002/jcb.240470207; KROLL S, 1989, J BIOL CHEM, V264, P4490; KUTUZOV M, 1994, EUR J BIOCHEM, V220, P963, DOI 10.1111/j.1432-1033.1994.tb18700.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; LIPKIN VM, 1993, BIOCHIM BIOPHYS ACTA, V1176, P250, DOI 10.1016/0167-4889(93)90052-Q; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; Mitchell W M, 1977, Methods Enzymol, V47, P165; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; MORRISON DF, 1987, FEBS LETT, V222, P266, DOI 10.1016/0014-5793(87)80383-6; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OPPERT B, 1991, BIOCHEM BIOPH RES CO, V181, P306, DOI 10.1016/S0006-291X(05)81418-4; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SLEPAK VZ, 1995, J BIOL CHEM, V270, P14319, DOI 10.1074/jbc.270.24.14319; SPICKOFSKY N, 1994, NAT STRUCT BIOL, V1, P771, DOI 10.1038/nsb1194-771; STEINMAN HM, 1974, J BIOL CHEM, V249, P7326; STRYER L, 1991, J BIOL CHEM, V266, P10711; TAKEMOTO DJ, 1992, BIOCHEM J, V281, P637, DOI 10.1042/bj2810637; VAILLANCOURT RR, 1995, BIOCHEM J, V311, P987, DOI 10.1042/bj3110987; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; WHALEN MM, 1989, BIOCHEM J, V259, P13, DOI 10.1042/bj2590013; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316	56	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26900	26907		10.1074/jbc.271.43.26900	http://dx.doi.org/10.1074/jbc.271.43.26900			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900174	hybrid			2022-12-25	WOS:A1996VP23300068
J	Marshall, NF; Peng, JM; Xie, Z; Price, DH				Marshall, NF; Peng, JM; Xie, Z; Price, DH			Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK-ACTIVATING KINASE; TRANSCRIPTION FACTOR TFIIH; ADENOSINE-DEAMINASE GENE; LARGEST SUBUNIT; PROTEIN-KINASE; MESSENGER-RNA; REPEAT DOMAIN; XENOPUS-OOCYTES; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER	The entry of RNA polymerase II into a productive mode of elongation is controlled, in part, by the postinitiation activity of positive transcription elongation factor b (P-TEFb) (Marshall, N.F., and Price, D.H. (1995) J. Biol. Chem. 270, 12335-12338). We report here that removal of the carboxyl-terminal domain (CTD) of the large subunit of RNA polymerase II abolishes productive elongation. Correspondingly, we found that P-TEFb can phosphorylate the CTD of pure RNA polymerase II. Furthermore, P-TEFb can phosphorylate the CTD of RNA polymerase II when the polymerase is in an early elongation complex. Both the function and kinase activity of P-TEFb are blocked by the drugs 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) and H-8. P-TEFb is distinct from transcription factor IIH (TFIIH) because the two factors have no subunits in common, P-TEFb is more sensitive to DRB than is TFIIH, and most importantly, TFIIH cannot substitute functionally for P-TEFb. We propose that phosphorylation of the CTD by P-TEFb controls the transition from abortive into productive elongation mode.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa			Peng, Junmin/N-2614-2018; Price, David H/F-6173-2010	Peng, Junmin/0000-0003-0472-7648; Price, David/0000-0002-5597-385X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35500] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; Austin RJ, 1996, P NATL ACAD SCI USA, V93, P5788, DOI 10.1073/pnas.93.12.5788; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; BRICKEY WJ, 1995, GENETICS, V140, P599; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHINSKY JM, 1989, J BIOL CHEM, V264, P14561; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; DAHMUS ME, 1994, PROG NUCLEIC ACID RE, V48, P143, DOI 10.1016/S0079-6603(08)60855-7; DAHMUS ME, 1995, BBA-GENE STRUCT EXPR, V1261, P171, DOI 10.1016/0167-4781(94)00233-S; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Egyhazi E, 1996, CHROMOSOMA, V104, P422, DOI 10.1007/s004120050134; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; HAIR A, 1993, MOL CELL BIOL, V13, P7925, DOI 10.1128/MCB.13.12.7925; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; KANG ME, 1993, J BIOL CHEM, V268, P25033; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KEPHART DD, 1992, MOL CELL BIOL, V12, P2067, DOI 10.1128/MCB.12.5.2067; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KESSLER M, 1989, J BIOL CHEM, V264, P9785; KESSLER M, 1991, J BIOL CHEM, V266, P13019; KIM WY, 1989, J BIOL CHEM, V264, P3169; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KRAUSKOPF A, 1991, MOL CELL BIOL, V11, P3515, DOI 10.1128/MCB.11.7.3515; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; MEULIA T, 1993, MOL CELL BIOL, V13, P5647, DOI 10.1128/MCB.13.9.5647; MIDDLETON KM, 1990, MOL CELL BIOL, V10, P727, DOI 10.1128/MCB.10.2.727; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; PAYNE JM, 1993, J BIOL CHEM, V268, P80; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; PRICE DH, 1987, J BIOL CHEM, V262, P3244; RAMAMURTHY V, 1990, MOL CELL BIOL, V10, P1484, DOI 10.1128/MCB.10.4.1484; RASMUSSEN EB, 1995, J MOL BIOL, V252, P522, DOI 10.1006/jmbi.1995.0517; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SPENCER CA, 1990, ONCOGENE, V5, P777; STONE N, 1992, J BIOL CHEM, V267, P6353; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; VENETIANER A, 1995, EUR J BIOCHEM, V233, P83, DOI 10.1111/j.1432-1033.1995.083_1.x; WRIGHT S, 1993, MOL BIOL CELL, V4, P661, DOI 10.1091/mbc.4.7.661; Xie Z, 1996, J BIOL CHEM, V271, P11043, DOI 10.1074/jbc.271.19.11043; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; YUE X, 1993, MOL CELL BIOL, V13, P3191, DOI 10.1128/MCB.13.6.3191; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x	70	514	525	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27176	27183		10.1074/jbc.271.43.27176	http://dx.doi.org/10.1074/jbc.271.43.27176			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900211	hybrid			2022-12-25	WOS:A1996VP23300105
J	McLaurin, J; Chakrabartty, A				McLaurin, J; Chakrabartty, A			Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific finding to either phospholipids or gangliosides - Implications for neurotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN A-BETA; PRECURSOR PROTEIN; CIRCULAR-DICHROISM; DISEASE; A-BETA-42(43); CONFORMATION; DEPOSITION; PLAQUES; BRAIN; CELLS	Increasing evidence implicates A beta peptides as neurotoxic agents in Alzheimer's disease. We investigated one possible mechanism of neurotoxicity, namely A beta-membrane lipid interactions, We find that A beta disruption membranes containing acidic phospholipids. This disruption is greater at slightly acidic pH (characteristic of endosomes) than at neutral pH (characteristic of the extracellular space). This pH dependence suggests that A beta has the capacity to disrupt endosomal and plasma membranes, and this disruption could account, at least in part, for the observed neurotoxic effects of the peptide. We also find that gangliosides induce A beta to adopt a novel alpha/beta conformation at neutral pH.	UNIV TORONTO,ONTARIO CANC INST,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto				Chakrabartty, Avi/0000-0001-7002-8381				ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Cataldo AM, 1996, J NEUROSCI, V16, P186; CHECLER F, 1995, J NEUROCHEM, V65, P1431; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; Fukumoto H, 1996, AM J PATHOL, V148, P259; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KEMPF C, 1982, J BIOL CHEM, V257, P2469; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LEYLAHUD E, 1995, SCIENCE, V269, P9770; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MARTIN BL, 1995, J BIOL CHEM, V270, P26727, DOI 10.1074/jbc.270.45.26727; MASLIAH E, 1993, J NEUROPATH EXP NEUR, V52, P619, DOI 10.1097/00005072-199311000-00009; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; PIKE CJ, 1993, J NEUROSCI, V13, P1676; QUERFURTH HW, 1995, MOL BRAIN RES, V28, P319, DOI 10.1016/0169-328X(94)00224-3; SELKOE DJ, 1995, NAT MED, V1, P998, DOI 10.1038/nm1095-998; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1992, NATURE, V359, P268; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; TERZI E, 1994, BIOCHEMISTRY-US, V33, P7434, DOI 10.1021/bi00189a051; WANG D, 1995, J NEUROPATH EXP NEUR, V54, P548, DOI 10.1097/00005072-199507000-00009; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	40	282	291	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26482	26489		10.1074/jbc.271.43.26482	http://dx.doi.org/10.1074/jbc.271.43.26482			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900116	hybrid			2022-12-25	WOS:A1996VP23300010
J	Bloch, DB; delaMonte, SM; Guigaouri, P; Filippov, A; Bloch, KD				Bloch, DB; delaMonte, SM; Guigaouri, P; Filippov, A; Bloch, KD			Identification and characterization of a leukocyte-specific component of the nuclear body	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; PRIMARY BILIARY-CIRRHOSIS; RECEPTOR-ALPHA GENE; ZINC-FINGER; CELL-LINE; TRANSCRIPTION FACTOR; VIRUS-INFECTION; PML PROTEIN; RAR-ALPHA; EXPRESSION	The nuclear body (NB) is a cellular organelle that is involved in the pathogenesis of acute promyelocytic leukemia and viral infection. The NB is also a target of antibodies in the serum of patients with the autoimmune disease primary biliary cirrhosis. In this study, serum from a patient with primary biliary cirrhosis was used to identify a cDNA encoding a novel component of the NB, a 140-kDa protein designated Sp140. The predicted amino acid sequence of the amino-terminal portion of Sp140 was similar to Sp100, a previously identified NB protein. The carboxyl portion of Sp140 contained a zinc-finger domain and a bromodomain, motifs that are present in proteins regulating gene transcription. High levels of Sp140 mRNA were detected in human spleen and peripheral blood leukocytes, but not other human tissues. The level of SP140 mRNA in myeloid precursor cell lines HL60 and NB4 markedly increased in response to chemically induced cellular differentiation. Immunohistochemical techniques were used to demonstrate that SP140 localized to the NB in differentiated HL60 and NB4 cells. The location of Sp140 in the NB, and expression of this gene in cells involved in host defense, suggest that Sp140 may be involved in the pathogenesis of acute promyelocytic leukemia and viral infection.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02129 USA; MASSACHUSETTS GEN HOSP, GEN MED SERV, ARTHRIT UNIT, BOSTON, MA 02129 USA; MASSACHUSETTS GEN HOSP, GEN MED SERV, CARDIOVASC RES CTR, BOSTON, MA 02129 USA; MASSACHUSETTS GEN HOSP, GEN MED SERV, CTR CANC, DIV NEUROPATHOL, BOSTON, MA 02129 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital			de la monte, suzanne/L-7670-2019	de la monte, suzanne/0000-0001-5886-2306; Bloch, Donald/0000-0002-6828-4754	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK051179] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45895] Funding Source: Medline; NIAMS NIH HHS [AR01866] Funding Source: Medline; NIDDK NIH HHS [DK51179] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COLLINS SJ, 1987, BLOOD, V70, P1233; DANIEL MT, 1993, BLOOD, V82, P1858; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVANS J, 1991, ARTHRITIS RHEUM, V34, P731, DOI 10.1002/art.1780340614; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GULDNER HH, 1992, J IMMUNOL, V149, P4067; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAPLAN MM, 1987, NEW ENGL J MED, V316, P521, DOI 10.1056/NEJM198702263160907; KOKEN MHM, 1995, CR ACAD SCI III-VIE, V318, P733; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANOTTE M, 1991, BLOOD, V77, P1080; LEE RT, 1988, J CLIN INVEST, V81, P431, DOI 10.1172/JCI113337; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; LYGEROU Z, 1994, NUCLEIC ACIDS RES, V22, P5332, DOI 10.1093/nar/22.24.5332; MAUL GG, 1994, J GEN VIROL, V75, P1223, DOI 10.1099/0022-1317-75-6-1223; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STERNSDORF T, 1995, SCAND J IMMUNOL, V42, P257, DOI 10.1111/j.1365-3083.1995.tb03652.x; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; STUURMAN N, 1992, J CELL SCI, V101, P773; SZOSTECKI C, 1992, SCAND J IMMUNOL, V36, P555, DOI 10.1111/j.1365-3083.1992.tb03224.x; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARRELL RP, 1993, BLOOD, V82, P1949, DOI 10.1182/blood.V82.7.1949.bloodjournal8271949; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; XIE KW, 1993, MOL CELL BIOL, V13, P6170, DOI 10.1128/MCB.13.10.6170; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359	52	80	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29198	29204		10.1074/jbc.271.46.29198	http://dx.doi.org/10.1074/jbc.271.46.29198			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910577	Green Published, hybrid			2022-12-25	WOS:A1996VT05200069
J	Kono, M; Yoshida, Y; Kojima, N; Tsuji, S				Kono, M; Yoshida, Y; Kojima, N; Tsuji, S			Molecular cloning and expression of a fifth type of alpha,8-sialyltransferase (ST8Sia V) - Its substrate specificity is similar to that of SAT-V/III, which synthesize G(D1c), G(T1a), G(Q1b) and G(T3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY-REGULATED MEMBER; RAT-LIVER GOLGI; G(D3) SYNTHASE; ALPHA-2,8-SIALYLTRANSFERASE; GANGLIOSIDES; BIOSYNTHESIS; GENE; CDNA; STX	The cDNAs encoding a new alpha 2,8-sialyltransferase (ST8Sia V) were cloned from a mouse brain cDNA library by means of a polymerase chain reaction-based method using the nucleotide sequence information on mouse ST8Sia I (G(D3) synthase) and mouse ST8Sia III (Sia alpha 2,3Gal beta 1,4GlcNAc alpha 2,8-sialyltransferase) both of which exhibit activity toward glycolipids. The predicted amino acid sequence of ST8Sia V shows 36.1% and 15.0% identity to those of mouse ST8Sia I and III, respectively. The recombinant protein A-fused ST8Sia V expressed in COS-7 cells exhibited an alpha 2,8-sialyltransferase activity toward G(M1b), G(D1a), G(T1b), and G(D3), and synthesized G(D1c), G(T1a), G(Q1b), and G(T3), respectively. The apparent K-m values for G(M1b), G(D1a), G(T1b) and G(D3) were 1.1, 0.082, 0.070, and 0.28 mM, respectively. However, ST8Sia V did not exhibit activity toward G(M3). Thus, the substrate specificity of ST8Sia V is different from those of ST8Sia I and III, both of which exhibit activity toward G(M3). Transfection of the ST8Sia V gene into COS-7 cells, which express G(D1a) as a major glycolipid, led to the expression of determinants for monoclonal antibody 4F10, which recognizes G(T1a) and G(Q1b), suggesting that ST8Sia V exhibits activity toward gangliosides G(D1a) and/or G(T1b) in vivo. The expression of the ST8Sia V gene was tissue- and developmental stage-specific, and was clearly different from those of other alpha 2,8-sialyltransferase genes. The ST8Sia V gene was strongly expressed in the brain and weakly in other tissues such as the liver. In addition, its expression was greater in the adult than fetal brain. These results strongly indicate that ST8Sia V is a candidate for SAT-V, the alpha 2,8-sialyltransferase involved in G(D1c), G(T1a), G(Q1b), and G(T3) synthesis.	INST PHYS & CHEM RES,FRONTIER RES PROGRAM,WAKO,SAITAMA 35101,JAPAN	RIKEN			Yoshida, Yukiko/ABB-7218-2020	Yoshida, Yukiko/0000-0002-0629-0219; Kono, Mari/0000-0003-2447-4350				ANDO S, 1983, NEUROCHEM INT, V5, P507, DOI 10.1016/0197-0186(83)90043-8; CHANG ML, 1995, GLYCOBIOLOGY, V5, P319, DOI 10.1093/glycob/5.3.319; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; IBER H, 1991, EUR J BIOCHEM, V195, P115, DOI 10.1111/j.1432-1033.1991.tb15683.x; IBER H, 1992, GLYCOBIOLOGY, V2, P137, DOI 10.1093/glycob/2.2.137; Kitagawa H, 1996, J BIOL CHEM, V271, P931, DOI 10.1074/jbc.271.2.931; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; Kojima N, 1996, J BIOL CHEM, V271, P19457, DOI 10.1074/jbc.271.32.19457; KOJIMA N, 1995, FEBS LETT, V373, P119, DOI 10.1016/0014-5793(95)01024-9; Kurosawa N, 1996, J BIOL CHEM, V271, P15109, DOI 10.1074/jbc.271.25.15109; LEE YC, 1993, EUR J BIOCHEM, V216, P377, DOI 10.1111/j.1432-1033.1993.tb18155.x; LEE YC, 1994, J BIOL CHEM, V269, P10028; Nakayama J, 1996, J BIOL CHEM, V271, P3684; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; SAMBROOK J, 1989, MOL C LONING LAB MAN; SASAKI K, 1994, J BIOL CHEM, V269, P15950; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; TSUJI S, 1996, IN PRESS GLYCOBIOLOG; WATANABE Y, 1995, GLYCOCONJUGATE J, V12, P555; YAMAMOTO H, 1990, J NEUROCHEM, V54, P513, DOI 10.1111/j.1471-4159.1990.tb01901.x; YOSHIDA Y, 1996, IN PRESS GLYCOBIOLOG; YOSHIDA Y, 1995, J BIOCHEM-TOKYO, V118, P685; YOSHIDA Y, 1995, J BIOL CHEM, V270, P1628	27	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29366	29371		10.1074/jbc.271.46.29366	http://dx.doi.org/10.1074/jbc.271.46.29366			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910600	hybrid			2022-12-25	WOS:A1996VT05200092
J	Laser, B; Meda, P; Constant, I; Philippe, J				Laser, B; Meda, P; Constant, I; Philippe, J			The caudal-related homeodomain protein Cdx-2/3 regulates glucagon gene expression in islet cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; BOX-CONTAINING GENE; HOMEOBOX GENE; INSULIN GENE; PROMOTER ELEMENT; TRANSGENIC MICE; MESSENGER-RNA; DNA-BINDING; TRANSCRIPTION; SEQUENCES	Glucagon gene transcription in the endocrine pancreas is regulated by at least four cis-acting DNA control elements. We showed previously that G1 is critical for alpha cell-specific expression. G1 contains three AT-rich sequences important for promoter function, which represent candidate binding sites for homeodomain transcription factors. Performing reverse transcription-polymerase chain reaction amplifications with degenerate oligonucleotide primers homologous to the Antennapedia homeobox, cDNA clones corresponding to the caudal-related gene cdx-2/3 were predominantly obtained from glucagon-producing cells and primary non-beta cells. From RNase protection and polymerase chain reaction analyses, cdx-2/3 turned out to be the only caudal-related gene that is expressed at significant levels in cells of the endocrine pancreas, Cdx-2/3 binds with high affinity to an AT-rich motif of G1, which matches the consensus binding site of caudal-related proteins. In the glucagon-producing hamster cell line InR1G9, Cdx-2/3 is a subunit of complex B3 formed on G1. Alternative splicing generates two cdx-2/3 transcripts in islet cells, coding for a full-length protein and an amino-terminally truncated isoform. Although both isoforms bind G1 with similar affinity, only the full-length Cdx-2/3 A protein activates glucagon gene transcription in non-glucagon-producing cells, transcriptional activation being dose-dependent. We therefore conclude that the caudal-related gene cdx-2/3 is implicated in the transcriptional control of glucagon gene expression in the alpha cells of the islets of Langerhans.	CTR MED UNIV GENEVA,DEPT MORPHOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva	Laser, B (corresponding author), CTR MED UNIV GENEVA,DEPT MED,1 RUE MICHEL SERVET,CH-1211 GENEVA 4,SWITZERLAND.							ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BARON A, 1987, EMBO J, V6, P2977, DOI 10.1002/j.1460-2075.1987.tb02603.x; BEACHY PA, 1993, MOL CELL BIOL, V13, P6941, DOI 10.1128/MCB.13.11.6941; BONNER CA, 1995, GENOMICS, V28, P206, DOI 10.1006/geno.1995.1132; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; CORDIERBUSSAT M, 1995, MOL CELL BIOL, V15, P3904; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DEAROLF CR, 1989, NATURE, V341, P340, DOI 10.1038/341340a0; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DRUCKER DJ, 1988, J BIOL CHEM, V263, P13475; Drummond F, 1996, EUR J BIOCHEM, V236, P670, DOI 10.1111/j.1432-1033.1996.t01-1-00670.x; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; FRUMKIN A, 1994, DEVELOPMENT, V120, P253; GALANG CK, 1993, MOL CELL BIOL, V13, P4609, DOI 10.1128/MCB.13.8.4609; GAMER LW, 1993, MECH DEVELOP, V43, P71, DOI 10.1016/0925-4773(93)90024-R; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GIORDANO E, 1993, AM J PHYSIOL, V265, pC358, DOI 10.1152/ajpcell.1993.265.2.C358; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HART C P, 1987, Genomics, V1, P182, DOI 10.1016/0888-7543(87)90011-5; HODGES D, 1994, ADV GENET, V31, P207, DOI 10.1016/S0065-2660(08)60399-5; HU YL, 1993, J BIOL CHEM, V268, P27214; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JAMES R, 1994, J BIOL CHEM, V269, P15229; Jin TR, 1996, MOL CELL BIOL, V16, P19; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YC, 1992, J BIOL CHEM, V267, P10705; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; MACFARLANE WM, 1994, BIOCHEM J, V303, P625, DOI 10.1042/bj3030625; MARGALIT Y, 1993, NUCLEIC ACIDS RES, V21, P4915, DOI 10.1093/nar/21.21.4915; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MLODZIK M, 1985, EMBO J, V4, P2961, DOI 10.1002/j.1460-2075.1985.tb04030.x; MOJSOV S, 1986, J BIOL CHEM, V261, P1880; MOREL C, 1995, J BIOL CHEM, V270, P3046, DOI 10.1074/jbc.270.7.3039; NORTHROP JL, 1994, DEV BIOL, V161, P490, DOI 10.1006/dbio.1994.1047; NOVAK U, 1987, EUR J BIOCHEM, V164, P553, DOI 10.1111/j.1432-1033.1987.tb11162.x; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OIE HK, 1983, ENDOCRINOLOGY, V112, P1070, DOI 10.1210/endo-112-3-1070; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; PETERSON RL, 1992, MECH DEVELOP, V37, P151, DOI 10.1016/0925-4773(92)90077-W; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1994, DIABETES, V43, P523, DOI 10.2337/diabetes.43.4.523; PHILIPPE J, 1987, J CLIN INVEST, V79, P351, DOI 10.1172/JCI112819; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; PHILIPPE J, 1995, J BIOL CHEM, V270, P3039, DOI 10.1074/jbc.270.7.3039; PHILIPPE J, 1994, ENDOCR REV, V2, P21; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; RENUCCI A, 1992, EMBO J, V11, P1459, DOI 10.1002/j.1460-2075.1992.tb05190.x; RUBIN MR, 1987, MOL CELL BIOL, V7, P3836, DOI 10.1128/MCB.7.10.3836; RUDNICK A, 1994, P NATL ACAD SCI USA, V91, P12203, DOI 10.1073/pnas.91.25.12203; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SAMBROOK E, 1989, MOL CLONING LAB MANU; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SERRANO J, 1993, BIOCHEM BIOPH RES CO, V190, P270, DOI 10.1006/bbrc.1993.1041; SERUP P, 1995, BIOCHEM J, V310, P997, DOI 10.1042/bj3100997; Stein S, 1996, MECH DEVELOP, V55, P91, DOI 10.1016/0925-4773(95)00494-7; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; TAKAKI R, 1986, IN VITRO CELL DEV B, V22, P120; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG M, 1995, J BIOL CHEM, V270, P12646, DOI 10.1074/jbc.270.21.12584; WINKLER M, 1991, CURR GENET, V20, P495, DOI 10.1007/BF00334778; XU X, 1994, DEVELOPMENT, V120, P277	72	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28984	28994		10.1074/jbc.271.46.28984	http://dx.doi.org/10.1074/jbc.271.46.28984			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910549	hybrid			2022-12-25	WOS:A1996VT05200041
J	Mehta, A; Banerjee, S; Driscoll, DM				Mehta, A; Banerjee, S; Driscoll, DM			Apobec-1 interacts with a 65-kDa complementing protein to edit apolipoprotein-B mRNA in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMMERHEAD RIBOZYME CATALYSIS; RNA-BINDING PROTEINS; MESSENGER-RNA; CYTIDINE DEAMINASE; MOLECULAR-CLONING; ENZYME; SITE; SUBUNIT; EXPRESSION; SEQUENCES	The editing of apolipoprotein-B (apoB) mRNA involves the deamination of cytidine at nucleotide 6666 to uridine, The catalytic subunit of the editing enzyme, apobec-1, is a cytidine deaminase that requires other unidentified proteins to edit apoB mRNA in vitro. We partially purified an activity from baboon kidney that functionally complements apobec-1, The complementing activity was protease-sensitive and micrococcal nuclease-resistant, had a native molecular mass of 65 +/- 10 kDa on size exclusion chromatography, and sedimented at 4.5 S in glycerol gradients, Purified recombinant His,tagged apobec-1 immobilized on beads depleted >90% of the complementing activity hom partially purified extracts, These beads edited apoB mRNA in vitro in the absence of exogenous apobec-1 or complementing activity, A functional holoenzyme containing apobec-1 and the complementing activity was eluted from the apobec-1-affinity resin using 0.5 nn imidazole, whereas buffer containing 0.4 M KCl eluted only the complementing activity, The carboxyl-terminal 59 amino acids of apobec-1 were not required for interaction with the complementing activity in vitro. Our results demonstrate that the complementing protein interacts directly with apobec-1 in the absence of apoB mRNA.	CLEVELAND CLIN FDN, DEPT CELL BIOL, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045478, R29HL045478] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45478] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; BACKUS JW, 1994, BBA-GENE STRUCT EXPR, V1217, P65; BACKUS JW, 1992, NUCLEIC ACIDS RES, V20, P6007, DOI 10.1093/nar/20.22.6007; BACKUS JW, 1991, NUCLEIC ACIDS RES, V19, P6781, DOI 10.1093/nar/19.24.6781; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DRISCOLL DM, 1994, J BIOL CHEM, V269, P19843; DRISCOLL DM, 1993, MOL CELL BIOL, V13, P7288, DOI 10.1128/MCB.13.12.7288; DRISCOLL DM, 1990, J BIOL CHEM, V265, P21401; GARCIA ZC, 1992, ARTERIOSCLER THROMB, V12, P172, DOI 10.1161/01.ATV.12.2.172; GIANNONI F, 1994, J BIOL CHEM, V269, P5932; GREEVE J, 1991, NUCLEIC ACIDS RES, V19, P3569, DOI 10.1093/nar/19.13.3569; HADJIAGAPIOU C, 1994, NUCLEIC ACIDS RES, V22, P1874, DOI 10.1093/nar/22.10.1874; Harlow E., 1988, ANTIBODIES LAB MANUA; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; HERSCHLAG D, 1994, EMBO J, V13, P2913, DOI 10.1002/j.1460-2075.1994.tb06586.x; HODGES P, 1992, TRENDS BIOCHEM SCI, V17, P77, DOI 10.1016/0968-0004(92)90506-5; JOHNSON DF, 1993, BIOCHEM BIOPH RES CO, V195, P1204, DOI 10.1006/bbrc.1993.2172; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; LAU PP, 1991, J BIOL CHEM, V266, P20550; LAU PP, 1990, NUCLEIC ACIDS RES, V18, P5817, DOI 10.1093/nar/18.19.5817; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; NAKAMUTA M, 1995, J BIOL CHEM, V270, P13042, DOI 10.1074/jbc.270.22.13042; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schock D, 1996, P NATL ACAD SCI USA, V93, P1097, DOI 10.1073/pnas.93.3.1097; SHAH RR, 1991, J BIOL CHEM, V266, P16301; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; TENG BB, 1990, J BIOL CHEM, V265, P20616; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; TENG BB, 1992, J BIOL CHEM, V267, P21265; TSUCHIHASHI Z, 1993, SCIENCE, V262, P99, DOI 10.1126/science.7692597; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; YAMANAKA S, 1995, CIRCULATION, V92, P788; Yang Y, 1996, BIOCHEM BIOPH RES CO, V218, P797, DOI 10.1006/bbrc.1996.0142	41	34	34	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28294	28299		10.1074/jbc.271.45.28294	http://dx.doi.org/10.1074/jbc.271.45.28294			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910449	hybrid			2022-12-25	WOS:A1996VU03300049
J	Wilkin, F; Savonet, V; Radulescu, A; Petermans, J; Dumont, JE; Maenhaut, C				Wilkin, F; Savonet, V; Radulescu, A; Petermans, J; Dumont, JE; Maenhaut, C			Identification and characterization of novel genes modulated in the thyroid of dogs treated with methimazole and propylthiouracil	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED MOUSE CELLS; HEAT-SHOCK PROTEINS; MAMMALIAN-CELLS; GROWTH-FACTORS; CYCLIC-AMP; MOLECULAR-CLONING; TYROSINE KINASE; RESPONSE GENES; PHORBOL ESTERS; EXPRESSION	Induction of cell proliferation by mitogen or growth factor stimulation leads to the specific stimulation or repression of a large number of genes. To better understand differentiated epithelial cell growth regulation, we have initiated a study to identify genes which are regulated by the thyrotropin-dependent mitogenic pathway in dog thyroid cells. A thyroid cDNA library was prepared from a methimazole and propylthiouracil-treated dog and differentially screened with probes derived from control or stimulated thyroids. Among 19 clones isolated, 6 encode known proteins (inwardly rectifying potassium channel, nucleosome assembly protein, ribosomal protein L7, elongation factor 1 alpha, non-muscle myosin light chain, and heat shock protein 90 beta). The 13 others correspond to proteins whose function is unknown, Among them, 5 correspond to mRNAs whose expression was modulated by mitogenic stimulation of thyrocytes in primary culture, A preliminary characterization of two of these cDNAs is reported: clone 5, which might represent a novel, atypical protein kinase, and clone 3, which contains ankyrin-like repeats, suggesting that it might interact with other proteins.	FREE UNIV BRUSSELS,INST RECH INTERDISCIPLINAIRE,B-1070 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel								ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BEELER JF, 1994, MOL CELL BIOL, V14, P982, DOI 10.1128/MCB.14.2.982; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BUREL C, 1992, EXPERIENTIA, V48, P629, DOI 10.1007/BF02118307; CATELLI MG, 1989, BIOCHEM J, V258, P895, DOI 10.1042/bj2580895; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COCLET J, 1989, CLIN ENDOCRINOL, V31, P655, DOI 10.1111/j.1365-2265.1989.tb01290.x; DREMIER S, 1994, ENDOCRINOLOGY, V135, P135, DOI 10.1210/en.135.1.135; Dumont J E, 1971, Vitam Horm, V29, P287; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERRIS DK, 1988, P NATL ACAD SCI USA, V85, P3850, DOI 10.1073/pnas.85.11.3850; GALAND P, 1995, LEUKEMIA, V9, P1075; GE L, 1995, J CELL BIOCHEM, V57, P331, DOI 10.1002/jcb.240570217; GERARD CM, 1989, MOL CELL ENDOCRINOL, V61, P23, DOI 10.1016/0303-7207(89)90186-X; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARA E, 1988, GENE, V70, P97; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1983, J BIOCHEM-TOKYO, V94, P735, DOI 10.1093/oxfordjournals.jbchem.a134414; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; JACQUIERSARLIN MR, 1995, J BIOL CHEM, V270, P14094, DOI 10.1074/jbc.270.23.14094; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; MAENHAUT C, 1992, J BIOL CHEM, V267, P3000; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; ROGER P, 1985, EUR J BIOCHEM, V122, P239; ROGER PP, 1986, CANCER RES, V46, P898; Roger PP, 1995, VITAM HORM, V51, P59, DOI 10.1016/S0083-6729(08)61038-9; ROGER PP, 1984, MOL CELL ENDOCRINOL, V36, P79, DOI 10.1016/0303-7207(84)90087-X; ROGER PP, 1982, MOL CELL ENDOCRINOL, V26, P165, DOI 10.1016/0303-7207(82)90014-4; ROGER PP, 1983, FEBS LETT, V157, P323, DOI 10.1016/0014-5793(83)80569-9; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SIMON HU, 1994, BIOCHEM J, V297, P389, DOI 10.1042/bj2970389; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VINCENT S, 1993, ONCOGENE, V8, P1603; WICK M, 1994, J CELL SCI, V107, P227; ZIEMIECKI A, 1986, BIOCHEM BIOPH RES CO, V138, P1298, DOI 10.1016/S0006-291X(86)80424-7	48	37	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28451	28457		10.1074/jbc.271.45.28451	http://dx.doi.org/10.1074/jbc.271.45.28451			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910471	hybrid			2022-12-25	WOS:A1996VU03300071
J	Leidich, SD; Orlean, P				Leidich, SD; Orlean, P			Gpi1, a Saccharomyces cerevisiae protein that participates in the first step in glycosylphosphatidylinositol anchor synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; PIG-A GENE; CELL-SURFACE; GLYCOSYL-PHOSPHATIDYLINOSITOL; ALPHA-AGGLUTININ; MEMBRANE-PROTEINS; CHITIN SYNTHESIS; SHUTTLE VECTORS; APPLE MACINTOSH; SPT14 GENE	The temperature-sensitive Saccharomyces cerevisiae gpi1 mutant is blocked in [H-3]inositol incorporation into protein and defective in the synthesis of N-acetylglucosaminylphosphatidylinositol, the first step in glycosylphosphatidylinositol (GPI) anchor assembly (Leidich, S, D., Drapp, D, A, and Orlean, P, (1994) J, Biol, Chem. 269, 10193-10196). The GPI1 gene, which encodes a 609-amino acid membrane protein, was cloned by complementation of the temperature sensitivity of gpi1 and corrects the mutant's [H-3]inositol labeling and enzymatic defects, Disruption of GPI1 yields viable haploid cells that are temperature-sensitive for growth, for [H-3]inositol incorporation into protein, and for GPI anchor dependent processing of the Gas1/Ggp1 protein and that lack in vitro N-acetylglucosaminylphosphatidylinositol synthetic activity, The Gpi1 protein thus participates in GPI synthesis and is required for growth at 37 degrees C. When grown at a semipermissive temperature of 30 degrees C, gpi1 cells and gpi1::URA3 disruptants form large, round, multiply budded cells with a separation defect, Homozygous gpi1/gpi1, gpi1::URA3/gpi1::URA3, gpi2/gpi2, and gpi3/gpi3 diploids undergo meiosis, but are defective in ascospore wall maturation for they fail to give the fluorescence due to the dityrosine-containing layer in the ascospore wall, These findings indicate that GPIs have key roles in the morphogenesis and development of S, cerevisiae.	UNIV ILLINOIS, DEPT BIOCHEM, ROGER ADAMS LAB 309, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046220] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46220] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARMSTRONG C, 1992, J BIOL CHEM, V267, P25347; BALLARD MJ, 1991, EMBO J, V10, P3753, DOI 10.1002/j.1460-2075.1991.tb04944.x; BRIZA P, 1986, J BIOL CHEM, V261, P4288; BRIZA P, 1990, GENE DEV, V4, P1775, DOI 10.1101/gad.4.10.1775; BRIZA P, 1994, P NATL ACAD SCI USA, V91, P4524, DOI 10.1073/pnas.91.10.4524; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BULAWA CE, 1992, MOL CELL BIOL, V12, P1764, DOI 10.1128/MCB.12.4.1764; BULAWA CE, 1993, ANNU REV MICROBIOL, V47, P505, DOI 10.1146/annurev.micro.47.1.505; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CONZELMANN A, 1986, EMBO J, V5, P3291, DOI 10.1002/j.1460-2075.1986.tb04642.x; CONZELMANN A, 1990, EMBO J, V9, P653, DOI 10.1002/j.1460-2075.1990.tb08157.x; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; DAUM G, 1982, J BIOL CHEM, V257, P3028; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FASSLER JS, 1991, MOL GEN GENET, V230, P310, DOI 10.1007/BF00290682; FATEMI SH, 1986, CELL, V46, P653, DOI 10.1016/0092-8674(86)90340-5; FREIFELDER D, 1960, J BACTERIOL, V80, P567, DOI 10.1128/JB.80.4.567-568.1960; FUCHS R, 1991, COMPUT APPL BIOSCI, V7, P105; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; HIROSE S, 1992, J BIOL CHEM, V267, P5272; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HYMAN R, 1988, TRENDS GENET, V4, P5, DOI 10.1016/0168-9525(88)90120-5; KAMITANI T, 1993, J BIOL CHEM, V268, P20733; KARAOGLU D, 1995, J CELL BIOL, V130, P567, DOI 10.1083/jcb.130.3.567; KAWAGOE K, 1994, GENOMICS, V23, P566, DOI 10.1006/geno.1994.1544; KIM YJ, 1994, J CELL BIOL, V127, P1381, DOI 10.1083/jcb.127.5.1381; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEIDICH SD, 1995, METHOD ENZYMOL, V250, P560; LEIDICH SD, 1994, J BIOL CHEM, V269, P10193; LEIDICH SD, 1995, J BIOL CHEM, V270, P13029, DOI 10.1074/jbc.270.22.13029; LIPKE PN, 1989, MOL CELL BIOL, V9, P3155, DOI 10.1128/MCB.9.8.3155; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LU CF, 1994, MOL CELL BIOL, V14, P4825, DOI 10.1128/MCB.14.7.4825; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; MULLER G, 1992, J BIOL CHEM, V267, P25337; NUOFFER C, 1993, J BIOL CHEM, V268, P10558; PAMMER M, 1992, YEAST, V8, P1089, DOI 10.1002/yea.320081211; POPOLO L, 1988, EUR J CELL BIOL, V47, P173; POPOLO L, 1993, J BACTERIOL, V175, P1879, DOI 10.1128/JB.175.7.1879-1885.1993; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; PUOTI A, 1991, J BIOL CHEM, V266, P21051; RAM AFJ, 1995, FEBS LETT, V358, P165, DOI 10.1016/0014-5793(94)01418-Z; ROSE MD, 1990, METHODS YEAST GENETI, P122; ROY A, 1991, MOL CELL BIOL, V11, P4196, DOI 10.1128/MCB.11.8.4196; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHONBACHLER M, 1995, EMBO J, V14, P1637, DOI 10.1002/j.1460-2075.1995.tb07152.x; SIKORSKI RS, 1989, GENETICS, V122, P19; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SNYDER M, 1989, J CELL BIOL, V108, P1419, DOI 10.1083/jcb.108.4.1419; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; TAKEDAJ, 1995, TRENDS BIOCHEM SCI, V20, P367; VOSSEN JH, 1995, BBA-GEN SUBJECTS, V1243, P549, DOI 10.1016/0304-4165(95)00002-S; WEINSTOCK KG, 1987, J BACTERIOL, V169, P4384, DOI 10.1128/jb.169.9.4384-4387.1987; WHELAN WL, 1975, J BACTERIOL, V124, P1545, DOI 10.1128/JB.124.3.1545-1557.1975; WILLIAMSON DH, 1983, EXP CELL RES, V145, P209, DOI 10.1016/S0014-4827(83)80022-6; WILSON RB, 1991, MOL CELL BIOL, V11, P3369, DOI 10.1128/MCB.11.6.3369; WOJCIECHOWICZ D, 1993, MOL CELL BIOL, V13, P2554, DOI 10.1128/MCB.13.4.2554; YEH ETH, 1988, CELL, V52, P665, DOI 10.1016/0092-8674(88)90404-7	67	70	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27829	27837		10.1074/jbc.271.44.27829	http://dx.doi.org/10.1074/jbc.271.44.27829			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910381	hybrid			2022-12-25	WOS:A1996VQ67900099
J	Neyroz, P; Menna, C; Polverini, E; Masotti, L				Neyroz, P; Menna, C; Polverini, E; Masotti, L			Intrinsic fluorescence properties and structural analysis of p13(suc1) from Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIME-RESOLVED FLUORESCENCE; CELL-CYCLE CONTROL; CDC2 PROTEIN-KINASE; HISTONE H-1 KINASE; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; ALCOHOL-DEHYDROGENASE; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; DIVISION CYCLE	p(13suc1) acts in the fission yeast cell division cycle as a component of p34(cdc2). I, the present work, structural information contained in the intrinsic fluorescence of p13(suc1) has been extracted by steady-state and time-resolved fluorescence techniques. In its native form, the steady-state emission spectrum of p13(suc1) is centered at 336 nm. Upon denaturation by guanidine HCl (4.0 M), the emission spectrum is shifted to 355-360 nm and the fluorescence intensity decreases 70%. The same changes are not obtained with p(13suc1) at 56 degrees C or after incubation at 100 degrees C, and the protein appears to be substantially temperature-stable. The fluorescence decay of p(13suc1) is best described by three discrete lifetimes of 0.6 ns (tau(1)), 2.9 ns (tau(2)), and 6.1 ns (tau(3)), with amplitudes that are dependent on the native or unfolded state of the protein. Under native conditions, the two predominant decay-associated spectra, DAS-tau(2), (lambda(max), = 332 nm) and DAS-tau(3) (lambda(max) = 340 nm), derive from two different excitation DAS. Moreover distinct quenching mechanisms and collisional accessibilities (k(q)(tau(2))much greater than k(q)(tau(3))) are resolved for each lifetime. An interpretation in terms of specific tryptophan residue (or protein conformer)-lifetime as signments is presented. The decay of the fluorescence anisotropy of native p13(suc1) is best described by a double exponential decay. The longer correlation time recovered (9 ns less than or equal to phi(2) less than or equal to 15ns) can be associated with the rotational motion of the protein as a whole and a Stokes radius of 21.2 Angstrom has been calculated for p13(suc1). Anisotropy measurements obtained as a function of temperature indicate that, in solution, the protein exists exclusively as a prolate monomer. In 1 mM zinc, changes of the anisotropy decay parameters are compatible with subunits oligomerization.			Neyroz, P (corresponding author), UNIV BOLOGNA, DIPARTIMENTO BIOCHIM G MORUZZI, SEZ BIOCHIM FARMACEUT, VIA SAN DONATO 19-2, I-40127 BOLOGNA, ITALY.			Polverini, Eugenia/0000-0003-1665-2129; NEYROZ, PAOLO/0000-0002-9790-4027				AMELOOT M, 1984, BIOPHYS J, V46, P525, DOI 10.1016/S0006-3495(84)84050-3; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; AZUMI T, 1962, J CHEM PHYS, V37, P2413, DOI 10.1063/1.1733019; Badea M G, 1979, Methods Enzymol, V61, P378; BEECHEM JM, 1985, ANAL INSTRUM, V14, P379; BEECHEM JM, 1985, ANNU REV BIOCHEM, V54, P43, DOI 10.1146/annurev.biochem.54.1.43; BENFENATI F, 1990, J BIOL CHEM, V265, P12584; Bevington PR, 1969, DATA REDUCTION ERROR; BIRCK C, 1995, FEBS LETT, V363, P145, DOI 10.1016/0014-5793(95)00300-X; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CROSS AJ, 1984, BIOPHYS J, V46, P45, DOI 10.1016/S0006-3495(84)83997-1; DAHMS TES, 1995, BIOPHYS J, V69, P569, DOI 10.1016/S0006-3495(95)79930-1; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; EFTINK MR, 1991, METHOD BIOCHEM ANAL, V35, P127; EFTINK MR, 1994, BIOPHYS J, V66, P482, DOI 10.1016/S0006-3495(94)80799-4; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ENDICOTT JA, 1995, EMBO J, V14, P1004, DOI 10.1002/j.1460-2075.1995.tb07081.x; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GAVIN AC, 1992, MOL REPROD DEV, V33, P287, DOI 10.1002/mrd.1080330309; Gilbert C. W., 1983, TIME RESOLVED FLUORE, P605; GRINVALD A, 1974, ANAL BIOCHEM, V59, P583, DOI 10.1016/0003-2697(74)90312-1; HARRIS DL, 1990, BIOCHEMISTRY-US, V29, P5276, DOI 10.1021/bi00474a009; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; JOHNSON ML, 1983, BIOPHYS J, V44, P101, DOI 10.1016/S0006-3495(83)84281-7; KNIGHT AEW, 1971, CHEM PHYS LETT, V10, P43, DOI 10.1016/0009-2614(71)80152-5; KNUTSON JR, 1992, METHOD ENZYMOL, V210, P357; KNUTSON JR, 1982, BIOCHEMISTRY-US, V21, P4671, DOI 10.1021/bi00262a024; KNUTSON JR, 1983, CHEM PHYS LETT, V102, P501, DOI 10.1016/0009-2614(83)87454-5; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Lakowicz JR., 1992, TOPICS FLUORESCENCE, V2; LAWS WR, 1992, METHOD ENZYMOL, V210, P448; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LEW J, 1992, J BIOL CHEM, V267, P13383; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NEYROZ P, 1987, J BIOL CHEM, V262, P15900; O'Connor D. V., 1984, TIME CORRELATED SING; PAOLETTI J, 1969, ANAL BIOCHEM, V31, P33, DOI 10.1016/0003-2697(69)90238-3; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; ROSS JBA, 1981, BIOCHEMISTRY-US, V20, P4369, DOI 10.1021/bi00518a021; ROYER CA, 1990, BIOPHYS J, V58, P363, DOI 10.1016/S0006-3495(90)82383-3; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SZABO AG, 1980, J AM CHEM SOC, V102, P554, DOI 10.1021/ja00522a020; TAO T, 1969, BIOPOLYMERS, V8, P609, DOI 10.1002/bip.1969.360080505; WAHL P, 1969, BIOCHIM BIOPHYS ACTA, V175, P55, DOI 10.1016/0005-2795(69)90145-7; WAHL P, 1974, REV SCI INSTRUM, V45, P28, DOI 10.1063/1.1686442	66	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27249	27258		10.1074/jbc.271.44.27249	http://dx.doi.org/10.1074/jbc.271.44.27249			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910298	hybrid			2022-12-25	WOS:A1996VQ67900016
J	Moriguchi, T; Toyoshima, F; Gotoh, Y; Iwamatsu, A; Irie, K; Mori, E; Kuroyanagi, N; Hagiwara, M; Matsumoto, K; Nishida, E				Moriguchi, T; Toyoshima, F; Gotoh, Y; Iwamatsu, A; Irie, K; Mori, E; Kuroyanagi, N; Hagiwara, M; Matsumoto, K; Nishida, E			Purification and identification of a major activator for p38 from osmotically shocked cells - Activation of mitogen-activated protein kinase 6 by osmotic shock, tumor necrosis factor-alpha, and H2O2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; C-JUN; MAMMALIAN-CELLS; HEAT-SHOCK; STRESS; PHOSPHORYLATION; YEAST; CASCADE; THREONINE; TYROSINE	A stress-activated, serine/threonine kinase, p38 (also known as HOG1 or MPK2) belongs to a subgroup of mitogen-activated protein kinase (MAPK) superfamily molecules, An activity to activate p38 (p38 activator activity) as well as p38 activity itself were greatly stimulated by hyperosmolar media in mouse lymphoma L5178Y cells, The activator activity has been purified by sequential chromatography. A 36-kDa polypeptide that was coeluted with the activity in the final chromatography step was identified as MAPK kinase 6 (MAPKK6) by protein microsequencing analysis, Monoclonal and polyclonal antibodies raised against recombinant MAPKK6 recognized specifically the 36-kDa MAPKK6 protein but did not cross react with MKK3 proteins. The use of these anti-MAPKK6 antibodies revealed that two major peaks of the p38 activator activity in the first chromatography step reside in the activated MAPKK6, Using a genetic screen in yeast, we isolated MKK3b, an alternatively spliced form of MKK3. Like MKK3 and MAPKK6, MKK3b was shown to be a specific activator for p38 and was activated by osmotic shock when expressed in COS7 cells, Immunoblotting analysis revealed that MAPKK6 is expressed highly in HeLa and KB cells and scarcely in PC12 cells, whereas MKK3 and MKK3b are expressed in all cells examined, Immunodepletion of MAPKK6 from the extracts obtained from L5178Y cells and KB cells exposed to hyperosmolar media depleted them of almost all of the p38 activator activity, indicating that MAPKK6 is a major activator for p38 in an osmosensing pathway in these cells. In addition, MAPKK6 was activated strongly by tumor necrosis factor-alpha, H2O2, and okadaic acid and moderately by cycloheximide in KB cells. Thus, there are at least three members of p38 activator, MKK3, MKK3b, and MAPKK6, and MAPKK6 may function as a major activator for p38 when expressed.	KYOTO UNIV,INST VIRUS RES,DEPT MOL BIOL & GENET,SAKYO KU,KYOTO 60601,JAPAN; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN; NAGOYA UNIV,FAC SCI,DEPT MOL BIOL,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN; NAGOYA UNIV,SCH MED,DEPT ANAT,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Kyoto University; Kirin Brewery Company Limited; Nagoya University; Nagoya University			Moriguchi, Tetsuo/D-7061-2012	Moriguchi, Tetsuo/0000-0002-9598-4991				AHN NG, 1993, P NATL ACAD SCI USA, V90, P5143, DOI 10.1073/pnas.90.11.5143; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN J, 1996, J BIOL CHEM, V271, P28886; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MEIER R, 1996, EUR J BIOCHEM, V236, P769; MERCURIO F, 1995, SCIENCE, V268, P286; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	36	149	153	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26981	26988		10.1074/jbc.271.43.26981	http://dx.doi.org/10.1074/jbc.271.43.26981			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900184	hybrid			2022-12-25	WOS:A1996VP23300078
J	Narayanaswami, V; Wang, JJ; Kay, CM; Scraba, DG; Ryan, RO				Narayanaswami, V; Wang, JJ; Kay, CM; Scraba, DG; Ryan, RO			Disulfide bond engineering to monitor conformational opening of apolipophorin III during lipid binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CHOLESTEROL ACYLTRANSFERASE ACTIVATION; MANDUCA-SEXTA; INSECT LIPOPROTEIN; TRANSFER PARTICLE; STRUCTURAL MOTIF; APOLIPOPROTEIN-E; PHOSPHOLIPASE-C; STABILITY; DIACYLGLYCEROL	Apolipophorin III (apoLp-III) from the Sphinx moth, Manduca sexta, is an exchangeable, amphipathic apolipoprotein that alternately exists in water-soluble and lipid-bound forms. It is organized as a five-helix bundle in solution, which has been postulated to open at putative hinge domains to expose the hydrophobic interior, thereby facilitating interaction with the lipoprotein surface (Breiter, D. R., Kanost, M. R., Benning, M. M., Wesenberg, G., Law, J. H., Wells, M. A., Rayment, I., and Holden, H. M. (1991) Biochemistry 30, 603-608). To test this hypothesis, we engineered two cysteine residues in apoLp-III, which otherwise lacks cysteine, by site-directed mutagenesis at Asn-40 and Leu-90. Under oxidizing conditions the two cysteines spontaneously form a disulfide bond, which should tether the helix bundle and thereby prevent opening and concomitant lipid interaction. N40C/L90C apoLp-III was overexpressed in Escherichia coli and characterized for disulfide bond formation, secondary structure content, and stability, under both oxidizing and reducing conditions. Functional characterization was carried out by comparing the abilities of the oxidized and reduced protein to associate with modified lipoproteins in vitro, While the reduced form behaved like wild type apoLp-III, the oxidized form was unable to associate with lipoproteins. These results suggest that opening of the helix bundle is required for interaction with lipoproteins and provide a molecular basis for the dual existence of water-soluble and lipid-bound forms of apoLp-III, However, in phospholipid bilayer association assays, wild type, reduced, and oxidized N40C/L90C apoLp-III exhibited similar abilities to transform dimyristoylphosphatidylcholine multilamellar vesicles to disclike complexes, as judged by electron microscopy. These data emphasize that underlying differences exist in initiating or maintaining a stable interaction of apoLp-III with phospholipid disc complexes versus spherical lipoprotein surfaces.	UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON,AB T6G 252,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 252,CANADA; UNIV ALBERTA,PROT ENGN NETWORK CTR EXCELLENCE,EDMONTON,AB T6G 252,CANADA	University of Alberta; University of Alberta; University of Alberta				Narayanaswami, Vasanthy/0000-0001-7088-4057				BAILEY CJ, 1982, BIOCHEM J, V203, P775, DOI 10.1042/bj2030775; BEENAKKERS AMT, 1985, PEPTIDES, V6, P437, DOI 10.1016/0196-9781(85)90411-5; BLACKLOCK BJ, 1994, INSECT BIOCHEM MOLEC, V24, P855, DOI 10.1016/0965-1748(94)90015-9; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; CARDAMONE M, 1995, BIOCHEMISTRY-US, V34, P5773, DOI 10.1021/bi00017a009; CHANG YY, 1995, J BIOL CHEM, V270, P7896, DOI 10.1074/jbc.270.14.7896; COLE KD, 1987, J BIOL CHEM, V262, P11794; DEPAUW M, 1995, BIOCHEMISTRY-US, V34, P10953, DOI 10.1021/bi00034a030; DUCHE D, 1994, J BIOL CHEM, V269, P6332; EDELSTEIN C, 1980, J BIOL CHEM, V255, P5747; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; EPAND RM, 1987, J BIOL CHEM, V262, P9389; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JIRGENSONS B, 1976, BIOCHIM BIOPHYS ACTA, V434, P58, DOI 10.1016/0005-2795(76)90035-0; KAWOOYA JK, 1986, J BIOL CHEM, V261, P3588; LIU H, 1993, FEBS LETT, V316, P27, DOI 10.1016/0014-5793(93)81730-N; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; NARAYANASWAMI V, 1995, BIOCHEMISTRY-US, V34, P11822, DOI 10.1021/bi00037a021; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; RYAN RO, 1990, J BIOL CHEM, V265, P10551; RYAN RO, 1995, J LIPID RES, V36, P1066; RYAN RO, 1993, J BIOL CHEM, V268, P1525; RYAN RO, 1988, J BIOL CHEM, V263, P14140; SAMBROOK J, 1989, MOL CLONINB LAB MANU, V3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; SINGH TKA, 1992, J BIOL CHEM, V267, P9275; SINGH TKA, 1994, J LIPID RES, V35, P1561; SMITH AF, 1994, J LIPID RES, V35, P1976; Soulages JL, 1996, BIOCHEMISTRY-US, V35, P5191, DOI 10.1021/bi952794d; SOULAGES JL, 1995, P NATL ACAD SCI USA, V92, P5650, DOI 10.1073/pnas.92.12.5650; SOULAGES JL, 1994, BIOCHEMISTRY-US, V33, P2356, DOI 10.1021/bi00175a002; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; UPADHYAYA M, 1995, ARCH INSECT BIOCHEM, V30, P211, DOI 10.1002/arch.940300210; VANDERHORST DJ, 1988, J BIOL CHEM, V263, P2027; VANDERHORST DJ, 1990, BIOCHIM BIOPHYS ACTA, V1047, P195, DOI 10.1016/0005-2760(90)90518-3; WANG JJ, 1995, BIOCHEMISTRY-US, V34, P6755, DOI 10.1021/bi00020a021; WANG JJ, 1992, BIOCHEMISTRY-US, V31, P8706, DOI 10.1021/bi00152a004; WEERS PMM, 1994, BIOCHEMISTRY-US, V33, P3617, DOI 10.1021/bi00178a019; WEINBERG RB, 1985, J BIOL CHEM, V260, P4914; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WELLS MA, 1987, J BIOL CHEM, V262, P4172; WETZEL R, 1988, P NATL ACAD SCI USA, V85, P401, DOI 10.1073/pnas.85.2.401; WIENTZEK M, 1994, J BIOL CHEM, V269, P4605; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WolffLong VL, 1995, J BIOL CHEM, V270, P31111, DOI 10.1074/jbc.270.52.31111; ZHANG YP, 1993, BIOCHEMISTRY-US, V32, P3942, DOI 10.1021/bi00066a014	50	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26855	26862		10.1074/jbc.271.43.26855	http://dx.doi.org/10.1074/jbc.271.43.26855			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900168	hybrid			2022-12-25	WOS:A1996VP23300062
J	Chen, JH; Vercamer, C; Li, ZL; Paulin, D; Vandenbunder, B; Stehelin, D				Chen, JH; Vercamer, C; Li, ZL; Paulin, D; Vandenbunder, B; Stehelin, D			PEA3 transactivates vimentin promoter in mammary epithelial and tumor cells	ONCOGENE			English	Article						PEA3; vimentin; promoter; mammary tumor	ETS-RELATED PROTEIN; DIFFERENTIAL DISPLAY; TRANSCRIPTION FACTOR; METASTATIC DISEASE; BREAST CARCINOMAS; MOLECULAR-CLONING; MOUSE EMBRYO; EXPRESSION; GENE; ONCOGENE	We have used differential display RT-PCR method to detect the genes specifically activated or repressed between mammary tumor and normal mammary epithelial cells, One of the genes identified is vimentin, The vimentin gene is abundantly expressed in both human and mouse mammary tumor cells and its expression decreased dramatically in normal mammary epithelial cells. The expression of vimentin gene correlates with the expression of transcription factor PEA3, Since the promoters of human and mouse vimentin genes contain one PEA3 binding site we investigated the ability of PEA3 to transactivate the vimentin promoter in mouse mammary epithelial cell CLS1, mouse mammary tumor MMT and human mammary tumor cell lines MCF7 and MDA231, Our results suggest that PEA3 specifically transactivates vimentin promoter through PEA3 site, Among members of the ETS transcription factor family only Erg showed ability to transactivate vimentin promoter besides PEA3, Our results also suggest that NFkB site on the vimentin promoter may act as positive regulatory element for the transcription of vimentin, In metastatic mammary tumors derived from mice carrying the polyoma middle T or neu transgene, PEA3 is overexpressed and vimentin has been shown to play a key role in the motility of cells, Our results suggest that one of the roles of PEA3 in mammary tumor is to participate the activation of vimentin gene whose gene product in turn contributes to the metastatic potential of mammary tumors.	TZU CHI COLL MED,INST MED RES,HUALIEN,TAIWAN; UNIV PARIS 07,F-75005 PARIS 15,FRANCE; INST PASTEUR,SERV CENT MICROSCOPIE ELECT,F-75005 PARIS 15,FRANCE	Tzu Chi University; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Chen, JH (corresponding author), INST PASTEUR,CNRS URA 1160,UNITE ONCOL MOL,F-59019 LILLE,FRANCE.		Li, Zhenlin/E-3937-2016	LI, Zhenlin/0000-0002-3706-4505				BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHEN JH, 1993, ONCOGENE, V8, P3375; COCHARD P, 1984, J NEUROSCI, V4, P2080; COCUCCIGUYON E, 1994, CELL, V79, P679; Crepieux Pascale, 1993, Gene Expression, V3, P215; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DOMAGALA W, 1990, AM J PATHOL, V136, P219; DOMAGALA W, 1990, AM J PATHOL, V137, P1059; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; FERRARI S, 1986, MOL CELL BIOL, V6, P3614, DOI 10.1128/MCB.6.11.3614; FRANKE WW, 1982, DIFFERENTIATION, V23, P43, DOI 10.1111/j.1432-0436.1982.tb01266.x; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FUERST D O, 1989, Journal of Cell Biology, V109, P517; GOULD VE, 1990, AM J PATHOL, V137, P1143; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HIGASHINO F, 1995, ONCOGENE, V10, P1461; LANE EB, 1983, NATURE, V303, P701, DOI 10.1038/303701a0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LILIENBAUM A, 1993, J BIOL CHEM, V268, P2180; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARCHIONI M, 1993, MOL CELL BIOL, V13, P7399; MONTE D, 1994, ONCOGENE, V9, P1397; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; RAYMOND WA, 1989, J PATHOL, V158, P107, DOI 10.1002/path.1711580205; RITTLING SR, 1987, MOL CELL BIOL, V7, P3908, DOI 10.1128/MCB.7.11.3908; SALVETTI A, 1993, MOL CELL BIOL, V13, P89, DOI 10.1128/MCB.13.1.89; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SOMMERS CL, 1994, CELL GROWTH DIFFER, V5, P839; SOMMERS CL, 1992, CANCER RES, V52, P5190; SOMMERS CL, 1989, CANCER RES, V49, P4258; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; STOVER DM, 1994, CANCER RES, V54, P3092; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; WASYLYKS B, 1993, NATURE, V234, P191; WERNERT N, 1994, CANCER RES, V54, P5683; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YONGANATHAN T, 1992, EUR J BIOCHEM, V207, P195; ZAPORI D, 1990, CANCER J, V3, P164	44	50	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1667	1675						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895512				2022-12-25	WOS:A1996VM88700011
J	Chen, Y; Knudsen, ES; Wang, JYJ				Chen, Y; Knudsen, ES; Wang, JYJ			The RB/p107/p130 phosphorylation pathway is not inhibited in rapamycin-induced G(1)-prolongation of NIH3T3 cells	ONCOGENE			English	Article						cdk2; cyclin A; cyclin E; p27(kip1)	ABL TYROSINE KINASE; HUMAN CYCLIN-E; S-PHASE ENTRY; RETINOBLASTOMA PROTEIN; MAMMALIAN FIBROBLASTS; GROWTH SUPPRESSION; TGF-BETA; EXPRESSION; G(1); ARREST	The immunosuppressant rapamycin has previously been shown to inhibit G(1)/S transition in several cell types. In Swiss-3T3 cells, rapamycin prolongs G(1) through the inhibition of the S6-kinase. In T-lymphocytes, rapamycin blocks the mitogen-induced down regulation of p27(Kip1), an inhibitor of the cdk/cyclin complexes. We show here that an NIH3T3 line (N-3T3) is also sensitive to the G(1)/S inhibitory effect of rapamycin. Unlike lymphocytes, rapamycin does not affect p27(Kip1) in these immortalized fibroblasts, nor does rapamycin affect the activity of cyclin D- or cyclin E-dependent kinases. As a result, rapamycin does not inhibit the phosphorylation of the retinoblastoma protein (RB) or two RB-related proteins, p107 and p130. Despite the phosphorylation of RB/p107/p130, the expression of cyclin A and its associated kinase activity is delayed in rapamycin-treated N-3T3 cells. Ectopic expression of cyclin A, but not cyclins D and E or E2F-1 and -4, can overcome the effect of rapamycin. Taken together, these results suggest that entry into S-phase is likely to involve rapamycin-sensitive pathways other than the phosphorylation of the pocket proteins.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR GENET MOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R01CA058320] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA058320, CA58320, CA5028] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERS MW, 1993, J BIOL CHEM, V268, P22825; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DOU QP, 1993, CANCER RES, V53, P1493; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUANG TS, 1995, P NATL ACAD SCI USA, V92, P4793, DOI 10.1073/pnas.92.11.4793; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; MARX SO, 1995, CIRC RES, V76, P412, DOI 10.1161/01.RES.76.3.412; MORICE WG, 1993, J BIOL CHEM, V268, P22737; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NAKAMURA T, 1995, EXP CELL RES, V216, P422, DOI 10.1006/excr.1995.1053; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pines Jonathon, 1994, Seminars in Cell Biology, V5, P399, DOI 10.1006/scel.1994.1047; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x	47	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1765	1771						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895523				2022-12-25	WOS:A1996VM88700022
J	McConkey, DJ; Goodrich, D; Bucana, C; Klostergaard, J				McConkey, DJ; Goodrich, D; Bucana, C; Klostergaard, J			The human retinoblastoma gene product suppresses ceramide-induced apoptosis in human bladder tumor cells	ONCOGENE			English	Article						Rb; N-hexanoyl-D-sphingosine; DNA fragmentation; bladder carcinoma	ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; SIGNALING PATHWAY; CARCINOMA-CELLS; HL-60 CELLS; BCL-2; DIFFERENTIATION; INACTIVATION; EXPRESSION; MECHANISM	The retinoblastoma gene product, Rb, has previously been implicated as an obligatory component in the antiproliferative effects mediated by the lipid second messenger, ceramide. We have evaluated both the apoptotic effects and the effects on cell cycle distribution of the exogenous cell-permeable ceramide, N-hexanoyl-D-sphingosine, in an Rb-null human bladder tumor cell line, 5637, as well as in retrovirally infected, Rb(+) clones derived therefrom. These cell lines demonstrated comparable sensitivity to N-hexanoyl-D-sphingosine in a neutral red dye uptake assay. Exposure of the Rb-null parental cell line to 20 mu M N-hexanoyl-D-sphingosine for 24 h resulted in a classical pattern of DNA fragmentation that was accompanied by apoptotic nuclear morphological alterations, In contrast, the Rb(+) clones demonstrated suppression of DNA fragmentation in response to N-hexanoyl-D-sphingosine. Similarly, the frequency and degree of alteration of nuclear morphology in Rb(+) cells was also suppressed, Flow cytometric analysis of the parental and infected clones indicated that expression of Rb was without effect on their cell cycle distribution, with or without exposure to N-hexanoyl-D-sphingosine for 25 h; tunel assay confirmed that in this time frame apoptotic cells were far less frequent in the Rb(+) clones than in the parental 5637 cells, Human tumor cell lines derived from three other histological origins, breast and prostatic carcinomas and osteogenic sarcoma, also demonstrated very similar cytotoxic sensitivities to N-hexanoyl-D-sphingosine, irrespective of the expression of Rb, We conclude that Rb is not required for ceramide-induced apoptosis and that Rb can actually inhibit the DNA fragmentation and nuclear morphological changes associated with classical apoptosis.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	McConkey, DJ (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Chang Y, 1995, P NATL ACAD SCI USA, V92, P12275, DOI 10.1073/pnas.92.26.12275; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; FERNANDEZ A, 1995, ONCOGENE, V10, P769; GILL BM, 1994, IMMUNOL REV, V142, P114; GOODRICH DW, 1992, CANCER RES, V52, P1968; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HAUPT Y, 1995, ONCOGENE, V10, P1563; HAUSER JML, 1994, J BIOL CHEM, V269, P6803; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jarvis WD, 1996, CLIN CANCER RES, V2, P1; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JAYADEV S, 1994, CMB, V1, P289; JOHNSTON DA, 1978, COMPUT BIOMED RES, V11, P393, DOI 10.1016/0010-4809(78)90020-4; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KALEN A, 1992, BIOCHIM BIOPHYS ACTA, V1125, P90, DOI 10.1016/0005-2760(92)90160-W; KIM MY, 1991, J BIOL CHEM, V266, P484; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LIU J, 1994, J BIOL CHEM, V269, P3047; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MULLER HK, 1994, CELL IMMUNOL, V157, P263, DOI 10.1006/cimm.1994.1221; NEAMATI N, 1995, J IMMUNOL, V154, P3788; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OBRHAMMER F, 1993, EMBO J, V120, P3679; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OVERTON WR, 1988, CYTOMETRY, V9, P619, DOI 10.1002/cyto.990090617; SCHNIER JB, 1996, IN PRESS P NATL ACAD, V93; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; STECK KD, 1995, CYTOMETRY, V20, P154, DOI 10.1002/cyto.990200208; STRUM JC, 1994, J BIOL CHEM, V269, P15493; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; YANG ZH, 1993, J BIOL CHEM, V268, P20520	41	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1693	1700						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895515				2022-12-25	WOS:A1996VM88700014
J	Peled, A; Schwartz, D; Elkind, NB; Wolkowicz, R; Li, RZ; Rotter, V				Peled, A; Schwartz, D; Elkind, NB; Wolkowicz, R; Li, RZ; Rotter, V			The role of p53 in the induction of polyploidity of myelomonocytic leukemic M1/2 cells	ONCOGENE			English	Article						wild type p53; mutant p53; giant cells; ploidity	WILD-TYPE P53; C-TERMINAL DOMAIN; DNA-DAMAGE; CYCLE CONTROL; IONIZING-RADIATION; FLOW-CYTOMETRY; SINGLE STRANDS; PROTEIN; REPAIR; GENE	p53 was shown to play a central role in the maintenance of genomic integrity. The present experiments suggest that p53 is involved in the control of cell ploidity. Using a p53 non-producer cell line, M1/2, that was reconstituted to express either wild type or mutant p53 protein, by infection with the temperature sensitive (Ts) p53 Val135 virus, it was found that both loss of wild type p53 or overexpression of mutant p53, may be associated with the generation of cell polyploidity. Overexpression of mutant p53 protein enhanced the appearance of giant cells that further accumulated following gamma-irradiation. Expression of wild type p53 reduced the level of giant cells which accumulated in the parental M1/2 p53 nonproducer cells following gamma-irradiation. This activity of the wild type p53 seems to be mediated by either the reduction in the rate of giant cell generation, as observed in M1/2 derived cell lines expressing low levels of wild type p53 protein or by facilitating their apoptosis, as observed in wild type p53 high-producer cells. The latter conclusion is further supported by the observation that isolated giant cells are directly induced to undergo apoptosis following wild type p53 expression.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								AFANASYEV VN, 1993, CYTOMETRY, V14, P603, DOI 10.1002/cyto.990140604; ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BELLOC F, 1994, CYTOMETRY, V17, P59, DOI 10.1002/cyto.990170108; BRAIN R, 1994, ONCOGENE, V9, P1775; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FRIEDBERG EC, 1994, BIOESSAYS, V16, P645, DOI 10.1002/bies.950160909; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1995, CANCER RES, V55, P7; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LINDAHL T, 1994, CURR BIOL, V4, P249, DOI 10.1016/S0960-9822(00)00056-7; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PARSHAD R, 1994, CARCINOGENESIS, V15, P33, DOI 10.1093/carcin/15.1.33; Peled A, 1996, CANCER RES, V56, P2148; PELED A, 1995, UNPUB EXPT HEMAT; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEWART N, 1995, ONCOGENE, V10, P109; WADEHARPER J, 1993, CELL, V75, P805; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZIPORI D, 1985, BLOOD, V66, P447	49	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1677	1685						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895513				2022-12-25	WOS:A1996VM88700012
J	Martin, SJ; Finucane, DM; AmaranteMendes, GP; OBrien, GA; Green, DR				Martin, SJ; Finucane, DM; AmaranteMendes, GP; OBrien, GA; Green, DR			Phosphatidylserine externalization during CD95-induced apoptosis of cells and cytoplasts requires ICE/CED-3 protease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITRONECTIN RECEPTOR; RECOGNITION; NUCLEUS; DEATH; MACROPHAGES; BCL-2	Phosphatidylserine (PS), a lipid normally confined to the inner leaflet of the plasma membrane, is exported to the outer plasma membrane leaflet during apoptosis to serve as a trigger for recognition of apoptotic cells by phagocytes. The mechanism of PS export during apoptosis is not known nor is it clear whether the nuclear changes that typify apoptosis contribute in any way to this event. Here, we demonstrate that ligation of the CD95 (Fas/APO-1) molecule on Jurkat cytoplasts induces dramatic PS externalization similar to that observed during apoptosis of intact cells. Apoptosis of both cells and cytoplasts was associated with proteolytic processing of CPP32, a member of the interleukin-1 beta converting enzyme (ICE)/CED-3 protease family, to its active form. Fodrin, a component of the cortical cytoskeleton, also underwent proteolytic cleavage during apoptosis of both cytoplasts and intact cells. Strikingly, CPP32 activation, fodrin proteolysis, and PS externalization were all inhibited in the presence of peptide inhibitors of ICE/CED-3 family proteases. These data provide strong support for the notion that the cell death machinery is extranuclear and is likely to be comprised of one or more members of the ICE/CED-3 family and that activation of this machinery does not require nuclear participation.	LA JOLLA INST ALLERGY & IMMUNOL,DIV CELLULAR IMMUNOL,LA JOLLA,CA 92121	La Jolla Institute for Immunology			Green, Douglas R/N-8083-2018; Mendes, Gustavo P Amarante/C-8187-2012	Green, Douglas R/0000-0002-7332-1417; Mendes, Gustavo P Amarante/0000-0002-7851-6205; Martin, Seamus/0000-0002-8539-3143	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052735, R37GM052735] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52735] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Casiano CA, 1996, J EXP MED, V184, P765, DOI 10.1084/jem.184.2.765; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; FADOK VA, 1992, J IMMUNOL, V149, P4029; FADOK VA, 1992, J IMMUNOL, V148, P2207; GUDAS JM, 1986, J CELL PHYSIOL, V128, P441, DOI 10.1002/jcp.1041280313; HASLETT C, 1994, PHILOS T ROY SOC B, V345, P327, DOI 10.1098/rstb.1994.0113; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAKAJIMA H, 1995, J EXP MED, V181, P1905, DOI 10.1084/jem.181.5.1905; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463	27	308	312	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28753	28756		10.1074/jbc.271.46.28753	http://dx.doi.org/10.1074/jbc.271.46.28753			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910516	hybrid			2022-12-25	WOS:A1996VT05200008
J	Mukherjee, JJ; Chung, T; Ways, DK; Kiss, Z				Mukherjee, JJ; Chung, T; Ways, DK; Kiss, Z			Protein kinase C alpha is a major mediator of the stimulatory effect of phorbol ester on phospholipase D-mediated hydrolysis of phosphatidylethanolamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIH 3T3 FIBROBLASTS; INDUCED DNA-SYNTHESIS; RAT FIBROBLASTS; PHOSPHATIDYLCHOLINE HYDROLYSIS; HYDROGEN-PEROXIDE; KIDNEY-CELLS; D ACTIVATION; OVEREXPRESSION; EPSILON; MECHANISMS	Stimulation of phospholipase D (PLD)-mediated hydrolysis of phosphatidylcholine (PtdCho) by phorbol 12-myristate 13-acetate (PMA) has been shown to be mediated by the alpha- and beta I-isoforms of protein kinase C (PKC). To determine the role of various PKC isozymes in the regulation of PLD-mediated phosphatidylethanolamine (PtdEtn) hydrolysis, MCF-7 human breast carcinoma cells overexpressing the alpha- and theta-isoforms, and R6 rat fibroblasts overexpressing the alpha-, beta I-, and epsilon-isoforms were used. In the vector control MCF-7 cells, which contain low levels of PKC-alpha, PMA (100 nM) had only small effects on the hydrolysis of PtdEtn (1.1-1.35-fold) and PtdCho (1.15-1.6-fold). Stable expression of PKC-alpha in MCF-7 cells, which was accompanied by increased levels of the beta I- and theta-isoforms as well, greatly enhanced both PMA-induced PLD-mediated formation of phosphatidylethanol (similar to 5-fold) and the hydrolysis of PtdEtn (2.5-2.9-fold) and PtdCho (5.5-7.2-fold). The effects of PMA on the hydrolysis of PtdEtn (and PtdCho) in MCF-7/PKC-alpha cells mere significantly inhibited by 0.5-3 mu M concentrations of Go 6976, a selective inhibitor of the conventional PKC subfamily. Stable expression of PKC-alpha in R6 fibroblasts enhanced, at a shorter (10 min) incubation time, the effects of PMA on the hydrolysis of both PtdEtn and, to a lesser extent, PtdCho. In contrast, stable expression of PKC-beta I in R6 fibroblasts, which originally did not contain this enzyme, enhanced the effects of PMA only on PtdCho, but not PtdEtn, hydrolysis. Overexpression of either PKC-theta in MCF-7 cells or PKC-epsilon in R6 and NIH 3T3 fibroblasts had no detectable effects on PMA-induced hydrolysis of PtdEtn. Collectively, the results suggest that PKC-alpha has a major role in the mediation of phorbol ester action on PtdEtn hydrolysis, while PtdCho hydrolysis may be regulated by both the alpha and beta I isoforms.	UNIV MINNESOTA,HORMEL INST,AUSTIN,MN 55912; LILLY CORP CTR,LILLY RES LABS,INDIANAPOLIS,IN 46285	University of Minnesota System; Eli Lilly								BAIER G, 1993, J BIOL CHEM, V268, P4997; BALBOA MA, 1994, J BIOL CHEM, V269, P10511; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLOBE GC, 1993, J BIOL CHEM, V268, P658; CACACE AM, 1993, ONCOGENE, V8, P2095; CONRICODE KM, 1994, FEBS LETT, V342, P149, DOI 10.1016/0014-5793(94)80490-7; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; ELDAR H, 1993, J BIOL CHEM, V268, P12560; EXTON JH, 1990, J BIOL CHEM, V265, P1; FISK HA, 1992, J CELL PHYSIOL, V153, P589, DOI 10.1002/jcp.1041530321; HII CST, 1991, J BIOL CHEM, V266, P20238; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; KISS Z, 1994, ARCH BIOCHEM BIOPHYS, V311, P430, DOI 10.1006/abbi.1994.1258; KISS Z, 1994, BIOCHEM J, V300, P751, DOI 10.1042/bj3000751; KISS Z, 1994, BIOCHEM J, V302, P649, DOI 10.1042/bj3020649; KISS Z, 1989, J BIOL CHEM, V264, P1483; KISS Z, 1995, FEBS LETT, V365, P146, DOI 10.1016/0014-5793(95)00445-F; Kiss Z, 1996, BIOCHEM BIOPH RES CO, V218, P505, DOI 10.1006/bbrc.1996.0090; Kiss Z, 1996, BIOCHEM BIOPH RES CO, V220, P125, DOI 10.1006/bbrc.1996.0368; Kiss Z, 1996, FEBS LETT, V381, P67, DOI 10.1016/0014-5793(96)00084-1; KISS Z, 1995, FEBS LETT, V371, P185, DOI 10.1016/0014-5793(95)00902-L; KISS Z, 1992, BIOCHEM J, V288, P853, DOI 10.1042/bj2880853; KISS Z, 1993, FEBS LETT, V333, P229, DOI 10.1016/0014-5793(93)80659-I; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; MARQUEZ C, 1992, J IMMUNOL, V149, P2560; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MIZUNUMA M, 1993, BIOCHIM BIOPHYS ACTA, V1168, P213; NATARAJAN V, 1993, J BIOL CHEM, V268, P930; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; TOMONO M, 1995, BIOCHEM BIOPH RES CO, V213, P980, DOI 10.1006/bbrc.1995.2225; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335	34	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28912	28917		10.1074/jbc.271.46.28912	http://dx.doi.org/10.1074/jbc.271.46.28912			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910539	hybrid			2022-12-25	WOS:A1996VT05200031
J	Mullins, C; Meyer, HA; Hartmann, E; Green, N; Fang, H				Mullins, C; Meyer, HA; Hartmann, E; Green, N; Fang, H			Structurally related Spc1p and Spc2p of yeast signal peptidase complex are functionally distinct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SHUTTLE VECTORS; SEC11 PROTEIN; GENE; PURIFICATION; GLYCOPROTEIN; POLYPEPTIDES; CONTAINS; SUBUNIT	Two subunits of the mammalian signal peptidase complex, SPC12 and SPC25, share similar membrane topologies with the majority of each protein oriented toward the cytoplasm. Such similarities may suggest that these proteins perform redundant functions in signal peptidase activity. In the present study, we addressed this issue through analysis of the yeast homologs to SPC12 and SPC25, Spc1p and Spc2p. We show that both Spc1p and Spc2p are nonessential for signal peptidase activity and growth of yeast cells and that null mutations in the genes encoding Spc1p and Spc2p are synthetically lethal with a conditional mutation affecting Sec11p, an essential subunit of yeast signal peptidase. However, a high copy plasmid encoding Spc1p suppresses the conditional sec11 mutation, whereas the corresponding plasmid encoding Spc2p does not suppress sec11. Moreover, Spc2p, but not Spc1p, is important for signal peptidase activity and cell viability at high temperatures. These results indicate that although both Spc1p and Spc2p are noncatalytic, they are functionally distinct. Evidence is also presented that a double mutant lacking Spc1p and Spc2p grows well relative to wild type yeast cells, indicating that the signal peptidase complex missing at least two of its subunits is sufficient for signal peptidase activity in vivo.	MAX DELBRUCK CTR MOL MED,D-13125 BERLIN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Mullins, C (corresponding author), VANDERBILT UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,NASHVILLE,TN 37232, USA.		Hartmann, Enno/C-5687-2013		NATIONAL CANCER INSTITUTE [T32CA009385] Funding Source: NIH RePORTER; NCI NIH HHS [2 T32 CA09385-11] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1990, J MOL BIOL, V215, P403; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; Fang H, 1996, J BIOL CHEM, V271, P16460, DOI 10.1074/jbc.271.28.16460; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GREEN N, 1992, MOL CELL BIOL, V12, P276, DOI 10.1128/MCB.12.1.276; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; GREENBURG G, 1994, J BIOL CHEM, V269, P25354; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1442; Kalies KU, 1996, J BIOL CHEM, V271, P3925; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MULLINS C, 1995, J BIOL CHEM, V270, P17139, DOI 10.1074/jbc.270.29.17139; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SHELNESS GS, 1988, J BIOL CHEM, V263, P17063; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; SHELNESS GS, 1993, J BIOL CHEM, V268, P5201; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEVENS TB, 1982, CELL, V30, P443; Von Heijne Gunnar, 1994, V22, P1; YADEAU JT, 1991, P NATL ACAD SCI USA, V88, P517, DOI 10.1073/pnas.88.2.517; ZWIZINSKI C, 1980, J BIOL CHEM, V255, P7973	29	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29094	29099		10.1074/jbc.271.46.29094	http://dx.doi.org/10.1074/jbc.271.46.29094			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910564	hybrid			2022-12-25	WOS:A1996VT05200056
J	Calaycay, JR; Kelly, TM; MacNaul, KL; McCauley, ED; Qi, HB; Grant, SK; Griffin, PR; Klatt, T; Raju, SM; Nussler, AK; Shah, S; Weidner, JR; Williams, HR; Wolfe, GC; Geller, DA; Billiar, TR; MacCoss, M; Mumford, RA; Tocci, MJ; Schmidt, JA; Wong, KK; Hutchinson, NI				Calaycay, JR; Kelly, TM; MacNaul, KL; McCauley, ED; Qi, HB; Grant, SK; Griffin, PR; Klatt, T; Raju, SM; Nussler, AK; Shah, S; Weidner, JR; Williams, HR; Wolfe, GC; Geller, DA; Billiar, TR; MacCoss, M; Mumford, RA; Tocci, MJ; Schmidt, JA; Wong, KK; Hutchinson, NI			Expression and immunoaffinity purification of human inducible nitric-oxide synthase - Inhibition studies with 2-amino-5,6-dihydro-4H-1,3-thiazine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; L-ARGININE; STRUCTURAL-ANALYSIS; MASS-SPECTROMETRY; MAMMALIAN-CELLS; MACROPHAGE; BRAIN; CALMODULIN; CLONING; TETRAHYDROBIOPTERIN	Recombinant human inducible nitric-oxide synthase (rH-iNOS) was expressed in the baculovirus system and purified by a novel immunoaffinity column. rH-iNOS and its native counterpart from cytokine-stimulated primary hepatocytes exhibited similar molecular mass of 130 kDa on SDS-polyacrylamide gel electrophoresis, recognition by antipeptide antibodies, specific activities, and IC50 values for inhibitors. The active dimeric form exhibited a specific activity range of 114-260 nmol/min/mg at 37 degrees C and contained 1.15 +/- 0.04 mol of calmedulin/monomer. The enzyme exhibited a Soret lambda(max) at 396 nm with a shoulder at 460 nm and contained 0.28-0.64 mel of heme/monomer. Dithionite reduction under CO yielded an absorbance maximum at 446 nm, indicating a P-450-type heme. Imidazole induced a type II difference spectrum, reversible by L-Arg. 2-Amino-5,6-dihydro-4H-1,3-thiazine (ADT) was competitive versus L-Arg (K-i = 22.6 +/- 1.9 nM), reversed the type II difference spectrum induced by imidazole (K-d = 17.7 nM), and altered the GO-ferrous absorbance of rH-iNOS. L-Arg did not perturb the CO-ferrous adduct directly, but it partially reversed the ADT-induced absorbance shift, indicating that both bind similarly to the protein but interact differently with the heme.	MERCK RES LABS,DEPT BIOCHEM,RAHWAY,NJ 07065; MERCK RES LABS,DEPT INFLAMMAT RES,RAHWAY,NJ 07065; MERCK RES LABS,DEPT MED CHEM,RAHWAY,NJ 07065; UNIV PITTSBURGH,DEPT SURG,PITTSBURGH,PA 15261	Merck & Company; Merck & Company; Merck & Company; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Calaycay, JR (corresponding author), MERCK RES LABS,DEPT MOL DESIGN & DIVERS,MAIL DROP RY80-A23,POB 2000,RAHWAY,NJ 07065, USA.		Nussler, Andreas/H-3557-2019	Nussler, Andreas/0000-0002-6666-6791				ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; AITHAL HN, 1988, J IMMUNOL METHODS, V112, P63, DOI 10.1016/0022-1759(88)90034-8; ANAGLI J, 1995, EUR J BIOCHEM, V233, P701, DOI 10.1111/j.1432-1033.1995.701_3.x; ATKINS WM, 1990, BIOCHEMISTRY-US, V29, P1271, DOI 10.1021/bi00457a024; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; CHENAIS B, 1991, J CHROMATOGR, V539, P433, DOI 10.1016/S0021-9673(01)83952-2; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; FELDMAN PL, 1993, J MED CHEM, V36, P491, DOI 10.1021/jm00056a009; GARVEY EP, 1994, J BIOL CHEM, V269, P26669; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; GRIFFIN PR, 1991, INT J MASS SPECTROM, V111, P131, DOI 10.1016/0168-1176(91)85052-N; GROSS SS, 1992, J BIOL CHEM, V267, P25722; JANSSENS SP, 1992, J BIOL CHEM, V267, P22694; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KEWIN JF, 1995, J MED CHEM, V38, P4343; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; KLATT P, 1993, J BIOL CHEM, V268, P14781; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laubach VE, 1996, BIOCHEM BIOPH RES CO, V218, P802, DOI 10.1006/bbrc.1996.0143; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MCLUCKEY SA, 1991, ANAL CHEM, V63, P375, DOI 10.1021/ac00004a015; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MOORE WM, 1994, J MED CHEM, V37, P3886, DOI 10.1021/jm00049a007; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NAKANE M, 1995, MOL PHARMACOL, V47, P831; NAKANE M, 1995, BIOCHEM BIOPH RES CO, V206, P511, DOI 10.1006/bbrc.1995.1073; NARAYANAN K, 1994, J MED CHEM, V37, P885, DOI 10.1021/jm00033a004; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; OLKEN NM, 1992, J MED CHEM, V35, P1137, DOI 10.1021/jm00084a020; OLKEN NM, 1991, BIOCHEM BIOPH RES CO, V177, P128; Rieske JS, 1967, METHOD ENZYMOL, V10, P488, DOI DOI 10.1016/0076-6879(67)10081-5; ROBERTSON CA, 1993, BIOCHEM BIOPH RES CO, V197, P523, DOI 10.1006/bbrc.1993.2510; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; SALTZMAN BE, 1954, ANAL CHEM, V26, P1949, DOI 10.1021/ac60096a025; SCHOBERL A, 1958, LIEBIGS ANN CHEM, V614, P83; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STEVENSTRUSS R, 1995, BIOCHEMISTRY-US, V34, P15638, DOI 10.1021/bi00048a006; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; WANG JL, 1993, J BIOL CHEM, V268, P22255; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YAMANAKA MK, 1987, NUCLEIC ACIDS RES, V15, P3335, DOI 10.1093/nar/15.8.3335	54	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28212	28219		10.1074/jbc.271.45.28212	http://dx.doi.org/10.1074/jbc.271.45.28212			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910438	hybrid			2022-12-25	WOS:A1996VU03300038
J	Chen, GL; Wang, LJ; Liu, SJ; Chuang, C; Roche, TE				Chen, GL; Wang, LJ; Liu, SJ; Chuang, C; Roche, TE			Activated function of the pyruvate dehydrogenase phosphatase through Ca2+-facilitated binding to the inner lipoyl domain of the dihydrolipoyl acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-X COMPONENT; BOVINE KIDNEY; CALCIUM-IONS; TRANSACETYLASE COMPONENT; SACCHAROMYCES-CEREVISIAE; ADENINE-NUCLEOTIDES; ALPHA-KETOGLUTARATE; B PHOSPHATASE; COMPLEX; PURIFICATION	Micromolar Ca2+ facilitates similar to 10-fold enhancement of pyruvate dehydrogenase phosphatase (PDP) activity by aiding the association of PDP with the dihydrolipoyl acetyltransferase (E2) component, Connected by linker regions, E2 consists of two lipoyl domains, the NH2-lipoyl domain (L1) and the interior lipoyl domain (L2), and a pyruvate dehydrogenase component binding domain surrounding a 60-mer inner core. Using recombinant constructs of L1 or L2, E2-enhanced PDP activity was markedly decreased by L2 but not by L1, effectively competing with intact E2 in Ca2+-dependent binding of PDP (half-maximal reduction at 2.0 mu M L2 versus 6.7 mu M E2 subunit). Using L2 fused to glutathione S-transferase resulted in direct Ca2+-dependent binding of PDP to L2 (K-d similar to 1.7 mu M L2). Affinity-bound glutathione S-transferase-L2 was used to purify PDP to homogeneity by selective binding and elution by Ca2+ chelation. The large activity enhancement of PDP by E2 was eliminated by enzymatic removal of lipoates from E2 and restored by their enzymatic reintroduction. The critical role of the L2 lipoate is not in binding of PDP to E2, since PDP was still bound by delipoylated L2, and delipoylated L2 inhibited E2-enhanced PDP activity, although lipoylated L2 was more effective in each of these tests, Thus, pyruvate dehydrogenase complex activity is increased by enhanced availability of PDP to its E2-bound, phosphorylated pyruvate dehydrogenase substrate as a consequence of the Ca2+-facilitated interchange of PDP among the mobile L2 domains and an essential (undetermined) step engaging the L2 lipoate.	KANSAS STATE UNIV,DEPT BIOCHEM,MANHATTAN,KS 66506	Kansas State University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018320, R55DK018320] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18320] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DAMUNI Z, 1984, BIOCHEM BIOPH RES CO, V124, P95, DOI 10.1016/0006-291X(84)90921-5; DAMUNI Z, 1987, J BIOL CHEM, V262, P5133; DAVIS PF, 1977, BIOCHEM BIOPH RES CO, V75, P541, DOI 10.1016/0006-291X(77)91506-6; DENTON RM, 1972, BIOCHEM J, V128, P161, DOI 10.1042/bj1280161; DENTON RM, 1978, BIOCHEM J, V176, P894; GREEN DE, 1995, BIOCHEM J, V309, P853, DOI 10.1042/bj3090853; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Hansford R.G., 1980, CURR TOP BIOENERG, VVolume 10, P217, DOI 10.1016/B978-0-12-152510-1.50012-2; HANSFORD RG, 1991, J BIOENERG BIOMEMBR, V23, P823, DOI 10.1007/BF00786004; HUCHO F, 1972, Archives of Biochemistry and Biophysics, V151, P328, DOI 10.1016/0003-9861(72)90504-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWLIS VB, 1981, BIOCHEMISTRY-US, V20, P2512, DOI 10.1021/bi00512a023; LAWLIS VB, 1981, BIOCHEMISTRY-US, V20, P2519, DOI 10.1021/bi00512a024; LAWSON JE, 1993, BIOCHEMISTRY-US, V32, P8987, DOI 10.1021/bi00086a002; LAWSON JE, 1991, BIOCHEMISTRY-US, V30, P2834, DOI 10.1021/bi00225a015; LINN TC, 1972, ARCH BIOCHEM BIOPHYS, V148, P327, DOI 10.1016/0003-9861(72)90151-8; LINN TC, 1969, P NATL ACAD SCI USA, V62, P227; LIU SJ, 1995, J BIOL CHEM, V270, P793, DOI 10.1074/jbc.270.2.793; LIU SJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P926, DOI 10.1006/abbi.1995.1124; MAENG CY, 1994, BIOCHEMISTRY-US, V33, P13801, DOI 10.1021/bi00250a034; Maeng CY, 1996, BIOCHEMISTRY-US, V35, P5879, DOI 10.1021/bi9600254; MCCORMACK JG, 1993, BIOCHEM SOC T, V21, P793, DOI 10.1042/bst0210793; MCCORMACK JG, 1979, BIOCHEM J, V180, P533, DOI 10.1042/bj1800533; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PETTIT FH, 1972, BIOCHEM BIOPH RES CO, V49, P563, DOI 10.1016/0006-291X(72)90448-2; PRATT ML, 1982, EUR J BIOCHEM, V125, P349, DOI 10.1111/j.1432-1033.1982.tb06690.x; RAHMATULLAH M, 1986, J BIOL CHEM, V261, P6515; RAHMATULLAH M, 1990, J BIOL CHEM, V265, P14512; RAHMATULLAH M, 1988, J BIOL CHEM, V263, P8106; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P2221; Ravindran S, 1996, J BIOL CHEM, V271, P653, DOI 10.1074/jbc.271.2.653; REED LJ, 1990, J BIOL CHEM, V265, P8971; REED LJ, 1996, ALPHA KETO ACID DEHY, P131; REED LJ, 1987, ADV PROT PHOSPHATASE, V4, P59; ROCHE TE, 1977, ARCH BIOCHEM BIOPHYS, V183, P664, DOI 10.1016/0003-9861(77)90400-3; ROCHE TE, 1996, ALPHA KETO ACID DEHY, P33; SUZUKI K, 1963, J BIOL CHEM, V238, P4021; TEAGUE WM, 1982, BIOCHEMISTRY-US, V21, P5585, DOI 10.1021/bi00265a031; THOMAS AP, 1986, BIOCHEM J, V238, P83, DOI 10.1042/bj2380083; THOMAS AP, 1986, BIOCHEM J, V238, P93, DOI 10.1042/bj2380093; WAGENKNECHT T, 1991, J BIOL CHEM, V266, P24650; Yan JG, 1996, P NATL ACAD SCI USA, V93, P4953, DOI 10.1073/pnas.93.10.4953	43	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28064	28070		10.1074/jbc.271.45.28064	http://dx.doi.org/10.1074/jbc.271.45.28064			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910418	hybrid			2022-12-25	WOS:A1996VU03300018
J	Brown, TJ; Shuford, WW; Wang, WC; Nadler, SG; Bailey, TS; Marquardt, H; Mittler, RS				Brown, TJ; Shuford, WW; Wang, WC; Nadler, SG; Bailey, TS; Marquardt, H; Mittler, RS			Characterization of a CD43/leukosialin-mediated pathway for inducing apoptosis in human T-lymphoblastoid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH SYNDROME; LYMPHOCYTE SURFACE SIALOGLYCOPROTEIN; O-LINKED OLIGOSACCHARIDES; FAS-INDUCED APOPTOSIS; PROTEIN KINASE-C; MAJOR SIALOGLYCOPROTEIN; AFFINITY-CHROMATOGRAPHY; SIGNAL-TRANSDUCTION; MEMBRANE-PROTEINS; SIALOPHORIN CD43	The monoclonal antibody (mAb) J393 induces apoptosis in Jurkat T-cells, NH2-terminal amino acid sequence analysis identified the 140-kDa surface antigen for mAb J393 as CD43/leukosialin, the major sialoglycoprotein of leukocytes, While Jurkat cells co-expressed two discrete cell-surface isoforms of CD43, recognized by mAb J393 and mAb G10-2, respectively, only J393/CD43 signaled apoptosis. J393/CD43 was found to be hyposialylated, bearing predominantly O-linked monosaccharide glycans, whereas G10-2/CD43 bore complex sialylated tetra- and hexasaccharide chains, Treatment with soluble, bivalent mAb J393 killed 25-50% of the cell population, while concomitant engagement of either the CD3 . TcR complex or the integrins CD18 and CD29 significantly potentiated this effect, Treatment of Jurkat cells with mAb J393 induced tyrosine phosphorylation of specific protein substrates that underwent hyperphosphorylation upon antigen receptor costimulation. Tyrosine kinase inhibition by herbimycin A diminished J393/CD43-mediated apoptosis, whereas inhibition of phosphotyrosine phosphatase activity by bis(maltolato) oxovanadium-IV enhanced cell death, Signal transduction through tyrosine kinase activation may lead to altered gene expression, as J393/CD43 ligation prompted decreases ill the nuclear Localization of the transcriptional regulatory protein NF-kappa B and proteins binding the interferon-inducible regulatory element, Since peripheral blood T-lymphocytes express cryptic epitopes for mAb J393, these findings demonstrate the existence of a tightly regulated CD43-mediated pathway for inducing apoptosis in human T-cell lineages.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	Bristol-Myers Squibb								ALVARADO M, 1995, EUR J IMMUNOL, V25, P1051, DOI 10.1002/eji.1830250429; ARDMAN B, 1992, P NATL ACAD SCI USA, V89, P5001, DOI 10.1073/pnas.89.11.5001; ARDMAN B, 1990, J EXP MED, V172, P1151, DOI 10.1084/jem.172.4.1151; AXELSSON B, 1988, J IMMUNOL, V141, P2912; AXELSSON B, 1989, SCAND J IMMUNOL, V30, P539, DOI 10.1111/j.1365-3083.1989.tb02461.x; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; BAZIL V, 1995, BLOOD, V86, P502, DOI 10.1182/blood.V86.2.502.bloodjournal862502; BERGER EG, 1994, TRANSFUS CLIN BIOL, V1, P103, DOI 10.1016/S1246-7820(94)80004-9; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; BOWEN DL, 1985, ANN INTERN MED, V103, P704, DOI 10.7326/0003-4819-103-5-704; BROWN WRA, 1981, NATURE, V289, P456, DOI 10.1038/289456a0; CARLSSON SR, 1986, J BIOL CHEM, V261, P12878; CHATILA TA, 1988, J IMMUNOL, V140, P4308; COOPER MD, 1968, AM J MED, V44, P499, DOI 10.1016/0002-9343(68)90051-X; CYSTER J, 1990, EUR J IMMUNOL, V20, P875, DOI 10.1002/eji.1830200424; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; DAKOUR J, 1987, ANAL BIOCHEM, V161, P140, DOI 10.1016/0003-2697(87)90663-4; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DINGHAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; ELLIES LG, 1994, GLYCOBIOLOGY, V4, P885, DOI 10.1093/glycob/4.6.885; FOX RI, 1983, J IMMUNOL, V131, P762; FUKUDA M, 1986, MED BIOL, V64, P335; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Hayden M S, 1994, Ther Immunol, V1, P3; HernandezCaselles T, 1996, J IMMUNOL, V156, P3668; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; INOUE M, 1994, CANCER RES, V54, P85; JONES AT, 1994, J IMMUNOL, V153, P3426; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KENNEY D, 1986, BLOOD, V68, P1329; KOJIMA N, 1994, EXP CELL RES, V214, P537, DOI 10.1006/excr.1994.1291; LEE N, 1990, J BIOL CHEM, V265, P20476; LEFEBVRE JC, 1994, J EXP MED, V180, P1609, DOI 10.1084/jem.180.5.1609; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MANJUNATH N, 1993, J IMMUNOL, V151, P1528; MANJUNATH N, 1995, NATURE, V377, P535, DOI 10.1038/377535a0; MARESH GA, 1994, ARCH BIOCHEM BIOPHYS, V311, P95, DOI 10.1006/abbi.1994.1213; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MENTZER SJ, 1987, J EXP MED, V165, P1383, DOI 10.1084/jem.165.5.1383; MITTLER RS, 1991, J IMMUNOL, V147, P3434; MITTLER RS, 1987, J IMMUNOL, V138, P3159; MITTLER RS, 1983, J EXP MED, V158, P99, DOI 10.1084/jem.158.1.99; NAKADA H, 1991, BIOCHEM BIOPH RES CO, V179, P762, DOI 10.1016/0006-291X(91)91882-D; OHLSON S, 1988, ANAL BIOCHEM, V169, P204, DOI 10.1016/0003-2697(88)90275-8; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; PARKMAN R, 1981, LANCET, V2, P1387; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; PILLER V, 1989, J BIOL CHEM, V264, P18824; PILLER V, 1990, J BIOL CHEM, V265, P9264; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; RUDD CE, 1994, IMMUNOL TODAY, V15, P225, DOI 10.1016/0167-5699(94)90248-8; SAITOH O, 1991, BLOOD, V77, P1491; SCHIEVEN GL, 1995, J BIOL CHEM, V270, P20824, DOI 10.1074/jbc.270.35.20824; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHELLEY CS, 1989, P NATL ACAD SCI USA, V86, P2819, DOI 10.1073/pnas.86.8.2819; SHELLEY CS, 1990, BIOCHEM J, V270, P569, DOI 10.1042/bj2700569; SILVERMAN LB, 1989, J IMMUNOL, V142, P4194; Siminovitch K A, 1993, Immunodeficiency, V4, P99; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SPERLING AI, 1995, J EXP MED, V182, P139, DOI 10.1084/jem.182.1.139; SPORTSMAN JR, 1985, J IMMUNOL, V135, P158; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; TEPPER MA, 1995, J IMMUNOL, V155, P2427; THOMAS ML, 1995, IMMUNOLOGY, V7, P279; THUNHER M, 1993, J CLIN INVEST, V91, P2103; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386; WANG WC, 1988, ANAL BIOCHEM, V175, P390, DOI 10.1016/0003-2697(88)90562-3; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WONG RCK, 1990, J IMMUNOL, V144, P1455	72	52	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27686	27695		10.1074/jbc.271.44.27686	http://dx.doi.org/10.1074/jbc.271.44.27686			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910360	hybrid			2022-12-25	WOS:A1996VQ67900078
J	Sakai, M; Miyazaki, A; Hakamata, H; Kodama, T; Suzuki, H; Kobori, S; Shichiri, M; Horiuchi, S				Sakai, M; Miyazaki, A; Hakamata, H; Kodama, T; Suzuki, H; Kobori, S; Shichiri, M; Horiuchi, S			The scavenger receptor serves as a route for internalization of lysophosphatidylcholine in oxidized low density lipoprotein-induced macrophage proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; MOUSE PERITONEAL-MACROPHAGES; ENDOTHELIAL-CELLS; CHOLESTEROL ACYLTRANSFERASE; ATHEROSCLEROTIC LESIONS; MONOCYTE MACROPHAGES; MEDIATED RECOGNITION; CULTURED HUMAN; GROWTH-FACTOR; DNA-SYNTHESIS	We have recently demonstrated that the growth of murine macrophages is induced by oxidized low density lipoprotein (OY-LDL) and that lysophosphatidylcholine (lyse-PC), a major phospholipid component of Ox-LDL, plays an essential role in its mitogenic effect, The present study was undertaken to further characterize the role of the macrophage scavenger receptor (MSR) in Ox-LDL-induced macrophage growth. The growth-stimulating effect of Ox-LDL on murine resident peritoneal macrophages was inhibited by maleylated bovine serum albumin (maleyl-BSA), a non-lipoprotein ligand for MSR but a poor carrier of lyse-PC, while maleyl-BSA itself failed to induce macrophage growth even in the presence of lyso-PC. Moreover, it competitively inhibited the endocytic uptake of I-125-Ox-LDL and the specific uptake of lyse-PC by MSR, whereas nonspecific lyse-PC transfer to cells was not affected. Furthermore, the Ox-LDL-induced cell growth of peritoneal macrophages obtained from MSR knockout mice was significantly weaker than that of macrophages obtained from their wild-type Littermates. Our results suggest that the MSR is an important and efficient internalization pathway for lyse-PC in Ox-LDL-induced macrophage growth.	KUMAMOTO UNIV,SCH MED,DEPT BIOCHEM,KUMAMOTO 860,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN	Kumamoto University; University of Tokyo								ACTON SL, 1994, J BIOL CHEM, V269, P21003; ALBERS JJ, 1984, ARTERIOSCLEROSIS, V4, P49, DOI 10.1161/01.ATV.4.1.49; ARAI H, 1989, BIOCHEM BIOPH RES CO, V159, P1375, DOI 10.1016/0006-291X(89)92262-6; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; DERIJKE YB, 1994, J BIOL CHEM, V269, P824; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; HABERLAND ME, 1985, P NATL ACAD SCI USA, V82, P2693, DOI 10.1073/pnas.82.9.2693; HAKAMATA H, 1995, FEBS LETT, V363, P29, DOI 10.1016/0014-5793(95)00273-C; HAMILTON JA, 1983, J CELL PHYSIOL, V115, P67, DOI 10.1002/jcp.1041150111; HAMILTON JA, 1981, J CELL PHYSIOL, V106, P445, DOI 10.1002/jcp.1041060314; HARA H, 1991, J BIOL CHEM, V266, P3080; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KUGIYAMA K, 1993, CIRC RES, V73, P335, DOI 10.1161/01.RES.73.2.335; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; KURIHARA Y, 1992, CIRCULATION, V86, P471; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MELKKO J, 1994, J EXP MED, V179, P405, DOI 10.1084/jem.179.2.405; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; MURAKAMI M, 1987, J BIOCHEM-TOKYO, V101, P729, DOI 10.1093/jb/101.3.729; MURATA Y, 1988, BIOCHIM BIOPHYS ACTA, V972, P17, DOI 10.1016/S0005-2728(88)80087-2; OTTNAD E, 1995, P NATL ACAD SCI USA, V92, P1391, DOI 10.1073/pnas.92.5.1391; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2085; RESINK TJ, 1992, ARTERIOSCLER THROMB, V12, P278, DOI 10.1161/01.ATV.12.3.278; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P680, DOI 10.1161/01.ATV.10.5.680; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAKAI M, 1994, J BIOL CHEM, V269, P31430; SAKAI M, 1992, FEBS LETT, V314, P199, DOI 10.1016/0014-5793(92)80974-L; Sakai M, 1996, ARTERIOSCL THROM VAS, V16, P600, DOI 10.1161/01.ATV.16.4.600; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; SHACKELFORD RE, 1995, J BIOL CHEM, V270, P3475, DOI 10.1074/jbc.270.8.3475; SHINOHARA M, 1992, J BIOL CHEM, V267, P1603; SPAGNOLI LG, 1991, ATHEROSCLEROSIS, V88, P87, DOI 10.1016/0021-9150(91)90260-A; STANTON LW, 1992, J BIOL CHEM, V267, P22446; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TAKATA K, 1989, BIOCHIM BIOPHYS ACTA, V984, P273, DOI 10.1016/0005-2736(89)90293-9; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; YUI S, 1986, J IMMUNOL, V136, P1334; YUI S, 1993, ARTERIOSCLER THROMB, V13, P331, DOI 10.1161/01.ATV.13.3.331	46	89	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27346	27352		10.1074/jbc.271.44.27346	http://dx.doi.org/10.1074/jbc.271.44.27346			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910311	hybrid			2022-12-25	WOS:A1996VQ67900029
J	Greene, JAL; Leytze, GM; Emswiler, J; Peach, R; Bajorath, J; Cosand, W; Linsley, PS				Greene, JAL; Leytze, GM; Emswiler, J; Peach, R; Bajorath, J; Cosand, W; Linsley, PS			Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; BINDING STOICHIOMETRY; LYMPHOCYTES-T; CD28 RECEPTOR; CTLA-4; ACTIVATION; ANTIGEN; B7-1; IMMOBILIZATION; SPECIFICITY	T lymphocyte receptors CD28 and CTLA-4 bind costimulatory molecules CD80 (B7-1) and CD86 (B7-2) on antigen presenting cells and regulate T cell activation, While distinct functional roles have been ascribed to each of these molecules, little is known about how they interact, To better characterize these interactions, we have used surface plasmon resonance to perform equilibrium and kinetic binding analyses of extracellular fragments of CD28/CTLA-4/CD80/CD86. We show that CTLA-4 and CD28 binding are both characterized by rapid kinetic on-rates and rapid dissociation rates, Native disulfide-linked homodimers of CD28 and CTLA-4 bound with two kinetically distinct binding sites, one of high avidity and slow dissociation and one of low avidity and more rapid dissociation, Monomeric CTLA-4 bound only with low affinity and rapid dissociation, Therefore, covalent dimerization of CTLA-4 is required for its high avidity binding. Oligomerization of CD80/CD86 is also required for high avidity CTLA-4 binding since CTLA-4 bound with low avidity to monomeric CD86, This contrasts with the ability of CD80/CD86 on antigen presenting cells to bind CTLA4Ig with high avidity and predicts their organization as oligomers or clusters that permit multivalent binding. Thus, covalent receptor dimerization and ligand oligomerization are two key features of the CD28/CTLA-4/CD80/CD86 receptor System that control ligand binding and may regulate signal transduction by controlling the duration of receptor occupancy.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	Bristol-Myers Squibb			Bajorath, Jürgen/F-7493-2014					ALLISON JP, 1994, CURR OPIN IMMUNOL, V6, P414, DOI 10.1016/0952-7915(94)90120-1; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; FREEMAN GJ, 1995, IMMUNITY, V2, P523, DOI 10.1016/1074-7613(95)90032-2; GRIBBEN JG, 1995, P NATL ACAD SCI USA, V92, P811, DOI 10.1073/pnas.92.3.811; GUINAN EC, 1994, BLOOD, V84, P3261; Hollenbaugh D, 1995, J IMMUNOL METHODS, V188, P1, DOI 10.1016/0022-1759(95)00194-8; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KHILKO SN, 1993, J BIOL CHEM, V268, P15425; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; KUCHROO VK, 1995, CELL, V80, P1; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; LINSLEY PS, 1995, J BIOL CHEM, V270, P15417, DOI 10.1074/jbc.270.25.15417; LINSLEY PS, 1995, RES IMMUNOL, V146, P130, DOI 10.1016/0923-2494(96)80246-X; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1995, J EXP MED, V182, P289, DOI 10.1084/jem.182.2.289; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, J EXP MED, V176, P1595, DOI 10.1084/jem.176.6.1595; Morton PA, 1996, J IMMUNOL, V156, P1047; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; PEACH RJ, 1994, J EXP MED, V180, P2049, DOI 10.1084/jem.180.6.2049; Schuck P, 1996, BIOPHYS J, V70, P1230, DOI 10.1016/S0006-3495(96)79681-9; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SYMINGTON FW, 1993, J IMMUNOL, V150, P1286; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985	31	175	195	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26762	26771		10.1074/jbc.271.43.26762	http://dx.doi.org/10.1074/jbc.271.43.26762			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900156	hybrid			2022-12-25	WOS:A1996VP23300050
J	Grimaldi, ME; Adamo, HP; Rega, AF; Penniston, JT				Grimaldi, ME; Adamo, HP; Rega, AF; Penniston, JT			Deletion of amino acid residues 18-75 inactivates the plasma membrane Ca2+ pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+ PUMP; ERYTHROCYTE-MEMBRANE; PROTEOLYSIS; MUTANTS; ATPASE; CELLS; SITE; CA2+-ATPASE; EXPRESSION; SEQUENCE	A mutant of the plasma membrane Ca2+ pump hPMCA4b(d18-75)(ct120) containing a deletion of the N-terminal amino acid residues 18-75 and lacking the C-terminal 120 amino acid residues was expressed in COS-1 cells, The deletion in the N-terminal region did not significantly affect the level of expression of the Ca2+ pump. Tryptic digestion of the hPMCA4b(d18-75)(ct120) mutant resulted in the appearance of the same fragments obtained by proteolysis of the hPMCA4b(ct120) enzyme, suggesting that deletion of residues 18-75 neither impeded the insertion in the membrane nor extensively affected the folding of the mutant protein. The functional competence of the hPMCA4b(d18-75)(ct120) enzyme was examined by measuring the Ca2+ transport and the Ca2+ ATPase activity of COS-1 cell microsomes expressing the mutant protein. Both tests proved the mutant to be inactive, Under conditions in which hPMCA4b(ct120) becomes phosphorylated, hPMCA4b(d18-75)(ct120) was incapable of reacting with ATP and Ca2+ to form the phosphoenzyme. Taken together these results suggest that the segment of amino acids 18-75 is essential for the activity of the plasma membrane Ca2+ pump.	UNIV BUENOS AIRES,FAC FARM & BIOQUIM,INST QUIM & FISICOQUIM BIOL,RA-1113 BUENOS AIRES,DF,ARGENTINA; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905	University of Buenos Aires; Mayo Clinic			Adamo, Hugo Pedro/ABB-8338-2021	Adamo, Hugo Pedro/0000-0002-1712-8049	NIGMS NIH HHS [GM28835] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; ADAMO HP, 1992, J BIOL CHEM, V267, P14244; ADAMO HP, 1995, J BIOL CHEM, V270, P30111; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FILOTEO AG, 1987, J BIOL CHEM, V262, P6526; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HEIM R, 1992, J BIOL CHEM, V267, P24476; JAMES P, 1988, J BIOL CHEM, V263, P2905; JAMES P, 1987, BIOCHEM BIOPH RES CO, V149, P7, DOI 10.1016/0006-291X(87)91597-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUTERBACHER S, 1983, EXPERIENTIA, V39, P311, DOI 10.1007/BF01955322; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; RICHARDS DE, 1978, BIOCHIM BIOPHYS ACTA, V511, P194, DOI 10.1016/0005-2736(78)90313-9; SARKADI B, 1986, J BIOL CHEM, V261, P9552; ZURINI M, 1984, J BIOL CHEM, V259, P618; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012	18	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26995	26997		10.1074/jbc.271.43.26995	http://dx.doi.org/10.1074/jbc.271.43.26995			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900186	hybrid			2022-12-25	WOS:A1996VP23300080
J	Jensen, PH; Jensen, TG; Laug, WE; Hager, H; Gliemann, J; Pepinsky, B				Jensen, PH; Jensen, TG; Laug, WE; Hager, H; Gliemann, J; Pepinsky, B			The Exon 3 encoded sequence of the intracellular serine proteinase inhibitor plasminogen activator inhibitor 2 is a protein binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLACENTA; BIOLOGICAL FUNCTION; CROSS-LINKING; LIPOCORTIN-I; TYPE-2; CELLS; VITRONECTIN; OVALBUMIN; RECEPTOR; TRANSGLUTAMINASE	We have used a combination of biochemical and immunological methods to probe for proteins that interact with the cytoplasmic form of plasminogen activator inhibitor 2 (PAI-2) and to identify the structure in PAI-2 that mediates the binding, By affinity chromatography on immobilized PAI-2, we purified a collection of PAI-2-binding proteins. These proteins bound I-125-labeled PAI-2 in vitro (IC50, similar to 10-100 nM) in a calcium-imdependent reaction that did not abrogate the proteinase inhibitory function of PAI-2. Annexin I was identified among the eluted proteins, and purified annexins I, II, IV, and V, but not III and VI, possessed I-125-labeled PAI-2 binding activity, Immune precipitation by anti-PAI-2 monoclonal and polyclonal antibodies of metabolically labeled melanoma cells treated with a cleavable cross-linker prior to analysis revealed three prominent proteins with apparent masses of 100, 70, and 50 kDa. We localized the protein binding domain in PAI-2 between amino acid residues 66 and 98, as determined by using a PAI-2 mutant lacking this domain and a synthetic peptide spanning this region, This region of PAI-2 corresponds to exon 3 of the gene sequence thought to be critical for PAI-2 functions.	AARHUS UNIV,DEPT HUMAN GENET,DK-8000 AARHUS C,DENMARK; CHILDRENS HOSP LOS ANGELES,DIV HEMATOL ONCOL,LOS ANGELES,CA 90027; BIOGEN INC,CAMBRIDGE,MA 02142	Aarhus University; Children's Hospital Los Angeles; Biogen	Jensen, PH (corresponding author), AARHUS UNIV,DEPT MED BIOCHEM,DK-8000 AARHUS C,DENMARK.			Jensen, Poul Henning/0000-0002-4439-9020				ANTALIS TM, P NATL ACAD SCI USA, V85, P985; BELIN D, 1989, EMBO J, V8, P3287, DOI 10.1002/j.1460-2075.1989.tb08489.x; CELIS JE, 1994, ELECTROPHORESIS, V15, P1349, DOI 10.1002/elps.11501501208; COUGHLIN P, 1993, P NATL ACAD SCI USA, V90, P9417, DOI 10.1073/pnas.90.20.9417; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JENSEN PH, 1994, J BIOL CHEM, V269, P15394; JENSEN PH, 1994, BRIT J CANCER, V70, P834, DOI 10.1038/bjc.1994.407; JENSEN PH, 1993, EUR J BIOCHEM, V214, P141, DOI 10.1111/j.1432-1033.1993.tb17906.x; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; JENSEN PH, 1989, BIOCHIM BIOPHYS ACTA, V986, P135, DOI 10.1016/0005-2736(89)90282-4; JENSEN PJ, 1995, EXP CELL RES, V217, P65, DOI 10.1006/excr.1995.1064; JOHNSON MD, 1990, HUM PATHOL, V21, P182, DOI 10.1016/0046-8177(90)90127-Q; KEIJER J, 1991, BLOOD, V78, P1254; KRUITHOF EKO, 1995, BLOOD, V86, P4007, DOI 10.1182/blood.V86.11.4007.bloodjournal86114007; KUHN LA, 1990, P NATL ACAD SCI USA, V87, P8506, DOI 10.1073/pnas.87.21.8506; KUMAR S, 1991, J BIOL CHEM, V266, P20960; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; MUELLER BM, 1995, P NATL ACAD SCI USA, V92, P205, DOI 10.1073/pnas.92.1.205; PEPINSKY RB, 1988, J BIOL CHEM, V263, P10799; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; PEPINSKY RB, 1990, FEBS LETT, V261, P247, DOI 10.1016/0014-5793(90)80564-Y; PRATT CW, 1992, J BIOL CHEM, V267, P8789; RADTKE KP, 1990, BIOL CHEM H-S, V371, P1119, DOI 10.1515/bchm3.1990.371.2.1119; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; STONE SR, 1994, BIOCHEMISTRY-US, V33, P7731, DOI 10.1021/bi00190a028; SUMINAMI Y, 1991, BIOCHEM BIOPH RES CO, V181, P51, DOI 10.1016/S0006-291X(05)81380-4; VARTICOVSKI L, 1988, BIOCHEMISTRY-US, V27, P3682, DOI 10.1021/bi00410a024; VONHEIJNE G, 1991, J BIOL CHEM, V266, P15240; WUN TC, 1987, J BIOL CHEM, V262, P3646; YE RD, 1987, J BIOL CHEM, V262, P3718; YE RD, 1989, J BIOL CHEM, V264, P5495; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	36	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26892	26899		10.1074/jbc.271.43.26892	http://dx.doi.org/10.1074/jbc.271.43.26892			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900173	hybrid			2022-12-25	WOS:A1996VP23300067
J	Kamatkar, S; Radha, V; Nambirajan, S; Reddy, RS; Swarup, G				Kamatkar, S; Radha, V; Nambirajan, S; Reddy, RS; Swarup, G			Two splice variants of a tyrosine phosphatase differ in substrate specificity, DNA binding, and subcellular location	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE PHOSPHATASES; ENHANCED EXPRESSION; TERMINAL SEQUENCE; PROTEIN-KINASE; HOMOLOGY; CLONING; CDNA; LOCALIZATION; PTP-1B; LIVER	Four different forms of a non-receptor type protein-tyrosine phosphatase are generated by alternative splicing; two of these forms (PTP-S2 and PTP-S4) are major forms, which are expressed in rat as well as human cells. Here we report that PTP-S2 binds to nonspecific DNA in vitro and localizes in the nucleus upon transfection in HeLa cells. PTP-S4 does not bind to nonspecific DNA and shows perinuclear and cytoplasmic localization. Removal of the C-terminal 34 amino acids of PTP-S4 gives rise to a truncated protein, which binds to nonspecific DNA and localizes to the nucleus, PTP-S4, but not PTP-S2, interacts strongly with the isolated nuclear matrix, The two forms of this tyrosine phosphatase show different substrate specificity in vitro, a feature novel to splice variants of tyrosine phosphatases, Mitogenic stimulation induces mRNAs for PTP-S2 as well as for PTP-S4 in the G(1) phase during liver regeneration, These results suggest that alternative splicing gives rise to two protein-tyrosine phosphatases with distinct substrate specificities and subcellular locations, The 34 amino acids at the C terminus of PTP-S4 play a critical role in determining substrate specificity, subcellular location, and interaction with nuclear matrix and DNA.	CTR CELLULAR & MOL BIOL,HYDERABAD 500007,ANDHRA PRADESH,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)				Swarup, Ghanshyam/0000-0002-8098-0509				BRAUTIGAN DL, 1992, BIOCHIM BIOPHYS ACTA, V1114, P63, DOI 10.1016/0304-419X(92)90007-L; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P1203; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; FAURE R, 1993, GLIA, V9, P311, DOI 10.1002/glia.440090409; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; HIGASHITSUJI H, 1995, ONCOGENE, V10, P407; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; LORENZEN JA, 1995, J CELL BIOL, V131, P631, DOI 10.1083/jcb.131.3.631; LOYER P, 1994, J BIOL CHEM, V269, P2491; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MCLAUGHLIN S, 1993, J BIOL CHEM, V268, P6839; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; NAMBIRAJAN S, 1995, J BIOSCIENCE, V20, P461, DOI 10.1007/BF02703529; PIENTA KJ, 1989, CANCER RES, V49, P2525; RADHA V, 1994, BIOCHEM J, V299, P41, DOI 10.1042/bj2990041; RADHA V, 1993, BIOCHEMISTRY-US, V32, P2194, DOI 10.1021/bi00060a010; Radha V, 1996, EUR J BIOCHEM, V236, P352, DOI 10.1111/j.1432-1033.1996.00352.x; RAJENDRAKUMAR GV, 1993, BIOCHIM BIOPHYS ACTA, V1216, P205, DOI 10.1016/0167-4781(93)90146-5; Reddy RS, 1995, DNA CELL BIOL, V14, P1007, DOI 10.1089/dna.1995.14.1007; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAITO H, 1991, CELL GROWTH DIFFER, V2, P59; SHIFRIN VI, 1993, J BIOL CHEM, V268, P25376; STONE RL, 1994, J BIOL CHEM, V269, P31323; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; SWARUP G, 1991, FEBS LETT, V280, P65, DOI 10.1016/0014-5793(91)80205-H; SWARUP G, 1992, CURR SCI INDIA, V62, P462; SWARUP G, 1989, J BIOL CHEM, V264, P7801; TILLMANN U, 1994, MOL CELL BIOL, V14, P3030, DOI 10.1128/MCB.14.5.3030; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; YANG Q, 1993, J BIOL CHEM, V268, P6622; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	38	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26755	26761		10.1074/jbc.271.43.26755	http://dx.doi.org/10.1074/jbc.271.43.26755			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900155	hybrid			2022-12-25	WOS:A1996VP23300049
J	SchulzeMuth, P; Irmler, S; Schroder, G; Schroder, J				SchulzeMuth, P; Irmler, S; Schroder, G; Schroder, J			Novel type of receptor-like protein kinase from a higher plant (Catharanthus roseus) - cDNA, gene intramolecular autophosphorylation, and identification of a threonine important for auto- and substrate phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUSPENSION CULTURES; ARABIDOPSIS-THALIANA; BRASSICA-OLERACEA; DISEASE RESISTANCE; MOLECULAR ANALYSIS; LOCUS; EXPRESSION; SENSITIVITY; TOMATO; SUPERFAMILY	We characterize CrRLK1, a novel type of receptor-like kinase (RLK), from the plant Catharanthus roseus (Madagascar periwinkle). The protein (90.2 kDa) deduced from the complete genomic and cDNA sequences is a RLK by predicting a N-terminal signal peptide, a large extracytoplasmic domain, a membrane-spanning hydrophobic region followed by a transfer-stop signal, and a C-terminal cytoplasmic protein kinase with all 11 conserved subdomains, It is a novel RLK type because the predicted extracytoplasmic region shares no similarity with other RLKs, The autophosphorylation was investigated with affinity-purified proteins expressed in Escherichia coli, The activity was higher with Mn2+ than with Mg2+ and achieved half-maximal rates at 2-2.5 mu M ATP. The phosphorylation was predominantly on Thr, less on Ser, and not on Tyr, In contrast to other plant RLK, the kinase used an intra- rather than an intermolecular phosphorylation mechanism, After protein cleavage with formic acid, most of the radioactivity Tvas in a 14.1-kDa peptide located at the end of the kinase domain, Mutagenesis of the four Thr residues in this peptide identified Thr-720 in the subdomain XI as important for autophosphorylation and for phosphorylation of beta-casein. This Thr is conserved in other related kinases, suggesting a subfamily sharing common autophosphorylation mechanisms.	UNIV FREIBURG, INST BIOL 2, D-79104 FREIBURG, GERMANY	University of Freiburg								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON PJ, 1985, ANAL BIOCHEM, V148, P105, DOI 10.1016/0003-2697(85)90634-7; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Braun DM, 1996, TRENDS BIOCHEM SCI, V21, P70, DOI 10.1016/S0968-0004(96)80185-X; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; CROWE J, 1992, QIAEXPRESSIONIST; DWYER KG, 1994, PLANT CELL, V6, P1829, DOI 10.1105/tpc.6.12.1829; GORING DR, 1992, PLANT CELL, V4, P1273, DOI 10.1105/tpc.4.10.1273; GORING DR, 1993, PLANT CELL, V5, P531, DOI 10.1105/tpc.5.5.531; HammondKosack KE, 1996, NEW PHYTOL, V133, P11, DOI 10.1111/j.1469-8137.1996.tb04338.x; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HENGEN PN, 1995, TRENDS BIOCHEM SCI, V20, P372, DOI 10.1016/S0968-0004(00)89079-9; HORN MA, 1994, BBA-PROTEIN STRUCT M, V1208, P65, DOI 10.1016/0167-4838(94)90160-0; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KNOBLOCH KH, 1980, Z NATURFORSCH C, V35, P551; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Landon, 1977, Methods Enzymol, V47, P145; LOH YT, 1995, PLANT PHYSIOL, V108, P1735, DOI 10.1104/pp.108.4.1735; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MARTIN GB, 1994, PLANT CELL, V6, P1543, DOI 10.1105/tpc.6.11.1543; MARUYAMA IN, 1995, NUCLEIC ACIDS RES, V23, P3796, DOI 10.1093/nar/23.18.3796; MU JH, 1994, PLANT CELL, V6, P709, DOI 10.1105/tpc.6.5.709; NASRALLAH JB, 1994, PLANT J, V5, P373, DOI 10.1111/j.1365-313X.1994.00373.x; NEUFELD E, 1989, ANAL BIOCHEM, V177, P138, DOI 10.1016/0003-2697(89)90028-6; ROMMENS CMT, 1995, PLANT CELL, V7, P249, DOI 10.1105/tpc.7.3.249; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHALLER GE, 1993, FEBS LETT, V333, P306, DOI 10.1016/0014-5793(93)80676-L; SCHIEL O, 1987, Z NATURFORSCH C, V42, P1075; SCHRODER G, 1988, EUR J BIOCHEM, V172, P161, DOI 10.1111/j.1432-1033.1988.tb13868.x; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; STEIN JC, 1993, PLANT PHYSIOL, V101, P1103, DOI 10.1104/pp.101.3.1103; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; STREBEL K, 1986, J VIROL, V57, P983, DOI 10.1128/JVI.57.3.983-991.1986; SWARUP R, 1996, PLANT PHYSL; TOBIAS CM, 1992, PLANT PHYSIOL, V99, P284, DOI 10.1104/pp.99.1.284; Torii KU, 1996, PLANT CELL, V8, P735, DOI 10.1105/tpc.8.4.735; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VETTER HP, 1992, PLANT PHYSIOL, V100, P998, DOI 10.1104/pp.100.2.998; VONLINTIG J, 1991, MOL PLANT MICROBE IN, V4, P370, DOI 10.1094/MPMI-4-370; Wang XQ, 1996, P NATL ACAD SCI USA, V93, P2598, DOI 10.1073/pnas.93.6.2598; ZHANG R, 1993, PLANT MOL BIOL, V21, P1171, DOI 10.1007/BF00023612	44	88	90	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26684	26689		10.1074/jbc.271.43.26684	http://dx.doi.org/10.1074/jbc.271.43.26684			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900145	hybrid			2022-12-25	WOS:A1996VP23300039
J	Schussler, O; Lantoine, F; Devynck, MA; Glotz, D; DavidDufilho, M				Schussler, O; Lantoine, F; Devynck, MA; Glotz, D; DavidDufilho, M			Human immunoglobulins inhibit thrombin-induced Ca2+ movements and nitric oxide production in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISCORDANT XENOGRAFT REJECTION; INOSITOL TRISPHOSPHATE; INTRACELLULAR CALCIUM; RELEASE; PROSTACYCLIN; BRADYKININ; ACTIVATION; MECHANISM; RECEPTOR; EDRF	Binding of natural antibodies to endothelial cell plays an important role in hyperacute xenograft rejection be tween discordant species. Human intravenous immunoglobulins (IVIg) delay this hyperacute rejection, but their mechanisms of action on endothelial cells have to be defined. Here we demonstrate that IVIg dose-dependently prevent thrombin from eliciting cytosolic Ca2+ movements and nitric oxide (NO) production in aortic endothelial cells from guinea pig. The Ca2+ response to thrombin was similarly affected by IVIg whether they were removed or not from the incubation medium before stimulation. Pretreatment by rat natural antibodies also suppress the thrombin-induced Ca2+ peak corresponding to Ca2+ release from intracellular stores but stimulate the subsequent sustained increase in [Ca2+](i) and the release of NO. The action of human intravenous immunoglobulins seems to be selective for the thrombin receptor because they do not affect [Ca2+](i) and NO responses to endothelin-l or thapsigargin. However, these antibodies also suppress the first phase of the cytosolic Ca2+ response to ATP, which does not release NO under our experimental conditions. These observations raise the possibility that IVIg selectively interact with targets localized on plasma membrane of endothelial cells for controlling receptor-activated Ca2+ pathways and NO release.	UNIV PARIS 05,NECKER UNIV SCH MED,DEPT PHARMACOL,CNRS,URA 1482,F-75015 PARIS,FRANCE; ECOLE NATL SUPER CHIM PARIS,LAB ELECTROCHIM & CHIM ANALYT,CNRS,URA 216,F-75231 PARIS 05,FRANCE; HOP BROUSSAIS,INSERM,U430,LAB IMMUNOL PATHOL HUMAINE,F-75674 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Chimie ParisTech; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Glotz, Denis/F-7881-2011	Glotz, Denis/0000-0001-5258-4237; DAVID-DUFILHO, Monique/0000-0002-7479-075X				ANTOINE F, 1995, BIOCHEM BIOPH RES CO, V215, P842; ASTARIE C, 1992, AM J HYPERTENS, V5, P281, DOI 10.1093/ajh/5.5.281; BACH FH, 1994, IMMUNOL REV, V141, P5, DOI 10.1111/j.1600-065X.1994.tb00870.x; BAZIN H, 1974, EUR J IMMUNOL, V4, P44, DOI 10.1002/eji.1830040112; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLAKELY ML, 1994, TRANSPLANTATION, V58, P1059, DOI 10.1097/00007890-199411270-00001; BLATTER LA, 1995, CIRC RES, V76, P922, DOI 10.1161/01.RES.76.5.922; BROCK TA, 1988, J CELL PHYSIOL, V136, P54, DOI 10.1002/jcp.1041360107; COHEN RA, 1995, CIRCULATION, V92, P3337, DOI 10.1161/01.CIR.92.11.3337; DOLOR RJ, 1992, AM J PHYSIOL, V262, pC171, DOI 10.1152/ajpcell.1992.262.1.C171; GOLIGORSKY MS, 1989, J BIOL CHEM, V264, P16771; GOSINK EC, 1993, AM J PHYSIOL, V265, pC1620, DOI 10.1152/ajpcell.1993.265.6.C1620; GROSCHNER K, 1994, CIRC RES, V75, P304, DOI 10.1161/01.RES.75.2.304; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIRATA Y, 1993, J CLIN INVEST, V91, P1367, DOI 10.1172/JCI116338; INAGAMI T, 1995, ANNU REV PHYSIOL, V57, P171; IOUZALEN L, 1995, EUR J PHARM-MOLEC PH, V289, P189, DOI 10.1016/0922-4106(95)90094-2; JAFFE EA, 1987, J BIOL CHEM, V262, P8557; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KORENAGA R, 1993, CELL STRUCT FUNCT, V18, P95, DOI 10.1247/csf.18.95; LANTOINE F, 1995, J ELECTROANAL CHEM, V392, P85, DOI 10.1016/0022-0728(95)04042-M; LATREMOUILLE C, 1994, TRANSPLANT P, V26, P1285; LEVENTHAL JR, 1993, TRANSPLANTATION, V56, P1, DOI 10.1097/00007890-199307000-00001; LUCKHOFF A, 1988, BRIT J PHARMACOL, V95, P189; Magee J C, 1994, Ther Immunol, V1, P45; MAGEE JC, 1995, TRANSPLANT P, V27, P271; MIYAGAWA S, 1988, TRANSPLANTATION, V46, P825, DOI 10.1097/00007890-198812000-00007; MONCADA S, 1991, PHARMACOL REV, V43, P109; NEWBY AC, 1990, ANNU REV PHYSIOL, V52, P661; RYAN US, 1986, J TISSUE CULTURE MET, V10, P3; TRACEY WR, 1993, J VASC RES, V30, P68; TSUKAHARA H, 1994, J BIOL CHEM, V269, P21778; TSUKAHARA H, 1993, BIOCHEM BIOPH RES CO, V193, P722, DOI 10.1006/bbrc.1993.1685; Wang YP, 1996, J BIOL CHEM, V271, P5647, DOI 10.1074/jbc.271.10.5647	34	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26473	26476		10.1074/jbc.271.43.26473	http://dx.doi.org/10.1074/jbc.271.43.26473			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900114	hybrid			2022-12-25	WOS:A1996VP23300008
